<SEC-DOCUMENT>0001628280-24-022272.txt : 20240509
<SEC-HEADER>0001628280-24-022272.hdr.sgml : 20240509
<ACCEPTANCE-DATETIME>20240509162910
ACCESSION NUMBER:		0001628280-24-022272
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		115
CONFORMED PERIOD OF REPORT:	20240331
FILED AS OF DATE:		20240509
DATE AS OF CHANGE:		20240509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Astrana Health, Inc.
		CENTRAL INDEX KEY:			0001083446
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MANAGEMENT CONSULTING SERVICES [8742]
		ORGANIZATION NAME:           	07 Trade & Services
		IRS NUMBER:				870042699
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37392
		FILM NUMBER:		24931182

	BUSINESS ADDRESS:	
		STREET 1:		1668 S. GARFIELD AVENUE
		STREET 2:		2ND FLOOR
		CITY:			ALHAMBRA
		STATE:			CA
		ZIP:			91801
		BUSINESS PHONE:		(626) 282-0288

	MAIL ADDRESS:	
		STREET 1:		1668 S. GARFIELD AVENUE
		STREET 2:		2ND FLOOR
		CITY:			ALHAMBRA
		STATE:			CA
		ZIP:			91801

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Apollo Medical Holdings, Inc.
		DATE OF NAME CHANGE:	20080715

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SICLONE INDUSTRIES INC
		DATE OF NAME CHANGE:	19990413
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>asth-20240331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:b0ef7e3c-019a-4a45-b736-b471aca8f6db,g:a1c00dc1-e4c6-4560-85ab-798755e5651c,d:3b9f0fcd8da04d6cb91e25daac4e060d-->
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:asth="http://www.apollomed.net/20240331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>asth-20240331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-28">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-29">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-30">Q1</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-31">0001083446</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" id="f-32">--12-31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="asth-20240331.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>asth:segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="financial_ratio"><xbrli:measure>asth:financial_ratio</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">asth:HealthCareCapitationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">asth:HealthCareCapitationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:MezzanineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:MezzanineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:MezzanineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:MezzanineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:MezzanineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:MezzanineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asth:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asth:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asth:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asth:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asth:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asth:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asth:OtherThirdPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asth:OtherThirdPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asth:PayorAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asth:PayorAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asth:PayorBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asth:PayorAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asth:PayorAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asth:PayerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asth:PayerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:AdvancedHealthManagementSystemsLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-31</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:PrimeCommunityCareOfCentralValleyIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-29</xbrli:startDate><xbrli:endDate>2024-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:CommunityFamilyCareMedicalGroupIPAInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-31</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:AdvancedDiagnosticAndSurgicalCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:OtherAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-31</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:TotalAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:CommunityFamilyCareMedicalGroupIPAInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:AdvancedHealthManagementSystemsLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:OtherAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:TotalAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">asth:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">asth:NetworkRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">asth:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">asth:ManagementContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">asth:MemberRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">asth:MemberRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">asth:MemberRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">asth:PatientManagementPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">asth:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">asth:NetworkRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">asth:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">asth:ManagementContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">asth:MemberRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">asth:MemberRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">asth:MemberRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">asth:PatientManagementPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:CAIPAMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:CAIPAMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:CAIPAMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:IHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:IHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:IHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">us-gaap:OtherInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">us-gaap:OtherInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">us-gaap:OtherInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:OneMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:OneMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:OneMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:CAIPAMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:CAIPAMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:CAIPAMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">us-gaap:OtherInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">us-gaap:OtherInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">us-gaap:OtherInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:IntraCareConvertiblePromissoryNoteReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:IntraCareConvertiblePromissoryNoteReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">asth:SeniorSecuredPromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:BassMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">asth:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">asth:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">asth:SecuredOvernightFinancingRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">asth:SecuredOvernightFinancingRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:AmendedAndRestatedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">asth:TruistBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-03</xbrli:startDate><xbrli:endDate>2023-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:AmendedAndRestatedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">asth:TruistBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:AmendedAndRestatedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">asth:TruistBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:AmendedAndRestatedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">asth:TruistBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:AmendedAndRestatedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">asth:SecuredOvernightFinancingRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">asth:SecuredOvernightFinancingRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AstranaMedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:SubordinatedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SubordinatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:SubordinatedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SubordinatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">asth:NewTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">asth:NewTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:ApcBusinessLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">asth:PreferredBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">asth:TruistBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">asth:TruistBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:CompanyAndAPCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:CompanyAndAPCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:CDSCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:CDSCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">asth:StockAwardsAndUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">asth:StockAwardsAndUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">asth:ApcStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">asth:PerformanceBasedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">asth:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:LmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AHMCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:IHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:ProviderServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:PmiocMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:ProviderServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:PmiocMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:PmiocMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:ProviderServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:SongPCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:ProviderServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:SongPCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AstranaMedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:SongPCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:ArroyoVistaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AHMCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:ArroyoVistaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AHMCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:ProviderServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:ArroyoVistaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:ProviderServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:ArroyoVistaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:ProfessionalMedicalCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:OfficeLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AlliedPacificHoldingsInvestmentManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:ProfessionalMedicalCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:OfficeLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AlliedPacificHoldingsInvestmentManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AlliedPacificHoldingsInvestmentManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AlliedPacificHoldingsInvestmentManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:ProviderServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:SunnyVillageCareCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:ProviderServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:SunnyVillageCareCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:ProfessionalMedicalCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:OfficeLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:FirstCommonwealthPropertyLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionRevenueRecognizedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionRevenueRecognizedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:HSMSOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionRevenueRecognizedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AurionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionRevenueRecognizedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionRevenueRecognizedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:HSMSOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionRevenueRecognizedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AurionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AHMCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionExpensesIncurredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:HSMSOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionExpensesIncurredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AurionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionExpensesIncurredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AHMCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionExpensesIncurredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:HSMSOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionExpensesIncurredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AurionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionExpensesIncurredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionRevenueExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:HSMSOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionRevenueExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AurionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionRevenueExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionRevenueExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:HSMSOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionRevenueExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AurionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionRevenueExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AHMCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AHMCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:ProviderServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:BoardMembersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:ProviderServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:BoardMembersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:BoardMembersWhoAreAlsoOfficersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:ProviderServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:BoardMembersWhoAreAlsoOfficersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:ProviderServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CarePartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CareDeliveryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CareEnablementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CarePartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CareDeliveryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CareEnablementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CarePartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CareDeliveryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CareEnablementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CarePartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CareDeliveryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CareEnablementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CarePartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CareDeliveryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CareEnablementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CarePartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CareDeliveryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CareEnablementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">asth:InterestRateCollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">asth:InterestRateCollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">asth:InterestRateCollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">asth:InterestRateCollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AAMGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AAMGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AAMGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AAMGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:VOMGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:VOMGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:VOMGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:VOMGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:DmgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:DmgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:DmgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:DmgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:ADSCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:ADSCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:ADSCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:ADSCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:CFCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:CFCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:CFCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:CFCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:PrimeCommunityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:PrimeCommunityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:PrimeCommunityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:PrimeCommunityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AAMGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AAMGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AAMGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AAMGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:VOMGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:VOMGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:VOMGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:VOMGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:DmgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:DmgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:DmgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:DmgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">asth:InterestRateCollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">asth:InterestRateCollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">asth:InterestRateCollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">asth:InterestRateCollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">asth:InterestRateCollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:DMGAndSunLabsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:DmgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:AAMGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:AAMGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">asth:A2023MetricMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:AAMGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">asth:A2024MetricMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:AAMGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">asth:A2023MetricMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:AAMGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">asth:A2023MetricMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:AAMGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">asth:A2024MetricMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:AAMGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">asth:A2024MetricMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:AAMGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">asth:A2023MetricMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:AAMGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">asth:A2023MetricMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:AdvancedDiagnosticAndSurgicalCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">asth:A2023MetricMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:AdvancedDiagnosticAndSurgicalCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">asth:A2024MetricMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:CommunityFamilyCareMedicalGroupIPAInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:CommunityFamilyCareMedicalGroupIPAInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">asth:FirstMetricMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:CommunityFamilyCareMedicalGroupIPAInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">asth:SecondMetricMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:CommunityFamilyCareMedicalGroupIPAInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">asth:ThirdMetricMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:PCCCVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:IHealthPromissioryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:IHealthPromissioryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">asth:RevolverLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-05-09</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-71 f-72 f-105 f-106" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-1" order="1"/></ix:resources></ix:header></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.021%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">March 31, 2024</ix:nonNumeric> </span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OR</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.021%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from &#160;___&#160;to ___.</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File No. <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-37392</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><img src="asth-20240331_g1.jpg" alt="Astrana_LogoLockup_RGB_Plum_with 1_2  height of the wordmark (002).jpg" style="height:82px;margin-bottom:5pt;vertical-align:text-bottom;width:470px"/></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">Astrana Health, Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">95-4472349</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or Other Jurisdiction</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">of Incorporation or Organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identification Number)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">1668 S. Garfield Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-10" continuedAt="f-10-1">2</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="f-10-1" continuedAt="f-10-2">nd</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="f-10-2"> Floor</ix:continuation>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Alhambra</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">California</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">91801</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices and zip code)</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">626</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">282-0288</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)&#160;</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.093%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.997%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.093%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.890%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title of Each Class</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trading Symbol</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of Each Exchange on Which Registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, $0.001 par value per share</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">ASTH</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">The Nasdaq Stock Market LLC</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-19">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-20">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.026%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.026%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.675%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-21">Large accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller reporting company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-22">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-23">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-24">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160; No</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April&#160;29, 2024, there were <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-25">56,025,538</ix:nonFraction> shares of common stock of the registrant, $0.001 par value per share, issued and outstanding, which includes <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-26"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-27">7,132,698</ix:nonFraction></ix:nonFraction> treasury shares that are owned by Allied Physicians of California, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA (&#8220;APC&#8221;), a consolidated affiliate of Astrana Health, Inc. These shares are legally issued and outstanding but treated as treasury shares for accounting purposes. </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Astrana Health, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO FORM 10-Q FILING</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:78.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.258%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PAGE</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_13">Introductory Note</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_13">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_13">Note About Forward-Looking Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_13">5</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_16">PART I</a></span></div><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_16">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_19">Item 1.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_19">Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_19">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_22">Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_22">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_25">Condensed Consolidated Statements of Income for the Three Months Ended March 31, 2024 and 2023</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_25">9</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_31">Condensed Consolidated Statements of Mezzanine and Stockholders&#8217; Equity for the Three Months Ended March 31, 2024 and 2023</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_31">10</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_34">Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2024 and 2023</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_34">11</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_37">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_37">13</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_142">Item 2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_142">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_142">41</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_199">Item 3.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_199">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_199">52</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_205">Item 4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_205">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_205">52</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_208">PART II</a></span></div><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_208">OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_211">Item 1.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_211">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_211">53</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_214">Item 1A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_214">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_214">53</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_217">Item 2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_217">Unregistered Sales of Equity Securities</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_217"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_217">and</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_217"> Use of Proceeds</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_217">53</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_223">Item 3.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_223">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_223">55</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_226">Item 4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_226">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_226">55</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_229">Item 5.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_229">Other Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_229">55</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_232">Item 6.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_232">Exhibits</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b9f0fcd8da04d6cb91e25daac4e060d_232">55</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Glossary</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following abbreviations or acronyms that may be used in this document shall have the adjacent meanings set forth below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.859%"><tr><td style="width:1.0%"/><td style="width:25.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:71.019%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AAMG</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All-American Medical Group</span></td></tr><tr><td colspan="3" style="background-color:#ebebec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ACO REACH</span></div></td><td colspan="3" style="background-color:#ebebec;padding:0 1pt"/><td colspan="3" style="background-color:#ebebec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ACO Realizing Equity, Access, and Community Health</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ADSC</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced Diagnostic and Surgical Center, Inc.</span></div></td></tr><tr><td colspan="3" style="background-color:#ebebec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AHMC</span></td><td colspan="3" style="background-color:#ebebec;padding:0 1pt"/><td colspan="3" style="background-color:#ebebec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AHMC Healthcare Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AHMS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced Health Management Systems, L.P.</span></div></td></tr><tr><td colspan="3" style="background-color:#ebebec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AHM</span></div></td><td colspan="3" style="background-color:#ebebec;padding:0 1pt"/><td colspan="3" style="background-color:#ebebec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Astrana Health Management, Inc. (f/k/a Network Medical Management Inc.)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AIPBP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All-Inclusive Population-Based Payments</span></td></tr><tr><td colspan="3" style="background-color:#ebebec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APAACO</span></td><td colspan="3" style="background-color:#ebebec;padding:0 1pt"/><td colspan="3" style="background-color:#ebebec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APA ACO, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allied Physicians of California, a Professional Medical Corporation</span></td></tr><tr><td colspan="3" style="background-color:#ebebec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APC-LSMA</span></td><td colspan="3" style="background-color:#ebebec;padding:0 1pt"/><td colspan="3" style="background-color:#ebebec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APC-LSMA Designated Shareholder Medical Corporation</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Astrana</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Astrana Health Inc. (f/k/a Apollo Medical Holdings, Inc.)</span></div></td></tr><tr><td colspan="3" style="background-color:#ebebec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Astrana Medical</span></div></td><td colspan="3" style="background-color:#ebebec;padding:0 1pt"/><td colspan="3" style="background-color:#ebebec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Astrana Health Medical Corporation (f/k/a AP-AMH Medical Corporation)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Astrana Care Partners Medical</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Astrana Care Partners Medical Corporation (f/k/a AP - AMH 2 Medical Corporation)</span></div></td></tr><tr><td colspan="3" style="background-color:#ebebec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAIPA MSO </span></td><td colspan="3" style="background-color:#ebebec;padding:0 1pt"/><td colspan="3" style="background-color:#ebebec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAIPA MSO, LLC</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CFC</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Community Family Care Medical Group IPA, Inc. </span></div></td></tr><tr><td colspan="3" style="background-color:#ebebec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CMS</span></td><td colspan="3" style="background-color:#ebebec;padding:0 1pt"/><td colspan="3" style="background-color:#ebebec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centers for Medicare &amp; Medicaid Services</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DMHC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California Department of Managed Health Care</span></div></td></tr><tr><td colspan="3" style="background-color:#ebebec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DMG</span></td><td colspan="3" style="background-color:#ebebec;padding:0 1pt"/><td colspan="3" style="background-color:#ebebec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostic Medical Group of Southern California </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HSMSO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health Source MSO Inc., a California corporation</span></td></tr><tr><td colspan="3" style="background-color:#ebebec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPA</span></td><td colspan="3" style="background-color:#ebebec;padding:0 1pt"/><td colspan="3" style="background-color:#ebebec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Independent Practice Association</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jade</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jade Health Care Medical Group, Inc. </span></td></tr><tr><td colspan="3" style="background-color:#ebebec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LMA</span></td><td colspan="3" style="background-color:#ebebec;padding:0 1pt"/><td colspan="3" style="background-color:#ebebec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LaSalle Medical Associates</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NGACO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Next Generation Accountable Care Organization</span></td></tr><tr><td colspan="3" style="background-color:#ebebec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prime Community Care</span></div></td><td colspan="3" style="background-color:#ebebec;padding:0 1pt"/><td colspan="3" style="background-color:#ebebec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary Community Care of Central Valley, Inc. </span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PMIOC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pacific Medical Imaging and Oncology Center, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ebebec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sun Labs</span></td><td colspan="3" style="background-color:#ebebec;padding:0 1pt"/><td colspan="3" style="background-color:#ebebec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sun Clinical Labs</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VIE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable Interest Entity</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_13"></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTRODUCTORY NOTE</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context dictates otherwise, references in this Quarterly Report on Form 10-Q to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and similar words are references to Astrana Health, Inc., a Delaware corporation (&#8220;Astrana&#8221;), and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (&#8220;VIEs&#8221;).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) have not reviewed any statements contained in this Report, including statements describing the participation of APA ACO, Inc. (&#8220;APAACO&#8221;) in the ACO Realizing Equity, Access, and Community Health Model (&#8220;ACO REACH Model&#8221;) and ApolloMed MSSP I, Inc. in the Medicare Shared Savings Program (&#8220;MSSP&#8221;). </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade names and trademarks of Astrana and its subsidiaries referred to herein, and their respective logos, are our property. This Quarterly Report on Form 10-Q may contain additional trade names and/or trademarks of other companies, which are the property of their respective owners. We do not intend our use or display of other companies&#8217; trade names and/or trademarks, if any, to imply an endorsement or sponsorship of us by such companies, or any relationship with any of these companies.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE ABOUT FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This Quarterly Report on Form 10-Q contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). All statements other than statements of historical fact are &#8220;forward-looking statements&#8221; for purposes of federal and state securities laws, including, but not limited to, any statements about our business, financial condition, operating results, plans, objectives, expectations, and intentions; any projections of earnings, revenue, earnings before interest, taxes, depreciation, and amortization (&#8220;EBITDA&#8221;), Adjusted EBITDA, or other financial items, such as our projected capitation from CMS, our forward-looking guidance and our future liquidity; any statements of any plans, strategies, and objectives of management for future operations, such as the material opportunities that we believe exist for our Company; any statements concerning proposed services, developments, mergers, or acquisitions; any statements with respect to dividends or stock repurchases and timing, methods, and payment of same; any statements regarding the outlook of the ACO REACH Model, the MSSP, or strategic transactions; any statements regarding management&#8217;s view of future expectations and prospects for us; any statements about prospective adoption of new accounting standards or effects of changes in accounting standards; our ability to maintain effective internal control over financial reporting and disclosure controls and procedures; any statements regarding potential changes to our tax structure; any statements regarding future economic conditions or performance; any statements of belief; any statements of assumptions underlying any of the foregoing; and other statements that are not historical facts. Forward-looking statements may be identified by the use of forward-looking terms, such as &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;can,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;should,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;project,&#8221; &#8220;believe,&#8221; &#8220;think,&#8221; &#8220;plan,&#8221; &#8220;envision,&#8221; &#8220;intend,&#8221; &#8220;continue,&#8221; &#8220;target,&#8221; &#8220;seek,&#8221; &#8220;contemplate,&#8221; &#8220;budgeted,&#8221; &#8220;will,&#8221; or &#8220;would,&#8221; and the negative of such terms, other variations on such terms or other similar or comparable words, phrases, or terminology. These forward-looking statements present our estimates and assumptions only as of the date of this Quarterly Report on Form 10-Q and are subject to change.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                Forward-looking statements involve risks and uncertainties, many of which are difficult to predict and are outside of our control, and are based on the current beliefs, expectations, and certain assumptions of management. Some or all of such beliefs, expectations, and assumptions may not materialize or may vary significantly from actual results. Such statements are qualified by important economic, competitive, governmental, and technological factors that could cause our business, strategy, or actual results or events to differ materially from those in our forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on February&#160;29, 2024, including the risk factors discussed under the heading &#8220;Risk Factors&#8221; in Part I, Item 1A thereof. Although we believe that the expectations reflected in our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and to significant risks and uncertainties that could cause actual conditions, outcomes, and results to differ materially from those indicated by such statements. Any forward-looking statement made by the Company in this Form 10-Q speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div><span><br/></span></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_19"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:10pt"><span><br/></span></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_22"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASTRANA HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.517%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-33">334,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-34">293,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">2,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">2,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-37">120,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">76,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net &#8211; related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-39">62,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-40">58,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:fixed-zero" scale="3" id="f-41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="f-42">10,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-43">1,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-44">1,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-45">17,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-46">17,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-47">538,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-48">461,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-49">7,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-50">7,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-51">119,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-52">71,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-53">410,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-54">278,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxesReceivableNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-55">15,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxesReceivableNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">15,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans receivable, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-57">47,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">26,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in other entities &#8211; equity method</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-59">35,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-60">25,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in privately held entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="asth:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" format="ixt:num-dot-decimal" scale="3" id="f-61">6,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="asth:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" format="ixt:num-dot-decimal" scale="3" id="f-62">6,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="f-63">645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="f-64">345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-65">39,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-66">37,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">4,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">1,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">687,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-70">471,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-71">1,226,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-72">933,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities, mezzanine equity and equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-73">146,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-74">59,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiduciary accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="asth:FiduciaryAccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-75">7,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="asth:FiduciaryAccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-76">7,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-77">136,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-78">106,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-79">5,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:fixed-zero" scale="3" id="f-80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DividendsPayableCurrent" scale="3" id="f-81">638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DividendsPayableCurrent" scale="3" id="f-82">638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.517%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-83">636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-84">646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-85">5,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-86">4,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-87">20,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-88">19,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-89">31,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-90">18,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-91">355,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-92">218,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-93">3,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-94">4,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-95">1,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-96">1,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-97">37,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-98">36,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion and deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-99">368,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-100">258,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-101">7,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-102">3,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-103">418,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-104">303,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-105">773,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-106">522,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments and contingencies (Note 12)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-107"/></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-6" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-108"/></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mezzanine equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest in Allied Physicians of California, a Professional Medical Corporation ("APC")</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="asth:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsNetOfDividends" format="ixt:num-dot-decimal" scale="3" id="f-109">205,557</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="asth:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsNetOfDividends" format="ixt:num-dot-decimal" scale="3" id="f-110">205,883</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-111"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-112">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-113"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-114">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized (inclusive of all preferred stock, including Series B Preferred stock); <ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-115"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-116">1,111,111</ix:nonFraction></ix:nonFraction> issued and <ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-117"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-118">zero</ix:nonFraction></ix:nonFraction> outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-119">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-120">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-121"><ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-122">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-123"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-124">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized (inclusive of all preferred stock, including Series A Preferred stock); <ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-125"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-126">555,555</ix:nonFraction></ix:nonFraction> issued and <ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-127"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-128">zero</ix:nonFraction></ix:nonFraction> outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-129">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-130">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-131"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-132">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-133"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-134">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-135"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-136">47,458,264</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-137"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-138">46,843,743</ix:nonFraction></ix:nonFraction> shares issued and outstanding, excluding <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-139">10,584,340</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-140">10,584,340</ix:nonFraction> treasury shares, as of March&#160;31, 2024 and December&#160;31, 2023, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-141">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-142">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-143">395,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-144">371,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-145">257,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-146">243,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-147">653,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-148">614,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="f-149">4,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="f-150">2,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-151">657,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-152">616,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities, mezzanine equity and equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-153">1,226,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-154">933,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><ix:footnote id="fn-1" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The condensed consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#8217;s consolidated VIEs totaling $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-155">717.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-156">540.8</ix:nonFraction>&#160;million as of March&#160;31, 2024 and December&#160;31, 2023, respectively, and total liabilities of the Company&#8217;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-157">179.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-158">146.0</ix:nonFraction>&#160;million as of March&#160;31, 2024 and December&#160;31, 2023, respectively. These VIE balances do not include $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="6" id="f-159">299.5</ix:nonFraction>&#160;million of investment in affiliates and $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:OtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-160">110.1</ix:nonFraction>&#160;million of amounts due to affiliates as of March&#160;31, 2024, and $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="6" id="f-161">273.2</ix:nonFraction>&#160;million of investment in affiliates and $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:OtherReceivables" format="ixt:num-dot-decimal" scale="6" id="f-162">107.3</ix:nonFraction>&#160;million of amounts due to affiliates as of December&#160;31, 2023, as these are eliminated upon consolidation and not presented within the condensed consolidated balance sheets. See Note 16 &#8212; &#8220;Variable Interest Entities (VIEs)&#8221; for further details.</span></ix:footnote></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASTRANA HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.454%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitation, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-163">365,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-164">300,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk pool settlements and incentives</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-165">17,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-166">13,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management fee income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-167">4,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-168">9,896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fee-for-service, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-169">15,937</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-170">12,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-171">1,054</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-172">1,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-173">404,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-174">337,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of services, excluding depreciation and amortization</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-175">330,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-176">289,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-177">38,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-178">21,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-179">5,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-180">4,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-181">374,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-182">314,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-183">30,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-184">22,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income (expense)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from equity method investments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="f-185">632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-186">2,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-187">7,585</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-188">3,269</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-189">3,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-190">3,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on investments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-191">1,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-192">6,392</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (loss) income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-193">4,277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-194">1,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expenses, net</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-195">6,135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-196">2,964</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-197">24,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-198">19,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-199">7,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-200">6,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-201">16,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-202">12,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) attributable to non-controlling interest</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-203">2,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="f-204">644</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to Astrana Health, Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-205">14,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-206">13,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per share &#8211; basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-207">0.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-208">0.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per share &#8211; diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-209">0.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-210">0.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASTRANA HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(IN THOUSANDS, EXCEPT SHARE DATA)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.558%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.558%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.558%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.558%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.319%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine<br/>Equity&#160;&#8211;<br/>Non-controlling<br/>Interest&#160;in&#160;APC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common&#160;Stock&#160;Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid-in&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="f-211">205,883</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-212">46,843,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-213">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-214">371,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-215">243,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-216">2,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-217">616,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:TemporaryEquityNetIncome" scale="3" id="f-218">326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="asth:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" format="ixt:num-dot-decimal" scale="3" id="f-219">14,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="asth:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" format="ixt:num-dot-decimal" scale="3" id="f-220">1,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="asth:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" format="ixt:num-dot-decimal" scale="3" id="f-221">16,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="f-222">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="f-223">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" scale="3" id="f-224">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" scale="3" id="f-225">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued for vesting of restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="f-226">5,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="3" id="f-227">2,407</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="3" id="f-228">2,407</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-229">5,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-230">5,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of shares for business acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-231">631,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="f-232">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-233">21,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-234">21,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-36" decimals="INF" name="asth:AcquisitionOfNonControllingInterestShares" format="ixt:num-dot-decimal" scale="0" id="f-235">22,340</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" sign="-" name="asth:NoncontrollingInterestIncreaseDecreaseFromBusinessCombination" scale="3" id="f-236">856</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="asth:NoncontrollingInterestIncreaseDecreaseFromBusinessCombination" scale="3" id="f-237">321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="asth:NoncontrollingInterestIncreaseDecreaseFromBusinessCombination" scale="3" id="f-238">535</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="asth:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" scale="3" id="f-239">95</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="asth:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" scale="3" id="f-240">95</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2024</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" sign="-" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="f-241">205,557</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-242">47,458,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-243">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-244">395,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-245">257,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-246">4,485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-247">657,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.583%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.558%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.558%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.558%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.558%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.232%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.320%"/><td style="width:0.1%"/></tr><tr style="height:10pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine<br/>Equity&#160;&#8211;<br/>Non-controlling<br/>Interest&#160;in&#160;APC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:19pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common&#160;Stock&#160;Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid-in&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="f-248">14,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-44" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-249">46,575,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-250">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-251">360,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-252">182,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-253">1,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-254">544,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" sign="-" name="us-gaap:TemporaryEquityNetIncome" format="ixt:num-dot-decimal" scale="3" id="f-255">1,729</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="asth:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" format="ixt:num-dot-decimal" scale="3" id="f-256">13,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="asth:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" format="ixt:num-dot-decimal" scale="3" id="f-257">1,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="asth:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" format="ixt:num-dot-decimal" scale="3" id="f-258">14,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued for vesting of restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-52" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="f-259">57,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-260">109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-261">109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued for exercise of options and warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-52" decimals="INF" name="asth:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" format="ixt:num-dot-decimal" scale="0" id="f-262">125,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="asth:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" format="ixt:num-dot-decimal" scale="3" id="f-263">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="asth:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" format="ixt:num-dot-decimal" scale="3" id="f-264">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-52" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="f-265">270,081</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" format="ixt:num-dot-decimal" scale="3" id="f-266">9,539</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" format="ixt:num-dot-decimal" scale="3" id="f-267">9,539</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-268">3,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-269">3,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" sign="-" name="asth:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" scale="3" id="f-270">120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="asth:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" scale="3" id="f-271">120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfer of common control entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="asth:TemporaryEquityTransferOfCommonControlEntities" format="ixt:num-dot-decimal" scale="3" id="f-272">1,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" sign="-" name="asth:StockholdersEquityTransferOfCommonControlEntities" format="ixt:num-dot-decimal" scale="3" id="f-273">2,447</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="asth:StockholdersEquityTransferOfCommonControlEntities" format="ixt:num-dot-decimal" scale="3" id="f-274">2,447</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="f-275">14,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-55" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-276">46,488,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-277">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-278">352,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-279">195,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-280">2,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-281">551,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASTRANA HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(IN THOUSANDS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-282">16,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-283">12,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile net income to net cash provided by operating activities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-284">5,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-285">4,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-286">458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-287">237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-288">5,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-289">3,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="asth:NoncashLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="f-290">3,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="asth:NoncashLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="f-291">2,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized (gain) loss on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="asth:UnrealizedGainLossFromInvestmentInEquitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-292">1,099</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="asth:UnrealizedGainLossFromInvestmentInEquitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-293">5,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="f-294">632</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-295">2,484</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:fixed-zero" scale="3" id="f-296">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="3" id="f-297">637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="f-298">7,248</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="f-299">283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromOtherOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-300">6,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:ProceedsFromOtherOperatingActivities" format="ixt:fixed-zero" scale="3" id="f-301">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of business combinations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-302">26,128</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-303">26,373</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivable, net &#8211; related parties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" format="ixt:num-dot-decimal" scale="3" id="f-304">3,374</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" format="ixt:num-dot-decimal" scale="3" id="f-305">9,730</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="f-306">1,403</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="3" id="f-307">94</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="asth:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-308">4,255</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="asth:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" scale="3" id="f-309">506</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-310">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-311">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="f-312">905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-313">4,517</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiduciary accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" id="f-314">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" id="f-315">911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="asth:IncreaseDecreaseInMedicalLiabilities" scale="3" id="f-316">808</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="asth:IncreaseDecreaseInMedicalLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-317">17,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable/receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" format="ixt:num-dot-decimal" scale="3" id="f-318">14,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" format="ixt:num-dot-decimal" scale="3" id="f-319">6,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-320">3,083</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-321">2,088</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="f-322">298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:fixed-zero" scale="3" id="f-323">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-324">5,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-325">7,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for business acquisition, net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="f-326">50,649</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="f-327">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from repayment of loans receivable &#8211; related parties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties" scale="3" id="f-328">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties" format="ixt:num-dot-decimal" scale="3" id="f-329">2,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="f-330">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-331">1,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of investment &#8211; equity method</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-332">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="3" id="f-333">325</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of loans receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToFundLongtermLoansToRelatedParties" format="ixt:num-dot-decimal" scale="3" id="f-334">20,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:PaymentsToFundLongtermLoansToRelatedParties" format="ixt:fixed-zero" scale="3" id="f-335">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-336">369</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-337">6,027</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposit for purchase of property</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="asth:DepositForPurchaseOfProperty" format="ixt:fixed-zero" scale="3" id="f-338">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="asth:DepositForPurchaseOfProperty" format="ixt:num-dot-decimal" scale="3" id="f-339">8,824</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-340">71,039</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-341">14,035</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfDividendsCommonStock" scale="3" id="f-342">95</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:PaymentsOfDividendsCommonStock" scale="3" id="f-343">120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings on long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-344">110,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-345">1,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfOtherLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-346">3,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:RepaymentsOfOtherLongTermDebt" scale="3" id="f-347">153</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of finance lease obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" scale="3" id="f-348">179</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" scale="3" id="f-349">154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the exercise of stock options and warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:fixed-zero" scale="3" id="f-350">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="3" id="f-351">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of treasury shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="asth:PaymentForRepurchaseOfTreasuryStockFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-352">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="asth:PaymentForRepurchaseOfTreasuryStockFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-353">9,539</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromPaymentsToMinorityShareholders" scale="3" id="f-354">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:ProceedsFromPaymentsToMinorityShareholders" format="ixt:fixed-zero" scale="3" id="f-355">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfDividendsMinorityInterest" scale="3" id="f-356">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:PaymentsOfDividendsMinorityInterest" format="ixt:fixed-zero" scale="3" id="f-357">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in) financing activities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-358">106,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-359">7,099</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-360">41,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-361">13,414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, cash equivalents, and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-362">294,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-363">288,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, cash equivalents, and restricted cash, end of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-364">335,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-365">274,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosures of cash flow information</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="f-366">194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:fixed-zero" scale="3" id="f-367">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-368">6,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-369">2,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosures of non-cash investing and financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business acquisition in accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="asth:NonCashBusinessAcquisition" format="ixt:num-dot-decimal" scale="3" id="f-370">63,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="asth:NonCashBusinessAcquisition" format="ixt:num-dot-decimal" scale="3" id="f-371">3,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-372">4,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-373">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued in business combination</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="f-374">21,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="f-375">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of investments - equity method in accounts payable and accrued liabilities and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:TransferToInvestments" format="ixt:num-dot-decimal" scale="3" id="f-376">9,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:TransferToInvestments" format="ixt:fixed-zero" scale="3" id="f-377">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Draw on letter of credit through Revolver Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="asth:DrawOnLetterOfCreditThroughRevolverLoan" format="ixt:num-dot-decimal" scale="3" id="f-378">4,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="asth:DrawOnLetterOfCreditThroughRevolverLoan" format="ixt:fixed-zero" scale="3" id="f-379">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets that sum to the total amounts of cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-380">334,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-381">274,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RestrictedCashEquivalentsNoncurrent" scale="3" id="f-382">645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:RestrictedCashEquivalentsNoncurrent" format="ixt:fixed-zero" scale="3" id="f-383">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-384">335,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-385">274,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.913%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="margin-top:5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASTRANA HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_40"></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:NatureOfOperations" id="f-386" continuedAt="f-386-1" escape="true">Description of Business</ix:nonNumeric></span></div><ix:continuation id="f-386-1" continuedAt="f-386-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context dictates otherwise, references in these notes to the financial statements to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and similar words are references to Astrana Health, Inc. (&#8220;Astrana&#8221;), formerly known as Apollo Medical Holdings, Inc., and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (&#8220;VIEs&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Headquartered in Alhambra, California, Astrana is a leading provider-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, Astrana operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver accessible, high-quality care to patients in a cost-effective manner. Together with Astrana&#8217;s affiliated physician groups and consolidated subsidiaries and VIEs, the Company provides value-based care enablement services and care delivery with its consolidated care partners to serve patients in California, Nevada, and Texas, the majority of whom are covered by private or public insurance provided through Medicare, Medicaid, and health maintenance organizations (&#8220;HMOs&#8221;), with a small portion of our revenue coming from non-insured patients. The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company&#8217;s physician network consists of primary care physicians, specialist physicians, physician and specialist extenders, and hospitalists.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-387">three</ix:nonFraction> reportable segments are Care Partners, Care Delivery and Care Enablement, which are described as follows:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Care Partners</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Care Partners segment is focused on building and managing high-quality and high-performance provider networks by partnering with, empowering, and investing in strong provider partners aligned on a shared vision for coordinated care delivery. By leveraging the Company&#8217;s unique care enablement platform and ability to recruit, empower, and incentivize physicians to effectively manage total cost of care, the Company is able to organize partnered providers into successful multi-payer risk-bearing organizations that take on varying levels of risk based on total cost of care across membership in all lines of business, including Medicare fee for service (&#8220;FFS&#8221;), Medicare Advantage, Medicaid, Commercial, and Exchange. Through the Company&#8217;s network of &#8220;independent practice associations&#8221; (&#8220;IPAs&#8221;), &#8220;accountable care organizations&#8221; (&#8220;ACOs&#8221;), and Restricted Knox-Keene licensed health plan, the Company&#8217;s healthcare delivery entities are responsible for coordinating and delivering high-quality care to the Company&#8217;s patients and ensuring continuity of care in Astrana&#8217;s ecosystem across age, stage of life, or life circumstance. Beginning in 2024, in addition to participating in the ACO REACH Model, the Company began participating in the Medicare Shared Savings Program (&#8220;MSSP&#8221;). The MSSP was created to promote accountability and improve coordination of care for Medicare beneficiaries. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Care Delivery</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Care Delivery segment is a patient-centric, data-driven care delivery organization focused on delivering high-quality and accessible care to all patients. The Company&#8217;s care delivery organization includes primary care, multi-specialty care, and ancillary care services. This segment includes the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Primary care clinics, including post-acute care services;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Multi-specialty care clinics and medical groups, including hospitalist, intensivist, and physician advisory services, cardiac care and diagnostic testing, and specialized care for women&#8217;s health; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ancillary service providers, such as urgent care centers, outpatient imaging centers, ambulatory surgery centers, and full-service labs.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="f-386-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Care Enablement</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Care Enablement segment is an integrated, end-to-end clinical, operational, financial, and administrative platform powered by the Company&#8217;s proprietary technology suite that enhances the delivery of high-quality, value-based care to patients and leads to superior clinical and financial outcomes. The Company provides solutions to providers, including independent physicians, provider and medical groups, accountable care organizations, and payers, including health plans and other risk-bearing organizations. The Company&#8217;s platform meets providers and payers where they are, with a wide spectrum of solutions across the total cost of care risk spectrum, ranging from solutions for fee-for-service entities to hospital-shared risk-bearing entities, and across patient types, including Medicare, Medicaid, Commercial, and Exchange patients. This segment includes the Company&#8217;s wholly owned subsidiaries which operate as management services organizations (&#8220;MSOs&#8221;), which enter into long-term management and/or administrative services agreements with IPAs, ACOs, clinics, or independent providers. By leveraging the Company&#8217;s care enablement platform, providers and payers can improve their ability to deliver high-quality care to their patients and achieve better patient outcomes.</span></div></ix:continuation><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_43"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="f-388" continuedAt="f-388-1" escape="true">Basis of Presentation and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-388-1" continuedAt="f-388-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-389" continuedAt="f-389-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-389-1">The accompanying condensed consolidated balance sheet at December&#160;31, 2023, has been derived from the Company&#8217;s audited condensed consolidated financial statements, but does not include all annual disclosures required by generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). The accompanying unaudited condensed consolidated financial statements as of March&#160;31, 2024, and for the three months ended March&#160;31, 2024 and 2023, have been prepared in accordance with U.S. GAAP for interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited condensed consolidated financial statements and related notes to the financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2023, as filed with the SEC on February&#160;29, 2024. In the opinion of management, all material adjustments (consisting of normal recurring adjustments as well as intercompany accounts and transactions, which have been eliminated) considered necessary for a fair presentation have been made to make the condensed consolidated financial statements not misleading, as required by Regulation S-X, Rule 10-01.</ix:continuation> Operating results for the three months ended March&#160;31, 2024, are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2024, or any future periods.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-390" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheets as of March&#160;31, 2024 and December&#160;31, 2023, and the condensed consolidated statements of income for the three months ended March&#160;31, 2024 and 2023, include Astrana&#8217;s wholly owned subsidiaries and consolidated variable interest entities (&#8220;VIEs&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read or have access to our audited condensed consolidated financial statements for the fiscal year ended December&#160;31, 2023.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-391" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred but not reported (&#8220;IBNR&#8221;) claims), determination of hospital shared-risk and health plan shared-risk revenue and receivables (including constraints, completion factors and historical margins), income tax-valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="f-388-2" continuedAt="f-388-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationsPolicy" id="f-392" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition-related costs separately from the business combination.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-393" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reportable Segments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, the Company operates in <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-394">three</ix:nonFraction> reportable segments:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Care Partners;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Care Delivery; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Care Enablement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 1 &#8212; &#8220;Description of Business&#8221; and Note 18 &#8212; &#8220;Segments&#8221; to the condensed consolidated financial statements for information on the Company&#8217;s segments.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-395" continuedAt="f-395-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within ninety days from their date of purchase to be cash equivalents.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-395-1">The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company believes it is not exposed to any significant credit risk with respect to its cash and cash equivalents and restricted cash.</ix:continuation> As of March&#160;31, 2024 and December&#160;31, 2023, the Company&#8217;s deposit accounts with banks exceeded the FDIC&#8217;s insured limit by approximately $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:CashUninsuredAmount" format="ixt:num-dot-decimal" scale="6" id="f-396">353.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:CashUninsuredAmount" format="ixt:num-dot-decimal" scale="6" id="f-397">318.9</ix:nonFraction> million, respectively. The Company has not experienced any losses to date and performs ongoing evaluations of these financial institutions to limit the Company&#8217;s concentration of risk exposure.</span></div><ix:nonNumeric contextRef="c-1" name="asth:ReceivablesReceivablesRelatedPartiesOtherReceivablesAndLoanReceivablesPolicyTextBlock" id="f-398" continuedAt="f-398-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables, Receivables &#8211; Related Parties, Other Receivables and Loan Receivables</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements, incentive receivables, management fee income, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables &#8211; related parties are comprised of risk pool settlements, management fee income, and other receivables. Receivables &#8211; related parties are recorded and stated at the amount expected to be collected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s loan receivables consists of promissory notes that accrue interest per annum. As of March&#160;31, 2024, promissory notes are expected to be collected by their maturity dates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation and claims receivables relate to each health plan&#8217;s capitation and are received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#8217;s hospital shared-risk pool receivable, which is recorded quarterly based on reports received from the Company&#8217;s hospital partners and management&#8217;s estimate of the Company&#8217;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately <ix:nonNumeric contextRef="c-1" name="asth:RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" format="ixt-sec:durmonth" id="f-399">18</ix:nonNumeric> months after the risk pool performance year is completed. Other receivables consist of receivables from fee-for-service (&#8220;FFS&#8221;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop-loss insurance premium reimbursements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains reserves for potential credit losses on the receivables. Management reviews the composition of the Company&#8217;s receivables and analyzes historical bad debts, customer concentrations, customer creditworthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis. </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="f-388-3" continuedAt="f-388-4"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-398-1">Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regard to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (&#8220;CECL&#8221;) model.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-400" continuedAt="f-400-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risks</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-400-1">The Company disaggregates revenue from contracts by service type and payer type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The condensed consolidated statements of income present disaggregated revenue by service type.</ix:continuation> <ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-401" continuedAt="f-401-1" escape="true">The following table presents disaggregated revenue generated by payer type for the three months ended March&#160;31, 2024 and 2023 (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-401-1"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-402">49,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-403">40,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-404">246,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-405">216,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-406">81,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-407">67,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other third parties</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-408">27,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-409">13,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-410">404,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-411">337,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="text-align:center"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" id="f-412" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payers that contributed the following percentages of net revenue:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payer A</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-68" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-413">34.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-69" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-414">41.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payer B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-70" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-415">13.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> *Less than 10% of total net revenues</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payers that contributed to the following percentages of receivables and receivables &#8211; related parties:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payer A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-71" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-416">31.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-72" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-417">36.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payer C</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-73" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-418">33.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-74" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-419">41.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-420" continuedAt="f-420-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives payments from the following sources for services rendered:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Commercial insurers;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Federal government under the Medicare program administered by CMS;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">State governments under Medicaid and other programs;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Other third-party payers (e.g., hospitals and IPAs); and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Individual patients and clients.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="f-388-4" continuedAt="f-388-5"><ix:continuation id="f-420-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue primarily consists of the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Capitation revenue;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk pool settlements and incentives;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Management fee revenue; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FFS revenue.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk Pool Settlements and Incentives</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Shared Savings Program Revenue</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2024, Astrana participates in MSSP. The MSSP has multiple risk tracks, and Astrana is currently participating in the ENHANCED risk track. Under the MSSP Model, Astrana recruits a group of Participant and Preferred (in-network) Providers. Based on the Participant Providers that join our ACO, CMS grants us a pool of Traditional Medicare patients (beneficiaries) to manage (the &#8220;MSSP Aligned Beneficiaries&#8221;). The Company&#8217;s MSSP Aligned Beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. CMS continues to pay participant and preferred providers on a fee-for-service basis for Medicare-covered services provided to MSSP Aligned Beneficiaries. The Company continues to bear risk on all Medicare expenditures (both in-network and out-of-network), excluding drug expenditures covered by Medicare Part D, based on a budgetary benchmark established with CMS. Astrana&#8217;s shared savings or losses in managing the Company&#8217;s beneficiaries are generally determined on an annual basis after reconciliation with CMS. Pursuant to Astrana&#8217;s risk-share agreement with CMS, the Company is eligible to receive the surplus (&#8220;shared savings&#8221;) or is liable for the deficit (&#8220;shared losses&#8221;) according to the budgetary benchmark established by CMS based on Astrana&#8217;s efficiency, or lack thereof, in managing the expenditures associated with the Company&#8217;s MSSP Aligned Beneficiaries. The Company estimates the shared service revenue by analyzing the activities during the relevant time period in contemplation of the agreed upon benchmarks, metrics, performance criteria, and attribution criteria based on those and any other contractually defined factors. Revenue is not recorded and is constrained until the shared service revenue can be reasonably estimated by the Company and to the extent that it is probable that a significant reversal will not occur once any uncertainty associated with the variable consideration is subsequently resolved.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-421" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted for both items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the condensed consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the condensed consolidated financial statements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-422" continuedAt="f-422-1" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-07 "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures," which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for the Company&#8217;s annual periods beginning January 1, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on its financial statement disclosures.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="f-422-1"><ix:continuation id="f-388-5"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for the Company&#8217;s annual periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on its financial statement disclosures.</span></div></ix:continuation></ix:continuation><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_52"></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="f-423" continuedAt="f-423-1" escape="true">Business Combinations, Asset Acquisitions, and Goodwill</ix:nonNumeric></span></div><ix:continuation id="f-423-1" continuedAt="f-423-2"><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advanced Health Management Systems, L.P. (&#8220;AHMS&#8221;)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2024, the Company, through its wholly owned subsidiary, purchased all of the outstanding general and limited partnership interests of Advanced Health Management Systems, L.P. (&#8220;AHMS&#8221;). AHMS is engaged in the business of providing management, consulting, administrative and other support services to entities that provide or arrange for the provision of professional healthcare services. In addition, one of AHMS&#8217;s wholly owned subsidiaries is a Restricted Knox-Keene licensed health plan with members in the Los Angeles, California area. Total consideration for the acquisition was $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="f-424">63.9</ix:nonFraction> million. As the cash was not paid on the closing date, the purchase price was accrued and presented within accounts payable and accrued expenses in the accompanying condensed consolidated balance sheet as of March&#160;31, 2024. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prime Community Care of Central Valley, Inc. (&#8220;PCCCV&#8221;)</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 29, 2024, the Company, through its consolidated subsidiary, acquired certain assets of Prime Community Care of Central Valley, Inc., a California professional medical corporation (&#8220;PCCCV&#8221;). Total consideration of the acquisition was approximately $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="f-425">10.3</ix:nonFraction> million, consisting of cash funded upon the close date and contingent considerations of $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-5" name="asth:ContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="f-426">2.3</ix:nonFraction> million (&#8220;PCCCV contingent considerations&#8221;). Refer to Note 19 - &#8220;Fair Value Measurements of Financial Instruments&#8221; for additional information on contingent considerations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Community Family Care Medical Group IPA, Inc. (&#8220;CFC&#8221;)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2024, the Company, through its consolidated subsidiary, acquired certain assets of CFC. CFC is an IPA that manages the healthcare of members in the Los Angeles, California area. The group serves patients across Medicare, Medicaid, and Commercial payers. The total consideration for the purchase was $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="f-427">120.2</ix:nonFraction> million, consisting of $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" name="asth:ConsiderationOfAcquisitionInCashFunded" format="ixt:num-dot-decimal" scale="6" id="f-428">91.0</ix:nonFraction> million cash funded upon the close date, $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" name="asth:BusinessAcquisitionOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-429">22.0</ix:nonFraction> million of the Company&#8217;s common stock, resulting in the issuance of <ix:nonFraction unitRef="shares" contextRef="c-77" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-430">631,712</ix:nonFraction> shares of common stock., and contingent considerations of $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" name="asth:ContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="f-431">7.3</ix:nonFraction> million (&#8220;CFC contingent considerations&#8221;). Refer to Note 19 - &#8220;Fair Value Measurements of Financial Instruments&#8221; for additional information on contingent considerations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advanced Diagnostic and Surgical Center, Inc. (&#8220;ADSC&#8221;)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2024, the Company acquired <ix:nonFraction unitRef="number" contextRef="c-78" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="f-432">95</ix:nonFraction>% of the equity interest of Advanced Diagnostic and Surgical Center, Inc. (&#8220;ADSC&#8221;). ADSC is a diagnostic and surgical center that also provides ambulatory surgery services. The total consideration consisted of cash funded upon close of the transaction and contingent considerations of $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-433">3.6</ix:nonFraction> million (&#8220;ADSC contingent considerations&#8221;). Refer to Note 19 - &#8220;Fair Value Measurements of Financial Instruments&#8221; for additional information on contingent considerations.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="f-423-2" continuedAt="f-423-3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is still in the process of finalizing the purchase price allocation for these acquisitions, and therefore, the balances are subject to change as a result of any working capital or fair value adjustments, and seller indemnification obligations. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="f-434" continuedAt="f-434-1" escape="true">The following table summarizes the preliminary purchase price allocation of the fair value of assets acquired and liabilities assumed  related to each acquisition at the acquisition date (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-434-1" continuedAt="f-434-2"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.257%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CFC</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;AHMS </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Others *</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net &#160;Total </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Total purchase consideration: </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Cash paid </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="f-435">90,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:fixed-zero" scale="3" id="f-436">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="f-437">12,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="f-438">103,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Cash payable </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="asth:PaymentsToAcquireBusinessCashPayable" format="ixt:fixed-zero" scale="3" id="f-439">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="asth:PaymentsToAcquireBusinessCashPayable" format="ixt:num-dot-decimal" scale="3" id="f-440">63,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="asth:PaymentsToAcquireBusinessCashPayable" format="ixt:fixed-zero" scale="3" id="f-441">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="asth:PaymentsToAcquireBusinessCashPayable" format="ixt:num-dot-decimal" scale="3" id="f-442">63,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Contingent consideration </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="3" id="f-443">7,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:fixed-zero" scale="3" id="f-444">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="3" id="f-445">5,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="3" id="f-446">13,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Common stock issued </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="3" id="f-447">21,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:fixed-zero" scale="3" id="f-448">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:fixed-zero" scale="3" id="f-449">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="3" id="f-450">21,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="f-451">120,214</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="f-452">63,935</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="f-453">18,397</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="f-454">202,546</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Cash and cash equivalents </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-455">16,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-456">33,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-457">3,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-458">54,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Investment in marketable securities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" scale="3" id="f-459">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" format="ixt:fixed-zero" scale="3" id="f-460">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" scale="3" id="f-461">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" scale="3" id="f-462">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Receivables </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" format="ixt:num-dot-decimal" scale="3" id="f-463">5,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" format="ixt:num-dot-decimal" scale="3" id="f-464">11,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" format="ixt:fixed-zero" scale="3" id="f-465">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" format="ixt:num-dot-decimal" scale="3" id="f-466">17,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Prepaid expenses and other current assets </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" format="ixt:fixed-zero" scale="3" id="f-467">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="3" id="f-468">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="3" id="f-469">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="3" id="f-470">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts due from affiliates</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates" format="ixt:num-dot-decimal" scale="3" id="f-471">3,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates" format="ixt:fixed-zero" scale="3" id="f-472">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates" format="ixt:fixed-zero" scale="3" id="f-473">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates" format="ixt:num-dot-decimal" scale="3" id="f-474">3,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Land, property and equipment </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-475">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-476">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="3" id="f-477">823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="3" id="f-478">823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Intangible assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="f-479">26,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="f-480">23,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="f-481">2,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="f-482">52,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Goodwill </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-483">90,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-484">29,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-485">12,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-486">132,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Restricted cash </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash" format="ixt:fixed-zero" scale="3" id="f-487">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash" scale="3" id="f-488">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash" format="ixt:fixed-zero" scale="3" id="f-489">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash" scale="3" id="f-490">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable assets acquired</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" format="ixt:num-dot-decimal" scale="3" id="f-491">142,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" format="ixt:num-dot-decimal" scale="3" id="f-492">99,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" format="ixt:num-dot-decimal" scale="3" id="f-493">19,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" format="ixt:num-dot-decimal" scale="3" id="f-494">261,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Accounts payable and accrued expenses </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses" format="ixt:num-dot-decimal" scale="3" id="f-495">4,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses" format="ixt:num-dot-decimal" scale="3" id="f-496">7,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses" scale="3" id="f-497">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses" format="ixt:num-dot-decimal" scale="3" id="f-498">11,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Medical liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-499">17,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-500">13,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities" format="ixt:fixed-zero" scale="3" id="f-501">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-502">30,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts due to affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates" format="ixt:fixed-zero" scale="3" id="f-503">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates" format="ixt:num-dot-decimal" scale="3" id="f-504">7,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates" scale="3" id="f-505">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates" format="ixt:num-dot-decimal" scale="3" id="f-506">7,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Income taxes payable </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable" scale="3" id="f-507">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable" format="ixt:num-dot-decimal" scale="3" id="f-508">1,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable" format="ixt:fixed-zero" scale="3" id="f-509">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable" format="ixt:num-dot-decimal" scale="3" id="f-510">1,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Deferred tax liability </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:fixed-zero" scale="3" id="f-511">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-512">6,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="3" id="f-513">271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-514">6,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Noncontrolling interest </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-515">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-516">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest" scale="3" id="f-517">428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest" scale="3" id="f-518">428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identified liabilities assumed</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-519">21,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-520">35,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-521">1,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-522">58,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total net identifiable assets acquired </span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-523">120,214</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-524">63,935</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-525">18,397</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-526">202,546</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Others consist of estimated fair values of the assets acquired, net of cash acquired, related to ADSC and PCCCV.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>Following the acquisition dates of CFC, AHMS, ADSC and PCCCV, the operating results have been included in our consolidated financial statements. For the period from the acquisition dates through March&#160;31, 2024, total revenues and net income were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" format="ixt:num-dot-decimal" scale="6" id="f-527">33.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" format="ixt:num-dot-decimal" scale="6" id="f-528">5.1</ix:nonFraction> million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Pro Forma Financial Information</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pro forma financial information in the table below presents the combined results of the Company and CFC, AHMS, ADSC and PCCCV as if the acquisitions had occurred on January 1, 2023. The pro forma information presented is shown for illustrative purposes only and is not necessarily indicative of future results of operations of the Company or results of operations of the Company that would have actually occurred had the transactions been in effect for the periods presented.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="f-423-3"><ix:continuation id="f-434-2"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except per share amounts)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="f-529">493,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="f-530">382,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-531">16,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-532">20,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - basic</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" scale="0" id="f-533">0.35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" scale="0" id="f-534">0.44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" scale="0" id="f-535">0.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" scale="0" id="f-536">0.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisitions were accounted for under the acquisition method of accounting. The fair value of the consideration for the acquired companies was allocated to acquired tangible and intangible assets and liabilities based upon their fair values. The excess of the purchase consideration over the fair value of the net tangible and identifiable intangible assets acquired was recorded as goodwill. Factors leading to goodwill being recognized are the Company&#8217;s expectation of synergies from combining operations of entities acquired and the Company, as well as the value of intangible assets that are not separately recognized, such as assembled workforce. The determination of the fair value of assets and liabilities acquired requires the Company to make estimates and use valuation techniques when market value is not readily available. The results of operations from the acquisitions have been included in the Company&#8217;s financial statements from the date of acquisition. Transaction costs associated with business acquisitions are expensed as they are incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time of acquisition, the Company estimates the amount of the identifiable intangible assets based on a valuation and the facts and circumstances available at the time. The Company determines the final value of the identifiable intangible assets as soon as information is available, but not more than one year from the date of acquisition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not deductible for tax purposes. The Company had <ix:nonFraction unitRef="usd" contextRef="c-27" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-537"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-538">no</ix:nonFraction></ix:nonFraction> impairment of its goodwill or indefinite-lived intangible assets during the three months ended March&#160;31, 2024 and 2023. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfGoodwillTextBlock" id="f-539" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying value of goodwill for the three months ended March&#160;31, 2024 was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:81.330%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-540">278,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="f-541">132,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GoodwillPurchaseAccountingAdjustments" scale="3" id="f-542">906</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-543">410,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="f-544" continuedAt="f-544-1" escape="true">Intangible Assets, Net</ix:nonNumeric></span></div><ix:continuation id="f-544-1" continuedAt="f-544-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="f-545" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2024, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.449%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net March 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-546">2,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-547">2,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-548">1,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-549">1,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized intangible assets:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Network relationships</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-87" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-550">11</ix:nonNumeric>-<ix:nonNumeric contextRef="c-88" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-551">21</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-552">155,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-553">107,137</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-554">48,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-90" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-555">15</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-556">22,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-557">17,002</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-558">5,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Member relationships</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-91" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-559">7</ix:nonNumeric>-<ix:nonNumeric contextRef="c-92" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-560">14</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-561">69,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-562">9,154</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-563">60,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient management platform</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-94" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-564">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-565">2,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-566">2,060</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="f-567">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tradename/trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-95" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-568">20</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-569">1,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="f-570">320</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="f-571">691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developed technology </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-96" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-572">6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="f-573">107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="f-574">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="f-575">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-576">255,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-577">135,712</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-578">119,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.449%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-579">2,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-580">2,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Network relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-98" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-581">11</ix:nonNumeric>-<ix:nonNumeric contextRef="c-99" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-582">21</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-583">150,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-584">104,859</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-585">45,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-101" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-586">15</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-587">22,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-588">16,662</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-589">6,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-102" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-590">10</ix:nonNumeric>-<ix:nonNumeric contextRef="c-103" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-591">14</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-592">24,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-593">7,345</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-594">16,732</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient management platform</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-105" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-595">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-596">2,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-597">2,060</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="f-598">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tradename/trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-106" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-599">20</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-600">1,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="f-601">308</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="f-602">703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-107" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-603">6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="f-604">107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="f-605">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="f-606">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-607">202,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-608">131,268</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-609">71,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2024 and 2023, the Company recognized amortization expenses of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-610">4.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-611">3.0</ix:nonFraction> million, respectively, in depreciation and amortization on the accompanying condensed consolidated statements of income. The Company determined that there was <ix:nonFraction unitRef="usd" contextRef="c-27" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="f-612"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="f-613">no</ix:nonFraction></ix:nonFraction> impairment of its finite-lived intangible or long-lived assets during the three months ended March&#160;31, 2024 and 2023.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-614" continuedAt="f-614-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense is estimated to be as follows for the following years ending December&#160;31 (in thousands):</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="f-614-1"><ix:continuation id="f-544-2"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.444%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (excluding the three months ended March 31, 2024)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="f-615">20,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-616">22,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-617">18,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="f-618">14,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="f-619">12,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="asth:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="f-620">28,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-621">115,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_61"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="asth:EquityMethodAndOtherEquityInvestmentsTextBlock" id="f-622" continuedAt="f-622-1" escape="true">Investments in Other Entities</ix:nonNumeric></span></div><ix:continuation id="f-622-1" continuedAt="f-622-2"><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Equity Method</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EquityMethodInvestmentsTextBlock" id="f-623" continuedAt="f-623-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2024 and 2023, the Company&#8217;s equity method investment balance consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:23.497%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.734%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.349%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Ownership</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Initial Investment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allocation of Net Income </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Distribution </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LaSalle Medical Associates &#8211; IPA line of business</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-108" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-624">25</ix:nonFraction>%</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-625">9,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="asth:EquityMethodInvestmentAdditionalInvestment" format="ixt:fixed-zero" scale="0" id="f-626">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="f-627">359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:fixed-zero" scale="3" id="f-628">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-629">10,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pacific Medical Imaging &amp; Oncology Center, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-111" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-630">40</ix:nonFraction>%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-631">1,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="asth:EquityMethodInvestmentAdditionalInvestment" format="ixt:fixed-zero" scale="3" id="f-632">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="f-633">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:fixed-zero" scale="3" id="f-634">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-635">1,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAIPA MSO, LLC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-114" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-636">30</ix:nonFraction>%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-637">13,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="asth:EquityMethodInvestmentAdditionalInvestment" format="ixt:fixed-zero" scale="3" id="f-638">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="f-639">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:fixed-zero" scale="3" id="f-640">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-641">13,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-117" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-642">25</ix:nonFraction>%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-643">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="asth:EquityMethodInvestmentAdditionalInvestment" format="ixt:num-dot-decimal" scale="3" id="f-644">9,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-645">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:fixed-zero" scale="3" id="f-646">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-647">9,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other *</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-120" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-648">25</ix:nonFraction>%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="3" id="f-649">557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="asth:EquityMethodInvestmentAdditionalInvestment" format="ixt:fixed-zero" scale="3" id="f-650">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="f-651">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:fixed-zero" scale="3" id="f-652">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="3" id="f-653">617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-654">25,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="asth:EquityMethodInvestmentAdditionalInvestment" format="ixt:num-dot-decimal" scale="3" id="f-655">9,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="f-656">632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:fixed-zero" scale="3" id="f-657">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-658">35,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:23.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.350%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Ownership</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Initial Investment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allocation of Net Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Distribution </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LaSalle Medical Associates &#8211; IPA line of business</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-123" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-659">25</ix:nonFraction>%</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-660">5,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="asth:EquityMethodInvestmentAdditionalInvestment" format="ixt:fixed-zero" scale="0" id="f-661">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-662">2,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:fixed-zero" scale="3" id="f-663">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-664">7,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pacific Medical Imaging &amp; Oncology Center, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-126" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-665">40</ix:nonFraction>%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-666">1,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="asth:EquityMethodInvestmentAdditionalInvestment" format="ixt:fixed-zero" scale="3" id="f-667">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="f-668">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:fixed-zero" scale="3" id="f-669">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-670">1,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531 W. College, LLC **</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-129" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-671">50</ix:nonFraction>%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-672">17,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="asth:EquityMethodInvestmentAdditionalInvestment" format="ixt:fixed-zero" scale="3" id="f-673">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="f-674">90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:fixed-zero" scale="3" id="f-675">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-676">17,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One MSO, LLC **</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-132" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-677">50</ix:nonFraction>%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-678">2,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="asth:EquityMethodInvestmentAdditionalInvestment" format="ixt:fixed-zero" scale="3" id="f-679">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="f-680">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:fixed-zero" scale="3" id="f-681">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-682">2,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAIPA MSO, LLC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-135" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-683">30</ix:nonFraction>%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-684">12,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="asth:EquityMethodInvestmentAdditionalInvestment" format="ixt:fixed-zero" scale="3" id="f-685">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="f-686">249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:fixed-zero" scale="3" id="f-687">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-688">12,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other *</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-138" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-689">25</ix:nonFraction>%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-690">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="asth:EquityMethodInvestmentAdditionalInvestment" scale="3" id="f-691">325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="f-692">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:fixed-zero" scale="3" id="f-693">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="3" id="f-694">362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-695">40,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="asth:EquityMethodInvestmentAdditionalInvestment" scale="3" id="f-696">325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-697">2,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:fixed-zero" scale="3" id="f-698">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-699">43,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Other consists of smaller equity method investments. </span></div></ix:nonNumeric><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-623-1">** Investment were solely for the benefit of APC and its shareholders.</ix:continuation> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">I Health, Inc. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2024, a wholly owned subsidiary of the Company acquired a <ix:nonFraction unitRef="number" contextRef="c-117" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-700">25</ix:nonFraction>% equity interest in I Health, Inc. (&#8220;I Health&#8221;), a management service organization. The Company accounts for its investment in I Health under the equity method of accounting as the Company has the ability to exercise significant influence, but not control over I Health&#8217;s operations. The purchase agreement includes a call option that allows the Company to purchase an additional <ix:nonFraction unitRef="number" contextRef="c-117" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-701">25</ix:nonFraction>% equity interest on each of the first, second and third anniversary of the purchase (&#8220;I Health Call Option&#8221;). The cash consideration was not paid on the closing date, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="f-622-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and was accrued and presented within accounts payable and accrued expenses and other liabilities in the accompanying condensed consolidated balance sheets. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:fixed-zero" scale="0" id="f-702"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="INF" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:fixed-zero" scale="0" id="f-703">no</ix:nonFraction></ix:nonFraction> impairment loss recorded related to equity method investments for the three months ended March&#160;31, 2024 and 2023.</span></div></ix:continuation><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_67"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="asth:LoanReceivableTextBlock" id="f-704" continuedAt="f-704-1" escape="true">Loans Receivable</ix:nonNumeric></span></div><ix:continuation id="f-704-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loans receivable</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IntraCare </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, the Company entered into a <ix:nonNumeric contextRef="c-141" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-705">five-year</ix:nonNumeric> convertible promissory note with IntraCare as the borrower. The principal on the note is $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-706">25.0</ix:nonFraction> million, with interest on the outstanding principal amount and unpaid interest at a rate per annum equal to <ix:nonFraction unitRef="number" contextRef="c-142" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-707">8.81</ix:nonFraction>%, compounded annually. In the event that the convertible promissory note remains outstanding on or after the maturity date of July&#160;27, 2028, the outstanding principal balance and any unpaid accrued interest shall, upon the election of the Company, convert into IntraCare preferred shares.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BASS Medical Group</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 29, 2024, the Company provided BASS Medical Group (&#8220;BASS&#8221;) with a $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-708">20.0</ix:nonFraction> million senior secured promissory note (&#8220;BASS secured promissory note&#8221;). The promissory note is secured by certain assets of BASS. BASS secured promissory note matures on January 11, 2031, and has an interest rate per annum equal to <ix:nonFraction unitRef="number" contextRef="c-143" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-709">8.21</ix:nonFraction>% compounded annually. The principal on the note, including unpaid interest, are due and payable on the maturity date.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the outstanding loans receivable under the CECL model by assessing the party&#8217;s ability to pay by reviewing their interest payment history quarterly, financial history annually, and reassessing any identified insolvency risk.</span></div></ix:continuation><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_73"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="f-710" continuedAt="f-710-1" escape="true">Accounts Payable and Accrued Expenses</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="f-711" escape="true"><ix:continuation id="f-710-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts payable and accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other accruals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-712">84,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-713">9,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitation payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="asth:SpecialtyCapitationPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-714">10,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="asth:SpecialtyCapitationPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-715">4,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subcontractor IPA payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="asth:SubcontractorIPAPayable" format="ixt:num-dot-decimal" scale="3" id="f-716">2,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="asth:SubcontractorIPAPayable" format="ixt:num-dot-decimal" scale="3" id="f-717">2,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-718">5,293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-719">4,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due to related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RelatedPartyDepositLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-720">11,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RelatedPartyDepositLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-721">9,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-722">3,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="f-723">744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-724">12,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-725">20,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other provider payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-726">16,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-727">9,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-728">146,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-729">59,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_76"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" id="f-730" continuedAt="f-730-1" escape="true">Medical Liabilities</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" id="f-731" escape="true"><ix:continuation id="f-730-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s medical liabilities consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-732">106,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-733">81,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired (see Note 3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-734">30,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" format="ixt:fixed-zero" scale="3" id="f-735">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-736">235,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-737">223,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-738">1,419</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-739">8,950</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="3" id="f-740">233,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="3" id="f-741">214,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="f-742">136,286</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="f-743">136,743</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="f-744">97,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="f-745">61,736</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-746">234,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-747">198,479</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" scale="3" id="f-748">503</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" scale="3" id="f-749">857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-750">136,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-751">98,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_79"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-752" continuedAt="f-752-1" escape="true">Credit Facility, Bank Loans, and Lines of Credit</ix:nonNumeric></span></div><ix:continuation id="f-752-1" continuedAt="f-752-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock" id="f-753" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s debt balance consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:63.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.471%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-754">296,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-755">280,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolver Loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-756">94,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="3" id="f-757">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Promissory Note Payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-758">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-759">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-760">393,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-761">282,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-762">20,750</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-763">19,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-764">4,061</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-765">3,561</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-766">368,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-767">258,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our long-term debt was determined using Level 2 inputs primarily related to comparable market prices. As of March&#160;31, 2024, and December&#160;31, 2023, the carrying value was not materially different from fair value, as the interest rates on the Company&#8217;s debt approximated rates currently available to the Company.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="f-768" continuedAt="f-768-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the future commitments of the Company&#8217;s debt for the years ending December 31 (in thousands):</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="f-752-2" continuedAt="f-752-3"><ix:continuation id="f-768-1"><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:81.330%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (excluding the three months ended March 31, 2024)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="f-769">17,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-770">16,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-771">117,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="f-772">24,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="3" id="f-773">217,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="3" id="f-774">393,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended Credit Facility</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amended Credit Agreement</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2021, the Company entered into an amended and restated credit agreement (as subsequently amended as described below, the &#8220;Amended Credit Agreement&#8221;) with Truist Bank, in its capacity as administrative agent for the lenders, issuing bank, swingline lender and lender, and the banks and other financial institutions from time to time party thereto, to, among other things, to amend and restate that certain credit agreement, dated September 11, 2019, by and among the Company, Truist Bank, and certain lenders thereto, in its entirety. The Amended Credit Agreement provides for a <ix:nonNumeric contextRef="c-150" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-775">five-year</ix:nonNumeric> revolving credit facility (the &#8220;Amended Credit Facility&#8221;) to the Company of $<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-776">400.0</ix:nonFraction> million (&#8220;Revolver Loan&#8221;), which includes a letter of credit sub-facility of up to $<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-777">25.0</ix:nonFraction> million (which was amended to $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-778">50.0</ix:nonFraction>&#160;million, as described below) and a swingline loan sub-facility of $<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-779">25.0</ix:nonFraction> million and which expires on June&#160;16, 2026. As of March&#160;31, 2024, the Company borrowed $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="f-780">94.8</ix:nonFraction> million on the Revolver Loan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 20, 2022, an amendment was made to the Amended Credit Agreement, in which all amounts borrowed under the Amended Credit Agreement as of the effective date were automatically converted from London Interbank Offer Rate (&#8220;LIBOR&#8221;) Loans to Secured Overnight Financing Rate (&#8220;SOFR&#8221;) Loans with an initial interest period of one month on and as of the amendment effective date. Amounts borrowed under the Revolver Loan bear interest at an annual rate equal to either, at the Company&#8217;s option, (a) the Term SOFR Reference Rate (as defined in the Amended Credit Agreement), adjusted for any Term SOFR Adjustment (as defined in the Amended Credit Agreement) plus a spread ranging from <ix:nonFraction unitRef="number" contextRef="c-155" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-781">1.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-156" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-782">2.50</ix:nonFraction>%, as determined on a quarterly basis based on the Company&#8217;s Consolidated Total Net Leverage Ratio (as defined in the Amended Credit Agreement), or (b) a base rate, plus a spread ranging from <ix:nonFraction unitRef="number" contextRef="c-157" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-783">0.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-158" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-784">1.50</ix:nonFraction>%, as determined on a quarterly basis based on the Company&#8217;s Consolidated Total Net Leverage Ratio.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, the interest rate on the Revolver Loan was <ix:nonFraction unitRef="number" contextRef="c-159" decimals="4" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="f-785">7.42</ix:nonFraction>%. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 8, 2023, a Second Amendment to the Amended Credit Agreement was entered into, which, among other things, increased the letter of credit sub-facility from $<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-786">25.0</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-787">50.0</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 3, 2023, the Company entered into a Third Amendment to the Amended Credit Agreement (&#8220;Third Amendment&#8221;) with Truist Bank and the other financial institutions party thereto. The Third Amendment provided a new term loan to the Company in an aggregate amount of up to $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="INF" name="asth:LineOfCreditFacilityAmountFundedAtClosing" format="ixt:num-dot-decimal" scale="6" id="f-788">300.0</ix:nonFraction>&#160;million, with $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-789">180.0</ix:nonFraction>&#160;million funded at the closing of the Third Amendment, and $<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="us-gaap:ProceedsFromRepaymentsOfBankOverdrafts" format="ixt:num-dot-decimal" scale="6" id="f-790">120.0</ix:nonFraction>&#160;million available to be drawn by the Company as delayed draw loans during the six months subsequent to the closing of the Third Amendment (collectively, the &#8220;Term Loan&#8221;). The Term Loan matures on November 3, 2028 (or such earlier date on which it is terminated in accordance with the provisions of the Amended Credit Agreement) and amortizes quarterly at <ix:nonFraction unitRef="number" contextRef="c-163" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-791">5</ix:nonFraction>% per annum for each of the first two years, <ix:nonFraction unitRef="number" contextRef="c-164" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-792">7.5</ix:nonFraction>% per annum for years three and four, and <ix:nonFraction unitRef="number" contextRef="c-165" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-793">10</ix:nonFraction>% per annum for year five. As of  March&#160;31, 2024, the Company borrowed $<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-794">296.5</ix:nonFraction> million on the Term Loan.  The Term Loan bears interest at an annual rate equal to either, at the Company&#8217;s option, (a) the Term SOFR Reference Rate, adjusted for any Term SOFR Adjustment, plus a spread from <ix:nonFraction unitRef="number" contextRef="c-167" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-795">1.50</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-168" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-796">2.75</ix:nonFraction>%, as determined on a quarterly basis based on the Company&#8217;s Consolidated Total Net Leverage Ratio, or (b) a base rate, plus a spread of <ix:nonFraction unitRef="number" contextRef="c-169" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-797">0.50</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-170" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-798">1.75</ix:nonFraction>%, as determined on a quarterly basis based on the Company&#8217;s Consolidated Total Net Leverage Ratio. As of March&#160;31, 2024, the interest rate on the Term Loan was <ix:nonFraction unitRef="number" contextRef="c-171" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-799">7.68</ix:nonFraction>%. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement requires the Company to comply with <ix:nonFraction unitRef="financial_ratio" contextRef="c-172" decimals="INF" name="asth:DebtInstrumentNumberOfKeyFinancialRatios" format="ixt-sec:numwordsen" scale="0" id="f-800">two</ix:nonFraction> key financial ratios, each calculated on a consolidated basis. The Company must maintain a maximum consolidated total net leverage ratio of not greater than <ix:nonFraction unitRef="number" contextRef="c-172" decimals="INF" name="asth:DebtInstrumentCovenantLeverageRatioMaximum" scale="0" id="f-801">3.75</ix:nonFraction> to 1.00 as of the last day of each fiscal quarter, provided that for any fiscal quarter during which the Company or certain subsidiaries consummate a permitted acquisition or investment, the aggregate purchase price is greater than $<ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" name="asth:DebtCovenantAggregatePurchasePriceMaximum" format="ixt:num-dot-decimal" scale="6" id="f-802">75.0</ix:nonFraction>&#160;million, the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="f-752-3"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">maximum consolidated total net leverage ratio may temporarily increase by <ix:nonFraction unitRef="number" contextRef="c-172" decimals="INF" name="asth:DebtInstrumentCovenantLeverageRatioIncrementalChange" scale="0" id="f-803">0.25</ix:nonFraction> to 1.00 to <ix:nonFraction unitRef="number" contextRef="c-172" decimals="INF" name="asth:DebtInstrumentCovenantLeverageRatioAdjustedMaximum" scale="0" id="f-804">4.00</ix:nonFraction> to 1.00. The Company must maintain a minimum consolidated interest coverage ratio of not less than <ix:nonFraction unitRef="number" contextRef="c-171" decimals="INF" name="asth:DebtInstrumentCovenantInterestCoverageRatioMinimum" scale="0" id="f-805">3.25</ix:nonFraction> to 1.00 as of the last day of each fiscal quarter.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Amended Credit Agreement, the terms and conditions of the Guaranty and Security Agreement (the &#8220;Guaranty and Security Agreement&#8221;) between the Company, Astrana Health Management, Inc. (&#8220;AHM&#8221;) and Truist Bank remain in effect. Pursuant to the Guaranty and Security Agreement, the Company and AHM have granted the lenders under the Amended Credit Agreement a security interest in substantially all of their assets to secure obligations under the Amended Credit Agreement, including, without limitation, all stock and other equity issued by their subsidiaries (including AHM) and all rights with respect to the $<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="6" id="f-806">545.0</ix:nonFraction>&#160;million loan from the Company to Astrana Medical.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Promissory Note Payable</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FYB Promissory Note Agreement with CCHCA</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, For Your Benefit, Inc. entered into a promissory note agreement with Chinese Community Health Care Association. The principal on the promissory note is $<ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-807">2.0</ix:nonFraction>&#160;million, with a maturity date of May&#160;9, 2024. The interest rate is the prime rate plus <ix:nonFraction unitRef="number" contextRef="c-175" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-808">1.0</ix:nonFraction>%. The prime rate is updated annually on the effective date of the note and published by the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Financing Costs</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2024, and December&#160;31, 2023, the unamortized deferred financing cost was $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="asth:UnamortizedDeferredFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="f-809">5.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="asth:UnamortizedDeferredFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="f-810">6.1</ix:nonFraction>&#160;million, respectively. As of March&#160;31, 2024 and December&#160;31, 2023, $<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="f-811">1.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="f-812">2.6</ix:nonFraction>&#160;million, respectively, of unamortized deferred financing costs was recognized in prepaid expenses and other current assets in the accompanying condensed consolidated balance sheets and consisted of unamortized deferred financing costs related to unborrowed amounts available on the Revolver Loan. As of March&#160;31, 2024, and December&#160;31, 2023, $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="f-813">4.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="f-814">3.6</ix:nonFraction>&#160;million, respectively, of unamortized deferred financing costs was recorded as a direct reduction against the amounts borrowed on the Term Loan and Revolver.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effective Interest Rate</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s average effective interest rate on its total debt during the three months ended March&#160;31, 2024 and 2023, was <ix:nonFraction unitRef="number" contextRef="c-27" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-815">6.51</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-816">5.69</ix:nonFraction>%, respectively. Interest expense in the condensed consolidated statements of income included amortization of deferred debt issuance costs for the three months ended March&#160;31, 2024 and 2023 of $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="f-817">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="f-818">0.2</ix:nonFraction> million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lines of Credit</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">APC Business Loan</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;10, 2019, the APC Business Loan Agreement with Preferred Bank (the &#8220;APC Business Loan Agreement&#8221;) was amended to, among other things, decrease loan availability to $<ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-819">4.1</ix:nonFraction> million, limit the purpose of the indebtedness under the APC Business Loan Agreement to the issuance of standby letters of credit, and include as a permitted lien, the security interest in all of its assets that APC granted to AHM under a Security Agreement dated on or about September 11, 2019, securing APC&#8217;s obligations to AHM under their management services agreement dated as of July 1, 1999, as amended.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standby Letters of Credit</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company established irrevocable standby letters of credit with Truist Bank under the Amended Credit Agreement for a total of $<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-820">31.8</ix:nonFraction> million for the benefit of CMS and certain health plans. Unless the institution provides notification that the standby letters of credit will be terminated prior to the expiration date, the letters will be automatically extended without amendment for additional <ix:nonNumeric contextRef="c-181" name="us-gaap:LineOfCreditFacilityExpirationPeriod" format="ixt-sec:durwordsen" id="f-821">one-year</ix:nonNumeric> periods from the present or any future expiration date.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain IPAs consolidated by the Company established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-822">3.9</ix:nonFraction> million for the benefit of certain health plans as of March&#160;31, 2024. The standby letters of credit are automatically extended without amendment for additional <ix:nonNumeric contextRef="c-183" name="us-gaap:LineOfCreditFacilityExpirationPeriod" format="ixt-sec:durwordsen" id="f-823">one-year</ix:nonNumeric> periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-824" continuedAt="f-824-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mezzanine and Stockholders&#8217; Equity</span></ix:nonNumeric></div><ix:continuation id="f-824-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Mezzanine Equity</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">APC</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the redemption feature of the APC shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as non-controlling interests in APC as mezzanine or temporary equity. APC&#8217;s shares were not redeemable, and it was not probable that the shares would become redeemable as of March&#160;31, 2024 and December&#160;31, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Stockholders&#8217; Equity</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="asth:StockIssuedDuringPeriodSharesMerger" format="ixt:num-dot-decimal" scale="0" id="f-825">41,048</ix:nonFraction> holdback shares have not been issued to certain former AHM shareholders who were AHM shareholders at the time of closing of the 2017 merger of Astrana with AHM, as they have yet to submit properly completed letters of transmittal to Astrana in order to receive their pro rata portion of Astrana common stock as contemplated under the 2017 merger agreement. Pending such receipt, such former AHM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the 2017 Merger. The condensed consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares in connection with the 2017 merger.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury Stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of  March&#160;31, 2024, and December&#160;31, 2023, APC owned <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-826"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-827">7,132,698</ix:nonFraction></ix:nonFraction> shares of Astrana&#8217;s common stock. While such shares of Astrana&#8217;s common stock are legally issued and outstanding, they are treated as treasury shares for accounting purposes and excluded from shares of common stock outstanding in the condensed consolidated financial statements. APC&#8217;s ownership in Astrana was <ix:nonFraction unitRef="number" contextRef="c-184" decimals="4" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-828">13.04</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-185" decimals="4" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-829">13.22</ix:nonFraction>% as of March&#160;31, 2024, and December&#160;31, 2023, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, and December&#160;31, 2023, the Company had previously repurchased <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="f-830"><ix:nonFraction unitRef="shares" contextRef="c-186" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="f-831">3,451,642</ix:nonFraction></ix:nonFraction> shares of its common stock. These are included as treasury stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of both March&#160;31, 2024, and December&#160;31, 2023, the total treasury stock, including the Company&#8217;s stock held by APC, was <ix:nonFraction unitRef="shares" contextRef="c-187" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-832"><ix:nonFraction unitRef="shares" contextRef="c-188" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-833">10,584,340</ix:nonFraction></ix:nonFraction>.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 and 2023, certain consolidated subsidiaries of the Company paid distributions of $<ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-5" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-834">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-5" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-835">0.1</ix:nonFraction>&#160;million, respectively, to the shareholders who own the non-controlling interests in the entities.</span></div></ix:continuation><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_91"></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-836" continuedAt="f-836-1" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-837" escape="true"><ix:continuation id="f-836-1" continuedAt="f-836-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock-based compensation expense recognized under all of the Company&#8217;s stock plans for the three months ended March&#160;31, 2024 and 2023, and associated with the issuance of restricted shares of common stock and vesting of stock options that are included in general and administrative expenses in the accompanying condensed consolidated statements of income (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-838">349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-839">566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-840">5,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-841">2,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-842">5,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-843">3,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="f-836-2" continuedAt="f-836-3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized compensation expense related to total share-based payments outstanding as of March&#160;31, 2024, was $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="f-844">42.4</ix:nonFraction> million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Options</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-845" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding stock options consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding at January&#160;1, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-846">504,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-847">34.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-186" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-848">2.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="f-849">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="f-850">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-851">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="f-852">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-853">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-854">7,271</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-855">50.56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-856">496,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-857">33.79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-858">1.61</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="f-859">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-860">459,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-861">28.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-862">1.41</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="f-863">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024, <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="f-864">no</ix:nonFraction> options were exercised. During the three months ended March&#160;31, 2023, options were exercised for <ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-865">125,000</ix:nonFraction> shares of the Company&#8217;s common stock, resulting in proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="f-866">1.3</ix:nonFraction> million. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants restricted stock to officers and employees, which is earned based on service conditions. The grant date fair value of the restricted stock is the grant date&#8217;s closing market price of the Company&#8217;s common stock. During the three months ended March&#160;31, 2024, the Company granted <ix:nonFraction unitRef="shares" contextRef="c-196" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-867">296,428</ix:nonFraction> shares of restricted stock with performance-based conditions and <ix:nonFraction unitRef="shares" contextRef="c-196" decimals="INF" name="asth:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance" format="ixt:num-dot-decimal" scale="0" id="f-868">255,781</ix:nonFraction> shares of restricted stock without performance-based conditions. During the three months ended March&#160;31, 2024, the weighted average grant date fair value of restricted stock with and without performance-based conditions was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-197" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-869">43.88</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-196" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-870">40.65</ix:nonFraction>, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan (&#8220;ESPP&#8221;)</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-836-3">The Company&#8217;s ESPP is a shareholder-approved plan that allows eligible employees to contribute a portion of their eligible earnings toward the semi-annual purchase of the Company&#8217;s common stock at a discounted price equal to <ix:nonFraction unitRef="number" contextRef="c-198" decimals="INF" name="asth:CommonStockDiscountedPricePercentage" scale="-2" id="f-871">85</ix:nonFraction>% up to <ix:nonFraction unitRef="number" contextRef="c-198" decimals="INF" name="asth:CommonStockDiscountedPricePercentageMaximum" scale="-2" id="f-872">90</ix:nonFraction>% of the fair market values of the stock on the exercise date, subject to a maximum number of shares that can be purchased during any single offering period as well as an annual maximum dollar amount of shares during any single calendar year. A maximum of <ix:nonFraction unitRef="shares" contextRef="c-198" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-873">5,000,000</ix:nonFraction> shares were authorized for issuance at the time the Plan was approved. For the three months ended March&#160;31, 2024, there are no shares purchased by employees.</ix:continuation> </span></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_100"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-874" continuedAt="f-874-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-874-1" continuedAt="f-874-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Matters</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laws and regulations governing the Medicare program and healthcare generally are complex and subject to interpretation. The Company believes it complies with all applicable laws and regulations and is unaware of any pending or threatened investigations involving allegations of potential wrongdoing. While no regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and exclusion from the Medicare and Medi-Cal programs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a risk-bearing organization, the Company is required to follow regulations of the Department of Managed Health Care (&#8220;DMHC&#8221;). The Company must comply with a minimum working capital requirement, tangible net equity (&#8220;TNE&#8221;) </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="f-874-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirement, cash-to-claims ratio, and claims payment requirements prescribed by the DMHC. TNE is defined as net assets less intangibles, less non-allowable assets (which include amounts due from affiliates), plus subordinated obligations. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the Company&#8217;s payer and provider contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services. Such differing interpretations may not come to light until a substantial period of time has passed following contract implementation. Liabilities for claims disputes are recorded when the loss is probable and can be estimated. Any adjustments to reserves are reflected in current operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standby Letters of Credit</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company established irrevocable standby letters of credit with Truist Bank for a total of $<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-875">31.8</ix:nonFraction> million for the benefit of CMS and certain health plans as of March&#160;31, 2024 (see Note 9 &#8212; &#8220;Credit Facility, Bank Loans, and Lines of Credit &#8212; Standby Letters of Credit&#8221;). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain IPAs consolidated by the Company established irrevocable standby letters of credit with Preferred Bank for a total of $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-876">3.9</ix:nonFraction> million for the benefit of certain health plans as of March&#160;31, 2024 (see Note 9 &#8212; &#8220;Credit Facility, Bank Loans, and Lines of Credit &#8212; Standby Letters of Credit&#8221;). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of its business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company&#8217;s financial condition, cash flows, or results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability Insurance</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its insurance coverage is appropriate based upon the Company&#8217;s claims experience and the nature and risks of the Company&#8217;s business. In addition to the known incidents that have resulted in the assertion of claims, the Company cannot be certain that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against the Company, the Company&#8217;s affiliated professional organizations or the Company&#8217;s affiliated hospitalists in the future where the outcomes of such claims are unfavorable. The Company believes that the ultimate resolution of all pending claims, including liabilities in excess of the Company&#8217;s insurance coverage, will not have a material adverse effect on the Company&#8217;s financial position, results of operations, or cash flows; however, there can be no assurance that future claims will not have such a material adverse effect on the Company&#8217;s business. Contracted physicians are required to obtain their own insurance coverage.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company currently maintains liability insurance policies on a claims-made basis which are intended to cover malpractice liability and certain other claims, the coverage must be renewed annually, and may&#160;not continue to be available to the Company in future years at acceptable costs and on favorable terms.</span></div></ix:continuation><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_103"></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-877" continuedAt="f-877-1" escape="true">Related-Party Transactions</ix:nonNumeric></span></div><ix:continuation id="f-877-1" continuedAt="f-877-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Method Investments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, AHM recognized approximately $<ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-878">5.0</ix:nonFraction> million in management fees from LMA. On August 31, 2023, the management service agreement between LMA&#8217;s IPA and AHM was terminated. LMA is accounted for under the equity method based on the <ix:nonFraction unitRef="number" contextRef="c-200" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-879">25</ix:nonFraction>% equity ownership interest held by APC in LMA&#8217;s IPA line of business (see Note 5 &#8212; &#8220;Investments in Other Entities - Equity Method&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 and 2023, APC paid approximately $<ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="f-880">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="f-881">0.6</ix:nonFraction> million, respectively, to PMIOC for provider services. APC and PMIOC have an Ancillary Service Contract together whereby PMIOC provides covered services on behalf of APC to enrollees of the plans of APC. PMIOC is accounted for under the equity method based on the <ix:nonFraction unitRef="number" contextRef="c-203" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-882">40</ix:nonFraction>% equity ownership interest held by APC (see Note 5 &#8212; &#8220;Investments in Other Entities &#8212; Equity Method&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 and 2023, the Company paid approximately $<ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="f-883">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="f-884">0.2</ix:nonFraction> million, respectively, to James Song, M.D., a Professional Corporation (&#8220;Song PC&#8221;) for provider services. Song PC is accounted for </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="f-877-2" continuedAt="f-877-3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under the equity method based on the <ix:nonFraction unitRef="number" contextRef="c-206" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-885">25</ix:nonFraction>% equity ownership interest held by Astrana, as Astrana has the ability to exercise significant influence, but not control over, Song PC&#8217;s operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Astrana Board Members and Officers</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 and 2023, AHM recognized approximately $<ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-886">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-887">0.5</ix:nonFraction> million, respectively, in management fees from Arroyo Vista Family Health Center (&#8220;Arroyo Vista&#8221;). The Company has a managed service agreement with Arroyo Vista. Arroyo Vista&#8217;s chief executive officer is a member of the Company&#8217;s board of directors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 and 2023, the Company paid approximately $<ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="f-888">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="0" id="f-889">64,000</ix:nonFraction>, respectively, to Arroyo Vista for services as a provider. The Company has provider contracts with Arroyo Vista. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 , the Company incurred rent expenses of approximately $<ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="f-890">0.9</ix:nonFraction> million from certain properties that are managed by Allied Pacific Holdings Investment Management, LLC. During the three months ended March&#160;31, 2023, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="f-891">0.9</ix:nonFraction> million in rent expense from the same properties, but it was eliminated upon consolidation.  These properties were previously consolidated by Astrana until they were spun off on December 26, 2023. The chief executive officer of the real estate business managing these properties is also a member of the Company&#8217;s board of directors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024 and December&#160;31, 2023, the Company&#8217;s operating right-of-use asset balance included $<ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-892">12.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-893">14.1</ix:nonFraction> million, respectively, and the Company&#8217;s operating lease liabilities included $<ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-894">13.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-895">14.5</ix:nonFraction> million, respectively, for certain properties that are managed by Allied Pacific Holdings Investment Management, LLC.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 and 2023, the Company incurred approximately $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="asth:RelatedPartyExpensesPayable" format="ixt:num-dot-decimal" scale="6" id="f-896">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-5" name="asth:RelatedPartyExpensesPayable" format="ixt:num-dot-decimal" scale="6" id="f-897">0.4</ix:nonFraction> million in expenses payable to Third Way Health for call center services. One of Astrana&#8217;s officers is a board member of Third Way Health.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 and 2023, the Company paid approximately $<ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-3" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="0" id="f-898">45,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="f-899">0.2</ix:nonFraction> million, respectively, to Sunny Village Care Center for services as a provider. The Company has provider contracts with Sunny Village Care Center. Sunny Village Care Center shares common ownership with certain Astrana board members.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, Astrana paid approximately $<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-900">9.5</ix:nonFraction> million to purchase Astrana&#8217;s stock from a board member. The Company did <ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="0" id="f-901">not</ix:nonFraction> make any similar purchases during the three months ended March&#160;31, 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024, the Company incurred rent expenses of approximately $<ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-3" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="0" id="f-902">38,000</ix:nonFraction> to First Commonwealth Property, LLC for an office lease. First Commonwealth Property, LLC shares common ownership with certain board members of APC and AHM. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with Health Source MSO Inc., a California corporation (&#8220;HSMSO&#8221;), Aurion Corporation (&#8220;Aurion&#8221;), and AHMC for services provided to the Company. One of the Company&#8217;s board members is an officer of AHMC, HSMSO, and Aurion. Aurion is also partially owned by one of the Company&#8217;s board members. Revenue with AHMC and HSMSO consists of capitation, risk pool, and miscellaneous fees and expenses consisting of claims expenses, management fees, and consulting fees. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="f-903" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth revenue recognized and fees incurred related to AHMC, HSMSO, and Aurion for the three months ended March&#160;31, 2024 and 2023 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.138%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AHMC</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">HSMSO</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aurion</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AHMC</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">HSMSO</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aurion</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-3" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="3" id="f-904">9,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-3" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" id="f-905">301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:fixed-zero" scale="3" id="f-906">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="3" id="f-907">14,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" id="f-908">315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:fixed-zero" scale="3" id="f-909">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-3" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="3" id="f-910">7,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:fixed-zero" scale="3" id="f-911">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" id="f-912">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="3" id="f-913">6,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" id="f-914">169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" id="f-915">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="3" id="f-916">2,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-3" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" id="f-917">301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-3" sign="-" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" id="f-918">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-3" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="3" id="f-919">8,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-3" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" id="f-920">146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-3" sign="-" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" id="f-921">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and AHMC have a risk-sharing agreement with certain AHMC hospitals to share the surplus and deficits of each of the hospital pools. Under this agreement, during the three months ended March&#160;31, 2024 and 2023, the Company has recognized risk pool revenues of $<ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-922">8.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-923">13.0</ix:nonFraction> million, respectively. The Company has a risk pool receivable balance of $<ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-5" name="us-gaap:DeferredCreditsAndOtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-924">58.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-5" name="us-gaap:DeferredCreditsAndOtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-925">54.0</ix:nonFraction> million as of March&#160;31, 2024 and December&#160;31, 2023, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="f-877-3" continuedAt="f-877-4"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">APC Board Members</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 and 2023, the Company paid an aggregate of approximately $<ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="f-926">4.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="f-927">9.4</ix:nonFraction> million, respectively, to board members for provider services which included approximately $<ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="f-928">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="f-929">0.9</ix:nonFraction> million, respectively, to Astrana board members and officers who are also board members and officers of APC.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, affiliates wholly owned by the Company&#8217;s key personnel are reported in the accompanying condensed consolidated statements of income on a consolidated basis, together with the Company&#8217;s subsidiaries, and therefore, the Company does not separately disclose transactions between such affiliates and the Company&#8217;s subsidiaries as related-party transactions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intercompany Transactions</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of corporate practice of medicine laws, the Company uses designated shareholder professional corporations, of which the sole shareholder is a member of the Company&#8217;s key personnel, to engage in certain transactions and make intercompany loans from time to time.</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-877-4">For equity method investments, see Note 5 &#8212; &#8220;Investment in Other Entities &#8212; Equity Method&#8221;</ix:continuation>.</span></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_109"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-930" continuedAt="f-930-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></ix:nonNumeric></div><ix:continuation id="f-930-1" continuedAt="f-930-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the liability method of accounting for income taxes as set forth in ASC 740 Income Taxes. Under the liability method, deferred taxes are determined based on differences between the financial statement and tax bases of assets and liabilities using enacted tax rates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an interim basis, the Company estimates what its anticipated annual effective tax rate will be and records a quarterly income tax provision in accordance with the estimated annual rate, plus the tax effect of certain discrete items that arise during the quarter. As the fiscal year progresses, the Company refines its estimates based on actual events and financial results during the quarter. This process can result in significant changes to the Company&#8217;s estimated effective tax rate. When this occurs, the income tax provision is adjusted during the quarter in which the estimates are refined so that the year-to-date provision reflects the estimated annual effective tax rate. These changes, along with adjustments to the Company&#8217;s deferred taxes and related valuation allowance, may create fluctuations in the overall effective tax rate from quarter to quarter.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective income tax rate for the three months ended March&#160;31, 2024 and 2023, was <ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-931">29.8</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-27" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-932">35.7</ix:nonFraction>%, respectively. The tax rate for the three months ended March&#160;31, 2024, differed from the U.S. federal statutory rate primarily due to state income taxes and income from flow-through entities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, the Company does not have any unrecognized tax benefits related to various federal and state income tax matters. The Company will recognize accrued interest and penalties related to unrecognized tax benefits in income tax expense.</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-930-2">The Company is subject to U.S. federal income tax as well as income tax in California. The Company and its subsidiaries&#8217; state and federal income tax returns are open to audit under the statute of limitations for the years ended December 31, 2019 through December&#160;31, 2023, and for the years ended December 31, 2020 through December&#160;31, 2023, respectively.</ix:continuation> </span></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_112"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-933" continuedAt="f-933-1" escape="true">Earnings Per Share</ix:nonNumeric></span></div><ix:continuation id="f-933-1" continuedAt="f-933-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is calculated using the weighted average number of shares of the Company&#8217;s common stock issued and outstanding during a certain period, and is calculated by dividing net income attributable to Astrana by the weighted average number of shares of the Company&#8217;s common stock issued and outstanding during such period. Diluted earnings per share is calculated using the weighted average number of shares of common stock and potentially dilutive shares of common stock outstanding during the period, using the as-if converted method for secured convertible notes and preferred stock, and the treasury stock method for options and common stock warrants.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024 and December&#160;31, 2023, APC held <ix:nonFraction unitRef="shares" contextRef="c-246" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-934"><ix:nonFraction unitRef="shares" contextRef="c-247" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-935">7,132,698</ix:nonFraction></ix:nonFraction> shares of Astrana&#8217;s common stock, which are treated as treasury shares for accounting purposes and not included in the number of shares of common stock outstanding used to calculate earnings per share. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="f-933-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2024 and 2023, restricted stock of <ix:nonFraction unitRef="shares" contextRef="c-248" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-936">118,142</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-249" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-937">136,932</ix:nonFraction>, respectively, were excluded from the computation of diluted weighted average common shares outstanding because the assumed proceeds, as calculated under the treasury stock method, resulted in these awards being antidilutive.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2024 and 2023, <ix:nonFraction unitRef="shares" contextRef="c-250" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-938"><ix:nonFraction unitRef="shares" contextRef="c-250" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-939">973,461</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-251" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-940"><ix:nonFraction unitRef="shares" contextRef="c-251" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-941">395,472</ix:nonFraction></ix:nonFraction> of contingently issuable shares were excluded from the computation of diluted weighted average common shares outstanding because these conditions were not achieved as of March&#160;31, 2024 and 2023, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-942" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the earnings per share computations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; basic</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-943">0.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-944">0.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; diluted</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-945">0.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-946">0.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-947">47,260,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-948">46,555,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; diluted</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-949">47,699,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-950">46,954,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="f-951" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the shares included in the diluted earnings per share computations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-952">47,260,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-953">46,555,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-252" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="f-954">188,083</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-253" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="f-955">306,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-248" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="f-956">225,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-249" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="f-957">48,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingently issuable shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares" format="ixt:num-dot-decimal" scale="0" id="f-958">25,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares" format="ixt:num-dot-decimal" scale="0" id="f-959">44,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-960">47,699,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-961">46,954,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_118"></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="f-962" continuedAt="f-962-1" escape="true">Variable Interest Entities (VIEs)</ix:nonNumeric></span></div><ix:continuation id="f-962-1" continuedAt="f-962-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed consolidated financial statements include its subsidiaries and consolidated VIEs. A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity investment at risk lack any of the following three characteristics: decision-making rights, the obligation to absorb losses, or the right to receive the expected residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity&#8217;s economic performance and the obligation to absorb expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain state laws prohibit a professional corporation that has more than one shareholder from being a shareholder in another professional corporation. As a result, the Company cannot directly own shares in other professional corporations. However, an exception to this regulation permits a professional corporation that has only one shareholder to own shares in another professional corporation. In reliance on this exception, the Company designated certain key personnel as the nominee shareholders of professional corporations that hold controlling and non-controlling ownership interests in several medical corporations. Via a Physician Shareholder Agreement with the nominee shareholder, the Company has the ability to designate another person to be the equity holder of the professional corporation. In addition, these entities are managed by the Company&#8217;s wholly owned MSOs via MSA. In accordance with relevant accounting guidance, the professional corporations and their consolidated medical corporations are consolidated by the Company in the accompanying condensed financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to corporate practice of medicine laws, the Company operates by maintaining long-term MSAs with its affiliated IPAs and medical groups, each of which is owned and operated by physicians only, and employs or contracts with additional physicians to provide medical services. AHM is a wholly owned subsidiary of the Company and has entered into MSAs with several affiliated IPAs, including APC. APC arranges for the delivery of healthcare services by contracting with physicians or professional medical corporations for primary care and specialty care services. The physicians in the IPA are exclusively in control of, and responsible for, all aspects of the practice of medicine for enrolled patients. In accordance with relevant accounting guidance, APC has been determined to be a VIE of AHM, as AHM is its primary beneficiary with the ability, through majority representation on the APC Joint Planning Board and otherwise, to direct the activities (excluding clinical </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="f-962-2" continuedAt="f-962-3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decisions) that most significantly affect APC&#8217;s economic performance. Therefore, APC and its wholly owned subsidiaries and VIEs are consolidated in the accompanying financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Astrana Medical and Astrana Care Partners Medical were formed in May 2019 and July 2021, respectively, as designated shareholder professional corporations. The Company&#8217;s Vice Chairman is the sole shareholder of Astrana Medical and Astrana Care Partners Medical. Via a Physician Shareholder Agreement, Astrana makes all the decisions on behalf of Astrana Medical and Astrana Care Partners Medical. Astrana has the obligation to absorb losses of, or the right to receive benefits from, Astrana Medical and Astrana Care Partners Medical. Therefore, Astrana Medical and Astrana Care Partners Medical are controlled by and consolidated by Astrana as the primary beneficiary of the VIEs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2024, a <ix:nonFraction unitRef="number" contextRef="c-254" decimals="INF" name="us-gaap:VariableInterestEntityOwnershipPercentage" scale="-2" id="f-963">25</ix:nonFraction>% equity interest of Eleanor Leung M.D. was re-acquired by the Company. As a result, Astrana Care Partners Medical now owns <ix:nonFraction unitRef="number" contextRef="c-255" decimals="INF" name="us-gaap:VariableInterestEntityOwnershipPercentage" scale="-2" id="f-964">100</ix:nonFraction>% of Eleanor Leung M.D.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfVariableInterestEntitiesTextBlock" id="f-965" continuedAt="f-965-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes assets that can only be used to settle the liabilities of the Company&#8217;s VIEs, and to which the creditors of Astrana have no recourse, and liabilities to which the creditors of the Company&#8217;s VIEs have no recourse to the general credit of Astrana, as the primary beneficiary of the VIEs. These assets and liabilities, with the exception of investments in affiliates and amounts due to, or from, affiliates, which are eliminated upon consolidation, are included in the accompanying consolidated balance sheets (in thousands).</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-966">212,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-967">184,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="f-968">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="f-969">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-970">47,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-971">21,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-972">61,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-973">58,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:fixed-zero" scale="3" id="f-974">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="f-975">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="f-976">997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="f-977">454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-978">11,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-979">9,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-980">334,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-981">275,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-982">5,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-983">5,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-984">85,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-985">60,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-986">236,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-987">140,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes receivable, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:IncomeTaxesReceivableNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-988">15,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:IncomeTaxesReceivableNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-989">15,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in other entities &#8211; equity method</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-990">12,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-991">12,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliates*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-992">299,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-993">273,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in a privately held entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" scale="3" id="f-994">405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" scale="3" id="f-995">405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="f-996">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="f-997">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-998">26,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-999">28,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1000">1,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1001">1,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1002">682,849</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1003">537,998</ix:nonFraction></span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total assets</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1004">1,016,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1005">813,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1006">44,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1007">32,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="f-965-1"><ix:continuation id="f-962-3"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiduciary accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="asth:FiduciaryAccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1008">7,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="asth:FiduciaryAccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1009">7,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1010">69,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1011">55,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:DividendsPayableCurrent" scale="3" id="f-1012">638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:DividendsPayableCurrent" scale="3" id="f-1013">638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1014">8,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:fixed-zero" scale="3" id="f-1015">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-1016">602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-1017">646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1018">3,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1019">3,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="f-1020">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1021">8,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount due to affiliates*</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:OtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1022">110,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:OtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1023">107,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1024">9,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:fixed-zero" scale="3" id="f-1025">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1026">253,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1027">216,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="f-1028">905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1029">1,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1030">26,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1031">28,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-1032">7,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-1033">7,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1034">1,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-1035">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1036">35,947</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1037">37,222</ix:nonFraction></span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-1038">289,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-1039">253,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Investment in affiliates includes the Company&#8217;s VIEs&#8217; investment in Astrana, which is reflected as treasury shares and eliminated upon consolidation. Amounts due to, or from, affiliates are receivables with Astrana&#8217;s subsidiaries. As a result, these balances are eliminated upon consolidation and are not reflected on Astrana&#8217;s condensed consolidated balance sheets  as of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2024, and December&#160;31, 2023.</span></div></ix:continuation></ix:continuation><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_121"></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-1041" continuedAt="f-1041-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeFinanceLeasesTextBlock" id="f-1040" continuedAt="f-1040-1" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="f-1041-1" continuedAt="f-1041-2"><ix:continuation id="f-1040-1" continuedAt="f-1040-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating and finance leases for corporate offices, physicians&#8217; offices, and certain equipment. These leases have remaining lease terms of <ix:nonNumeric contextRef="c-262" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:durwordsen" id="f-1042"><ix:nonNumeric contextRef="c-262" name="us-gaap:LesseeFinanceLeaseRemainingLeaseTerm" format="ixt-sec:durwordsen" id="f-1043">four months</ix:nonNumeric></ix:nonNumeric> to <ix:nonNumeric contextRef="c-263" name="us-gaap:LesseeFinanceLeaseRemainingLeaseTerm" format="ixt-sec:durwordsen" id="f-1044"><ix:nonNumeric contextRef="c-263" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:durwordsen" id="f-1045">seventeen years</ix:nonNumeric></ix:nonNumeric>. Some of the leases may include options to extend the lease terms for up to <ix:nonNumeric contextRef="c-5" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-1046"><ix:nonNumeric contextRef="c-5" name="us-gaap:LesseeFinanceLeaseRenewalTerm1" format="ixt-sec:durwordsen" id="f-1047">ten years</ix:nonNumeric></ix:nonNumeric>, and some of the leases may include options to terminate the leases within <ix:nonNumeric contextRef="c-1" name="asth:LesseeOperatingLeaseTerminationPeriodIfApplicable" format="ixt-sec:durwordsen" id="f-1048"><ix:nonNumeric contextRef="c-1" name="asth:LesseeFinanceLeaseTerminationPeriodIfApplicable" format="ixt-sec:durwordsen" id="f-1049">one year</ix:nonNumeric></ix:nonNumeric>. As of March&#160;31, 2024, and December&#160;31, 2023, assets recorded under finance leases were $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-1050">1.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-1051">1.7</ix:nonFraction> million, respectively, and accumulated depreciation associated with finance leases was $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1052">1.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1053">1.6</ix:nonFraction> million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the balance sheets.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-1054" continuedAt="f-1054-1" escape="true"><ix:continuation id="f-1041-2" continuedAt="f-1041-3"><ix:continuation id="f-1040-2" continuedAt="f-1040-3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows (dollars in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1055">3,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1056">1,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="f-1057">179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="f-1058">154</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="f-1059">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="f-1060">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="f-1061">226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="f-1062">248</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1063">3,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1064">1,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="f-1041-3"><ix:continuation id="f-1040-3"><ix:continuation id="f-1054-1"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-1065">2,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-1066">1,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="f-1067">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="f-1068">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-1069">179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-1070">154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1071">8.39</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-59" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1072">6.64</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-5" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1073">2.96</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-59" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1074">3.22</ix:nonNumeric> years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1075">6.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-59" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1076">5.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="4" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1077">5.53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-59" decimals="4" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1078">4.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-1080" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="f-1079" escape="true"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are future minimum lease payments under non-cancellable leases for the years ending December 31 (in thousands) below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (excluding the three months ended March 31, 2024)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="f-1081">5,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="f-1082">560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-1083">7,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="f-1084">599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-1085">7,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="f-1086">345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-1087">6,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="f-1088">265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-1089">6,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="3" id="f-1090">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="asth:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="f-1091">22,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="asth:FinanceLeaseLiabilityToBePaidAfterYearFour" scale="3" id="f-1092">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-1093">55,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-1094">1,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-1095">13,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-1096">152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1097">42,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1098">1,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1099">5,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-1100">636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1101">37,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1102">1,015</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation></ix:continuation><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-1103" continuedAt="f-1103-1" escape="true">Segments</ix:nonNumeric></span></div><ix:continuation id="f-1103-1" continuedAt="f-1103-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the performance of its operating segments based on segment revenue growth as well as operating income.  Management uses revenue growth and total segment operating income as a measure of the performance of operating businesses separate from non-operating factors. The Company&#8217;s operations are based in the United States. All revenues of the Company are derived from the United States. The Company&#8217;s segments are not evaluated using asset information.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, our reportable segments enter into transactions with each other. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues recognized by a segment and expenses incurred by the counterparty are eliminated in consolidation and do not affect consolidated results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate costs are unallocated and primarily include corporate initiatives, corporate infrastructure costs and corporate shared costs, such as finance, human resources, legal, and executives.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-1104" continuedAt="f-1104-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts disclosed in prior period have been recast to conform to the current period presentation. Specifically, reclassifications were made between cost of services and general and administrative expenses in the accompanying segment table for the three months ended March 31, 2023. The following table presents information about our segments (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.458%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Care Partners</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Care Delivery</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Care Enablement</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intersegment Elimination</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Third-Party</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1105">382,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1106">17,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1107">4,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1108">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1109">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1110">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1111">404,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intersegment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1112">14,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1113">12,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1114">29,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1115">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1116">56,732</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1117">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1118">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1119">397,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1120">30,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1121">33,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1122">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1123">56,732</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1124">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1125">404,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1126">314,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1127">24,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1128">17,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:fixed-zero" scale="3" id="f-1129">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" sign="-" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1130">26,734</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:fixed-zero" scale="3" id="f-1131">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1132">330,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1133">38,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1134">6,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1135">12,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization" format="ixt:fixed-zero" scale="3" id="f-1136">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" sign="-" name="asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1137">30,075</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3" name="asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1138">16,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1139">43,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1140">353,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1141">30,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1142">29,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:fixed-zero" scale="3" id="f-1143">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" sign="-" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1144">56,809</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1145">16,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1146">374,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1147">43,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" scale="3" id="f-1148">238</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1149">3,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:fixed-zero" scale="3" id="f-1150">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="us-gaap:OperatingIncomeLoss" scale="3" id="f-1151">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1152">16,400</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1153">30,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Care Partners</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Care Delivery</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Care Enablement</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intersegment Elimination</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate Costs</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Third-Party</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1154">314,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1155">12,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1156">10,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-1157">205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1158">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1159">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1160">337,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intersegment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-1161">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1162">13,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1163">20,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-1164">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1165">33,598</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1166">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1167">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1168">314,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1169">25,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1170">30,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-1171">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1172">33,598</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1173">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1174">337,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1175">266,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1176">20,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1177">15,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" scale="3" id="f-1178">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" sign="-" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1179">13,302</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:fixed-zero" scale="3" id="f-1180">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1181">289,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1182">26,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1183">5,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1184">9,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization" scale="3" id="f-1185">660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" sign="-" name="asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1186">21,460</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1187">5,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1188">25,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1189">292,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1190">26,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1191">24,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:CostsAndExpenses" scale="3" id="f-1192">723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" sign="-" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1193">34,762</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1194">5,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1195">314,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1196">22,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" scale="3" id="f-1197">966</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1198">5,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" scale="3" id="f-1199">483</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1200">1,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1201">5,409</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1202">22,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Balance includes general and administrative expenses and depreciation and amortization. </span></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-align:justify"><ix:continuation id="f-1104-1" continuedAt="f-1104-2"><ix:continuation id="f-1103-2" continuedAt="f-1103-3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1104-2"><ix:continuation id="f-1103-3"> Income from operations for the intersegment elimination represents rental income from segments renting from other segments. Rental income is presented within other income which is not presented in the table.</ix:continuation></ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-1203" continuedAt="f-1203-1" escape="true">Fair Value Measurements of Financial Instruments</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="f-1204" escape="true"><ix:continuation id="f-1203-1" continuedAt="f-1203-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of March&#160;31, 2024, are presented below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.526%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market accounts*</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1205">31,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-1206">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-1207">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1208">31,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-1209">2,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-1210">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-1211">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-1212">2,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="f-1213">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="f-1214">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="f-1215">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="f-1216">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate collar</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="f-1217">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-3" name="us-gaap:DerivativeAssets" scale="3" id="f-1218">438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="f-1219">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-3" name="us-gaap:DerivativeAssets" scale="3" id="f-1220">438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1221">34,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="f-1222">438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-1223">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1224">34,732</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AAMG contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-1225">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-312" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-1226">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-1227">7,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-1228">7,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VOMG contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-1229">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-1230">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-317" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="f-1231">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-318" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="f-1232">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DMG remaining equity interest purchase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-3" name="asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent" format="ixt:fixed-zero" scale="3" id="f-1233">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-3" name="asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent" format="ixt:fixed-zero" scale="3" id="f-1234">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-321" decimals="-3" name="asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1235">8,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-322" decimals="-3" name="asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1236">8,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sun Labs remaining equity interest purchase</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-323" decimals="-3" name="asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent" format="ixt:fixed-zero" scale="3" id="f-1237">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-3" name="asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent" format="ixt:fixed-zero" scale="3" id="f-1238">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-3" name="asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1239">7,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" name="asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1240">7,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADSC contingent considerations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-1241">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-1242">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-1243">3,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-330" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-1244">3,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CFC contingent considerations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-1245">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-332" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-1246">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-333" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-1247">7,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-334" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-1248">7,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PCCCV contingent considerations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-335" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-1249">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-336" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-1250">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-337" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-1251">2,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-338" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-1252">2,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-1253">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-1254">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1255">36,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1256">36,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Included in cash and cash equivalents</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of December&#160;31, 2023, are presented below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.526%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market accounts*</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1257">4,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-340" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-1258">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-341" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-1259">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1260">4,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-1261">2,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-340" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-1262">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-341" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-1263">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-1264">2,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="f-1265">348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-340" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="f-1266">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-341" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="f-1267">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="f-1268">348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1269">7,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-340" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-1270">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-341" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-1271">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1272">7,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AAMG contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-342" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-1273">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-343" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-1274">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-1275">5,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-345" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-1276">5,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VOMG contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-346" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-1277">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-1278">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="f-1279">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="f-1280">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DMG remaining equity interest purchase</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-3" name="asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent" format="ixt:fixed-zero" scale="3" id="f-1281">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-3" name="asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent" format="ixt:fixed-zero" scale="3" id="f-1282">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-352" decimals="-3" name="asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1283">8,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-353" decimals="-3" name="asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1284">8,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sun Labs remaining equity interest purchase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-354" decimals="-3" name="asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent" format="ixt:fixed-zero" scale="3" id="f-1285">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-355" decimals="-3" name="asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent" format="ixt:fixed-zero" scale="3" id="f-1286">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-356" decimals="-3" name="asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1287">7,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-357" decimals="-3" name="asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1288">7,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate collar</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-358" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="0" id="f-1289">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="f-1290">252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-360" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="0" id="f-1291">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-361" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="f-1292">252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-1293">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-340" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="f-1294">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-341" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1295">21,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1296">22,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Included in cash and cash equivalents</span></div></ix:continuation></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="f-1203-2" continuedAt="f-1203-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-1297" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the fair value of Level 3 liabilities for the three months ended March&#160;31, 2024, was as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.444%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-1298">21,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="asth:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdditions" format="ixt:num-dot-decimal" scale="3" id="f-1299">13,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of existing Level 3 liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-1300">1,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-1301">36,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesPolicy" id="f-1302" continuedAt="f-1302-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Marketable Securities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit are reported at par value, plus accrued interest, with maturity dates greater than <ix:nonNumeric contextRef="c-362" name="asth:MarketableSecuritiesCurrentMaturityPeriod" format="ixt-sec:durwordsen" id="f-1303">ninety days</ix:nonNumeric>. As of March&#160;31, 2024, and December&#160;31, 2023, certificates of deposit amounted to approximately $<ix:nonFraction unitRef="usd" contextRef="c-363" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-1304">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-364" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-1305">2.2</ix:nonFraction>&#160;million, respectively. Investments in certificates of deposit are classified as Level 1 investments in the fair value hierarchy.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1302-1">Equity securities are reported at fair value. These securities are classified as Level 1 in the valuation hierarchy, where quoted market prices from reputable third-party brokers are available in an active market and unadjusted.</ix:continuation> As of March&#160;31, 2024, and December&#160;31, 2023, the equity securities were approximately $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="f-1306">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="f-1307">0.3</ix:nonFraction>&#160;million, respectively, in the accompanying condensed consolidated balance sheets. Gains and losses recognized on equity securities sold are recognized in the accompanying condensed consolidated statements of income as other income. <ix:nonNumeric contextRef="c-1" name="us-gaap:GainLossOnInvestmentsTextBlock" id="f-1308" continuedAt="f-1308-1" escape="true">The components comprising total gains and losses on equity securities are as follows (in thousands) for the periods listed below:</ix:nonNumeric></span></div><ix:continuation id="f-1308-1"><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Total losses recognized on equity securities  </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="3" id="f-1309">116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-1310">4,353</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Gains recognized on equity securities sold  </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" format="ixt:fixed-zero" scale="3" id="f-1311">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" format="ixt:fixed-zero" scale="3" id="f-1312">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Unrealized losses recognized on equity securities held at end of period  </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="3" id="f-1313">116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-1314">4,353</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativesPolicyTextBlock" id="f-1315" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Derivative Financial Instruments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Collar Agreements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s collar agreement is designed to limit the interest rate risk associated with the Company&#8217;s Revolver Loan. The principal objective of the collar agreement is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#8217;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. Refer to Note 9 - &#8220;Credit Facility, Bank Loans, and Lines of Credit,&#8221; for further information on the Company&#8217;s debt. Under the terms of the agreement, the ceiling is <ix:nonFraction unitRef="number" contextRef="c-310" decimals="3" name="asth:DerivativeCeilingInterestRate" scale="-2" id="f-1316">5.0</ix:nonFraction>% and the floor is <ix:nonFraction unitRef="number" contextRef="c-310" decimals="4" name="us-gaap:DerivativeFloorInterestRate" scale="-2" id="f-1317">2.34</ix:nonFraction>%.  The collar agreement is not designated as a hedging instrument. Changes in the fair value of this contract are recognized as unrealized gain or loss on investments in the accompanying condensed consolidated statements of income and reflected in the accompanying condensed consolidated statements of cash flows as unrealized loss on investments. The estimated fair value of the collar was determined using Level 2.  As of March&#160;31, 2024 and December&#160;31, 2023, the fair value of the collar was $<ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="6" id="f-1318">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-361" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="6" id="f-1319">0.3</ix:nonFraction> million, and presented within other assets and other long-term liabilities, respectively, in the accompanying condensed consolidated balance sheets. For the three months ended March&#160;31, 2024, the Company recognized unrealized gains of $<ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-5" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1320">0.7</ix:nonFraction> million.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Remaining equity interest purchase</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the Company entered into a financing obligation to purchase the remaining equity interest in Diagnostic Medical Group of Southern California (&#8220;DMG&#8221;) and Sun Clinical Laboratories (&#8220;Sun Labs&#8221;) within <ix:nonNumeric contextRef="c-366" name="asth:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" format="ixt-sec:durwordsen" id="f-1321">three years</ix:nonNumeric> from the date the Company consolidated DMG and Sun Labs. The purchase of the remaining DMG equity value is considered a financing obligation with a carrying value of $<ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1322">8.5</ix:nonFraction>&#160;million as of March&#160;31, 2024 and December&#160;31, 2023. Changes in the fair value of the remaining equity purchase are presented in unrealized gain and loss on investments in the accompanying condensed consolidated statements of income. The purchase of the remaining Sun Labs equity value is considered a financing obligation with a carrying value of $<ix:nonFraction unitRef="usd" contextRef="c-368" decimals="-5" name="asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1323">7.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-369" decimals="-5" name="asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1324">7.8</ix:nonFraction> million as of March&#160;31, 2024 and December&#160;31, 2023, respectively. For the three months ended March&#160;31, 2024, and 2023, the Company recognized an unrealized gain of $<ix:nonFraction unitRef="usd" contextRef="c-370" decimals="-5" name="asth:BusinessCombinationChangeInFairValueOfEquityInterestPurchaseObligation" format="ixt:num-dot-decimal" scale="6" id="f-1325">0.5</ix:nonFraction> million and unrealized loss of $<ix:nonFraction unitRef="usd" contextRef="c-371" decimals="-5" name="asth:BusinessCombinationChangeInFairValueOfEquityInterestPurchaseObligation" format="ixt:num-dot-decimal" scale="6" id="f-1326">1.4</ix:nonFraction> million, respectively, due to the change in the fair value of Sun Labs equity value obligation. As the financing obligations </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="f-1203-3" continuedAt="f-1203-4"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are embedded in the non-controlling interest, the non-controlling interests are recognized in other liabilities in the accompanying condensed consolidated balance sheets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent considerations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">All American Medical Group</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AAMG&#8221;)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon acquiring <ix:nonFraction unitRef="number" contextRef="c-372" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="f-1327">100</ix:nonFraction>% of the equity interest in AAMG, the purchase price consisted of cash funded upon close of the transaction and additional consideration (&#8220;AAMG contingent consideration&#8221;) and stock consideration (&#8220;AAMG stock contingent consideration&#8221;) contingent on AAMG meeting revenue and capitated member metrics for fiscal years 2023  (&#8220;2023 metric&#8221;) and 2024 (&#8220;2024 metric&#8221;). If the contingent considerations are met, the settlement will be paid in the Company&#8217;s common stock. The total amount of stock that can be issued for the 2023 and 2024 metrics is <ix:nonFraction unitRef="shares" contextRef="c-373" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1328">157,048</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-374" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1329">184,361</ix:nonFraction>, respectively. The Company determined the fair value of the contingent considerations using a probability-weighted model that includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of revenue and assigned probabilities to each such scenario in determining fair value. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024 and December&#160;31, 2023, the AAMG contingent consideration for the 2023 metric was valued at $<ix:nonFraction unitRef="usd" contextRef="c-375" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-1330">3.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-376" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-1331">2.6</ix:nonFraction>&#160;million, respectively, and was included within other liabilities in the accompanying condensed consolidated balance sheets. The 2023 metric was met, but remains in other liabilities until the shares are issued.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The AAMG contingent consideration for the 2024 metric was valued at $<ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-1332">3.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-378" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-1333">2.9</ix:nonFraction>&#160;million as of March&#160;31, 2024 and December&#160;31, 2023, respectively, and was included in other liabilities and other long-term liabilities in the accompanying condensed consolidated balance sheets, respectively. Changes in the AAMG contingent consideration are presented in general and administrative expenses in the accompanying condensed consolidated statements of income. The AAMG stock contingent consideration for 2023 and 2024 metric was valued at $<ix:nonFraction unitRef="usd" contextRef="c-379" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-1334"><ix:nonFraction unitRef="usd" contextRef="c-380" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-1335">5.6</ix:nonFraction></ix:nonFraction>&#160;million as of March&#160;31, 2024 and December&#160;31, 2023 and is included in additional paid-in capital in the accompanying condensed consolidated balance sheets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADSC</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon acquiring <ix:nonFraction unitRef="number" contextRef="c-78" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="f-1336">95</ix:nonFraction>% of the equity interest of Advanced Diagnostic and Surgical Center in 2024, the total consideration of the acquisition included contingent considerations. The contingent considerations will be settled in cash contingent on ADSC achieving revenue and EBITDA metrics for fiscal years 2023 (&#8220;ADSC 2023 Metric&#8221;) and 2024 (&#8220;ADSC 2024 Metric&#8221;) (collectively, &#8220;ADSC contingent considerations&#8221;). The Company determined the fair value of the contingent consideration using a probability-weighted model that includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of revenue and assigned probabilities to each such scenario in determining fair value. As of March&#160;31, 2024, the ADSC 2023 Metric and the 2024 Metric were valued at $<ix:nonFraction unitRef="usd" contextRef="c-381" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-1337">2.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-382" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-1338">1.6</ix:nonFraction>&#160;million, respectively and were included in other liabilities in the accompanying condensed consolidated balance sheets. Changes in the ADSC contingent considerations are presented in general and administrative expenses in the accompanying condensed consolidated statements of income.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CFC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon acquiring certain assets of CFC in 2024, the total consideration of the acquisition included contingent considerations. The contingent considerations will be settled in cash contingent upon CFC maintaining or exceeding the target member month amount for the first, second and third measurement period (&#8220;CFC contingent considerations&#8221;). The contingent liability will be paid after achieving the metric in each measurement period. The Company will pay $<ix:nonFraction unitRef="usd" contextRef="c-383" decimals="-5" name="asth:BusinessCombinationContingentConsiderationLiabilityEachMeasurementPeriod" format="ixt:num-dot-decimal" scale="6" id="f-1339">5.0</ix:nonFraction>&#160;million for each metric achieved for each measurement period or a total of $<ix:nonFraction unitRef="usd" contextRef="c-383" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-1340">15.0</ix:nonFraction>&#160;million. In the event that the CFC first and/or second contingent considerations are not achieved during the first and/or the second measurement period, if the metric is met within the second and/or third measurement period, there is a catch-up payment that shall be paid concurrently with the payments of the CFC second contingent consideration and/or CFC third contingent consideration. The Company determined the fair value of the contingent consideration using a probability-weighted model that includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of revenue and assigned probabilities to each such scenario in determining fair value. As of March&#160;31, 2024, the first, second, and third metric were valued at $<ix:nonFraction unitRef="usd" contextRef="c-384" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-1341">3.1</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-385" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-1342">2.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-1343">1.9</ix:nonFraction>&#160;million, respectively, and were all included in other long-term liabilities in the accompanying condensed consolidated balance sheets. Changes in the CFC contingent considerations are presented in general and administrative expenses in the accompanying condensed consolidated statements of income.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="f-1203-4"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PCCCV</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon acquiring certain assets of PCCCV in 2024, the total consideration of the acquisition included contingent considerations. The contingent considerations will be settled in cash contingent upon PCCCV meeting certain metrics related to financial ratios and member months for the first and second measurement periods (&#8220;PCCCV contingent considerations&#8221;). The Company determined the fair value of the contingent considerations using a probability-weighted model that includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of revenue and assigned probabilities to each such scenario in determining fair value. As of March&#160;31, 2024, the value of the contingent consideration was valued at $<ix:nonFraction unitRef="usd" contextRef="c-387" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-1344">2.3</ix:nonFraction>&#160;million. Changes in the PCCCV contingent considerations are presented in general and administrative expenses in the accompanying condensed consolidated statements of income.</span></div></ix:continuation><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_136"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-1345" continuedAt="f-1345-1" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="f-1345-1"><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">I Health Promissory Note Payable</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2024, the Company received $<ix:nonFraction unitRef="usd" contextRef="c-388" decimals="-5" name="us-gaap:ProceedsFromRelatedPartyDebt" format="ixt:num-dot-decimal" scale="6" id="f-1346">8.3</ix:nonFraction>&#160;million as a promissory note with a maturity date of March 31, 2027. I Health may accelerate the maturity date if the Company does not exercise the call options (see Note 5 &#8212; &#8220;Investments in Other Entities - Equity Method&#8221;) The promissory note has an interest rate of <ix:nonFraction unitRef="number" contextRef="c-389" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1347">4.30</ix:nonFraction>% per annum on the principal amount. Accrued interest is payable on each anniversary of  the promissory note payable. I Health is accounted for under the equity method based on the <ix:nonFraction unitRef="number" contextRef="c-200" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-1348">25</ix:nonFraction>% equity ownership interest held by the Company (see Note 5 &#8212; &#8220;Investments in Other Entities - Equity Method&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Elimination of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 24, 2024, the Company filed a Certificate of Elimination to its Restated Certificate of Incorporation with the Secretary of State of the State of Delaware, eliminating from the Certificate of Incorporation all matters set forth in the Amended and Restated Certificate of Designation with respect to the Company&#8217;s Series A Convertible Preferred Stock and Series B Convertible Preferred Stock and returning each of the Series A Preferred Stock and Series B Preferred Stock to the status of authorized and unissued shares of preferred stock of the Company, without designation as to series. There were no outstanding shares of the Series A Preferred Stock or Series B Preferred Stock as of April 24, 2024.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Drawdown on Revolver Loan</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to March&#160;31, 2024, the Company drew down $<ix:nonFraction unitRef="usd" contextRef="c-390" decimals="-5" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="f-1349">52.0</ix:nonFraction>&#160;million on its Revolver Loan.</span></div></ix:continuation><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_142"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the unaudited condensed consolidated financial statements and the notes thereto included in Part I, Item 1, &#8220;Financial Statements&#8221; of this Quarterly Report on Form 10-Q. In addition, reference is made to our audited condensed consolidated financial statements and notes thereto and related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February&#160;29, 2024.</span></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_145"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><br/>Overview</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Astrana Health, Inc. (&#8220;Astrana&#8221;) is a leading physician-centric, technology-powered, risk-bearing healthcare management company. Leveraging its proprietary population health management and healthcare delivery platform, Astrana operates an integrated, value-based healthcare model, which aims to empower the providers in its network to deliver the highest quality of care to its patients in a cost-effective manner. Together with our affiliated physician groups and consolidated entities, we provide coordinated outcomes-based medical care in a cost-effective manner.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our accountable care organization and a network of IPAs with more than 10,000 contracted physicians, we are responsible for coordinating care in value-based care arrangements for approximately 1.0&#160;million patients primarily in California as of March&#160;31, 2024. These covered patients are comprised of managed care members whose health coverage is provided either through their employers, acquired directly from a health plan, or as a result of their eligibility for Medicaid or Medicare benefits. Our managed patients benefit from an integrated approach that places physicians at the center of patient care and utilizes sophisticated risk management techniques and clinical protocols to provide high-quality, cost-effective care. </span></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_148"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><br/>Recent Developments</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Second Closing of Community Family Care (&#8220;CFC&#8221;) Acquisition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2024, the Company successfully closed the second and final part of the CFC acquisition. This acquisition marks the largest in Astrana&#8217;s history and allows the Company to take on greater responsibility for the outcomes of the patients we serve with CFC&#8217;s full-risk Medicaid Restricted Knox-Keene license.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Closing of Prime Community Care of Central Valley (&#8220;PCCCV&#8221;) Acquisition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 29, 2024, the Company completed the acquisition of PCCCV, a risk-bearing provider organization with over 150 primary care and multi-specialty care providers which serves around 26,000 primarily Medicaid members in the Central Valley of California.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_151"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Financial Measures and Indicators</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Revenues</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue, which is recorded in the period in which services are rendered and earned, primarily consists of capitation revenue, risk pool settlements and incentives, management fee income, and fee-for-service (&#8220;FFS&#8221;) revenue. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our largest expenses consist of the cost of (i) patient care paid to contracted providers; (ii) information technology equipment and software; and (iii) hiring staff to provide management and administrative support services to our affiliated physician groups, as further described in the following sections. These services include claims processing, utilization management, contracting, accounting, credentialing, and administrative oversight.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adjusted EBITDA and Adjusted EBITDA Margin</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Adjusted EBITDA and Adjusted EBITDA margin are supplemental performance measures of our operations for financial and operational decision-making, and as a supplemental means of evaluating period-to-period comparisons on a consistent basis. Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation, and amortization, excluding income or loss from equity method investments, non-recurring and non-cash transactions, stock-based compensation, and APC excluded assets costs. The Company defines Adjusted EBITDA margin as Adjusted EBITDA over total revenue.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_154"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Astrana Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Income</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$ Change</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitation, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk pool settlements and incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,915&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management fee income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,896&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,818)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fee-for-services, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,062&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,054&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(566)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404,356&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,244&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,112&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating expenses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of services, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374,217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,346&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other income (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,852)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,585)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,269)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,316)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,009&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on investments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,392)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (loss) income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,277)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,481)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(455)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other expense, net</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,135)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,964)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,171)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income before provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,862&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,488&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,374&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(644)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(415)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income attributable to Astrana Health, Inc.</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,835&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,132&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,703&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Physician Groups and Patients</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024 and 2023, we managed a total of 18 and 15 independent physician groups that are affiliated and non-affiliated, respectively. The total number of patients for whom we managed the delivery of healthcare services was approximately 1.0&#160;million and 1.3&#160;million as of  March&#160;31, 2024 and 2023, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total revenue for the three months ended March&#160;31, 2024, was $404.4 million, as compared to $337.2 million for the three months ended March&#160;31, 2023, an increase of $67.1 million, or 20%. The increase in revenue was primarily attributable to the following:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) Capitation revenue increased by $65.7 million primarily as a result of our recent acquisitions within our Care Partners segment, including the acquisition of CFC IPA assets that closed on January 31, 2024. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Services, Excluding Depreciation and Amortization</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses related to cost of services for the three months ended March&#160;31, 2024 were $330.4 million, as compared to $289.4 million for the same period in 2023, an increase of $41.0 million. The increase was primarily due to our recent acquisitions within our Care Partners segment. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses for the three months ended March&#160;31, 2024 were $38.7 million, as compared to $21.2 million for the same period in 2023, an increase of $17.5 million, or 83%. The increase was primarily due to general and administrative expenses to support operational growth.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Depreciation and Amortization</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses for the three months ended March&#160;31, 2024 were $5.1 million, as compared to $4.3 million for the same period in 2023. This amount includes depreciation of property and equipment and the amortization of intangible assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income From Equity Method Investments</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from equity method investments for the three months ended March&#160;31, 2024 was $0.6 million, as compared to income from equity method investments of $2.5 million for the same period in 2023, a decrease of $1.9 million. The decrease was primarily due to APC&#8217;s equity method investment in LMA. For the three months ended March&#160;31, 2024 and 2023, APC recognized income from this investment of $0.4 million and $2.2 million, respectively. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the three months ended March&#160;31, 2024 was $7.6 million, as compared to $3.3 million for the same period in 2023, an increase of $4.3 million. The increase in interest expense was due to greater amounts borrowed on the Amended Credit Facility. As of March 31, 2024, the Company borrowed $391.3 million on the Amended Credit Facility compared to $180.0 million as of March 31, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income for the three months ended March&#160;31, 2024 was $4.0 million compared to $3.0 million for the three months ended March&#160;31, 2023. Interest income reflects interest earned on cash held in bank accounts, money market and certificate of deposit accounts and the interest from notes receivable. The increase in interest income was primarily from the IntraCare convertible promissory note and BASS secured promissory note.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unrealized Gain (Loss) on Investments</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized gain for the three months ended March&#160;31, 2024 was $1.1 million, as compared to a $6.4 million loss for the same period in 2023, a decrease in unrealized loss of $7.5 million. The decrease in unrealized loss on investments was primarily driven by changes in the fair value of equity securities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Loss)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other loss for the three months ended March&#160;31, 2024 was $4.3 million, as compared to other income of $1.2 million for the same period in 2023, a decrease of $5.5 million. The decrease in other income was primarily due to an expense related to a  financial guarantee via a letter of credit that we provided almost three years ago in support of two local provider-led ACOs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes was $7.1 million for the three months ended March&#160;31, 2024, as compared to a provision for income taxes of $6.9 million for the same period in 2023, an increase of $0.2 million. The increase in provision for income taxes was due to an increase in pretax income. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income (Loss) Attributable to Non-controlling Interests</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to non-controlling interests for the three months ended March&#160;31, 2024 was $2.0 million, as compared to net loss attributable to non-controlling interests for the three months ended March&#160;31, 2023 of $0.6 million, an increase in net income attributable to non-controlling interest of $2.7 million. The increase was primarily driven by a decrease in unrealized loss resulting from the change in the fair value of equity securities held by APC.</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income Attributable to Astrana Health, Inc.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net income attributable to Astrana Health, Inc. for the three months ended March&#160;31, 2024 was $14.8 million, as compared to $13.1 million for the same period in 2023, an increase of $1.7 million. </span></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_160"></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Financial Performance</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has three reportable segments consisting of Care Partners, Care Delivery and Care Enablement. The Company evaluates the performance of its operating segments based on segment revenue growth as well as operating income.  Management uses revenue growth and total segment operating income as a measure of the performance of operating businesses separate from non-operating factors. For more information about our segments, refer to Note 1 &#8212; &#8220;Description of Business&#8221; and Note 18 - &#8220;Segments&#8221; to our condensed consolidated financial statements under Item 1 in this Quarterly Report on Form 10-Q for additional information. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth our revenue and operating income by segment for the three months ended March&#160;31, 2024 and 2023 (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Revenue</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$ Change</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Care Partners</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Care Delivery</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Care Enablement</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Operating Income (Loss)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$ Change</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Care Partners</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Care Delivery</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(966)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Care Enablement</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,242)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Care Partners Segment</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for the three months ended March&#160;31, 2024 was $397.1 million, as compared to $314.7 million for the three months ended March&#160;31, 2023, an increase of $82.4 million, or 26%. Operating income for the three months ended March&#160;31, 2024 was $43.2 million, as compared to $22.3 million for the three months ended March&#160;31, 2023, an increase in operating income of $20.9 million, or 94%. The increase in revenue and operating income was primarily due to recent acquisitions within our Care Partners segment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Care Delivery Segment</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for the three months ended March&#160;31, 2024 was $30.7 million, as compared to $25.4 million for the three months ended March&#160;31, 2023, an increase of $5.3 million, or 21%. Operating loss for the three months ended March&#160;31, 2024 was $0.2 million, as compared to a loss of $1.0 million for the three months ended March&#160;31, 2023, an increase in operating income of $0.7 million, or 75%. The increase in revenue and operating income was primarily driven by increased volume in patient visits at our primary, multi-specialty, and ancillary care delivery entities. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Care Enablement Segment</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Revenue for the three months ended March&#160;31, 2024 was $33.3 million, as compared to $30.6 million for the three months ended March&#160;31, 2023. Operating income for the three months ended March&#160;31, 2024 was $3.5 million, as compared to operating income of $5.7 million for the three months ended March&#160;31, 2023, a decrease in operating income of $2.2 million, or 39%. The increase in revenue was primarily due to managing more IPAs and the decrease in operating income was due to more expenses incurred to support the growth in Care Enablement operations. </span></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_163"></div><div style="margin-bottom:5pt;margin-top:5pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024 Guidance</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Astrana is reiterating the following guidance for total revenue, net income attributable to Astrana, Adjusted EBITDA, and EPS - diluted, based on the Company&#8217;s existing business, current view of existing market conditions and assumptions for the year ending December 31, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions, except per share amounts)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024 Guidance Range</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Low</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">High</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,650.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,850.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Astrana Health, Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPS &#8211; diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA&#8221; and &#8220;Use of Non-GAAP Financial Measures&#8221; below for additional information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See &#8220;Note about Forward-Looking Statements&#8221; for additional information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024 Guidance Range</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Low</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">High</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EBITDA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from equity method investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_169"></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EBITDA</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set forth below are reconciliations of Net Income to EBITDA and Adjusted EBITDA as well as the reconciliation to Adjusted EBITDA margin for the three months ended March&#160;31, 2024 and 2023. The Company defines Adjusted EBITDA margin as Adjusted EBITDA over total revenue.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.582%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,996)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,009)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EBITDA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,689&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,961&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from equity method investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(632)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APC excluded asset costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA margin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Other, net for the three months ended March&#160;31, 2024 relates to financial guarantee via a letter of credit that we provided almost three years ago in support of two local provider-led ACOs, non-cash changes related to change in the fair value of our financing obligation to purchase the remaining equity interests in one of our investments, non-cash changes related to change in the fair value of the Company&#8217;s Collar Agreement, and transaction costs incurred for our investments and tax restructuring fees. </span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other, net for the three months ended March 31, 2023 relates to changes in the fair value of our financing obligation to purchase the remaining equity interest in one of our investments.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Non-GAAP Financial Measures</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains the non-GAAP financial measures EBITDA, Adjusted EBITDA and Adjusted EBITDA margin, of which the most directly comparable financial measure presented in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) is net income. These measures are not in accordance with, or alternatives to, GAAP, and may be calculated differently from similar non-GAAP financial measures used by other companies. The Company uses Adjusted EBITDA as a supplemental performance measure of our operations, for financial and operational decision-making and as a supplemental means of evaluating period-to-period comparisons on a consistent basis. Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation, and amortization, excluding income or loss from equity method investments, non-recurring and non-cash transactions, stock-based compensation, and APC excluded assets costs. The Company defines Adjusted EBITDA margin as Adjusted EBITDA over total revenue.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes the presentation of these non-GAAP financial measures provides investors with relevant and useful information, as it allows investors to evaluate the operating performance of the business activities without having to account for differences recognized because of non-core or non-recurring financial information. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of the Company&#8217;s ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating operational performance, allocating resources, and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation, or as a substitute for, GAAP financial measures. Other companies may calculate both EBITDA and Adjusted EBITDA differently, limiting the usefulness of these measures for comparative purposes. To the extent this Form 10-Q contains historical or future non-GAAP financial measures, the Company has provided corresponding GAAP financial measures for comparative purposes. The reconciliation between certain GAAP and non-GAAP measures is provided above.</span></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_172"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and investment in marketable securities at March&#160;31, 2024 totaled $337.3 million as compared to $296.3 million at December&#160;31, 2023. Working capital totaled $183.5 million at March&#160;31, 2024, as compared to $242.8 million at December&#160;31, 2023, a decrease of $59.3 million.   </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically financed our operations primarily through internally generated funds. We generate cash primarily from capitation contracts, risk pool settlements and incentives, fees for medical management services provided to our affiliated physician groups, and FFS reimbursements. We generally invest cash in money market accounts and certificates of deposit, which are classified as cash and cash equivalents. We also have the Amended Credit Agreement, which provides for a five-year revolving credit facility of $400.0 million and a term loan of up to $300.0&#160;million and expires June 2026 and November 2028, respectively. In addition, we have a current shelf registration statement filed with the SEC under which we may issue common stock, preferred stock, debt securities and other securities that may be offered in one or more offerings on terms to be determined at the time of the offering. We believe we have sufficient liquidity to fund our operations through at least the next 12 months and the foreseeable future.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow Activities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash flows are summarized as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$ Change</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,743)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,039)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,035)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,004)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,099)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net decrease in cash and cash equivalents and restricted cash</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,289&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,414)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,703&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(408)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Percentage change of over 500%</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities for the three months ended March&#160;31, 2024 was $6.0 million, as compared to cash provided by operating activities of $7.7 million for the three months ended March&#160;31, 2023. The decrease in cash provided by operating activities was primarily driven by changes in net income and working capital. For the three months ended March&#160;31, 2024, net income exclusive of depreciation and amortization, amortization of debt issuance cost, share-based compensation, unrealized gains or losses, income from equity method investments, deferred tax and other was $29.1 million compared to $26.7 million for the three months ended March&#160;31, 2023. Working capital for the three months ended March&#160;31, 2024, decreased operating cash flow by $23.2 million, compared to an $18.9 million decrease in operating cash flow at March&#160;31, 2023. The change in working capital for the three months ended March&#160;31, 2024 was mainly driven by an increase in receivables, net, other receivables and related party receivables primarily due to timing of our receivables including risk pool settlements that occur approximately 18 months after the risk pool performance year is completed, and increase in income tax payable as a result of timing in income tax payments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities during the three months ended March&#160;31, 2024, was $71.0 million, primarily due to payments for business and asset acquisitions, net of cash acquired of $50.6 million, issuance of loan receivable of $20.0 million,  and purchases of property and equipment of $0.4 million. Cash used in investing activities during the three months ended March 31, 2023 was $14.0 million, primarily due to a deposit for purchase of property of $8.8 million, purchases of property and equipment of $6.0 million, purchase of marketable securities of $1.0 million, and purchase of an equity method investment of $0.3 million, partially offset by proceeds from the repayment of a loan receivable of $2.1 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities during the three months ended March&#160;31, 2024, was $106.4 million, primarily due to borrowings on long-term debt totaling $110.0 million, partially offset by repayment of long term-debt of $3.5 million. Cash used in financing activities during the three months ended March 31, 2023, was primarily due to repurchase of treasury stock of $9.5 million, dividend payments of $0.1 million, repayment of debt of $0.2 million, and repayment of finance lease obligations of $0.2 million, partially offset by borrowings from bank loans totaling $1.6 million and proceeds from the exercise of options of $1.3 million.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_181"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Facilities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s debt balance consisted of the following (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.444%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolver Loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Promissory Note Payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393,259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,750)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,061)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368,448&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the future commitments of the Company&#8217;s debt for the years ending December 31 (in thousands) below:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.444%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (excluding the three months ended March 31, 2024)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393,259&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended Credit Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement provides for a five-year revolving credit facility to the Company of $400.0 million, which includes a letter of credit sub-facility of up to $50.0 million and a swingline loan sub-facility of $25.0 million, which expires on June&#160;16, 2026. On November 3, 2023, the Company entered into the third amendment to the Amended Credit Agreement, which provided a new term loan to the Company in an aggregate amount of up to $300.0 million. This increased the Company&#8217;s facility under the Amended Credit Agreement to $700.0 million, including the existing $400.0 million revolver. Refer to Note 9 &#8212; &#8220;Credit Facility, Bank Loans, and Lines of Credit&#8221; to our condensed consolidated financial statements under Item 1 in this quarterly report on Form 10-Q for additional information.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Promissory Note Payable</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, For Your Benefit, Inc. entered into a promissory note agreement with Chinese Community Health Care Association. The principal on the promissory note is $2.0&#160;million with a maturity date of May&#160;9, 2024. Refer to Note 9 &#8212; &#8220;Credit Facility, Bank Loans, and Lines of Credit&#8221; to our condensed consolidated financial statements under Item 1 in this quarterly report on Form 10-Q for additional information.</span></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_187"></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The preparation of financial statements and related disclosures in conformity with U.S. GAAP requires our management to make judgments, assumptions, and estimates that affect the amounts of revenue, expenses, income, assets and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">liabilities reported in our condensed consolidated financial statements and accompanying notes. Actual results and the timing of recognition of such amounts could differ from those judgments, assumptions, and estimates. In addition, judgments, assumptions, and estimates routinely require adjustment based on changing circumstances and the receipt of new or better information. Understanding our accounting policies and the extent to which our management uses judgment, assumptions, and estimates in applying these policies, therefore, is integral to understanding our financial statements. Critical accounting policies and estimates are defined as those that reflect significant judgments and uncertainties, potentially resulting in materially different results under different assumptions and conditions.&#160;We summarize our most significant accounting policies in relation to the accompanying condensed consolidated financial statements in Note 2 &#8212; &#8220;Basis of Presentation and Summary of Significant Accounting Policies&#8221; thereto. Please also refer to the Critical Accounting Policies section of Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2023.</span></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_193"></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, we had no off-balance sheet arrangements that are or have been reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that are material to investors.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_199"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Term Loan provided for under our Amended Credit Agreement, as of March&#160;31, 2024, were $296.5 million. The Term Loan bears interest at an annual rate equal to either, at the Company&#8217;s option, (a) the Term SOFR Reference Rate (as defined in the Amended Credit Agreement), adjusted for any Term SOFR Adjustment (as defined in the Amended Credit Agreement), plus a spread from 1.50% to 2.75%, as determined on a quarterly basis based on the Company&#8217;s Consolidated Total Net Leverage Ratio, or (b) a base rate, plus a spread of 0.50% to 1.75%, as determined on a quarterly basis based on the Company&#8217;s Consolidated Total Net Leverage Ratio. As of March&#160;31, 2024, the Company borrowed $94.8 million under the Revolver Loan. The Revolver Loan bears interest at an annual rate equal to either, at the Company&#8217;s option, (a) the Term SOFR Reference Rate (as defined in the Amended Credit Agreement), adjusted for any Term SOFR Adjustment (as defined in the Amended Credit Agreement) plus a spread ranging from 1.25% to 2.50%, as determined on a quarterly basis based on the Company&#8217;s Consolidated Total Net Leverage Ratio (as defined in the Amended Credit Agreement), or (b) a base rate, plus a spread ranging from 0.25% to 1.50%, as determined on a quarterly basis based on the Company&#8217;s Consolidated Total Net Leverage Ratio. Borrowings under the Promissory Note Payable, as of March&#160;31, 2024, was $2.0 million. The interest rate is defined as the prime rate plus 1.0%. The prime rate is updated annually on the effective date of the note and published by the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company has entered into a collar agreement for its Revolver Loan to effectively convert its floating-rate debt to a fixed-rate basis. The principal objective of the collar agreement is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#8217;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. A hypothetical 1% change in our interest rates for our outstanding borrowings would have increased or decreased our interest expense for the three months ended March&#160;31, 2024, by $3.9 million.</span></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_205"></div><div style="margin-top:10pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act, designed to ensure that information required to be disclosed by a company in the reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial and Operating Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on that evaluation, our management, including our Chief Executive Officer and Chief Financial and Operating Officer, concluded that our disclosure controls and procedures were effective as of March&#160;31, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the quarter ended March&#160;31, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><span><br/></span></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_208"></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II &#8211; OTHER INFORMATION</span></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_211"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are, from time to time, party to lawsuits, threatened lawsuits, disputes and other claims arising in the normal course of business. We assess our liabilities and contingencies in connection with outstanding legal proceedings utilizing the latest information available. Where it is probable that we will incur a loss and the amount of the loss can be reasonably estimated, we record a liability in our consolidated financial statements. These legal accruals may be increased or decreased to reflect any relevant developments on a quarterly basis. Where a loss is not probable or the amount of the loss is not estimable, we do not record an accrual, consistent with applicable accounting guidance. In the opinion of management, while the outcome of such claims and disputes cannot be predicted with certainty, our ultimate liability in connection with these matters is not expected to have a material adverse effect on our results of operations, financial position or cash flows, and the amounts accrued for any individual matter are not material. However, legal proceedings are inherently uncertain. As a result, the outcome of a particular matter or a combination of matters may be material to our results of operations for a particular period, depending upon the size of the loss or our income for that particular period.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the pending or threatened legal proceedings or claims in which we are involved are discussed under Note 12 - &#8220;Commitments and Contingencies,&#8221; to our unaudited consolidated financial statements in this Quarterly Report on Form 10-Q, which disclosure is incorporated by reference herein.</span></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_214"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business, financial condition, and operating results are affected by a number of factors, whether currently known or unknown, including risks specific to us or the healthcare industry, as well as&#160;risks that affect businesses in general. In addition to the information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, Item 1A, &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2023, filed with the SEC on February 29, 2024. The risks disclosed in such Annual Report could materially adversely affect our business, financial condition, cash flows, or results of operations and thus our stock price. We believe there have been no material changes in our risk factors from those disclosed in the Annual Report. However, additional risks and uncertainties not currently known or which we currently deem to be immaterial may also materially adversely affect our business, financial condition, or results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of such risk factors, as well as other factors affecting the Company&#8217;s financial condition and operating results, past financial performance should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate results or trends in future periods. In addition, the disclosure of any risk factor should not be interpreted to imply that the risk has not already materialized.<br/></span></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_217"></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ITEM 2.&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 the Company issued an aggregate of 631,712 shares of common stock. The foregoing issuances was exempt from the registration provisions of the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof, and/or Regulation D promulgated thereunder, as a transaction not involving public offering.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024, no shares were repurchased under the Company&#8217;s share repurchase plan. In December 2022, Astrana&#8217;s Board of Directors approved a share repurchase plan authorizing the Company to repurchase up to $50.0 million of its shares of common stock on the open market and through privately negotiated transactions. This share repurchase plan does not have an expiration date. The Board may suspend or discontinue the repurchase program at any time. This repurchase program does not obligate the Company to make additional repurchases at any specific time or in any specific situation. As of March&#160;31, 2024, $40.5 million remained available for repurchase under the repurchase plan.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about purchases made by the Company of shares of the Company's common stock during the three months ended March&#160;31, 2024.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.549%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of Shares Purchased</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Price Paid per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Approximate Dollar Value of Shares that May Yet be Purchased Under the Plans or Programs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2024 to January 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 1, 2024 to February 29, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2024 to March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,740&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,461&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Shares were repurchased to satisfy tax withholding obligations due upon the vesting of restricted stock held by certain employees. We did not pay cash to repurchase these shares, nor were these repurchases part of a publicly announced plan or program. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_223"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_226"></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_229"></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;OTHER INFORMATION</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rule 10b5-1 Trading Plans </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended March&#160;31, 2024, none of the Company&#8217;s directors or executive officers <ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1350"><ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1351">adopted</ix:nonNumeric></ix:nonNumeric>, modified or <ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1352"><ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1353">terminated</ix:nonNumeric></ix:nonNumeric> any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act or any &#8220;non-Rule 10b5-1 trading arrangement&#8221; (as defined in Item 408(c) of Regulation S-K).</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Bylaws Amendments</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2024, the Company&#8217;s board of directors approved the amendment and restatement of the Company&#8217;s Restated Bylaws (as amended and restated, the &#8220;Amended and Restated Bylaws&#8221;), which became effective immediately upon adoption. Among other things, the Amended and Restated Bylaws:</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish certain procedural mechanics and disclosure requirements for stockholder nominations of directors and submissions of proposals for other business made in connection with annual and special meetings of stockholders, including to address rules related to the use of universal proxy cards adopted by the SEC under Rule 14a-19 promulgated under the Exchange Act;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require stockholders directly or indirectly soliciting proxies from other stockholders to use a proxy card color other than white, with the white proxy card being reserved for exclusive use by the board of directors; and </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">include various updates throughout to conform to current Delaware law (including the recent amendments to the Delaware General Corporation Law), including amendments relating to stockholder lists and stockholder meeting adjournments</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Amended and Restated Bylaws also incorporate ministerial, clarifying and conforming changes.</span></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_232"></div><div style="-sec-extract:summary;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;EXHIBITS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are either incorporated by reference into or filed or furnished with this Quarterly Report on Form 10-Q, as indicated below.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">No.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm#a_annexa">Agreement and Plan of Merger, dated December 21, 2016, among Astrana Health, Inc. (f/k/a Apollo Medical Holdings, Inc.), Astrana Health Management, Inc. (f/k/a Network Medical Management, Inc.), Apollo Acquisition Corp., and Kenneth Sim, M.D. (incorporated herein by reference to Annex A to the joint proxy statement/prospectus filed pursuant to Rule 424(b)(3) on November 15, 2017, that is a part of a Registration Statement on Form S-4)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm#a_annexa">Amendment to the Agreement and Plan of Merger, dated March 30, 2017, among Astrana Health, Inc. (f/k/a Apollo Medical Holdings, Inc.), Astrana Health Management, Inc. (f/k/a Network Medical Management, Inc.), Apollo Acquisition Corp., and Kenneth Sim, M.D. (incorporated herein by reference to Annex A to the joint proxy statement/prospectus filed pursuant to Rule 424(b)(3) on November 15, 2017 that is a part of a Registration Statement on Form S-4)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm">Amendment No. 2 to the Agreement and Plan of Merger, dated October 17, 2017, among Astrana Health, Inc. (f/k/a Apollo Medical Holdings, Inc.), Astrana Health Management, Inc. (f/k/a Network Medical Management, Inc.), Apollo Acquisition Corp. and Kenneth Sim, M.D. (incorporated herein by reference to Annex A to the joint proxy statement/prospectus filed pursuant to Rule 424(b)(3) on November 15, 2017 that is a part of a Registration Statement on Form S-4)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420419025049/tv520199_ex2-4.htm">Stock Purchase Agreement, dated March 15, 2019, by and between Allied Physicians of California, APC-LSMA Designated Shareholder Medical Corporation, and Dr. Kevin Tyson (incorporated herein by reference to Exhibit 2.4 to the Company&#8217;s Quarterly Report on Form 10-Q filed on May 10, 2019)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.5&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000110465920057432/tm2018794d1_ex2-1.htm">Stock Purchase Agreement, dated as of December 31, 2019, among Bright Health Company of California, Inc., the sellers party thereto, Universal Care, Inc., the seller representatives set forth therein, and Bright Health, Inc. (solely for purposes of Section 13.22 thereto) (incorporated herein by reference to Exhibit 2.1 to the Company&#8217;s Current Report on Form 8-K filed on May 6, 2020)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420415002897/v398912_ex3-1.htm">Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on January 21, 2015)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420415025170/v408340_ex3-1.htm">Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on April 27, 2015)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420417063540/tv481301_ex3-1.htm">Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on December 13, 2017)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420418035195/tv496923_ex3-1.htm">Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on June 21, 2018)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000110465924006988/tm244161d1_ex3-1.htm">Certificate of Amendment of Restated Certificate of Incorporation (effective February 26, 2024) (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on January 26, 2024)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420415059991/v422440_ex3-1.htm">Certificate of Designation of Series A Convertible Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on October 19, 2015)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420416092455/v436045_ex3-1.htm">Amended and Restated Certificate of Designation of Astrana Health Inc. (f/k/a Apollo Medical Holdings, Inc.) (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on April 4, 2016)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000110465924028972/tm247268d2_ex3-1.htm">Amended and Restated By-laws (effective February 28, 2024) (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on February 29, 2024)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000110465924050973/tm2412389d1_ex3-1.htm">Certificate of Elimination of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (filed April 24, 2024) (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on April 24, 2024)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000110465924000337/tm2333902d1_ex10-1.htm">Amended Certificate of Determination of Preferences of Series A Preferred Stock of Allied Physicians of California, a Professional Medical Corporation (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on January 2, 2024)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000110465924009754/tm244783d1_ex10-1.htm">Amendment No. 1 to Asset and Equity Purchase Agreement, dated as of January 31, 2024, by and among Metropolitan IPA, a California professional corporation, Astrana Health Enablement of CAL LLC (f/k/a ApolloCare Enablement of CA, LLC), Astrana Health Management, Inc. (f/k/a Network Medical Management, Inc.), Astrana Health, Inc. (f/k/a Apollo Medical Holdings, Inc.), Community Family Care Medical Group IPA, Inc., Advanced Health Management Systems, L.P., Accie M. Mitchell and Gloria C. Mitchell, as Co-Trustees of the Mitchell Family Trust dated July 2, 2003, CFC Management, LLC, the other parties thereto and Marc Mitchell, as the Equityholder Representative (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on February 2, 2024)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.3+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000162828024008024/exhibit101-2015equityincen.htm">2015 Equity Incentive Plan (as amended and restated February 26, 2024) (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Annual Report on Form 10-K filed on February 29, 2024) </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.4+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000162828024008024/exhibit102-formofrestricte.htm">Form of Restricted Stock Agreement (2015 Equity Incentive Plan) (incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Annual Report on Form 10-K filed on February 29, 2024) </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.5+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000162828024008024/exhibit103-formofrestricte.htm">Form of Restricted Stock Unit Agreement (2015 Equity Incentive Plan) (incorporated herein by reference to Exhibit 10.3 to the Company&#8217;s Annual Report on Form 10-K filed on February 29, 2024) </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.6+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000162828024008024/exhibit104-formofincentive.htm">Form of Incentive Stock Option Agreement (2015 Equity Incentive Plan) (incorporated herein by reference to Exhibit 10.4 to the Company&#8217;s Annual Report on Form 10-K filed on February 29, 2024) </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.7+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000162828024008024/exhibit105-formofnonqualif.htm">Form of Nonqualified Stock Option Agreement (2015 Equity Incentive Plan) (incorporated herein by reference to Exhibit 10.5 to the Company&#8217;s Annual Report on Form 10-K filed on February 29, 2024) </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.8+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000162828024008024/exhibit1048-astranaemploye.htm">Employee Stock Purchase Plan (amended and restated effective February 26, 2024) (incorporated herein by reference to Exhibit 10.48 to the Company&#8217;s Annual Report on Form 10-K filed on February 29, 2024)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.9+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000162828024008024/exhibit1049-astrananonqual.htm">Nonqualified Deferred Compensation Plan (amended and restated effective February 26, 2024) (incorporated herein by reference to Exhibit 10.49 to the Company&#8217;s Annual Report on Form 10-K filed on February 29, 2024)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.10+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000162828024008024/exhibit1054-astranaxemploy.htm">Employment Inducement Award Plan (amended and restated effective February 26, 2024) (incorporated herein by reference to Exhibit 10.54 to the Company&#8217;s Annual Report on Form 10-K filed on February 29, 2024) </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.11+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000162828024008024/exhibit1057-formofstockopt.htm">Form of Stock Option Agreement (Employment Inducement Award Plan) (2024) (incorporated herein by reference to Exhibit 10.57 to the Company&#8217;s Annual Report on Form 10-K filed on February 29, 2024)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.12+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000162828024008024/exhibit1058-formofrestrict.htm">Form of Restricted Stock Agreement (Employment Inducement Award Plan) (2024) (incorporated herein by reference to Exhibit 10.58 to the Company&#8217;s Annual Report on Form 10-K filed on February 29, 2024)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.13+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000162828024008024/exhibit1059-formofrestrict.htm">Form of Restricted Stock Unit Agreement (Employment Inducement Award Plan) (2024) (incorporated herein by reference to Exhibit 10.59 to the Company&#8217;s Annual Report on Form 10-K filed on February 29, 2024)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.14+&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000162828024008024/exhibit1060-kumaremploym.htm">Employment Agreement, dated January 23, 2024, by and between Astrana Health Enablement of Nevada, Inc. (f/k/a ApolloCare Enablement of Nevada) and Dinesh Kumar, MD (incorporated herein by reference to Exhibit 10.60 to the Company&#8217;s Annual Report on Form 10-K filed on February 29, 2024)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.15</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000162828024008024/exhibit1061-loanandsecur.htm">Loan and Security Agreement, dated January 31, 2024, by and between Astrana Care Partners Medical Corporation (f/k/a AP-AMH 2 Medical Corporation), a California professional corporation, and Astrana Health, Inc. (f/k/a Apollo Medical Holdings, Inc.) (incorporated herein by reference to Exhibit 10.61 to the Company&#8217;s Annual Report on Form 10-K filed on February 29, 2024)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.16</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000162828024008024/exhibit1062-securedpromi.htm">Secured Promissory Note, dated January 31, 2024, between Astrana Care Partners Medical Corporation (f/k/a AP-AMH 2 Medical Corporation), a California professional corporation, as the Borrower, and Astrana Health, Inc. (f/k/a Apollo Medical Holdings, Inc.), as the Lender (incorporated herein by reference to Exhibit 10.62 to the Company&#8217;s Annual Report on Form 10-K filed on February 29, 2024)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.17&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000110465924042549/tm2410366d1_ex10-2.htm">Amendment No. 1 to Stock Purchase Agreement, dated as of March 31, 2024, by and among Astrana Health Management, Inc. (f/k/a Network Medical Management, Inc.), I Health, Inc., Ronald Brandt and Allison Brandt (incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on April 2, 2024)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.18</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000110465924042549/tm2410366d1_ex10-1.htm">Amendment No. 2 to Asset and Equity Purchase Agreement, dated as of March 29, 2024, by and among Metropolitan IPA, a California professional corporation, Astrana Health Enablement of CA LLC (f/k/a ApolloCare Enablement of CA, LLC), Astrana Health Management, Inc. (f/k/a Network Medical Management, Inc.), Astrana Health, Inc. (f/k/a Apollo Medical Holdings, Inc.), Community Family Care Medical Group IPA, Inc., Advanced Health Management Systems, L.P., Accie M. Mitchell and Gloria C. Mitchell, as Co-Trustees of the Mitchell Family Trust dated July 2, 2003, CFC Management, LLC, the other parties thereto and Marc Mitchell, as the Equityholder Representative (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on April 2, 2024)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.19+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000110465924043762/tm2410938d1_ex10-1.htm">Employment Agreement between Astrana Health, Inc. and Brandon Sim (Amended and Restated as of April 2, 2024) (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on April 5, 2024)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.20+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000110465924043762/tm2410938d1_ex10-2.htm">Employment Agreement between Astrana Health, Inc. and Chandan Basho (Amended and Restated as of April 2, 2024) (incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on April 5, 2024)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.21+*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1021-independentc.htm">Independent Contractor Agreement, dated December 1, 2023, between AMG, a California Professional Medical Corporation, and Thomas S. Lam, M.D., a Professional Corporation.</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex3112024033110-q.htm">Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex3122024033110-q.htm">Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex322024033110-q.htm">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Instance Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filed herewith.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furnished herewith</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management contract or compensatory plan, contract or arrangement</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Company agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="i3b9f0fcd8da04d6cb91e25daac4e060d_235"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIGNATURE</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:39.895%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:53.367%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASTRANA HEALTH, INC.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: May 9, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Brandon K. Sim</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brandon K. Sim, M.S.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: May 9, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Chandan Basho</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chandan Basho, M.B.A.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial and Operating Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.21
<SEQUENCE>2
<FILENAME>exhibit1021-independentc.htm
<DESCRIPTION>EX-10.21
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>exhibit1021-independentc</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- exhibit1021-independentc001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1021-independentc001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">pg. 1  INDEPENDENT CONTRACTOR AGREEMENT  This Independent Contractor Agreement (&#8220;Agreement&#8221;) is dated effective as of December 1, 2023  (the &#8220;Effective Date&#8221;), by and between AMG, a California Professional Medical Corporation (&#8220;Group&#8221;),  and Thomas S Lam, M.D., A Professional Corporation (&#8220;Provider&#8217;&#8217;).  Recitals:  WHEREAS, Group is a professional corporation organized under the laws of the State of  California which delivers medical and health care services to fee-for-service patients, to  members of preferred provider organizations (hereinafter referred to as &#8220;PPOs&#8221;), to members of  health maintenance organizations (hereinafter referred to as &#8220;HMOs&#8221;), and to other managed  care plans or programs, whether prepaid or fee-for-service or employer self-funded or insured  (hereinafter referred to as &#8220;Carriers&#8221;); and  WHEREAS, Provider shall cause Thomas S. Lam, MD (&#8220;Physician&#8221;) an independent medical  practitioner, to provide medical services pursuant to the terms of this Agreement; and  WHEREAS, Group desires to engage Provider as an independent contractor in accordance with the  terms and conditions of this Agreement to provide professional medical services as set forth herein; and  WHEREAS, Provider is agreeable to such engagement.  NOW, THEREFORE, in consideration of the mutual promises and covenants contained herein and  for other valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Group and  Provider hereby agree as follows:  Agreement:  ARTICLE I SERVICES TO BE PROVIDED  1.1. Provider Services. Provider agrees to cause Physician to provide professional medical services  to Group&#8217;s and participating hospitals&#8217; admitted patients as may from time to time be mutually agreed upon  between the parties, including, but not limited to, those services set forth in Exhibit A attached hereto.  Provider agrees that Group may list Physician on Group&#8217;s directories, letterhead and other marketing  materials as a physician who provides services on Group&#8217;s behalf. Provider shall cause Physician to  perform services for any patient of Group as reasonably requested by Group, provided that Physician has  the requisite skill, experience and expertise to treat such patient. Physician&#8217;s provision of patient care  services shall be limited to the provision of outpatient gastroenterology services and at times inpatient  gastroenterology services on an as needed basis. Group shall ensure adequate staffing to meet the needs of  Group&#8217;s patients, including, but not limited to, securing the services of additional gastroenterology  physicians as patient volume requires.  1.2. Location of Services. Provider agrees to cause Physician to provide the services set forth herein  at AMG clinic location(s) as may from time to time be mutually agreed upon by Group and Provider.  1.3. Expenses. Provider agrees to pay expenses incurred by Provider and/or Physician in  connection with the performance of Provider&#8217;s and Physician&#8217;s services hereunder, including but not limited </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit1021-independentc002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1021-independentc002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">to:  Physician&#8217;s annual medical license fees; dues and membership expenses relating to specialty  organizations; any expense relating to Provider&#8217;s office as it may be used in connection with the practice.  1.4. Credentialing and Proctoring. Provider shall be responsible for Physician meeting all  California physician licensing requirements and all credentialing and proctoring qualifications of Group,  and for maintaining full, active membership on the medical staffs (with appropriate clinical privileges) at  any hospital at which Provider provides services throughout the term of this Agreement.  1.5. Observation of Utilization Review and Quality Assurance Procedures. Provider shall cooperate  and comply with any reasonable quality assurance and utilization review procedures adopted by Group.  Upon Group&#8217;s invitation, Physician shall have the opportunity, but not the obligation, to participate in  quality assurance meetings and make recommendations with respect to protocols for patient treatment,  training of physician assistants and Group&#8217;s other non-physician staff, and other matters related to quality  assurance.  1.6. Medical and Administrative Records. Provider shall cause Physician to timely complete in a  legible form, regular and accurate medical records of the treatment and services provided to patients. In no  event shall such medical records, and all administrative records relating thereto, be completed no later than  seven (7) business days after the provision of service. Group may withhold payment to Provider hereunder  until such time as such records are. All medical and other patient-related records shall be maintained in  such form as shall be specified by Group. Provider expressly acknowledges and agrees that all of the  patients to whom Physician renders services pursuant to this Agreement are patients of Group and not of  Provider. All medical and patient-related records created or maintained in association with Provider&#8217;s  services hereunder shall remain the sole property of Group. Upon the expiration or earlier termination of  this Agreement, Group shall retain all medical and patient-related records for any patient who was under  the care and treatment of Group at any time during the term of this Agreement.  1.7. On-Call Schedule. Physician will be responsible for nighttime and weekend on call for patients  receiving gastroenterology specialty care. Physician can secure alternative coverage with other  gastroenterologist(s).  ARTICLE II REPRESENTATIONS, WARRANTIES AND COVENANTS  2.1. Compliance. With Policies, Law and Ethical Standards. Provider shall at all times during the  term of this Agreement cause Physician to provide services and otherwise act in accordance with the  policies, protocols, rules and regulations of Group, however, to the extent any Group policy, protocol, rule,  or regulation is inconsistent with the terms of this Agreement, the terms of this Agreement shall prevail.  Provider shall at all times during the term of this Agreement comply with the policies, protocols, rules and  regulations of all Group contracted IPAs and all applicable rules and regulations of the Medical Board of  California, and the ethical standards of the American and California Medical Associations. Provider agrees  to perform its obligations under this Agreement in continuous compliance with all federal, state, and local  laws and regulations applicable to the provision of medical care, including but not limited to all laws relating  to licensure of physicians, confidentiality of patient-related information, and laws governing billing and  collecting payments from payors and arrangements between providers and sources of patient referrals.  2.2. Continuing Education. During the entire term of this Agreement, Provider represents, warrants  and covenants that Physician shall, at Provider&#8217;s expense, maintain professional competence and skills  commensurate with the medical standards of the community, as required by the policies, rules and  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit1021-independentc003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1021-independentc003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">regulations of any hospitals at which Physician provides services, such hospital&#8217;s medical staff and Group,  and as required by law, by attending continuing education courses in Physician&#8217;s area of practice.  2.3. Licenses and Certification. Provider represents, warrants and covenants that Physician is a  physician duly licensed to practice medicine in the State of California, that Physician shall remain duly  licensed to practice medicine in the State of California throughout the entire term of this Agreement, that  Physician is board-eligible or board-certified to practice in Physician&#8217;s area of specialty, that (if board  certified) Physician shall remain board-certified throughout the remaining term of this Agreement unless  the Group determines otherwise, that Physician is in good standing with the Medical Board of California,  that Physician has not been subject to any disciplinary action or investigation by any medical licensing  authority or health care facility, that Physician either participates or is eligible to participate in the Medicare  and Medi-Cal programs and that Physician shall continue to participate in the Medicare and Medi-Cal  programs throughout the entire term of this Agreement. Upon Group&#8217;s request, Provider shall furnish  Group with evidence indicating that Physician licenses, certificates and qualifications are then existing,  valid and in full force and effect.  2.4. Claims, Incidents, Suits and Disciplinary Actions. Provider agrees that Provider shall promptly  report to Group any claim made, suit filed or disciplinary action (including, without limitation, any  revocation, suspension or limitation of Physician&#8217;s license or any action pertaining thereto, or any action  to exclude Physician from participating in the Medicare or Medi-Cal program) commenced against  Physician related to the provision of medical services, whether or not those services were provided to a  patient of Group. Provider shall also promptly advise Group of any incident in which any of Group&#8217;s  patients or other patients served hereunder express dissatisfaction with any services provided by Physician.  The reports required by this Section shall be provided to Group in writing. In the context of this Section,  the requirement of &#8220;prompt&#8221; reporting means that a written report shall be submitted at the earliest date  reasonably possible, but in no event more than two (2) business days after Provider learns of any claim,  suit, disciplinary proceeding, patient dissatisfaction or an incident affecting Physician&#8217;s professional  qualifications or otherwise related to Physician&#8217;s provision of professional services.  2.5. Confidentiality. During the course of its operations, Group has developed and will develop,  and Provider may gain access to, confidential or privileged information regarding Group&#8217;s patients or  business activities, including without limitation records, files, charts, documents, patient lists, patient files,  books, data, operating manuals, symbols, trademarks, trade names, service marks, designs, patient lists,  procedures, processes, and other copyrighted, patented, trademarked, or legally protectable information  which is confidential and proprietary to Group (collectively, &#8220;Trade Secrets&#8221;). Any and all records and  files respecting any patient or services provided to any patient, and any and all documentation relating to  the provision of services anticipated hereunder are confidential and proprietary to Group and shall be  deemed to be included within Trade Secrets. During the term of this Agreement and thereafter, Provider  shall treat all of the Trade Secrets as confidential and proprietary to Group and shall not: (a) disclose the  Trade Secrets, in whole or in part, to any third party without the prior written consent of Group; (b) permit  the use or appropriation of the Trade Secrets by any third party; (c) use or appropriate the Trade Secrets for  any purpose other than the performance of Provider&#8217;s obligations under this Agreement; or (d) otherwise  use or appropriate the Trade Secrets for Provider&#8217;s own account, or as an agent, employee, contractor,  partner, director or stockholder of, or in concert with, any person, firm, corporation or other organization.  2.6. Non-Solicitation. Provider agrees that as a material condition to Group&#8217;s willingness to enter  into this Agreement, Provider agrees that during the term of this Agreement and any extensions or renewals  hereof, and for a further period of two (2) years after termination of this Agreement, Provider will not  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit1021-independentc004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1021-independentc004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">pg. 4  request or advise, solicit or attempt to solicit, or assist any other party to request or advise, solicit or attempt  to solicit: (i) any present or future Group client or patient to withdraw or terminate treatment with, or to  transfer services or treatment from, Group or to seek to be covered by any payor other than the existing  payor with which Group contracts; or (ii) any payor or other party or referring physician or organization to  withdraw or terminate treatment, employment or service with Group or to otherwise utilize any competitors  of Group for any such treatment, employment or service; or (iii) any existing employee, contractor or agent  of Group, including without limitation any physician employed or otherwise engaged by Group, to  terminate or modify their existing relationship with Group or to provide services to any competitor of  Group.  2.7. Equitable Remedies. Group and Provider acknowledge and agree that the Group&#8217;s remedy at  law for a breach or threatened breach of any of the provisions set forth in Sections 2.5, 2.6 or 2.7  (collectively, the &#8220;Protective Provisions&#8221;) would be inadequate. In recognition of this fact, in the event of  a breach or threatened breach of any of the Protected Provisions, Group shall be entitled to, without posting  any bond, and the Provider agrees not to oppose Group&#8217;s right to seek equitable relief in the form of specific  erformance, temporary restraining order, temporary or permanent injunction or any other available  equitable remedy in the event of any breach by Provider of any of the Protective Provisions. Nothing herein  shall be construed as prohibiting Group from pursuing any other remedies available to Group for such  breach or threatened breach.  ARTICLE I COMPENSATION, BENEFITS, BILLING AND INSURANCE  3.1. Compensation. The total compensation to be paid Provider for the services to be  rendered under this Agreement shall be as set forth in Exhibit B attached hereto, which is incorporated by  reference herein. Group shall not be required to offer or pay Provider any compensation or benefits other  than those expressly set forth in this Agreement.  3.2. Fair Value Warranty. Each party represents and warrants on behalf of itself, that the aggregate  benefit given or received under this Agreement has been determined in advance through a process of arms-  length negotiations that were intended to achieve an exchange of goods and/or services consistent with fair  market value under the circumstances, and that any benefit given or received under this Agreement is not  intended to induce, does not require, and is not contingent upon, the admission, recommendation or referral  of any patient, directly or indirectly, to Group, or to Provider, and further, is not determined in any manner  that takes into account the value of business generated between the parties.  3.3. Scheduling. Physician shall be available to render Services to patients as may from time to  time be mutually agreed upon by Group and Provider. Provider agrees to give Group sixty (60) days&#8217;  advance notice of any period of unavailability, excepting unavailability due to Physician&#8217;s illness or  emergency, in which event(s) Provider shall notify Group as soon as reasonably possible.  3.4. Benefits. Group shall not be required to offer Provider or Physician any compensation or  benefits other than those expressly set forth in this Agreement.  3.5. Witness Fees. Royalties. and Honoraria. Notwithstanding any other provision of this  Agreement, Provider shall be entitled to retain any and all compensation received by Provider as  compensation for expert witness fees, royalties, or honoraria.  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit1021-independentc005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1021-independentc005.jpg" title="slide5" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">pg. 5  3.6. Professional Fees and Billing. Group shall establish fee levels and shall bill or have its agent  bill for all services of Provider pursuant to the terms of this Agreement. Provider hereby exclusively assigns  to Group any rights Provider may have to patient and third-party collections (including, but not limited to,  payments due from the Medicare and Medicaid programs) with respect to services rendered pursuant to this  Agreement. Provider shall timely submit all information required by Group for billing third party payers  relating to each patient receiving Provider&#8217;s services, but in no event later than one (1) week after  Physician&#8217;s services have been rendered. Provider agrees to cooperate with Group and/or its agent, to  execute such other documents and take such other actions as may be reasonably necessary or desirable, to  effectuate the efficient day-to-day billing and collection of Provider&#8217;s fees and charges in accordance with  the terms of this Agreement. Group shall be solely entitled to proceeds resulting from collection of all  charges for the services to be performed hereunder for patients or third-party payors.  3.7. Provider Not to Bill Patients. Provider shall not, under any circumstances, including, without  limitation, the nonpayment or insolvency of Group, a preferred provider organization (&#8220;PPO&#8221;), health  maintenance organization (&#8220;HMO&#8221;) or other managed care program or breach or termination of this  Agreement, seek compensation from, have any recourse against, or impose any additional charge upon, any  patient treated by Provider or any client rendered services pursuant to this Agreement, including, without  limitation, governmental payment programs. Neither Provider, nor any agent, employee, representative,  trustee or assignee thereof, may maintain any action at law or in equity against a Group client or patient to  collect sums owed by Group or by any PPO, HMO, other managed care program or payor. Provider agrees  to look solely to Group for payment for services provided by Provider hereunder. Provider further agrees  that these requirements shall survive the termination of this Agreement regardless of the cause giving rise  to such termination.  3.8. Insurance. In consideration of Physician&#8217;s role as the CEO and Medical Director of AMG, A  Professional Medical Corporation, Group shall provide and cover Physician&#8217;s malpractice insurance  during the entire term of this Agreement &#8220;claims made&#8221; malpractice insurance in a minimum amount of at  least One Million Dollars ($1,000,000) per claim and an annual aggregate amount of Three Million Dollars  ($3,000,000) to cover any loss, liability or damage alleged to have been committed by Physician during the  performance of any services under this Agreement. Should Group or Provider/Physician terminate this  Agreement for any reason, Group shall procure and provide insurance coverages for a &#8220;tail&#8221; policy for the  Provider/Physician.  ARTICLE IV TERM AND TERMINATION  4.1. Term. The initial term of this Agreement is for a period of one (1) year, commencing on the  Effective Date (the &#8220;Initial Term&#8221;), unless earlier terminated as provided herein. Upon expiration of the  Initial Term, this Agreement shall automatically renew for successive one (1) year terms (the &#8220;Extended  Terms&#8221;), unless either party terminates the Agreement in a manner provided herein or provides the other  party with written notice of nonrenewal at least sixty_days prior to the expiration of the then-current term.  4.2. Termination.  4.2.1. Termination With Cause.  (a) Termination By Group. Subject to Sections 4.2.2 and 4.2.3 below, this  Agreement may be terminated at any time by Group, with cause, by giving written notice to  Provider. Grounds for termination with cause are as follows: (i) Provider&#8217;s failure to comply with  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit1021-independentc006.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1021-independentc006.jpg" title="slide6" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">any material terms or conditions of this Agreement, Group&#8217;s Articles of Incorporation, Bylaws,  policies and procedures or any other governing document or instrument of Group; (ii) loss or  restriction of Physician&#8217;s medical staff privileges at any hospital; (iii) Physician&#8217;s ineligibility or  failure to participate in the Medicare or Medi-Cal program; (iv) Provider&#8217;s inability to obtain or  maintain professional liability insurance covering Physician; (v) provision by Physician of  substandard care or services, as determined by Group; or (vi) Provider&#8217;s or Physician&#8217;s participation  in conduct or activity which may jeopardize Group&#8217;s agreement with any client, HMO, PPO, or  other payor, or which exposes Group to financial liability.  (b) Termination by Provider. Subject to Section 4.2.3 below, this Agreement  may be terminated at any time by Provider, with cause, by written notice to the Group. Grounds  for termination with cause by Provider shall be limited to non-payment of compensation by Group  as provided hereunder or failure to meet any other material obligation of Group hereunder and  failure by Group to cure such failure within the applicable cure period addressed below.  (c) Notice and Cure. Any termination notice given for cause pursuant to this  Section shall be accompanied by a notice specifying any defects arising under this Agreement and  shall include suggested methods for curing such defects. The party receiving such notice of defect  shall have thirty (30) days from the receipt of the termination notice to cure any defects specified  therein, except with respect to defaults threatening patient welfare or violation of law or otherwise  constituting an immediate and material threat to Group&#8217;s licensure or contracts with any Group  clients or payors, in which case no advance notice or cure period is required. If the party which  served the termination notice reasonably agrees that the defects have been cured at the end of the  thirty (30) day period, the termination notice shall be rendered inoperative and shall be null and  void.  4.2.2. Immediate Termination. Notwithstanding anything herein to the contrary, Group  may terminate this Agreement immediately upon written notice to Provider in the event that: (i) Physician&#8217;s  license to practice medicine or DEA Certificate is suspended or revoked; (ii) Physician&#8217;s right to practice  at any health care facility is terminated or restricted for a medical disciplinary reason (as defined in  California&#8217;s Business and Professions Code Section 805); (iii) Physician is excluded from participation in  the Medicare or Medicaid program; (iv) Provider or Physician is convicted of a felony or other crime related  to the provision of health care services; (v) Group&#8217;s credentials verification process discloses incomplete  or incorrectly reported material information; (vi) Physician dies or becomes incompetent or disabled  (wherein for purposes of this Section 4.2.2 only, Physician shall be deemed to be incompetent or disabled  if Physician is diagnosed as being physically or mentally unable to provide the services required by this  Agreement, despite reasonable accommodations being provided by Group, by another physician licensed  in California and reasonably qualified to make such a diagnosis, and such failure or inability continues for  ninety (90) days during any six (6) consecutive month period of the term of this Agreement); and/or (vii)  Group determines, in its reasonable discretion, that Physician is jeopardizing the health, safety or wellbeing  of any patient.  4.2.3. Termination Without Cause. Either party may terminate this Agreement without  cause at any time upon sixty (60) days&#8217; advance written notice to the other party. </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit1021-independentc007.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1021-independentc007.jpg" title="slide7" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">pg. 7  ARTICLE V MISCELLANEOUS PROVISIONS  5.1. Status of Provider as Independent Contractor. Group and Provider acknowledge and agree that  the parties are independent contractors, and nothing in this Agreement is intended, and nothing shall be  construed, to create a partnership, joint venture, employer-employee relationship, trust, or any other form  of legal organization or association between Group and Provider. No party shall be held to be a guarantor,  surety, fiduciary or trustee, or to have any guarantee or fiduciary obligation to the other party. Provider  expressly agrees that Provider shall not be considered an employee of Group for any purpose associated  with the performance under this Agreement. None of the benefits that Group provides to its employees will  be available to Provider (or Provider&#8217;s employees, if any). Provider shall be liable for its own debts,  obligations, acts, and omissions, including the payment of all withholding, social security, and other taxes  incurred by Provider. As an independent contractor, Provider shall be responsible for filing such tax returns  and paying such self-employment taxes as may be required by law or regulations. Provider shall indemnify,  defend, and hold Group harmless from any and all taxes, liabilities, costs, and expenses incurred by Group  as a result of any audit or other action that arises out of Provider&#8217;s breach of this Section. The provisions  of this Section shall survive the termination of this Agreement.  5.1.1. Provider shall choose the time, location, and manner in which all services are  performed, according to Provider&#8217;s own judgment, as long as the objectives set forth in this Agreement are  met in a satisfactory manner. Group does not have the right to control the details and means by which  Provider&#8217;s services are rendered. Group only seeks the benefits of the results of Provider&#8217;s efforts and,  except as otherwise provided in this Agreement, Provider assumes and retains discretion for the methods,  details, means, techniques and procedures to be utilized in the performance of Provider&#8217;s services covered  by this Agreement. In particular, Group has no right or authority to direct or control Provider regarding the  number of hours worked, place of work, or dates of work.  5.2. Confidentiality of Agreement. Each party agrees to maintain this Agreement as a confidential  document and not to disclose the Agreement or any of its terms without the prior written approval of the  other party.  5.3. Duty to Defend and Indemnify. To the extent not covered by liability insurance carried by the  parties, each party shall be solely responsible for its own claims, liabilities, damages, injuries, suits,  demands and expenses of all kinds (including, without limitation, attorneys&#8217; fees and court costs), which  may result or arise from any act or omission by such party, or by any member, shareholder, partner,  employee, representative, agent or contractor of such party, in connection with the performance of this  Agreement, and such party shall defend, indemnify and hold harmless the other party and any members,  shareholders, partners, employees, agents, representatives and contractors of the other party from and  against such losses or damages. In the event that a claim is made against both parties, it is the intent of both  parties to cooperate in the defense of said claim and to cause their insurers to do likewise.  5.4. Notices. Any notices required or permitted to be given hereunder by either party to the other  may be effected either by personal delivery in writing or by registered or certified mail, postage prepaid,  return receipt requested, addressed as follows:  If to Group: AMG, A Professional Medical Corporation  925 S. Garfield Avenue  Alhambra, CA 91801  Attn: CEO </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit1021-independentc008.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1021-independentc008.jpg" title="slide8" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">pg. 8  If to Provider Thomas S. Lam, M.D.  2307 Pennerton Drive  Glendale, CA 91206  Each party may change the address for such notice by written notice given in accordance with this Section.  Notices delivered personally shall be deemed delivered upon actual receipt. Mailed notices shall be deemed  delivered three (3) business days after deposit in the United States Mail, as provided above.  5.5. Entire Agreement of the Parties. This Agreement supersedes any and all agreements, written  and oral, between the parties hereto with respect to the rendering of services by Provider and contains all  of the covenants and agreements between the parties. All exhibits, schedules, and addendum attached  hereto are incorporated as if fully set forth herein. Each party to this Agreement acknowledges that no  representations, inducements, promises or agreements, oral or otherwise, have been made by any party, or  anyone acting on behalf of any party, which are not embodied herein, and that no other such agreement,  statement or promise not contained in this Agreement shall be valid or binding. Any modification of this  Agreement shall be effective only if it is in writing signed by the party to be charged.  5.6. Severability. If any provision of this Agreement is held by a court of competent jurisdiction to  be invalid, void or unenforceable, the remaining provisions will nevertheless continue in full force and  effect.  5.7. Waiver of Breach. Any waiver of any term, covenant or condition of this Agreement by any  party hereto shall not be effective unless set forth in writing signed by the party granting such waiver, and  in no event shall any such waiver be deemed to be a waiver of any other term, covenant or condition of this  Agreement, whether or not similar, or to be a continuing waiver.  5.8. Arbitration. Any dispute, claim or controversy arising out of or relating to this Agreement or  the breach, termination, enforcement, interpretation or validity thereof, including the determination of the  scope or applicability of this Agreement to arbitrate, shall be determined by arbitration in Los Angeles,  California before one arbitrator. The arbitration shall be administered by JAMS pursuant to its  Comprehensive Arbitration Rules and Procedures. Judgment on the award rendered by the arbitrator may  be entered in any court having competent jurisdiction. This clause shall not preclude parties from seeking  provisional or equitable remedies from a court of competent jurisdiction. The arbitrator shall not have the  power to commit errors of law or legal reasoning, and the award may be vacated or corrected on appeal to  a court of competent jurisdiction for any such error. Group and Provider will each pay one-half of the costs  and expenses of the arbitration, and each will separately pay their own counsel fees and expenses.  5.9. Governing Law. This Agreement shall be governed by and construed in accordance with the  laws of the State of California.  5.10. Assignment. This Agreement shall be binding upon, and shall inure to the benefit of, the  parties to it, and their respective heirs, legal representatives, successors and assigns. Notwithstanding the  foregoing, however, Provider may not assign any of Provider&#8217;s rights, nor delegate any of Provider&#8217;s duties  hereunder without the prior written consent of Group.  5.11. Headings. The subject headings of the articles and sections of this Agreement are included  for purposes of convenience only, and shall! not affect the construction or interpretation of any of its  provisions. </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit1021-independentc009.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1021-independentc009.jpg" title="slide9" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">5.12. Counterparts. This Agreement may be executed in multiple counterparts, each of which shall  be deemed an original and all of which together shall constitute one document.  5.13. Additional Documents. Provider agrees to execute and deliver any and all further agreements,  documents or instruments necessary to fulfill Group&#8217;s obligations hereunder.  5.14. Survival. The provisions of this Agreement which by their nature are intended to survive this  Agreement shall survive the termination or expiration of this Agreement.  IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first  appearing above.  &#8220;PROVIDER&#8221;  Thomas S. Lam, M.D., A Professional  Corporation  Signed: Dw hpi  Date: December 1*, 2023  NPI: 1437185295  Tax ID #: 20-2357548  &#8220;GROUP&#8221;  AMG, A PROFESSIONAL MEDICAL  CORPO Cutt     ear Sim, MD , Executive Qui _  Date: December 1%, 2023 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit1021-independentc010.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1021-independentc010.jpg" title="slide10" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">pg. 10  EXHIBIT A  Services  The services to be provided by Physician under this Agreement shall include, without limitation, the  following:  1. Gastroenterology Consultation and follow up.  2. Communicate directly with patient&#8217;s primary care physician.  3. Promptly enter all patient information and encounter data, including but not limited to, daily visit  codes and billing codes, into Group&#8217;s web-based database.  10 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit1021-independentc011.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1021-independentc011.jpg" title="slide11" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">pg. 11  EXHIBIT B  Compensation  1) In consideration for the services provided by Provider under this Agreement, during the term of  this Agreement, Group shall pay Provider sixty (60) percents of the claims payment attributable  to Provider payable on a quarterly basis  11 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>ex3122024033110-q.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="id79c3555c692493a882034af75e1ab5b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> EXHIBIT 31.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">PURSUANT TO</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Chandan Basho, M.B.A., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this quarterly report on Form 10-Q of Astrana Health, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Chandan Basho</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chandan Basho, M.B.A.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Chief Operating Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>ex3112024033110-q.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ibf3eb4c335fd4165869b40836a94baf4_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> EXHIBIT 31.1</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">PURSUANT TO</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Brandon K. Sim, M.S., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this quarterly report on Form 10-Q of Astrana Health, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Brandon K. Sim</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Brandon K. Sim, M.S.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer &#38; President</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>5
<FILENAME>ex322024033110-q.htm
<DESCRIPTION>EX-32
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i7f24ab1a6ebc4c4196b7b10764d09c35_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICERS AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Brandon K. Sim, M.S., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of Astrana Health, Inc. for the quarter ended March&#160;31, 2024 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Astrana Health, Inc.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.391%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Brandon K. Sim</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Brandon K. Sim, M.S.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Chandan Basho, M.B.A., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of Astrana Health, Inc. for the quarter ended March&#160;31, 2024 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Astrana Health, Inc.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.391%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Chandan Basho</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chandan Basho, M.B.A.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Chief Operating Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>asth-20240331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:b0ef7e3c-019a-4a45-b736-b471aca8f6db,g:a1c00dc1-e4c6-4560-85ab-798755e5651c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:asth="http://www.apollomed.net/20240331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.apollomed.net/20240331">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="asth-20240331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="asth-20240331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="asth-20240331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="asth-20240331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.apollomed.net/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" roleURI="http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME">
        <link:definition>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY" roleURI="http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY">
        <link:definition>0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://www.apollomed.net/role/DescriptionofBusiness">
        <link:definition>0000007 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsAssetAcquisitionsandGoodwill" roleURI="http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwill">
        <link:definition>0000009 - Disclosure - Business Combinations, Asset Acquisitions, and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNet" roleURI="http://www.apollomed.net/role/IntangibleAssetsNet">
        <link:definition>0000010 - Disclosure - Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntities" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntities">
        <link:definition>0000011 - Disclosure - Investments in Other Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoansReceivable" roleURI="http://www.apollomed.net/role/LoansReceivable">
        <link:definition>0000012 - Disclosure - Loans Receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedExpenses" roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpenses">
        <link:definition>0000013 - Disclosure - Accounts Payable and Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalLiabilities" roleURI="http://www.apollomed.net/role/MedicalLiabilities">
        <link:definition>0000014 - Disclosure - Medical Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoansandLinesofCredit" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCredit">
        <link:definition>0000015 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MezzanineandStockholdersEquity" roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquity">
        <link:definition>0000016 - Disclosure - Mezzanine and Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.apollomed.net/role/StockBasedCompensation">
        <link:definition>0000017 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.apollomed.net/role/CommitmentsandContingencies">
        <link:definition>0000018 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.apollomed.net/role/RelatedPartyTransactions">
        <link:definition>0000019 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.apollomed.net/role/IncomeTaxes">
        <link:definition>0000020 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.apollomed.net/role/EarningsPerShare">
        <link:definition>0000021 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesVIEs" roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEs">
        <link:definition>0000022 - Disclosure - Variable Interest Entities (VIEs)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.apollomed.net/role/Leases">
        <link:definition>0000023 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Segments" roleURI="http://www.apollomed.net/role/Segments">
        <link:definition>0000024 - Disclosure - Segments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsofFinancialInstruments" roleURI="http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstruments">
        <link:definition>0000025 - Disclosure - Fair Value Measurements of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.apollomed.net/role/SubsequentEvents">
        <link:definition>0000026 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>9954472 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsAssetAcquisitionsandGoodwillTables" roleURI="http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillTables">
        <link:definition>9954473 - Disclosure - Business Combinations, Asset Acquisitions, and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetTables" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetTables">
        <link:definition>9954474 - Disclosure - Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesTables" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesTables">
        <link:definition>9954475 - Disclosure - Investments in Other Entities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedExpensesTables" roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables">
        <link:definition>9954476 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalLiabilitiesTables" roleURI="http://www.apollomed.net/role/MedicalLiabilitiesTables">
        <link:definition>9954477 - Disclosure - Medical Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoansandLinesofCreditTables" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditTables">
        <link:definition>9954478 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.apollomed.net/role/StockBasedCompensationTables">
        <link:definition>9954479 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsTables" roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsTables">
        <link:definition>9954480 - Disclosure - Related-Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.apollomed.net/role/EarningsPerShareTables">
        <link:definition>9954481 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesVIEsTables" roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables">
        <link:definition>9954482 - Disclosure - Variable Interest Entities (VIEs) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.apollomed.net/role/LeasesTables">
        <link:definition>9954483 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsTables" roleURI="http://www.apollomed.net/role/SegmentsTables">
        <link:definition>9954484 - Disclosure - Segments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsofFinancialInstrumentsTables" roleURI="http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsTables">
        <link:definition>9954485 - Disclosure - Fair Value Measurements of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessDetails" roleURI="http://www.apollomed.net/role/DescriptionofBusinessDetails">
        <link:definition>9954486 - Disclosure - Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>9954487 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofDisaggregatedRevenuebyEachPayerTypeDetails" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofDisaggregatedRevenuebyEachPayerTypeDetails">
        <link:definition>9954488 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Disaggregated Revenue by Each Payer Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofContributionstoRevenueandReceivablesbyPayerDetails" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofContributionstoRevenueandReceivablesbyPayerDetails">
        <link:definition>9954489 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Contributions to Revenue and Receivables by Payer (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsAssetAcquisitionsandGoodwillAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillAdditionalInformationDetails">
        <link:definition>9954490 - Disclosure - Business Combinations, Asset Acquisitions, and Goodwill - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails" roleURI="http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails">
        <link:definition>9954491 - Disclosure - Business Combinations, Asset Acquisitions, and Goodwill - Summary of Purchase Price Allocation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsAssetAcquisitionsandGoodwillScheduleofBusinessAcquisitionProFormaInformationNonrecurringAdjustmentsDetails" roleURI="http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillScheduleofBusinessAcquisitionProFormaInformationNonrecurringAdjustmentsDetails">
        <link:definition>9954492 - Disclosure - Business Combinations, Asset Acquisitions, and Goodwill - Schedule of Business Acquisition, Pro Forma Information, Nonrecurring Adjustments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsAssetAcquisitionsandGoodwillScheduleofGoodwillDetails" roleURI="http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillScheduleofGoodwillDetails">
        <link:definition>9954493 - Disclosure - Business Combinations, Asset Acquisitions, and Goodwill - Schedule of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetScheduleofIntangibleAssetsDetails" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails">
        <link:definition>9954494 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1">
        <link:definition>9954494 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails">
        <link:definition>9954495 - Disclosure - Intangible Assets, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails">
        <link:definition>9954496 - Disclosure - Intangible Assets, Net - Schedule of Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesScheduleofEquityMethodInvestmentsDetails" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesScheduleofEquityMethodInvestmentsDetails">
        <link:definition>9954497 - Disclosure - Investments in Other Entities - Schedule of Equity Method Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails">
        <link:definition>9954498 - Disclosure - Investments in Other Entities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoansReceivableDetails" roleURI="http://www.apollomed.net/role/LoansReceivableDetails">
        <link:definition>9954499 - Disclosure - Loans Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedExpensesDetails" roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesDetails">
        <link:definition>9954500 - Disclosure - Accounts Payable and Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalLiabilitiesDetails" roleURI="http://www.apollomed.net/role/MedicalLiabilitiesDetails">
        <link:definition>9954501 - Disclosure - Medical Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityDetails" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityDetails">
        <link:definition>9954502 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Schedule of Credit Facility (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails">
        <link:definition>9954503 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Schedule of Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails">
        <link:definition>9954504 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MezzanineandStockholdersEquityDetails" roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityDetails">
        <link:definition>9954505 - Disclosure - Mezzanine and Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofShareBasedCompensationExpenseDetails" roleURI="http://www.apollomed.net/role/StockBasedCompensationScheduleofShareBasedCompensationExpenseDetails">
        <link:definition>9954506 - Disclosure - Stock-Based Compensation - Schedule of Share-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails">
        <link:definition>9954507 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofStockOptionTransactionsUnderStockOptionPlansDetails" roleURI="http://www.apollomed.net/role/StockBasedCompensationScheduleofStockOptionTransactionsUnderStockOptionPlansDetails">
        <link:definition>9954508 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Transactions Under Stock Option Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.apollomed.net/role/CommitmentsandContingenciesDetails">
        <link:definition>9954509 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>9954510 - Disclosure - Related-Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsScheduleofFeesIncurredandRevenueEarnedfromRelatedPartyTransactionsDetails" roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofFeesIncurredandRevenueEarnedfromRelatedPartyTransactionsDetails">
        <link:definition>9954511 - Disclosure - Related-Party Transactions - Schedule of Fees Incurred and Revenue Earned from Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.apollomed.net/role/IncomeTaxesDetails">
        <link:definition>9954512 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails">
        <link:definition>9954513 - Disclosure - Earnings Per Share - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareScheduleofEarningsPerShareComputationsDetails" roleURI="http://www.apollomed.net/role/EarningsPerShareScheduleofEarningsPerShareComputationsDetails">
        <link:definition>9954514 - Disclosure - Earnings Per Share - Schedule of Earnings Per Share Computations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareScheduleofSharesIncludedintheDilutedEarningsPerShareComputationsDetails" roleURI="http://www.apollomed.net/role/EarningsPerShareScheduleofSharesIncludedintheDilutedEarningsPerShareComputationsDetails">
        <link:definition>9954515 - Disclosure - Earnings Per Share - Schedule of Shares Included in the Diluted Earnings Per Share Computations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesVIEsAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsAdditionalInformationDetails">
        <link:definition>9954516 - Disclosure - Variable Interest Entities (VIEs)- Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesVIEsDetails" roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails">
        <link:definition>9954517 - Disclosure - Variable Interest Entities (VIEs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalinformationDetails" roleURI="http://www.apollomed.net/role/LeasesAdditionalinformationDetails">
        <link:definition>9954518 - Disclosure - Leases - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofComponentsofLeaseExpenseDetails" roleURI="http://www.apollomed.net/role/LeasesScheduleofComponentsofLeaseExpenseDetails">
        <link:definition>9954519 - Disclosure - Leases - Schedule of Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofOtherInformationRelatedtoLeasesDetails" roleURI="http://www.apollomed.net/role/LeasesScheduleofOtherInformationRelatedtoLeasesDetails">
        <link:definition>9954520 - Disclosure - Leases - Schedule of Other Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails" roleURI="http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails">
        <link:definition>9954521 - Disclosure - Leases - Schedule of Future Minimum Payments Under Non-cancelable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1" roleURI="http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1">
        <link:definition>9954521 - Disclosure - Leases - Schedule of Future Minimum Payments Under Non-cancelable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsDetails" roleURI="http://www.apollomed.net/role/SegmentsDetails">
        <link:definition>9954522 - Disclosure - Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails" roleURI="http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails">
        <link:definition>9954523 - Disclosure - Fair Value Measurements of Financial Instruments - Schedule of Carrying Amounts and Fair Values of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsofFinancialInstrumentsScheduleofChangeinFairValueofLevel3LiabilitiesDetails" roleURI="http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofChangeinFairValueofLevel3LiabilitiesDetails">
        <link:definition>9954524 - Disclosure - Fair Value Measurements of Financial Instruments - Schedule of Change in Fair Value of Level 3 Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails">
        <link:definition>9954525 - Disclosure - Fair Value Measurements of Financial Instruments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsofFinancialInstrumentsScheduleofGainLossonEquitySecuritiesDetails" roleURI="http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofGainLossonEquitySecuritiesDetails">
        <link:definition>9954526 - Disclosure - Fair Value Measurements of Financial Instruments - Schedule of Gain (Loss) on Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.apollomed.net/role/SubsequentEventsDetails">
        <link:definition>9954527 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="asth_TruistBankMember" abstract="true" name="TruistBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_StockholdersEquityTransferOfCommonControlEntities" abstract="false" name="StockholdersEquityTransferOfCommonControlEntities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_DepositForPurchaseOfProperty" abstract="false" name="DepositForPurchaseOfProperty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_LasalleMedicalAssociatesIpaMember" abstract="true" name="LasalleMedicalAssociatesIpaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_LmaMember" abstract="true" name="LmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_CareEnablementMember" abstract="true" name="CareEnablementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_SpecialtyCapitationPayableCurrent" abstract="false" name="SpecialtyCapitationPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" abstract="false" name="NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_CareDeliveryMember" abstract="true" name="CareDeliveryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_PatientManagementPlatformMember" abstract="true" name="PatientManagementPlatformMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" abstract="false" name="StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="asth_IHealthPromissioryNoteMember" abstract="true" name="IHealthPromissioryNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_CFCMember" abstract="true" name="CFCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_DmgMember" abstract="true" name="DmgMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_ApcStockOptionMember" abstract="true" name="ApcStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_SecuredOvernightFinancingRateMember" abstract="true" name="SecuredOvernightFinancingRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_NetworkRelationshipsMember" abstract="true" name="NetworkRelationshipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_AmendedCreditAgreementMember" abstract="true" name="AmendedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_TemporaryEquityTransferOfCommonControlEntities" abstract="false" name="TemporaryEquityTransferOfCommonControlEntities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_FiveThreeOneW.CollegeLLCMember" abstract="true" name="FiveThreeOneW.CollegeLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_MemberRelationshipsMember" abstract="true" name="MemberRelationshipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_FiduciaryAccountsPayableCurrent" abstract="false" name="FiduciaryAccountsPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_A2023MetricMember" abstract="true" name="A2023MetricMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_NoncashLeaseExpense" abstract="false" name="NoncashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_EquityMethodInvestmentAdditionalInvestment" abstract="false" name="EquityMethodInvestmentAdditionalInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_FirstMetricMember" abstract="true" name="FirstMetricMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_ThirdMetricMember" abstract="true" name="ThirdMetricMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_ContingentConsideration" abstract="false" name="ContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="asth_DebtInstrumentCovenantLeverageRatioAdjustedMaximum" abstract="false" name="DebtInstrumentCovenantLeverageRatioAdjustedMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="asth_RelatedPartyTransactionExpensesIncurredMember" abstract="true" name="RelatedPartyTransactionExpensesIncurredMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_PacificMedicalImagingAndOncologyCenterIncMember" abstract="true" name="PacificMedicalImagingAndOncologyCenterIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_CompanyAndAPCMember" abstract="true" name="CompanyAndAPCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_PayorBMember" abstract="true" name="PayorBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_SecondMetricMember" abstract="true" name="SecondMetricMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_NonCashBusinessAcquisition" abstract="false" name="NonCashBusinessAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_ProviderServicesMember" abstract="true" name="ProviderServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_LesseeFinanceLeaseTerminationPeriodIfApplicable" abstract="false" name="LesseeFinanceLeaseTerminationPeriodIfApplicable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="asth_DebtInstrumentNumberOfKeyFinancialRatios" abstract="false" name="DebtInstrumentNumberOfKeyFinancialRatios" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" abstract="false" name="BusinessCombinationEquityInterestPurchaseObligationNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_AstranaMedicalMember" abstract="true" name="AstranaMedicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_MarketableSecuritiesCurrentMaturityPeriod" abstract="false" name="MarketableSecuritiesCurrentMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="asth_DebtCovenantAggregatePurchasePriceMaximum" abstract="false" name="DebtCovenantAggregatePurchasePriceMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" abstract="false" name="StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_LeaseWeightedAverageRemainingLeaseTermAbstract" abstract="true" name="LeaseWeightedAverageRemainingLeaseTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="asth_HealthCareCapitationRevenueMember" abstract="true" name="HealthCareCapitationRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_DebtInstrumentCovenantLeverageRatioIncrementalChange" abstract="false" name="DebtInstrumentCovenantLeverageRatioIncrementalChange" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="asth_CarePartnersMember" abstract="true" name="CarePartnersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_BusinessCombinationContingentConsiderationLiabilityEachMeasurementPeriod" abstract="false" name="BusinessCombinationContingentConsiderationLiabilityEachMeasurementPeriod" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_MedicaidMember" abstract="true" name="MedicaidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_CommunityFamilyCareMedicalGroupIPAInc.Member" abstract="true" name="CommunityFamilyCareMedicalGroupIPAInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_PerformanceBasedRestrictedStockMember" abstract="true" name="PerformanceBasedRestrictedStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_BoardMembersMember" abstract="true" name="BoardMembersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_AmendedAndRestatedCreditAgreementMember" abstract="true" name="AmendedAndRestatedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_CommercialMember" abstract="true" name="CommercialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_PmiocMember" abstract="true" name="PmiocMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_RelatedPartyTransactionRevenueExpenseNetMember" abstract="true" name="RelatedPartyTransactionRevenueExpenseNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_TotalPurchaseConsiderationAbstract" abstract="true" name="TotalPurchaseConsiderationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="asth_EarningsPerShareLineItems" abstract="true" name="EarningsPerShareLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="asth_IntraCareConvertiblePromissoryNoteReceivableMember" abstract="true" name="IntraCareConvertiblePromissoryNoteReceivableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_StockIssuedDuringPeriodSharesMerger" abstract="false" name="StockIssuedDuringPeriodSharesMerger" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="asth_CommonStockDiscountedPricePercentageMaximum" abstract="false" name="CommonStockDiscountedPricePercentageMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="asth_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" abstract="true" name="ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="asth_StockAwardsAndUnitsMember" abstract="true" name="StockAwardsAndUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_PrimeCommunityCareMember" abstract="true" name="PrimeCommunityCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_NewTermLoanMember" abstract="true" name="NewTermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_OtherAcquisitionsMember" abstract="true" name="OtherAcquisitionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_BassMedicalGroupMember" abstract="true" name="BassMedicalGroupMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_OfficeLeaseMember" abstract="true" name="OfficeLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_UnamortizedDeferredFinancingCosts" abstract="false" name="UnamortizedDeferredFinancingCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_ApolloMedicalHoldingsIncMember" abstract="true" name="ApolloMedicalHoldingsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_RelatedPartyTransactionRevenueRecognizedMember" abstract="true" name="RelatedPartyTransactionRevenueRecognizedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_AccountsReceivableAndNetRevenueTable" abstract="true" name="AccountsReceivableAndNetRevenueTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="asth_RevolverLoanMember" abstract="true" name="RevolverLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_AlliedPacificOfCaliforniaIPAMember" abstract="true" name="AlliedPacificOfCaliforniaIPAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="asth_ArroyoVistaMember" abstract="true" name="ArroyoVistaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" abstract="false" name="NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_IHealthIncMember" abstract="true" name="IHealthIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_LeaseWeightedAverageDiscountRateAbstract" abstract="true" name="LeaseWeightedAverageDiscountRateAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="asth_AHMCMember" abstract="true" name="AHMCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_ConsiderationOfAcquisitionInCashFunded" abstract="false" name="ConsiderationOfAcquisitionInCashFunded" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_FinanceLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="FinanceLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_CDSCMember" abstract="true" name="CDSCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_InterestRateCollarMember" abstract="true" name="InterestRateCollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_BusinessAcquisitionOfCommonStock" abstract="false" name="BusinessAcquisitionOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_DebtInstrumentCovenantLeverageRatioMaximum" abstract="false" name="DebtInstrumentCovenantLeverageRatioMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_IncreaseDecreaseInMedicalLiabilities" abstract="false" name="IncreaseDecreaseInMedicalLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_A2024MetricMember" abstract="true" name="A2024MetricMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_SongPCMember" abstract="true" name="SongPCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_ProfessionalMedicalCorporationMember" abstract="true" name="ProfessionalMedicalCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_PaymentsToAcquireBusinessCashPayable" abstract="false" name="PaymentsToAcquireBusinessCashPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_SunnyVillageCareCenterMember" abstract="true" name="SunnyVillageCareCenterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_BusinessCombinationChangeInFairValueOfEquityInterestPurchaseObligation" abstract="false" name="BusinessCombinationChangeInFairValueOfEquityInterestPurchaseObligation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_CAIPAMSOLLCMember" abstract="true" name="CAIPAMSOLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_CommonStockDiscountedPricePercentage" abstract="false" name="CommonStockDiscountedPricePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="asth_FinanceLeaseCostsAbstract" abstract="true" name="FinanceLeaseCostsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="asth_LesseeOperatingLeaseTerminationPeriodIfApplicable" abstract="false" name="LesseeOperatingLeaseTerminationPeriodIfApplicable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="asth_NetworkMedicalManagementMember" abstract="true" name="NetworkMedicalManagementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_LineOfCreditFacilityAmountFundedAtClosing" abstract="false" name="LineOfCreditFacilityAmountFundedAtClosing" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_UnrealizedGainLossFromInvestmentInEquitySecurities" abstract="false" name="UnrealizedGainLossFromInvestmentInEquitySecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_GeneralAndAdministrativeExpensesAndDepreciationAndAmortization" abstract="false" name="GeneralAndAdministrativeExpensesAndDepreciationAndAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_MezzanineMember" abstract="true" name="MezzanineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_OtherThirdPartiesMember" abstract="true" name="OtherThirdPartiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_TermLoanMember" abstract="true" name="TermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_NoncontrollingInterestIncreaseDecreaseFromBusinessCombination" abstract="false" name="NoncontrollingInterestIncreaseDecreaseFromBusinessCombination" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_ApolloSunLabsManagementLLCMember" abstract="true" name="ApolloSunLabsManagementLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_HSMSOMember" abstract="true" name="HSMSOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_OneMSOLLCMember" abstract="true" name="OneMSOLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="asth_BoardMembersWhoAreAlsoOfficersMember" abstract="true" name="BoardMembersWhoAreAlsoOfficersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="asth_AurionMember" abstract="true" name="AurionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" abstract="false" name="RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="asth_ApcBusinessLoanAgreementMember" abstract="true" name="ApcBusinessLoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_CreditAgreementMember" abstract="true" name="CreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_EarningsPerShareTable" abstract="true" name="EarningsPerShareTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="asth_AccountsReceivableAndNetRevenueLineItems" abstract="true" name="AccountsReceivableAndNetRevenueLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="asth_AcquisitionOfNonControllingInterestShares" abstract="false" name="AcquisitionOfNonControllingInterestShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="asth_PayorAMember" abstract="true" name="PayorAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_DMGAndSunLabsMember" abstract="true" name="DMGAndSunLabsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_MezzanineEquityAbstract" abstract="true" name="MezzanineEquityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="asth_DerivativeCeilingInterestRate" abstract="false" name="DerivativeCeilingInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="asth_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsNetOfDividends" abstract="false" name="TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsNetOfDividends" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_EquityMethodAndOtherEquityInvestmentsTextBlock" abstract="false" name="EquityMethodAndOtherEquityInvestmentsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="asth_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdditions" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_ADSCMember" abstract="true" name="ADSCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_PaymentForRepurchaseOfTreasuryStockFinancingActivities" abstract="false" name="PaymentForRepurchaseOfTreasuryStockFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="asth_PayerCMember" abstract="true" name="PayerCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_PCCCVMember" abstract="true" name="PCCCVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_EquityMethodInvestmentsRollForward" abstract="true" name="EquityMethodInvestmentsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="asth_DebtInstrumentCovenantInterestCoverageRatioMinimum" abstract="false" name="DebtInstrumentCovenantInterestCoverageRatioMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="asth_ManagementContractsMember" abstract="true" name="ManagementContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="asth_AlliedPacificHoldingsInvestmentManagementLLCMember" abstract="true" name="AlliedPacificHoldingsInvestmentManagementLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_TotalAcquisitionsMember" abstract="true" name="TotalAcquisitionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_CashPaidForLeaseLiabilitiesAbstractAbstract" abstract="true" name="CashPaidForLeaseLiabilitiesAbstractAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="asth_PrimeCommunityCareOfCentralValleyIncMember" abstract="true" name="PrimeCommunityCareOfCentralValleyIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_RelatedPartyExpensesPayable" abstract="false" name="RelatedPartyExpensesPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_AAMGMember" abstract="true" name="AAMGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_DrawOnLetterOfCreditThroughRevolverLoan" abstract="false" name="DrawOnLetterOfCreditThroughRevolverLoan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_SubcontractorIPAPayable" abstract="false" name="SubcontractorIPAPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_AdvancedDiagnosticAndSurgicalCenterIncMember" abstract="true" name="AdvancedDiagnosticAndSurgicalCenterIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_ReceivablesReceivablesRelatedPartiesOtherReceivablesAndLoanReceivablesPolicyTextBlock" abstract="false" name="ReceivablesReceivablesRelatedPartiesOtherReceivablesAndLoanReceivablesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="asth_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" abstract="false" name="BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_AdvancedHealthManagementSystemsLPMember" abstract="true" name="AdvancedHealthManagementSystemsLPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_SeniorSecuredPromissoryNoteMember" abstract="true" name="SeniorSecuredPromissoryNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_SubordinatedLoanAgreementMember" abstract="true" name="SubordinatedLoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_LoanReceivableTextBlock" abstract="false" name="LoanReceivableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="asth_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" abstract="false" name="InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_PreferredBankMember" abstract="true" name="PreferredBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_VOMGMember" abstract="true" name="VOMGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="asth_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" abstract="false" name="IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="asth_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="asth_FirstCommonwealthPropertyLLCMember" abstract="true" name="FirstCommonwealthPropertyLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>asth-20240331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:b0ef7e3c-019a-4a45-b736-b471aca8f6db,g:a1c00dc1-e4c6-4560-85ab-798755e5651c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="asth-20240331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_81624928-73a6-4cbf-8ff2-9df448fbb395" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1a761208-0d6d-411c-97b3-680b7e2d9b56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_81624928-73a6-4cbf-8ff2-9df448fbb395" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_1a761208-0d6d-411c-97b3-680b7e2d9b56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_66d1ffe0-9d68-4e78-aae4-de6e476e2e25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_81624928-73a6-4cbf-8ff2-9df448fbb395" xlink:to="loc_us-gaap_IncomeTaxesReceivable_66d1ffe0-9d68-4e78-aae4-de6e476e2e25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4aaaa06b-bbaf-462d-843c-e19e011adae8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_81624928-73a6-4cbf-8ff2-9df448fbb395" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4aaaa06b-bbaf-462d-843c-e19e011adae8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_29d94fb8-724d-426e-b2f5-59d92ff5e515" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_81624928-73a6-4cbf-8ff2-9df448fbb395" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_29d94fb8-724d-426e-b2f5-59d92ff5e515" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_b731bdf7-3246-4938-a4f9-aac1ad2ac709" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_81624928-73a6-4cbf-8ff2-9df448fbb395" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_b731bdf7-3246-4938-a4f9-aac1ad2ac709" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_bec1d761-8c34-41ce-9b63-9a3329d6bb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_81624928-73a6-4cbf-8ff2-9df448fbb395" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_bec1d761-8c34-41ce-9b63-9a3329d6bb7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_928bae92-e132-4afd-8ff2-804cf7080a24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ad9951b6-e921-41c4-8896-ccf391298476" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_928bae92-e132-4afd-8ff2-804cf7080a24" xlink:to="loc_us-gaap_StockholdersEquity_ad9951b6-e921-41c4-8896-ccf391298476" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_bb040c79-1fb0-4d5e-9368-30b1539b8bec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_928bae92-e132-4afd-8ff2-804cf7080a24" xlink:to="loc_us-gaap_MinorityInterest_bb040c79-1fb0-4d5e-9368-30b1539b8bec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_c0fad642-6fd0-448b-ae2a-2aef846d554d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_2261a2d1-4046-4d6b-956c-4ade5149e2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_c0fad642-6fd0-448b-ae2a-2aef846d554d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_2261a2d1-4046-4d6b-956c-4ade5149e2bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a8ab4e95-d813-4d1a-9e1a-ad5f05cc4828" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_c0fad642-6fd0-448b-ae2a-2aef846d554d" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a8ab4e95-d813-4d1a-9e1a-ad5f05cc4828" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9202ef6a-c015-42fe-b98b-33eb31578ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_c0fad642-6fd0-448b-ae2a-2aef846d554d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9202ef6a-c015-42fe-b98b-33eb31578ddf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_696d0ea4-3700-4a78-89df-221016136a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_c0fad642-6fd0-448b-ae2a-2aef846d554d" xlink:to="loc_us-gaap_Goodwill_696d0ea4-3700-4a78-89df-221016136a8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_09992819-01e7-488c-afec-be407420cb40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_c0fad642-6fd0-448b-ae2a-2aef846d554d" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_09992819-01e7-488c-afec-be407420cb40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a18ed66f-4b19-464c-89fe-91ce9b127316" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_c0fad642-6fd0-448b-ae2a-2aef846d554d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a18ed66f-4b19-464c-89fe-91ce9b127316" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_c3fedbcf-4f51-4f62-898b-e28eec75bb28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_c0fad642-6fd0-448b-ae2a-2aef846d554d" xlink:to="loc_us-gaap_EquityMethodInvestments_c3fedbcf-4f51-4f62-898b-e28eec75bb28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_ab5cd925-fe4b-4c56-b15c-d8a554693893" xlink:href="asth-20240331.xsd#asth_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_c0fad642-6fd0-448b-ae2a-2aef846d554d" xlink:to="loc_asth_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_ab5cd925-fe4b-4c56-b15c-d8a554693893" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_d28369b8-8b91-4830-8ec6-058a95fea88c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_c0fad642-6fd0-448b-ae2a-2aef846d554d" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_d28369b8-8b91-4830-8ec6-058a95fea88c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivableNoncurrent_3f8e73ce-7534-422c-be0b-3a24063a924b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesReceivableNoncurrent"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_c0fad642-6fd0-448b-ae2a-2aef846d554d" xlink:to="loc_us-gaap_IncomeTaxesReceivableNoncurrent_3f8e73ce-7534-422c-be0b-3a24063a924b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_dcbf450e-e52a-4131-996f-56dc212a4681" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_a0a5719b-c170-4e14-b4e5-c53082c18cda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dcbf450e-e52a-4131-996f-56dc212a4681" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_a0a5719b-c170-4e14-b4e5-c53082c18cda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_d38222a5-83e8-40b4-b5d2-1c8d8dd9c9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dcbf450e-e52a-4131-996f-56dc212a4681" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_d38222a5-83e8-40b4-b5d2-1c8d8dd9c9c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_e9e70ee2-ada5-4411-9eb2-0936993f3b83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dcbf450e-e52a-4131-996f-56dc212a4681" xlink:to="loc_us-gaap_DividendsPayableCurrent_e9e70ee2-ada5-4411-9eb2-0936993f3b83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_79e8caad-0f86-4279-aca7-72950cad9e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dcbf450e-e52a-4131-996f-56dc212a4681" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_79e8caad-0f86-4279-aca7-72950cad9e6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_75561c8c-9475-4e35-a65c-97de76739cda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dcbf450e-e52a-4131-996f-56dc212a4681" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_75561c8c-9475-4e35-a65c-97de76739cda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_4d9e2f6e-9845-4cd8-b16c-7fa82380dd52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dcbf450e-e52a-4131-996f-56dc212a4681" xlink:to="loc_us-gaap_LongTermDebtCurrent_4d9e2f6e-9845-4cd8-b16c-7fa82380dd52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_FiduciaryAccountsPayableCurrent_658ef68d-b6b0-415d-a4ac-9e6cd18ccd4a" xlink:href="asth-20240331.xsd#asth_FiduciaryAccountsPayableCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dcbf450e-e52a-4131-996f-56dc212a4681" xlink:to="loc_asth_FiduciaryAccountsPayableCurrent_658ef68d-b6b0-415d-a4ac-9e6cd18ccd4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_7ed8173c-010a-40e6-a7a3-ef9bff5e4f70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dcbf450e-e52a-4131-996f-56dc212a4681" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_7ed8173c-010a-40e6-a7a3-ef9bff5e4f70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_b4d85516-1a2b-40aa-9d0e-928ad5c73760" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dcbf450e-e52a-4131-996f-56dc212a4681" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_b4d85516-1a2b-40aa-9d0e-928ad5c73760" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5c4837ee-d2d1-4632-9657-3ebfe19143b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b1c3e9f8-d67f-4487-bd81-ab3ba209c473" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5c4837ee-d2d1-4632-9657-3ebfe19143b0" xlink:to="loc_us-gaap_Liabilities_b1c3e9f8-d67f-4487-bd81-ab3ba209c473" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_07591122-152a-4949-b88c-1b4dcad6bf25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5c4837ee-d2d1-4632-9657-3ebfe19143b0" xlink:to="loc_us-gaap_CommitmentsAndContingencies_07591122-152a-4949-b88c-1b4dcad6bf25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsNetOfDividends_629cf1ec-2068-49fb-a7d8-c93cc5748880" xlink:href="asth-20240331.xsd#asth_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsNetOfDividends"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5c4837ee-d2d1-4632-9657-3ebfe19143b0" xlink:to="loc_asth_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsNetOfDividends_629cf1ec-2068-49fb-a7d8-c93cc5748880" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f79d5ed4-e1ae-467f-84ec-e732fd2a79c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5c4837ee-d2d1-4632-9657-3ebfe19143b0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f79d5ed4-e1ae-467f-84ec-e732fd2a79c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5f317502-f2fc-4342-810e-49351482539d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ca1ea4f0-cd37-4e4a-88df-542dd585939d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5f317502-f2fc-4342-810e-49351482539d" xlink:to="loc_us-gaap_LiabilitiesCurrent_ca1ea4f0-cd37-4e4a-88df-542dd585939d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_6e1abf30-f9f3-4d05-a4aa-3291d768281e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5f317502-f2fc-4342-810e-49351482539d" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_6e1abf30-f9f3-4d05-a4aa-3291d768281e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2b25ee41-69ae-4243-bfb3-9d341314a4a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_bd31f686-08dc-47b9-8f2b-137a8a52b190" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2b25ee41-69ae-4243-bfb3-9d341314a4a8" xlink:to="loc_us-gaap_PreferredStockValue_bd31f686-08dc-47b9-8f2b-137a8a52b190" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_cec4256f-bea3-4281-9f3b-c06d6090e8e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2b25ee41-69ae-4243-bfb3-9d341314a4a8" xlink:to="loc_us-gaap_CommonStockValue_cec4256f-bea3-4281-9f3b-c06d6090e8e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_05eaebdd-2432-42d2-9d19-be3a1902cc43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2b25ee41-69ae-4243-bfb3-9d341314a4a8" xlink:to="loc_us-gaap_AdditionalPaidInCapital_05eaebdd-2432-42d2-9d19-be3a1902cc43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_08bc6b25-ab31-48c6-ac3a-0074da806964" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2b25ee41-69ae-4243-bfb3-9d341314a4a8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_08bc6b25-ab31-48c6-ac3a-0074da806964" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1dac3222-59f7-49c8-b588-551024382a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0eb1dd7e-d4a2-4989-8cac-b4ecfebd70ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1dac3222-59f7-49c8-b588-551024382a9e" xlink:to="loc_us-gaap_AssetsCurrent_0eb1dd7e-d4a2-4989-8cac-b4ecfebd70ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_9b49f4d7-d770-487d-b839-65f24f1b6371" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1dac3222-59f7-49c8-b588-551024382a9e" xlink:to="loc_us-gaap_AssetsNoncurrent_9b49f4d7-d770-487d-b839-65f24f1b6371" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_5bc9341e-5018-45c1-bcab-edb142abe00e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_87505729-7180-4c4e-b29a-00c301f211bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_5bc9341e-5018-45c1-bcab-edb142abe00e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_87505729-7180-4c4e-b29a-00c301f211bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_8db865fc-7ec1-4757-8175-42a91d0ee6e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_5bc9341e-5018-45c1-bcab-edb142abe00e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_8db865fc-7ec1-4757-8175-42a91d0ee6e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8b46b035-b6dd-4a17-8760-03d7f0aaee62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_5bc9341e-5018-45c1-bcab-edb142abe00e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8b46b035-b6dd-4a17-8760-03d7f0aaee62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_eda4ab3e-6d87-4965-b9af-d2cf6393611e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_5bc9341e-5018-45c1-bcab-edb142abe00e" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_eda4ab3e-6d87-4965-b9af-d2cf6393611e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6466f2f6-8e91-41d7-8f5a-ce318b2969ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_5bc9341e-5018-45c1-bcab-edb142abe00e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_6466f2f6-8e91-41d7-8f5a-ce318b2969ef" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="asth-20240331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_48d0eb6c-a5ec-4b90-9337-57ea3d0db3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ff9e97c4-8a1a-4788-bda7-340d9eda3999" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_48d0eb6c-a5ec-4b90-9337-57ea3d0db3b4" xlink:to="loc_us-gaap_ProfitLoss_ff9e97c4-8a1a-4788-bda7-340d9eda3999" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b351a6fc-7ead-4052-9e16-bdbf48146dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_48d0eb6c-a5ec-4b90-9337-57ea3d0db3b4" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b351a6fc-7ead-4052-9e16-bdbf48146dbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ff7f3237-acb0-4678-8b5d-7396426bd763" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f0c83d00-6b05-44a7-86d4-ed3a5bd70c20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ff7f3237-acb0-4678-8b5d-7396426bd763" xlink:to="loc_us-gaap_OperatingIncomeLoss_f0c83d00-6b05-44a7-86d4-ed3a5bd70c20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_58775a40-f74a-4e6e-877a-893db5ab411d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ff7f3237-acb0-4678-8b5d-7396426bd763" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_58775a40-f74a-4e6e-877a-893db5ab411d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b9d65775-44f4-46bc-938c-5940ee626f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a67adf51-7c9b-4c71-bab3-536d54b09b99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b9d65775-44f4-46bc-938c-5940ee626f7b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a67adf51-7c9b-4c71-bab3-536d54b09b99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_85e59058-0a1e-45eb-a549-58d7214fbf67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b9d65775-44f4-46bc-938c-5940ee626f7b" xlink:to="loc_us-gaap_CostsAndExpenses_85e59058-0a1e-45eb-a549-58d7214fbf67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_83b9160c-abc6-4ffc-8d15-3ba73f3f0556" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f0c48fc1-19d9-45ba-ac1d-2856ea7e6001" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_83b9160c-abc6-4ffc-8d15-3ba73f3f0556" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f0c48fc1-19d9-45ba-ac1d-2856ea7e6001" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b74a3c88-241c-4e29-b129-f336440819cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_83b9160c-abc6-4ffc-8d15-3ba73f3f0556" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b74a3c88-241c-4e29-b129-f336440819cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_24378865-2f8b-48bc-809a-a3fdb07785d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_29d459ee-bf54-42e6-b993-2c14e743f1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_24378865-2f8b-48bc-809a-a3fdb07785d2" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_29d459ee-bf54-42e6-b993-2c14e743f1eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0c338fd5-8834-4d12-a53c-40c20fd57b02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_24378865-2f8b-48bc-809a-a3fdb07785d2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_0c338fd5-8834-4d12-a53c-40c20fd57b02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_c52b68df-34fd-4b63-9f0d-b5d289ed605d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_24378865-2f8b-48bc-809a-a3fdb07785d2" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_c52b68df-34fd-4b63-9f0d-b5d289ed605d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_68d06908-917d-4593-a795-449d63270e10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2d960d15-f0f6-481d-a922-cc29536a4f35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_68d06908-917d-4593-a795-449d63270e10" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2d960d15-f0f6-481d-a922-cc29536a4f35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f0e9e75c-f955-48e3-8aed-0a70ee773591" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_68d06908-917d-4593-a795-449d63270e10" xlink:to="loc_us-gaap_InterestExpense_f0e9e75c-f955-48e3-8aed-0a70ee773591" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_8284d476-cb1c-408e-9946-8b7fab61c899" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_68d06908-917d-4593-a795-449d63270e10" xlink:to="loc_us-gaap_InvestmentIncomeInterest_8284d476-cb1c-408e-9946-8b7fab61c899" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_2a388504-be34-4aae-be21-dab3e91d2419" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_68d06908-917d-4593-a795-449d63270e10" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_2a388504-be34-4aae-be21-dab3e91d2419" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1705ef9f-08bc-42da-aef0-1e33d5a2d314" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_68d06908-917d-4593-a795-449d63270e10" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1705ef9f-08bc-42da-aef0-1e33d5a2d314" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="asth-20240331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_750e7611-4119-436c-9ca4-f929eb21b283" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_5bb7b263-d7dc-46fe-9cd8-85248f6b3691" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_750e7611-4119-436c-9ca4-f929eb21b283" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_5bb7b263-d7dc-46fe-9cd8-85248f6b3691" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_UnrealizedGainLossFromInvestmentInEquitySecurities_588439cc-1df2-4092-a8da-6f0d40703790" xlink:href="asth-20240331.xsd#asth_UnrealizedGainLossFromInvestmentInEquitySecurities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_750e7611-4119-436c-9ca4-f929eb21b283" xlink:to="loc_asth_UnrealizedGainLossFromInvestmentInEquitySecurities_588439cc-1df2-4092-a8da-6f0d40703790" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherOperatingActivities_60fc75ea-421d-4550-8a2a-8f27ec262331" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromOtherOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_750e7611-4119-436c-9ca4-f929eb21b283" xlink:to="loc_us-gaap_ProceedsFromOtherOperatingActivities_60fc75ea-421d-4550-8a2a-8f27ec262331" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_957951f0-0503-44fa-9d06-1914151e9725" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_750e7611-4119-436c-9ca4-f929eb21b283" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_957951f0-0503-44fa-9d06-1914151e9725" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_39af5ae0-c1b2-4df4-9548-8d9dd12473bf" xlink:href="asth-20240331.xsd#asth_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_750e7611-4119-436c-9ca4-f929eb21b283" xlink:to="loc_asth_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_39af5ae0-c1b2-4df4-9548-8d9dd12473bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_6c2e6c55-96f1-4a5f-9d26-6653705e3ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_750e7611-4119-436c-9ca4-f929eb21b283" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_6c2e6c55-96f1-4a5f-9d26-6653705e3ed5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a143341e-3cd2-4ee0-8d8a-986bff61c5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_750e7611-4119-436c-9ca4-f929eb21b283" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a143341e-3cd2-4ee0-8d8a-986bff61c5d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_629ae65c-3115-44b3-872e-ca62ea30c324" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_750e7611-4119-436c-9ca4-f929eb21b283" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_629ae65c-3115-44b3-872e-ca62ea30c324" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_d3cf99f4-4d94-43bd-8c33-4039ffd82d29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_750e7611-4119-436c-9ca4-f929eb21b283" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_d3cf99f4-4d94-43bd-8c33-4039ffd82d29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_97ea8505-6da3-44d8-9ac1-724db2cc5123" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_750e7611-4119-436c-9ca4-f929eb21b283" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_97ea8505-6da3-44d8-9ac1-724db2cc5123" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_583602b5-7dcf-441b-bca3-6b7d11fc88af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_750e7611-4119-436c-9ca4-f929eb21b283" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_583602b5-7dcf-441b-bca3-6b7d11fc88af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_IncreaseDecreaseInMedicalLiabilities_002ac5f6-1156-470d-9710-67a46283d99d" xlink:href="asth-20240331.xsd#asth_IncreaseDecreaseInMedicalLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_750e7611-4119-436c-9ca4-f929eb21b283" xlink:to="loc_asth_IncreaseDecreaseInMedicalLiabilities_002ac5f6-1156-470d-9710-67a46283d99d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_19a76cda-faad-4e3a-b77d-b3d1628f221b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_750e7611-4119-436c-9ca4-f929eb21b283" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_19a76cda-faad-4e3a-b77d-b3d1628f221b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1b5efb56-f661-4968-af87-ff069fc67902" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_750e7611-4119-436c-9ca4-f929eb21b283" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1b5efb56-f661-4968-af87-ff069fc67902" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_d5dc05f8-73ab-4c3a-a6db-885e940476b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_750e7611-4119-436c-9ca4-f929eb21b283" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_d5dc05f8-73ab-4c3a-a6db-885e940476b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_23ecd27e-317b-467e-abce-7eb9970ebc1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_750e7611-4119-436c-9ca4-f929eb21b283" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_23ecd27e-317b-467e-abce-7eb9970ebc1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_33cea821-3534-4de3-bf04-b2ee6b0ed389" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_750e7611-4119-436c-9ca4-f929eb21b283" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_33cea821-3534-4de3-bf04-b2ee6b0ed389" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_e5690c22-b5bb-47fc-a969-e30025ab861a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_750e7611-4119-436c-9ca4-f929eb21b283" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_e5690c22-b5bb-47fc-a969-e30025ab861a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_89251361-b995-4432-9bff-62fc0e4cec60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_750e7611-4119-436c-9ca4-f929eb21b283" xlink:to="loc_us-gaap_ProfitLoss_89251361-b995-4432-9bff-62fc0e4cec60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_861d50f7-d4e7-47d3-9c9b-ba3068150e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_750e7611-4119-436c-9ca4-f929eb21b283" xlink:to="loc_us-gaap_ShareBasedCompensation_861d50f7-d4e7-47d3-9c9b-ba3068150e8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_NoncashLeaseExpense_964da046-bdce-4efb-8639-c88208b7d8cf" xlink:href="asth-20240331.xsd#asth_NoncashLeaseExpense"/>
    <link:calculationArc order="21" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_750e7611-4119-436c-9ca4-f929eb21b283" xlink:to="loc_asth_NoncashLeaseExpense_964da046-bdce-4efb-8639-c88208b7d8cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c973fa41-d5a1-4dc0-a162-db76c3a48daa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_ff9d1c81-1c13-48d5-82b7-2f41cf7d99c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c973fa41-d5a1-4dc0-a162-db76c3a48daa" xlink:to="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_ff9d1c81-1c13-48d5-82b7-2f41cf7d99c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a789bf03-b57a-4cfd-b507-b530ccba339f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c973fa41-d5a1-4dc0-a162-db76c3a48daa" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a789bf03-b57a-4cfd-b507-b530ccba339f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ef02b0c4-5411-46c6-96ec-cbe8fed02fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c81581f-fa4b-4771-9532-398ede3f8eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ef02b0c4-5411-46c6-96ec-cbe8fed02fa9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c81581f-fa4b-4771-9532-398ede3f8eaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2ab51e0d-6bbc-435d-a539-a515a2318785" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ef02b0c4-5411-46c6-96ec-cbe8fed02fa9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2ab51e0d-6bbc-435d-a539-a515a2318785" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d9bedc32-cd86-44d5-95fb-31b2b4ff980e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ef02b0c4-5411-46c6-96ec-cbe8fed02fa9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d9bedc32-cd86-44d5-95fb-31b2b4ff980e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1bf97c53-b0c9-40ad-8970-361481a79177" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsMinorityInterest_44dc388a-a460-476e-a048-83559b29d9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsMinorityInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1bf97c53-b0c9-40ad-8970-361481a79177" xlink:to="loc_us-gaap_PaymentsOfDividendsMinorityInterest_44dc388a-a460-476e-a048-83559b29d9f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt_4a65ca92-c548-4582-9867-4d1f6694e495" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfOtherLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1bf97c53-b0c9-40ad-8970-361481a79177" xlink:to="loc_us-gaap_RepaymentsOfOtherLongTermDebt_4a65ca92-c548-4582-9867-4d1f6694e495" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_9e7e5364-6836-4e23-837a-e8ca4bf6f31f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1bf97c53-b0c9-40ad-8970-361481a79177" xlink:to="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_9e7e5364-6836-4e23-837a-e8ca4bf6f31f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_fccbf043-148d-41fa-a06b-655acb8020e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1bf97c53-b0c9-40ad-8970-361481a79177" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_fccbf043-148d-41fa-a06b-655acb8020e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_c53f7fd0-23fe-4f67-8511-1acb110f5dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1bf97c53-b0c9-40ad-8970-361481a79177" xlink:to="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_c53f7fd0-23fe-4f67-8511-1acb110f5dfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_505cb858-c419-4411-82db-36fb14de956b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1bf97c53-b0c9-40ad-8970-361481a79177" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_505cb858-c419-4411-82db-36fb14de956b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_ce9a799a-0121-45d6-9410-94b1c6c7a0ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1bf97c53-b0c9-40ad-8970-361481a79177" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_ce9a799a-0121-45d6-9410-94b1c6c7a0ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PaymentForRepurchaseOfTreasuryStockFinancingActivities_5d4939f1-ec5c-457f-8b77-c74ea2cf9761" xlink:href="asth-20240331.xsd#asth_PaymentForRepurchaseOfTreasuryStockFinancingActivities"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1bf97c53-b0c9-40ad-8970-361481a79177" xlink:to="loc_asth_PaymentForRepurchaseOfTreasuryStockFinancingActivities_5d4939f1-ec5c-457f-8b77-c74ea2cf9761" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_11fd9e69-1a33-4b9f-a817-8093e39af96b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_DepositForPurchaseOfProperty_57f55b37-d4bf-4f7c-aa47-31c37f266645" xlink:href="asth-20240331.xsd#asth_DepositForPurchaseOfProperty"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_11fd9e69-1a33-4b9f-a817-8093e39af96b" xlink:to="loc_asth_DepositForPurchaseOfProperty_57f55b37-d4bf-4f7c-aa47-31c37f266645" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_52c52150-c3ad-410d-b15b-e1d0b47d5a01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_11fd9e69-1a33-4b9f-a817-8093e39af96b" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_52c52150-c3ad-410d-b15b-e1d0b47d5a01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6097dc76-4b0e-45ed-99a5-cf2a7fc88957" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_11fd9e69-1a33-4b9f-a817-8093e39af96b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6097dc76-4b0e-45ed-99a5-cf2a7fc88957" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4b71f424-aadd-4af6-a811-0f8516a9be81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_11fd9e69-1a33-4b9f-a817-8093e39af96b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4b71f424-aadd-4af6-a811-0f8516a9be81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_ac9bc6ed-e969-4ce2-b465-92475671bf69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_11fd9e69-1a33-4b9f-a817-8093e39af96b" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_ac9bc6ed-e969-4ce2-b465-92475671bf69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_998b7c7b-4c85-471f-9d0a-516425336edf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_11fd9e69-1a33-4b9f-a817-8093e39af96b" xlink:to="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_998b7c7b-4c85-471f-9d0a-516425336edf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_397a59a0-a00e-4fb4-bd42-07048062488c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_11fd9e69-1a33-4b9f-a817-8093e39af96b" xlink:to="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_397a59a0-a00e-4fb4-bd42-07048062488c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_9d7bab04-ceb3-49bb-95ab-6a479e349d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_9f71dbdf-8046-4897-91b3-d09b30885b72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_9d7bab04-ceb3-49bb-95ab-6a479e349d1a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_9f71dbdf-8046-4897-91b3-d09b30885b72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash_13cdc4e0-bce7-40ab-a436-24ee22b07c14" xlink:href="asth-20240331.xsd#asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_9d7bab04-ceb3-49bb-95ab-6a479e349d1a" xlink:to="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash_13cdc4e0-bce7-40ab-a436-24ee22b07c14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_f31e4c68-482e-4ae1-b03a-f3db87d90b03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_9d7bab04-ceb3-49bb-95ab-6a479e349d1a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_f31e4c68-482e-4ae1-b03a-f3db87d90b03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_35d0a049-6783-4a8b-9111-85adaffa2700" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_9d7bab04-ceb3-49bb-95ab-6a479e349d1a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_35d0a049-6783-4a8b-9111-85adaffa2700" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_d5ce0cdc-6c54-4f65-8054-966f8b6a1db9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_9d7bab04-ceb3-49bb-95ab-6a479e349d1a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_d5ce0cdc-6c54-4f65-8054-966f8b6a1db9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_440f4265-60ca-403f-8a71-5762762d7d25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_9d7bab04-ceb3-49bb-95ab-6a479e349d1a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_440f4265-60ca-403f-8a71-5762762d7d25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates_b5f2a5bc-e26c-4ba7-8180-ecd3dc0f8c3a" xlink:href="asth-20240331.xsd#asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_9d7bab04-ceb3-49bb-95ab-6a479e349d1a" xlink:to="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates_b5f2a5bc-e26c-4ba7-8180-ecd3dc0f8c3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_debac285-6b89-4cfe-86c2-fd52b2992fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_9d7bab04-ceb3-49bb-95ab-6a479e349d1a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_debac285-6b89-4cfe-86c2-fd52b2992fe2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_805d1310-a274-44af-8d89-1acba03c0072" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_9d7bab04-ceb3-49bb-95ab-6a479e349d1a" xlink:to="loc_us-gaap_Goodwill_805d1310-a274-44af-8d89-1acba03c0072" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_a85fd74a-76ed-4c7d-8863-2fb5cf748429" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_d146fb4a-8e0e-4b43-874b-817b312af0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_a85fd74a-76ed-4c7d-8863-2fb5cf748429" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_d146fb4a-8e0e-4b43-874b-817b312af0cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_a558d872-8cb2-4f5d-b8f0-c4ae48ceae4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_a85fd74a-76ed-4c7d-8863-2fb5cf748429" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_a558d872-8cb2-4f5d-b8f0-c4ae48ceae4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_a0e72c3a-9347-43a0-8e8b-a9cb6ecb8dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_a85fd74a-76ed-4c7d-8863-2fb5cf748429" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_a0e72c3a-9347-43a0-8e8b-a9cb6ecb8dd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PaymentsToAcquireBusinessCashPayable_0d416af9-bb7d-425c-8137-e24e91815633" xlink:href="asth-20240331.xsd#asth_PaymentsToAcquireBusinessCashPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_a85fd74a-76ed-4c7d-8863-2fb5cf748429" xlink:to="loc_asth_PaymentsToAcquireBusinessCashPayable_0d416af9-bb7d-425c-8137-e24e91815633" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_25a7217c-d3c8-4a90-9fc1-d33b81c01d09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses_c14b2f9a-36fa-4776-9362-cbc6eb69e7b2" xlink:href="asth-20240331.xsd#asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_25a7217c-d3c8-4a90-9fc1-d33b81c01d09" xlink:to="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses_c14b2f9a-36fa-4776-9362-cbc6eb69e7b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest_b2e419c0-d9fd-4190-914b-7258ee79ec84" xlink:href="asth-20240331.xsd#asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_25a7217c-d3c8-4a90-9fc1-d33b81c01d09" xlink:to="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest_b2e419c0-d9fd-4190-914b-7258ee79ec84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_e4d8d59f-1ac0-455d-b7c4-6ea063994a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_25a7217c-d3c8-4a90-9fc1-d33b81c01d09" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_e4d8d59f-1ac0-455d-b7c4-6ea063994a4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates_9edb33d5-6ea0-4fb7-af59-a3aeec38208d" xlink:href="asth-20240331.xsd#asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_25a7217c-d3c8-4a90-9fc1-d33b81c01d09" xlink:to="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates_9edb33d5-6ea0-4fb7-af59-a3aeec38208d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities_a8d9d0f9-8d82-46c0-92fe-07ac16cea077" xlink:href="asth-20240331.xsd#asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_25a7217c-d3c8-4a90-9fc1-d33b81c01d09" xlink:to="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities_a8d9d0f9-8d82-46c0-92fe-07ac16cea077" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable_cf49b162-8c6c-4569-ae81-de33d3f95e76" xlink:href="asth-20240331.xsd#asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_25a7217c-d3c8-4a90-9fc1-d33b81c01d09" xlink:to="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable_cf49b162-8c6c-4569-ae81-de33d3f95e76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_71b6a53f-a800-415a-8b7e-611737b8ec7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_f121066f-7f2f-434d-bd90-05899d260b05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_71b6a53f-a800-415a-8b7e-611737b8ec7e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_f121066f-7f2f-434d-bd90-05899d260b05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_11cf4e90-5b35-4f15-a202-b353795eb3e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_71b6a53f-a800-415a-8b7e-611737b8ec7e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_11cf4e90-5b35-4f15-a202-b353795eb3e2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_bfc740f1-3bdb-4709-8d7a-b005bcc3615f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_283a8ad9-2426-469a-a84a-884c61f770d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_bfc740f1-3bdb-4709-8d7a-b005bcc3615f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_283a8ad9-2426-469a-a84a-884c61f770d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b5518d75-a7df-4551-8959-7d75f6452199" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_bfc740f1-3bdb-4709-8d7a-b005bcc3615f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b5518d75-a7df-4551-8959-7d75f6452199" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_c98f402e-9378-4d7b-86aa-271c5bfe82cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b387665a-e3ec-4087-b300-3e0d9c3918f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_c98f402e-9378-4d7b-86aa-271c5bfe82cc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b387665a-e3ec-4087-b300-3e0d9c3918f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b790040d-ee7e-4e34-9b1a-c3063533755c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0b60e8bc-58dc-45e6-ae67-36bb91a12823" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b790040d-ee7e-4e34-9b1a-c3063533755c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0b60e8bc-58dc-45e6-ae67-36bb91a12823" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c9ea1cfb-f599-46ba-ae7f-e3ec3cc855bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b790040d-ee7e-4e34-9b1a-c3063533755c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c9ea1cfb-f599-46ba-ae7f-e3ec3cc855bc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="asth-20240331.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_35012499-3c6f-4741-b1c6-3ce678db865a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_093869d0-4e7a-4037-9685-1d324a7e2bab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_35012499-3c6f-4741-b1c6-3ce678db865a" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_093869d0-4e7a-4037-9685-1d324a7e2bab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d5f03f30-dd34-4cf4-8d8e-5c47aa39478b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_35012499-3c6f-4741-b1c6-3ce678db865a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d5f03f30-dd34-4cf4-8d8e-5c47aa39478b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4468c30e-675f-44d7-9790-994091daafc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_3d88ccf1-3f63-4d06-ba89-75555e9c4e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4468c30e-675f-44d7-9790-994091daafc0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_3d88ccf1-3f63-4d06-ba89-75555e9c4e5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0ec857a4-5bad-400b-8b4c-5d34eb30fc69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4468c30e-675f-44d7-9790-994091daafc0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0ec857a4-5bad-400b-8b4c-5d34eb30fc69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_f1513f42-2975-406e-9085-b57b23b2debf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4468c30e-675f-44d7-9790-994091daafc0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_f1513f42-2975-406e-9085-b57b23b2debf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3185acf7-d943-4843-8977-f36525eb87e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4468c30e-675f-44d7-9790-994091daafc0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3185acf7-d943-4843-8977-f36525eb87e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_6cc7554e-acbf-48b6-aa48-21edfa083472" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4468c30e-675f-44d7-9790-994091daafc0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_6cc7554e-acbf-48b6-aa48-21edfa083472" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_9d5c06d1-a89e-4f09-8508-0effa18c1dc5" xlink:href="asth-20240331.xsd#asth_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4468c30e-675f-44d7-9790-994091daafc0" xlink:to="loc_asth_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_9d5c06d1-a89e-4f09-8508-0effa18c1dc5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#AccountsPayableandAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_e51c2ca4-ecd9-4ab1-a3af-3dac108c29f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_d534a273-bdf7-451e-8ccd-cc426e6d2e27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_e51c2ca4-ecd9-4ab1-a3af-3dac108c29f1" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_d534a273-bdf7-451e-8ccd-cc426e6d2e27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_SpecialtyCapitationPayableCurrent_9c369a0c-a921-4f29-9a34-258afcb526db" xlink:href="asth-20240331.xsd#asth_SpecialtyCapitationPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_e51c2ca4-ecd9-4ab1-a3af-3dac108c29f1" xlink:to="loc_asth_SpecialtyCapitationPayableCurrent_9c369a0c-a921-4f29-9a34-258afcb526db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_SubcontractorIPAPayable_3797fd7c-d0e1-4c39-b8a4-373c27ca896d" xlink:href="asth-20240331.xsd#asth_SubcontractorIPAPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_e51c2ca4-ecd9-4ab1-a3af-3dac108c29f1" xlink:to="loc_asth_SubcontractorIPAPayable_3797fd7c-d0e1-4c39-b8a4-373c27ca896d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_98408501-fc16-4fe4-84a6-3d11f8ad8e97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_e51c2ca4-ecd9-4ab1-a3af-3dac108c29f1" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_98408501-fc16-4fe4-84a6-3d11f8ad8e97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDepositLiabilities_adb2b45c-0067-4729-b6a7-d8744cc72c35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDepositLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_e51c2ca4-ecd9-4ab1-a3af-3dac108c29f1" xlink:to="loc_us-gaap_RelatedPartyDepositLiabilities_adb2b45c-0067-4729-b6a7-d8744cc72c35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1bffa1d5-00b8-4c17-9bdc-4e1a4b7a5461" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_e51c2ca4-ecd9-4ab1-a3af-3dac108c29f1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1bffa1d5-00b8-4c17-9bdc-4e1a4b7a5461" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_36e5573c-8358-4b1a-a4f8-28d885bd5b03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_e51c2ca4-ecd9-4ab1-a3af-3dac108c29f1" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_36e5573c-8358-4b1a-a4f8-28d885bd5b03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7d7d7bbc-5589-400b-99b2-d21ef267dcdc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_e51c2ca4-ecd9-4ab1-a3af-3dac108c29f1" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7d7d7bbc-5589-400b-99b2-d21ef267dcdc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilitiesDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#MedicalLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_6954b61e-ac6b-437c-9d0b-68eee3594926" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_02ee008e-f53b-4dc8-8647-0f12b194ea0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_6954b61e-ac6b-437c-9d0b-68eee3594926" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_02ee008e-f53b-4dc8-8647-0f12b194ea0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_532a2c12-f3b5-4b1e-ad32-fce4c7246a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_6954b61e-ac6b-437c-9d0b-68eee3594926" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_532a2c12-f3b5-4b1e-ad32-fce4c7246a7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_6d537de0-7a15-4fab-b45f-a262e0911401" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_5cf1add7-3643-45e5-aeb9-00f613409292" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_6d537de0-7a15-4fab-b45f-a262e0911401" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_5cf1add7-3643-45e5-aeb9-00f613409292" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_8ae35652-ac64-4e08-88bd-3673e2a0315c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_6d537de0-7a15-4fab-b45f-a262e0911401" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_8ae35652-ac64-4e08-88bd-3673e2a0315c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_323cb873-fb8c-4085-8851-09fc376c54cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_70c88fea-e799-4f90-b019-6038924c2e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_323cb873-fb8c-4085-8851-09fc376c54cc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_70c88fea-e799-4f90-b019-6038924c2e9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e7377e2f-3f18-4f3b-8bbf-cddc4c15124b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_323cb873-fb8c-4085-8851-09fc376c54cc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e7377e2f-3f18-4f3b-8bbf-cddc4c15124b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_e2272add-1a10-41c5-add8-438ee46781f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_323cb873-fb8c-4085-8851-09fc376c54cc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_e2272add-1a10-41c5-add8-438ee46781f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c37bd9e0-bfd5-4913-8a4a-88d7963b34cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_323cb873-fb8c-4085-8851-09fc376c54cc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c37bd9e0-bfd5-4913-8a4a-88d7963b34cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_59d9ccfb-206f-40c0-8983-d1a3ac62a5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_323cb873-fb8c-4085-8851-09fc376c54cc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_59d9ccfb-206f-40c0-8983-d1a3ac62a5fd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareScheduleofSharesIncludedintheDilutedEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#EarningsPerShareScheduleofSharesIncludedintheDilutedEarningsPerShareComputationsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareScheduleofSharesIncludedintheDilutedEarningsPerShareComputationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7e09244c-4870-4958-bcdf-3eeef0889636" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_39187f3b-f1b5-4d21-9171-7c9c0592713c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7e09244c-4870-4958-bcdf-3eeef0889636" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_39187f3b-f1b5-4d21-9171-7c9c0592713c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_38cea245-8219-48b4-9c74-213fcbb31b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7e09244c-4870-4958-bcdf-3eeef0889636" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_38cea245-8219-48b4-9c74-213fcbb31b0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares_8219b99f-8a8d-4306-8c88-e71db36efce0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7e09244c-4870-4958-bcdf-3eeef0889636" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares_8219b99f-8a8d-4306-8c88-e71db36efce0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#VariableInterestEntitiesVIEsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_fbf73702-160e-47a7-bc4e-34b6bc76bcf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_c9730290-2932-4326-a01f-06606a9fa19e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fbf73702-160e-47a7-bc4e-34b6bc76bcf9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_c9730290-2932-4326-a01f-06606a9fa19e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_9e7bfa36-7141-4c1f-b847-c915e56e07e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fbf73702-160e-47a7-bc4e-34b6bc76bcf9" xlink:to="loc_us-gaap_IncomeTaxesReceivable_9e7bfa36-7141-4c1f-b847-c915e56e07e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d10af74e-9a69-4b84-9d50-7bbff1aa517d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fbf73702-160e-47a7-bc4e-34b6bc76bcf9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d10af74e-9a69-4b84-9d50-7bbff1aa517d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2ebb648c-b9e2-428a-afa0-64577a1be9dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fbf73702-160e-47a7-bc4e-34b6bc76bcf9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2ebb648c-b9e2-428a-afa0-64577a1be9dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_59f119a5-609e-409f-aab3-13bf8e0f3d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fbf73702-160e-47a7-bc4e-34b6bc76bcf9" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_59f119a5-609e-409f-aab3-13bf8e0f3d9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_946bb980-cf24-4fdb-8af0-db6d78680da5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fbf73702-160e-47a7-bc4e-34b6bc76bcf9" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_946bb980-cf24-4fdb-8af0-db6d78680da5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_943ad20b-be5e-44b4-9804-7d15df130df7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fbf73702-160e-47a7-bc4e-34b6bc76bcf9" xlink:to="loc_us-gaap_RestrictedCash_943ad20b-be5e-44b4-9804-7d15df130df7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9a77eac9-4f7e-4ecb-b906-800d30b72f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_b04e19b7-ca2e-4f5c-b87f-e1253fa44df0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9a77eac9-4f7e-4ecb-b906-800d30b72f4b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_b04e19b7-ca2e-4f5c-b87f-e1253fa44df0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_727f78b5-f6e0-41b4-af41-bccec3b3a787" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9a77eac9-4f7e-4ecb-b906-800d30b72f4b" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_727f78b5-f6e0-41b4-af41-bccec3b3a787" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_FiduciaryAccountsPayableCurrent_ab9e1040-f543-49c9-be78-ab65e7f0bc59" xlink:href="asth-20240331.xsd#asth_FiduciaryAccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9a77eac9-4f7e-4ecb-b906-800d30b72f4b" xlink:to="loc_asth_FiduciaryAccountsPayableCurrent_ab9e1040-f543-49c9-be78-ab65e7f0bc59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_dbe26703-ecbd-4002-ae2f-021c6ff5f1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9a77eac9-4f7e-4ecb-b906-800d30b72f4b" xlink:to="loc_us-gaap_OtherLiabilities_dbe26703-ecbd-4002-ae2f-021c6ff5f1c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_f305ffab-abfa-43e2-bbb8-78e0cefae748" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9a77eac9-4f7e-4ecb-b906-800d30b72f4b" xlink:to="loc_us-gaap_LongTermDebtCurrent_f305ffab-abfa-43e2-bbb8-78e0cefae748" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_35983e81-8c45-4337-9071-72506400219a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9a77eac9-4f7e-4ecb-b906-800d30b72f4b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_35983e81-8c45-4337-9071-72506400219a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0ed1a908-191a-460b-94b0-6a1e87aedd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9a77eac9-4f7e-4ecb-b906-800d30b72f4b" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0ed1a908-191a-460b-94b0-6a1e87aedd7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_60444729-6a70-470f-8066-e0b7bbe37c79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9a77eac9-4f7e-4ecb-b906-800d30b72f4b" xlink:to="loc_us-gaap_DividendsPayableCurrent_60444729-6a70-470f-8066-e0b7bbe37c79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_860828ae-aa63-451c-85d2-1885c96fa758" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9a77eac9-4f7e-4ecb-b906-800d30b72f4b" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_860828ae-aa63-451c-85d2-1885c96fa758" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_51c21bba-a11b-4151-a4bf-436ef2f58061" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9a77eac9-4f7e-4ecb-b906-800d30b72f4b" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_51c21bba-a11b-4151-a4bf-436ef2f58061" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesScheduleofComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#LeasesScheduleofComponentsofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/LeasesScheduleofComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_b3b7d915-cf88-4713-b404-99c1d2ec1fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_9f6b37e1-eabb-462f-aff5-0d4931128104" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_b3b7d915-cf88-4713-b404-99c1d2ec1fe6" xlink:to="loc_us-gaap_OperatingLeaseCost_9f6b37e1-eabb-462f-aff5-0d4931128104" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_3b76380e-5998-440e-94c2-1d21ba732e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_b3b7d915-cf88-4713-b404-99c1d2ec1fe6" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_3b76380e-5998-440e-94c2-1d21ba732e9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_a8cf1ad6-5a40-4c38-8b18-bd46ae3b4e90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_b3b7d915-cf88-4713-b404-99c1d2ec1fe6" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_a8cf1ad6-5a40-4c38-8b18-bd46ae3b4e90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_c3f3e7fc-1c2e-43a8-bd8b-f9acd01111a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_b3b7d915-cf88-4713-b404-99c1d2ec1fe6" xlink:to="loc_us-gaap_SubleaseIncome_c3f3e7fc-1c2e-43a8-bd8b-f9acd01111a1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_56519a75-68e4-4926-99c6-a529e2ab26d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4878d9df-b79f-4854-9309-35ca97b0b8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_56519a75-68e4-4926-99c6-a529e2ab26d9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4878d9df-b79f-4854-9309-35ca97b0b8dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_353cf533-ce8f-45a6-ae4d-5ae24a03ad8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_56519a75-68e4-4926-99c6-a529e2ab26d9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_353cf533-ce8f-45a6-ae4d-5ae24a03ad8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_80c38b6f-d6a9-41d1-ba53-f6a2bb06b41a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_12412b09-538f-4544-bb0b-62da4770ac06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_80c38b6f-d6a9-41d1-ba53-f6a2bb06b41a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_12412b09-538f-4544-bb0b-62da4770ac06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_16e31ee3-1de2-4e75-a664-90de3bf60298" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_80c38b6f-d6a9-41d1-ba53-f6a2bb06b41a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_16e31ee3-1de2-4e75-a664-90de3bf60298" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2d0666b0-934f-4b97-8e1b-609bea0ee430" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_3d84d81e-e531-44f9-99ba-87fcf5815b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2d0666b0-934f-4b97-8e1b-609bea0ee430" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_3d84d81e-e531-44f9-99ba-87fcf5815b1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_56928f4d-47ad-478a-be71-4e4271b5afdc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2d0666b0-934f-4b97-8e1b-609bea0ee430" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_56928f4d-47ad-478a-be71-4e4271b5afdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_690349b6-db54-459d-8a18-439323407385" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2d0666b0-934f-4b97-8e1b-609bea0ee430" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_690349b6-db54-459d-8a18-439323407385" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a74f3c23-42dd-4b54-9365-920e96ab6434" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2d0666b0-934f-4b97-8e1b-609bea0ee430" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a74f3c23-42dd-4b54-9365-920e96ab6434" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_79e88070-1234-4e31-926c-0118cd71a631" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2d0666b0-934f-4b97-8e1b-609bea0ee430" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_79e88070-1234-4e31-926c-0118cd71a631" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_3a40d40c-a59f-496f-a032-3116795a0f9e" xlink:href="asth-20240331.xsd#asth_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2d0666b0-934f-4b97-8e1b-609bea0ee430" xlink:to="loc_asth_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_3a40d40c-a59f-496f-a032-3116795a0f9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_0c8949fb-0003-4565-8981-28bd20bea87c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_9f8a1065-6e55-4564-a7b2-920f9c7ffd60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_0c8949fb-0003-4565-8981-28bd20bea87c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_9f8a1065-6e55-4564-a7b2-920f9c7ffd60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_8850942b-fd77-41ae-8828-563543ec45ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_0c8949fb-0003-4565-8981-28bd20bea87c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_8850942b-fd77-41ae-8828-563543ec45ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_835270e1-a88b-43a3-b96b-071da16b1ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_0c8949fb-0003-4565-8981-28bd20bea87c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_835270e1-a88b-43a3-b96b-071da16b1ba6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_a966df00-321d-4c29-860f-5bf1127faa32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_0c8949fb-0003-4565-8981-28bd20bea87c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_a966df00-321d-4c29-860f-5bf1127faa32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_fbe7f699-6b8b-472e-af31-70b7f60a6f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_0c8949fb-0003-4565-8981-28bd20bea87c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_fbe7f699-6b8b-472e-af31-70b7f60a6f0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_FinanceLeaseLiabilityToBePaidAfterYearFour_b0c5d2d4-ab42-4a8b-af85-ea360141a9b9" xlink:href="asth-20240331.xsd#asth_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_0c8949fb-0003-4565-8981-28bd20bea87c" xlink:to="loc_asth_FinanceLeaseLiabilityToBePaidAfterYearFour_b0c5d2d4-ab42-4a8b-af85-ea360141a9b9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1" xlink:type="simple" xlink:href="asth-20240331.xsd#LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_1c6a11c6-4cd4-4aa5-80f2-afad00a8d12d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_da683579-b505-4165-bf91-535a15e725d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_1c6a11c6-4cd4-4aa5-80f2-afad00a8d12d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_da683579-b505-4165-bf91-535a15e725d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_1b90e02f-8edc-44a7-9b02-e0d5e28c3c24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_1c6a11c6-4cd4-4aa5-80f2-afad00a8d12d" xlink:to="loc_us-gaap_FinanceLeaseLiability_1b90e02f-8edc-44a7-9b02-e0d5e28c3c24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_52abb3d6-b11b-402e-8528-0ad9d154d5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ea21dc15-29ed-468f-8642-0290da899e98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_52abb3d6-b11b-402e-8528-0ad9d154d5f7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ea21dc15-29ed-468f-8642-0290da899e98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0a7bb495-5f8e-4aa5-8f74-8fcd24349999" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_52abb3d6-b11b-402e-8528-0ad9d154d5f7" xlink:to="loc_us-gaap_OperatingLeaseLiability_0a7bb495-5f8e-4aa5-8f74-8fcd24349999" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_6a67d0b5-7e8c-4cf5-928c-42355122d15d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2a04db44-b705-47c7-b7cd-7c03ff3a39de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_6a67d0b5-7e8c-4cf5-928c-42355122d15d" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2a04db44-b705-47c7-b7cd-7c03ff3a39de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5be9d827-5944-467d-87ca-fc0887d8f8c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_6a67d0b5-7e8c-4cf5-928c-42355122d15d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5be9d827-5944-467d-87ca-fc0887d8f8c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_faa80057-1cf5-45fe-9214-0bb349b0ac92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_6a67d0b5-7e8c-4cf5-928c-42355122d15d" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_faa80057-1cf5-45fe-9214-0bb349b0ac92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_3be13446-c673-4a31-8713-05fa71dfc088" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_6a67d0b5-7e8c-4cf5-928c-42355122d15d" xlink:to="loc_us-gaap_DerivativeAssets_3be13446-c673-4a31-8713-05fa71dfc088" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_5111bb48-0033-48f2-99de-0732c9b62de8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f99b2ed4-b2f4-4a2c-a058-65a3cba473fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_5111bb48-0033-48f2-99de-0732c9b62de8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f99b2ed4-b2f4-4a2c-a058-65a3cba473fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_4ea35eec-2b41-4fbf-b1a2-a008470bb61c" xlink:href="asth-20240331.xsd#asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_5111bb48-0033-48f2-99de-0732c9b62de8" xlink:to="loc_asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_4ea35eec-2b41-4fbf-b1a2-a008470bb61c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofGainLossonEquitySecuritiesDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#FairValueMeasurementsofFinancialInstrumentsScheduleofGainLossonEquitySecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofGainLossonEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_348ce813-6d46-4d0c-ad0a-71c3990250a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_1ea24d4a-df43-4b1a-a86e-acfddfc92ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_348ce813-6d46-4d0c-ad0a-71c3990250a4" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_1ea24d4a-df43-4b1a-a86e-acfddfc92ac9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_f0901b8e-c62d-423d-ac43-3b95a8633fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_348ce813-6d46-4d0c-ad0a-71c3990250a4" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_f0901b8e-c62d-423d-ac43-3b95a8633fc9" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>asth-20240331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:b0ef7e3c-019a-4a45-b736-b471aca8f6db,g:a1c00dc1-e4c6-4560-85ab-798755e5651c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="asth-20240331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0c873971-222a-4636-b85c-2bcf494032f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ed60d260-585f-438e-bbcb-cf65ed3cb808" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0c873971-222a-4636-b85c-2bcf494032f5" xlink:to="loc_us-gaap_StatementTable_ed60d260-585f-438e-bbcb-cf65ed3cb808" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8dd97ada-1157-4402-9d3c-54388038556f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ed60d260-585f-438e-bbcb-cf65ed3cb808" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8dd97ada-1157-4402-9d3c-54388038556f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8dd97ada-1157-4402-9d3c-54388038556f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8dd97ada-1157-4402-9d3c-54388038556f" xlink:to="loc_us-gaap_RelatedPartyDomain_8dd97ada-1157-4402-9d3c-54388038556f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f00dd92b-d286-47fd-9f4b-db099d2e8237" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8dd97ada-1157-4402-9d3c-54388038556f" xlink:to="loc_us-gaap_RelatedPartyDomain_f00dd92b-d286-47fd-9f4b-db099d2e8237" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_4f983fee-bd3c-4405-ba60-1302cd06be85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_f00dd92b-d286-47fd-9f4b-db099d2e8237" xlink:to="loc_us-gaap_NonrelatedPartyMember_4f983fee-bd3c-4405-ba60-1302cd06be85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_6b2428f9-817e-4fff-acc9-fdc70f3074a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_f00dd92b-d286-47fd-9f4b-db099d2e8237" xlink:to="loc_us-gaap_RelatedPartyMember_6b2428f9-817e-4fff-acc9-fdc70f3074a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4b46ac1b-81bf-4c1e-9499-63b75a61abe5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ed60d260-585f-438e-bbcb-cf65ed3cb808" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4b46ac1b-81bf-4c1e-9499-63b75a61abe5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4b46ac1b-81bf-4c1e-9499-63b75a61abe5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4b46ac1b-81bf-4c1e-9499-63b75a61abe5" xlink:to="loc_us-gaap_ClassOfStockDomain_4b46ac1b-81bf-4c1e-9499-63b75a61abe5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_36db3f88-6691-4d49-87be-58363b1e2299" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4b46ac1b-81bf-4c1e-9499-63b75a61abe5" xlink:to="loc_us-gaap_ClassOfStockDomain_36db3f88-6691-4d49-87be-58363b1e2299" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_bcd40cd7-9e73-4572-b62e-9edea2895361" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_36db3f88-6691-4d49-87be-58363b1e2299" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_bcd40cd7-9e73-4572-b62e-9edea2895361" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_43b51424-5041-4e56-8bd4-27d1bef662d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_36db3f88-6691-4d49-87be-58363b1e2299" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_43b51424-5041-4e56-8bd4-27d1bef662d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_0add10b9-ae04-4782-ae48-6dc86459e13c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c873971-222a-4636-b85c-2bcf494032f5" xlink:to="loc_us-gaap_AssetsAbstract_0add10b9-ae04-4782-ae48-6dc86459e13c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_184823bc-0e0a-47a8-89db-294b361b2012" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_0add10b9-ae04-4782-ae48-6dc86459e13c" xlink:to="loc_us-gaap_AssetsCurrentAbstract_184823bc-0e0a-47a8-89db-294b361b2012" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_719cc48f-6826-4765-a7ec-35cc8e135ace" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_184823bc-0e0a-47a8-89db-294b361b2012" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_719cc48f-6826-4765-a7ec-35cc8e135ace" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_f76a43cc-4281-439e-b7ef-d0c32a3030ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_184823bc-0e0a-47a8-89db-294b361b2012" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_f76a43cc-4281-439e-b7ef-d0c32a3030ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e7eccfba-f352-41bd-929f-9b7316ca1c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_184823bc-0e0a-47a8-89db-294b361b2012" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e7eccfba-f352-41bd-929f-9b7316ca1c2e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_3487c06c-b5cb-4109-9bf3-14b751df1e25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_184823bc-0e0a-47a8-89db-294b361b2012" xlink:to="loc_us-gaap_IncomeTaxesReceivable_3487c06c-b5cb-4109-9bf3-14b751df1e25" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_aed995e5-ccfc-4227-b67b-3c467185628a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_184823bc-0e0a-47a8-89db-294b361b2012" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_aed995e5-ccfc-4227-b67b-3c467185628a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bc7c6656-4f08-40c8-be6a-3bd998fe00a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_184823bc-0e0a-47a8-89db-294b361b2012" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bc7c6656-4f08-40c8-be6a-3bd998fe00a1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ec1f2759-ff5b-4cbd-8ea3-da816fbbca43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_184823bc-0e0a-47a8-89db-294b361b2012" xlink:to="loc_us-gaap_AssetsCurrent_ec1f2759-ff5b-4cbd-8ea3-da816fbbca43" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_0e6f58b8-488f-4aac-8c30-9926b9244542" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_0add10b9-ae04-4782-ae48-6dc86459e13c" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_0e6f58b8-488f-4aac-8c30-9926b9244542" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d55ac490-0753-4600-b9bd-56704dabc8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0e6f58b8-488f-4aac-8c30-9926b9244542" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d55ac490-0753-4600-b9bd-56704dabc8d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_09f1935f-535b-4ec4-bf92-1106cf1e3839" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0e6f58b8-488f-4aac-8c30-9926b9244542" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_09f1935f-535b-4ec4-bf92-1106cf1e3839" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ecdc9eba-04f2-4e1f-981b-b4aa853ca883" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0e6f58b8-488f-4aac-8c30-9926b9244542" xlink:to="loc_us-gaap_Goodwill_ecdc9eba-04f2-4e1f-981b-b4aa853ca883" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivableNoncurrent_541d8814-6595-4035-85c4-9ab82413553e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesReceivableNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0e6f58b8-488f-4aac-8c30-9926b9244542" xlink:to="loc_us-gaap_IncomeTaxesReceivableNoncurrent_541d8814-6595-4035-85c4-9ab82413553e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_1a382cd8-cde7-425f-8d02-15bc9b4c1382" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0e6f58b8-488f-4aac-8c30-9926b9244542" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_1a382cd8-cde7-425f-8d02-15bc9b4c1382" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_c81e1921-5709-4e0c-b4d5-a1095869f2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0e6f58b8-488f-4aac-8c30-9926b9244542" xlink:to="loc_us-gaap_EquityMethodInvestments_c81e1921-5709-4e0c-b4d5-a1095869f2e3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_6a0e5934-b29c-4121-a1f4-9c55ae47d946" xlink:href="asth-20240331.xsd#asth_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0e6f58b8-488f-4aac-8c30-9926b9244542" xlink:to="loc_asth_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_6a0e5934-b29c-4121-a1f4-9c55ae47d946" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_d39f593f-1386-43e6-9184-2c79de0a33d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0e6f58b8-488f-4aac-8c30-9926b9244542" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_d39f593f-1386-43e6-9184-2c79de0a33d9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_13c595c3-4ffa-44bd-94ec-0018e49df139" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0e6f58b8-488f-4aac-8c30-9926b9244542" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_13c595c3-4ffa-44bd-94ec-0018e49df139" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0f2980d6-e4e5-4586-a1f7-10ba35c14bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0e6f58b8-488f-4aac-8c30-9926b9244542" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_0f2980d6-e4e5-4586-a1f7-10ba35c14bd2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_4719bbba-6331-4f46-8518-95a760428791" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0e6f58b8-488f-4aac-8c30-9926b9244542" xlink:to="loc_us-gaap_AssetsNoncurrent_4719bbba-6331-4f46-8518-95a760428791" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6140160d-4a99-48e1-a869-b43158db39c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_0add10b9-ae04-4782-ae48-6dc86459e13c" xlink:to="loc_us-gaap_Assets_6140160d-4a99-48e1-a869-b43158db39c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77b73640-6d30-4de8-ad7e-fac2e4c26160" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c873971-222a-4636-b85c-2bcf494032f5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77b73640-6d30-4de8-ad7e-fac2e4c26160" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_8f39721d-4980-40a2-92cf-09e7f3559136" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77b73640-6d30-4de8-ad7e-fac2e4c26160" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_8f39721d-4980-40a2-92cf-09e7f3559136" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_afe6c983-b63a-46db-abf5-d8d8fe44a5a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8f39721d-4980-40a2-92cf-09e7f3559136" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_afe6c983-b63a-46db-abf5-d8d8fe44a5a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_FiduciaryAccountsPayableCurrent_8b4f6ce9-26e1-41c8-8ef2-52c6acb4e090" xlink:href="asth-20240331.xsd#asth_FiduciaryAccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8f39721d-4980-40a2-92cf-09e7f3559136" xlink:to="loc_asth_FiduciaryAccountsPayableCurrent_8b4f6ce9-26e1-41c8-8ef2-52c6acb4e090" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_c7d26691-7bf2-4a4e-8624-54ed3aeda473" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8f39721d-4980-40a2-92cf-09e7f3559136" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_c7d26691-7bf2-4a4e-8624-54ed3aeda473" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_4654c136-d576-422e-882a-36979ae3de02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8f39721d-4980-40a2-92cf-09e7f3559136" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_4654c136-d576-422e-882a-36979ae3de02" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_b1cc82c4-6a98-48b4-99c9-d84371a28d25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8f39721d-4980-40a2-92cf-09e7f3559136" xlink:to="loc_us-gaap_DividendsPayableCurrent_b1cc82c4-6a98-48b4-99c9-d84371a28d25" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_2d5cf7ea-2343-4566-a14d-82bee11260ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8f39721d-4980-40a2-92cf-09e7f3559136" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_2d5cf7ea-2343-4566-a14d-82bee11260ad" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_87243acd-dfc5-47e7-9c19-ee6e5d752835" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8f39721d-4980-40a2-92cf-09e7f3559136" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_87243acd-dfc5-47e7-9c19-ee6e5d752835" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_273633ba-6879-4c96-9840-4625d92d814b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8f39721d-4980-40a2-92cf-09e7f3559136" xlink:to="loc_us-gaap_LongTermDebtCurrent_273633ba-6879-4c96-9840-4625d92d814b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_b91520f7-40aa-4e75-8fd9-8c85c63dcbaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8f39721d-4980-40a2-92cf-09e7f3559136" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_b91520f7-40aa-4e75-8fd9-8c85c63dcbaf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5f1b4930-6b71-4f71-b2e5-8f4306ef3e16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8f39721d-4980-40a2-92cf-09e7f3559136" xlink:to="loc_us-gaap_LiabilitiesCurrent_5f1b4930-6b71-4f71-b2e5-8f4306ef3e16" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_0a4d7ba7-2914-4fc6-b6f6-cb1d82ee158f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77b73640-6d30-4de8-ad7e-fac2e4c26160" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_0a4d7ba7-2914-4fc6-b6f6-cb1d82ee158f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_21301111-f055-49e9-ba28-707c2101c644" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0a4d7ba7-2914-4fc6-b6f6-cb1d82ee158f" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_21301111-f055-49e9-ba28-707c2101c644" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_77781ae0-a998-4417-b12d-dab4c1bb8391" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0a4d7ba7-2914-4fc6-b6f6-cb1d82ee158f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_77781ae0-a998-4417-b12d-dab4c1bb8391" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c9c16e91-d2d8-44d3-9a29-f7b335b75d26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0a4d7ba7-2914-4fc6-b6f6-cb1d82ee158f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c9c16e91-d2d8-44d3-9a29-f7b335b75d26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_d56b228f-0ffd-4fa4-9699-4dae684b46ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0a4d7ba7-2914-4fc6-b6f6-cb1d82ee158f" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_d56b228f-0ffd-4fa4-9699-4dae684b46ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f33bbebd-aa14-4ddd-aac8-4f84945b6a13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0a4d7ba7-2914-4fc6-b6f6-cb1d82ee158f" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f33bbebd-aa14-4ddd-aac8-4f84945b6a13" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_de904f32-732f-4e37-835b-01a1ba7cfb46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0a4d7ba7-2914-4fc6-b6f6-cb1d82ee158f" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_de904f32-732f-4e37-835b-01a1ba7cfb46" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2d913925-1596-45d6-aa8b-14153a76cb7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77b73640-6d30-4de8-ad7e-fac2e4c26160" xlink:to="loc_us-gaap_Liabilities_2d913925-1596-45d6-aa8b-14153a76cb7f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4970c269-fb9f-41ce-a01a-6ce8b63bb2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77b73640-6d30-4de8-ad7e-fac2e4c26160" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4970c269-fb9f-41ce-a01a-6ce8b63bb2ae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_MezzanineEquityAbstract_91d252eb-29d3-4862-81c6-ac88b0d31df4" xlink:href="asth-20240331.xsd#asth_MezzanineEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77b73640-6d30-4de8-ad7e-fac2e4c26160" xlink:to="loc_asth_MezzanineEquityAbstract_91d252eb-29d3-4862-81c6-ac88b0d31df4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsNetOfDividends_c9d44776-7ead-4107-93c0-21b68867f902" xlink:href="asth-20240331.xsd#asth_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsNetOfDividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_asth_MezzanineEquityAbstract_91d252eb-29d3-4862-81c6-ac88b0d31df4" xlink:to="loc_asth_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsNetOfDividends_c9d44776-7ead-4107-93c0-21b68867f902" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_74e55824-1d67-4f9b-b5b5-e23988c9ef13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77b73640-6d30-4de8-ad7e-fac2e4c26160" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_74e55824-1d67-4f9b-b5b5-e23988c9ef13" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_934d66c0-9313-453d-b3b2-83c79b218588" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_74e55824-1d67-4f9b-b5b5-e23988c9ef13" xlink:to="loc_us-gaap_PreferredStockValue_934d66c0-9313-453d-b3b2-83c79b218588" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_58eee894-1a8d-47e4-9913-8c46bc9fbd00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_74e55824-1d67-4f9b-b5b5-e23988c9ef13" xlink:to="loc_us-gaap_CommonStockValue_58eee894-1a8d-47e4-9913-8c46bc9fbd00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_08668f7b-5372-4a8f-8394-73ea06e47388" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_74e55824-1d67-4f9b-b5b5-e23988c9ef13" xlink:to="loc_us-gaap_AdditionalPaidInCapital_08668f7b-5372-4a8f-8394-73ea06e47388" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6120828a-e5e2-4ca1-bde2-7efbf5cbfb57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_74e55824-1d67-4f9b-b5b5-e23988c9ef13" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6120828a-e5e2-4ca1-bde2-7efbf5cbfb57" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_db77a24f-3568-4a70-8422-43621132ed03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_74e55824-1d67-4f9b-b5b5-e23988c9ef13" xlink:to="loc_us-gaap_StockholdersEquity_db77a24f-3568-4a70-8422-43621132ed03" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_3de4d614-8b7e-40d0-8e12-4ddadb5b3bab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_74e55824-1d67-4f9b-b5b5-e23988c9ef13" xlink:to="loc_us-gaap_MinorityInterest_3de4d614-8b7e-40d0-8e12-4ddadb5b3bab" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4545bd56-4af2-46b5-8456-c2f8cfb5ee87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_74e55824-1d67-4f9b-b5b5-e23988c9ef13" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4545bd56-4af2-46b5-8456-c2f8cfb5ee87" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a9891eb8-0956-4497-b263-518c5475be9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77b73640-6d30-4de8-ad7e-fac2e4c26160" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_a9891eb8-0956-4497-b263-518c5475be9e" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="asth-20240331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bdd6d13d-49e0-4ae4-a170-369a59cba239" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8d57630d-cd0c-473b-83ef-c3a264f55b12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_bdd6d13d-49e0-4ae4-a170-369a59cba239" xlink:to="loc_us-gaap_StatementTable_8d57630d-cd0c-473b-83ef-c3a264f55b12" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f13ffa88-8491-4930-b6a5-726df2440e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8d57630d-cd0c-473b-83ef-c3a264f55b12" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f13ffa88-8491-4930-b6a5-726df2440e9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f13ffa88-8491-4930-b6a5-726df2440e9d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f13ffa88-8491-4930-b6a5-726df2440e9d" xlink:to="loc_us-gaap_ClassOfStockDomain_f13ffa88-8491-4930-b6a5-726df2440e9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b31f0d44-00ca-4ed4-bce2-f0b142437889" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f13ffa88-8491-4930-b6a5-726df2440e9d" xlink:to="loc_us-gaap_ClassOfStockDomain_b31f0d44-00ca-4ed4-bce2-f0b142437889" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_70b32c2c-e740-48a4-9429-4419b7e2ded1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b31f0d44-00ca-4ed4-bce2-f0b142437889" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_70b32c2c-e740-48a4-9429-4419b7e2ded1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_03267229-3386-4623-a13e-46a9ff0d303a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b31f0d44-00ca-4ed4-bce2-f0b142437889" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_03267229-3386-4623-a13e-46a9ff0d303a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_8b8a34e8-dd34-440b-96b2-c55c72c7aec0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8d57630d-cd0c-473b-83ef-c3a264f55b12" xlink:to="loc_srt_ConsolidatedEntitiesAxis_8b8a34e8-dd34-440b-96b2-c55c72c7aec0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_8b8a34e8-dd34-440b-96b2-c55c72c7aec0_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_8b8a34e8-dd34-440b-96b2-c55c72c7aec0" xlink:to="loc_srt_ConsolidatedEntitiesDomain_8b8a34e8-dd34-440b-96b2-c55c72c7aec0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_1e8d381a-c60c-46db-9351-28c6c7b57d4d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_8b8a34e8-dd34-440b-96b2-c55c72c7aec0" xlink:to="loc_srt_ConsolidatedEntitiesDomain_1e8d381a-c60c-46db-9351-28c6c7b57d4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_fef504f1-0ef5-4f2e-bb84-052a1d8d9d77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1e8d381a-c60c-46db-9351-28c6c7b57d4d" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_fef504f1-0ef5-4f2e-bb84-052a1d8d9d77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a68a690e-ecea-4020-bdce-8bb9a4f3f2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bdd6d13d-49e0-4ae4-a170-369a59cba239" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a68a690e-ecea-4020-bdce-8bb9a4f3f2ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_b72e5455-e8fa-458d-975d-08370c4fdd62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bdd6d13d-49e0-4ae4-a170-369a59cba239" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_b72e5455-e8fa-458d-975d-08370c4fdd62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_ead0a2a6-4d1e-4ef0-9b80-0253b42dbff1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bdd6d13d-49e0-4ae4-a170-369a59cba239" xlink:to="loc_us-gaap_PreferredStockSharesIssued_ead0a2a6-4d1e-4ef0-9b80-0253b42dbff1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_8114a03d-7f3c-46e2-8cc9-62029730aec7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bdd6d13d-49e0-4ae4-a170-369a59cba239" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_8114a03d-7f3c-46e2-8cc9-62029730aec7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e10c0f15-0e6b-4091-8aaa-10633ec8a08b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bdd6d13d-49e0-4ae4-a170-369a59cba239" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e10c0f15-0e6b-4091-8aaa-10633ec8a08b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_9f0b46ed-50d8-47a4-be2a-e58a0b08e504" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bdd6d13d-49e0-4ae4-a170-369a59cba239" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_9f0b46ed-50d8-47a4-be2a-e58a0b08e504" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f8c11323-6afa-4878-beeb-878843ec8e56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bdd6d13d-49e0-4ae4-a170-369a59cba239" xlink:to="loc_us-gaap_CommonStockSharesIssued_f8c11323-6afa-4878-beeb-878843ec8e56" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_3d09277c-bfe9-4e07-866f-7389c9e5b5ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bdd6d13d-49e0-4ae4-a170-369a59cba239" xlink:to="loc_us-gaap_SharesOutstanding_3d09277c-bfe9-4e07-866f-7389c9e5b5ad" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_cbabf2e0-367c-4041-869c-4171b3fd5870" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bdd6d13d-49e0-4ae4-a170-369a59cba239" xlink:to="loc_us-gaap_TreasuryStockCommonShares_cbabf2e0-367c-4041-869c-4171b3fd5870" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_873d5571-3324-4541-a137-9c30eb726ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bdd6d13d-49e0-4ae4-a170-369a59cba239" xlink:to="loc_us-gaap_Assets_873d5571-3324-4541-a137-9c30eb726ef2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7a250887-23b9-421a-82a3-f8c2e0ea7cea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bdd6d13d-49e0-4ae4-a170-369a59cba239" xlink:to="loc_us-gaap_Liabilities_7a250887-23b9-421a-82a3-f8c2e0ea7cea" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_047fd2d5-de19-4589-bc1b-c9297b9031ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bdd6d13d-49e0-4ae4-a170-369a59cba239" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_047fd2d5-de19-4589-bc1b-c9297b9031ee" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_53223a10-be6c-42f4-bd1c-39b550a9a096" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bdd6d13d-49e0-4ae4-a170-369a59cba239" xlink:to="loc_us-gaap_OtherLiabilities_53223a10-be6c-42f4-bd1c-39b550a9a096" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivables_8b461f7a-2d43-4090-9bbf-bc51e2142dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bdd6d13d-49e0-4ae4-a170-369a59cba239" xlink:to="loc_us-gaap_OtherReceivables_8b461f7a-2d43-4090-9bbf-bc51e2142dd2" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="asth-20240331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_73b5cf48-7237-416a-b3ff-f8dfe8f3c7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0f5dcc4f-d266-4f64-99c4-893afcbc07c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_73b5cf48-7237-416a-b3ff-f8dfe8f3c7a5" xlink:to="loc_us-gaap_StatementTable_0f5dcc4f-d266-4f64-99c4-893afcbc07c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cf0d4c02-8f06-4801-a9be-48bf1b5bd2c5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0f5dcc4f-d266-4f64-99c4-893afcbc07c3" xlink:to="loc_srt_ProductOrServiceAxis_cf0d4c02-8f06-4801-a9be-48bf1b5bd2c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cf0d4c02-8f06-4801-a9be-48bf1b5bd2c5_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_cf0d4c02-8f06-4801-a9be-48bf1b5bd2c5" xlink:to="loc_srt_ProductsAndServicesDomain_cf0d4c02-8f06-4801-a9be-48bf1b5bd2c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d1753542-36fc-4c52-8306-572b981fff5d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_cf0d4c02-8f06-4801-a9be-48bf1b5bd2c5" xlink:to="loc_srt_ProductsAndServicesDomain_d1753542-36fc-4c52-8306-572b981fff5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_HealthCareCapitationRevenueMember_3f5f3a26-08a2-452f-802b-3a34607e9566" xlink:href="asth-20240331.xsd#asth_HealthCareCapitationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d1753542-36fc-4c52-8306-572b981fff5d" xlink:to="loc_asth_HealthCareCapitationRevenueMember_3f5f3a26-08a2-452f-802b-3a34607e9566" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOtherMember_de9553d6-b5b6-4e07-9aab-e7353ff8c550" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d1753542-36fc-4c52-8306-572b981fff5d" xlink:to="loc_us-gaap_HealthCareOtherMember_de9553d6-b5b6-4e07-9aab-e7353ff8c550" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember_81b8239c-e52f-4e0e-9226-f59c90c29d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagementServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d1753542-36fc-4c52-8306-572b981fff5d" xlink:to="loc_us-gaap_ManagementServiceMember_81b8239c-e52f-4e0e-9226-f59c90c29d0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCarePatientServiceMember_93ec2ad3-155a-4505-bf64-c5a07ea36b99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCarePatientServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d1753542-36fc-4c52-8306-572b981fff5d" xlink:to="loc_us-gaap_HealthCarePatientServiceMember_93ec2ad3-155a-4505-bf64-c5a07ea36b99" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_a79fd51f-180a-45d9-875e-72d4eaf95660" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d1753542-36fc-4c52-8306-572b981fff5d" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_a79fd51f-180a-45d9-875e-72d4eaf95660" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_61b0ac68-2f9a-4550-acc3-6e4d1f47c046" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_73b5cf48-7237-416a-b3ff-f8dfe8f3c7a5" xlink:to="loc_us-gaap_RevenuesAbstract_61b0ac68-2f9a-4550-acc3-6e4d1f47c046" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_54088aef-a214-4593-90dd-02e4352d8c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_61b0ac68-2f9a-4550-acc3-6e4d1f47c046" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_54088aef-a214-4593-90dd-02e4352d8c1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_d943206c-47b5-4ed2-a8be-c3192455d30c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_73b5cf48-7237-416a-b3ff-f8dfe8f3c7a5" xlink:to="loc_us-gaap_OperatingExpensesAbstract_d943206c-47b5-4ed2-a8be-c3192455d30c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_5dcbd6a2-056b-4b43-aa77-fb4a6b331420" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d943206c-47b5-4ed2-a8be-c3192455d30c" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_5dcbd6a2-056b-4b43-aa77-fb4a6b331420" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d54512e9-e485-4d45-b08f-49b412f17eac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d943206c-47b5-4ed2-a8be-c3192455d30c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d54512e9-e485-4d45-b08f-49b412f17eac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_1a487115-bf1e-4d4a-abd7-b92b61024964" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d943206c-47b5-4ed2-a8be-c3192455d30c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_1a487115-bf1e-4d4a-abd7-b92b61024964" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_1dd783a1-20ae-433a-9985-94133a5bcdfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d943206c-47b5-4ed2-a8be-c3192455d30c" xlink:to="loc_us-gaap_CostsAndExpenses_1dd783a1-20ae-433a-9985-94133a5bcdfb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9a0f8d44-480a-45ad-8654-bdba2545764a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_73b5cf48-7237-416a-b3ff-f8dfe8f3c7a5" xlink:to="loc_us-gaap_OperatingIncomeLoss_9a0f8d44-480a-45ad-8654-bdba2545764a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_23c03c83-762c-4b9e-8b34-d36bce0f6437" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_73b5cf48-7237-416a-b3ff-f8dfe8f3c7a5" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_23c03c83-762c-4b9e-8b34-d36bce0f6437" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4af79748-d698-4df6-83e5-8c617623919a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_23c03c83-762c-4b9e-8b34-d36bce0f6437" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4af79748-d698-4df6-83e5-8c617623919a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f5d4986e-e1ac-485c-80a7-b7c0db2580a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_23c03c83-762c-4b9e-8b34-d36bce0f6437" xlink:to="loc_us-gaap_InterestExpense_f5d4986e-e1ac-485c-80a7-b7c0db2580a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_e0874159-e1e0-48ed-b97e-4042dcf74326" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_23c03c83-762c-4b9e-8b34-d36bce0f6437" xlink:to="loc_us-gaap_InvestmentIncomeInterest_e0874159-e1e0-48ed-b97e-4042dcf74326" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_3fec6bad-09f5-42ec-8725-704896e2e083" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_23c03c83-762c-4b9e-8b34-d36bce0f6437" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_3fec6bad-09f5-42ec-8725-704896e2e083" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ee3cc99a-6965-4454-b75f-61a75d5d3ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_23c03c83-762c-4b9e-8b34-d36bce0f6437" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_ee3cc99a-6965-4454-b75f-61a75d5d3ea3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_307d64ce-5797-4ac7-8aba-158e25764f16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_23c03c83-762c-4b9e-8b34-d36bce0f6437" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_307d64ce-5797-4ac7-8aba-158e25764f16" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_102cad84-2213-47f7-b353-611568346495" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_73b5cf48-7237-416a-b3ff-f8dfe8f3c7a5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_102cad84-2213-47f7-b353-611568346495" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f282646c-3f60-4471-807e-82076b2b8e64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_73b5cf48-7237-416a-b3ff-f8dfe8f3c7a5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f282646c-3f60-4471-807e-82076b2b8e64" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1eebd33c-1c65-4857-b6cd-a7c1d0ccf928" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_73b5cf48-7237-416a-b3ff-f8dfe8f3c7a5" xlink:to="loc_us-gaap_ProfitLoss_1eebd33c-1c65-4857-b6cd-a7c1d0ccf928" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e8c4cffa-871c-4efa-9923-2fe328a3c6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_73b5cf48-7237-416a-b3ff-f8dfe8f3c7a5" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e8c4cffa-871c-4efa-9923-2fe328a3c6d3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_094e6e7d-1c0a-4f74-b7bc-4eee7740c45d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_73b5cf48-7237-416a-b3ff-f8dfe8f3c7a5" xlink:to="loc_us-gaap_NetIncomeLoss_094e6e7d-1c0a-4f74-b7bc-4eee7740c45d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_fbafcba3-62dc-42d8-83a5-c2ce98a7cf5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_73b5cf48-7237-416a-b3ff-f8dfe8f3c7a5" xlink:to="loc_us-gaap_EarningsPerShareBasic_fbafcba3-62dc-42d8-83a5-c2ce98a7cf5b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_45c286cd-4b74-4c76-b09d-d2eaab3c4a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_73b5cf48-7237-416a-b3ff-f8dfe8f3c7a5" xlink:to="loc_us-gaap_EarningsPerShareDiluted_45c286cd-4b74-4c76-b09d-d2eaab3c4a3f" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="asth-20240331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bc564805-781f-41ef-b016-2e6aa3907e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2b4e7f1c-b42c-49f2-b124-fad7631fcc01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_bc564805-781f-41ef-b016-2e6aa3907e7c" xlink:to="loc_us-gaap_StatementTable_2b4e7f1c-b42c-49f2-b124-fad7631fcc01" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_dd7c9fa9-78b5-468e-891e-805f1151176b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2b4e7f1c-b42c-49f2-b124-fad7631fcc01" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_dd7c9fa9-78b5-468e-891e-805f1151176b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_dd7c9fa9-78b5-468e-891e-805f1151176b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_dd7c9fa9-78b5-468e-891e-805f1151176b" xlink:to="loc_us-gaap_EquityComponentDomain_dd7c9fa9-78b5-468e-891e-805f1151176b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cede7c7e-a99a-41e4-9a9b-57827d45ed69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_dd7c9fa9-78b5-468e-891e-805f1151176b" xlink:to="loc_us-gaap_EquityComponentDomain_cede7c7e-a99a-41e4-9a9b-57827d45ed69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bfbf1706-9348-4a3f-8d9c-171dcd7ef930" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cede7c7e-a99a-41e4-9a9b-57827d45ed69" xlink:to="loc_us-gaap_CommonStockMember_bfbf1706-9348-4a3f-8d9c-171dcd7ef930" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0a75f655-14f8-4844-ad85-10065f34baef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cede7c7e-a99a-41e4-9a9b-57827d45ed69" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0a75f655-14f8-4844-ad85-10065f34baef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d3d9510c-5d2b-4208-9aa0-fc708fdef107" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cede7c7e-a99a-41e4-9a9b-57827d45ed69" xlink:to="loc_us-gaap_RetainedEarningsMember_d3d9510c-5d2b-4208-9aa0-fc708fdef107" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_e1de470b-cf60-4a2b-a01c-0eccbd2026a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cede7c7e-a99a-41e4-9a9b-57827d45ed69" xlink:to="loc_us-gaap_NoncontrollingInterestMember_e1de470b-cf60-4a2b-a01c-0eccbd2026a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d4eed923-207c-409c-84cd-712534eddbba" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2b4e7f1c-b42c-49f2-b124-fad7631fcc01" xlink:to="loc_dei_LegalEntityAxis_d4eed923-207c-409c-84cd-712534eddbba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d4eed923-207c-409c-84cd-712534eddbba_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_d4eed923-207c-409c-84cd-712534eddbba" xlink:to="loc_dei_EntityDomain_d4eed923-207c-409c-84cd-712534eddbba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d691d1eb-cb32-4564-8464-2b6aad8a4a7f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_d4eed923-207c-409c-84cd-712534eddbba" xlink:to="loc_dei_EntityDomain_d691d1eb-cb32-4564-8464-2b6aad8a4a7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_MezzanineMember_1638c2f6-095b-49cd-9315-ff3eae481da8" xlink:href="asth-20240331.xsd#asth_MezzanineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_d691d1eb-cb32-4564-8464-2b6aad8a4a7f" xlink:to="loc_asth_MezzanineMember_1638c2f6-095b-49cd-9315-ff3eae481da8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_a3f1cd45-bb7c-4592-bae4-bc8d3664dbce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bc564805-781f-41ef-b016-2e6aa3907e7c" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_a3f1cd45-bb7c-4592-bae4-bc8d3664dbce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_e3d037c9-e938-44e7-b09e-e3cd0c64909a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_a3f1cd45-bb7c-4592-bae4-bc8d3664dbce" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_e3d037c9-e938-44e7-b09e-e3cd0c64909a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome_660f9b35-9a12-4df3-aa31-b8588ed10942" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_a3f1cd45-bb7c-4592-bae4-bc8d3664dbce" xlink:to="loc_us-gaap_TemporaryEquityNetIncome_660f9b35-9a12-4df3-aa31-b8588ed10942" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_TemporaryEquityTransferOfCommonControlEntities_64d0476d-cbd0-4e2c-a023-553c0eacaaa6" xlink:href="asth-20240331.xsd#asth_TemporaryEquityTransferOfCommonControlEntities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_a3f1cd45-bb7c-4592-bae4-bc8d3664dbce" xlink:to="loc_asth_TemporaryEquityTransferOfCommonControlEntities_64d0476d-cbd0-4e2c-a023-553c0eacaaa6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_1500c526-1088-4223-ae59-77e8d73dd8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bc564805-781f-41ef-b016-2e6aa3907e7c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_4763c914-4319-4fd7-b31e-593fba2902df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_us-gaap_SharesOutstanding_4763c914-4319-4fd7-b31e-593fba2902df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a4f187f9-be72-4480-a93e-31ee3b48eead" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a4f187f9-be72-4480-a93e-31ee3b48eead" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_4759cd35-4a21-497a-8c27-de48c3098b08" xlink:href="asth-20240331.xsd#asth_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_asth_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_4759cd35-4a21-497a-8c27-de48c3098b08" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_793d5354-4038-4c81-9a2c-5ac3591426eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_793d5354-4038-4c81-9a2c-5ac3591426eb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_74304696-6fc6-4f2d-adb3-3d3674076737" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_74304696-6fc6-4f2d-adb3-3d3674076737" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_4212202a-518a-4ea9-bd07-6e6508049786" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_4212202a-518a-4ea9-bd07-6e6508049786" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_24faea63-48c1-4719-8f54-a5248776deb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_24faea63-48c1-4719-8f54-a5248776deb1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_26923dbe-4409-4c33-b048-bf3c3960e6dc" xlink:href="asth-20240331.xsd#asth_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_asth_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_26923dbe-4409-4c33-b048-bf3c3960e6dc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_a7afb578-d059-4421-9dd0-33c983045b8d" xlink:href="asth-20240331.xsd#asth_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_asth_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_a7afb578-d059-4421-9dd0-33c983045b8d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_30d7d301-18cc-4992-897f-7c9364e34290" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_30d7d301-18cc-4992-897f-7c9364e34290" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_bf15963b-8ea6-43e5-9c2f-6bd1e98a4b94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredParValueMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_bf15963b-8ea6-43e5-9c2f-6bd1e98a4b94" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_68b63d71-8201-4aa2-b289-7f6007871fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_68b63d71-8201-4aa2-b289-7f6007871fe7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2a13ea39-2ca9-4560-a025-795568061526" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2a13ea39-2ca9-4560-a025-795568061526" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_48222091-245a-4a2b-bc13-235a1c816dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_48222091-245a-4a2b-bc13-235a1c816dbd" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AcquisitionOfNonControllingInterestShares_ced4d6c2-a1fb-46eb-a986-6cde3f8d9291" xlink:href="asth-20240331.xsd#asth_AcquisitionOfNonControllingInterestShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_asth_AcquisitionOfNonControllingInterestShares_ced4d6c2-a1fb-46eb-a986-6cde3f8d9291" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_NoncontrollingInterestIncreaseDecreaseFromBusinessCombination_2ccf7b56-da56-4502-8a53-1e5dda57b19c" xlink:href="asth-20240331.xsd#asth_NoncontrollingInterestIncreaseDecreaseFromBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_asth_NoncontrollingInterestIncreaseDecreaseFromBusinessCombination_2ccf7b56-da56-4502-8a53-1e5dda57b19c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares_cbff1a25-96f5-4258-8131-719b7c9c0898" xlink:href="asth-20240331.xsd#asth_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_asth_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares_cbff1a25-96f5-4258-8131-719b7c9c0898" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_StockholdersEquityTransferOfCommonControlEntities_a3ab3ee8-31a4-4500-b26d-77d109cc5d5f" xlink:href="asth-20240331.xsd#asth_StockholdersEquityTransferOfCommonControlEntities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_asth_StockholdersEquityTransferOfCommonControlEntities_a3ab3ee8-31a4-4500-b26d-77d109cc5d5f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_bd9a0dbe-a991-418e-b6c2-c07083ccecd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f0dea49b-7aea-43c0-be75-36b609642edb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofDisaggregatedRevenuebyEachPayerTypeDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofDisaggregatedRevenuebyEachPayerTypeDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofDisaggregatedRevenuebyEachPayerTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_c3f47734-1e98-4e14-9629-fce7bb7ae3e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7381ad5b-1e68-4647-9322-bf6981cc2dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c3f47734-1e98-4e14-9629-fce7bb7ae3e6" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7381ad5b-1e68-4647-9322-bf6981cc2dc3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_56c12747-e606-4e68-9970-09a6bc9b755d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7381ad5b-1e68-4647-9322-bf6981cc2dc3" xlink:to="loc_srt_MajorCustomersAxis_56c12747-e606-4e68-9970-09a6bc9b755d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_56c12747-e606-4e68-9970-09a6bc9b755d_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_56c12747-e606-4e68-9970-09a6bc9b755d" xlink:to="loc_srt_NameOfMajorCustomerDomain_56c12747-e606-4e68-9970-09a6bc9b755d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_bcee3021-9319-44d4-8ebb-9f694ab302fb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_56c12747-e606-4e68-9970-09a6bc9b755d" xlink:to="loc_srt_NameOfMajorCustomerDomain_bcee3021-9319-44d4-8ebb-9f694ab302fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CommercialMember_36de31c1-99c0-4ac6-9d97-f315889e95a3" xlink:href="asth-20240331.xsd#asth_CommercialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_bcee3021-9319-44d4-8ebb-9f694ab302fb" xlink:to="loc_asth_CommercialMember_36de31c1-99c0-4ac6-9d97-f315889e95a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_MedicareMember_3346a07a-d30a-46f3-a57f-59c6c2d7647d" xlink:href="asth-20240331.xsd#asth_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_bcee3021-9319-44d4-8ebb-9f694ab302fb" xlink:to="loc_asth_MedicareMember_3346a07a-d30a-46f3-a57f-59c6c2d7647d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_MedicaidMember_3341bbe1-8f77-4c37-a0c4-302caaa26469" xlink:href="asth-20240331.xsd#asth_MedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_bcee3021-9319-44d4-8ebb-9f694ab302fb" xlink:to="loc_asth_MedicaidMember_3341bbe1-8f77-4c37-a0c4-302caaa26469" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_OtherThirdPartiesMember_27e3cec2-463c-4b0c-9dcb-f3009b4b13df" xlink:href="asth-20240331.xsd#asth_OtherThirdPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_bcee3021-9319-44d4-8ebb-9f694ab302fb" xlink:to="loc_asth_OtherThirdPartiesMember_27e3cec2-463c-4b0c-9dcb-f3009b4b13df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a8d38264-b361-4b42-87f7-a132a5958d08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c3f47734-1e98-4e14-9629-fce7bb7ae3e6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a8d38264-b361-4b42-87f7-a132a5958d08" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofContributionstoRevenueandReceivablesbyPayerDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofContributionstoRevenueandReceivablesbyPayerDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofContributionstoRevenueandReceivablesbyPayerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_asth_AccountsReceivableAndNetRevenueLineItems_d84a1fc4-3d80-4b62-a77a-73fbdda72b58" xlink:href="asth-20240331.xsd#asth_AccountsReceivableAndNetRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AccountsReceivableAndNetRevenueTable_82aa756b-d4a8-4850-b4d4-13a5ee99ca68" xlink:href="asth-20240331.xsd#asth_AccountsReceivableAndNetRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_asth_AccountsReceivableAndNetRevenueLineItems_d84a1fc4-3d80-4b62-a77a-73fbdda72b58" xlink:to="loc_asth_AccountsReceivableAndNetRevenueTable_82aa756b-d4a8-4850-b4d4-13a5ee99ca68" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d7d23bd6-cc73-4049-bad0-e6a6e80268c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_asth_AccountsReceivableAndNetRevenueTable_82aa756b-d4a8-4850-b4d4-13a5ee99ca68" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d7d23bd6-cc73-4049-bad0-e6a6e80268c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d7d23bd6-cc73-4049-bad0-e6a6e80268c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d7d23bd6-cc73-4049-bad0-e6a6e80268c2" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d7d23bd6-cc73-4049-bad0-e6a6e80268c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_44f86d11-518d-41fe-81bc-d030fe4a74fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d7d23bd6-cc73-4049-bad0-e6a6e80268c2" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_44f86d11-518d-41fe-81bc-d030fe4a74fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_60e72eb8-1473-4b4d-8478-ca4119f79e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_44f86d11-518d-41fe-81bc-d030fe4a74fc" xlink:to="loc_us-gaap_SalesRevenueNetMember_60e72eb8-1473-4b4d-8478-ca4119f79e1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_c207c462-1aa6-4b0f-9cb9-557fa3fd3aff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_44f86d11-518d-41fe-81bc-d030fe4a74fc" xlink:to="loc_us-gaap_AccountsReceivableMember_c207c462-1aa6-4b0f-9cb9-557fa3fd3aff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_0d90c6e3-17af-45bc-becb-75e8de217454" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_asth_AccountsReceivableAndNetRevenueTable_82aa756b-d4a8-4850-b4d4-13a5ee99ca68" xlink:to="loc_srt_MajorCustomersAxis_0d90c6e3-17af-45bc-becb-75e8de217454" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0d90c6e3-17af-45bc-becb-75e8de217454_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_0d90c6e3-17af-45bc-becb-75e8de217454" xlink:to="loc_srt_NameOfMajorCustomerDomain_0d90c6e3-17af-45bc-becb-75e8de217454_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_8ec49487-a824-44a4-b959-6a7329d2556f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_0d90c6e3-17af-45bc-becb-75e8de217454" xlink:to="loc_srt_NameOfMajorCustomerDomain_8ec49487-a824-44a4-b959-6a7329d2556f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PayorAMember_a8f208df-f627-4a2e-b1f1-492e203c1994" xlink:href="asth-20240331.xsd#asth_PayorAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_8ec49487-a824-44a4-b959-6a7329d2556f" xlink:to="loc_asth_PayorAMember_a8f208df-f627-4a2e-b1f1-492e203c1994" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PayorBMember_a44f5494-2cb8-4e1d-bf63-f3eabdf9977f" xlink:href="asth-20240331.xsd#asth_PayorBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_8ec49487-a824-44a4-b959-6a7329d2556f" xlink:to="loc_asth_PayorBMember_a44f5494-2cb8-4e1d-bf63-f3eabdf9977f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PayerCMember_a4f446bd-ae05-48ed-a05d-4c3de2df6047" xlink:href="asth-20240331.xsd#asth_PayerCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_8ec49487-a824-44a4-b959-6a7329d2556f" xlink:to="loc_asth_PayerCMember_a4f446bd-ae05-48ed-a05d-4c3de2df6047" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_43a7b0fa-3e6d-4d6e-85d3-4ef61da07fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_asth_AccountsReceivableAndNetRevenueTable_82aa756b-d4a8-4850-b4d4-13a5ee99ca68" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_43a7b0fa-3e6d-4d6e-85d3-4ef61da07fa9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_43a7b0fa-3e6d-4d6e-85d3-4ef61da07fa9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_43a7b0fa-3e6d-4d6e-85d3-4ef61da07fa9" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_43a7b0fa-3e6d-4d6e-85d3-4ef61da07fa9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c1e0165a-5c47-42d2-ba0f-033469602f17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_43a7b0fa-3e6d-4d6e-85d3-4ef61da07fa9" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c1e0165a-5c47-42d2-ba0f-033469602f17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_819b8fe6-7fbf-4bf3-8cde-b3732efdef4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_c1e0165a-5c47-42d2-ba0f-033469602f17" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_819b8fe6-7fbf-4bf3-8cde-b3732efdef4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ebe17e8f-c05d-4de7-b8c1-a74c7acdc3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_asth_AccountsReceivableAndNetRevenueLineItems_d84a1fc4-3d80-4b62-a77a-73fbdda72b58" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ebe17e8f-c05d-4de7-b8c1-a74c7acdc3f0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillAdditionalInformationDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#BusinessCombinationsAssetAcquisitionsandGoodwillAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_eb5a3d08-4a4c-47e8-acca-b7e517b83745" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_fa592d95-b436-43dd-b4a9-1a23ab9836eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_eb5a3d08-4a4c-47e8-acca-b7e517b83745" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_fa592d95-b436-43dd-b4a9-1a23ab9836eb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b188e01f-d393-4a84-b32d-9747954587e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_fa592d95-b436-43dd-b4a9-1a23ab9836eb" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b188e01f-d393-4a84-b32d-9747954587e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b188e01f-d393-4a84-b32d-9747954587e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b188e01f-d393-4a84-b32d-9747954587e8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b188e01f-d393-4a84-b32d-9747954587e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d1126f2-b717-4fbc-ba79-2ac7718147f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b188e01f-d393-4a84-b32d-9747954587e8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d1126f2-b717-4fbc-ba79-2ac7718147f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AdvancedHealthManagementSystemsLPMember_189c4e9a-e0b9-490f-9451-258d7b6b27b8" xlink:href="asth-20240331.xsd#asth_AdvancedHealthManagementSystemsLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d1126f2-b717-4fbc-ba79-2ac7718147f6" xlink:to="loc_asth_AdvancedHealthManagementSystemsLPMember_189c4e9a-e0b9-490f-9451-258d7b6b27b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PrimeCommunityCareOfCentralValleyIncMember_61279230-e871-4584-9a5c-28ef34c17a4d" xlink:href="asth-20240331.xsd#asth_PrimeCommunityCareOfCentralValleyIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d1126f2-b717-4fbc-ba79-2ac7718147f6" xlink:to="loc_asth_PrimeCommunityCareOfCentralValleyIncMember_61279230-e871-4584-9a5c-28ef34c17a4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CommunityFamilyCareMedicalGroupIPAInc.Member_6bf222bd-0cca-4381-b374-9b3f63471706" xlink:href="asth-20240331.xsd#asth_CommunityFamilyCareMedicalGroupIPAInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d1126f2-b717-4fbc-ba79-2ac7718147f6" xlink:to="loc_asth_CommunityFamilyCareMedicalGroupIPAInc.Member_6bf222bd-0cca-4381-b374-9b3f63471706" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AdvancedDiagnosticAndSurgicalCenterIncMember_4473190f-38a9-4170-a2c3-8544eff07563" xlink:href="asth-20240331.xsd#asth_AdvancedDiagnosticAndSurgicalCenterIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d1126f2-b717-4fbc-ba79-2ac7718147f6" xlink:to="loc_asth_AdvancedDiagnosticAndSurgicalCenterIncMember_4473190f-38a9-4170-a2c3-8544eff07563" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_8d2e6fef-ca61-4d29-af1c-8717c6609be4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_eb5a3d08-4a4c-47e8-acca-b7e517b83745" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_8d2e6fef-ca61-4d29-af1c-8717c6609be4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ContingentConsideration_2b10b111-55dd-4e19-a59e-f3f6a65a094f" xlink:href="asth-20240331.xsd#asth_ContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_eb5a3d08-4a4c-47e8-acca-b7e517b83745" xlink:to="loc_asth_ContingentConsideration_2b10b111-55dd-4e19-a59e-f3f6a65a094f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ConsiderationOfAcquisitionInCashFunded_cf3dbf2b-a7e2-449e-9d72-048a6897e744" xlink:href="asth-20240331.xsd#asth_ConsiderationOfAcquisitionInCashFunded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_eb5a3d08-4a4c-47e8-acca-b7e517b83745" xlink:to="loc_asth_ConsiderationOfAcquisitionInCashFunded_cf3dbf2b-a7e2-449e-9d72-048a6897e744" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessAcquisitionOfCommonStock_dc212944-f0e7-450b-b203-d3a2ea8eafe0" xlink:href="asth-20240331.xsd#asth_BusinessAcquisitionOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_eb5a3d08-4a4c-47e8-acca-b7e517b83745" xlink:to="loc_asth_BusinessAcquisitionOfCommonStock_dc212944-f0e7-450b-b203-d3a2ea8eafe0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_661470be-c711-497e-8806-a41c7232d94a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_eb5a3d08-4a4c-47e8-acca-b7e517b83745" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_661470be-c711-497e-8806-a41c7232d94a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_69f130fc-e14b-4c34-b329-aa78a8397a16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_eb5a3d08-4a4c-47e8-acca-b7e517b83745" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_69f130fc-e14b-4c34-b329-aa78a8397a16" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_40b47235-2dfd-4d05-a6e0-f96700591645" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_eb5a3d08-4a4c-47e8-acca-b7e517b83745" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_40b47235-2dfd-4d05-a6e0-f96700591645" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_038b921b-9c08-416f-aa64-6004b7407b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_eb5a3d08-4a4c-47e8-acca-b7e517b83745" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_038b921b-9c08-416f-aa64-6004b7407b1f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_f8a58639-9435-4f13-a951-143c7bf1f944" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_eb5a3d08-4a4c-47e8-acca-b7e517b83745" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_f8a58639-9435-4f13-a951-143c7bf1f944" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_18fa80e2-27e6-4021-b296-a544b858f125" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_eb5a3d08-4a4c-47e8-acca-b7e517b83745" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_18fa80e2-27e6-4021-b296-a544b858f125" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_fb6f70bc-86c8-4958-ad20-6536ef125fad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0dee7bec-8f5a-4713-9597-2a2d69d0c7f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb6f70bc-86c8-4958-ad20-6536ef125fad" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0dee7bec-8f5a-4713-9597-2a2d69d0c7f0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_42f846bb-ed4f-4e2b-a727-4b7e7fbc3a52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0dee7bec-8f5a-4713-9597-2a2d69d0c7f0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_42f846bb-ed4f-4e2b-a727-4b7e7fbc3a52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_42f846bb-ed4f-4e2b-a727-4b7e7fbc3a52_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_42f846bb-ed4f-4e2b-a727-4b7e7fbc3a52" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_42f846bb-ed4f-4e2b-a727-4b7e7fbc3a52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cfa1e921-babf-4307-8302-32d8b14e67ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_42f846bb-ed4f-4e2b-a727-4b7e7fbc3a52" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cfa1e921-babf-4307-8302-32d8b14e67ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CommunityFamilyCareMedicalGroupIPAInc.Member_ec2091e5-7bf0-45a8-9d28-dbb2f9331bda" xlink:href="asth-20240331.xsd#asth_CommunityFamilyCareMedicalGroupIPAInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cfa1e921-babf-4307-8302-32d8b14e67ff" xlink:to="loc_asth_CommunityFamilyCareMedicalGroupIPAInc.Member_ec2091e5-7bf0-45a8-9d28-dbb2f9331bda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AdvancedHealthManagementSystemsLPMember_b681d17b-079a-4b5f-9a3d-e35d45b1db11" xlink:href="asth-20240331.xsd#asth_AdvancedHealthManagementSystemsLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cfa1e921-babf-4307-8302-32d8b14e67ff" xlink:to="loc_asth_AdvancedHealthManagementSystemsLPMember_b681d17b-079a-4b5f-9a3d-e35d45b1db11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_OtherAcquisitionsMember_609f7f1c-05b9-47f9-8f7d-f9872119c7f0" xlink:href="asth-20240331.xsd#asth_OtherAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cfa1e921-babf-4307-8302-32d8b14e67ff" xlink:to="loc_asth_OtherAcquisitionsMember_609f7f1c-05b9-47f9-8f7d-f9872119c7f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_TotalAcquisitionsMember_a2680805-93b0-469c-98b3-499a3aad9894" xlink:href="asth-20240331.xsd#asth_TotalAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cfa1e921-babf-4307-8302-32d8b14e67ff" xlink:to="loc_asth_TotalAcquisitionsMember_a2680805-93b0-469c-98b3-499a3aad9894" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_TotalPurchaseConsiderationAbstract_d84bafe4-314a-47df-b871-0ae6ed533faf" xlink:href="asth-20240331.xsd#asth_TotalPurchaseConsiderationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb6f70bc-86c8-4958-ad20-6536ef125fad" xlink:to="loc_asth_TotalPurchaseConsiderationAbstract_d84bafe4-314a-47df-b871-0ae6ed533faf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_a1d76029-4a99-4c91-bb6d-dff581f624ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_asth_TotalPurchaseConsiderationAbstract_d84bafe4-314a-47df-b871-0ae6ed533faf" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_a1d76029-4a99-4c91-bb6d-dff581f624ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PaymentsToAcquireBusinessCashPayable_325b4e43-281e-44dc-b5f8-3ec565de6e65" xlink:href="asth-20240331.xsd#asth_PaymentsToAcquireBusinessCashPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_asth_TotalPurchaseConsiderationAbstract_d84bafe4-314a-47df-b871-0ae6ed533faf" xlink:to="loc_asth_PaymentsToAcquireBusinessCashPayable_325b4e43-281e-44dc-b5f8-3ec565de6e65" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_4efd86a9-2a67-4a59-90ed-e96c2686257f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_asth_TotalPurchaseConsiderationAbstract_d84bafe4-314a-47df-b871-0ae6ed533faf" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_4efd86a9-2a67-4a59-90ed-e96c2686257f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_1c8c3b0e-2f1c-4781-8cfa-89eb725b51c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_asth_TotalPurchaseConsiderationAbstract_d84bafe4-314a-47df-b871-0ae6ed533faf" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_1c8c3b0e-2f1c-4781-8cfa-89eb725b51c9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_0157a8b4-0d17-4636-bc24-56b6859650de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_asth_TotalPurchaseConsiderationAbstract_d84bafe4-314a-47df-b871-0ae6ed533faf" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_0157a8b4-0d17-4636-bc24-56b6859650de" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_a6008f49-428c-4364-8e1f-8862d6515431" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb6f70bc-86c8-4958-ad20-6536ef125fad" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_a6008f49-428c-4364-8e1f-8862d6515431" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_896b89c5-d1a8-45af-83cf-e570a86b1932" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_a6008f49-428c-4364-8e1f-8862d6515431" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_896b89c5-d1a8-45af-83cf-e570a86b1932" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_68ae5395-3140-46ac-b308-15eb8695b77d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_a6008f49-428c-4364-8e1f-8862d6515431" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_68ae5395-3140-46ac-b308-15eb8695b77d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_679de290-dbb7-4c0a-a795-b5d627ceab8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_a6008f49-428c-4364-8e1f-8862d6515431" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_679de290-dbb7-4c0a-a795-b5d627ceab8b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_d1d25c36-e621-43f2-9237-78729c29f647" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_a6008f49-428c-4364-8e1f-8862d6515431" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_d1d25c36-e621-43f2-9237-78729c29f647" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates_2a728afa-36b2-4bc5-b587-eba6d7b909ab" xlink:href="asth-20240331.xsd#asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_a6008f49-428c-4364-8e1f-8862d6515431" xlink:to="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates_2a728afa-36b2-4bc5-b587-eba6d7b909ab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_60bc9b46-e556-4568-9784-a5a1bf996ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_a6008f49-428c-4364-8e1f-8862d6515431" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_60bc9b46-e556-4568-9784-a5a1bf996ce2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_536a3f14-d54b-40b6-b1f7-3bf639b3512c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_a6008f49-428c-4364-8e1f-8862d6515431" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_536a3f14-d54b-40b6-b1f7-3bf639b3512c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_379fc5a8-b6d1-410e-8f74-1c2483060728" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_a6008f49-428c-4364-8e1f-8862d6515431" xlink:to="loc_us-gaap_Goodwill_379fc5a8-b6d1-410e-8f74-1c2483060728" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash_096beffd-4a07-4288-8c8a-5c97a806fa09" xlink:href="asth-20240331.xsd#asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_a6008f49-428c-4364-8e1f-8862d6515431" xlink:to="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash_096beffd-4a07-4288-8c8a-5c97a806fa09" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_3c2dd371-b6cd-42ad-97e9-d62f54a6c101" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_a6008f49-428c-4364-8e1f-8862d6515431" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_3c2dd371-b6cd-42ad-97e9-d62f54a6c101" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_c8fa1114-8356-4646-84cc-64ed96e28579" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb6f70bc-86c8-4958-ad20-6536ef125fad" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_c8fa1114-8356-4646-84cc-64ed96e28579" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses_280fbc7e-a0f1-4e9d-b586-fa3310b7757f" xlink:href="asth-20240331.xsd#asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_c8fa1114-8356-4646-84cc-64ed96e28579" xlink:to="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses_280fbc7e-a0f1-4e9d-b586-fa3310b7757f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities_8b6fa248-7232-4e6a-ae0e-a01c474ec232" xlink:href="asth-20240331.xsd#asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_c8fa1114-8356-4646-84cc-64ed96e28579" xlink:to="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities_8b6fa248-7232-4e6a-ae0e-a01c474ec232" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates_056bb75b-23d9-4346-ad71-28084a46503e" xlink:href="asth-20240331.xsd#asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_c8fa1114-8356-4646-84cc-64ed96e28579" xlink:to="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates_056bb75b-23d9-4346-ad71-28084a46503e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable_76247c03-c276-49f9-ba8a-5aec71eb3b39" xlink:href="asth-20240331.xsd#asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_c8fa1114-8356-4646-84cc-64ed96e28579" xlink:to="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable_76247c03-c276-49f9-ba8a-5aec71eb3b39" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_8524118e-3e80-4fed-bf7d-70451f881762" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_c8fa1114-8356-4646-84cc-64ed96e28579" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_8524118e-3e80-4fed-bf7d-70451f881762" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest_ee982574-2df6-4694-ba77-2a65c800cdea" xlink:href="asth-20240331.xsd#asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_c8fa1114-8356-4646-84cc-64ed96e28579" xlink:to="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest_ee982574-2df6-4694-ba77-2a65c800cdea" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_cd62f9aa-cd7d-4912-abdd-9c21f1348a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_c8fa1114-8356-4646-84cc-64ed96e28579" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_cd62f9aa-cd7d-4912-abdd-9c21f1348a6b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_44122515-4ae0-4da8-af78-faedc4754cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb6f70bc-86c8-4958-ad20-6536ef125fad" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_44122515-4ae0-4da8-af78-faedc4754cd6" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_953dec26-15d8-48c5-98e1-34e0994ef0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_66693459-eb57-4a3d-9949-45c26cdf9981" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_953dec26-15d8-48c5-98e1-34e0994ef0ab" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_66693459-eb57-4a3d-9949-45c26cdf9981" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2477e7c7-c93d-491a-bac9-46092d5367d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_66693459-eb57-4a3d-9949-45c26cdf9981" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2477e7c7-c93d-491a-bac9-46092d5367d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2477e7c7-c93d-491a-bac9-46092d5367d9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2477e7c7-c93d-491a-bac9-46092d5367d9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2477e7c7-c93d-491a-bac9-46092d5367d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cbfd8a0f-af9f-4dca-bf2a-89a0d46b1a68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2477e7c7-c93d-491a-bac9-46092d5367d9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cbfd8a0f-af9f-4dca-bf2a-89a0d46b1a68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_NetworkRelationshipsMember_4e798b79-8aae-4f61-9083-df3aa0e0393c" xlink:href="asth-20240331.xsd#asth_NetworkRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cbfd8a0f-af9f-4dca-bf2a-89a0d46b1a68" xlink:to="loc_asth_NetworkRelationshipsMember_4e798b79-8aae-4f61-9083-df3aa0e0393c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ManagementContractsMember_656bb8c4-679f-4d71-856d-c28b795f3c98" xlink:href="asth-20240331.xsd#asth_ManagementContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cbfd8a0f-af9f-4dca-bf2a-89a0d46b1a68" xlink:to="loc_asth_ManagementContractsMember_656bb8c4-679f-4d71-856d-c28b795f3c98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_MemberRelationshipsMember_05bfac51-3f2c-4279-9330-8283524ed535" xlink:href="asth-20240331.xsd#asth_MemberRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cbfd8a0f-af9f-4dca-bf2a-89a0d46b1a68" xlink:to="loc_asth_MemberRelationshipsMember_05bfac51-3f2c-4279-9330-8283524ed535" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PatientManagementPlatformMember_d98ee51a-9c7c-4189-93fb-1e15b2ec3655" xlink:href="asth-20240331.xsd#asth_PatientManagementPlatformMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cbfd8a0f-af9f-4dca-bf2a-89a0d46b1a68" xlink:to="loc_asth_PatientManagementPlatformMember_d98ee51a-9c7c-4189-93fb-1e15b2ec3655" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_f5228be2-35d9-4fb4-a223-272bc128a4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cbfd8a0f-af9f-4dca-bf2a-89a0d46b1a68" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_f5228be2-35d9-4fb4-a223-272bc128a4aa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_3a893b73-7e5b-4c9f-a91f-a4448566c019" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cbfd8a0f-af9f-4dca-bf2a-89a0d46b1a68" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_3a893b73-7e5b-4c9f-a91f-a4448566c019" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_162095b1-2e01-41fa-89b2-cd3a908e1ab4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_66693459-eb57-4a3d-9949-45c26cdf9981" xlink:to="loc_srt_RangeAxis_162095b1-2e01-41fa-89b2-cd3a908e1ab4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_162095b1-2e01-41fa-89b2-cd3a908e1ab4_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_162095b1-2e01-41fa-89b2-cd3a908e1ab4" xlink:to="loc_srt_RangeMember_162095b1-2e01-41fa-89b2-cd3a908e1ab4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_882d276d-86fd-4324-8184-9a486d9943c5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_162095b1-2e01-41fa-89b2-cd3a908e1ab4" xlink:to="loc_srt_RangeMember_882d276d-86fd-4324-8184-9a486d9943c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e89841b6-fc8a-4932-8d34-0cd110b13a4d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_882d276d-86fd-4324-8184-9a486d9943c5" xlink:to="loc_srt_MinimumMember_e89841b6-fc8a-4932-8d34-0cd110b13a4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ba374db5-2b57-46ad-8675-05ebf3dde1da" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_882d276d-86fd-4324-8184-9a486d9943c5" xlink:to="loc_srt_MaximumMember_ba374db5-2b57-46ad-8675-05ebf3dde1da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_94921fec-27e1-4001-9a0d-082ef889b643" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_66693459-eb57-4a3d-9949-45c26cdf9981" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_94921fec-27e1-4001-9a0d-082ef889b643" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_94921fec-27e1-4001-9a0d-082ef889b643_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_94921fec-27e1-4001-9a0d-082ef889b643" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_94921fec-27e1-4001-9a0d-082ef889b643_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_cfd59589-0116-4aae-b7a3-97edee6ab03d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_94921fec-27e1-4001-9a0d-082ef889b643" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_cfd59589-0116-4aae-b7a3-97edee6ab03d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_33a6901a-eb92-4cb5-90bc-00f4cf1679d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_cfd59589-0116-4aae-b7a3-97edee6ab03d" xlink:to="loc_us-gaap_TrademarksMember_33a6901a-eb92-4cb5-90bc-00f4cf1679d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_85ad2904-b9c6-413f-8bb3-047d4a216805" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_cfd59589-0116-4aae-b7a3-97edee6ab03d" xlink:to="loc_us-gaap_LicenseMember_85ad2904-b9c6-413f-8bb3-047d4a216805" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2777ff4d-efe7-4a49-ada2-c420e0793ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_953dec26-15d8-48c5-98e1-34e0994ef0ab" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2777ff4d-efe7-4a49-ada2-c420e0793ad6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_755b7b32-e89a-4ff3-b1da-9e003febb0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_953dec26-15d8-48c5-98e1-34e0994ef0ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_755b7b32-e89a-4ff3-b1da-9e003febb0ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_faa2b934-a55e-475a-a497-65587a0f62df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_953dec26-15d8-48c5-98e1-34e0994ef0ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_faa2b934-a55e-475a-a497-65587a0f62df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_82e6ca30-3689-481e-8c3d-e8e278773d69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_953dec26-15d8-48c5-98e1-34e0994ef0ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_82e6ca30-3689-481e-8c3d-e8e278773d69" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9b8f5b6a-fa5e-4259-aec5-548cb7da7a96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_953dec26-15d8-48c5-98e1-34e0994ef0ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9b8f5b6a-fa5e-4259-aec5-548cb7da7a96" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_0481aa79-3978-4195-9541-4d048dff68c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_fb23faea-0d38-4209-8518-8321de544808" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_0481aa79-3978-4195-9541-4d048dff68c4" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_fb23faea-0d38-4209-8518-8321de544808" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_48788a0d-4208-425f-a40a-ce78863ac6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_fb23faea-0d38-4209-8518-8321de544808" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_48788a0d-4208-425f-a40a-ce78863ac6a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_48788a0d-4208-425f-a40a-ce78863ac6a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5cbee2bd-3f5b-4e86-8873-eb9ce1faaadb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_120c2123-c4c2-4b34-881f-a1ef9a827c35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_98a68cac-8f65-4f3c-8fd7-bd08c21f2dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_0481aa79-3978-4195-9541-4d048dff68c4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_98a68cac-8f65-4f3c-8fd7-bd08c21f2dc2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesScheduleofEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#InvestmentsinOtherEntitiesScheduleofEquityMethodInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesScheduleofEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_dee47340-aadd-411a-a2e0-5eeaba30aeac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2aa95968-de07-49c0-9bd2-625f954efc04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_dee47340-aadd-411a-a2e0-5eeaba30aeac" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2aa95968-de07-49c0-9bd2-625f954efc04" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d4544bb5-bb07-4a47-aeff-a20d61e13408" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2aa95968-de07-49c0-9bd2-625f954efc04" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d4544bb5-bb07-4a47-aeff-a20d61e13408" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_d4544bb5-bb07-4a47-aeff-a20d61e13408_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d4544bb5-bb07-4a47-aeff-a20d61e13408" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_d4544bb5-bb07-4a47-aeff-a20d61e13408_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f3e15769-0ab2-4b19-928d-2e91421a7a3b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d4544bb5-bb07-4a47-aeff-a20d61e13408" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f3e15769-0ab2-4b19-928d-2e91421a7a3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_LasalleMedicalAssociatesIpaMember_bd760090-f127-438b-ad16-06fc71a8a3a8" xlink:href="asth-20240331.xsd#asth_LasalleMedicalAssociatesIpaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f3e15769-0ab2-4b19-928d-2e91421a7a3b" xlink:to="loc_asth_LasalleMedicalAssociatesIpaMember_bd760090-f127-438b-ad16-06fc71a8a3a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PacificMedicalImagingAndOncologyCenterIncMember_05852ecb-1e69-455c-a56a-c7e3d077b1ba" xlink:href="asth-20240331.xsd#asth_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f3e15769-0ab2-4b19-928d-2e91421a7a3b" xlink:to="loc_asth_PacificMedicalImagingAndOncologyCenterIncMember_05852ecb-1e69-455c-a56a-c7e3d077b1ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_FiveThreeOneW.CollegeLLCMember_aee9e1fe-c7f4-47db-bd42-fdeb26f22730" xlink:href="asth-20240331.xsd#asth_FiveThreeOneW.CollegeLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f3e15769-0ab2-4b19-928d-2e91421a7a3b" xlink:to="loc_asth_FiveThreeOneW.CollegeLLCMember_aee9e1fe-c7f4-47db-bd42-fdeb26f22730" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_OneMSOLLCMember_f7bc171d-7126-44d3-9c3e-a58d3a449c34" xlink:href="asth-20240331.xsd#asth_OneMSOLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f3e15769-0ab2-4b19-928d-2e91421a7a3b" xlink:to="loc_asth_OneMSOLLCMember_f7bc171d-7126-44d3-9c3e-a58d3a449c34" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CAIPAMSOLLCMember_710120da-b8cc-41b2-9e22-d4bd0a05cba5" xlink:href="asth-20240331.xsd#asth_CAIPAMSOLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f3e15769-0ab2-4b19-928d-2e91421a7a3b" xlink:to="loc_asth_CAIPAMSOLLCMember_710120da-b8cc-41b2-9e22-d4bd0a05cba5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_IHealthIncMember_f2c4e8b6-600e-4a6d-87fe-950ef8f5bb5e" xlink:href="asth-20240331.xsd#asth_IHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f3e15769-0ab2-4b19-928d-2e91421a7a3b" xlink:to="loc_asth_IHealthIncMember_f2c4e8b6-600e-4a6d-87fe-950ef8f5bb5e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvesteesMember_863839b6-09bf-476e-8264-60039d45ac1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvesteesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f3e15769-0ab2-4b19-928d-2e91421a7a3b" xlink:to="loc_us-gaap_OtherInvesteesMember_863839b6-09bf-476e-8264-60039d45ac1d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_0e10e7da-df2c-4dda-9f51-cf98f4c504e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_dee47340-aadd-411a-a2e0-5eeaba30aeac" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_0e10e7da-df2c-4dda-9f51-cf98f4c504e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_EquityMethodInvestmentsRollForward_f3cab99e-0eed-4cde-a9db-f78c80a5b92b" xlink:href="asth-20240331.xsd#asth_EquityMethodInvestmentsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_dee47340-aadd-411a-a2e0-5eeaba30aeac" xlink:to="loc_asth_EquityMethodInvestmentsRollForward_f3cab99e-0eed-4cde-a9db-f78c80a5b92b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_e93b3452-aca7-459c-9188-690f7d8452e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_asth_EquityMethodInvestmentsRollForward_f3cab99e-0eed-4cde-a9db-f78c80a5b92b" xlink:to="loc_us-gaap_EquityMethodInvestments_e93b3452-aca7-459c-9188-690f7d8452e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_EquityMethodInvestmentAdditionalInvestment_398c75c1-e62a-484d-80d8-4e02545f474d" xlink:href="asth-20240331.xsd#asth_EquityMethodInvestmentAdditionalInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_asth_EquityMethodInvestmentsRollForward_f3cab99e-0eed-4cde-a9db-f78c80a5b92b" xlink:to="loc_asth_EquityMethodInvestmentAdditionalInvestment_398c75c1-e62a-484d-80d8-4e02545f474d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fbd35859-7adb-4774-8861-2db182b3c3a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_asth_EquityMethodInvestmentsRollForward_f3cab99e-0eed-4cde-a9db-f78c80a5b92b" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fbd35859-7adb-4774-8861-2db182b3c3a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_af4fce24-9584-4aec-88cb-4610e82cb5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_asth_EquityMethodInvestmentsRollForward_f3cab99e-0eed-4cde-a9db-f78c80a5b92b" xlink:to="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_af4fce24-9584-4aec-88cb-4610e82cb5a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_5d7cd189-1ae4-42fc-8348-84f0b9b4a543" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#InvestmentsinOtherEntitiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_db328024-2546-438f-b1e6-1e22be5c0348" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_06539f8e-8cdc-4a9e-b077-84025ea0b2df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_db328024-2546-438f-b1e6-1e22be5c0348" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_06539f8e-8cdc-4a9e-b077-84025ea0b2df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_edf00eb7-4d0d-4b7c-a071-62954844c251" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_06539f8e-8cdc-4a9e-b077-84025ea0b2df" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_edf00eb7-4d0d-4b7c-a071-62954844c251" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_edf00eb7-4d0d-4b7c-a071-62954844c251_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_edf00eb7-4d0d-4b7c-a071-62954844c251" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_edf00eb7-4d0d-4b7c-a071-62954844c251_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_32b79154-0026-4d46-b5b9-6cb4dac84c87" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_edf00eb7-4d0d-4b7c-a071-62954844c251" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_32b79154-0026-4d46-b5b9-6cb4dac84c87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_IHealthIncMember_697f056a-4333-4e0d-91bb-34dcfd7eb84b" xlink:href="asth-20240331.xsd#asth_IHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_32b79154-0026-4d46-b5b9-6cb4dac84c87" xlink:to="loc_asth_IHealthIncMember_697f056a-4333-4e0d-91bb-34dcfd7eb84b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_66e7199e-24ab-4951-8904-3da9fbc65e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_db328024-2546-438f-b1e6-1e22be5c0348" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_66e7199e-24ab-4951-8904-3da9fbc65e1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_85217375-6cd9-4618-a1ea-ee804b8161e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_db328024-2546-438f-b1e6-1e22be5c0348" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_85217375-6cd9-4618-a1ea-ee804b8161e7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LoansReceivableDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#LoansReceivableDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/LoansReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_bcd1a8e1-ec13-4ce6-a1d4-e468e962c433" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_75512128-4970-4b89-8a92-cb774efb26ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_bcd1a8e1-ec13-4ce6-a1d4-e468e962c433" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_75512128-4970-4b89-8a92-cb774efb26ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9028004f-e65a-484c-a510-9e9835f723e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_75512128-4970-4b89-8a92-cb774efb26ba" xlink:to="loc_us-gaap_DebtInstrumentAxis_9028004f-e65a-484c-a510-9e9835f723e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9028004f-e65a-484c-a510-9e9835f723e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9028004f-e65a-484c-a510-9e9835f723e5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9028004f-e65a-484c-a510-9e9835f723e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b8966aa9-3fb0-4cc2-9496-a04404264179" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9028004f-e65a-484c-a510-9e9835f723e5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b8966aa9-3fb0-4cc2-9496-a04404264179" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_IntraCareConvertiblePromissoryNoteReceivableMember_40c7396d-2586-4bde-bd57-b0e88f5b5f12" xlink:href="asth-20240331.xsd#asth_IntraCareConvertiblePromissoryNoteReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b8966aa9-3fb0-4cc2-9496-a04404264179" xlink:to="loc_asth_IntraCareConvertiblePromissoryNoteReceivableMember_40c7396d-2586-4bde-bd57-b0e88f5b5f12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BassMedicalGroupMember_bf61e334-eb03-4bc1-8a86-d1cb843018f4" xlink:href="asth-20240331.xsd#asth_BassMedicalGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b8966aa9-3fb0-4cc2-9496-a04404264179" xlink:to="loc_asth_BassMedicalGroupMember_bf61e334-eb03-4bc1-8a86-d1cb843018f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ba6b4aac-449b-4503-b968-582c21c2d5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_75512128-4970-4b89-8a92-cb774efb26ba" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ba6b4aac-449b-4503-b968-582c21c2d5b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ba6b4aac-449b-4503-b968-582c21c2d5b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ba6b4aac-449b-4503-b968-582c21c2d5b1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ba6b4aac-449b-4503-b968-582c21c2d5b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_eceb9535-4828-4fff-ba74-a1fa75685465" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ba6b4aac-449b-4503-b968-582c21c2d5b1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_eceb9535-4828-4fff-ba74-a1fa75685465" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_9847ae97-b45b-46ab-8b71-1f808893ed7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_eceb9535-4828-4fff-ba74-a1fa75685465" xlink:to="loc_us-gaap_NotesReceivableMember_9847ae97-b45b-46ab-8b71-1f808893ed7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_SeniorSecuredPromissoryNoteMember_89cb7bf5-820e-46ff-a3e9-63bb85a01e5f" xlink:href="asth-20240331.xsd#asth_SeniorSecuredPromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_eceb9535-4828-4fff-ba74-a1fa75685465" xlink:to="loc_asth_SeniorSecuredPromissoryNoteMember_89cb7bf5-820e-46ff-a3e9-63bb85a01e5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_fbedd785-4e4c-465a-8d4b-b377335fb248" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_bcd1a8e1-ec13-4ce6-a1d4-e468e962c433" xlink:to="loc_us-gaap_DebtInstrumentTerm_fbedd785-4e4c-465a-8d4b-b377335fb248" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8ff985fe-2948-4c3f-ad00-8c11bc0407e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_bcd1a8e1-ec13-4ce6-a1d4-e468e962c433" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8ff985fe-2948-4c3f-ad00-8c11bc0407e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0c76a67c-e429-4f62-ac66-0c784ff00bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_bcd1a8e1-ec13-4ce6-a1d4-e468e962c433" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0c76a67c-e429-4f62-ac66-0c784ff00bb4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_037e18fe-f71a-41b1-bdd9-f581989bf818" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_a983aa2a-d50c-4338-9ea0-392d470afae1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_037e18fe-f71a-41b1-bdd9-f581989bf818" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_a983aa2a-d50c-4338-9ea0-392d470afae1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_0426d975-8ad8-42db-8cf2-038a7a9f15e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a983aa2a-d50c-4338-9ea0-392d470afae1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_0426d975-8ad8-42db-8cf2-038a7a9f15e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0426d975-8ad8-42db-8cf2-038a7a9f15e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0426d975-8ad8-42db-8cf2-038a7a9f15e2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0426d975-8ad8-42db-8cf2-038a7a9f15e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9119080e-dc4b-46f7-8280-bca59bb49ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0426d975-8ad8-42db-8cf2-038a7a9f15e2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9119080e-dc4b-46f7-8280-bca59bb49ebb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_TermLoanMember_b16a9153-74e4-4499-8039-b734a9374cbc" xlink:href="asth-20240331.xsd#asth_TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9119080e-dc4b-46f7-8280-bca59bb49ebb" xlink:to="loc_asth_TermLoanMember_b16a9153-74e4-4499-8039-b734a9374cbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_598cc7db-1ec2-4bb2-a400-08c2385c6fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9119080e-dc4b-46f7-8280-bca59bb49ebb" xlink:to="loc_us-gaap_NotesPayableToBanksMember_598cc7db-1ec2-4bb2-a400-08c2385c6fe2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_09f5d0db-7bbb-4062-acd8-e27cb77ef2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a983aa2a-d50c-4338-9ea0-392d470afae1" xlink:to="loc_us-gaap_CreditFacilityAxis_09f5d0db-7bbb-4062-acd8-e27cb77ef2e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_09f5d0db-7bbb-4062-acd8-e27cb77ef2e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_09f5d0db-7bbb-4062-acd8-e27cb77ef2e5" xlink:to="loc_us-gaap_CreditFacilityDomain_09f5d0db-7bbb-4062-acd8-e27cb77ef2e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_09546853-e207-4d29-aa7c-2fc5b43f1d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_09f5d0db-7bbb-4062-acd8-e27cb77ef2e5" xlink:to="loc_us-gaap_CreditFacilityDomain_09546853-e207-4d29-aa7c-2fc5b43f1d1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_3027c71a-dbc4-4950-88f3-b7e4da401b59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_09546853-e207-4d29-aa7c-2fc5b43f1d1b" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_3027c71a-dbc4-4950-88f3-b7e4da401b59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_b8b2f2c3-5b90-472c-ba48-a599efcdd3af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_037e18fe-f71a-41b1-bdd9-f581989bf818" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_b8b2f2c3-5b90-472c-ba48-a599efcdd3af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_b511b5c7-f839-49b4-94b7-3708c8ea5a33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_037e18fe-f71a-41b1-bdd9-f581989bf818" xlink:to="loc_us-gaap_LongTermDebtCurrent_b511b5c7-f839-49b4-94b7-3708c8ea5a33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_e2a3ee01-b078-4142-a0c7-1744b36d20f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_037e18fe-f71a-41b1-bdd9-f581989bf818" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_e2a3ee01-b078-4142-a0c7-1744b36d20f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_c3777e10-967d-4594-b438-fc44e36d4c13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_037e18fe-f71a-41b1-bdd9-f581989bf818" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_c3777e10-967d-4594-b438-fc44e36d4c13" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_eeb44428-66ee-4b5b-8d73-5b3e993f9515" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_us-gaap_DebtInstrumentTable_eeb44428-66ee-4b5b-8d73-5b3e993f9515" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_9b514abf-589f-4e2f-8d3c-8e2ff25fccfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_eeb44428-66ee-4b5b-8d73-5b3e993f9515" xlink:to="loc_us-gaap_CreditFacilityAxis_9b514abf-589f-4e2f-8d3c-8e2ff25fccfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_9b514abf-589f-4e2f-8d3c-8e2ff25fccfd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_9b514abf-589f-4e2f-8d3c-8e2ff25fccfd" xlink:to="loc_us-gaap_CreditFacilityDomain_9b514abf-589f-4e2f-8d3c-8e2ff25fccfd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_00ca1315-e39d-459b-bbd7-aafe4645c8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_9b514abf-589f-4e2f-8d3c-8e2ff25fccfd" xlink:to="loc_us-gaap_CreditFacilityDomain_00ca1315-e39d-459b-bbd7-aafe4645c8c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_d492a767-bccc-4d77-a797-8dcd1b93284b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_00ca1315-e39d-459b-bbd7-aafe4645c8c6" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_d492a767-bccc-4d77-a797-8dcd1b93284b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember_2aed3e4d-1e87-40a4-a867-b507107e5291" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BridgeLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_00ca1315-e39d-459b-bbd7-aafe4645c8c6" xlink:to="loc_us-gaap_BridgeLoanMember_2aed3e4d-1e87-40a4-a867-b507107e5291" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_b3b72e8d-2837-4a66-afc0-f73c3844e045" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_00ca1315-e39d-459b-bbd7-aafe4645c8c6" xlink:to="loc_us-gaap_LetterOfCreditMember_b3b72e8d-2837-4a66-afc0-f73c3844e045" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_NewTermLoanMember_db4b65fb-bb0c-4a02-86ef-c7d7e33a2880" xlink:href="asth-20240331.xsd#asth_NewTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_00ca1315-e39d-459b-bbd7-aafe4645c8c6" xlink:to="loc_asth_NewTermLoanMember_db4b65fb-bb0c-4a02-86ef-c7d7e33a2880" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_a03da606-28fc-43e3-b9d4-0f2e3405c8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_00ca1315-e39d-459b-bbd7-aafe4645c8c6" xlink:to="loc_us-gaap_LineOfCreditMember_a03da606-28fc-43e3-b9d4-0f2e3405c8dc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_79a78e48-f174-472b-aa3c-6ce19b49c212" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_00ca1315-e39d-459b-bbd7-aafe4645c8c6" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_79a78e48-f174-472b-aa3c-6ce19b49c212" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_21581409-269a-4c20-b3a2-b15d217b1cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_eeb44428-66ee-4b5b-8d73-5b3e993f9515" xlink:to="loc_us-gaap_DebtInstrumentAxis_21581409-269a-4c20-b3a2-b15d217b1cc7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_21581409-269a-4c20-b3a2-b15d217b1cc7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_21581409-269a-4c20-b3a2-b15d217b1cc7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_21581409-269a-4c20-b3a2-b15d217b1cc7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0076cc6b-4ece-436c-be5a-b781442ea433" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_21581409-269a-4c20-b3a2-b15d217b1cc7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0076cc6b-4ece-436c-be5a-b781442ea433" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AmendedCreditAgreementMember_816a0209-34bf-444f-bfb5-f89f968780b5" xlink:href="asth-20240331.xsd#asth_AmendedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0076cc6b-4ece-436c-be5a-b781442ea433" xlink:to="loc_asth_AmendedCreditAgreementMember_816a0209-34bf-444f-bfb5-f89f968780b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AmendedAndRestatedCreditAgreementMember_ff112c2e-9c74-408b-ab9b-69084c4f5b66" xlink:href="asth-20240331.xsd#asth_AmendedAndRestatedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0076cc6b-4ece-436c-be5a-b781442ea433" xlink:to="loc_asth_AmendedAndRestatedCreditAgreementMember_ff112c2e-9c74-408b-ab9b-69084c4f5b66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CreditAgreementMember_60f3f69c-465f-4d23-82cc-5ca6110b16b4" xlink:href="asth-20240331.xsd#asth_CreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0076cc6b-4ece-436c-be5a-b781442ea433" xlink:to="loc_asth_CreditAgreementMember_60f3f69c-465f-4d23-82cc-5ca6110b16b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_SubordinatedLoanAgreementMember_794c188b-ff27-46a0-a828-65957ee4fc47" xlink:href="asth-20240331.xsd#asth_SubordinatedLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0076cc6b-4ece-436c-be5a-b781442ea433" xlink:to="loc_asth_SubordinatedLoanAgreementMember_794c188b-ff27-46a0-a828-65957ee4fc47" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ApcBusinessLoanAgreementMember_02ecebc8-c761-41d2-be06-6d022edebb14" xlink:href="asth-20240331.xsd#asth_ApcBusinessLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0076cc6b-4ece-436c-be5a-b781442ea433" xlink:to="loc_asth_ApcBusinessLoanAgreementMember_02ecebc8-c761-41d2-be06-6d022edebb14" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e330b228-9a1b-4d47-8a95-380f2dd0675e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_eeb44428-66ee-4b5b-8d73-5b3e993f9515" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e330b228-9a1b-4d47-8a95-380f2dd0675e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e330b228-9a1b-4d47-8a95-380f2dd0675e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e330b228-9a1b-4d47-8a95-380f2dd0675e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e330b228-9a1b-4d47-8a95-380f2dd0675e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f7ce7654-86be-4931-aece-5882a9415d89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e330b228-9a1b-4d47-8a95-380f2dd0675e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f7ce7654-86be-4931-aece-5882a9415d89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_83cc5505-5350-419e-8450-a04e97f40bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f7ce7654-86be-4931-aece-5882a9415d89" xlink:to="loc_us-gaap_LineOfCreditMember_83cc5505-5350-419e-8450-a04e97f40bfb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_c9a6dfa4-785f-4e64-a50a-07f0e205efce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f7ce7654-86be-4931-aece-5882a9415d89" xlink:to="loc_us-gaap_SecuredDebtMember_c9a6dfa4-785f-4e64-a50a-07f0e205efce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubordinatedDebtMember_83365254-eb5c-4a62-b41c-8863d4e300a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubordinatedDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f7ce7654-86be-4931-aece-5882a9415d89" xlink:to="loc_us-gaap_SubordinatedDebtMember_83365254-eb5c-4a62-b41c-8863d4e300a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_06e292cf-2c0a-4401-8f0e-ec82a61337ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f7ce7654-86be-4931-aece-5882a9415d89" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_06e292cf-2c0a-4401-8f0e-ec82a61337ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e6df1196-2169-4f50-8edf-ef7648b5e2e7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_eeb44428-66ee-4b5b-8d73-5b3e993f9515" xlink:to="loc_srt_RangeAxis_e6df1196-2169-4f50-8edf-ef7648b5e2e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e6df1196-2169-4f50-8edf-ef7648b5e2e7_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e6df1196-2169-4f50-8edf-ef7648b5e2e7" xlink:to="loc_srt_RangeMember_e6df1196-2169-4f50-8edf-ef7648b5e2e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5cd123ff-b1f5-4a2f-adf0-f7c3c0fa54e3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e6df1196-2169-4f50-8edf-ef7648b5e2e7" xlink:to="loc_srt_RangeMember_5cd123ff-b1f5-4a2f-adf0-f7c3c0fa54e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b37ba38e-2e98-49ff-ae4a-2482e63045b4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5cd123ff-b1f5-4a2f-adf0-f7c3c0fa54e3" xlink:to="loc_srt_MinimumMember_b37ba38e-2e98-49ff-ae4a-2482e63045b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1481056b-2ff0-49ed-9b0d-512da549fb13" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5cd123ff-b1f5-4a2f-adf0-f7c3c0fa54e3" xlink:to="loc_srt_MaximumMember_1481056b-2ff0-49ed-9b0d-512da549fb13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_31c8c36f-8529-49c9-a643-60959953ae37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_eeb44428-66ee-4b5b-8d73-5b3e993f9515" xlink:to="loc_us-gaap_VariableRateAxis_31c8c36f-8529-49c9-a643-60959953ae37" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_31c8c36f-8529-49c9-a643-60959953ae37_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_31c8c36f-8529-49c9-a643-60959953ae37" xlink:to="loc_us-gaap_VariableRateDomain_31c8c36f-8529-49c9-a643-60959953ae37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_8922f47f-e386-4754-a176-4335b605c539" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_31c8c36f-8529-49c9-a643-60959953ae37" xlink:to="loc_us-gaap_VariableRateDomain_8922f47f-e386-4754-a176-4335b605c539" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_SecuredOvernightFinancingRateMember_20ab65df-2a89-4568-b337-4f57a6f3c06b" xlink:href="asth-20240331.xsd#asth_SecuredOvernightFinancingRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_8922f47f-e386-4754-a176-4335b605c539" xlink:to="loc_asth_SecuredOvernightFinancingRateMember_20ab65df-2a89-4568-b337-4f57a6f3c06b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_741dbaa0-b7fa-4960-af52-9dbf0a18509e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_8922f47f-e386-4754-a176-4335b605c539" xlink:to="loc_us-gaap_BaseRateMember_741dbaa0-b7fa-4960-af52-9dbf0a18509e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_e98af1c0-724a-4c05-816f-efa2bd098c89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_eeb44428-66ee-4b5b-8d73-5b3e993f9515" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_e98af1c0-724a-4c05-816f-efa2bd098c89" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_e98af1c0-724a-4c05-816f-efa2bd098c89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_e98af1c0-724a-4c05-816f-efa2bd098c89" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_e98af1c0-724a-4c05-816f-efa2bd098c89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_e586d021-59b5-4a65-90c4-f8470175773c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_e98af1c0-724a-4c05-816f-efa2bd098c89" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_e586d021-59b5-4a65-90c4-f8470175773c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_TruistBankMember_3bbb3690-5795-4233-84cd-43d33c16e229" xlink:href="asth-20240331.xsd#asth_TruistBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_e586d021-59b5-4a65-90c4-f8470175773c" xlink:to="loc_asth_TruistBankMember_3bbb3690-5795-4233-84cd-43d33c16e229" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PreferredBankMember_b2bfcfc7-3267-4e0d-9dea-b77794f3e2e2" xlink:href="asth-20240331.xsd#asth_PreferredBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_e586d021-59b5-4a65-90c4-f8470175773c" xlink:to="loc_asth_PreferredBankMember_b2bfcfc7-3267-4e0d-9dea-b77794f3e2e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_3b15c56c-147b-4afe-9224-785d2ab63152" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_eeb44428-66ee-4b5b-8d73-5b3e993f9515" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_3b15c56c-147b-4afe-9224-785d2ab63152" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_3b15c56c-147b-4afe-9224-785d2ab63152_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_3b15c56c-147b-4afe-9224-785d2ab63152" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_3b15c56c-147b-4afe-9224-785d2ab63152_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1fd8b5f6-2f55-4eb6-b562-c733ffc1ab08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_3b15c56c-147b-4afe-9224-785d2ab63152" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1fd8b5f6-2f55-4eb6-b562-c733ffc1ab08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_e8fc9448-c532-4e20-b3b4-0d633a2252c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1fd8b5f6-2f55-4eb6-b562-c733ffc1ab08" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_e8fc9448-c532-4e20-b3b4-0d633a2252c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_2d93e28f-beec-43b3-96f3-5f00fb443421" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1fd8b5f6-2f55-4eb6-b562-c733ffc1ab08" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_2d93e28f-beec-43b3-96f3-5f00fb443421" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_5ca0f0b3-46e5-4423-90d3-ef60dbc33bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1fd8b5f6-2f55-4eb6-b562-c733ffc1ab08" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_5ca0f0b3-46e5-4423-90d3-ef60dbc33bbb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_690ef282-27fb-40e6-8dac-2ed201cd34b9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_eeb44428-66ee-4b5b-8d73-5b3e993f9515" xlink:to="loc_srt_CounterpartyNameAxis_690ef282-27fb-40e6-8dac-2ed201cd34b9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_690ef282-27fb-40e6-8dac-2ed201cd34b9_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_690ef282-27fb-40e6-8dac-2ed201cd34b9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_690ef282-27fb-40e6-8dac-2ed201cd34b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e89947d3-9d34-4b83-bdfa-ab469eb62700" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_690ef282-27fb-40e6-8dac-2ed201cd34b9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e89947d3-9d34-4b83-bdfa-ab469eb62700" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AstranaMedicalMember_440fd82d-6f00-4ec1-9576-7e67d73c8175" xlink:href="asth-20240331.xsd#asth_AstranaMedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e89947d3-9d34-4b83-bdfa-ab469eb62700" xlink:to="loc_asth_AstranaMedicalMember_440fd82d-6f00-4ec1-9576-7e67d73c8175" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_cccd25d6-388a-4bff-9727-a55b1614ccb7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_eeb44428-66ee-4b5b-8d73-5b3e993f9515" xlink:to="loc_dei_LegalEntityAxis_cccd25d6-388a-4bff-9727-a55b1614ccb7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_cccd25d6-388a-4bff-9727-a55b1614ccb7_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_cccd25d6-388a-4bff-9727-a55b1614ccb7" xlink:to="loc_dei_EntityDomain_cccd25d6-388a-4bff-9727-a55b1614ccb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_14e5cd5e-d8f1-4590-a218-f7e05d967b97" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_cccd25d6-388a-4bff-9727-a55b1614ccb7" xlink:to="loc_dei_EntityDomain_14e5cd5e-d8f1-4590-a218-f7e05d967b97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AlliedPacificOfCaliforniaIPAMember_93ff51f0-8143-4d3d-8be0-a5f601c198a9" xlink:href="asth-20240331.xsd#asth_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_14e5cd5e-d8f1-4590-a218-f7e05d967b97" xlink:to="loc_asth_AlliedPacificOfCaliforniaIPAMember_93ff51f0-8143-4d3d-8be0-a5f601c198a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_5c722faa-3300-4e0e-ada0-756c296b8b35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_eeb44428-66ee-4b5b-8d73-5b3e993f9515" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_5c722faa-3300-4e0e-ada0-756c296b8b35" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_5c722faa-3300-4e0e-ada0-756c296b8b35_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_5c722faa-3300-4e0e-ada0-756c296b8b35" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_5c722faa-3300-4e0e-ada0-756c296b8b35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_bbe65948-c32b-484f-9348-a762ab6e6113" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_5c722faa-3300-4e0e-ada0-756c296b8b35" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_bbe65948-c32b-484f-9348-a762ab6e6113" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_e7279313-d2a3-4ec9-bd4f-6c88043aca6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_bbe65948-c32b-484f-9348-a762ab6e6113" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_e7279313-d2a3-4ec9-bd4f-6c88043aca6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_79ffd8be-4442-42d1-bf4f-b2f1d01eca86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_us-gaap_DebtInstrumentTerm_79ffd8be-4442-42d1-bf4f-b2f1d01eca86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_884aafbe-9e2a-431e-9c30-695ad60cf864" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_884aafbe-9e2a-431e-9c30-695ad60cf864" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_d3b45181-bbdd-4dfb-81e2-640f52aba92e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_d3b45181-bbdd-4dfb-81e2-640f52aba92e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_cc1a0970-5238-485d-b978-9da41940308d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_cc1a0970-5238-485d-b978-9da41940308d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_2a0697e3-a54a-4949-b8aa-86801f29c049" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_2a0697e3-a54a-4949-b8aa-86801f29c049" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_LineOfCreditFacilityAmountFundedAtClosing_7c00a2b0-2d60-46ea-ad6e-ee7c9ae19530" xlink:href="asth-20240331.xsd#asth_LineOfCreditFacilityAmountFundedAtClosing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_asth_LineOfCreditFacilityAmountFundedAtClosing_7c00a2b0-2d60-46ea-ad6e-ee7c9ae19530" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_fe5c938a-d417-4b8c-8e12-6b8966917032" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_us-gaap_RepaymentsOfDebt_fe5c938a-d417-4b8c-8e12-6b8966917032" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfBankOverdrafts_df6e80ca-0a25-4d3d-b06f-6d46fdc247b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfBankOverdrafts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfBankOverdrafts_df6e80ca-0a25-4d3d-b06f-6d46fdc247b5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_32142500-3270-452a-9562-ae439f01e7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_32142500-3270-452a-9562-ae439f01e7f2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_5b5d014b-e1ad-4e56-95db-eec5dc271cee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_5b5d014b-e1ad-4e56-95db-eec5dc271cee" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_44f4fe31-a8ce-4376-a78c-1bb41eff27fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_44f4fe31-a8ce-4376-a78c-1bb41eff27fe" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_DebtInstrumentNumberOfKeyFinancialRatios_ad39eca7-1906-421c-9091-9614d00da26a" xlink:href="asth-20240331.xsd#asth_DebtInstrumentNumberOfKeyFinancialRatios"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_asth_DebtInstrumentNumberOfKeyFinancialRatios_ad39eca7-1906-421c-9091-9614d00da26a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_DebtInstrumentCovenantLeverageRatioMaximum_03630e50-adca-445b-beba-983c58404d52" xlink:href="asth-20240331.xsd#asth_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_asth_DebtInstrumentCovenantLeverageRatioMaximum_03630e50-adca-445b-beba-983c58404d52" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_DebtCovenantAggregatePurchasePriceMaximum_cb146fba-1eaf-4d1f-9eaa-2e3d79c1dcd2" xlink:href="asth-20240331.xsd#asth_DebtCovenantAggregatePurchasePriceMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_asth_DebtCovenantAggregatePurchasePriceMaximum_cb146fba-1eaf-4d1f-9eaa-2e3d79c1dcd2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_DebtInstrumentCovenantLeverageRatioIncrementalChange_256a4aa0-b7f3-4b7f-ac93-d2af70a56bab" xlink:href="asth-20240331.xsd#asth_DebtInstrumentCovenantLeverageRatioIncrementalChange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_asth_DebtInstrumentCovenantLeverageRatioIncrementalChange_256a4aa0-b7f3-4b7f-ac93-d2af70a56bab" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_DebtInstrumentCovenantLeverageRatioAdjustedMaximum_c3f37254-09c2-4ca6-88b8-7b1e0831a117" xlink:href="asth-20240331.xsd#asth_DebtInstrumentCovenantLeverageRatioAdjustedMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_asth_DebtInstrumentCovenantLeverageRatioAdjustedMaximum_c3f37254-09c2-4ca6-88b8-7b1e0831a117" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_DebtInstrumentCovenantInterestCoverageRatioMinimum_fc5a92ce-f13a-43be-a17b-626987d627cf" xlink:href="asth-20240331.xsd#asth_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_asth_DebtInstrumentCovenantInterestCoverageRatioMinimum_fc5a92ce-f13a-43be-a17b-626987d627cf" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_443a17ae-986a-4446-8008-97e1d1a16bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_us-gaap_LineOfCredit_443a17ae-986a-4446-8008-97e1d1a16bfc" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_7874523e-1a6f-424b-a605-2889a1b4fa6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_7874523e-1a6f-424b-a605-2889a1b4fa6f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_UnamortizedDeferredFinancingCosts_de575faf-386d-4fdb-bab0-8530143d1b9e" xlink:href="asth-20240331.xsd#asth_UnamortizedDeferredFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_asth_UnamortizedDeferredFinancingCosts_de575faf-386d-4fdb-bab0-8530143d1b9e" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_7fb7eca4-d13e-41fa-87ed-085dd6e8294b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_7fb7eca4-d13e-41fa-87ed-085dd6e8294b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_453e7405-56e4-48ad-ad45-27f194f2a09d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_us-gaap_InterestExpense_453e7405-56e4-48ad-ad45-27f194f2a09d" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_3b4ddea7-75fb-4276-b2b2-2174a8598aff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_3b4ddea7-75fb-4276-b2b2-2174a8598aff" xlink:type="arc" order="22"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#MezzanineandStockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_5579f0ed-8aeb-42f0-9a50-0010f1babf61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_bdcc6ba6-a3bd-4727-9340-1f95fe81a0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_5579f0ed-8aeb-42f0-9a50-0010f1babf61" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_bdcc6ba6-a3bd-4727-9340-1f95fe81a0d5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_3e67bddb-4c2a-4ef5-b6ce-e6b3b2e8c07e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bdcc6ba6-a3bd-4727-9340-1f95fe81a0d5" xlink:to="loc_dei_LegalEntityAxis_3e67bddb-4c2a-4ef5-b6ce-e6b3b2e8c07e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3e67bddb-4c2a-4ef5-b6ce-e6b3b2e8c07e_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_3e67bddb-4c2a-4ef5-b6ce-e6b3b2e8c07e" xlink:to="loc_dei_EntityDomain_3e67bddb-4c2a-4ef5-b6ce-e6b3b2e8c07e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e8e607d9-589b-45c7-81a8-01d36491afd7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_3e67bddb-4c2a-4ef5-b6ce-e6b3b2e8c07e" xlink:to="loc_dei_EntityDomain_e8e607d9-589b-45c7-81a8-01d36491afd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AlliedPacificOfCaliforniaIPAMember_976ba78e-84da-434c-83d0-5475db7d78e6" xlink:href="asth-20240331.xsd#asth_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e8e607d9-589b-45c7-81a8-01d36491afd7" xlink:to="loc_asth_AlliedPacificOfCaliforniaIPAMember_976ba78e-84da-434c-83d0-5475db7d78e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CDSCMember_a8be932f-7236-4838-8160-4c3643516214" xlink:href="asth-20240331.xsd#asth_CDSCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e8e607d9-589b-45c7-81a8-01d36491afd7" xlink:to="loc_asth_CDSCMember_a8be932f-7236-4838-8160-4c3643516214" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CompanyAndAPCMember_2e62ab3d-5c7b-47a8-b88c-2c3dee86f611" xlink:href="asth-20240331.xsd#asth_CompanyAndAPCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e8e607d9-589b-45c7-81a8-01d36491afd7" xlink:to="loc_asth_CompanyAndAPCMember_2e62ab3d-5c7b-47a8-b88c-2c3dee86f611" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d9c801cd-18a5-40e4-a436-082907bc64f8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bdcc6ba6-a3bd-4727-9340-1f95fe81a0d5" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d9c801cd-18a5-40e4-a436-082907bc64f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_d9c801cd-18a5-40e4-a436-082907bc64f8_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d9c801cd-18a5-40e4-a436-082907bc64f8" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_d9c801cd-18a5-40e4-a436-082907bc64f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_2f776509-ea1b-4eb1-a547-f701c160b3c8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d9c801cd-18a5-40e4-a436-082907bc64f8" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_2f776509-ea1b-4eb1-a547-f701c160b3c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ApolloMedicalHoldingsIncMember_0908bb71-8be1-4ea2-9cab-3ec9d8335d92" xlink:href="asth-20240331.xsd#asth_ApolloMedicalHoldingsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_2f776509-ea1b-4eb1-a547-f701c160b3c8" xlink:to="loc_asth_ApolloMedicalHoldingsIncMember_0908bb71-8be1-4ea2-9cab-3ec9d8335d92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_StockIssuedDuringPeriodSharesMerger_0fbf79b5-29d1-4860-829d-c00d29c747f6" xlink:href="asth-20240331.xsd#asth_StockIssuedDuringPeriodSharesMerger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5579f0ed-8aeb-42f0-9a50-0010f1babf61" xlink:to="loc_asth_StockIssuedDuringPeriodSharesMerger_0fbf79b5-29d1-4860-829d-c00d29c747f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_9bf14281-f1df-4d58-b4bf-6fe42b768eff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5579f0ed-8aeb-42f0-9a50-0010f1babf61" xlink:to="loc_us-gaap_TreasuryStockCommonShares_9bf14281-f1df-4d58-b4bf-6fe42b768eff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_928f9fe4-b967-4052-b680-f5743d80409b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5579f0ed-8aeb-42f0-9a50-0010f1babf61" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_928f9fe4-b967-4052-b680-f5743d80409b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_cd729fa1-7396-4705-aa79-4c416d5c2ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5579f0ed-8aeb-42f0-9a50-0010f1babf61" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_cd729fa1-7396-4705-aa79-4c416d5c2ca1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_8ab47ed0-16ee-420f-a2b7-ca06992df513" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5579f0ed-8aeb-42f0-9a50-0010f1babf61" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_8ab47ed0-16ee-420f-a2b7-ca06992df513" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationScheduleofShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#StockBasedCompensationScheduleofShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationScheduleofShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fb585ec5-c527-48cc-982b-17ff1f688350" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88a41316-9997-46e4-a27b-f98ca5b0a5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fb585ec5-c527-48cc-982b-17ff1f688350" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88a41316-9997-46e4-a27b-f98ca5b0a5fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0d775f41-fbe5-4986-8675-8651cdbca38b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88a41316-9997-46e4-a27b-f98ca5b0a5fc" xlink:to="loc_us-gaap_AwardTypeAxis_0d775f41-fbe5-4986-8675-8651cdbca38b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d775f41-fbe5-4986-8675-8651cdbca38b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0d775f41-fbe5-4986-8675-8651cdbca38b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d775f41-fbe5-4986-8675-8651cdbca38b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19acedc5-e9eb-4d56-adc1-55754d1bf6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0d775f41-fbe5-4986-8675-8651cdbca38b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19acedc5-e9eb-4d56-adc1-55754d1bf6ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7e222842-7f5f-4a4c-941b-b39479cc5455" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19acedc5-e9eb-4d56-adc1-55754d1bf6ec" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7e222842-7f5f-4a4c-941b-b39479cc5455" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_StockAwardsAndUnitsMember_8c2310e7-d2d0-4e82-9287-4960919b53ee" xlink:href="asth-20240331.xsd#asth_StockAwardsAndUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19acedc5-e9eb-4d56-adc1-55754d1bf6ec" xlink:to="loc_asth_StockAwardsAndUnitsMember_8c2310e7-d2d0-4e82-9287-4960919b53ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3f567204-7721-44ce-9400-8c888027db9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fb585ec5-c527-48cc-982b-17ff1f688350" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3f567204-7721-44ce-9400-8c888027db9e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91421281-c342-4ffd-8dc9-bc94e2273597" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ed669893-9e36-4502-b013-1728214fea79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91421281-c342-4ffd-8dc9-bc94e2273597" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ed669893-9e36-4502-b013-1728214fea79" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_b56bd110-bad5-44db-aba4-70b6153fdaeb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ed669893-9e36-4502-b013-1728214fea79" xlink:to="loc_srt_TitleOfIndividualAxis_b56bd110-bad5-44db-aba4-70b6153fdaeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b56bd110-bad5-44db-aba4-70b6153fdaeb_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_b56bd110-bad5-44db-aba4-70b6153fdaeb" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b56bd110-bad5-44db-aba4-70b6153fdaeb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_eeef2dfb-506b-4589-a884-b63ded8d4723" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_b56bd110-bad5-44db-aba4-70b6153fdaeb" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_eeef2dfb-506b-4589-a884-b63ded8d4723" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ApcStockOptionMember_cc0f1320-7e73-4dcb-aa55-28eea6f5e9b0" xlink:href="asth-20240331.xsd#asth_ApcStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_eeef2dfb-506b-4589-a884-b63ded8d4723" xlink:to="loc_asth_ApcStockOptionMember_cc0f1320-7e73-4dcb-aa55-28eea6f5e9b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c98d3434-4065-4fed-81d8-52c1eb68b799" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ed669893-9e36-4502-b013-1728214fea79" xlink:to="loc_us-gaap_AwardTypeAxis_c98d3434-4065-4fed-81d8-52c1eb68b799" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c98d3434-4065-4fed-81d8-52c1eb68b799_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c98d3434-4065-4fed-81d8-52c1eb68b799" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c98d3434-4065-4fed-81d8-52c1eb68b799_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_318cca89-e6db-4948-88ec-081cb6b4627c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c98d3434-4065-4fed-81d8-52c1eb68b799" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_318cca89-e6db-4948-88ec-081cb6b4627c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_1d8aa3b4-d16d-43ce-926e-8e5e94e5e00e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_318cca89-e6db-4948-88ec-081cb6b4627c" xlink:to="loc_us-gaap_RestrictedStockMember_1d8aa3b4-d16d-43ce-926e-8e5e94e5e00e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PerformanceBasedRestrictedStockMember_155ff4b7-d2d8-4652-9792-94cdb42ecacc" xlink:href="asth-20240331.xsd#asth_PerformanceBasedRestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_318cca89-e6db-4948-88ec-081cb6b4627c" xlink:to="loc_asth_PerformanceBasedRestrictedStockMember_155ff4b7-d2d8-4652-9792-94cdb42ecacc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_EmployeeStockPurchasePlanMember_67de90e2-c410-4ab5-ad75-4668f06ba556" xlink:href="asth-20240331.xsd#asth_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_318cca89-e6db-4948-88ec-081cb6b4627c" xlink:to="loc_asth_EmployeeStockPurchasePlanMember_67de90e2-c410-4ab5-ad75-4668f06ba556" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_03125f25-6446-4fd0-a89b-e424be56291f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91421281-c342-4ffd-8dc9-bc94e2273597" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_03125f25-6446-4fd0-a89b-e424be56291f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4d946aaf-d378-45be-96fb-60d09999cf12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91421281-c342-4ffd-8dc9-bc94e2273597" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4d946aaf-d378-45be-96fb-60d09999cf12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0a80dec0-d55f-485a-b36e-ca0acee284ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91421281-c342-4ffd-8dc9-bc94e2273597" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0a80dec0-d55f-485a-b36e-ca0acee284ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f6f5debe-d516-42ce-ac6a-50dbcbc6fd02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91421281-c342-4ffd-8dc9-bc94e2273597" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f6f5debe-d516-42ce-ac6a-50dbcbc6fd02" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance_99330d2e-4dd8-4c5f-b286-d9370790a2f2" xlink:href="asth-20240331.xsd#asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91421281-c342-4ffd-8dc9-bc94e2273597" xlink:to="loc_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance_99330d2e-4dd8-4c5f-b286-d9370790a2f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_74c4f810-10c9-425d-a455-fa2443e555ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91421281-c342-4ffd-8dc9-bc94e2273597" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_74c4f810-10c9-425d-a455-fa2443e555ef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CommonStockDiscountedPricePercentage_4be95cfa-83de-484b-961e-10717ea539ff" xlink:href="asth-20240331.xsd#asth_CommonStockDiscountedPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91421281-c342-4ffd-8dc9-bc94e2273597" xlink:to="loc_asth_CommonStockDiscountedPricePercentage_4be95cfa-83de-484b-961e-10717ea539ff" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CommonStockDiscountedPricePercentageMaximum_1e987cd6-dc46-4b0a-bbe7-e77a83fded11" xlink:href="asth-20240331.xsd#asth_CommonStockDiscountedPricePercentageMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91421281-c342-4ffd-8dc9-bc94e2273597" xlink:to="loc_asth_CommonStockDiscountedPricePercentageMaximum_1e987cd6-dc46-4b0a-bbe7-e77a83fded11" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c460b6e9-7cf8-4d53-9ea7-97f577258362" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91421281-c342-4ffd-8dc9-bc94e2273597" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c460b6e9-7cf8-4d53-9ea7-97f577258362" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_asth_CommitmentsAndContingenciesLineItems_c8d362d7-a84d-4f48-8d7a-ee3dee2f0e8d" xlink:href="asth-20240331.xsd#asth_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CommitmentsAndContingenciesTable_7b68f01f-bbb1-4d77-aa66-b757a09f1ec0" xlink:href="asth-20240331.xsd#asth_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_asth_CommitmentsAndContingenciesLineItems_c8d362d7-a84d-4f48-8d7a-ee3dee2f0e8d" xlink:to="loc_asth_CommitmentsAndContingenciesTable_7b68f01f-bbb1-4d77-aa66-b757a09f1ec0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_28f07ac1-d647-4045-b8ed-d664f43ae87c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_asth_CommitmentsAndContingenciesTable_7b68f01f-bbb1-4d77-aa66-b757a09f1ec0" xlink:to="loc_dei_LegalEntityAxis_28f07ac1-d647-4045-b8ed-d664f43ae87c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_28f07ac1-d647-4045-b8ed-d664f43ae87c_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_28f07ac1-d647-4045-b8ed-d664f43ae87c" xlink:to="loc_dei_EntityDomain_28f07ac1-d647-4045-b8ed-d664f43ae87c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4c5f0ec5-4b1e-446d-8304-b2ce82c9c6d8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_28f07ac1-d647-4045-b8ed-d664f43ae87c" xlink:to="loc_dei_EntityDomain_4c5f0ec5-4b1e-446d-8304-b2ce82c9c6d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AlliedPacificOfCaliforniaIPAMember_74d1a334-c4bc-415b-94bc-23682fa35af1" xlink:href="asth-20240331.xsd#asth_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4c5f0ec5-4b1e-446d-8304-b2ce82c9c6d8" xlink:to="loc_asth_AlliedPacificOfCaliforniaIPAMember_74d1a334-c4bc-415b-94bc-23682fa35af1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1032b7cc-6a3f-40e0-9f72-9fba2c687f66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_asth_CommitmentsAndContingenciesTable_7b68f01f-bbb1-4d77-aa66-b757a09f1ec0" xlink:to="loc_us-gaap_DebtInstrumentAxis_1032b7cc-6a3f-40e0-9f72-9fba2c687f66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1032b7cc-6a3f-40e0-9f72-9fba2c687f66_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1032b7cc-6a3f-40e0-9f72-9fba2c687f66" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1032b7cc-6a3f-40e0-9f72-9fba2c687f66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b0573a9a-d21a-4c50-9a04-9e998565d5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1032b7cc-6a3f-40e0-9f72-9fba2c687f66" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b0573a9a-d21a-4c50-9a04-9e998565d5f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AmendedCreditAgreementMember_61a72637-9182-4695-a71a-8f7111492ec9" xlink:href="asth-20240331.xsd#asth_AmendedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0573a9a-d21a-4c50-9a04-9e998565d5f9" xlink:to="loc_asth_AmendedCreditAgreementMember_61a72637-9182-4695-a71a-8f7111492ec9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_000a6535-ff69-4563-91cb-e5a0dd66480a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_asth_CommitmentsAndContingenciesTable_7b68f01f-bbb1-4d77-aa66-b757a09f1ec0" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_000a6535-ff69-4563-91cb-e5a0dd66480a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_000a6535-ff69-4563-91cb-e5a0dd66480a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_000a6535-ff69-4563-91cb-e5a0dd66480a" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_000a6535-ff69-4563-91cb-e5a0dd66480a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_73ca0bc0-7f2d-4f00-a4a3-786a50c0133e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_000a6535-ff69-4563-91cb-e5a0dd66480a" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_73ca0bc0-7f2d-4f00-a4a3-786a50c0133e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_TruistBankMember_fb19d6c6-a113-489b-8e29-85bca9f13074" xlink:href="asth-20240331.xsd#asth_TruistBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_73ca0bc0-7f2d-4f00-a4a3-786a50c0133e" xlink:to="loc_asth_TruistBankMember_fb19d6c6-a113-489b-8e29-85bca9f13074" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_1d4ce2ab-fbaa-44a1-a1d6-178cb6e64239" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_asth_CommitmentsAndContingenciesTable_7b68f01f-bbb1-4d77-aa66-b757a09f1ec0" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_1d4ce2ab-fbaa-44a1-a1d6-178cb6e64239" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_1d4ce2ab-fbaa-44a1-a1d6-178cb6e64239_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_1d4ce2ab-fbaa-44a1-a1d6-178cb6e64239" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_1d4ce2ab-fbaa-44a1-a1d6-178cb6e64239_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_7547a61c-c2d7-452a-ac2b-76d8c8a07bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_1d4ce2ab-fbaa-44a1-a1d6-178cb6e64239" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_7547a61c-c2d7-452a-ac2b-76d8c8a07bdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_76ed46a9-7c15-43ec-a64e-1b8b53875fee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_7547a61c-c2d7-452a-ac2b-76d8c8a07bdd" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_76ed46a9-7c15-43ec-a64e-1b8b53875fee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_b5c5a0c4-bf63-4075-92d2-08102b5513f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_asth_CommitmentsAndContingenciesLineItems_c8d362d7-a84d-4f48-8d7a-ee3dee2f0e8d" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_b5c5a0c4-bf63-4075-92d2-08102b5513f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_6209bdb7-225e-4df0-bc7a-79ee4e0642ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_asth_CommitmentsAndContingenciesLineItems_c8d362d7-a84d-4f48-8d7a-ee3dee2f0e8d" xlink:to="loc_us-gaap_LineOfCredit_6209bdb7-225e-4df0-bc7a-79ee4e0642ae" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_8bd3b73e-431f-4757-a8c1-0e63463320fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_252f4b71-6fa9-41b4-bfd0-fdeb1d495997" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8bd3b73e-431f-4757-a8c1-0e63463320fe" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_252f4b71-6fa9-41b4-bfd0-fdeb1d495997" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f13bc089-cb95-432e-99db-3bca805aa4ea" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_252f4b71-6fa9-41b4-bfd0-fdeb1d495997" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f13bc089-cb95-432e-99db-3bca805aa4ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f13bc089-cb95-432e-99db-3bca805aa4ea_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f13bc089-cb95-432e-99db-3bca805aa4ea" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f13bc089-cb95-432e-99db-3bca805aa4ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_23922cf5-b968-405b-beb7-510ebeb8cbe0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f13bc089-cb95-432e-99db-3bca805aa4ea" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_23922cf5-b968-405b-beb7-510ebeb8cbe0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_LmaMember_fd0b05dd-28f9-4d9d-a103-78e499a5c831" xlink:href="asth-20240331.xsd#asth_LmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_23922cf5-b968-405b-beb7-510ebeb8cbe0" xlink:to="loc_asth_LmaMember_fd0b05dd-28f9-4d9d-a103-78e499a5c831" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PmiocMember_cdae2359-1e15-4ed3-b4ab-7151c2c80879" xlink:href="asth-20240331.xsd#asth_PmiocMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_23922cf5-b968-405b-beb7-510ebeb8cbe0" xlink:to="loc_asth_PmiocMember_cdae2359-1e15-4ed3-b4ab-7151c2c80879" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_SongPCMember_a56e73f9-cb63-4e1e-8a2b-73dbfd80c67b" xlink:href="asth-20240331.xsd#asth_SongPCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_23922cf5-b968-405b-beb7-510ebeb8cbe0" xlink:to="loc_asth_SongPCMember_a56e73f9-cb63-4e1e-8a2b-73dbfd80c67b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_1592afee-dbf5-4494-a1d0-5ed7057a4b61" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_252f4b71-6fa9-41b4-bfd0-fdeb1d495997" xlink:to="loc_dei_LegalEntityAxis_1592afee-dbf5-4494-a1d0-5ed7057a4b61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1592afee-dbf5-4494-a1d0-5ed7057a4b61_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1592afee-dbf5-4494-a1d0-5ed7057a4b61" xlink:to="loc_dei_EntityDomain_1592afee-dbf5-4494-a1d0-5ed7057a4b61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_bd7486d5-5685-4434-a001-d7502d952a06" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1592afee-dbf5-4494-a1d0-5ed7057a4b61" xlink:to="loc_dei_EntityDomain_bd7486d5-5685-4434-a001-d7502d952a06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AHMCMember_d3c6774d-6d7e-464f-8637-72410e0cf6ce" xlink:href="asth-20240331.xsd#asth_AHMCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_bd7486d5-5685-4434-a001-d7502d952a06" xlink:to="loc_asth_AHMCMember_d3c6774d-6d7e-464f-8637-72410e0cf6ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AlliedPacificOfCaliforniaIPAMember_59d7245f-38aa-4ec4-9af6-b51d120cd290" xlink:href="asth-20240331.xsd#asth_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_bd7486d5-5685-4434-a001-d7502d952a06" xlink:to="loc_asth_AlliedPacificOfCaliforniaIPAMember_59d7245f-38aa-4ec4-9af6-b51d120cd290" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_NetworkMedicalManagementMember_e233e33c-7681-40f7-ae97-ce9a5a5b246b" xlink:href="asth-20240331.xsd#asth_NetworkMedicalManagementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_bd7486d5-5685-4434-a001-d7502d952a06" xlink:to="loc_asth_NetworkMedicalManagementMember_e233e33c-7681-40f7-ae97-ce9a5a5b246b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ProfessionalMedicalCorporationMember_9583dc5a-6653-4b9b-87e9-1033e561259c" xlink:href="asth-20240331.xsd#asth_ProfessionalMedicalCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_bd7486d5-5685-4434-a001-d7502d952a06" xlink:to="loc_asth_ProfessionalMedicalCorporationMember_9583dc5a-6653-4b9b-87e9-1033e561259c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AstranaMedicalMember_7e38f67d-62d2-4ab8-9353-ba77a4bc1ae7" xlink:href="asth-20240331.xsd#asth_AstranaMedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_bd7486d5-5685-4434-a001-d7502d952a06" xlink:to="loc_asth_AstranaMedicalMember_7e38f67d-62d2-4ab8-9353-ba77a4bc1ae7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_99b26c16-a44d-4ea0-9883-817c09f6c57c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_252f4b71-6fa9-41b4-bfd0-fdeb1d495997" xlink:to="loc_srt_CounterpartyNameAxis_99b26c16-a44d-4ea0-9883-817c09f6c57c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_99b26c16-a44d-4ea0-9883-817c09f6c57c_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_99b26c16-a44d-4ea0-9883-817c09f6c57c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_99b26c16-a44d-4ea0-9883-817c09f6c57c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eb45b2a-0bff-4a60-a0ca-384ad58cd364" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_99b26c16-a44d-4ea0-9883-817c09f6c57c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eb45b2a-0bff-4a60-a0ca-384ad58cd364" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_LmaMember_415561b8-31c8-4d71-a26b-da34634b766d" xlink:href="asth-20240331.xsd#asth_LmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eb45b2a-0bff-4a60-a0ca-384ad58cd364" xlink:to="loc_asth_LmaMember_415561b8-31c8-4d71-a26b-da34634b766d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PmiocMember_c75ae23c-5d54-4aa6-b4f9-e851a6cd99bc" xlink:href="asth-20240331.xsd#asth_PmiocMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eb45b2a-0bff-4a60-a0ca-384ad58cd364" xlink:to="loc_asth_PmiocMember_c75ae23c-5d54-4aa6-b4f9-e851a6cd99bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_SongPCMember_d89414ef-5740-4d98-b2fc-480c9598caa2" xlink:href="asth-20240331.xsd#asth_SongPCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eb45b2a-0bff-4a60-a0ca-384ad58cd364" xlink:to="loc_asth_SongPCMember_d89414ef-5740-4d98-b2fc-480c9598caa2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ArroyoVistaMember_467fcc9f-7658-40c9-998a-6d2f5c9dc32d" xlink:href="asth-20240331.xsd#asth_ArroyoVistaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eb45b2a-0bff-4a60-a0ca-384ad58cd364" xlink:to="loc_asth_ArroyoVistaMember_467fcc9f-7658-40c9-998a-6d2f5c9dc32d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_SunnyVillageCareCenterMember_7679d999-d9c9-47d5-a3bb-c9012b4ec2ba" xlink:href="asth-20240331.xsd#asth_SunnyVillageCareCenterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eb45b2a-0bff-4a60-a0ca-384ad58cd364" xlink:to="loc_asth_SunnyVillageCareCenterMember_7679d999-d9c9-47d5-a3bb-c9012b4ec2ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_FirstCommonwealthPropertyLLCMember_e3edcf0c-b0b0-4801-80ba-1799f922a746" xlink:href="asth-20240331.xsd#asth_FirstCommonwealthPropertyLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eb45b2a-0bff-4a60-a0ca-384ad58cd364" xlink:to="loc_asth_FirstCommonwealthPropertyLLCMember_e3edcf0c-b0b0-4801-80ba-1799f922a746" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AHMCMember_e7783052-4028-43b3-a513-306b88c17f15" xlink:href="asth-20240331.xsd#asth_AHMCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eb45b2a-0bff-4a60-a0ca-384ad58cd364" xlink:to="loc_asth_AHMCMember_e7783052-4028-43b3-a513-306b88c17f15" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BoardMembersMember_b1fe8261-43b6-451e-9455-0570a2961111" xlink:href="asth-20240331.xsd#asth_BoardMembersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eb45b2a-0bff-4a60-a0ca-384ad58cd364" xlink:to="loc_asth_BoardMembersMember_b1fe8261-43b6-451e-9455-0570a2961111" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BoardMembersWhoAreAlsoOfficersMember_32677d14-b115-46fb-9382-f995a54cafa9" xlink:href="asth-20240331.xsd#asth_BoardMembersWhoAreAlsoOfficersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eb45b2a-0bff-4a60-a0ca-384ad58cd364" xlink:to="loc_asth_BoardMembersWhoAreAlsoOfficersMember_32677d14-b115-46fb-9382-f995a54cafa9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AlliedPacificHoldingsInvestmentManagementLLCMember_8e2c0eb6-4003-49cb-8a4c-3824b017e432" xlink:href="asth-20240331.xsd#asth_AlliedPacificHoldingsInvestmentManagementLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eb45b2a-0bff-4a60-a0ca-384ad58cd364" xlink:to="loc_asth_AlliedPacificHoldingsInvestmentManagementLLCMember_8e2c0eb6-4003-49cb-8a4c-3824b017e432" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_269246cb-d495-4e71-81dd-4e2111bd62a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_252f4b71-6fa9-41b4-bfd0-fdeb1d495997" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_269246cb-d495-4e71-81dd-4e2111bd62a1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_269246cb-d495-4e71-81dd-4e2111bd62a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_269246cb-d495-4e71-81dd-4e2111bd62a1" xlink:to="loc_us-gaap_RelatedPartyDomain_269246cb-d495-4e71-81dd-4e2111bd62a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3b4f53eb-382c-4d9d-94ed-0e70eb4927e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_269246cb-d495-4e71-81dd-4e2111bd62a1" xlink:to="loc_us-gaap_RelatedPartyDomain_3b4f53eb-382c-4d9d-94ed-0e70eb4927e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_26ff362d-cec3-431b-af13-62770e48aaa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3b4f53eb-382c-4d9d-94ed-0e70eb4927e3" xlink:to="loc_us-gaap_RelatedPartyMember_26ff362d-cec3-431b-af13-62770e48aaa7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_984036a4-106e-40f3-94a0-3e23f366f2d2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3b4f53eb-382c-4d9d-94ed-0e70eb4927e3" xlink:to="loc_srt_DirectorMember_984036a4-106e-40f3-94a0-3e23f366f2d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_4b947f8f-aac3-4db2-9b01-af37d755218a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_252f4b71-6fa9-41b4-bfd0-fdeb1d495997" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_4b947f8f-aac3-4db2-9b01-af37d755218a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_4b947f8f-aac3-4db2-9b01-af37d755218a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_4b947f8f-aac3-4db2-9b01-af37d755218a" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_4b947f8f-aac3-4db2-9b01-af37d755218a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_710101b9-ef45-4085-85d0-574235f5e9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_4b947f8f-aac3-4db2-9b01-af37d755218a" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_710101b9-ef45-4085-85d0-574235f5e9a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ProviderServicesMember_34697441-03c4-4f1c-9061-377a87840c49" xlink:href="asth-20240331.xsd#asth_ProviderServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_710101b9-ef45-4085-85d0-574235f5e9a6" xlink:to="loc_asth_ProviderServicesMember_34697441-03c4-4f1c-9061-377a87840c49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_OfficeLeaseMember_79f035e3-9bce-458e-bebc-88c1d4792ecc" xlink:href="asth-20240331.xsd#asth_OfficeLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_710101b9-ef45-4085-85d0-574235f5e9a6" xlink:to="loc_asth_OfficeLeaseMember_79f035e3-9bce-458e-bebc-88c1d4792ecc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e888b56b-d162-4244-9e7f-3022f41deda6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_252f4b71-6fa9-41b4-bfd0-fdeb1d495997" xlink:to="loc_srt_ProductOrServiceAxis_e888b56b-d162-4244-9e7f-3022f41deda6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e888b56b-d162-4244-9e7f-3022f41deda6_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e888b56b-d162-4244-9e7f-3022f41deda6" xlink:to="loc_srt_ProductsAndServicesDomain_e888b56b-d162-4244-9e7f-3022f41deda6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d98b62de-3f47-4a2b-aba5-d4cf68a283c7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e888b56b-d162-4244-9e7f-3022f41deda6" xlink:to="loc_srt_ProductsAndServicesDomain_d98b62de-3f47-4a2b-aba5-d4cf68a283c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOtherMember_25648d9f-62ac-4b90-9064-a7f4cdd75541" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d98b62de-3f47-4a2b-aba5-d4cf68a283c7" xlink:to="loc_us-gaap_HealthCareOtherMember_25648d9f-62ac-4b90-9064-a7f4cdd75541" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_4ec3cdb4-5150-41d4-9713-26ad5882f063" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_252f4b71-6fa9-41b4-bfd0-fdeb1d495997" xlink:to="loc_srt_TitleOfIndividualAxis_4ec3cdb4-5150-41d4-9713-26ad5882f063" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4ec3cdb4-5150-41d4-9713-26ad5882f063_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_4ec3cdb4-5150-41d4-9713-26ad5882f063" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4ec3cdb4-5150-41d4-9713-26ad5882f063_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_43986b39-998a-4018-87cd-fc19f75e20af" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_4ec3cdb4-5150-41d4-9713-26ad5882f063" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_43986b39-998a-4018-87cd-fc19f75e20af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_05b8c0fc-b985-4efd-a285-a2d120f39a95" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_43986b39-998a-4018-87cd-fc19f75e20af" xlink:to="loc_srt_ChiefExecutiveOfficerMember_05b8c0fc-b985-4efd-a285-a2d120f39a95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_de17709e-992e-4b82-835c-3f541058a095" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8bd3b73e-431f-4757-a8c1-0e63463320fe" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_de17709e-992e-4b82-835c-3f541058a095" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4573ce13-7d81-483d-92db-d74369d1e476" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8bd3b73e-431f-4757-a8c1-0e63463320fe" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4573ce13-7d81-483d-92db-d74369d1e476" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_79a906a1-359c-4a72-95ef-dfbccdf2e3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8bd3b73e-431f-4757-a8c1-0e63463320fe" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_79a906a1-359c-4a72-95ef-dfbccdf2e3d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ee40155c-50d7-48a7-8672-9038fc605469" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8bd3b73e-431f-4757-a8c1-0e63463320fe" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ee40155c-50d7-48a7-8672-9038fc605469" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_630bd894-3d42-443e-a283-4c0fe0acf3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8bd3b73e-431f-4757-a8c1-0e63463320fe" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_630bd894-3d42-443e-a283-4c0fe0acf3b3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_RelatedPartyExpensesPayable_3a2ea358-8db1-4a53-a3c0-9d28f6b6e989" xlink:href="asth-20240331.xsd#asth_RelatedPartyExpensesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8bd3b73e-431f-4757-a8c1-0e63463320fe" xlink:to="loc_asth_RelatedPartyExpensesPayable_3a2ea358-8db1-4a53-a3c0-9d28f6b6e989" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_2caa7a89-b933-4645-9378-e712ce15855e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8bd3b73e-431f-4757-a8c1-0e63463320fe" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_2caa7a89-b933-4645-9378-e712ce15855e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities_9543f078-0409-4d28-a702-6308ccd35ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCreditsAndOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8bd3b73e-431f-4757-a8c1-0e63463320fe" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilities_9543f078-0409-4d28-a702-6308ccd35ff7" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofFeesIncurredandRevenueEarnedfromRelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#RelatedPartyTransactionsScheduleofFeesIncurredandRevenueEarnedfromRelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofFeesIncurredandRevenueEarnedfromRelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_c1a94bed-66a5-4267-b32c-6c241d087cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1eb7951c-c60b-438b-9438-ba1198b0fed1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c1a94bed-66a5-4267-b32c-6c241d087cbc" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1eb7951c-c60b-438b-9438-ba1198b0fed1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ce98cbcc-2b89-4fcc-b741-a2a9e42f75d6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1eb7951c-c60b-438b-9438-ba1198b0fed1" xlink:to="loc_srt_CounterpartyNameAxis_ce98cbcc-2b89-4fcc-b741-a2a9e42f75d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ce98cbcc-2b89-4fcc-b741-a2a9e42f75d6_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ce98cbcc-2b89-4fcc-b741-a2a9e42f75d6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ce98cbcc-2b89-4fcc-b741-a2a9e42f75d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aea7e21d-986d-4801-8602-2aa1bef5e71f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ce98cbcc-2b89-4fcc-b741-a2a9e42f75d6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aea7e21d-986d-4801-8602-2aa1bef5e71f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AHMCMember_dfddb4c8-ce8d-4c5a-8739-bc8fb354435c" xlink:href="asth-20240331.xsd#asth_AHMCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aea7e21d-986d-4801-8602-2aa1bef5e71f" xlink:to="loc_asth_AHMCMember_dfddb4c8-ce8d-4c5a-8739-bc8fb354435c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_HSMSOMember_34771228-9b86-4ecb-bace-5f9986f3c495" xlink:href="asth-20240331.xsd#asth_HSMSOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aea7e21d-986d-4801-8602-2aa1bef5e71f" xlink:to="loc_asth_HSMSOMember_34771228-9b86-4ecb-bace-5f9986f3c495" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AurionMember_da6f0e85-3434-4f73-821b-05600cc7d1cc" xlink:href="asth-20240331.xsd#asth_AurionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aea7e21d-986d-4801-8602-2aa1bef5e71f" xlink:to="loc_asth_AurionMember_da6f0e85-3434-4f73-821b-05600cc7d1cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_d71a0e6c-9ff9-4af8-b3a6-37026478d44c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1eb7951c-c60b-438b-9438-ba1198b0fed1" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_d71a0e6c-9ff9-4af8-b3a6-37026478d44c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_d71a0e6c-9ff9-4af8-b3a6-37026478d44c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_d71a0e6c-9ff9-4af8-b3a6-37026478d44c" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_d71a0e6c-9ff9-4af8-b3a6-37026478d44c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_0db58689-d99e-405a-a695-eb55098f6e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_d71a0e6c-9ff9-4af8-b3a6-37026478d44c" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_0db58689-d99e-405a-a695-eb55098f6e6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_RelatedPartyTransactionRevenueRecognizedMember_1f6259b9-76ef-4cdb-be67-126b883d2555" xlink:href="asth-20240331.xsd#asth_RelatedPartyTransactionRevenueRecognizedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0db58689-d99e-405a-a695-eb55098f6e6b" xlink:to="loc_asth_RelatedPartyTransactionRevenueRecognizedMember_1f6259b9-76ef-4cdb-be67-126b883d2555" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_RelatedPartyTransactionExpensesIncurredMember_af111657-51f0-4c03-aa6d-9be0fb1e52c8" xlink:href="asth-20240331.xsd#asth_RelatedPartyTransactionExpensesIncurredMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0db58689-d99e-405a-a695-eb55098f6e6b" xlink:to="loc_asth_RelatedPartyTransactionExpensesIncurredMember_af111657-51f0-4c03-aa6d-9be0fb1e52c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_RelatedPartyTransactionRevenueExpenseNetMember_15205e61-1cd2-4ca6-8c1a-a4e2f506e8da" xlink:href="asth-20240331.xsd#asth_RelatedPartyTransactionRevenueExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0db58689-d99e-405a-a695-eb55098f6e6b" xlink:to="loc_asth_RelatedPartyTransactionRevenueExpenseNetMember_15205e61-1cd2-4ca6-8c1a-a4e2f506e8da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_9ff6770a-64dd-4a82-aa9f-b3f152c49686" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c1a94bed-66a5-4267-b32c-6c241d087cbc" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_9ff6770a-64dd-4a82-aa9f-b3f152c49686" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#EarningsPerShareAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_asth_EarningsPerShareLineItems_d66e43c8-34a6-477b-8374-384595cc0938" xlink:href="asth-20240331.xsd#asth_EarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_EarningsPerShareTable_edc66a45-182f-4f98-9a8d-60e83b380a26" xlink:href="asth-20240331.xsd#asth_EarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_asth_EarningsPerShareLineItems_d66e43c8-34a6-477b-8374-384595cc0938" xlink:to="loc_asth_EarningsPerShareTable_edc66a45-182f-4f98-9a8d-60e83b380a26" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_63386148-bd4d-4de5-abf4-27a1b1e6bd5a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_asth_EarningsPerShareTable_edc66a45-182f-4f98-9a8d-60e83b380a26" xlink:to="loc_dei_LegalEntityAxis_63386148-bd4d-4de5-abf4-27a1b1e6bd5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_63386148-bd4d-4de5-abf4-27a1b1e6bd5a_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_63386148-bd4d-4de5-abf4-27a1b1e6bd5a" xlink:to="loc_dei_EntityDomain_63386148-bd4d-4de5-abf4-27a1b1e6bd5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_045f6b31-a10e-443c-bbed-a21804b3e22e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_63386148-bd4d-4de5-abf4-27a1b1e6bd5a" xlink:to="loc_dei_EntityDomain_045f6b31-a10e-443c-bbed-a21804b3e22e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AlliedPacificOfCaliforniaIPAMember_2dbd65d9-9ec5-4db8-8bda-9713db1aab64" xlink:href="asth-20240331.xsd#asth_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_045f6b31-a10e-443c-bbed-a21804b3e22e" xlink:to="loc_asth_AlliedPacificOfCaliforniaIPAMember_2dbd65d9-9ec5-4db8-8bda-9713db1aab64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c5339b36-56f1-4e6e-b92f-35903214f936" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_asth_EarningsPerShareTable_edc66a45-182f-4f98-9a8d-60e83b380a26" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c5339b36-56f1-4e6e-b92f-35903214f936" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c5339b36-56f1-4e6e-b92f-35903214f936_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c5339b36-56f1-4e6e-b92f-35903214f936" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c5339b36-56f1-4e6e-b92f-35903214f936_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_982d32fd-8d45-4981-8179-29e5c09bca9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c5339b36-56f1-4e6e-b92f-35903214f936" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_982d32fd-8d45-4981-8179-29e5c09bca9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_854e2bb0-5346-48bf-b9ae-66030f28195a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_982d32fd-8d45-4981-8179-29e5c09bca9f" xlink:to="loc_us-gaap_RestrictedStockMember_854e2bb0-5346-48bf-b9ae-66030f28195a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_7e101c78-528f-4091-a333-f27e37454d03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_982d32fd-8d45-4981-8179-29e5c09bca9f" xlink:to="loc_us-gaap_PerformanceSharesMember_7e101c78-528f-4091-a333-f27e37454d03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_99e08db4-52c2-4f06-80be-15d090cb5042" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_asth_EarningsPerShareLineItems_d66e43c8-34a6-477b-8374-384595cc0938" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_99e08db4-52c2-4f06-80be-15d090cb5042" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareScheduleofSharesIncludedintheDilutedEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#EarningsPerShareScheduleofSharesIncludedintheDilutedEarningsPerShareComputationsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/EarningsPerShareScheduleofSharesIncludedintheDilutedEarningsPerShareComputationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_asth_EarningsPerShareLineItems_0d10c2ea-afe6-4bc4-81bb-603c6bcf10d2" xlink:href="asth-20240331.xsd#asth_EarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_EarningsPerShareTable_a5f4767e-80a6-49a4-8218-c18b9e9f4b3e" xlink:href="asth-20240331.xsd#asth_EarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_asth_EarningsPerShareLineItems_0d10c2ea-afe6-4bc4-81bb-603c6bcf10d2" xlink:to="loc_asth_EarningsPerShareTable_a5f4767e-80a6-49a4-8218-c18b9e9f4b3e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d8d3b5f7-5a22-49ba-bfb6-8769d9437d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_asth_EarningsPerShareTable_a5f4767e-80a6-49a4-8218-c18b9e9f4b3e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d8d3b5f7-5a22-49ba-bfb6-8769d9437d4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d8d3b5f7-5a22-49ba-bfb6-8769d9437d4b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d8d3b5f7-5a22-49ba-bfb6-8769d9437d4b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d8d3b5f7-5a22-49ba-bfb6-8769d9437d4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_242459f9-cef7-4f3c-933a-f703624840a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d8d3b5f7-5a22-49ba-bfb6-8769d9437d4b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_242459f9-cef7-4f3c-933a-f703624840a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3899fc89-5db1-42ae-9057-d289b8b5a88d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_242459f9-cef7-4f3c-933a-f703624840a0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3899fc89-5db1-42ae-9057-d289b8b5a88d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_567564e4-db6b-42bb-96bb-d36e9a051755" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_242459f9-cef7-4f3c-933a-f703624840a0" xlink:to="loc_us-gaap_RestrictedStockMember_567564e4-db6b-42bb-96bb-d36e9a051755" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_467ff699-8aec-4e3b-970a-21d81035f7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_asth_EarningsPerShareLineItems_0d10c2ea-afe6-4bc4-81bb-603c6bcf10d2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_467ff699-8aec-4e3b-970a-21d81035f7a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e6d089c5-2c12-4f97-b012-e240e8c2a238" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_asth_EarningsPerShareLineItems_0d10c2ea-afe6-4bc4-81bb-603c6bcf10d2" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e6d089c5-2c12-4f97-b012-e240e8c2a238" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares_bcc98907-7fd9-4f50-aa22-d4b959cea6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_asth_EarningsPerShareLineItems_0d10c2ea-afe6-4bc4-81bb-603c6bcf10d2" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares_bcc98907-7fd9-4f50-aa22-d4b959cea6c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_72ae112b-4c61-4e39-97a2-965d455fd945" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_asth_EarningsPerShareLineItems_0d10c2ea-afe6-4bc4-81bb-603c6bcf10d2" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_72ae112b-4c61-4e39-97a2-965d455fd945" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsAdditionalInformationDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#VariableInterestEntitiesVIEsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_5d2cef47-47b3-4ae8-81a8-d6969932412b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_cca44940-9dee-4aa1-9588-8bf8995bcef7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_5d2cef47-47b3-4ae8-81a8-d6969932412b" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_cca44940-9dee-4aa1-9588-8bf8995bcef7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_6d86382b-4418-47c4-9b95-d768ac0b7dbc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_cca44940-9dee-4aa1-9588-8bf8995bcef7" xlink:to="loc_srt_ConsolidatedEntitiesAxis_6d86382b-4418-47c4-9b95-d768ac0b7dbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_6d86382b-4418-47c4-9b95-d768ac0b7dbc_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_6d86382b-4418-47c4-9b95-d768ac0b7dbc" xlink:to="loc_srt_ConsolidatedEntitiesDomain_6d86382b-4418-47c4-9b95-d768ac0b7dbc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_497685f8-8c57-46ff-ace5-12fdf4e341c0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_6d86382b-4418-47c4-9b95-d768ac0b7dbc" xlink:to="loc_srt_ConsolidatedEntitiesDomain_497685f8-8c57-46ff-ace5-12fdf4e341c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_4f70d79d-4b06-4c53-a1ed-3138c1bc2ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_497685f8-8c57-46ff-ace5-12fdf4e341c0" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_4f70d79d-4b06-4c53-a1ed-3138c1bc2ffa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_b1acf2f7-19c8-4705-83d1-14feb608f57c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_5d2cef47-47b3-4ae8-81a8-d6969932412b" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_b1acf2f7-19c8-4705-83d1-14feb608f57c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#VariableInterestEntitiesVIEsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_2cb9019e-a251-4a55-9f46-63b1c567b487" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_94dd62c4-584a-403a-a032-9fc65a3e9e53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2cb9019e-a251-4a55-9f46-63b1c567b487" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_94dd62c4-584a-403a-a032-9fc65a3e9e53" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_46e84e65-5931-4098-82ef-5ce27d6be038" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_94dd62c4-584a-403a-a032-9fc65a3e9e53" xlink:to="loc_srt_ConsolidatedEntitiesAxis_46e84e65-5931-4098-82ef-5ce27d6be038" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_46e84e65-5931-4098-82ef-5ce27d6be038_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_46e84e65-5931-4098-82ef-5ce27d6be038" xlink:to="loc_srt_ConsolidatedEntitiesDomain_46e84e65-5931-4098-82ef-5ce27d6be038_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_a4e0b134-3030-40e7-910a-0d956a097723" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_46e84e65-5931-4098-82ef-5ce27d6be038" xlink:to="loc_srt_ConsolidatedEntitiesDomain_a4e0b134-3030-40e7-910a-0d956a097723" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_5deb2c48-1add-45ef-bfbe-d69cfb0f0c26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_a4e0b134-3030-40e7-910a-0d956a097723" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_5deb2c48-1add-45ef-bfbe-d69cfb0f0c26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c8ecfa24-dd60-47e7-9cfc-3db9b3f33163" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_94dd62c4-584a-403a-a032-9fc65a3e9e53" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c8ecfa24-dd60-47e7-9cfc-3db9b3f33163" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c8ecfa24-dd60-47e7-9cfc-3db9b3f33163_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c8ecfa24-dd60-47e7-9cfc-3db9b3f33163" xlink:to="loc_us-gaap_RelatedPartyDomain_c8ecfa24-dd60-47e7-9cfc-3db9b3f33163_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_199d9ec3-8ef8-45e7-9351-4f426597d731" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c8ecfa24-dd60-47e7-9cfc-3db9b3f33163" xlink:to="loc_us-gaap_RelatedPartyDomain_199d9ec3-8ef8-45e7-9351-4f426597d731" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_9507bdd7-b7cb-4201-b2fc-75b86fe779e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_199d9ec3-8ef8-45e7-9351-4f426597d731" xlink:to="loc_us-gaap_NonrelatedPartyMember_9507bdd7-b7cb-4201-b2fc-75b86fe779e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_2dd7a5f2-3df5-4282-a760-1e6abc04939b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_199d9ec3-8ef8-45e7-9351-4f426597d731" xlink:to="loc_us-gaap_RelatedPartyMember_2dd7a5f2-3df5-4282-a760-1e6abc04939b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_388f3557-2414-45b6-8d15-ad608397e169" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2cb9019e-a251-4a55-9f46-63b1c567b487" xlink:to="loc_us-gaap_AssetsAbstract_388f3557-2414-45b6-8d15-ad608397e169" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_91236fc5-5345-4a3f-a258-0132f96eb4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_388f3557-2414-45b6-8d15-ad608397e169" xlink:to="loc_us-gaap_AssetsCurrentAbstract_91236fc5-5345-4a3f-a258-0132f96eb4cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_41aefa12-8cf2-48b4-ab89-d8ede3335e26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_91236fc5-5345-4a3f-a258-0132f96eb4cb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_41aefa12-8cf2-48b4-ab89-d8ede3335e26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_d18ad6fa-33b4-4ea1-adb3-95578a5be5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_91236fc5-5345-4a3f-a258-0132f96eb4cb" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_d18ad6fa-33b4-4ea1-adb3-95578a5be5e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_094a0954-b72c-4854-afd1-788f94466849" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_91236fc5-5345-4a3f-a258-0132f96eb4cb" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_094a0954-b72c-4854-afd1-788f94466849" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_cb044eec-4d32-4210-b730-551f48dd86cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_91236fc5-5345-4a3f-a258-0132f96eb4cb" xlink:to="loc_us-gaap_IncomeTaxesReceivable_cb044eec-4d32-4210-b730-551f48dd86cf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_fd1a7b1b-ba93-4449-bcb2-044859af7020" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_91236fc5-5345-4a3f-a258-0132f96eb4cb" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_fd1a7b1b-ba93-4449-bcb2-044859af7020" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_faddbede-7279-47f7-95d3-d461e6a6b67b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_91236fc5-5345-4a3f-a258-0132f96eb4cb" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_faddbede-7279-47f7-95d3-d461e6a6b67b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_81e9ef59-6efe-4f3c-9585-89f6918e23c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_91236fc5-5345-4a3f-a258-0132f96eb4cb" xlink:to="loc_us-gaap_AssetsCurrent_81e9ef59-6efe-4f3c-9585-89f6918e23c0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_914a8590-4c3c-4c3a-935f-fa0a761d1dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_388f3557-2414-45b6-8d15-ad608397e169" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_914a8590-4c3c-4c3a-935f-fa0a761d1dd3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6673f8c1-4c32-4912-8182-4c591ab890f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_914a8590-4c3c-4c3a-935f-fa0a761d1dd3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6673f8c1-4c32-4912-8182-4c591ab890f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a812bb26-7a10-4bcc-b632-468c1d6c743d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_914a8590-4c3c-4c3a-935f-fa0a761d1dd3" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a812bb26-7a10-4bcc-b632-468c1d6c743d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f6304514-4b73-47a3-a4c8-3011ff067af4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_914a8590-4c3c-4c3a-935f-fa0a761d1dd3" xlink:to="loc_us-gaap_Goodwill_f6304514-4b73-47a3-a4c8-3011ff067af4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivableNoncurrent_b9913566-214f-4869-b7cb-838ad78830c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesReceivableNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_914a8590-4c3c-4c3a-935f-fa0a761d1dd3" xlink:to="loc_us-gaap_IncomeTaxesReceivableNoncurrent_b9913566-214f-4869-b7cb-838ad78830c4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_77359c10-18cf-4956-af1f-55de271e4b29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_914a8590-4c3c-4c3a-935f-fa0a761d1dd3" xlink:to="loc_us-gaap_EquityMethodInvestments_77359c10-18cf-4956-af1f-55de271e4b29" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_484c164b-04f9-438a-9cb4-cc8c5ae6f6da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_914a8590-4c3c-4c3a-935f-fa0a761d1dd3" xlink:to="loc_us-gaap_OtherLongTermInvestments_484c164b-04f9-438a-9cb4-cc8c5ae6f6da" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_35a83765-64f5-4a9a-82ae-b95ff0052362" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_914a8590-4c3c-4c3a-935f-fa0a761d1dd3" xlink:to="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_35a83765-64f5-4a9a-82ae-b95ff0052362" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_915cdc18-44f1-43a3-aca6-03d6cb6eaf7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_914a8590-4c3c-4c3a-935f-fa0a761d1dd3" xlink:to="loc_us-gaap_RestrictedCash_915cdc18-44f1-43a3-aca6-03d6cb6eaf7b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8b66980b-a692-4596-aebd-8042819db967" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_914a8590-4c3c-4c3a-935f-fa0a761d1dd3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8b66980b-a692-4596-aebd-8042819db967" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6dee3135-0992-4f7a-b92c-4d57dbff6b11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_914a8590-4c3c-4c3a-935f-fa0a761d1dd3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6dee3135-0992-4f7a-b92c-4d57dbff6b11" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_1c35e0df-3b09-4323-a548-9036ad75cbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_914a8590-4c3c-4c3a-935f-fa0a761d1dd3" xlink:to="loc_us-gaap_AssetsNoncurrent_1c35e0df-3b09-4323-a548-9036ad75cbcf" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0b9138c0-7206-4a4b-ab42-0ad041634a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_388f3557-2414-45b6-8d15-ad608397e169" xlink:to="loc_us-gaap_Assets_0b9138c0-7206-4a4b-ab42-0ad041634a6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_ced0449a-a71f-4d8d-a49a-0161c7e322f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2cb9019e-a251-4a55-9f46-63b1c567b487" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_ced0449a-a71f-4d8d-a49a-0161c7e322f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c18ac336-d5e9-48a5-b6f3-6edcccf74a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ced0449a-a71f-4d8d-a49a-0161c7e322f9" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c18ac336-d5e9-48a5-b6f3-6edcccf74a3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_FiduciaryAccountsPayableCurrent_54a86636-a7e1-4ad4-8821-0f29d7c5b594" xlink:href="asth-20240331.xsd#asth_FiduciaryAccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ced0449a-a71f-4d8d-a49a-0161c7e322f9" xlink:to="loc_asth_FiduciaryAccountsPayableCurrent_54a86636-a7e1-4ad4-8821-0f29d7c5b594" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_f1123c03-3a17-4302-b217-3b8c671afbb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ced0449a-a71f-4d8d-a49a-0161c7e322f9" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_f1123c03-3a17-4302-b217-3b8c671afbb4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_2f1571d6-e7fd-4daf-ac38-642099058dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ced0449a-a71f-4d8d-a49a-0161c7e322f9" xlink:to="loc_us-gaap_DividendsPayableCurrent_2f1571d6-e7fd-4daf-ac38-642099058dd6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_b146c33d-f6eb-4436-a672-1f4921e22dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ced0449a-a71f-4d8d-a49a-0161c7e322f9" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_b146c33d-f6eb-4436-a672-1f4921e22dd6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_f1c6357a-ea34-41e5-b7a1-c6025efded2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ced0449a-a71f-4d8d-a49a-0161c7e322f9" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_f1c6357a-ea34-41e5-b7a1-c6025efded2a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e8b33978-d77d-41ab-ae69-c8b361dd4872" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ced0449a-a71f-4d8d-a49a-0161c7e322f9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e8b33978-d77d-41ab-ae69-c8b361dd4872" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_c96c8137-d066-4349-9a74-b4051777c4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ced0449a-a71f-4d8d-a49a-0161c7e322f9" xlink:to="loc_us-gaap_LongTermDebtCurrent_c96c8137-d066-4349-9a74-b4051777c4dd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_7b737d3c-1c9a-40ee-912f-ae639ae96321" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ced0449a-a71f-4d8d-a49a-0161c7e322f9" xlink:to="loc_us-gaap_OtherLiabilities_7b737d3c-1c9a-40ee-912f-ae639ae96321" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_904c8f59-15df-4385-8346-767ee0dbeb4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ced0449a-a71f-4d8d-a49a-0161c7e322f9" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_904c8f59-15df-4385-8346-767ee0dbeb4c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6bd19bde-c79a-483b-b536-52d320f19f27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ced0449a-a71f-4d8d-a49a-0161c7e322f9" xlink:to="loc_us-gaap_LiabilitiesCurrent_6bd19bde-c79a-483b-b536-52d320f19f27" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_918ca151-8049-4c4a-a09e-551d7664b3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2cb9019e-a251-4a55-9f46-63b1c567b487" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_918ca151-8049-4c4a-a09e-551d7664b3a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_ed9f1fc8-a20b-483b-b870-3497499b9c85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_918ca151-8049-4c4a-a09e-551d7664b3a7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_ed9f1fc8-a20b-483b-b870-3497499b9c85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9a04e660-b439-479a-bec7-d532484d317d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_918ca151-8049-4c4a-a09e-551d7664b3a7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9a04e660-b439-479a-bec7-d532484d317d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_10f9a651-be17-4729-ba0b-420ddd09dfa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_918ca151-8049-4c4a-a09e-551d7664b3a7" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_10f9a651-be17-4729-ba0b-420ddd09dfa0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c9e8f5a7-de0e-4373-bc64-18b64b1a3782" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_918ca151-8049-4c4a-a09e-551d7664b3a7" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c9e8f5a7-de0e-4373-bc64-18b64b1a3782" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_bf70cc6a-bb3f-40ed-9c90-1a63c99334aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_918ca151-8049-4c4a-a09e-551d7664b3a7" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_bf70cc6a-bb3f-40ed-9c90-1a63c99334aa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d9f58f11-33a6-4324-8a8a-2b4f764d6078" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2cb9019e-a251-4a55-9f46-63b1c567b487" xlink:to="loc_us-gaap_Liabilities_d9f58f11-33a6-4324-8a8a-2b4f764d6078" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#LeasesAdditionalinformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_f43f61f8-aa6b-4f73-9d53-b554d822c9d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_98de0eb1-ad8c-42e2-a575-4c6f154153d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f43f61f8-aa6b-4f73-9d53-b554d822c9d1" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_98de0eb1-ad8c-42e2-a575-4c6f154153d5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6ba5904f-33e9-4e6b-8789-24264c878651" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_98de0eb1-ad8c-42e2-a575-4c6f154153d5" xlink:to="loc_srt_RangeAxis_6ba5904f-33e9-4e6b-8789-24264c878651" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6ba5904f-33e9-4e6b-8789-24264c878651_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6ba5904f-33e9-4e6b-8789-24264c878651" xlink:to="loc_srt_RangeMember_6ba5904f-33e9-4e6b-8789-24264c878651_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c39bcf94-47f3-426e-9d1e-14c1bac702bd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6ba5904f-33e9-4e6b-8789-24264c878651" xlink:to="loc_srt_RangeMember_c39bcf94-47f3-426e-9d1e-14c1bac702bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_995ca091-7b67-4241-a255-2dcea85895fe" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c39bcf94-47f3-426e-9d1e-14c1bac702bd" xlink:to="loc_srt_MinimumMember_995ca091-7b67-4241-a255-2dcea85895fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_89b776d9-3c2f-46cc-a3f8-ef1c2a35518d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c39bcf94-47f3-426e-9d1e-14c1bac702bd" xlink:to="loc_srt_MaximumMember_89b776d9-3c2f-46cc-a3f8-ef1c2a35518d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_ac6a0434-3540-493e-97ad-1bc397b46449" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f43f61f8-aa6b-4f73-9d53-b554d822c9d1" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_ac6a0434-3540-493e-97ad-1bc397b46449" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_88a86ca3-a96a-43c2-8d18-9ff18296c991" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f43f61f8-aa6b-4f73-9d53-b554d822c9d1" xlink:to="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_88a86ca3-a96a-43c2-8d18-9ff18296c991" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_755a7eed-ff19-4f2e-bbc5-86d598db6e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f43f61f8-aa6b-4f73-9d53-b554d822c9d1" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_755a7eed-ff19-4f2e-bbc5-86d598db6e0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_65c1bd92-f371-494b-aaad-722747fa08f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f43f61f8-aa6b-4f73-9d53-b554d822c9d1" xlink:to="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_65c1bd92-f371-494b-aaad-722747fa08f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_LesseeOperatingLeaseTerminationPeriodIfApplicable_cf968966-e994-4f2a-849b-9ebb8c4b6018" xlink:href="asth-20240331.xsd#asth_LesseeOperatingLeaseTerminationPeriodIfApplicable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f43f61f8-aa6b-4f73-9d53-b554d822c9d1" xlink:to="loc_asth_LesseeOperatingLeaseTerminationPeriodIfApplicable_cf968966-e994-4f2a-849b-9ebb8c4b6018" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_LesseeFinanceLeaseTerminationPeriodIfApplicable_e56f59e2-70ae-4a1f-bde5-6a1ee19b1260" xlink:href="asth-20240331.xsd#asth_LesseeFinanceLeaseTerminationPeriodIfApplicable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f43f61f8-aa6b-4f73-9d53-b554d822c9d1" xlink:to="loc_asth_LesseeFinanceLeaseTerminationPeriodIfApplicable_e56f59e2-70ae-4a1f-bde5-6a1ee19b1260" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_a38418fc-262a-406e-866b-969fd547eaa8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f43f61f8-aa6b-4f73-9d53-b554d822c9d1" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_a38418fc-262a-406e-866b-969fd547eaa8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_dc9ead5e-fca8-41a8-96c0-6b25601a0425" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f43f61f8-aa6b-4f73-9d53-b554d822c9d1" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_dc9ead5e-fca8-41a8-96c0-6b25601a0425" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/SegmentsDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#SegmentsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/SegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_3a3d7ccb-3e0e-4761-a8b4-7838f26d8abc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_72f14753-77f3-4b69-aafd-d0096a842bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3a3d7ccb-3e0e-4761-a8b4-7838f26d8abc" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_72f14753-77f3-4b69-aafd-d0096a842bf5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_6967b584-eb1f-4543-8da2-96088c942422" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_72f14753-77f3-4b69-aafd-d0096a842bf5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_6967b584-eb1f-4543-8da2-96088c942422" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6967b584-eb1f-4543-8da2-96088c942422_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6967b584-eb1f-4543-8da2-96088c942422" xlink:to="loc_us-gaap_SegmentDomain_6967b584-eb1f-4543-8da2-96088c942422_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ec00868a-6405-47d7-8729-7752f1b95e89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6967b584-eb1f-4543-8da2-96088c942422" xlink:to="loc_us-gaap_SegmentDomain_ec00868a-6405-47d7-8729-7752f1b95e89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CarePartnersMember_b7c70720-5926-46af-9016-aa8ce66adad9" xlink:href="asth-20240331.xsd#asth_CarePartnersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ec00868a-6405-47d7-8729-7752f1b95e89" xlink:to="loc_asth_CarePartnersMember_b7c70720-5926-46af-9016-aa8ce66adad9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CareDeliveryMember_162f0639-6a7c-43ab-a942-6b397d766c9e" xlink:href="asth-20240331.xsd#asth_CareDeliveryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ec00868a-6405-47d7-8729-7752f1b95e89" xlink:to="loc_asth_CareDeliveryMember_162f0639-6a7c-43ab-a942-6b397d766c9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CareEnablementMember_e3a58a0d-afb5-41e8-81dd-eba18de8e0bb" xlink:href="asth-20240331.xsd#asth_CareEnablementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ec00868a-6405-47d7-8729-7752f1b95e89" xlink:to="loc_asth_CareEnablementMember_e3a58a0d-afb5-41e8-81dd-eba18de8e0bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_853251dd-fb9a-4eb5-9aac-31d5626eef90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ec00868a-6405-47d7-8729-7752f1b95e89" xlink:to="loc_us-gaap_AllOtherSegmentsMember_853251dd-fb9a-4eb5-9aac-31d5626eef90" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_5b2cb0b6-e439-4422-96c3-4736cd173117" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_72f14753-77f3-4b69-aafd-d0096a842bf5" xlink:to="loc_srt_ConsolidationItemsAxis_5b2cb0b6-e439-4422-96c3-4736cd173117" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_5b2cb0b6-e439-4422-96c3-4736cd173117_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_5b2cb0b6-e439-4422-96c3-4736cd173117" xlink:to="loc_srt_ConsolidationItemsDomain_5b2cb0b6-e439-4422-96c3-4736cd173117_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_e2524abf-477c-45f1-a819-f387a460797b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_5b2cb0b6-e439-4422-96c3-4736cd173117" xlink:to="loc_srt_ConsolidationItemsDomain_e2524abf-477c-45f1-a819-f387a460797b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_a43ccde9-d7b3-4c44-856d-fdf262ee408d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_e2524abf-477c-45f1-a819-f387a460797b" xlink:to="loc_us-gaap_OperatingSegmentsMember_a43ccde9-d7b3-4c44-856d-fdf262ee408d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_f76acdee-dd50-4295-9610-7e9bc9c2e5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_e2524abf-477c-45f1-a819-f387a460797b" xlink:to="loc_us-gaap_IntersegmentEliminationMember_f76acdee-dd50-4295-9610-7e9bc9c2e5cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_30e82249-07a9-4ca9-9b3c-adc8d026dcb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_e2524abf-477c-45f1-a819-f387a460797b" xlink:to="loc_us-gaap_CorporateNonSegmentMember_30e82249-07a9-4ca9-9b3c-adc8d026dcb4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_c81af3a0-0fcf-494c-8506-75866d10252a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_72f14753-77f3-4b69-aafd-d0096a842bf5" xlink:to="loc_us-gaap_SubsegmentsAxis_c81af3a0-0fcf-494c-8506-75866d10252a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_c81af3a0-0fcf-494c-8506-75866d10252a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_c81af3a0-0fcf-494c-8506-75866d10252a" xlink:to="loc_us-gaap_SubsegmentsDomain_c81af3a0-0fcf-494c-8506-75866d10252a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_5b71b975-25cb-4c0e-9932-c3cda2d6aeca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_c81af3a0-0fcf-494c-8506-75866d10252a" xlink:to="loc_us-gaap_SubsegmentsDomain_5b71b975-25cb-4c0e-9932-c3cda2d6aeca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCarePatientServiceMember_220e6227-7131-4686-9eb4-7b2d1c04f575" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCarePatientServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_5b71b975-25cb-4c0e-9932-c3cda2d6aeca" xlink:to="loc_us-gaap_HealthCarePatientServiceMember_220e6227-7131-4686-9eb4-7b2d1c04f575" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_c3bc7a79-f8a7-4c06-b99f-d2932df8acfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_5b71b975-25cb-4c0e-9932-c3cda2d6aeca" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_c3bc7a79-f8a7-4c06-b99f-d2932df8acfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_05ed08c9-7c66-4c61-880a-509fe0e8aa92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3a3d7ccb-3e0e-4761-a8b4-7838f26d8abc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_05ed08c9-7c66-4c61-880a-509fe0e8aa92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_25a5e509-8504-4425-8cd2-3f1bc18bc574" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3a3d7ccb-3e0e-4761-a8b4-7838f26d8abc" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_25a5e509-8504-4425-8cd2-3f1bc18bc574" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_GeneralAndAdministrativeExpensesAndDepreciationAndAmortization_b7959191-91b7-4df5-ae49-9a3e0c4ddd8d" xlink:href="asth-20240331.xsd#asth_GeneralAndAdministrativeExpensesAndDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3a3d7ccb-3e0e-4761-a8b4-7838f26d8abc" xlink:to="loc_asth_GeneralAndAdministrativeExpensesAndDepreciationAndAmortization_b7959191-91b7-4df5-ae49-9a3e0c4ddd8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ee945176-fae4-4f5e-a9d7-1a505b3c21ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3a3d7ccb-3e0e-4761-a8b4-7838f26d8abc" xlink:to="loc_us-gaap_CostsAndExpenses_ee945176-fae4-4f5e-a9d7-1a505b3c21ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a093889b-23b7-411c-8e1a-9f3e0f5a095b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3a3d7ccb-3e0e-4761-a8b4-7838f26d8abc" xlink:to="loc_us-gaap_OperatingIncomeLoss_a093889b-23b7-411c-8e1a-9f3e0f5a095b" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e0ee9bd5-0035-43a5-9f7e-2ba290277bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a60e7921-b318-4e83-ba0f-b2d19bd84c16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e0ee9bd5-0035-43a5-9f7e-2ba290277bf0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a60e7921-b318-4e83-ba0f-b2d19bd84c16" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aae95f91-9d80-4445-b9ff-5039334ee67e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a60e7921-b318-4e83-ba0f-b2d19bd84c16" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aae95f91-9d80-4445-b9ff-5039334ee67e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_aae95f91-9d80-4445-b9ff-5039334ee67e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aae95f91-9d80-4445-b9ff-5039334ee67e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_aae95f91-9d80-4445-b9ff-5039334ee67e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dac66c41-f403-4423-bca9-eb0a19d419d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aae95f91-9d80-4445-b9ff-5039334ee67e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dac66c41-f403-4423-bca9-eb0a19d419d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_333e1dfd-d198-40ed-aaba-6d8de539c0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dac66c41-f403-4423-bca9-eb0a19d419d9" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_333e1dfd-d198-40ed-aaba-6d8de539c0ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_11008e64-caf9-4088-b7fb-9e2502aaa5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dac66c41-f403-4423-bca9-eb0a19d419d9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_11008e64-caf9-4088-b7fb-9e2502aaa5f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_79348295-e15c-4ecd-aa22-2323dfdd9cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dac66c41-f403-4423-bca9-eb0a19d419d9" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_79348295-e15c-4ecd-aa22-2323dfdd9cd8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_0bdd3a06-4414-455b-8c0e-a0c691e9d5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a60e7921-b318-4e83-ba0f-b2d19bd84c16" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_0bdd3a06-4414-455b-8c0e-a0c691e9d5c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0bdd3a06-4414-455b-8c0e-a0c691e9d5c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0bdd3a06-4414-455b-8c0e-a0c691e9d5c6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0bdd3a06-4414-455b-8c0e-a0c691e9d5c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b9043d0f-c8c9-40d3-b892-1550ae0db1b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0bdd3a06-4414-455b-8c0e-a0c691e9d5c6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b9043d0f-c8c9-40d3-b892-1550ae0db1b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_InterestRateCollarMember_4d4d0ec6-8a43-47d6-a889-b60244a974df" xlink:href="asth-20240331.xsd#asth_InterestRateCollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b9043d0f-c8c9-40d3-b892-1550ae0db1b5" xlink:to="loc_asth_InterestRateCollarMember_4d4d0ec6-8a43-47d6-a889-b60244a974df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_68a08270-6571-4f37-944b-4c01e3f45e38" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a60e7921-b318-4e83-ba0f-b2d19bd84c16" xlink:to="loc_dei_LegalEntityAxis_68a08270-6571-4f37-944b-4c01e3f45e38" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_68a08270-6571-4f37-944b-4c01e3f45e38_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_68a08270-6571-4f37-944b-4c01e3f45e38" xlink:to="loc_dei_EntityDomain_68a08270-6571-4f37-944b-4c01e3f45e38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_85e8418f-157d-4a98-8f42-8b3580d50a89" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_68a08270-6571-4f37-944b-4c01e3f45e38" xlink:to="loc_dei_EntityDomain_85e8418f-157d-4a98-8f42-8b3580d50a89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AAMGMember_37785d2e-cf68-4301-9c12-3b65d89d782e" xlink:href="asth-20240331.xsd#asth_AAMGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_85e8418f-157d-4a98-8f42-8b3580d50a89" xlink:to="loc_asth_AAMGMember_37785d2e-cf68-4301-9c12-3b65d89d782e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_VOMGMember_86743d7e-d76a-459b-ba38-5032caae9c7d" xlink:href="asth-20240331.xsd#asth_VOMGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_85e8418f-157d-4a98-8f42-8b3580d50a89" xlink:to="loc_asth_VOMGMember_86743d7e-d76a-459b-ba38-5032caae9c7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_DmgMember_70f9519f-5d68-44d1-be79-e2aeec1608fe" xlink:href="asth-20240331.xsd#asth_DmgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_85e8418f-157d-4a98-8f42-8b3580d50a89" xlink:to="loc_asth_DmgMember_70f9519f-5d68-44d1-be79-e2aeec1608fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ApolloSunLabsManagementLLCMember_01c6cbfe-9d1d-4588-ac91-68bf7cf38d8f" xlink:href="asth-20240331.xsd#asth_ApolloSunLabsManagementLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_85e8418f-157d-4a98-8f42-8b3580d50a89" xlink:to="loc_asth_ApolloSunLabsManagementLLCMember_01c6cbfe-9d1d-4588-ac91-68bf7cf38d8f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ADSCMember_6db94de1-fdcd-4c28-b38e-d8ac60c471cc" xlink:href="asth-20240331.xsd#asth_ADSCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_85e8418f-157d-4a98-8f42-8b3580d50a89" xlink:to="loc_asth_ADSCMember_6db94de1-fdcd-4c28-b38e-d8ac60c471cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CFCMember_87776054-d915-430e-946f-991e20089f9d" xlink:href="asth-20240331.xsd#asth_CFCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_85e8418f-157d-4a98-8f42-8b3580d50a89" xlink:to="loc_asth_CFCMember_87776054-d915-430e-946f-991e20089f9d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PrimeCommunityCareMember_3183d831-afba-460f-bfee-04f82c81dd96" xlink:href="asth-20240331.xsd#asth_PrimeCommunityCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_85e8418f-157d-4a98-8f42-8b3580d50a89" xlink:to="loc_asth_PrimeCommunityCareMember_3183d831-afba-460f-bfee-04f82c81dd96" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1c0a3645-1ab7-4747-9735-534b73f7d4a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e0ee9bd5-0035-43a5-9f7e-2ba290277bf0" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1c0a3645-1ab7-4747-9735-534b73f7d4a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f83a192b-f40a-4e30-9fa6-23268ac26418" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e0ee9bd5-0035-43a5-9f7e-2ba290277bf0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f83a192b-f40a-4e30-9fa6-23268ac26418" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_58366e9a-a615-48a8-a129-53eeb4108ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e0ee9bd5-0035-43a5-9f7e-2ba290277bf0" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_58366e9a-a615-48a8-a129-53eeb4108ec5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_d4516eb9-f0aa-4c78-b8df-1d71609fff6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e0ee9bd5-0035-43a5-9f7e-2ba290277bf0" xlink:to="loc_us-gaap_DerivativeAssets_d4516eb9-f0aa-4c78-b8df-1d71609fff6a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ee3d4aa7-c8d4-436c-ba0a-df190b1b5f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e0ee9bd5-0035-43a5-9f7e-2ba290277bf0" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_ee3d4aa7-c8d4-436c-ba0a-df190b1b5f0f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0a8eea2b-0537-4b61-8890-f5d56acf2823" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e0ee9bd5-0035-43a5-9f7e-2ba290277bf0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0a8eea2b-0537-4b61-8890-f5d56acf2823" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_b0a8312c-bf39-4608-9606-59564ecab1d2" xlink:href="asth-20240331.xsd#asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e0ee9bd5-0035-43a5-9f7e-2ba290277bf0" xlink:to="loc_asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_b0a8312c-bf39-4608-9606-59564ecab1d2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_e7de5684-7b37-4674-ad8f-cf245fb12466" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e0ee9bd5-0035-43a5-9f7e-2ba290277bf0" xlink:to="loc_us-gaap_DerivativeLiabilities_e7de5684-7b37-4674-ad8f-cf245fb12466" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_a8bcb909-ea5f-4642-b66d-097ae9904318" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e0ee9bd5-0035-43a5-9f7e-2ba290277bf0" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_a8bcb909-ea5f-4642-b66d-097ae9904318" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f37cdaa0-69d7-4758-b79d-11e0d3b71320" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dc950cc9-35dc-4a16-8556-e6632cdf42d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f37cdaa0-69d7-4758-b79d-11e0d3b71320" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dc950cc9-35dc-4a16-8556-e6632cdf42d0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9c9b4154-0528-45b8-9cd1-c39fe40958c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dc950cc9-35dc-4a16-8556-e6632cdf42d0" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9c9b4154-0528-45b8-9cd1-c39fe40958c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9c9b4154-0528-45b8-9cd1-c39fe40958c4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9c9b4154-0528-45b8-9cd1-c39fe40958c4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9c9b4154-0528-45b8-9cd1-c39fe40958c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8541eedf-41de-48bf-b89b-01bf0ed5ce94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9c9b4154-0528-45b8-9cd1-c39fe40958c4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8541eedf-41de-48bf-b89b-01bf0ed5ce94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_cd931cd8-74d4-468c-b28d-0a275d74465e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8541eedf-41de-48bf-b89b-01bf0ed5ce94" xlink:to="loc_us-gaap_CertificatesOfDepositMember_cd931cd8-74d4-468c-b28d-0a275d74465e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_7d468aeb-0b5b-419c-b07f-503240ec2d11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dc950cc9-35dc-4a16-8556-e6632cdf42d0" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_7d468aeb-0b5b-419c-b07f-503240ec2d11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7d468aeb-0b5b-419c-b07f-503240ec2d11_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7d468aeb-0b5b-419c-b07f-503240ec2d11" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7d468aeb-0b5b-419c-b07f-503240ec2d11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1bb214c7-6f37-4bd2-bb50-eb1a144d7b70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7d468aeb-0b5b-419c-b07f-503240ec2d11" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1bb214c7-6f37-4bd2-bb50-eb1a144d7b70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_InterestRateCollarMember_f09bc691-fc02-4030-ac69-99623e99c2d3" xlink:href="asth-20240331.xsd#asth_InterestRateCollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1bb214c7-6f37-4bd2-bb50-eb1a144d7b70" xlink:to="loc_asth_InterestRateCollarMember_f09bc691-fc02-4030-ac69-99623e99c2d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cd1c722d-a4e7-489a-ac03-7c5c09a75f79" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dc950cc9-35dc-4a16-8556-e6632cdf42d0" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cd1c722d-a4e7-489a-ac03-7c5c09a75f79" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_cd1c722d-a4e7-489a-ac03-7c5c09a75f79_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cd1c722d-a4e7-489a-ac03-7c5c09a75f79" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_cd1c722d-a4e7-489a-ac03-7c5c09a75f79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_b652eb5d-a53b-44b6-b572-631fba8fcc69" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cd1c722d-a4e7-489a-ac03-7c5c09a75f79" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_b652eb5d-a53b-44b6-b572-631fba8fcc69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_DMGAndSunLabsMember_110ea9d2-2721-4a6b-ab11-07783eb5ea5e" xlink:href="asth-20240331.xsd#asth_DMGAndSunLabsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b652eb5d-a53b-44b6-b572-631fba8fcc69" xlink:to="loc_asth_DMGAndSunLabsMember_110ea9d2-2721-4a6b-ab11-07783eb5ea5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_DmgMember_2ce1162f-393a-4a25-9538-cfcf61db3585" xlink:href="asth-20240331.xsd#asth_DmgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b652eb5d-a53b-44b6-b572-631fba8fcc69" xlink:to="loc_asth_DmgMember_2ce1162f-393a-4a25-9538-cfcf61db3585" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_36d5cd1a-737b-4ce4-8fe5-6e0625830898" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dc950cc9-35dc-4a16-8556-e6632cdf42d0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_36d5cd1a-737b-4ce4-8fe5-6e0625830898" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_36d5cd1a-737b-4ce4-8fe5-6e0625830898_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_36d5cd1a-737b-4ce4-8fe5-6e0625830898" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_36d5cd1a-737b-4ce4-8fe5-6e0625830898_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_074185cc-8d7d-4828-a713-3681dc6185c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_36d5cd1a-737b-4ce4-8fe5-6e0625830898" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_074185cc-8d7d-4828-a713-3681dc6185c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ApolloSunLabsManagementLLCMember_1eb8237d-f0be-4123-9be6-95ee7b6fed76" xlink:href="asth-20240331.xsd#asth_ApolloSunLabsManagementLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_074185cc-8d7d-4828-a713-3681dc6185c6" xlink:to="loc_asth_ApolloSunLabsManagementLLCMember_1eb8237d-f0be-4123-9be6-95ee7b6fed76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_VOMGMember_7233702c-8a06-42fc-b49d-edda445476cf" xlink:href="asth-20240331.xsd#asth_VOMGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_074185cc-8d7d-4828-a713-3681dc6185c6" xlink:to="loc_asth_VOMGMember_7233702c-8a06-42fc-b49d-edda445476cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AAMGMember_ab67e6c9-0bf7-4326-b7e1-ad634da4b441" xlink:href="asth-20240331.xsd#asth_AAMGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_074185cc-8d7d-4828-a713-3681dc6185c6" xlink:to="loc_asth_AAMGMember_ab67e6c9-0bf7-4326-b7e1-ad634da4b441" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AdvancedDiagnosticAndSurgicalCenterIncMember_c3ecdb63-a425-4bda-9e52-d025ae832fc9" xlink:href="asth-20240331.xsd#asth_AdvancedDiagnosticAndSurgicalCenterIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_074185cc-8d7d-4828-a713-3681dc6185c6" xlink:to="loc_asth_AdvancedDiagnosticAndSurgicalCenterIncMember_c3ecdb63-a425-4bda-9e52-d025ae832fc9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CommunityFamilyCareMedicalGroupIPAInc.Member_59aecc36-fbaf-41a6-8606-712e61ab077f" xlink:href="asth-20240331.xsd#asth_CommunityFamilyCareMedicalGroupIPAInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_074185cc-8d7d-4828-a713-3681dc6185c6" xlink:to="loc_asth_CommunityFamilyCareMedicalGroupIPAInc.Member_59aecc36-fbaf-41a6-8606-712e61ab077f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PCCCVMember_c857026f-7057-48ce-b88b-8feb666bfabc" xlink:href="asth-20240331.xsd#asth_PCCCVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_074185cc-8d7d-4828-a713-3681dc6185c6" xlink:to="loc_asth_PCCCVMember_c857026f-7057-48ce-b88b-8feb666bfabc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_d73387e6-8397-4b3c-a768-fc4e965e89d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dc950cc9-35dc-4a16-8556-e6632cdf42d0" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_d73387e6-8397-4b3c-a768-fc4e965e89d2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d73387e6-8397-4b3c-a768-fc4e965e89d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d73387e6-8397-4b3c-a768-fc4e965e89d2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d73387e6-8397-4b3c-a768-fc4e965e89d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c5635bef-b650-4e6b-8853-367f34f15838" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d73387e6-8397-4b3c-a768-fc4e965e89d2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c5635bef-b650-4e6b-8853-367f34f15838" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember_419e8db2-e497-4d7b-a49c-5e87875cf69c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c5635bef-b650-4e6b-8853-367f34f15838" xlink:to="loc_us-gaap_OtherLiabilitiesMember_419e8db2-e497-4d7b-a49c-5e87875cf69c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_04a7230e-e3dc-455f-8933-ae27583d1441" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c5635bef-b650-4e6b-8853-367f34f15838" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_04a7230e-e3dc-455f-8933-ae27583d1441" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_a18783a0-375e-482b-b967-126cc558628c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dc950cc9-35dc-4a16-8556-e6632cdf42d0" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_a18783a0-375e-482b-b967-126cc558628c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_a18783a0-375e-482b-b967-126cc558628c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_a18783a0-375e-482b-b967-126cc558628c" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_a18783a0-375e-482b-b967-126cc558628c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_c5358b62-26bb-4160-9820-e45005e2a358" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_a18783a0-375e-482b-b967-126cc558628c" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_c5358b62-26bb-4160-9820-e45005e2a358" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_A2023MetricMember_7517d887-2165-43e2-9a08-a62e50323e10" xlink:href="asth-20240331.xsd#asth_A2023MetricMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_c5358b62-26bb-4160-9820-e45005e2a358" xlink:to="loc_asth_A2023MetricMember_7517d887-2165-43e2-9a08-a62e50323e10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_A2024MetricMember_a0efb500-2e80-4443-88fc-6453ceffb88a" xlink:href="asth-20240331.xsd#asth_A2024MetricMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_c5358b62-26bb-4160-9820-e45005e2a358" xlink:to="loc_asth_A2024MetricMember_a0efb500-2e80-4443-88fc-6453ceffb88a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_FirstMetricMember_e92c0ad8-afd5-478b-b881-27d9cb917b1a" xlink:href="asth-20240331.xsd#asth_FirstMetricMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_c5358b62-26bb-4160-9820-e45005e2a358" xlink:to="loc_asth_FirstMetricMember_e92c0ad8-afd5-478b-b881-27d9cb917b1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_SecondMetricMember_9de7bec4-0565-4284-8efe-9ad8b193cc01" xlink:href="asth-20240331.xsd#asth_SecondMetricMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_c5358b62-26bb-4160-9820-e45005e2a358" xlink:to="loc_asth_SecondMetricMember_9de7bec4-0565-4284-8efe-9ad8b193cc01" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ThirdMetricMember_7e138d6c-94b6-4b34-9a19-46dba3abeaa4" xlink:href="asth-20240331.xsd#asth_ThirdMetricMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_c5358b62-26bb-4160-9820-e45005e2a358" xlink:to="loc_asth_ThirdMetricMember_7e138d6c-94b6-4b34-9a19-46dba3abeaa4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_MarketableSecuritiesCurrentMaturityPeriod_4a6c112c-d999-4c28-8fba-eff1e606d369" xlink:href="asth-20240331.xsd#asth_MarketableSecuritiesCurrentMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f37cdaa0-69d7-4758-b79d-11e0d3b71320" xlink:to="loc_asth_MarketableSecuritiesCurrentMaturityPeriod_4a6c112c-d999-4c28-8fba-eff1e606d369" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bed9106d-57b0-4908-9280-6ed2c7ef03e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f37cdaa0-69d7-4758-b79d-11e0d3b71320" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bed9106d-57b0-4908-9280-6ed2c7ef03e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_152f4d38-4ff0-4608-834e-a718544045ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f37cdaa0-69d7-4758-b79d-11e0d3b71320" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_152f4d38-4ff0-4608-834e-a718544045ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_DerivativeCeilingInterestRate_7e4a5370-f91d-49ed-9fb1-79802e2ea6cd" xlink:href="asth-20240331.xsd#asth_DerivativeCeilingInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f37cdaa0-69d7-4758-b79d-11e0d3b71320" xlink:to="loc_asth_DerivativeCeilingInterestRate_7e4a5370-f91d-49ed-9fb1-79802e2ea6cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFloorInterestRate_ea52b7f5-f9d1-42c9-9a00-54bab449ddbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFloorInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f37cdaa0-69d7-4758-b79d-11e0d3b71320" xlink:to="loc_us-gaap_DerivativeFloorInterestRate_ea52b7f5-f9d1-42c9-9a00-54bab449ddbf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_1d3c9592-08fe-47e7-baee-b64edbd7ac9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f37cdaa0-69d7-4758-b79d-11e0d3b71320" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_1d3c9592-08fe-47e7-baee-b64edbd7ac9b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_c186aee6-5e70-4588-81dc-7ba5b0c4a9d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f37cdaa0-69d7-4758-b79d-11e0d3b71320" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_c186aee6-5e70-4588-81dc-7ba5b0c4a9d2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_840a04c2-f6c8-42e2-a486-1c11f7e9ed2f" xlink:href="asth-20240331.xsd#asth_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f37cdaa0-69d7-4758-b79d-11e0d3b71320" xlink:to="loc_asth_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_840a04c2-f6c8-42e2-a486-1c11f7e9ed2f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_f479ed4e-bcc0-4aa4-ad4e-319b83fa74a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f37cdaa0-69d7-4758-b79d-11e0d3b71320" xlink:to="loc_us-gaap_EquityMethodInvestments_f479ed4e-bcc0-4aa4-ad4e-319b83fa74a4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_061604cf-2d9e-41a0-b1ad-9b7b93d7f451" xlink:href="asth-20240331.xsd#asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f37cdaa0-69d7-4758-b79d-11e0d3b71320" xlink:to="loc_asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_061604cf-2d9e-41a0-b1ad-9b7b93d7f451" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationChangeInFairValueOfEquityInterestPurchaseObligation_9fcd2b34-7dfa-4d58-a761-f0a7d74d1411" xlink:href="asth-20240331.xsd#asth_BusinessCombinationChangeInFairValueOfEquityInterestPurchaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f37cdaa0-69d7-4758-b79d-11e0d3b71320" xlink:to="loc_asth_BusinessCombinationChangeInFairValueOfEquityInterestPurchaseObligation_9fcd2b34-7dfa-4d58-a761-f0a7d74d1411" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_38c1b146-8db8-4deb-b0a2-0a110d68a538" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f37cdaa0-69d7-4758-b79d-11e0d3b71320" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_38c1b146-8db8-4deb-b0a2-0a110d68a538" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_858d1aa9-4d00-404e-8a2f-c50ce273dc1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f37cdaa0-69d7-4758-b79d-11e0d3b71320" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_858d1aa9-4d00-404e-8a2f-c50ce273dc1b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_bfb4adfd-8a45-4afb-ba5c-74a96f09ecda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f37cdaa0-69d7-4758-b79d-11e0d3b71320" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_bfb4adfd-8a45-4afb-ba5c-74a96f09ecda" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationContingentConsiderationLiabilityEachMeasurementPeriod_8915baa0-280c-420b-a50f-458a266f5db8" xlink:href="asth-20240331.xsd#asth_BusinessCombinationContingentConsiderationLiabilityEachMeasurementPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f37cdaa0-69d7-4758-b79d-11e0d3b71320" xlink:to="loc_asth_BusinessCombinationContingentConsiderationLiabilityEachMeasurementPeriod_8915baa0-280c-420b-a50f-458a266f5db8" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_b072b4c7-f1f7-47e4-a2f5-a03142a4b60d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_9fca0aa5-3ece-434a-8a8a-f6d1bcfe2fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_b072b4c7-f1f7-47e4-a2f5-a03142a4b60d" xlink:to="loc_us-gaap_SubsequentEventTable_9fca0aa5-3ece-434a-8a8a-f6d1bcfe2fc1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_55377c05-8ae6-40dd-b02a-bc356eb88733" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_9fca0aa5-3ece-434a-8a8a-f6d1bcfe2fc1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_55377c05-8ae6-40dd-b02a-bc356eb88733" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_55377c05-8ae6-40dd-b02a-bc356eb88733_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_55377c05-8ae6-40dd-b02a-bc356eb88733" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_55377c05-8ae6-40dd-b02a-bc356eb88733_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_91b16089-1218-43f0-8b02-2caed468052a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_55377c05-8ae6-40dd-b02a-bc356eb88733" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_91b16089-1218-43f0-8b02-2caed468052a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a337ef91-0c4e-4ccd-b943-450aa14c8243" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_91b16089-1218-43f0-8b02-2caed468052a" xlink:to="loc_us-gaap_SubsequentEventMember_a337ef91-0c4e-4ccd-b943-450aa14c8243" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_55826c75-9580-46f0-9479-db328a1acae2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_9fca0aa5-3ece-434a-8a8a-f6d1bcfe2fc1" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_55826c75-9580-46f0-9479-db328a1acae2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_55826c75-9580-46f0-9479-db328a1acae2_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_55826c75-9580-46f0-9479-db328a1acae2" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_55826c75-9580-46f0-9479-db328a1acae2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_dabaa82a-bf4c-4b89-971f-c0ac4ca442f2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_55826c75-9580-46f0-9479-db328a1acae2" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_dabaa82a-bf4c-4b89-971f-c0ac4ca442f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_IHealthIncMember_409fbc0d-3f92-410b-9d76-d8d780890209" xlink:href="asth-20240331.xsd#asth_IHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_dabaa82a-bf4c-4b89-971f-c0ac4ca442f2" xlink:to="loc_asth_IHealthIncMember_409fbc0d-3f92-410b-9d76-d8d780890209" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e0bf48c6-de66-4e68-ac57-617157532bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_9fca0aa5-3ece-434a-8a8a-f6d1bcfe2fc1" xlink:to="loc_us-gaap_DebtInstrumentAxis_e0bf48c6-de66-4e68-ac57-617157532bf1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e0bf48c6-de66-4e68-ac57-617157532bf1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e0bf48c6-de66-4e68-ac57-617157532bf1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e0bf48c6-de66-4e68-ac57-617157532bf1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bca7a655-8f38-4e6c-9d84-b264adcf14d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e0bf48c6-de66-4e68-ac57-617157532bf1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bca7a655-8f38-4e6c-9d84-b264adcf14d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_IHealthPromissioryNoteMember_940eac3b-89d1-417b-a437-104a460c5794" xlink:href="asth-20240331.xsd#asth_IHealthPromissioryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bca7a655-8f38-4e6c-9d84-b264adcf14d6" xlink:to="loc_asth_IHealthPromissioryNoteMember_940eac3b-89d1-417b-a437-104a460c5794" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_68e21cf5-3e0a-440b-89b7-acef74cda4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_9fca0aa5-3ece-434a-8a8a-f6d1bcfe2fc1" xlink:to="loc_us-gaap_CreditFacilityAxis_68e21cf5-3e0a-440b-89b7-acef74cda4c1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_68e21cf5-3e0a-440b-89b7-acef74cda4c1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_68e21cf5-3e0a-440b-89b7-acef74cda4c1" xlink:to="loc_us-gaap_CreditFacilityDomain_68e21cf5-3e0a-440b-89b7-acef74cda4c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_9e736210-d941-419b-9c51-7a09a7130d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_68e21cf5-3e0a-440b-89b7-acef74cda4c1" xlink:to="loc_us-gaap_CreditFacilityDomain_9e736210-d941-419b-9c51-7a09a7130d2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_RevolverLoanMember_f80a79a3-e316-4302-98d0-cf660247c8d0" xlink:href="asth-20240331.xsd#asth_RevolverLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_9e736210-d941-419b-9c51-7a09a7130d2c" xlink:to="loc_asth_RevolverLoanMember_f80a79a3-e316-4302-98d0-cf660247c8d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_b3c8f6f8-c358-4cb4-bc42-9bd1d2f5d709" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b072b4c7-f1f7-47e4-a2f5-a03142a4b60d" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_b3c8f6f8-c358-4cb4-bc42-9bd1d2f5d709" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_24737f16-8b5a-4f91-88dc-fa8a3b5dc328" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b072b4c7-f1f7-47e4-a2f5-a03142a4b60d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_24737f16-8b5a-4f91-88dc-fa8a3b5dc328" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_b90b5ee5-b482-4fe2-9639-614466e6db71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b072b4c7-f1f7-47e4-a2f5-a03142a4b60d" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_b90b5ee5-b482-4fe2-9639-614466e6db71" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_24cbb5b4-50c6-461f-904e-1bec61c1a2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b072b4c7-f1f7-47e4-a2f5-a03142a4b60d" xlink:to="loc_us-gaap_LineOfCredit_24cbb5b4-50c6-461f-904e-1bec61c1a2ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_90864185-a828-4443-9a27-f0a6ea9cae62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b072b4c7-f1f7-47e4-a2f5-a03142a4b60d" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_90864185-a828-4443-9a27-f0a6ea9cae62" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_StockAwardsAndUnitsMember_d8fdb630-ba6c-48f0-8fb8-0191381a7399" xlink:href="asth-20240331.xsd#asth_StockAwardsAndUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_asth_StockAwardsAndUnitsMember_d8fdb630-ba6c-48f0-8fb8-0191381a7399" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockMember" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PerformanceBasedRestrictedStockMember_0963495a-473a-4f68-ace7-c9e7a2616b49" xlink:href="asth-20240331.xsd#asth_PerformanceBasedRestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_asth_PerformanceBasedRestrictedStockMember_0963495a-473a-4f68-ace7-c9e7a2616b49" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_EmployeeStockPurchasePlanMember_8c9c377c-35a8-4662-89d4-fd93a2d01178" xlink:href="asth-20240331.xsd#asth_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_asth_EmployeeStockPurchasePlanMember_8c9c377c-35a8-4662-89d4-fd93a2d01178" xlink:type="arc" order="7"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>asth-20240331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:b0ef7e3c-019a-4a45-b736-b471aca8f6db,g:a1c00dc1-e4c6-4560-85ab-798755e5651c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_f1b2d51d-94f8-4355-9c39-bdd65e5c4091_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8d61ed06-74fd-4fa4-8d48-9e252fa17b3c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum loan availability</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_IHealthIncMember_a05be588-aa57-424c-ad3c-f50c888504be_terseLabel_en-US" xlink:label="lab_asth_IHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">I Health, Inc.</link:label>
    <link:label id="lab_asth_IHealthIncMember_label_en-US" xlink:label="lab_asth_IHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">I Health, Inc. [Member]</link:label>
    <link:label id="lab_asth_IHealthIncMember_documentation_en-US" xlink:label="lab_asth_IHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">I Health, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_IHealthIncMember" xlink:href="asth-20240331.xsd#asth_IHealthIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_IHealthIncMember" xlink:to="lab_asth_IHealthIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_be3e95f4-b8e9-4127-b58a-60523c353ed9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities, net of business combinations:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_db6ce817-966d-4359-a6a7-87c4780b9594_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9395cac0-717e-4b69-b9b2-3db55d469257_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_d3e100b6-e12d-40ca-81c3-7a30cd555a10_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_IHealthPromissioryNoteMember_33ba6c72-bf9d-4986-94d1-e685249350d2_terseLabel_en-US" xlink:label="lab_asth_IHealthPromissioryNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">I Health Promissiory Note</link:label>
    <link:label id="lab_asth_IHealthPromissioryNoteMember_label_en-US" xlink:label="lab_asth_IHealthPromissioryNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">I Health Promissiory Note [Member]</link:label>
    <link:label id="lab_asth_IHealthPromissioryNoteMember_documentation_en-US" xlink:label="lab_asth_IHealthPromissioryNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">I Health Promissiory Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_IHealthPromissioryNoteMember" xlink:href="asth-20240331.xsd#asth_IHealthPromissioryNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_IHealthPromissioryNoteMember" xlink:to="lab_asth_IHealthPromissioryNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_a3afdc48-323c-48d9-a7a7-e77477f27c06_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Interest Rate at Period End</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_cd0b1eb4-3e7f-4894-8d49-9af40b4afa37_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_MedicaidMember_125aedfb-ece7-47cb-acda-52ec3cff0fee_terseLabel_en-US" xlink:label="lab_asth_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medicaid</link:label>
    <link:label id="lab_asth_MedicaidMember_label_en-US" xlink:label="lab_asth_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medicaid [Member]</link:label>
    <link:label id="lab_asth_MedicaidMember_documentation_en-US" xlink:label="lab_asth_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ameh:MedicaidMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_MedicaidMember" xlink:href="asth-20240331.xsd#asth_MedicaidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_MedicaidMember" xlink:to="lab_asth_MedicaidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_f6b9a960-155f-4389-8744-98b54b46c23f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in affiliates</link:label>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_label_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermInvestments" xlink:to="lab_us-gaap_OtherLongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1_c5dd8b5f-317c-4244-8f16-50aea7100ee5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease option to extend (up to)</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Finance Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:to="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_109d09ef-afb4-4ac7-84a9-563833222895_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_eb4e74f2-ecba-47af-ab3e-97b2ace6454e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_PaymentForRepurchaseOfTreasuryStockFinancingActivities_13904e1b-7b82-4b01-b415-7f9a17f042a2_negatedTerseLabel_en-US" xlink:label="lab_asth_PaymentForRepurchaseOfTreasuryStockFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of treasury shares</link:label>
    <link:label id="lab_asth_PaymentForRepurchaseOfTreasuryStockFinancingActivities_label_en-US" xlink:label="lab_asth_PaymentForRepurchaseOfTreasuryStockFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment For Repurchase Of Treasury Stock, Financing Activities</link:label>
    <link:label id="lab_asth_PaymentForRepurchaseOfTreasuryStockFinancingActivities_documentation_en-US" xlink:label="lab_asth_PaymentForRepurchaseOfTreasuryStockFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment For Repurchase Of Treasury Stock, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PaymentForRepurchaseOfTreasuryStockFinancingActivities" xlink:href="asth-20240331.xsd#asth_PaymentForRepurchaseOfTreasuryStockFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_PaymentForRepurchaseOfTreasuryStockFinancingActivities" xlink:to="lab_asth_PaymentForRepurchaseOfTreasuryStockFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4f0f3562-7e86-4f75-a672-ff865001354b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_4267b8a4-43fd-401c-a7c8-f5178d954e11_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9760b926-64a8-4524-9abf-5e5409bce263_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mezzanine and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_CommercialMember_47cb3ace-1cdf-4d6c-8d65-cca551828b0a_terseLabel_en-US" xlink:label="lab_asth_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial</link:label>
    <link:label id="lab_asth_CommercialMember_label_en-US" xlink:label="lab_asth_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial [Member]</link:label>
    <link:label id="lab_asth_CommercialMember_documentation_en-US" xlink:label="lab_asth_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ameh:CommercialMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CommercialMember" xlink:href="asth-20240331.xsd#asth_CommercialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_CommercialMember" xlink:to="lab_asth_CommercialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_047057be-8868-4962-9d37-465722c8dfd7_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_8f2d1b46-61b9-4ef1-a3d2-f695f1fee6db_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_1823d411-69d9-44f0-a874-4f84fa28a436_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubordinatedDebtMember_79af7acf-ee91-49fc-a841-bd4a6a138c61_terseLabel_en-US" xlink:label="lab_us-gaap_SubordinatedDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subordinated Debt</link:label>
    <link:label id="lab_us-gaap_SubordinatedDebtMember_label_en-US" xlink:label="lab_us-gaap_SubordinatedDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subordinated Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubordinatedDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubordinatedDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubordinatedDebtMember" xlink:to="lab_us-gaap_SubordinatedDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_b948fb0d-9776-464e-af5e-0df5c0154674_totalLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_08b5cbdf-1f97-40b6-8205-1dc431506837_verboseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Board Member</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_CommonStockDiscountedPricePercentage_796812c5-d8df-4803-9b49-3390b4090bf0_terseLabel_en-US" xlink:label="lab_asth_CommonStockDiscountedPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, discounted price, percentage</link:label>
    <link:label id="lab_asth_CommonStockDiscountedPricePercentage_label_en-US" xlink:label="lab_asth_CommonStockDiscountedPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Discounted Price, Percentage</link:label>
    <link:label id="lab_asth_CommonStockDiscountedPricePercentage_documentation_en-US" xlink:label="lab_asth_CommonStockDiscountedPricePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Discounted Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CommonStockDiscountedPricePercentage" xlink:href="asth-20240331.xsd#asth_CommonStockDiscountedPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_CommonStockDiscountedPricePercentage" xlink:to="lab_asth_CommonStockDiscountedPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_CDSCMember_cb692d85-40f2-4545-ab47-1925f8547478_terseLabel_en-US" xlink:label="lab_asth_CDSCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CDSC</link:label>
    <link:label id="lab_asth_CDSCMember_label_en-US" xlink:label="lab_asth_CDSCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CDSC [Member]</link:label>
    <link:label id="lab_asth_CDSCMember_documentation_en-US" xlink:label="lab_asth_CDSCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CDSC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CDSCMember" xlink:href="asth-20240331.xsd#asth_CDSCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_CDSCMember" xlink:to="lab_asth_CDSCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_67e079e5-6e51-4a04-a228-a42558e3424b_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsNoncurrent_c6525151-9575-432e-b00b-7396a676e079_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_39ff8ad3-777f-4687-9fcb-caf38bea1426_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_2039a62e-6fa2-425c-946d-749f8ff29630_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_IncreaseDecreaseInMedicalLiabilities_48f184be-a07e-43ab-90d8-daad8c4b40cd_verboseLabel_en-US" xlink:label="lab_asth_IncreaseDecreaseInMedicalLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Medical liabilities</link:label>
    <link:label id="lab_asth_IncreaseDecreaseInMedicalLiabilities_label_en-US" xlink:label="lab_asth_IncreaseDecreaseInMedicalLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Medical Liabilities</link:label>
    <link:label id="lab_asth_IncreaseDecreaseInMedicalLiabilities_documentation_en-US" xlink:label="lab_asth_IncreaseDecreaseInMedicalLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase (decrease) during the reporting period in the aggregate amount of medical liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_IncreaseDecreaseInMedicalLiabilities" xlink:href="asth-20240331.xsd#asth_IncreaseDecreaseInMedicalLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_IncreaseDecreaseInMedicalLiabilities" xlink:to="lab_asth_IncreaseDecreaseInMedicalLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ManagementServiceMember_59d97984-a012-43ba-a3d4-b7790ea1fa71_terseLabel_en-US" xlink:label="lab_us-gaap_ManagementServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Management fee income</link:label>
    <link:label id="lab_us-gaap_ManagementServiceMember_label_en-US" xlink:label="lab_us-gaap_ManagementServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Management Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagementServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManagementServiceMember" xlink:to="lab_us-gaap_ManagementServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_120f82d5-0ef1-4d79-a293-37fced5b249b_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_bd244ad8-f0ca-412c-acea-3ad4688492c0_terseLabel_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intersegment Elimination</link:label>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_label_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intersegment Eliminations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntersegmentEliminationMember" xlink:to="lab_us-gaap_IntersegmentEliminationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_486f9adf-df33-4a66-b633-136688f79b7c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_bbd08d25-4986-44b8-b13b-10dca118a324_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_f3e86b1d-ccc4-42d7-b150-3eeeffdef6a9_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of ordinary dividends common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_76b9bba7-ce09-4736-80c7-0598a389c240_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Earnings per share &#8211; diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_c3d12e62-f51e-4401-a58f-012961784a93_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_NonCashBusinessAcquisition_1b4e0d7a-c6d9-4eda-943b-82db1650cf5e_terseLabel_en-US" xlink:label="lab_asth_NonCashBusinessAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business acquisition in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_asth_NonCashBusinessAcquisition_label_en-US" xlink:label="lab_asth_NonCashBusinessAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Business Acquisition</link:label>
    <link:label id="lab_asth_NonCashBusinessAcquisition_documentation_en-US" xlink:label="lab_asth_NonCashBusinessAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Business Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_NonCashBusinessAcquisition" xlink:href="asth-20240331.xsd#asth_NonCashBusinessAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_NonCashBusinessAcquisition" xlink:to="lab_asth_NonCashBusinessAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_f1ab89c3-a223-4ec5-a340-a499d8067ac1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivables, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_cda80767-94ed-4c51-9350-cab4a337fc82_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Receivables, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_AstranaMedicalMember_2a2aaaec-8fb7-4d6d-89bc-437c52f55fa4_terseLabel_en-US" xlink:label="lab_asth_AstranaMedicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Astrana Medical</link:label>
    <link:label id="lab_asth_AstranaMedicalMember_label_en-US" xlink:label="lab_asth_AstranaMedicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Astrana Medical [Member]</link:label>
    <link:label id="lab_asth_AstranaMedicalMember_documentation_en-US" xlink:label="lab_asth_AstranaMedicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Astrana Medical</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AstranaMedicalMember" xlink:href="asth-20240331.xsd#asth_AstranaMedicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_AstranaMedicalMember" xlink:to="lab_asth_AstranaMedicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_01cb468e-bbcf-436c-bfac-10dc5d4dd1bc_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_b0356d76-7038-4894-b6a0-8df35a074e52_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_11a18812-1302-44c3-a3cc-27545e55f831_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_ce69bcb7-147f-4a40-ad0c-6b7f1630a0f7_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_fb3bfcbf-b1bd-4fbe-a308-9e07808d39e5_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of investment &#8211; equity method</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_93636cf1-59b1-4174-8183-b5d90d297199_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_ThirdMetricMember_d07d1859-b764-4bea-8a37-f49522fa0d96_terseLabel_en-US" xlink:label="lab_asth_ThirdMetricMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Third Metric</link:label>
    <link:label id="lab_asth_ThirdMetricMember_label_en-US" xlink:label="lab_asth_ThirdMetricMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Third Metric [Member]</link:label>
    <link:label id="lab_asth_ThirdMetricMember_documentation_en-US" xlink:label="lab_asth_ThirdMetricMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Third Metric</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ThirdMetricMember" xlink:href="asth-20240331.xsd#asth_ThirdMetricMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_ThirdMetricMember" xlink:to="lab_asth_ThirdMetricMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1be5cad3-c4e1-4782-9029-541cef4e4b9a_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2a596d43-33fe-4d04-8030-133bc9626390_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_fa0b0270-47de-4ff7-9622-92d7a035adfc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b28af46d-3ac9-4d4f-a9d6-8af88ecd87a2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share Computations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_ac06925c-9f13-4460-9a1c-b17a0e75b39e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party transaction, amount of transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_50241026-3b15-4bb0-accc-7de8cce49fa5_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Shares Included in the Diluted Earnings Per Share Computations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_418bbccc-657f-4db5-b130-a8f59f738815_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4efff5bb-ca31-40a5-856a-7cfaedebc6e8_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_a2319d4a-46f9-418c-8c45-f73d28d036cc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_TruistBankMember_8411a5cc-34da-4e92-a6fa-a5d32cd07cd4_terseLabel_en-US" xlink:label="lab_asth_TruistBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Truist Bank</link:label>
    <link:label id="lab_asth_TruistBankMember_label_en-US" xlink:label="lab_asth_TruistBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Truist Bank [Member]</link:label>
    <link:label id="lab_asth_TruistBankMember_documentation_en-US" xlink:label="lab_asth_TruistBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Truist Bank</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_TruistBankMember" xlink:href="asth-20240331.xsd#asth_TruistBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_TruistBankMember" xlink:to="lab_asth_TruistBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_f6c7345c-d60d-4f45-bea0-71c83e124a95_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investment in marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_d652125e-fe1a-4362-bf1c-172a1ed6e906_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_SubcontractorIPAPayable_fc634433-d9bf-404f-bf55-dcf4129463ef_verboseLabel_en-US" xlink:label="lab_asth_SubcontractorIPAPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Subcontractor IPA payable</link:label>
    <link:label id="lab_asth_SubcontractorIPAPayable_label_en-US" xlink:label="lab_asth_SubcontractorIPAPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subcontractor IPA Payable</link:label>
    <link:label id="lab_asth_SubcontractorIPAPayable_documentation_en-US" xlink:label="lab_asth_SubcontractorIPAPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Subcontractor IPA Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_SubcontractorIPAPayable" xlink:href="asth-20240331.xsd#asth_SubcontractorIPAPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_SubcontractorIPAPayable" xlink:to="lab_asth_SubcontractorIPAPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_72ef3873-5c46-411d-ad58-3abed1923db7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ba8c61b0-ab53-477c-9cee-4d25e9491d6f_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_7f2af51b-7f2d-4d65-a082-de980346e39f_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certificates of Deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_9b5eabd6-2dda-4c55-abe5-634592b25a15_negatedLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Current period</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_45c6ddbd-4a72-47ac-9d05-999d1d4d06c0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_b88a905c-c096-4947-98f8-50dbf41e2cd0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_0541103b-2715-4b93-8d9f-0aa2d8baa26f_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_cc51c5ea-1026-4a2e-b1fb-0e3dd1f603ee_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_fa9fad43-82b9-455d-b180-56967587a9a8_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_cc5b6a47-74ae-453e-b541-22a588b14cb7_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_6ad108ea-247d-4bdc-9f56-bb74864577ef_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Receivables and Receivables-Related Parties</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_MarketableSecuritiesCurrentMaturityPeriod_d92b6482-8eb7-43da-90b1-caf900ed435f_terseLabel_en-US" xlink:label="lab_asth_MarketableSecuritiesCurrentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term marketable securities, maturity period</link:label>
    <link:label id="lab_asth_MarketableSecuritiesCurrentMaturityPeriod_label_en-US" xlink:label="lab_asth_MarketableSecuritiesCurrentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Current, Maturity Period</link:label>
    <link:label id="lab_asth_MarketableSecuritiesCurrentMaturityPeriod_documentation_en-US" xlink:label="lab_asth_MarketableSecuritiesCurrentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Marketable Securities, Current, Maturity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_MarketableSecuritiesCurrentMaturityPeriod" xlink:href="asth-20240331.xsd#asth_MarketableSecuritiesCurrentMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_MarketableSecuritiesCurrentMaturityPeriod" xlink:to="lab_asth_MarketableSecuritiesCurrentMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_deda8ef9-c498-48df-a215-4c54afc73442_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_PmiocMember_39bc7eba-dd79-4c2f-ac77-f4ec2923673b_terseLabel_en-US" xlink:label="lab_asth_PmiocMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PMIOC</link:label>
    <link:label id="lab_asth_PmiocMember_label_en-US" xlink:label="lab_asth_PmiocMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PMIOC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PmiocMember" xlink:href="asth-20240331.xsd#asth_PmiocMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_PmiocMember" xlink:to="lab_asth_PmiocMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_f680e1a2-b663-4175-b8f5-f53329438144_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_BoardMembersMember_9e0f7166-a2e5-419e-a6ae-a5c32877cb00_terseLabel_en-US" xlink:label="lab_asth_BoardMembersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Board Members</link:label>
    <link:label id="lab_asth_BoardMembersMember_label_en-US" xlink:label="lab_asth_BoardMembersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Board Members [Member]</link:label>
    <link:label id="lab_asth_BoardMembersMember_documentation_en-US" xlink:label="lab_asth_BoardMembersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Board Members</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BoardMembersMember" xlink:href="asth-20240331.xsd#asth_BoardMembersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_BoardMembersMember" xlink:to="lab_asth_BoardMembersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_TotalPurchaseConsiderationAbstract_bf0f7590-6c97-4a88-ab65-e037de90e5a3_terseLabel_en-US" xlink:label="lab_asth_TotalPurchaseConsiderationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total purchase consideration:</link:label>
    <link:label id="lab_asth_TotalPurchaseConsiderationAbstract_label_en-US" xlink:label="lab_asth_TotalPurchaseConsiderationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Purchase Consideration [Abstract]</link:label>
    <link:label id="lab_asth_TotalPurchaseConsiderationAbstract_documentation_en-US" xlink:label="lab_asth_TotalPurchaseConsiderationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Purchase Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_TotalPurchaseConsiderationAbstract" xlink:href="asth-20240331.xsd#asth_TotalPurchaseConsiderationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_TotalPurchaseConsiderationAbstract" xlink:to="lab_asth_TotalPurchaseConsiderationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_6f7935e2-fb80-47fa-8a41-ea2ca1ecc023_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash_315eb885-ab1e-4b58-9f93-299f336b4ad9_terseLabel_en-US" xlink:label="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash_label_en-US" xlink:label="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Restricted Cash</link:label>
    <link:label id="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash_documentation_en-US" xlink:label="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash" xlink:href="asth-20240331.xsd#asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash" xlink:to="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_d40194d3-021b-4898-b17f-04952506920b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashUninsuredAmount_40efc241-ec1f-4a82-b25f-42723440f673_terseLabel_en-US" xlink:label="lab_us-gaap_CashUninsuredAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount deposit accounts exceeded FDIC insured limit</link:label>
    <link:label id="lab_us-gaap_CashUninsuredAmount_label_en-US" xlink:label="lab_us-gaap_CashUninsuredAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Uninsured Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashUninsuredAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashUninsuredAmount" xlink:to="lab_us-gaap_CashUninsuredAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_946af8fc-6316-4dd9-82d0-5d50baceffd5_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_5d51de68-80e1-45fe-9122-74ff740c3d1f_terseLabel_en-US" xlink:label="lab_asth_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk pool surplus or deficits, settlement period after risk pool performance year</link:label>
    <link:label id="lab_asth_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_label_en-US" xlink:label="lab_asth_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk Pool Surplus Or Deficits, Settlement Period After Performance Year</link:label>
    <link:label id="lab_asth_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_documentation_en-US" xlink:label="lab_asth_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Risk Pool Surplus Or Deficits, Settlement Period After Performance Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:href="asth-20240331.xsd#asth_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:to="lab_asth_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_fa9dc501-577c-467b-9ffe-6edb55473613_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_AmendedCreditAgreementMember_a830e339-7669-4fe0-88f2-17e100e47e4a_terseLabel_en-US" xlink:label="lab_asth_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amended Credit Agreement</link:label>
    <link:label id="lab_asth_AmendedCreditAgreementMember_label_en-US" xlink:label="lab_asth_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:label id="lab_asth_AmendedCreditAgreementMember_documentation_en-US" xlink:label="lab_asth_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amended Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AmendedCreditAgreementMember" xlink:href="asth-20240331.xsd#asth_AmendedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_AmendedCreditAgreementMember" xlink:to="lab_asth_AmendedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_abb6d385-1295-41ac-bebb-48c72d9a0721_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities not included in the calculation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_aff47e21-f029-4cd0-a77d-7bad865ca4f3_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4d5cad03-3921-4f07-a204-62d508a365ad_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock awards granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_AlliedPacificOfCaliforniaIPAMember_e768114e-887a-4a44-874c-4d62f6f8b856_terseLabel_en-US" xlink:label="lab_asth_AlliedPacificOfCaliforniaIPAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allied Pacific Of California IPA</link:label>
    <link:label id="lab_asth_AlliedPacificOfCaliforniaIPAMember_5f84bfe9-c1a5-4258-a985-abb3960078b6_verboseLabel_en-US" xlink:label="lab_asth_AlliedPacificOfCaliforniaIPAMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">APC</link:label>
    <link:label id="lab_asth_AlliedPacificOfCaliforniaIPAMember_label_en-US" xlink:label="lab_asth_AlliedPacificOfCaliforniaIPAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allied Pacific Of California IPA [Member]</link:label>
    <link:label id="lab_asth_AlliedPacificOfCaliforniaIPAMember_documentation_en-US" xlink:label="lab_asth_AlliedPacificOfCaliforniaIPAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Allied Pacific Of California IPA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AlliedPacificOfCaliforniaIPAMember" xlink:href="asth-20240331.xsd#asth_AlliedPacificOfCaliforniaIPAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_AlliedPacificOfCaliforniaIPAMember" xlink:to="lab_asth_AlliedPacificOfCaliforniaIPAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_2e5eb817-f3dd-4e37-bfb3-d37e43fdfd3a_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_85a4e65e-9db7-46c5-b58b-69b45c1ca4c9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_a49f2fe4-a1cc-4d71-94a5-482f8eb28680_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total paid</link:label>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:to="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_876c1d3c-9e84-4a03-9173-2145798553e6_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_f7c39abe-f513-4c16-bdd6-fde13f675292_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Related-Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e6681d0a-3451-4adb-8e3c-b10827019dd7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_094ce227-12d8-4f93-b414-498a3c5be73d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_640f5a30-0d70-4181-bb11-11ce3e7a5482_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_aeb535a3-b27c-4b77-9fe5-75867fdd3ba1_netLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_fe023b05-8608-4b7a-9cf6-af77c45ef99a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_c5b80aa1-3cfe-45cb-b372-c8333ee04098_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licenses</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_465196e5-b32b-4652-8181-67e29ba37d9c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_PaymentsToAcquireBusinessCashPayable_970ecad6-6da7-4a3d-bef5-92a37534e8b1_terseLabel_en-US" xlink:label="lab_asth_PaymentsToAcquireBusinessCashPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash payable</link:label>
    <link:label id="lab_asth_PaymentsToAcquireBusinessCashPayable_label_en-US" xlink:label="lab_asth_PaymentsToAcquireBusinessCashPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Business, Cash Payable</link:label>
    <link:label id="lab_asth_PaymentsToAcquireBusinessCashPayable_documentation_en-US" xlink:label="lab_asth_PaymentsToAcquireBusinessCashPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments to Acquire Business, Cash Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PaymentsToAcquireBusinessCashPayable" xlink:href="asth-20240331.xsd#asth_PaymentsToAcquireBusinessCashPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_PaymentsToAcquireBusinessCashPayable" xlink:to="lab_asth_PaymentsToAcquireBusinessCashPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6f98042f-92e5-441e-8789-74baf78741aa_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_a7a577a6-5691-48a2-911d-342ae0466807_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3582061e-ccc7-42d2-bdeb-541e28826ac3_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_9d307441-f560-4053-9d41-e6401b3a2182_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_41cbd84b-23a1-4341-83cd-2a5c2aa4de0a_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_21d78397-09ad-433f-85d2-21b6f216a673_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_PayorAMember_1ebbd9d4-1510-4fc3-84c8-6c968cfed460_terseLabel_en-US" xlink:label="lab_asth_PayorAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payer A</link:label>
    <link:label id="lab_asth_PayorAMember_label_en-US" xlink:label="lab_asth_PayorAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payor A [Member]</link:label>
    <link:label id="lab_asth_PayorAMember_documentation_en-US" xlink:label="lab_asth_PayorAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payor A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PayorAMember" xlink:href="asth-20240331.xsd#asth_PayorAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_PayorAMember" xlink:to="lab_asth_PayorAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_8aa73d98-bd31-4a62-8025-4aa2ea804681_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_14e587a6-4bf5-400e-8a09-94b6be40f970_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_ad4e3f6d-1260-45db-9890-a0d9f5205fd0_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_dac8468c-3acd-4115-bf3f-e088980f161a_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_444fdb9b-a408-40df-902c-d0c688b01713_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_DebtInstrumentNumberOfKeyFinancialRatios_52fdb880-1dfb-4cb7-a853-0c315e827b5b_terseLabel_en-US" xlink:label="lab_asth_DebtInstrumentNumberOfKeyFinancialRatios" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of key financial ratios</link:label>
    <link:label id="lab_asth_DebtInstrumentNumberOfKeyFinancialRatios_label_en-US" xlink:label="lab_asth_DebtInstrumentNumberOfKeyFinancialRatios" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number Of Key Financial Ratios</link:label>
    <link:label id="lab_asth_DebtInstrumentNumberOfKeyFinancialRatios_documentation_en-US" xlink:label="lab_asth_DebtInstrumentNumberOfKeyFinancialRatios" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number Of Key Financial Ratios</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_DebtInstrumentNumberOfKeyFinancialRatios" xlink:href="asth-20240331.xsd#asth_DebtInstrumentNumberOfKeyFinancialRatios"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_DebtInstrumentNumberOfKeyFinancialRatios" xlink:to="lab_asth_DebtInstrumentNumberOfKeyFinancialRatios" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_ac2a3dc8-85ad-4a25-b522-04a6cd223fd2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_4f0405e8-dff7-4a2e-8886-0b1b49f36f11_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_1a6b3ce9-852b-422e-b161-e2e4536e155f_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_6f3b5a7a-7ba3-4491-8063-20772da61749_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_0dca8d74-5dbb-4114-96a7-19204cd7eb95_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_CommonStockDiscountedPricePercentageMaximum_fa45c1f2-7ca2-4c75-87a2-5a366d0be10a_terseLabel_en-US" xlink:label="lab_asth_CommonStockDiscountedPricePercentageMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, discounted price, percentage (up to)</link:label>
    <link:label id="lab_asth_CommonStockDiscountedPricePercentageMaximum_label_en-US" xlink:label="lab_asth_CommonStockDiscountedPricePercentageMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Discounted Price, Percentage, Maximum</link:label>
    <link:label id="lab_asth_CommonStockDiscountedPricePercentageMaximum_documentation_en-US" xlink:label="lab_asth_CommonStockDiscountedPricePercentageMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Discounted Price, Percentage, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CommonStockDiscountedPricePercentageMaximum" xlink:href="asth-20240331.xsd#asth_CommonStockDiscountedPricePercentageMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_CommonStockDiscountedPricePercentageMaximum" xlink:to="lab_asth_CommonStockDiscountedPricePercentageMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_69f37dbd-3d0f-42be-a2ec-4acb5d604cc5_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_d87f3e04-20ef-4c33-97d7-065208937154_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fees Incurred and Revenue Earned from Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_45dc9c5f-f0a7-4296-95ec-07572e07a433_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_452a8117-d0bf-4cfa-b79a-301270ada63d_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of services, excluding depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_9053925e-99e5-4c15-87e0-52177f95f78b_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost of services</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_61465d38-5823-47cc-9fb3-526bf8bf0c2c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_daa5ad62-f696-44b5-8b11-a866c44fdb90_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_StockIssuedDuringPeriodSharesMerger_c6f40921-44dc-4d1b-87bb-74980f91f3ec_terseLabel_en-US" xlink:label="lab_asth_StockIssuedDuringPeriodSharesMerger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Holdback shares not issued to former shareholders (in shares)</link:label>
    <link:label id="lab_asth_StockIssuedDuringPeriodSharesMerger_label_en-US" xlink:label="lab_asth_StockIssuedDuringPeriodSharesMerger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Merger</link:label>
    <link:label id="lab_asth_StockIssuedDuringPeriodSharesMerger_documentation_en-US" xlink:label="lab_asth_StockIssuedDuringPeriodSharesMerger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares of stock issued during the period pursuant to merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_StockIssuedDuringPeriodSharesMerger" xlink:href="asth-20240331.xsd#asth_StockIssuedDuringPeriodSharesMerger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_StockIssuedDuringPeriodSharesMerger" xlink:to="lab_asth_StockIssuedDuringPeriodSharesMerger" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_2bf07f0b-491e-4afc-a3b9-fa5fad4948b5_terseLabel_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chief Executive Officer</link:label>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember" xlink:to="lab_srt_ChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_ConsiderationOfAcquisitionInCashFunded_d72d0868-3da3-4968-bcbc-7f3c983a1cfa_terseLabel_en-US" xlink:label="lab_asth_ConsiderationOfAcquisitionInCashFunded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration of acquisition in cash funded</link:label>
    <link:label id="lab_asth_ConsiderationOfAcquisitionInCashFunded_label_en-US" xlink:label="lab_asth_ConsiderationOfAcquisitionInCashFunded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consideration of Acquisition in Cash Funded</link:label>
    <link:label id="lab_asth_ConsiderationOfAcquisitionInCashFunded_documentation_en-US" xlink:label="lab_asth_ConsiderationOfAcquisitionInCashFunded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consideration of Acquisition in Cash Funded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ConsiderationOfAcquisitionInCashFunded" xlink:href="asth-20240331.xsd#asth_ConsiderationOfAcquisitionInCashFunded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_ConsiderationOfAcquisitionInCashFunded" xlink:to="lab_asth_ConsiderationOfAcquisitionInCashFunded" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a537755d-317d-449e-a025-ed7227745d8b_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0aff9704-c968-40a2-b75a-c2036a37090e_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_deeaea85-6342-4bba-bf02-9821472874f6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_0a6abf27-d932-468a-bff8-74c8e0793972_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tradename/trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_DepositForPurchaseOfProperty_772b08e3-0610-4a50-8217-3c4a72ce023f_negatedTerseLabel_en-US" xlink:label="lab_asth_DepositForPurchaseOfProperty" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deposit for purchase of property</link:label>
    <link:label id="lab_asth_DepositForPurchaseOfProperty_label_en-US" xlink:label="lab_asth_DepositForPurchaseOfProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deposit For Purchase Of Property</link:label>
    <link:label id="lab_asth_DepositForPurchaseOfProperty_documentation_en-US" xlink:label="lab_asth_DepositForPurchaseOfProperty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deposit For Purchase Of Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_DepositForPurchaseOfProperty" xlink:href="asth-20240331.xsd#asth_DepositForPurchaseOfProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_DepositForPurchaseOfProperty" xlink:to="lab_asth_DepositForPurchaseOfProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_2d948e49-b59a-4277-a236-9a0ccb40ea8f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Credit Facility</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Line of Credit Facilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_b5ac9cc5-3770-44c1-a864-923010b930cf_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_631b8e0f-d776-429d-b891-b173a8e594dc_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_8ff890ec-6098-4dbe-a0b7-c9a4f8f4a997_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_CommunityFamilyCareMedicalGroupIPAInc.Member_5d5773d3-9cf0-4d66-9b84-25df97a0ae50_terseLabel_en-US" xlink:label="lab_asth_CommunityFamilyCareMedicalGroupIPAInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Community Family Care Medical Group IPA, Inc.</link:label>
    <link:label id="lab_asth_CommunityFamilyCareMedicalGroupIPAInc.Member_4dea114b-6a91-4a07-98d8-dbf7d6b35723_verboseLabel_en-US" xlink:label="lab_asth_CommunityFamilyCareMedicalGroupIPAInc.Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">CFC</link:label>
    <link:label id="lab_asth_CommunityFamilyCareMedicalGroupIPAInc.Member_label_en-US" xlink:label="lab_asth_CommunityFamilyCareMedicalGroupIPAInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Community Family Care Medical Group IPA, Inc. [Member]</link:label>
    <link:label id="lab_asth_CommunityFamilyCareMedicalGroupIPAInc.Member_documentation_en-US" xlink:label="lab_asth_CommunityFamilyCareMedicalGroupIPAInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Community Family Care Medical Group IPA, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CommunityFamilyCareMedicalGroupIPAInc.Member" xlink:href="asth-20240331.xsd#asth_CommunityFamilyCareMedicalGroupIPAInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_CommunityFamilyCareMedicalGroupIPAInc.Member" xlink:to="lab_asth_CommunityFamilyCareMedicalGroupIPAInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_63f728dc-c121-4e3a-874a-18c9383863d8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_aa717719-2318-42e9-a3b9-a2e12ab92e46_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Options forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_ae8cc030-c2b2-4bdf-9dfd-de6783ec3618_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_59a774c5-1f93-4b7c-a310-a608997768c5_negatedLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_3eabd19f-8ae9-49fc-bfc2-67c7e86bcc33_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combinations, Asset Acquisitions, and Goodwill</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_b522c836-e763-4feb-a133-20cb91c5f3c1_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsMinorityInterest_96bbfcd8-d8db-4250-a251-e2649e409d25_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsMinorityInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of non-controlling interest</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsMinorityInterest_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsMinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Ordinary Dividends, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsMinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsMinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsMinorityInterest" xlink:to="lab_us-gaap_PaymentsOfDividendsMinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_dc0176db-e471-42a1-a360-014bb681daa8_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite lived assets:</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_cb4790ba-2a94-4899-852d-eefeb0bb814e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_af753733-74ab-46bd-bfbf-15a75ed4219d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_3211161b-044d-495e-9490-d99f8c813e25_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_OtherThirdPartiesMember_dfae12b6-aa0e-4b49-becb-fda1ec441c61_terseLabel_en-US" xlink:label="lab_asth_OtherThirdPartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other third parties</link:label>
    <link:label id="lab_asth_OtherThirdPartiesMember_label_en-US" xlink:label="lab_asth_OtherThirdPartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Third Parties [Member]</link:label>
    <link:label id="lab_asth_OtherThirdPartiesMember_documentation_en-US" xlink:label="lab_asth_OtherThirdPartiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ameh:OtherThirdPartiesMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_OtherThirdPartiesMember" xlink:href="asth-20240331.xsd#asth_OtherThirdPartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_OtherThirdPartiesMember" xlink:to="lab_asth_OtherThirdPartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_eadb8671-8828-48b2-89d3-114f43edc0e5_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease cost, net</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_1083a50b-d3e5-4a94-b91a-1ed4e5ca45a0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_b84f5201-871a-4a77-8404-b0bb14e3cf9c_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_066fe001-0dff-49c3-a37a-7cab7394c514_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_6ee58536-7db9-476b-a8df-39cd71e692f7_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_10524ced-d7de-44cc-9486-88fdf196010b_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_OtherAcquisitionsMember_c59b39b0-3626-41ff-a0ca-1fdc050a4d31_terseLabel_en-US" xlink:label="lab_asth_OtherAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Acquisitions</link:label>
    <link:label id="lab_asth_OtherAcquisitionsMember_label_en-US" xlink:label="lab_asth_OtherAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Acquisitions [Member]</link:label>
    <link:label id="lab_asth_OtherAcquisitionsMember_documentation_en-US" xlink:label="lab_asth_OtherAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_OtherAcquisitionsMember" xlink:href="asth-20240331.xsd#asth_OtherAcquisitionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_OtherAcquisitionsMember" xlink:to="lab_asth_OtherAcquisitionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21d3aadc-a82c-4c33-8be0-20e11b5080de_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_535db82d-3db9-4bc8-8f6c-a29b9910734d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_6940ecb5-08e9-475b-8b3e-b7e1e7055d28_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_80287c8f-4f3a-4f5b-b916-55da00bf4fad_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_fd9d6ce6-a1c7-458d-b068-6816826347c2_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and other accruals</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_860aba24-e120-4085-b175-603589bc6389_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_CFCMember_3c6382b5-b7cd-4f25-b6b7-543039ee2e8e_terseLabel_en-US" xlink:label="lab_asth_CFCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CFC contingent considerations</link:label>
    <link:label id="lab_asth_CFCMember_label_en-US" xlink:label="lab_asth_CFCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CFC [Member]</link:label>
    <link:label id="lab_asth_CFCMember_documentation_en-US" xlink:label="lab_asth_CFCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CFC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CFCMember" xlink:href="asth-20240331.xsd#asth_CFCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_CFCMember" xlink:to="lab_asth_CFCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_17d37e71-df1c-46c6-abcf-a60124892cea_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e9a03eb4-3dd1-4eee-9dfa-9ee172fde847_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_fa5f65db-6525-4045-9823-b371a2377eb7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_5a933bf0-5d99-4d90-8ef6-d2b2c532d4e5_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_CommitmentsAndContingenciesTable_c6802144-28ac-4c1c-b2af-83b8e232eac7_terseLabel_en-US" xlink:label="lab_asth_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_asth_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_asth_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CommitmentsAndContingenciesTable" xlink:href="asth-20240331.xsd#asth_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_CommitmentsAndContingenciesTable" xlink:to="lab_asth_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_PCCCVMember_33a07618-0761-47bf-ab52-4b70dc5942a6_terseLabel_en-US" xlink:label="lab_asth_PCCCVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PCCCV</link:label>
    <link:label id="lab_asth_PCCCVMember_label_en-US" xlink:label="lab_asth_PCCCVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PCCCV [Member]</link:label>
    <link:label id="lab_asth_PCCCVMember_documentation_en-US" xlink:label="lab_asth_PCCCVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">PCCCV</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PCCCVMember" xlink:href="asth-20240331.xsd#asth_PCCCVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_PCCCVMember" xlink:to="lab_asth_PCCCVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_b46570f9-f768-493b-8b68-5f5b2db525c3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of Credit Risks</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromOtherOperatingActivities_28b22146-c783-455e-9524-bcb798591b4e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromOtherOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromOtherOperatingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromOtherOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Other Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromOtherOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromOtherOperatingActivities" xlink:to="lab_us-gaap_ProceedsFromOtherOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_PayerCMember_6110edae-548e-4fdb-b1ee-2149d6614041_terseLabel_en-US" xlink:label="lab_asth_PayerCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payer C</link:label>
    <link:label id="lab_asth_PayerCMember_label_en-US" xlink:label="lab_asth_PayerCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payer C [Member]</link:label>
    <link:label id="lab_asth_PayerCMember_documentation_en-US" xlink:label="lab_asth_PayerCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payer C</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PayerCMember" xlink:href="asth-20240331.xsd#asth_PayerCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_PayerCMember" xlink:to="lab_asth_PayerCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_a16aa755-7ff0-4156-85ea-5b5a4c28bcc3_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_45a8115e-2c5f-42dd-b563-9e690c124ed9_verboseLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_056a6e77-b22e-4f7d-afea-ed9f35446ec2_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Equity, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_8e5e479d-2518-4d01-8a80-624cdb081773_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Equity, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_TotalAcquisitionsMember_ec8f30f1-bbf1-49e6-b5bc-d8485aced09d_terseLabel_en-US" xlink:label="lab_asth_TotalAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Acquisitions</link:label>
    <link:label id="lab_asth_TotalAcquisitionsMember_label_en-US" xlink:label="lab_asth_TotalAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Acquisitions [Member]</link:label>
    <link:label id="lab_asth_TotalAcquisitionsMember_documentation_en-US" xlink:label="lab_asth_TotalAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_TotalAcquisitionsMember" xlink:href="asth-20240331.xsd#asth_TotalAcquisitionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_TotalAcquisitionsMember" xlink:to="lab_asth_TotalAcquisitionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod_36fc679b-7b9c-4553-ba57-377190245628_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of treasury shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value, Acquired, Par Value Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredParValueMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_26c738ed-0674-41e2-9e1d-30a32af5c1ce_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_bad02aa8-7c18-484b-9eb3-690696fb7aa9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_c287307b-3784-4901-a859-5d6a1e425b30_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_eef01a9f-9525-45dc-b190-7a6d84c0ba72_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities &#8211; equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_c99955a0-ccc5-4060-ac8e-2e84d933febc_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_9f5d806e-84dd-4d8d-922e-5ca955963e93_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_NetworkRelationshipsMember_ba640d93-5431-45b6-b21e-431564adfa63_terseLabel_en-US" xlink:label="lab_asth_NetworkRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Network relationships</link:label>
    <link:label id="lab_asth_NetworkRelationshipsMember_label_en-US" xlink:label="lab_asth_NetworkRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Network Relationships [Member]</link:label>
    <link:label id="lab_asth_NetworkRelationshipsMember_documentation_en-US" xlink:label="lab_asth_NetworkRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Network Relationships</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_NetworkRelationshipsMember" xlink:href="asth-20240331.xsd#asth_NetworkRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_NetworkRelationshipsMember" xlink:to="lab_asth_NetworkRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_c99f120e-08ec-41bd-808f-93648365c55d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue since acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_499d622c-039e-4819-9dab-41d55ea7fd1d_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_44912b80-8efb-48de-871e-ae32a012ff80_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 (excluding the three months ended March 31, 2024)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_d49936c4-3b95-473d-9b0c-fd1a4a113da0_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_b97d88f8-0490-4baf-b4a3-191430aa9697_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Commitments of Credit Facility</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_5d8f1dee-4047-4f5b-b407-83d0ef7b317e_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_2e23ec4c-8aaf-4e98-af67-83d1e5f2cc82_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_f07f0eee-4985-40c5-9813-98102ff666d6_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_us-gaap_SeriesBPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_a95d0496-8f5d-41bf-b43e-6cc1fc71969d_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_238556f7-1025-4899-b845-8cc79f541fea_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_4d97dbb1-bfe9-426e-9d9f-053c4aaa0a0f_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_CarePartnersMember_f1f3eda1-210f-403b-b8e9-13f4dc828260_terseLabel_en-US" xlink:label="lab_asth_CarePartnersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Care Partners</link:label>
    <link:label id="lab_asth_CarePartnersMember_label_en-US" xlink:label="lab_asth_CarePartnersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Care Partners [Member]</link:label>
    <link:label id="lab_asth_CarePartnersMember_documentation_en-US" xlink:label="lab_asth_CarePartnersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Care Partners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CarePartnersMember" xlink:href="asth-20240331.xsd#asth_CarePartnersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_CarePartnersMember" xlink:to="lab_asth_CarePartnersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_d433fd38-0446-40fa-95f5-583332f032d6_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_ApolloSunLabsManagementLLCMember_460f431d-9d89-4754-8d82-522e7334b457_verboseLabel_en-US" xlink:label="lab_asth_ApolloSunLabsManagementLLCMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sun Labs remaining equity interest purchase</link:label>
    <link:label id="lab_asth_ApolloSunLabsManagementLLCMember_aeae2f3e-8ed9-4577-bb3d-ccb6a10d2cb2_terseLabel_en-US" xlink:label="lab_asth_ApolloSunLabsManagementLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Apollo-Sun Labs Management, LLC</link:label>
    <link:label id="lab_asth_ApolloSunLabsManagementLLCMember_label_en-US" xlink:label="lab_asth_ApolloSunLabsManagementLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Apollo-Sun Labs Management, LLC [Member]</link:label>
    <link:label id="lab_asth_ApolloSunLabsManagementLLCMember_documentation_en-US" xlink:label="lab_asth_ApolloSunLabsManagementLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Apollo-Sun Labs Management, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ApolloSunLabsManagementLLCMember" xlink:href="asth-20240331.xsd#asth_ApolloSunLabsManagementLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_ApolloSunLabsManagementLLCMember" xlink:to="lab_asth_ApolloSunLabsManagementLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_587e3e17-f98f-4a44-913a-230f1eb6ac34_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_a53dbaa6-4541-4f77-b803-7ffef3798941_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_d4ebbc10-d60c-44f6-898f-b1f6db559aee_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_ecf6ecf1-1ffa-49e4-810b-af5fe8df206a_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_SongPCMember_470d1447-f5a3-46d9-b700-1c0a396d61da_terseLabel_en-US" xlink:label="lab_asth_SongPCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Song PC</link:label>
    <link:label id="lab_asth_SongPCMember_label_en-US" xlink:label="lab_asth_SongPCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Song PC [Member]</link:label>
    <link:label id="lab_asth_SongPCMember_documentation_en-US" xlink:label="lab_asth_SongPCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Song PC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_SongPCMember" xlink:href="asth-20240331.xsd#asth_SongPCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_SongPCMember" xlink:to="lab_asth_SongPCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_fd31cc4a-8109-4eb3-bfb3-096fd2d565e5_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reportable Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_b1d1ac86-4a50-411d-add4-fc48f96eca1c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_23176d15-301c-4f01-90af-2410465bda82_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in affiliates</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_f72319f5-2f1d-4c84-9df9-21739f2cbdb6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value of the contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_f4c1db46-4ee6-4ea4-a2ad-fa6c830cd698_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosures of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsNetOfDividends_2aba0b8a-e3f5-49c0-b55a-bacc4798c4b1_terseLabel_en-US" xlink:label="lab_asth_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsNetOfDividends" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest in Allied Physicians of California, a Professional Medical Corporation ("APC")</link:label>
    <link:label id="lab_asth_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsNetOfDividends_label_en-US" xlink:label="lab_asth_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsNetOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests, Net of Dividends</link:label>
    <link:label id="lab_asth_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsNetOfDividends_documentation_en-US" xlink:label="lab_asth_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsNetOfDividends" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests, Net of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsNetOfDividends" xlink:href="asth-20240331.xsd#asth_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsNetOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsNetOfDividends" xlink:to="lab_asth_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsNetOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_d6b97ea0-c5cf-4fa1-8f1c-acb8b1db03be_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Temporary equity, carrying amount, beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_7048eea8-c2fc-4fdf-aac3-68104d0fa2ec_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Temporary equity, carrying amount, ending balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilities_3d94a9d6-e8b4-479e-b3d7-d945ecc29b17_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount due to affiliates</link:label>
    <link:label id="lab_us-gaap_OtherLiabilities_label_en-US" xlink:label="lab_us-gaap_OtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilities" xlink:to="lab_us-gaap_OtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_58a18198-5676-48e3-8387-6c249a267566_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a688c4a5-2be3-4938-a8a8-306f9b6f9134_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_10077e7d-111a-4bf2-8e74-3384e5b3b268_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_TemporaryEquityTransferOfCommonControlEntities_c93f7a43-d2bd-4dc8-bc34-7fa411c598db_terseLabel_en-US" xlink:label="lab_asth_TemporaryEquityTransferOfCommonControlEntities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary Equity, Transfer Of Common Control Entities</link:label>
    <link:label id="lab_asth_TemporaryEquityTransferOfCommonControlEntities_label_en-US" xlink:label="lab_asth_TemporaryEquityTransferOfCommonControlEntities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Transfer Of Common Control Entities</link:label>
    <link:label id="lab_asth_TemporaryEquityTransferOfCommonControlEntities_documentation_en-US" xlink:label="lab_asth_TemporaryEquityTransferOfCommonControlEntities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Transfer Of Common Control Entities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_TemporaryEquityTransferOfCommonControlEntities" xlink:href="asth-20240331.xsd#asth_TemporaryEquityTransferOfCommonControlEntities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_TemporaryEquityTransferOfCommonControlEntities" xlink:to="lab_asth_TemporaryEquityTransferOfCommonControlEntities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_57b63cf9-7ea5-45c2-b344-efa5dd091e21_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_42d3e297-d4ae-422d-89f0-e5dc8ff22a1c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining lease term, finance</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Finance Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_400362e4-ce05-4e7d-9c4a-ce061fd169b8_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_c4ee1dd8-59d6-47bf-ada7-f97e544e7d3f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d519740d-e589-4777-8432-9c3f6ce455ef_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_3f536516-a1e5-41ec-b6a0-3924c2afef3e_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_PrimeCommunityCareMember_c193fff5-1d77-433f-a4bf-f1b3bd534bc2_terseLabel_en-US" xlink:label="lab_asth_PrimeCommunityCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PCCCV contingent considerations</link:label>
    <link:label id="lab_asth_PrimeCommunityCareMember_label_en-US" xlink:label="lab_asth_PrimeCommunityCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prime Community Care [Member]</link:label>
    <link:label id="lab_asth_PrimeCommunityCareMember_documentation_en-US" xlink:label="lab_asth_PrimeCommunityCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prime Community Care</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PrimeCommunityCareMember" xlink:href="asth-20240331.xsd#asth_PrimeCommunityCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_PrimeCommunityCareMember" xlink:to="lab_asth_PrimeCommunityCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_1477b0f7-94d6-4231-94ce-d7b0bfac40e1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_FinanceLeaseCostsAbstract_eea42a65-ebaa-4baa-b3ec-851e66c677f4_terseLabel_en-US" xlink:label="lab_asth_FinanceLeaseCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease cost</link:label>
    <link:label id="lab_asth_FinanceLeaseCostsAbstract_label_en-US" xlink:label="lab_asth_FinanceLeaseCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease Costs [Abstract]</link:label>
    <link:label id="lab_asth_FinanceLeaseCostsAbstract_documentation_en-US" xlink:label="lab_asth_FinanceLeaseCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finance Lease Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_FinanceLeaseCostsAbstract" xlink:href="asth-20240331.xsd#asth_FinanceLeaseCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_FinanceLeaseCostsAbstract" xlink:to="lab_asth_FinanceLeaseCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_5e50a9ec-40d6-4b45-93cb-6b7438ad5f6b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period Three</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_3e3285c8-eafd-441c-9b26-78634ef4a784_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_96465c17-688c-43f8-8c09-4a1f005b4094_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the exercise of stock options and warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_b974f874-ff41-40d4-9e7d-53bc75af6663_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_79904928-09c2-4047-a453-6ce5d6357c89_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_0a008c63-1ec3-4d54-adf8-4dae3bdebb2f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_47a05afd-b9db-492a-8b1e-9999d9d818c5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_bc378631-4937-4ec3-a432-3977bcfe92e2_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsAxis_40f309a9-68c4-4635-aec1-af921a001a3f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis" xlink:to="lab_us-gaap_SubsegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_7f4aa2eb-b2f2-4e36-a321-189f88b548a9_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entities (VIEs)</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1a2deccc-4cb3-40e8-b0a8-73d4e1fafe6a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_FinanceLeaseLiabilityToBePaidAfterYearFour_21d269fe-dc25-43f4-9c40-4866d523d95b_terseLabel_en-US" xlink:label="lab_asth_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_asth_FinanceLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_asth_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_asth_FinanceLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_asth_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:href="asth-20240331.xsd#asth_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_asth_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_dba54e0b-e758-4ea8-9f68-efffda8e9448_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_a6e3597f-d28a-4515-ae4f-3b6e9bc2fd53_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total identified liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilities_26651b20-ff49-427e-91e6-3c7163d4c099_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount outstanding under agreement</link:label>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Credits and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCreditsAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:to="lab_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_3e5f8708-a13f-4a98-b325-557094fb54d5_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_ADSCMember_f949b1f1-3748-4035-9795-a0e25dc3b1e9_terseLabel_en-US" xlink:label="lab_asth_ADSCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ADSC contingent considerations</link:label>
    <link:label id="lab_asth_ADSCMember_label_en-US" xlink:label="lab_asth_ADSCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ADSC [Member]</link:label>
    <link:label id="lab_asth_ADSCMember_documentation_en-US" xlink:label="lab_asth_ADSCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ADSC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ADSCMember" xlink:href="asth-20240331.xsd#asth_ADSCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_ADSCMember" xlink:to="lab_asth_ADSCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvesteesMember_f97f16da-8720-4b90-9fd6-dcbfed51a28e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvesteesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherInvesteesMember_label_en-US" xlink:label="lab_us-gaap_OtherInvesteesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonconsolidated Investees, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvesteesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvesteesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvesteesMember" xlink:to="lab_us-gaap_OtherInvesteesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_bd83d080-7121-4189-a2a6-ae8fb0c7f57c_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_b46e9bb4-1815-4cd7-880a-d8926ae21399_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_027bf64d-f976-4b69-a280-6065c5fe160a_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_a7c3ab45-db7a-413b-ac4b-3b7436e2c36b_verboseLabel_en-US" xlink:label="lab_asth_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments in privately held entities</link:label>
    <link:label id="lab_asth_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_label_en-US" xlink:label="lab_asth_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment In Privately Held Entity That Does Not Report Net Asset Value</link:label>
    <link:label id="lab_asth_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_documentation_en-US" xlink:label="lab_asth_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total of Investment in privately held entity that does not report net asset value per share .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:href="asth-20240331.xsd#asth_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:to="lab_asth_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_529d2d12-001a-43e2-88d9-4dce9e9751da_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c8459371-c55d-49db-807c-df2a200f1ed1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_PrimeCommunityCareOfCentralValleyIncMember_6817cd4f-c527-4628-8faf-4f0d5ca510cf_terseLabel_en-US" xlink:label="lab_asth_PrimeCommunityCareOfCentralValleyIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prime Community Care of Central Valley, Inc</link:label>
    <link:label id="lab_asth_PrimeCommunityCareOfCentralValleyIncMember_label_en-US" xlink:label="lab_asth_PrimeCommunityCareOfCentralValleyIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prime Community Care of Central Valley, Inc [Member]</link:label>
    <link:label id="lab_asth_PrimeCommunityCareOfCentralValleyIncMember_documentation_en-US" xlink:label="lab_asth_PrimeCommunityCareOfCentralValleyIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prime Community Care of Central Valley, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PrimeCommunityCareOfCentralValleyIncMember" xlink:href="asth-20240331.xsd#asth_PrimeCommunityCareOfCentralValleyIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_PrimeCommunityCareOfCentralValleyIncMember" xlink:to="lab_asth_PrimeCommunityCareOfCentralValleyIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7cce7826-d3d0-495f-8fc3-8fd809cae21f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_LesseeOperatingLeaseTerminationPeriodIfApplicable_4bda3522-3e9e-42e3-97c6-b79f302e3d89_terseLabel_en-US" xlink:label="lab_asth_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, termination period, if applicable</link:label>
    <link:label id="lab_asth_LesseeOperatingLeaseTerminationPeriodIfApplicable_label_en-US" xlink:label="lab_asth_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Termination Period, If Applicable</link:label>
    <link:label id="lab_asth_LesseeOperatingLeaseTerminationPeriodIfApplicable_documentation_en-US" xlink:label="lab_asth_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Termination Period, If Applicable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:href="asth-20240331.xsd#asth_LesseeOperatingLeaseTerminationPeriodIfApplicable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:to="lab_asth_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_aa2c24f8-85ab-457b-9ad2-3cee63b30aa7_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common&#160;Stock&#160;Outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_cb0306af-1df4-4283-b991-9c3c3bd3c280_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_626c244f-49d0-4d06-b6ec-d0c5c2d1de7e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_71d07536-fedb-4e6f-b439-6391fe1187bd_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medical Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_b21b52b2-6997-4836-af5a-6d2b9b8f5359_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Carrying Amounts and Fair Values of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6101f0b6-d81a-40aa-9c2b-54f48d8fbc00_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Change in Fair Value of Level 3 Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_f5cab04a-c33e-4a95-b7da-05095acd9214_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Support to Nonconsolidated Legal Entity [Domain]</link:label>
    <link:label id="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_label_en-US" xlink:label="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Support to Nonconsolidated Legal Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:to="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfBankOverdrafts_13e43ec1-8ae3-4282-8c81-757ea3efa166_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfBankOverdrafts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from (repayments of) bank overdrafts</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfBankOverdrafts_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfBankOverdrafts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Repayments of) Bank Overdrafts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfBankOverdrafts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfBankOverdrafts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfBankOverdrafts" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfBankOverdrafts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_eb3d213f-7761-4b8f-90ac-2cfbc5a4d559_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2f695e3f-fdc9-47c0-9724-df2026f8dcb8_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Equity, beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6aa164a4-3078-4e0d-8a61-68e902d0c688_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Equity, ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_98882c2f-53d1-47be-b1d9-511c5d99f2cb_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_9f8c954a-94fb-4fd7-8971-ceb82941a907_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land, property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_29d52b36-ebaa-4aa2-9242-0e41ba451d77_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_739f610c-6ca6-4d00-ae81-73034ad5f973_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_6e11b1b3-7e3a-4502-8584-30f233af5b81_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_33fa83cf-8b71-49dd-9d77-cd7cb7aa8d03_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total medical care costs</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_be55ee8a-5823-4f98-9255-33f1c31b043d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_EquityMethodAndOtherEquityInvestmentsTextBlock_fc6830fb-a88a-4995-8e4f-a5be328c8f51_verboseLabel_en-US" xlink:label="lab_asth_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments in Other Entities</link:label>
    <link:label id="lab_asth_EquityMethodAndOtherEquityInvestmentsTextBlock_label_en-US" xlink:label="lab_asth_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method And Other Equity Investments [Text Block]</link:label>
    <link:label id="lab_asth_EquityMethodAndOtherEquityInvestmentsTextBlock_documentation_en-US" xlink:label="lab_asth_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method And Other Equity Investments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:href="asth-20240331.xsd#asth_EquityMethodAndOtherEquityInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:to="lab_asth_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_1271ff9e-87b2-44b3-9bf2-e31b8b8b180e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of finance lease obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_26400a30-09ab-4e1b-bac5-f00b51b2b037_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_459118cc-09c4-4d97-a8c5-9d0a02dd3e6e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_87a5f864-e384-4e0a-b1db-f4398c29fd18_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_e47cac67-0579-4063-ba0c-9d3141c55c21_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable_d3698d0b-37a3-43ce-9bad-0c8ce8f4d1cb_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fiduciary accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_a8fe54a9-ccd6-43e0-a7ed-03b6e9e1273d_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_80298e40-7c45-4763-8436-cd8bab963c3e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_84cd498f-1326-4f3f-917a-b10baf5bb12f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Current portion of debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_76938417-9691-4479-9ddc-ac8a4815ef8f_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCarePatientServiceMember_2f3d17df-1b93-425c-aa41-38e96dafdb0a_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCarePatientServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fee-for-service, net</link:label>
    <link:label id="lab_us-gaap_HealthCarePatientServiceMember_a464b57a-25bd-4c3c-9ec1-46c7c4141a8c_verboseLabel_en-US" xlink:label="lab_us-gaap_HealthCarePatientServiceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Third-Party</link:label>
    <link:label id="lab_us-gaap_HealthCarePatientServiceMember_label_en-US" xlink:label="lab_us-gaap_HealthCarePatientServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Health Care, Patient Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCarePatientServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCarePatientServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCarePatientServiceMember" xlink:to="lab_us-gaap_HealthCarePatientServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_HealthCareCapitationRevenueMember_706364bd-7f73-4740-b3d6-3aae7210cd5d_verboseLabel_en-US" xlink:label="lab_asth_HealthCareCapitationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Capitation, net</link:label>
    <link:label id="lab_asth_HealthCareCapitationRevenueMember_label_en-US" xlink:label="lab_asth_HealthCareCapitationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Health Care Capitation Revenue [Member]</link:label>
    <link:label id="lab_asth_HealthCareCapitationRevenueMember_documentation_en-US" xlink:label="lab_asth_HealthCareCapitationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ameh_HealthCareCapitationRevenueMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_HealthCareCapitationRevenueMember" xlink:href="asth-20240331.xsd#asth_HealthCareCapitationRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_HealthCareCapitationRevenueMember" xlink:to="lab_asth_HealthCareCapitationRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_SunnyVillageCareCenterMember_a5c09b77-f3eb-4d93-abf4-27494108bab3_terseLabel_en-US" xlink:label="lab_asth_SunnyVillageCareCenterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sunny Village Care Center</link:label>
    <link:label id="lab_asth_SunnyVillageCareCenterMember_label_en-US" xlink:label="lab_asth_SunnyVillageCareCenterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sunny Village Care Center [Member]</link:label>
    <link:label id="lab_asth_SunnyVillageCareCenterMember_documentation_en-US" xlink:label="lab_asth_SunnyVillageCareCenterMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sunny Village Care Center</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_SunnyVillageCareCenterMember" xlink:href="asth-20240331.xsd#asth_SunnyVillageCareCenterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_SunnyVillageCareCenterMember" xlink:to="lab_asth_SunnyVillageCareCenterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_0419a566-15c1-483a-b9f7-09606b6decca_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_439c0d8c-5c1a-4ddd-92f6-f1d0e6a59cd8_terseLabel_en-US" xlink:label="lab_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_documentation_en-US" xlink:label="lab_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:href="asth-20240331.xsd#asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_e34364b6-3a1f-4d83-96ae-7f1559d75412_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Earnings per share &#8211; basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_4ac87343-6cd8-4d38-aa18-7281ab9ebdf8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivableNoncurrent_6520fbcc-2cb5-4d05-b8f8-b141e98be554_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivableNoncurrent_1ee3315b-bbe9-4a04-a998-d40e023b0c7b_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income taxes receivable, non-current</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivableNoncurrent_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Receivable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivableNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesReceivableNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivableNoncurrent" xlink:to="lab_us-gaap_IncomeTaxesReceivableNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_b175bb4f-f293-4954-9def-776c589e9884_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued in business combination</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_46497863-a0c8-479a-9d6c-04dc4cbbefa5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_ReceivablesReceivablesRelatedPartiesOtherReceivablesAndLoanReceivablesPolicyTextBlock_ced311b8-e4e4-47e5-9079-cc21aa43b0ed_verboseLabel_en-US" xlink:label="lab_asth_ReceivablesReceivablesRelatedPartiesOtherReceivablesAndLoanReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Receivables, Receivables &#8211; Related Parties, Other Receivables and Loan Receivables</link:label>
    <link:label id="lab_asth_ReceivablesReceivablesRelatedPartiesOtherReceivablesAndLoanReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_asth_ReceivablesReceivablesRelatedPartiesOtherReceivablesAndLoanReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Receivables &#8211; Related Parties, Other Receivables And Loan Receivables [Policy Text Block]</link:label>
    <link:label id="lab_asth_ReceivablesReceivablesRelatedPartiesOtherReceivablesAndLoanReceivablesPolicyTextBlock_documentation_en-US" xlink:label="lab_asth_ReceivablesReceivablesRelatedPartiesOtherReceivablesAndLoanReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The Receivables and receivables from related parties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ReceivablesReceivablesRelatedPartiesOtherReceivablesAndLoanReceivablesPolicyTextBlock" xlink:href="asth-20240331.xsd#asth_ReceivablesReceivablesRelatedPartiesOtherReceivablesAndLoanReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_ReceivablesReceivablesRelatedPartiesOtherReceivablesAndLoanReceivablesPolicyTextBlock" xlink:to="lab_asth_ReceivablesReceivablesRelatedPartiesOtherReceivablesAndLoanReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_f7be265a-402d-43c9-9814-105a18a6e5d1_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_f059764f-7ee6-49a5-9725-90fd184422bb_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_80430c4f-e25a-4703-bc55-c323d1b0d515_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Drawdowns</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_14996e0b-0113-4c6f-ad7f-d78abd5a6f73_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_783bce94-31ab-4391-8a51-052c9f9bd0c5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:to="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareOtherMember_4770aafd-b5c0-4438-99fb-064564f17d15_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk pool settlements and incentives</link:label>
    <link:label id="lab_us-gaap_HealthCareOtherMember_label_en-US" xlink:label="lab_us-gaap_HealthCareOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Health Care, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOtherMember" xlink:to="lab_us-gaap_HealthCareOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_PreferredBankMember_741d57f3-6a20-4708-b379-231258676576_terseLabel_en-US" xlink:label="lab_asth_PreferredBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Bank</link:label>
    <link:label id="lab_asth_PreferredBankMember_label_en-US" xlink:label="lab_asth_PreferredBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Bank [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PreferredBankMember" xlink:href="asth-20240331.xsd#asth_PreferredBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_PreferredBankMember" xlink:to="lab_asth_PreferredBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f56e8e4d-12a0-448d-a0fe-e8bee6cb63bd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_CareEnablementMember_bbb41849-0d64-4c18-a9ff-64808d410b4a_terseLabel_en-US" xlink:label="lab_asth_CareEnablementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Care Enablement</link:label>
    <link:label id="lab_asth_CareEnablementMember_label_en-US" xlink:label="lab_asth_CareEnablementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Care Enablement [Member]</link:label>
    <link:label id="lab_asth_CareEnablementMember_documentation_en-US" xlink:label="lab_asth_CareEnablementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Care Enablement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CareEnablementMember" xlink:href="asth-20240331.xsd#asth_CareEnablementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_CareEnablementMember" xlink:to="lab_asth_CareEnablementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_440deaaa-a129-4e69-965e-f311861ae47f_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Support to Nonconsolidated Legal Entity [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_label_en-US" xlink:label="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Support to Nonconsolidated Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:to="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_AccountsReceivableAndNetRevenueTable_347e9591-8959-4a41-8388-86c29b1b88a3_terseLabel_en-US" xlink:label="lab_asth_AccountsReceivableAndNetRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable And Net Revenue [Table]</link:label>
    <link:label id="lab_asth_AccountsReceivableAndNetRevenueTable_label_en-US" xlink:label="lab_asth_AccountsReceivableAndNetRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable And Net Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AccountsReceivableAndNetRevenueTable" xlink:href="asth-20240331.xsd#asth_AccountsReceivableAndNetRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_AccountsReceivableAndNetRevenueTable" xlink:to="lab_asth_AccountsReceivableAndNetRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_de0ed639-8844-4c7a-a31a-56cb64bcf251_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for medical care costs related to claims incurred:</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_417daff0-bcf2-4b4b-8315-4e90cc9e88db_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_c7d59d58-2892-4780-be19-2e1bfd03fc45_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Contributions to Revenue and Receivables by Payor</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_71b34cba-20c6-460f-8bfc-36dd922204e9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_974ad8fe-873a-45d1-94e5-b9f574d79377_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableMember_0a6404af-1005-4994-8060-63218a89a6ac_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Secured Promissory Note</link:label>
    <link:label id="lab_us-gaap_NotesReceivableMember_label_en-US" xlink:label="lab_us-gaap_NotesReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableMember" xlink:to="lab_us-gaap_NotesReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_CAIPAMSOLLCMember_dbc6ac1b-5f9d-45bd-988d-5844e9884f68_terseLabel_en-US" xlink:label="lab_asth_CAIPAMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CAIPA MSO, LLC</link:label>
    <link:label id="lab_asth_CAIPAMSOLLCMember_label_en-US" xlink:label="lab_asth_CAIPAMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CAIPA MSO, LLC [Member]</link:label>
    <link:label id="lab_asth_CAIPAMSOLLCMember_documentation_en-US" xlink:label="lab_asth_CAIPAMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CAIPA MSO, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CAIPAMSOLLCMember" xlink:href="asth-20240331.xsd#asth_CAIPAMSOLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_CAIPAMSOLLCMember" xlink:to="lab_asth_CAIPAMSOLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_MemberRelationshipsMember_13fd10de-20f9-4eed-8703-c2aa25167f3e_terseLabel_en-US" xlink:label="lab_asth_MemberRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Member relationships</link:label>
    <link:label id="lab_asth_MemberRelationshipsMember_label_en-US" xlink:label="lab_asth_MemberRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Member Relationships [Member]</link:label>
    <link:label id="lab_asth_MemberRelationshipsMember_documentation_en-US" xlink:label="lab_asth_MemberRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Member Relationships</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_MemberRelationshipsMember" xlink:href="asth-20240331.xsd#asth_MemberRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_MemberRelationshipsMember" xlink:to="lab_asth_MemberRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDepositLiabilities_2402ab9e-ba60-4d66-96ee-1e76d45251d5_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDepositLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due to related parties</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDepositLiabilities_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDepositLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Deposit Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDepositLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDepositLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDepositLiabilities" xlink:to="lab_us-gaap_RelatedPartyDepositLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_DMGAndSunLabsMember_cb844ad5-976c-4c7a-b761-b9441a8b5b89_terseLabel_en-US" xlink:label="lab_asth_DMGAndSunLabsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DMG And Sun Labs</link:label>
    <link:label id="lab_asth_DMGAndSunLabsMember_label_en-US" xlink:label="lab_asth_DMGAndSunLabsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DMG And Sun Labs [Member]</link:label>
    <link:label id="lab_asth_DMGAndSunLabsMember_documentation_en-US" xlink:label="lab_asth_DMGAndSunLabsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">DMG And Sun Labs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_DMGAndSunLabsMember" xlink:href="asth-20240331.xsd#asth_DMGAndSunLabsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_DMGAndSunLabsMember" xlink:to="lab_asth_DMGAndSunLabsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_563c455c-b305-45d6-b31d-11253c201b0d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate collar</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_SeniorSecuredPromissoryNoteMember_767fd99a-acca-4095-866c-4a08c8aa28b1_terseLabel_en-US" xlink:label="lab_asth_SeniorSecuredPromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Secured Promissory Note</link:label>
    <link:label id="lab_asth_SeniorSecuredPromissoryNoteMember_label_en-US" xlink:label="lab_asth_SeniorSecuredPromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Secured Promissory Note [Member]</link:label>
    <link:label id="lab_asth_SeniorSecuredPromissoryNoteMember_documentation_en-US" xlink:label="lab_asth_SeniorSecuredPromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Secured Promissory Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_SeniorSecuredPromissoryNoteMember" xlink:href="asth-20240331.xsd#asth_SeniorSecuredPromissoryNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_SeniorSecuredPromissoryNoteMember" xlink:to="lab_asth_SeniorSecuredPromissoryNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_226ef27b-4c0b-4f41-ac05-4911a86db09b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued for vesting of restricted stock awards</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_25f6bc42-f536-41b2-8ceb-5b02be6b5ddf_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_RelatedPartyExpensesPayable_e57d2683-8ab1-46e1-af8b-e3fc10f35355_terseLabel_en-US" xlink:label="lab_asth_RelatedPartyExpensesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses payable</link:label>
    <link:label id="lab_asth_RelatedPartyExpensesPayable_label_en-US" xlink:label="lab_asth_RelatedPartyExpensesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party, Expenses Payable</link:label>
    <link:label id="lab_asth_RelatedPartyExpensesPayable_documentation_en-US" xlink:label="lab_asth_RelatedPartyExpensesPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party, Expenses Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_RelatedPartyExpensesPayable" xlink:href="asth-20240331.xsd#asth_RelatedPartyExpensesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_RelatedPartyExpensesPayable" xlink:to="lab_asth_RelatedPartyExpensesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_6b89730f-2e1b-4396-a594-1389ab2de0ec_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_51333a64-6024-4157-9d17-149e4837c2e4_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_f4cbfef9-4fe9-435b-9da4-bbe2d5557e32_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired (see Note 3)</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0c518bc3-a58c-4098-8d16-d1c199740d8e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_945f56d9-1988-4f0e-a39f-d68062b02b9e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity interest issued, number of shares (shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e626ee6f-e3d7-4a9e-be13-29d7ae8b3121_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3c5c40a6-a22e-4ee0-8584-327bca0f13e7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_af089524-7301-45e6-8f67-77ce0c780e53_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period One</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_b17990c5-df07-4ecc-a658-81c60eb00c61_terseLabel_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_label_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherSegmentsMember" xlink:to="lab_us-gaap_AllOtherSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_874ca943-6366-4002-b6de-951ae5197761_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from repayment of loans receivable &#8211; related parties</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Collection of Long-Term Loans to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:to="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_CompanyAndAPCMember_4bd1b3ff-24e4-4a82-98ae-669182d69597_terseLabel_en-US" xlink:label="lab_asth_CompanyAndAPCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company And APC</link:label>
    <link:label id="lab_asth_CompanyAndAPCMember_label_en-US" xlink:label="lab_asth_CompanyAndAPCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company And APC [Member]</link:label>
    <link:label id="lab_asth_CompanyAndAPCMember_documentation_en-US" xlink:label="lab_asth_CompanyAndAPCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Company And APC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CompanyAndAPCMember" xlink:href="asth-20240331.xsd#asth_CompanyAndAPCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_CompanyAndAPCMember" xlink:to="lab_asth_CompanyAndAPCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_7eb1dbe7-2afc-4008-b532-186b1540759e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized losses recognized on equity securities held at end of period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_e6bcca73-223f-4537-b06d-6c1004e85c83_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of shares for business acquisition (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_0c6c87dd-da9b-47a5-81a1-df7fcaa32057_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_2a6e4542-ad29-45a2-8b50-803bbfd66da2_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_388fc490-2a55-40c6-8b54-fea32e65720d_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_66b074bb-d156-4d27-8c5d-eef153459978_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finance lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_00c27a16-fd7e-4be1-9d9f-9fff7ddc8ba8_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_CashPaidForLeaseLiabilitiesAbstractAbstract_1afb1ef2-3c9b-4cf7-8b8b-8bc79319b20a_verboseLabel_en-US" xlink:label="lab_asth_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_asth_CashPaidForLeaseLiabilitiesAbstractAbstract_label_en-US" xlink:label="lab_asth_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Paid For Lease Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:href="asth-20240331.xsd#asth_CashPaidForLeaseLiabilitiesAbstractAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:to="lab_asth_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_NetworkMedicalManagementMember_db302df4-f0c7-42d5-9bce-645856f8b50a_terseLabel_en-US" xlink:label="lab_asth_NetworkMedicalManagementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NMM</link:label>
    <link:label id="lab_asth_NetworkMedicalManagementMember_label_en-US" xlink:label="lab_asth_NetworkMedicalManagementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Network Medical Management [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_NetworkMedicalManagementMember" xlink:href="asth-20240331.xsd#asth_NetworkMedicalManagementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_NetworkMedicalManagementMember" xlink:to="lab_asth_NetworkMedicalManagementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_9f2c8342-702f-4edd-bde2-62d56fc7ec83_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_AdvancedDiagnosticAndSurgicalCenterIncMember_dd8208c1-3c3b-46af-ad13-267102497b66_terseLabel_en-US" xlink:label="lab_asth_AdvancedDiagnosticAndSurgicalCenterIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advanced Diagnostic and Surgical Center, Inc</link:label>
    <link:label id="lab_asth_AdvancedDiagnosticAndSurgicalCenterIncMember_label_en-US" xlink:label="lab_asth_AdvancedDiagnosticAndSurgicalCenterIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Diagnostic and Surgical Center, Inc [Member]</link:label>
    <link:label id="lab_asth_AdvancedDiagnosticAndSurgicalCenterIncMember_documentation_en-US" xlink:label="lab_asth_AdvancedDiagnosticAndSurgicalCenterIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Advanced Diagnostic and Surgical Center, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AdvancedDiagnosticAndSurgicalCenterIncMember" xlink:href="asth-20240331.xsd#asth_AdvancedDiagnosticAndSurgicalCenterIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_AdvancedDiagnosticAndSurgicalCenterIncMember" xlink:to="lab_asth_AdvancedDiagnosticAndSurgicalCenterIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_2e487659-9b86-47a3-a023-6a9e8363eef3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_ArroyoVistaMember_4bb0ab24-232f-4cfb-bbf0-2f0042d9abcd_terseLabel_en-US" xlink:label="lab_asth_ArroyoVistaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arroyo Vista</link:label>
    <link:label id="lab_asth_ArroyoVistaMember_label_en-US" xlink:label="lab_asth_ArroyoVistaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arroyo Vista [Member]</link:label>
    <link:label id="lab_asth_ArroyoVistaMember_documentation_en-US" xlink:label="lab_asth_ArroyoVistaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Arroyo Vista</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ArroyoVistaMember" xlink:href="asth-20240331.xsd#asth_ArroyoVistaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_ArroyoVistaMember" xlink:to="lab_asth_ArroyoVistaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_6d76fb53-41fb-4962-9516-15f69c572718_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income per share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_e8c5ce6a-738c-4bce-8a42-c17865a03c3c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets recorded under finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_AdvancedHealthManagementSystemsLPMember_aee00de4-c11d-499c-84e7-e877b9be9b4e_terseLabel_en-US" xlink:label="lab_asth_AdvancedHealthManagementSystemsLPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AHMS</link:label>
    <link:label id="lab_asth_AdvancedHealthManagementSystemsLPMember_label_en-US" xlink:label="lab_asth_AdvancedHealthManagementSystemsLPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Health Management Systems, L.P. [Member]</link:label>
    <link:label id="lab_asth_AdvancedHealthManagementSystemsLPMember_documentation_en-US" xlink:label="lab_asth_AdvancedHealthManagementSystemsLPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Advanced Health Management Systems, L.P.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AdvancedHealthManagementSystemsLPMember" xlink:href="asth-20240331.xsd#asth_AdvancedHealthManagementSystemsLPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_AdvancedHealthManagementSystemsLPMember" xlink:to="lab_asth_AdvancedHealthManagementSystemsLPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_NoncashLeaseExpense_d1c00f23-ede2-489b-8bb7-f5448257cf94_verboseLabel_en-US" xlink:label="lab_asth_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_asth_NoncashLeaseExpense_label_en-US" xlink:label="lab_asth_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Lease Expense</link:label>
    <link:label id="lab_asth_NoncashLeaseExpense_documentation_en-US" xlink:label="lab_asth_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncash Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_NoncashLeaseExpense" xlink:href="asth-20240331.xsd#asth_NoncashLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_NoncashLeaseExpense" xlink:to="lab_asth_NoncashLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_e7177302-1cb3-4763-872c-e6c1cae04784_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_UnrealizedGainLossFromInvestmentInEquitySecurities_f31f6efb-9ec1-4276-8e1f-eee005e656c0_negatedLabel_en-US" xlink:label="lab_asth_UnrealizedGainLossFromInvestmentInEquitySecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized (gain) loss on investments</link:label>
    <link:label id="lab_asth_UnrealizedGainLossFromInvestmentInEquitySecurities_label_en-US" xlink:label="lab_asth_UnrealizedGainLossFromInvestmentInEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized (Gain) Loss from Investment in Equity Securities</link:label>
    <link:label id="lab_asth_UnrealizedGainLossFromInvestmentInEquitySecurities_documentation_en-US" xlink:label="lab_asth_UnrealizedGainLossFromInvestmentInEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrealized (Gain) Loss from Investment in Equity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_UnrealizedGainLossFromInvestmentInEquitySecurities" xlink:href="asth-20240331.xsd#asth_UnrealizedGainLossFromInvestmentInEquitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_UnrealizedGainLossFromInvestmentInEquitySecurities" xlink:to="lab_asth_UnrealizedGainLossFromInvestmentInEquitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_e153d31c-47be-4902-ae10-7ee32d9c8b00_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_db9c8b2d-cd97-40ce-9e22-57aed9c466ae_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_9e70b336-3dd1-4100-ab72-2a54037fb19a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_9c547adb-64f2-45a0-8669-615d665ad41a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_DebtInstrumentCovenantLeverageRatioIncrementalChange_7c401106-acdd-4cc5-abb9-ae2fe2714476_terseLabel_en-US" xlink:label="lab_asth_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated leverage ratio, annual decrease</link:label>
    <link:label id="lab_asth_DebtInstrumentCovenantLeverageRatioIncrementalChange_label_en-US" xlink:label="lab_asth_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Incremental Change</link:label>
    <link:label id="lab_asth_DebtInstrumentCovenantLeverageRatioIncrementalChange_documentation_en-US" xlink:label="lab_asth_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Incremental Change</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:href="asth-20240331.xsd#asth_DebtInstrumentCovenantLeverageRatioIncrementalChange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:to="lab_asth_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_5659dd06-b6b7-4074-909b-594199af947d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss on interest rate swaps</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_EarningsPerShareTable_e729442a-4003-4fe0-9751-3e5907ff3386_terseLabel_en-US" xlink:label="lab_asth_EarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Table]</link:label>
    <link:label id="lab_asth_EarningsPerShareTable_label_en-US" xlink:label="lab_asth_EarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Table]</link:label>
    <link:label id="lab_asth_EarningsPerShareTable_documentation_en-US" xlink:label="lab_asth_EarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_EarningsPerShareTable" xlink:href="asth-20240331.xsd#asth_EarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_EarningsPerShareTable" xlink:to="lab_asth_EarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_c3c5be2f-189f-499f-b639-4ff2cb5bc4de_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_ddc5f362-adf3-4318-b1f7-a2e3d40c0032_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6e8ff8a5-565d-4086-a4c4-4aab98f17ba1_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments for business acquisition, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_AlliedPacificHoldingsInvestmentManagementLLCMember_e083b2e6-6560-4c14-81c9-a167a0de758d_terseLabel_en-US" xlink:label="lab_asth_AlliedPacificHoldingsInvestmentManagementLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allied Pacific Holdings Investment Management, LLC</link:label>
    <link:label id="lab_asth_AlliedPacificHoldingsInvestmentManagementLLCMember_label_en-US" xlink:label="lab_asth_AlliedPacificHoldingsInvestmentManagementLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allied Pacific Holdings Investment Management, LLC [Member]</link:label>
    <link:label id="lab_asth_AlliedPacificHoldingsInvestmentManagementLLCMember_documentation_en-US" xlink:label="lab_asth_AlliedPacificHoldingsInvestmentManagementLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Allied Pacific Holdings Investment Management, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AlliedPacificHoldingsInvestmentManagementLLCMember" xlink:href="asth-20240331.xsd#asth_AlliedPacificHoldingsInvestmentManagementLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_AlliedPacificHoldingsInvestmentManagementLLCMember" xlink:to="lab_asth_AlliedPacificHoldingsInvestmentManagementLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_19f0dbe8-a840-4f39-aa83-75a43211a84c_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_f463071c-891e-4f54-935c-0048b3b871f4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of treasury shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_0a4f6b68-8ddf-40e3-9c1b-ec2f919f3341_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock repurchased (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e201c91f-f71c-4ee3-8b17-75a16294ad6f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_LesseeFinanceLeaseTerminationPeriodIfApplicable_92ba8d55-409a-4923-bc79-94258b6d5665_terseLabel_en-US" xlink:label="lab_asth_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease, termination period, if applicable</link:label>
    <link:label id="lab_asth_LesseeFinanceLeaseTerminationPeriodIfApplicable_label_en-US" xlink:label="lab_asth_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Finance Lease, Termination Period, If Applicable</link:label>
    <link:label id="lab_asth_LesseeFinanceLeaseTerminationPeriodIfApplicable_documentation_en-US" xlink:label="lab_asth_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Finance Lease, Termination Period, If Applicable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:href="asth-20240331.xsd#asth_LesseeFinanceLeaseTerminationPeriodIfApplicable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:to="lab_asth_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_dab7952e-4eb4-4fbf-a25f-594af75de356_verboseLabel_en-US" xlink:label="lab_asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Remaining equity interest purchase</link:label>
    <link:label id="lab_asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_304c4cdb-fe6f-462f-aba6-71d08ec86688_terseLabel_en-US" xlink:label="lab_asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity interest purchase obligation, noncurrent</link:label>
    <link:label id="lab_asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_label_en-US" xlink:label="lab_asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Equity Interest Purchase Obligation, Noncurrent</link:label>
    <link:label id="lab_asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_documentation_en-US" xlink:label="lab_asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Equity Interest Purchase Obligation, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" xlink:href="asth-20240331.xsd#asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" xlink:to="lab_asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_d90b0717-a571-4039-a9ff-4cc65067709d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_1afc0138-314d-4682-b98c-1dafdb45b462_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in&#160; Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_c2ad6c1d-790f-4d4d-94a5-614368dd475a_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains recognized on equity securities sold</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_36b198b5-3c10-4a97-94bc-0425c68e8ff0_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_f62edb5b-5395-4c9d-8f10-4a0750eea5c3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_bf3c9c59-3202-4f29-b645-7a549c439528_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_45d68fa5-e086-4929-a16f-6a0c9ac2f2b2_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Allocation of Net Income</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesMember_eede41f1-856b-46d4-8acc-7081aaf14060_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesMember" xlink:to="lab_us-gaap_OtherLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_df2a2e60-6545-4068-8797-6e41f569c0f9_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_adc24436-7978-4677-8b3b-274fc70e6828_verboseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_e22b58c7-ce1d-4eb4-bd25-5d611af08119_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt issuance cost</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_DerivativeCeilingInterestRate_82583a8a-b0ab-42ce-b5c2-f1080439195b_terseLabel_en-US" xlink:label="lab_asth_DerivativeCeilingInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, ceiling interest rate</link:label>
    <link:label id="lab_asth_DerivativeCeilingInterestRate_label_en-US" xlink:label="lab_asth_DerivativeCeilingInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Ceiling Interest Rate</link:label>
    <link:label id="lab_asth_DerivativeCeilingInterestRate_documentation_en-US" xlink:label="lab_asth_DerivativeCeilingInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Ceiling Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_DerivativeCeilingInterestRate" xlink:href="asth-20240331.xsd#asth_DerivativeCeilingInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_DerivativeCeilingInterestRate" xlink:to="lab_asth_DerivativeCeilingInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_f9266c5a-2163-4612-8e30-0cd6f8d74321_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_52560edb-e99a-4892-903c-f2d08bbd48b5_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_FirstCommonwealthPropertyLLCMember_0257e362-503c-4bb8-b676-c471683620f1_terseLabel_en-US" xlink:label="lab_asth_FirstCommonwealthPropertyLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">First Commonwealth Property, LLC</link:label>
    <link:label id="lab_asth_FirstCommonwealthPropertyLLCMember_label_en-US" xlink:label="lab_asth_FirstCommonwealthPropertyLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">First Commonwealth Property, LLC [Member]</link:label>
    <link:label id="lab_asth_FirstCommonwealthPropertyLLCMember_documentation_en-US" xlink:label="lab_asth_FirstCommonwealthPropertyLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">First Commonwealth Property, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_FirstCommonwealthPropertyLLCMember" xlink:href="asth-20240331.xsd#asth_FirstCommonwealthPropertyLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_FirstCommonwealthPropertyLLCMember" xlink:to="lab_asth_FirstCommonwealthPropertyLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_55d4dd13-3c2e-4485-acd6-692219c294a0_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_a58ef3f3-9deb-4143-a45c-4a14e1bcf06b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of lease expense</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_3f05509e-2a2d-4223-ad1b-495c5beddbfc_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_31e9a224-f611-4fff-8c2a-27e9da0075c9_verboseLabel_en-US" xlink:label="lab_asth_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares issued for exercise of options and warrants (in shares)</link:label>
    <link:label id="lab_asth_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_label_en-US" xlink:label="lab_asth_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During the Period Shares of Exercise of Option and Warrants</link:label>
    <link:label id="lab_asth_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_documentation_en-US" xlink:label="lab_asth_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">It represents number of share issued exercise of option and warrants during the period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:href="asth-20240331.xsd#asth_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:to="lab_asth_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7d4f2e40-ea0c-41a1-a4ba-6ac286b2435f_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_54161e3f-de83-41d6-9bc5-4d46b7ba9f84_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_be3f2ab2-4d74-4309-970f-27409427f6af_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease option to extend (up to)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_cd9cc25f-a011-4677-a607-9533c7cf5fa5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_33885394-6892-4540-a005-a5590658a45a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_c5cd34e9-3d6c-475c-a936-989e361933d4_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_12337d20-cb2f-45ca-9f85-c72d05b65c6a_netLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_65671380-ae20-4c22-834b-71b772d89dad_verboseLabel_en-US" xlink:label="lab_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_label_en-US" xlink:label="lab_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_documentation_en-US" xlink:label="lab_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:href="asth-20240331.xsd#asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:to="lab_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_47276bb5-7ee1-4c99-8a71-22d7a4176853_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_3d6895f8-7c87-4a9b-bb5a-2d2134907655_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_aae107cb-8644-4ffd-b296-c6e4132115a7_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_7050aab4-fdd8-467f-8152-5887fc98f319_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_14511df3-26d7-4fe8-afba-ca0c685b9a97_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_2a62a743-09cd-4b47-a30f-d37b5dd1c074_terseLabel_en-US" xlink:label="lab_asth_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_asth_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_label_en-US" xlink:label="lab_asth_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation Of Cash Cash Equivalents And Restricted Cash [Abstract]</link:label>
    <link:label id="lab_asth_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_documentation_en-US" xlink:label="lab_asth_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reconciliation Of Cash Cash Equivalents And Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:href="asth-20240331.xsd#asth_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="lab_asth_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_PerformanceBasedRestrictedStockMember_ff9627a2-392c-4819-b8b4-bbe062f1636b_terseLabel_en-US" xlink:label="lab_asth_PerformanceBasedRestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Based Restricted Stock</link:label>
    <link:label id="lab_asth_PerformanceBasedRestrictedStockMember_label_en-US" xlink:label="lab_asth_PerformanceBasedRestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Based Restricted Stock [Member]</link:label>
    <link:label id="lab_asth_PerformanceBasedRestrictedStockMember_documentation_en-US" xlink:label="lab_asth_PerformanceBasedRestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Based Restricted Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PerformanceBasedRestrictedStockMember" xlink:href="asth-20240331.xsd#asth_PerformanceBasedRestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_PerformanceBasedRestrictedStockMember" xlink:to="lab_asth_PerformanceBasedRestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_DrawOnLetterOfCreditThroughRevolverLoan_60e883b0-e599-42b4-b806-32be9460eb6e_terseLabel_en-US" xlink:label="lab_asth_DrawOnLetterOfCreditThroughRevolverLoan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Draw on letter of credit through Revolver Loan</link:label>
    <link:label id="lab_asth_DrawOnLetterOfCreditThroughRevolverLoan_label_en-US" xlink:label="lab_asth_DrawOnLetterOfCreditThroughRevolverLoan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Draw On Letter Of Credit Through Revolver Loan</link:label>
    <link:label id="lab_asth_DrawOnLetterOfCreditThroughRevolverLoan_documentation_en-US" xlink:label="lab_asth_DrawOnLetterOfCreditThroughRevolverLoan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Draw On Letter Of Credit Through Revolver Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_DrawOnLetterOfCreditThroughRevolverLoan" xlink:href="asth-20240331.xsd#asth_DrawOnLetterOfCreditThroughRevolverLoan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_DrawOnLetterOfCreditThroughRevolverLoan" xlink:to="lab_asth_DrawOnLetterOfCreditThroughRevolverLoan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_d36751bb-ce30-4ddc-be2d-4383a633bf46_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_EquityMethodInvestmentsRollForward_05c0a613-4d7c-44a8-8c40-632f6ea63da3_terseLabel_en-US" xlink:label="lab_asth_EquityMethodInvestmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investments [Roll Forward]</link:label>
    <link:label id="lab_asth_EquityMethodInvestmentsRollForward_label_en-US" xlink:label="lab_asth_EquityMethodInvestmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments [Roll Forward]</link:label>
    <link:label id="lab_asth_EquityMethodInvestmentsRollForward_documentation_en-US" xlink:label="lab_asth_EquityMethodInvestmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investments [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_EquityMethodInvestmentsRollForward" xlink:href="asth-20240331.xsd#asth_EquityMethodInvestmentsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_EquityMethodInvestmentsRollForward" xlink:to="lab_asth_EquityMethodInvestmentsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFloorInterestRate_dde2631c-2959-4ad8-9e1a-3fdaa0798995_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFloorInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, floor interest rate</link:label>
    <link:label id="lab_us-gaap_DerivativeFloorInterestRate_label_en-US" xlink:label="lab_us-gaap_DerivativeFloorInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Floor Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFloorInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFloorInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFloorInterestRate" xlink:to="lab_us-gaap_DerivativeFloorInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_4c454b4b-31c5-4be8-961d-038c229e0bc2_totalLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_4e125b7a-785e-4db7-8ea5-5475e22bc8bc_netLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Loan from company</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_8d4d1738-0464-4beb-8daf-298b3f74ad60_verboseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amount outstanding</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_8d28275b-c146-4c11-969f-865d541b5509_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Drew down on revolver loan</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_EquityMethodInvestmentAdditionalInvestment_729fcb22-9ba6-4f2e-b3fe-211e555ebc8b_terseLabel_en-US" xlink:label="lab_asth_EquityMethodInvestmentAdditionalInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Investment</link:label>
    <link:label id="lab_asth_EquityMethodInvestmentAdditionalInvestment_label_en-US" xlink:label="lab_asth_EquityMethodInvestmentAdditionalInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Additional Investment</link:label>
    <link:label id="lab_asth_EquityMethodInvestmentAdditionalInvestment_documentation_en-US" xlink:label="lab_asth_EquityMethodInvestmentAdditionalInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Additional Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_EquityMethodInvestmentAdditionalInvestment" xlink:href="asth-20240331.xsd#asth_EquityMethodInvestmentAdditionalInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_EquityMethodInvestmentAdditionalInvestment" xlink:to="lab_asth_EquityMethodInvestmentAdditionalInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_56b57d20-b619-4ff8-ae3e-94bb685affa7_terseLabel_en-US" xlink:label="lab_asth_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_asth_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_label_en-US" xlink:label="lab_asth_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity</link:label>
    <link:label id="lab_asth_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_documentation_en-US" xlink:label="lab_asth_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:href="asth-20240331.xsd#asth_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:to="lab_asth_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bd408787-72d7-44be-a862-c66f5789a255_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_CreditAgreementMember_61937f08-4981-4698-b51e-85da5631c6d2_terseLabel_en-US" xlink:label="lab_asth_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Agreement</link:label>
    <link:label id="lab_asth_CreditAgreementMember_label_en-US" xlink:label="lab_asth_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:label id="lab_asth_CreditAgreementMember_documentation_en-US" xlink:label="lab_asth_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CreditAgreementMember" xlink:href="asth-20240331.xsd#asth_CreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_CreditAgreementMember" xlink:to="lab_asth_CreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_1cd0b04d-84a4-4ca6-80d6-cd383adcd1fd_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_d7eca7d2-67df-40bb-b602-6a5a4b015fea_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8e290cc8-27c3-4c59-b37b-e903f6eafb69_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of existing Level 3 liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_f4d25375-3ec6-49d3-9d59-fd261704145a_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0378f488-7475-4193-ac0e-047fb4801f0f_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_e71f1eb7-e249-4766-b9f0-6eb339a8e7e4_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent_2f909aa9-9efe-40bf-a832-7b4942840746_terseLabel_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loans receivable, non-current</link:label>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:to="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_b333f1b8-5782-4d62-9cbf-31b5d551b067_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_4baefb11-bbb7-4aae-ae2b-cec47ccec224_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_86d1b91c-fd90-4254-9155-1962d3ec1a59_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining lease term, operating</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_2f8b553c-b2ce-4837-830d-bff743217243_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility, Bank Loans, and Lines of Credit</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_38053dbf-9a24-4c89-b70b-42e0dea61953_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_StockholdersEquityTransferOfCommonControlEntities_03a4ef78-b782-4ef1-b1fd-cc00529afb75_terseLabel_en-US" xlink:label="lab_asth_StockholdersEquityTransferOfCommonControlEntities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfer of common control entities</link:label>
    <link:label id="lab_asth_StockholdersEquityTransferOfCommonControlEntities_label_en-US" xlink:label="lab_asth_StockholdersEquityTransferOfCommonControlEntities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Transfer of Common Control Entities</link:label>
    <link:label id="lab_asth_StockholdersEquityTransferOfCommonControlEntities_documentation_en-US" xlink:label="lab_asth_StockholdersEquityTransferOfCommonControlEntities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Transfer of Common Control Entities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_StockholdersEquityTransferOfCommonControlEntities" xlink:href="asth-20240331.xsd#asth_StockholdersEquityTransferOfCommonControlEntities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_StockholdersEquityTransferOfCommonControlEntities" xlink:to="lab_asth_StockholdersEquityTransferOfCommonControlEntities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_946c2eaa-f82a-4360-be07-765aac7a85a0_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_afbbb9d2-d084-4374-bf6b-b9ac43dce6b0_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revolver Loan</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_a419e604-0ccf-4ba9-a92f-fbfbbd775a48_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_104a8afa-2b7a-491c-b99b-b22fe3f3fbff_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_7e37d80c-8741-4415-bc63-124fd2e86227_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_54963099-87e6-4c26-916f-81a515415611_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income since acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7b00bb8b-65be-4ca1-af0a-835dd384df47_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_603d054d-1cd4-4809-846e-6921b3a63f33_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_08122ff2-f42c-4356-be16-d2a417c274a4_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other expenses, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_affb2bbd-e0d6-4bc9-9839-4a8365de1c1d_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 12)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b649ee5a-f9c4-4f2b-86e1-689aa12a6705_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_7c1cb5e0-8304-4ace-b7e1-472955858a8e_terseLabel_en-US" xlink:label="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]</link:label>
    <link:label id="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:to="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_A2024MetricMember_d8df9ea6-02dd-4f45-913e-a3d3ec0119cc_terseLabel_en-US" xlink:label="lab_asth_A2024MetricMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 Metric</link:label>
    <link:label id="lab_asth_A2024MetricMember_label_en-US" xlink:label="lab_asth_A2024MetricMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2024 Metric [Member]</link:label>
    <link:label id="lab_asth_A2024MetricMember_documentation_en-US" xlink:label="lab_asth_A2024MetricMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2024 Metric</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_A2024MetricMember" xlink:href="asth-20240331.xsd#asth_A2024MetricMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_A2024MetricMember" xlink:to="lab_asth_A2024MetricMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityOwnershipPercentage_1fd733ca-6352-462c-8816-a98b74784765_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable interest entity, ownership percentage</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:to="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_StockAwardsAndUnitsMember_6880a2cc-30e0-4bc1-aead-dceb27f5eb83_terseLabel_en-US" xlink:label="lab_asth_StockAwardsAndUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock</link:label>
    <link:label id="lab_asth_StockAwardsAndUnitsMember_label_en-US" xlink:label="lab_asth_StockAwardsAndUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Awards And Units [Member]</link:label>
    <link:label id="lab_asth_StockAwardsAndUnitsMember_documentation_en-US" xlink:label="lab_asth_StockAwardsAndUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Awards And Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_StockAwardsAndUnitsMember" xlink:href="asth-20240331.xsd#asth_StockAwardsAndUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_StockAwardsAndUnitsMember" xlink:to="lab_asth_StockAwardsAndUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_c43d8932-7267-49ce-90ae-f794bbedf15e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_de9a421a-c167-4e31-8263-c5b40649c715_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medical liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_05eeabe8-09bc-410a-814a-5a873c2c7412_periodStartLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Medical liabilities, beginning of period</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_7f3bb3d2-a3e5-495d-ad13-ad44dd325c6a_periodEndLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Medical liabilities, end of period</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_2c6af378-37a6-4454-a3dc-a0635cb54152_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Medical liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_A2023MetricMember_678bb1f3-803c-4863-bbb8-d3298c41f99d_terseLabel_en-US" xlink:label="lab_asth_A2023MetricMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Metric</link:label>
    <link:label id="lab_asth_A2023MetricMember_label_en-US" xlink:label="lab_asth_A2023MetricMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023 Metric [Member]</link:label>
    <link:label id="lab_asth_A2023MetricMember_documentation_en-US" xlink:label="lab_asth_A2023MetricMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2023 Metric</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_A2023MetricMember" xlink:href="asth-20240331.xsd#asth_A2023MetricMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_A2023MetricMember" xlink:to="lab_asth_A2023MetricMember" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities_ef199c26-16f0-451a-9393-0fef76dfbc97_terseLabel_en-US" xlink:label="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medical liabilities</link:label>
    <link:label id="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities_label_en-US" xlink:label="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities, Medical Liabilities</link:label>
    <link:label id="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities_documentation_en-US" xlink:label="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities, Medical Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities" xlink:href="asth-20240331.xsd#asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities" xlink:to="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_8553880e-cd4c-48d7-932c-f7f16fbe1154_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land, property and equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_NoncontrollingInterestIncreaseDecreaseFromBusinessCombination_3f4d3b29-b421-45cc-9305-a2689b5762e8_terseLabel_en-US" xlink:label="lab_asth_NoncontrollingInterestIncreaseDecreaseFromBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of non-controlling interest</link:label>
    <link:label id="lab_asth_NoncontrollingInterestIncreaseDecreaseFromBusinessCombination_label_en-US" xlink:label="lab_asth_NoncontrollingInterestIncreaseDecreaseFromBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Increase (Decrease) from Business Combination</link:label>
    <link:label id="lab_asth_NoncontrollingInterestIncreaseDecreaseFromBusinessCombination_documentation_en-US" xlink:label="lab_asth_NoncontrollingInterestIncreaseDecreaseFromBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Increase (Decrease) from Business Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_NoncontrollingInterestIncreaseDecreaseFromBusinessCombination" xlink:href="asth-20240331.xsd#asth_NoncontrollingInterestIncreaseDecreaseFromBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_NoncontrollingInterestIncreaseDecreaseFromBusinessCombination" xlink:to="lab_asth_NoncontrollingInterestIncreaseDecreaseFromBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_5da3cf15-f0b5-4ae0-a044-88d10a8b398c_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_caad8578-dc88-47da-8462-e706c21932f2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_ApolloMedicalHoldingsIncMember_4d4cf8d6-efa8-4c35-a566-4b99e7a0db71_terseLabel_en-US" xlink:label="lab_asth_ApolloMedicalHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Apollo Medical Holdings, Inc</link:label>
    <link:label id="lab_asth_ApolloMedicalHoldingsIncMember_label_en-US" xlink:label="lab_asth_ApolloMedicalHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Apollo Medical Holdings, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ApolloMedicalHoldingsIncMember" xlink:href="asth-20240331.xsd#asth_ApolloMedicalHoldingsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_ApolloMedicalHoldingsIncMember" xlink:to="lab_asth_ApolloMedicalHoldingsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e1f68631-7ef6-40cb-b0d3-004c41bf74c1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_DmgMember_47fcd56f-c686-4748-89c0-546a8cc3c2d7_terseLabel_en-US" xlink:label="lab_asth_DmgMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DMG remaining equity interest purchase</link:label>
    <link:label id="lab_asth_DmgMember_label_en-US" xlink:label="lab_asth_DmgMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DMG [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_DmgMember" xlink:href="asth-20240331.xsd#asth_DmgMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_DmgMember" xlink:to="lab_asth_DmgMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_d7d8079f-b262-46ba-8c83-0a50a40ac990_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b1d8abbd-22e1-4e6b-b25a-535cb7437747_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_7ec460ca-10c2-4f01-af79-8a6e46074219_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_19ef89d1-cea8-4725-a58d-bb09f0631099_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, common, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_4d1d3e98-b279-4e49-8ace-cde368a5af9c_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6a4edcab-adaf-4802-b9a7-a5d7f392453f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ef76122f-09f4-4574-825a-7165f6fc700b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_BusinessCombinationContingentConsiderationLiabilityEachMeasurementPeriod_db56e8c7-cfa0-4eb3-9384-69bd22b5ff74_terseLabel_en-US" xlink:label="lab_asth_BusinessCombinationContingentConsiderationLiabilityEachMeasurementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration, liability, each measurement period</link:label>
    <link:label id="lab_asth_BusinessCombinationContingentConsiderationLiabilityEachMeasurementPeriod_label_en-US" xlink:label="lab_asth_BusinessCombinationContingentConsiderationLiabilityEachMeasurementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Each Measurement Period</link:label>
    <link:label id="lab_asth_BusinessCombinationContingentConsiderationLiabilityEachMeasurementPeriod_documentation_en-US" xlink:label="lab_asth_BusinessCombinationContingentConsiderationLiabilityEachMeasurementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Each Measurement Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationContingentConsiderationLiabilityEachMeasurementPeriod" xlink:href="asth-20240331.xsd#asth_BusinessCombinationContingentConsiderationLiabilityEachMeasurementPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_BusinessCombinationContingentConsiderationLiabilityEachMeasurementPeriod" xlink:to="lab_asth_BusinessCombinationContingentConsiderationLiabilityEachMeasurementPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9557e09e-00c7-402d-b004-3f7c3cba69bf_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price adjustment from merger</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_e2c234b3-a15a-4942-92e7-b968fe3bd849_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Receivable, net &#8211; related parties</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Due from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_40361c83-05f9-496a-9616-fd6647786734_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Astrana Health, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_e31aa3cd-056e-474b-8fa9-c530f95a6878_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_7ed8dd0a-63c8-49e8-b06b-3f5da56f0c3c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_fb408046-474a-424e-95e5-88cd9ea59d92_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_375faef2-f802-4ab3-93fa-12f114336186_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_906fc509-e825-4b8d-88de-6e458456f265_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land, property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c6a987f3-8699-479a-84da-a22e944ec03e_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liabilities, mezzanine equity and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_58d2d1c1-b8e1-4be1-926a-9b1087692255_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_ProviderServicesMember_622b8e84-20e7-4a8e-b02f-c50936640f83_terseLabel_en-US" xlink:label="lab_asth_ProviderServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provider Services</link:label>
    <link:label id="lab_asth_ProviderServicesMember_label_en-US" xlink:label="lab_asth_ProviderServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provider Services [Member]</link:label>
    <link:label id="lab_asth_ProviderServicesMember_documentation_en-US" xlink:label="lab_asth_ProviderServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provider Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ProviderServicesMember" xlink:href="asth-20240331.xsd#asth_ProviderServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_ProviderServicesMember" xlink:to="lab_asth_ProviderServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_b02d1f9b-5ae2-4d40-8b2f-700b3beb6601_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_c172d811-ab75-4133-8fe0-7e13c68818fa_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_f1ccf1e3-b9a4-4a3a-b0ba-7d499d9c133e_terseLabel_en-US" xlink:label="lab_asth_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity interest purchase obligation, period to purchase</link:label>
    <link:label id="lab_asth_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_label_en-US" xlink:label="lab_asth_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Equity Interest Purchase Obligation, Period to Purchase</link:label>
    <link:label id="lab_asth_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_documentation_en-US" xlink:label="lab_asth_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Equity Interest Purchase Obligation, Period to Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" xlink:href="asth-20240331.xsd#asth_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" xlink:to="lab_asth_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8c396256-448f-426c-b604-95a54e6e58c6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued for exercise of options and warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_60eb895e-3953-4de2-a577-a413234d4a56_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_LineOfCreditFacilityAmountFundedAtClosing_16dd3be6-c13b-4b88-84c0-13af6db9a50b_terseLabel_en-US" xlink:label="lab_asth_LineOfCreditFacilityAmountFundedAtClosing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount funded at closing</link:label>
    <link:label id="lab_asth_LineOfCreditFacilityAmountFundedAtClosing_label_en-US" xlink:label="lab_asth_LineOfCreditFacilityAmountFundedAtClosing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line Of Credit Facility, Amount Funded At Closing</link:label>
    <link:label id="lab_asth_LineOfCreditFacilityAmountFundedAtClosing_documentation_en-US" xlink:label="lab_asth_LineOfCreditFacilityAmountFundedAtClosing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line Of Credit Facility, Amount Funded At Closing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_LineOfCreditFacilityAmountFundedAtClosing" xlink:href="asth-20240331.xsd#asth_LineOfCreditFacilityAmountFundedAtClosing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_LineOfCreditFacilityAmountFundedAtClosing" xlink:to="lab_asth_LineOfCreditFacilityAmountFundedAtClosing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_7e7cc6e7-3712-4666-8d9d-c6f1686d0f01_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_0a825285-88a1-498f-80c7-e7626d67444e_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_70b6138f-6f7f-4c7d-a1a7-8e2470e8d308_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_662fe5d0-76e5-43af-9a8e-969c5f22d2b5_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable_7b04731b-d7ad-42a2-9d1a-77cb9aeb200c_terseLabel_en-US" xlink:label="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable_label_en-US" xlink:label="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities, Income Taxes Payable</link:label>
    <link:label id="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable_documentation_en-US" xlink:label="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities, Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable" xlink:href="asth-20240331.xsd#asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable" xlink:to="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_4a51d7e6-edd0-47d8-9f59-fbe817d3486c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_ManagementContractsMember_8b34378d-fc9e-4462-a0ce-cff42dde2b06_verboseLabel_en-US" xlink:label="lab_asth_ManagementContractsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Management contracts</link:label>
    <link:label id="lab_asth_ManagementContractsMember_label_en-US" xlink:label="lab_asth_ManagementContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Management Contracts [Member]</link:label>
    <link:label id="lab_asth_ManagementContractsMember_documentation_en-US" xlink:label="lab_asth_ManagementContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Management Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ManagementContractsMember" xlink:href="asth-20240331.xsd#asth_ManagementContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_ManagementContractsMember" xlink:to="lab_asth_ManagementContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_LasalleMedicalAssociatesIpaMember_5f629780-528e-491a-82f1-70a1fa238a20_terseLabel_en-US" xlink:label="lab_asth_LasalleMedicalAssociatesIpaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LaSalle Medical Associates &#8211; IPA line of business</link:label>
    <link:label id="lab_asth_LasalleMedicalAssociatesIpaMember_label_en-US" xlink:label="lab_asth_LasalleMedicalAssociatesIpaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">LaSalle Medical Associates IPA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_LasalleMedicalAssociatesIpaMember" xlink:href="asth-20240331.xsd#asth_LasalleMedicalAssociatesIpaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_LasalleMedicalAssociatesIpaMember" xlink:to="lab_asth_LasalleMedicalAssociatesIpaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_99e6032c-c728-49cb-a2e2-bc79ddf0b26c_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_b175e2a0-c638-4d2d-953f-3027d323847d_negatedLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prior periods</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_ddea7e5a-a025-434c-b4bc-6a4e96c66a0f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_51cfb879-f0c4-4832-98fd-33f2fae8dc48_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_6fecc2ea-0ea8-4a05-9965-494c2598e00c_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_a5be7ac2-45ae-426b-9f18-7f54d2a50849_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_5b3df84c-5270-4991-936b-c594cf7a4fdd_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of medical care costs related to claims incurred:</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_2561c40c-a94c-4cef-a29a-1a834a7cdbd1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Issuance of loans receivable</link:label>
    <link:label id="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_label_en-US" xlink:label="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Fund Long-Term Loans to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:to="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_3f438140-a0ce-4bdd-9c44-e1725b7dd238_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revolving credit facility term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_e77e794a-18be-424c-9d5d-62eccdd42f9c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_HSMSOMember_3f06cef2-5e6a-4a82-8e49-8756c633304c_verboseLabel_en-US" xlink:label="lab_asth_HSMSOMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">HSMSO</link:label>
    <link:label id="lab_asth_HSMSOMember_label_en-US" xlink:label="lab_asth_HSMSOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">HSMSO [Member]</link:label>
    <link:label id="lab_asth_HSMSOMember_documentation_en-US" xlink:label="lab_asth_HSMSOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">xxx_HSMSO Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_HSMSOMember" xlink:href="asth-20240331.xsd#asth_HSMSOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_HSMSOMember" xlink:to="lab_asth_HSMSOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_BusinessAcquisitionOfCommonStock_9ab9773b-a48a-4900-850a-c766f8fc38f0_terseLabel_en-US" xlink:label="lab_asth_BusinessAcquisitionOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business acquisition of common stock</link:label>
    <link:label id="lab_asth_BusinessAcquisitionOfCommonStock_label_en-US" xlink:label="lab_asth_BusinessAcquisitionOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition Of Common Stock</link:label>
    <link:label id="lab_asth_BusinessAcquisitionOfCommonStock_documentation_en-US" xlink:label="lab_asth_BusinessAcquisitionOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Acquisition Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessAcquisitionOfCommonStock" xlink:href="asth-20240331.xsd#asth_BusinessAcquisitionOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_BusinessAcquisitionOfCommonStock" xlink:to="lab_asth_BusinessAcquisitionOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_291b14bc-f74e-421d-a5e4-d773267b9535_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_5d260fe7-793c-41e1-8a39-f0c7f748dd33_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Unamortized financing costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_e3c843a9-9f55-4bab-8d7e-08cd197131a7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized deferred financing costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_AurionMember_d0349df3-9ff3-4398-82d0-1166517a273c_verboseLabel_en-US" xlink:label="lab_asth_AurionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Aurion</link:label>
    <link:label id="lab_asth_AurionMember_label_en-US" xlink:label="lab_asth_AurionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aurion [Member]</link:label>
    <link:label id="lab_asth_AurionMember_documentation_en-US" xlink:label="lab_asth_AurionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">xxx_Aurion Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AurionMember" xlink:href="asth-20240331.xsd#asth_AurionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_AurionMember" xlink:to="lab_asth_AurionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ac427531-6095-4083-9f9a-db9bb0f1c2e1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Operating Lease Payments Under Non-cancelable Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7de28db4-9ec9-41e9-9f53-92c2027b1e4e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to weighted average shares of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0f026286-ff8a-46f3-8651-f431b2878cbc_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_c3428256-8966-4b0a-8b64-6ea01b9b2565_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfOtherLongTermDebt_581fb5fe-8f7e-4586-a3ad-0cbc034bf31e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfOtherLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Other Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfOtherLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_9fe7667e-630a-4485-ab2d-a901fe937199_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_51a6c273-89c9-4a2b-98cb-ce97a814f489_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Information Related to Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_RevolverLoanMember_553040db-e97c-43c0-9262-09bedf3a848f_terseLabel_en-US" xlink:label="lab_asth_RevolverLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revolver Loan</link:label>
    <link:label id="lab_asth_RevolverLoanMember_label_en-US" xlink:label="lab_asth_RevolverLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolver Loan [Member]</link:label>
    <link:label id="lab_asth_RevolverLoanMember_documentation_en-US" xlink:label="lab_asth_RevolverLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revolver Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_RevolverLoanMember" xlink:href="asth-20240331.xsd#asth_RevolverLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_RevolverLoanMember" xlink:to="lab_asth_RevolverLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_13e8146c-aac9-496a-9a89-b0360651d50e_terseLabel_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Standby Letters of Credit</link:label>
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_label_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Standby Letters of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandbyLettersOfCreditMember" xlink:to="lab_us-gaap_StandbyLettersOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_86e25125-c03f-4edc-96e4-1db1b69a7138_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_UnamortizedDeferredFinancingCosts_dfafd67c-c2dd-42e1-a58d-1ac70a9ddf3c_terseLabel_en-US" xlink:label="lab_asth_UnamortizedDeferredFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label id="lab_asth_UnamortizedDeferredFinancingCosts_label_en-US" xlink:label="lab_asth_UnamortizedDeferredFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unamortized Deferred Financing Costs</link:label>
    <link:label id="lab_asth_UnamortizedDeferredFinancingCosts_documentation_en-US" xlink:label="lab_asth_UnamortizedDeferredFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unamortized Deferred Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_UnamortizedDeferredFinancingCosts" xlink:href="asth-20240331.xsd#asth_UnamortizedDeferredFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_UnamortizedDeferredFinancingCosts" xlink:to="lab_asth_UnamortizedDeferredFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_431d2a6f-5ae8-48a4-902a-3e874457515e_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Increase from Sale of Parent Equity Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_MezzanineEquityAbstract_c39446dd-b12e-408f-8518-3d7fa9c34e8c_verboseLabel_en-US" xlink:label="lab_asth_MezzanineEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mezzanine equity</link:label>
    <link:label id="lab_asth_MezzanineEquityAbstract_label_en-US" xlink:label="lab_asth_MezzanineEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MEZZANINE EQUITY [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_MezzanineEquityAbstract" xlink:href="asth-20240331.xsd#asth_MezzanineEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_MezzanineEquityAbstract" xlink:to="lab_asth_MezzanineEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_FiduciaryAccountsPayableCurrent_a2287688-6373-46d5-9a86-7bdb2d02d586_terseLabel_en-US" xlink:label="lab_asth_FiduciaryAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fiduciary accounts payable</link:label>
    <link:label id="lab_asth_FiduciaryAccountsPayableCurrent_97f19420-af53-47f8-896c-7bea62318873_verboseLabel_en-US" xlink:label="lab_asth_FiduciaryAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fiduciary accounts payable</link:label>
    <link:label id="lab_asth_FiduciaryAccountsPayableCurrent_label_en-US" xlink:label="lab_asth_FiduciaryAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fiduciary Accounts Payable Current</link:label>
    <link:label id="lab_asth_FiduciaryAccountsPayableCurrent_documentation_en-US" xlink:label="lab_asth_FiduciaryAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_FiduciaryAccountsPayableCurrent" xlink:href="asth-20240331.xsd#asth_FiduciaryAccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_FiduciaryAccountsPayableCurrent" xlink:to="lab_asth_FiduciaryAccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_402255b3-7db5-492a-8ffe-bb024ec1b9d8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_e814ddb9-47ac-48e6-889f-490fdf093b64_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_dbb9a7fa-336e-4e15-bfff-dfa0995e66c8_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3bf66a3f-e13d-492d-84cc-d1d85d02bf7e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_OfficeLeaseMember_afe8e76e-00da-42d5-8982-9e17197d2858_terseLabel_en-US" xlink:label="lab_asth_OfficeLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office Lease</link:label>
    <link:label id="lab_asth_OfficeLeaseMember_label_en-US" xlink:label="lab_asth_OfficeLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Lease [Member]</link:label>
    <link:label id="lab_asth_OfficeLeaseMember_documentation_en-US" xlink:label="lab_asth_OfficeLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Office Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_OfficeLeaseMember" xlink:href="asth-20240331.xsd#asth_OfficeLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_OfficeLeaseMember" xlink:to="lab_asth_OfficeLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1de8cffb-90ed-47e3-8849-fac25ae496ef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3b83f3c4-d3b2-4875-a3c6-638d2a37c672_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_ContingentConsideration_c0537e83-d709-4b9e-b031-9f11c2876b9b_terseLabel_en-US" xlink:label="lab_asth_ContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_asth_ContingentConsideration_label_en-US" xlink:label="lab_asth_ContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_asth_ContingentConsideration_documentation_en-US" xlink:label="lab_asth_ContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ContingentConsideration" xlink:href="asth-20240331.xsd#asth_ContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_ContingentConsideration" xlink:to="lab_asth_ContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_df2ec8d4-fa81-41e8-baec-a7a9c8ce5fec_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 (excluding the nine months ended September 30, 2023)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_e896a4a5-f7da-4429-a603-29ad8b254d5e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_DebtInstrumentCovenantInterestCoverageRatioMinimum_1d6c52b5-084f-4789-b1a3-1c534334d6fc_terseLabel_en-US" xlink:label="lab_asth_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum consolidated interest coverage ratio (not less than)</link:label>
    <link:label id="lab_asth_DebtInstrumentCovenantInterestCoverageRatioMinimum_label_en-US" xlink:label="lab_asth_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</link:label>
    <link:label id="lab_asth_DebtInstrumentCovenantInterestCoverageRatioMinimum_documentation_en-US" xlink:label="lab_asth_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:href="asth-20240331.xsd#asth_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:to="lab_asth_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_0c988781-29ae-4a9a-aa41-ddc9bd504b05_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_87dd9699-7807-4a49-b68a-867371993003_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_AccountsReceivableAndNetRevenueLineItems_53461d29-df99-4e01-a0fc-2834406cc8bf_terseLabel_en-US" xlink:label="lab_asth_AccountsReceivableAndNetRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable And Net Revenue [Line Items]</link:label>
    <link:label id="lab_asth_AccountsReceivableAndNetRevenueLineItems_label_en-US" xlink:label="lab_asth_AccountsReceivableAndNetRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable And Net Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AccountsReceivableAndNetRevenueLineItems" xlink:href="asth-20240331.xsd#asth_AccountsReceivableAndNetRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_AccountsReceivableAndNetRevenueLineItems" xlink:to="lab_asth_AccountsReceivableAndNetRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_8e9b2cf4-6dc2-4a40-9f88-a5ea6422aabe_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_GeneralAndAdministrativeExpensesAndDepreciationAndAmortization_54d98408-80d7-4054-97f8-0cd182dde204_terseLabel_en-US" xlink:label="lab_asth_GeneralAndAdministrativeExpensesAndDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_asth_GeneralAndAdministrativeExpensesAndDepreciationAndAmortization_label_en-US" xlink:label="lab_asth_GeneralAndAdministrativeExpensesAndDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expenses and Depreciation and Amortization</link:label>
    <link:label id="lab_asth_GeneralAndAdministrativeExpensesAndDepreciationAndAmortization_documentation_en-US" xlink:label="lab_asth_GeneralAndAdministrativeExpensesAndDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">General and Administrative Expenses and Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_GeneralAndAdministrativeExpensesAndDepreciationAndAmortization" xlink:href="asth-20240331.xsd#asth_GeneralAndAdministrativeExpensesAndDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_GeneralAndAdministrativeExpensesAndDepreciationAndAmortization" xlink:to="lab_asth_GeneralAndAdministrativeExpensesAndDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_9bc3e5ff-ce65-424e-9a3b-53ef9c679e03_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_ApcStockOptionMember_5ef0c6b9-270b-413d-9696-2be87df55860_terseLabel_en-US" xlink:label="lab_asth_ApcStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">APC Stock Option</link:label>
    <link:label id="lab_asth_ApcStockOptionMember_label_en-US" xlink:label="lab_asth_ApcStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APC Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ApcStockOptionMember" xlink:href="asth-20240331.xsd#asth_ApcStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_ApcStockOptionMember" xlink:to="lab_asth_ApcStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_bb75a95e-7b37-48e8-85f9-63d1f781fb88_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_ed440b98-1d52-4b95-93a2-bc35a894a58b_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount_3521c817-bc02-4b3e-b37f-6749f1c8ef29_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Distribution</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Amount Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:to="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_1a6973e1-5004-4d3d-896d-63d025a7721c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance_139ff1a8-c2e1-4e13-a996-205fbf425bcb_terseLabel_en-US" xlink:label="lab_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent on performance (in shares)</link:label>
    <link:label id="lab_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance_label_en-US" xlink:label="lab_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Contingent on Performance</link:label>
    <link:label id="lab_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance_documentation_en-US" xlink:label="lab_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Contingent on Performance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance" xlink:href="asth-20240331.xsd#asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance" xlink:to="lab_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_0e1b3002-8e48-4213-948f-6077ee9eb4c7_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income taxes payable/receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e68e4196-bfa8-44ea-a75a-4779673f424d_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f6ae124c-0652-424c-9b13-cb076544b33a_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_152e86f4-39b1-4113-a5df-85b267f90021_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_AHMCMember_ad2b6b07-f0f5-4f1b-bbf7-bb5f89e4f621_terseLabel_en-US" xlink:label="lab_asth_AHMCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AHMC</link:label>
    <link:label id="lab_asth_AHMCMember_7f7ed591-ba3b-4f94-84d7-e743cffbadc0_verboseLabel_en-US" xlink:label="lab_asth_AHMCMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">AHMC</link:label>
    <link:label id="lab_asth_AHMCMember_label_en-US" xlink:label="lab_asth_AHMCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AHMC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AHMCMember" xlink:href="asth-20240331.xsd#asth_AHMCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_AHMCMember" xlink:to="lab_asth_AHMCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_AcquisitionOfNonControllingInterestShares_b1ab1d4f-67e8-4e6d-a482-4d66541156af_negatedTerseLabel_en-US" xlink:label="lab_asth_AcquisitionOfNonControllingInterestShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of non-controlling interest (in shares)</link:label>
    <link:label id="lab_asth_AcquisitionOfNonControllingInterestShares_label_en-US" xlink:label="lab_asth_AcquisitionOfNonControllingInterestShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisition of Non-Controlling Interest, Shares</link:label>
    <link:label id="lab_asth_AcquisitionOfNonControllingInterestShares_documentation_en-US" xlink:label="lab_asth_AcquisitionOfNonControllingInterestShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acquisition of Non-Controlling Interest, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AcquisitionOfNonControllingInterestShares" xlink:href="asth-20240331.xsd#asth_AcquisitionOfNonControllingInterestShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_AcquisitionOfNonControllingInterestShares" xlink:to="lab_asth_AcquisitionOfNonControllingInterestShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_beb3b1b5-2477-4393-8613-03e425f2a42c_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_ea1a3707-4cda-4b79-9b15-a8452c3bf967_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_29545bc5-cf4b-4738-886b-f6e7bfbd0da2_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_8e49d579-78e0-4822-85e9-cd66b23f9787_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_VOMGMember_8b242d69-22af-4d4e-a98e-e648b8a55862_terseLabel_en-US" xlink:label="lab_asth_VOMGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">VOMG contingent consideration</link:label>
    <link:label id="lab_asth_VOMGMember_label_en-US" xlink:label="lab_asth_VOMGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">VOMG [Member]</link:label>
    <link:label id="lab_asth_VOMGMember_documentation_en-US" xlink:label="lab_asth_VOMGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">VOMG</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_VOMGMember" xlink:href="asth-20240331.xsd#asth_VOMGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_VOMGMember" xlink:to="lab_asth_VOMGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableToBanksMember_f65d9ae5-9dae-41ea-adbc-54866a9152d5_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableToBanksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Promissory Note Payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableToBanksMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableToBanksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable to Banks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableToBanksMember" xlink:to="lab_us-gaap_NotesPayableToBanksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_331e5864-c86b-4e93-9c51-99db6965c64a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_fa1f67c8-1ce9-4730-bf0d-2ea33767a307_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of shares for business acquisition</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_4cdf2861-67a7-4d61-a64f-71c4646b7f91_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_a78232e7-8794-4e34-8734-89dc753a4603_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_b182d2f9-39dc-47d6-b88b-8afc46b287b3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_621a5631-6a73-4edd-8cbd-809e58adb23a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_43bedc38-6c8d-43d4-8dc9-e08c1ea1a01b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_d192055e-ab9e-4a0a-8bc9-65ed87a6d33e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_50b83e5a-c9c8-485b-8820-efc093636981_netLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_bbcdd60e-18ed-4e93-afee-5b2b5aafc12e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_74b7c525-3b3e-4edf-a59c-2a02d684e41c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Operations</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_FirstMetricMember_b17fd0c2-c2e0-4812-bc60-c5ad2e11c879_terseLabel_en-US" xlink:label="lab_asth_FirstMetricMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">First Metric</link:label>
    <link:label id="lab_asth_FirstMetricMember_label_en-US" xlink:label="lab_asth_FirstMetricMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">First Metric [Member]</link:label>
    <link:label id="lab_asth_FirstMetricMember_documentation_en-US" xlink:label="lab_asth_FirstMetricMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">First Metric</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_FirstMetricMember" xlink:href="asth-20240331.xsd#asth_FirstMetricMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_FirstMetricMember" xlink:to="lab_asth_FirstMetricMember" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_OneMSOLLCMember_c48a4f35-b6cf-46ac-88d3-bcb92399e0f7_terseLabel_en-US" xlink:label="lab_asth_OneMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">One MSO, LLC</link:label>
    <link:label id="lab_asth_OneMSOLLCMember_label_en-US" xlink:label="lab_asth_OneMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">One MSO, LLC [Member]</link:label>
    <link:label id="lab_asth_OneMSOLLCMember_documentation_en-US" xlink:label="lab_asth_OneMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">One MSO, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_OneMSOLLCMember" xlink:href="asth-20240331.xsd#asth_OneMSOLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_OneMSOLLCMember" xlink:to="lab_asth_OneMSOLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3ba2f39d-7985-4d51-941f-1248d6ab1926_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market accounts</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_6bf819d8-9760-45b4-9bee-4eecc25c78d5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_5b66a622-b817-4b46-9cd8-94079ee7e593_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_efa3ca73-d80f-41e7-98e1-d1786bdf1307_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_ae896953-dba8-4e7e-a7f8-262440af0187_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_8fc81362-c98d-4386-a2b6-90563b540d10_verboseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Dividend payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrent" xlink:to="lab_us-gaap_DividendsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_e357ff48-c9d0-45c4-b6e1-aab1e00884ac_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_DebtInstrumentCovenantLeverageRatioAdjustedMaximum_53cf92fc-72f1-45e9-824c-a806f2edf1c5_terseLabel_en-US" xlink:label="lab_asth_DebtInstrumentCovenantLeverageRatioAdjustedMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, covenant, leverage ratio, adjusted maximum</link:label>
    <link:label id="lab_asth_DebtInstrumentCovenantLeverageRatioAdjustedMaximum_label_en-US" xlink:label="lab_asth_DebtInstrumentCovenantLeverageRatioAdjustedMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Adjusted Maximum</link:label>
    <link:label id="lab_asth_DebtInstrumentCovenantLeverageRatioAdjustedMaximum_documentation_en-US" xlink:label="lab_asth_DebtInstrumentCovenantLeverageRatioAdjustedMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Adjusted Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_DebtInstrumentCovenantLeverageRatioAdjustedMaximum" xlink:href="asth-20240331.xsd#asth_DebtInstrumentCovenantLeverageRatioAdjustedMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_DebtInstrumentCovenantLeverageRatioAdjustedMaximum" xlink:to="lab_asth_DebtInstrumentCovenantLeverageRatioAdjustedMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_8410cec3-647d-4f03-8acb-5f5300c3a1cb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Medical Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_LoanReceivableTextBlock_046b61e9-df37-4c64-8b0c-34a8a6b33ed7_verboseLabel_en-US" xlink:label="lab_asth_LoanReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Loans Receivable</link:label>
    <link:label id="lab_asth_LoanReceivableTextBlock_label_en-US" xlink:label="lab_asth_LoanReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loan Receivable [Text Block]</link:label>
    <link:label id="lab_asth_LoanReceivableTextBlock_documentation_en-US" xlink:label="lab_asth_LoanReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loan Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_LoanReceivableTextBlock" xlink:href="asth-20240331.xsd#asth_LoanReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_LoanReceivableTextBlock" xlink:to="lab_asth_LoanReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_29efc16c-46a4-4f62-b6a3-514fb044b753_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments in other entities &#8211; equity method</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_b4174194-38fe-4bea-b2df-b8cdf843ec81_periodStartLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_286ef203-8b92-4875-9cc2-7ac25250e725_periodEndLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_f0f1d3c4-8cc8-4cbe-a516-e6b16908dc16_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in other entities &#8211; equity method</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_BassMedicalGroupMember_4d91a0e1-8aa7-4e58-9e7d-8e52b6a2dfeb_terseLabel_en-US" xlink:label="lab_asth_BassMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BASS Medical Group</link:label>
    <link:label id="lab_asth_BassMedicalGroupMember_label_en-US" xlink:label="lab_asth_BassMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bass Medical Group [Member]</link:label>
    <link:label id="lab_asth_BassMedicalGroupMember_documentation_en-US" xlink:label="lab_asth_BassMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bass Medical Group</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BassMedicalGroupMember" xlink:href="asth-20240331.xsd#asth_BassMedicalGroupMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_BassMedicalGroupMember" xlink:to="lab_asth_BassMedicalGroupMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders_7018e111-b10e-423e-8b78-b96ad537c4c6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of non-controlling interest</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payments to) Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:to="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_43256b3a-0a4d-4092-9349-feaa6d8b32dc_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_CommitmentsAndContingenciesLineItems_72885c1c-994d-47f9-b8bc-0456db9db73e_terseLabel_en-US" xlink:label="lab_asth_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_asth_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_asth_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CommitmentsAndContingenciesLineItems" xlink:href="asth-20240331.xsd#asth_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_CommitmentsAndContingenciesLineItems" xlink:to="lab_asth_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_27d0ed5c-6b1b-4c1c-b936-63a1a4ce0dab_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for repurchase of shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_c5cd7146-30a9-4afa-b93e-5bf8cc947a3b_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_LmaMember_678d5cc1-122d-470d-8d10-ec686c02c995_terseLabel_en-US" xlink:label="lab_asth_LmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LMA</link:label>
    <link:label id="lab_asth_LmaMember_label_en-US" xlink:label="lab_asth_LmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">LMA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_LmaMember" xlink:href="asth-20240331.xsd#asth_LmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_LmaMember" xlink:to="lab_asth_LmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b1fd349f-f35a-4cb3-b0ce-5f0ced7015c2_verboseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosures of non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_40b8980f-6e8f-4238-bda8-00bfb42655e7_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_6847b100-9a88-4b4c-93b7-80b406d585aa_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_7284361e-8059-453d-b873-61f1c408a481_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_d7077d68-4ed1-4b95-aedb-9ea11d8841c9_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_bf6cfa48-82e6-4672-a3a1-bfa9e193781f_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_5f111e96-9a81-4dec-9c59-0e4d1abf5e4b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued for vesting of restricted stock awards (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_7e063d65-c4de-4ce0-8680-dab1a8c7c6d8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt, principal sum</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_5e0e110c-133e-4214-8866-989b89ee1dc8_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_c127f8b8-325f-46c0-8533-6350bc28c546_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_IntraCareConvertiblePromissoryNoteReceivableMember_7d290cce-7bfe-4b1a-9159-c506483b9b10_terseLabel_en-US" xlink:label="lab_asth_IntraCareConvertiblePromissoryNoteReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IntraCare Convertible Promissory Note Receivable</link:label>
    <link:label id="lab_asth_IntraCareConvertiblePromissoryNoteReceivableMember_label_en-US" xlink:label="lab_asth_IntraCareConvertiblePromissoryNoteReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IntraCare Convertible Promissory Note Receivable [Member]</link:label>
    <link:label id="lab_asth_IntraCareConvertiblePromissoryNoteReceivableMember_documentation_en-US" xlink:label="lab_asth_IntraCareConvertiblePromissoryNoteReceivableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">IntraCare Convertible Promissory Note Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_IntraCareConvertiblePromissoryNoteReceivableMember" xlink:href="asth-20240331.xsd#asth_IntraCareConvertiblePromissoryNoteReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_IntraCareConvertiblePromissoryNoteReceivableMember" xlink:to="lab_asth_IntraCareConvertiblePromissoryNoteReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_8b61b9c1-1501-4e86-96a1-50b6cb4f0a98_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_747fd9b6-cc42-447e-9d8c-5dfc4d3d1a54_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior periods</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_873b28cd-0e4a-4c5b-80d2-ee902cb2499e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_838957ef-65d8-4058-ba15-14cd84fb7a3f_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ebab1f6d-f5a3-4993-adcf-08bd53d6fdc9_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivables_b07ba3c3-1485-43fe-ac4e-b6486f4f0d18_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due from affiliates</link:label>
    <link:label id="lab_us-gaap_OtherReceivables_label_en-US" xlink:label="lab_us-gaap_OtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivables" xlink:to="lab_us-gaap_OtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_MedicareMember_260de91b-4d9c-429a-aff1-0de807c2fe19_terseLabel_en-US" xlink:label="lab_asth_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_asth_MedicareMember_label_en-US" xlink:label="lab_asth_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_asth_MedicareMember_documentation_en-US" xlink:label="lab_asth_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ameh:MedicareMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_MedicareMember" xlink:href="asth-20240331.xsd#asth_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_MedicareMember" xlink:to="lab_asth_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8735f1ce-edac-4069-b8b0-3c3d2e130c9d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_122dc886-9e52-48f6-b951-bcd30fa33e92_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative asset, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_CareDeliveryMember_cd8c627f-db71-4393-9d9a-37d5f00c555a_terseLabel_en-US" xlink:label="lab_asth_CareDeliveryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Care Delivery</link:label>
    <link:label id="lab_asth_CareDeliveryMember_label_en-US" xlink:label="lab_asth_CareDeliveryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Care Delivery [Member]</link:label>
    <link:label id="lab_asth_CareDeliveryMember_documentation_en-US" xlink:label="lab_asth_CareDeliveryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Care Delivery</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CareDeliveryMember" xlink:href="asth-20240331.xsd#asth_CareDeliveryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_CareDeliveryMember" xlink:to="lab_asth_CareDeliveryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_40f62cba-e4fe-42e0-b35e-4c4ea9c2f606_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_0343f6e8-c632-4e9b-b79f-688ce2a87a28_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b0a74aa6-127a-4752-bf2a-2e18e6d719a6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7cb34eb5-62cc-4bcc-868b-ec5c75318ad9_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_c9d2f189-4554-450d-9d20-398152284369_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_AmendedAndRestatedCreditAgreementMember_677e0d73-5030-4a09-94cf-87fe0ef7d1ba_terseLabel_en-US" xlink:label="lab_asth_AmendedAndRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Agreement Amendment</link:label>
    <link:label id="lab_asth_AmendedAndRestatedCreditAgreementMember_label_en-US" xlink:label="lab_asth_AmendedAndRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amended and Restated Credit Agreement [Member]</link:label>
    <link:label id="lab_asth_AmendedAndRestatedCreditAgreementMember_documentation_en-US" xlink:label="lab_asth_AmendedAndRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amended and Restated Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AmendedAndRestatedCreditAgreementMember" xlink:href="asth-20240331.xsd#asth_AmendedAndRestatedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_AmendedAndRestatedCreditAgreementMember" xlink:to="lab_asth_AmendedAndRestatedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_fb3ff988-5c30-4b7b-b342-52e55bda84d8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_3ff02e0f-283c-4a92-97e3-e826b01a7293_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_7b70814d-541d-4130-8390-6c5868fa1730_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_be6b5c23-5c22-41ec-97fc-ea7a87ef8a5c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_d4a61a8d-43f5-4506-b262-e859ec487416_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assets and Liabilities, Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Variable Interest Entities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates_95254c48-dc26-4688-8837-0428945725d6_terseLabel_en-US" xlink:label="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts due to affiliates</link:label>
    <link:label id="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates_label_en-US" xlink:label="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities, Amounts Due To Affiliates</link:label>
    <link:label id="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates_documentation_en-US" xlink:label="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities, Amounts Due To Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates" xlink:href="asth-20240331.xsd#asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates" xlink:to="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_3f1f7b8d-1b4a-416c-93b3-973b71bebf06_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, value, issued</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_TermLoanMember_a130b833-849e-4d47-a2b9-9fb814584258_terseLabel_en-US" xlink:label="lab_asth_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan</link:label>
    <link:label id="lab_asth_TermLoanMember_label_en-US" xlink:label="lab_asth_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:label id="lab_asth_TermLoanMember_documentation_en-US" xlink:label="lab_asth_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_TermLoanMember" xlink:href="asth-20240331.xsd#asth_TermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_TermLoanMember" xlink:to="lab_asth_TermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c3e5d593-f984-4758-a2a6-6759fd1f88a6_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_2f7114d9-4252-4459-98f1-22ee3d24e600_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financing cash flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_ab65ab31-a562-4621-af8b-2101fc41c625_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Finance Lease Payments Under Non-cancelable Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_d9658cf8-df1f-434a-a15e-9dfad3a922fd_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_EmployeeStockPurchasePlanMember_52ba4d78-8ac0-487e-a01b-57458d579218_terseLabel_en-US" xlink:label="lab_asth_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_asth_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_asth_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_asth_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_asth_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_EmployeeStockPurchasePlanMember" xlink:href="asth-20240331.xsd#asth_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_EmployeeStockPurchasePlanMember" xlink:to="lab_asth_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_c0ef2c56-8a52-4438-805c-14d8e26fa60f_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_ed388c0c-824f-408a-863e-e7f86ff90b8f_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_064d4263-5702-4562-8bb0-17652fce51e8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_81b42054-3b7c-4706-abd6-7152cca848bd_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost, Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_2139afeb-9926-40df-bffd-f15f7457e864_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsDomain_3ddcb307-d676-4a87-9765-4a98330c6f6a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsegmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain" xlink:to="lab_us-gaap_SubsegmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_4a306c09-9151-466d-9060-d925b71a0775_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_81362645-fa6b-423c-89a6-e869d08eda56_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in marketable securities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_c376ca2d-34cb-4a4e-82ff-36afecb0ea8a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_8cba056d-c032-4074-9161-7a622ea51c59_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_3b70a44f-2ab9-4904-9844-8ccfc7731104_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Change in Carrying Value of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_8a77b592-6547-4ed5-8a50-eb3ea8bd9a6b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_BusinessCombinationChangeInFairValueOfEquityInterestPurchaseObligation_d4338902-a86a-48f1-bb81-63ae1b4d7d73_terseLabel_en-US" xlink:label="lab_asth_BusinessCombinationChangeInFairValueOfEquityInterestPurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of equity interest</link:label>
    <link:label id="lab_asth_BusinessCombinationChangeInFairValueOfEquityInterestPurchaseObligation_label_en-US" xlink:label="lab_asth_BusinessCombinationChangeInFairValueOfEquityInterestPurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Change in Fair Value Of Equity Interest Purchase Obligation</link:label>
    <link:label id="lab_asth_BusinessCombinationChangeInFairValueOfEquityInterestPurchaseObligation_documentation_en-US" xlink:label="lab_asth_BusinessCombinationChangeInFairValueOfEquityInterestPurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Change in Fair Value Of Equity Interest Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationChangeInFairValueOfEquityInterestPurchaseObligation" xlink:href="asth-20240331.xsd#asth_BusinessCombinationChangeInFairValueOfEquityInterestPurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_BusinessCombinationChangeInFairValueOfEquityInterestPurchaseObligation" xlink:to="lab_asth_BusinessCombinationChangeInFairValueOfEquityInterestPurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_1903fc1f-8e78-4f9e-b97d-fac2f8e5b7b1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other provider payable</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_6f3c7b98-c556-4916-a3cc-f6af247026f3_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate Costs</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_635d2d6f-d853-46e0-9846-eb13f453d4bb_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_ProfessionalMedicalCorporationMember_33e26020-3b9f-4d79-8e1d-dd481e3611a0_terseLabel_en-US" xlink:label="lab_asth_ProfessionalMedicalCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AMG</link:label>
    <link:label id="lab_asth_ProfessionalMedicalCorporationMember_label_en-US" xlink:label="lab_asth_ProfessionalMedicalCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Professional Medical Corporation [Member]</link:label>
    <link:label id="lab_asth_ProfessionalMedicalCorporationMember_documentation_en-US" xlink:label="lab_asth_ProfessionalMedicalCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Professional Medical Corporation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ProfessionalMedicalCorporationMember" xlink:href="asth-20240331.xsd#asth_ProfessionalMedicalCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_ProfessionalMedicalCorporationMember" xlink:to="lab_asth_ProfessionalMedicalCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_0b3b9519-d1c3-45b5-98e3-94b5378dc1cc_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_c25928aa-be12-415d-b38a-aca6d3c762e0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ff6158a9-0bb1-40a2-a3dc-73635d18f5b8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_de8ebe94-1c0d-4863-ad7f-e93d765b76d3_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_b9cfee76-605f-4c55-bb94-c04979c7776a_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_f4af397e-e1f6-4c01-a4d7-b9223be783ac_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_3cb5301b-92c7-4d9f-bc0a-725adf9ba29d_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d6e2cc39-076a-41b2-b6d8-07ad73a28899_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityNetIncome_6e7e1150-431e-4887-916a-4ad61494765c_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityNetIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityNetIncome_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityNetIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Net Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityNetIncome" xlink:to="lab_us-gaap_TemporaryEquityNetIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_LeaseWeightedAverageDiscountRateAbstract_4958c624-89c6-421e-9581-38fe3db1ee89_verboseLabel_en-US" xlink:label="lab_asth_LeaseWeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Discount Rate</link:label>
    <link:label id="lab_asth_LeaseWeightedAverageDiscountRateAbstract_label_en-US" xlink:label="lab_asth_LeaseWeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Weighted Average Discount Rate [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_LeaseWeightedAverageDiscountRateAbstract" xlink:href="asth-20240331.xsd#asth_LeaseWeightedAverageDiscountRateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_LeaseWeightedAverageDiscountRateAbstract" xlink:to="lab_asth_LeaseWeightedAverageDiscountRateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_f4f7bc8e-9b4c-49d5-915d-d3588e64ce89_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_a656a4b1-156e-4c67-a9d8-597e72d6bc89_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_ccd2a419-649d-4171-b895-7a79ac36648e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation associated with finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_792e06c7-b74e-42ea-81f7-5e7f82a99cfb_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_cc124a1e-f190-44f9-bb8a-222cb08a330f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_52110f62-c511-4cb7-9b15-4be9075c1964_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_4bb3b8b3-7c22-46e0-baf5-88db47716617_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_973f2187-537a-4014-8e79-bc8d0054a334_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_EarningsPerShareLineItems_317e3ec5-b016-4612-8274-b8b4c7a6d92e_terseLabel_en-US" xlink:label="lab_asth_EarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_asth_EarningsPerShareLineItems_label_en-US" xlink:label="lab_asth_EarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_asth_EarningsPerShareLineItems_documentation_en-US" xlink:label="lab_asth_EarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_EarningsPerShareLineItems" xlink:href="asth-20240331.xsd#asth_EarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_EarningsPerShareLineItems" xlink:to="lab_asth_EarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_SecondMetricMember_f269a204-9257-419a-b24a-8046dea031e3_terseLabel_en-US" xlink:label="lab_asth_SecondMetricMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Second Metric</link:label>
    <link:label id="lab_asth_SecondMetricMember_label_en-US" xlink:label="lab_asth_SecondMetricMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Second Metric [Member]</link:label>
    <link:label id="lab_asth_SecondMetricMember_documentation_en-US" xlink:label="lab_asth_SecondMetricMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Second Metric</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_SecondMetricMember" xlink:href="asth-20240331.xsd#asth_SecondMetricMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_SecondMetricMember" xlink:to="lab_asth_SecondMetricMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_b5573315-e490-47ff-92cf-431072d36ce2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_a2685eb6-77f4-4e73-92df-62fbb552dd8a_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current period</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_7cf91559-040a-49b4-b17c-157816edfce4_terseLabel_en-US" xlink:label="lab_asth_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_asth_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_asth_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_asth_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_asth_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="asth-20240331.xsd#asth_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_asth_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_4456d54a-27bc-4c1d-a3dd-19a9e76defbb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings on long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Other Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_ca556b04-213e-4ea0-a8dd-9e528abd90b4_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total net identifiable assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_45467e7e-8958-47fc-86f0-85e161ef2efc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_RelatedPartyTransactionRevenueExpenseNetMember_22922534-7f17-48f7-b9eb-ba298a6cafe7_terseLabel_en-US" xlink:label="lab_asth_RelatedPartyTransactionRevenueExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net</link:label>
    <link:label id="lab_asth_RelatedPartyTransactionRevenueExpenseNetMember_label_en-US" xlink:label="lab_asth_RelatedPartyTransactionRevenueExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Revenue (Expense), Net [Member]</link:label>
    <link:label id="lab_asth_RelatedPartyTransactionRevenueExpenseNetMember_documentation_en-US" xlink:label="lab_asth_RelatedPartyTransactionRevenueExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Revenue (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_RelatedPartyTransactionRevenueExpenseNetMember" xlink:href="asth-20240331.xsd#asth_RelatedPartyTransactionRevenueExpenseNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_RelatedPartyTransactionRevenueExpenseNetMember" xlink:to="lab_asth_RelatedPartyTransactionRevenueExpenseNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_877baa06-9d88-448c-b08b-95240d926fde_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_f0dc6c1f-f514-45e2-b209-22c303f93158_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful Life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_246195d0-4bc5-48c5-8346-d7e408ba003c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9dc0e3e4-9486-4a5e-b9c7-70f0374fc4e6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5536ab4b-189f-415c-99bb-571c88e48a5a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_dbac1044-e130-4b74-8b4d-72439ce5ce52_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_60338b55-d86d-475b-959c-5bfe4a6b1f23_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_InterestRateCollarMember_f7104317-ea0f-41cd-993f-90635873841f_terseLabel_en-US" xlink:label="lab_asth_InterestRateCollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Rate Collar</link:label>
    <link:label id="lab_asth_InterestRateCollarMember_label_en-US" xlink:label="lab_asth_InterestRateCollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Collar [Member]</link:label>
    <link:label id="lab_asth_InterestRateCollarMember_documentation_en-US" xlink:label="lab_asth_InterestRateCollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Rate Collar</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_InterestRateCollarMember" xlink:href="asth-20240331.xsd#asth_InterestRateCollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_InterestRateCollarMember" xlink:to="lab_asth_InterestRateCollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_RelatedPartyTransactionRevenueRecognizedMember_96957082-308e-4931-a273-854f914a988d_terseLabel_en-US" xlink:label="lab_asth_RelatedPartyTransactionRevenueRecognizedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_asth_RelatedPartyTransactionRevenueRecognizedMember_label_en-US" xlink:label="lab_asth_RelatedPartyTransactionRevenueRecognizedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Revenue Recognized [Member]</link:label>
    <link:label id="lab_asth_RelatedPartyTransactionRevenueRecognizedMember_documentation_en-US" xlink:label="lab_asth_RelatedPartyTransactionRevenueRecognizedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_RelatedPartyTransactionRevenueRecognizedMember" xlink:href="asth-20240331.xsd#asth_RelatedPartyTransactionRevenueRecognizedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_RelatedPartyTransactionRevenueRecognizedMember" xlink:to="lab_asth_RelatedPartyTransactionRevenueRecognizedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a1aa17a6-1b6c-4f74-b251-d9a910a598d7_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_c8490d0f-1926-4e6f-9569-46aa6e0ca397_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_b1d486ff-1788-4f32-8914-159c454bd116_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_RelatedPartyTransactionExpensesIncurredMember_ae43e39b-a16c-438f-8204-43bd977c2b66_terseLabel_en-US" xlink:label="lab_asth_RelatedPartyTransactionExpensesIncurredMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_asth_RelatedPartyTransactionExpensesIncurredMember_label_en-US" xlink:label="lab_asth_RelatedPartyTransactionExpensesIncurredMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Expenses Incurred [Member]</link:label>
    <link:label id="lab_asth_RelatedPartyTransactionExpensesIncurredMember_documentation_en-US" xlink:label="lab_asth_RelatedPartyTransactionExpensesIncurredMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Expenses Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_RelatedPartyTransactionExpensesIncurredMember" xlink:href="asth-20240331.xsd#asth_RelatedPartyTransactionExpensesIncurredMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_RelatedPartyTransactionExpensesIncurredMember" xlink:to="lab_asth_RelatedPartyTransactionExpensesIncurredMember" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses_546c246b-add6-4151-a4c5-8a5de31f6e48_terseLabel_en-US" xlink:label="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses_label_en-US" xlink:label="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities, Accounts Payable And Accrued Expenses</link:label>
    <link:label id="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses_documentation_en-US" xlink:label="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities, Accounts Payable And Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses" xlink:href="asth-20240331.xsd#asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses" xlink:to="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_3a4a705b-54f7-4e80-bbcb-115afb7f2583_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">% of Ownership</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_da30de4e-8dfa-476e-8600-fdef0377c4ce_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity interest (as a percent)</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_72b1eb63-65f3-467e-ba4f-566502f160ec_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_LeaseWeightedAverageRemainingLeaseTermAbstract_fadcca45-0ccc-464e-8df0-e11e0806b7f8_verboseLabel_en-US" xlink:label="lab_asth_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Lease Term</link:label>
    <link:label id="lab_asth_LeaseWeightedAverageRemainingLeaseTermAbstract_label_en-US" xlink:label="lab_asth_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Weighted Average Remaining Lease Term [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:href="asth-20240331.xsd#asth_LeaseWeightedAverageRemainingLeaseTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:to="lab_asth_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_75c841b2-e12a-40a8-8b36-e54c4d5c7d7d_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_70a8680e-52a5-456c-92cd-cb53775295f2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Transactions Under Stock Option Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8e060e59-eb5f-4ad9-8182-316b6a566284_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates_e1f39362-7e57-4579-99f8-e71c9322cb12_terseLabel_en-US" xlink:label="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts due from affiliates</link:label>
    <link:label id="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates_label_en-US" xlink:label="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Amounts Due From Affiliates</link:label>
    <link:label id="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates_documentation_en-US" xlink:label="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Amounts Due From Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates" xlink:href="asth-20240331.xsd#asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates" xlink:to="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_BoardMembersWhoAreAlsoOfficersMember_1dbbc8e1-e2e5-4b1e-86e3-f933ee29df46_terseLabel_en-US" xlink:label="lab_asth_BoardMembersWhoAreAlsoOfficersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Board Members Who Are Also Officers</link:label>
    <link:label id="lab_asth_BoardMembersWhoAreAlsoOfficersMember_label_en-US" xlink:label="lab_asth_BoardMembersWhoAreAlsoOfficersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Board Members Who Are Also Officers [Member]</link:label>
    <link:label id="lab_asth_BoardMembersWhoAreAlsoOfficersMember_documentation_en-US" xlink:label="lab_asth_BoardMembersWhoAreAlsoOfficersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Board Members Who Are Also Officers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BoardMembersWhoAreAlsoOfficersMember" xlink:href="asth-20240331.xsd#asth_BoardMembersWhoAreAlsoOfficersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_BoardMembersWhoAreAlsoOfficersMember" xlink:to="lab_asth_BoardMembersWhoAreAlsoOfficersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_PayorBMember_46974b4f-6db0-4d29-8548-39942be75e7f_terseLabel_en-US" xlink:label="lab_asth_PayorBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payer B</link:label>
    <link:label id="lab_asth_PayorBMember_label_en-US" xlink:label="lab_asth_PayorBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payor B [Member]</link:label>
    <link:label id="lab_asth_PayorBMember_documentation_en-US" xlink:label="lab_asth_PayorBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payor B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PayorBMember" xlink:href="asth-20240331.xsd#asth_PayorBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_PayorBMember" xlink:to="lab_asth_PayorBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5813be0f-21fe-4904-ab4a-c00efba6c53f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_246f6d74-d26c-4fce-92fc-70a15170b1bf_terseLabel_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonrelated Party</link:label>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonrelated Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonrelatedPartyMember" xlink:to="lab_us-gaap_NonrelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_380ae923-68d9-4757-88ad-4801caefc8bc_verboseLabel_en-US" xlink:label="lab_asth_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares issued for exercise of options and warrants</link:label>
    <link:label id="lab_asth_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_label_en-US" xlink:label="lab_asth_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During the Period Value of Exercise of Option and Warrants</link:label>
    <link:label id="lab_asth_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_documentation_en-US" xlink:label="lab_asth_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">It represents value of stock issued during the period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:href="asth-20240331.xsd#asth_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:to="lab_asth_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_9e0137e4-8930-40b9-ba07-00146ea4c608_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenue</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_311177ca-8824-4316-a585-8f97f6b971f7_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intersegment</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_4cf04771-f1f7-4fc3-b5d6-a5803fedb269_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_0aa5c8c9-9438-42d5-84ae-b8b01f7b4eeb_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_d47b089e-9694-4eec-b84d-43a5b8f23955_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_654f5f9f-7d17-43eb-9478-ec702ca1fbb9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_47bd9490-d78f-4b13-8a3a-b97fd9beca87_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities, mezzanine equity and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_97c0e108-b8cb-41f9-b823-3812553a83e8_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_d33d73eb-374a-4d89-800e-f6397b000cef_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_4fa6a026-19c0-439e-a26f-a0b24d909233_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_290a317a-a96e-41d4-a5c9-3007181a1ee9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_bd2f5fd2-ea2f-431d-81a5-a19c57ae8b59_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investment in a privately held entity</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI and without Readily Determinable Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:to="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_SpecialtyCapitationPayableCurrent_a03696c3-abab-400e-895c-3178cdab5414_verboseLabel_en-US" xlink:label="lab_asth_SpecialtyCapitationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Capitation payable</link:label>
    <link:label id="lab_asth_SpecialtyCapitationPayableCurrent_label_en-US" xlink:label="lab_asth_SpecialtyCapitationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Specialty Capitation Payable Current</link:label>
    <link:label id="lab_asth_SpecialtyCapitationPayableCurrent_documentation_en-US" xlink:label="lab_asth_SpecialtyCapitationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of specialty capitation payable current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_SpecialtyCapitationPayableCurrent" xlink:href="asth-20240331.xsd#asth_SpecialtyCapitationPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_SpecialtyCapitationPayableCurrent" xlink:to="lab_asth_SpecialtyCapitationPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_1c3c73a5-46d0-45f8-891a-0363b22839ea_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_AAMGMember_84206773-bb20-4ad8-997e-f6b0e8c49519_terseLabel_en-US" xlink:label="lab_asth_AAMGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AAMG contingent consideration</link:label>
    <link:label id="lab_asth_AAMGMember_label_en-US" xlink:label="lab_asth_AAMGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AAMG [Member]</link:label>
    <link:label id="lab_asth_AAMGMember_documentation_en-US" xlink:label="lab_asth_AAMGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AAMG</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AAMGMember" xlink:href="asth-20240331.xsd#asth_AAMGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_AAMGMember" xlink:to="lab_asth_AAMGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_6e644c09-31ed-4449-a601-c82cb2df407b_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1ff20eb6-96d3-4545-9b18-2d57665a427a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 (excluding the three months ended March 31, 2024)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a815c9a0-54c1-44ba-867d-8f4a4225a67a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_8dc2a552-5b5b-450f-8c1c-f8cb6c98bc03_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Information about our Segments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_d2cf3861-2ce2-484e-889e-b0a04363ecda_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_FiveThreeOneW.CollegeLLCMember_2742dfc4-9c6e-4f49-8229-d5d81046c983_verboseLabel_en-US" xlink:label="lab_asth_FiveThreeOneW.CollegeLLCMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">531 W. College, LLC</link:label>
    <link:label id="lab_asth_FiveThreeOneW.CollegeLLCMember_label_en-US" xlink:label="lab_asth_FiveThreeOneW.CollegeLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Five Three One W. College LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_FiveThreeOneW.CollegeLLCMember" xlink:href="asth-20240331.xsd#asth_FiveThreeOneW.CollegeLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_FiveThreeOneW.CollegeLLCMember" xlink:to="lab_asth_FiveThreeOneW.CollegeLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_8d123429-3dce-4086-9c2e-954b482470c9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of non-controlling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_243ad78d-57c4-478d-ba80-70520f97b29a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_66d4aac4-a142-4700-9a51-f42d9e44c007_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities &#8211; certificates of deposit</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_dbf5d27d-31aa-42fe-b517-6dae587c435a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_6598e83a-1bb6-4125-90f3-41d146c6022f_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total losses recognized on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_SubordinatedLoanAgreementMember_b6833c04-cd3d-4619-8327-570e3177cb3f_terseLabel_en-US" xlink:label="lab_asth_SubordinatedLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subordinated Loan Agreement</link:label>
    <link:label id="lab_asth_SubordinatedLoanAgreementMember_label_en-US" xlink:label="lab_asth_SubordinatedLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subordinated Loan Agreement [Member]</link:label>
    <link:label id="lab_asth_SubordinatedLoanAgreementMember_documentation_en-US" xlink:label="lab_asth_SubordinatedLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Subordinated Loan Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_SubordinatedLoanAgreementMember" xlink:href="asth-20240331.xsd#asth_SubordinatedLoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_SubordinatedLoanAgreementMember" xlink:to="lab_asth_SubordinatedLoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_45fdb460-fa3f-454f-a3a6-a971d2cec57c_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_82c675bb-4f11-453e-95e6-edb8e49ec698_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_8b7a8ebc-2335-41e1-9c3b-04a6ce990b20_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BridgeLoanMember_92c0c500-b91a-420d-ac01-15310ad5e8fa_terseLabel_en-US" xlink:label="lab_us-gaap_BridgeLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bridge Loan</link:label>
    <link:label id="lab_us-gaap_BridgeLoanMember_label_en-US" xlink:label="lab_us-gaap_BridgeLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bridge Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BridgeLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BridgeLoanMember" xlink:to="lab_us-gaap_BridgeLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_89af633f-9b4f-4e30-8bd2-391b8efd24ae_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_9c256d4d-8f28-4f83-89d1-72f176eb7bb4_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total identifiable assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_2cebd807-68e3-4dd1-943a-06a36c8b537e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_ef29b5a9-97be-4699-8e4c-8920aa15934f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_8d32089d-879b-41b9-8605-2b782bd2d733_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_5111679a-6f76-464f-a344-c927f1350555_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d5ac4281-dde4-416a-a5f7-d55348017d60_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_78f93ade-c3cd-4bb6-89f1-6068a10e45c4_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_5b41723e-5bbc-4cef-8fba-f91e0dbcc2b6_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_dceadbcf-3b40-4a72-853b-3074b35690fe_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8d6a336c-65c1-4c6f-8a8e-0701410602f7_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_476e4879-f5f9-46e4-a1e4-7d67ba922874_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_cb07ba43-6130-4bf4-b8c3-281db2b4aba4_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_4e5ca368-bd52-4f29-8330-394e4eba35e8_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:to="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a10a3656-a7ed-4140-8dfe-6c08ac35a4e4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5685cd8f-86c5-4d78-b54b-f2d3b3280d22_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_b9a6bc94-15dc-4383-a6ab-8766a53899e4_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRelatedPartyDebt_3ae0ee89-4465-415a-8060-7530be7523bf_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from promissory note</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRelatedPartyDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Related Party Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="lab_us-gaap_ProceedsFromRelatedPartyDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_PatientManagementPlatformMember_965f29ea-2a8c-4118-a954-bb15f01b0df1_terseLabel_en-US" xlink:label="lab_asth_PatientManagementPlatformMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patient management platform</link:label>
    <link:label id="lab_asth_PatientManagementPlatformMember_label_en-US" xlink:label="lab_asth_PatientManagementPlatformMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patient Management Platform [Member]</link:label>
    <link:label id="lab_asth_PatientManagementPlatformMember_documentation_en-US" xlink:label="lab_asth_PatientManagementPlatformMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Patient Management Platform</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PatientManagementPlatformMember" xlink:href="asth-20240331.xsd#asth_PatientManagementPlatformMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_PatientManagementPlatformMember" xlink:to="lab_asth_PatientManagementPlatformMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_1782635d-0b68-4c84-a41d-c645dd34af96_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares_a3db9219-040f-4d3c-9ed1-c4c956a5f055_terseLabel_en-US" xlink:label="lab_asth_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_asth_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares_label_en-US" xlink:label="lab_asth_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders And Stock Repurchased During Period, Value, Release Of Hold Back Shares</link:label>
    <link:label id="lab_asth_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares_documentation_en-US" xlink:label="lab_asth_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders And Stock Repurchased During Period, Value, Release Of Hold Back Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" xlink:href="asth-20240331.xsd#asth_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" xlink:to="lab_asth_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_5359102e-fffb-48af-a0dc-13dc4b6d3af9_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_cc9cf565-1ac7-416e-b246-026dbf2f0919_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_ffd0dd47-b91a-45e8-ba45-c79dddf257fe_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized intangible assets, Gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares_5f89073b-2b8c-4284-a394-c0b158bb83b2_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingently issuable shares (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_3a20ebda-70b5-45b3-981b-a3e9ac249c4b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_4681641b-8c95-4cd0-b12c-cc45b42d8370_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Other than Temporary Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:to="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest_ea0413cd-a6f2-42b4-8a2a-2755965eb7ca_terseLabel_en-US" xlink:label="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest_label_en-US" xlink:label="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities, Noncontrolling Interest</link:label>
    <link:label id="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest_documentation_en-US" xlink:label="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest" xlink:href="asth-20240331.xsd#asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest" xlink:to="lab_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_43793505-6582-44fb-bfef-3834f1ff0cb0_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_MezzanineMember_ba5c6ab0-8399-4aa1-b655-3791a3f04c55_terseLabel_en-US" xlink:label="lab_asth_MezzanineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mezzanine</link:label>
    <link:label id="lab_asth_MezzanineMember_label_en-US" xlink:label="lab_asth_MezzanineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mezzanine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_MezzanineMember" xlink:href="asth-20240331.xsd#asth_MezzanineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_MezzanineMember" xlink:to="lab_asth_MezzanineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_ApcBusinessLoanAgreementMember_2a981235-213e-48af-9e77-0edc6c8e0c5c_terseLabel_en-US" xlink:label="lab_asth_ApcBusinessLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">APC Business Loan Agreement</link:label>
    <link:label id="lab_asth_ApcBusinessLoanAgreementMember_label_en-US" xlink:label="lab_asth_ApcBusinessLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APC Business Loan Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ApcBusinessLoanAgreementMember" xlink:href="asth-20240331.xsd#asth_ApcBusinessLoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_ApcBusinessLoanAgreementMember" xlink:to="lab_asth_ApcBusinessLoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_39ef67d5-55af-4581-9914-a28667d8f24b_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_36759da1-5f3b-4e3b-851e-79ae3086c0be_verboseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Disaggregated Revenue by Each Payor Type</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8e6e1fc7-cca6-47a2-9c5b-62fc46fa7b3e_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0b11050a-08fd-4206-bfe6-9f7d782281b0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_6df2438f-5b7a-49d4-91d1-e6444f5fbfc3_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_fde982ee-c54f-45c6-9581-a8edcb3d862f_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_67e3d934-b4e2-47fc-8c78-c13ee0744137_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_b0dc9676-edea-40e0-a25b-1547c5b65e12_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_54961343-a42f-489b-954a-d055a3dacc91_negatedLabel_en-US" xlink:label="lab_asth_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_asth_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_label_en-US" xlink:label="lab_asth_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Prepaid Expenses And Other Current Assets</link:label>
    <link:label id="lab_asth_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_documentation_en-US" xlink:label="lab_asth_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase (decrease) during the reporting period in the value of prepaid expenses and other current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:href="asth-20240331.xsd#asth_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:to="lab_asth_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_4b3b8fc2-876c-4e3b-94e4-6b2a4e247238_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_SecuredOvernightFinancingRateMember_5722c77b-5845-4ca5-aed1-30f9a0151d89_terseLabel_en-US" xlink:label="lab_asth_SecuredOvernightFinancingRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Overnight Financing Rate</link:label>
    <link:label id="lab_asth_SecuredOvernightFinancingRateMember_label_en-US" xlink:label="lab_asth_SecuredOvernightFinancingRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Overnight Financing Rate [Member]</link:label>
    <link:label id="lab_asth_SecuredOvernightFinancingRateMember_documentation_en-US" xlink:label="lab_asth_SecuredOvernightFinancingRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Secured Overnight Financing Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_SecuredOvernightFinancingRateMember" xlink:href="asth-20240331.xsd#asth_SecuredOvernightFinancingRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_SecuredOvernightFinancingRateMember" xlink:to="lab_asth_SecuredOvernightFinancingRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_ea43b5ac-0d8b-4b85-828a-eb107a493bac_terseLabel_en-US" xlink:label="lab_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value (in millions)</link:label>
    <link:label id="lab_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:href="asth-20240331.xsd#asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_c5667b28-d12c-423c-a52a-9427701f8a03_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_3f5e5308-555b-429e-a56a-f816718924b2_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_70fa0bc5-c92f-4ef9-b49a-15e97a7bc35c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medical Liabilities [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_b26240e2-e424-49d3-8957-f54764bb8128_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_b51333f9-0fe7-454f-83a2-58813dcc6f11_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_a7e49f04-78a7-48b1-ba94-659cf1504564_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, net of current portion and deferred financing costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_2a3ad369-31ef-45f8-afcd-aa9a9415bfda_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_536e035c-0f29-46c6-b717-ff270899651a_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_e7289e6d-1964-488d-9cef-259084d91f57_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Gain (Loss) on Equity Securities</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:to="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_056dbd72-c85d-4823-9676-194c4712d2d9_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares of common stock outstanding &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_28572235-c495-4551-9e22-0eefedc2615f_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares of common stock outstanding &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_4ab57e29-bc61-499d-b036-d7f6108d74c8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_30e0077d-325a-4013-90f1-03c827c01a27_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_NewTermLoanMember_0a89d502-2d48-4198-9ff5-ed83a3bac148_terseLabel_en-US" xlink:label="lab_asth_NewTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Term Loan</link:label>
    <link:label id="lab_asth_NewTermLoanMember_label_en-US" xlink:label="lab_asth_NewTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Term Loan [Member]</link:label>
    <link:label id="lab_asth_NewTermLoanMember_documentation_en-US" xlink:label="lab_asth_NewTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">New Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_NewTermLoanMember" xlink:href="asth-20240331.xsd#asth_NewTermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_NewTermLoanMember" xlink:to="lab_asth_NewTermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_a14c9a00-5007-46cf-8bbf-4a895b16ad1f_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_2ac54f2d-0c75-4671-bde6-f842c0eadb57_verboseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_73c4c18f-83f5-4771-b381-b162aac59ee8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_5b835410-e302-44bc-a530-0e90c9d4ab18_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_ee8ae6f1-43f0-494b-ae4b-e923e4a37794_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating cash flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_e7ed14c2-20a9-444c-a9df-0fcfcaad42ca_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_85060709-a5b0-4f54-8a22-ae5904294ff0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_c36359ae-69e8-4ba6-8c04-61300fa4ed2f_terseLabel_en-US" xlink:label="lab_asth_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_asth_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_asth_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:label id="lab_asth_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_asth_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="asth-20240331.xsd#asth_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_asth_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_ddb5aebe-324d-4479-b73d-254836a0ac70_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7703decf-a4e8-4499-be3d-9d39fcddca7a_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares of common stock outstanding &#8211; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_b7ec15c2-8914-41c0-908a-642bc0588f1d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_1163ecee-6c39-4167-bfa2-6fe0f8c5bb68_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_1eba3bcb-5869-47e3-8428-682fa27f59b0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period Two</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_2ca7e648-6121-4567-8645-891e7caa3a06_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_93abb515-9ce1-44e3-87d0-0c2121c163ee_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_DebtInstrumentCovenantLeverageRatioMaximum_cd166506-b410-4dcc-87fe-5fa969e936a5_terseLabel_en-US" xlink:label="lab_asth_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum consolidated leverage ratio (not greater than)</link:label>
    <link:label id="lab_asth_DebtInstrumentCovenantLeverageRatioMaximum_label_en-US" xlink:label="lab_asth_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Maximum</link:label>
    <link:label id="lab_asth_DebtInstrumentCovenantLeverageRatioMaximum_documentation_en-US" xlink:label="lab_asth_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_DebtInstrumentCovenantLeverageRatioMaximum" xlink:href="asth-20240331.xsd#asth_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_DebtInstrumentCovenantLeverageRatioMaximum" xlink:to="lab_asth_DebtInstrumentCovenantLeverageRatioMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdditions_6d64dc55-1453-4089-82f1-c9bcdb17d611_terseLabel_en-US" xlink:label="lab_asth_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_asth_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdditions_label_en-US" xlink:label="lab_asth_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability, Additions</link:label>
    <link:label id="lab_asth_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdditions_documentation_en-US" xlink:label="lab_asth_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdditions" xlink:href="asth-20240331.xsd#asth_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdditions" xlink:to="lab_asth_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_a45acf0d-a32d-4050-8b58-021c49d9772c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_b4ca8da8-c820-4f42-85ff-06d1a566db97_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_PacificMedicalImagingAndOncologyCenterIncMember_5abd5681-8bc9-448d-8f6a-f52714e3ef75_terseLabel_en-US" xlink:label="lab_asth_PacificMedicalImagingAndOncologyCenterIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pacific Medical Imaging &amp; Oncology Center, Inc.</link:label>
    <link:label id="lab_asth_PacificMedicalImagingAndOncologyCenterIncMember_label_en-US" xlink:label="lab_asth_PacificMedicalImagingAndOncologyCenterIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pacific Medical Imaging and Oncology Center, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PacificMedicalImagingAndOncologyCenterIncMember" xlink:href="asth-20240331.xsd#asth_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_PacificMedicalImagingAndOncologyCenterIncMember" xlink:to="lab_asth_PacificMedicalImagingAndOncologyCenterIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_asth_DebtCovenantAggregatePurchasePriceMaximum_1a64cac7-6b7b-4298-b80e-bce898fe4849_terseLabel_en-US" xlink:label="lab_asth_DebtCovenantAggregatePurchasePriceMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt covenant, aggregate purchase price, maximum</link:label>
    <link:label id="lab_asth_DebtCovenantAggregatePurchasePriceMaximum_label_en-US" xlink:label="lab_asth_DebtCovenantAggregatePurchasePriceMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Covenant, Aggregate Purchase Price, Maximum</link:label>
    <link:label id="lab_asth_DebtCovenantAggregatePurchasePriceMaximum_documentation_en-US" xlink:label="lab_asth_DebtCovenantAggregatePurchasePriceMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Covenant, Aggregate Purchase Price, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_asth_DebtCovenantAggregatePurchasePriceMaximum" xlink:href="asth-20240331.xsd#asth_DebtCovenantAggregatePurchasePriceMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_asth_DebtCovenantAggregatePurchasePriceMaximum" xlink:to="lab_asth_DebtCovenantAggregatePurchasePriceMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferToInvestments_7cf73c31-7044-46bf-8e0a-a3d0e3d63527_terseLabel_en-US" xlink:label="lab_us-gaap_TransferToInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase of investments - equity method in accounts payable and accrued liabilities and other liabilities</link:label>
    <link:label id="lab_us-gaap_TransferToInvestments_label_en-US" xlink:label="lab_us-gaap_TransferToInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transfer to Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferToInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransferToInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferToInvestments" xlink:to="lab_us-gaap_TransferToInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_12df28f6-13ad-4fb3-9419-57aaa938b5ec_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>asth-20240331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:b0ef7e3c-019a-4a45-b736-b471aca8f6db,g:a1c00dc1-e4c6-4560-85ab-798755e5651c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.apollomed.net/role/Cover" xlink:type="simple" xlink:href="asth-20240331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_c46dea1f-840c-442e-8e32-1862515d1d67" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_cc2b6e50-de36-48fd-80e1-a10c9db0096f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c46dea1f-840c-442e-8e32-1862515d1d67" xlink:to="loc_dei_DocumentType_cc2b6e50-de36-48fd-80e1-a10c9db0096f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_40b70493-7248-42f4-9315-34ed3032873d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c46dea1f-840c-442e-8e32-1862515d1d67" xlink:to="loc_dei_DocumentQuarterlyReport_40b70493-7248-42f4-9315-34ed3032873d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_5f3233c5-d4e6-416e-8077-20690ceb0e62" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c46dea1f-840c-442e-8e32-1862515d1d67" xlink:to="loc_dei_DocumentPeriodEndDate_5f3233c5-d4e6-416e-8077-20690ceb0e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_00608357-49f9-428e-a121-76c484c5cfe7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c46dea1f-840c-442e-8e32-1862515d1d67" xlink:to="loc_dei_DocumentTransitionReport_00608357-49f9-428e-a121-76c484c5cfe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ef722380-c087-4600-8b71-a3ee435c8cbb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c46dea1f-840c-442e-8e32-1862515d1d67" xlink:to="loc_dei_EntityFileNumber_ef722380-c087-4600-8b71-a3ee435c8cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_be31e6a2-5c5f-44ac-9b3b-c01cbb80f089" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c46dea1f-840c-442e-8e32-1862515d1d67" xlink:to="loc_dei_EntityRegistrantName_be31e6a2-5c5f-44ac-9b3b-c01cbb80f089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_7c046082-9828-4d87-bda6-3b054638b86e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c46dea1f-840c-442e-8e32-1862515d1d67" xlink:to="loc_dei_EntityIncorporationStateCountryCode_7c046082-9828-4d87-bda6-3b054638b86e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_b348927b-2a42-4fff-9dd0-899df678a5f0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c46dea1f-840c-442e-8e32-1862515d1d67" xlink:to="loc_dei_EntityTaxIdentificationNumber_b348927b-2a42-4fff-9dd0-899df678a5f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_a3f7cc66-a18d-4618-94e9-ea1114da6b54" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c46dea1f-840c-442e-8e32-1862515d1d67" xlink:to="loc_dei_EntityAddressAddressLine1_a3f7cc66-a18d-4618-94e9-ea1114da6b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_efa08afc-f711-4e1c-8709-a2cd16a8ddd8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c46dea1f-840c-442e-8e32-1862515d1d67" xlink:to="loc_dei_EntityAddressAddressLine2_efa08afc-f711-4e1c-8709-a2cd16a8ddd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_0f24b1d6-0da7-4222-b103-4b54148e924c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c46dea1f-840c-442e-8e32-1862515d1d67" xlink:to="loc_dei_EntityAddressCityOrTown_0f24b1d6-0da7-4222-b103-4b54148e924c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e3bccc3a-8ab9-49fa-98b9-610f85be128c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c46dea1f-840c-442e-8e32-1862515d1d67" xlink:to="loc_dei_EntityAddressStateOrProvince_e3bccc3a-8ab9-49fa-98b9-610f85be128c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f590bc27-c47b-4d15-95f3-849d4babdd48" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c46dea1f-840c-442e-8e32-1862515d1d67" xlink:to="loc_dei_EntityAddressPostalZipCode_f590bc27-c47b-4d15-95f3-849d4babdd48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_1ba383ec-c8be-4024-85bf-2e9a82964bfa" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c46dea1f-840c-442e-8e32-1862515d1d67" xlink:to="loc_dei_CityAreaCode_1ba383ec-c8be-4024-85bf-2e9a82964bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_0b4a84d1-bcaa-42ac-b76e-1cb6353933c4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c46dea1f-840c-442e-8e32-1862515d1d67" xlink:to="loc_dei_LocalPhoneNumber_0b4a84d1-bcaa-42ac-b76e-1cb6353933c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ca896b58-9441-49ec-98cc-04b73a322a62" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c46dea1f-840c-442e-8e32-1862515d1d67" xlink:to="loc_dei_Security12bTitle_ca896b58-9441-49ec-98cc-04b73a322a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_af1cc170-f3c3-4a44-a328-a89cec335629" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c46dea1f-840c-442e-8e32-1862515d1d67" xlink:to="loc_dei_TradingSymbol_af1cc170-f3c3-4a44-a328-a89cec335629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_550d700b-6f57-4f89-9a37-6db7efac4f66" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c46dea1f-840c-442e-8e32-1862515d1d67" xlink:to="loc_dei_SecurityExchangeName_550d700b-6f57-4f89-9a37-6db7efac4f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_10142edb-a36b-4914-8fa8-65892d98a644" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c46dea1f-840c-442e-8e32-1862515d1d67" xlink:to="loc_dei_EntityCurrentReportingStatus_10142edb-a36b-4914-8fa8-65892d98a644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_8a13a4b8-5b9f-43f0-bd88-8d02cdab234f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c46dea1f-840c-442e-8e32-1862515d1d67" xlink:to="loc_dei_EntityInteractiveDataCurrent_8a13a4b8-5b9f-43f0-bd88-8d02cdab234f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_c0d1f1c9-27c5-49ff-abbc-200f63dd73a4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c46dea1f-840c-442e-8e32-1862515d1d67" xlink:to="loc_dei_EntityFilerCategory_c0d1f1c9-27c5-49ff-abbc-200f63dd73a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_bab91474-78e1-4525-a5df-40e1aae2909a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c46dea1f-840c-442e-8e32-1862515d1d67" xlink:to="loc_dei_EntitySmallBusiness_bab91474-78e1-4525-a5df-40e1aae2909a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_908aca20-97a9-407d-ab55-897eba39dbd7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c46dea1f-840c-442e-8e32-1862515d1d67" xlink:to="loc_dei_EntityEmergingGrowthCompany_908aca20-97a9-407d-ab55-897eba39dbd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_52ae3060-224c-4315-a630-812b90c9ec98" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c46dea1f-840c-442e-8e32-1862515d1d67" xlink:to="loc_dei_EntityShellCompany_52ae3060-224c-4315-a630-812b90c9ec98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_99565f43-5dc4-4c07-9915-0fe86427ad7d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c46dea1f-840c-442e-8e32-1862515d1d67" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_99565f43-5dc4-4c07-9915-0fe86427ad7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c092e9b2-9cf1-40db-a7aa-9511ada21a8a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c46dea1f-840c-442e-8e32-1862515d1d67" xlink:to="loc_dei_AmendmentFlag_c092e9b2-9cf1-40db-a7aa-9511ada21a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_74498723-aac6-4680-810c-7c42eb9e53c0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c46dea1f-840c-442e-8e32-1862515d1d67" xlink:to="loc_dei_DocumentFiscalYearFocus_74498723-aac6-4680-810c-7c42eb9e53c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_0bae2cd2-1997-492d-be51-383caa738011" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c46dea1f-840c-442e-8e32-1862515d1d67" xlink:to="loc_dei_DocumentFiscalPeriodFocus_0bae2cd2-1997-492d-be51-383caa738011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_08905653-49bd-4ca4-8ca3-bcb56a78b61d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c46dea1f-840c-442e-8e32-1862515d1d67" xlink:to="loc_dei_EntityCentralIndexKey_08905653-49bd-4ca4-8ca3-bcb56a78b61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_de42c9c3-f949-4056-8527-6ac35af8b034" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c46dea1f-840c-442e-8e32-1862515d1d67" xlink:to="loc_dei_CurrentFiscalYearEndDate_de42c9c3-f949-4056-8527-6ac35af8b034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="asth-20240331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_731ab9c7-8c26-467b-8ad7-5467fd424a56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ed60d260-585f-438e-bbcb-cf65ed3cb808" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_731ab9c7-8c26-467b-8ad7-5467fd424a56" xlink:to="loc_us-gaap_StatementTable_ed60d260-585f-438e-bbcb-cf65ed3cb808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8dd97ada-1157-4402-9d3c-54388038556f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ed60d260-585f-438e-bbcb-cf65ed3cb808" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8dd97ada-1157-4402-9d3c-54388038556f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f00dd92b-d286-47fd-9f4b-db099d2e8237" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8dd97ada-1157-4402-9d3c-54388038556f" xlink:to="loc_us-gaap_RelatedPartyDomain_f00dd92b-d286-47fd-9f4b-db099d2e8237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_4f983fee-bd3c-4405-ba60-1302cd06be85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_f00dd92b-d286-47fd-9f4b-db099d2e8237" xlink:to="loc_us-gaap_NonrelatedPartyMember_4f983fee-bd3c-4405-ba60-1302cd06be85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_6b2428f9-817e-4fff-acc9-fdc70f3074a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_f00dd92b-d286-47fd-9f4b-db099d2e8237" xlink:to="loc_us-gaap_RelatedPartyMember_6b2428f9-817e-4fff-acc9-fdc70f3074a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4b46ac1b-81bf-4c1e-9499-63b75a61abe5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ed60d260-585f-438e-bbcb-cf65ed3cb808" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4b46ac1b-81bf-4c1e-9499-63b75a61abe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_36db3f88-6691-4d49-87be-58363b1e2299" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4b46ac1b-81bf-4c1e-9499-63b75a61abe5" xlink:to="loc_us-gaap_ClassOfStockDomain_36db3f88-6691-4d49-87be-58363b1e2299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_bcd40cd7-9e73-4572-b62e-9edea2895361" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_36db3f88-6691-4d49-87be-58363b1e2299" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_bcd40cd7-9e73-4572-b62e-9edea2895361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_43b51424-5041-4e56-8bd4-27d1bef662d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_36db3f88-6691-4d49-87be-58363b1e2299" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_43b51424-5041-4e56-8bd4-27d1bef662d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0c873971-222a-4636-b85c-2bcf494032f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ed60d260-585f-438e-bbcb-cf65ed3cb808" xlink:to="loc_us-gaap_StatementLineItems_0c873971-222a-4636-b85c-2bcf494032f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_0add10b9-ae04-4782-ae48-6dc86459e13c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c873971-222a-4636-b85c-2bcf494032f5" xlink:to="loc_us-gaap_AssetsAbstract_0add10b9-ae04-4782-ae48-6dc86459e13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_184823bc-0e0a-47a8-89db-294b361b2012" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0add10b9-ae04-4782-ae48-6dc86459e13c" xlink:to="loc_us-gaap_AssetsCurrentAbstract_184823bc-0e0a-47a8-89db-294b361b2012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_719cc48f-6826-4765-a7ec-35cc8e135ace" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_184823bc-0e0a-47a8-89db-294b361b2012" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_719cc48f-6826-4765-a7ec-35cc8e135ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_f76a43cc-4281-439e-b7ef-d0c32a3030ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_184823bc-0e0a-47a8-89db-294b361b2012" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_f76a43cc-4281-439e-b7ef-d0c32a3030ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e7eccfba-f352-41bd-929f-9b7316ca1c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_184823bc-0e0a-47a8-89db-294b361b2012" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e7eccfba-f352-41bd-929f-9b7316ca1c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_3487c06c-b5cb-4109-9bf3-14b751df1e25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_184823bc-0e0a-47a8-89db-294b361b2012" xlink:to="loc_us-gaap_IncomeTaxesReceivable_3487c06c-b5cb-4109-9bf3-14b751df1e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_aed995e5-ccfc-4227-b67b-3c467185628a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_184823bc-0e0a-47a8-89db-294b361b2012" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_aed995e5-ccfc-4227-b67b-3c467185628a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bc7c6656-4f08-40c8-be6a-3bd998fe00a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_184823bc-0e0a-47a8-89db-294b361b2012" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bc7c6656-4f08-40c8-be6a-3bd998fe00a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ec1f2759-ff5b-4cbd-8ea3-da816fbbca43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_184823bc-0e0a-47a8-89db-294b361b2012" xlink:to="loc_us-gaap_AssetsCurrent_ec1f2759-ff5b-4cbd-8ea3-da816fbbca43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_0e6f58b8-488f-4aac-8c30-9926b9244542" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0add10b9-ae04-4782-ae48-6dc86459e13c" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_0e6f58b8-488f-4aac-8c30-9926b9244542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d55ac490-0753-4600-b9bd-56704dabc8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0e6f58b8-488f-4aac-8c30-9926b9244542" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d55ac490-0753-4600-b9bd-56704dabc8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_09f1935f-535b-4ec4-bf92-1106cf1e3839" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0e6f58b8-488f-4aac-8c30-9926b9244542" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_09f1935f-535b-4ec4-bf92-1106cf1e3839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ecdc9eba-04f2-4e1f-981b-b4aa853ca883" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0e6f58b8-488f-4aac-8c30-9926b9244542" xlink:to="loc_us-gaap_Goodwill_ecdc9eba-04f2-4e1f-981b-b4aa853ca883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivableNoncurrent_541d8814-6595-4035-85c4-9ab82413553e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesReceivableNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0e6f58b8-488f-4aac-8c30-9926b9244542" xlink:to="loc_us-gaap_IncomeTaxesReceivableNoncurrent_541d8814-6595-4035-85c4-9ab82413553e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_1a382cd8-cde7-425f-8d02-15bc9b4c1382" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0e6f58b8-488f-4aac-8c30-9926b9244542" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_1a382cd8-cde7-425f-8d02-15bc9b4c1382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_c81e1921-5709-4e0c-b4d5-a1095869f2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0e6f58b8-488f-4aac-8c30-9926b9244542" xlink:to="loc_us-gaap_EquityMethodInvestments_c81e1921-5709-4e0c-b4d5-a1095869f2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_6a0e5934-b29c-4121-a1f4-9c55ae47d946" xlink:href="asth-20240331.xsd#asth_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0e6f58b8-488f-4aac-8c30-9926b9244542" xlink:to="loc_asth_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_6a0e5934-b29c-4121-a1f4-9c55ae47d946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_d39f593f-1386-43e6-9184-2c79de0a33d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0e6f58b8-488f-4aac-8c30-9926b9244542" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_d39f593f-1386-43e6-9184-2c79de0a33d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_13c595c3-4ffa-44bd-94ec-0018e49df139" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0e6f58b8-488f-4aac-8c30-9926b9244542" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_13c595c3-4ffa-44bd-94ec-0018e49df139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0f2980d6-e4e5-4586-a1f7-10ba35c14bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0e6f58b8-488f-4aac-8c30-9926b9244542" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_0f2980d6-e4e5-4586-a1f7-10ba35c14bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_4719bbba-6331-4f46-8518-95a760428791" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0e6f58b8-488f-4aac-8c30-9926b9244542" xlink:to="loc_us-gaap_AssetsNoncurrent_4719bbba-6331-4f46-8518-95a760428791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6140160d-4a99-48e1-a869-b43158db39c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0add10b9-ae04-4782-ae48-6dc86459e13c" xlink:to="loc_us-gaap_Assets_6140160d-4a99-48e1-a869-b43158db39c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77b73640-6d30-4de8-ad7e-fac2e4c26160" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c873971-222a-4636-b85c-2bcf494032f5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77b73640-6d30-4de8-ad7e-fac2e4c26160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_8f39721d-4980-40a2-92cf-09e7f3559136" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77b73640-6d30-4de8-ad7e-fac2e4c26160" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_8f39721d-4980-40a2-92cf-09e7f3559136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_afe6c983-b63a-46db-abf5-d8d8fe44a5a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8f39721d-4980-40a2-92cf-09e7f3559136" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_afe6c983-b63a-46db-abf5-d8d8fe44a5a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_FiduciaryAccountsPayableCurrent_8b4f6ce9-26e1-41c8-8ef2-52c6acb4e090" xlink:href="asth-20240331.xsd#asth_FiduciaryAccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8f39721d-4980-40a2-92cf-09e7f3559136" xlink:to="loc_asth_FiduciaryAccountsPayableCurrent_8b4f6ce9-26e1-41c8-8ef2-52c6acb4e090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_c7d26691-7bf2-4a4e-8624-54ed3aeda473" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8f39721d-4980-40a2-92cf-09e7f3559136" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_c7d26691-7bf2-4a4e-8624-54ed3aeda473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_4654c136-d576-422e-882a-36979ae3de02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8f39721d-4980-40a2-92cf-09e7f3559136" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_4654c136-d576-422e-882a-36979ae3de02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_b1cc82c4-6a98-48b4-99c9-d84371a28d25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8f39721d-4980-40a2-92cf-09e7f3559136" xlink:to="loc_us-gaap_DividendsPayableCurrent_b1cc82c4-6a98-48b4-99c9-d84371a28d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_2d5cf7ea-2343-4566-a14d-82bee11260ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8f39721d-4980-40a2-92cf-09e7f3559136" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_2d5cf7ea-2343-4566-a14d-82bee11260ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_87243acd-dfc5-47e7-9c19-ee6e5d752835" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8f39721d-4980-40a2-92cf-09e7f3559136" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_87243acd-dfc5-47e7-9c19-ee6e5d752835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_273633ba-6879-4c96-9840-4625d92d814b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8f39721d-4980-40a2-92cf-09e7f3559136" xlink:to="loc_us-gaap_LongTermDebtCurrent_273633ba-6879-4c96-9840-4625d92d814b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_b91520f7-40aa-4e75-8fd9-8c85c63dcbaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8f39721d-4980-40a2-92cf-09e7f3559136" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_b91520f7-40aa-4e75-8fd9-8c85c63dcbaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5f1b4930-6b71-4f71-b2e5-8f4306ef3e16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8f39721d-4980-40a2-92cf-09e7f3559136" xlink:to="loc_us-gaap_LiabilitiesCurrent_5f1b4930-6b71-4f71-b2e5-8f4306ef3e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_0a4d7ba7-2914-4fc6-b6f6-cb1d82ee158f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77b73640-6d30-4de8-ad7e-fac2e4c26160" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_0a4d7ba7-2914-4fc6-b6f6-cb1d82ee158f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_21301111-f055-49e9-ba28-707c2101c644" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0a4d7ba7-2914-4fc6-b6f6-cb1d82ee158f" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_21301111-f055-49e9-ba28-707c2101c644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_77781ae0-a998-4417-b12d-dab4c1bb8391" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0a4d7ba7-2914-4fc6-b6f6-cb1d82ee158f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_77781ae0-a998-4417-b12d-dab4c1bb8391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c9c16e91-d2d8-44d3-9a29-f7b335b75d26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0a4d7ba7-2914-4fc6-b6f6-cb1d82ee158f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c9c16e91-d2d8-44d3-9a29-f7b335b75d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_d56b228f-0ffd-4fa4-9699-4dae684b46ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0a4d7ba7-2914-4fc6-b6f6-cb1d82ee158f" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_d56b228f-0ffd-4fa4-9699-4dae684b46ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f33bbebd-aa14-4ddd-aac8-4f84945b6a13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0a4d7ba7-2914-4fc6-b6f6-cb1d82ee158f" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f33bbebd-aa14-4ddd-aac8-4f84945b6a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_de904f32-732f-4e37-835b-01a1ba7cfb46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0a4d7ba7-2914-4fc6-b6f6-cb1d82ee158f" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_de904f32-732f-4e37-835b-01a1ba7cfb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2d913925-1596-45d6-aa8b-14153a76cb7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77b73640-6d30-4de8-ad7e-fac2e4c26160" xlink:to="loc_us-gaap_Liabilities_2d913925-1596-45d6-aa8b-14153a76cb7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4970c269-fb9f-41ce-a01a-6ce8b63bb2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77b73640-6d30-4de8-ad7e-fac2e4c26160" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4970c269-fb9f-41ce-a01a-6ce8b63bb2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_MezzanineEquityAbstract_91d252eb-29d3-4862-81c6-ac88b0d31df4" xlink:href="asth-20240331.xsd#asth_MezzanineEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77b73640-6d30-4de8-ad7e-fac2e4c26160" xlink:to="loc_asth_MezzanineEquityAbstract_91d252eb-29d3-4862-81c6-ac88b0d31df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsNetOfDividends_c9d44776-7ead-4107-93c0-21b68867f902" xlink:href="asth-20240331.xsd#asth_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsNetOfDividends"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_MezzanineEquityAbstract_91d252eb-29d3-4862-81c6-ac88b0d31df4" xlink:to="loc_asth_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsNetOfDividends_c9d44776-7ead-4107-93c0-21b68867f902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_74e55824-1d67-4f9b-b5b5-e23988c9ef13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77b73640-6d30-4de8-ad7e-fac2e4c26160" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_74e55824-1d67-4f9b-b5b5-e23988c9ef13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_934d66c0-9313-453d-b3b2-83c79b218588" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_74e55824-1d67-4f9b-b5b5-e23988c9ef13" xlink:to="loc_us-gaap_PreferredStockValue_934d66c0-9313-453d-b3b2-83c79b218588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_58eee894-1a8d-47e4-9913-8c46bc9fbd00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_74e55824-1d67-4f9b-b5b5-e23988c9ef13" xlink:to="loc_us-gaap_CommonStockValue_58eee894-1a8d-47e4-9913-8c46bc9fbd00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_08668f7b-5372-4a8f-8394-73ea06e47388" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_74e55824-1d67-4f9b-b5b5-e23988c9ef13" xlink:to="loc_us-gaap_AdditionalPaidInCapital_08668f7b-5372-4a8f-8394-73ea06e47388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6120828a-e5e2-4ca1-bde2-7efbf5cbfb57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_74e55824-1d67-4f9b-b5b5-e23988c9ef13" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6120828a-e5e2-4ca1-bde2-7efbf5cbfb57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_db77a24f-3568-4a70-8422-43621132ed03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_74e55824-1d67-4f9b-b5b5-e23988c9ef13" xlink:to="loc_us-gaap_StockholdersEquity_db77a24f-3568-4a70-8422-43621132ed03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_3de4d614-8b7e-40d0-8e12-4ddadb5b3bab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_74e55824-1d67-4f9b-b5b5-e23988c9ef13" xlink:to="loc_us-gaap_MinorityInterest_3de4d614-8b7e-40d0-8e12-4ddadb5b3bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4545bd56-4af2-46b5-8456-c2f8cfb5ee87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_74e55824-1d67-4f9b-b5b5-e23988c9ef13" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4545bd56-4af2-46b5-8456-c2f8cfb5ee87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a9891eb8-0956-4497-b263-518c5475be9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77b73640-6d30-4de8-ad7e-fac2e4c26160" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_a9891eb8-0956-4497-b263-518c5475be9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="asth-20240331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3b5b73b7-1bc1-4355-b361-e4284a310783" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8d57630d-cd0c-473b-83ef-c3a264f55b12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3b5b73b7-1bc1-4355-b361-e4284a310783" xlink:to="loc_us-gaap_StatementTable_8d57630d-cd0c-473b-83ef-c3a264f55b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f13ffa88-8491-4930-b6a5-726df2440e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8d57630d-cd0c-473b-83ef-c3a264f55b12" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f13ffa88-8491-4930-b6a5-726df2440e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b31f0d44-00ca-4ed4-bce2-f0b142437889" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f13ffa88-8491-4930-b6a5-726df2440e9d" xlink:to="loc_us-gaap_ClassOfStockDomain_b31f0d44-00ca-4ed4-bce2-f0b142437889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_70b32c2c-e740-48a4-9429-4419b7e2ded1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b31f0d44-00ca-4ed4-bce2-f0b142437889" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_70b32c2c-e740-48a4-9429-4419b7e2ded1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_03267229-3386-4623-a13e-46a9ff0d303a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b31f0d44-00ca-4ed4-bce2-f0b142437889" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_03267229-3386-4623-a13e-46a9ff0d303a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_8b8a34e8-dd34-440b-96b2-c55c72c7aec0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8d57630d-cd0c-473b-83ef-c3a264f55b12" xlink:to="loc_srt_ConsolidatedEntitiesAxis_8b8a34e8-dd34-440b-96b2-c55c72c7aec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_1e8d381a-c60c-46db-9351-28c6c7b57d4d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_8b8a34e8-dd34-440b-96b2-c55c72c7aec0" xlink:to="loc_srt_ConsolidatedEntitiesDomain_1e8d381a-c60c-46db-9351-28c6c7b57d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_fef504f1-0ef5-4f2e-bb84-052a1d8d9d77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1e8d381a-c60c-46db-9351-28c6c7b57d4d" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_fef504f1-0ef5-4f2e-bb84-052a1d8d9d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bdd6d13d-49e0-4ae4-a170-369a59cba239" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8d57630d-cd0c-473b-83ef-c3a264f55b12" xlink:to="loc_us-gaap_StatementLineItems_bdd6d13d-49e0-4ae4-a170-369a59cba239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a68a690e-ecea-4020-bdce-8bb9a4f3f2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bdd6d13d-49e0-4ae4-a170-369a59cba239" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a68a690e-ecea-4020-bdce-8bb9a4f3f2ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_b72e5455-e8fa-458d-975d-08370c4fdd62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bdd6d13d-49e0-4ae4-a170-369a59cba239" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_b72e5455-e8fa-458d-975d-08370c4fdd62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_ead0a2a6-4d1e-4ef0-9b80-0253b42dbff1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bdd6d13d-49e0-4ae4-a170-369a59cba239" xlink:to="loc_us-gaap_PreferredStockSharesIssued_ead0a2a6-4d1e-4ef0-9b80-0253b42dbff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_8114a03d-7f3c-46e2-8cc9-62029730aec7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bdd6d13d-49e0-4ae4-a170-369a59cba239" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_8114a03d-7f3c-46e2-8cc9-62029730aec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e10c0f15-0e6b-4091-8aaa-10633ec8a08b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bdd6d13d-49e0-4ae4-a170-369a59cba239" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e10c0f15-0e6b-4091-8aaa-10633ec8a08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_9f0b46ed-50d8-47a4-be2a-e58a0b08e504" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bdd6d13d-49e0-4ae4-a170-369a59cba239" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_9f0b46ed-50d8-47a4-be2a-e58a0b08e504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f8c11323-6afa-4878-beeb-878843ec8e56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bdd6d13d-49e0-4ae4-a170-369a59cba239" xlink:to="loc_us-gaap_CommonStockSharesIssued_f8c11323-6afa-4878-beeb-878843ec8e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_3d09277c-bfe9-4e07-866f-7389c9e5b5ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bdd6d13d-49e0-4ae4-a170-369a59cba239" xlink:to="loc_us-gaap_SharesOutstanding_3d09277c-bfe9-4e07-866f-7389c9e5b5ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_cbabf2e0-367c-4041-869c-4171b3fd5870" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bdd6d13d-49e0-4ae4-a170-369a59cba239" xlink:to="loc_us-gaap_TreasuryStockCommonShares_cbabf2e0-367c-4041-869c-4171b3fd5870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_873d5571-3324-4541-a137-9c30eb726ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bdd6d13d-49e0-4ae4-a170-369a59cba239" xlink:to="loc_us-gaap_Assets_873d5571-3324-4541-a137-9c30eb726ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7a250887-23b9-421a-82a3-f8c2e0ea7cea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bdd6d13d-49e0-4ae4-a170-369a59cba239" xlink:to="loc_us-gaap_Liabilities_7a250887-23b9-421a-82a3-f8c2e0ea7cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_047fd2d5-de19-4589-bc1b-c9297b9031ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bdd6d13d-49e0-4ae4-a170-369a59cba239" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_047fd2d5-de19-4589-bc1b-c9297b9031ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_53223a10-be6c-42f4-bd1c-39b550a9a096" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bdd6d13d-49e0-4ae4-a170-369a59cba239" xlink:to="loc_us-gaap_OtherLiabilities_53223a10-be6c-42f4-bd1c-39b550a9a096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivables_8b461f7a-2d43-4090-9bbf-bc51e2142dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bdd6d13d-49e0-4ae4-a170-369a59cba239" xlink:to="loc_us-gaap_OtherReceivables_8b461f7a-2d43-4090-9bbf-bc51e2142dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="asth-20240331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_0baf1e5e-31d1-4d50-b724-b5a31f5a7647" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0f5dcc4f-d266-4f64-99c4-893afcbc07c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0baf1e5e-31d1-4d50-b724-b5a31f5a7647" xlink:to="loc_us-gaap_StatementTable_0f5dcc4f-d266-4f64-99c4-893afcbc07c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cf0d4c02-8f06-4801-a9be-48bf1b5bd2c5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0f5dcc4f-d266-4f64-99c4-893afcbc07c3" xlink:to="loc_srt_ProductOrServiceAxis_cf0d4c02-8f06-4801-a9be-48bf1b5bd2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d1753542-36fc-4c52-8306-572b981fff5d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_cf0d4c02-8f06-4801-a9be-48bf1b5bd2c5" xlink:to="loc_srt_ProductsAndServicesDomain_d1753542-36fc-4c52-8306-572b981fff5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_HealthCareCapitationRevenueMember_3f5f3a26-08a2-452f-802b-3a34607e9566" xlink:href="asth-20240331.xsd#asth_HealthCareCapitationRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d1753542-36fc-4c52-8306-572b981fff5d" xlink:to="loc_asth_HealthCareCapitationRevenueMember_3f5f3a26-08a2-452f-802b-3a34607e9566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOtherMember_de9553d6-b5b6-4e07-9aab-e7353ff8c550" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d1753542-36fc-4c52-8306-572b981fff5d" xlink:to="loc_us-gaap_HealthCareOtherMember_de9553d6-b5b6-4e07-9aab-e7353ff8c550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember_81b8239c-e52f-4e0e-9226-f59c90c29d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagementServiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d1753542-36fc-4c52-8306-572b981fff5d" xlink:to="loc_us-gaap_ManagementServiceMember_81b8239c-e52f-4e0e-9226-f59c90c29d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCarePatientServiceMember_93ec2ad3-155a-4505-bf64-c5a07ea36b99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCarePatientServiceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d1753542-36fc-4c52-8306-572b981fff5d" xlink:to="loc_us-gaap_HealthCarePatientServiceMember_93ec2ad3-155a-4505-bf64-c5a07ea36b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_a79fd51f-180a-45d9-875e-72d4eaf95660" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d1753542-36fc-4c52-8306-572b981fff5d" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_a79fd51f-180a-45d9-875e-72d4eaf95660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_73b5cf48-7237-416a-b3ff-f8dfe8f3c7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0f5dcc4f-d266-4f64-99c4-893afcbc07c3" xlink:to="loc_us-gaap_StatementLineItems_73b5cf48-7237-416a-b3ff-f8dfe8f3c7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_61b0ac68-2f9a-4550-acc3-6e4d1f47c046" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_73b5cf48-7237-416a-b3ff-f8dfe8f3c7a5" xlink:to="loc_us-gaap_RevenuesAbstract_61b0ac68-2f9a-4550-acc3-6e4d1f47c046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_54088aef-a214-4593-90dd-02e4352d8c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_61b0ac68-2f9a-4550-acc3-6e4d1f47c046" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_54088aef-a214-4593-90dd-02e4352d8c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_d943206c-47b5-4ed2-a8be-c3192455d30c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_73b5cf48-7237-416a-b3ff-f8dfe8f3c7a5" xlink:to="loc_us-gaap_OperatingExpensesAbstract_d943206c-47b5-4ed2-a8be-c3192455d30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_5dcbd6a2-056b-4b43-aa77-fb4a6b331420" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d943206c-47b5-4ed2-a8be-c3192455d30c" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_5dcbd6a2-056b-4b43-aa77-fb4a6b331420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d54512e9-e485-4d45-b08f-49b412f17eac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d943206c-47b5-4ed2-a8be-c3192455d30c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d54512e9-e485-4d45-b08f-49b412f17eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_1a487115-bf1e-4d4a-abd7-b92b61024964" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d943206c-47b5-4ed2-a8be-c3192455d30c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_1a487115-bf1e-4d4a-abd7-b92b61024964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_1dd783a1-20ae-433a-9985-94133a5bcdfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d943206c-47b5-4ed2-a8be-c3192455d30c" xlink:to="loc_us-gaap_CostsAndExpenses_1dd783a1-20ae-433a-9985-94133a5bcdfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9a0f8d44-480a-45ad-8654-bdba2545764a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_73b5cf48-7237-416a-b3ff-f8dfe8f3c7a5" xlink:to="loc_us-gaap_OperatingIncomeLoss_9a0f8d44-480a-45ad-8654-bdba2545764a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_23c03c83-762c-4b9e-8b34-d36bce0f6437" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_73b5cf48-7237-416a-b3ff-f8dfe8f3c7a5" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_23c03c83-762c-4b9e-8b34-d36bce0f6437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4af79748-d698-4df6-83e5-8c617623919a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_23c03c83-762c-4b9e-8b34-d36bce0f6437" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4af79748-d698-4df6-83e5-8c617623919a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f5d4986e-e1ac-485c-80a7-b7c0db2580a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_23c03c83-762c-4b9e-8b34-d36bce0f6437" xlink:to="loc_us-gaap_InterestExpense_f5d4986e-e1ac-485c-80a7-b7c0db2580a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_e0874159-e1e0-48ed-b97e-4042dcf74326" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_23c03c83-762c-4b9e-8b34-d36bce0f6437" xlink:to="loc_us-gaap_InvestmentIncomeInterest_e0874159-e1e0-48ed-b97e-4042dcf74326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_3fec6bad-09f5-42ec-8725-704896e2e083" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_23c03c83-762c-4b9e-8b34-d36bce0f6437" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_3fec6bad-09f5-42ec-8725-704896e2e083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ee3cc99a-6965-4454-b75f-61a75d5d3ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_23c03c83-762c-4b9e-8b34-d36bce0f6437" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_ee3cc99a-6965-4454-b75f-61a75d5d3ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_307d64ce-5797-4ac7-8aba-158e25764f16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_23c03c83-762c-4b9e-8b34-d36bce0f6437" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_307d64ce-5797-4ac7-8aba-158e25764f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_102cad84-2213-47f7-b353-611568346495" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_73b5cf48-7237-416a-b3ff-f8dfe8f3c7a5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_102cad84-2213-47f7-b353-611568346495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f282646c-3f60-4471-807e-82076b2b8e64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_73b5cf48-7237-416a-b3ff-f8dfe8f3c7a5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f282646c-3f60-4471-807e-82076b2b8e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1eebd33c-1c65-4857-b6cd-a7c1d0ccf928" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_73b5cf48-7237-416a-b3ff-f8dfe8f3c7a5" xlink:to="loc_us-gaap_ProfitLoss_1eebd33c-1c65-4857-b6cd-a7c1d0ccf928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e8c4cffa-871c-4efa-9923-2fe328a3c6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_73b5cf48-7237-416a-b3ff-f8dfe8f3c7a5" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e8c4cffa-871c-4efa-9923-2fe328a3c6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_094e6e7d-1c0a-4f74-b7bc-4eee7740c45d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_73b5cf48-7237-416a-b3ff-f8dfe8f3c7a5" xlink:to="loc_us-gaap_NetIncomeLoss_094e6e7d-1c0a-4f74-b7bc-4eee7740c45d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_fbafcba3-62dc-42d8-83a5-c2ce98a7cf5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_73b5cf48-7237-416a-b3ff-f8dfe8f3c7a5" xlink:to="loc_us-gaap_EarningsPerShareBasic_fbafcba3-62dc-42d8-83a5-c2ce98a7cf5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_45c286cd-4b74-4c76-b09d-d2eaab3c4a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_73b5cf48-7237-416a-b3ff-f8dfe8f3c7a5" xlink:to="loc_us-gaap_EarningsPerShareDiluted_45c286cd-4b74-4c76-b09d-d2eaab3c4a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="asth-20240331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0738dcb1-536c-4fa3-9b0e-76efb6d00736" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2b4e7f1c-b42c-49f2-b124-fad7631fcc01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0738dcb1-536c-4fa3-9b0e-76efb6d00736" xlink:to="loc_us-gaap_StatementTable_2b4e7f1c-b42c-49f2-b124-fad7631fcc01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_dd7c9fa9-78b5-468e-891e-805f1151176b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2b4e7f1c-b42c-49f2-b124-fad7631fcc01" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_dd7c9fa9-78b5-468e-891e-805f1151176b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cede7c7e-a99a-41e4-9a9b-57827d45ed69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_dd7c9fa9-78b5-468e-891e-805f1151176b" xlink:to="loc_us-gaap_EquityComponentDomain_cede7c7e-a99a-41e4-9a9b-57827d45ed69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bfbf1706-9348-4a3f-8d9c-171dcd7ef930" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cede7c7e-a99a-41e4-9a9b-57827d45ed69" xlink:to="loc_us-gaap_CommonStockMember_bfbf1706-9348-4a3f-8d9c-171dcd7ef930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0a75f655-14f8-4844-ad85-10065f34baef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cede7c7e-a99a-41e4-9a9b-57827d45ed69" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0a75f655-14f8-4844-ad85-10065f34baef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d3d9510c-5d2b-4208-9aa0-fc708fdef107" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cede7c7e-a99a-41e4-9a9b-57827d45ed69" xlink:to="loc_us-gaap_RetainedEarningsMember_d3d9510c-5d2b-4208-9aa0-fc708fdef107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_e1de470b-cf60-4a2b-a01c-0eccbd2026a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cede7c7e-a99a-41e4-9a9b-57827d45ed69" xlink:to="loc_us-gaap_NoncontrollingInterestMember_e1de470b-cf60-4a2b-a01c-0eccbd2026a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d4eed923-207c-409c-84cd-712534eddbba" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2b4e7f1c-b42c-49f2-b124-fad7631fcc01" xlink:to="loc_dei_LegalEntityAxis_d4eed923-207c-409c-84cd-712534eddbba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d691d1eb-cb32-4564-8464-2b6aad8a4a7f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_d4eed923-207c-409c-84cd-712534eddbba" xlink:to="loc_dei_EntityDomain_d691d1eb-cb32-4564-8464-2b6aad8a4a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_MezzanineMember_1638c2f6-095b-49cd-9315-ff3eae481da8" xlink:href="asth-20240331.xsd#asth_MezzanineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_d691d1eb-cb32-4564-8464-2b6aad8a4a7f" xlink:to="loc_asth_MezzanineMember_1638c2f6-095b-49cd-9315-ff3eae481da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bc564805-781f-41ef-b016-2e6aa3907e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2b4e7f1c-b42c-49f2-b124-fad7631fcc01" xlink:to="loc_us-gaap_StatementLineItems_bc564805-781f-41ef-b016-2e6aa3907e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_a3f1cd45-bb7c-4592-bae4-bc8d3664dbce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bc564805-781f-41ef-b016-2e6aa3907e7c" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_a3f1cd45-bb7c-4592-bae4-bc8d3664dbce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_e3d037c9-e938-44e7-b09e-e3cd0c64909a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_a3f1cd45-bb7c-4592-bae4-bc8d3664dbce" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_e3d037c9-e938-44e7-b09e-e3cd0c64909a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome_660f9b35-9a12-4df3-aa31-b8588ed10942" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_a3f1cd45-bb7c-4592-bae4-bc8d3664dbce" xlink:to="loc_us-gaap_TemporaryEquityNetIncome_660f9b35-9a12-4df3-aa31-b8588ed10942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_TemporaryEquityTransferOfCommonControlEntities_64d0476d-cbd0-4e2c-a023-553c0eacaaa6" xlink:href="asth-20240331.xsd#asth_TemporaryEquityTransferOfCommonControlEntities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_a3f1cd45-bb7c-4592-bae4-bc8d3664dbce" xlink:to="loc_asth_TemporaryEquityTransferOfCommonControlEntities_64d0476d-cbd0-4e2c-a023-553c0eacaaa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_1500c526-1088-4223-ae59-77e8d73dd8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_a3f1cd45-bb7c-4592-bae4-bc8d3664dbce" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_1500c526-1088-4223-ae59-77e8d73dd8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bc564805-781f-41ef-b016-2e6aa3907e7c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_4763c914-4319-4fd7-b31e-593fba2902df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_us-gaap_SharesOutstanding_4763c914-4319-4fd7-b31e-593fba2902df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a4f187f9-be72-4480-a93e-31ee3b48eead" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a4f187f9-be72-4480-a93e-31ee3b48eead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_4759cd35-4a21-497a-8c27-de48c3098b08" xlink:href="asth-20240331.xsd#asth_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_asth_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_4759cd35-4a21-497a-8c27-de48c3098b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_793d5354-4038-4c81-9a2c-5ac3591426eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_793d5354-4038-4c81-9a2c-5ac3591426eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_74304696-6fc6-4f2d-adb3-3d3674076737" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_74304696-6fc6-4f2d-adb3-3d3674076737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_4212202a-518a-4ea9-bd07-6e6508049786" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_4212202a-518a-4ea9-bd07-6e6508049786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_24faea63-48c1-4719-8f54-a5248776deb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_24faea63-48c1-4719-8f54-a5248776deb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_26923dbe-4409-4c33-b048-bf3c3960e6dc" xlink:href="asth-20240331.xsd#asth_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_asth_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_26923dbe-4409-4c33-b048-bf3c3960e6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_a7afb578-d059-4421-9dd0-33c983045b8d" xlink:href="asth-20240331.xsd#asth_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_asth_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_a7afb578-d059-4421-9dd0-33c983045b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_30d7d301-18cc-4992-897f-7c9364e34290" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_30d7d301-18cc-4992-897f-7c9364e34290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_bf15963b-8ea6-43e5-9c2f-6bd1e98a4b94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredParValueMethod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_bf15963b-8ea6-43e5-9c2f-6bd1e98a4b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_68b63d71-8201-4aa2-b289-7f6007871fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_68b63d71-8201-4aa2-b289-7f6007871fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2a13ea39-2ca9-4560-a025-795568061526" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2a13ea39-2ca9-4560-a025-795568061526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_48222091-245a-4a2b-bc13-235a1c816dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_48222091-245a-4a2b-bc13-235a1c816dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AcquisitionOfNonControllingInterestShares_ced4d6c2-a1fb-46eb-a986-6cde3f8d9291" xlink:href="asth-20240331.xsd#asth_AcquisitionOfNonControllingInterestShares"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_asth_AcquisitionOfNonControllingInterestShares_ced4d6c2-a1fb-46eb-a986-6cde3f8d9291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_NoncontrollingInterestIncreaseDecreaseFromBusinessCombination_2ccf7b56-da56-4502-8a53-1e5dda57b19c" xlink:href="asth-20240331.xsd#asth_NoncontrollingInterestIncreaseDecreaseFromBusinessCombination"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_asth_NoncontrollingInterestIncreaseDecreaseFromBusinessCombination_2ccf7b56-da56-4502-8a53-1e5dda57b19c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares_cbff1a25-96f5-4258-8131-719b7c9c0898" xlink:href="asth-20240331.xsd#asth_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_asth_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares_cbff1a25-96f5-4258-8131-719b7c9c0898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_StockholdersEquityTransferOfCommonControlEntities_a3ab3ee8-31a4-4500-b26d-77d109cc5d5f" xlink:href="asth-20240331.xsd#asth_StockholdersEquityTransferOfCommonControlEntities"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_asth_StockholdersEquityTransferOfCommonControlEntities_a3ab3ee8-31a4-4500-b26d-77d109cc5d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_bd9a0dbe-a991-418e-b6c2-c07083ccecd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_us-gaap_SharesOutstanding_bd9a0dbe-a991-418e-b6c2-c07083ccecd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f0dea49b-7aea-43c0-be75-36b609642edb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b7ce61b4-2011-4b61-ba06-badf918bc36d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f0dea49b-7aea-43c0-be75-36b609642edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="asth-20240331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_a5c07969-c3a3-4bdb-b85b-72f981cfc911" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2d406f4f-782c-4f19-bd53-bb2a7925825b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a5c07969-c3a3-4bdb-b85b-72f981cfc911" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2d406f4f-782c-4f19-bd53-bb2a7925825b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8513d409-757e-430b-819a-6e1ead74a465" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2d406f4f-782c-4f19-bd53-bb2a7925825b" xlink:to="loc_us-gaap_ProfitLoss_8513d409-757e-430b-819a-6e1ead74a465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3fd3a436-7f5e-402b-aa32-7ec8f41f3892" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2d406f4f-782c-4f19-bd53-bb2a7925825b" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3fd3a436-7f5e-402b-aa32-7ec8f41f3892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ed617439-0e14-4511-b527-f0e8ed5e4b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3fd3a436-7f5e-402b-aa32-7ec8f41f3892" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ed617439-0e14-4511-b527-f0e8ed5e4b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_617867ff-e2cf-47c8-933f-01431bc3a27a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3fd3a436-7f5e-402b-aa32-7ec8f41f3892" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_617867ff-e2cf-47c8-933f-01431bc3a27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ea97a2e3-6734-4c0c-8b3e-8f98a19186a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3fd3a436-7f5e-402b-aa32-7ec8f41f3892" xlink:to="loc_us-gaap_ShareBasedCompensation_ea97a2e3-6734-4c0c-8b3e-8f98a19186a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_NoncashLeaseExpense_a8eb726e-6e94-4f40-b7c9-8baae8b19adc" xlink:href="asth-20240331.xsd#asth_NoncashLeaseExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3fd3a436-7f5e-402b-aa32-7ec8f41f3892" xlink:to="loc_asth_NoncashLeaseExpense_a8eb726e-6e94-4f40-b7c9-8baae8b19adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_UnrealizedGainLossFromInvestmentInEquitySecurities_36eb762b-8669-4df2-afc3-e876770fd501" xlink:href="asth-20240331.xsd#asth_UnrealizedGainLossFromInvestmentInEquitySecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3fd3a436-7f5e-402b-aa32-7ec8f41f3892" xlink:to="loc_asth_UnrealizedGainLossFromInvestmentInEquitySecurities_36eb762b-8669-4df2-afc3-e876770fd501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_47de28bc-d044-4269-9a90-71e184769c29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3fd3a436-7f5e-402b-aa32-7ec8f41f3892" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_47de28bc-d044-4269-9a90-71e184769c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_6cba58bd-e769-4aa2-8bb1-8f2ff6c8d725" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3fd3a436-7f5e-402b-aa32-7ec8f41f3892" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_6cba58bd-e769-4aa2-8bb1-8f2ff6c8d725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_14b2a337-692b-47ad-b818-93e8c8b5943f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3fd3a436-7f5e-402b-aa32-7ec8f41f3892" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_14b2a337-692b-47ad-b818-93e8c8b5943f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherOperatingActivities_fc984518-8118-4cb5-ad72-ea51a9ba62bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromOtherOperatingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3fd3a436-7f5e-402b-aa32-7ec8f41f3892" xlink:to="loc_us-gaap_ProceedsFromOtherOperatingActivities_fc984518-8118-4cb5-ad72-ea51a9ba62bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26982ad7-ccd8-4f4f-b9be-e6e040bfaf04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3fd3a436-7f5e-402b-aa32-7ec8f41f3892" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26982ad7-ccd8-4f4f-b9be-e6e040bfaf04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8389e7db-e5a9-47b0-a96c-5052de384cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26982ad7-ccd8-4f4f-b9be-e6e040bfaf04" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8389e7db-e5a9-47b0-a96c-5052de384cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_f53d4783-8fe5-42b6-9a58-721f8958c596" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26982ad7-ccd8-4f4f-b9be-e6e040bfaf04" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_f53d4783-8fe5-42b6-9a58-721f8958c596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_337ead11-f254-40f5-ae07-1faafc8d78d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26982ad7-ccd8-4f4f-b9be-e6e040bfaf04" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_337ead11-f254-40f5-ae07-1faafc8d78d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_3e59333c-d115-48c1-a321-44ca8101d8e0" xlink:href="asth-20240331.xsd#asth_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26982ad7-ccd8-4f4f-b9be-e6e040bfaf04" xlink:to="loc_asth_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_3e59333c-d115-48c1-a321-44ca8101d8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8ea537ba-5946-476e-8209-a56f10a4b329" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26982ad7-ccd8-4f4f-b9be-e6e040bfaf04" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8ea537ba-5946-476e-8209-a56f10a4b329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_4a6d88f2-0fa8-4e27-9a69-28929c9c867d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26982ad7-ccd8-4f4f-b9be-e6e040bfaf04" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_4a6d88f2-0fa8-4e27-9a69-28929c9c867d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_8e8c144a-b2ae-41f7-a276-0afa77844620" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26982ad7-ccd8-4f4f-b9be-e6e040bfaf04" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_8e8c144a-b2ae-41f7-a276-0afa77844620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_IncreaseDecreaseInMedicalLiabilities_08829d5d-67e4-4607-a4e2-b5762cb78b8e" xlink:href="asth-20240331.xsd#asth_IncreaseDecreaseInMedicalLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26982ad7-ccd8-4f4f-b9be-e6e040bfaf04" xlink:to="loc_asth_IncreaseDecreaseInMedicalLiabilities_08829d5d-67e4-4607-a4e2-b5762cb78b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_ffa36878-ac1c-4507-a8a8-4ce4d2371a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26982ad7-ccd8-4f4f-b9be-e6e040bfaf04" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_ffa36878-ac1c-4507-a8a8-4ce4d2371a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_4873f596-10c4-4743-b558-0201e491f629" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26982ad7-ccd8-4f4f-b9be-e6e040bfaf04" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_4873f596-10c4-4743-b558-0201e491f629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_16154182-4139-4102-b20e-ec4fe3e86d61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26982ad7-ccd8-4f4f-b9be-e6e040bfaf04" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_16154182-4139-4102-b20e-ec4fe3e86d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b493c257-c83b-4310-9c56-c7ce399c5559" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2d406f4f-782c-4f19-bd53-bb2a7925825b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b493c257-c83b-4310-9c56-c7ce399c5559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8f932ab4-f441-44ce-b01b-463e969500c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a5c07969-c3a3-4bdb-b85b-72f981cfc911" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8f932ab4-f441-44ce-b01b-463e969500c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_722ef024-1aaf-41d6-a50d-5f2032ccb50d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8f932ab4-f441-44ce-b01b-463e969500c9" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_722ef024-1aaf-41d6-a50d-5f2032ccb50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_55616beb-bf93-445a-a35d-cf0c79c01c78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8f932ab4-f441-44ce-b01b-463e969500c9" xlink:to="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_55616beb-bf93-445a-a35d-cf0c79c01c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_c0fe454c-6a3b-486b-95de-df82a280888f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8f932ab4-f441-44ce-b01b-463e969500c9" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_c0fe454c-6a3b-486b-95de-df82a280888f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_3d967b57-d42b-41a5-9879-5b48285276ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8f932ab4-f441-44ce-b01b-463e969500c9" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_3d967b57-d42b-41a5-9879-5b48285276ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_aa37d775-92a2-486a-b64d-fb356fb9b308" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8f932ab4-f441-44ce-b01b-463e969500c9" xlink:to="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_aa37d775-92a2-486a-b64d-fb356fb9b308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e3dd770c-405d-4096-81b3-4e5cf43b6c61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8f932ab4-f441-44ce-b01b-463e969500c9" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e3dd770c-405d-4096-81b3-4e5cf43b6c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_DepositForPurchaseOfProperty_5024dc28-c80c-4992-ba76-5ffd55d3b177" xlink:href="asth-20240331.xsd#asth_DepositForPurchaseOfProperty"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8f932ab4-f441-44ce-b01b-463e969500c9" xlink:to="loc_asth_DepositForPurchaseOfProperty_5024dc28-c80c-4992-ba76-5ffd55d3b177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_75d12538-be89-47bf-b920-bd9e5577633a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8f932ab4-f441-44ce-b01b-463e969500c9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_75d12538-be89-47bf-b920-bd9e5577633a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_074d9a36-1924-4bb4-818f-e15d0dfac265" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a5c07969-c3a3-4bdb-b85b-72f981cfc911" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_074d9a36-1924-4bb4-818f-e15d0dfac265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_9f928aec-f7e2-43eb-bdb4-300dca8b366e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_074d9a36-1924-4bb4-818f-e15d0dfac265" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_9f928aec-f7e2-43eb-bdb4-300dca8b366e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_19bd0d38-1c87-49e4-a2b9-b944553a7487" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_074d9a36-1924-4bb4-818f-e15d0dfac265" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_19bd0d38-1c87-49e4-a2b9-b944553a7487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt_0c8a958b-bfce-4929-b155-edfab853b88f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfOtherLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_074d9a36-1924-4bb4-818f-e15d0dfac265" xlink:to="loc_us-gaap_RepaymentsOfOtherLongTermDebt_0c8a958b-bfce-4929-b155-edfab853b88f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_407f6f82-ff1f-4a42-b1a5-c81d26169a70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_074d9a36-1924-4bb4-818f-e15d0dfac265" xlink:to="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_407f6f82-ff1f-4a42-b1a5-c81d26169a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_ccb96773-cae4-4415-80fd-7b18188e0e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_074d9a36-1924-4bb4-818f-e15d0dfac265" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_ccb96773-cae4-4415-80fd-7b18188e0e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PaymentForRepurchaseOfTreasuryStockFinancingActivities_d5bc78c1-d3a6-40c2-891b-abc7018144c2" xlink:href="asth-20240331.xsd#asth_PaymentForRepurchaseOfTreasuryStockFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_074d9a36-1924-4bb4-818f-e15d0dfac265" xlink:to="loc_asth_PaymentForRepurchaseOfTreasuryStockFinancingActivities_d5bc78c1-d3a6-40c2-891b-abc7018144c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_ea323fff-c1c4-4514-b24f-b7b78eb3f009" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_074d9a36-1924-4bb4-818f-e15d0dfac265" xlink:to="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_ea323fff-c1c4-4514-b24f-b7b78eb3f009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsMinorityInterest_18da1740-0b9e-44e5-b282-3e887e1642df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsMinorityInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_074d9a36-1924-4bb4-818f-e15d0dfac265" xlink:to="loc_us-gaap_PaymentsOfDividendsMinorityInterest_18da1740-0b9e-44e5-b282-3e887e1642df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_adfcc879-f568-41fe-b461-9e8e084d95db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_074d9a36-1924-4bb4-818f-e15d0dfac265" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_adfcc879-f568-41fe-b461-9e8e084d95db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e4d166fc-b07b-417f-a62e-fd5e0fc166ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a5c07969-c3a3-4bdb-b85b-72f981cfc911" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e4d166fc-b07b-417f-a62e-fd5e0fc166ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_99b52b56-d990-4694-a6df-995ecf36a20c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a5c07969-c3a3-4bdb-b85b-72f981cfc911" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_99b52b56-d990-4694-a6df-995ecf36a20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9dbf0fb3-033e-4141-81bc-13b6fb133fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a5c07969-c3a3-4bdb-b85b-72f981cfc911" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9dbf0fb3-033e-4141-81bc-13b6fb133fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_e5b390ac-cc52-415f-81f8-83f812e52ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a5c07969-c3a3-4bdb-b85b-72f981cfc911" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_e5b390ac-cc52-415f-81f8-83f812e52ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_d9f24b24-a21b-41dd-aadd-d6a195993da3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_e5b390ac-cc52-415f-81f8-83f812e52ff2" xlink:to="loc_us-gaap_IncomeTaxesPaid_d9f24b24-a21b-41dd-aadd-d6a195993da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_e3daffc7-8e28-4550-a156-c715348938cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_e5b390ac-cc52-415f-81f8-83f812e52ff2" xlink:to="loc_us-gaap_InterestPaidNet_e3daffc7-8e28-4550-a156-c715348938cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_67521b71-37e8-4e1e-91bd-ad356cd752a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a5c07969-c3a3-4bdb-b85b-72f981cfc911" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_67521b71-37e8-4e1e-91bd-ad356cd752a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_NonCashBusinessAcquisition_b0d978b8-ec88-4205-9e3f-cbd2cb77235a" xlink:href="asth-20240331.xsd#asth_NonCashBusinessAcquisition"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_67521b71-37e8-4e1e-91bd-ad356cd752a9" xlink:to="loc_asth_NonCashBusinessAcquisition_b0d978b8-ec88-4205-9e3f-cbd2cb77235a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_bfd8418d-f0d2-4952-871e-f2e5c95780f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_67521b71-37e8-4e1e-91bd-ad356cd752a9" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_bfd8418d-f0d2-4952-871e-f2e5c95780f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_4b848d24-497c-40b1-bb31-9f3b79d0cffd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_67521b71-37e8-4e1e-91bd-ad356cd752a9" xlink:to="loc_us-gaap_StockIssued1_4b848d24-497c-40b1-bb31-9f3b79d0cffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferToInvestments_7aec185f-b966-4f82-9502-05b09f79bdf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransferToInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_67521b71-37e8-4e1e-91bd-ad356cd752a9" xlink:to="loc_us-gaap_TransferToInvestments_7aec185f-b966-4f82-9502-05b09f79bdf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_DrawOnLetterOfCreditThroughRevolverLoan_46b7afc2-5d94-4b12-ba39-a55c6c755006" xlink:href="asth-20240331.xsd#asth_DrawOnLetterOfCreditThroughRevolverLoan"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_67521b71-37e8-4e1e-91bd-ad356cd752a9" xlink:to="loc_asth_DrawOnLetterOfCreditThroughRevolverLoan_46b7afc2-5d94-4b12-ba39-a55c6c755006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_cf4571da-48e9-4a57-bd29-dcfeaa11171f" xlink:href="asth-20240331.xsd#asth_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a5c07969-c3a3-4bdb-b85b-72f981cfc911" xlink:to="loc_asth_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_cf4571da-48e9-4a57-bd29-dcfeaa11171f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_28f78d52-4751-45d8-8e59-6d3258137288" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_cf4571da-48e9-4a57-bd29-dcfeaa11171f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_28f78d52-4751-45d8-8e59-6d3258137288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_d940a870-6daa-433e-95d9-96bff0cc988f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_cf4571da-48e9-4a57-bd29-dcfeaa11171f" xlink:to="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_d940a870-6daa-433e-95d9-96bff0cc988f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d9d0f25e-f833-483e-b57c-cc992b710b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_cf4571da-48e9-4a57-bd29-dcfeaa11171f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d9d0f25e-f833-483e-b57c-cc992b710b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/DescriptionofBusiness" xlink:type="simple" xlink:href="asth-20240331.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c7acadbc-d413-46e1-adbd-d96f24596633" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_5d6375f8-ce00-4d33-a22d-4c0d05d752b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c7acadbc-d413-46e1-adbd-d96f24596633" xlink:to="loc_us-gaap_NatureOfOperations_5d6375f8-ce00-4d33-a22d-4c0d05d752b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="asth-20240331.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_68614eae-22e9-4a6c-b1a8-30eaf9c606d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_f65d74f9-0c7f-45bc-9a5f-5e7758a24e58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_68614eae-22e9-4a6c-b1a8-30eaf9c606d5" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_f65d74f9-0c7f-45bc-9a5f-5e7758a24e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwill" xlink:type="simple" xlink:href="asth-20240331.xsd#BusinessCombinationsAssetAcquisitionsandGoodwill"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b4742fef-b24e-441e-8621-10ba4deb4611" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_39028196-af0b-449d-a8b9-361fe1ef626f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b4742fef-b24e-441e-8621-10ba4deb4611" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_39028196-af0b-449d-a8b9-361fe1ef626f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNet" xlink:type="simple" xlink:href="asth-20240331.xsd#IntangibleAssetsNet"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3ebaa242-8312-4505-83e6-0999a69efdab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_32c8c14a-66fe-4fe7-891d-f67a7eb5b6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3ebaa242-8312-4505-83e6-0999a69efdab" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_32c8c14a-66fe-4fe7-891d-f67a7eb5b6bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntities" xlink:type="simple" xlink:href="asth-20240331.xsd#InvestmentsinOtherEntities"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_67069a8b-d889-4b8a-b9bc-ae9997a0b9cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_EquityMethodAndOtherEquityInvestmentsTextBlock_f5b97316-0b61-47ae-ba98-ebaa97861fc9" xlink:href="asth-20240331.xsd#asth_EquityMethodAndOtherEquityInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_67069a8b-d889-4b8a-b9bc-ae9997a0b9cb" xlink:to="loc_asth_EquityMethodAndOtherEquityInvestmentsTextBlock_f5b97316-0b61-47ae-ba98-ebaa97861fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LoansReceivable" xlink:type="simple" xlink:href="asth-20240331.xsd#LoansReceivable"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LoansReceivable" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_5fea490b-35cb-4bfc-8fb7-276c5a2ee674" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_LoanReceivableTextBlock_c93b75a8-9ca9-4890-bdb1-0022fba17fc2" xlink:href="asth-20240331.xsd#asth_LoanReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_5fea490b-35cb-4bfc-8fb7-276c5a2ee674" xlink:to="loc_asth_LoanReceivableTextBlock_c93b75a8-9ca9-4890-bdb1-0022fba17fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpenses" xlink:type="simple" xlink:href="asth-20240331.xsd#AccountsPayableandAccruedExpenses"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_88ee2c75-9f2d-4e61-b881-95150f880295" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_3f54636c-437c-46df-8ae5-d4210f51e9a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_88ee2c75-9f2d-4e61-b881-95150f880295" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_3f54636c-437c-46df-8ae5-d4210f51e9a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilities" xlink:type="simple" xlink:href="asth-20240331.xsd#MedicalLiabilities"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_b7d61ec7-a354-4338-b082-db21d8a7fae0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_b8b0957b-92e2-41c3-a43b-d6f5798e6fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_b7d61ec7-a354-4338-b082-db21d8a7fae0" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_b8b0957b-92e2-41c3-a43b-d6f5798e6fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCredit" xlink:type="simple" xlink:href="asth-20240331.xsd#CreditFacilityBankLoansandLinesofCredit"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCredit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f9e2e21a-17bc-4bf8-998e-80bd130e0e00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_88f73441-2a32-4d3e-9321-a1564188a04c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f9e2e21a-17bc-4bf8-998e-80bd130e0e00" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_88f73441-2a32-4d3e-9321-a1564188a04c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquity" xlink:type="simple" xlink:href="asth-20240331.xsd#MezzanineandStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_01c0b2b8-e9c4-4a98-a3db-b496e4283642" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9b6860a8-8b8b-48ea-b19c-a16ec62dc43d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_01c0b2b8-e9c4-4a98-a3db-b496e4283642" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9b6860a8-8b8b-48ea-b19c-a16ec62dc43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensation" xlink:type="simple" xlink:href="asth-20240331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_02b9b1a9-425e-4ac7-8e52-6c38cb194808" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9f885708-3239-4bc4-9323-2bbc73d6c159" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_02b9b1a9-425e-4ac7-8e52-6c38cb194808" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9f885708-3239-4bc4-9323-2bbc73d6c159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="asth-20240331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_960faca6-773f-47c4-af0d-66052ef23e24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_dc341273-7eed-4a36-b2df-5185b0b7823e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_960faca6-773f-47c4-af0d-66052ef23e24" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_dc341273-7eed-4a36-b2df-5185b0b7823e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="asth-20240331.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_95a8a484-63f3-4b17-8089-be6762553165" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_31159c8d-bcbf-4dc0-b23b-828163680038" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_95a8a484-63f3-4b17-8089-be6762553165" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_31159c8d-bcbf-4dc0-b23b-828163680038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IncomeTaxes" xlink:type="simple" xlink:href="asth-20240331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6397b8f5-2bba-4707-818e-0c95da56f2cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_e20d9287-8333-4c5e-8530-05bd07a999e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6397b8f5-2bba-4707-818e-0c95da56f2cc" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_e20d9287-8333-4c5e-8530-05bd07a999e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShare" xlink:type="simple" xlink:href="asth-20240331.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b3b4e508-7456-4cf3-a89b-0a62470b8795" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_92b34e07-f4dd-437a-ad71-b6ffa4648f66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b3b4e508-7456-4cf3-a89b-0a62470b8795" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_92b34e07-f4dd-437a-ad71-b6ffa4648f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEs" xlink:type="simple" xlink:href="asth-20240331.xsd#VariableInterestEntitiesVIEs"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEs" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1195d57b-ced3-4a32-99f9-ae1477557171" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_b0ab2073-4316-41b4-9832-5e2f1f919fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1195d57b-ced3-4a32-99f9-ae1477557171" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_b0ab2073-4316-41b4-9832-5e2f1f919fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/Leases" xlink:type="simple" xlink:href="asth-20240331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5f3e44d2-bb8d-4cf5-be7f-b4256ba9fbdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_5b5b28fa-ccef-4886-ba6d-4e208d83dc1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5f3e44d2-bb8d-4cf5-be7f-b4256ba9fbdd" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_5b5b28fa-ccef-4886-ba6d-4e208d83dc1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_8bca39a1-70da-4b43-b1db-50ed19ae6323" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5f3e44d2-bb8d-4cf5-be7f-b4256ba9fbdd" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_8bca39a1-70da-4b43-b1db-50ed19ae6323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/Segments" xlink:type="simple" xlink:href="asth-20240331.xsd#Segments"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/Segments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c71f0231-8ea2-43dc-bd6d-1e069def69cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_2ab105eb-bbb6-44ff-acae-1b9beebf5ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c71f0231-8ea2-43dc-bd6d-1e069def69cd" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_2ab105eb-bbb6-44ff-acae-1b9beebf5ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstruments" xlink:type="simple" xlink:href="asth-20240331.xsd#FairValueMeasurementsofFinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_daab189d-3b19-4e10-8200-2f899f759ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_d2dce6f2-9d68-4303-aaeb-adc49563e6f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_daab189d-3b19-4e10-8200-2f899f759ff9" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_d2dce6f2-9d68-4303-aaeb-adc49563e6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/SubsequentEvents" xlink:type="simple" xlink:href="asth-20240331.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_66c22781-adf6-4323-9e90-a979a162eaa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_cfbf44e7-81e2-4639-8394-2ad4387adcac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_66c22781-adf6-4323-9e90-a979a162eaa5" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_cfbf44e7-81e2-4639-8394-2ad4387adcac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="asth-20240331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b215cc21-e371-4dde-845f-a5966752e4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5f28356e-5471-493f-a9d1-8e83582a5327" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b215cc21-e371-4dde-845f-a5966752e4fa" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5f28356e-5471-493f-a9d1-8e83582a5327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_33254b26-0ff3-4d40-8110-b11525d21a17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b215cc21-e371-4dde-845f-a5966752e4fa" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_33254b26-0ff3-4d40-8110-b11525d21a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_186ae6a6-19d2-42f9-ae7a-c4ae038f415b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b215cc21-e371-4dde-845f-a5966752e4fa" xlink:to="loc_us-gaap_UseOfEstimates_186ae6a6-19d2-42f9-ae7a-c4ae038f415b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_e4d0daa7-9e73-451a-9489-738ec5aad0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b215cc21-e371-4dde-845f-a5966752e4fa" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_e4d0daa7-9e73-451a-9489-738ec5aad0c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_2de77ffe-b879-4215-9635-8e8a9da1a981" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b215cc21-e371-4dde-845f-a5966752e4fa" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_2de77ffe-b879-4215-9635-8e8a9da1a981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_7ec9cdcd-2985-4e65-a6f2-016de58188f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b215cc21-e371-4dde-845f-a5966752e4fa" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_7ec9cdcd-2985-4e65-a6f2-016de58188f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ReceivablesReceivablesRelatedPartiesOtherReceivablesAndLoanReceivablesPolicyTextBlock_9d0621b7-7f6c-4ff4-a38a-0d83fb3be86d" xlink:href="asth-20240331.xsd#asth_ReceivablesReceivablesRelatedPartiesOtherReceivablesAndLoanReceivablesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b215cc21-e371-4dde-845f-a5966752e4fa" xlink:to="loc_asth_ReceivablesReceivablesRelatedPartiesOtherReceivablesAndLoanReceivablesPolicyTextBlock_9d0621b7-7f6c-4ff4-a38a-0d83fb3be86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_da190b81-3c00-4ebb-a4af-292cb231d1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b215cc21-e371-4dde-845f-a5966752e4fa" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_da190b81-3c00-4ebb-a4af-292cb231d1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_ecdf455e-58d8-47a0-a098-877372e55394" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b215cc21-e371-4dde-845f-a5966752e4fa" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_ecdf455e-58d8-47a0-a098-877372e55394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_f2e13fb8-a5e6-4226-9256-bd93092f0d78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b215cc21-e371-4dde-845f-a5966752e4fa" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_f2e13fb8-a5e6-4226-9256-bd93092f0d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2f94a238-662a-48af-ac08-cce39d682641" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b215cc21-e371-4dde-845f-a5966752e4fa" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2f94a238-662a-48af-ac08-cce39d682641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_23f7ede0-521f-4c74-85fb-383a6ddcac78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b215cc21-e371-4dde-845f-a5966752e4fa" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_23f7ede0-521f-4c74-85fb-383a6ddcac78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_4d68f786-7d76-4a75-8357-1f2e52e1dfce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b215cc21-e371-4dde-845f-a5966752e4fa" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_4d68f786-7d76-4a75-8357-1f2e52e1dfce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="asth-20240331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_be570426-ff95-401a-972a-2f8dc949cd34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_8c846f09-3d11-4950-b167-026c093fe0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_be570426-ff95-401a-972a-2f8dc949cd34" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_8c846f09-3d11-4950-b167-026c093fe0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_be5a2c1e-4030-4d90-927d-4e34ea9d7847" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_be570426-ff95-401a-972a-2f8dc949cd34" xlink:to="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_be5a2c1e-4030-4d90-927d-4e34ea9d7847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillTables" xlink:type="simple" xlink:href="asth-20240331.xsd#BusinessCombinationsAssetAcquisitionsandGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_ba9500a6-7e70-49ef-9d16-42a6df332f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_bd276de4-65b1-42f7-ac1b-37ef3055606b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_ba9500a6-7e70-49ef-9d16-42a6df332f8d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_bd276de4-65b1-42f7-ac1b-37ef3055606b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_c4baee39-8bc3-4d6e-a685-7b465c3e7c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_ba9500a6-7e70-49ef-9d16-42a6df332f8d" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_c4baee39-8bc3-4d6e-a685-7b465c3e7c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetTables" xlink:type="simple" xlink:href="asth-20240331.xsd#IntangibleAssetsNetTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9635da6b-7ad6-430d-87cb-94ca95996b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_3f51df5b-71b8-4ce7-8d57-90dd629dc2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9635da6b-7ad6-430d-87cb-94ca95996b8b" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_3f51df5b-71b8-4ce7-8d57-90dd629dc2d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_778a64d2-af8a-4555-ab70-c1e05cff6526" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9635da6b-7ad6-430d-87cb-94ca95996b8b" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_778a64d2-af8a-4555-ab70-c1e05cff6526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesTables" xlink:type="simple" xlink:href="asth-20240331.xsd#InvestmentsinOtherEntitiesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_84d4f7d6-13eb-4cd4-9d46-98e21c356456" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_dc1586c4-2b03-41ec-ae14-7dcf2cf306ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_84d4f7d6-13eb-4cd4-9d46-98e21c356456" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_dc1586c4-2b03-41ec-ae14-7dcf2cf306ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables" xlink:type="simple" xlink:href="asth-20240331.xsd#AccountsPayableandAccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_da21e95a-5174-4f6a-8533-5aeebc848309" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_18eda7c6-d360-459d-b88c-88317211e77d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_da21e95a-5174-4f6a-8533-5aeebc848309" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_18eda7c6-d360-459d-b88c-88317211e77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilitiesTables" xlink:type="simple" xlink:href="asth-20240331.xsd#MedicalLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_4a90e0b2-9438-4361-8bb1-d76a4fad311d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_d241b190-6d2c-4f9d-9946-78f88208e406" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_4a90e0b2-9438-4361-8bb1-d76a4fad311d" xlink:to="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_d241b190-6d2c-4f9d-9946-78f88208e406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditTables" xlink:type="simple" xlink:href="asth-20240331.xsd#CreditFacilityBankLoansandLinesofCreditTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_28c3ad38-a155-424c-aef0-ded35b8a59b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_40c80ed8-4ef7-4a56-8500-88dad6f5925b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_28c3ad38-a155-424c-aef0-ded35b8a59b7" xlink:to="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_40c80ed8-4ef7-4a56-8500-88dad6f5925b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_53c4b8ff-6ae7-4fb3-a7ea-c2fc5000eece" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_28c3ad38-a155-424c-aef0-ded35b8a59b7" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_53c4b8ff-6ae7-4fb3-a7ea-c2fc5000eece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="asth-20240331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1a8d171e-a1ee-485e-be50-7cc8021d5d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_21fffb96-782e-4c3a-81e8-f9a55d172be5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1a8d171e-a1ee-485e-be50-7cc8021d5d7e" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_21fffb96-782e-4c3a-81e8-f9a55d172be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0c4dfc3d-2f51-4071-b81e-f827c7601b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1a8d171e-a1ee-485e-be50-7cc8021d5d7e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0c4dfc3d-2f51-4071-b81e-f827c7601b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsTables" xlink:type="simple" xlink:href="asth-20240331.xsd#RelatedPartyTransactionsTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_a24eede7-f166-4fbc-a39e-9fb50bd02760" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_5aa040b3-ab68-4e8d-b00a-d5a677632073" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_a24eede7-f166-4fbc-a39e-9fb50bd02760" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_5aa040b3-ab68-4e8d-b00a-d5a677632073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareTables" xlink:type="simple" xlink:href="asth-20240331.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2e920cfb-8912-44bb-992d-a8a5005d4946" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f384f264-1aa9-48e7-875a-8e393943f135" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2e920cfb-8912-44bb-992d-a8a5005d4946" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f384f264-1aa9-48e7-875a-8e393943f135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_0a6b61c6-1a67-4fa8-a11d-a712dceec7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2e920cfb-8912-44bb-992d-a8a5005d4946" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_0a6b61c6-1a67-4fa8-a11d-a712dceec7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables" xlink:type="simple" xlink:href="asth-20240331.xsd#VariableInterestEntitiesVIEsTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5951056e-de8d-4d6b-a47d-f5b76f5e0d16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_1faac433-c19b-41c1-9f8a-5708f0c20519" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5951056e-de8d-4d6b-a47d-f5b76f5e0d16" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_1faac433-c19b-41c1-9f8a-5708f0c20519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesTables" xlink:type="simple" xlink:href="asth-20240331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b9dab293-5fb2-476c-aaa0-4558d1bc73ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_a1a4d5ea-c1fa-4a14-ad2a-dae41d8a5070" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b9dab293-5fb2-476c-aaa0-4558d1bc73ef" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_a1a4d5ea-c1fa-4a14-ad2a-dae41d8a5070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_830f3267-9404-4f6e-a4ee-124b4f57d0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b9dab293-5fb2-476c-aaa0-4558d1bc73ef" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_830f3267-9404-4f6e-a4ee-124b4f57d0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_3b992498-a48b-4d47-9669-0d3b9ec5873a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b9dab293-5fb2-476c-aaa0-4558d1bc73ef" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_3b992498-a48b-4d47-9669-0d3b9ec5873a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/SegmentsTables" xlink:type="simple" xlink:href="asth-20240331.xsd#SegmentsTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/SegmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_22d42265-f2ad-4349-860b-1c9cf32c8a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_43170474-6927-4b8e-9404-20a2641d6d36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_22d42265-f2ad-4349-860b-1c9cf32c8a1c" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_43170474-6927-4b8e-9404-20a2641d6d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsTables" xlink:type="simple" xlink:href="asth-20240331.xsd#FairValueMeasurementsofFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6703df7d-d470-460f-ae91-4ecf5403f27e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_a1ea06ba-565a-44aa-aa89-5d43c34d83a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6703df7d-d470-460f-ae91-4ecf5403f27e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_a1ea06ba-565a-44aa-aa89-5d43c34d83a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2bfc1d47-ead1-41dd-b228-14f4c25d8e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6703df7d-d470-460f-ae91-4ecf5403f27e" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2bfc1d47-ead1-41dd-b228-14f4c25d8e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_8cfff1d5-4097-4f0a-b413-61b78888203f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6703df7d-d470-460f-ae91-4ecf5403f27e" xlink:to="loc_us-gaap_GainLossOnInvestmentsTextBlock_8cfff1d5-4097-4f0a-b413-61b78888203f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#DescriptionofBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/DescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e6c816ee-84a2-46d6-991f-896c96405f52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_fadb50c8-8a34-4a7b-b01c-52c7ada8480a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e6c816ee-84a2-46d6-991f-896c96405f52" xlink:to="loc_us-gaap_NumberOfReportableSegments_fadb50c8-8a34-4a7b-b01c-52c7ada8480a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_46f4ad7b-fa78-4bee-b29d-baa1855489b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_b55d5973-f636-4637-9150-74f0a3272f73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_46f4ad7b-fa78-4bee-b29d-baa1855489b7" xlink:to="loc_us-gaap_NumberOfReportableSegments_b55d5973-f636-4637-9150-74f0a3272f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount_1b56bbe0-8837-467f-8d53-3dfbf68c2672" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashUninsuredAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_46f4ad7b-fa78-4bee-b29d-baa1855489b7" xlink:to="loc_us-gaap_CashUninsuredAmount_1b56bbe0-8837-467f-8d53-3dfbf68c2672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_43f1993f-fafe-4837-9ebf-5372d4eed2eb" xlink:href="asth-20240331.xsd#asth_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_46f4ad7b-fa78-4bee-b29d-baa1855489b7" xlink:to="loc_asth_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_43f1993f-fafe-4837-9ebf-5372d4eed2eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofDisaggregatedRevenuebyEachPayerTypeDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofDisaggregatedRevenuebyEachPayerTypeDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofDisaggregatedRevenuebyEachPayerTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_dd0141a0-2b07-4425-9f9f-0620d936528f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7381ad5b-1e68-4647-9322-bf6981cc2dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd0141a0-2b07-4425-9f9f-0620d936528f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7381ad5b-1e68-4647-9322-bf6981cc2dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_56c12747-e606-4e68-9970-09a6bc9b755d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7381ad5b-1e68-4647-9322-bf6981cc2dc3" xlink:to="loc_srt_MajorCustomersAxis_56c12747-e606-4e68-9970-09a6bc9b755d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_bcee3021-9319-44d4-8ebb-9f694ab302fb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_56c12747-e606-4e68-9970-09a6bc9b755d" xlink:to="loc_srt_NameOfMajorCustomerDomain_bcee3021-9319-44d4-8ebb-9f694ab302fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CommercialMember_36de31c1-99c0-4ac6-9d97-f315889e95a3" xlink:href="asth-20240331.xsd#asth_CommercialMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_bcee3021-9319-44d4-8ebb-9f694ab302fb" xlink:to="loc_asth_CommercialMember_36de31c1-99c0-4ac6-9d97-f315889e95a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_MedicareMember_3346a07a-d30a-46f3-a57f-59c6c2d7647d" xlink:href="asth-20240331.xsd#asth_MedicareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_bcee3021-9319-44d4-8ebb-9f694ab302fb" xlink:to="loc_asth_MedicareMember_3346a07a-d30a-46f3-a57f-59c6c2d7647d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_MedicaidMember_3341bbe1-8f77-4c37-a0c4-302caaa26469" xlink:href="asth-20240331.xsd#asth_MedicaidMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_bcee3021-9319-44d4-8ebb-9f694ab302fb" xlink:to="loc_asth_MedicaidMember_3341bbe1-8f77-4c37-a0c4-302caaa26469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_OtherThirdPartiesMember_27e3cec2-463c-4b0c-9dcb-f3009b4b13df" xlink:href="asth-20240331.xsd#asth_OtherThirdPartiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_bcee3021-9319-44d4-8ebb-9f694ab302fb" xlink:to="loc_asth_OtherThirdPartiesMember_27e3cec2-463c-4b0c-9dcb-f3009b4b13df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_c3f47734-1e98-4e14-9629-fce7bb7ae3e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7381ad5b-1e68-4647-9322-bf6981cc2dc3" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_c3f47734-1e98-4e14-9629-fce7bb7ae3e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a8d38264-b361-4b42-87f7-a132a5958d08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c3f47734-1e98-4e14-9629-fce7bb7ae3e6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a8d38264-b361-4b42-87f7-a132a5958d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofContributionstoRevenueandReceivablesbyPayerDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofContributionstoRevenueandReceivablesbyPayerDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofContributionstoRevenueandReceivablesbyPayerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6a443c6c-a528-460a-a2c8-233f8f773feb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AccountsReceivableAndNetRevenueTable_82aa756b-d4a8-4850-b4d4-13a5ee99ca68" xlink:href="asth-20240331.xsd#asth_AccountsReceivableAndNetRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a443c6c-a528-460a-a2c8-233f8f773feb" xlink:to="loc_asth_AccountsReceivableAndNetRevenueTable_82aa756b-d4a8-4850-b4d4-13a5ee99ca68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d7d23bd6-cc73-4049-bad0-e6a6e80268c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_AccountsReceivableAndNetRevenueTable_82aa756b-d4a8-4850-b4d4-13a5ee99ca68" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d7d23bd6-cc73-4049-bad0-e6a6e80268c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_44f86d11-518d-41fe-81bc-d030fe4a74fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d7d23bd6-cc73-4049-bad0-e6a6e80268c2" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_44f86d11-518d-41fe-81bc-d030fe4a74fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_60e72eb8-1473-4b4d-8478-ca4119f79e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_44f86d11-518d-41fe-81bc-d030fe4a74fc" xlink:to="loc_us-gaap_SalesRevenueNetMember_60e72eb8-1473-4b4d-8478-ca4119f79e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_c207c462-1aa6-4b0f-9cb9-557fa3fd3aff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_44f86d11-518d-41fe-81bc-d030fe4a74fc" xlink:to="loc_us-gaap_AccountsReceivableMember_c207c462-1aa6-4b0f-9cb9-557fa3fd3aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_0d90c6e3-17af-45bc-becb-75e8de217454" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_AccountsReceivableAndNetRevenueTable_82aa756b-d4a8-4850-b4d4-13a5ee99ca68" xlink:to="loc_srt_MajorCustomersAxis_0d90c6e3-17af-45bc-becb-75e8de217454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_8ec49487-a824-44a4-b959-6a7329d2556f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_0d90c6e3-17af-45bc-becb-75e8de217454" xlink:to="loc_srt_NameOfMajorCustomerDomain_8ec49487-a824-44a4-b959-6a7329d2556f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PayorAMember_a8f208df-f627-4a2e-b1f1-492e203c1994" xlink:href="asth-20240331.xsd#asth_PayorAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_8ec49487-a824-44a4-b959-6a7329d2556f" xlink:to="loc_asth_PayorAMember_a8f208df-f627-4a2e-b1f1-492e203c1994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PayorBMember_a44f5494-2cb8-4e1d-bf63-f3eabdf9977f" xlink:href="asth-20240331.xsd#asth_PayorBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_8ec49487-a824-44a4-b959-6a7329d2556f" xlink:to="loc_asth_PayorBMember_a44f5494-2cb8-4e1d-bf63-f3eabdf9977f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PayerCMember_a4f446bd-ae05-48ed-a05d-4c3de2df6047" xlink:href="asth-20240331.xsd#asth_PayerCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_8ec49487-a824-44a4-b959-6a7329d2556f" xlink:to="loc_asth_PayerCMember_a4f446bd-ae05-48ed-a05d-4c3de2df6047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_43a7b0fa-3e6d-4d6e-85d3-4ef61da07fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_AccountsReceivableAndNetRevenueTable_82aa756b-d4a8-4850-b4d4-13a5ee99ca68" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_43a7b0fa-3e6d-4d6e-85d3-4ef61da07fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c1e0165a-5c47-42d2-ba0f-033469602f17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_43a7b0fa-3e6d-4d6e-85d3-4ef61da07fa9" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c1e0165a-5c47-42d2-ba0f-033469602f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_819b8fe6-7fbf-4bf3-8cde-b3732efdef4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_c1e0165a-5c47-42d2-ba0f-033469602f17" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_819b8fe6-7fbf-4bf3-8cde-b3732efdef4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AccountsReceivableAndNetRevenueLineItems_d84a1fc4-3d80-4b62-a77a-73fbdda72b58" xlink:href="asth-20240331.xsd#asth_AccountsReceivableAndNetRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_AccountsReceivableAndNetRevenueTable_82aa756b-d4a8-4850-b4d4-13a5ee99ca68" xlink:to="loc_asth_AccountsReceivableAndNetRevenueLineItems_d84a1fc4-3d80-4b62-a77a-73fbdda72b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ebe17e8f-c05d-4de7-b8c1-a74c7acdc3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_AccountsReceivableAndNetRevenueLineItems_d84a1fc4-3d80-4b62-a77a-73fbdda72b58" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ebe17e8f-c05d-4de7-b8c1-a74c7acdc3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillAdditionalInformationDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#BusinessCombinationsAssetAcquisitionsandGoodwillAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_04e68d6b-6287-4014-859f-2909f7d01079" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_fa592d95-b436-43dd-b4a9-1a23ab9836eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_04e68d6b-6287-4014-859f-2909f7d01079" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_fa592d95-b436-43dd-b4a9-1a23ab9836eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b188e01f-d393-4a84-b32d-9747954587e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_fa592d95-b436-43dd-b4a9-1a23ab9836eb" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b188e01f-d393-4a84-b32d-9747954587e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d1126f2-b717-4fbc-ba79-2ac7718147f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b188e01f-d393-4a84-b32d-9747954587e8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d1126f2-b717-4fbc-ba79-2ac7718147f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AdvancedHealthManagementSystemsLPMember_189c4e9a-e0b9-490f-9451-258d7b6b27b8" xlink:href="asth-20240331.xsd#asth_AdvancedHealthManagementSystemsLPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d1126f2-b717-4fbc-ba79-2ac7718147f6" xlink:to="loc_asth_AdvancedHealthManagementSystemsLPMember_189c4e9a-e0b9-490f-9451-258d7b6b27b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PrimeCommunityCareOfCentralValleyIncMember_61279230-e871-4584-9a5c-28ef34c17a4d" xlink:href="asth-20240331.xsd#asth_PrimeCommunityCareOfCentralValleyIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d1126f2-b717-4fbc-ba79-2ac7718147f6" xlink:to="loc_asth_PrimeCommunityCareOfCentralValleyIncMember_61279230-e871-4584-9a5c-28ef34c17a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CommunityFamilyCareMedicalGroupIPAInc.Member_6bf222bd-0cca-4381-b374-9b3f63471706" xlink:href="asth-20240331.xsd#asth_CommunityFamilyCareMedicalGroupIPAInc.Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d1126f2-b717-4fbc-ba79-2ac7718147f6" xlink:to="loc_asth_CommunityFamilyCareMedicalGroupIPAInc.Member_6bf222bd-0cca-4381-b374-9b3f63471706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AdvancedDiagnosticAndSurgicalCenterIncMember_4473190f-38a9-4170-a2c3-8544eff07563" xlink:href="asth-20240331.xsd#asth_AdvancedDiagnosticAndSurgicalCenterIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d1126f2-b717-4fbc-ba79-2ac7718147f6" xlink:to="loc_asth_AdvancedDiagnosticAndSurgicalCenterIncMember_4473190f-38a9-4170-a2c3-8544eff07563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_eb5a3d08-4a4c-47e8-acca-b7e517b83745" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_fa592d95-b436-43dd-b4a9-1a23ab9836eb" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_eb5a3d08-4a4c-47e8-acca-b7e517b83745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_8d2e6fef-ca61-4d29-af1c-8717c6609be4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_eb5a3d08-4a4c-47e8-acca-b7e517b83745" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_8d2e6fef-ca61-4d29-af1c-8717c6609be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ContingentConsideration_2b10b111-55dd-4e19-a59e-f3f6a65a094f" xlink:href="asth-20240331.xsd#asth_ContingentConsideration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_eb5a3d08-4a4c-47e8-acca-b7e517b83745" xlink:to="loc_asth_ContingentConsideration_2b10b111-55dd-4e19-a59e-f3f6a65a094f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ConsiderationOfAcquisitionInCashFunded_cf3dbf2b-a7e2-449e-9d72-048a6897e744" xlink:href="asth-20240331.xsd#asth_ConsiderationOfAcquisitionInCashFunded"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_eb5a3d08-4a4c-47e8-acca-b7e517b83745" xlink:to="loc_asth_ConsiderationOfAcquisitionInCashFunded_cf3dbf2b-a7e2-449e-9d72-048a6897e744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessAcquisitionOfCommonStock_dc212944-f0e7-450b-b203-d3a2ea8eafe0" xlink:href="asth-20240331.xsd#asth_BusinessAcquisitionOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_eb5a3d08-4a4c-47e8-acca-b7e517b83745" xlink:to="loc_asth_BusinessAcquisitionOfCommonStock_dc212944-f0e7-450b-b203-d3a2ea8eafe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_661470be-c711-497e-8806-a41c7232d94a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_eb5a3d08-4a4c-47e8-acca-b7e517b83745" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_661470be-c711-497e-8806-a41c7232d94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_69f130fc-e14b-4c34-b329-aa78a8397a16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_eb5a3d08-4a4c-47e8-acca-b7e517b83745" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_69f130fc-e14b-4c34-b329-aa78a8397a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_40b47235-2dfd-4d05-a6e0-f96700591645" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_eb5a3d08-4a4c-47e8-acca-b7e517b83745" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_40b47235-2dfd-4d05-a6e0-f96700591645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_038b921b-9c08-416f-aa64-6004b7407b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_eb5a3d08-4a4c-47e8-acca-b7e517b83745" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_038b921b-9c08-416f-aa64-6004b7407b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_f8a58639-9435-4f13-a951-143c7bf1f944" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_eb5a3d08-4a4c-47e8-acca-b7e517b83745" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_f8a58639-9435-4f13-a951-143c7bf1f944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_18fa80e2-27e6-4021-b296-a544b858f125" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_eb5a3d08-4a4c-47e8-acca-b7e517b83745" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_18fa80e2-27e6-4021-b296-a544b858f125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_75e9b5f7-07d0-4347-a928-e1dd8844770e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0dee7bec-8f5a-4713-9597-2a2d69d0c7f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_75e9b5f7-07d0-4347-a928-e1dd8844770e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0dee7bec-8f5a-4713-9597-2a2d69d0c7f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_42f846bb-ed4f-4e2b-a727-4b7e7fbc3a52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0dee7bec-8f5a-4713-9597-2a2d69d0c7f0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_42f846bb-ed4f-4e2b-a727-4b7e7fbc3a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cfa1e921-babf-4307-8302-32d8b14e67ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_42f846bb-ed4f-4e2b-a727-4b7e7fbc3a52" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cfa1e921-babf-4307-8302-32d8b14e67ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CommunityFamilyCareMedicalGroupIPAInc.Member_ec2091e5-7bf0-45a8-9d28-dbb2f9331bda" xlink:href="asth-20240331.xsd#asth_CommunityFamilyCareMedicalGroupIPAInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cfa1e921-babf-4307-8302-32d8b14e67ff" xlink:to="loc_asth_CommunityFamilyCareMedicalGroupIPAInc.Member_ec2091e5-7bf0-45a8-9d28-dbb2f9331bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AdvancedHealthManagementSystemsLPMember_b681d17b-079a-4b5f-9a3d-e35d45b1db11" xlink:href="asth-20240331.xsd#asth_AdvancedHealthManagementSystemsLPMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cfa1e921-babf-4307-8302-32d8b14e67ff" xlink:to="loc_asth_AdvancedHealthManagementSystemsLPMember_b681d17b-079a-4b5f-9a3d-e35d45b1db11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_OtherAcquisitionsMember_609f7f1c-05b9-47f9-8f7d-f9872119c7f0" xlink:href="asth-20240331.xsd#asth_OtherAcquisitionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cfa1e921-babf-4307-8302-32d8b14e67ff" xlink:to="loc_asth_OtherAcquisitionsMember_609f7f1c-05b9-47f9-8f7d-f9872119c7f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_TotalAcquisitionsMember_a2680805-93b0-469c-98b3-499a3aad9894" xlink:href="asth-20240331.xsd#asth_TotalAcquisitionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cfa1e921-babf-4307-8302-32d8b14e67ff" xlink:to="loc_asth_TotalAcquisitionsMember_a2680805-93b0-469c-98b3-499a3aad9894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_fb6f70bc-86c8-4958-ad20-6536ef125fad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0dee7bec-8f5a-4713-9597-2a2d69d0c7f0" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_fb6f70bc-86c8-4958-ad20-6536ef125fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_TotalPurchaseConsiderationAbstract_d84bafe4-314a-47df-b871-0ae6ed533faf" xlink:href="asth-20240331.xsd#asth_TotalPurchaseConsiderationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb6f70bc-86c8-4958-ad20-6536ef125fad" xlink:to="loc_asth_TotalPurchaseConsiderationAbstract_d84bafe4-314a-47df-b871-0ae6ed533faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_a1d76029-4a99-4c91-bb6d-dff581f624ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_TotalPurchaseConsiderationAbstract_d84bafe4-314a-47df-b871-0ae6ed533faf" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_a1d76029-4a99-4c91-bb6d-dff581f624ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PaymentsToAcquireBusinessCashPayable_325b4e43-281e-44dc-b5f8-3ec565de6e65" xlink:href="asth-20240331.xsd#asth_PaymentsToAcquireBusinessCashPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_TotalPurchaseConsiderationAbstract_d84bafe4-314a-47df-b871-0ae6ed533faf" xlink:to="loc_asth_PaymentsToAcquireBusinessCashPayable_325b4e43-281e-44dc-b5f8-3ec565de6e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_4efd86a9-2a67-4a59-90ed-e96c2686257f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_TotalPurchaseConsiderationAbstract_d84bafe4-314a-47df-b871-0ae6ed533faf" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_4efd86a9-2a67-4a59-90ed-e96c2686257f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_1c8c3b0e-2f1c-4781-8cfa-89eb725b51c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_TotalPurchaseConsiderationAbstract_d84bafe4-314a-47df-b871-0ae6ed533faf" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_1c8c3b0e-2f1c-4781-8cfa-89eb725b51c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_0157a8b4-0d17-4636-bc24-56b6859650de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_TotalPurchaseConsiderationAbstract_d84bafe4-314a-47df-b871-0ae6ed533faf" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_0157a8b4-0d17-4636-bc24-56b6859650de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_a6008f49-428c-4364-8e1f-8862d6515431" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb6f70bc-86c8-4958-ad20-6536ef125fad" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_a6008f49-428c-4364-8e1f-8862d6515431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_896b89c5-d1a8-45af-83cf-e570a86b1932" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_a6008f49-428c-4364-8e1f-8862d6515431" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_896b89c5-d1a8-45af-83cf-e570a86b1932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_68ae5395-3140-46ac-b308-15eb8695b77d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_a6008f49-428c-4364-8e1f-8862d6515431" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_68ae5395-3140-46ac-b308-15eb8695b77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_679de290-dbb7-4c0a-a795-b5d627ceab8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_a6008f49-428c-4364-8e1f-8862d6515431" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_679de290-dbb7-4c0a-a795-b5d627ceab8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_d1d25c36-e621-43f2-9237-78729c29f647" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_a6008f49-428c-4364-8e1f-8862d6515431" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_d1d25c36-e621-43f2-9237-78729c29f647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates_2a728afa-36b2-4bc5-b587-eba6d7b909ab" xlink:href="asth-20240331.xsd#asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_a6008f49-428c-4364-8e1f-8862d6515431" xlink:to="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates_2a728afa-36b2-4bc5-b587-eba6d7b909ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_60bc9b46-e556-4568-9784-a5a1bf996ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_a6008f49-428c-4364-8e1f-8862d6515431" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_60bc9b46-e556-4568-9784-a5a1bf996ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_536a3f14-d54b-40b6-b1f7-3bf639b3512c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_a6008f49-428c-4364-8e1f-8862d6515431" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_536a3f14-d54b-40b6-b1f7-3bf639b3512c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_379fc5a8-b6d1-410e-8f74-1c2483060728" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_a6008f49-428c-4364-8e1f-8862d6515431" xlink:to="loc_us-gaap_Goodwill_379fc5a8-b6d1-410e-8f74-1c2483060728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash_096beffd-4a07-4288-8c8a-5c97a806fa09" xlink:href="asth-20240331.xsd#asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_a6008f49-428c-4364-8e1f-8862d6515431" xlink:to="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash_096beffd-4a07-4288-8c8a-5c97a806fa09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_3c2dd371-b6cd-42ad-97e9-d62f54a6c101" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_a6008f49-428c-4364-8e1f-8862d6515431" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_3c2dd371-b6cd-42ad-97e9-d62f54a6c101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_c8fa1114-8356-4646-84cc-64ed96e28579" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb6f70bc-86c8-4958-ad20-6536ef125fad" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_c8fa1114-8356-4646-84cc-64ed96e28579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses_280fbc7e-a0f1-4e9d-b586-fa3310b7757f" xlink:href="asth-20240331.xsd#asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_c8fa1114-8356-4646-84cc-64ed96e28579" xlink:to="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses_280fbc7e-a0f1-4e9d-b586-fa3310b7757f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities_8b6fa248-7232-4e6a-ae0e-a01c474ec232" xlink:href="asth-20240331.xsd#asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_c8fa1114-8356-4646-84cc-64ed96e28579" xlink:to="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities_8b6fa248-7232-4e6a-ae0e-a01c474ec232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates_056bb75b-23d9-4346-ad71-28084a46503e" xlink:href="asth-20240331.xsd#asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_c8fa1114-8356-4646-84cc-64ed96e28579" xlink:to="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates_056bb75b-23d9-4346-ad71-28084a46503e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable_76247c03-c276-49f9-ba8a-5aec71eb3b39" xlink:href="asth-20240331.xsd#asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_c8fa1114-8356-4646-84cc-64ed96e28579" xlink:to="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable_76247c03-c276-49f9-ba8a-5aec71eb3b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_8524118e-3e80-4fed-bf7d-70451f881762" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_c8fa1114-8356-4646-84cc-64ed96e28579" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_8524118e-3e80-4fed-bf7d-70451f881762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest_ee982574-2df6-4694-ba77-2a65c800cdea" xlink:href="asth-20240331.xsd#asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_c8fa1114-8356-4646-84cc-64ed96e28579" xlink:to="loc_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest_ee982574-2df6-4694-ba77-2a65c800cdea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_cd62f9aa-cd7d-4912-abdd-9c21f1348a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_c8fa1114-8356-4646-84cc-64ed96e28579" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_cd62f9aa-cd7d-4912-abdd-9c21f1348a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_44122515-4ae0-4da8-af78-faedc4754cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb6f70bc-86c8-4958-ad20-6536ef125fad" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_44122515-4ae0-4da8-af78-faedc4754cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillScheduleofBusinessAcquisitionProFormaInformationNonrecurringAdjustmentsDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#BusinessCombinationsAssetAcquisitionsandGoodwillScheduleofBusinessAcquisitionProFormaInformationNonrecurringAdjustmentsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillScheduleofBusinessAcquisitionProFormaInformationNonrecurringAdjustmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_942ec746-77b2-4434-b662-828d433bb709" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_782d2c1e-b443-4a79-bb20-e35ab838de68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_942ec746-77b2-4434-b662-828d433bb709" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_782d2c1e-b443-4a79-bb20-e35ab838de68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_dafca4c4-22a9-4c4b-b505-6df9edb0175f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_942ec746-77b2-4434-b662-828d433bb709" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_dafca4c4-22a9-4c4b-b505-6df9edb0175f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_d0ec75d0-8137-4038-b584-0011538d62e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_942ec746-77b2-4434-b662-828d433bb709" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_d0ec75d0-8137-4038-b584-0011538d62e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_764967e1-585d-41e4-bed5-4beec2964cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_942ec746-77b2-4434-b662-828d433bb709" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_764967e1-585d-41e4-bed5-4beec2964cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillScheduleofGoodwillDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#BusinessCombinationsAssetAcquisitionsandGoodwillScheduleofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillScheduleofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4b3bed59-235b-4913-9cc7-8bea15c2c27c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_49fa66cc-e788-4172-aec3-4c93de3ed2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4b3bed59-235b-4913-9cc7-8bea15c2c27c" xlink:to="loc_us-gaap_GoodwillRollForward_49fa66cc-e788-4172-aec3-4c93de3ed2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1db596e2-a0b7-42e5-a592-1fbd7d86df49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_49fa66cc-e788-4172-aec3-4c93de3ed2d9" xlink:to="loc_us-gaap_Goodwill_1db596e2-a0b7-42e5-a592-1fbd7d86df49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_90824ff0-bbfc-4365-963d-01449557934c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_49fa66cc-e788-4172-aec3-4c93de3ed2d9" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_90824ff0-bbfc-4365-963d-01449557934c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_6fbbd347-a6ce-46dd-877a-4928bba34dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_49fa66cc-e788-4172-aec3-4c93de3ed2d9" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_6fbbd347-a6ce-46dd-877a-4928bba34dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5fcb6a80-f7a0-4234-92f9-967860280adf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_49fa66cc-e788-4172-aec3-4c93de3ed2d9" xlink:to="loc_us-gaap_Goodwill_5fcb6a80-f7a0-4234-92f9-967860280adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c66a234f-b849-4bb4-a798-687e4d05732b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_66693459-eb57-4a3d-9949-45c26cdf9981" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c66a234f-b849-4bb4-a798-687e4d05732b" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_66693459-eb57-4a3d-9949-45c26cdf9981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2477e7c7-c93d-491a-bac9-46092d5367d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_66693459-eb57-4a3d-9949-45c26cdf9981" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2477e7c7-c93d-491a-bac9-46092d5367d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cbfd8a0f-af9f-4dca-bf2a-89a0d46b1a68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2477e7c7-c93d-491a-bac9-46092d5367d9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cbfd8a0f-af9f-4dca-bf2a-89a0d46b1a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_NetworkRelationshipsMember_4e798b79-8aae-4f61-9083-df3aa0e0393c" xlink:href="asth-20240331.xsd#asth_NetworkRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cbfd8a0f-af9f-4dca-bf2a-89a0d46b1a68" xlink:to="loc_asth_NetworkRelationshipsMember_4e798b79-8aae-4f61-9083-df3aa0e0393c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ManagementContractsMember_656bb8c4-679f-4d71-856d-c28b795f3c98" xlink:href="asth-20240331.xsd#asth_ManagementContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cbfd8a0f-af9f-4dca-bf2a-89a0d46b1a68" xlink:to="loc_asth_ManagementContractsMember_656bb8c4-679f-4d71-856d-c28b795f3c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_MemberRelationshipsMember_05bfac51-3f2c-4279-9330-8283524ed535" xlink:href="asth-20240331.xsd#asth_MemberRelationshipsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cbfd8a0f-af9f-4dca-bf2a-89a0d46b1a68" xlink:to="loc_asth_MemberRelationshipsMember_05bfac51-3f2c-4279-9330-8283524ed535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PatientManagementPlatformMember_d98ee51a-9c7c-4189-93fb-1e15b2ec3655" xlink:href="asth-20240331.xsd#asth_PatientManagementPlatformMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cbfd8a0f-af9f-4dca-bf2a-89a0d46b1a68" xlink:to="loc_asth_PatientManagementPlatformMember_d98ee51a-9c7c-4189-93fb-1e15b2ec3655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_f5228be2-35d9-4fb4-a223-272bc128a4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cbfd8a0f-af9f-4dca-bf2a-89a0d46b1a68" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_f5228be2-35d9-4fb4-a223-272bc128a4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_3a893b73-7e5b-4c9f-a91f-a4448566c019" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cbfd8a0f-af9f-4dca-bf2a-89a0d46b1a68" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_3a893b73-7e5b-4c9f-a91f-a4448566c019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_162095b1-2e01-41fa-89b2-cd3a908e1ab4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_66693459-eb57-4a3d-9949-45c26cdf9981" xlink:to="loc_srt_RangeAxis_162095b1-2e01-41fa-89b2-cd3a908e1ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_882d276d-86fd-4324-8184-9a486d9943c5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_162095b1-2e01-41fa-89b2-cd3a908e1ab4" xlink:to="loc_srt_RangeMember_882d276d-86fd-4324-8184-9a486d9943c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e89841b6-fc8a-4932-8d34-0cd110b13a4d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_882d276d-86fd-4324-8184-9a486d9943c5" xlink:to="loc_srt_MinimumMember_e89841b6-fc8a-4932-8d34-0cd110b13a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ba374db5-2b57-46ad-8675-05ebf3dde1da" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_882d276d-86fd-4324-8184-9a486d9943c5" xlink:to="loc_srt_MaximumMember_ba374db5-2b57-46ad-8675-05ebf3dde1da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_94921fec-27e1-4001-9a0d-082ef889b643" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_66693459-eb57-4a3d-9949-45c26cdf9981" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_94921fec-27e1-4001-9a0d-082ef889b643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_cfd59589-0116-4aae-b7a3-97edee6ab03d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_94921fec-27e1-4001-9a0d-082ef889b643" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_cfd59589-0116-4aae-b7a3-97edee6ab03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_33a6901a-eb92-4cb5-90bc-00f4cf1679d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_cfd59589-0116-4aae-b7a3-97edee6ab03d" xlink:to="loc_us-gaap_TrademarksMember_33a6901a-eb92-4cb5-90bc-00f4cf1679d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_85ad2904-b9c6-413f-8bb3-047d4a216805" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_cfd59589-0116-4aae-b7a3-97edee6ab03d" xlink:to="loc_us-gaap_LicenseMember_85ad2904-b9c6-413f-8bb3-047d4a216805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_953dec26-15d8-48c5-98e1-34e0994ef0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_66693459-eb57-4a3d-9949-45c26cdf9981" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_953dec26-15d8-48c5-98e1-34e0994ef0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2777ff4d-efe7-4a49-ada2-c420e0793ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_953dec26-15d8-48c5-98e1-34e0994ef0ab" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2777ff4d-efe7-4a49-ada2-c420e0793ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_755b7b32-e89a-4ff3-b1da-9e003febb0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_953dec26-15d8-48c5-98e1-34e0994ef0ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_755b7b32-e89a-4ff3-b1da-9e003febb0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_faa2b934-a55e-475a-a497-65587a0f62df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_953dec26-15d8-48c5-98e1-34e0994ef0ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_faa2b934-a55e-475a-a497-65587a0f62df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_82e6ca30-3689-481e-8c3d-e8e278773d69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_953dec26-15d8-48c5-98e1-34e0994ef0ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_82e6ca30-3689-481e-8c3d-e8e278773d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9b8f5b6a-fa5e-4259-aec5-548cb7da7a96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_953dec26-15d8-48c5-98e1-34e0994ef0ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9b8f5b6a-fa5e-4259-aec5-548cb7da7a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_fb23faea-0d38-4209-8518-8321de544808" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c66a234f-b849-4bb4-a798-687e4d05732b" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_fb23faea-0d38-4209-8518-8321de544808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_48788a0d-4208-425f-a40a-ce78863ac6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_fb23faea-0d38-4209-8518-8321de544808" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_48788a0d-4208-425f-a40a-ce78863ac6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5cbee2bd-3f5b-4e86-8873-eb9ce1faaadb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_120c2123-c4c2-4b34-881f-a1ef9a827c35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_0481aa79-3978-4195-9541-4d048dff68c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_fb23faea-0d38-4209-8518-8321de544808" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_0481aa79-3978-4195-9541-4d048dff68c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_98a68cac-8f65-4f3c-8fd7-bd08c21f2dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_0481aa79-3978-4195-9541-4d048dff68c4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_98a68cac-8f65-4f3c-8fd7-bd08c21f2dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_4d08893f-6e8a-4a5c-b2b6-247359c485c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c66a234f-b849-4bb4-a798-687e4d05732b" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_4d08893f-6e8a-4a5c-b2b6-247359c485c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d1b50c61-1492-4e9e-969b-db22d5cbb7db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c66a234f-b849-4bb4-a798-687e4d05732b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d1b50c61-1492-4e9e-969b-db22d5cbb7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#IntangibleAssetsNetAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cf6c67b3-3038-4440-b223-72d4b1874ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_57bab372-c620-4d27-9dfb-0682b5e78be9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cf6c67b3-3038-4440-b223-72d4b1874ce7" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_57bab372-c620-4d27-9dfb-0682b5e78be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_62f37d18-65d8-4cd6-9435-591d015c6370" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cf6c67b3-3038-4440-b223-72d4b1874ce7" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_62f37d18-65d8-4cd6-9435-591d015c6370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_597dd3f3-ec8b-42f3-821c-830395739ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_adcd4ed6-fa82-4e7b-8b3d-6844a4d2df92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_597dd3f3-ec8b-42f3-821c-830395739ddb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_adcd4ed6-fa82-4e7b-8b3d-6844a4d2df92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0c2d5f67-9c97-4ba5-8785-59b9e80460ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_597dd3f3-ec8b-42f3-821c-830395739ddb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0c2d5f67-9c97-4ba5-8785-59b9e80460ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5f1a3ba1-1536-4905-838e-a60d73efd9a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_597dd3f3-ec8b-42f3-821c-830395739ddb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5f1a3ba1-1536-4905-838e-a60d73efd9a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d891181c-f88f-40a1-b3e1-8d41c68b3975" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_597dd3f3-ec8b-42f3-821c-830395739ddb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d891181c-f88f-40a1-b3e1-8d41c68b3975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_de4e26e7-baad-44cd-b37e-8ff7bef9fd02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_597dd3f3-ec8b-42f3-821c-830395739ddb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_de4e26e7-baad-44cd-b37e-8ff7bef9fd02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_e358de1d-03b9-4d19-9555-6e0357120c47" xlink:href="asth-20240331.xsd#asth_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_597dd3f3-ec8b-42f3-821c-830395739ddb" xlink:to="loc_asth_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_e358de1d-03b9-4d19-9555-6e0357120c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_78fffc25-df92-4514-bfbb-358ff35653bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_597dd3f3-ec8b-42f3-821c-830395739ddb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_78fffc25-df92-4514-bfbb-358ff35653bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesScheduleofEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#InvestmentsinOtherEntitiesScheduleofEquityMethodInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesScheduleofEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_f16c6ecb-9ea6-408e-a6e5-4a14a83ea12c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2aa95968-de07-49c0-9bd2-625f954efc04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_f16c6ecb-9ea6-408e-a6e5-4a14a83ea12c" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2aa95968-de07-49c0-9bd2-625f954efc04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d4544bb5-bb07-4a47-aeff-a20d61e13408" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2aa95968-de07-49c0-9bd2-625f954efc04" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d4544bb5-bb07-4a47-aeff-a20d61e13408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f3e15769-0ab2-4b19-928d-2e91421a7a3b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d4544bb5-bb07-4a47-aeff-a20d61e13408" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f3e15769-0ab2-4b19-928d-2e91421a7a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_LasalleMedicalAssociatesIpaMember_bd760090-f127-438b-ad16-06fc71a8a3a8" xlink:href="asth-20240331.xsd#asth_LasalleMedicalAssociatesIpaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f3e15769-0ab2-4b19-928d-2e91421a7a3b" xlink:to="loc_asth_LasalleMedicalAssociatesIpaMember_bd760090-f127-438b-ad16-06fc71a8a3a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PacificMedicalImagingAndOncologyCenterIncMember_05852ecb-1e69-455c-a56a-c7e3d077b1ba" xlink:href="asth-20240331.xsd#asth_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f3e15769-0ab2-4b19-928d-2e91421a7a3b" xlink:to="loc_asth_PacificMedicalImagingAndOncologyCenterIncMember_05852ecb-1e69-455c-a56a-c7e3d077b1ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_FiveThreeOneW.CollegeLLCMember_aee9e1fe-c7f4-47db-bd42-fdeb26f22730" xlink:href="asth-20240331.xsd#asth_FiveThreeOneW.CollegeLLCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f3e15769-0ab2-4b19-928d-2e91421a7a3b" xlink:to="loc_asth_FiveThreeOneW.CollegeLLCMember_aee9e1fe-c7f4-47db-bd42-fdeb26f22730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_OneMSOLLCMember_f7bc171d-7126-44d3-9c3e-a58d3a449c34" xlink:href="asth-20240331.xsd#asth_OneMSOLLCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f3e15769-0ab2-4b19-928d-2e91421a7a3b" xlink:to="loc_asth_OneMSOLLCMember_f7bc171d-7126-44d3-9c3e-a58d3a449c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CAIPAMSOLLCMember_710120da-b8cc-41b2-9e22-d4bd0a05cba5" xlink:href="asth-20240331.xsd#asth_CAIPAMSOLLCMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f3e15769-0ab2-4b19-928d-2e91421a7a3b" xlink:to="loc_asth_CAIPAMSOLLCMember_710120da-b8cc-41b2-9e22-d4bd0a05cba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_IHealthIncMember_f2c4e8b6-600e-4a6d-87fe-950ef8f5bb5e" xlink:href="asth-20240331.xsd#asth_IHealthIncMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f3e15769-0ab2-4b19-928d-2e91421a7a3b" xlink:to="loc_asth_IHealthIncMember_f2c4e8b6-600e-4a6d-87fe-950ef8f5bb5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvesteesMember_863839b6-09bf-476e-8264-60039d45ac1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvesteesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f3e15769-0ab2-4b19-928d-2e91421a7a3b" xlink:to="loc_us-gaap_OtherInvesteesMember_863839b6-09bf-476e-8264-60039d45ac1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_dee47340-aadd-411a-a2e0-5eeaba30aeac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2aa95968-de07-49c0-9bd2-625f954efc04" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_dee47340-aadd-411a-a2e0-5eeaba30aeac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_0e10e7da-df2c-4dda-9f51-cf98f4c504e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_dee47340-aadd-411a-a2e0-5eeaba30aeac" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_0e10e7da-df2c-4dda-9f51-cf98f4c504e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_EquityMethodInvestmentsRollForward_f3cab99e-0eed-4cde-a9db-f78c80a5b92b" xlink:href="asth-20240331.xsd#asth_EquityMethodInvestmentsRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_dee47340-aadd-411a-a2e0-5eeaba30aeac" xlink:to="loc_asth_EquityMethodInvestmentsRollForward_f3cab99e-0eed-4cde-a9db-f78c80a5b92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_e93b3452-aca7-459c-9188-690f7d8452e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_EquityMethodInvestmentsRollForward_f3cab99e-0eed-4cde-a9db-f78c80a5b92b" xlink:to="loc_us-gaap_EquityMethodInvestments_e93b3452-aca7-459c-9188-690f7d8452e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_EquityMethodInvestmentAdditionalInvestment_398c75c1-e62a-484d-80d8-4e02545f474d" xlink:href="asth-20240331.xsd#asth_EquityMethodInvestmentAdditionalInvestment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_EquityMethodInvestmentsRollForward_f3cab99e-0eed-4cde-a9db-f78c80a5b92b" xlink:to="loc_asth_EquityMethodInvestmentAdditionalInvestment_398c75c1-e62a-484d-80d8-4e02545f474d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fbd35859-7adb-4774-8861-2db182b3c3a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_EquityMethodInvestmentsRollForward_f3cab99e-0eed-4cde-a9db-f78c80a5b92b" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fbd35859-7adb-4774-8861-2db182b3c3a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_af4fce24-9584-4aec-88cb-4610e82cb5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_EquityMethodInvestmentsRollForward_f3cab99e-0eed-4cde-a9db-f78c80a5b92b" xlink:to="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_af4fce24-9584-4aec-88cb-4610e82cb5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_5d7cd189-1ae4-42fc-8348-84f0b9b4a543" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_EquityMethodInvestmentsRollForward_f3cab99e-0eed-4cde-a9db-f78c80a5b92b" xlink:to="loc_us-gaap_EquityMethodInvestments_5d7cd189-1ae4-42fc-8348-84f0b9b4a543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#InvestmentsinOtherEntitiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_3817419e-8755-432e-a363-8b201c37bf8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_06539f8e-8cdc-4a9e-b077-84025ea0b2df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_3817419e-8755-432e-a363-8b201c37bf8c" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_06539f8e-8cdc-4a9e-b077-84025ea0b2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_edf00eb7-4d0d-4b7c-a071-62954844c251" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_06539f8e-8cdc-4a9e-b077-84025ea0b2df" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_edf00eb7-4d0d-4b7c-a071-62954844c251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_32b79154-0026-4d46-b5b9-6cb4dac84c87" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_edf00eb7-4d0d-4b7c-a071-62954844c251" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_32b79154-0026-4d46-b5b9-6cb4dac84c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_IHealthIncMember_697f056a-4333-4e0d-91bb-34dcfd7eb84b" xlink:href="asth-20240331.xsd#asth_IHealthIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_32b79154-0026-4d46-b5b9-6cb4dac84c87" xlink:to="loc_asth_IHealthIncMember_697f056a-4333-4e0d-91bb-34dcfd7eb84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_db328024-2546-438f-b1e6-1e22be5c0348" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_06539f8e-8cdc-4a9e-b077-84025ea0b2df" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_db328024-2546-438f-b1e6-1e22be5c0348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_66e7199e-24ab-4951-8904-3da9fbc65e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_db328024-2546-438f-b1e6-1e22be5c0348" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_66e7199e-24ab-4951-8904-3da9fbc65e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_85217375-6cd9-4618-a1ea-ee804b8161e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_db328024-2546-438f-b1e6-1e22be5c0348" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_85217375-6cd9-4618-a1ea-ee804b8161e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LoansReceivableDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#LoansReceivableDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LoansReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_9f59fa8d-6312-41bf-926b-156f746165f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_75512128-4970-4b89-8a92-cb774efb26ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_9f59fa8d-6312-41bf-926b-156f746165f3" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_75512128-4970-4b89-8a92-cb774efb26ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9028004f-e65a-484c-a510-9e9835f723e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_75512128-4970-4b89-8a92-cb774efb26ba" xlink:to="loc_us-gaap_DebtInstrumentAxis_9028004f-e65a-484c-a510-9e9835f723e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b8966aa9-3fb0-4cc2-9496-a04404264179" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9028004f-e65a-484c-a510-9e9835f723e5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b8966aa9-3fb0-4cc2-9496-a04404264179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_IntraCareConvertiblePromissoryNoteReceivableMember_40c7396d-2586-4bde-bd57-b0e88f5b5f12" xlink:href="asth-20240331.xsd#asth_IntraCareConvertiblePromissoryNoteReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b8966aa9-3fb0-4cc2-9496-a04404264179" xlink:to="loc_asth_IntraCareConvertiblePromissoryNoteReceivableMember_40c7396d-2586-4bde-bd57-b0e88f5b5f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BassMedicalGroupMember_bf61e334-eb03-4bc1-8a86-d1cb843018f4" xlink:href="asth-20240331.xsd#asth_BassMedicalGroupMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b8966aa9-3fb0-4cc2-9496-a04404264179" xlink:to="loc_asth_BassMedicalGroupMember_bf61e334-eb03-4bc1-8a86-d1cb843018f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ba6b4aac-449b-4503-b968-582c21c2d5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_75512128-4970-4b89-8a92-cb774efb26ba" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ba6b4aac-449b-4503-b968-582c21c2d5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_eceb9535-4828-4fff-ba74-a1fa75685465" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ba6b4aac-449b-4503-b968-582c21c2d5b1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_eceb9535-4828-4fff-ba74-a1fa75685465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_9847ae97-b45b-46ab-8b71-1f808893ed7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_eceb9535-4828-4fff-ba74-a1fa75685465" xlink:to="loc_us-gaap_NotesReceivableMember_9847ae97-b45b-46ab-8b71-1f808893ed7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_SeniorSecuredPromissoryNoteMember_89cb7bf5-820e-46ff-a3e9-63bb85a01e5f" xlink:href="asth-20240331.xsd#asth_SeniorSecuredPromissoryNoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_eceb9535-4828-4fff-ba74-a1fa75685465" xlink:to="loc_asth_SeniorSecuredPromissoryNoteMember_89cb7bf5-820e-46ff-a3e9-63bb85a01e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_bcd1a8e1-ec13-4ce6-a1d4-e468e962c433" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_75512128-4970-4b89-8a92-cb774efb26ba" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_bcd1a8e1-ec13-4ce6-a1d4-e468e962c433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_fbedd785-4e4c-465a-8d4b-b377335fb248" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_bcd1a8e1-ec13-4ce6-a1d4-e468e962c433" xlink:to="loc_us-gaap_DebtInstrumentTerm_fbedd785-4e4c-465a-8d4b-b377335fb248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8ff985fe-2948-4c3f-ad00-8c11bc0407e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_bcd1a8e1-ec13-4ce6-a1d4-e468e962c433" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8ff985fe-2948-4c3f-ad00-8c11bc0407e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0c76a67c-e429-4f62-ac66-0c784ff00bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_bcd1a8e1-ec13-4ce6-a1d4-e468e962c433" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0c76a67c-e429-4f62-ac66-0c784ff00bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#AccountsPayableandAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_4f0e989e-8791-447c-88e6-c02a54a4d65d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_95004856-77c9-4a27-a0ac-2cfa5015d637" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4f0e989e-8791-447c-88e6-c02a54a4d65d" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_95004856-77c9-4a27-a0ac-2cfa5015d637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_SpecialtyCapitationPayableCurrent_d83c101c-62a9-489e-9c56-f246dc8359af" xlink:href="asth-20240331.xsd#asth_SpecialtyCapitationPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4f0e989e-8791-447c-88e6-c02a54a4d65d" xlink:to="loc_asth_SpecialtyCapitationPayableCurrent_d83c101c-62a9-489e-9c56-f246dc8359af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_SubcontractorIPAPayable_39c3d7e6-970e-4215-a64b-16b7b9d31975" xlink:href="asth-20240331.xsd#asth_SubcontractorIPAPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4f0e989e-8791-447c-88e6-c02a54a4d65d" xlink:to="loc_asth_SubcontractorIPAPayable_39c3d7e6-970e-4215-a64b-16b7b9d31975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_153f892d-65b1-45b9-9ff2-e269e1903fee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4f0e989e-8791-447c-88e6-c02a54a4d65d" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_153f892d-65b1-45b9-9ff2-e269e1903fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDepositLiabilities_2a435c21-0cd8-4440-8dd8-cb9adcf9a29c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDepositLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4f0e989e-8791-447c-88e6-c02a54a4d65d" xlink:to="loc_us-gaap_RelatedPartyDepositLiabilities_2a435c21-0cd8-4440-8dd8-cb9adcf9a29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6b6fd85c-0ef0-4261-b6bb-44f00944f46f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4f0e989e-8791-447c-88e6-c02a54a4d65d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6b6fd85c-0ef0-4261-b6bb-44f00944f46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c609b4a0-e01b-4871-9c00-ad8c8c914992" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4f0e989e-8791-447c-88e6-c02a54a4d65d" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c609b4a0-e01b-4871-9c00-ad8c8c914992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_677973f3-c37e-478a-aa4f-652b6a54081c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4f0e989e-8791-447c-88e6-c02a54a4d65d" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_677973f3-c37e-478a-aa4f-652b6a54081c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1c97067a-3f95-43d2-8f71-1eed52965cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4f0e989e-8791-447c-88e6-c02a54a4d65d" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1c97067a-3f95-43d2-8f71-1eed52965cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilitiesDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#MedicalLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_dfa3ba58-7dfe-4710-9c29-acb8618d7f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_9d3e06d7-fa72-4df6-8bf4-8328eeb507e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_dfa3ba58-7dfe-4710-9c29-acb8618d7f7f" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_9d3e06d7-fa72-4df6-8bf4-8328eeb507e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_0a3802f8-375b-4578-933a-1b276e4c4b65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_9d3e06d7-fa72-4df6-8bf4-8328eeb507e8" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_0a3802f8-375b-4578-933a-1b276e4c4b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_4556f2df-66a1-4c52-b3a4-6041fb4df464" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_9d3e06d7-fa72-4df6-8bf4-8328eeb507e8" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_4556f2df-66a1-4c52-b3a4-6041fb4df464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_2fe9d490-5b3e-42e1-a2d5-542cc3440c68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_9d3e06d7-fa72-4df6-8bf4-8328eeb507e8" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_2fe9d490-5b3e-42e1-a2d5-542cc3440c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_ecdd2565-35a1-40b2-b53e-58e477952f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_2fe9d490-5b3e-42e1-a2d5-542cc3440c68" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_ecdd2565-35a1-40b2-b53e-58e477952f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_bb430fa6-10a5-4ea0-a165-2726aa0c79f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_2fe9d490-5b3e-42e1-a2d5-542cc3440c68" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_bb430fa6-10a5-4ea0-a165-2726aa0c79f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_b1c428a6-468a-4774-847a-24900a8827ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_2fe9d490-5b3e-42e1-a2d5-542cc3440c68" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_b1c428a6-468a-4774-847a-24900a8827ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_a55f8e94-2207-416c-8b78-78e6a97f9d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_9d3e06d7-fa72-4df6-8bf4-8328eeb507e8" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_a55f8e94-2207-416c-8b78-78e6a97f9d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_a9bde849-b4f6-4fad-aafa-daf8345afd8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_a55f8e94-2207-416c-8b78-78e6a97f9d4d" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_a9bde849-b4f6-4fad-aafa-daf8345afd8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_88f61778-24ac-4ac1-9193-dc86e0a9d896" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_a55f8e94-2207-416c-8b78-78e6a97f9d4d" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_88f61778-24ac-4ac1-9193-dc86e0a9d896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_7b94b96d-2d5d-43c9-8945-21d167d0eebc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_a55f8e94-2207-416c-8b78-78e6a97f9d4d" xlink:to="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_7b94b96d-2d5d-43c9-8945-21d167d0eebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_2a645e31-362a-460b-91dc-cdd08fa2fe15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_9d3e06d7-fa72-4df6-8bf4-8328eeb507e8" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_2a645e31-362a-460b-91dc-cdd08fa2fe15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_d4d9c39c-b912-4801-92bb-f84c79ef19cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_9d3e06d7-fa72-4df6-8bf4-8328eeb507e8" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_d4d9c39c-b912-4801-92bb-f84c79ef19cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8e0e5d3e-4dd7-4701-adfd-b45d7e0075ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_a983aa2a-d50c-4338-9ea0-392d470afae1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8e0e5d3e-4dd7-4701-adfd-b45d7e0075ec" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_a983aa2a-d50c-4338-9ea0-392d470afae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_0426d975-8ad8-42db-8cf2-038a7a9f15e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a983aa2a-d50c-4338-9ea0-392d470afae1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_0426d975-8ad8-42db-8cf2-038a7a9f15e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9119080e-dc4b-46f7-8280-bca59bb49ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0426d975-8ad8-42db-8cf2-038a7a9f15e2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9119080e-dc4b-46f7-8280-bca59bb49ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_TermLoanMember_b16a9153-74e4-4499-8039-b734a9374cbc" xlink:href="asth-20240331.xsd#asth_TermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9119080e-dc4b-46f7-8280-bca59bb49ebb" xlink:to="loc_asth_TermLoanMember_b16a9153-74e4-4499-8039-b734a9374cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_598cc7db-1ec2-4bb2-a400-08c2385c6fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9119080e-dc4b-46f7-8280-bca59bb49ebb" xlink:to="loc_us-gaap_NotesPayableToBanksMember_598cc7db-1ec2-4bb2-a400-08c2385c6fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_09f5d0db-7bbb-4062-acd8-e27cb77ef2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a983aa2a-d50c-4338-9ea0-392d470afae1" xlink:to="loc_us-gaap_CreditFacilityAxis_09f5d0db-7bbb-4062-acd8-e27cb77ef2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_09546853-e207-4d29-aa7c-2fc5b43f1d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_09f5d0db-7bbb-4062-acd8-e27cb77ef2e5" xlink:to="loc_us-gaap_CreditFacilityDomain_09546853-e207-4d29-aa7c-2fc5b43f1d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_3027c71a-dbc4-4950-88f3-b7e4da401b59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_09546853-e207-4d29-aa7c-2fc5b43f1d1b" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_3027c71a-dbc4-4950-88f3-b7e4da401b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_037e18fe-f71a-41b1-bdd9-f581989bf818" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a983aa2a-d50c-4338-9ea0-392d470afae1" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_037e18fe-f71a-41b1-bdd9-f581989bf818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_b8b2f2c3-5b90-472c-ba48-a599efcdd3af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_037e18fe-f71a-41b1-bdd9-f581989bf818" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_b8b2f2c3-5b90-472c-ba48-a599efcdd3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_b511b5c7-f839-49b4-94b7-3708c8ea5a33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_037e18fe-f71a-41b1-bdd9-f581989bf818" xlink:to="loc_us-gaap_LongTermDebtCurrent_b511b5c7-f839-49b4-94b7-3708c8ea5a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_e2a3ee01-b078-4142-a0c7-1744b36d20f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_037e18fe-f71a-41b1-bdd9-f581989bf818" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_e2a3ee01-b078-4142-a0c7-1744b36d20f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_c3777e10-967d-4594-b438-fc44e36d4c13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_037e18fe-f71a-41b1-bdd9-f581989bf818" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_c3777e10-967d-4594-b438-fc44e36d4c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d408732b-226e-486f-a678-c23534fc57e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_4db7ae42-09dc-4cec-923b-29cd27ecd1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d408732b-226e-486f-a678-c23534fc57e3" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_4db7ae42-09dc-4cec-923b-29cd27ecd1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9f4f638a-0a1a-45ad-906c-000e871ea068" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d408732b-226e-486f-a678-c23534fc57e3" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9f4f638a-0a1a-45ad-906c-000e871ea068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_315e45c0-7925-46e2-94c7-dc041d0ba091" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d408732b-226e-486f-a678-c23534fc57e3" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_315e45c0-7925-46e2-94c7-dc041d0ba091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_4d243e4d-ea0f-49b6-b941-f0efc549ed29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d408732b-226e-486f-a678-c23534fc57e3" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_4d243e4d-ea0f-49b6-b941-f0efc549ed29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_7fd15658-bde5-46fc-9f89-1827983ccf2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d408732b-226e-486f-a678-c23534fc57e3" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_7fd15658-bde5-46fc-9f89-1827983ccf2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_7d3bbb1f-5007-4178-b5b4-44c18ad99ede" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d408732b-226e-486f-a678-c23534fc57e3" xlink:to="loc_us-gaap_LineOfCredit_7d3bbb1f-5007-4178-b5b4-44c18ad99ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_bb7d4dec-8b9f-41c7-ba51-513a5b3ff732" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_eeb44428-66ee-4b5b-8d73-5b3e993f9515" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bb7d4dec-8b9f-41c7-ba51-513a5b3ff732" xlink:to="loc_us-gaap_DebtInstrumentTable_eeb44428-66ee-4b5b-8d73-5b3e993f9515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_9b514abf-589f-4e2f-8d3c-8e2ff25fccfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_eeb44428-66ee-4b5b-8d73-5b3e993f9515" xlink:to="loc_us-gaap_CreditFacilityAxis_9b514abf-589f-4e2f-8d3c-8e2ff25fccfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_00ca1315-e39d-459b-bbd7-aafe4645c8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_9b514abf-589f-4e2f-8d3c-8e2ff25fccfd" xlink:to="loc_us-gaap_CreditFacilityDomain_00ca1315-e39d-459b-bbd7-aafe4645c8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_d492a767-bccc-4d77-a797-8dcd1b93284b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_00ca1315-e39d-459b-bbd7-aafe4645c8c6" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_d492a767-bccc-4d77-a797-8dcd1b93284b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember_2aed3e4d-1e87-40a4-a867-b507107e5291" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BridgeLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_00ca1315-e39d-459b-bbd7-aafe4645c8c6" xlink:to="loc_us-gaap_BridgeLoanMember_2aed3e4d-1e87-40a4-a867-b507107e5291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_b3b72e8d-2837-4a66-afc0-f73c3844e045" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_00ca1315-e39d-459b-bbd7-aafe4645c8c6" xlink:to="loc_us-gaap_LetterOfCreditMember_b3b72e8d-2837-4a66-afc0-f73c3844e045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_NewTermLoanMember_db4b65fb-bb0c-4a02-86ef-c7d7e33a2880" xlink:href="asth-20240331.xsd#asth_NewTermLoanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_00ca1315-e39d-459b-bbd7-aafe4645c8c6" xlink:to="loc_asth_NewTermLoanMember_db4b65fb-bb0c-4a02-86ef-c7d7e33a2880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_a03da606-28fc-43e3-b9d4-0f2e3405c8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_00ca1315-e39d-459b-bbd7-aafe4645c8c6" xlink:to="loc_us-gaap_LineOfCreditMember_a03da606-28fc-43e3-b9d4-0f2e3405c8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_79a78e48-f174-472b-aa3c-6ce19b49c212" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_00ca1315-e39d-459b-bbd7-aafe4645c8c6" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_79a78e48-f174-472b-aa3c-6ce19b49c212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_21581409-269a-4c20-b3a2-b15d217b1cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_eeb44428-66ee-4b5b-8d73-5b3e993f9515" xlink:to="loc_us-gaap_DebtInstrumentAxis_21581409-269a-4c20-b3a2-b15d217b1cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0076cc6b-4ece-436c-be5a-b781442ea433" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_21581409-269a-4c20-b3a2-b15d217b1cc7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0076cc6b-4ece-436c-be5a-b781442ea433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AmendedCreditAgreementMember_816a0209-34bf-444f-bfb5-f89f968780b5" xlink:href="asth-20240331.xsd#asth_AmendedCreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0076cc6b-4ece-436c-be5a-b781442ea433" xlink:to="loc_asth_AmendedCreditAgreementMember_816a0209-34bf-444f-bfb5-f89f968780b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AmendedAndRestatedCreditAgreementMember_ff112c2e-9c74-408b-ab9b-69084c4f5b66" xlink:href="asth-20240331.xsd#asth_AmendedAndRestatedCreditAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0076cc6b-4ece-436c-be5a-b781442ea433" xlink:to="loc_asth_AmendedAndRestatedCreditAgreementMember_ff112c2e-9c74-408b-ab9b-69084c4f5b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CreditAgreementMember_60f3f69c-465f-4d23-82cc-5ca6110b16b4" xlink:href="asth-20240331.xsd#asth_CreditAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0076cc6b-4ece-436c-be5a-b781442ea433" xlink:to="loc_asth_CreditAgreementMember_60f3f69c-465f-4d23-82cc-5ca6110b16b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_SubordinatedLoanAgreementMember_794c188b-ff27-46a0-a828-65957ee4fc47" xlink:href="asth-20240331.xsd#asth_SubordinatedLoanAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0076cc6b-4ece-436c-be5a-b781442ea433" xlink:to="loc_asth_SubordinatedLoanAgreementMember_794c188b-ff27-46a0-a828-65957ee4fc47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ApcBusinessLoanAgreementMember_02ecebc8-c761-41d2-be06-6d022edebb14" xlink:href="asth-20240331.xsd#asth_ApcBusinessLoanAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0076cc6b-4ece-436c-be5a-b781442ea433" xlink:to="loc_asth_ApcBusinessLoanAgreementMember_02ecebc8-c761-41d2-be06-6d022edebb14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e330b228-9a1b-4d47-8a95-380f2dd0675e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_eeb44428-66ee-4b5b-8d73-5b3e993f9515" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e330b228-9a1b-4d47-8a95-380f2dd0675e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f7ce7654-86be-4931-aece-5882a9415d89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e330b228-9a1b-4d47-8a95-380f2dd0675e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f7ce7654-86be-4931-aece-5882a9415d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_83cc5505-5350-419e-8450-a04e97f40bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f7ce7654-86be-4931-aece-5882a9415d89" xlink:to="loc_us-gaap_LineOfCreditMember_83cc5505-5350-419e-8450-a04e97f40bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_c9a6dfa4-785f-4e64-a50a-07f0e205efce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f7ce7654-86be-4931-aece-5882a9415d89" xlink:to="loc_us-gaap_SecuredDebtMember_c9a6dfa4-785f-4e64-a50a-07f0e205efce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubordinatedDebtMember_83365254-eb5c-4a62-b41c-8863d4e300a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubordinatedDebtMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f7ce7654-86be-4931-aece-5882a9415d89" xlink:to="loc_us-gaap_SubordinatedDebtMember_83365254-eb5c-4a62-b41c-8863d4e300a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_06e292cf-2c0a-4401-8f0e-ec82a61337ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f7ce7654-86be-4931-aece-5882a9415d89" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_06e292cf-2c0a-4401-8f0e-ec82a61337ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e6df1196-2169-4f50-8edf-ef7648b5e2e7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_eeb44428-66ee-4b5b-8d73-5b3e993f9515" xlink:to="loc_srt_RangeAxis_e6df1196-2169-4f50-8edf-ef7648b5e2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5cd123ff-b1f5-4a2f-adf0-f7c3c0fa54e3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e6df1196-2169-4f50-8edf-ef7648b5e2e7" xlink:to="loc_srt_RangeMember_5cd123ff-b1f5-4a2f-adf0-f7c3c0fa54e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b37ba38e-2e98-49ff-ae4a-2482e63045b4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5cd123ff-b1f5-4a2f-adf0-f7c3c0fa54e3" xlink:to="loc_srt_MinimumMember_b37ba38e-2e98-49ff-ae4a-2482e63045b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1481056b-2ff0-49ed-9b0d-512da549fb13" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5cd123ff-b1f5-4a2f-adf0-f7c3c0fa54e3" xlink:to="loc_srt_MaximumMember_1481056b-2ff0-49ed-9b0d-512da549fb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_31c8c36f-8529-49c9-a643-60959953ae37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_eeb44428-66ee-4b5b-8d73-5b3e993f9515" xlink:to="loc_us-gaap_VariableRateAxis_31c8c36f-8529-49c9-a643-60959953ae37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_8922f47f-e386-4754-a176-4335b605c539" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_31c8c36f-8529-49c9-a643-60959953ae37" xlink:to="loc_us-gaap_VariableRateDomain_8922f47f-e386-4754-a176-4335b605c539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_SecuredOvernightFinancingRateMember_20ab65df-2a89-4568-b337-4f57a6f3c06b" xlink:href="asth-20240331.xsd#asth_SecuredOvernightFinancingRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_8922f47f-e386-4754-a176-4335b605c539" xlink:to="loc_asth_SecuredOvernightFinancingRateMember_20ab65df-2a89-4568-b337-4f57a6f3c06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_741dbaa0-b7fa-4960-af52-9dbf0a18509e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_8922f47f-e386-4754-a176-4335b605c539" xlink:to="loc_us-gaap_BaseRateMember_741dbaa0-b7fa-4960-af52-9dbf0a18509e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_e98af1c0-724a-4c05-816f-efa2bd098c89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_eeb44428-66ee-4b5b-8d73-5b3e993f9515" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_e98af1c0-724a-4c05-816f-efa2bd098c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_e586d021-59b5-4a65-90c4-f8470175773c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_e98af1c0-724a-4c05-816f-efa2bd098c89" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_e586d021-59b5-4a65-90c4-f8470175773c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_TruistBankMember_3bbb3690-5795-4233-84cd-43d33c16e229" xlink:href="asth-20240331.xsd#asth_TruistBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_e586d021-59b5-4a65-90c4-f8470175773c" xlink:to="loc_asth_TruistBankMember_3bbb3690-5795-4233-84cd-43d33c16e229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PreferredBankMember_b2bfcfc7-3267-4e0d-9dea-b77794f3e2e2" xlink:href="asth-20240331.xsd#asth_PreferredBankMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_e586d021-59b5-4a65-90c4-f8470175773c" xlink:to="loc_asth_PreferredBankMember_b2bfcfc7-3267-4e0d-9dea-b77794f3e2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_3b15c56c-147b-4afe-9224-785d2ab63152" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_eeb44428-66ee-4b5b-8d73-5b3e993f9515" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_3b15c56c-147b-4afe-9224-785d2ab63152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1fd8b5f6-2f55-4eb6-b562-c733ffc1ab08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_3b15c56c-147b-4afe-9224-785d2ab63152" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1fd8b5f6-2f55-4eb6-b562-c733ffc1ab08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_e8fc9448-c532-4e20-b3b4-0d633a2252c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1fd8b5f6-2f55-4eb6-b562-c733ffc1ab08" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_e8fc9448-c532-4e20-b3b4-0d633a2252c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_2d93e28f-beec-43b3-96f3-5f00fb443421" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1fd8b5f6-2f55-4eb6-b562-c733ffc1ab08" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_2d93e28f-beec-43b3-96f3-5f00fb443421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_5ca0f0b3-46e5-4423-90d3-ef60dbc33bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1fd8b5f6-2f55-4eb6-b562-c733ffc1ab08" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_5ca0f0b3-46e5-4423-90d3-ef60dbc33bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_690ef282-27fb-40e6-8dac-2ed201cd34b9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_eeb44428-66ee-4b5b-8d73-5b3e993f9515" xlink:to="loc_srt_CounterpartyNameAxis_690ef282-27fb-40e6-8dac-2ed201cd34b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e89947d3-9d34-4b83-bdfa-ab469eb62700" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_690ef282-27fb-40e6-8dac-2ed201cd34b9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e89947d3-9d34-4b83-bdfa-ab469eb62700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AstranaMedicalMember_440fd82d-6f00-4ec1-9576-7e67d73c8175" xlink:href="asth-20240331.xsd#asth_AstranaMedicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e89947d3-9d34-4b83-bdfa-ab469eb62700" xlink:to="loc_asth_AstranaMedicalMember_440fd82d-6f00-4ec1-9576-7e67d73c8175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_cccd25d6-388a-4bff-9727-a55b1614ccb7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_eeb44428-66ee-4b5b-8d73-5b3e993f9515" xlink:to="loc_dei_LegalEntityAxis_cccd25d6-388a-4bff-9727-a55b1614ccb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_14e5cd5e-d8f1-4590-a218-f7e05d967b97" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_cccd25d6-388a-4bff-9727-a55b1614ccb7" xlink:to="loc_dei_EntityDomain_14e5cd5e-d8f1-4590-a218-f7e05d967b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AlliedPacificOfCaliforniaIPAMember_93ff51f0-8143-4d3d-8be0-a5f601c198a9" xlink:href="asth-20240331.xsd#asth_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_14e5cd5e-d8f1-4590-a218-f7e05d967b97" xlink:to="loc_asth_AlliedPacificOfCaliforniaIPAMember_93ff51f0-8143-4d3d-8be0-a5f601c198a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_5c722faa-3300-4e0e-ada0-756c296b8b35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_eeb44428-66ee-4b5b-8d73-5b3e993f9515" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_5c722faa-3300-4e0e-ada0-756c296b8b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_bbe65948-c32b-484f-9348-a762ab6e6113" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_5c722faa-3300-4e0e-ada0-756c296b8b35" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_bbe65948-c32b-484f-9348-a762ab6e6113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_e7279313-d2a3-4ec9-bd4f-6c88043aca6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_bbe65948-c32b-484f-9348-a762ab6e6113" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_e7279313-d2a3-4ec9-bd4f-6c88043aca6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_eeb44428-66ee-4b5b-8d73-5b3e993f9515" xlink:to="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_79ffd8be-4442-42d1-bf4f-b2f1d01eca86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_us-gaap_DebtInstrumentTerm_79ffd8be-4442-42d1-bf4f-b2f1d01eca86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_884aafbe-9e2a-431e-9c30-695ad60cf864" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_884aafbe-9e2a-431e-9c30-695ad60cf864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_d3b45181-bbdd-4dfb-81e2-640f52aba92e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_d3b45181-bbdd-4dfb-81e2-640f52aba92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_cc1a0970-5238-485d-b978-9da41940308d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_cc1a0970-5238-485d-b978-9da41940308d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_2a0697e3-a54a-4949-b8aa-86801f29c049" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_2a0697e3-a54a-4949-b8aa-86801f29c049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_LineOfCreditFacilityAmountFundedAtClosing_7c00a2b0-2d60-46ea-ad6e-ee7c9ae19530" xlink:href="asth-20240331.xsd#asth_LineOfCreditFacilityAmountFundedAtClosing"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_asth_LineOfCreditFacilityAmountFundedAtClosing_7c00a2b0-2d60-46ea-ad6e-ee7c9ae19530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_fe5c938a-d417-4b8c-8e12-6b8966917032" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_us-gaap_RepaymentsOfDebt_fe5c938a-d417-4b8c-8e12-6b8966917032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfBankOverdrafts_df6e80ca-0a25-4d3d-b06f-6d46fdc247b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfBankOverdrafts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfBankOverdrafts_df6e80ca-0a25-4d3d-b06f-6d46fdc247b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_32142500-3270-452a-9562-ae439f01e7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_32142500-3270-452a-9562-ae439f01e7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_5b5d014b-e1ad-4e56-95db-eec5dc271cee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_5b5d014b-e1ad-4e56-95db-eec5dc271cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_44f4fe31-a8ce-4376-a78c-1bb41eff27fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_44f4fe31-a8ce-4376-a78c-1bb41eff27fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_DebtInstrumentNumberOfKeyFinancialRatios_ad39eca7-1906-421c-9091-9614d00da26a" xlink:href="asth-20240331.xsd#asth_DebtInstrumentNumberOfKeyFinancialRatios"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_asth_DebtInstrumentNumberOfKeyFinancialRatios_ad39eca7-1906-421c-9091-9614d00da26a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_DebtInstrumentCovenantLeverageRatioMaximum_03630e50-adca-445b-beba-983c58404d52" xlink:href="asth-20240331.xsd#asth_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_asth_DebtInstrumentCovenantLeverageRatioMaximum_03630e50-adca-445b-beba-983c58404d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_DebtCovenantAggregatePurchasePriceMaximum_cb146fba-1eaf-4d1f-9eaa-2e3d79c1dcd2" xlink:href="asth-20240331.xsd#asth_DebtCovenantAggregatePurchasePriceMaximum"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_asth_DebtCovenantAggregatePurchasePriceMaximum_cb146fba-1eaf-4d1f-9eaa-2e3d79c1dcd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_DebtInstrumentCovenantLeverageRatioIncrementalChange_256a4aa0-b7f3-4b7f-ac93-d2af70a56bab" xlink:href="asth-20240331.xsd#asth_DebtInstrumentCovenantLeverageRatioIncrementalChange"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_asth_DebtInstrumentCovenantLeverageRatioIncrementalChange_256a4aa0-b7f3-4b7f-ac93-d2af70a56bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_DebtInstrumentCovenantLeverageRatioAdjustedMaximum_c3f37254-09c2-4ca6-88b8-7b1e0831a117" xlink:href="asth-20240331.xsd#asth_DebtInstrumentCovenantLeverageRatioAdjustedMaximum"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_asth_DebtInstrumentCovenantLeverageRatioAdjustedMaximum_c3f37254-09c2-4ca6-88b8-7b1e0831a117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_DebtInstrumentCovenantInterestCoverageRatioMinimum_fc5a92ce-f13a-43be-a17b-626987d627cf" xlink:href="asth-20240331.xsd#asth_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_asth_DebtInstrumentCovenantInterestCoverageRatioMinimum_fc5a92ce-f13a-43be-a17b-626987d627cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_443a17ae-986a-4446-8008-97e1d1a16bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_us-gaap_LineOfCredit_443a17ae-986a-4446-8008-97e1d1a16bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_7874523e-1a6f-424b-a605-2889a1b4fa6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_7874523e-1a6f-424b-a605-2889a1b4fa6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_UnamortizedDeferredFinancingCosts_de575faf-386d-4fdb-bab0-8530143d1b9e" xlink:href="asth-20240331.xsd#asth_UnamortizedDeferredFinancingCosts"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_asth_UnamortizedDeferredFinancingCosts_de575faf-386d-4fdb-bab0-8530143d1b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_7fb7eca4-d13e-41fa-87ed-085dd6e8294b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_7fb7eca4-d13e-41fa-87ed-085dd6e8294b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_453e7405-56e4-48ad-ad45-27f194f2a09d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_us-gaap_InterestExpense_453e7405-56e4-48ad-ad45-27f194f2a09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_3b4ddea7-75fb-4276-b2b2-2174a8598aff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1506e3a0-c830-4e70-9d69-561a2b0bae49" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_3b4ddea7-75fb-4276-b2b2-2174a8598aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#MezzanineandStockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_3a3ef828-fce0-4544-b398-e9895bc27878" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_bdcc6ba6-a3bd-4727-9340-1f95fe81a0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_3a3ef828-fce0-4544-b398-e9895bc27878" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_bdcc6ba6-a3bd-4727-9340-1f95fe81a0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_3e67bddb-4c2a-4ef5-b6ce-e6b3b2e8c07e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bdcc6ba6-a3bd-4727-9340-1f95fe81a0d5" xlink:to="loc_dei_LegalEntityAxis_3e67bddb-4c2a-4ef5-b6ce-e6b3b2e8c07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e8e607d9-589b-45c7-81a8-01d36491afd7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_3e67bddb-4c2a-4ef5-b6ce-e6b3b2e8c07e" xlink:to="loc_dei_EntityDomain_e8e607d9-589b-45c7-81a8-01d36491afd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AlliedPacificOfCaliforniaIPAMember_976ba78e-84da-434c-83d0-5475db7d78e6" xlink:href="asth-20240331.xsd#asth_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e8e607d9-589b-45c7-81a8-01d36491afd7" xlink:to="loc_asth_AlliedPacificOfCaliforniaIPAMember_976ba78e-84da-434c-83d0-5475db7d78e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CDSCMember_a8be932f-7236-4838-8160-4c3643516214" xlink:href="asth-20240331.xsd#asth_CDSCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e8e607d9-589b-45c7-81a8-01d36491afd7" xlink:to="loc_asth_CDSCMember_a8be932f-7236-4838-8160-4c3643516214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CompanyAndAPCMember_2e62ab3d-5c7b-47a8-b88c-2c3dee86f611" xlink:href="asth-20240331.xsd#asth_CompanyAndAPCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e8e607d9-589b-45c7-81a8-01d36491afd7" xlink:to="loc_asth_CompanyAndAPCMember_2e62ab3d-5c7b-47a8-b88c-2c3dee86f611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d9c801cd-18a5-40e4-a436-082907bc64f8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bdcc6ba6-a3bd-4727-9340-1f95fe81a0d5" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d9c801cd-18a5-40e4-a436-082907bc64f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_2f776509-ea1b-4eb1-a547-f701c160b3c8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d9c801cd-18a5-40e4-a436-082907bc64f8" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_2f776509-ea1b-4eb1-a547-f701c160b3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ApolloMedicalHoldingsIncMember_0908bb71-8be1-4ea2-9cab-3ec9d8335d92" xlink:href="asth-20240331.xsd#asth_ApolloMedicalHoldingsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_2f776509-ea1b-4eb1-a547-f701c160b3c8" xlink:to="loc_asth_ApolloMedicalHoldingsIncMember_0908bb71-8be1-4ea2-9cab-3ec9d8335d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_5579f0ed-8aeb-42f0-9a50-0010f1babf61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bdcc6ba6-a3bd-4727-9340-1f95fe81a0d5" xlink:to="loc_us-gaap_ClassOfStockLineItems_5579f0ed-8aeb-42f0-9a50-0010f1babf61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_StockIssuedDuringPeriodSharesMerger_0fbf79b5-29d1-4860-829d-c00d29c747f6" xlink:href="asth-20240331.xsd#asth_StockIssuedDuringPeriodSharesMerger"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5579f0ed-8aeb-42f0-9a50-0010f1babf61" xlink:to="loc_asth_StockIssuedDuringPeriodSharesMerger_0fbf79b5-29d1-4860-829d-c00d29c747f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_9bf14281-f1df-4d58-b4bf-6fe42b768eff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5579f0ed-8aeb-42f0-9a50-0010f1babf61" xlink:to="loc_us-gaap_TreasuryStockCommonShares_9bf14281-f1df-4d58-b4bf-6fe42b768eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_928f9fe4-b967-4052-b680-f5743d80409b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5579f0ed-8aeb-42f0-9a50-0010f1babf61" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_928f9fe4-b967-4052-b680-f5743d80409b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_cd729fa1-7396-4705-aa79-4c416d5c2ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5579f0ed-8aeb-42f0-9a50-0010f1babf61" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_cd729fa1-7396-4705-aa79-4c416d5c2ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_8ab47ed0-16ee-420f-a2b7-ca06992df513" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5579f0ed-8aeb-42f0-9a50-0010f1babf61" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_8ab47ed0-16ee-420f-a2b7-ca06992df513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationScheduleofShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#StockBasedCompensationScheduleofShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationScheduleofShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_92cf1455-cc9a-4ba9-b028-b1d43c86bbce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88a41316-9997-46e4-a27b-f98ca5b0a5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_92cf1455-cc9a-4ba9-b028-b1d43c86bbce" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88a41316-9997-46e4-a27b-f98ca5b0a5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0d775f41-fbe5-4986-8675-8651cdbca38b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88a41316-9997-46e4-a27b-f98ca5b0a5fc" xlink:to="loc_us-gaap_AwardTypeAxis_0d775f41-fbe5-4986-8675-8651cdbca38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19acedc5-e9eb-4d56-adc1-55754d1bf6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0d775f41-fbe5-4986-8675-8651cdbca38b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19acedc5-e9eb-4d56-adc1-55754d1bf6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7e222842-7f5f-4a4c-941b-b39479cc5455" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19acedc5-e9eb-4d56-adc1-55754d1bf6ec" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7e222842-7f5f-4a4c-941b-b39479cc5455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_StockAwardsAndUnitsMember_8c2310e7-d2d0-4e82-9287-4960919b53ee" xlink:href="asth-20240331.xsd#asth_StockAwardsAndUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19acedc5-e9eb-4d56-adc1-55754d1bf6ec" xlink:to="loc_asth_StockAwardsAndUnitsMember_8c2310e7-d2d0-4e82-9287-4960919b53ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fb585ec5-c527-48cc-982b-17ff1f688350" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88a41316-9997-46e4-a27b-f98ca5b0a5fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fb585ec5-c527-48cc-982b-17ff1f688350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3f567204-7721-44ce-9400-8c888027db9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fb585ec5-c527-48cc-982b-17ff1f688350" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3f567204-7721-44ce-9400-8c888027db9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_74db5f2a-5dd9-43ca-a926-ee9a1cd803f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ed669893-9e36-4502-b013-1728214fea79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_74db5f2a-5dd9-43ca-a926-ee9a1cd803f9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ed669893-9e36-4502-b013-1728214fea79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_b56bd110-bad5-44db-aba4-70b6153fdaeb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ed669893-9e36-4502-b013-1728214fea79" xlink:to="loc_srt_TitleOfIndividualAxis_b56bd110-bad5-44db-aba4-70b6153fdaeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_eeef2dfb-506b-4589-a884-b63ded8d4723" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_b56bd110-bad5-44db-aba4-70b6153fdaeb" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_eeef2dfb-506b-4589-a884-b63ded8d4723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ApcStockOptionMember_cc0f1320-7e73-4dcb-aa55-28eea6f5e9b0" xlink:href="asth-20240331.xsd#asth_ApcStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_eeef2dfb-506b-4589-a884-b63ded8d4723" xlink:to="loc_asth_ApcStockOptionMember_cc0f1320-7e73-4dcb-aa55-28eea6f5e9b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c98d3434-4065-4fed-81d8-52c1eb68b799" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ed669893-9e36-4502-b013-1728214fea79" xlink:to="loc_us-gaap_AwardTypeAxis_c98d3434-4065-4fed-81d8-52c1eb68b799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_318cca89-e6db-4948-88ec-081cb6b4627c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c98d3434-4065-4fed-81d8-52c1eb68b799" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_318cca89-e6db-4948-88ec-081cb6b4627c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_1d8aa3b4-d16d-43ce-926e-8e5e94e5e00e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_318cca89-e6db-4948-88ec-081cb6b4627c" xlink:to="loc_us-gaap_RestrictedStockMember_1d8aa3b4-d16d-43ce-926e-8e5e94e5e00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PerformanceBasedRestrictedStockMember_155ff4b7-d2d8-4652-9792-94cdb42ecacc" xlink:href="asth-20240331.xsd#asth_PerformanceBasedRestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_318cca89-e6db-4948-88ec-081cb6b4627c" xlink:to="loc_asth_PerformanceBasedRestrictedStockMember_155ff4b7-d2d8-4652-9792-94cdb42ecacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_EmployeeStockPurchasePlanMember_67de90e2-c410-4ab5-ad75-4668f06ba556" xlink:href="asth-20240331.xsd#asth_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_318cca89-e6db-4948-88ec-081cb6b4627c" xlink:to="loc_asth_EmployeeStockPurchasePlanMember_67de90e2-c410-4ab5-ad75-4668f06ba556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91421281-c342-4ffd-8dc9-bc94e2273597" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ed669893-9e36-4502-b013-1728214fea79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91421281-c342-4ffd-8dc9-bc94e2273597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_03125f25-6446-4fd0-a89b-e424be56291f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91421281-c342-4ffd-8dc9-bc94e2273597" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_03125f25-6446-4fd0-a89b-e424be56291f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4d946aaf-d378-45be-96fb-60d09999cf12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91421281-c342-4ffd-8dc9-bc94e2273597" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4d946aaf-d378-45be-96fb-60d09999cf12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0a80dec0-d55f-485a-b36e-ca0acee284ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91421281-c342-4ffd-8dc9-bc94e2273597" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0a80dec0-d55f-485a-b36e-ca0acee284ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f6f5debe-d516-42ce-ac6a-50dbcbc6fd02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91421281-c342-4ffd-8dc9-bc94e2273597" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f6f5debe-d516-42ce-ac6a-50dbcbc6fd02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance_99330d2e-4dd8-4c5f-b286-d9370790a2f2" xlink:href="asth-20240331.xsd#asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91421281-c342-4ffd-8dc9-bc94e2273597" xlink:to="loc_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance_99330d2e-4dd8-4c5f-b286-d9370790a2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_74c4f810-10c9-425d-a455-fa2443e555ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91421281-c342-4ffd-8dc9-bc94e2273597" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_74c4f810-10c9-425d-a455-fa2443e555ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CommonStockDiscountedPricePercentage_4be95cfa-83de-484b-961e-10717ea539ff" xlink:href="asth-20240331.xsd#asth_CommonStockDiscountedPricePercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91421281-c342-4ffd-8dc9-bc94e2273597" xlink:to="loc_asth_CommonStockDiscountedPricePercentage_4be95cfa-83de-484b-961e-10717ea539ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CommonStockDiscountedPricePercentageMaximum_1e987cd6-dc46-4b0a-bbe7-e77a83fded11" xlink:href="asth-20240331.xsd#asth_CommonStockDiscountedPricePercentageMaximum"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91421281-c342-4ffd-8dc9-bc94e2273597" xlink:to="loc_asth_CommonStockDiscountedPricePercentageMaximum_1e987cd6-dc46-4b0a-bbe7-e77a83fded11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c460b6e9-7cf8-4d53-9ea7-97f577258362" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91421281-c342-4ffd-8dc9-bc94e2273597" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c460b6e9-7cf8-4d53-9ea7-97f577258362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationScheduleofStockOptionTransactionsUnderStockOptionPlansDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#StockBasedCompensationScheduleofStockOptionTransactionsUnderStockOptionPlansDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationScheduleofStockOptionTransactionsUnderStockOptionPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_33c421c8-ca2e-4966-aaef-6d2cfd1b6df9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_19a8c057-0833-4c60-9b3c-1dae3209cb8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_33c421c8-ca2e-4966-aaef-6d2cfd1b6df9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_19a8c057-0833-4c60-9b3c-1dae3209cb8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_590781f3-8ecc-4779-9eda-ac6c061f5ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_19a8c057-0833-4c60-9b3c-1dae3209cb8e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_590781f3-8ecc-4779-9eda-ac6c061f5ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_23c90e3b-e83a-44c8-a821-527887a83bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_19a8c057-0833-4c60-9b3c-1dae3209cb8e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_23c90e3b-e83a-44c8-a821-527887a83bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4bc720f4-e644-432a-8e62-6e06c05c4474" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_19a8c057-0833-4c60-9b3c-1dae3209cb8e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4bc720f4-e644-432a-8e62-6e06c05c4474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8de4bb3d-5335-4c4a-b6ff-360367d1d622" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_19a8c057-0833-4c60-9b3c-1dae3209cb8e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8de4bb3d-5335-4c4a-b6ff-360367d1d622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b85460ec-60a5-437b-9fd6-da21580d7961" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_19a8c057-0833-4c60-9b3c-1dae3209cb8e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b85460ec-60a5-437b-9fd6-da21580d7961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ffdf8bca-eed4-4203-bdbe-3161f1de3e68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_33c421c8-ca2e-4966-aaef-6d2cfd1b6df9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ffdf8bca-eed4-4203-bdbe-3161f1de3e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_227c2246-6607-4d22-9a19-561c162cd3ca" xlink:href="asth-20240331.xsd#asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_33c421c8-ca2e-4966-aaef-6d2cfd1b6df9" xlink:to="loc_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_227c2246-6607-4d22-9a19-561c162cd3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_59002fd0-2bd4-4cac-b412-6c5c35ed93c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_227c2246-6607-4d22-9a19-561c162cd3ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_59002fd0-2bd4-4cac-b412-6c5c35ed93c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_14ba9a37-8c7d-43f8-99da-855b28228799" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_227c2246-6607-4d22-9a19-561c162cd3ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_14ba9a37-8c7d-43f8-99da-855b28228799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d3a6aeba-0350-4c06-a84c-7209a67742f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_227c2246-6607-4d22-9a19-561c162cd3ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d3a6aeba-0350-4c06-a84c-7209a67742f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0373000-67b6-428b-90ea-ecfd203033de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_227c2246-6607-4d22-9a19-561c162cd3ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0373000-67b6-428b-90ea-ecfd203033de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_de5a9e6d-8a0e-4f40-873f-7c0cf78e89dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_227c2246-6607-4d22-9a19-561c162cd3ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_de5a9e6d-8a0e-4f40-873f-7c0cf78e89dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_9a05be95-e4ba-4c06-b4b7-67f86200fa6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_33c421c8-ca2e-4966-aaef-6d2cfd1b6df9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_9a05be95-e4ba-4c06-b4b7-67f86200fa6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_935fe289-8dcc-426d-97cf-cf69da3b186c" xlink:href="asth-20240331.xsd#asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_33c421c8-ca2e-4966-aaef-6d2cfd1b6df9" xlink:to="loc_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_935fe289-8dcc-426d-97cf-cf69da3b186c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_376e1244-9022-4e72-8d01-bffcd1a3da98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_935fe289-8dcc-426d-97cf-cf69da3b186c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_376e1244-9022-4e72-8d01-bffcd1a3da98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_261f3adb-9577-418a-b9cc-1b41654e1ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_935fe289-8dcc-426d-97cf-cf69da3b186c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_261f3adb-9577-418a-b9cc-1b41654e1ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_f38f6eec-302d-40ca-841c-72434525ce7b" xlink:href="asth-20240331.xsd#asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_33c421c8-ca2e-4966-aaef-6d2cfd1b6df9" xlink:to="loc_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_f38f6eec-302d-40ca-841c-72434525ce7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1b269273-9c1d-432c-bff0-0143ad45a8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_f38f6eec-302d-40ca-841c-72434525ce7b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1b269273-9c1d-432c-bff0-0143ad45a8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5137b805-42f0-4975-8e81-ff69e9351e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_f38f6eec-302d-40ca-841c-72434525ce7b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5137b805-42f0-4975-8e81-ff69e9351e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fdc09f01-db80-4b63-828e-333eac22521a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CommitmentsAndContingenciesTable_7b68f01f-bbb1-4d77-aa66-b757a09f1ec0" xlink:href="asth-20240331.xsd#asth_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fdc09f01-db80-4b63-828e-333eac22521a" xlink:to="loc_asth_CommitmentsAndContingenciesTable_7b68f01f-bbb1-4d77-aa66-b757a09f1ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_28f07ac1-d647-4045-b8ed-d664f43ae87c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_CommitmentsAndContingenciesTable_7b68f01f-bbb1-4d77-aa66-b757a09f1ec0" xlink:to="loc_dei_LegalEntityAxis_28f07ac1-d647-4045-b8ed-d664f43ae87c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4c5f0ec5-4b1e-446d-8304-b2ce82c9c6d8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_28f07ac1-d647-4045-b8ed-d664f43ae87c" xlink:to="loc_dei_EntityDomain_4c5f0ec5-4b1e-446d-8304-b2ce82c9c6d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AlliedPacificOfCaliforniaIPAMember_74d1a334-c4bc-415b-94bc-23682fa35af1" xlink:href="asth-20240331.xsd#asth_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4c5f0ec5-4b1e-446d-8304-b2ce82c9c6d8" xlink:to="loc_asth_AlliedPacificOfCaliforniaIPAMember_74d1a334-c4bc-415b-94bc-23682fa35af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1032b7cc-6a3f-40e0-9f72-9fba2c687f66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_CommitmentsAndContingenciesTable_7b68f01f-bbb1-4d77-aa66-b757a09f1ec0" xlink:to="loc_us-gaap_DebtInstrumentAxis_1032b7cc-6a3f-40e0-9f72-9fba2c687f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b0573a9a-d21a-4c50-9a04-9e998565d5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1032b7cc-6a3f-40e0-9f72-9fba2c687f66" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b0573a9a-d21a-4c50-9a04-9e998565d5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AmendedCreditAgreementMember_61a72637-9182-4695-a71a-8f7111492ec9" xlink:href="asth-20240331.xsd#asth_AmendedCreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0573a9a-d21a-4c50-9a04-9e998565d5f9" xlink:to="loc_asth_AmendedCreditAgreementMember_61a72637-9182-4695-a71a-8f7111492ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_000a6535-ff69-4563-91cb-e5a0dd66480a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_CommitmentsAndContingenciesTable_7b68f01f-bbb1-4d77-aa66-b757a09f1ec0" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_000a6535-ff69-4563-91cb-e5a0dd66480a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_73ca0bc0-7f2d-4f00-a4a3-786a50c0133e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_000a6535-ff69-4563-91cb-e5a0dd66480a" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_73ca0bc0-7f2d-4f00-a4a3-786a50c0133e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_TruistBankMember_fb19d6c6-a113-489b-8e29-85bca9f13074" xlink:href="asth-20240331.xsd#asth_TruistBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_73ca0bc0-7f2d-4f00-a4a3-786a50c0133e" xlink:to="loc_asth_TruistBankMember_fb19d6c6-a113-489b-8e29-85bca9f13074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_1d4ce2ab-fbaa-44a1-a1d6-178cb6e64239" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_CommitmentsAndContingenciesTable_7b68f01f-bbb1-4d77-aa66-b757a09f1ec0" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_1d4ce2ab-fbaa-44a1-a1d6-178cb6e64239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_7547a61c-c2d7-452a-ac2b-76d8c8a07bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_1d4ce2ab-fbaa-44a1-a1d6-178cb6e64239" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_7547a61c-c2d7-452a-ac2b-76d8c8a07bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_76ed46a9-7c15-43ec-a64e-1b8b53875fee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_7547a61c-c2d7-452a-ac2b-76d8c8a07bdd" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_76ed46a9-7c15-43ec-a64e-1b8b53875fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CommitmentsAndContingenciesLineItems_c8d362d7-a84d-4f48-8d7a-ee3dee2f0e8d" xlink:href="asth-20240331.xsd#asth_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_CommitmentsAndContingenciesTable_7b68f01f-bbb1-4d77-aa66-b757a09f1ec0" xlink:to="loc_asth_CommitmentsAndContingenciesLineItems_c8d362d7-a84d-4f48-8d7a-ee3dee2f0e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_b5c5a0c4-bf63-4075-92d2-08102b5513f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_CommitmentsAndContingenciesLineItems_c8d362d7-a84d-4f48-8d7a-ee3dee2f0e8d" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_b5c5a0c4-bf63-4075-92d2-08102b5513f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_6209bdb7-225e-4df0-bc7a-79ee4e0642ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_CommitmentsAndContingenciesLineItems_c8d362d7-a84d-4f48-8d7a-ee3dee2f0e8d" xlink:to="loc_us-gaap_LineOfCredit_6209bdb7-225e-4df0-bc7a-79ee4e0642ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_27079f51-52b9-4113-ae5a-f9d61678507e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_252f4b71-6fa9-41b4-bfd0-fdeb1d495997" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_27079f51-52b9-4113-ae5a-f9d61678507e" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_252f4b71-6fa9-41b4-bfd0-fdeb1d495997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f13bc089-cb95-432e-99db-3bca805aa4ea" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_252f4b71-6fa9-41b4-bfd0-fdeb1d495997" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f13bc089-cb95-432e-99db-3bca805aa4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_23922cf5-b968-405b-beb7-510ebeb8cbe0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f13bc089-cb95-432e-99db-3bca805aa4ea" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_23922cf5-b968-405b-beb7-510ebeb8cbe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_LmaMember_fd0b05dd-28f9-4d9d-a103-78e499a5c831" xlink:href="asth-20240331.xsd#asth_LmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_23922cf5-b968-405b-beb7-510ebeb8cbe0" xlink:to="loc_asth_LmaMember_fd0b05dd-28f9-4d9d-a103-78e499a5c831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PmiocMember_cdae2359-1e15-4ed3-b4ab-7151c2c80879" xlink:href="asth-20240331.xsd#asth_PmiocMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_23922cf5-b968-405b-beb7-510ebeb8cbe0" xlink:to="loc_asth_PmiocMember_cdae2359-1e15-4ed3-b4ab-7151c2c80879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_SongPCMember_a56e73f9-cb63-4e1e-8a2b-73dbfd80c67b" xlink:href="asth-20240331.xsd#asth_SongPCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_23922cf5-b968-405b-beb7-510ebeb8cbe0" xlink:to="loc_asth_SongPCMember_a56e73f9-cb63-4e1e-8a2b-73dbfd80c67b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_1592afee-dbf5-4494-a1d0-5ed7057a4b61" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_252f4b71-6fa9-41b4-bfd0-fdeb1d495997" xlink:to="loc_dei_LegalEntityAxis_1592afee-dbf5-4494-a1d0-5ed7057a4b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_bd7486d5-5685-4434-a001-d7502d952a06" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1592afee-dbf5-4494-a1d0-5ed7057a4b61" xlink:to="loc_dei_EntityDomain_bd7486d5-5685-4434-a001-d7502d952a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AHMCMember_d3c6774d-6d7e-464f-8637-72410e0cf6ce" xlink:href="asth-20240331.xsd#asth_AHMCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_bd7486d5-5685-4434-a001-d7502d952a06" xlink:to="loc_asth_AHMCMember_d3c6774d-6d7e-464f-8637-72410e0cf6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AlliedPacificOfCaliforniaIPAMember_59d7245f-38aa-4ec4-9af6-b51d120cd290" xlink:href="asth-20240331.xsd#asth_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_bd7486d5-5685-4434-a001-d7502d952a06" xlink:to="loc_asth_AlliedPacificOfCaliforniaIPAMember_59d7245f-38aa-4ec4-9af6-b51d120cd290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_NetworkMedicalManagementMember_e233e33c-7681-40f7-ae97-ce9a5a5b246b" xlink:href="asth-20240331.xsd#asth_NetworkMedicalManagementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_bd7486d5-5685-4434-a001-d7502d952a06" xlink:to="loc_asth_NetworkMedicalManagementMember_e233e33c-7681-40f7-ae97-ce9a5a5b246b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ProfessionalMedicalCorporationMember_9583dc5a-6653-4b9b-87e9-1033e561259c" xlink:href="asth-20240331.xsd#asth_ProfessionalMedicalCorporationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_bd7486d5-5685-4434-a001-d7502d952a06" xlink:to="loc_asth_ProfessionalMedicalCorporationMember_9583dc5a-6653-4b9b-87e9-1033e561259c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AstranaMedicalMember_7e38f67d-62d2-4ab8-9353-ba77a4bc1ae7" xlink:href="asth-20240331.xsd#asth_AstranaMedicalMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_bd7486d5-5685-4434-a001-d7502d952a06" xlink:to="loc_asth_AstranaMedicalMember_7e38f67d-62d2-4ab8-9353-ba77a4bc1ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_99b26c16-a44d-4ea0-9883-817c09f6c57c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_252f4b71-6fa9-41b4-bfd0-fdeb1d495997" xlink:to="loc_srt_CounterpartyNameAxis_99b26c16-a44d-4ea0-9883-817c09f6c57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eb45b2a-0bff-4a60-a0ca-384ad58cd364" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_99b26c16-a44d-4ea0-9883-817c09f6c57c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eb45b2a-0bff-4a60-a0ca-384ad58cd364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_LmaMember_415561b8-31c8-4d71-a26b-da34634b766d" xlink:href="asth-20240331.xsd#asth_LmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eb45b2a-0bff-4a60-a0ca-384ad58cd364" xlink:to="loc_asth_LmaMember_415561b8-31c8-4d71-a26b-da34634b766d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PmiocMember_c75ae23c-5d54-4aa6-b4f9-e851a6cd99bc" xlink:href="asth-20240331.xsd#asth_PmiocMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eb45b2a-0bff-4a60-a0ca-384ad58cd364" xlink:to="loc_asth_PmiocMember_c75ae23c-5d54-4aa6-b4f9-e851a6cd99bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_SongPCMember_d89414ef-5740-4d98-b2fc-480c9598caa2" xlink:href="asth-20240331.xsd#asth_SongPCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eb45b2a-0bff-4a60-a0ca-384ad58cd364" xlink:to="loc_asth_SongPCMember_d89414ef-5740-4d98-b2fc-480c9598caa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ArroyoVistaMember_467fcc9f-7658-40c9-998a-6d2f5c9dc32d" xlink:href="asth-20240331.xsd#asth_ArroyoVistaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eb45b2a-0bff-4a60-a0ca-384ad58cd364" xlink:to="loc_asth_ArroyoVistaMember_467fcc9f-7658-40c9-998a-6d2f5c9dc32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_SunnyVillageCareCenterMember_7679d999-d9c9-47d5-a3bb-c9012b4ec2ba" xlink:href="asth-20240331.xsd#asth_SunnyVillageCareCenterMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eb45b2a-0bff-4a60-a0ca-384ad58cd364" xlink:to="loc_asth_SunnyVillageCareCenterMember_7679d999-d9c9-47d5-a3bb-c9012b4ec2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_FirstCommonwealthPropertyLLCMember_e3edcf0c-b0b0-4801-80ba-1799f922a746" xlink:href="asth-20240331.xsd#asth_FirstCommonwealthPropertyLLCMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eb45b2a-0bff-4a60-a0ca-384ad58cd364" xlink:to="loc_asth_FirstCommonwealthPropertyLLCMember_e3edcf0c-b0b0-4801-80ba-1799f922a746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AHMCMember_e7783052-4028-43b3-a513-306b88c17f15" xlink:href="asth-20240331.xsd#asth_AHMCMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eb45b2a-0bff-4a60-a0ca-384ad58cd364" xlink:to="loc_asth_AHMCMember_e7783052-4028-43b3-a513-306b88c17f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BoardMembersMember_b1fe8261-43b6-451e-9455-0570a2961111" xlink:href="asth-20240331.xsd#asth_BoardMembersMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eb45b2a-0bff-4a60-a0ca-384ad58cd364" xlink:to="loc_asth_BoardMembersMember_b1fe8261-43b6-451e-9455-0570a2961111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BoardMembersWhoAreAlsoOfficersMember_32677d14-b115-46fb-9382-f995a54cafa9" xlink:href="asth-20240331.xsd#asth_BoardMembersWhoAreAlsoOfficersMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eb45b2a-0bff-4a60-a0ca-384ad58cd364" xlink:to="loc_asth_BoardMembersWhoAreAlsoOfficersMember_32677d14-b115-46fb-9382-f995a54cafa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AlliedPacificHoldingsInvestmentManagementLLCMember_8e2c0eb6-4003-49cb-8a4c-3824b017e432" xlink:href="asth-20240331.xsd#asth_AlliedPacificHoldingsInvestmentManagementLLCMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eb45b2a-0bff-4a60-a0ca-384ad58cd364" xlink:to="loc_asth_AlliedPacificHoldingsInvestmentManagementLLCMember_8e2c0eb6-4003-49cb-8a4c-3824b017e432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_269246cb-d495-4e71-81dd-4e2111bd62a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_252f4b71-6fa9-41b4-bfd0-fdeb1d495997" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_269246cb-d495-4e71-81dd-4e2111bd62a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3b4f53eb-382c-4d9d-94ed-0e70eb4927e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_269246cb-d495-4e71-81dd-4e2111bd62a1" xlink:to="loc_us-gaap_RelatedPartyDomain_3b4f53eb-382c-4d9d-94ed-0e70eb4927e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_26ff362d-cec3-431b-af13-62770e48aaa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3b4f53eb-382c-4d9d-94ed-0e70eb4927e3" xlink:to="loc_us-gaap_RelatedPartyMember_26ff362d-cec3-431b-af13-62770e48aaa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_984036a4-106e-40f3-94a0-3e23f366f2d2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3b4f53eb-382c-4d9d-94ed-0e70eb4927e3" xlink:to="loc_srt_DirectorMember_984036a4-106e-40f3-94a0-3e23f366f2d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_4b947f8f-aac3-4db2-9b01-af37d755218a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_252f4b71-6fa9-41b4-bfd0-fdeb1d495997" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_4b947f8f-aac3-4db2-9b01-af37d755218a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_710101b9-ef45-4085-85d0-574235f5e9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_4b947f8f-aac3-4db2-9b01-af37d755218a" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_710101b9-ef45-4085-85d0-574235f5e9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ProviderServicesMember_34697441-03c4-4f1c-9061-377a87840c49" xlink:href="asth-20240331.xsd#asth_ProviderServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_710101b9-ef45-4085-85d0-574235f5e9a6" xlink:to="loc_asth_ProviderServicesMember_34697441-03c4-4f1c-9061-377a87840c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_OfficeLeaseMember_79f035e3-9bce-458e-bebc-88c1d4792ecc" xlink:href="asth-20240331.xsd#asth_OfficeLeaseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_710101b9-ef45-4085-85d0-574235f5e9a6" xlink:to="loc_asth_OfficeLeaseMember_79f035e3-9bce-458e-bebc-88c1d4792ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e888b56b-d162-4244-9e7f-3022f41deda6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_252f4b71-6fa9-41b4-bfd0-fdeb1d495997" xlink:to="loc_srt_ProductOrServiceAxis_e888b56b-d162-4244-9e7f-3022f41deda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d98b62de-3f47-4a2b-aba5-d4cf68a283c7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e888b56b-d162-4244-9e7f-3022f41deda6" xlink:to="loc_srt_ProductsAndServicesDomain_d98b62de-3f47-4a2b-aba5-d4cf68a283c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOtherMember_25648d9f-62ac-4b90-9064-a7f4cdd75541" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d98b62de-3f47-4a2b-aba5-d4cf68a283c7" xlink:to="loc_us-gaap_HealthCareOtherMember_25648d9f-62ac-4b90-9064-a7f4cdd75541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_4ec3cdb4-5150-41d4-9713-26ad5882f063" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_252f4b71-6fa9-41b4-bfd0-fdeb1d495997" xlink:to="loc_srt_TitleOfIndividualAxis_4ec3cdb4-5150-41d4-9713-26ad5882f063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_43986b39-998a-4018-87cd-fc19f75e20af" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_4ec3cdb4-5150-41d4-9713-26ad5882f063" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_43986b39-998a-4018-87cd-fc19f75e20af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_05b8c0fc-b985-4efd-a285-a2d120f39a95" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_43986b39-998a-4018-87cd-fc19f75e20af" xlink:to="loc_srt_ChiefExecutiveOfficerMember_05b8c0fc-b985-4efd-a285-a2d120f39a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_8bd3b73e-431f-4757-a8c1-0e63463320fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_252f4b71-6fa9-41b4-bfd0-fdeb1d495997" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_8bd3b73e-431f-4757-a8c1-0e63463320fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_de17709e-992e-4b82-835c-3f541058a095" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8bd3b73e-431f-4757-a8c1-0e63463320fe" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_de17709e-992e-4b82-835c-3f541058a095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4573ce13-7d81-483d-92db-d74369d1e476" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8bd3b73e-431f-4757-a8c1-0e63463320fe" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4573ce13-7d81-483d-92db-d74369d1e476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_79a906a1-359c-4a72-95ef-dfbccdf2e3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8bd3b73e-431f-4757-a8c1-0e63463320fe" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_79a906a1-359c-4a72-95ef-dfbccdf2e3d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ee40155c-50d7-48a7-8672-9038fc605469" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8bd3b73e-431f-4757-a8c1-0e63463320fe" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ee40155c-50d7-48a7-8672-9038fc605469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_630bd894-3d42-443e-a283-4c0fe0acf3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8bd3b73e-431f-4757-a8c1-0e63463320fe" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_630bd894-3d42-443e-a283-4c0fe0acf3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_RelatedPartyExpensesPayable_3a2ea358-8db1-4a53-a3c0-9d28f6b6e989" xlink:href="asth-20240331.xsd#asth_RelatedPartyExpensesPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8bd3b73e-431f-4757-a8c1-0e63463320fe" xlink:to="loc_asth_RelatedPartyExpensesPayable_3a2ea358-8db1-4a53-a3c0-9d28f6b6e989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_2caa7a89-b933-4645-9378-e712ce15855e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8bd3b73e-431f-4757-a8c1-0e63463320fe" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_2caa7a89-b933-4645-9378-e712ce15855e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities_9543f078-0409-4d28-a702-6308ccd35ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCreditsAndOtherLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8bd3b73e-431f-4757-a8c1-0e63463320fe" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilities_9543f078-0409-4d28-a702-6308ccd35ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofFeesIncurredandRevenueEarnedfromRelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#RelatedPartyTransactionsScheduleofFeesIncurredandRevenueEarnedfromRelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofFeesIncurredandRevenueEarnedfromRelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_c7eb6083-b7c8-4e55-895f-3691baa975fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1eb7951c-c60b-438b-9438-ba1198b0fed1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_c7eb6083-b7c8-4e55-895f-3691baa975fe" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1eb7951c-c60b-438b-9438-ba1198b0fed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ce98cbcc-2b89-4fcc-b741-a2a9e42f75d6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1eb7951c-c60b-438b-9438-ba1198b0fed1" xlink:to="loc_srt_CounterpartyNameAxis_ce98cbcc-2b89-4fcc-b741-a2a9e42f75d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aea7e21d-986d-4801-8602-2aa1bef5e71f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ce98cbcc-2b89-4fcc-b741-a2a9e42f75d6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aea7e21d-986d-4801-8602-2aa1bef5e71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AHMCMember_dfddb4c8-ce8d-4c5a-8739-bc8fb354435c" xlink:href="asth-20240331.xsd#asth_AHMCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aea7e21d-986d-4801-8602-2aa1bef5e71f" xlink:to="loc_asth_AHMCMember_dfddb4c8-ce8d-4c5a-8739-bc8fb354435c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_HSMSOMember_34771228-9b86-4ecb-bace-5f9986f3c495" xlink:href="asth-20240331.xsd#asth_HSMSOMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aea7e21d-986d-4801-8602-2aa1bef5e71f" xlink:to="loc_asth_HSMSOMember_34771228-9b86-4ecb-bace-5f9986f3c495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AurionMember_da6f0e85-3434-4f73-821b-05600cc7d1cc" xlink:href="asth-20240331.xsd#asth_AurionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aea7e21d-986d-4801-8602-2aa1bef5e71f" xlink:to="loc_asth_AurionMember_da6f0e85-3434-4f73-821b-05600cc7d1cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_d71a0e6c-9ff9-4af8-b3a6-37026478d44c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1eb7951c-c60b-438b-9438-ba1198b0fed1" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_d71a0e6c-9ff9-4af8-b3a6-37026478d44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_0db58689-d99e-405a-a695-eb55098f6e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_d71a0e6c-9ff9-4af8-b3a6-37026478d44c" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_0db58689-d99e-405a-a695-eb55098f6e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_RelatedPartyTransactionRevenueRecognizedMember_1f6259b9-76ef-4cdb-be67-126b883d2555" xlink:href="asth-20240331.xsd#asth_RelatedPartyTransactionRevenueRecognizedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0db58689-d99e-405a-a695-eb55098f6e6b" xlink:to="loc_asth_RelatedPartyTransactionRevenueRecognizedMember_1f6259b9-76ef-4cdb-be67-126b883d2555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_RelatedPartyTransactionExpensesIncurredMember_af111657-51f0-4c03-aa6d-9be0fb1e52c8" xlink:href="asth-20240331.xsd#asth_RelatedPartyTransactionExpensesIncurredMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0db58689-d99e-405a-a695-eb55098f6e6b" xlink:to="loc_asth_RelatedPartyTransactionExpensesIncurredMember_af111657-51f0-4c03-aa6d-9be0fb1e52c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_RelatedPartyTransactionRevenueExpenseNetMember_15205e61-1cd2-4ca6-8c1a-a4e2f506e8da" xlink:href="asth-20240331.xsd#asth_RelatedPartyTransactionRevenueExpenseNetMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0db58689-d99e-405a-a695-eb55098f6e6b" xlink:to="loc_asth_RelatedPartyTransactionRevenueExpenseNetMember_15205e61-1cd2-4ca6-8c1a-a4e2f506e8da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_c1a94bed-66a5-4267-b32c-6c241d087cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1eb7951c-c60b-438b-9438-ba1198b0fed1" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_c1a94bed-66a5-4267-b32c-6c241d087cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_9ff6770a-64dd-4a82-aa9f-b3f152c49686" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c1a94bed-66a5-4267-b32c-6c241d087cbc" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_9ff6770a-64dd-4a82-aa9f-b3f152c49686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4e24e925-7876-407b-810a-43ed9cedcb0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6a904edf-d6f1-4008-b598-7f2ae1c3ec37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4e24e925-7876-407b-810a-43ed9cedcb0b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6a904edf-d6f1-4008-b598-7f2ae1c3ec37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#EarningsPerShareAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_82be845a-4c65-4dfe-b2b4-da2ff8c6a6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_EarningsPerShareTable_edc66a45-182f-4f98-9a8d-60e83b380a26" xlink:href="asth-20240331.xsd#asth_EarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_82be845a-4c65-4dfe-b2b4-da2ff8c6a6c0" xlink:to="loc_asth_EarningsPerShareTable_edc66a45-182f-4f98-9a8d-60e83b380a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_63386148-bd4d-4de5-abf4-27a1b1e6bd5a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_EarningsPerShareTable_edc66a45-182f-4f98-9a8d-60e83b380a26" xlink:to="loc_dei_LegalEntityAxis_63386148-bd4d-4de5-abf4-27a1b1e6bd5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_045f6b31-a10e-443c-bbed-a21804b3e22e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_63386148-bd4d-4de5-abf4-27a1b1e6bd5a" xlink:to="loc_dei_EntityDomain_045f6b31-a10e-443c-bbed-a21804b3e22e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AlliedPacificOfCaliforniaIPAMember_2dbd65d9-9ec5-4db8-8bda-9713db1aab64" xlink:href="asth-20240331.xsd#asth_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_045f6b31-a10e-443c-bbed-a21804b3e22e" xlink:to="loc_asth_AlliedPacificOfCaliforniaIPAMember_2dbd65d9-9ec5-4db8-8bda-9713db1aab64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c5339b36-56f1-4e6e-b92f-35903214f936" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_EarningsPerShareTable_edc66a45-182f-4f98-9a8d-60e83b380a26" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c5339b36-56f1-4e6e-b92f-35903214f936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_982d32fd-8d45-4981-8179-29e5c09bca9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c5339b36-56f1-4e6e-b92f-35903214f936" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_982d32fd-8d45-4981-8179-29e5c09bca9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_854e2bb0-5346-48bf-b9ae-66030f28195a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_982d32fd-8d45-4981-8179-29e5c09bca9f" xlink:to="loc_us-gaap_RestrictedStockMember_854e2bb0-5346-48bf-b9ae-66030f28195a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_7e101c78-528f-4091-a333-f27e37454d03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_982d32fd-8d45-4981-8179-29e5c09bca9f" xlink:to="loc_us-gaap_PerformanceSharesMember_7e101c78-528f-4091-a333-f27e37454d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_EarningsPerShareLineItems_d66e43c8-34a6-477b-8374-384595cc0938" xlink:href="asth-20240331.xsd#asth_EarningsPerShareLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_EarningsPerShareTable_edc66a45-182f-4f98-9a8d-60e83b380a26" xlink:to="loc_asth_EarningsPerShareLineItems_d66e43c8-34a6-477b-8374-384595cc0938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_99e08db4-52c2-4f06-80be-15d090cb5042" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_EarningsPerShareLineItems_d66e43c8-34a6-477b-8374-384595cc0938" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_99e08db4-52c2-4f06-80be-15d090cb5042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareScheduleofEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#EarningsPerShareScheduleofEarningsPerShareComputationsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareScheduleofEarningsPerShareComputationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_032557b6-c829-4a66-938c-22a0f2bac38b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_01dd4ebd-1feb-4cd0-9280-381e121703fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_032557b6-c829-4a66-938c-22a0f2bac38b" xlink:to="loc_us-gaap_EarningsPerShareBasic_01dd4ebd-1feb-4cd0-9280-381e121703fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_674947fb-fe9f-4cbc-8789-04d40aa03225" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_032557b6-c829-4a66-938c-22a0f2bac38b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_674947fb-fe9f-4cbc-8789-04d40aa03225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5efe08e3-86ef-402e-bf55-37f44b449523" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_032557b6-c829-4a66-938c-22a0f2bac38b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5efe08e3-86ef-402e-bf55-37f44b449523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ad2a38b9-3e4a-4030-86d4-c9287ad3c3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_032557b6-c829-4a66-938c-22a0f2bac38b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ad2a38b9-3e4a-4030-86d4-c9287ad3c3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareScheduleofSharesIncludedintheDilutedEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#EarningsPerShareScheduleofSharesIncludedintheDilutedEarningsPerShareComputationsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareScheduleofSharesIncludedintheDilutedEarningsPerShareComputationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b8a7b7b1-579a-47ea-8514-bd8fa0c03b42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_EarningsPerShareTable_a5f4767e-80a6-49a4-8218-c18b9e9f4b3e" xlink:href="asth-20240331.xsd#asth_EarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b8a7b7b1-579a-47ea-8514-bd8fa0c03b42" xlink:to="loc_asth_EarningsPerShareTable_a5f4767e-80a6-49a4-8218-c18b9e9f4b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d8d3b5f7-5a22-49ba-bfb6-8769d9437d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_EarningsPerShareTable_a5f4767e-80a6-49a4-8218-c18b9e9f4b3e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d8d3b5f7-5a22-49ba-bfb6-8769d9437d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_242459f9-cef7-4f3c-933a-f703624840a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d8d3b5f7-5a22-49ba-bfb6-8769d9437d4b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_242459f9-cef7-4f3c-933a-f703624840a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3899fc89-5db1-42ae-9057-d289b8b5a88d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_242459f9-cef7-4f3c-933a-f703624840a0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3899fc89-5db1-42ae-9057-d289b8b5a88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_567564e4-db6b-42bb-96bb-d36e9a051755" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_242459f9-cef7-4f3c-933a-f703624840a0" xlink:to="loc_us-gaap_RestrictedStockMember_567564e4-db6b-42bb-96bb-d36e9a051755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_EarningsPerShareLineItems_0d10c2ea-afe6-4bc4-81bb-603c6bcf10d2" xlink:href="asth-20240331.xsd#asth_EarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_EarningsPerShareTable_a5f4767e-80a6-49a4-8218-c18b9e9f4b3e" xlink:to="loc_asth_EarningsPerShareLineItems_0d10c2ea-afe6-4bc4-81bb-603c6bcf10d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_467ff699-8aec-4e3b-970a-21d81035f7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_EarningsPerShareLineItems_0d10c2ea-afe6-4bc4-81bb-603c6bcf10d2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_467ff699-8aec-4e3b-970a-21d81035f7a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e6d089c5-2c12-4f97-b012-e240e8c2a238" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_EarningsPerShareLineItems_0d10c2ea-afe6-4bc4-81bb-603c6bcf10d2" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e6d089c5-2c12-4f97-b012-e240e8c2a238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares_bcc98907-7fd9-4f50-aa22-d4b959cea6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_EarningsPerShareLineItems_0d10c2ea-afe6-4bc4-81bb-603c6bcf10d2" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares_bcc98907-7fd9-4f50-aa22-d4b959cea6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_72ae112b-4c61-4e39-97a2-965d455fd945" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_EarningsPerShareLineItems_0d10c2ea-afe6-4bc4-81bb-603c6bcf10d2" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_72ae112b-4c61-4e39-97a2-965d455fd945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsAdditionalInformationDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#VariableInterestEntitiesVIEsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f640caec-4cb3-46b8-90c0-db5d71239a17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_cca44940-9dee-4aa1-9588-8bf8995bcef7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f640caec-4cb3-46b8-90c0-db5d71239a17" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_cca44940-9dee-4aa1-9588-8bf8995bcef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_6d86382b-4418-47c4-9b95-d768ac0b7dbc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_cca44940-9dee-4aa1-9588-8bf8995bcef7" xlink:to="loc_srt_ConsolidatedEntitiesAxis_6d86382b-4418-47c4-9b95-d768ac0b7dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_497685f8-8c57-46ff-ace5-12fdf4e341c0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_6d86382b-4418-47c4-9b95-d768ac0b7dbc" xlink:to="loc_srt_ConsolidatedEntitiesDomain_497685f8-8c57-46ff-ace5-12fdf4e341c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_4f70d79d-4b06-4c53-a1ed-3138c1bc2ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_497685f8-8c57-46ff-ace5-12fdf4e341c0" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_4f70d79d-4b06-4c53-a1ed-3138c1bc2ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_5d2cef47-47b3-4ae8-81a8-d6969932412b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_cca44940-9dee-4aa1-9588-8bf8995bcef7" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_5d2cef47-47b3-4ae8-81a8-d6969932412b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_b1acf2f7-19c8-4705-83d1-14feb608f57c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_5d2cef47-47b3-4ae8-81a8-d6969932412b" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_b1acf2f7-19c8-4705-83d1-14feb608f57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#VariableInterestEntitiesVIEsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d789945d-ba9a-4b49-90f1-7de5388bf939" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_94dd62c4-584a-403a-a032-9fc65a3e9e53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d789945d-ba9a-4b49-90f1-7de5388bf939" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_94dd62c4-584a-403a-a032-9fc65a3e9e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_46e84e65-5931-4098-82ef-5ce27d6be038" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_94dd62c4-584a-403a-a032-9fc65a3e9e53" xlink:to="loc_srt_ConsolidatedEntitiesAxis_46e84e65-5931-4098-82ef-5ce27d6be038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_a4e0b134-3030-40e7-910a-0d956a097723" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_46e84e65-5931-4098-82ef-5ce27d6be038" xlink:to="loc_srt_ConsolidatedEntitiesDomain_a4e0b134-3030-40e7-910a-0d956a097723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_5deb2c48-1add-45ef-bfbe-d69cfb0f0c26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_a4e0b134-3030-40e7-910a-0d956a097723" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_5deb2c48-1add-45ef-bfbe-d69cfb0f0c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c8ecfa24-dd60-47e7-9cfc-3db9b3f33163" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_94dd62c4-584a-403a-a032-9fc65a3e9e53" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c8ecfa24-dd60-47e7-9cfc-3db9b3f33163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_199d9ec3-8ef8-45e7-9351-4f426597d731" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c8ecfa24-dd60-47e7-9cfc-3db9b3f33163" xlink:to="loc_us-gaap_RelatedPartyDomain_199d9ec3-8ef8-45e7-9351-4f426597d731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_9507bdd7-b7cb-4201-b2fc-75b86fe779e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_199d9ec3-8ef8-45e7-9351-4f426597d731" xlink:to="loc_us-gaap_NonrelatedPartyMember_9507bdd7-b7cb-4201-b2fc-75b86fe779e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_2dd7a5f2-3df5-4282-a760-1e6abc04939b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_199d9ec3-8ef8-45e7-9351-4f426597d731" xlink:to="loc_us-gaap_RelatedPartyMember_2dd7a5f2-3df5-4282-a760-1e6abc04939b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_2cb9019e-a251-4a55-9f46-63b1c567b487" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_94dd62c4-584a-403a-a032-9fc65a3e9e53" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_2cb9019e-a251-4a55-9f46-63b1c567b487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_388f3557-2414-45b6-8d15-ad608397e169" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2cb9019e-a251-4a55-9f46-63b1c567b487" xlink:to="loc_us-gaap_AssetsAbstract_388f3557-2414-45b6-8d15-ad608397e169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_91236fc5-5345-4a3f-a258-0132f96eb4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_388f3557-2414-45b6-8d15-ad608397e169" xlink:to="loc_us-gaap_AssetsCurrentAbstract_91236fc5-5345-4a3f-a258-0132f96eb4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_41aefa12-8cf2-48b4-ab89-d8ede3335e26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_91236fc5-5345-4a3f-a258-0132f96eb4cb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_41aefa12-8cf2-48b4-ab89-d8ede3335e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_d18ad6fa-33b4-4ea1-adb3-95578a5be5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_91236fc5-5345-4a3f-a258-0132f96eb4cb" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_d18ad6fa-33b4-4ea1-adb3-95578a5be5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_094a0954-b72c-4854-afd1-788f94466849" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_91236fc5-5345-4a3f-a258-0132f96eb4cb" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_094a0954-b72c-4854-afd1-788f94466849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_cb044eec-4d32-4210-b730-551f48dd86cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_91236fc5-5345-4a3f-a258-0132f96eb4cb" xlink:to="loc_us-gaap_IncomeTaxesReceivable_cb044eec-4d32-4210-b730-551f48dd86cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_fd1a7b1b-ba93-4449-bcb2-044859af7020" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_91236fc5-5345-4a3f-a258-0132f96eb4cb" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_fd1a7b1b-ba93-4449-bcb2-044859af7020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_faddbede-7279-47f7-95d3-d461e6a6b67b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_91236fc5-5345-4a3f-a258-0132f96eb4cb" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_faddbede-7279-47f7-95d3-d461e6a6b67b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_81e9ef59-6efe-4f3c-9585-89f6918e23c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_91236fc5-5345-4a3f-a258-0132f96eb4cb" xlink:to="loc_us-gaap_AssetsCurrent_81e9ef59-6efe-4f3c-9585-89f6918e23c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_914a8590-4c3c-4c3a-935f-fa0a761d1dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_388f3557-2414-45b6-8d15-ad608397e169" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_914a8590-4c3c-4c3a-935f-fa0a761d1dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6673f8c1-4c32-4912-8182-4c591ab890f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_914a8590-4c3c-4c3a-935f-fa0a761d1dd3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6673f8c1-4c32-4912-8182-4c591ab890f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a812bb26-7a10-4bcc-b632-468c1d6c743d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_914a8590-4c3c-4c3a-935f-fa0a761d1dd3" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a812bb26-7a10-4bcc-b632-468c1d6c743d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f6304514-4b73-47a3-a4c8-3011ff067af4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_914a8590-4c3c-4c3a-935f-fa0a761d1dd3" xlink:to="loc_us-gaap_Goodwill_f6304514-4b73-47a3-a4c8-3011ff067af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivableNoncurrent_b9913566-214f-4869-b7cb-838ad78830c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesReceivableNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_914a8590-4c3c-4c3a-935f-fa0a761d1dd3" xlink:to="loc_us-gaap_IncomeTaxesReceivableNoncurrent_b9913566-214f-4869-b7cb-838ad78830c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_77359c10-18cf-4956-af1f-55de271e4b29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_914a8590-4c3c-4c3a-935f-fa0a761d1dd3" xlink:to="loc_us-gaap_EquityMethodInvestments_77359c10-18cf-4956-af1f-55de271e4b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_484c164b-04f9-438a-9cb4-cc8c5ae6f6da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_914a8590-4c3c-4c3a-935f-fa0a761d1dd3" xlink:to="loc_us-gaap_OtherLongTermInvestments_484c164b-04f9-438a-9cb4-cc8c5ae6f6da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_35a83765-64f5-4a9a-82ae-b95ff0052362" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_914a8590-4c3c-4c3a-935f-fa0a761d1dd3" xlink:to="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_35a83765-64f5-4a9a-82ae-b95ff0052362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_915cdc18-44f1-43a3-aca6-03d6cb6eaf7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_914a8590-4c3c-4c3a-935f-fa0a761d1dd3" xlink:to="loc_us-gaap_RestrictedCash_915cdc18-44f1-43a3-aca6-03d6cb6eaf7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8b66980b-a692-4596-aebd-8042819db967" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_914a8590-4c3c-4c3a-935f-fa0a761d1dd3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8b66980b-a692-4596-aebd-8042819db967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6dee3135-0992-4f7a-b92c-4d57dbff6b11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_914a8590-4c3c-4c3a-935f-fa0a761d1dd3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6dee3135-0992-4f7a-b92c-4d57dbff6b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_1c35e0df-3b09-4323-a548-9036ad75cbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_914a8590-4c3c-4c3a-935f-fa0a761d1dd3" xlink:to="loc_us-gaap_AssetsNoncurrent_1c35e0df-3b09-4323-a548-9036ad75cbcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0b9138c0-7206-4a4b-ab42-0ad041634a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_388f3557-2414-45b6-8d15-ad608397e169" xlink:to="loc_us-gaap_Assets_0b9138c0-7206-4a4b-ab42-0ad041634a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_ced0449a-a71f-4d8d-a49a-0161c7e322f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2cb9019e-a251-4a55-9f46-63b1c567b487" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_ced0449a-a71f-4d8d-a49a-0161c7e322f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c18ac336-d5e9-48a5-b6f3-6edcccf74a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ced0449a-a71f-4d8d-a49a-0161c7e322f9" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c18ac336-d5e9-48a5-b6f3-6edcccf74a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_FiduciaryAccountsPayableCurrent_54a86636-a7e1-4ad4-8821-0f29d7c5b594" xlink:href="asth-20240331.xsd#asth_FiduciaryAccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ced0449a-a71f-4d8d-a49a-0161c7e322f9" xlink:to="loc_asth_FiduciaryAccountsPayableCurrent_54a86636-a7e1-4ad4-8821-0f29d7c5b594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_f1123c03-3a17-4302-b217-3b8c671afbb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ced0449a-a71f-4d8d-a49a-0161c7e322f9" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_f1123c03-3a17-4302-b217-3b8c671afbb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_2f1571d6-e7fd-4daf-ac38-642099058dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ced0449a-a71f-4d8d-a49a-0161c7e322f9" xlink:to="loc_us-gaap_DividendsPayableCurrent_2f1571d6-e7fd-4daf-ac38-642099058dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_b146c33d-f6eb-4436-a672-1f4921e22dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ced0449a-a71f-4d8d-a49a-0161c7e322f9" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_b146c33d-f6eb-4436-a672-1f4921e22dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_f1c6357a-ea34-41e5-b7a1-c6025efded2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ced0449a-a71f-4d8d-a49a-0161c7e322f9" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_f1c6357a-ea34-41e5-b7a1-c6025efded2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e8b33978-d77d-41ab-ae69-c8b361dd4872" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ced0449a-a71f-4d8d-a49a-0161c7e322f9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e8b33978-d77d-41ab-ae69-c8b361dd4872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_c96c8137-d066-4349-9a74-b4051777c4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ced0449a-a71f-4d8d-a49a-0161c7e322f9" xlink:to="loc_us-gaap_LongTermDebtCurrent_c96c8137-d066-4349-9a74-b4051777c4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_7b737d3c-1c9a-40ee-912f-ae639ae96321" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ced0449a-a71f-4d8d-a49a-0161c7e322f9" xlink:to="loc_us-gaap_OtherLiabilities_7b737d3c-1c9a-40ee-912f-ae639ae96321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_904c8f59-15df-4385-8346-767ee0dbeb4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ced0449a-a71f-4d8d-a49a-0161c7e322f9" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_904c8f59-15df-4385-8346-767ee0dbeb4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6bd19bde-c79a-483b-b536-52d320f19f27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ced0449a-a71f-4d8d-a49a-0161c7e322f9" xlink:to="loc_us-gaap_LiabilitiesCurrent_6bd19bde-c79a-483b-b536-52d320f19f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_918ca151-8049-4c4a-a09e-551d7664b3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2cb9019e-a251-4a55-9f46-63b1c567b487" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_918ca151-8049-4c4a-a09e-551d7664b3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_ed9f1fc8-a20b-483b-b870-3497499b9c85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_918ca151-8049-4c4a-a09e-551d7664b3a7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_ed9f1fc8-a20b-483b-b870-3497499b9c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9a04e660-b439-479a-bec7-d532484d317d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_918ca151-8049-4c4a-a09e-551d7664b3a7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9a04e660-b439-479a-bec7-d532484d317d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_10f9a651-be17-4729-ba0b-420ddd09dfa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_918ca151-8049-4c4a-a09e-551d7664b3a7" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_10f9a651-be17-4729-ba0b-420ddd09dfa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c9e8f5a7-de0e-4373-bc64-18b64b1a3782" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_918ca151-8049-4c4a-a09e-551d7664b3a7" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c9e8f5a7-de0e-4373-bc64-18b64b1a3782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_bf70cc6a-bb3f-40ed-9c90-1a63c99334aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_918ca151-8049-4c4a-a09e-551d7664b3a7" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_bf70cc6a-bb3f-40ed-9c90-1a63c99334aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d9f58f11-33a6-4324-8a8a-2b4f764d6078" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2cb9019e-a251-4a55-9f46-63b1c567b487" xlink:to="loc_us-gaap_Liabilities_d9f58f11-33a6-4324-8a8a-2b4f764d6078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#LeasesAdditionalinformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3cf82d9a-21ee-4112-b6fc-ad5943fc494a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_98de0eb1-ad8c-42e2-a575-4c6f154153d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3cf82d9a-21ee-4112-b6fc-ad5943fc494a" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_98de0eb1-ad8c-42e2-a575-4c6f154153d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6ba5904f-33e9-4e6b-8789-24264c878651" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_98de0eb1-ad8c-42e2-a575-4c6f154153d5" xlink:to="loc_srt_RangeAxis_6ba5904f-33e9-4e6b-8789-24264c878651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c39bcf94-47f3-426e-9d1e-14c1bac702bd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6ba5904f-33e9-4e6b-8789-24264c878651" xlink:to="loc_srt_RangeMember_c39bcf94-47f3-426e-9d1e-14c1bac702bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_995ca091-7b67-4241-a255-2dcea85895fe" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c39bcf94-47f3-426e-9d1e-14c1bac702bd" xlink:to="loc_srt_MinimumMember_995ca091-7b67-4241-a255-2dcea85895fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_89b776d9-3c2f-46cc-a3f8-ef1c2a35518d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c39bcf94-47f3-426e-9d1e-14c1bac702bd" xlink:to="loc_srt_MaximumMember_89b776d9-3c2f-46cc-a3f8-ef1c2a35518d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_f43f61f8-aa6b-4f73-9d53-b554d822c9d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_98de0eb1-ad8c-42e2-a575-4c6f154153d5" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_f43f61f8-aa6b-4f73-9d53-b554d822c9d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_ac6a0434-3540-493e-97ad-1bc397b46449" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f43f61f8-aa6b-4f73-9d53-b554d822c9d1" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_ac6a0434-3540-493e-97ad-1bc397b46449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_88a86ca3-a96a-43c2-8d18-9ff18296c991" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f43f61f8-aa6b-4f73-9d53-b554d822c9d1" xlink:to="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_88a86ca3-a96a-43c2-8d18-9ff18296c991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_755a7eed-ff19-4f2e-bbc5-86d598db6e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f43f61f8-aa6b-4f73-9d53-b554d822c9d1" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_755a7eed-ff19-4f2e-bbc5-86d598db6e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_65c1bd92-f371-494b-aaad-722747fa08f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f43f61f8-aa6b-4f73-9d53-b554d822c9d1" xlink:to="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_65c1bd92-f371-494b-aaad-722747fa08f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_LesseeOperatingLeaseTerminationPeriodIfApplicable_cf968966-e994-4f2a-849b-9ebb8c4b6018" xlink:href="asth-20240331.xsd#asth_LesseeOperatingLeaseTerminationPeriodIfApplicable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f43f61f8-aa6b-4f73-9d53-b554d822c9d1" xlink:to="loc_asth_LesseeOperatingLeaseTerminationPeriodIfApplicable_cf968966-e994-4f2a-849b-9ebb8c4b6018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_LesseeFinanceLeaseTerminationPeriodIfApplicable_e56f59e2-70ae-4a1f-bde5-6a1ee19b1260" xlink:href="asth-20240331.xsd#asth_LesseeFinanceLeaseTerminationPeriodIfApplicable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f43f61f8-aa6b-4f73-9d53-b554d822c9d1" xlink:to="loc_asth_LesseeFinanceLeaseTerminationPeriodIfApplicable_e56f59e2-70ae-4a1f-bde5-6a1ee19b1260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_a38418fc-262a-406e-866b-969fd547eaa8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f43f61f8-aa6b-4f73-9d53-b554d822c9d1" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_a38418fc-262a-406e-866b-969fd547eaa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_dc9ead5e-fca8-41a8-96c0-6b25601a0425" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f43f61f8-aa6b-4f73-9d53-b554d822c9d1" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_dc9ead5e-fca8-41a8-96c0-6b25601a0425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesScheduleofComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#LeasesScheduleofComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesScheduleofComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4fbf707c-0299-4f25-ab61-856af0c73d20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_057bcb9c-73b6-4e37-b6d8-fb6a6b8ab7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4fbf707c-0299-4f25-ab61-856af0c73d20" xlink:to="loc_us-gaap_OperatingLeaseCost_057bcb9c-73b6-4e37-b6d8-fb6a6b8ab7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_FinanceLeaseCostsAbstract_cfcc3407-dd01-498a-9907-edd76dc9a86d" xlink:href="asth-20240331.xsd#asth_FinanceLeaseCostsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4fbf707c-0299-4f25-ab61-856af0c73d20" xlink:to="loc_asth_FinanceLeaseCostsAbstract_cfcc3407-dd01-498a-9907-edd76dc9a86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_3799ca83-e332-45f6-9e1e-9b93e883d812" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_FinanceLeaseCostsAbstract_cfcc3407-dd01-498a-9907-edd76dc9a86d" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_3799ca83-e332-45f6-9e1e-9b93e883d812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_4861ecf4-31aa-4524-ba0f-33127d4c4f93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_FinanceLeaseCostsAbstract_cfcc3407-dd01-498a-9907-edd76dc9a86d" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_4861ecf4-31aa-4524-ba0f-33127d4c4f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_59653873-1d44-4a80-a173-3a1f37d91261" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4fbf707c-0299-4f25-ab61-856af0c73d20" xlink:to="loc_us-gaap_SubleaseIncome_59653873-1d44-4a80-a173-3a1f37d91261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_3e2f4d59-3784-4a89-96e7-c2d82805b7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4fbf707c-0299-4f25-ab61-856af0c73d20" xlink:to="loc_us-gaap_LeaseCost_3e2f4d59-3784-4a89-96e7-c2d82805b7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesScheduleofOtherInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#LeasesScheduleofOtherInformationRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesScheduleofOtherInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_fea9859c-72fc-4f26-a282-c7dfd8bf3fae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CashPaidForLeaseLiabilitiesAbstractAbstract_f49ba452-44f5-44de-ba54-3bcc38249b3a" xlink:href="asth-20240331.xsd#asth_CashPaidForLeaseLiabilitiesAbstractAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fea9859c-72fc-4f26-a282-c7dfd8bf3fae" xlink:to="loc_asth_CashPaidForLeaseLiabilitiesAbstractAbstract_f49ba452-44f5-44de-ba54-3bcc38249b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_9eb9a595-bcde-4f89-a4d9-40c5f71e265f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_CashPaidForLeaseLiabilitiesAbstractAbstract_f49ba452-44f5-44de-ba54-3bcc38249b3a" xlink:to="loc_us-gaap_OperatingLeasePayments_9eb9a595-bcde-4f89-a4d9-40c5f71e265f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_86b41d75-8766-46ff-99a5-cd53f374225c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_CashPaidForLeaseLiabilitiesAbstractAbstract_f49ba452-44f5-44de-ba54-3bcc38249b3a" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_86b41d75-8766-46ff-99a5-cd53f374225c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_f726e7bb-d4ab-4af1-955e-a84a8168bf97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_CashPaidForLeaseLiabilitiesAbstractAbstract_f49ba452-44f5-44de-ba54-3bcc38249b3a" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_f726e7bb-d4ab-4af1-955e-a84a8168bf97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_LeaseWeightedAverageRemainingLeaseTermAbstract_fcee612c-dd2b-4642-bf6a-492c0a26f006" xlink:href="asth-20240331.xsd#asth_LeaseWeightedAverageRemainingLeaseTermAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fea9859c-72fc-4f26-a282-c7dfd8bf3fae" xlink:to="loc_asth_LeaseWeightedAverageRemainingLeaseTermAbstract_fcee612c-dd2b-4642-bf6a-492c0a26f006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_94f441c4-b55e-4c94-bded-85e4c3457675" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_LeaseWeightedAverageRemainingLeaseTermAbstract_fcee612c-dd2b-4642-bf6a-492c0a26f006" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_94f441c4-b55e-4c94-bded-85e4c3457675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_75c639d8-0133-4b96-aee9-a6748160f651" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_LeaseWeightedAverageRemainingLeaseTermAbstract_fcee612c-dd2b-4642-bf6a-492c0a26f006" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_75c639d8-0133-4b96-aee9-a6748160f651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_LeaseWeightedAverageDiscountRateAbstract_7237cf15-d87f-43e8-a7c8-01c9d0a5f652" xlink:href="asth-20240331.xsd#asth_LeaseWeightedAverageDiscountRateAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fea9859c-72fc-4f26-a282-c7dfd8bf3fae" xlink:to="loc_asth_LeaseWeightedAverageDiscountRateAbstract_7237cf15-d87f-43e8-a7c8-01c9d0a5f652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_8467df7e-926b-4c29-bd1b-cfa933581e42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_LeaseWeightedAverageDiscountRateAbstract_7237cf15-d87f-43e8-a7c8-01c9d0a5f652" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_8467df7e-926b-4c29-bd1b-cfa933581e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_7c782b9f-4300-4cc4-8295-ba4b063aae08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_asth_LeaseWeightedAverageDiscountRateAbstract_7237cf15-d87f-43e8-a7c8-01c9d0a5f652" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_7c782b9f-4300-4cc4-8295-ba4b063aae08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e1605e2d-a234-40a9-9f83-68300e447243" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c14352af-5de4-4ea0-a3ee-c851b26ff630" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e1605e2d-a234-40a9-9f83-68300e447243" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c14352af-5de4-4ea0-a3ee-c851b26ff630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_516c2ab6-6d65-4ca1-8b6a-499eaca9ae32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c14352af-5de4-4ea0-a3ee-c851b26ff630" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_516c2ab6-6d65-4ca1-8b6a-499eaca9ae32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0e610936-10c3-4f51-8b1e-16f18530a93d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c14352af-5de4-4ea0-a3ee-c851b26ff630" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0e610936-10c3-4f51-8b1e-16f18530a93d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6587c524-717b-440e-a5e5-b5a97564b074" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c14352af-5de4-4ea0-a3ee-c851b26ff630" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6587c524-717b-440e-a5e5-b5a97564b074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a8405654-af26-45a5-bae5-d821572c3b98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c14352af-5de4-4ea0-a3ee-c851b26ff630" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a8405654-af26-45a5-bae5-d821572c3b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ad29736e-8792-45d3-83a5-7c823da29e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c14352af-5de4-4ea0-a3ee-c851b26ff630" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ad29736e-8792-45d3-83a5-7c823da29e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_03e2e4bb-0592-4986-80c9-a9218e20a9b6" xlink:href="asth-20240331.xsd#asth_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c14352af-5de4-4ea0-a3ee-c851b26ff630" xlink:to="loc_asth_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_03e2e4bb-0592-4986-80c9-a9218e20a9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e91a2a6c-6ac0-42e7-b06f-18aeeef412e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c14352af-5de4-4ea0-a3ee-c851b26ff630" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e91a2a6c-6ac0-42e7-b06f-18aeeef412e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_570324d3-25e5-45dc-8422-9e14020473f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c14352af-5de4-4ea0-a3ee-c851b26ff630" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_570324d3-25e5-45dc-8422-9e14020473f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_691dcfd5-3638-4631-9ea8-31eea371dfea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c14352af-5de4-4ea0-a3ee-c851b26ff630" xlink:to="loc_us-gaap_OperatingLeaseLiability_691dcfd5-3638-4631-9ea8-31eea371dfea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_eae2081c-3fb0-4a66-afef-85471520562b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c14352af-5de4-4ea0-a3ee-c851b26ff630" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_eae2081c-3fb0-4a66-afef-85471520562b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4e3eb20b-055e-47d8-92a2-debe1fd02e18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c14352af-5de4-4ea0-a3ee-c851b26ff630" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4e3eb20b-055e-47d8-92a2-debe1fd02e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_919688b2-1b59-4e9e-935b-4458f3c79a61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e1605e2d-a234-40a9-9f83-68300e447243" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_919688b2-1b59-4e9e-935b-4458f3c79a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_9ba8701a-4f76-4f40-9e54-1b8b5a3340df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_919688b2-1b59-4e9e-935b-4458f3c79a61" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_9ba8701a-4f76-4f40-9e54-1b8b5a3340df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_605660c5-15c9-4a44-b110-388030cec56f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_919688b2-1b59-4e9e-935b-4458f3c79a61" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_605660c5-15c9-4a44-b110-388030cec56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_7e0b60a1-c9d2-4ded-8fa2-4b415229d74a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_919688b2-1b59-4e9e-935b-4458f3c79a61" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_7e0b60a1-c9d2-4ded-8fa2-4b415229d74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_81197e2d-cd51-48c6-a39d-d2a0531c6873" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_919688b2-1b59-4e9e-935b-4458f3c79a61" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_81197e2d-cd51-48c6-a39d-d2a0531c6873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_77ca6e57-ef3e-4e4b-8bb1-7d77d3d79ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_919688b2-1b59-4e9e-935b-4458f3c79a61" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_77ca6e57-ef3e-4e4b-8bb1-7d77d3d79ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_FinanceLeaseLiabilityToBePaidAfterYearFour_69ec3a1e-1cb2-4daf-ae2c-1568b42ea836" xlink:href="asth-20240331.xsd#asth_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_919688b2-1b59-4e9e-935b-4458f3c79a61" xlink:to="loc_asth_FinanceLeaseLiabilityToBePaidAfterYearFour_69ec3a1e-1cb2-4daf-ae2c-1568b42ea836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_62a30666-1add-4033-9f17-77e8f3e5b5e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_919688b2-1b59-4e9e-935b-4458f3c79a61" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_62a30666-1add-4033-9f17-77e8f3e5b5e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_5364910b-25ef-42fe-bf23-d8e346a2eea4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_919688b2-1b59-4e9e-935b-4458f3c79a61" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_5364910b-25ef-42fe-bf23-d8e346a2eea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_f0c5050f-4c4c-4455-a2b8-deff9c2f37b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_919688b2-1b59-4e9e-935b-4458f3c79a61" xlink:to="loc_us-gaap_FinanceLeaseLiability_f0c5050f-4c4c-4455-a2b8-deff9c2f37b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_9148858e-5f4d-4964-beed-f7e5d916b0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_919688b2-1b59-4e9e-935b-4458f3c79a61" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_9148858e-5f4d-4964-beed-f7e5d916b0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_5e0f67ef-21fb-427a-a0ec-606fe0b3ca9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_919688b2-1b59-4e9e-935b-4458f3c79a61" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_5e0f67ef-21fb-427a-a0ec-606fe0b3ca9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/SegmentsDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#SegmentsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/SegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_0ced0c31-f1d2-4416-9edf-30bdebe6c9dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_72f14753-77f3-4b69-aafd-d0096a842bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0ced0c31-f1d2-4416-9edf-30bdebe6c9dd" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_72f14753-77f3-4b69-aafd-d0096a842bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_6967b584-eb1f-4543-8da2-96088c942422" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_72f14753-77f3-4b69-aafd-d0096a842bf5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_6967b584-eb1f-4543-8da2-96088c942422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ec00868a-6405-47d7-8729-7752f1b95e89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6967b584-eb1f-4543-8da2-96088c942422" xlink:to="loc_us-gaap_SegmentDomain_ec00868a-6405-47d7-8729-7752f1b95e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CarePartnersMember_b7c70720-5926-46af-9016-aa8ce66adad9" xlink:href="asth-20240331.xsd#asth_CarePartnersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ec00868a-6405-47d7-8729-7752f1b95e89" xlink:to="loc_asth_CarePartnersMember_b7c70720-5926-46af-9016-aa8ce66adad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CareDeliveryMember_162f0639-6a7c-43ab-a942-6b397d766c9e" xlink:href="asth-20240331.xsd#asth_CareDeliveryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ec00868a-6405-47d7-8729-7752f1b95e89" xlink:to="loc_asth_CareDeliveryMember_162f0639-6a7c-43ab-a942-6b397d766c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CareEnablementMember_e3a58a0d-afb5-41e8-81dd-eba18de8e0bb" xlink:href="asth-20240331.xsd#asth_CareEnablementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ec00868a-6405-47d7-8729-7752f1b95e89" xlink:to="loc_asth_CareEnablementMember_e3a58a0d-afb5-41e8-81dd-eba18de8e0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_853251dd-fb9a-4eb5-9aac-31d5626eef90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ec00868a-6405-47d7-8729-7752f1b95e89" xlink:to="loc_us-gaap_AllOtherSegmentsMember_853251dd-fb9a-4eb5-9aac-31d5626eef90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_5b2cb0b6-e439-4422-96c3-4736cd173117" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_72f14753-77f3-4b69-aafd-d0096a842bf5" xlink:to="loc_srt_ConsolidationItemsAxis_5b2cb0b6-e439-4422-96c3-4736cd173117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_e2524abf-477c-45f1-a819-f387a460797b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_5b2cb0b6-e439-4422-96c3-4736cd173117" xlink:to="loc_srt_ConsolidationItemsDomain_e2524abf-477c-45f1-a819-f387a460797b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_a43ccde9-d7b3-4c44-856d-fdf262ee408d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_e2524abf-477c-45f1-a819-f387a460797b" xlink:to="loc_us-gaap_OperatingSegmentsMember_a43ccde9-d7b3-4c44-856d-fdf262ee408d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_f76acdee-dd50-4295-9610-7e9bc9c2e5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_e2524abf-477c-45f1-a819-f387a460797b" xlink:to="loc_us-gaap_IntersegmentEliminationMember_f76acdee-dd50-4295-9610-7e9bc9c2e5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_30e82249-07a9-4ca9-9b3c-adc8d026dcb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_e2524abf-477c-45f1-a819-f387a460797b" xlink:to="loc_us-gaap_CorporateNonSegmentMember_30e82249-07a9-4ca9-9b3c-adc8d026dcb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_c81af3a0-0fcf-494c-8506-75866d10252a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_72f14753-77f3-4b69-aafd-d0096a842bf5" xlink:to="loc_us-gaap_SubsegmentsAxis_c81af3a0-0fcf-494c-8506-75866d10252a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_5b71b975-25cb-4c0e-9932-c3cda2d6aeca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_c81af3a0-0fcf-494c-8506-75866d10252a" xlink:to="loc_us-gaap_SubsegmentsDomain_5b71b975-25cb-4c0e-9932-c3cda2d6aeca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCarePatientServiceMember_220e6227-7131-4686-9eb4-7b2d1c04f575" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCarePatientServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_5b71b975-25cb-4c0e-9932-c3cda2d6aeca" xlink:to="loc_us-gaap_HealthCarePatientServiceMember_220e6227-7131-4686-9eb4-7b2d1c04f575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_c3bc7a79-f8a7-4c06-b99f-d2932df8acfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_5b71b975-25cb-4c0e-9932-c3cda2d6aeca" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_c3bc7a79-f8a7-4c06-b99f-d2932df8acfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_3a3d7ccb-3e0e-4761-a8b4-7838f26d8abc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_72f14753-77f3-4b69-aafd-d0096a842bf5" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_3a3d7ccb-3e0e-4761-a8b4-7838f26d8abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_05ed08c9-7c66-4c61-880a-509fe0e8aa92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3a3d7ccb-3e0e-4761-a8b4-7838f26d8abc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_05ed08c9-7c66-4c61-880a-509fe0e8aa92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_25a5e509-8504-4425-8cd2-3f1bc18bc574" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3a3d7ccb-3e0e-4761-a8b4-7838f26d8abc" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_25a5e509-8504-4425-8cd2-3f1bc18bc574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_GeneralAndAdministrativeExpensesAndDepreciationAndAmortization_b7959191-91b7-4df5-ae49-9a3e0c4ddd8d" xlink:href="asth-20240331.xsd#asth_GeneralAndAdministrativeExpensesAndDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3a3d7ccb-3e0e-4761-a8b4-7838f26d8abc" xlink:to="loc_asth_GeneralAndAdministrativeExpensesAndDepreciationAndAmortization_b7959191-91b7-4df5-ae49-9a3e0c4ddd8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ee945176-fae4-4f5e-a9d7-1a505b3c21ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3a3d7ccb-3e0e-4761-a8b4-7838f26d8abc" xlink:to="loc_us-gaap_CostsAndExpenses_ee945176-fae4-4f5e-a9d7-1a505b3c21ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a093889b-23b7-411c-8e1a-9f3e0f5a095b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3a3d7ccb-3e0e-4761-a8b4-7838f26d8abc" xlink:to="loc_us-gaap_OperatingIncomeLoss_a093889b-23b7-411c-8e1a-9f3e0f5a095b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_00279c54-c747-4fa2-b63a-8f0617395d80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a60e7921-b318-4e83-ba0f-b2d19bd84c16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_00279c54-c747-4fa2-b63a-8f0617395d80" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a60e7921-b318-4e83-ba0f-b2d19bd84c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aae95f91-9d80-4445-b9ff-5039334ee67e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a60e7921-b318-4e83-ba0f-b2d19bd84c16" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aae95f91-9d80-4445-b9ff-5039334ee67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dac66c41-f403-4423-bca9-eb0a19d419d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aae95f91-9d80-4445-b9ff-5039334ee67e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dac66c41-f403-4423-bca9-eb0a19d419d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_333e1dfd-d198-40ed-aaba-6d8de539c0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dac66c41-f403-4423-bca9-eb0a19d419d9" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_333e1dfd-d198-40ed-aaba-6d8de539c0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_11008e64-caf9-4088-b7fb-9e2502aaa5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dac66c41-f403-4423-bca9-eb0a19d419d9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_11008e64-caf9-4088-b7fb-9e2502aaa5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_79348295-e15c-4ecd-aa22-2323dfdd9cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dac66c41-f403-4423-bca9-eb0a19d419d9" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_79348295-e15c-4ecd-aa22-2323dfdd9cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_0bdd3a06-4414-455b-8c0e-a0c691e9d5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a60e7921-b318-4e83-ba0f-b2d19bd84c16" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_0bdd3a06-4414-455b-8c0e-a0c691e9d5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b9043d0f-c8c9-40d3-b892-1550ae0db1b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0bdd3a06-4414-455b-8c0e-a0c691e9d5c6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b9043d0f-c8c9-40d3-b892-1550ae0db1b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_InterestRateCollarMember_4d4d0ec6-8a43-47d6-a889-b60244a974df" xlink:href="asth-20240331.xsd#asth_InterestRateCollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b9043d0f-c8c9-40d3-b892-1550ae0db1b5" xlink:to="loc_asth_InterestRateCollarMember_4d4d0ec6-8a43-47d6-a889-b60244a974df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_68a08270-6571-4f37-944b-4c01e3f45e38" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a60e7921-b318-4e83-ba0f-b2d19bd84c16" xlink:to="loc_dei_LegalEntityAxis_68a08270-6571-4f37-944b-4c01e3f45e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_85e8418f-157d-4a98-8f42-8b3580d50a89" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_68a08270-6571-4f37-944b-4c01e3f45e38" xlink:to="loc_dei_EntityDomain_85e8418f-157d-4a98-8f42-8b3580d50a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AAMGMember_37785d2e-cf68-4301-9c12-3b65d89d782e" xlink:href="asth-20240331.xsd#asth_AAMGMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_85e8418f-157d-4a98-8f42-8b3580d50a89" xlink:to="loc_asth_AAMGMember_37785d2e-cf68-4301-9c12-3b65d89d782e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_VOMGMember_86743d7e-d76a-459b-ba38-5032caae9c7d" xlink:href="asth-20240331.xsd#asth_VOMGMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_85e8418f-157d-4a98-8f42-8b3580d50a89" xlink:to="loc_asth_VOMGMember_86743d7e-d76a-459b-ba38-5032caae9c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_DmgMember_70f9519f-5d68-44d1-be79-e2aeec1608fe" xlink:href="asth-20240331.xsd#asth_DmgMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_85e8418f-157d-4a98-8f42-8b3580d50a89" xlink:to="loc_asth_DmgMember_70f9519f-5d68-44d1-be79-e2aeec1608fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ApolloSunLabsManagementLLCMember_01c6cbfe-9d1d-4588-ac91-68bf7cf38d8f" xlink:href="asth-20240331.xsd#asth_ApolloSunLabsManagementLLCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_85e8418f-157d-4a98-8f42-8b3580d50a89" xlink:to="loc_asth_ApolloSunLabsManagementLLCMember_01c6cbfe-9d1d-4588-ac91-68bf7cf38d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ADSCMember_6db94de1-fdcd-4c28-b38e-d8ac60c471cc" xlink:href="asth-20240331.xsd#asth_ADSCMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_85e8418f-157d-4a98-8f42-8b3580d50a89" xlink:to="loc_asth_ADSCMember_6db94de1-fdcd-4c28-b38e-d8ac60c471cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CFCMember_87776054-d915-430e-946f-991e20089f9d" xlink:href="asth-20240331.xsd#asth_CFCMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_85e8418f-157d-4a98-8f42-8b3580d50a89" xlink:to="loc_asth_CFCMember_87776054-d915-430e-946f-991e20089f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PrimeCommunityCareMember_3183d831-afba-460f-bfee-04f82c81dd96" xlink:href="asth-20240331.xsd#asth_PrimeCommunityCareMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_85e8418f-157d-4a98-8f42-8b3580d50a89" xlink:to="loc_asth_PrimeCommunityCareMember_3183d831-afba-460f-bfee-04f82c81dd96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e0ee9bd5-0035-43a5-9f7e-2ba290277bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a60e7921-b318-4e83-ba0f-b2d19bd84c16" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e0ee9bd5-0035-43a5-9f7e-2ba290277bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1c0a3645-1ab7-4747-9735-534b73f7d4a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e0ee9bd5-0035-43a5-9f7e-2ba290277bf0" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1c0a3645-1ab7-4747-9735-534b73f7d4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f83a192b-f40a-4e30-9fa6-23268ac26418" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e0ee9bd5-0035-43a5-9f7e-2ba290277bf0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f83a192b-f40a-4e30-9fa6-23268ac26418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_58366e9a-a615-48a8-a129-53eeb4108ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e0ee9bd5-0035-43a5-9f7e-2ba290277bf0" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_58366e9a-a615-48a8-a129-53eeb4108ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_d4516eb9-f0aa-4c78-b8df-1d71609fff6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e0ee9bd5-0035-43a5-9f7e-2ba290277bf0" xlink:to="loc_us-gaap_DerivativeAssets_d4516eb9-f0aa-4c78-b8df-1d71609fff6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ee3d4aa7-c8d4-436c-ba0a-df190b1b5f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e0ee9bd5-0035-43a5-9f7e-2ba290277bf0" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_ee3d4aa7-c8d4-436c-ba0a-df190b1b5f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0a8eea2b-0537-4b61-8890-f5d56acf2823" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e0ee9bd5-0035-43a5-9f7e-2ba290277bf0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0a8eea2b-0537-4b61-8890-f5d56acf2823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_b0a8312c-bf39-4608-9606-59564ecab1d2" xlink:href="asth-20240331.xsd#asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e0ee9bd5-0035-43a5-9f7e-2ba290277bf0" xlink:to="loc_asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_b0a8312c-bf39-4608-9606-59564ecab1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_e7de5684-7b37-4674-ad8f-cf245fb12466" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e0ee9bd5-0035-43a5-9f7e-2ba290277bf0" xlink:to="loc_us-gaap_DerivativeLiabilities_e7de5684-7b37-4674-ad8f-cf245fb12466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_a8bcb909-ea5f-4642-b66d-097ae9904318" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e0ee9bd5-0035-43a5-9f7e-2ba290277bf0" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_a8bcb909-ea5f-4642-b66d-097ae9904318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofChangeinFairValueofLevel3LiabilitiesDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#FairValueMeasurementsofFinancialInstrumentsScheduleofChangeinFairValueofLevel3LiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofChangeinFairValueofLevel3LiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_fe713904-850e-41ef-a73a-92001b51e5fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_eef250e3-c9c2-4071-8643-df39999776cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fe713904-850e-41ef-a73a-92001b51e5fb" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_eef250e3-c9c2-4071-8643-df39999776cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_71e89359-e747-490a-910e-20ac284b31e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_eef250e3-c9c2-4071-8643-df39999776cf" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_71e89359-e747-490a-910e-20ac284b31e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdditions_cec3c423-e173-4d5b-a3e6-08f5874caf21" xlink:href="asth-20240331.xsd#asth_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_eef250e3-c9c2-4071-8643-df39999776cf" xlink:to="loc_asth_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdditions_cec3c423-e173-4d5b-a3e6-08f5874caf21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a48a6051-e3fc-4cd2-ae55-93bf330f877d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_eef250e3-c9c2-4071-8643-df39999776cf" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a48a6051-e3fc-4cd2-ae55-93bf330f877d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6d3fceed-f549-4c40-8c9d-f07b2298b082" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_eef250e3-c9c2-4071-8643-df39999776cf" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6d3fceed-f549-4c40-8c9d-f07b2298b082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_eb66898d-1931-4a50-a6a1-5e6739fb02ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dc950cc9-35dc-4a16-8556-e6632cdf42d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_eb66898d-1931-4a50-a6a1-5e6739fb02ce" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dc950cc9-35dc-4a16-8556-e6632cdf42d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9c9b4154-0528-45b8-9cd1-c39fe40958c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dc950cc9-35dc-4a16-8556-e6632cdf42d0" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9c9b4154-0528-45b8-9cd1-c39fe40958c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8541eedf-41de-48bf-b89b-01bf0ed5ce94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9c9b4154-0528-45b8-9cd1-c39fe40958c4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8541eedf-41de-48bf-b89b-01bf0ed5ce94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_cd931cd8-74d4-468c-b28d-0a275d74465e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8541eedf-41de-48bf-b89b-01bf0ed5ce94" xlink:to="loc_us-gaap_CertificatesOfDepositMember_cd931cd8-74d4-468c-b28d-0a275d74465e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_7d468aeb-0b5b-419c-b07f-503240ec2d11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dc950cc9-35dc-4a16-8556-e6632cdf42d0" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_7d468aeb-0b5b-419c-b07f-503240ec2d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1bb214c7-6f37-4bd2-bb50-eb1a144d7b70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7d468aeb-0b5b-419c-b07f-503240ec2d11" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1bb214c7-6f37-4bd2-bb50-eb1a144d7b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_InterestRateCollarMember_f09bc691-fc02-4030-ac69-99623e99c2d3" xlink:href="asth-20240331.xsd#asth_InterestRateCollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1bb214c7-6f37-4bd2-bb50-eb1a144d7b70" xlink:to="loc_asth_InterestRateCollarMember_f09bc691-fc02-4030-ac69-99623e99c2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cd1c722d-a4e7-489a-ac03-7c5c09a75f79" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dc950cc9-35dc-4a16-8556-e6632cdf42d0" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cd1c722d-a4e7-489a-ac03-7c5c09a75f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_b652eb5d-a53b-44b6-b572-631fba8fcc69" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cd1c722d-a4e7-489a-ac03-7c5c09a75f79" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_b652eb5d-a53b-44b6-b572-631fba8fcc69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_DMGAndSunLabsMember_110ea9d2-2721-4a6b-ab11-07783eb5ea5e" xlink:href="asth-20240331.xsd#asth_DMGAndSunLabsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b652eb5d-a53b-44b6-b572-631fba8fcc69" xlink:to="loc_asth_DMGAndSunLabsMember_110ea9d2-2721-4a6b-ab11-07783eb5ea5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_DmgMember_2ce1162f-393a-4a25-9538-cfcf61db3585" xlink:href="asth-20240331.xsd#asth_DmgMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b652eb5d-a53b-44b6-b572-631fba8fcc69" xlink:to="loc_asth_DmgMember_2ce1162f-393a-4a25-9538-cfcf61db3585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_36d5cd1a-737b-4ce4-8fe5-6e0625830898" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dc950cc9-35dc-4a16-8556-e6632cdf42d0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_36d5cd1a-737b-4ce4-8fe5-6e0625830898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_074185cc-8d7d-4828-a713-3681dc6185c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_36d5cd1a-737b-4ce4-8fe5-6e0625830898" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_074185cc-8d7d-4828-a713-3681dc6185c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ApolloSunLabsManagementLLCMember_1eb8237d-f0be-4123-9be6-95ee7b6fed76" xlink:href="asth-20240331.xsd#asth_ApolloSunLabsManagementLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_074185cc-8d7d-4828-a713-3681dc6185c6" xlink:to="loc_asth_ApolloSunLabsManagementLLCMember_1eb8237d-f0be-4123-9be6-95ee7b6fed76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_VOMGMember_7233702c-8a06-42fc-b49d-edda445476cf" xlink:href="asth-20240331.xsd#asth_VOMGMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_074185cc-8d7d-4828-a713-3681dc6185c6" xlink:to="loc_asth_VOMGMember_7233702c-8a06-42fc-b49d-edda445476cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AAMGMember_ab67e6c9-0bf7-4326-b7e1-ad634da4b441" xlink:href="asth-20240331.xsd#asth_AAMGMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_074185cc-8d7d-4828-a713-3681dc6185c6" xlink:to="loc_asth_AAMGMember_ab67e6c9-0bf7-4326-b7e1-ad634da4b441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_AdvancedDiagnosticAndSurgicalCenterIncMember_c3ecdb63-a425-4bda-9e52-d025ae832fc9" xlink:href="asth-20240331.xsd#asth_AdvancedDiagnosticAndSurgicalCenterIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_074185cc-8d7d-4828-a713-3681dc6185c6" xlink:to="loc_asth_AdvancedDiagnosticAndSurgicalCenterIncMember_c3ecdb63-a425-4bda-9e52-d025ae832fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_CommunityFamilyCareMedicalGroupIPAInc.Member_59aecc36-fbaf-41a6-8606-712e61ab077f" xlink:href="asth-20240331.xsd#asth_CommunityFamilyCareMedicalGroupIPAInc.Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_074185cc-8d7d-4828-a713-3681dc6185c6" xlink:to="loc_asth_CommunityFamilyCareMedicalGroupIPAInc.Member_59aecc36-fbaf-41a6-8606-712e61ab077f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PCCCVMember_c857026f-7057-48ce-b88b-8feb666bfabc" xlink:href="asth-20240331.xsd#asth_PCCCVMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_074185cc-8d7d-4828-a713-3681dc6185c6" xlink:to="loc_asth_PCCCVMember_c857026f-7057-48ce-b88b-8feb666bfabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_d73387e6-8397-4b3c-a768-fc4e965e89d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dc950cc9-35dc-4a16-8556-e6632cdf42d0" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_d73387e6-8397-4b3c-a768-fc4e965e89d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c5635bef-b650-4e6b-8853-367f34f15838" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d73387e6-8397-4b3c-a768-fc4e965e89d2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c5635bef-b650-4e6b-8853-367f34f15838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember_419e8db2-e497-4d7b-a49c-5e87875cf69c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c5635bef-b650-4e6b-8853-367f34f15838" xlink:to="loc_us-gaap_OtherLiabilitiesMember_419e8db2-e497-4d7b-a49c-5e87875cf69c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_04a7230e-e3dc-455f-8933-ae27583d1441" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c5635bef-b650-4e6b-8853-367f34f15838" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_04a7230e-e3dc-455f-8933-ae27583d1441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_a18783a0-375e-482b-b967-126cc558628c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dc950cc9-35dc-4a16-8556-e6632cdf42d0" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_a18783a0-375e-482b-b967-126cc558628c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_c5358b62-26bb-4160-9820-e45005e2a358" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_a18783a0-375e-482b-b967-126cc558628c" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_c5358b62-26bb-4160-9820-e45005e2a358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_A2023MetricMember_7517d887-2165-43e2-9a08-a62e50323e10" xlink:href="asth-20240331.xsd#asth_A2023MetricMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_c5358b62-26bb-4160-9820-e45005e2a358" xlink:to="loc_asth_A2023MetricMember_7517d887-2165-43e2-9a08-a62e50323e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_A2024MetricMember_a0efb500-2e80-4443-88fc-6453ceffb88a" xlink:href="asth-20240331.xsd#asth_A2024MetricMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_c5358b62-26bb-4160-9820-e45005e2a358" xlink:to="loc_asth_A2024MetricMember_a0efb500-2e80-4443-88fc-6453ceffb88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_FirstMetricMember_e92c0ad8-afd5-478b-b881-27d9cb917b1a" xlink:href="asth-20240331.xsd#asth_FirstMetricMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_c5358b62-26bb-4160-9820-e45005e2a358" xlink:to="loc_asth_FirstMetricMember_e92c0ad8-afd5-478b-b881-27d9cb917b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_SecondMetricMember_9de7bec4-0565-4284-8efe-9ad8b193cc01" xlink:href="asth-20240331.xsd#asth_SecondMetricMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_c5358b62-26bb-4160-9820-e45005e2a358" xlink:to="loc_asth_SecondMetricMember_9de7bec4-0565-4284-8efe-9ad8b193cc01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_ThirdMetricMember_7e138d6c-94b6-4b34-9a19-46dba3abeaa4" xlink:href="asth-20240331.xsd#asth_ThirdMetricMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_c5358b62-26bb-4160-9820-e45005e2a358" xlink:to="loc_asth_ThirdMetricMember_7e138d6c-94b6-4b34-9a19-46dba3abeaa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f37cdaa0-69d7-4758-b79d-11e0d3b71320" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dc950cc9-35dc-4a16-8556-e6632cdf42d0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f37cdaa0-69d7-4758-b79d-11e0d3b71320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_MarketableSecuritiesCurrentMaturityPeriod_4a6c112c-d999-4c28-8fba-eff1e606d369" xlink:href="asth-20240331.xsd#asth_MarketableSecuritiesCurrentMaturityPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f37cdaa0-69d7-4758-b79d-11e0d3b71320" xlink:to="loc_asth_MarketableSecuritiesCurrentMaturityPeriod_4a6c112c-d999-4c28-8fba-eff1e606d369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bed9106d-57b0-4908-9280-6ed2c7ef03e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f37cdaa0-69d7-4758-b79d-11e0d3b71320" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bed9106d-57b0-4908-9280-6ed2c7ef03e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_152f4d38-4ff0-4608-834e-a718544045ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f37cdaa0-69d7-4758-b79d-11e0d3b71320" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_152f4d38-4ff0-4608-834e-a718544045ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_DerivativeCeilingInterestRate_7e4a5370-f91d-49ed-9fb1-79802e2ea6cd" xlink:href="asth-20240331.xsd#asth_DerivativeCeilingInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f37cdaa0-69d7-4758-b79d-11e0d3b71320" xlink:to="loc_asth_DerivativeCeilingInterestRate_7e4a5370-f91d-49ed-9fb1-79802e2ea6cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFloorInterestRate_ea52b7f5-f9d1-42c9-9a00-54bab449ddbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFloorInterestRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f37cdaa0-69d7-4758-b79d-11e0d3b71320" xlink:to="loc_us-gaap_DerivativeFloorInterestRate_ea52b7f5-f9d1-42c9-9a00-54bab449ddbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_1d3c9592-08fe-47e7-baee-b64edbd7ac9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f37cdaa0-69d7-4758-b79d-11e0d3b71320" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_1d3c9592-08fe-47e7-baee-b64edbd7ac9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_c186aee6-5e70-4588-81dc-7ba5b0c4a9d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f37cdaa0-69d7-4758-b79d-11e0d3b71320" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_c186aee6-5e70-4588-81dc-7ba5b0c4a9d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_840a04c2-f6c8-42e2-a486-1c11f7e9ed2f" xlink:href="asth-20240331.xsd#asth_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f37cdaa0-69d7-4758-b79d-11e0d3b71320" xlink:to="loc_asth_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_840a04c2-f6c8-42e2-a486-1c11f7e9ed2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_f479ed4e-bcc0-4aa4-ad4e-319b83fa74a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f37cdaa0-69d7-4758-b79d-11e0d3b71320" xlink:to="loc_us-gaap_EquityMethodInvestments_f479ed4e-bcc0-4aa4-ad4e-319b83fa74a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_061604cf-2d9e-41a0-b1ad-9b7b93d7f451" xlink:href="asth-20240331.xsd#asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f37cdaa0-69d7-4758-b79d-11e0d3b71320" xlink:to="loc_asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_061604cf-2d9e-41a0-b1ad-9b7b93d7f451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationChangeInFairValueOfEquityInterestPurchaseObligation_9fcd2b34-7dfa-4d58-a761-f0a7d74d1411" xlink:href="asth-20240331.xsd#asth_BusinessCombinationChangeInFairValueOfEquityInterestPurchaseObligation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f37cdaa0-69d7-4758-b79d-11e0d3b71320" xlink:to="loc_asth_BusinessCombinationChangeInFairValueOfEquityInterestPurchaseObligation_9fcd2b34-7dfa-4d58-a761-f0a7d74d1411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_38c1b146-8db8-4deb-b0a2-0a110d68a538" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f37cdaa0-69d7-4758-b79d-11e0d3b71320" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_38c1b146-8db8-4deb-b0a2-0a110d68a538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_858d1aa9-4d00-404e-8a2f-c50ce273dc1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f37cdaa0-69d7-4758-b79d-11e0d3b71320" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_858d1aa9-4d00-404e-8a2f-c50ce273dc1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_bfb4adfd-8a45-4afb-ba5c-74a96f09ecda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f37cdaa0-69d7-4758-b79d-11e0d3b71320" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_bfb4adfd-8a45-4afb-ba5c-74a96f09ecda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_BusinessCombinationContingentConsiderationLiabilityEachMeasurementPeriod_8915baa0-280c-420b-a50f-458a266f5db8" xlink:href="asth-20240331.xsd#asth_BusinessCombinationContingentConsiderationLiabilityEachMeasurementPeriod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f37cdaa0-69d7-4758-b79d-11e0d3b71320" xlink:to="loc_asth_BusinessCombinationContingentConsiderationLiabilityEachMeasurementPeriod_8915baa0-280c-420b-a50f-458a266f5db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofGainLossonEquitySecuritiesDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#FairValueMeasurementsofFinancialInstrumentsScheduleofGainLossonEquitySecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofGainLossonEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0bb921ac-b6b7-4f26-a6a1-2c85db3d9cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_85b5215a-8e7e-4835-8b9b-f95c488a1028" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0bb921ac-b6b7-4f26-a6a1-2c85db3d9cc7" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_85b5215a-8e7e-4835-8b9b-f95c488a1028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_40fc8fc6-76aa-4127-87e4-85074f45844a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0bb921ac-b6b7-4f26-a6a1-2c85db3d9cc7" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_40fc8fc6-76aa-4127-87e4-85074f45844a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_a7477cee-8bec-4030-bc86-323da3ff202d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0bb921ac-b6b7-4f26-a6a1-2c85db3d9cc7" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_a7477cee-8bec-4030-bc86-323da3ff202d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="asth-20240331.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_530abca1-4b97-432e-89fe-7f2a7ebafbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_9fca0aa5-3ece-434a-8a8a-f6d1bcfe2fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_530abca1-4b97-432e-89fe-7f2a7ebafbb6" xlink:to="loc_us-gaap_SubsequentEventTable_9fca0aa5-3ece-434a-8a8a-f6d1bcfe2fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_55377c05-8ae6-40dd-b02a-bc356eb88733" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_9fca0aa5-3ece-434a-8a8a-f6d1bcfe2fc1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_55377c05-8ae6-40dd-b02a-bc356eb88733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_91b16089-1218-43f0-8b02-2caed468052a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_55377c05-8ae6-40dd-b02a-bc356eb88733" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_91b16089-1218-43f0-8b02-2caed468052a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a337ef91-0c4e-4ccd-b943-450aa14c8243" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_91b16089-1218-43f0-8b02-2caed468052a" xlink:to="loc_us-gaap_SubsequentEventMember_a337ef91-0c4e-4ccd-b943-450aa14c8243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_55826c75-9580-46f0-9479-db328a1acae2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_9fca0aa5-3ece-434a-8a8a-f6d1bcfe2fc1" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_55826c75-9580-46f0-9479-db328a1acae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_dabaa82a-bf4c-4b89-971f-c0ac4ca442f2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_55826c75-9580-46f0-9479-db328a1acae2" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_dabaa82a-bf4c-4b89-971f-c0ac4ca442f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_IHealthIncMember_409fbc0d-3f92-410b-9d76-d8d780890209" xlink:href="asth-20240331.xsd#asth_IHealthIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_dabaa82a-bf4c-4b89-971f-c0ac4ca442f2" xlink:to="loc_asth_IHealthIncMember_409fbc0d-3f92-410b-9d76-d8d780890209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e0bf48c6-de66-4e68-ac57-617157532bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_9fca0aa5-3ece-434a-8a8a-f6d1bcfe2fc1" xlink:to="loc_us-gaap_DebtInstrumentAxis_e0bf48c6-de66-4e68-ac57-617157532bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bca7a655-8f38-4e6c-9d84-b264adcf14d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e0bf48c6-de66-4e68-ac57-617157532bf1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bca7a655-8f38-4e6c-9d84-b264adcf14d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_IHealthPromissioryNoteMember_940eac3b-89d1-417b-a437-104a460c5794" xlink:href="asth-20240331.xsd#asth_IHealthPromissioryNoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bca7a655-8f38-4e6c-9d84-b264adcf14d6" xlink:to="loc_asth_IHealthPromissioryNoteMember_940eac3b-89d1-417b-a437-104a460c5794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_68e21cf5-3e0a-440b-89b7-acef74cda4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_9fca0aa5-3ece-434a-8a8a-f6d1bcfe2fc1" xlink:to="loc_us-gaap_CreditFacilityAxis_68e21cf5-3e0a-440b-89b7-acef74cda4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_9e736210-d941-419b-9c51-7a09a7130d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_68e21cf5-3e0a-440b-89b7-acef74cda4c1" xlink:to="loc_us-gaap_CreditFacilityDomain_9e736210-d941-419b-9c51-7a09a7130d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_RevolverLoanMember_f80a79a3-e316-4302-98d0-cf660247c8d0" xlink:href="asth-20240331.xsd#asth_RevolverLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_9e736210-d941-419b-9c51-7a09a7130d2c" xlink:to="loc_asth_RevolverLoanMember_f80a79a3-e316-4302-98d0-cf660247c8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_b072b4c7-f1f7-47e4-a2f5-a03142a4b60d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_9fca0aa5-3ece-434a-8a8a-f6d1bcfe2fc1" xlink:to="loc_us-gaap_SubsequentEventLineItems_b072b4c7-f1f7-47e4-a2f5-a03142a4b60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_b3c8f6f8-c358-4cb4-bc42-9bd1d2f5d709" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b072b4c7-f1f7-47e4-a2f5-a03142a4b60d" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_b3c8f6f8-c358-4cb4-bc42-9bd1d2f5d709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_24737f16-8b5a-4f91-88dc-fa8a3b5dc328" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b072b4c7-f1f7-47e4-a2f5-a03142a4b60d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_24737f16-8b5a-4f91-88dc-fa8a3b5dc328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_b90b5ee5-b482-4fe2-9639-614466e6db71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b072b4c7-f1f7-47e4-a2f5-a03142a4b60d" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_b90b5ee5-b482-4fe2-9639-614466e6db71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_24cbb5b4-50c6-461f-904e-1bec61c1a2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b072b4c7-f1f7-47e4-a2f5-a03142a4b60d" xlink:to="loc_us-gaap_LineOfCredit_24cbb5b4-50c6-461f-904e-1bec61c1a2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_90864185-a828-4443-9a27-f0a6ea9cae62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b072b4c7-f1f7-47e4-a2f5-a03142a4b60d" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_90864185-a828-4443-9a27-f0a6ea9cae62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_StockAwardsAndUnitsMember" xlink:href="asth-20240331.xsd#asth_StockAwardsAndUnitsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_asth_StockAwardsAndUnitsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_PerformanceBasedRestrictedStockMember" xlink:href="asth-20240331.xsd#asth_PerformanceBasedRestrictedStockMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_asth_PerformanceBasedRestrictedStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_asth_EmployeeStockPurchasePlanMember" xlink:href="asth-20240331.xsd#asth_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_asth_EmployeeStockPurchasePlanMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>asth-20240331_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 asth-20240331_g1.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X0".17AI9@  34T *@    @  @$2  ,
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M]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$
M @$"! 0#! <%! 0  0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S
M4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC
M9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.T
MM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H
M# ,!  (1 Q$ /P#ZIHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBL7QEXEL/"7AZZU?5'(@A'"+]Z1S]U%]R?\>@HW'&+D
M[+<VJ*^+_&'QC\6^(KR1H-1FTJSS^[M[%S&5'NXPS'\<>PK-T#XH>,=$NEFM
M]>O;A0<F*\E,Z,/3#$X_#!K;V+L>FLJJN-VU<^XJ*X?X3_$&T\?:&TZ1BVU*
MV(2ZMLYVD]&7U4X./3!'N>XK)IIV9YTX2IR<9+5!1112("BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BO#/VG?&=UHMCI>BZ1>SVE[<L;
MF:2WD,;K&N0HR#G#-G_OBOGK_A,O$_\ T,>M?^!TO_Q5:QI.2N>CA\NG6@IW
MM<^^**^!_P#A,O$__0QZU_X'2_\ Q5=S\%_B)JUA\0-/CUO5[^[T^]/V21;J
MY>14+XVL Q(&&V\^A--T6E<NIE<X1<E*]CZ_HHHK$\L**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %?.O[7%_,%\.:>I(MV,UPX[,PVJOY M_P!]5]%5
MY)^T?X-N?$_A*"^TR)IK_2F:01*,M)$P&\ =R-JG\#WJZ;2DKG7@9QA7BY'R
M)11178?4'JW[,]_-:?%*UMXB?*O+>:*4=B I<?J@_.OL"OF[]EOP9<B^N/%=
M]$T=LL;6]GN&/,8GYW'L -N>^3Z5](URU6G+0^<S*<95_=Z!11161YX4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH?#NH&S\^.9YL1(^[!0+]Y3C'S=/6JC%R=D:T:,JTU".[/<**^*_^%S>/O\
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M$NB!O3[?%G_T*G9E*$GLC?HJE8:OINH?\>&H6=U_UPF5_P"1J[2$TUN%%%%
M@HHHH **** /._VA/^2/^(/I!_Z/CKXMK[2_:$_Y(_X@^D'_ */CKXMKIH_"
M?093_!?K^B"OT.T[_D'VO_7)?Y"OSQK]#M._Y!]K_P!<E_D*5?H8YOM#Y_H6
M****YSQ0KY3_ &J]22Y\=V-E&P/V.R7?[,[$X_[YVG\:^E/%OB/3_"N@W.K:
MM*([>%>%S\TC=D4=R?\ /%?"WBK6[GQ)XBU#6+[_ %]Y*9" <A1T"CV   ^E
M;48ZW/5RNBW4=1[(RJ^MOV6O^2:2_P#80E_]!2ODFOK;]EK_ ))I+_V$)?\
MT%*TK?"=V:?P/F>P4445RGS@4444 ?&'[0__ "6#7OI;_P#I/'7G%>C_ +0_
M_)8->^EO_P"D\=><5VP^%'UN&_@P]%^1[Y^R1_R'?$/_ %[1?^A&OIJOF7]D
MC_D.^(?^O:+_ -"-?35<U7XCP,Q_WA_+\@HHJCJ&L:9IW_(0U&SM/^N\ZQ_S
M-9G$DWHB]16#'XS\+R-MC\2:*S>BWT1/_H5;%K=6]Y%YEI/%/'_>B<,/S%%F
M-QDMT34444$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 ([K&C.Y"JHR2>@%9OAG6K7Q%H-EJUAN^S7
M<?F(&ZCL0?<$$5R_QO\ $ \._#75IU?;<72?8X.>2TG!Q[A=Q_"N-_97\0"^
M\'WFBROF;39]\:D_\LI,G_T(/^8J^7W>8Z8X=N@ZW9_U^A[;1114',%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 444C,%4LQ 4#))Z"@#P/]JW
MQ-]GTK3?#=N^)+IOM5P ?^6:G" ^Q;)_X!7S-75?%#Q*?%GCG5=55BUN\OEV
MX](E^5?S S]2:Y6NR$>6-CZK"4?8TE'J=E\(?#?_  E/Q TJPD3?:I)]HN>.
M/+3D@_7A?^!5]R5X)^REX;^S:+J7B*=,27C_ &: D?\ +-.6(]BV!_P"O>ZP
MJRO*QXN95O:5N5;(*^5OVIO#7]G>++378$Q!J<6R4@=)HP!^J[?R-?5-<'\;
M_#7_  D_PZU*WB3?=VJ_;+?C)WH"2![E=P_&IIRY9&6"K>RK)O9Z'Q+7;?!O
MQ/\ \(I\0--O97V6<S?9;KG \M\#)]@=K?\  :XFBNMJZL?33@IQ<7U/T6HK
M@O@CXG_X2GX>:=<2OOO+4?8[G)Y+H!@GZKM/U)KO:XFK.Q\C4@Z<G!] HHHI
M$!1110 9QUKQ?XC_ !WTO0)I;#PW%'JVH(2K3%L6\9^HY<_3 ]ZY?]HOXG3?
M:I_">@3F../Y=0GC."Q_YY ^@_B]>G8Y^>:WITKZR/8P67*454J_<=EXE^)O
MB[Q$[_;M:N8X6_Y86K>3&!Z87&?QS7',S.Q9R68G)).2:$5G8*BEF8X  R2:
M[#2OACXTU6-9+3P[?;&Y#3*(0?\ OLBM](GK_NZ*Z)?<<=5BQOKNPF\VPNI[
M:4?QPR%#^8KN)_@WX]A3<_AZ0C_8N(7/Y!R:Y36_#NLZ$X76=+O;')P#/"R!
MOH2,'\*$T]@C5ISTC),[;PM\:O&6A.BS7XU2V'6*^&\D?[_#9^I/TKZ"^&_Q
M>T'QF\=FY.FZNW M9V!$A_Z9OT;Z<'VKXRI49D8,A*LIR"#@@U$J<9'-7P%*
MJM%9^1^BM%>&_ #XJR:_L\.>(YM^J(O^BW+GFX4#E6_VP.<]P/4<^Y5S2BXN
MS/GJU&5&?),\0\2_M"Z1IEY=V=AHM_=7%O(T),SI$A920<$;CCCTKQ3XA?%/
MQ#XV4V][*EIIN<BSMLJC>A<]6/UX] *YCQ;_ ,C5K/\ U^S?^AFLJNJ,(K5'
MT=#!T:=I16H44459UG1^"_&FM>#+FYGT"XC@DN$"2%XE?(!R.HKK/^%Z>._^
M@E;_ /@)'_A7F%%2XI[HRE0I3?-**;/3_P#A>GCO_H)6_P#X"1_X5[?^SYXT
MUKQGI.KSZ_<1SR6\Z)&4B5, J2>@KY!KZ:_9(_Y /B#_ *^8_P#T$UG4BE'1
M'#CZ%*%!RC%)Z'OE?+/Q4^*OC/0OB#K6FZ5K/D65O,%BC^RPMM&T'JR$GD]S
M7U-7Q%\</^2K>(_^NX_] 6LZ*3>IPY93C.HU-7T+G_"Z_B!_T'__ "3M_P#X
MW7O'[._B[6_%VA:K<>(;W[9-!<K'&WE)'M4KG'R*.]?(5?27[,>IV>B^ _$V
MHZE,L%G;7*R22-V 0?F>P'<UK4BN71'?CZ%.-%N$5?3H>]ZE?VFF6,UYJ-Q%
M;6L*[I)96"JH]R:\'\;?M$6UO));>$+ 797C[9=Y6,^ZH,,1[DCZ5Y+\5?B-
MJ/CS5F+L]OI$+'[-9@\ ?WW]7/Z=![\)2A26\C/#99&*YJVK['?:M\7_ !QJ
M;L7UV:W0]$M46(#\5&?S-:WPA\8>)=1^)F@VU_X@U>YMI;C$D,MY(R.-IX*D
MX->5UV_P2_Y*KX<_Z^?_ &5JMQ23T.VK1IQI2Y8K9]#[?HHJAKNKV6A:3<ZG
MJDZP6=LF^1V_D/4D\ =R:XSY9)MV18O[RVT^SEN[Z>*WMH5W22RL%51ZDFO
M_'O[0L,$DEIX,M%N"/E-]=*0GU1."?J<?0UY5\5?B5J7CO4F4L]MHT39M[,'
MC_??U;]!T'<G@:Z(4EO(]S"Y;&*YJVK['2^(O'7B?Q$['5]:O9D;K"LFR/\
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M^>::=F%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK1116)Y05B>-M:'AWPCJ^K\%K2V>1 >A?&%'XL0*VZ\Y_:&+#X0Z[LS_ ,L
M?IY\=.*NTC6C%3J1B^K1\9W$TES<2SSNTDTK%W=CDLQ.231;02W5Q%!;H9)I
M7$:(O5F)P!^=1UO> ;R#3_''A^\O"%MH+^"21CT51("3^'6NUGULGRQ;1];?
M"OX8Z5X)TR&62&*YUQT!GNV7<5)ZK'G[JCIQR>_H/0J.O2BN)MMW9\A4J2J2
MYIN["HKJWAN[=X+J&.>"0;7CD4,K#T(/!J6BD0?.?QJ^"UM;6-QKW@Z$Q"$&
M2YT]>5V]WC],=2OITQC!^=:_1;KUKS_0_A!X-TC4Y[]=+6[GDE:5!='S(X<G
M.U$^[@=L@GCK6T*ME9GK87,O9P<:NO8^6O /@SQ;KNH6M[X9L+A3#(LD=ZW[
MN)&4Y!WG@X/89/M7V]8?:?L-O]O$0N_+7SA"24#X^;:2 <9SC-3(JHH5 %51
M@ #  I:B<^8Y,5BWB6FU:Q5;3;%F+-96Q).23$O/Z4G]F6'_ #XVO_?E?\*M
MT5!RW9\:?M%11P?%;4TAC2-!%!A47 '[M>U>:5Z=^TA_R5K4_P#KE!_Z*6O,
M:[8?"CZO"_P8>B/=OV4+:"YU[7A<0QR@6T9 = V/F/K7TK_9EA_SXVO_ 'Y7
M_"OF_P#9(_Y#_B#_ *]8_P#T,U]-US5?B/"S%OZP_E^14_LRP_Y\;7_ORO\
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MEU:2F)P.AQT(]B,$>QK.KK/I$TU='3?##_DH_A?_ +"=O_Z,6OO"O@_X8?\
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M'\.Z"FA:9*4U/4D/F.IPT4'0GV+'('L&]J^3JZ7XC^))/%GC35-69B8I92L
M/\,2\(/R )]R:YJNR$>5'U.#H*A24>O4*]M^$/P3F\16\.L>*#+::4X#PVR_
M++<+V8G^%3^9[8X)Q_V?? :>+O$SWVIQ;](TTJ\B,.)I#]U/<<9/T [U]@@
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M?/\ 0G=%D1D=0R,,%2,@BJO]F6'_ #XVO_?E?\*MT5SGC7:*G]F6'_/C:_\
M?E?\*^!?$H"^(]5"@ "[E  [?.:_06OS[\3?\C)JW_7W+_Z&:WH[L]C*6W*7
MR,VOJ_\ 9ALK6X^&\KSVT$K_ &^4;GC#'&U/6OE"OK;]EK_DFDO_ &$)?_04
MJZWPG5F?\#YGJO\ 9EA_SXVO_?E?\*/[,L/^?&U_[\K_ (5;HKE/G>9C8HTA
MC"1(J(.BJ, ?A3J**!'QA^T/_P E@U[Z6_\ Z3QUYQ7H_P"T/_R6#7OI;_\
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M+7F->G?M(?\ )6M3_P"N4'_HI:\QKMA\*/K,+_!AZ(][_9(_Y#_B#_KUC_\
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M6MITF&/56!_I76]CZ::YHM'Z%T4RWFCN((YH6#Q2*'1AT((R#3ZX3XX****
M"BBB@ K$\<.(_!7B!W^ZNGW#'Z"-JVZX7XX:FNE?"S7Y"V&F@^RJ/4R$(?T)
M/X4X[FE*/-4BEW/B.BBBNX^O/T+TG_D%67_7!/\ T$5;JII/_(*LO^N"?^@B
MK=<!\:]PHHHH$%%%% !7YV3?ZY_]XU^B=?G9-_KG_P!XUO0ZGLY1]OY?J,KZ
ML_9/_P"2?:E_V%'_ /145?*=?5G[)_\ R3[4O^PH_P#Z*BJZOPG7F?\  ?JC
MVJBBBN4^;"BBB@ HHHH *S/%'_(LZO\ ]><W_H!K3K,\4?\ (LZO_P!><W_H
M!IK<J'Q(_/RBBBNX^Q/KS]F'_DEZ?]?DW_LM>M5Y+^S#_P DO3_K\F_]EKUJ
MN*?Q,^4Q?\>?J?%O[0BE?B_K^>Y@(_[\1UYW7K7[3UD;7XH/,1@7=G#,#ZXR
MG_LE>2UUP^%'TF%=Z,/1&CHNAZKKDDD>C:;>7[Q ,ZVT+2%0>YP.*UO^%?\
MC#_H5]:_\ I/\*]&_91O5A\<:G:,<?:+ LON5=>/R)_*OJFLYU'%V.+%X^="
MIR)'PA_PK_QA_P!"OK7_ (!2?X4?\*_\8?\ 0KZU_P" 4G^%?=]%1[9]CF_M
M:?\ *CX0_P"%?^,/^A7UK_P"D_PH_P"%?^,/^A7UK_P"D_PK[OHH]L^P?VM/
M^5'PA_PK_P 8?]"OK7_@%)_A1_PK_P 8?]"OK7_@%)_A7W?11[9]@_M:?\J/
MA#_A7_C#_H5]:_\  *3_  H_X5_XP_Z%?6O_  "D_P *^[Z*/;/L']K3_E1#
M9J4LX$;AEC4'ZXKQK]K!2? .F,.@U- ?^_4M>UUY7^TO8F[^%=U*HS]DN89S
M[?-L_P#9ZB'Q(XL([5XOS/CVK6DN(]5LW;[JS(3]-PJK178?5/4_1:BLOPMJ
M2ZSX:TK4D.1=VL<WXLH)'YUJ5P'QK33LPHHHH$%%%% !2,P52S'  R32U@>/
M]371O!&NZ@S;3!9RLGNY4A1^+$"A%1BY-11\$N=SL1QDYI***[S[$^\/AC_R
M3CPO_P!@RV_]%K735S/PQ_Y)QX7_ .P9;?\ HM:Z:N%[GQ]7XWZGG?[0G_)'
M_$'T@_\ 1\=?%M?:7[0G_)'_ !!](/\ T?'7Q;711^$]W*?X+]?T05^AVG?\
M@^U_ZY+_ "%?GC7Z':=_R#[7_KDO\A2K]#'-]H?/]"Q1117.>*%?GWXF_P"1
MDU;_ *^Y?_0S7Z"5^??B;_D9-6_Z^Y?_ $,UO0W9[&4?%/Y&;7UM^RU_R327
M_L(2_P#H*5\DU];?LM?\DTE_["$O_H*5=;X3KS3^!\SV"BBBN4^<"BBB@#XP
M_:'_ .2P:]]+?_TGCKSBO1_VA_\ DL&O?2W_ /2>.O.*[8?"CZW#?P8>B_(]
M\_9(_P"0[XA_Z]HO_0C7TU7S+^R1_P AWQ#_ ->T7_H1KZ:KFJ_$>!F/^\/Y
M?D%%%%9G"%%%% 'SO^UY_JO"O^]=?^TJ^<:^COVO/]5X5_WKK_VE7SC772^%
M'TV7?[O'Y_FSMO@K_P E4\-_]?7_ +*:^X*^'_@K_P E4\-_]?7_ +*:^X*R
MK;GG9M_$CZ!1116)Y04444 %%%% !1110 4444 %%%% !1110 4444 %%%97
MB;Q!IGAC2)=2UJZ2VM8^,GDLW95'4D^@H&DY.R-6BOG36/VDL73+HWA_=;@\
M274^&8?[J@@?F:Z/P/\ '[1=;O([+7K1M'GD.U)C)YD!/NV 5_$8]2*MTY6O
M8ZI8&O&/,XGM%% .1D<BBH.0**** (;RU@O;66VNX8Y[>92DD<B[E=3U!!ZB
MOD+XX?#%_!.I"_TM7DT"Z?$9/)MWZ^6Q]/0_@>1D_8=9WB'1K/Q!HMYI6IQ"
M6TNHS&Z]QZ$>A!P0?45<)N+.K"8F6'G?IU/SZHK;\:>';KPIXFO]&ON9+:3"
MOC D0\JX^H(/Z5E6=M->W<-K:QM+<3.L<<:C)9B< #ZFNN_4^H4E)<RV.J^&
M'@:]\=^(EL;8F*SBP]W<XR(D]O5CT _H#7VEX:T'3O#6CP:9H]NMO:0C@#JQ
M[LQ[L>YK&^%_@VW\$>$[;38@K7;#S;N8?\M)2.?P'0>P]S76URU)\S/F\;BW
M7G9?"OZN%%%%9G"%%%% !17F'Q(^,NA>#;N33X(WU358^'@A<*D1]'?G!]@"
M?7%>>6G[2ER+D?;/#D)MR>?*NB& _%<']*M4Y-72.J&"KU(\T8Z'TE17,> _
M'&B^-]-:ZT6=B\>!-;RC;+"3TW#T]",BNGJ6K:,YY1E!\LE9A1112)"BBB@
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M7!PZECG&,J1C!YZUSQCS.R/#H476GR1/8?$WBK0_#%OYVO:G;6:D95';+O\
M[J#YC^ J'P1XNTOQGI#ZCHKR-;I,T#"5=K!ACMGH001[&O@^[NKB\N'N+R>6
MXGD.7DE<NS'U)/)KT/X'_$#_ (0?Q(R7S,=&OML=R!SY9'W9 /;)S['U K5T
M;+3<].IE?+2;B[R/LVBH[:>*ZMXI[:5)8)5#I(C;E93R"".HJ2L#Q@HHHH @
MO[.VU"RFM+Z".XM9E*212+N5E/8BOAKXH>&D\)>.M4TB L;:)P\!8Y/EN RC
M/<@'&?:ONROBCX[:U;ZY\3M7N+)UDMX2ELKJ<ABBA6/TW;OPK:C>YZN4RE[1
MI;6. KVG]E.\:'Q]?VN3Y=Q8,2/]I70@_D6_.O%J]H_93LGF\?7UU@^5;V#@
MG_:9T 'Y!ORK:I\+/5QMO82OV/JZBBBN,^5/C?\ :0'_ !=G4_\ KE!_Z*6O
M,:]@_:DL6MOB1%<8^2ZL8W!]U+*1_P".C\Z\?KMA\*/J\([T(>A[W^R0?^*@
MU\=_LL?_ *&:^FZ^._V<O$EOX?\ B$D5](L5MJ4)M-[' 5R0R$_4C;_P*OL2
MN>JO>/$S.+5=M]0HHHK(\\*^(OCA_P E6\1_]=Q_Z M?;M?$7QP_Y*MXC_Z[
MC_T!:VH[GJ93_%?H<-7T5^R%U\5_]NG_ +6KYUKZ*_9"Z^*_^W3_ -K5K5^%
MGIYA_N\OE^:/HRBBBN0^8"BBB@#QG]J71&U#P);:G$NZ33;D,YQTCD^4_P#C
MVROD^OT'U[2[?6]%OM,O5S;W<+0OZ@,,9'N.HKX*\2:-=>'M>OM)U!=MS:2F
M)N.&QT8>Q&"/8UTT9:6/>RJLI0=-]"A;S26\\<T+%)8V#HPZJ0<@U]Z> _$<
M'BOPEINL6Y7-Q$/-0?P2#AU_ @_ABO@BO5/@3\2?^$*U9[#578Z%>N#(1S]G
MDZ"0#TQ@-[ 'M@NK#F6AMF&&=:G>.Z/L*BH[:>*ZMXY[:5)89%#I(C!E93T(
M(ZBI*Y3YL**** "BBO(OCI\48/"FFS:/HTZOK]PFTE#G[(I'WC_M8Z#\3VRX
MIR=D:4J4JTE")XS^T7XJ3Q%X^DM;60/9:4IM4(.0TF<R$?CA?^ UY9022222
M2>2317:E96/K*5-4H*"Z'3?##_DH_A?_ +"=O_Z,6OO"O@_X8?\ )1_"_P#V
M$[?_ -&+7WA7/6W1XN;?''T"OAOXQ_\ )4/$O_7XW]*^Y*^&_C'_ ,E0\2_]
M?C?THH[BRG^)+T.-KZ2_9%_X\?$__72W_E)7S;7TE^R+_P >/B?_ *Z6_P#*
M2M:OPL]',?\ =Y?+\SZ$HHHKD/F0HHHH *^:/VN/^0OX<_ZX3?\ H2U]+U\T
M?M<?\A?PY_UPF_\ 0EK2E\1W9=_O$?G^1X!7I?[.?_)7-'_W)_\ T2]>:5Z7
M^SG_ ,E<T?\ W)__ $2]=,_A9[V*_@S]&?9=<7\9=$/B#X:ZY9Q+NG2'[1$
M.2T9#X'N0"/QKM*",C!Z5QIV=SY6$W"2DNA^=-%=K\8/"3^#_'-]8I&5L9F^
MT6AQP8F)P/\ @)ROX5Q5=J=U<^OA-3BI1V9]D_L]^*4\1?#VTMY) ;[2P+29
M2>=H'[MOH5P/JIKTVOAGX6^-KKP+XGBU"$-+9R#RKN '_61Y[?[0ZC\NA-?:
MWA_6K#Q!I-OJ6D7*7-G.NY'4]/4$=B.X/2N6I#E=SYW'X9T:CDMF:%%%%9G
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MU4445RGS84444 %%%% !69XH_P"19U?_ *\YO_0#6G69XH_Y%G5_^O.;_P!
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M="DU#5) 9""MO;*?GG?^Z/;U/:OB7Q7K]]XGU^\U?5'WW-R^X@?=1>@5?8#
M%:TH7=ST\MPSG/VLME^9DT445U'T!]X?#'_DG'A?_L&6W_HM:Z:N9^&/_)./
M"_\ V#+;_P!%K735PO<^/J_&_4\[_:$_Y(_X@^D'_H^.OBVOM/\ :"!;X0>(
M .>(#_Y'CKXLKHH_">[E/\%^OZ(*_0[3O^0?:_\ 7)?Y"OSQK]"=#GCNM%L+
MB%@T4MO'(C#N"H(-*OT,LWVA\_T+M%%%<YX@5^?GB<8\2ZL#_P _<W_H9K]
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M %W'_H"U]NU\1?'#_DJWB/\ Z[C_ - 6HH[G+E/\5^APU?17[(77Q7_VZ?\
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MV]!T'YDN4U'1&E?%0HM4X[NWR/D*BBBM#L/T+TG_ )!5E_UP3_T$5;JII/\
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M2?L]>#68E9M70>BW"8_5*]AHJE.2ZF\<36BK*3/'/^&>/!__ #\ZS_X$1_\
MQ%=O\/O >E>!+2[M]&DNY$NG61_M+JQ! P,845UE%#FWHV$\35J+EE*Z"O+?
M%7P1\-^)?$%[K%_>:O'<W;AW6&:,(#@#@&,GMZUZE123:V(IU9TG>#L>,?\
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M/P7E1^ KT>BFFUL:0JSI_ ['CI_9Y\'$\7.LCV%PG_Q%)_PSQX/_ .?G6?\
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E** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>exhibit1021-independentc001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit1021-independentc001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4+^6$V9Z$YR?^ UD^!=+GU'7-9NK>^=8[/Q$MQ+;[T$;H&?+'//&<]<<=,T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *1LXXI:* .)\;^&M7\0O:BR3
M19(H@=RZG TF"?[N*Y7_ (5SXFVHOD>#0J'*+]A?"GV]*]@HH \[FT?XE7,:
MI-JWAUT5U=5-FY 92"I&>X(!_"L\^"?&+7$]P[^$GFG<O+(^F%F=CW)->J44
M >;#P[\018/8C4O#2V;J4:!;!@A!ZC XJHG@CQ>B*B-X/"J, ?V5V_*O5**
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M )GS6/\ OU#_ /$UW]% 'GY\!:^W7QYK)^D<(_\ 9:4> M9 ^;QYKF?I$/\
MV6N_HH \_P#^%?ZJ3_R/6N?^0_\ XFE_X5]J9X;QOKI'UC_^)KOZ* . _P"%
M=WW?QIK_ /WW'_\ $T?\*ZNSU\9^(#])4'_LM=_10!P/_"N;GOXQ\1?]_P!/
M_B:/^%<3_P#0W>(__ A/_B:[ZB@#@?\ A6[]_%OB/'_7RO\ A2CX<#OXL\1'
M_MZ'^%=[10!P?_"N$_Z&GQ'_ .!8_P *3_A6T9_YFGQ'_P"!8_PKO:* ."_X
M5BG_ $-'B'_P,/\ A1_PK*'OXG\0X_Z_37>T4 < ?A;:-][Q'XA;_N(,*/\
MA55C_P!#!XA_\&+UW]% 'G__  JC33UU[Q#G_L(O6QX:\%6OAF[FN(-1U.Z:
M50I6[N3(H]Q7444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !116==^(-%L)W@O-7L+>:/&^.:Y1&7(R,@GC@T :-%8MSXP\.6EG-=RZY8&
M&$ R-'.KD ].%))S["MA)%EC61#E& 93Z@T .HJAI.LZ?KMHUWIERMQ LC1%
MU! W*<$<BK] !16-8^*M$U/47T^ROTFNT^_$J-E/KQQ^-;- !15'5]9T_0;
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M//)!QZT =I1137=8T9W8*JC)8G  H =16*^LW&H:39:AX>@BOHKB=59I)/+
MBR0SCUQC@=ZVLT %%-9U498@#IR:=0 44T2(7*!E+#J,\BD\V/?LWKO_ +N>
M: 'T4A( )/ '>FB:,H7#J4'5L\4 /HKD_#?B#6M?:RU%+2Q_L:[61ODD/G0
M$[-V>&W8Z #&>^,U!?>)=?B\=#PU:6.FOOM#>1SS3.O[O=MP0%/S9_"@#LZ*
MY?2_%D[^(_\ A'=:TW[!J31&6!XY?-@N5'WBC$ @CT(S72)<0R2O$DL;2)]]
M P)7ZCM0!)142W,+3M LT9F49:,,-P'J11]J@^T_9O/C\_;N\K>-V/7'7% $
MM%1/=01,BR31H7;8H9P-S>@]3[4Q[CS4N([.6"2YB&-C/PK8X#8Y% %BBN>\
M)>(CKGAZPN[U[:*]NE=O)C;' =EX!.<8%;3WMK'<);R7,*3O]V)I &;Z#J:
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MSBX:S6)&$;[@S;6/(4D=!T..O0W-2\"27&M_VOIOB'4--O)HDAO'B5#]I"C
M8C  ?'<#Z 4 41XC\5ZEXBLM+M$T_3VN=*-XZW$32/;N)%1E.&PW.<?=Z\YQ
MSG_\)]KK66GZ=)9[=9EOKFSN7LX!+_J "S1HS+R0R]3@8)P>!4UUI;VWQ*TZ
MQT>^;3Q;Z*\*3&'SE+>:&V/GJ2,MU!R,UL77P[L+C2;:!;Z\BU&WN7O$U-&
MF\YSEV/;!P!CI@#TH RY_$7C&TT&&:X@MK:X_M*&V5KN$;KB&1PJLR(Y\MAD
MY'?MBI9/%VH^&IO$T.MWD&H-IMI#>0&.'R6;?E2F 3\H8+SU&[DFM"\\"M=Z
M;%;G6[O[5]J2[GO'17>:1,;,@\!5P,*!C]:=<> X-0UO4M0U&_EN4U"S%G-
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MW6W%LD8A;G)!')SQU[@XZX$?CB47TVGZ UK<W5M<N9[Y+=-["!.@([;GVCZ
MUT>CZ5;Z'I-MIEH9#;VZ;(_,;)"]AFH[718+76[S55FN'N+M$CD5V!7:N=H
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MV.C^ _#.@ZK)J>FZ5'!=OD;@S$)GKM!.%_"DLO /A?3M:?5[/28H;QLD.K,
MA/!*KG"GW % 'F;ZEK4?@NYUL:_J9O;'7&M(29_D\OS "&7&'Z_Q9QVQ717.
MKWOA;5?&5I:WE]>O;:9%?6RW<IF$;?,'(SR!DJ<=.#TKK7\#^'GTU]/-D_V1
MYS<O$+F7#2_WC\V<]_KS5Z/P]I<>J3:F+8M>3P^1+(\KMOC_ +I!.,<>G\Z
M//M$@UB.XT_4CKUM]DU&UE5UAO9YWN7\HL' <8C9=O)& .F!P*QM$N+^+1O
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M#=F'RF,;-V &#@#V->T+;P),\R0QK*_WG"@,WU-.:&)I5E:)#(H(5RHR/H:
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MW,.BG.%YR%Z5EVUYK]W\,'UV+5=0FNM.OY9)U%P5,]NK_.I(QC"@G(P1@XH
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MTK1U6\N[*VC:RL3>3R3)$(]Y15!/+,P!PH'/2@"]7//X-TV76+G5C/J*WUP
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M#@G(R.,#T%+H_AG3-"TV;3K&*06DS,SQRRM("6^]]XGK6K)-%$H:21$!Z%F
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MF?\ "2R6T&FPPSVKO;P%4WKN(?*9*CIU!QWJYHGQ+TU_"VF7^OS+97UW"[K
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M6EE:V,;1VMO%"C,781J%W,>I/J?>IZ** "BBB@ HHHH **** "BBB@ HHHH
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MWJQ:K-.;473>7U^1F0'!!YQG@UI:?9Z%J?Q7\3*\.G7-U%;VQA5U5]LB[MY
M]00F3U'%>CK&B9V(JYZX&*!&BL6"*&/4@<T >.Q36UY\+)="D4)XKBN#_HS\
MW/VOS=PE'\7(YW],<9Q6]#?6<?QLBAN;ZU>Y&@+;N=RC=/YV[;CLQ'..N*]$
MV+OW[1N]<<TGE1[]^Q=WKCF@#Q3PT;"ZL;'1=3&N?\)'8W@E^P+E%:7S"?.W
MA, <L2S'/! SQ6UH%P;#Q786=C?IJ6GS7L\OV&>(K<Z:["3<P(_@)W#)X.[C
MKFO4\#=NP,],T;1NW8&3WH \M\'7#66L:=907L6J:.EK*Z--#LN-+7:I*2$<
M8/ YY./05G^')IK+1?!-])#(VGV-[>I>@(3Y#2.XB=AC(&&//;=7L0 !) &3
MUI: /&?%MK%/IOCR^MXI&TZ_6U2WPA(GN5P69 !DC@9/0D'FMJ_>RA^(/GV]
MO]IB;PO)"L$((67#[UC4@<$KG&.:],HH \8T&Y(\9^$[]Y+J2T6PEA"K8ND5
MJ=H A7Y<G;W))]>*ZKX4,/\ A'=1C(8.-3N'PP(.UB"#SV(KO:* /.[1CX*\
M?:Y-?6T_]E:T8[B.]BB9TAD4$,DF =I).0>G(_"]XLO+GQ-X+UJUT*VGFS;J
M4E:-D$QW M&H8 ME01D<?-CKG';44 <#/>6>OZ]X8U/389(WL_,DO)6A9/L\
M/E,#&Y(X.['R^V>G-<[IUA91_!K7Y_L*1:@([SS)'M]DN&9F7D@'!0J1VQ7L
M%9VO:2NNZ%>:4\S0I=1F)W5<D*>N,]Z /,HK8>*+7P4OAYF2ZTZT;[1="%D$
M , 7!) SENPSGD]*<8;K4OAG9^$TM+NW\16LT$0WP/B%DE!,V_&-NT,=V><X
MKT_2; Z7I%II_FF86T2PJY7!*J,#(]< 5=H \\\+6[IXO\:RRZ?)(\MQ'+;&
M: HLVQ2/E9AC[V/YUS6ABZ&O>"KZ:RU2**V:Z2>V739$ALM\9"HH"DGD\MDY
MXSCH/:** /(/])3X4>(-%;3=1%]'/.-GV1R'+SDKM('S<<Y' KH[2];2_'>K
MZA>6=X^G:M;6[VMTEJ[A/+0AHV !92220"!U/>N\HH \DT[2Y](O_!L=Q9W2
MQ)?WET8A;NXM8Y%81*Q (4Y(X['Z9KHO )G76O%PD@N8HIM4:>'S8'C#J0 6
M&X#/3]*[FB@#B?#T;V/Q/\603;LWL5K=P%C]Y I1L?1N*[:J-]I5O?W%M<.9
M([BV</'+$^UL9!*$CJIP,J>#QW J]0!YM9Z#9:S\3?$5QK&@236LJV_V2>[M
M'V,43#@$C;CIUZXXK5URT*>/?"!M]/G:SLDN5=X;9C%"'1509 P.1^'L*[2B
M@#@8%OM"U'Q5:WVGWM_%J4C75I+;VYD60,@00G PI7:!\V!CG-9UYX2UK1?!
MGA:YL8Q>:[H$@;RU/^L23B2,'T (&?137I]% '"^*--N+'P#::=%!<7UVMS;
M22FV@9S(XF625R .,D,>?6J$HU?3=<\4QMI.HWUOK< DLKB!-P4^7M\MPV-F
M,]\?G7I-% 'B]IIVM:1%X;U6X\-:E>VT>DC3KFSB)6:)U<L'"JV2#G'..G..
M*W?[.N8KOPH;?P]-911:A)=RVT,986\;*4!=NA<D@D Y&>G%>ET4 )7'_$A7
MO= M=&MPK7>I7T$42]\*XD9OH%0D^U=C53^S;8ZE_:#(7N0NQ'=B?+!ZA0>%
MS@9QU[T 165_=W.I7]M-IDUM!;E!#<NZE;C())4#D8]_6M"BB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%127
M$$,D<<LT:/(<(K, 6/L.]2T %%%% !14<4\,YD$4J2&-BC[&!VL.H/H>1Q4E
M !1110 45%/=6]L8Q//%$96"1B1PN]CP ,]3[5+0 4444 %%%% !1110 444
M4 %%5KO4+.P,(N[J& SR"*(2N%\QST49ZGVJS0 4444 %%%% !1110 4444
M%%49]7T^VU2VTR:\A2^N59H8&;YG ZD#_/0^E7J "BBFR2)%&TDCJB*"S,QP
M !U)- #J*HZ5K.G:W;/<Z9>17<"2&,R1-E=P )&?Q%7J "BBB@ HJAJ&M:;I
M4UM#?7D<$EU(L4*MU=R< #\:OT %%%% !16;J6O:9I%S96]_=+#->RK#;J58
MF1R0 . <<D=:TJ "BBJ&KZS8:#8F]U*<PVX8(7$;/@GIPH)H OT444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZO;-(HLY%VG=L3)RQ(7& /PZTD.BZO)KVF:I9:%>:-K+W*OJIBE06<T.3NR
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M3:.0>3^/2KESX;\2:;KUIKFCW%E>7LML+;4DN\QK+@E@ZD D8)QCT ZT /\
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M_9YY#<RA0S(IC4JN,XY)Y[ <D [:BN$/C+7KC7M*TVUT2"$ZC9&Y47<KH\!
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M%=9BO=.O+4W"BVS&%CRI*M_$#@'C@9Z]Z]0U6X_XIZZF,%P2]NV(DB9Y,L,
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M=E::Q93W4B!TACF4LRD9R!].:B\8&.;P)KK JZ-IL[*>H/[MB#7G,-KI.I^
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MD>^.<&@#H-.?2?#-Y,^GZ'J,-YJ2?:)=-C,7[E4RN['F>6NXGHK$GTX.'O\
M$S0UT^QO5M]2DANY_LP\NU+&*7./+<9X;V&2>U8'BO3POBRW\27'A>;Q#I5W
M:+;M;"T+3VSJQ(;RV&<$$CM_+,VI"]%EHGD^&9[6--6BOA:V=KS#;HNW]X1Q
MYASG:,D#CM0!I2_%"P@N+:VE\/\ B)+JY5VBMVL0)&V]0 6Y_#BM.7QG#Y(D
MM-+OKDK;)=7$8"(T".NX*P9AE\?PC/X9&<G6TNYOB?X<U"'3KV2SM()DFF6
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MF10S?+"-V @&.F ..O6@#T)O&<;W5PEGI\UU;VM^FGW$R2)F.1F52=N<[06
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M:V/MMIY<TGVJ'9"NZ5O,&$&,Y;T&.>:;9:C8ZE L]C>6]U"Q($D$@=21UY%
M%@(H.0H!]A4?V: W(N/)C\\+L$NT;MO7&>N/:JUKK6EWMY+9VFI6<]U#GS88
MIU9T^J@Y%)-KND6P!GU2RB!F\@;[A1F3 .SD_>P0<=>: +](5#=0#]:Q-2EN
MU\2Z2L.M6MK:GS!-8R*IDNB5RNTGD8P3QZ&G3>,/#-O-)#-XATF.6-BCH]Y&
M&5AP003P: -G:I &!@=.*,#&,<5FS>(]#MGA2?6=/B>=5>)7N44R*WW2N3R#
MV(ZU1O/&>BV7B>WT&6^MUNY$9WWRA1&?EVJ<_P 3;N!UX^E '0;5QC:,>F*
M !@# K%T.>XDO=76?7+3446YS#% JAK5",B-]IY/N>?Y"S8>(-'U6ZEM=/U2
MSNIXAEXX9E<@>O!Z4 :)4'J ?K2%%;J ?J*SI_$>AVJ,]QK.GQ(LGE,SW**
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M?O9 )*D9!P>>><=*IV?CM[JYTJ1](DBTO59C!:79G4LS88C='C*@A3W..^*
M.RHKD]0\:FT.K3VNERWFGZ.VR^G250P8 ,PC0_>VJ03DK[9J2_\ &(@2RCMK
M#=>W<)N%M[JYC@$<0Z,S98#)(P!D]>F#0!U%0I=V\ES);)<1-/& 7B5P64'H
M2.HKD[+XA6FIZ3;36-H\NI7%T]DEB95'[Y!N?,@R-@7G<,\$<9.*I>"ENAX^
M\6FXTRWTT[+3?! X=6)$GSA@J]>3R,T =_1110 4444 %%%% !1110 4444
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MW>[2Z9L*!()'R2?Q%=\%"J%4 *!@ =!6)%X?^RZS=SPO')IVH-YEW9S+N E
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M3^&O$^JZ&ERZ76FO;/J%U<7#&XE*G9$JRDEB ,Y'3('KCUG YX'/7WH "C
M '84 >5>.Y]+;P!H+6S6S+-=VC$1 '<J##9 [+T/ITJYXPNK73?%VDZQ>QWS
MZ#<6;PFYTV:5/*D9PV]C$02& 'KG'M7I5% 'D-XMGIQTGQ#H^G7R>'H-6>ZN
MY&,TDMP7C"^>4DRVT'(R>3R<<\ZF@:Q::E\8-0O+5;E[6YTR..&8VLJJQ#9/
M)7@<'DX!(P*]*HH XGXBW*6)\-7\ZR?9K76(Y)GCC9]B['&2%!/4BL_1]6CT
M+QAXD?7!);0:H(KRSFEB($D83:8\8^^O V]3Z>OHU% ')?#C3+C2O!EO!<0O
M ))99HH'&#%&[EE4CL<'..V:X'Q=J"W\'C'2Y(+JRO$D9H;2SM2HNT4 ^?+(
MJ_-D9X+ 8QP37M=% 'CM_=:7<?8K^RU+4M$UNWTR!(KG[+)Y5V,']TZ%?FY'
M?J"",BO3_#K7;^'=.:_LX[.Z-NGF6T:[5B./N@9. /3M6G10 5YNATS4?B_?
M&\L_M%NVGQVT;SV;-&95<D@,RXZ'KT->D44 >;12Z9IGQB1[2R:WMCI;6;O!
M8LD8G,P8 L%P>!UZ>]5-5M6\5:!KITXS+J>G:F=0TYGMWC/RA3\I*@G)#@>^
M.U>J44 >1>,(KB+P79->6LYUG4M0AU"ZBA@>0Q@'[I(!X10J_A[UOWUI-IGC
MRV\9V=O-=:7>V7V6]\J)GEB&05D"8W$<*" "1@G%=]10!Y]XGB/Q ;3]'TZW
MN/[.BNDN;V]EA>)550<(F\ NQSVR%[]:P=>C;^V]0O/#UKJEEK[7OE&R-K))
M9ZDH8 NQV[!D<EB1C!^M>OT4 %<=\34-WX/;2X^;C4;J"VA .&W&16)'T"D_
MA78U0?28)=734IV>:6)2L"/C9!G[Q4 =3W))/88!.0"C9>(H9/$<_A]['4(9
MH(M\=Q/#B*X4;=Q1^^-PS6/XTN+^/6M'A&GZE<:3()/M,VF1%IT;C:NY?F13
MSDC&?6NJATVV@O[B^16-S< !W=RV%'15R?E'? QSS5N@#P^\M]5A\&ZMIL7A
MW6H;A]?-W"B6K2;8]ZL,,N<X Z],CK73:NC:KX_EDM;#58UO- ET_P"V/83+
M&DCL'0$E1MP"<DXP>#R./2J* /'KR?7+SP3H^@2>%]7%_I=U:K.RP Q,L;8W
M(V<,"%[<#/)[UZU,'GL9 (V5WB/R,1D$CH<''ZU/FB@#R:SL]=;PIX3N[;0[
M]+KP[,JW%K.JHTZ;2DAC4G+$#IG&<\9KI+"TN-;^(47B5;.[M;"WTTVJ_:X3
M%))(9"3A&^8 #N0.HQFNUHH X[QGI>HOKGAO7]/MVNAI,\IGMT(WM%(H5F4'
MJ0!T[YJ&+2KG6O%UYXD%G<6L(TG[!!'<KY<DK,Q<L5/*@9 YP<YXKMZ* /*7
MBUF3P+X:TT^'-46ZTN\LVE0JAW+%@LRX;IZ9QFM/7-+O];\8:D(K"ZBMKWP]
M)IRW,B (LK,6YYSC!_/BO0Z* /./"\&K)!I]I>>";2QO;-E^TWYCB*,J=X]I
MW%VQ]!G.>U7_ (<VE_8+K\5]IUU:&ZU:>]A,R@!HWVXZ$\\<BNXHH XOQ];W
MMS<^'#9:==78L]5BO)C H.V-0P/4CGD<4VV%_;_$'6=3;1[XV4ME'!'*JI\[
MQ[F( W9YS@'&,^E=M10!Y)I&B^)]'\#^'=)N-%O9+>WN9O[2M;6ZC62168M'
MA@^"F6^89&<<\57N/#GB&7PUXOT6+PL\(U&Z2:U6WGA6-1\A"\D<#9SCOP/6
MO8Z3(SB@#B+NTUFX\7>'M0AT:Y2*TLYX97DDAQ&\BJ%R ^2 5YQGVS7.1:3X
MC>WT:^G\+32ZQ::FMQ?7,MU$7GX<$(<\1_,#C@#' /6O6\T9H \EDM-5O=6\
M3)8:'J$NF7MT8;E+&[MTBF(4"0_O/F#$DJQ7&<>H-7K^VUFXUG3_ !?X>T2*
M_B:R.G7.E7,B1/%LD;D,?ERK CO[#G(Z1_A_X?-Y<W,45Y;-<N7G2VO9HDD)
MZY56 YKH[:W@L[:.VMHDBAB4*D:# 4#L!0!P%_I'BJ231/$4.G68O[&XE=M)
MBD50L,B*C)YAP&?Y<YX'.!TYO>';+7CX[U;6=0TD65I>VT"*#=)(RE <Y"]^
M<>GN:[6EH **:'4N4##< "1GD __ *C3J "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_NEY&"V",YXR2>,U.L5W;MXUT_;<Z7##I*7<-K;WSOY$FV0Y#<8)VC('!]Z
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M2^G-I<P1ME)X=N=Y!/5<9W=>>M8MUIMSJVEZM UI/-XJ.IM'!J,$3[43S%(
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MK%1=A-9N7N(HI.6@^T;G&1T!7J?0DT >F6/B'1]3F:&RU.UGE5=^Q) 25_O
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MY"H&.!SD$]:N>'[R.'QOXRNY8[E+>5K5XY&MI '"1!&V_+SAN.*@\'64VK>
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M@Q1<L0>G XK(U73;J6P\<:K'8WX_MB%;6SMEMW+RE8MOF,@&5R<C+8P!SU%
M'9:#XGM?$,MRMK:WL20"-EEN("B3*XR"A/WA_GI6:+K1T^(-[(MEJ/\ :\.F
MY>38_ER0A^B+GYCGN!VZUO:+*)M$LV$4T.(54QS1-&RD#!!5@".E<U-=-!\3
MGO&L=1:U72C;&=+*5D\P2;\ A>>.XXSQ0 V'XG:1-91WWV#5([+S_L\]S);A
M4MGW[!YASW..F<9&<$XK1U7QA#IMQJ,,.EW]_P#V;$DMVUJ(SY08%@,,X).T
M9X!XK@-3@O[SX,ZAH\6CZK_:,MZ[+;FQE#%6N3*#TQC;^O%:GB>S.J:A>7^G
M:5K=AK21I]BOK6!PMT#&"$F4_* "Q4[L8]3@B@#KH/%L-SX@N]$CTZ]^V068
MO%!\L+,A( "G?U)./FQTK,D^)6EQ:3INI2:=J:P7]TUHF(58QR!RF&PQ[@D
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M.5)!!/.<]Z]*K@/#,.KR?$C7=6N=#N[.QOK>%8I)V3(V#'(#$Y/MG'?%=_0
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M['CGOG)J:[\%>&[_ %">_NM'MI;FX7;,S XDXQDKG!/OC-;U1S.Z0NT<?F.
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M)H&9QO8GA" F<$]ZO:?XCFDO;"'4;/[/'J<*S6<H/&=@9H7ST<<D=B >A!H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%Q>FXNXG5@XRKQJ%^4@G@<@C ^N'IVL^)U\,ZOXIG\0RS1Z7<7<2V;6Z;9L
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M;9=SKL9!G:N,=!GCOQR30!QUI+K_ (MM-8N]+U 07<5_+##(VHR(ML(W^53
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M S]2*QO#GB:'Q-%<RVUA>V\=O,T#M<B,?O%.&4!7)X_*MPUQ/PS_ .09KO\
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M@U%8^%=!TRSN;2QTJVMX;H;9UB3;Y@]">O<U:O-9TS3].74+N_MH;-L;9WD
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M"XDRH92!G<,9.3R>P'%3^';SQ)J4>O:C/XH$<6DZG=VRI<0QK$ZI'A3(P P
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MQC:(+,H!3H3^[!R><DDGT](G\+Z1<:U)K$EO+]OD@-NTRW,B_NR,%0 V ._
MZ\]>:AM_!>@6MC:645B1;6<AEMXVGD81.>I7+<=_S/J: /.[FXUKQ%J'B26'
M7K/3+C3+Z2-&DFF66"&(Y4A P0JPSDE3G)]L7-0$/BG2O&D^I7ES]MTR)XX+
M>.9XA"BP!MVP$??8MG<#P,5W-]X+\.:EK*:O>:1;S7Z$$2MGDC&"1G!Q@=0:
M35/!7AS6K\WVHZ3!/<LNQI#D%A[X.#^- '+:>\D&L_#CR[F=4N=,D66(3-Y;
M;;="OR9VYR3SC/Y57T.;3=2TZR\2WFMW%OJ\>H.+A([AF,G[UE6W\HGH05
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MTNU@N6SF2., \]<>F>^.M ',_%"WAET_06FGEMU_MFUC:6.8Q[$9OF.0< C
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M00Q8]NP%2^+O%.GPZCX-\51W.80)F,,@8H%= 'RRAL2+D#&/7IBO4@ H
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M^&)48X'4\9XKT&BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"VX?(2"/W:]\T =+)-%$8Q)(B&1MB!F W-@G ]3@'\J621(HVDD=41 69F.
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M3/"#>((T,L3PQR0(QV[S)@(#Z9+#-<;>RZE8?%70[O7+FS=8]+N92;:%HQ&
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M:+"#$%)W3*')#!MHW'G)QSG(]/% !1110 4444 %%%% !1110 4444 %%%%
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M+@DE=W)4$_-R>36EHMUJEU8LVKZ?'9722,FR.82(ZCHZGL#Z'D5I9H R-?\
M#EEXCMH(KMIXGMIEG@GMWV21..A4UC3_  XTB>WU. WNJB/4F5[E?M98,P*G
M/S \DJ.?P&!Q789K/LKC4Y=1OX[RRA@LXV46DJ2[FE&/F+#'R\XH AA\/V\6
MN1ZRT]Q+?):BT,CL,-'G."  ,EOFR,<^W%.U'0;74]5T[49Y)UGT]F:W\M]H
M!888D8YR..>U:F:,T <S)X%TJ;2]1TV22\:VU&X^U72F;F20XR<XR,[5X''
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MMZ7J%G)>6>HVEQ;1Y#RQS*RICKD@\?C0 TZ%IIUF/5_LJ_;XXO)2;<WRI_=
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %4]6CGETB[2VN7MIC$VV9%!*''4 \5<IDL8EA>-L[74J<>AH \LT#6]
M8T_P?X4LX;N>ZN=:+;9/+B+PJJEV"[BJLQ/=R>IZ\"K>M>(?&.B^&+^:=8XK
MF&]A2TFG2-GFBD;;B18V*H0?XAP?05J_\*UTYM MM*EU+4G-FP:QN1(J2VN.
MFPJH'?DD$GCT&)9_A]!<: VERZUJLCRS)-/=S2K+-+L.44E@0%!Y  'ZF@#*
MFOO&%CXUTO0+C7;25+])YO.6Q *(HX &>O7'7MG-9(\7^*;;PU_;-SJ$3-9Z
MO_9\MO\ 9%3SU$F"6/9L'^$#&.]=Y>^%TO?$^FZZVH7*7%A$T2(JIM<-][=E
M>_MCVJC)X!M)=-N;%]4U$QSWPU#>3%N6;.<YV8(W8.,=O2@#+\3>*;_2O$SV
M%U?RZ3!*T0TZX-NKV]QT\Q9&P65LD@8P ,&NG\7:A=:7X7O;RQN+:"YC5?+D
MN.47+ '@=3@G YR<<&JFH^#H=4DN5N=3OC9WK(]Y9CR_+G*JJCG;N7(09VD5
M?\1^'K3Q-HSZ;=R2Q(761)82 \;J<AE)!YH XN'Q#K4.C^,(X;ZZ+:3:1W5I
M/?VR><0T;.0RC QE>,@$ \CBM&VUK6M.UW2QJ6HI>6E]I<UT\26RQ^4\81OE
M.<G(;H3_ /6N_P#"!6A.IE]7U:0ZG;BWNR\R-Y@ 89Y3@X8CC '85=/A2W;4
MM.OGOKUWL+=K:.-C'L9& #!ALYR ,].@H X/4I-7U72_!GB"\U)F2_UJSE>Q
M"KY40+DIL.W=D#@Y)SGMBN]\8:W)H'AR6\@:))VDC@C>491&=PNYO8 D_A6.
MGPRTR-+6W35-72PL[D75K9K< 1PN&+<';NQDGJ>*ZG5M)L];TFXTR_B\VUN$
MV2+D@GN#GU! /X4 <;K^J:[X%TO5+Z74X]3M1;*]JMWCSQ,752<(J@QC>#ZC
M@9YJU>W6J^&_$>CVLFL7%_:ZQ));OY\2;H)=NY6CVJ/ER"-IS@5>TWP)I%C9
MW5K<27NIQW$7D-_:,YF*Q_W%Z;1D \<Y ]!5FQ\*6]E+;RMJ.H74EK 8+1KF
M1&^S@C!9?E +8XW-N../6@#SW3_%?B,^&?#WB"XU9I7N=9%A+;"%%C>-I'!)
MXSNX&"" !V[FUXFOK[Q1X6\:W2ZG/:VNES3645M"J[)!&JES)D9.22.",8[U
MTR_#C2TT&TT9+_45M;2\^VPD/'N63.1SLY ))Q[_ $Q)J'P\TG4+O4K@W6HV
MXU- EY%;S[(YB!C<1CK], ]P03D RK*\OXK[P'I\-]+%9W^E2"6)%7[R0(58
M$C.?F^G K!L9-0T;X5^(-8LM7OENX[NYVERCC(FVYY4G)'4YKOU\'6$=WH]Q
M'<WR'2$\NT7SMP53PP)();<  <G@ 8Q57_A7NC?8=1LO-OS:7\C/+";EBB[F
M#,%'8%@#Z^^": *$5_>>(O$(T)M2N;*&VTR"[=[5PDLTK]\X/R@#IQDGG(K%
M;7?$<UEI%F=6:"\CU]](N)XXD(G158^801PV .AQGM79W'@ZPFN+.[CN;VVO
M;2#[,EU!-B1HLYV-D$,/J,^]#^#-*:UTRW3[1%'IT_VF'9*<F7))=R>6)R<Y
MZY- ',077B*#3_&.EZ??76HWFGW4*VCSN@F*NJ,ZAMNW."VWC ...U:O@358
M]0EU*)+_ %.1[?RUDLM37]_:O\V<MCY@>,'GI6C)X,TV635)#/?!]2DCEG9+
M@J0\;!D9<?=(V@<=A5_2]#MM+GN+E))[B[N0JS7%P^YV5<[1V  R>@[T <[/
M<W/B/QOJ^@_VC?:?;Z;;0.OV1Q&\KR DMNP25 P,=,YS7$^(I-1UGPSHAU:]
MN/MMGXD739'A?8LNUV'F;0,!AC /UKU.^\,Z??:NFK SVVH+$8?M%M*49HSS
MM;L1GGFJ=[X'T:]TNPTTK<PVMA+Y\"0SLI\S.=Y/5FR2<GN30!9U>Q:#P=?6
MB7MZ&CM7VW/G'SL@$YW]<\5YKI.G2?\ "">!6CU"\66[U6)O,>3?Y)\J8?(&
M&!Z]^:]@$"&U^SRYF39L;S.=XQ@Y]<US,'P]T2VCLXK=[^**SN/M$""[<JCC
M., GH 2 /<^M &!+<:I8^'O'=B-9O9'TDF6TNG<&908%E"%B.0#QZXS2>*+[
M4H!9WERVIOHR::CRSZ9<E9K68YS+(@(+KCUX&#77'PAI+QZHDJW4@U3_ (_"
MUU(/-&,8X88&WY>,<#%02^!]'F$89K\;(%MF*7TJ^;""Q$;X;YE^8CGG'>@#
M;TZYAO-,M;JWG$\,L2NDH_C!&0?QKRGQ5!J&K6.H^*[/3+IKNSN$N-,NPT01
M;:$G)P7WX;,C8V\_+7JDNF6DFE'3!&8K3RQ$(X7:/:@&, J01QQP:BMM%LK/
M1%T>!9DLDB\E5\]]RITP'SN&!P.>.U '+^(M>GOO"VA:I8/.FGWUS ;PVI;S
MA"PY"[?FSNP#MYQGWK NH]9MO!OBR_35]9CM+8O_ &8TTI5S& ,YW+OP&R 2
M<D?F=?7? UM::1IVFZ1HK7FD0W1N+BS%\ZRYVD+Y3.WR\G) 9<_B:;I/@*TG
MEO8Y].OK#1;J 12:?/J+N\KA@0Y*NVT 9& YSGD"@"IK1U+1-6T32UU:\NEU
MV=WFDN[LPJC1QKB-61<HK$GA>IP/7-'4[_7- M;?P_<:K%-]JU5(6D%W*'MH
M74LL33D;N2.OWMN?4$>A:GX5T;6M%BTG4K/[59PX\M997+J0, [\[LX[YJ+_
M (0OP]_PC[Z$=,B;3I&+O&S,69_[Q<G=N]\YH \]\3'Q#X<\,ZT&U^1'CN;6
MXM8[>YDDD@21V1E:1P"RD@X';'YVY]-N3X[UK0_[>UL62Z2+X 7K!A-G;D-U
M [[1@9[8XKKU^'WAA- _L./3?+T\S"=HHYY%+N.A9@VYL>A..!Z"K$O@_1IM
M2GU%XKHW<]O]EDE%[,"T6 -O#^V?KSU- '#IK^HWNE>!K*>\0'4K5Y)7ENI+
M?SI4"A5,B#/.XG'<XIL\>J6\.@:7<^(KJ6=-;-E-):7+_P"J:,N$9R/G9>!D
MY(^M=K+X#\-7'AZ'0IM-$NG0,7BC>9V,9/\ =8MN'4]#5C_A$-"%CI]DNGJM
MOIS;[5$D=?+;^]P>6]SD\GU- 'E?BVW>'P;X]L'O+VY@TZ]M?LOVFY>0H',6
M1DGD?,>#G\Z]BM["!=+6S!F\EEP<SN6Y_P!LG=^M49/".A3+J"S6 D742#=A
MY782D$$$Y/48&/3%:5AI]II=E'9V4"0V\?W47\S]3[T >2Z#,-+\!^&EAGG@
M34]9:RN76=^(S/+PO.$R5 )&#R>>]=AID$VB?$.72;.>5])N--^U&WEE:3[/
M*L@7*[B2JL">.Y4UKP>#O#MM;7=M%H]J(;LDSH4W;^<]^G//'0\U=TW1-.TA
MIFLK81O,09)&9G=\# !9B3@=AG YH XOQ;;RW7Q)\-Z=_:.H06>H07(N8H+I
MXU<(@(X!X]R,&N4U&74+'0KNS@UG42FG^)H[.VF^T,7$3!3M)Z-M/3(.*[CQ
M1X:N=;\=^';UK$S:;91S"X<3!""XPN/F#<$ G'X9K<N?"6A7FFVVGSZ>C6EL
MV^*(.RA6_O<'DYYR><T <Q%I]O:^.+/PK-<WDVFIILEY%'/<NQFF:;!W'/S;
M1R >F<UA:A::L/"VK/#=7-R_AO5B;=S.VZXMEV.\+D<L!GO_ '0*]/U'1=.U
M581>VRRF [HGW%7C.,':P((X]#S4]O86EI8BRM[:*.U"E1$JX7!Z\>^30!QA
M$&LZ!XE\26TTRPWMJRVCQNT;!(D/SC&""7!^H5:R=+OFU#4O ^BZA*YLI=!6
M[*F4@7,^Q1ANYVKN;ZG/:O0FT;3FT8:/]E0:>(Q$(%)"[!_#QSCC\:K7WA30
M-2TZ&PN](LY;2#_4Q&( 1_[N/N].U 'D-A=/I/A^\LH+Q;&QE\73V\]Q+O95
MC"#:KE65MI( /S#WXS7HW@RUEL-2U>V;6(+^)C'.L5K$RPVY8,"JEG?KM!*Y
MXSGO6Q%X4\/P6%Q8Q:-8I:W+;YHA"NUSZGZ=O3M5S2])T_1;)+/3+.&UMUZ1
MQ+@9]3ZGW/- '"W&BVNL?$?Q!97EW>K;_P!GPRA$NW4(S;P7 S@8P,=AZ5S&
MFPW'B"7P!9ZM?7KK>6E['-Y4[QB>) ?+8\YR5QDX!(/-=U+X174O'FH:GJNF
MVMQI\MM%%"7;<P9"2<KCH<],\XY%=)+HNESW5M=2Z=:O<6H MY6A4M$!T"G'
MR_A0!PFD:;8ZW=^)=-U=9%;29!;66^5B]M;B/"2(Q.<GEBW4\9Z50^SIK^D_
M#ZZUVUBGN[JXV2M(,F:,12%6(/J K'W->E7NAZ3J4XGOM,M+F8)L#S0J[;<Y
MQDCIGM3+WP]HVI3137VE65S+"H6-YH%8H!S@$CB@#S&Z2QU+5?$UIJ6MV6EW
M5C= VS2PMY]M BJ8VA;S% '7@*<D\YR*L:ZD\.J3:M=6]KK%C&]H+IQB*\T]
MPJ$%0<C:<ABH_O'GO7I-SHFE7M]%>W6F6<]W#CRYY(%9TQTPQ&13)/#^C2ZD
M=2DTJR>^+*QN&@4R9 P#NQG('2@#S^^CDL_%DFHW%K::KILVKPQB\C;;=V$P
M=4"-D<INP,#LQ/>JWB.ZN-&?QW)8F5(_M%CY[([;HXW4>85[CJ>F,9]J],_L
M/2?[0&H?V99_;0=WVCR%\S/KNQG/)YJ6'3+"WDFDALK:-Y\^:R1*#)GKN..>
MO>@#@=0TZQL?&.D_V"L26=_IMU]MAMW C:)4!CDVCN6(&[N*Y+0+6&R\.?#K
M5+<&.^NM4\F:<,=SQEW!4GTP.E>RV>A:1I\<T=EI=E;I.")5B@51(#V; Y_&
MG#1-)$<48TRRV0L6B7[.N$8]2HQP>!TH \>N9[!M8AU.UNK<;_%,0,]VX-XW
M[P*Z@C'EPA1@*V[(R>,@5Z#H$L<OQ$\4/'(CJ]K8,I5LAAMEY'J.16_)H6D3
M>=YFEV3^<P:7=;H?,(.06XYYYYJ2+2]/M[MKN&QMH[E\[IDA4.V>N6 S0!QG
MB33K.^^*?AJ.X565[2Z,L9/$H 7 8=QR3CVKSV>RM8?ASK=_"@^T:=XA,-C+
MN)-O&)5PJ9/RCYCP.N:]VFTVQN+N.[GLK:6YBQY<SQ*SI@Y&"1D<\U /#^BB
M%H1I%@(F8,4^S)M+#(!QCJ,G\S0!YIKUQI=QXZ\2:?XEU.&PA>"!;)[F$,#&
M4^8QLWW2'YXQSCTJS87>EGQ3#8^)9UGLET:)M.?50/WJG=YCL&& Y  ]<#ZB
MO29=,L)Q );&VD%OCR=\2GR\=-O''0=*=<V%G>-&UU:03M$VZ,RQAMA]1GH:
M /#4%@WP:T7R9(I3:ZV%5\C<BF=NOIE<'\JZ"ZO_  W-J7BK3/&+"VU!KX26
M[J&$KP *8?);!(/R]%[D^IKU!M-L7A2%K*V:*/.Q#$I5<]<#''4T][&TDFBF
M>U@:6$8C=HP60>Q[4 >+>.+^SDN/%AWP6UPD%HC"_<23E\!E6 9'E@ G)RV3
MV'6N]BOK2[^*UM);74$R/H;[&CD#!OWZG@CKP#75R6%G-.9Y;2!Y2H4R-&"Q
M Z#..G)IRVELLHD6WB$BC 8(,CC'7Z4 <CX]@-Q/H_V>_LH-0BEDEMH-07=;
M7&$PROZ'#9!^M<"=43'A>ZNE&A:$ZW<9/DI<017!E8_+N4C:>=IQP"0#C)KV
MRYM+:\C\NZMXIT_NRH&'Y&G/;PR1")X8VC&,(5! QTXH \=.E^'5G\)002O=
M6$NJS!)KL(OG1^6250 +^YWD@+C!R>H(K9\3:;%X'\0:)KFAZ9&(GB?2G@B4
M#YGYA/\ WV,$GL:](DMH)2ADAC<I]W<@.WZ>E2,BN &4, 01D9Y% 'G?B>RL
M-!T[P>MW);K<0:O 7N9-JLQ;<97R>@+<GMTK$&J>'93X@T+Q6EQ_:\NJO+%&
ML3^=.H8&#RV Z8  &0/SKUN:W@N !-#')CIO4''YTXPQ&593&AD48#E1D#ZT
M >-7T^F_VUXITGQ;?WUI=7UWYEM#;VZ.;B':HB".8V.X;<<$ 'IWJWX@NEL=
M3OY[6\M+UI'M8-2T2\Q]I=PJ!6A<<LW*]L9!/M7K;1QLZNR*73.UB.5SUQ2-
M%&TBR,BETSM8CE<]<&@#E?B3/:P>";MKVU-Q;F2%67>54?O%P7(YV@XR!R1Q
M[UY^VI:*\_C&&^ULB.^BL'6]M;0H#AB#(JCJBL5R<G(XR37MM)M 8M@;B,$X
MY_SS0!Q7@74+VYO]6MKPV-X\)CQJE@<17((.T,.@<#KCCD?CB>,[F*P\0:I=
MV&H6TEY]FBBO-'OER+R/G:(2/F#_ #$8'<UZC24 >/:G/IL7BOQ+I_BR?4K6
M/4C');K!'N2YB$:C8,(264C\\]ZU=$DM-'^)5O;SQ2VWVC0;6&VBF4NY8-C:
M2!RP[GV)KTVB@#S[XRW%O%X GCEDC662>'RU8C<V)%)P/8=:DGU>UL/B'#J=
MY-&-%NM,\FRO0V8%DWEG7<.%+#')Z[<5WAI: /$]1TN%3HOFVH?3+GQ1)=6\
M3Q946K!<G;CY4+9.,8P178SR:=X?^)^FPB!;6VGTI[:V2"W.PR&8-M 48'&2
M:[NB@#Q1VM8_A_<R"']__P ))YC%83O*^?O#=,D;.<^E>C^.Y%/@#6R#N\VR
MD1-HSN++A0,>I(KI** /)AM.L^"4L#Y,C:+/ 71"H5VC4*&X_O@]>X-4/!\%
MDXTC3-2L->?7=,N$_P!'N'<6UN5;YI0P^7;MR<'J3CG.:]HHH \@L]*77/ _
MC2'2[5'U.74[N2!C'L<H[#&UB!PR CWZ5K>%;C2-5UFVU*VTS6TNK*W9+F?4
M))=ENI7F,;C\QSV XP3QQGTFB@#PV"6,^"? D3Q2DV_B R3J8&^1!*[$GCIA
MU/XUTUA?PZ-XI\?WNHV-U-9LUM(D2VQ?S@J[&* \-AB,UZ95:_L8M2L9;.=I
M5BE&U_*D:-B.XW*01GIQVH AMK^*^T.._P!.B\Z.6W\V",_)O!7*KS]WT]J\
MBTF>1_%?@S4#::FD%I]JAN+86$BPV3&+ C0;<G!ZL2<XSQT'M$$$5M;QP0H$
MBB4(B+T50, "I* /&XHF7P#IT1T^\$\/B,7#)]BDWA!.7WXVYQL/7\/:M#5+
MV;3M-\;Z3?:5J,]SJ3S2V4L%F\R3+)$%C&X @%2!P<8QQ7JE% &7X;1X_#&E
M1RQO')':1(Z2*596"@$$'W%:E%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV "PN3HP"VSF,Q"5V3>-[L^T;01GI]10!W=%>?Z+XVU"XU#5K9T-]':Z6M_
MR6KPM*W(**&^^"1PP'YU4T[Q?KUQ<^&9$N[*YM]8MI;F[46^?L8C +!=K#C)
MV?-DY!^E 'I=%>;:/XP\2ZU+IFJ66G3R:9=W&R6-X8TBCA+%0ZR;]Q8<9!7!
MYP!5+4?%WBVST37]82[L'CTC5C:>2MF?WR HIR=YVCY\]SGOB@#U:BO/QXIU
MC1/$FN6&KSPW\5GH[:JAA@\K9M)!C')R#ZDU+I>I^,)Y=.GD@WV=[ 3-+,D"
MI;N5RC1A92SKV*GGOD=* .[I,C..]>5:5XW\13Z%X3UVZN;5HM6U,6$MK';[
M1M9W7?N+$Y&WMQ6MX,;4;KQSXMDN-3EEAM[M(1$T:?, AV\@< <\#KWH ] H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQR/0T =K34=)!E&##)&0<\@X(_,5RIUQ([6PT71M(%Y,^GI/]EDN!&D5N0%
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MME1RTR*2=NXXP=PYXQC '/;T/Q5KA\.Z!+J.U<*\:%W5F2(,P4NP7G:,YXH
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M;QR22QLSSLP 56W=@<G( _$U%XC\/ZS?WVEZUH]];VFKV2-&\<P+P2H^-ZG
MW=0,'C\*ZRB@#@]1\'^(9Y],UNVUBV'B&TDD:0RQM]F=' !B Y8* O'?))X)
MI^K>#M<U&TL-1CUJ./Q)9SM/',4/V==Z*CQA3DA,*/?.3WX[FB@#AM9\+^)-
M8\'W-A=:A93ZG>21&5R'C@B2-@X"* 23D<DXSD^@%9DSZW_PN&X_L]-+%U_8
M<?G+-(^T_.>05!.0V.H&5 Z9S7IE5!I>GK?F_%C;"\/6X$*^8>,?>QGIQ0!Q
M<_P^O+6VT"32;^W6_P!+N)[AWN8B4E>8'><*<\'H,].IK<\7Z!>>(- BL[6>
MW$\<\4S+<(3#-L.2CJ/X3Z<]*Z.B@#SB\^'^MWT7B:.34]. UR. /LMG'E-&
M /E^;I@8]^O'2M&?P5>7GB"RO[FYM3;1Z4VFSPJC9=6!W,#V^AKMJ* /.4^'
M^O?8M"TZ77+%[31+R.XM6-FWF,$SM#_/C@$#C'UKM=8M;^ZLD33[B&*=959O
M.0LCJ#\RD YP16C10!Y\OPYN(M)O(K:]MK:ZFU.+4HHHH6^S1.A!"A2V<''.
M".V ,5H6WA;7+;4];U0ZO:37>IVT<.QK4K'&R@@$8;. &/!R3ZBNQHH \\N?
M >LW'@/3?#?]HV"M93HXF\E\,J'*C&[KG.?:MV]T#5+OQ?HNM_:[1([&W>*:
M$1MF0R8W;3G@<+C\<UTU% '#Z-X#O])9=./B":;P[#*)8+$Q /PVX(TG4J#S
MCO\ 2DF^'*75GKT%SJCYU2\6]22&'8UO*IRI'S'(X'IW_#N:* .,D\':QJ6A
M7EIK/B$75Y<P/:B<6@5(XF(W812,L=J\D\8X'7-N7PG<W>KV=[>:C#+%#8/8
M2P+:E?-1\;CNW_*3M'TKJ** ./TKP?=:,+>&?Q%=W6C6+>9;630JI4+R@9Q\
MSA>H''('IBJ>A#3/%GC0>*]-2<6L%H(2\B-&)9LG!VD<E%+#/^WCL:[RC% &
M7XAT&U\2:+/IEVTB))M99(CAXW4@JP/J"!52WT"[_M*+4]0U&.[OK:W>"U86
MWEI'NQN<KN)9CM7/S 8& !FM^B@#G_"7AR?PSI\]G)?I=QR3O.I$'EE2YRP^
M\<C/3^M.\0>$]/\ $E[I5S>AMVG3F50/^6BD<H?]DD*3],=ZWJ* ,/3/"]AI
M.O:OK%LN+C4F5GRO"8'./J>362/ 6SP[9:/'JKJMG??;XIC "WF!RX!&<$;F
M/X8KLJ* .7E\%6MUK>L7]Y<&>+5K5;6XMRF %48!4YR#WS4>C^"I=):V+Z_J
M%ZME&T=C'<!2D&X;<D  N0O W'@$UUE% ''Q>!G@T71=,BU>18])N1<P/Y"E
MF8!@ W.,?,WY^U:WB7PY'XCM+2)KN:UFM+J.[@EB .V1.F5/!'/0UM44 <+>
M_#9;ZTUBWFU^^=-6>)[DO'&263:01A1C[@XZ 9X/!&KXA\'0^(4L)Y-0N[34
M[$'R;^U8(XR &XZ8..E=+10!F:'HL6AV+0)<7%U+(YDFN;E]\DK8 RQX[  >
MP%83^ +>?1=8TJXU:]>'5KK[5<NBQJV\XW ?*0%.U>,9&.O-=A10!R&I^ HM
M0UG^UH-9U/3[R:)(KQ[*41BY"C )&.#QU%:%CX2M-.\0)JUM=7:^79K9):EE
M:)8EY &1NSD9SGFM^B@#C&^'&G?VM=W46I:G#97LC2W>G13[8)F/7( S@\Y&
M>:T;SPC#=7VIW,>IZA:C4UC6ZB@:,*X1=HP2A9<KP<$?A7144 </XD@M=8B'
M@>#0[LP 0?Z1Y6RVAB5E)*OG.X*" !WXZ9KMHXTAB2*-%2-%"JJC  '0"G44
M <:WPXL"MNB:OJ\<5K=M=VT:3(%A=BQ;;\G/+'DY(SP1S3C\.-(_MF:_CN]3
MBAN)/-N+"*[*VT[]V=!USW&<&NPHH Y.X\ :=?+JR7U[>W*:G*D\@?RQY<B8
M"M&50%2  /I5F'P?#%J]IJS:IJ,M_;6QM5FE:,EHR2?F^3!.2.>O SWST=%
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M8VCVZ"M*P\%Q:QH]U9:W_:TM@\J36B:C=^9=0.%(+AU)V@Y&%R<8)[XKNZ*
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M4\9>'[CQ/H#:7;W,5OOEC=I)$+<(P8  $=Q6;J'@J?5_$.H7U]=6[6=_IO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M44 %%%% !136#$C:<#/-.H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J,0QB4R!0'/4U)10 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M117/^,/$$7A_0I)/M,$-Y<$6]IYSA096. 3GLN=Q/H* *GA_QS8:]XLUK0H"
MOF:>1L89_>@?*Y_X"W'XUF^*/&&M:)XRTK0K6/3W353B&:6-\P\@'< WS<\\
M8_K7GVM6M_\ #GQ;X=\13R::8/+6TG2R+9DC P78-R25YR.,J*TOB/J&F:I\
M1_"*Q:ND<)'SW-M< &(,PPVX?=- '7:=XXU0>,-2\*:I9VK7]M;-<07%KNV3
M84,J[#D@X/\ >[5CZKXX\::+>^&+*\@T5+C7'5"GV>7_ $8ED&#^\Y(W\].E
M9?@>]_X1#XB:CI'B;9-?WI!MM:E)+3*0-JER?ND*,?[0QSQB?XJ7UI_PL/P6
M1<PG['>*USAP?)'F1-E_[O SSVH Z+7_ !+XO\.^']<U"[ATIFTYXC"ZVTHC
MN$<A3UDX()YY-#_$.31_AY9^)=:6":YOE4VUK:Q-'EB"0I)9NPR3Q]*D^*]_
M9R_##41'=0.;I(S;[9 ?.Q(A.S^]QSQ7":[IUSKGPA\+WFCA;R;1]AN+>+YG
M7C!RHYX(''H<T >C7-]XXLO#;:F\&CS7:1&1[&.&0%1C. ^\[B/3 SC -9FJ
M^,]?L_BA9>$K?^S?(NX_-6>2VD+1C#G! D 8_)UXZ]*WH/'V@7=C#/:7375Q
M+@+90+NN-Q_A*?P_4X ]:X7Q=JVEVOQO\.WKW4"PVMNZ74JG(C;$@ 8CH>1Q
M[T >JZD]Y'IDTEG+ ERB%@TT1=#@9Z!@?U_.O/?"WC;Q/XI\*R:I;2:-'>^=
M+%%9FTE;S"B!\;O,X)SZ5KR^/M(U"_N[2SO[=K&"PDEN;A\J-Y("*K' )Y;(
M^F.]>:?">?0]%TT:YJ>I+:W-I<SHT$DC$O$\:8*Q\Y.Y3R!]>@H ][B>:>P2
M0 13O$#\Z'"L1W7(/![9%<+X/\8:YX@\9ZYHUW_9R6^DS-&SQ6[AYL,RY&9"
M%^[GH:['2-3&H^'[+5)E$ N+9+AU8X"!E#'.?3->5?#+4K+_ (6AXQ8W40%[
M<LUL2V!,/-<_+Z\$'B@#M/'7C'_A%IM(MO,AMAJ,[1O>3J72W1<9.T<DG< .
M<#J:LVUYKL[WT(N[.6W^R1W%EJ,-L2C$EMP8;\$X"]#T.:I^/)=%FDL-*\0V
M9FTN[29WF6-F-NZ;-K[EY1?F8$^XSQFN0\'V*^$-?UU;'6/M7A%;89F<[D2X
M9@%12.&;KDKQR,\XH M>%?&GBKQ=H,NH0ZAIEG>-<O:VMI]A=UE=(A)]_?\
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M5*JIY5RN%)P#V_A/X8_B71O[<^*W]H7VB:C/H26K6<THM'.),,H91C) +##
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0$IY9#V[IQ([>Q&X9[EA5J[T:_L_'%_HUI$ZZ1KP2[ED4?+$R$>:/3YP/UH
M[#^TA<^*;5(-7MQ;R6I<V.S,DG(P^>PP16'XI\8Q07VEV>DZI$+DZC##<1!,
M[D8D$#\N?2H=867_ (69:):QN'.CSQ*ZH<*Y(V@L!@=!7++J7F>%/#FD-IUZ
MNJ:=J<(O$\ACM96)9]V,'/7/O0!ZM<>*-&M=06QFO42X9@FT@X#'H">@-177
MC+P]8SO!=:M;12HZQLA;Y@S=!BO+1;00ZCK.A:YI6LW5S=W\D]NL!?R+H,RL
MF6_AVD=^E=3X>@AD^)>O--9,%:UME1WA)0E5P0&(P2#^= &G\0?$MSX<L].:
M&1;:&\NE@FO'7<MNIYW?7Z\5;TA]5BU!C/J$.HZ4\'F07&P*P;/.6!P1CG\*
M?XIO4M5M(+JP:]T^Y=H[I%@,FU=I() [9%>?VOAV9+CQ'I_A1KI-)NM+D&R4
M-Y:7)(VB,G!Y&[/I0!Z3:^+M$NYY((+T,\:&3E& 91U*DCYL8[51?XD>$D(_
MXG,)S'YN5!(VYQDX''-<=X4:QN+[3)&T+5X]0TQ&69[HR;+;"X;9V;/&!6CX
M*T*+4_AD=*O;1HI9(Y8G\V,HPRV5/(SUP: .TN-=TX7$5JUQLGEB:5!M/W1U
M/3M65HGB"PLO"T-Y<:T^IQO*ZI=>40TIW'"A0.3QC\*RO \.IR::^H:Y \=[
M;6XL%4Y)98LJ7Q_M'FN2TBWU33O"GAO4ETF[N%TR]NA=V@C82A'<X=5/7 H
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MEFB9/W6.1DD$GIC(YR#4_A33KR6YLH+SP5#I][IZGS[^4 I)A2O[K!ZMP<]
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MRUEAS@NN3G /J!7+:_XG35=3\)2Z='JD5K<ZJBI<DF."YBP<C;NR<D*1N4<
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MMMLPE=E7YU;:_P @QP@Y&>OMSZ1574=1M=)TZXO[V7RK6W0R2OM+;5'? Y-
M''_\(UXDG\86/B"ZDTAG.GFPO(D\S:JF0OE,C+<'')6F>'?"WBS1(X]$;5[)
M] @EW13('%WY8.X1_P!T#MG).,X[8[BWN(KFWBGA?='*@=#C&5(R#@U+0!YE
M/X'\50^';_PU8WFDG29+CSK62?S?.C4RB380!CKWS^'/'2^-O/7X::T+IHVG
M_L^3S#&"%+;>< DG&:V=8UBQT*P:]U";RH%(7=M)Y/0<59N+6VOK8P74$5Q
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MM:\/VNC7PG>&UV^1,'VRQE1@$,!UQQ5:3X>Z#<>'FT>YBGN$:03-=2S%KAI
M,!S)UR!QZ8XQBNJS7.Z9XDFO_&FM:$]JD<>FQ0NLH<L9#(">F!CC''- $(\
M:(?#\VD3K<W*3NLDMS/.6N'=?NL7ZY'0=@*FT?P;8:-JC:FEYJ=U>M$(6EN[
MQY-RCH".AZGMQVQ4_BC6[C0-,ANX+6.</=0P/OD*[ [A,@8.>O3BMO- &)JW
MA;3M9U*WU"X:ZBN88VAWV]PT1>,D$HVTC()%<EX@\'PZ;8>'-'T6UU'['!JZ
MW<KP.S&!,-D@_P /+#@>Y]:](S29P,F@##C\(:.-/U"RG@>Z343F[DN9"[S'
MMENV.V,8[46_A2QMX)HS/>SO) ;<3SW+/)'&>JHQ^[GC)')P,G@5?U+5[+2=
M-?4+J95MQC!##YR>@7U)[5;DECB7=(ZHN<98X&: .<C\":+%!IL$?VQ8M,D,
MEFHNGQ$Q.>.>>XYSP373444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4UU5T9'4,K#!!&013J* /
M'?"7B:;PEX>UZZ&A33Z5;:U/YT\,B+Y:EE7Y4ZD#C/0<CWQTVN?$ZPTNXNX[
M9+6X%FB/*LEV(WEW+NQ$H5MQ (ZE>O>JT'@O6XM$USP[OLQ9:K>RW!O1(Q=(
MY"-R^7MP6P,9W8YSVP;*>&/$N@>([RZ\-7.G/IM^(_-M[_?F%U4+N4J,L,*.
M"?\ &@!EMXLUC4_B!%9Z?;V[Z>^BB^ABEG:,N'=,,WR'##IMZ<DY[4X_$I4\
M/VNK2Z8L*OJ!T^YBDN@&MW#8R?E^88Y..0/TN1^%]6L_'%KKL%Y;7$0TQ-/N
M#<[O,.'#%QC@DX[D8SWZ5%<_#^&]UOQ!<3S@6.J0;4@4?ZN9EVO+C'7 7'/=
MJ +FL>-8M*DNU-JKK%=164+M+M$L[KN*GCY55>2>?0 GBL^/XBB*RU!KS3=M
MU:3PP1^3,6@N&E^YLD95X&#NR.,=Z2Y\"W[>!],TVVU-8];T^X2^2[8;D>X&
M[);(R5^8CIV'TJ74_#7B37M$D&H:K9VVJ)+#-:&TC8PPR1,6#?-R2V<'L,#@
MXY *U[\1YK'3]7E?24FFT^)9@T%P3#*C'&0Y0$$$@%<9K7TGQ5>7?BI]!U'2
MA93-8B_A99_,S&7VE7^4 ,#C@$CWK+UGPWXL\0>&K^SU&_TW[7<P+;I% 9$@
M4;@S2'()9CM  P !GU-:<.BZLWCJVUV=;)+:/339.B3.S[BP<L,H!C(QUZ<^
MU $_CG4]0T?P;J=_IOE"XAA9@\A/R#'4 #D^@/%<1JESJ<GC'X?7ILK26_DA
MN_+6.Y8K(I@7:S2,@/<D\'OC)KT/Q/I#Z_X8U'2HI5BDNH&C5V&0I/K7-VWA
M+6VU?PM?WESI_P#Q(XI(_+AW_.'C$>,GN N<\9SC QD@!%\1XO[$>XGLTAOT
MU.32S!YK-&)4&6.\)NV[>>%)Z#'IK>%O%9\13:A;R6A@ELY% ==YCF1AD,K,
MJGL01CBN:'P]UA-,N_L^J6]KJ;:R^KVL\89EC9UVM&P(Y&.^.?2NPT*RUJ(S
M76NWMO/=RJJ"*T1D@B49Z!B2223DGT'I0!4\4^);W0+C2H;32UOFU"X^S*/M
M'EE7()'4$8XZYK,7QSJ40U^TN= +:MI(B9;6VG,BW"R=&#%5PH[G' IGQ$>9
M-0\)&VDA2?\ MA=AG.$)V/P?KT_&H]2\"ZCK$&K7=U>VD>J:@UN-B(S0)%$0
M?*;HSJW)/3/''% #K?Q_<26'B5Q;6%W/H<"3L]K=$PS*RLQ .TD$;",<Y/<5
MG:QXD\7SV&B3_8;/3[:_U&R5&2Z8O*LGS;&P,IR,-C/!P,\FKL_@O7YCKN+_
M $I4U>Q2T>-+9T6$*KJ F&Z#>3SGIT';1U7PQJ>H>&-$LHKNTBU#2[F"X61H
MV:)S$"!D9!P>#UH JRZ_#I_Q O(M0TFTBGMM":]DOH6+R-$KC,?*CC(8]\X'
M3I2Z9XXU"\N]+,FC2O9ZC&7WV\,Q-M\NY0[,@5MPP,@@ ^HYJ27P??7_ (LG
MU74;NVD@N=';2IT@1D8ACN+KDG')QC)X[TSP_P"%/$FE+#9WGB87&F6:E;6)
M+<([8!";WZD+QQWP/Q )?"_C&Y\1WEN8DLVMY%D^T11N1/9N#\JR*3WY&0,9
M'IS795P2>$-2CU.TUZ\O;"#4;&SEC>[M;=MURS)M#RC/./O8P<GTZ5T7A2;6
M9]!C?7=AO-[@.L1C+IGY6*'[I([=?7!XH HZYJAM/''AJPDTRSG%X;CR;N0Y
ME@98R6V_+QD8&0>>>*P;CXA:S;Z7K.JOI=@++1M1-E<@7#EY,.BDI\N.-X//
M7\.>DUKP_=ZGXIT/5X;J"--*:1O*>,L9?,78W((QA>1P>:Q+KX>WEUX;\0Z.
MVKP :SJ!OGE%H?W1+*Q4#?S]P<_6@#0U#Q#K=U?ZK;>';2UG.DE!,DY.ZX=E
MW&-,$!< CYCGDXQ6=<&>;XJZ).UL;:[ET.4LKG>J-N!V\=<$G./459O?!NLI
MXBGUC0O$(TV2_5%U",VBRH[*N Z!C\I]CGKU/2M!?"]Q'XHTO58]1!@L+-K0
M0RQ%WDW8RQ?=UX';UH R;;QOJ-QX?\-ZP;:U5-3U$6$\.&RN960.K9[!#P1W
MZ\<YWC/6-8UWPAXFETO[!'I=GYUK+YR.TL^T#S&4@@)C) R#DCM5N/X>:I#I
M^FZ='XBC%EINH"^MD-B"W#L^UVW\\L>1COP>,2WGP_U V^NV&G:^MKI>L.\L
MEO):>:T3O]\H^X<'C((/M@\T :*ZA<)XLTK3_L5DX?2Y)H;AL^:I7RP5SCY5
M.X9QG.*QK7QCXD:PL-5NK;2Q92:J=/GBB+F0@S&(,I. ,''!!SUXZ#:/AG5A
MKFE:FNL6Y>QLWM6#V9_?;L9)PXQRJG K.7P+JZ^';;2AKEH3#J/]H&4V#?.?
M,\T*1YG W$_A@>Y &Z[XUU*S/B*XL!9+#H7EK);7*-YEP6 .X,&&T<X'!R0>
MF:[339;J;3K>6]6)+AT#.L6=H)[#/->3:K%_:/C74;^;Q%%ID\-P((K6_P!'
M6X9E0#:R$@':6)( SSSG)X[/19_$]WK&F7%[.\=J]D6O+0V0C17R=KAR=P<_
M+F/G'.<<9 +_ (\_Y$#Q!_V#YO\ T URV@^(=:T:U\(VE]%8'2]6M8[>U,(<
MR6[>6ICWDG#Y'7 7!_7O=8TR+6=&O=,F=TBNX7A=DQN 88R,_6L#2?!\]M)I
M7]JZC'?1:/&(["..W\H*0NT._P S;FVC'8<DXST ,&W\<Z[-X'BUPBP%PNJ"
MSE3R'VNAE"9'SY4\Y[UH>&;C6+CXB>*8;F_MY8+1[="OV8ABC1LRJIWX4*6.
M<@YR>G:O+\-+DV=QIT'B.:#3'O1>Q6RVJ'8V\.06/+#(XZ>^>E;^G^%Y=/\
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M:]U.W?2+6&UN+:;"HB)*'.=W?HO)K@_##VD\OPYM[BW<O;17D4ZS6[ (S+A
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M,2%Q[=*W"<#)KC].US5_%RW%UH5Q:6&F0SO!'<7%L9WN2IP64!U"IV&<D^U
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M)Y0P=RNS<,0 "2#QWH Z *     .@%9VH^'M%U>99M2TFQO)47:KW%NLA ]
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M:-IGAWX=WUK<7*S7E^;>8&=RC1,S@KLSM XSTZ\UNS?:/"GBK6="3S6A\0Q
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MXBT_48(D785+VTB C&#T4C!S0!VEQXNTU!;BT6XU&2XM_M21V4>]O)X^<Y(
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M@<)A@2<<>E9\'A?Q(MGX2@F72O\ B1RIO*7,GSHL0C&,Q\L<L>P' YZU6O\
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M?B7R(K#3Y-:M3;_9+:5V@1B&!ER5!R=WW0H''7GB:X\):_;:I9ZSHFH65KJ
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M41H'+A%#GJP')IU8">)],O[P:9#-=QR7)DAM[@6SA)'4-NV.5VDKM;KQQWH
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M-P96QP3@C.?K5#4_B#J7_$O^P>'+Y(;N]MH4N+DK&)5D^;" GJ0I'.,9Y[4
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M%JS77FHZ D$/A1@CT&0?7O5_P%?ZCJ?@W3KW42C2S0JXD60LSYYRV0,'V&:
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M]WR<X!SCK_>[8YEG\4ZSI5CHNLZB;*73M5FAB>&&)E>U\U<JVXL=X'<;1[4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*?E)/S###D<>IY%>E3^'5F\5V^O_ &ZX26"W:W$"A/+*$Y.<KG.0._;ZUM4
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MITD-M+:6D$4ZJBQNT(<-M4,2H.X8!'05V-1FXA6=8#+&)F!98RPW$#J0.N*
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M#J2(EQ;6\RK$=BA5(&TG@ <9Q[5;TCP;;Z/JL.H1:IJ<\D5HMD$N)$93$"2
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MR.<#!)//%0^'O"WB;2&30I;'2C802[H=9"(9EB#9"!",[^,9/ SWQ0!MP_$
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MQVQT]0:U-.U#4;7QEX7)U&^N4U?2I+F[ADDW*SA PV)PJ<\?+BNN?P;H4@U
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M" 3GU KU]0 H"_=QQ60_A30)=/AT^31[-[.%_,B@>(%$;U /2M< *H   '
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M@12.7W%.<KT'3TK&L'U34K7P#NU[4XCJ-O.+HQRC+GRF?=R#SS@$],#&",T
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M.>,X_.N:AO)]0N/AI>W3^9<7$;RROC&YFLV)/YFI_ G_ "-?C?\ [":_^@4
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M#,"""R\$C';/&:NI+'*"8Y%<#KM.:\25M-TSP9JYMHK6)QKLB7PMU59A9+<
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MN1,JS0NQRVUE4#!))Y'\A5B?X>Z)=:#'I4_VN0QRB=;UIR;D2XQO\SUP /3
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MK G!Z&@#%MO!>A6D>GI!:RH-.??:D7,N8ST/.[GCCGMQTJYIN@:;I%U=W-E
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M;"\M C_9[C"@[]ZL!P"O R,'MFO0_A_9V%EH-PFEF\DT^2[>2">Z(S,"!EU
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MD>1_8>F>3NW^7]DCV[L8SC&,X[U*N@Z.EZ+U=)L5NP=PG%L@D!]=V,YK0HH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFC&-;ZZ$;R9*1JC.[ =3M4$X'<XP*Y?PY9*/B'XI>ZL)CYBVA@N);9]C^7&
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MVCDC>6UDC)V@_,%*L">A.#UK7\&:+<:+I-T;M3'<W]]/?20[PPA,C9" CC@
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MAB[T@:E;!Y]3_M 2^0Q"_O/,VXW<\@#.>E=TN[:-V-V.<=,T +1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !165)XDT6*_^PR:E;K<"40E"W20]$)Z!CV!YJE8>,+#4/%=_H4(
MD\RT2/,C1L SMNR!QT 4<]#GB@#HJ*BN+B*TMI;F=PD,*&1W/15 R3^5<AX%
M\777B*YU>SU*U>TN[6998HG !^SR#='TZG'7ZB@#M**\^;Q3JND?$\:/J$XF
MT6\Q#;R&-5:&<J&520.0>0/J/0TOQ$\6:GHLUA::,ZI(UQ%]LF*AO+21BJ
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MMLK)'-;..58@E65@5(X';M5C3-'CTZ6:XDN;B\O)P!+<7# L0,X4!0%51D\
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MRYT90F^+*\* !CUZ9QS5F^\*^);7Q3?:IX;UJTL[74=C7,%S 9 LB@+O4>I
M'I7;@!5"J  . !VI: .)N_".NV.OMJOAS6HHFN;>.WO(]0C:82&,;5D!!!W
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM?LOEIY7EJG)& 4)R&);))YZY'%8CV$OAK0XO"6GZ9J.M6\\$B1S7*QF&'/
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MMYXS:%=1N++2;F_L]-N!;7,D#9<R9 <(F"6V[AGIW]*GN?$UQ)J%[:Z1I9U
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M:/Y1EC$RR!UD \O#< $D@$'@9ZU!:_$S3B;[[<D"QVUN;E9K&Z%U&Z@@;-P
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M  < 4 +1110 4444 %%%% !1110 4444 %%%% !1110 44E+0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %5K73[*R9FM;.W@9E"L8HE7(&< X'09/YU9HH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH 2EI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BDI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2EI*6
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BH(;J*:1TCEC=XSAU5N5/H:GH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@!*6DI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ H/(Q110!PG@>V@L?$WBZUMHHX8DOT(CC7 &8D_P-=W7-Z%X>O-
M+UW6-0N+B&1-0G$X1%(*87: 3GGBNDH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@!*6DI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH 2EI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *#132P09
M8X% #A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% "4M)2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #) Q3Y"
M ?>F31N^"C8*@X!Z$]LU,>E-#!B0.U !'NV#>!OQ\V.F:=110 4444 -4,"V
M<<GBG444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -7D
M4ZD%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 444E "T@ZTM% !1110 AX
M!I,G<H&,'K3J3 SG S0 M%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% "4M)2T %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1NC-]UL<
M@_AZ5)110 4444 %%%% !24M% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
+ %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>exhibit1021-independentc002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit1021-independentc002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **3(S
MC(SZ4,RJ,LP ]S0 M%%% !17,ZEJ_B@7TT6D>'(IK>%MIFN[P1>:<9^10#Q[
MG'TXK1\.Z[;^)-$AU*WCDB#ED>*3[T;J2K*?<$&@#5HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "N6^(ZE_AYK6UF5A!N5E.""&!'/U%=37*_$J%+CX=:W')G;Y
M ;Y>O# C^5 '.>*O#%GX5\,-XEL)9UUVR>*9[Z2=V>X)=0ZMSA@P8@#&.0.*
MB\276@7?Q"N;7Q6'GTZ"PB>UCVR/'%(Q8MN"='(48SR0..O.Y'X%FN6LX+WQ
M%>WVB6KI-!8S1J&)7E0\@PS@'!P1V&:Q;P6]O\2M=N-6N]4TA)8(%MI+,.$N
ME5>69E# L"<8XP!WH W/AIH\>F^'Y[A;2:W-W=2O&+@MYGD[V\H,&.0=OXUV
ME<!X;MM7UW1M=LVU?5H]-EE5=,U&<>7=%< NW13C<."0#@FNZM83;VL,+2O*
M8T5#)(<L^!C)]S0!C>)_$L6@6L4<49N=4NV\JRLTY:60]"1V4=2>PIWA+0V\
M.^'+;3Y95EN06EN)5& \KL68_F<?0"L:^\"7UQXFN=<M?%-[;7$J[$!MXI/)
M3^XA8?*N><#KWSUKH]$TZ^TVS>&_U>?4Y6<L)IHT0J,#Y<*!]?QH TJ*** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ H) ZT5QOQ"DOHX=!%I>M;I-K-I#(JH&WYD!!.?0J#CO
MWH [*BN/34=8UC6M6TC3M3CM7TE(5>9[=7:>9U+<C/"8QTY///%/T#6]5\4:
M-IE_:M!:21731:G$Z%@VS*LJ'W;!!H ZVFB0;MIP#V![TZHV@C:9)6&9$SM;
MTS0!)5/5-4M-&L)+Z^=X[:,9=UB9]H]2%!('OT%7*P/''_(A>(/^P=/_ .BS
M0 NF^,] U:[CM+._W3RJ7B1X7C\U0,DIN4;QCG*YJ[HVMV&OV;W>G2-)"DK0
MDM&R'<IP1A@#7!Z3HNJ^(M&\!,;6*TL=+BM[MK@RAI)=L:A54 <!N^:S+#4=
M;T30M4U6ROH4M8_$<L9M3 &\U7N K;F/(^]QC'3\@#V"BN&N?$&H>'O'TUKK
M6HLVC75G)<6/[I!AHQND0D+DD+DCG\S535?$&L:+I^EW.J7>I065S#)-<7EO
M:1RM;.=I1)%V<* 3DX))[B@#M+O6K.QU:PTR8R_:;[?Y(6)F7Y1DY8# _&M"
MN&M?$&I_VKX,A_M.WO+;5+>=KF2*( 2LD>X,#Q@$D<8'2H]&U?Q!XDT*U\2:
M=J=M#!+>.7M;F-5B6U21E/S ;M^%!R3CKP* .OM-7M+W4[_3X3)]HL"@GW1D
M+\Z[EP3P>/3I5ZO.W\3ZZFH>/+47UF#I*6YLGN$V1Q>8C,=V,DGICKD@>M00
M^*=:DA\7117ER!IVG)>6<U[9I'+DHY.4  VG9QE01F@#TNLO1/$>D^(XKB72
M;Q;E;>4Q2X1E*L.V& /X]*Y/2-9\01Z]X534-2CN[;6["29XEMUC$3I&CY!'
M)^]W/KTX W]2M+S1M!U:ZT@37FIS$R@R;6=N@VJ,!?E7.T8Z]<DG(!T-%<?X
M(UT:Q-J"IK%S>1PK&/L]_ L5U;/\VX.%500?EP?8BNMF<QP2.&12JD@N<*..
M_M0 ^BO+]%\3ZY+XG\-V[ZA)>6VI"YCNIO)46S2(A8?9SM5R!C!)R#VSS4!U
MWQ)!X<OM:?79)9;#6VLA ;>,1RQ^<(_FP,YYR,$8QWZT >KT5YYJ%YKTWB3Q
M7:0Z]<6UOI]E%<VZQP1$JS*YQDJ<KE>>YXY'==)\1:K?^(O"JRW;+#JVC-=7
M$"(NP2!5.5R,CJ>YH ]"K.UW6K7P]H]QJEXLS6\"[G\E-S8^E>?V/B?69/"U
MM)+JN9I-9EM781@W,T2N<)"H7:7. ,D8 R<CK5:ZUN^U;X8>-H-1DFDFL+F:
MV1IU02!!M*AMGREADY(H ]8C<2QI(N<, PS[TZH+/_CR@_ZYK_*N2\=:CJEA
MJ?AN#3M2EM%O[\6LP6-&!5@>?F4\CMSCV- ':45Y%>7&OVFA>*9(_$VHG_A'
MKK-J7V%I>%?$K;<L/F(P,#Z]*VM;U76=6\1KHFGM.GEZ='=-]ENTMW9W8C.6
M5B0NT<#'WN<\4 >A,VU"V"<#.!U-<VGC6SET3^U8;#49HA>&S,<<&Z16#;2Q
M4'[H-<UI^JZWKFM:;X7U34/LUQ'I\MU>W&F2@&61)?*"[\?*1@E@._'3BLS3
M+W4='^'YGM-0E2=?$+PR.$3]Z&N-K9!4XSD],4 >NT5PK3ZCXDU?Q#%9:U+I
MUQI$R16L(&$!V!O,E&/G5B2 .P7/4UD>+=>U)5U*\T_5IK@V>G17,(TTA8H&
M(W%YMW#!P!M7YCCG SF@#O)-?MHO$MOH30S_ &F>!YTDVCR]JD \YZ\CM6K7
M!0W9O_'_ (5O&SFXT2:4Y_VO+/\ 6N]H Q(?$]K/XEOM!6VNA=6=N+AV*C:Z
MGIMYR3^%7='U+^U])M[\6MS:"9=WDW*;)$Y(Y';IFN0%M(OQ;ULI.T33:'$R
M21@;D^<KD;@1G*]P:S-!\07FIZ5X,TN^U&XB.JV\TT]TKE9)FC/$8?\ ASG)
MQS@8'6@#U"BO.M1U#5=-GTGPV=9BO)+J]FB>?SC!,$5!)'$T@#8<AERV,D8[
MG-4M5E\2:7I4=G<:\R3KK5M'&;><32I!*_"2NR#<1@XXY'7(H ]2S1FO.(Y-
M7LM1\7Z-9ZM=7#PVULUDU[<+N664,,!R.,D #W/%8<OBFYTO2M7CM9]2L;T2
MV=L]IJMP6-F6=P\B2MNRC#'S8XQGTH ]CHKB/"5IKVF^(;BWU*]MVLKFV\Z"
MU%]+=R(RL 7#NH(4[NA)YZ=Z[8C*D<\^E '.WGBMHK^:"QT>]U&&UN%M[N:V
MVGRG*AL!2<M@,N<=,]\$5T>:\6M[NY\-:?X_U33[BY:XLM1\N+S9GD0;RJF1
MER=Q .<D'I6P)?$'ANRNM<&H6\EO)8S21VOV^6^$SJA=9%+J-H&#G!P1CH<4
M >HYHS7FNBIJRW.D:Y'KUO\ 8;V-DE62]EN/M3LI92%90L94@D[0  ".,4SP
MQ).-?@T[6)M5M-6FLYAYJW;SVU\#@^=$22J,.H&!@,/I0!Z;FBJ.DV']EZ5;
M61N[B[\E=OGW+[Y']V/<UC>/]7N-&\)3W%M+Y#R2Q0-/CF%7<*SCW )Q[XH
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MJKR2$C(<@?[/0^E;>MQ17O@32/%6AM%)?Z!$LZ/M.V150"5#QR, \CH0><T
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M!SENV.>@7P'X;2X>==. E>W^S._FOED]SGDX)&>N.,XXH Y313>6FJ_#^?\
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ML-K?F^L&\51?Z7(%C5D9<RB/;@+&"!G&!GZ5[2VG636?V1K2W-MC'DF(;/\
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MFDLA%<2/"D4* ,I16"1H#)UQUP ?:H/'E_I]OXIABNKNVL9/[)G(N;S+H5+
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M$[$?+O\ ,#[2>F=H)QZ5QND36EG\-_!"R 1W$&N)+<+Y9WHJR.69L#( 5D_
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MH **** "BBB@ HHHH *",T44  &!BBBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.T')QZT 3456-_:K.8#/&)0,E"PS^53HXD7<O2@!U%07%Y;VB[KB9(ESC+L
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MD45K(Y=00/EP,,>>W3!SB@#<HKEK;X@Z!>+9/#+<M%>2K!'*;9PBRL2 C-C
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M>JS7D.Z1&W(^,?=8X(V\_45U-%% !1110 4444 %%%% !1110 4444 %%%%
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MB5W+3H&YV$D$GI\P]14]MJ=A:MK7A?Q-I5S>ZK<:E+=6T A9OMH+9C97'"@
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MD59,=0K%<%O]GKSTJ]:^)]%O-)N=4AO5%G;2-%/)*C1F-QC*LK $'D<8[BN
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M_F=YK2)UDB)FD=)(B 2^ 0?E!'/X5T/@*/5HM*O!JK2RYNV-O<SVXAFGBVJ
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M6W9.\ =^/I5?PK+JMAJ^ES^)M'U6&6. :;;7$TT4D2;BN,A?FW,5 W>@'UH
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MQV2@@<*3@C'?UI/[$UW7- T30M6TT6QL+B%[B\$Z.DBP]"@!W;GQW QD]>E
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MH$E5A-!W=&.,@8.<@'ZT =;17):7XV:_U/1[2XT:YLTU>W>>UEDD1L[5#$$
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MV#"VLT@#2XY^49R2,9R.F*H:5X?\.6&I[;1_.O8.5CGOI+AH>,9579MIP<9
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M.UAM;6^O$;RU'^LE5>2,GD@9SBMJN*75-9@\3>%[+6].TDW=XMT)+B ,S1E
M3^[W<J"NS/)SDC Q5"'QUJX\1Z9I]S%IZ+J$\]N;9%8S6;+G9YC;MK9QDJ I
M (H [6'1=.@U>;58K8+?S+LDGW'++Z'GIQ6A7ENC>*==TK2-:U/59K2\']K2
M64<<4#AS/O6,'@GY !]T L<=2374^&M?U?4-6O+#4;"3R8XUEAOUL9K6.3.
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ME.US'*AM8;N5>5PA7((7/S;>V.^3U'C70]5\0:9!9:;)9Q!;B.=WN"W5&#
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M.@TG3+>PMC(88$VJ97+L?<D]30!;HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.>"&Z@>"XB26&12KHZY5AZ$
M&I** (+*RM=.M([6RMXK>WC&$BB0*J_0"IZ** "BBB@!DT4=Q"\,J!XY%*NI
MZ$'@BJ^GZ98Z3:"UT^UBM;<$D1Q*%4$]>!5NB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *C$$(E\T1()#_&%&?SJ2B@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *,444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1136=4QN8+DX&3CF
M@!U%%1R3PQ$"25$)YPS 4 2445'+/%"K-(X15&69C@ ?6@"2BJ=OJEC>!_LU
MU%-LQN$;!B,],XI]O?VEV\J6]Q'(\+;9%1@2A]#[T 6:*;O7GGI2A@: %HIN
M]?6EW#&>U "T4TNHS[=:02H<<]>1F@!]%5;/4K/4/.^R7,<WD2&*38<[7'4'
MWYJSN ..] "T4FX9H)Q0 M%-:15!+' '<UD6GBS0KZ6YBMM1BDDMD\R50""J
M^O(Y% &S16?8ZYIFIPRS6-Y%<1Q??:,Y _SBGV&KV&J*S65RDX0[6V?PGT-
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MDLK0Z?(T5QMA8L&7&0 !D]:UX+N&>"*9&^65 Z[A@XQGH: )Z*;O!^GK3LT
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M-^AB8J%  RNX#Y5Z$=*BU'PE/J;ZGYND7T<.I,'NK>+4D6-W&/FQMSGY1WH
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M_MSS]>OY/[:2);LF.(%B@P",(,<>F/QK4/A"-]3TN]EOY7_L^T:S6+8H61&
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M9O#4^HWDL!\11V"Z@\G[WR73S/+WGG=R!NZX)QCBK_B"YU#1[WQ1I5IJE_\
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MAT#2(EU&^M?L^8R%+^FXL0/<GJ?<U>\*>&;/2M-L)Y+"2'4(K81/Y\YE,9P
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MZKJ]Q9V>L6$<<$=U&QV76G\</"2",'=D@=3QZUZ?;6MO96Z6]K;Q00)]V.)
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M_#,O_";:CK=TEE-;74,421LA9XRF<')&.<G\A71RP17$1BFB22,]4=00?P-
M'B^I0:9%I>H>:UNNB'Q- ;%G8*JH73S_ "CV3.[E>.#727L&A>%?B#X;2%+6
MPL)+2Z5 .$:1C'@#W->BB*,(J"-0JC  ' I'BC<H7C5BARI(SM/J/2@#Q*?6
M+.T\&WFF74R0W=MXG+-"3EE07 ?>0/NK@]3P:T[V'P_/X@^(\LD>G/*NG1/$
MSJA(8PMO(ST.\ID]<D=Z]8-K;F1I#!$78@LQ09..F3[4_P M.?D7GKQ0!Y&U
MY8/J?PJNC<6Y<VS1O*77)Q"J@$_[^X8]<CK4_A+3-.\1>'O%_AB[=1<R:K=,
MR;<M"-R['/I\PX]<'T->K"-./D7CIQ6;KECJ5[8>5I&JC2[HR*QN!;I-E>XV
MMQSZT <IX0U*\NK.76O$"/:_V+;/82[N0SH<S2@#L0J=NS8KL]+U2RUK38=0
MTZX2XM)AF.1<X/.#UY!R,8-0V&D)INB#3;>YF4[6S<_*9&=B2TAR"I8L2>01
MSTJ?3--MM)T^*RM581)DY8Y9F))9B>Y)))^M '"^(TTJ/XKZ?<:ZEH+#^R)$
M62]5?*\SS,X!;C=MS[XS7+BQGTC3-$U&X#0:'!XI>XM6DR%M[1CB,D'E5)R1
M]1ZU[8RJPPP!^HH(!&" 1Z4 >&ZA=0ZAI/Q,EM=\J27%M,A$3<H"N6Y'3'/T
MYZ5[/I>I66KZ=%>Z?+YMK*,QN$*AAZC(%6]J\\#GKQ2@ # Z4 ><7,FA'XQ7
M_P!K.GEDT(>9YNSA][;\Y[^61G_9]JY_PIJ$-MI/@+49Y%?2K2.Z@N95^9+2
M=ON&3'W>#C)QC=7LNQ"<[5SZXI0B@8"C![8H \7\76C2Z%XPU+3XY&TBXO;.
M>)T&4=U(\Z5<=5^[ENA*GTKV*RO(-0LX[JV<O#(,HQ4KD?0@&IMHQC QZ4M
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MO&'B'0EALQ]@MHY;5SN^9G7(#G/3/H*\UO-1T]K^VO(;BSLXU\4QO+#<MOO
M1( [NY(\N/ ^[@\=^U=.DEC=_$+QN)G@DMWTF$G>05*A.OX<4 =?;>(XK.'1
M;/6;NS&JWZD%;>0%-RHS,PR<[?EQGU(%;D=Q#*2(YHWQUVL#BO'+"72+>R^&
M=]J+6:6@M[A)YIMNS(AP Q/'WN,'O6M>64_AGQI=6.BQ!;7Q5!^Y9!Q;W"GY
MV! X7RV9\<\CL* /4%974,C!E/0@Y!J%[VTCNDM7NH5N'&5B:0!V'L.II;2T
M@L;.&TMHUC@A01QHHP%4# %>)>*;_3KBYUR:.6VM)K?68-\=PVZZD=70%P3_
M *N(#. ,YQU'2@#VJ;4;&VN$MY[RWBFDQLC>559LG P"<FDDU*QANUM9;VW2
MY;&V%I5#G/3 SFO+O$%[;1:]?ZI976G:K8W-U:"\TZ8@7"L%3RY+=@<L""K
M?[WOA^KROI.OW5Y9RV&KV4NK1M<:>XVWL$X9 #$1RPRH.#_#GMDT >F?VMIO
MV=[C^T+3R$?8TGG+M5O0G.,^U/GU"RMB1/>6\1"[B'E"X7(&>3TR0/QKQ37+
MNUL_#OQ)L+B5(KN?4@\,#'#NI*D,%ZXP#STK=32O#FO_ !,LX;NVL[I)/#Z2
M,I/WY!(N"<=6V_H/:@#TXZC9+>+:->6XN6Z0F5=Y[_=SFFRZKIT#E)K^UC8-
ML(>900WIR>OM7B>KZII'FS3074%D$\2QRO:R@FX#*P5Y'8GY$P. !@>I)P+^
MI6^BRZ;\2Y5CL6D#AH6 7()C4Y7TR^>G4T >NWNJ:?IOE_;KZVM?,;:GGRJF
MX^@R>32WNI6.FQ++?7MO:QLP57GE5 2>@!)ZUYK+KNAV>NSIXF.=/U+1K>*U
MNF5GC= '\V,,N<$D@^I_*J.IW=GIGB?2QJ5WJ6B:)-HL=O9.(T<( 3F.3S$?
M!*[<]^ #0![ KJZ*Z,&5AD$'((JM<ZII]FSK=7UM 47>XEF5=J^IR>!R.:Q_
M UI:67A&R@T\WS62ES U]_K60N2"1@8!Z@8'&*YS5HM(E^--@+Q;)BNDR%A+
MM_UF\8SGOMSC/:@#MUUS27FMH4U2R:6Z7?;H)U+2KZJ,_,/I3KO6-,T^>."]
MU&TMII1F..:949^<< GGFO&-,_L*R^'6EW EL$NDU]&\X%5?:MQU]0/+P?I6
MKJ=_IEIXL\16/B:?48;?5C&;1H(!,ES#L V@A&/!SC'KGK0!ZE?:QI>F.B7^
MHVEHTGW%GG5"W..,GFLVZ\8Z)9^)H=!FU"W2\DC+D/*JA#E0J')^\V[(7K@>
MXKSBXNK#1?$6H6/B0ZK96.H6%K%:D1"8R((@K0L?+8[MV>F.<^U:6FI!I'Q+
MT%[F"XM;:;P\MM;B[RSF039$9..7"D9':@#M=*U=8XM0FU/7=+GB^W.D#PRJ
MJQ)@%8V.?O@<GZBM&QUK2M3EEBL-2L[N2'_6K!.LA3Z@'CH:\3U%+:X^&?C:
M*TA1C+X@>6TC0;BR%X\/'@<J0&P1VS77E+4_%2\6U(CL9O#/E(ULOREM^0%Q
MP6V<@>E ':Q>*-!FG>&/6+$R(<$>>HR>G'//.1QGD$=:D7Q#HSZF=-&J6GVT
M-L\@R@,6YX [G@Y Z=Z\F\'^(-'O=0\*VNH7]A:RZ/ \<(:*1'N/,38H.Y J
M\$$X9LMT/>M32KYU\2Z>EA,=2T^XU&21M,NHL7.FR,9-TRL!_J\E^O'S8% '
MJS,J*68@*!DD] *RK+Q/H>I&<6>JVDOV<%I<2CY5'\7/5?\ :Z>]-\52"'PG
MJ[FR-\!:29M@2/-&TY7CGGVY]*\U\/ZC;6WB_1+N>:Y>V316@/\ H+I# <H1
M$GR[B% .2Q/0Y(YH ],@\4:#=:A!86^KV4UU/&9(HXYE8R*,\@C@]#^1]*Y[
MQ]XVM] TN:'3]4MX]822+; 4\PD,X!![ [23SV'O7'Z:(+?PW\/2B+%)'J9>
MXVIM9?O@E^X^\O7U%5M4O'M/A]X@\/ZI%=?VX^J>9@0.QF!F1Q(K $$; ?RQ
M0![A6'<>,?#=I.\$^N6$<J2K"R&=<JYZ _U].];$$BRP)(F_:P!&]2I_$'D5
MX]J*1O\ \+2)BW-,(A#\F2Y"%3M]?FP..] 'JMKKNE7VHSZ?:ZA;S7<"AI(H
MY 649Q_,8/IWJ&W\2Z+>ZBVG6NJ6TEX-P$:N"6*_>V]F([XSCO7G]D4A\7^
MWACP(]&=)-JX 8Q\*?<L#^.:PM-OU%_X/N1;ZA#!!?3>991V4GE61?=A Q4L
M[$MDDD_110!W7A/Q@[Z1JESXAOHP;;6)M/BD6+;O"XVC:N>3S72WWB31],F6
M*]U"&%V 8AC]P$X!;^Z">[8'7TKQ_P .7UUX>UB^\0NCW>EG6;J&6W$9+P+*
M5*W$8[YVD'V''6M>_N+>V\3^(;?6K'6;RQUDQR6;V D*7"&,+Y9Q@9&* /7
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M:@+;U9 2 3G@\]*P-4\&:S?Z1JU]#:$7E]K$%^ED\JAEBCP,$YVACR<9].:
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MU'3?''B&ZFL9(]/NX;:.VG>6-MWDH4.0#D9SD<=N<=*ZJ_\ ^0;=?]<7_D:
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M.UB2"C[N-PQG Z9&>HKI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *1E5T*,H96&"",@BEK$\6>)
M+?PIX>N=4N$DD\M2(T1&8,^/E!(!V@GN>* *+^&+E?B!:^((&M8[.&Q:S, !
M#'+%MPP,=>U=&EK;QG*01*2=V50#GU^O)_.N<D^(7ANTMK:2_P!1^R//"9EC
MF@D5MHX/!7/4''KVS5B;QQX=MT\R34@(MD4C2B&1DC6090NP7"9'3<10!M_9
M+?+'[/%ESN8[!\QZY-(;.V9W<V\19QAB4&6'OZUAR:I90>,;E)-<D#6^G&27
M3?+)1%# F;('7! Q[TMAXZ\.:G=6EO9ZD)7NR1 ?)D"R$#)4,5V[L=LYH W!
M:6ZHJ+!$$5MRJ$& ?4>]8>D:%JD>JMJ&N:JFH2PF1;)8X!$L2.1G=C[S8 &>
MPSUR35.V\1Z3I;Z]J-[XCFN+2&Y5)(Y8&"V;8^XN%R<Y'K^=:VF^*-&U>^EL
MK&]$EQ%&)BAC9-T9. ZE@ RY_B7(H V*B:WA<N6AC)< .2H^;'3/K6##XYT"
M>\AMDNI=]QN-LQMI-MP%^\8VVX8#U'UZ<UMWM[;Z=937EY,L-O"I>21N@% #
M_LL!G\_R8_-_YZ;!N].M*8(C,)C&GF@8#[1NQ]:R;/Q3I=]=7%I&]PEW!$9W
MMY;66.4QYQN5"N6'T!KD_#%W=>+KV?41K6J6L]KJDH\A(I%@\A" (F##86(P
M2?O#/2@#T%K>%V+-%&S,,$E0213PBJ6(4 L<D@=:QM5\6:-HM_%8WURZ74R%
MXXEA=RX']W .3[#FN0\9^,(+WPGIVLZ%J\\-N-4A@N"F8SC/S*X(W#&/;KW%
M 'HQ@B+,QC0EL;CM'..F?I4F*YIO'6B+:ZC<%KO;IVPW2&TD#HK E7VE<[2
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M!P 2<#I0!TV*,5SUQXSTV&YL[>.&^N9;VV^U6P@MF;S$^7IT_O#KT[XK.O\
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M,J63Y!EE;'!]0?KI7?B_5=,LK87.BPBX-FUS/)+>E+= #A5$QCP7;^[@8]:
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M)&/EE!W8X)Z@=?4@'!XK9^&.FWVC^"H+#4K22UN8II2R28Y#.6!!!/8UV5%
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MQO!*B[/XR 5*@=.<CI6/9>#]:\/P^'KBPM[6]NK.>ZENHFN#&NZ<?PL5.0O
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M#))4[1WW]3V';!KMZ* ,#P9H"^&_"UEIWEB.4)OF&[=\YZC/?' 'L!6_110
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M-SJZ7UJ(+D!$7<K;<%1A1L 'KGH * .P@\;0)=:O!JEA/IITVV6[;SF5M\3
MX(VG .1C&>M.C\8B"XFBU?2KK3DCLFOO-;$B>6IY#,O <?W>>O6L+6/"VK>(
MO$&N">T%I8:EI<=HMQYRLR2(Q<$J.HR<=>WOQ9@TKQAX@T2ZTGQ&;&Q@:U>W
M\RU8R/.Y7:'(/ 49)P.2<=!0!=TOQ_8:AKUKI,B1PRWL)EMBERDV[')1]I.Q
ML<XY'7FNNKC?#UOXT$MO!K0TV&WLEP9+9BS7A"E1G(^1>C'C.0.,9KH]&EU2
M;2XGUFWM[>^);?';N70#<<8)]L4 7Z*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBD9E498@#U- "T44R6:.")I9I%CC499W(  ]R: 'T4R*:.>)989%DC<9
M5T((8>H(ILUS#;J6FD2-1W=@!^M $M%,CE65 Z$%6&000<U$M[;O.8!-%YPZ
MQ[QN'X4 6**,U6GO[6VN(H)IXDEFR(HV<!G([ =Z +-%58=2M+B>:""XBEE@
M(66.-PS(3R-P'2K5 !139)$BC:1V"JHR23@"H;.^MK^!9[2:.>%L[9(F#*?Q
M% %BBBB@ HI"<"JEEJEEJ+2"RN8K@1,4D,3AMC#'!]^: +E%-=PBEC3+>YBN
MH%F@D62)ONNAR"/4&@"6BJ=]JECID2RWUU%;QLX16E8+EB< "K8((!'0T +1
M2$X&:JV6J6.HR7$=I=13/;OY<P1L[&QG!]#0!;HIDDBQ1M([!4499B> /6J]
MCJ5GJ=FEW8W$<]N^=LB-E3@X/- %NBFAP:7.* %HII<#IS]*J7^K6.EVWVF^
MN([>'<J;W.!N)P!]<T 7:*:'5E# C!&12[AZC\Z %HII;'45C3^,/#]O-)#+
MJ]FDT?WT>4*5^N>@]Z -NBH+:[@O+=+BWE26&0922-@RL/4$<&IMP(R#GZ4
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M(\2\L <XX]]IQ]* )Z*H:-J;:OI<5\UA>6)DS_H]Y'LE7!(Y7)QG&?H:OYH
M**,UAZIXEATOQ%H^C26L[R:HT@CE&-B[%W'/.<].W>@#<HHS1F@ HHS1F@ H
MHS1F@ HHS6%IOB:/4?$^K:']CFAFTU8V=Y&4B0/D@C!/&.>>>>@H W:*0L%4
MLQ  &23VJ*TNX+ZSAN[:02V\Z"2-UZ,I&01^% $U%&:SH]0O'\036#:9(MDE
MN)5OC(-KN3C8%ZYQSG_ZV0#1HHS10 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+=MV/2@#HHO%EOIE]XG?^QK>*]M+J"#;#)E[MY!A,G''Z]*V%U[Q#9G44O\
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MTOPPNF>)=9UD7DDIU79YT#(H5=@VK@]> 2/?-9T'P^M(--?1QJ%VVAO<>?\
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M?7%=MK][)H7A+4;VWW22V5F\D?F,6+%5.,D\GI6?H5MJ6K:JFO:YI$6FW5O
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M$0(JJ%1F4<G.3DXQTYS6DOB_7!IFCP:E9-I5Y>7YLY[J5%*HH7<'"Y(5GR
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MZ$]S:HB^<#C?" JDQ^FX<BET;7?$;6G@S5+O6?/75Y_(N+86R(FTHQ!R!NW
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MR\6DXX(AA,Z_DI ^AK6\4W%A'=W^HZ5=Z5?V'V");O2Y=H\R#YBK6[CH<MT
MQG'?% 'K-17(G-M(+5HTGV_(TJEE!]P""1^-4=/U_3M2OI[""?\ TZWCCDGM
MF!#Q!U#+GMT(Z=*T)I8X(FEFD2.-!EG=@ ![DT <MX'\477B'PNFLZLUE;"6
M5T1(P4"[6*\EF.22/:NE@O+6Z:1;>YAF:,X<1R!BI]\=*\/M)=/E^ \"3RV[
M21ZDH 9QN0FYR<=P=A)^F>U=SHBZ79_%G4;73OLL,;Z1 ?*@*@%@[=AWVX_
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MM[#RGLVW0%)I!L. ,_>Y^4!>>P Z<4_5_!WA[7KZ*]U32K>YN8@ LC@YP#D
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MXDMKV43W,;W<I$KC/S'YNO3Z[5]!0!SNG:= _P ;-9<O= I80S#%U* 6+="
MV"O^R?E]JTO&S:JE]836L-W>:;!%*][::?>-!<]MLB[64OC#?+GG/0\8W/\
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M$"S-/(Q$8& N"V,<>G7GKS3[KP[I=[K%OJUQ;L]];KMAE$SC8.X !QSWXYH
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MU]::-H?_  A>H);6T.ASR*VI7"#*/*(L0M*W?#ECECUR37JR11QQB-(U5%&
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M4$VWTVXQV;8.)&48!/8!CC)YKA=-N[5?!7Q%M;FXEFDDNIWC>6%D:4LHV'
M +'!Q@?3% '4Z7XU2UUC3(]1\36-[!JD&\Q[4C-I($W'+#C;QMPQW9/6NRG\
M0Z-:Z@EA<:I9Q7;L%6%YE#;CT&,]3G@=^U<%=7-K#JGP[UQI\V<%O-!(T<;/
MAFMP ,*"<Y&,8SFN<%K:-=:OH/B*?7SK$M\]S;6D!Q%?$MF-U.P[>B@DG  ]
ML  ]>;Q)H:WRV1UBP^UM+Y(@%PI?S/[N,YS[56USQ;I>@:CIUA=SHMQ>R;5#
M-M")@DNQ/ '&*Y3P;8Z=>>/?&$MQ:6LL\=]#+ SQABA52"R$CLW<=ZO^.9WL
M/%?@W42L@MX+N9)9$C+A=\>T# !Y/(% #M%\8Q0:EKL.O:S9K';WRP6K-MB!
M0HI&.>>6ZY_*NGU/7])T8HNI:A;VK2 E1*X!('4X]!Z]*\IU2YTV72OB23Y1
MN9Y0(MT?SN-B  9&>'SQV-7+N]L+7Q2U[K0OWTG5=*@AM;FT\QE8J#OB8)SD
MENAH ]5>[MH[1KMYXEME3S#,S@(%QG=NZ8QSFLRV\5^'KR_CL;76[">ZE7='
M'%<*Q<>V#R?:JNFV<5IX!^RI8R6<*VD@2VFD,C1IAB Q/.<8X[=.U>9^'8M/
MUGP+X1L=*2-]=MKZ.=GCC^>!%D)D=SCIMQUZ\ 9H ]7M_%.@7=_'8VVL64UU
M(S(D4<RL6*C+ 8]!_7TI]IXDT:]N?L]MJ-O+,59E16Y<*<,5_O >V:\[T33X
M-7\.^.9-'B@;59-0NS:SK& ^QU&W8W4!AN (]:LM+'X@TWP?9:2LD&K:==0-
M<IY3(]I&B$2AL@8!^[C^+MF@#N8?$^BW.G7.H0W\;V=LVV:8 [4/<$X[=_2J
MUM?B3Q/?G_A(;>6UAM59]-\M5:V/7S'?[PR.QQUKEWTF_MOB!=Z'#&?[#U9T
MU61NBQF,@2ICOO;R\CT-/O7B_P"$[\4LUM<S1-HBQ/\ 9X6)=QO)0'&-^UEP
M/<4 =3/XATR[TV_^R:S!;216Y?[3(/EAW A9"&P",_@<46VMV5AX?T^ZO]6C
MN_.B7;<I%@W+;<EE1<GGK@#BN$L9M0.E^(-.AO)-=T]=(E2"]>V9;B)BI"P/
MQ\[<Y]1WQFDT22;09O".K:G:W,>FPZ(;*:1HF/V68LIRRXRN=NW.* /0&\5:
M FG0Z@VKV:VDTGE1RM* &?."OUJ72O$&DZW)<)IM]%<O;,%E5#RN>G7L<'!Z
M'%>::MISMHVKW%M87/V#4->MI[6V6U<DHI3S9-@7*JQ#'D#('N,]7I0_XNGK
M<RP3+#+86Z+*8&5'92Q(#$8) *]_Y4 ='J>N:=H_EB^N-CRYV1HC2.P'4A5!
M) R,G&!D5S/CCQQ!HW@TZEI-TDTUUA+6:-#*@^90S$@%00#T/?L>14EZ]YI/
MQ(&I7<=Q-I5UIXMHI(86D%O*KEBK!03AASN]@.U<3KNDWUOX UR%;.\;^TM<
M:[L;6.W=F6'S%.2H!*Y )P<4 >E>'(YD@N+MM9N+^PG(>W^UP^7)"!D."2%)
M!(R,@8]ZGM/%&CWUX;6"[/FB W/[R%XU:($ N&8 %<D<@XJS>W*-H=S=)#)<
M(;=Y!$%*O(-I.T C()Z=,UY=;:1J\UC?:-I-Q?:AID^CSI;OJ5JT,]FYV@1>
M8RKD-@<?[([ $@'H4/C+P_<22(FI1@I$9OWB,@:,<EE+ !P!SE<U4E^(OA.&
M/>VL1LGE"8M'&[A4)VY)53CD@<^H]17)Z2UOJ0M;F3PKK5OJ&G6THGGOY)V6
M >6RD1!F.\L<  #I]!6IX'T*/4_A';Z+J-M+ \EO+;S++"4="78@X8#ID$=J
M .O;7-/$MK#Y[![J!KB']T_,:@$L3C QD=<=1ZUD:%K5C9>%[2ZN?$#ZM'/,
M\<-V8"'G;>1M5%&6(((X!Z9Z50\ 6FJ_8FO->MGBO+.(:;%N!)>.(G,@_P!\
MX^NP'O7,Z5%J^@Z!X6U,Z+J%PNFW-\MY:)"PE5978JX4XW8![?WNU 'HJ>*=
M%DTT:@E\C6YF^SC"L7,N<>6$QNW?[.,U:TW6+#5XY7L;@2^3(8I4*E'C<=59
M6 *GZBO-_$EO?:E;6&NV_A>Z6QM]2>>73X0T-S<(\>UIF"$$/G/OCKP:W="D
MMM&T[4]9T[PMJD,,[0XB??)=W)Z%BC,2 -W?G@GTH [FN2U'6+[4O&*^&=+N
M#:+!;"ZOKQ$5V0$X6-0P(#'KD@\=*ZVN&U#3M1T+XB-XEM+2:]TZ^M!;WL<'
MS21,OW7"9^88 &!SUH U8+:_TK6;9!KLM[8N&2>"\,7F1G!*LK!02,X&WGJ#
MZTMIX[\-7MZEI!J<;3,91@HP"F,9?<2,+@ GG' S6+>6@UGXE:#JEKI=P;:R
M@N#=7$]FT."R@1CYU!8@@],XS69I&AW^H^ _%VF+9SVUY>7MW+;_ &F%HO,6
M3E2"P'49'MGF@#M[3Q3I-Y>QV<4TJS31F6 2P/&)T'),98 /QSQGCGI4*^,]
M"DL+:^CNI'M[F[%DCB!^)B<!6&,KSQD\5STMM?\ B*\\(LMC=6,VF2^??&6%
MHQ%A-IC5B,.&/'RDC'6N:ATW6;+0X]&&A:C-/;>(Q>/(D0\MHA*&#*Q(!R/R
M[XH [^^\?^'-.GNH+B]D$MHX2X1+>1C%D9RP"\+C^+I6X^HVD>F'4C,&LQ%Y
MWFH"P*8SD8Y/'I7GS:AY7BCQ]9#2;R]DN5@5%A@+I(S6R+L9APO7.20,9YKI
M=-TRXT/X<PZ9/OGN+;3S$PB4N6;;C:H&2>>!0 R'XB>&;@VA2]EV7BDV\AM9
M0LA'5%.W!?I\HYR0,9-6H_&>A2:->:JUV\5K9S&"X\V%T>.3@;2A&[/(XQWK
MDK+2]0M].^'\<FG7(;3&/VP"(GR?W13)QU^8]L^M5]2L=:AT?Q8;;1I;AKO6
M$G1'MP[-!A 7C5@06!7@$<=<4 =E-XVT2WL+Z\FEN42P=4ND:UD$D.X94LFW
M(4COC%:8UBT/V #S2;\9@ C8DC&[)X^48QU]:XWPOITLOB'Q-!?:+J<6GZE#
M %DOG\SS$$95MS%B<G/W>W?'2I?A]HU_8F=+^X2X@TLR:=82*22T>_<S$^OW
M$QV\N@#J+SQ!I]AK5EI-R\J7=\&^SCRF*R;1DC=C&0.V>XJI;>,='O+/4;F&
M2X*Z=)Y5RAMW#H_3;M(R3["JOCO1KO4M&@N],0OJNFW,=W:*#C>RG!4^Q4FL
M6T\)ZE8^,+5P?,L+^-;O57Y(-U$VY2O/ +,O'I'0!H7&O66G:MX@U1)M8NI+
M&SB:?3_+98T!W89%8#G"DD],#O7/:MXINKF/P)J[37ULMU,ANX(DD"RYC#':
M@Y<9/&,YK6O[#4;GQ#XPBATZX:+4=)6"WG("HTBI(-N2>YD&#TX-9*V&L3VG
M@&)M$OHCI$L2W1=5X"Q*I;@GC.??C- &AXR\3+JOPWUJ^TB[N]/N["9(I5<F
M"6)PZ@JWU5N,'G(KI[#Q9IM_J5W8@7%M+;0"Y)NH3$'A)(\Q=W5<@\G%>=ZU
MH6L76B^.K>WTB],FJ7\$MJ&0?O%5U+'KP/E/7VK<UG1K_7?'&H-%:W=O:7WA
MQM/6[9,+'*SE\'G.,'!]^* .CM/&6F7=W:0F.[MX[XXLKBXAV17)QD!#ZD<C
M<!GMFLW1M3BTG5/&,VI:A+]ALKN-E:XE9Q$K0HQ5<]LMP!["J0TW5=;\.Z!H
MEWID]E<V%Q ]S<$KL00]XV!R2V !QP&.<5FZUH&M:W!XNCLK&>&:XOK:[M!<
M81+@1*@*YSW*$C..W2@#5M]=DO\ XHZ=;+!JUD&TV:66VNVVH_*!&"AB,_>!
MZ&NCUWQ5IWAVYLK>]6Y:6]<I"L,#/N(&<<=_;KR*YZ ZSJ?CG1M9D\-7%G%%
M9RV]P\LL6Y2S(>S9*@AL>N2<5'\1I);;7O!MY':RW*Q:D08XL;V)3H 2,G )
M_"@#7@\?:-+I>J7LJW=L=,D$5S;3P[9E9L!1MSSN)P.:/^$ZLEL=3GFTW4H[
MC2]IO+/RE:6)&7<'X8@K@$Y![&N;U71M>NU\0Z[8Z;);3:@UK&EJ"@N&AB.7
M?))59#GCT"CO5OPCHM]I_C'7Y)M#GM],U*&WV//<+*?D5E(?YB2Q)YZ^YH Z
M=?$]K)IVF7L=K=R+J(W0QQJKN%VE]Q 8\;1VR>0,9XK%@^)ND3PZ?<BPU9;2
M_D:**X-H2GF L G!)+':<8!Z_7%7P1H<VDW6J[9C>V.ES36NEQIC(5BLDBY)
MQD-A.<<H?PS+'0-?M_!W@_3GT6?[3INK+=72B:'Y8U9SD'?@YWCIZ'VR ==9
M^-=-GL]6N+N*ZTXZ2P%W%=Q@.@(W*<*3G<.F.?TJ&#QYI[R7$5U97UI/%;&[
M6&1%9I8AU*[&89'=3@C-<[K7A36-<F\=6RV<MM'J@MGLYWECVR-"J@J0&) 8
MKW'3KZ58LK#7+O3+DW'@_3])G6SEC(MFA:2YD9"H"$8")R2<MGH/7(!M6'CR
MPU"XT^-+&_C348#+9RRQJJS,%W&-<MG=CN<*<<$TWP;XHO?$AOWN=*N;6*.Y
MD2-W,95=A"F/AB2V0Q)QCWKG[+0M<AA\ (^CS@Z1N%Y^]A_=Y39Q\_///';W
MXK;\$V6LZ3+JFG:AI8AM3>SW,-X+A6$HD?< $'(X)ZT *OC&[_X3F]T:72+F
M.RM8%D>X+Q[5!)_>M\V0F%.,9/J!5F'QM:23V!EL+ZWL=1?R[._E51%*Q^YT
M8LN_^'<!FLS6- U6\\6ZN8K3=I^KZ6MDUVLRK]G(+9)7[QX;(QZ=159-!UK5
M/#FB^&-0TLV\.GS0">\6X0QR108VE #OR^ ,$#'- &Q\2 Z> M5N89YX)[>$
MRQ203-&RL#ZJ1^5<M9:HUOXE\.0^&M7GU='MF_M:WCNC<Q@*@^<LS$(Y/09&
M3CUY[#QW8W^J^#[_ $S3K0W%S>1^4O[Q45,_Q,6(XX[9-7]"AFMO#]JLUD8+
MM(%66+*99U&"<J2#DC@Y[]J ,2Q^(FG7MC-?G3M3@L(8Y&DNIH0$5D8KL^]R
MQ/0#/4#KQ5J+Q@5O8[&^T6^LKVXA>:SAE:,FYVC)12&(#@8X8CKUK"L/"6K7
M7PQO?#]W&+&_>>2>)O,5UW>=YR<CWP#6E%8ZOX@UW1-0U72QIG]DF21@94D\
MZ1TVX0J3A.2><'@<4 7--\9VNJZ#%JEO970\V[%H+9B@E#[MI!&[ QR3SD $
MU2LM=T33]6\6WTEM=63VC0M?2W!XE.TA/+7)X( QC&2W2FZ1X1N=.\<ZA?!U
M&CNYO;>$?PW4BE)#UXPH/;_EI[5F:YX5UK6YO%L<< M1J!MI+*=I%8%H,8!
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M7%<CHT:1_$OQ/L&-]I9,?K^]K7US74T;[%&+:6YN+V<00QIP,XR2S=%  )H
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MT<Q>=$)%DWB7_5X88&3D#!Z'O5!_B9#!#J?G:>LD]E:?; MG=I/&\>X*1Y@
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M\ 7*06:ZG(+X >86ASY8P=PY*XY_'M6U:>+=7G\/ZA(]E:#4[#4CI\[!B+=
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M ]A-I.I"YM-86XN4%G(3"B2.Q+#&>CKCUY]#7L-% %#7 #X?U(&S:]!M9?\
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M P2.Q./>I-1T7QIKOA:_L-4ETM;F:T-LB6\CB.1F()E<E<@@# 4<<GVQWM%
M%/2HKF#2;.&[2)+B.%4D$393(&..!Q^%<;?2ZG%\8W.FVUM<'^P4\Q)YS%@>
M>^""%;OCMTKOJSQH6EC6#JXL81J)7:;G'SD8QC/I0!QS>#-:MGT9X);&\2&Y
MN+N^M[AV2)YY6+!U 4YV$G ('X'D5M,\%>(--T'2K8#3'N=.U8WP FD59@1(
M#D[3M.'&  ?N]>:])JE9:M8:C<WEM:7*RS6;B.X50?D8C('Y>E '(:GX,U+7
M=6UXW[6L-IJ6FQ6JRPR,SK(AW!MA4<9/3=V]^+>GZ9XTN;"ZAU^]TMV^S200
M+:!U$K,,;Y21Q@9X"]_:NRHH X>U\)ZM;KX.0O9%="1EF(E?,N8_+ROR>G//
MT]ZETWP9,#J]CK*:?>:/>ZA/?+$5<R%G<,H)R -OXYSVQSV=0W5U#96LMS</
MLAB4N[8)P![#F@#EKOPBUI?:#_8%I86MCIMR]P\3.R%RZ%#C"GLQ.3Z 5#?^
M'/$MIXLO=9\.:E81Q:BD8NK>^C=U#HNT.NT]=H'I^/;K;"^MM3T^WOK.3S+:
MX021/@C<IY!P>:L4 <;=^%M5F\3>%]2-Y#<)H\<RSRS.5DG:5-K$*%(&.H&?
M;C&:P8_A_P")HUTC_B8:.T^G7[79N7AD+W)8DEY.1EN>F?Q&*]0HH \_F\!:
MI=V?B#3I-4M8;*_OWU"UDBA8S13%U8;CNVX&W& ,GKD5-/X0\0>(=!U#3_%.
MLVTOGP>5"MG"51&R&$C9^\V5''  SZUW59\&MV%SK-QI$4KF]MHUEEC,3@*I
M. =Q&#G!Z&@#F8/#WBNXUG0M0U/4M*9M,$B/Y4$A,P<!2V=PPQ ], \_-G W
M/%FCS^(/"]]I-O+'$]VGE^9)DA1D9.!UXK:K+U3Q!IVC75A;7LDB2W\ZV]OB
M)F#.QP 6 P/Q- &#K7A#4+_1]#-AJ,=GK.C ?9Y]F^-ODV,"#V('OCWJ'4/!
MNN:MID5Q=Z\J^(+>=+BVN(8=L,)4$;-A)R#N;)/)R.,#%=Q10!Q%UX,U?6-(
M=M6UM#K0FAGMY[>$K#;M$25 3/S<LV2<'D>@JY)X;U._O+C5-0GL?[1^P/96
MR0QMY<>\Y9R2<DG X&,#(R<YKJZ* .,?P1/-X&TK17OHX]1TIHI;2\CBRJRQ
MGY&*D\\<'\:@B\)>)7\1WNO7&M:>E]-IQL8_L]HX5.=RMRYY#8]<CCBNZHH
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MSV[7 AFN_(+J"!M3Y6W,3VX^M)X+T*Z\.Z!]@NIM^)Y'BC\TR"&,ME4#$ G
M[X'4U0\8>'+WQ#--!_9VG7-J;3;;3S2&.>UN-Q^=6"D[<;.A_AH YZ:]N[?X
MP/?:?I!GN[CPVLCV[RB':3*"=[$9&  O0G...I'11>.6O]'T.]TS3//;54=R
M9IC'#;;%)</*$;&""HXY/I5#3_"_B"Q\6+JLK6UVL6@KI@D>=@\LH(;>WR\
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M01R>8^Q@W"$X&<>I^E #IO$_B67Q-<Z38:%:,((8+@F:[*L8W8@YPN _!XY
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%9GB+49](\-ZEJ5O'')+:6TDX20D*VU2Q''L* -.BN!MO&>MPW'AN?5+'3
MUT[72L<;6TK,\+LFY<Y&&!]NGJ<<PV/C/6I/$EE9W:V*+>74UJ]G&I=[1E5F
M0M*K%6)"\K\I&: .]O+RVT^SFO+N9(;>%2\DCGA5'4FGV]Q#=VT5Q;RI+#*H
M='0Y#*1D$&O.=,U37?\ A'/&E_?36&H"RN[M##+;E4<11J,8W$;2J_=QU/)K
M0G\47\LMGI6E)'#<KIT-Y-(+)YT7?PJ!$(VC@\YXXP#V .ZHK@&\8>(I=3\-
M:;_9=M87>KPSF9;O<6@>($D@ \@CD#OTR.M9=_KWB+6/#^DR)>6EG<)KR:?<
M[("ZRNDP"N,L"%RN2O4^HH ]3HKA;OQ3J-IXD719+VQBNXU@5(KF QB_W;=[
MQ.7PN"6 3DY7OFNE\237=OX;U&XL;J*UN(8'D6:6/>J;1DG&1V'_ -8]* -6
MBO-?#.L:S;>&O"NFF\MIKW6(BT$SP$"WB2,,VX;OWC=!U7K[5TGA_6M2FU[5
M-!U>*(W5DJ31W, *I/$Y;!VG.TC&#R>E '345ROBC6M2T+6]#E$UNFBW=P+6
MZ+Q9>-V!*$-N  )X/''OFL"Q\;ZE(NOZ>]U:W&J6]Q'#I[);%$F#OY8;:6R0
M'SG!P ,T =Y:ZM87U_>6-K=1RW-F5%Q&O6,MG /UP:NUY7J%[K6E>)?'>H:9
M<6:RV=E9SS-/"6\S;%(=JJ&&,\\Y.,#@YXZ&T\47GB*]LK#2I8+*:32XM2GD
MEC\[;Y@&V,+E?7).?3CG@ [.BO-CXT\1W$>F1006$5P=7?2+UI%9E\U5)WIA
M@=I SCVQGO59_%WBM-'\3S?:M)$N@7#(TCV[*+A0 0 -_P IZ]SDD#WH ]2K
M&E\6^'X)YH9M7M(Y8"!,KOM,>>F[/3\:TK.X^U65O<;=OFQJ^W.<9&<5YE'<
M7T7Q&\?P6.CR:E)<16<>Q9(T128"!O+D<'/8&@#T*77M,BU&PT\W:&YOPS6R
M)EA(H4L2".,8!K2KR.T\/:KX;?X>Z.;J#^T8Y+[]XZF2.,M$S8QD$X!]1S6G
M+K_BV7PAKMU97-M+J>B:A-;/BV&+F-%4[MN?E8!B>./E]Z /2:@O;R#3[&XO
M;EBL$$;2R,%)(4#)X')KEQX@OM1476A2F]@@TAKHH47%Q.P_=)D=#\K$@=,B
MLC3/$^HWVB:S>6FOQ7%Q:6'FM;75D(IK6902P= 1D$# YX]Z .YMI[#7M'BN
M$1+FQNX@X66/AU//*L/T-03W>E>'(+*W\N.TAN;E;6"."'"F1\X&%&!T/-<W
M8:]JNK?\([IL=XEM<WNDKJ5U=>4K$\(-B*> <OG)!X'OD+?:KXFTNQT(7ESI
MYN9-5BLKWR4+"1';AAG&P[<9&#UX- ';T5YKXE\7:YI%]J,\4T7DV5Y!$MK%
M#YJ-$Y4$RR8_=N2W SGCH1R9=3UKQ.=3\816NK6UO!HD$=Q$/L89GS$S["2W
M3C!/TZ<B@#T6BJ&BWKZEH.G7\JJLES:QS,J] 64$X_.O/[+Q/XG:+Q'JT^H6
MLECH-]=0R6HM0K3I&OR@-GY><>O4]>E 'I]%><:%J_C.ZU"T-S'-'87UNS&X
MNXK<+#+MW)Y2QON93@\-D]\]:K:+XF\2R:?X0UF]U*&>#5[K[)-:);J@ 8/M
M?=UW I[#G&.] '?:YKNG^'=,?4=3F:*U0A2ZQL_)Z< &M*O(?&=]K/B/X?Z[
MK-KJAM]/BG> :>L"$21)($8NY&X,2"W!X''/6MO5M>\2:KK^L:=X=6XC?2O+
M0!!;E99&7=^\\P[@G0?+SU.>P /0&AB>1)'B1I(\[&*@E<]<'M3Z\T_MCQAJ
MOBO^PH=1M=,FDT>._.($F$4@D",H.2&!/?L.V>:M67B'5!XR.E:KJ$UA<->N
M(+::V46]W; ':8I "=_ )!;J2,>@!Z#16/XHN=3M/#]S/I,+S7:;2$C +[=P
MW% >"P7. >,UQ)\9W*Z0K6&KSZA-J&IQ6D*S0Q17%GE<LCJ0J[OE8 GCGOCD
M ].HKR[6=8\:Z/X?UNYGN6MS!/;O8R7"V[RM&\@1D=4RO!;AL<U:UFX\4>$I
M=*U'5?$SWVG2:AY5ZL5E%"L<;@!/X6. P.3G)! ]Z .YUC5(-%TN;4+B.>2*
M+;N6",NYRP484=>34[6MM-*D\EO$\J@;7= 67N,$\BN!\5>(=8M/ 6N>(M-U
M%X@ETHLMT4; 1!UB)&5Y#,68$YXQ5^:_U37_ !)JVC6.JMIKZ;9PR1&-4)FE
MD4L&;<#\BX P!SNY[4 =M17F^H:[XCO-9M]#T^7[1<V^G+/=RZ=+%'OFWE"1
MYH(**5Y [G!QTJ*^U_Q)9V.DSZV;RUMTAE6_N=)6.8Q3*X57D&&PF ^0.^1V
MQ0!Z;15#19S=:#I\YO$O6DMHV:Z1=HF.T9<#MD\X[5YY-<>+9M$\2ZA'XI9'
MT2]G$2?8X@)5C16VN<=,$X]_7C !ZE17GFG^)M5U+Q9<VXO'BLYO#T>HQ0A$
M/DRL1T;;DX]\UBV7B7Q)J6F>!'_MMXI=8:XBNG6WC.=NX!@-O! Z=L@$@T >
MNT5YCXBU#6/#["TU+6-2CM!;11PZU!$K1QSY.[ST )&[Y1Z8/UJY>ZAJ"6WQ
M 6/4[G_B6QK/9N&&8S]F$N <?=W'IZ4 >A45YOX@US4T@0VU_=22Q:']J-O9
M@!XY2"?.E9OEV?+@+G).>#VIPZWKNL:MX&B_MFXMH]8T^62[6&.,998\EAE>
M"?R'84 >HRRQPH&E=44LJ@L<#+$ #ZDD#\:?7CR7NHZWH-@E]J=V\EIXK6P6
M5'",Z*XP6P,%AV..U>L_9?\ 0C:^=-@IL\W?\_UW>OO0 ^"XAN4+P2I(@9D+
M*<@,I((^H((J6O&/!^IW6F_#GPRL5W=))K.J&TEF+@B)3+(6*Y!PS8QGKR3U
M%=OID]_I7CZ70&N[F\TZ73A=PFX.]X&#[""_4@]>2>E '5RRPPE#(ZH78(N3
MC<QZ >]9>C>)+36M2U6P@@N8IM,F$,WG*H#$@D%<$Y&!WQ7/>.+(3^*/"#_:
M;F,M?-'B.4J!^[<Y Z9]_2N2N_MMK<?$6_L]3N[633YHY8_)8#>^P8+G&6'!
M^7I\QH ]7GU-H=;M--%C=2+<1O(;I$S%'MQ\K'L3GBM"N#O=4U)/B-H%JE_(
MMM=:;--) V!'O"\,<#/YFH?!^IWZ:[!INN?VI;ZI]FD\Q9W,MM>L"I\V)NBX
M&?E  PP[B@#T*LS3M>T_5=1U*QM)M\^G2K%<#T8C(Q^H^H/I3M<U)M*T:YO(
MXC-.B[881UDE8A47\6('XUY=I/VSPIXST6^N-)O-/M-1B&GZA-<M%B>Y;<ZR
M81VY+9&3C /6@#V*BO/O%%YJ!\3:A9&YU"&-=)\[35LF8;KC<1\VSDG(4 -P
M>:ISV7B)I?"&F76OZC9WE_;7 OFC=2=RQAN., C)&>W;UH ]-HKRV%]=U34-
M?TBUUAA<Z2L4%O-<7[PO'B-3YSHJ$2[FR3N.,<8'4@O_ !!XCUB^TZWU.T\V
MWT^V:-X[V:V!:2+<TR!%^<;CT;@ #CDT >I45YI8MJ6L>,=.LKGQ!=/#/H1G
MG-A,8XI95E5-Z< @'KD8S]#SEZ5>:NOACPEK4NN:C-=7.M)93+)-^[>'SGCP
M5Z$X4'<><]Z /7Z*\RNKC4_$.N^)(4U2+3Y=*EVV[->2Q&W0(K"0QKA'4DL<
MMGTX')@Q>:OJ7B;SM<U P0:1;74:VT[Q(9&B=MRC[RC(SMX]P<4 >G3W=O;3
M6\4TJI)<N8X5/5V"EB!^"L?PJ:O)C;)KVM_#>YU)[N:>\TR9YI([F2,[A"C;
MOD8;3ECDC&<@'(KT+Q-=II_A74KA[]K!8[=\703>8B1@,!W.2./6@#7I*\KM
M;C5;?Q!J%C))>64,GAR2Z$#7S2R+*KA1(3D[&([*Q'OFJ%O<7NF?#71M??5]
M2DGU%X+:\GFNG,<,+2'<_&=AP NX<\^M 'LE%<?X9MY[3Q#=@:Q#<6MQ;+*E
ME%/).(R#C>'<D@,.V><$]C5/QFUP_COP?8QWUY;V]ZUTMPD%PR!PL8(X!Z_,
M>>O/7@8 .[J"]O;?3K*:\NY5BMX4+R.QX %>4W%Q<:7-X@T"75-3:R35;.&Q
M?SB\L[RH':WWL057IDD\ GKT./K\;?\ "$^-K"XVJFG7]M]EMX[IY4M]S1AE
M4G!(^8\$8!)H ]FN[V\@U6QM8=.DGMKC?YURL@ M\#(R#R<].*T*XK5%.G^/
M/"%M9W%R+>5;U9(OM+LK[8\C<"2"02>3S^0KD?#DU[K-K9^(I]=LK'4%NMMR
M5\R6X;,A7[.T>_;M.1@!>.#UYH ]CJM]OMO[1_L\2J;KRO.,8ZA,XR?3G^1]
M*\?U6U9/"7C75!>W_P!KTS6V-F[7<C>45\G!P2<G!QSGBND;3--@^+.JW$BB
M'&E1732&1@!)YC_,>><8''3B@#T6BO+O!D7]E^*;&UU6Q=-4N;24PZG;SF:#
M4D^1FD;/*MP#_P "]Q70^.+R2*Z\/V,I9-+OK\07L@8J"-IV(2.0&; ]\8Z&
M@#K9I4@A>61@J(I9B>P')KF_#WB;4-?:RNTT<)I-["\L5T+@%DVM@*Z8&"1S
MP3W]*YRZTJ*Q\1Z_HL$0?0YM&-Z]JV62"X#$+M!^[N )P/[M:GPHT^UM/A[I
M<\$(22YBWS,"?G;)&?RH V]2\1"UUB#1K&T:^U*5#*T8<(D,><;Y&YV@G@8!
M)]*=9ZM?OK?]F7^E_9V,#3QW$4_FQ.%*@KDJI#?,."*Y?2ICI/Q@UZ#4?W?]
MKP0/83/PL@C7#1J>A()SCKQ5G4+[4?\ A:=EHO\ :<_]FW6GR3R6P6,8(.W
M<+O /7KG/>@#N*0,#T(...*\7BLFTWX52>)K*>];5")+>6<W3DQPFYPV!GL
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MXTW1DP_/MQR,G.<=\YKO* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M16@9+B-?NAHV; (]<FNUHH Y(>"I$UW0-3757=M)6;<)XM[W#2YWL6##'7@
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MV:IC[8OVF3$F.G?CTX[5T.X<<CGI[U5U6[EL=*NKJ"..2:*)G1)'**Q S@D
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MWEY;:?:O=7<R06\>-\CG"KDXY/;K0!#::1IVGVCVEG86MO;2$EX8851&)ZY
M&#FF:=H>EZ07.G:?;6I?[QBC"DCT^GMT%1KXDT9IK:%=3MFDNAFW D!\[YMO
MR?WN?3^59^NZ[!]C=;'7[+3YX+R.&9YP&&<@M'@]6*GM_P#7H O+X8T!&++H
MFFJWF^=D6J?ZS^]TZ\GGWK!T'PCY7B'7-0UC2=-E^UWGVFUG.)9%   !RHQ@
MKNX/4T7_ ,0-,?4-8T:POH5U"TM2T4C?,&E <E .Y4*">>^.U6O"7BRQU72M
M)MKK5;:;6KBSCGEA#*')*AC\HX[]/2@#J<5DIX6\/Q',>A:8I\P2Y6T0?/\
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MQ6NQ/J48CN6%R_S*.!CGY< D#'3)J[I&DVNAZ7!IMD)!;0#;&KN7*CTR><4
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M;D\DCVKT%M*TYC(6L+4F4YD)A7YSG//'/-*NF:>DD<BV-LKQC",(E!7Z''%
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M^#(-0L]>@M[0ZC)H(LW(CU2R>.:Q<E2(ED=077CH"<;/IGT2DSCK2T %%%%
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MR5R.G2@#L9M:TJVMHKF?4[.*WE;;'*\ZJKG., DX)S4]Q>VMJ,W%S#"-A?\
M>2!?E'4\]AW->2>(K31- \<+8W=W+H6ERZ<$M)(K>*2#)=C(F'1MI)(/&.G/
M:G:18^'D\4>%+"55F":?=$?VDB><T8=3"6! _A#%0>0* /45UG2WDM8UU*S9
M[M=UNHG4F8>J#/S#Z4ZYU;3K.[AM+K4+6"YG_P!5#+,JO)SCY5)R?PKPFQ33
M;;X=:'>1"UCNT\2(#,NT.JK(Q'/4  _K6CX\U&QN'\:P*\%I<#[.#',#--=E
M1E609Q&@!Z@'KDD=* /6WN;M/%0A:_L%T_["9/LI;%QY@?F3_KGC ^M68-;T
MJZN4MK?4[*:XD0ND4=PK,RCJ0 <D<'FN#-WH=Y\4()O-LI8;CP[(96;;ME D
M4_-GK\JD\]AZ5S6AOI%EX0^'EU$]I#=MJP$TRE5<C$BL&/7'* Y]O:@#U[6]
M;L/#^E3ZCJ-PD,$2DC<P!=L$A5]2<<"N:/C9)?$.BF&_T\:)>V<UQ++O&8F0
M+D-)NVC&[D8&"*O_ !$MVN?A[KBH%+K:.XW#.,#)Q[XR/QKD+:XT+4_%'@@*
MUG-;QZ=,2& V"3:F#@\9RK?BI[B@#TPZG8#3O[1-];"QV[_M)E7R]OKNSC'O
M3K.^M-1MEN;&Z@N;=LA98) ZG!P<$<5XI'>I:^'K"[CNIH]%L-?NS<M9A7\B
M-BWE,$(8;?FR.".>.<5Z#X#72Y&U6^T6ZOKNSNY4D:YN$$:2RX(<H@1,?PY.
M.3]#D Z._P!;TG2Y(X]1U2RLY)!E%N+A(RP]@Q&:6^UC2]+>)-0U*SM'ESY:
MW$ZQE_IDC/4?G7G?CB]33M<U2YL]2M&N7M(X;K1M03Y+V,;B/*8'._EA@=_P
MJ>UU.UM/$WB=?%FVT34H(#:QW6,/#Y9#1*>A8,2"H[\\T =-K&L7UGXR\-:?
M!)#]AU%K@3 QY<[(BXPV<8SCMVZUJ_V]I!U;^RAJ=I_:&,_9?.7S.F?NYSG'
M./2O-M,$NEWGPTM-2D:.YB^U!DF;YT5XV6(-Z=57Z\5A:';V3@:+K5[KA\26
M^I-.NGP@(DDN_(E#^6<#:<EB>@/M0![A=7EK8V[7%Y<0V\"<M),X15^I/%5(
M=?T>YO+FS@U2SDN;8%IXEF4M&!U)&> ._I6-\1T1_AWKFY5;;:L1D9P?6N0M
M%T>_UGPC/H/V5!IMI(^J211A%BA,0!23@#)8GY3R,DX[T >C6OB+1+V58K35
M[&XD:,RA8KA'R@."W!Z Y&?:FV'B?0M5\_[!J]E<?9P6E\N=3L4=SST]^E>3
M^&]+CNO@:9M/T^&?5H#()U5 )GC\_<\9.,_-& ,=P174W4EAXG\;>%[[0BDJ
MVL<_VV1(^$@9,".3W+=%/3DXH ZN+Q=X<N+F"VAUS3Y)K@E846X4F0AMN!SS
MR"!Z]JFN?$.CV5\+*YU.TBN2RKY3R@,"WW01VSVSU[5XCI<6G:M\*O[&TV.&
M3Q*^I9@5(OWJ,)@=Y('"A <MT XK9F>TAU'7_#_B>/67N[V_>6WCM=WE7BM@
MQ@$#@C"@D\# ]#0!ZA>>*_#^GR2QW6LV43PNL<B&891VSA2.Q.T\>U8VE_$W
MPSJ,-[-)J,-K';7#0@S/C<HQA\8X!.<9]*QO#]M8WGQ5UYKRVA>X6SME4%/,
M02* 9 '(Y*MMYZ]^*@\&:;:ZWX;\4^&+^*>-Y=1NC)NA8",,R[&R1C.1D#VH
M ]$;5[!+FSMFNHUGO5+6T9.#* ,D@>PYJ2^U&STRW$][<QP1%U0,YQEB< #U
M)]*X_P !#5-17[=KD06ZTU&TN-MV[S"CXDE'^\50?\ /K5KQA+-8:[X<UB6!
MY=+LYY1=E%+F$NFU)-H[ D@GL&- %_5?%VFV7AB_UFUN(KI+59%"H<YE52=A
M]#QWJIX0GU7488=4N-;6]M+BU1GM_LZKY,Y 8A&4#*8.,')Z<FN5U:,7-KXZ
MUFP1SINIZ?'# RH?])G","47&2.5&<<G/I7<^#75_!>BJ,AH[*&-U8$%65 "
M"#W!% &8FL:GXFUS5-.T>Z73['3)!!/>^4))))L9*(&^4!>,D@Y/3UJ[:7&K
M:-<W0U[4;2;288%D2_DC$#!MQ!63G;Z8( ZU@:*C^!?$&NQ:E#(-*U*[:]MK
MV*-I%1F^]')@$J1@8)X/K5"!K>?QQK^MVD$_]D?V056?R'6,SYP=@(Y8C'W1
MSGWH [6U\8>';R*>6WUBT=((A-*?,QL0XP3GIG(_.I;?Q-H]S%=217J_Z(@>
MX5T9'B4\AF4@$#'.<8Q7G,6F32?"OPS<Z?8.T^G7-M->P)!MEDCB<LZ8(!/S
M'=CN?K6QJ=O)XF\0S:GHZS_9TT6XM99&A:,3O(/DC&X G!R3CIP.] ':+K>F
M/+8QK>Q%K^,RVO/^N4+N)4]_EY^E9L?CSPK+<P6\>O632SN8XP).&8<8ST[\
M>O:N%T*^FGO/AW$UC?[],CFMKMC:2*L3>1Y8!R.W&3T&>M4XOLVM>$?$_ANW
MM)9M5N=;N/)40D#=YN1)OQM 4 Y.>V.XH ]HHK+L=5275KG1_)NS-9Q1L]Q)
M%B.3</X6SR?6M2@#C?#-WK$_C3Q-8W^J37%KI\D*V\+1Q 8D3?DE4!)'0<_7
M-7EO)-+UO5[G4M:F.F6T,<HCECB"0[RV?F5 Q V@#)[G.>M9$,LWAOXA^(+[
M4H;A=,U5+9K>XBA:1 \:;&5]H)4^F>,=Z9K\TM_X3\8ZG]FEAM9M.,5N9D*-
M(JQN2^T\@$O@9P>.E '1:=XQ\/:MJ$=C8:K!/<R1>='&N1O7&<@D8..XZC!S
MT-2+XJT1KJ.W%^FZ68P1R%&$<DG]Q9,;2V01@'.0:X71MGB73?!$>EQW"RZ9
M /M-TUN\:PC[,4(#,!N)8KC;GIG-0V]I=W7P^L?!LVFW46NV\T:[A"XCAVRY
M^T"7[I& 3P<DG&* .WN?'/AJSGNH9]6B62T?9<*$9O+/O@<#WZ5N-<1BU-RI
M+Q!/,!C4N6&,\ <GZ#K7FNH6MS+_ ,+(QIM\YOXD2U_T.0^<PA\OY?EYP_\
MCTYKO?#^X>'--5XY(W6VC5DD0HRD* 000".10!P>M>.)M3\&3:OIUS=Z;Y.H
M+'N-N45H?.$9W,Z8SC)PI!'?H:[;3O%&CZK<7,%K=YDMHQ+()(VC C(R'!8
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M;W4(/AQXMN1J=\9['5Y8XI?/(<H'1-I(QQ@G@8H ]9Q2;5W;L#=C&:@MY?\
MB7Q2D-CR@Q"@L>F>.YKED^)>@O#;7#)?QVL\S0"YDM&6-'!(VL3T)VGCK]*
M-OQ)HS>(/#U[I*W(MQ=1F-I3'OVJ>N!D<_C5O3;-K'3;>U>1)'BC5&D1-@;
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MV.I6VIBSF:$R2+Y(0%=X8*Y!/(]>W/ Q#;?$;2+J^M84246UY,8+6XWQD2R
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M^);^V6#1X].TZ_-O<,6D,K)L!&SC&>>2<?2NVH **** "BBB@ HHHH ****
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M+[SI)IFWJ0B*S,2HP<M@=O>O7Z* . CBF'B_PC/]AO1%;Z5+'+)]DDVQLRH
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MBW1NH-<%Y)$'BR(A.9,YWXS@],]:]5J&YNK>RMWN+J>*"!/O22N%5>W)/ H
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M9^[UXZFGW'ACQ5K/AK4+#6]9L9+FXMS;1_9X66-02I+MW9OEX   R?6NYHH
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MA!3 (#G#X/+,2 !VZ8YJV_@*^@/A0'5K=E\/[@!]D8&8-P?^6GR_*!Z\\^U
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **0\4@);J,4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@!LD:31/%(BO&ZE65AD$'J"*K:?I>GZ3 T
M&G6-M9PLV\QV\012WK@#KQ5NB@ HHHH **** "J\-A9V]U<74%K!'<7!!FE2
M,!I"!@;B.3@>M6** "BBB@ HHHH **** "BBB@ HHHH *BCM;>&5Y8H(DD?[
M[J@!;ZGO4M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@!U%%% !1145S<P6=K+<W,J101(7DD<X55'))/I0!+16:OB#27^PA=0MRU^
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M0 445!+>6\-U!:R2JL]QN\I#U;:,MCZ4 3T444 %%%% !1110 4444 %%%%
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M>C3V@MTL;=+C[0TH(=6+#..P^7N:\XU^^NH[E-8TVZN)4'B(0?;9IV5@-V#
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M:B->CM5TY6TTP%WO?/ *R9X39U/'.:\BF2.[\#7,=Z8I3;>*?)B E+K%'YR
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M%%% !1110 4444 %%%% !1110 57OK>2[L+BWBG,$DL9190H8ID8S@\&K%%
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MLJ 4P5P67.<]17HU8WBG7O\ A&?#]SJQL9[Q8!EHX2 0/4D] .^,_2@#)L_
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MH6\EVT\5J+-3+<,X,0.0ISUY.?\ ZW%4G^'OA]M?FUCR)EEG?S)X%F80S/\
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M@\>2=C*C ,,L>"#UJOJW@?PUKE[;7FI:1!//;J$B;+* HZ*0" 0/0@BN@HH
MP]:\'>'O$4MM+JNEPW+VW^J)RN!Z':1D>QR*DU3PMHFM&S-_8)+]C!$ 5F0(
MI !7"D94@ 8/%;%% & O@GPXD$<$>EQ1Q1S_ &A$C9E E_O\'KZ'MVJ;7?">
MA>)A#_;&G171A.8V8E67VRI!Q[=*V:* (X8(K:".""-(HHU"HB+A5 Z #L*D
MHHH Y^?P-X7N9;B2;0[-Y+B3S9&*<E\YR/3)ZXQGO5M/#6CQZG/J*V,?VN>,
MQ2NQ)WIC&T@G&,<8QBM6B@#!'@KPTNC'2!HMG]@+^88?+_C_ +V>N>V<YQQT
MI\W@_P /W&EVNF/I<'V*U;?#"N55&_O<$<^YYK;HH SIM!TNXU*/49;*-[V)
M0D=P<[T7!& >H'S'CO55O!_AU[$63:-9FV$HF$?EC'F 8W?[V.IZGOFMNB@#
M%/A#PZ;6[MO[&LQ#=L&G01 !R,8Z=,8&,583P]HT=S;7,6EV<=Q;#;#+'"JM
M&N", @9 Y/'2M*B@"%;.W2]DO%A07,D:QO*!\S*I) )]BQ_.J-WX;T6^U.'4
MKK2[2:]A^Y.\0+#_ !QVST[5J44 %%%% %&ST72]/N9KFRTVSMKB;_6RPP*C
M/SGYB!D\TU-"TB.]-ZFEV2W9?>9UMT#ENF=V,Y]ZT** (I+:":6&66&-Y(6+
M1.R F,D8)4]C@D<>M0:AI.G:LB)J-A:WB(=R+<0K(%/J,@XJY10!0;1-*>]A
MO6TRS:[@ 6*<P*7C Z!6QD?A3;CP_HUW/+/<Z3832S+MEDDMD9G'H21R*T:*
M .&U7P?>W&NW-W'IGAS4K65(UA74X#OME48V)A2-O?L<D^U;>E^%--L] BTJ
M[L[2ZA61IS$]NIB5V8L=B$$*H).!V%;U% #8XTAC6.-%1%&%51@ >@%.HHH
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M-EI-L+*.4Z5\UK(ZC<KD89N.YZGWY["@#<HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/"# ^8XX0=<]Z=X3\ _\(=JEY+IVK3-IMT[.;"2,%4)Z%6SG(&!GN!S7944
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M-CQLJ# )4K][WJE>> +.[\-7FBB^N8UOYC/?7 5#)<.6#9)(P.0.@' KKZ*
M.-M_ +PZ59Z2_B'49=+M6C(M3'"JR*AR$8A-Q4]QGFMFQT*:SU^]U5M4GF^U
MA5>!XXPBA<[<$+GC)[\]ZV:* ,>T\-V%EXEO-=MD,=S>0K%.J@!7(.=W3[W8
MGVK(U3X?VNJ^*(_$<NJZA'J5N MLT?E;(5&<#:4.>68\^M=?10!E:EH:ZGJ5
MA>O?WD)L9/,CAB*>6S8()8%23P2.O&>,'FLKQ%X#T_Q+K-EJMS>W]O=60_<-
M:NB;#G.<E"3SZG^9KJJ* .>\3^$;;Q;ID>G:C?7J6JD,ZP&-?,8="Q*'],#V
MJY9Z']AT!-(AU*]\N.,11SMY9E1    =F.@ZD$^]:M% '*^%_ .E^$K6ZM+&
MXO)[.ZSYMO=&-T8D8SP@/3C&<>U-M_ =K86EQI^FZMJ=EIEPS,]G#(FU=W4(
MS*60'G@'OVKK** .;F\%Z>=!M=%L;B[TVQMW5PEFR*796# L65B3N&??OFKV
MM>'K'Q!HXTW4P\\8*L),@.'7HX(& ?PQR>,5K44 85SX7@FUZ76H+^_M+Z2-
M(F:"1=I5<X!1E*G[W<'';%8'B7X=V%_X4N-,MK:2YN[B[^U&XFGVL9V!4RN0
M.0 3\H';  KO** *]A:_8=.MK02-(((EBWMU;: ,GWXJE)X>T^7Q-#X@>,F_
MAMVMD;C&TG.>F<]1G/0FM6B@#-M=#L;/7+_6(8R+N^2-)FXP0@(&/SY^@J.T
MT""RUV\U>.ZO'GNU"RI)+NCP#E0 1\N,G&/4UK44 <E!\/-)M-;NM8MKO4X+
M^Z),TL=SMWY.3D8Q4FD> -%T6WOK:W-U):WP87,$\WF)(6ZD@CK[UU-% '$#
MX5^'UT5M&$VI#3FD\TVWVH["WKT]JMWWPZT'4_#]GHMZMS-;639MV:8^9&,8
MVAO[N,<>P]*ZRB@#!T_PK;:=JJZDE_J4]PL(@_TBY,@*#H"#[G/UJ@?AYI'_
M  D4VOQW6I1:G,3OGCN2"01C&,=, #'L*ZVB@#*T/0;?0+>6"VN;R:.60R$7
M,QDPS$EB,],DDGWJ6PT6RTNRN+2PC-M#/(\I6([=K/U*^G]*T** .6T/P%I/
MA_6)M4L9[_[5<$F<RW)<3$Y/S9Z\G-+J/@+1M6UH:O>O?2WJ$&"07;K]G(Y'
ME@$ <\UU%% '+7?P_P!#O=5759OM_P#:2#"7:WTHD0<\+\V .3P!CDU,? ^A
MM%J$<D-S-_: C6Z::[ED:14;<J[F8D#/4#J*Z.B@#G[?P;I4%[!<M]KN?L[!
MK>&ZNI)HX&_O(K$@'W[=L5?UG1+/7K'['?B9H-X<K%.\62.1DJ03SSCU ]*T
M:* ,+6O".D>(M.M[#58[BXMK?[J-=2#<<8RQ#98^YR>3ZFH;?P3H]K/931'4
M ]D,6^[49V$8X& "^,8 &.F*Z.B@"I=Z9:7UQ:3W,"O+9R^; _0HVTJ3^1/%
M<]+\.?#DVK'59(;UK\];C^T)]^,8QG?G&.,5UE% %+3-(T_1K8V^G6<-M$6W
M,(UQN;U)ZD^YJ2_TZRU6S>TO[6&YMW^]'*@93^!JS10!S^G^"]"TQXS;VDC+
M$P:*.>XDECB(S@HCL57&>,#BKVJ:#INLM#)>VP>:#/DSHQ22+(P=KJ0P_ UI
M44 9FF>'],TBXFN;2VQ=3 "6XE=I)9 .@+L2Q'XU/J6EV6KVJVU_;K/"LB2A
M6[,K!E/YBKE% $%W9P7UJ]M<J6B?AE#%<_B"#6)%X$\,P6<EG%I21VLAR\*2
M.$8^Z[L&NBHH R(_#&CQ75I<QV026S01VY5V C4 #:!G&.!QWQS5Z:PM;B[M
MKJ:WC>XMBQ@E*_-'N&TX/N#BK-% &7IWA[2])-P;&U\@W)+3;9&.\GJ3D]??
MK5"+P'X9@:=H=*CC:X!68I(X,@/4-@\@^]='10!3T_2[+2K!;&R@6*U486+)
M( ]!GM[4?V79?V8--^S(+)5""%>%"CH..U7** ,W3?#VD:-(SZ9IMM9EAAA;
MQA W3J!P>@JL?"'A\J5_LBU"L<NJI@2<Y^<#[W/][-;=% #418T5$4*BC"JH
MP /04ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=M $,GC'2$FN(XVN;A;8D3RV]O))'&1U!8#&1WK5TW4;35;&&]LIED@E&Y'
MQN%<[\/1:+\/]%^S,&C>U5F<XRSD?-^.<YJG?SB'Q#IWAC3+AK.WF@GNI)H&
M!<8;[JDYQDY)XH [DNH."P]:4NHZL*\FOO$OB"SM[NR&H*+FRUB&T\]H5;SH
M9/N[AZC![59EN/$"ZCXCTO\ X2.7R]/@%S'.8%$NY@3M/&-@QCUH ]0W#&<C
M%9FN:W::!I%QJEYYAMX%W/Y<9<X_"N#N?$&O7UIX(DM;U;1M8)%T$B# ?)DD
M9Z&LS5]0U5/#OCKP]J5ZU\+&T62WNG0!F1USM;WXH ]+_MZ ZAIEN(;@C4(V
MDBE6,E% 7=\Y[<>M:VY<@9&37GHU.]M?$/@NRANPEE=VDGGP\?,4A# D_E61
M;>(-876=-N!J4MW%<ZHUK,8P!:;,-A5!P2PP/FZ4 >L[U(!W#!X%&]1_$*\B
MOM7U]-&U_5(]?G']E:D8X454 D7Y?E?U'S&MV:\U'Q%XAUW3;+4Y;"338HA;
M^41M:21-VY^#E1P,?6@#T$LJC)( I:\RO-4UK6M;;1+>Z)>UL(Y6DL+A86FD
M8D%AG/RC!X[&NP\+3ZI-HMO_ &O):R7L8*3/;-N5F'<?U]Z +'B#7;7PYI4F
MIWRS&UB_UC1(7*CID@=JH7/C'3K._P!,LYDN5DU+'V7$+%7.,X)[<8.*U=6L
M8-8T>[T^==T5S$T39'J,5X>U_J%_X6LK=&9M4\(R/<7 *DLPC<*H)_VDW'_@
M- 'M%QK4,&L+IGD7,D[0&?,<>5"@XY.>I/ IVGZS#>Z9#>RPRV8F;8D=RNQ\
M^F#]*P=!N!KK:IK]O.RP7JB&SE7@B)%/(!_VB?RKC UUKFC^!+J]U*[,\]\T
M;,DFW?C?AC_M#;P: /3-,U^#4M;U'3(X94EL-HE+K@'<,C'X5JR2#8Q3YB%)
MVKU->37]M=#5/'=Q::I=VC:?!;S*8V :1DA+?,QY(]J]*T6[EO-%L+FXV^=-
M;QR/@\9*@G]<T 8,?Q#TEXKBXD@OHK6TF\BYN'MR4B<<$''(P<<XQ766\\<]
MO'+'(K(ZA@P/4$9'Z5Y%I&DZOK^D>*](M9;*"RN]8GCFEFW&1%)YVCIFMO3K
M234-;U+P[_:-]96>B6]O! ;>4(\C,FXR$D<XZ#M0!UFM>((M$NM.AFAG?[?<
M"VC9,;58@D9_ &K%GJC7.KWEDUG<1);!<3R+A)<C/RGOBO-IM6O=7T;PG+J!
M5[J'Q!]G>0#B0H)!N_$"K&M>(M1T2^\7;;Z:2.WDM(X3(<BW$I568?0,30!Z
M==2F&!Y0C2%$+;$&2V!G ^M0:1?MJ.EP7<EI-9O*,^1.,.GL1VKEULKC3)K]
M8]>FEMKBQ+P12N&E1U!S(K>G(_2N2L?$&LZGH_A#3OMI:74;*2>9VN/)>=E.
M  _4'O0!["'4G 89Z4H(/0UY7,/%%OI%O;7-PVHBUNI!<0V=R5N3#CY!O;&]
ME;DGN*[#P;J%K?\ AZUEM[^XO$RRB2XXER"<JP]5Z&@#0\1:W#X=T:;5;F*:
M2WMQNE\D9*KZX[U/I-Z=0T^&[,$D F4.J2,"V#R.A-8'Q+8'X<:Z.G^BO_*M
M+3[R"P\,6ES=2>5#':QEV;H!@?XT ;1=1U(HW+DC(R*\?U2_OQJCZK:ZA>3A
M=:AMO.20I"(BZ*8E3^+JV3ZYJ[K-Q/I'BC5-+GN[MH-8LQ)INV8@QS*V"B'M
M]X-]!0!ZGD>HH+*N,D#)P*\U\%:C<ZW)8V%U+*MSHPDBU B0_O)P60;L]00"
M_P#P(5L>.KEF&E:?%=SJ]U<;?LEN=KW VGY2X^Z/4T =CO4_Q"EW#&<BO%S?
MZQ_PA%\AOKNVDLM:CMHFBN275#*BE"^/F SC-7[W5KWPEJGB:.SN;F[2'2X+
MR-+J3>5D9F4L.G&.?PH [N]\0?8/$6F:0UI(XU#>4G# !"HR1CKTJ7Q/KB^&
M]!GU66VDN(+<;Y A 8#U&:X1--AL_%W@NXBO+J=KA96D:6<R!CY62W/0G^5=
M-\4"I^&>O$\C[*Q'- $L7B6_\RQ,^@7%O;7<BQK.)HW$>X$@E1SCC]:EUWQ1
M!HN@:IJ=O&+PZ:<7$2/M*G ;DGV8''O6?!;ZC8P:;?WVM"734AVR0F()G<H5
M<$9).37!#3K6'P#\0Y8A*TL=[<Q(6E<Y0*A'![@'KCTH ]KL[C[5903E=IEC
M5]N<XR,XJAHM]>WUF9K_ $Y]/G$KIY+NKG:#PV1V(YKB-'@?3_'NDV\%W>/;
M:AHSS3+)*6RP* $ _=X)Z"LC3-9EA\,Z19ZAJ$\=I=ZY/;7%P[G?L#,40MV!
M^4?3- 'L0D0YPPX.#[&LGQ+K']A>'KS55@-P+6(R&-7VD@>]<3K"6FDV%SIE
MKK]\XN+Z(1VT9WLI;_E@')^56XYZBL>-[T>%?B#I\[$16T86&#SVD6',?*@M
M[T >L:?=?:],M;PIL,\*2%2<[<J#U[URP\;S3VMUJ=GI%Q<:1;.\9N$F7<Y4
MX)"=<>^170Z#C_A&M,;G!M(3_P"."O.;_3KKPW8WGBKPC?B72Y2\]YI=WEHW
MY^<H/X6H ].CU.U?4?L(G!N?*\WRQ_<SUJYO4]&'YUY9;PZ>WQ$UK4)UEME&
MC178<EM\9Y).,\D#M5#PU<2KXG\."*20VNIV=P[2RSL9[I<;ED<9P">,#D@4
M >QEU R6&*P_%&N-H.@WFJ16ZW+6T1D$>\+N QW[=:\PM;>2'PWHVM+>WC7R
M^(?LZM+<NRK&;ED*[>A&WUJ379+;7?"/C6_U&>1;VRN9((D+E/)0;0H ST;&
M?>@#U^RNEN;"WG.U#+&K;<]"0#C]:L;E'<5XWXEE%W'>?9[EWN++1(Y&$TYC
MBM<KN#)CDN>QZ#I5R.P_M_Q'H-M>WEYY-YH3M,L4S*7;*\D^O- '?>*=;;0O
M#M]J<$2W$EK$9?*+A<XJ_I]X+JPMKAPL9GB5PN>A*AL?K7CVK1VFI^&?&LE]
M._V[3W>"*-Y2&AC50(PN3T8 D^M7]:^T"PM+P1Q:CIL6E0"Z@2<I/;+LR)(N
MV3W^E 'KP.>E%9>BZC8W-E:Q6]RC2/;K.L+L!*(ST++U]LXZUJ4 <6WC#67\
M0ZIHUIX?@N+C35667;?;=Z.,KLS']['8X&>];_A[7K/Q+HL&J6/F"*7(*2KM
M=&!PRL.Q!%<;!!=ZC\5O%5M;:@U@5L;:,O%&K,P*DY^;N,]?I575/".E:9XD
M\%Z%"UTMDZWJ2C[2RM-^[W'<01DDLV<8R#CIQ0!ZC25YSIFDZ9J/B+Q#HFLV
MZM;:=;V]O8Q3N3Y=ML/SHQYR6'+CD8 S6 ?[1C\$^&?'%[ 9K_2[C]_(Z9>6
MR+,H8^I ((/7O0!ZOK$NI0:9+)I%K#=7HQY<4TFQ6YYYQZ9JQ*\J6I95B,^W
MY5=]JE^P)P2!GV/TKS/Q/9H_PH\0ZS);>1=:E)]LP0595+*L8/?.S!(]6:KJ
MS:9J/CR_T_Q%Y#06^F0-8)<X$>ULF5QNXW9V#(Y % '5^%M;DU[PQ::M<11P
M/,'+HK95=K,O4_2MI6#*&4@@\@CO7A<5^B>%? ]I+?6\&BO-=)=331^?$L@9
MC&)%S@CG^+COVJ?6M,L(=&TFTMM7.I6S>*8$\V >7%&LBEGBB*L<*#@\'@T
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M2[L6BU30XXU^V>9L4,S[2I1&W*<DD<=N:[OP1'IL7@W38=*NXKNVBA$?GQ#
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M<JSYVX/'&3G&?0^E '28I*Y/Q5KNEOI.KVEQJFI::MC)$EQ=V<;AD9@KJJL
M>H*@^F[WJ>/Q";KQ7=^'1;7B)#:HQN F"2Q8;L]A\O7N: "Z\/ZQ'KEUJ.D:
MY';+>;/.AN;3SP"HVC8=RD#';D9R>];.EZ<--L_),[W$KNTDLS@!I')R20H
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M!7 4@ L,-D8^]Z5ZZJA4"#. ,<DD_G6;>^'-)U&2UDNK)7:TQ]GPS+Y6.FT
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ML30A"R_NEZ;PR\].0>M9WQ \.6_AKX;>(;JVNKN>^O+F">>[N) 9&82IMP5
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M[@.F1U.<Y6NZ!<WUIXHODTZ]>UU>_LFBM%@8.T<6SS'*CE<_/UP>.G->LT4
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MVQ<9033*FX>V3S5SJ,UY%K'E:99VDMG?P0O#HZ02:7KF%:\MLN5"L,,).",
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M>1\DQD]0X(/ YYQZUU/A[Q+IP@T71)XFL-3GL(Y4L#%)A%"_=W$8X"G@G/%
M&Y>ZKIVG/&E[?6ULTF=BS2JA; R<9/.!56V\3Z#>+*UMK-A,L,?FR&.X5MB=
M-QP>![US/Q BL+O7?"5K>PPSH;]GDCECWKY80@E@1C;N*]>.E13R6'AOXGJ/
MLWV6SET(06L=O;G:[B=F*(JC&<$''O0!>\5^)KBT7PQ=Z+?6\MGJ.K06DCHH
MD$D;DYVMT_A(XKH[G7=)LKM;2ZU*TAN&*@123*K$MPO!/?M7DD&X_#OX=IY4
MP:WUJWDE#1,-B*SDL<C[H##GIS4UT+)=:\1Z%XB37C)>WDD]I!:ES#>QM@HH
MP, C"@D\# YXH ]4N->TFTU!+"XU&VBNW*A8GD 8EB H^IR,#J:MW5W;V-K)
M=7<\<$$8W/)(P55'N37EFJ27&E:K=OI=TUQ<374/VO0+Q"_VB0",;X9<9)&%
M^8\<9/2NK^(\A3PA(/[/6]5YXE971W6(;Q^\*IRP7T% &Q#XGT.>QFO4U:T%
MM"=LLCRA1&3T#9Q@GWZU)8^(='U2]DL[#4[6YN(TWM'%*&(7.,\=L\>U>57D
MT$EIX]@NI=1O7O;"W:WFFLGC,[A&"D!4 "[\ 9ZX[C)K2O80WB/13I+F.Y;P
MY/;1;4*I'(5'EC., EMW'^S0!NZ]XRA7Q%H.G:1JT+O/J(@NX44/N3!SAL<8
M( ./7M76:EJNGZ/;?:=1O(;6$L%#S.%!/H,]3[5Y9!J$%SI/@*TCTR_ANM-O
M8DNHC929@VQLK9.WH3@_3D]*ZSXJ%7\ WMOL:22:6 )&J%BV)D9N /[H)_"@
M#:C\6:!-:FYBU6VEA\YH T;;MTBC+* .20.>.W-3MX@TE=/M[_[?"UM<D""1
M&W>:3V4#DG@\#T/I7">+0FB^*M)UV/3KV71);62*9M+#(\<CE2)"$()R%4<^
MGL!65JDUMH$'AO6=.T?4K18M0N9H;:=7E:1)$P[.,ED9NJCG')(YQ0!Z*/&7
MAQK=)UUFT:)I%BW+)G#MT4^AX/7%7/[2M+V[O-*M;]8]0AC!=5&7B#=&P1@_
MJ*\NO&CO?ASJ<6E7$MU>#44U*^MX[22)@KS!B$C89*C'7I\AYK=T.]%Q\5=;
MU-;6]6QDTZ)8YGM) K[3GCC\O7M0!L>%_%,;^"-%U'7+Y!=WL1.2OS2,,DX5
M1V [#BI-8\>:3I<&D31,;R/5+E(87A!*!6;#-D ].?EZDC'KCB=)>YLM(\$V
M]Q8WUGY%O<1RW:6$CSPN0/W2J5.TL/XBIZ<8ZUDZ7;W<'@SPQYNGZ@ITSQ()
M;M6M)-T:;VYQM^;J/NYY.* /5K'4X;GQ/?)'K\4\:6R/_9PC4-;^KLW7G(X.
M,59M/$^B7UPEO;ZE \LBEXQG'F*.I0G[P'J,UP6HV.H:MXP\5FRMKJ(WF@+!
M#(\3*OFXSLW8QNY QFK4\\GBA_"$=E97=I=Z=>)<7J2VSI]F1$(="Q 'S'
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M0OY,P78P98]^6/\ #GC ]/K71:#XMTW4)8-.WW*70LQ<;[B!XUE08#,K,/F
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M'-<O;A8X)"VT!B3TSZ9QD9YXKG]*T;Q+;:OX<U6Y\.RM>6PFBO99+^-G<NN
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M>*M*:R@6XU6^GN(#]H!4+*V?F..,8_'- '27_B5-/>YM-/L);^33[99[I(W
M,49!*@9^\Y"DA?;DC(RR'QG;3:WI6G?8KJ)=4MS<6MQ* JL NXJ03D,,],5E
M2:/XITWQ3<:WHT-A,FJ6\27EK=S%/)DC7:K*R@[A@GMS4?C"V\_0K"T.K6S^
M*;.Y@FM6!4-YS.!]SJ(SD_\  5YS@T =AINI+J:W+QPND4,[P*[$$2[3@LN#
MTSD<]P:J>)_$,?A?1FU.:TGN8UD2,K#C(+,%!Y/J0.,GGI5'4+JZ\+V6BV&F
MVUO=(TB6[K+-LE<< L@ ^9N2Q] "35/XJ&0> KHQ -(+BVVAC@$^>F,T 2IX
MY*:GJ&G7NAWUI=6MFU]%&SQDSPJ<$@AL ^Q-06'Q"%WIJW\VA7]M!<"!;(RE
M1]KDEZ(G/KW/&,FG7VBZUJ]_<ZI<VMO!)'IDMG:VJW&XM)+C>S-MP!\H Z]S
MQ5=O"&IW?@3P_8L;:VUG17@F@)<O$SQ< ,0,X8>@XSWH MZGXSN=/@U:VDTQ
M8=6L[)KV&&2<&.>( Y96 R=I'*X!Z>N:DTSQ+>#1M!BN;59]5U*!7BC6;AU$
M89Y7;;\HY' !Y88]JNI>%M0\17EYJ-]%;V=PVDS:?:Q),9 K2 AG8[1QT  S
MQD^U0P>&O$$*^'M25+%-0T> VC6PG8I<0E%4Y?;\K97(&W'J: -)?'%JD5_%
M=6<L.IV=U%:-8AU9I))<>5L;(!#9SDXQ@YZ5(_B[[%'JQU72[FT.GB,[E^>.
M?S,!1&^!EMQ"X[$UD:OX&O\ 6!J6IK=Q66LSW-M<VNTF2.%H 1&&.!G)9B2!
MQD=<<RWGA_Q1XDT*_M]:O+&TGDCC%K%:;GC21)!)O<L,G)11CL,^M &M'X@$
MNMIX?UC3A;37D#20#S!+'.H^^F<#D#J".0:J_#153X?Z:BC"J9@!Z#SGI\6D
MZOJ6MZ;K&JP6=O/ID,RPPP3LXFDD 4L25&U<+P,$\\],'(LAXB\'^'M%TP)I
M,LWVUDEB6:1WFC>3=^[^088;R3G@!<YYX .B\8^)1X2\.3ZPUF]VL3*IC5PG
MWC@')]R.QZUG2>,[ZSU'3[74O#\MF+^^^R0%KE7."H8.0!C')&,GD&K'Q \/
MWWBGPA<Z1I[6Z3SO&=]P[*JA6#=E))XQ^-1^*- U/6DT*]M19IJ.F7BW30RS
M-Y3C!#*'"9],';^% '.^+O$/]O>#?&]A/8)"VDD1!_-\P.3R&&5&TX^OUK63
MQ?%IEMIFE0+9O=KID5P_VJ\%N@4KA0#M8EB0>W [\BJ2^!=:ET[Q;!=W6G/+
MKS!E*!U6(XQD]^/3O@>N*GO/"7B.SU#3]7\/7VGPZA'8I8W<-VK-#*J=&! W
M _EV_$ ZCPYKD?B/0;758K>:W$ZG,4PPR,"01^8//>M6N25_$6F:QHEB+RVO
MHIO,;4-Z.),DEMZ=0J*> "1V'/;K: "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *ANXWFLYXHRH=XV
M52W0$CC-34A.!DT <UX(\+GPMX<MM.N/LLUS;[E%Q%'M+J6+<YY[X_ 5T36\
M#S),\,;2I]URH++]#VK$B\8Z+-?06JW$H^T2&&"=H'6&60$@JLA&TG@]^>V:
MC3QUX=DU5=,2_9KQKC[,8O(D!60C(!RO /KTH W7M+:2=9WMXFF7[LC("P^A
MI(K*UA618K:&,2##A(P-WU]>IJGK>O:;X<T_[?JUS]GMMX3S-C-R>G"@FLZ'
MQSH5U;+-:SSW#/,\"0PVTC2NZ %L)C. "#D\<CUH Z*.-(HUCC1411@*HP /
MI3'MH)8TCD@C=$(*JR A2.A [5D+XMT:72K348+OSX+R3R;81HQ>63)&T+C.
M1@YR!C!SBJO_  G_ (<&F3:BU[*EM!*L,[-:RYBD)QM8;>#GC\O44 =%)!#*
MR-)$CE#N0LH.T^H]*I1Z3"NN2ZL\CR7#1>3&"%"Q)P2!@9.2H)))Z#&*IWVM
MV-Q<:CHD%[-#JD-HUP0D;*R)T#*S+M//UK&\,^*(K3P-X>FU.:ZN[^^M\HD:
M---,0,L<#).!R30!H:QX4;5O%VD:V]S!Y.GI(AMI;??Y@<8/.X8]N#72JJHH
M50%4#  & !7&:C\0[*&ST.[TVUNKVWU2Y$2R);O\H!8,,8R7RI 7V)Z=;UAJ
MUA>^-+J.+4K_ .TQV*F6PFC9(HANSO\ F &[G!(ST]J .DDC26-HY$5T88*L
M,@TZN>A\9Z/-=6<7F3I'?,4M+B2!EBG8=E8COVSU[9JG/\1_#MNMVS2WC)9R
M>7<LMG)B'IRV5X&2!GOVS0!UM%(K!E#*<@C(-<EHVO:3')KEQ#J6IW96_$4D
M-RKDQ2M@"*)" 0,GI_2@#KJ*S]*U>#5TN6@CGC:VF,$J31E&5P W0^S Y]ZR
M[Z_L$\<V%M)J&I1WHM976SC#_9Y5[LPQAF';!S0!TE4WTR&75(]0E>622%2(
M8V;Y(R006 _O$'&3GC@8R<\[#\2/#TZ)*CWGV=KD6AG:T<1K*3@*Q(X_&K^K
M>+M-T>2X69;F5;0*UV\$6];96Y!?\.<#)QSB@#?HK#O?%%E:O'';PW6H3/ +
MGRK*,.RQ'HYR1P>W<]A567QYH4=IIMTLUS+#J+%8&BMI&RP!RIXX;Y2-O7VH
M Z:BN=M_&>F7&F7-[Y=W&UM=?8Y+:2+;*)B0%3&<<[EP<XYY(K,\2^)--G\(
MZK)J*ZUIT-M<+;7!MUVSQL-CC#*2 IW*-V<'=B@#M:*Y_5O%MGI+7VZTO;E-
M/19+Q[:-6$ 89&<L">.3M!P.M4K/QA+-XNU;2[C3;J"SL8HV-RZJ%7(D+.YW
M<*0HV\9X.<4 =;17-P^-+"6ZM86M+^+[;"\UF\D'%RJC<=@!)SCD!@"156P^
M(>D:B-/DBM]02WOY#!;SRV^V-Y><)G/4XZ]/?K@ ZZBN9\+^([W7KS5EN--F
MMH;6\>WC+;"%V!00Q#DEB23P, <9-7=6\1VVCZIIMA<6]RS:C+Y,,J!=@?T8
ME@1QSTY[9H V:P]:\.OJFH6NH6VK7NG7ELCQJ]OL965L$@JZD'[HY]JKP>,[
M&>WUB7[+>1OI4HBN(I%0.6/0+\V#G(QR,YXS6/J&OV.DZ[XCU"VL-3FU:STU
M)IX)'58C&H)!7+8XYR1GH<9/4 Z?2M%73I9;F:[GOK^9%CEN[C:&95)*J H"
MJ 68X [\YK5KR:_\0ZA=GX>ZK/%?)-<OF:*)ABYS$K95%8C!)XW8([X%>@^'
M_$$'B&VNI(K>XMI;2Y:UGAN% 9)% )'!(/WAR#0!L45R6J^)=1M?'&GZ'!I<
M\MM+;R3O)&\>Z3&!@!F& "1DY!/88KG_  UXIA\/V>M_;+?4;BUBU^X@DNN9
M%@4R!$W,[;F[#C<?6@#TVBN:UCQI9Z3<WD7V6YN5L45[N2$H!"",XPS L0OS
M$*#Q^5;<-[%=::E]9YN8I8A+%Y9 ,@(R,9P.??% %JBN&T3QY)/I%[J6J6%Q
M!&+U[:W4-$Q9]^Q8@%;.[C)+8').<<U8G^(FFVEAJUS<6=XLFE-&+J!/+=E5
M_N."&VE2>.#D=Q0!V-%<HWCB-+NUMI-#UA)+N9XK;="H\W:F\$9;H1ZXQWQ@
MU5?XC6T5C?W<FB:JJZ;,8;\%8_\ 1SD<YWX?KGY"QQR<9&0#M:*PM1\3PV5\
MUE;VLU]<K:?;#' Z ^5D@$;F&[)!Z9_45LP2B>WCF *B1 P#=1D9YH DI"0H
MR2 /4UR5WX[AM;-]5&FW,VA1R&-]0C9< A]A8(3N*!LC=[< CFLK7KO^U?B1
M8Z%>Z6;[3'TZ25(2Z%'8LH\T@G!  (&>022* /0Z3@?C7-ZS++X.\#7+Z1;/
M<_8+9C&LTV=JJ"=S$\D#TZGI7*76HWC:S\/=1NK*YDO7CG#(K(7G)MN#P0H!
M+$\XQSTH [32O#5MHNL:IJD5Y=/)J3B2=)2FP$<#&%!&!QU_7FM06-L+\WWE
M W)3R_,))(7.<#TSQG'7 KAM:\4Z?J_@+6+C5M#NW@L[LV5[:),H*NI4YWY&
M5R5Y'//3%;>I^*)+'49],TS31?3V<"S30BY6-PASC8I!+X .>G8<DT =-117
MG'Q"U358KM+_ $DL]OX<DCN[V)<CSBW5,_[,9+'K]\4 >CT5B:GXFL].\-IK
M8#SP3+'Y"1XS*TA 09Z#)(Y/2LJ3QM<VUWJ=G=:!<?:M.MA=S"&XC=#&02"&
M8J2>",8[4 =A17"?\+*2+2(]5O-(FM+"Y6$64\TZ!9Y) 25)_@"[6R3V&<<@
M%MO\4](ETW5KF18Q)ISQ1D17"O%,TN=FR3@8X.20,8/I0!WM%>=)\5K;^S-6
MN/L,5Q<::B3,EG>++&\;'&X/@8(/!&,\CJ*TYO&6J+J\ND0^&I&OS:?;;='N
MT57BW;3O;'RL#C@;NH[<T =5=6-K>B(74"3"*02H'&0''0X]1VJQ7%K\1+*?
MPKI6KP1(LVI[Q!!<3>6JLA(?<^#@ C&0"3D<<\51\2BVC1W<>CR37(OX[&>&
M.==BLYPK(Y #@]NGOB@#OJ*\[U?QSK<.C^)HDTF"TU32(TD.ZY,B>5(I(=2%
M&6&#QTSWKK_#DNHS:%:OJ<,<=QY:CY)S+O&!ABQ5>3W&* -6F&2-9%C+J'8$
MJI/)QZ"N:^(6L:EH/@K4-1TM(C/&F"\C$>6"<;E ')&1@<>OM6#J$FJ6WC?P
M_=C1K>36)-/NXWBCN1M(#1[2TK*"0 <_=)Y. : /1J*XK_A8,2^'[*\FM$M[
M^ZN9+3[--/B..2,D/ND /RC:>0#G(&*T_"GBE/$L5ZOV?R9[.<Q2;&+Q..=K
MHY W @>@(H Z*BN)U/6]:B^)MEI-NMK]B_L^2X"/.R>8=R@EL(>1@X7W))[5
M1MOBM:7>HV*P6BS65Y<BW5HW<SQ@DA79-FW:3Z,2 1QGB@#T2BN"M_''B"^7
M49;/PO%+#IMY<6MTQU!1@QKG*Y7)R>.G<>^(;?X@ZS/+H'_%/VX3787:T7[;
M\P=5#?.=F O/;)QVSQ0!Z'17%)XYGA\-ZW?ZA906]WI-Y]CE42LT1)* /N"[
MMOS@GC.!6YX=U+4-2MI)+Z&S"@J8;BRG,L4ZD9RN0",=,'TH V:1F5%+,0J@
M9))X K#U#6[@:_#H6EQPR7I@-U.\Y8)#%G:.G5F;@#C@$_7B_%WBN[U/X:^(
MU\F.TO[!C9ZA#N+8+,%!C;C*D'/(]10!V&@6?A8ZEJ.I:$;":\N),W<]O,)&
MW'G!Y.W/7 P#6W<75O9VSW%U/'! @R\DKA54>Y/ K+\/V#PVJ7MY9V,.I31(
MDTEIDAT7[F20"< UQ$FIZQJ8^(D%[-;O;65L\*QJC<#R7*E020#SR>^* /38
M)X;JWCN+>5)895#QR(V5=2,@@CJ"*9;7EK>>;]EN(IO)E:&7RW#;'7JIQT([
MBN!\(>(]3LK;P=H][8VJ6NI:8!:21SLTF8H5;+C;@ CGC.*=!XR&G>&]9U Z
M=86,L&MO93F$,T2ON4/-(0H+=2<XYXZ<X /0Z0UC^&]1O=3L9I[PV<BB7;!<
M6;[HIX]BD.,DD<EAC/&WOUJMXRU);/2HK);V*SGU*46J3R2!?*4@EWR>X0-C
MW(]: -BYMK75M.DMY?WMK<QX;RY" Z'_ &E(."/0\BEL-/M=,LHK.SB\JWB&
MV.,$D*/09[5Q'PMU-18:CX:>[6XET:Y:*&02!_,MV.8VR..F1[8 II\>ZK)8
M6FJVUC8R6=YJO]F16SR,DB,7*"1WP1U!^4*< @Y- '9:IHFG:TL"ZC;^>L$@
MEB!=@%<=&X(Y'8]JOA0J@#. ,<G-<2OB?Q++XIU;2XM-TO[-IIMWFE:X?/E2
M9)(^7D@ G'&,'KD5%9>-=5U*73+RPTQ[G3;VX\MD6SG5X8B<"4RD;".Y Z=B
M>M '>45Y^/'.K7<<E_I>F->6BWA@6VCLIVDDB5RC2"7&P'(SMP>!USQ45_XX
M\0P67B2XAL=,7^PI]LH>21O-3"D!< 8.">3WQQWH ]%K/.A:4VLC6#I]N=2"
M;!<E!O QCK].*YS3_%>IKXAAL]9BL(;6[TQ]0A^SEV>,*PRC$\-\ISD =#Q5
M;3/&>L:D^DW<&F//8:A,%>-+*=6MHF^[(96^1QT+  8SP3C- '=&-#(LA12Z
M@@,1R >O/X"J>JZ18:W9_8]1MQ<6Y8.8V8@$CIT->>CXA^($TB[UJ:STP6%G
MJQL)8U\PR2+N"E@<X!&>^<Y[8YZ#0IM6F\>^(HKF^MY+>V6V41K;LORE'8!3
MO..2<D@Y]J .NC18XUC7.U0 ,DDX'N:I7FM:=87UI8W5Y'%=7C;;>$GYI#["
MLOQCK[^'=,M[D3+;Q2W AENGMVF6W4JQWE%()&0!UXS7*Z_?:CJ4/A"[CGTV
MXNGUEA;SP9\ATV2!6(R3TP2N>O&10!Z;5:_O[32[*6]OKB.WMHAEY9#@**XU
M?%6NQ:1XC1X;";4=(NQ")<^3"8F"MYC;GXVJ22-W. *IKXGGUSPWXWL9IXKA
M;&P8Q3I;/ 9$D@=@2C'V(![]: .UC\0:5++IT27T32ZE'YMHG.Z5-N_<!Z;1
MGFM*O+5N'M;3X421XRT<<9R.S6P4_H37H'B"]N=-\.ZC?V@B,]K;/.@E4E3M
M4M@@$'MZT :5%>>6OBSQ)#>^''U(:9]CU^+$0AC?=;RF/<F26^8$D9Z8_6HK
M7QCXF7PC_P )/>6^FM9@/%]GB#AWD,PCC8$G 7)Y!YXSGG@ ](HKASJGC&2\
MN[.WME\LV1EM[RXM?+'V@'F(IYA)!'<=,]\4[PYXJO/$EEX>>WE19KF.6:_!
MB^XL9V,H&>"7( ]@30!VU8[>*-(1M65[HK_9.W[:?*8^6&7<#P.>/3-<?:>,
M]6_MW2XI;FVF%Y?O9W-M%"3%;8W%0DPX=L+SUQSP*==ZW?:C:?$?3[LP&+3K
M-DA,46PD- YRV2<GH/PZ"@#T"TNH;ZR@N[=BT,\:RQL1C*L,@X^AJ:L?PFZR
M>#M$=3E3808/_;,5L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 55U*V>]TN[M8W"/-"\:L?X25(!
M_6K5% 'EILM1U/P'8>#9-+N[?5;9H(FG,+""-8G!\T2=&RJG SDD]!6]X06=
M/%?BMIM.O($N;Q9H9IK<HDBJ@3@GW!_ YKM** .)^*EG=ZAX*DM;*TN+J>2Y
MA(C@B+G <,2<=!@&L[QMILT_B#1]=&B7^K::;=H+FVMG>.:+)#*X0%3GJ"#Z
M#..*]'HH \EU>T?1[3PU-8:!=VLL>I37%K:VZ>?-%&4.[S(S)\[-U.&&T$#.
M>L=U#)JG@/Q+I.G:=J@UB>X74;BWO[40O+OD4DQ*&(QB,@#)/'O7HFM>'['6
M+NSNIKFZM+VVW+;SVT_EN V-P]&!P."#5G3]+M=)6642S2S2X\ZYN92[OC.,
MD\ #)P!@#)XYH XB(:C=_$'5-;;1-2@L9=",$;2PC<SAMV-H).>",=?;D5DZ
M1::Q!X8\(V5WI&K".%+B*[:V@"W,39^10[8*(P."RD<#J*]>HH \@TW3]:L_
M!_AJ&3P]J?FZ/K333Q!4+NC/,<I\WS ;U!)P._(YK5OK+4-7\>:PL=CJ-G'?
M:%]ABNG@8)'-RV"XR.,XR"1G@9XKTJFLZH,LP4$XY..: /-'TS5->\(Z)X8F
MTVZL[[3YK<3SR1XA58<#>CYPVX#@#G)YP*2>TU+4=%\>VMOH]^)-0N";7S8O
M+$H,:)QN([J3],5Z=10!5TV8W&F6TQAFA+1J3',FUU..A'8UYS'X>O"OBM-2
MT*[N+2_U99XQ#(JRF,?\M$(;(92 <=2.W:O2A=6YB\T3Q&,MMW[QC=G&,^N>
M*FH Y/P);ZS;6-['J<EW+:B<?8'OE N3%M'^LQW!XYYXYQP*KZMI^H/\4-'U
M6*QFEL;:RFBEF3;@,W08)R?RKM** /(X/#^NQ?#BYTMM%NC>OK N5B#1_P"K
M\T/G.['1<8SU(K;6/Q'HGB;7GM_#S:KIVKLD\3>=&GEOL5620,?N\=L]/R]!
MJ/[1#YK1>='YBKO9-PR%]2/2@#CK&RUS0_%5WJ=Q9F_@U*SMUF^Q[1Y$T2D$
M!78?(<DC!^OK6)'X;UO3?[!>/3W:0:W-J5RD#(5MXY-PV9)&2 V./?%>FQ31
M3Q"6&1)(SG#(P(.#@\CWIS,JJ68@*!DD] * /,Y]&U&:Z\3PW_ANZOM-U'48
MI1$LR(QC";3(AWC#!E4\XR!5?5?#GB.7X<Z_HL<=]>K/<1KIL5W(C3K&&1FW
MMNQC*L!SG&*]1@GAN85F@E26)N5>-@RGZ$5)0!YGXGT34]4UB[U+2](U&PUB
M,1?8K^VFC5)UVJ2DZE^0K%@>#P!UZ&]>Z%K%UK/B*VDLRT.MZ9#;?;4=?+B=
M4D5L@G=U<8 %=]10!YUX4TW5[=K*"^\%Z=82V"XDOXO)9KC:I \L8R&8X))(
MXSZU5L?#>O6W@WPCISZ5(;K2M56YN5$T6/+4R'(.[D_../8^V?3Z@GO;6U>)
M+BYAA>9@D2R.%+L>@&>I]A0!RGA'2M4T?Q#XE6ZLL6M[J#W<-R)%*LK 84#K
MGKG( &.^:O>.M$GUWPM<16*_\3*W9;FR8$ K*A!&">F>1^-=)10!Y[;^ [NW
M\5:;J!E1K>:+S=75<!9KE',B/CJ?G<X] @%/U3PWJM]XG\531VK+;:EHILH)
MGD3;YNTCH#N ^8=NN:[BWO;6[DGCMKF&9X'\N98W#&-O[K =#[&IZ /,H= \
M0/%X%2;1VC_L1PMR1<1-\HC5-WWO4$X&>!Z\5O\ @W2]3TW5O$TM]:O!!?:@
MUU;EI$8%2,=%8X/ _2NNHH Y/6].U9?'&D:S86*7<$-K-;S*9Q&4+E2#SU''
M;)]JY:Y\,^(I?!OB33DTN87>HZV;Z!3/#A8S*LG7=@$;.GJPZ\X]+34K&34'
ML([VW>]1-[VZRJ9%7@9*YR!R.?<5:H \ZGT3Q'8>+=1U"RT33]3L-5"2E+MT
M62TE"!>3SE>!D+GV]^[TZWFM=-MH+B1))HXE61XT"*S <D*.@SVJU10!Y8G@
M_P 1QZ#?V$%E:1W%OK#ZG:RS3AX[K+'Y63'R@J<<GKZ9S5G5M(\3ZUX&U:TD
M\/V-E>78BBBM+66/^%]S.[\#!Z <X_&O2J* .8U2QU+4-;\,:BMB46RDDEND
M:5<IOB9-HYY(+<]N.*YN\\):Y<:5XUMEME#:U<"2U4S+A1P"6YX/';/:O2Z*
M /.O$7A6_P!5LK*$Z1YES;:?%':WMO=K#-:W #;B6SRGW.F>_%=UID-U;Z5:
M0WTXGNXX46:4#AW  8_B<U;JGJ.K6&DQ"6_NXK=#G&]N3CDX'4X')]* .'M_
M#'B&Q\)7W@^**WFM)VEC@U!I,"."1B6#)U+C<V,<=.:T7T'48_B-IVK0V@.F
MVFGFRW&5=YR<[L>@_.NNM[F"[MH[FVF2:"50\<D;!E8'H01U%0)JNGR:H^F)
M>0-?I'YKVZN"ZID#)'4#YAU]: (/$>G2ZOX9U738&59KNTEA0N< ,RD#/MS7
M&IX>\337'@R2ZM+93HIVW#1W.2R^4J$_=')(8X';'-=W?:E9::D3WMS';K-*
ML,9D; 9VZ+]35J@#S2\\*>(+GPOXNTM;. 2:KJ1N[9C<#&UF0D-QQ@1C_OKV
MJUXI\,:IXG,GFZ1:0W8CC:RU&.YV2VDF!N!(&64'<1Z^W4>@U$MU UT]JLR&
MX1%=H@PW*I) )'H<'\J &MY\%E\@-Q.D? )"^8P'KT&37(Z7X,LKW3+BX\2>
M'[&;5IY)9)F)$F\L20%;J  0H]-M=K10!Y'J6D:YHWPM3PSJ7]FRS3W<5K8,
MTY/RL^X*Q*@*R@'!&>G%6].MM>A-]I>I:;8G4]9M)8!>B^,KG;&0N\;<J@'&
M1_$1W->D7UA::E:O:WUM#<V[_>CE0,I_ U7TO0M)T1'72].M;-7.7\B(+N^N
M* .1N?!6L2?#[0M*M[NU@UC1Y8IX9"2\+.@88.5S@ACVI=2\+>(O$V@R'5I[
M&TU.*2.:RBMMS01R1L2&?/+$YQTX'K7?44 >?ZGH/C#Q#X2U*PU,Z1#>7,*P
M11V\CK$/F!9V)4DGY1@#H">>:TSHVLOXUAUMHK$0+I+63(+AMWF%@^1\F-N1
MCUYSCM76TF* /,].\!>(=*\)^'HK.[L(M<T2:<Q.SN\$T<I8LK?*".H['I^6
MKK.@>*-8TBS\^737U!-0ANI(UED2"-(FR%3Y223W) Z^PKN** .!U3PCK>IZ
MCXN=FL([?6+)+:V82N60H" 7&S'.XYP3CWJY:WWB?3[_ $'3+O\ L60R*4NX
MK<RF15 .UUR,!>.2V,G@<UV5% &)XOT27Q'X2U+2(94BEN8MJ._W0P((SCMD
M5E+I7B>?Q-H^KWL6DDVMI/#.L,\B_-(01MRAR!L7DD=3QQSV%% 'G"^"?$8T
M:"6&[L;36K+4Y[ZU9)'DA=922R/E01]XC@'I[\=AH5IJ\4+W.N74$M_,JJ\=
MH&6"(+G 0,<D\G)/7CT%:Q.!GTJCI.LV.M0SRV$IEC@G:W<E2N'7&X<^F: ,
M+6?#>IW/C?3=?T^XM%6&V>TG2X#$A&;.Y<=3U&"16=X<\)>)]$C717UBU?P]
M!+O@9$87>S=N$9;[H7L3R<$@8XQWM% '&Z'X:UC2]+\26\KV+3:K=SW<15WV
MHTHP5;Y>@P.1UJE;>"M7AD\%EKBQ(T!727#/^]# )E>/[H!Y[\>]=_6?;ZU9
M76M7NDQ,_P!KLT1YE*$ !QE<'H>G:@#F;3PWXALHM<>*?3//U'4%NU5P[1E,
M -&X([JHY'J>E:'A+PP?#TVJ7!6W@^WS++]EM"WDQ87!*YQRQR3P!T':M2YU
MW3[75-/TZ25OM.H;OLP5"5<*I8G=C'0>O<>M:5 '-:KX=NSXFM_$>D30I?I
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M X->EWGA6"[\2+KL>HZA:W0@6!TMY$"2(K%@&!4GJ?7FLW_A7=A_PCUAHO\
M:>I_9K"\%Y VZ+>'!+ $^7@C+,>G?TH PGU[Q?K.HZO<:*D@CTV^DMHHR]N+
M=Q&P#"7<?,R1DY&W&1UKL_$5Y>0>#]0O[&=;>ZALWN$?:) "J%L>AZ8S67<_
M#S2Y]8N-1BO]4M!=D->6UK<^7#<GN74#.3WP1^IK4\5HW_"':Q###)([V,L4
M<4,9=F9D*J J@GJ10!R4>L>)-&F\-:GJ>K1WMEJH2&>T2W5/*8Q%U96ZGH<Y
M_#':*;Q#KI\!Q>.(-2W#>)WTX(AA\@N%,>[&[<!SNSUSQTK5\&^&,:)X>OM2
MO-3N+BSM%\NTOE55MI"F&PNQ6R.5&XG Z>M:$7@;3X8OLB7E]_97G_:!IA9/
M(#;MV/N[]N[G;NQ[4 9>EM<3?$GQ4+<F'S-/LV$K+DQMM?;E3]3Q[5F^&/%>
MIZ[I?A6PNK^2&\U2*XN9[M$0,PBD($: C:"1U..B^IS76KX52/Q#J&M0ZMJ,
M5Q?0B&1%,1C4*,*0#&>5R2,D]><CBLS_ (5IH_\ PC=EHWVS40+"1I+.\25$
MN+?<<L%=5'!/J#^@P 5-9O?$6B:%IXGUJ*:[76(;:66*)<R0NXPK@C"MM(S@
M#K5>]UCQ/K%_KR:&TZ-IUR+>!%>!8P5"DF0/\Q#$GICCISFMVZ\"V-UHEKI@
MU'4XU@N$NFN!,KS32KC:TC.K9(P/0< =!BH[[X>Z5?:^VL_;=3MKB4*+I+6Y
M\J.ZVC \P*.>.N"* ,/7?$^IVEUYVHW5SI6G7%M ]E?6R)-;"4@%UD;:QP2<
M \# S7I"L'4,I!!&01WKG=0\&V6H/=*U[?0V=V$6YLH600RA0% Y4LO"@':1
MD4NDZ-=V7BG5+XW-[]@F1$BMY[GS$##&6C7^!>V,Y)SP !D Q_$M[K/_  L+
M0]&L=8DL[2_MIVD"PQN5*+G*EAU^N1[5STFO^)X8O[,.M.;RU\1Q:<;LV\>)
MH91D;EQU'MCK6YXMT:\U+XB^'+B+^T(+6""=9+RS4YB9AA><$<GU!'K6Q/X$
MTR>QM[7[1?)Y-Y]N,R3#S);C.1(S$<D=N@]J ,NWDU*7Q6OA2[UR\D%O8->2
M72*D4LY>7:HX' 0#JO4GGTKF;B^U+5KO2+6^U"[\_3O$S::9XRJK.H5F5RNW
M&\# Z8]N:]*U3P[9ZI>VU\9+BVOK<%4NK9]DFP]4)P0R]\$=15:\\':7>Z;:
MV3-=1?9KC[5'/#,5E\[G+ENY.XY^M &+!+J/B*Y\110:S=64FESBUM1$4^\J
M!C)("/FW$XP>, UGZ#XFOO&UY96,MS/I;'2!>.L/RM-*7:/<#_<&T, .NX=A
M74W/@ZPFO7NH+J_LWEC6*Y%M<%?M*J,#S"026Q_$"&]ZBU7P'HFJ_83LN+*6
MQB\B"6RF,+K'C&S([4 9EKJ%_=:WI?A>_P!6\RX2QENKNZM#Y9G=)/+" C[N
M/F)QW4>]8.K7VH-X/\4Z+J%TUZ^E7]K''=N!ND1Y8G4-@ ;@#@FN[NO"6E7$
M5BL22V<MAG[-/:R%)(P?O#/<'N#G-17G@W3+W06TAY+M(9)1--*DV)9W!SN=
ML<G(!_ =AB@#F?&&M7^F:Q>F\EOK72MD:6^HV3[X[23 )$\8YY)'/H1BO14=
M7175@RL,@@Y!%<Y-X)TZYN;F6XN]0ECNUC6Z@:X(CGV*J@L !R0HSC&>_'%.
MTGP])8^*]4U8,\-O<HD2V_GLZL5Q\X7HF ,!1GOTZ4 9'B$:O?\ C^ST6SUR
MZT^TN--EGD\E4)#*Z@%21QU&?;.,9K%N-4U:VC^(T!U.[)TN"![1RY#1L8F8
MD?4CI^%=_<^'[&YUVVUIO/2_MU,:2),P!0]4*YVD$\],\"J6I>"-%U6_O;RY
M2XWWT(AN42X=4E &%+*#@E1T[=\9H YBXOYWU7X=ZA,)+FX;3;J=PH^:1OLR
M,<>Y/\ZK>&+KQ/J<6B^(FU*U6TN9A]K+Z@[K(KMM$:P^6%1PQ &&ZCDFNWC\
M)Z5%=Z9<*D^=+B\JR4W#E85(P>_S9& =V> *JZ=X"\/:5K#ZG9V;)*7,B1>:
MQBC<YRRQYV@G/IQVQ0!S>AZG?P>,+>SUR34[>ZN+F<V\PG,ME?18<JJ@';&0
M"IZ?P<\FNA\:W4D-MIL$%W<QRSWBJ+:U.V6[ 5B8U?(V#H2V1@ U=L_"FF65
M_%=QFZ?R26@AFN7DCA8YRR*Q.#@D>PZ8JQK/A_3-?2W748&D-M*)H7CE>)XW
M]0R$$?G0!Y5/KFNCP=X@!U2[MYK#Q +2)DG+LD9=1L\QAN8#)Y//\JW-:U34
M?!^J>(OLU_>7L<>BI>QQW4AE\N8R-'N&>B\9(&![5TC?#OPNT-U#_9\BQW4J
MS3*EU,N]UZ'ANN>?K5]O"ND2:I)J,L$TUQ)!]FD\ZYD='BQ]QD9BI')/(ZG/
M6@#@KBQ6#Q[\.KP:A>7CW4-RSM/<M*I;R02R@DA<[NBX' XXKU:N9MOA_P"&
M;2>TFBTYMUFS-;;[F5Q%NQD*"Q ''3IU]:Z:@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBHY_-\
MB3R"@FVG87!*[L<9QVS0!)17F5IX\\3-X6E\37-AI1TZ(21&*)I/.>82^6F!
MT"DD9')X)SS@:&D>+->6XU'^T],N9K2"RDO%N6T^2S =>L.'+;LCD'.>#Q0!
MWM%<!IWB?7Y]6\/6QN-+N8=:MFN]R1,I@  8J,.=PP0 3CD'Z!B>--:/A2QU
M4I8&9]7^P3J(7"LGG&/<OSY4\9Y)% ':VVK:?>:A=6%M>0RW5KM\^)&R8\YQ
MGT/!XJ[7!QSW%I\0/%]Q9VZW%S'IMJ\<32! [ 28!8\ >]9VG^-=9O;_ %;2
M%OK">XCTHZC!?0VC"-&#;60 N1(!GAP<9!SGI0!W^I:OI^CI ^H720+<3+!$
M6S\\C=%&/I5ZO+M)UC5['P+X0N+F6QNX[^_M86,MNV]%=B2<ER"_!^; Z]*W
M)]>UO5!K=YH5SIZ6FD3/!Y4\#2&YD1 S@L'&P9.!P>0<T =K17G5OXSUOQ!K
MFE6FB_8;:UU+2VO ]S$SO"P8*<@$!L'( XZYSQ@M;QSJD'A32]1OHU@#7DUK
MJ-Y!;-*D C9EW[0> Q4<\@9/M0!Z/16-X7O+N_T**YO+RTO'=WV7%I_JY$W'
M:0,G!QC(SP:QVUS6-9N=>_L2XLX8])E-NJSQ&3SYE4,X8AAM7G;QSG)]J .G
MO]1M-,MQ/=R[$+!% 4NSL>BJJ@EC[ $TS2M6L-;L%O=.N!/;LQ7<%*D$'!!!
M ((/8BO,=5UR[\42^ -4M;@6J7UTS"(Q!Q%*JE2<G!89W#'%>F7;SZ=H=S-;
MQ03744+2;21"DD@&223PH)[D\>M %R61(8GED8*B*68^@%88\:>'CI,&J#40
M;.>?[-%((G)>3.-H7;GK[5@>%/%VHZIXJ72;J>"YA?2_MAFBMFC"RAU1E1B2
M)$^;AAGIUKC+*86WP8LIRNX1ZXKD#OBXS0![C6+J'BS0]+O&M+J^'VE<;XHH
MWE9,]-P0';^.*MZW=366@:C=6R[KB"UEDB&,Y95)'ZBN9^%ZJ?AW87D6V:[N
MQ)-/*[?--*7;)9N3G(QWQB@#J=-U;3]8MFN-.NX;J%6V%XFW -@'&?7D5<KR
MRZ\5WMKX9\3ZEHEE;Z=/9:L(;E)3YPEF+1QN4Q@*.0<D-GGCO6X-3\10:Q:^
M';W4+4:A?O-<K=6\'RP6ZJN$"MU;<2,G/ ]: .WHKS75?%VNZ/I.OVLL\$FI
MZ-/;,+@P82Y@F8!25SPPR<XXRM;6H:SJT'C#4])M[F(1+HWV^$RP[O+DWE,<
M%<KA<\G.3UQQ0!V%%>76GB7Q;;Z7X9\0WM[8SZ=J4T$%S:I;;#$)#@2!\Y)S
MV P/0]:[;Q;KI\.^';C4$1&E#)%$)#A-[L%!;V!.3["@#;HKC-7U77/"=IJN
MHWUS#J&G06/FPED5)?M&0-N%P/+Y![D>IIE[J>N^'[S0Q=:A'?0ZK,+24M;J
M!!,RDHR;2,ID'())P.M ';4FY2Q4$;AR1GD5Y?IGBCQ/+H?AO6KK4;9X[[5U
ML)+>.U"[T:5T+%L\$;1@#TYSFI8)M8M-3\>WL&LS,^GA6C2>)'4X@W@8 & ,
MD#&/4Y- 'IE%>?0:EXFA\*Z?J^H:Y:!;_P"S,RQV@5X4926$?WO,D8[0!M]<
M"J.F>.=5NK&2UD=EN)/$']D17$T*I)'&1NW,@^7> "!QC.,CJ" >CB"TLP\R
MQ00 *2[A0N!UY/I5BO,O&5MKD/A'7+'4-<\V#S8!;O'L6>6"214=90$  R3@
MKC/?TJYJNJ^(WUV]T/27OKB2QMHY?/B:U61Y'+$;Q( -@  ^50>O/2@#OY'$
M<;.P)"@D[5+'\ .3^%4-%UJRU[3_ +=8.[0;WCR\90[E.""" 1R*Y:UU37=9
MU:ST&XODTR[ATX75]+9^7(\DF\Q@)N#*%RK$\9&0*E^%B21^#2DTGFRK?70>
M3&-S>:V3CWH WW\2Z4FO?V&9I?[2\OSO(%M(?DZ;MVW&,\9SUK/7Q]X=/G;[
MJXB%O+Y%P\EE,J029QM=]FU>2.IQ64O_ "7A_P#L6_\ VX%<]I5CJNKP_$#2
M=-M[,B\U6>%IKF9E$>X $[0IR0.1R.: /6!-$T G$J&$KO$@8;=N,YSZ8[U#
MINHVNK:;;ZA92"2VN$$D;XQD&N/U_9HGA'1O"VRYNFFBBM95M8FDD:WC51*0
MJ\\@!<_[=4?A=>_8I]8\,20W-NMK.UU8QW4)BD-M(>/E/HW\Z /2**\^\.^(
M-0N?$\&G:O?WEIJ0>8R6,\*+!<1C=M:!PN6P-I^]T!ZUT/BZ_N;#3K5[6]2U
M,EW''(=F^5T.<I"N#F0\8R",9/O0!T%%>3W7B?Q%!X/\7W'V^YANM*NT%L\\
M,/FJC!3M<*"I.&ZCG^5;5QKNI^&?%.I07VHR:E91:')J>QXD0I(DF"J%0/E(
M/1LD8')H Z?6/$5EHEWIUM=K/OU"X6VA*1Y7>W3)[5K5Y-KR7US#\/=4O-5F
MNGN]5M97BV((E9QN^7"AL#.!DGCKS7HOB6[EL/#6HW<%U!:316[M'//RB-C@
MG@YY[8/TH TI'$43R%68*"<*,D_0=S6"OC'37T;3M66.Z^RW]PMO$?*Y5V?8
M-PSP-U<[X1UO5)/'5YHMS-?RV9TY+R/^T%02[RP4D;0-JG/W2,C'05F6G_)*
MO#7_ &&(/_2PT >K455U*=K;2[N=9H8&CA=EEF^XA ."WL.]>?>&=:UBZ\36
M%C+?7YM;[2'F::XC53),"H\V)2,HOS<!AC&.* /2Z*\AM-7\2Q>"-$\6/K]Q
M<2O>K%<6CI$L<D33LA&-N2_3D'@=!P:M2W/B:ZT;Q?J$?B>YC;0[VX%J@@BP
MZQ(KE9,+\PP< #&#DG/& #OI=>MHO$\&@M#/]IGMWN$DVCR]JD C.<YY]*ET
MC55U>VEG2TN[81SO#MNHMC,5.-P'=3V-<=9WTFK^-_"M_(IAEN]!EE8 8*EC
M&>_UK)T3Q1J=QI=E97VJSH]]KL]DU^P4,D:#*HN!@,Q 4''&3CM0!ZQ63XDU
M^V\,:%<:O>13RV\&-X@4%N2 .I'<C\ZYC6KJ]T33;NQ_X2@&X:^A,(9-]R(9
M#@0K_>=BK[3Z#J,9KF]?O-1OO!OC_2[Z2=8[!K=H4NG622,,$D*EEX//3DXS
MU- 'KBS;[83(C,&3>%&,GC./3-4/#^NV_B+2$U&VBFBC:22/9, &!1BIS@D=
M0>]<G:S:KH?CCP]IQU2[O['5;.4RQW 0^4\:A@R[5&T'(&*YS1]2U"/0O#^B
MV+*O]I7VH[Q]J-LS[)6(02!&*YW$\ '@<B@#V.BN<\()K,%C>6NMW=O<7$-R
MPC$4QE:*(@,J.Y5=S 'K@9&*Q#%J.K_$;6-,'B#4+>SM(+:Y2*$J-KEB=N=O
M*D#D'.<\GC% '?&L2+Q+#+XRF\-?99TN(K/[9YS;=C+N"\8.>I/7'2N-.MZB
M?!NHW*WMT+BS\0FS25GY,7VE4V^XVMCG_P"O4'B75)]$^)6N:G:QAY[;PL9(
MP5R-PF&"1Z#J?84 >J45YUI8UJ-[+5(=<M$L[ZSD)$]^]RLLOEEUD7<BB, @
M[@,+@=!W?X,OY$\2OIVJ1ZQ9:Q]D+2V]Y=-/!/AES+$Q.!R3P !@^U 'H5%<
M;XSN96UG0]-@N;IGN&F9K"TF,$EQM7()E# HB\D]SP,&N2BUC5[GP[X.675+
M^*XN=9DLY9(IP28UD=0&.WYR H&3UYR#F@#U^L>37XX_%D.@-:S"66U>Y6<E
M=A56 (ZYSSW K@M0U?4O"UCXQM8M4N)5M;JU6VN+IS*UNLX7=RQ.=N216G;Z
M3!I7Q<T\075Y,)-'F)%S=/-C$B#(+$D9]N.* /0J*X_XBS7D.CZ=]AO[BRFE
MU.VA\R%L'#. <CO]#P:YW5K/4(_%5KX2M=4EGB-FUZAU+4)D>:1I&!4/'@ML
M"@A<XYSCB@#U*BO+YKG4[6W\,:9K>I&_LC<W%M?R69DWRL@_=Y(^=U4@AB.,
M@9[YKZC'J^G_  [O+^ZOM5AF35$^QM-<R)(MMYZH@89!Y0G(;GH30!ZG<2M!
M;2S+$TI1"P12 6P.@R0/SK+\*>($\4^&K36H[=K=+G?B)FW%=KLO7_@.:Q5G
MF7XF:O:BYG:W_L:.;R6E9D5R[ D*3@' '2N+\,-Y_P /_ ^G+-/(]S-=,+")
MS$MT%:0G?(""JKD-WR<#!H ]ANKN"RA$MQ((T+I&">[,P51^)(%56O-0&OI9
MC3"=.-N9&OO/7Y9,X\O9UZ<YZ5Y%#:-JW@JS35Y9+F6Q\3+8Q,EU(RK&9D4J
MK9!88R QY Z8KJKHOH7C^9=/>YEB@\,S316KSO(A=)$"X#$\G &>IH ]#I*\
MJ:66V\&^&?%6FWMS-JUU<6PN6:9G%R92%DC*D[0 20,#Y=O&*R=1@N4T7QW=
MF_U-FTF_!L':[D/EM\N><_-Q@8.<#TS0![72UY3XJGO'BN-6O[>;4-*:RA65
MK"Y:.?37*;F<)T8'<#R>W/ KT+6=0FMO#%]J-C$9IH[1YH4[L0I(H TZYN]\
M2WW]KWVGZ/I U&33Q$;H-="%OW@R @((8[>>2HZ<URTD:V&@^$_$&CWEQ)?7
M5S;1SN\SR?:EE_U@922,YR>/N[3C%7_#&CV,?Q(\6ND)#6[VAB.]OE+0DGOS
M^- ':7>H6UA%#)=2"+SI8X45CRSNP55'J<G^9K/L=<FNO%6I:-):+$MG!%,L
MHDW&0.7'3''W?>N;^)5E8W-UX4-Q%OF?6X(5.XCY#G<.#WP*J7VAZ=JWBOQ#
M:RF5K2+1;81K%,P7CS0I.#\Q&.,YH ]*HKQMM3FO3X*T_5=0M8K.[T82B34(
MFEBFN,*/GQ(F2%Z$D\MTR01WO@6T%AX?:Q35_P"U8K>XDCCN!&54#.=BDLQ8
M*21G)Z8[4 00>-67Q_)X5U"P6V=HS):W*3EUF[A2"HVMM!.,GIUZ5;\6^+8?
M"UM:G[,]U=7<PA@A5MHR2!N9L':N64$X/WA7'>+](N-2UKQ'>V3.-1T>.QO[
M/#<;E$I88[Y4?F!537-3FUSPY#XIEC,%OJ%_8P6L4G6.%) S$_[T@//=56@#
MUN RM!&;A$28J-ZQN656[@$@9'O@?2DN'E2VE>"-99E0E$9]H9L< G!Q]<&O
M+=95=<\9^(M.U/6;#3VMXXA9_;8'W1Q% QDA83( P?.3@G@#..*GTU[3Q!XC
MGTOQ'<F]BM]'@>U:X7R5F5U/F3[<\/TY_A XQS0!T^D>(]5U[PQHNL6&F0DW
MLZ_:8FGQY$.Y@S X&XC X[YKJ"R@@$@$]!GK7B-ML/P^^&TT<C;UUNWB8+(<
M8,CD@J#@G@=1G\ZVH[KPWJ[:^/$-R+76[/4F(=7"W")&P,0@SDX*@#"CDD^N
M: /4RZA@I8!FZ#/)K!77KS_A8!\/O;0+:G3FO4G$A+L1(J8(P O5O7/'(Z5Y
M7XWN8+V/Q3JELT4=Q:30H);^4?:()$V_N[=5Y09)).2"<\<9KT!98YOC#;O'
M(KJ?#SD%3D'_ $A* -3QAXANO#&A/JMOI\5ZD;HDD;7!B/SLJ+CY6SRPZXJM
M/XIOM)UG3;#7-*AMX]2E\BWN+2Z,ZB7LKAD0C/J,U4^*I7_A76H!I/+!EMAN
MS@C]_'S6+XVM_P"R==\,:FNIRZK=K?)%%8715MP?K(BH%PPQ]X@CF@#TPNJL
MJE@&;H">M#R)&1O=5SP,G&:\L9+#5[+QY-KB0IJMC<S>3)(<2VT(B7R&C8_=
M!(SD=2><YK-UR[34M,E_M%[9-4A\/P&Z?5'^6,NI)\F,8;S"V 6SP0HP: /9
M6=4&68*/<XK/US4)=-T2\O+80//%"TD:32;5<J,XR*\Q33M)\4ZSX(AOG%Y'
M/HCBY"7#?O&1$X<J<D@EL^XYZ4^<Z&W_  G5CKJP1W%G#Y-I'<-DQVJQ 1>5
MNR<YYXYR1F@#TKPYJ4NL>&M,U.9$26[M8YG5,[064$@9[<U>>Y@CG2!YXUF<
M92,N S#V'>L'P#-%-X T$Q2(X6QA0E6!PP0 CZ@\5PSG2[[P;XL_M54B\107
M=R2\A"SB4'-OY9^]C'EA<=><=: .ZUK7YK;7+'1+![5+RZCDF:6Y!9(T0#C
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M$4D.G"_%_;0K:JS1OOWD,Q/S#/3I[YKJO$>OV_AK1Y-3NH)Y849580J"1N.
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M_J4TUW'JFEI8K"%9)DN1+'*""3SA2"".<C\:S=0\816TWA\VML+JTUF<0QW
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M#!JEE##)YAEM9 #+<#;D>7SVZGVJ?^W=)_M"2P_M.S^V1@EX/.7>H R<KG/
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MAMYDY 9LYW,H.TGW(JQ=^$M"OK^XOKBP5KFY0)-(LCJ7 &!T(YP2,]<$CN:
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M @,7&21A0 N<$9[U%#JUIX<OQ9^/(Y?*U#1;2".6:)I@616$L?R@G<6?)_\
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MHX-"FLI8%DACQ'#<.X<NP4<;E7&[\ZS+?PS+KFA>+_L@>"TU"[^TZ5G*E9$
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M(M,E2_5H]3?99N$8K(W]W., ^QP>#Z5(GB32'@OIOM@1+"3RKDR(R>6_'&&
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M/MLDNGD?:EALY&\H$$[FXX7 Z].17!^)]*U[4?[40:+J4DT>L+<1+;JD=NT
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M1-G) B4-M5.F3@<G^(UT-WHFM3P^/U329P=64+99EB_>XB$?]_Y>>><<>_%
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MX7DA6&2WN[7SHPHR?EPRLN2<GGD@9Z"GP^--%GEM%6>98;V3RK6Y>!UAF?\
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M;NSE,MO/#M;:Q4J<JP*MP3U'%&EZ%+:78O\ 4=3GU*_$1A661%C2-"06"HH
M&2H))R>!S@5D'XCZ,FDZEJ$UOJ,/]FR)'=6\EL1-'N^Z2N> ?7-68O&]C<1J
M(+'4FNI9FAM[5X/+DN"JABR;B!M"D'<2!S[B@#I\48KD;CXA:79Z5=W]U:7\
M/V*=;>\@>-?,MV;&TL-V"IR,,I(YK;GU:%;PV/DW$DAM3<MY6#M3. .#G).<
M8ZX//% &GBC%<1X8\1:/:>$-&_LF/4;J&^GEBM(KAU,SD,Y8LS,!@;6/7I@=
M:GU+4]*U.7PY<7MKJD,KZB4MD^YLF7>I63#8(^1CWSCT)H [#%&*YN_\8VUD
M+^6+3[Z\M=/D\N[N+9498F !;@L&;:""=H..?0TVX\;6$>K0:9;6E[>W-S9B
M\MOLZ*5F0D8PQ8 =<_-@<=<X! .FQ1BLKP[K]IXFT6'5+(2K%(64I* '1E)!
M!P2.H]:S9O&]C;VHU"2TNQI!F\G^T@$,6=VS=C=O"[OESM_3!H Z?%%>=:J9
M-?\ B)<:'?Z==R6 TM2B+,B[&:4@SK\_'  '\7!XP>>@O?$T&AZM9>'UL=1O
M+N6V+P>7L8RA, Y9F'/<DX'O0!TM&*XJW^)6G7%I:W8TW4DM)KL64D[H@6"8
MMMVM\^3]5!'OGBK.N^/=/T2\NK;RGN6L5#WFV6-#$I7<-H=@7;&#A>QZYX(!
MUF*2N6U#Q7'=VZ0:-IL^LO<60NS'%((0('R%)9L'+8. .>#TKD?#EW8/\.O"
M UBSOKCSM2VV[Q2 ;)_/DV!R6!(QGL>!]* /6,48KF-5\8#36NY8]+NKJQL9
M5BN[F(K\A.,[5SE]NX9Z8[9((JOK?CVWT>YOE73[BXMM-$1OIPP01B0978&_
MUAQR0.G'7L ==QG%+BN )1OCC:R1EMLN@-)R3U,N,X[< ?E71ZKX@>RO7LK*
MPDOKJ&#[3.BN$$47S ')ZLQ5@%'7!SB@#<Q1BN0N/'D)BLVT_3;FY:YL6OR)
M3Y CB'&"S#&_/ 'ZXQF.\^(=O%;:+-9:/J%Z-8C9[41[ 20I;81NSG@=L8.<
M\8H [.BN'O?B1;V4$TDEAM>SCC:_@DNHTEA9@&*(I_UC*#DXQZ#G('96=W#?
MV4%Y;/O@GC62-O[RL,@_D: )>,XSS2XKEKN\LA\1+:V.D2R:DFFRRQ7?F@#R
M]P!15SR2Q')Q]:R],^)B:A::-?R:+<V^G:I=_8HKEYD.)2S!1M')!V]>WOW
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M_O<G@FJ'BS4]0UOX9>*H-6TZ2W:U*^5/Y$D*7*!U9757^8'CD'/UYH ].!#
M$'(/(I:X'Q9XMU30&F%O]CAAMK%;F,31M,]VPSN0!6!10!RY!'/:JAU?6]5^
M(V@QV]]!;6L^C_;A"T!D WE=RD[AD\<-QCT- '=6&M:?JEQ>P65TDTME*8;A
M5!_=N.QS_2KU>::AXQUG2?#GBS4HK;3!<:7J(APL3!9 1&,GG);Y^OM6UI_B
M358O&4FAZF+><2Z6-1A^R1,I3YRIC)+'=VP<#Z"@#LJ*\[L?%OB"_'AF:WFT
MEDUQI-T9A<FV"*7(R'^8@#:2<8./6O1* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0G )]/2EHH
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M*:JEIIG]GWEA-Y9>,@@[UW':>1^6?6N_T&PFAT&:.33;33'G:1UM+=5"Q \
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"[G XW.CC Q@KZ5U.C^$!I/B*[UIM9U&[GNXT2=)RFURN0#A5& ,\ 8 YZU
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MG/&* .\O+.VU"TDM;R".>WE&'BD7<K#T([TMK:6]C:QVMK"D,$2[4C0851Z
M=A7FVD>-/$U]IVDZG<'35@EU5-+N(8X7+2$N5,@8M\O;"X/U[5?U+Q=K=S?Z
MU%H5JTO]F2""./[&THGE #,&8,-@YVC\_:@#T"J5OI>G6=[<7EO96T-S<D&:
M9(PK2'_:(Y-<7-XD\47GC%=$LSIUDLND)J7^D0/(\)+!2APP#'/?@8K%_P"$
MEU7Q+8^ M1DNX[0:A>2++$D.Y3+'O4-UR1D9 S@9SSB@#UND8A5+,0 !DD]J
M\_N/%NIIXLET:2\CLKI;F**V@N;4K'>1?)O=9<XWX+X7Z#DUTGC%)W\'ZOY$
MXA*V<S,2F[<OEMD=>/K0!+IOBG1M6OOL5G>%[@Q>>J/$Z;X\XWJ6 #+[C(K8
MKS&XU;Q#HNE>#H+"YTZ1]36*V5KBU;,0,8/4/R.G&.<=:UK#4/$NHZC<:$VI
M64%_IEM&]Y=1V^]9I9"Q0*I(PH5?F/4D\8Q0!W%%>8Q>-/$6H-HUK;M86UY)
MJ4^F7X>!G598U)+(=W*XP<>O&145QXE\86NA^)+J34=.9] N?+++9D&Z VM@
MC=A!M;'&3GOQR >IT5 'EGL@\3(DKQY4LI958CC(R,CVR*\GL_&WBT>#+#QA
M=W=@U@;ORKFTCM2&,9EV%@V[J.@&/<YH ]?HKS;6?&&K:5KT(:\B:$ZQ'9R6
MT5OOC2!N 6D[2GKMSQZ5?D\47V@>*-5L->NO,M?L9N]-,,(#2J"=R'UD'R@
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MC0A1DX/9B<C\ZYC3_%7BN7PCX8UQ]<WSZGJPT^2%K2/RPK/(NXX )8;1T(&
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M@GCC(.*YO5M/M]-\96GAR>[M+71Q92SVO]K%YXY)7D)?GS$^8#H6)('3DYH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5Y$;YFZ@Y3I[#'4]^:[&B@#SWQ'X3.EZ)J[:>-8OCJU[%/>K;R()8U#AF:(
M+DX &"3V]\GA[2[N2^BABG\3S::5=+U-?*E'C92 J@@.6W%3GH ".X%>A44
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M)IT9B5E39;( H;[V !WII\*>'3;+;'0=+\A'+K%]CCVAB "0,8R0!S[5L44
M4QI.G*EJ@L+4+:'=;*(5Q">F4X^7\*N444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11FB@ HHHSB
M@ HHHH ***,T %%%&0>] !1110 4444 %%'6B@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$ R6&/7M7ES>+-?DM[*$36T-[%K7]E7+F'*2@JS"0#/RYV].?K57Q!JNM_\
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M;2J&;/3 SSFK=>2ZC?)!KMS>6ES9:O8S:I;F;3;@".ZMY1LV/$1RR@*IVXZ
MCUKUJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6^V6-[I_AK4K&ZLXO(5X[RW;?'G.U@6Y&23^->A"YMC>FS$B_:%C$IC[A2<
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M$T74U@L;@7$3-J-N26!)&?;FO5@/K^=<O=^+KBW\6MX=AT*>YNOLWVM62XC
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MR23BK%(S*B%W8*JC)). !0!@GP7X?,5Q%]@(CGF\]T$T@ ?=N^4!OE&[YL#
MSSUJR_AO2Y+V:\:&4W,T'V>27[1)EH_[OWNE7EO[-RP2[@8J@D8"0'"GHQYZ
M>].%W;&U^U"XB-OC=YN\;,>N>E &1'X0T.&&UAAM)(DM4>.#R[F5"BL064$-
MG!P..E:#:38MI)TH6ZQV/E^5Y,1* )_=&W&!4&HWD\NAW-QHMUI[7 7]U+<2
M$P YYW%>W6K/VZ""!#=W5LD@C#N?, 7L"1GMDCGW% #4TFSCT@:4D;BS$?E"
M/S6R$]-V<X[=>G%<?XA\%0QV.E6>E:)%>Z7:W#S36#711CE2%\MF)V@$DD K
MDX]ZZ+5/%FCZ1/IT-S>1;]0D"0;77!&/ODYQM'K[UI'4+(3QPF[MQ+( 40RC
M<P/0@9YH XO2/ EG++<M=:2^FZ;<0"*33!>O()6W!M[X; (Q@ $YR<]JZF]\
M.Z1J6D)I5]8QW-E& $CFRVW'0AB<@^^<T@FU%?$DJ27&G#2EM@RQAF^T"3=U
M/;9C\<U9BU;39[E;:'4+62X==ZQ),I8KZ@ YQ[T 54\,:''H?]BKI=K_ &;W
MMS&"I/KSW]^M0P^#O#MOI/\ 9<6D6RV._>8=ORLW8M_>/N<UN$@ DG '4FJ(
MUK2C/# -3LS-.2(8Q.NZ0@D':,\X((..XH A/AW2&NY;LV,9N)8O)DEYW,G]
MTG/3VIDGA;0IM&&CR:7;-IP.Y;<I\JGU'H>3T]:M-K&EK<BV;4K,3F01"(SK
MN+GD+C.<^U"ZOICWQL4U&T:\!(-N)U,@(Z_+G- %/_A$] _LVWT[^RK;[';M
MOBAV?*K?WOK[]:FD\.Z1+=W5U)I\#SW49BN'9<F5,8VMZC'8US&K>+7NO%4W
MA[2=;TRRGBM0Z23,K^;<%RHA(SQC'( +<C\>HT_5[:8Q6-QJ&GOJJH//M[><
M-AP/FPI.[ /J* ,R;P5I?VK2FLK.RM(-/G,X$=N/,W<'"MGY02HSP20 .*UM
M4T73=:A2'4[.*ZB0[@DHRH/KBE36M*EOQ81ZG9/>$E?LZSJ9,@9(VYSP <TU
M-;TJ:YDM8=4LGN4#%HEG0LNWJ2H.>.] %AK&V:P-BT0:V*>68R205Z8^F*KP
M:%I5OI3:5%86ZZ>P(-ML!C(/7Y3Q571;^2+P\EWJ^L:==$,^^\MR$A(W$ 9R
M1QT//45:&NZ2UBUZNJV)M$8JTXN$\M3Z%LXS0 [3]'T[2M_V"SAMRX 8HN"0
M.@)ZX'8=JL16EO#///%!&DLY!E=5 +D# R>^!Q4%IJ^FW\\D%GJ%I<RQ &2.
M&979 >F0#Q45GX@TC4;V:RLM3M9[J+.^*.4,PQU..X'?'3I0 D'AW1[9[MHM
M-ME-YD7.8P?.S_>SUIECX8T+39XY[+2+.":-2B2)"H90>2 >O>LKP-KFH:Y!
MKG]HO$\ECJ\]E&T4>P%$"XXR?4]ZZ.\O;;3[9[F[G2"%.KN<#Z>Y]N] %.S\
M.:)I\]S-9Z59P270VSM'"H\P=P>.GM5FPTNPTJ)XM/LK>TB=M[1P1A%+8 S@
M<=A3(=9TVXTO^TXKZ!K$*6,X<; !UR>V/2H;?Q'HUU937D6J6OV> XFD>4*(
MC_MYQM_'% %E-*TZ+4'OX["U2]<8>X6%1(P]"V,FF#1=+74?[173;,7W_/R(
M%\WIC[V,]*I+XP\.-<30+KE@TD,?FR 3J0J\<YSCN/S%2Q^)M$DTA-675+46
M#L52=I JLP)&!GJ<@\=: .>\/^#6BU[6M0US3-+F^U7OVJT< 2R1Y&,$E!Z
MCD@'IZUU::3IL>H-J":?:+>O]ZY6%1(>W+8S5;3?$FC:Q/<0Z=J=K=26Q(E6
M*0$KVS]/?I42>+=!E2Y>+5()%MHO.D\LEODSC<,?>&1C(S0!<31=*CU%M133
M+-;YB2;E8%$ASP?FQFB'1-*MKQKR#3+**Z9F9IXX%5R6ZDL!G)[UEZ1XTTG5
M- CU=IQ;0N0-LF<@DG:!QR2!T&:LGQ9H"V,%ZVKVBV\\IAC=I -S@X*X/.0>
MOI0!=32--CU!M033[1;UA@W"PJ)"/][&:@C\.Z'%')''HVGI'(X=U6U0!F (
M!(QR<$\^YIMAXDT;5(+J>RU*WFBM?]>ROQ&,9R<]!@'GVI--\3Z-JS7*V=\C
M-;+OF616C*+S\Q# ?+P>>E %I=)TU9X9UT^T$L$7DQ2"%=T<?38IQPOL.*B7
M1-/MK:ZBL+&SM&N01(T=L@#'U8 #=^-0Z5XHT;6KI[;3[Y99D0/L*,A93_$N
MX#<ON,BM&ZNH+&UENKJ9(8(E+R2.<!0.Y- $&DZ9;Z-ID-A; ^7%DY.,LQ)9
MF..,EB3Q@<\5:\J/<[>6NYP QQRWU]:QK?Q=H5S:WEPM^(X[-!)<">-XFC4C
M(8JX!P1T..>U&F^,- UB\AM+#4HYIYHO.B78RB1< G:2 "1D9 Y'<#% &J]C
M:2VJVTEM"]NH 6)HP4 '0 =.*B?2M.D#"2PM6#,&8-"IR0, GCKBN,\;>,4M
MHK.VTC4I$N?[3AMIBD#%&&\!T\PKMW#N <]:[Z@"M)IUC++'+)9V[R1@!':)
M25 Z8..,4][*TEE>62UA>1T\MG:,$LO]TGN/:LY/$NE7.HKIL-U+]IE>2*-A
M;R;&= 2P60KL)&#W/0US/@7Q4[^%(;C7+Z>XNI[^>WB80M([E6. %13@  ]L
M"@#M3I]D2,V=OP-H_=+P,$8Z=,$CZ&GM:6S1^6T$13(;:4&,CH<5S\-[:7?C
M:_M+?7;O[4MB%>Q"82#YO]:-R[2W('>N7CUG4S\-_#FHS:O<1S3ZE#%<SEE!
M>-IRK!B1P OIB@#TC[+;_:1<?9XO/ P)=@W >F>M35CW'B;3+6^-K+)/N69+
M=I$MW:-)7QM0N!@$[E^F1G&:V* "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1F"*68@*!DD]J6D90
MRE6 ((P0>] 'DNGZIJD>N>&;V'4+Z:VU*_GBFGGG/EW:'<5,<!)"* !@@ _@
M16;J=WK5AX4\4ZR=>U-KW2=>:&V!N3Y>S=$,,HP&&&Z'@<X R<^@_P#"M?"G
MFV[_ -FM_H\C20K]IEVQY.2%7=@+DYP!BKA\$^'VTVZT][!FM+N;[1<1-/(1
M+)UW'YNN0/R'H* .<U2<^(M3\7V-S=WEO'I5H$@MX+EH=Q:(N96"D%@<@ '*
MX'3FMCX:?\DWT+_KV'\S5C5/ OAW6;U;R^L#+<"+R3()Y%+IZ/AOF_'-:VE:
M38Z)IL6GZ= (+6(82,$G'XGF@#E=0F?7O&.JZ$^K7%A]CL8Y;46TQC)=]V96
MP07"X7Y3\O//45#;7+:QXEM= N]9NIXH-)6X\ZUE:V-W)YAC:3*$' V@@!L?
M-GGBN@U[P=H/B:>WGU?3H[F6W_U;EF4X]#@C(]CQ4E[X7TB^%H7M3#)9IY=O
M+:RM!)$F,;59""%QVSB@#S>[N];C\-W.J/?7]P?#>MO!(T5S(OVNT1QN#A2
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M;#1K/[)IMK';6X8L(XQA03UXJM?>&=%U.^%[?:9;7%R$">9(F25!R%/J,]J
M.#NM.L?$/B[7GN1.]N="MYD3S63)(<J6VGDC\L\^E4;>YCUNR\)V-Y-]LNSH
MQN)8[Z;9;!"-AE<_>>0 $  Y'WLCJ?2IO#&B7%[<WDVF6[W-S'Y4TA7F1, ;
M3[8 J)?"/AU8[2,:+8E+-BUN&A4^62<G&??F@#SM;Q[WP)\-Y9;@SS#6K179
MFW-D"0<^^,5U^DW$-KX[\83W$T<,*)9%I)&"JO[MNI-:3>"_#3VT%N=$LA#;
MNTD2"( (S8R1COP/RI+[PEI,Z:C+;Z;IZWM^A2:::W\P/D@_,,C/(!QD<@4
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M;88_WC*QS@L5!XSCKVH X.[-EJ%_X@M/$&NFPU6&_:2* 6J&=U!!A,#D;B2
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M@=>!WK2L[2[27X;C^S[U#8VDD=T3:2 0,;;RQN.WCY_\>G->F4E 'B[R:D/
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MS3:G!"T4]DMO$FT&,^:)OD!9,YY).2>Y-<]I,-E:?#KP7J$<=O%>?\)'&CW
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MGQ.PMS&0IQS\Q_KTYHM1J%GK/A'4O[%U*6*+2&LY42'#Q2_(,.&(VCY3R>*
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M1F-]I(!4AB6SC)XK0UNPUA#XWLK;1KFY.L1AK::-D$>/LX0@DG.<@\8YX^M
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M$D?F,7?8H&YCU)]3[U)110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !67K>DMK5M':-=SV]J9,W"P.4>9,$;-PY4$D$XY(&.]:E8GBG^W
MSH[1>'8H&O93M,DTNSRE[LO!RWIGCOSTH Q/!=A-I7B'Q#IMM=7,VBVSPK:K
M/(9!%(REI$5CR<97C)QGUKMJY'P</$<1-KJFB6FEV,,?R>7<^?)+(3DL6S]2
M2>26SFNNH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
&BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>exhibit1021-independentc003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit1021-independentc003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HKE[KQS:0SW,=II.L:BEK(T4\UG:;D1E^\,L1N([[<UN:7JEGK6F6^
MHV$PFM;A=T;X(R.G0\B@"Y1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_A;P\/#NC_9'N6N9Y)7GGF*[=\CL68@=AD]* -RBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH :YP.N.^:;!,L\*R(<J>^*DH
MH **** "BBB@ HHHH **** "BBB@ J&ZM;>]MGMKNWBN('^_%*@=6YSR#P>:
MFHH 15"J%4  #  [50U+0M)UAHVU+3+2\:/[AGA5ROTR*T** (X((K:%(8(D
MBB0!41%"JH] !T%2444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME3D96-R1R#_> ZCIWH ZZBO/8O'.O_85U*?2+%+*'5#I]SMN&9S^]\H-'QR
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MZT >A55BU.QN+Z:RAO()+J$ RPI("\8_V@.1^-5+'4;J\UW4K=5B^P6FR,2
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>);>[41Q[+>%S\ORQEL[5&">?RKK&\'WUV-:O[N_MO[8U.S^Q"2* ^3!%C!
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M=AD\U(R,;#\NUEP!U4]*G7PI9QP1+#=7D5Q'</=&Z20>:\K@AF;(*G(.,8P
M  .!6]10!YKXF\-I9ZEX9M;)=6(;5)+RZO;:$NZNRXWNRH5&25'(QC/&,UU,
MG@^QETO5+)KF[+ZI_P ?MT74S2C&W&2N -O& !@=,5H:G=ZA:R62V.F?;5FN
M%CN&\]8_(C/63!^]CT'-:% '.MX,L'N-+N&NK_SM/M_LR.D^PRQ9!VOM S]T
M=,>^:S(_A;H420Q1W>KI#;W/VFWA2^=4@;).$ Z=3S][WKJ%N;XZW):M8*M@
ML =;SS@2TA."FS&1@<YSWJZ* ,C3O#=GIFN:AJ\$MPUU?A1<>8X96VC"<8XV
MC@?7G)YJ;5M%@U<VSO<7-O-;.9(9K:38RDJ5/8@\$\$$5HUBV^MW<GBNYT:X
MTJ2"!8/.M[SSE=9@"H;*CE,%@!GK@^E %S2=(M=&M'M[7S"))7FDDD?<TDC'
M+,3ZD_A6._@329-(O-+>6]:UO+K[7.#/R\N022<9Y(!QTX%=,#S2YH QU\-V
M0\0?VV\EQ)>?9?LAWOE6BZ[2N,=<GZFL_2OA_P"'M&U 7=G;S+LD:6*!KAVA
MB<YR50G:#@D=.*Z<T9H XZ?X8^')TFA(OTLYI_/>SCO)%A+YSG8#@?A6NOA7
M3%UN75F$TMQ+:BTD660NC1#^$@]?7)R36WFB@#E])^'OAW1FF^RVLK++&\/E
MS3NZQH_WE4$X7/3(Y]Z99_#S0K&:QFA-^7L21 6OI3L4X^3[WW>!QT]:ZHUA
MZOK5S;ZQ:Z/IT$,E[<6\MP&G<JBJFT8X&<DL![<GVH L:)X?M- 6Z6TEN7%U
M,T\@GE+_ +QCEF&>F3UJK>^#]+U"[O9KIKJ2*]DCDN;;SV$,C(%"DK]$7/K@
M9S6GID]W<Z9;37]I]DNWC!F@WA_+;N-PX-6Z .<U'P+H&JZA?WMY;2R27\2Q
MW"^>X1\  -M!QN  P>V*;:> ]$M-134$^WO>+#Y'G27TS,5]SN[=O2NC\Q!N
MRZC:,MD]!ZFECD26,21NKH>0RG(/XT <XG@30XM";0XTNETEF#?9!=2;1SG
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M]R> .*Z"BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M# KUZG-=A!X2T^"*5?-O))7@^S+<2W#-)%%_=1C]W^9XSG I+/P=I-G::;;
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M2Q2-$^W^Z60@E?\ 9/'M3+WPKH6HV-I97.FPFVM&#6\: Q^4?]G:01[COWH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ***YS6/'.AZ%>26U[-<9@V_:)(K:22.WW8V[W PN<]* .CHJ.&:*X@C
MGAD62*10Z.IR&4C((/I6!'XYT*35;?3Q-.&N96AMYVMW$,T@ZJLA&TGZ'% '
M1T45GZSK%MH6F2ZC>+*;:$;I&B3<47U(]* -"BJFF:C%JVG0WT$<J0S*'C\U
M-I92,@X]ZCM=52[U.]L1:7D;6FS,TL)6.3<,_(W\6.] %^BBB@ HHS1F@ HH
MS1F@ HHS1F@ HHS6/KOB"'0?L'G6T\JWMW':*T8&$9V !;)Z<]L]* -BBBN?
M'BN*ZDE&DZ;>ZI#!(8YI[8((U(SD*79=Y!X^7- '0450T?5[?6]-2^M5F2)G
M=-LR;'4HY0@J>1RIJ_F@ HJ-IXEN$@9P)75F5.Y"XR?PW#\ZRX=> TW4[^_L
M;FPM[!Y03.!F2-!GS% ['G'TH V**Y*S\8W]U?V4/_"+:DMM>%&CNU*O&L3@
MD.Y'W2.,KZ'KVKK<T %%&:@%Y;F^:R$JFY6,2M'W"$D _B0?RH GHK.T34;G
M5-,2ZN]-GTZ8LRFWG(+#!(SD=CC-:.: "BC-% !137+*C%5W, 2%SC)]*XFW
M^(ZNFHW%QX?U&&RTRX:WO;E6CD$+K][*JVX@9R2 >* .XHJ*VN8;RUANK>02
M03(LD;KT92,@C\#4N: "BC-4-0OKNTN+&.VTZ2[2>;RYI%<*($Q]\YZCV% %
M^BLCQ/KA\.>'[K5A:-=+;+O>-7"';ZY-:<,HF@CEQC>H;'ID4 2449HS0 44
M9HS0 449HS0 449HS0 449HS0 457M+ZVOEE:VD$BQ2M"Y'0.O##\#Q5B@ H
MHHS0 449HS0 4444 %%%4[G4[6TOK.RED_TB\9EAC R3M7<Q]@!W]QZT 7**
M,T9H **,T4 %%8/B?7KC05TMX;6.9+S4(;.0O(5,8D;&X#'/?N*WLT %%-#J
M6*A@6'49Y%'F)YGE[AOQG;GG'KB@!U%&::\B1(7D=44=68X H =132ZKC+ ;
MC@9/4T@EC,7FAU,>,[L\8]<T /HID<L<J!XW5U/=3D4U[JWC65GGC58AND)<
M#8/4^E $M%9VEZW8:OIBZC:3J;9B<.Q X#%0>O0XR/8BKT<L<J;XW5U/=3D4
M /HK'?Q)I[:Q<Z+;W,3:E#;^<R,WRKDX 8^I].N/PJKX)\1R>)O"MCJ=T+>*
MYN?-)BB)QA9&0$9.>BT =%149N(5E$1E02'HA89/X52M=<T^]U>\TVWN(Y+B
MT">:%8'#-N^7Z@+D_44 :-%%<OKFO:I8>+=&T6UCLV35%G*R2ALQF)0QS@\Y
MS[4 =117GEUXZU9;+446TLX+_2M1@M+Q69I$=)7"J\9XP3G.#TKNHM1L9TE>
M*\MY%B<QR%)5(1A_">>#[4 6:*KRW]G"(3+=P1B=Q'$7D \QC_"O/)]A4,6L
MZ9<WDEE;ZE9RW<>=T"3JSKCKE0<C'>@"]16-HE_<CP^+S6K[37=6D,EQ:OB
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M*!<VZ8RR3@'!7!P2?XNM>@Z'I3:39.DURUU=SR&:YN"NWS)" "0O\(   '8
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M"'S!O(]=O7%3UX-I2:?>>;#JFN74.NVNK/+_ &<MM$L\LWF'9MDV[R""!][
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M+GO6C8ZUI>IRO%8ZA:W,B*'9(I0Q"GH<#M[T -BT#1X+>XMX=*LHX;G/GQI
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MR1@@]<\#N0*S-7^(J_\ "/:9J6CV5Q*+W4DL7$@16@??AE92WWB <=NY(XR
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M(..OXUW0HH \.2RN[/PUX,OK_2=8EL;"&XMKZWM1-#<0LQ!#8!5L<#OBO2?
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M@ ^1*#O R%/  Y/U-=]X\TR^U;PC=6^G O<J\<RQ X\T(ZL4SZD#CWQ72T4
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M5MYK_P /7ULB!9[BUDC5"W 9D(QGZFM"HQ<0FX-N)8S,%#F/<-P4\9QUQ[T
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M5BRZ/K5IXUU_48+".YLM2LHXU<7 5T9$88VD<DD^H'OVKMJ* /*K+PIX@M]
M\$6+Z8WFZ/?&>[(GCP%W$_+\W/#?I6M8^'M5BO?%TUSI$$\&K7,3Q6\\JD21
MJ=KAL$[25R1[XS7;?VC9_P!I_P!F_:8OMWD^?Y&[Y_+SMW8],\58+!5+,0 !
MDD]J .0\">'[W06U1'@DL],FD1K.QEN1.T& =^". "<8&3TJUK6FW.M>(+"V
MN].,NB6^Z5V,J_/,1A"5SG:HW>^XCC S6Y8ZC9:G"TUA=0W,2N8S)"X9=PZC
M(XJU0!P<OA.ZTCX@6.M^'["!+(VK6]]'YNTR G*D YY! /;IBN=EL]4N;[5K
MVTT>VU#09=3:Y>./4T@A9XL*78,F<Y7)^;:2,XQ@GUZL%_!GAN34'OGT:T-P
M[^8S%.&;^\5Z$^^* ,S0+.]O?$VI:_):>3IVKV%MY.Z0>:F%)PRXX/SGN>GO
M53POHGB[0[:'09)-/_LFUF_<WJ.WGM &W!"FW&X]"<C SC)P:["[U2PL+BUM
M[N[AAFNG\N"-VPTC>@'>KE 'GNA>'_&6A^9H<-W8?V+]H+P7I),\,18L4"8P
M3SC)/&2>>!5:\\*>(;GPKXHTI;.V$VJ:HUY"QN> C.C8/R]1L_7VKTNB@#C+
MO0=4U#QI/?SVT4=A=:,=.D9)]SHS,6) QR!G'ZU7\,Z7XVTF"UTJ^ETN33-/
M4)%+!N$UPBJ0B'/"]%R?08YZUVEQ>6UHT*W$Z1M,XCB5CR['L!WJ"SUC3K];
MQK6[CD6RF>"Y/01NOW@2?2@#A-'\(^(;+PIX:TI[>R$^DZFUY*SW)VNFYR ,
M(3D^:?\ OGWJZ]KX@\,#Q1>VO]D+#=W1NX)[RX95!8(NUE"]L'OR<#OQU.F^
M(-*UB>6"QNUEEB 9D*LIVGHP! RI[,,@^M2PZMIMWJ4^FPW<,MY;@/-"K9:/
MGC/IS0 ND7-S>Z19W-Y;_9[F6%7DA_N,1R.>?SYK@KKP/X@D\->)]$CDTSRM
M5OIKN&5II R[Y%8!ALXP%/3.2>V.?2J* .!OO"6OW6OP:E;W%E:-'HCZ<'2=
MV>.4Y(=?D&0#CT-5M%\%^(--U3P_=E-%B_LZWDMYS$\C-,7V[I22HW,<'@XP
M3G)S@>CT4 <OX*T75_#^G/IU^UB]LDLKPO SL[;Y"_S9  QNQ@9^M=15+3=7
ML-7CG?3[E9T@F:"4J" LBX)7GTR*NT %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5R'Q-GN;'P)J&H
MV5Y<VMW:JK1R02E>KJ#D#@\'O77UR?Q(L[O5? ^H:7I]I-<W=VJI$D8XR'5C
MDG@# /4T 8G]HW^F>-/#VCVVIW5_;:O:.UW!-+N>WP@(E5_O+GG@G'!QU&(O
MAWXVA_X1K3H-8NKZ:[NKR2!;J:.1T,A=MB&0C&<#@9X]J[+1+&PT[2([FUTE
M+27R1YB1VPCD) Y! ')R/QKS.V\/ZY#\/O#^G/H]W]KLM=6\GB"@E8E9G+#G
M!X<<#G.1VH ]+T_Q5I^I7FIVD*7*SZ8!]I62+;MR"1CUR!FJLOCG28M.%\([
MV2$6RW<@CMF+0Q-G:SCMG!(]@3TK&\4Z#=-XSL+G3)4C_MB%K#4D)/S0*-WF
M#'\0&5S_ +2U!XTTB\N-3ENM+T_48-3AMUCLKNRVF.;[V8IE)QL!QU&.?:@#
M=75-,;QZ8O[4U%+I=-\QK.3<MKY>X'S>1C=SC(/0$=JM6?B[2;Z^M[-&N(Y;
MJ$SVOFP,HN(QR63CGCG!P<'I7&:WH&KZWXRDCDM9HUN/#3:?)=A,0K<,2^,C
M^'Z?2MKPS?\ B.X;3['4_#?V-[",I<WLCJRR87:!"!SEN"3T !'.: 'Z)XFT
M33M EN8]4U*_C?47M8A>;GG><D8B0, <>@/3G-7F\>:'%I-QJ-P]S"EK<"UN
M8FMV,D$I(&'"@X'(YS@]B:X>UTCQ#9>&9+0Z5>IYGB%KFX$(0S+;MR'B.<!L
MX&1R.>G6HX?#VM1:;XJLHM OT^VZE;7-MYDL;DHLB.<L7.6PISR>>] 'I6E>
M)M/UC4;JP@%S%=6R+(\5Q T3%&SA@& )!Q3?%LUI!X6U![ZZO;6V\H^9/9!O
M-C'JN <?7IZU0M[>]/Q)N-0-A.ME+I<5NL[;=OF+([D$9ST8=NN:N>-+6YOO
M!FKV=E;/<7-Q:O#'&A )9A@<D@8YS0!&_B.QTNUM+9%OKYQ9I<-Y:>9(L.,"
M1\D=<'U)(/%;T,JSPQRIRCJ&7/H>:\WUW1;F^CTYAI&K6NHV^G11VVHV#H)(
MY06#12?/RG"GT^8\BN_TA;Y='LUU/ROMPA43^4,)OQSCVS0!YUI7B^/P]XA\
M8-J9U6ZM(;],,D;SI;)MY))X5>1P/RXKMKCQ/9HT*64%UJ4DUN+I4LT#$1'[
MKDL0!GG SDX.!7*#1=9L[OQM -)DG76W_P!%E62,1X9"F7);(QG)X/MFI=#\
M/:IX,UF&2*VGU2SFTR"UF:%UWPRP@@85R/D;)Z'@_G0!O_\ ":Z1):Z9-:/+
M=R:F[I:V\2@2.R EP0Q 7;CG)%5W^(6A1Z?I]ZWVSRKZX-M&/LS$K*"048=C
MD$8YSVS7*1>%]>TR'3XVL)[FPN[ZZOM0M;.=%DC:0#RX]Y9?DQ][:>>>HQFE
M;>&_$%MI/A^Q_P"$>N$&G>(/MS[)HF40[V/R_-DX!'7&>: .\;QA97%K%'%8
M:I)=3PO(UDD.RXBC4E2S L-O(('.2>F:@^&=T][X T^YDEGE,DEP0\[EG(\^
M3&XDDDXQ5>[M=;T?X@W.LVFEOJ6GW]G' X@E1)(9$)VY#D J<]0?PXYJ^'O!
MUS>^%;.TUHZGI=S;37#;+._*!Q)*S@G8>>N.?ZT =-JGB.VTV6>);6[O);:(
M3W"6J!C$AS@G)'7:V ,GCI6)?ZA#?^+_  ;?Z?>2R6EZMR<)*PCD40DJ2F<9
M!)YQG\JR-5\/:KH_B1[JT\,VOB;3[BUA@Q=S)YT+QC;N+2 Y!'7U/IWTYM.U
M.#7?"+#2=T=B)FNFLUC2&$R(5"J"P)"D]ATYZ\4 2Z5XGT*PT[Q!JGGZBD-O
M?L+A+P'<LI"_)&IZ Y  XYK1MO%]K<:Q<:2UAJ$-_;Q>=) \2L0A&0058@YZ
M<$\\5P^IZ3?0>'_&%K>Z2WF:IJRRV"R3HOFLY4)L*EL."N<$ >IQFM+PQ=7U
MGXC:\\0:%J<&KZE']FBFDG@D1A&I<(NS;M) ))(QD#D4 9%_J]G#IG@F_P!&
MN-8DL7U61#')([RS ,V04!PQW XSV]*ZB_\ %$&O^$O%,$<-_IVHZ9:RM+#(
M3%+&=C-&P93T.W/!_3KSUEX2U^R\,>%U?3&:XT;4Y+J>W6:,O)&SLWR'=M)P
MPX)%;-SX>U*__P"$IUI["6*\U33S86MCYL995VD!W.=H))S@$X [DXH TX_$
MT6DZ)I%G';RWVHRV$<RVZ2(A*!5!8NY ZGUR:VM"URR\1:3%J5@[&&0E2KC#
M(P."K#L0:X"7PGK=H?#6JPZ'9:I/9Z5%IMYIUX\8*E.1(CG*YSG\"..3CO?#
M\%[#I2_VA!;6]Q([.;>V V0@GA00!N(&,GN<]J (-0\1"UU%]/L=/N=2O(8U
MEN(K9D'DHQ(!8NP&3@X49)Q69)\1-(V:0]O!>7(U0NL'E19(=0<HPSPV0!Z#
M.<XYIIT[6-$\;ZIJ]G9/J-AJL,7FQI,B/!+&I48#D J1C/.<US\'@O5=-OO#
M$L5D9OLU_<7]\8Y4VQ&7^!=Q!.WCMSC/?% 'HNFWC:CIL%V]K<6C2KEH+A=K
MQGN"*\UT/Q2/#%QXI>XL=4O;2'691-<)F46\85 "S,<G'H,D <]J]5KSQO#V
MN6]MXOTJ*P65==N97AN_.41Q)*@0[P3NRHR< '- '0W'BR)IS!I%A<:M*D"7
M$PMV5?+C<90G>1DL 2%'/':HSXWT^>WTHZ;#/>W&J"0VMNH"']V/WFXL0%*X
M(QGK65H_AG4/!FO7$VG6\NIZ=>6=O P$J+)"\";%^^0"K D\=#VK.7P?K6EQ
M:3;PV:ZC9-+=7&HV@NA%&\LA!0-G[R+T/'.,[3TH WV^(6EKI&DZF+:^>WU*
MX-K'LBW%)02"K '.<JV,9SBG_P#"6F\BBM(=$OVU&:&266P=DBDAC5BFYB6
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M8^]G /U],9(!W%G=PW]C!>6[;H)XUEC;&,JPR#^1KCI==L=&O?%^J0Z"XO;
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MNT3709,;IB6(XP3CUYSVK$\!Z!?^(_ GAV+4+FS&CVDPNHXX%8S2,CMA7).
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M)P6(&3CUX!->8W.I:W>^)?$]O_;ES#;VFE17D26Q3:LAC+?*Q7.W//J>,^E
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MWW#CV_PJ.Y\ 7MMKC:EX;\17&D>?#'!=1F%;@2K& JG+_P 6!U.3U]37<T4
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M<(@.&,KHJLI49(#')(QWKHF\"WK>'VTG^VXP&O\ [?YPLOFW^9YF,;\8W8_
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M9R:;<V\5HR".YD V7&Y<DI]#P: ,'5? @O?$DFMZ=K5_I-Q<HL=X+4C$ZJ,
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MV ::0]LG@ =23P*IG7=<T^\L8]7T:U2VO)Q!Y]G=M+Y#-]T.K(O4X&1QD]J
M)Y/"&F2:CJ5]FX6;4;?[-/MEP#'C  '; _G42^"-(6WTJ'-Y_P 2M62V<73A
M@C8RA(.2N !CT&*Z2N7M?$6J7FK>)]-BTZW-SI2QFU43G$_F*S+N) V]!GKC
M)Y/6@#=U/3;36-,N-.OHO-M;A"DB9(R/J.16)!X%T>"\%X'OWNQ:M:"=[R1G
M$9SQG/Y?3UJ6]UR^L;/1H);:W36-2E6'R3(3'&VTNYR!D@!3]215[1KO4Y[1
MO[9LX;.[$SHJQ3;UE4='7N,CL>>* ,^'P3H\-GI5LHN]FE/OLS]I?,9S['!X
M)'(/!Q4O_"':&6U0O:-(NJ@"]629W$N.AY)P1V(QBMW(R!D9/:AF51EB!SCF
M@#FM/\!>'M,TZXL8+68PW""-R]S(S; <A5;=E0"!]W'2ISX/TB2">.X2ZN'G
MV!YI;N4RX1]Z*)-VY0&YP"*N7DVK)K6G1VL%J^FR>8+N21R)4(7*;!T//7K^
M%:(EC,AC#KO R5SS^5 %'3-%L]*::2 2O//CS9YY6ED?'0%F).!V%:%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %<=\1VU&/PY$]A?+;*;N".4&'>7#2HH&<C &<GUZ<5V-9/B
M/0U\0Z++IYN7MF9TDCF10Q1T8.IP>",J.* .,O%UA/BQ8VMO?6HO)-!99;J2
MV)7 F)RJ!NN0!R?6DTGX@:CJ^B^'XXX5&IZB\XG:&'?A(20S(I8#).WJ>,GB
MNEC\)RCQ1;:_+JTTUW#:FTPT2 ,ARQ/&.=QR.V!C'>LAOAC;1>'[#3K'5[RV
MNM/N7N+2^ 4O&7.64@8!!]* -_PM>ZU>65R-<LQ;W$-PR1L %\Z+@J^T$[3V
M(SVKGO"#F_\ B'XQNKOYKNUFBM80QSY4.TD8] Q&3ZUU.@Z.^C63)/?37]Y,
M_F7%U, &D;  X'"@   #TJE?^$XI=;DUS3+V;3=4DB\J66)5=)@/N^8C#G&!
MR"#[T 9,^L7"^--5M;73(8-2@TWS3=O,7C>,$E,H I)W9'48!//KGVOBOQ2G
MA>PUF\.EL-6^S6]G'&C_ +F65@-SG/*X).!SG ]ZZ&R\(RQ7U]J5[J\UUJ5Y
M:BT>984C1(P21M09YYZDFFCP+I[>#+?PS-<7,EM;%6AG!"RQLK;E((&,@^U
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M$RG<OS!=[ 'D!F/0=: .%>TG_P"$)^(QN=1NKL1WURFV<(0Q5(RK$A0<C
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MQ(&W<91,C>P!X)"YP/YUR$.L:G97NOZIIE_J%WH-CI1NH!>997N-F=NYUW$
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MSZ^E 'K%10W,%QGR)XY=O78X;'Y5S/Q'GO[;P/?36&\%2GGF/.X0[AYA&/\
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M9]ZYCP]XHNM0M+?7;O6-)72)H?,N878(]DQ^XN[.#W!W8YZ>E=9'JNGRZ?\
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MG\QMJ%P-H8KC SZ>HSM:1J4T/CCQ=%?:C(UC9PVDJ"=@$@5ED9L8  ''4\X
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M:0H5(ESG!)&!QR:L_P#"=:? FK#4;6\L+C2XEFN()D5F*-]TJ49E;/3KUZT
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MM+4DAT2?XB6NBP+!%';V#_9K0;<(01,548Q\N<D5ZFNC:6B%%TVS5"Y<J(%
MW'J>G4^M3)8VD<KRQVL"R."&=8P"V>N3WH \ZO+71)O&/AF70DL393V<\>H)
M$5\LV@C!7S .,9/!/>LKP]X=\/M\'+O6?(CFOI-)GBEGDE+X*Y8+@G PRKC
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M\*>,=1TJW7[/=VAWWLFY4GN-C*JHKCJ..1W;N<XCO-0LIO'?PXDCNX'C^R7
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M)2P("@9R3[=SQ6AK5M/>^(?'T%K;S2R7>DQQ0!8SB5T4AE4XP2"PX]Z]5HH
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M;Z\D*0QE1\J9'\3$_D.]:.AV>J6\,LVLWD5Q?3L"RVZE88@. J DGW)/))]
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M=VK-=[QE<?+( GR_>!R"W6N=G\37;_"6YUO7]'L]3M6D)D@-RP\P&X*@8*'
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MCN_$-MX+OM)%O]AO=3A(BF9@WGJ6^1\ _*".H[CITH ]/L[ZTU&W%Q974%S
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M8KID4%I#;W!EF#9"LQW*<=20#SP!CISQ6?QAJ\OA23QE:&UDTJ.5S]A,9WO
MDAC9A)G[QP6 QC''- '8MHNFMJZZLUE"=05=BW)7YPN,8SZ5?K@IO$VN+J?C
M.UCEM_+TJSCNK24VY^4LA?:WS<\#&>/6D_X27Q%=W?ANRLCIZ/JVDFZ>65&_
M=R!%). >1EA@<?6@#LM2U6PTBV%SJ-W#:P%P@DF<*NX]!DU<!!&1TKB-(ENO
M&N@ZII&NQV\=Y8WK6=Q)%$'23: =Z!\[20W7MG(]F^+O$MYHFKQ:?%?0:7;R
M6>^VNKJW+PS3[B/*9\@)@ ')_O>W(!W-%-C8O$CE=I902,YQ^-<)'K_B6;Q'
MKL#7&F0Z;HMQ$\[>4Y=X"F]@.3AMO?U[4 =[17FFC>,_$^I3Z7?KI%S)IM[)
M^^!MDC2&-C\K+)YF6QQG*C//2H-7\:ZX_@ZX\8:7>6\5D+GR(+-[??O02^7O
M9\@Y)!.!P <<]: /4J*Y%]8U7_A+=<TE;F%88--2[MF,.3&[%AAN?F&5SVZ_
MC7.KXZUG4=/T.SM4N!J-[IOV^>6RM$F91OV !'90!G.3D]ACG( /4*0D @$C
M)Z5YS?>+/$5CH6ERZS"VD,\SQW]Y# MP(  #&60$A X//)QCWJO/<Z[J/B_P
MGMU^V>"ZMKF1'MHE>,NBX+@9YRK<9/'/% 'I]4-5UK3]$@6?4K@6\+';YK*V
MP'W(&!GMGK5\5Q'Q;R/AQJ! R?-M\#U_?)0!TNG>(-*U:9H+*]CDG10[0G*R
M*I[E&P0/PK2K@;O1==UCQI9>(GM8])CTVSFC3S)%E>9W4@953C8I.>6Y]JS-
M*\6^)E\&6?B?4+ZQEBO56WAMA!LVS/-L5V?/0#.1Z <YR: /4:*XN2[U_3/$
M]GHEQJ?VJWU2VE\B[,$:26\T:Y/ &&4CU'XFL[0O$6N:MH]CILM_Y7B!-2DM
MK\B%#L2/+,0N,8*E #ZL* .WM-7L[[4;^P@=FN+$HLX*$ %AD8)X/'I3)-;L
M8==@T9Y'%]/$TR)Y;8*+U.[&._3-<5)XVU/2[KQNUXT%S'I$ELEF@3RES-D
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M&>U;RIA)D[6&XD88Y!YZ5TTFLVL>OPZ,RS?:I8&N%81'R]H.,%NF?;_$9T*
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MH +.UBL;&WLX-WE01K$FYBQVJ,#)/4X'6LC3/#GV#5]9OYKH7/\ :K*TT31
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MT^X1K9PC9G"*5^;Y>""?O=?:O1W#%&"-M8C@D9P:XO\ X0*?^Q/[+&O3"/\
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MR:7J<MO&\]T$A6*)@")$"'.5R2V<Y/& *Z:W^'V@VVF6EA$MXL5I.T]NPNY
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MX;Q?*N7B>ZF;@YD4AB5"[L9YW$G.*BD:\-UHN@GQ)=:Q<0Q7"3I;2-:-*R'
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M3R!+ARS@^5E=Y)8 Y[$5D+JUW;:#H6D/J"I9S:M>VLLUY,XW)$[^6K2 ANH
MZ\X Z9%>AVG@OP_87%K/:6!AEM$:.!DGD&Q6SD?>[Y[^WH*%\%^'UTFXTHZ<
MKV-Q)YLD,LCN"_\ >&XD@^XP: . U2TO=.T%K7^WY9BFMVQB^QSR8MTE<9CW
M$G>!U ;..*Z?PQ =,\>^(M*@N+E[)+>VG2.>=Y2KMO#$,Y)YP.];@\(^'QI$
M.D_V5;_8(6WI;X.W=_>([GW/-6K?0]-M=4EU.&T1;Z9=DD^27=>.">XX'Y4
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M 'JM17$WV>VEF*/((U+;(QEFP.@'<UY9J-SK\&C>+=23Q)?>9HNH$VZ%4VN
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF+7#E& Z#83MXYQQQD^M1:OX6TW6]0M+Z]^U&>S.ZW,=R\8C;U 4@9]ZVZ*
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M;SW<<+G6;:0@RA65!NR_J /7M5WQ#H.B:?X/\3:O'B:>]TR0->7$QE+CRSL
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&P:0V*QL8IQLR9&;'4<]^N/Q .MQ1@5R\7Q$\-SO"(KR9EEN1:B3[-($64G
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MX6:MX5_L5VNGF9H95N8MDH,P?(RV0-H[X//2NIAM-6T;Q;?ZQ'IEQ>6FK6\
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M?#6JQV%M<M;7=P?+(@96VG(#?-@]<<#U-7-5^(VF:;)?%%2>"P*"X87"*YW
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M$\EK?6(N ,E"&R'!''*G(Y]JO-XIFM=8@\/Z;H,LTG]FB[A_TA43:"%"DG)
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M9A)M(0R("O3G<"1^-5TO[7PMKYLM-\(RQZCJ=N9VBLYD$;B+C@9 4X;K@9)
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M[EC 1G8XR,G"$ 9ZD4 ;5%<5>:]KV@V1M]4^PR7ESJ45CIURO"R+)T>1,\$
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M&1@GGWZ>NS%I/BN_T74_[9N]/-_=6KVL%O:EUMH@PP78G+,W/IQC ZFNPHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:WBN+EY(XB>"54G ."1[9-,T[P'X=TG49;ZRL?)E<EE59&V1,0061<X4X)Y
MXSQ0!R&AZ%K?B.QU:=_%^L1RVU]>6ENJS;5^4[49MN,D'GL.P JYX+UFX\31
MZ+:M/>I/I,#_ -J[KAMS3@^6JOSSDAWP>. .]=AH'ANP\-P3P:>;GRYY3,XF
MG:3YSU/S'J>_K5JPTBQTR:]FM+=8GO9S/.1_&Y !/Z?J: /./^$AU+1]*U>.
M]U65P_B?^SS>R'FVMV1#D=EP,C., G-:?B>ZN_"&EZU<6NO22"=8#;6]PQ=K
M-6D6-Y/,8L2#NR,C@CH:Z2+P=H<>FWFGO9F>VO7\VY6XE>3S7X^<[B?FX'(P
M>!Z4S3/!/A[2=)N=,M]/1K:Z7;.)B9&E'8%CS@9X]* .:FA\0V;7/V+6+5$O
M]-;['#+J$ERS3#&)4D=%"@A@/3)!Q6AX*U5;G5M2L;F/4['48XHFETV_N&G\
ML L#)%(Q.Y6R!QW ]:T=.\!>&M+L;JSMM-40W2[)=TC,Q7.0H8G(&>PQT%:6
MEZ%8Z2\LMN)I)Y0%::XG>:0J"2%W.2=HR<#IS0!SOQ(^W66CVNN6%S>I_9MS
M'-<PV\S*)K?<-ZL!P>.<]AFN;C\17</B+4XK:ZNI+'7H=NARRW,C@2AA&Y0$
M_*,L7_W1P<<#U.YMX;RUFMKB,20S(8Y$;HRD8(/X5671].46&+.+_0!BU.W_
M %7R[?E]..* /.+MM<UOQ9KGA^QOQ;G2X(5LS/J$L4@W)DS?*"9#D\[LCD>N
M:(_[7USQK;:-+XFO8X9_#\=W+-ITNQ7F$NS>F1P#UXQFNZU;PAX?UV\CN]2T
MN"XN(QM$IRK$>A((R/8U-'X;TF+68]7CM-E['"($D61P%C P$"YVA?;&,\]:
M /.K:;4];M=8U5=?73[G3-0DC\V6YE/D1QL %>(81@RCN"23^%>K.OFV[*69
M=R$;E.",CJ/2L67P7X;GUHZQ)I%LU^6#F4@_,PZ,5SM)[Y(Z\UMRLR0NZQM*
MRJ2(U(!8^@R0.?<T >+:&^J?\*^\/^*AKVIR:DVHI%)%+=,R3QM<%#'L[^N>
M3U]L7].&H,GC36_[7U66XT6_N_LEO]H)C.V,X#+_ !#[O'3Y?<YZ'X>^#8])
M\/6@U726M]1@GED$<EQYJ(2S%64!BH(4@9P#P?QZK3- TS1Y+R2QMS$]Y)YM
MP3([^8_/S'<3SS^- '#W#7&FZ7X1UC3+R]NYK^>"WNT:X9UNDE0EV()(!!!(
M(QCD=*J(+G3=9UGP2;B]DFU*XCGL;E[ARZ6S<R;6SD>6%;'J<9KO[+PSHVGW
M27%K8QQO&6,0!)6+=][8I.U,]]H%76T^T?4H]1:W0WD<30I-CY@A()'Y@4 >
M?:CJE]I'C_7_ ++-<2Q6?ALW,%J\K.@D4X! )/)VC]?6J"V]M+=?#G58M0GN
MY[J8F9Y+AG\UC$2S;2< ALC@<9Q7I1T733JKZF;2/[:\?E/-SN9/[I]1[=*S
M;?P+X6M;I+F#0[-)8Y/-0A.$;U Z#Z#C//6@#@-)N]4U:V&M'Q!;VUS;:FWV
MB)VF:53YI46[1A]A!!  "^X.<FJ7B>5=9^&OBK7+JYEDU*'4'MEVS,HAC$Z(
M(]@.,;3GD<DYKU0>$] 76SK0TBU&HD[OM'E_-N_O>F??K3+WP;X<U*ZENKS1
M;.:>4AI'>(9<CN?4T :\2A[5%/0H >?:O(=-D&@>"_%M]9M+!)'KLUN9$=B8
MX#-&K$#/!"D_-C/O7L$,,5O"D,$:11(-J(BA54>@ Z50C\/Z1%=7ERFFVHFO
M 5N7\H'S0>H;U![^M '+R6JZ%XZ\/1Z)*ZV>II<?;(/-:175$#)*-Q.#D@$]
M]PK1^(5W%:>#+PR7UU9F5HXDEM/];N+C"J20!GIG/ )K9L-#TO2Y/,LK&"!]
M@C#(O(4?P@]A[#BI[_3[/5+*2SO[:*YMI!AXI5W*>_2@#B?!LEQ:^.?$.G2F
M&WA6&VDCLX9S)'$[*V0,X^8A03@#U]Z[^LNR\-:)IMX+NRTFSM[A4V"6*%5;
M'U'U/-:E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%<[X[O+S3O!.JWVGW;VMS;P&1)$56/';Y@
M1_6@#HJ*\Z>^US0?%7ATW.N27MCK$,HN(IHD5(9$BWAEP,A?7)Z DD]J6@:Q
MKDVM:#!<:E>7$.I+=1S7>U%AF(0NKP*1N ' !( /H: /0M4U:#2]+N]0\J:Z
M6V'[R*T3S)">. ,]><_2KZMN4-@C(S@]:\=M9-2T3X8^)M6LM9OQ=0WUPB&1
ME<#$VW=ROWB#R?RQ717>IZ[K/B?4M'TVY,!L+*!XRDRQLTLBD[VRK;@, 8X'
M/.<C !Z#3'DCB ,CJ@9@HW'&2>@^M>=PWVOWOBS1M)O->$ N=+E>Y%B$96E1
MPI,;%<@G!SG./F QUK)\S4->\/\ @^[O-8OA,VM-9LT3*NX*9@'/R\OA!STZ
M\4 >NT5'$GEQ)&79RJ@;G.2V.Y]Z\\.J:IJ_@W6/$]GJT]O<VLMP\%NNPQ(D
M+$;'7'.X*23G/S#'04 =AJ_B"WTFY@M!;7-Y>SI))';6JJ7*(,L?F91W QG)
M)XJYIFH1ZKIEO?Q13PI.@<1SQE'7V93T->;A3K'Q/\.7KSW4+7NAFY(CD(\L
MM@[5]!STKTK4#<#3;HV@S<B%S$/]O!Q^N* ,M_%%L^H3V6GVEYJ4MLVRX:T1
M2D3?W2[,JEAW )(]*O:1K%IK5J\]IYH$<C12)-&8W1QU!4\@\C\ZY/X3.LWP
MTL_(D3[7OF$[,"Q$WF,?G&02<%3U'%<SJ'BSQ#)X)US5H;FTL;BWU<6>ZRM]
MIE*LJ,S[RW4;<8P1MZF@#V&BN$G34+;Q-I_ANY\17TD5\MQ=M,=D<K!0H$*L
MH&!RS$CGC'%<YKNOZ[I%IKNGIJEP[Z9JEHEO<D@N89ADQL<?-CU//- 'KU%>
M;ZQK.JV_BGQ?:V^HSQ0VFA_;+=1M;RY0"<C<#UQ^IQBJUO?:YIH\$:V^LWE]
M_;;06]Y:2A?*Q+'N#(H VE><GOCGO0!ZC1110!SNK>+8-(UJUTB33=0GO+M6
M:U6%8R)]HRVTEP!@?WL5;T#Q)IWB."XDL7E#VTIAGAFC*21..S*?_P!76N7\
M8"8_$[P0;8Q>>%OB@ESM)\I<@X]L_E69K^B:OX8\,ZSK(UIDUG4=1@DDEM4V
M1JI=8P@!R2 &/<'IZ<@'J5%<%(L]CXNTSPM+J^JS6UU%/>O<33A9)6!4"%74
M @#YF(7!Y'..*QK^77;BP\8:5:ZE?F?P_)%/97 F97E1D\QHG*D;\ $9//(Y
MH ]4=BJ,P4L0,[5ZGV%4](OY=3TN&\FL+FPDD!)M[D .F"1S@GKU_&N9\.WR
M^+IY-3M+R\@LDL8K9!'<$CSG3>[8.060.JY(/.<]*P-&\07VI6/@;2;J^N5_
MM6&:>ZN1*4DE\L$A XY&3C.,'  [T =UHGB*'6[W5;6.UN()--N/L\HFV_,V
M,Y&TGBMFO&VO+OPM!XS^R7$BLVM6\)GN)262.0+D[SDC@_>.2/<UJZW%XBTC
M3=>N1K*P6;:6T]K;Q7TES,DB;?G$CJ#M.>1[C% 'I]%87A;3KBSTQ+BZU6]O
MY;N*.5_M+@JC;>=@ &T'/3FLGQK<ZK:7MG<6EM=:A811O]KL;"Y:&Y&2-LJ[
M2"X&&&WW_( V)?$D,/B^V\.-;3>?<6S7*S979M4XQUSG\*VZ\CMHX=<\<>%?
M)U:]FADT.0_:XY#'-)A^=S#D'(P<'J"*-'U>_P!:\*:%97=]>74\VH7,#PQ.
M5ENXX]V-\H(**N5RPY/'6@#T7Q'KJ>'=+_M"6TGN(A(D;>45&S<P4$Y(XR1T
MR:1?$$3>+9/#QMY$G2T%V)69=KH6V_* <]0<Y Z>XKSS^T;[4/A%JPU"5I)K
M;5EME+N78*MU'@%CRV,XR>N*WY?^2[P_]BZ?_2@T =Y4-W<?9;.>X\MI?*C9
M]B$9; S@9(&?J:R_%=\-.\*ZC=_;S8%(3MN1%YAC).!A<C)R0![FN+\.W%S8
M^-M5TF:.\CL/['%VUK<WC3DONP6R2=A()R 2/>@#N/#>NP^)?#]IK$$4D,5R
MI94D(W##$<X^E:U>0:)'J$OPM\+&SMI+ZUC6:2[T^WNG@GFC#G#(4()VDCY<
MX.1[5IZ;J<'B34-#T>2_U#^R[FPGN=LTCQ3SRK*5\MW4[ODPW0\XYH ],HKD
M? \]ZMQK^EW%Q+=6VG7YAM9I7WML**VPMW*YQSSS4/BR":Y\8^&K5-2O;6"[
M^TQS)!-M#!8B1QZ\D9Z^A!YH [2BO&M1_M+3]-UK2(=6OS:Z?K5G%:70G8N%
ME*EXRQX;;N'!SSUKIHM+@MO%MMX6N-0U">Q-E+>J)[MM\TK2!2"RX)"@$@=M
MV?2@#OZ*\;N[_5C:V]B=2ODCL_%D>EPW*3D-);L<[6[,5X&XY_G5F\T@I_PG
M]HM_JJVNE0+<V2_;I,)*T'F$YSN;! X8D8/3/- 'K5175U!9Q"6XD$:%TC!/
M=F8*H_$D"O/]0-S?^(_ \+:C=I!J5C/]L2.X*B8+"I&!V;+'E<''?BN3O;&1
M9)]*O)[F\L=-\36<%I<3S,6"2$%TW9YV\<]1GM0!ZTNN$^+7T%K1U(L_M:SE
MQAAO"XQUZGOZ5L5Q+6-K+\1Q888VQ\/M%A9&SM\\#[V<Y]\YK!T2.;S+KP!>
MO<M<PWXG-SYCAY+,'>'W@YR2!&>?XO:@#U2BF2.L4+.[;4122?0"O'M&N'@U
MOPOJ=K/+-'J%Q=![R>X(FOHPKM\\?W44$ #G/ X7I0!Z7XFUUO#ND?V@+-KF
M-98XW"R!-H=P@//7EA6S7BMRMIK_ ,-'\4WLSMK3WT8F/G,!'BY51#MS@*%P
M<8Z@'KS70>(+QO!OCU;\0S75GK-J\44&]F"W:\JJ#H/,R!TZ\T =Y?7-[!=6
M,=K8_:(IIMEQ)Y@7R$VD[L'[W( P/6KU<%JVEG11X+MUN9VD34TBF;SG*RDQ
M2,Q*DX/S#(].@K$61M/\5PWNHV\MY'?ZHPT_5K*Z.TDLP2VF4\ #!&0.P]#0
M!ZQ17C7AYGUJQTKQ&_B:RMM42\7[2J6[FYE=FVFW<>;@J>, *,  C'->NWT<
M\VGW,5M((KAXF6)R,A6(.#CV- &-;^(YM6N+E-#L4O(+:0Q/=2W'E1-(/O*A
M"L6QQSC'7GBKVCZJ^J17/G6<MG/;3F"6&1@Q!"JP((X((8'\:Y;X57*-X(CT
M=]\&HZ:\EO=1, )(W+,0<'L0>"1S@UQVO:IJNI?#;Q1<WNIW$LMEK7V*$J$B
M^1'1<G8HR2&(.>.!@"@#VVBO/KW3-.T?Q1I&AN9QI>IO<7$JSSM(L]R @56+
M'.,;CMS@GM7/ZW ++3O%MDI)T[3-0L9;%V)Q;M(Z>:BL3P!GIV#4 >PT5YY?
M&QN/'OB""&9,2: AE$,VTF3?)SE3D-M"^^,5A:=ID-CHW@+7-,N;A]5NI[:"
M<F=I/.B9,2J5S@!%4].FWGF@#V"DR"2 1D=JHZW<7-IH.H7-DA>ZBMI'A4#.
M7"DCCOS7FJP6\7A[P7XBTALZS>7=LES.C_-=;P?/63^]@AC_ +..* .RN_$6
MIRZMJ-CHFG07K:;Y0N4EG,3.SC=M3@CA<')/?%=,"2 2,'TK@?"FD:;%\0_%
MTD=E LEM<6QA8(,Q[H 6QZ9R:V/B!/:0^$;A+Q[A8IY8H1]GD",S&1< L00%
M/0GTS0!TH8$;@01Z@TH922 P)'49KQB6.VM] ^(&GM)8Q)!%'+!;V$I6*-_)
M.=@SSSC/ R>PZ5T5EHVFV/CS3(8(_DU+19?MBM(7\_#1X9B3DGYFY]/I0!Z*
M74 DL !U.>E+7E.A6+QW-S\.[JU:6VMKX7C3.N1+:;O-3<<?,Q<*A]L^E>JX
MXQVH H:7-J4L5P=4AMH76X=81!(6!BS\I.>C'N*O!@W*D$>QKP0VT4?@UBN]
M&A\9&.)ED8,J[EZ'.?X1SUXK=U4MX>'Q M-%C:"V@CL'\BWS^[5P1,RCL2O)
M/L#0!ZW([&"0VYC>4*=@9N-V. 2.@JKI,VH/I,$NL1VT-Z0?.6W<M&#DXP3[
M8_&N1TZW\'7FHW4N@W,,ZW.F-#<6UG(ODK&,89P.5?G R<XSZ&N5T>_A32_A
MW9ZL\2Z)/#,\OG']W).OW _;@G(!XS]* /0?"WB2YUW4-=MKF""+^S;O[.IB
M<L'&,Y)-=('1E+!E('4@UX2;FSL-)\;PZ?-''9C6XFE2W ?%OO <A0?N9.#C
M [<5IZE::,^B>*;NPUJSU%9])+R0V,*QV\++C8Q 8XD/;O\ *: /8S+&,Y=>
M!D\]!ZU3TK5K36;/[792^9!YCHK@C#;6*DCU!(.#W%>?:;I6DV/B/P8]O;PK
M)J&ESK=DG<;@>7&0'R3N&<XS].U6?@U]@7P1"D7V87RR2^>J[?- \UMN[OCT
MS0!V^I2:C&+3^SDMGW7*+<?:&(Q"<[BN.K=, \5:DN(8%W331QC(7+L!R>@Y
MKB?B3'")O"4[*@E7Q!:*'/4*221],@?D*YS5M%T.:?XER26MLTEM;K)"">(W
M^S;MP&<!M_?KGB@#UZH6N[9,[KB(8SG+CC!P?U('XUG>%+A[OPAHMQ))YDDE
MC"SOGJQ09_7-<9XJLAHGCA+VVT];A/$=H^FRIMRHGX*,W'0C.?92>U 'H5U<
MK%#\DT"S2?+")7PKOV'O^%<[X&\43>)?#T-[?FVANY9ID6&(XRJ.1P"23QU-
M<[X(LKQ+Q= U!/\ 1_"TT@69U $^\9A;\$+D_5>]<9ID5G9^ /#NIPK#'?GQ
M(JM<<;]N]P1GL,8XZ<T >U03:L?$EW#-]A_LM84:#8Q\_>?O;ATQP<5/=7RF
MQO'L9[>6X@1CM+[@K 'A@.1TKSG4P;3Q1X^BT@"/4)M(BEC2#'F.^'W, .2>
M1^8JUHVI>#;_ .R76A@&_CTQX)$@R@AB"Y)E7@<,,#J<M^( .E\%^)6\1^&-
M-O[Q[:*^NT=S!&V. [#@$DXPM=+7@^B06-EX9^&]]"D,-W+JNV:<8#LI9E()
MZXQ@8KW2=Q%;R2%78*I;:@RQP.@]Z &1WMK+.T$=S"\R?>C60%E^HZT@U"R9
MT07<!=V**HD&68=0.>HKQ70+_1$UGP7+%>Z?#:"6Z46S,'EA5XWXGE)Y9F8?
M+@=<#/6LU+?3;7X>S:C%';1WJ>)0JSK@.H5\@ ]@!DX% 'OL5Y:SS/#%<PR2
MQ_?1'!9>W([5)%+'-&)(I$D0YPR'(...M>>^(H+SPYXT34](B9AXBB^P3%%R
M(K@#]U,>.F,Y]@37>6%C#INGP65NN(H$"+GJ<=S[GJ: &W>JZ=8310WE_:V\
MLO\ JTFF5&?Z GFL;Q/XD32;O3--BO+:VNM0G,?FSD$0H%9BVTD9)*A1VR?P
M/.07.E#5?&&G^+##&TT^^+[40#+:E J"//7!#=.A/K6?#*+&W^'47B*YMTOU
M=S,+EU#A##($W9^JCGO[T >B:&-6&FJ-8FLY[G<=LUH"$D3^%L'H<=<<5DZ?
MKFI^);JYFT:2TM])MY6@%Q<0M(]PZ\,44,H" \9)R<'BNH      '  KSGP)
M=V_A;2[KPEKTT=G-9SR"&6=O*2ZB<E@R,3@GDY .10!U6E:GJ,,.H_\ "2"S
MM/LMQMCN4)CAEB**0V6/!R6!';'?K6@=8TP6\MP=2L_(AD,4LGGKM1_[K'.
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MDR@?+N[CO\I]:]$H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KFO'\,]UX$U>UMK>:XN)X#''%#&7
M9F/3@5TM)0!S&B>%[ V=E=71O;N5+/[/&M^S%H49<.H4@$$XP2><#K4=K\.]
M$M&T]HIM2!T]B;8B^D'EJ<Y08/"\GZ]"<5U8-&X9QD9% ',3> ='FT[4-/\
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M+5( EHH><RYCV*> V& XSQD<55_X6%X3\N1_[;MBL:*[$;C@,,KVZGTZT ;
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MC\* /,;30-*UWQQIUAJ@FO8I/#N^0W#&.6<B90CN%.<[0#SSP,]*VOC!%"/
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MY+0_9H?*8!638-I Z B@#Q+Q!;Z - ^V:7>R7D$VNV\HN955$$C9\P18"X&
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MCDCM&C$A6*3. %X4< $DYR!DG%6-2U33K[PUX EBN #9:E9K*9(V0+L0;^6
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MTDHX7>H(4KT.XC YKTNB@#S;6M UK1=&\+:II4+7NN:5''93*,L)8W38V>O
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M:!80:WK4;ZK-<31%I!MW-YKA5) VAMH7"\'!'K746/B;2-1N;ZWM;HO-8?\
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MLHUO;V<0BXQ96S3 QD@!@1P1SU''![U/?>--/L)96>VO7LK=_+N;Z.',,#9
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M;K0!V5Q$9[>2$2R1%U*^9&<,N>X/K5#0-#M?#FC0Z59/,]M#GR_.8,P!.<9
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M(FKZ?)K,FD)=1MJ$<7G/ /O*F0,G\Q5VO.=4&MQ_$Y/[.GLC>KX>)>6>%BA
MGSP@;.2<#[W&<\]*AB^(M_J&A^'C;VQ74=4AFEF%M;&=HEC;:2L>X=3TR<
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MB-CAH?*!QD<@Y)'/&.I.!2N?"6OWVBZG(FGQ1W9\0?VS;6URZ,LJ;0OEO@D
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M26U-O=R6K1RLI;<AP<[21U]"?K5W4[N6PTNZN[>TDO)H8V=+>+[TA ^Z/<T
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M9-I#KMND-W$;82'*H44JQ88&#R,?0CL 48[[7K[XC:-MO[6.TFTDW7V?[,Q
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M%HPYE\P_O"S$YR?T-,N_ JOKUYJFG:UJ&F#4 !?06Q7;-@8R,@[&Q_$.?3%
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M.MHT.D74=Y(Z*,6\2 [4SZN=O'HI)[59@TZ?0?%>HS003/I^M%':6$%VMK@
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MSD,EK=VS[982>#@D$8(X((YK%F^&FESVNH12ZAJ;S7MS'=M<-.-\<R='7Y<
M]>WL, "@#/L[_P 3ZI9^*--L]2NHK_3VCDL9[FVA$K!X]X1U"[,$\ X!YY]*
MMZ%XCO/$=AI<NFWDOG163W%Y'*B#?)DHD;G;\N763[H!PGO4LFC0>"[B]\0P
M#Q!K$]T466VB?SF8XQOV\9P/P / ':_H/AZ*+1M26YLDLYM7EFFN8HB"4#Y
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MPP+$9&1VI:P+7PU!;^,[OQ$J1I--:BV)5G+2#Y>7R<<; !@>N2>V_0 4444
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ML1A2>>X\Q[=#_#'N&%' [=AZ5R?B/PF^F7'@[3-/DUJ6RL+F1FN88S));(0
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MOGIM).#^% %9?#>E+>6=VMKBXLD\NWD$CYC3&-HYZ>U:M5WOK2*58I+J%)&
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M.J-?78C#QF4;49_D&,L=H.!SU/%::.LD:NC!E8 @CN#0!1T[28K+1UT^9A=
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MNFM8&N5^[,8P7'T/6G+:VZ3&98(EE.27" $YZ\U-10!%';6\+L\4$:,W5E0
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M>E;=% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*HO_  D5^43E$,-N50^JCR^#56Q\%:X9S=:KXMO;BZ3<L3PPQ(%4^Q4\^IH
MZ>SU#2XK\:%:S1+<V]NLOV:,8V19P#P,#Z5I56LK3[);11O*T\J($,T@&]A[
MX JS0!YQKVK:=IWQFTF:]O[6VBCTN57>:94"L6R 23P2*EU:=/&'C;P['H^+
MFQTN9KRZOHQNA!QA8U?HQ/<"N\DL[65R\MO"['JS(":D151 B*%4#  & * /
M''U73;?P>=-DN8DO+;Q)OEM_XX5%YG<P_A7!ZG YQ6UX?L/#NI?$_P 5YBL9
MYH9K2XMPI!VN$!=U [A\9/7)YZUZ.+> .SB&/>Q!+;1DD=#2);01RM*D,:R-
MU95 )_&@#P.5M)C^&.O K:ND/B8^3&K*"$+IPA'0%5;IV!]*ZJ[^PP?$+Q):
M6=Q'9V[^&< VB@[".A55ZD*<@#M7J'V*TV%/LL.TG.WRQC/K535M&@U32[RS
M4BVDN86B\^)!O4$8_'Z>E 'EWA.XT/6]9\'R76H:2+C2+#[-#"DV^2XEVA5)
M!48Q@D#KN/%=A\5H&N/AIK*I$9'6-' "Y( =23^ S^&:L6WA2]EF@_M:_L9X
M+:9)HX[33U@+,A!4LQ9L $9PN.G7&175$!E*L 01@@]Z /+&N-(U;XD>$6B:
MUN+5--EP"H*AN<<'OD''T/I6%;7:V'A3P[>.\Z:78ZS=?:FM8U<VY9G\I]K*
MPP-V>G<8YQ7MWDQ @^6F1C!VCC'3^9IS!64JP!4C!!'!H Y3P/'8>7J=UI4]
MY<V=W<>?]IN?E$TC#YRB;%PO3D#DY]*P=5U>PTCQ_KMKXG@N#IVJV4,-G(8F
MD1U56$D0V@G)+9P/3Z5Z2 %4*  !P .U(RJV-R@[3D9'0^M 'GMC>VNC>+[6
M75+4Z=IT^C0P:<]VV%M]K'=$S-T<@H3DY. .:Q;:(Z3H>BWL\<D.E)XHDN+;
M=&?W-HRR!"0!\JDG(]F%>NLJN,,H89!Y'<=*6@#P_P 8WMM?^'O'WD+(3<7E
ME);AX'0R#;%RNX#/ 8_3GIS77^(K#2;'^R;C0]0M-!NW62>UNDA7[-,-B I)
MCC!!7!_V37H-% 'D*ZM/!=>&]9UJTN[#3IK.>)I;)&V03M+DOC:6"R  CV-=
MWX*M;*UT.0:;;74-C)</)#]I+;I%.#O"L 54G) ].>]='10!Y]:7MKINN^+;
M+Q(@C>]E\V"1T;;<VQC"K&G'S%>1M'.6/6N=G671].^&MGJT@AN[6X$EPLC<
MPI@@%O0#@<^A]*]CHH 8Y3RF+E?+VDL6Z8]_:O([.]MO^%<:7(C$QV/B));C
M:A/EI]K9]Q&.FT@YKU^B@#ROQ+?R)K6H7NA7YGG=K?[1H=W 2+T;$*M%GYE.
MTCZ%237H^J)=3Z)>I:92[>V<0\X*N5.WGZXJ[10!Y7&%U3P'X9T>TM9HM=L;
MBT!@*%7M7C(\R20$?*I4.<GKN&,U69]&#_$2SNK=);VXN'2&(0DR3$Q#:J$#
MD[B3@<C.:]=-8FB:"VCW^K71NQ-_:-R;EE\K;L. N!R<C 'X_E0!YS&;CPUK
M%K'XE&J1V<^B6EJMQ:1M(JR(I#QL54G)8D_C5G3=(@3QWX;MI=)F2QCT>:)8
M;I3-Y89V*HY(P&V'[O;I7K HH \/\77%Q)_;RVD=U;/;:M%*+&VLW<2;"@^T
M.Y4C! &%&!QWKM-#U".#XA>(YYX+R**_@LY8'DM9%7:D+%BQ*X7&0,-CDXZU
MWE% 'CGA>*]L/#O@N_DLKEK33;V\6^B$+;X3(SA)"F,D -G(Z T[QO82:C9>
M+]1L(KC[)>P6=NJB%P;B9)06=5QE@J<9]CZ5[#10!YIJ#1+\1)G^R7%Q8'PL
MT)\I'4.0S/Y8(XW%>G<4OA[4+K0KJY+W-[K>C6FG^9!.UBXN8/G4"'D#?D<^
MHV\XKTJHKB!;FWD@=I%5QM)C<HP'LPY'U% $.EZC!J^F6^H6V_R9T#J'7:P]
MB.Q!X(KC?#RS>"=6U?3-0@N#IMY>/>V5Y% \D:ASS&Y4':P(&">#GK7;VMM!
M96L5M;1B.&)0B(O0 5-0!Y*;.**X\?:G9:1)'I]QI_DV4JVCH9':,B144@'!
M?!) P36I>V\T&@^"M5M+"::UTYXGN[>& [POE%-^S&3L))QC/I7HU% 'FVM:
M7/K,_BW4M*M)C#=:-]D7]VRF[G&XY53@G"X7..<\=*33+V74/&'A2XBTS4DM
MK?3)(9)I;1T5798^#D9&",9/'H3@UZ537!9&"MM8CAL9Q[T >*Z8@\0_#K3_
M  ]IT,[:F-5:4R"W<)"!<.QE,A&WA>.#G)Q7JWBC<?">K(D4LLCV<J)'#&TC
M,S*0 %4$GDT>&]!B\-:+'ID%Q-/%&[NKS;=WSL6(^4 =2:UJ /,K:"XBO?AR
MXTR^WV-A)'<G['(!"QMP@5SM^7YP1S]>G-85LFI3WOA*[ET7686M-0EEN;9=
M/D2&T#EB @"Y;KDMSUZC.*]JHH \RT^/4X?$UM<:7#JT=K=:E(U]IE_9N8HL
MEBT\4S* H)Y !YW5TOQ"T^_U+P9=P:=;_:;A7BE^S@X\U4D5F7WR!TKJ** /
M.;RXNO$/C"UEM-)U6UCDT>YMC<W%F\2QRR%=H)(!&-IY]^,U0\(VTDT&B:7?
M>$=4BU+36CWW5X\GV:(1@#S(R6P6(& H'!/H*]5HH \^M_#VH6GCZ]LHK=CX
M?O9X]6D?&$69<@Q].2SB-_HO?-8TUC-I?B#Q#I^J^%M6UBVU*[:ZMI[-G,,@
M<#]W)A@J[<8R?3Z5ZU10!Y[=V-Y+XYMK>.VN(/\ BGI;+[3%;2&"*9BI #XQ
M@ 'OVQUK-73]0U'X?:9X0DTN]M]5MIX(GF:W/E0B.0,95E^Z1M'&#G+8QUKU
M-6##*D$>HHH \Q748K?Q7\0+-])O=0:X$"K%!;-(LN8 NQF (7KU; QDUE6V
MB:EX1U*U_M#0]5UFTN-*MK9CICOF"1 04(5AE>>I..?K7I.D>&X](UC4]22^
MNIY=1</,DVS:".%VX4$87"]>@]:VZ /-+6UOO"OB?3=1'AV?^S)=,-G]GT]#
M.UF_G&0 ]\$$9(XR/05M?#B.\@T"ZAO=.N[*3[=/*%N$"E@\C,,<GL?\,UV-
M% 'F/C2'4)M<UN,Z'J,L,VE&*UFTV'FX<@@B608;"D\)G! .0>!3/#]KJ+>*
M_"M[-I&H6T%IH?V29IH"-L@ XXSC.._XXKU&B@#QS0=)U_2=+T'4/[*O9/[+
MU.ZDN;$1[9'28%5D7/7:&/&>]=/X+AU!_&GBS5;G2KVRM=0:V,!ND"D^6A4@
MC)]:[RB@#E?&^C7FH65AJ&E1JVJZ9=QW%N&_B&0'0GT*DY^E9&C^#-0TGQB6
M%RTNE3JE]=%L_O+Q05)'H"6#_517H-% '!PO>P^(?&ETVD:CY<\$*6Q$.?/*
M(R';SZL,9[<U2T^UU&+3/ (?2KX'3,B\4Q<Q?N3%DC//S,#QGC)KTFB@#!\:
M:3=:YX-U73;)MMS/ 5CYQN(YVY]\8_&N,OX=<\3>*O#%U+X=O[%+6"[AO'E,
M96-I(O+RIW?, 3GMD=,UZC4,]U;VS1">>*(RN(XQ(X7>QZ*,]3[4 >9^$-#O
M[:XT_3K[P;:V]WIL@5]8.PHZ+T:,==S# ]N2>>*V++PO>V7C^\,:@:#/*NJ8
MQTNL,A7\20_U KNJ* /*;[PY>6_B[5EN/!5EKD&H3>?:7TFP>26 !60GG:",
M\<]<9S@7[KPQJ%WXVU)([-[?3I_#C:3'=*JK&LA.1A0<A0/;MBO1Z* //4TW
M6]4\/Z%X?O-(DMYK">W:XO&>,Q;8"#N3!W$L%  P,;CFL72YK^6\^(6F6.CW
M%[)=WTD22*Z+&K,NWYBQ!&,YX!KURLG2?#MAHEU?7%FLPEOI?-N#)*S[W]<$
M\?A0!DZ!=W.C:E8^$)-.<V]KIZ>5?B92)=BJ&S']Y1DXR>_UKK*A2UMX[J2Y
M2");B4!7E" ,P'0$]3BIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *BN;F&SMI;FYE2*")2\DCG
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MR6>L6,5N7GF97A*(R_= ^;.[U%=]10!PEKX<\06!\)30II\DVEV+V-R&F8*
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M8KVWCA54G8R*4'4@H!SSWXHO] U6Z^(VEZ]&+(6%G;R0,&F;S6WCJ%V8X/\
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MN"[#_(Z*561-O7C@KQGUK+L/!.LZ=X*TO0771=3CMTF6XM[M76-R[!E97 +
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MIM\"0P&-I7"[5>0ECR 3P !DY]JZJB@#B-#\#:CH^S3F\0R3Z!#,)H+(P 2
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MEC].<\=-110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !6%XU_Y$3Q#_V#;C_T6U;M4M8TY=7T2_TU
MY#&EW;R0,ZC)4.I7(_.@#A]%\3ZUI5MX5CU2RL%TC4X8K>&:"<M)$_E@IOR
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MH[!B&4C!(QP:2R\-W>B:YH5KH\]['H]E;R)<1O(GDR [B..ID+L#D   >^*
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M9PN"<#J6YXXIMQJ>N_VEX?\ #DFJ6UU<R17#7D\,_P!F\]XV "!@K%2 3D
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M>Y=_W778<DY&>>>])-X*T&YL]1M+BS>:'49A/=*]Q)\\@((;[WRG@?=QP,4
M<QXQO=1T:[N&F;5?[%6T2.*\T^<O)9R_-EY4SEP?E.22 ![UZ''*DT:O&P96
M4,"/0]*P[GP=I%T"K_;MCQB*5!?S8F09^5P6^8<D<\XXS2V?AN"T\6W6N0Q)
M TUL+=@DKMYP&S!93\J[0F %Z@DD]J (/'.K7&DZ#$;:X-K)=7D%J;D*#Y*N
MX#/SD=,]>Y%<?J4MQX5^(6J75J]YJ#IX9>=/M$AD*%93@9QG!(SCW->D:MI-
MAKFF3:=J5LMQ:3##QL2,]P01R#[BLO3O!&@Z9>)>0VTSW20&V\V>ZEE)C/\
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MRJ;.)XQ*P\TIM&&8>O3/O6O6!#X7M(?%4>M10V\/DVGV6-8H]K%>/O'., #
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MTO((S@&%BQ!*\<?P\'-<_!X@UZ_TOP'Y>KW,$FL+-#=.T2$DA2-XXZ\Y'..
M<>H!ZU17DTEUXPU/5=4T73+R>XGT411)=?:4MB\C)NWR)L;>">,9 P/4YJQX
MAUW5[1;2]U6YOK73WTY-U[I!#16]V=P<R*024R1@]..Y.0 >HT5%;3)/:PS1
MR"1)$5E=>C C((K \>W%W9^"-6O+&\EM+B"!I$DB"YX'3D'],'WH Z2F/%%(
M<O&C'&,E0>*\_8ZWHOC+1+9]>N;NVUV.:.9953-O(D>\/$,8 [8(/OG-8L>K
M:_I_P^M_%4FNW4\\Z&T\EXU,<9>XVB4_[0&1SQR!@#B@#UVBO.];U+4/!&O6
MRPWMWJ-G>:?=S-%=R>84E@CWA@<?*&S@CIZ 5-9M?Z9I^F^(SXAEN[>XLF>Z
MMKAMXGE,9=?) X0@@C [#UYH [ZBO,O#LWBF_AT'Q$=3MQ9W10WHEO6=)0Y"
M[4B\H"-@QP &Z\$GK3+'4]1A\2PVNIWE_8:PWVEX([B4R6-^NURA7:<)M&TD
M<<#N3P >H45Y'#XHN]%L]3N+R;5H==L]+=Y+"]<RPS/N7$\1!V[0<\#'!]CG
M:T6V\36]_87QU.!K&[M71A<:B]QYTI0NCH#$H3H<@<;1TXH ]"HKSKP7J-R?
M$XT_5IM9MM62Q;S[.\E\VWF;>O[Z)LX'<8QC#<=#GT6@ HKS?QQJ%_'JVJ):
M7U^WV31WN$@LG,2V[C>?-E;(#9V@!><X/'<P6=YJVO:SX4276KVVBU'1#<7*
M6[*@+@)RO'!);KS[8H ]/K%L/$=OJ'B75-#2WGCN-.2-I6DV[6WY(VX)[ 'G
M'6O/=+\3ZK-H.FZ3)?W)DNM>ETU[XMF40J2V-_9SPH/IGO6_X7T\:;\3O$\*
MW-Q<*UI:N&N)#(ZYW\;CR1QWH [VBN7\<:O/IEAID$#R0_VCJ4%E)<1G!AC=
MOF8'L< @'WKF=:MKG2-7U#08K_4I]-O='GO,2W3M);R1]UD+;MK9&1SS[9H
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MHC3G<*( ^\F4+V#$%2?4"N'EM(EC\-BZ6 Z9+XGE&G!^]D6PHY_@/IT((]:
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MI+<2.LC#H<%OE/3D8Z#TK:DFCB!,DB( "QW,!P.IH\V/:K>8NUL;3G@YZ8H
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M/ ..>M6-'?6TU0Q7E];:AICVHE@NXH-C%\@$,02IXY&,=_2@#3_L;3/MYO\
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MY'UH \K)T^^MO ^FW+6TDT>A"X,.H,!:*GE*#(PQEG #8 (P 3D=VZ5=I/\
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MSXZM(M*ULO?2I+;?:+61Y)@509R!U)!..H'!Q7LE% '&75V;GXA^'[N.SO\
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MT86$%WY5ZPDNS8NB0[FAG_N-@XSZ8SFK%EXTM;O6;+2I-,U.SN;Q)'B%U$J
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M\<AA[8[]-6]\7W$+"RTRQ4S0V,=R^897CRRDK$OEJ<'CJ>@QP>P!VE%>>_\
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MLN[)8;6Z_P!T]/TK-M/&&OQR>&KO5-/L4TO6_+B!@=VDAE=-R$YXPW/';N:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%R0JHO Y8DGJ?PINI:+J,NMC5M,U9;646X@:":W\V*0!F(+ ,IR-W&"._7-
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M\I%N+,L=PEV@@[N.,CG(X&02<CJ-%\ QZ(L<2:WJ-U;VH8V,%R59+9R" P
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M-0GFQ/*I8AHU0#'E#L#S["I]:TR*\?XC3W%Q>R'3MDEHC7DNV)S%NW ;NQZ
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MM00V$QFM+D7!\V DY(4XP![8IX^'.@-;ZI!<K=W2:FZR7/GW+-EAR&'H??\
M#IQ76T4 87A[PGI_AL2&UDN[B:10AGNYVE<("2$!/11GH/QS4VJ^'K75KVVO
M7FNK>\M4=()[:8HR!\;N.C?='# CVK7K/U6XU*W6T.FV4=T7N42X#RA/+A.=
MSCU(XX[YH HQ^#]'%EJ5O<0O=_VGC[9+<.6>; P,GMCMC&.U5]+\!Z%I=E<V
MBPS7,5S#]G?[5,TI$7]Q2?NKWP,<_05TM+0!RNF_#[1-)@N([0WJF:$VX=[E
MG:*,G)5-V0H^E6G\&:--X53PW<PR7.G1@+&LLA+)CIAAR,=JW\TF]=X3<-Q&
M0N><>M '-1> =#CT*^TATN9[>]55G>>X>21@IR@#$\!>P%2+X+TY(Q&EWJ:I
M]F%K(!>.?-C#,V&).<Y=N000#@8KHB0 22 !U-5-+U2TUBR%Y8RB6W,DD8<=
M&*.4)'J,J<'O0 ^'3[6#3$TZ*%5M$A$"Q=@@&,?E7-6_PWT"VDTZ1#?L^G$_
M9BUY(=BG^ <_=Z\=^AXKJKB>&UMY+BXE2*&-2SNYPJ@=234%CJ$%_I5MJ43;
M;:X@6=&?C",H89].#0!F:=X/TK2Y+)H!<M'8EC:12W#.D!8%3M!/H3USC/&*
MM:_X>TWQ-I;Z=JD'G6[$,,,596'0@CH:TD=70,K!E89!!R"*1YHXW1'D16?A
M0S %OIZT <_;^!M!MM!GT86KR6L[!Y6DE9I&88PV_.01@8QTJPOA73?(NXYS
M=7+WD(MYYIKAC(T0S\F[/ Y/3&<\\UL/(D2%Y'5$'5F. *=F@#%3PGI*7FG7
M:QW'GZ=%Y-JWVF3Y$[C[W/&!SG@"DM_".CVUKJ=M#%.L6INTEV/M,A\QF^\<
M[L@GH<8K9$B,[('4NN"R@\C/3-8]WXDM%N-2L;.2&;4;*W\YXFDVJ"0Q"DC)
MSA2<8Z4 5[GP-H%W!IT4MK-G3HS%:R)=2I)&F,;=ZL&(QQR:;_P@'AK^Q;G2
M#IVZQN9?/DC>>1OGS]X$ME3]"*N^&=:.N>'=-OY_*CN;NV6=H4/3/H#SBI[*
M;4UFOFU1;**V67_16A=B3'ZOG@-].* ,P> _#HT5M(6RD%FTXN'47,FYY!C!
M9MVXXP."<<"K3>%-(DU&YOY(9I+BZMOLDY>XD8218QM*DX_^OS6K]HAV._FQ
M[$)#-N&%(Z@^E87ASQ!<:UJFNVLT=N$T^Y6&)X'+!U*!LDGOSVH 8O@+P^FG
M6U@EO<K;VTRSQ*+V8%74 *<[L\8&!T':H[SX=>%[][QKC3W<WDGG3 7,H#29
MSO #8#<=1SU]:Z62>*'/F2HF!D[F XZ9_6AYXHXA+)*B1G^-F 'YT 9=MX8T
MJSUE=6@AE2\6W%L&\]RHB'1=N=N._3KSUIVM>&M*\0-:OJ5NTDEHY>!TE>-D
M)ZX*D'G K1-Q"(TD,L81^%8L,-]#WK/;Q'I2ZM'IHO8&N'A:8A95PB@@9//&
M2W'T/I0!ECX=^&5A>&.SGCB>X%R4CNYE D!R" &XP><#O]*T/^$5T@ZQ=ZJ]
MO))=7</D3^9.[))'C&TH3MQ^'KZUII=V\D;2)<1,B?>97!"_4TKW$,<0E>6-
M8SC#E@ <].: .<M/A[X9LKRUNX;"3SK0G[.SW4K>4#V4%L >W3D^M0_$K3KO
M5_!-SI]G8S7DL\T(,41 .U9%9CDD=E(^I%=.M[:LZHMS"7;[JAQD_2J&LW=\
MEO$=*GT]95NHTG-VY"B,GY@,?Q'@ 'UH K67A;24LIL6MTK7EL()3<7,CS+%
MMQY>XL2N/13UJ>V\+Z/;>'?^$?6T#Z7M*_9Y7:08)SC+$GKSUXJK<^++*0ZQ
M:Z;<6\U]IL(=@[_(6(8[>#DD!><=,CWJ?PSKBZQH&EW-Q- +ZZM$N'A1@",@
M$D+G..: &Q^'+'2K2ZDL+666Y>V^SJ9)VD?8!\J!I&X'MD"LGP1X*M-$T32S
M=6<T>HVL9W))=-(B2D8=T7<5&>>0!U/3-=4^H6<=XEF]W MT_*0M( [?1<Y-
M.DO+:)96DN(4$(W2EG V#U;T_&@"A8^&M)TT7_V2U:,WY)NCYSDR$YR22>#R
M>1S55_!/AV70/[#?3$;30V]8&=R$;U4DY7\".I]:ENO%FB6=_8V<FI6OFW@+
M1_OEP%"YW$YZ'@#U)J?7M?L/#FF27U_,B*H^2,NJM*W95R1DF@"M_P (;X?_
M +#AT7^S(AI\,@ECB4L,./XL@YSSUS4,O@/PO/)+)+HUNS2Q+"XYP55=J\9Q
MD <'K5&;Q=(OC>QL([FQ;19K"2[DN0P.TJVWE]VW&>/J<5U#ZA91V0O9+RW6
MT(!$[2J$(/0[LXH S[#PKHNF:E_:%E9"&Z\KR?,$CGY/[N"<8_KS5/1[76=1
MU:/5]?T^TLI+:)X;6"&;SF&\C>Y; '(50 /?/6NAAGBN84F@E26)QE71@RL/
M4$=:K3:OIMN[)/J%I$ZL$97F52&.<#D]3@\>U %P@$8(R*P8?!/ANWTR?3H=
M)@2TGE$TD:Y&7!R&!SD$=L8K6N-0L[//VJ[MX,+N/FR!<#(&>3TR0/QJGI]Q
M>OJNII<W=C+;(R&WC@)\R)2#GS/J1Q^- %K3],M-+A:*SB**[;W+.SLS8QDL
MQ)/  Y/:DU+2K'6+0VNHVL5S 2&V2+G!'0CT/N*+;5=/O/,^RW]K/Y0S)Y4R
MML^N#Q1;:KI]Y+Y5K?6L\F"VR*96. <$X!Z9X^M %2Q\,:-I]['>6]GFYC0I
M'++(\K1J>H4N3M_#%2:5X>TO1%N5TZU$(NI/,G!=GWMW)W$\GOZU.VK:<EQ+
M;OJ%JL\*EY(S,H9% R21G(&*%U73WM%NEO[4VS-L683+L+9Q@'.,Y[4 5=.\
M,Z-I%R;BPL(H)#NQM)PFXY.U2<+D]< 56G\$>&KJXN+B?1K622XD$LI920SY
M!SCIDD#/KWS5N?6]/>.2&VU:P6Z:%Y(]TRD #*[B,\J&X/T-8L'C33M,BT6Q
MU?6M-GO[R+=+<13*D6 I._D]&. /7GT- &=%X#BO?'VMZMJ^G0S6%TD"6H$I
M&W8@5@R@@8.!P<]*[U$6-%1%544855& !Z"L#1_&>AZY=W\%EJ-JYLV()$RY
M=5 +.!_<!;&[H<&M&WUW2;JWGN+?4[.6&#'G2).I6/(R-QSQ^- &>_@?PQ(U
MPTFAV3FXF\^4M'G<^<Y]N>PX-6#X4T$K>+_95MMO,?:1MXEP<C=ZU8M==TB^
MNQ:6FJ6<]R8Q*(HIU9MAP0V <XY'/O5NXN(;2!Y[B:.&&,9>21@JJ/4D]* ,
MN;PGH%S:6EK/I%G+;V>?L\;Q!A%DY.,]![5?L-,L=+B>*PLX+9'8NRPQA=S'
MJ3CJ:9;:OIU[;RW%K?VTT,.?-DCE4JF!D[CGCCUJ*V\0:/>I,]MJME,L"[Y2
MDZD1KZMSP/>@!DWAG1+C4VU*;3+:2]9D=IF3+,5P%)]<8&/I49\*:"5O5.E6
MI6^.;D;/]<<[OF]>>:E@\2:'=7D-I;ZQ82W,R[HHDN%9G'/( .3T/Y4O_"0Z
M/_:7]G?VG:_;=VP0&4;BW]T#N>.G44 1?\(KH/\ HF='LF^QJ4M]T(;RU/)
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MHZ7:W,=M_J5DC!"#T'MP..G%22:!I,MS:W$FGV[36BA+9B@_<@=D_N_A[>E
M'E\UI<WNMZ[H\NO6VGG2UCCM'OI97GBB6-3YR,)%&23DG!ZX/'%:&E16<OC^
M:]O)P\O_  C\%VURRM&6;><R;,\=%X[=*[O4?#&AZO?PWVHZ5:W-U#@)++&"
M0!T'N/K4MYH.D:A>I>7FFVEQ=1IL266(,RKSP">W)_.@#@?"MTVC>(K2UUR
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MC+$-SCG.,UJ:A ?$.O:MJVC))-:R>'IK-I%C91-,Q)11D#<0,Y],X]J]&HH
M\HT6^-_JWPZ$%C>F*QLIH;B9K9PJ/Y"QE>1T#<$].>M9&CP6FM_#IM"M('?6
M7U-I8F%N_P"ZQ<<R[\8 "Y&<^W7BO;&!*D*<''!QG%8_ACP]'X9TDZ=#<R7$
M?FO*&D4 @L=Q''N30 [3-4L;K6=2L;>RGM[JW96F>2V,8FSD!E;^,<$9K"F@
MDMOC-:WDI(@N]$DMH2>AD2578?7:<UU=O806US/<H',TY!=W=F.!G &3PHR>
M!QR:9J>EV^JP(DQ=)(G$D,T1Q)$X_B4^O4>A!(((.* .%E$=GXI\:P7NFW$Q
MU:.%;-1;.RW0$&TJ& ('S<')&.M&MZ9<:;\,= \/W(6;47GLK5 #NVNKJQP?
M0*C#/H*]% ( !)/N>]4I-)MYM7BU.;?+- A6!7QMAW<,5&.I'&3GC@8R: .=
M^*N/^%::SD9&R/C_ +:I6%K^G7'B?58I]"TVXMXX=#N[9GF@:V^:6/;%$ P'
M0Y/' S]*[?Q+H4?B70;G2)IY((KC:'>, L &#<9XZ@5IPH\<,:22&5U4!I"
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M4?H $8,K9_NY /U'J*76C)YOCZUTS<T$5[8RRP6>-_E*J^;L7!&?EYR,<'-
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MQ1X?DGB@37--::9MD<:W2%G.<8 SR<\5Q;7-IXBF\&_V*Z_VC8SH;K$9W6T
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M>)8=*U^PN[^:UO-/\664DRV<MM;2I+(R.PBVG&) PV]SC)Y% 'H-SKEAI=I
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MRN)6^P';="2VEB,9Y)!#J#G@\"GV/B72]1U*+3[::1KF6S%\B-"Z9A+;0WS
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M+FXM8//BN[<*TMO<PM%(JM]TX8<@^U&I^(;/2[C[,\=U<7 B\YHK6!I62/)
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M*8G6<GYG.<J5W$GCMQFHK*:;PW\08M/2WN=4^Q^'8+<"U0%UVMU;<1U(_44
M=&WQ%T#R=,EC-Y,NI1N]J(K5V+E,@J..6R,;1SDCL<U%;Z_H]]XOLIO/U2"[
MDTHW"PS*T< AW9+,I_CSW&>E<O:>&-7TW7?"4YTR8K'?7E[=B$JR6OGX"IG/
M.WN1[XS6WK%EJ[?%"+4;+3II(5T>2U2X(7RQ,267.3TZ4 ;&G>.-.U.XM88+
M6]!O89)[%G156Z5#\VP[N#WPVW@@U4T'QPM_X<;5[^PN;9'N9(85 1S,WFLB
M1H%8EFX / &0><#-<KHVCZ\/$OA+59_#]^LULL\>H3W%Q&26:,*"%!PJ#G
M'ICN4?PIX@N?!%OI7]CQFZT?4WO4CNFC:&^!DD.P<G@K)U;'/'N #T72O$-K
MJU]?6 AN+:^L2HGM[A5# ,,JP*D@@\\@]JR/^$GN[CXAS^&O[-G%K'8^:\JN
M@8EG"A\AP0H&>GS9[4O@VTE#W%Z_A6S\.I(BQB&-8S+(022S% ,+T !YZGCC
M-:;3]5L?BL^L1:9)=V%UIBVQEBD0>4RON.X,1^&/7ZT 8?PW\9PVWA#1;;53
MJ$DMW<R0+?2QLT1E:1]J%R<DD#W'O75:CX[TK3;BY62*YDMK.40W5U&%\N%S
MC@@L&;&1DJ"!WKC=,\-^(K+X>^'M(DT.<WEEJZ74ZK/!@1K*9,@^9@Y!QCUS
M4LOAG4;3Q#J\+^"],UB/4;J2YMM3N/*/D;P/ED# L0I].O:@#T?5+'^UM,:U
M2\GMED:-C-;2%'VAU8@,I!&X C(/0UPFBZ;]N^('B[29M3UG['8I:?94&K7(
M,1>++$'S,GGGG->B6T1@M8HF8.R(%+!0N2!C.!P/I7&Z#8:M:?$CQ+J5QI$\
M>GZFMN(9S+$<&*/:<J'+<GIQ]<4 30>-K*QO_P#A'S:ZQ?7UBT%M<RI:,PRP
M $C-GH>#D\G/&>:M:9XXL=5O[&WAL[Q(=0:9;2Z=4\N8Q9W]&+#H<9 S46DV
MNJ1>-_$EY)ILL%K=Q0);7#R1E7,2L"2 Q89+<<=!SCI7+Z1H7BE=8T'5=1T)
MGU&UEG6]N9+Z-C('1E5E .%C&?N@9]CUH G\<>(H]4TB![.QU%K9-5A@BU".
M4+ S"50V0'RR\,H)4C-=+J_CO3-(>]+Q3W$-@RI>2PE"(6..-I8,Q ()V@XK
ME(?#WBNV\&KX2&E0S)97<;PW[7:(DT2S"4?*,L&XQ@C'?)[VHM"\2:3XFU1;
M?0-,U/3]4N#=+=3SJILW8?.&RI9QD< #MVSP =IK<U]/X7O9M"</>O;,UHPQ
M@L1E2,\?G7"^"[S2=9GTO[#?ZC9ZQ8N?[1T^]O92\WR,&+(Q(?YF!S@8]NE=
MWJ5MJ*^&IK?3I5.HK;[87.$!<#@^@!KE]3T.]\2:]HU])H+:5>V%TDTU^T\;
M;XUSF--C%F#9'W@N!GZ4 :5[X]TRQG)>*=[);H6DEY&4*))G!RN[?@'@G;C-
M6+SQA:VDLA^Q7DUG%=+:37<2JR)(3@C&=Q ) ) .#]#7+Z;X?\1Z+J=[I4.A
M:;>6%Q=27$&KS2(&@5SN(:/!9F!SCH.G/I<M[+QII&IZGI=C;6DVFW]W-<P:
MDTP4V8E8LP,9R7().,<>O7@ UO\ A-[4^(;K1ETO4WEM)HXKB98 8X@Z[@[,
M#PN,<U'%X^T^6YLHA:W"QZAN%C,S1[9V RJ_>RA<?=W ?A4&CZ5J3^*/%\EY
MI\UK::F(EM[AI(VW!(O+)PK$C/49'3K@\5F^%=&\36!L=&OM$TZVM]/* ZQ!
M(A:XC3HJIM+ D *Q..-Q'.* +FA^.+FX\-MJFI:>\;RWKVT""6-5+>8RJFXM
MQC&"3U[9X%=3I&IR:E#.9[">RF@F,,D4Q!R=JME2"05^88-<98^'=6M?"USH
MFH:#9ZC:_:Y)3&;D9G1Y';Y<@;6&5()(Y].M;7@?1+_0]-N8+IYDMGFWV=G-
M-YSVL6!\A?H><\ D#U- '/7;Q^*?B%J^C:OI$D]C9V<2*KRI^X+DDS YRI(V
M\C)&WMTK9A\9V>G:187CV-W'H#E+>'4)9 ^!]U'<9+;6_O'GGD#-10>';]_'
M7B*]N[0?V7JMHEJ&68;P%7:21Z')Z<U2_P"$0U:]\$Q^"[^.$6<<D<?V^*7E
MX$<.#LQD.0-N.@ZY/2@#5B\=?:-=FTJ#0-5DDMKN.VN71%980XR'8JQ&.?P&
M2<=#UU<IX9TC4;#Q/XDOKNW6.WU&>.2 B0,<*FW! Z>M=70 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1145U<PV5I-=7,BQ00HTDDC=%4#))^@% $M%<_8>,M&U&58H99U=[7[9$
MLENZF6'^^O'(_7VJMI_Q!\.ZI/916MU,WVUS%!(UO(J,XS\FXC ;C.* .FCB
MCB7;&BHN2<*,#).2?SI^*P]/\6:7J2ZD8&G!TT'[6LD#(8R 25P1R<#/'M6A
M:ZC!=Z5%J*>8MO)%YPWH0VW&<[>O3M0!9EABGC,<L:2(<$JZ@CCD<4211S1M
M'*BNC<%6&0?PKE(?B7X6N)[>*.^E_?S>0)#;R!%?<5"LQ&%)(X![<G K1D\6
M:;%#JTCK=9TDC[6GD-N0$;@P'=<<Y':@#=Q3/*C,HEV+Y@7:'QSCTSZ5S>H^
M/_#VEO%'=74RRRVPNHXUMI&+1D Y&!@\'D#I@YQBJT_Q-\+P/.AN[ES $,H2
MTE.Q67<&/R\#'4^XH ["BL6;Q1IB+9^2\MVUY#]HACM8FD9HL9WD <#D=>_%
M)'XJTJXTZSO;69[E+QBD$<,9:1F )8%>H( .<XQ0!'XOT"Y\2Z*NG6][': S
MQRR.\)DW!&# #YACD#FM+5+.>_T:ZLXIHXIIX6B\QXRRKN&"=N03U]:H1>*]
M-FM8)H_M+//-)!' (&\TO&2'&WMC:<D\?F*N:-K=CKUDUU82F2-)6AD#*59'
M7AE8'D$4 ,\/:7)HGAZPTN6=)VM(%A$J(4#!1@'&3S@>M:=8FI^*+'3+F:W,
M=S=36\8EN$M8O,,"'.&?TS@\<GCI6/>^/8%U_P /66GV\MW::K')/]HB3<&1
M4)P@SG=G&<C@?H =D0<'! /8D9K!\(>&SX5T0Z9]K%T@F>5'\O80&.2#R<\Y
M_#%<9X;\80Z'?>*%U>XU&XAAUIX1.R/*MO&<*NYNBC/&!^5=KJOBNPTF:XB>
M*\N6M4$EU]F@+BW0@D,YZ= 3@9..U &[17)W_P 1?#VGW2V[S7,SM;+=IY%L
M[AXF/#*0.1C)R..#WXK8U[6ET/P]=ZM]FFN%MX6E\N-<-@#/.>@]?2@#4HKS
M74/$TO\ ;7@K5;B2_MX;E9OM%LJ/LE;[.2I6,9+?,W'7M71)X]T9M!N=6D%W
M#%;79LI(982)1-Q\FWU^8=\4 =1BBN6G\?:1::;J5Y<QWT+:;(([NW:W)DB+
M<KG&1@]FSCIS5[3/%-AJFKR:9'%=PW"P"Y3[1"8Q+$3C<N>2,^N* -NC%<OX
MX\4R^%=+@N(K.68SW"0F54#+$"P!)&02<$X'<]Q7./KT]A\6)9'CU>6WFT(3
MC3QF1D<R@$A,[5^5>>?7N<4 >ET5@V_B[2[W2].OK)I;H:B#]EAB7]Y)M^]P
M2 -N,$D@#UY%6M$UZSU^TEGM!,C03-!-#.A22*1>JL/7D4 :E%<QJGCC3M*U
M:XTM[34Y[R"(3F.WM&?<A_B7U P<GIQCK4\7C#3+NSTZXL%N+UM1C:6WA@0;
MV5<!B=Q 4 D Y/4]Z .@HKDG^(N@K96-TINY$O)6@C5+=F995!S&P[/D8QWR
M.W-8^J^))-;\1>'+"+3M3&G7T,\[Q;A!)*54 <;P1M)).2.V,XH ]%HQ7&V_
MB73O#.F&U;^UKS3M/D-M/JDH$BH^[&&;(9@I.TD*0,8)S5C4O'VE:;J4VG_9
M]0NKJ*))C':VQDW1LP 88ZCG.?Z\4 =5BC%<4_Q.T2.SGO&MM3^RVUT;2XF^
MRG;"X('S<^I[9/MR,ZVG^+;&_P!2N=/:WO;2X@MQ=%;J'9NB)(W@9)[=#@^U
M &_17+:;X[T[4KRTMQ:WL OX7FL))47%TJ#+; K$@XYPP!-0V/Q$TN_:S:*R
MU);>YNC9BXD@VQQS;BJHQSWQU&0,@$@\4 =?BC%<S?>-M.L)W\R"Z:RBN1:3
MWR*IBBF) V$;MYY(&0I&3UINJ^.M,TB2Z,L5Q+:V<@BN[J+84@8XX(+!FQN7
M.U3C/UH ZC%&*C,T:P&=I%$07>7SQMQG-<[%XVLI)=-:2SO8++4Y/+LKV15$
M<K$97C=N7<!QE1F@#IL45YF/.\6^-M?TW4M+U.**U^SQ6]Q#<1HUD-I??D.>
M7/=03C .,5H_%J22T\%/?P7$]M<031JDT,S1E59P&^Z1U% '=UBZ_P"'1KYM
M ^IZC9QP.QDCLY_+$ZD8*OCG'T]3]1QEIJRZ7\0/LN@7=UJ6B)I[SWT*W)N$
MA<9*[&8G#'CY=W?-;UA\0K"_TK^TQINIPVCQHT$DL( N'9M@C3#<ON..P[YQ
MS0!U<$$5M;QP0H(XHE"(BCA5 P *DKG/^$M1+V;3Y]+O8=12W-S%:,8BUP@X
M.PARN0>Q(-&G>,+75=%TO4[.TN9$U&?R8H@4WJ?F)+?-@ !6)Y)XH Z/%8NO
M^'4U][/S-2U"TCMW+/':3F,3J1@H^.H_Q-9%IKFBZ1-XGU!H+ZW:WND6[$KA
M_,E*C:(U#'KN7CCD_ED1ZL[?&!)+RTO-/B30WE9+B52HPXR^%9AT&.QXH ]$
M@@BM;>.W@C6.&)0B(HP%4#  J2N1L_B'I%[?6-JD<ZM?JYM26C;S"HSM(5R4
M)'3<!^%+I_BVV\51/9V>FZPL,ZSV\ETB*@@=,@J7#<-T((R/F'.00 #K<48K
MD[&YNO"/A;3+.^\^^U">5H((VN S%CO=4:5L [57&[OC@<@5OZ9?MJ%JTKVD
MUK(DC1O%-M+ J<9RI((/4<T 7<4G%<[?>*FAO;RWT_2[C41I^#>O%(B^5E=V
M%#'+MCG ]>M<QKFMPW7BSP5KFDVUQJ NK>\,4,)P9/W:[0=Q"K@L<D].: .N
MN_#4-WXKLO$#7=PEQ9Q-#'$H7RRK9W9R,YZ=".E;?'3O7E?CCQ/!XC^$VN7$
M,5Q97UC/%#<6\AVR02B5 1D=1@G![UTTU]IH^).GVTMC<C4AITACNC(!'Y60
M2 H.2<CN!^- '7XI*XL?$)673;B/1+V:PU28P6,\4D>Z1N?O*S#:#AB.3P.<
M=*FG\>0PZF\)T^8V*:@NFM=%PI,QP/E0X+*"0"1^6* -31O#%IHU[=7BW-]>
M7-PQ/FWDYE,2$Y\M,_=7/;KZDX%:0L;4W_V_R@USY?EB4DDJN<D#TS@9QUP,
M]*Y'3_$NM7_B[Q!ID^B%[*Q6./;'<)N *,X.#C)<%1C("X'O3M"U_3++PMH$
M&B:6R-J*N;'3_-Y"C+.S.V< 9R3R>0 #0!UE_I]IJEF]I>P+- ^"5;L1R"".
M00>01R*FAB\F&.+>[[%"[G.6.!U)[FN,U'XC6^E:-JEW=Z7=+>:7(D=W9JZ$
MIO\ ]6X;."C<<C)]15M/&HBU#5[/4-+N+.33[$Z@H:1':6$;N< _*?EZ$]Z
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MY2N1Z=:XVRT/7;KPUH/AZ_TU;<:=/ 9[M9D:-XX""I0 EMS;5ZJ,9->@TA(
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M...E:%<U>:%<W7CO3]8C>>*"UMV21A<G9+G< GE=.I#%B?X0,=QTM !1110
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MA,85O+.[&2<CICOQ3+SQKKVG^%-4U-5TYKBQUQ[!U6!E61 ZKD?-\I.3R=U
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M29-O3.W  Z9YYQ6G-JFJVNM:WX>U*87<#Z3)>V=SY01MH^1T?& 2"000!P:
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M:#@DG))(.?H*S_#5FFO>/M,U35()X[V?P_%?2!;F5?WHFP#@-PI !V?=YZ4
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M=M!;:9:FTAM!&"I1OO98\Y) .?;W-;&L:19Z]I%SIFH1>9:W";77H?4$>A!
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M[1?M,G[M^><YR>IX/'-=#10!S6H^#M.FL]:$-N\TVJ[3<)->2HDC*1C)&2N
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M:I=OF9SN^]USS]>>M/O_  7X=U34X=1OM)@N+R(*%EDR2=O3=S\W_ LUO44
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ K.UC7M+T"V2?5+Q+:-VV)N!)8]<  $G\*T:I7J6-N
MXU2\$:-:QN!,Y_U:MC=^>T4 )I.L:?KEBM[IEW'=6[$KOC/0CJ".H/L:EO\
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MF[8,R?O) %R ,KD;OQ- 'J5%<!9CQ1&UK=OJT/V&\LGWL]PLKM+Y9=9(E\L
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MG- 'KU%><:G<M_PD_C6&&]F58=%295BN&7RY0'.1@_*>%SC\>M8EA;W%C8>
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M\0R0/;VXTH6P>.8/^\,N[E2OICO6@)$+!0ZEB,@9[4 16=G;Z?90V=I$L5O
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M-K!=#4+3[/<.(X9?.79*QR JG."3@\#TJ:ZNK>R@:>ZN(H(5^])*X51]2>*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1EV!X\94M@M_M$%O>NIT2*;2OB'IMA#?WTMOJ&B&>=9[AG'F @!E!.%P!@8
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MDTVW\B]8O<Q,NY96/5F!X)]^M 'F^H:?>:?H/B8/X@@E5].-W%;:;-,JP.G
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M8I+#9=9,$#RQ@#:K%5ZL0.P-:/B+3[/P[XDT?2X[J*TTK47FN9GU+?<6\MR
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M*_9(\1L2"2HQP3@=/04 >4ZK;VFM2>)],NGLOM\FL_N-3GNXD^SQC9E,,PD
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MFO\ ,5Y<[C#;,$;YG (SUP 2!GKTKM<#T%+C/6@#YXO;NP;P=XBM9[B"2?\
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M$\LT_P ,S]BOD%C&8KCS+61?+/DHF3D<#<",^WI7K5% 'F&F"]MO%%B='BU
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MX(FF6$2I;7$%Q*AZ%$D!;\,5=\6>*!H6G1&VBN)KFZXA:&V>98UXR[!1T /
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MH P_%&@2>(K&WM4O%M1#<QW.XP^9N*'<!]X<9ZUM*,* <9[X&!3J* "BBB@
MHHHH **** "BBB@ HHHH **** &R1I-$\4J*\;J596&0P/4$52TG2HM&L196
M\LSVR$^2DK;O*7L@/4J.V<D#CM5^B@"GJ6GIJEC)9RRRI!*-LHB;:70]5SU
M/?&#[U9BBC@A2&%%CBC4*B*,!0.  /2GT4 85QX8CO/$2ZI=:C?RPH4>.P,N
M+=9%Z/M[D$ _7FMVBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F8_ NDP32&WFU&"UE8L]
ME#>R) 222?D!X!).0,"NCBBC@A2&&-8XT4*B(,!0.@ ["GT4 %%%% !1110
M4444 (0",&HK2TMK&V2VM((H($SMCB4*HR<G@>_-344 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9>M6][<
MVX2VU(:=$,M/<*BLX4#HN[Y1[D@\#WR-2LK6]1M[*!(KK3KR^@N"8W6WM3<
M#'\:C)P?H: ,OP'>:E=Z)<G4=0CU#RKV:&WNT"@S1*<!F"\9SN_#%=37)>!M
M"DT:+5I1:?8K2^OFN+:S/!B3 7D=%)VYQV&![5UM !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 48HHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
>HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>exhibit1021-independentc004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit1021-independentc004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF,21EE*DJ>G!K)T+P]>6>K7FLZOJ"7NI74:P?N8O*BBB4DA%4DD\DDDGO71
M # Z4 <*?#GB^W\1:GJMCJVD%KQP%-Q:.SQQ+]R,$,, =?<DFH/A)'JR^%E>
M[N;5[(RSB&..)@ZOYS[B6)P03G Q7H-(  , 8% "T444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"]T:PB:YN7M!;Q#<JY. ,DD@4 ,L_'FE7\'F6UOJ#,\P@MXFMBK7+%2V8]V
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M)8*(T/1GR1QT]^#B2#X@Z0UO?-=)-:7-EL\RVD*,S!R A5E8J020.O!ZXZT
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M ZNYU:PL]1L]/GNHX[N\W?9XC]Z3:,MCZ"C4=6L=(@6?4+J.WC=Q&I<_>8]
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MG.U/;RL5U6OZ!I_B72VT[4HW>W+J^$<H05.1R*N6=I;V%I%:VD*0P1+M1$&
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MM=W=2WDZ1_<C>1LE%/<#@9[U>.C6!UC^U_(_T_R_*\[>V=G]W&<8[X]>:OT
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M_ W;>F>^*XJ[\"7%YKGB:62]A_L[7X8DF3RSYL9CC*C:<XZD')STQCO7;T4
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M1_>. ,XQ@"N@\'Z/J.@Z!;Z9J%W;W'V9%BA,$10!%&!G).2?PJ.30;\^.?\
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MSYD0!I& 7>P')P.!DUYWH7BO7+K7]$M;J\29;\W4=SY5N/LZ,BEE\F3@O@
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MBGOK2*_MDM;FWMI0D<B(FQ?X2>!QUP>X(S63J]D9]/'@"+1]6N[9XXD_M.Z
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MX(QNYR..>P [5A>(? ]M%I1ATK3)+R&;41?7UO\ ;&665L-EHW8_*Q)&>1D
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MQ9,0D,0))5<L02/7WQ7=:E%86GCCPL^@1680V5^($MB!$Q500 %X^\6Z>IH
M]$#+N*[AN],\T%U'5@/QKQ^*&"Y^%EAK=DXB\3I<KBX529Y+HR;6C<_>.>A!
MXQCL*9?Z5I^H77Q0DEMHQ):1I+ QY\MQ"S;EST8L.HYY- 'LC,%4LQ  Y))Z
M52TO5K/6=/6^LY0]N[.%?/4*Q7/T.,CVJMH6V_\ ">F&Z"W FLHC)Y@W!\H,
MYSUKRW3+K3+?P!X;*BU-I_:2IK)B"Y$>^38)<<[=VWKQ0![);W,%W"LUM-'-
M$WW7C8,I^A%2UQ.D6T5I\3KR/2%5-+DTM9+F.  0BX\S"G X#% <X[ 9KMJ
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *Y3XEHDOP[UF)U9B\.$5026?<"H 'N!75T4 <?I_A9=5@
MLM1U34C?2+IYM[5HHQ&L22H S 9.6(P,]/:JUMX'N-)ETF_;Q!>2C1K=X8XX
M[2/+PX'R  9W$*!GDGM@UW-9^IZE+I\UC''I]U=BZN!"S0+D0 @G>_HHQU]Z
M .6\-I8^)_%TOC"TLKF&W%HMM%)<+L,TF3EPO^RN%#=]S#M6A)X.9-1U2>PU
M:XM+?526O;<1JV6*[2T;'E"1UZ_A6IK&NP:1I=_?>5+="P0O/%!M+J NX]2!
M]WGZ5;TZ]74=,M+Y$*+<PI,%/4!E!Q^M &-:^$;>QUW3]1M+AX8K&R^PPVH0
M%?*X/)/.<@'-=$Z*Z%& 96&""."*QO$'B*+P\VFB:UGF%_>1V:-'C:C.< MD
MY]>@/2MJ@#C(OAIHB>&8="8RO;Q7HO-^?F9@W"GVV?)QV%:VM>&DUG6-'U$W
M<D$FERM+$BH"'+  [L]L#M6[10!Q5Q\.K:;3-<TU-5O([+5[AKF6$*A".S*S
M%3C/\ ')X&?K6C#X3$7B>SUUM0E>>VLA9>68U"NF<Y/?.>:Z2B@#/US1[;7]
M$N]*O 3!<QE&( ROHPSW!P1]*SX_!ND0ZEH]]%#METJ!H+?@<JP RWJ1R<^K
M&N@J*YN(K2VEN9Y!'#$A=W/15 R30!SDW@\RW^OW8U6=#K4"P3*(D(C505&W
M(Z[68<^N>U1KX'02>&W;5+AO[!79 /+3]X,!?FX_N@#CZUUE% '%P?#>QM=5
MEN+?5-3BTZ:8SR:6D^+=W)R<CJ5)'(_#IQ4DW@*.>TU^V?5;C;K;A[@^6F5P
M,?+QZ 5V%% %73[-K'3;>TDG:X,,8C\QU + <#(''2L2W\(+I<]W)H>J76FQ
M73F22V1(Y(5<]6164[2>^#CVK3T[4KJ\O]1MY],GM([64)#/(05N5(^\N.F/
M\/PTJ ./?X>6!T Z/'J%_'#)>_;II0R>9)+D'.=N!\P!X%:FJ>&HM1U"PU-+
MN:UU.R!6.ZB"G<K##*RD$$'K['I6Y5>TO;>^C>2VE65$D>)F7H&4E6'X$$4
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M8#VQ60/A=H8T>/3?M>J;8)S/;3_:OWMLQ))\ML?*"3D\<G!.2!7;55O-0M;
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M/KQ4M9EAKVGZG=&VMI93-Y0F"R6\D>Y"<!AN49'N*TZ "BBB@ HHHH ****
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MH;T6,(NH(O)BE5<-''C&U<=!STJJ?"/AXZ>-/.CV9M!+YPA,0*B3&-V/7WH
MT;2ZLYMUO:7,,I@"JZ1R!RF1QGG(R/6O-?$<LVM^.=6T2]O].M(K:"&2Q%Z9
M%/*DM+&5=1N#<9YQMXQS7;:7X:MM-UZ]U2&&VMS/&L*QVT>P%5[OSAFZ <#
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MK6F_#R\UN*.Y>5;N&:6X;.Z.-9-@))Z# KOOB%=M9Z/ID;.T>G7&IP6^H.O
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M=+T[4K2VENX;"_BN;JUB7<TD:YZ#_9)#?A[5JZ!H+:.DDMWJ$^I:A,%6:\G
M5F5<[5"C@ ;C^9K:H \OUR=-?T#4=4T#0+DQFYM+BZ9H#'+>^7)EE"$9;:H'
M/?.!G%3ZTT>K^*AK.FLYM(-&N(+J80L!(SX$</(R6R<XZCOU%>DT4 >56%KL
M@^&J/8S!K16^T VK?N282OS<?+\^.O?FJ>JKL\"_$8&":)9=0:>/S(60.C>6
M RY !Y4]/ZU[#63XET-?$F@76D27#017("R.B@L!G/&>.PH \]URRE\7:Q'>
M>%TD40Z)<V\DXA,09G3$<66QSU/^SQ2>%8++4IM,/]B:['J^GPRQ2"^FF,5H
M#$5(3>=IW94!1V.>U>JPH\<*([!V50"P&,^^*DH \9MA<)\$;327T_45OK:Y
MB62$V4N[(N?,.!MYPHR2..0,YXK?O8[J?QAXKM+>VO%?6-)BAL[D0.(@PCD&
M6?&%P6'O7H]% 'F<*RZSX5\,:.-+N[75;"ZM?-62V=%MO)(WN'QMP5! P3G<
M/PE\*QEI_'CS:;=2Q7%W)+'$\#QFX0H1A2P&<X(X]?>O1Z* //O!D.I6GB0V
M\-Q?7NABR)234K9HY[1]PQ#O907& >.@P/;/H-%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<
MI\2+J>S\!ZC- )=OR+/Y/W_)+J),>GR%N>U '4+-&X)616"]2#G%<K:^)-5U
M?47?1[:RGT^WU!K*X260K-M7 :53G& Q/RXY Z\\8\UAID/Q!\-2: ML+2_L
MKA;V"V5?*EM@@V,P'&-Q SWSCM4_PST[2X8M<N;6RLTN(]8N[<2Q1*&6,."$
MR!D+C''3I0!N:MXDFAUJ+0M'M([W57C\^199#'%;Q=-[L 2<G "@9/M4MGJ6
MMIKD>GZEIUH()87E2[MKAF&5*C8R,HP?F)SD]*YJ&<>'_B]JLNJ-'!::U:P_
M8[B1@%+Q*%:/)Z$Y)QWXJ36+R8?%31M,CU2?['=6TTEU:K*"F57Y<CL#^M '
M>"1"VT.I// /I2+-$P8K(I"_>(8<?6O%K?1[2Q^&%_XDTJ.4ZG!)=1+/#.Q9
M(#<D/MYP,1Y(]R3U.:ZJ2PTJ+Q;X3G\/"!(+JWFCGB@ V36GEY#..X#;1D]V
MH [X31$*?-3#\+\PY^E*TL:'#2(#G&"PZUXE8ZAI4/@3P5!)<VB7-KXA4LC,
MH:%!<2%B?[HP5SVZ5;O-#\*W&I>/_P"TTMHGMF62W_>;3$3 #N10>N[VYZ4
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MMFL&;Q!=6WCY=(G:UCTPZ8]YYC9#JRR*O+$XQR>U<7+K&@#7M1MO%9C6RO\
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M1]X8'C=SCC)(J*4:#INGZ>]E?2/9SZV]Q;ZCJ1 MDD,19GV*$W+G@#@;N^*
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M+"^6>:TB8AY8]K*=N.<C=FN7UJR^T>';JYTWPGJ%E]JNK7$36[O<R^7(&9G
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ML\]\L.8(I,X(+=< \$@$ \$U%?>.](LM2N].\G4)[JUB\Z2."T=LIR<@\ C
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MC37KM[6)[#4Y8YEG\[#1[8]NW9@Y.?<#'Y5UE !1110 4444 %%%% !1110
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MO3BU$43L\YYX1 -Q/![4 :8M+9;CSUMX1-G/F!!N_/K2M:V[N[O!$S.NUF*
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M"-0!EF9R#@#C@ DYK 3XF++80SPZ2\\AU--.F6&Y5D5F("LCD .".1T]\=:
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MVEV:6EI'LB4DX+%B23DDD\DDDDDT 9/CE'E\#ZS!%')++-:211QQH69G8;5
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M9Z1I+6]PJ%V<X7+,H"\XQTZF@!(?'MU,FC7*Z3$UIK4S169%R0ZXS@N"N!D
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MBSC<<DDDDDGN223^-8^K^#HM5UF744U*[LS<VAL[J.#;B:/)(&6!VGD\CUH
MY:/Q;XDU2]\%16MW9VBZ[:3/-_HV_8\<>XL,MS[#MCG-5YO%7BJ3P5JFJ6UY
M&USH>IS6EWLME_TB%"N7 .=K -GTP#72Z;\/K?3I_#TW]JWLKZ&DB6X98PK!
MQA@1MSTXZU#]GM? -M<V\=EK6MC6+R6X>."V20+(P&[=C:%4\=?0T ;6F:I+
MK&LF6SN,Z5#:QL?E'[V60;QSVPA4X_VQZ4WQAK<VA:(L]ML%Q<7,5K&\@RL;
M2,%W$=P!DXJ3PEH$/AKPY;:=#$D;*"\H0DC>W)P3R0.@SV JQX@T"P\3:--I
M>I1E[>7!RIPRL.0P/8B@#F]6U37?"&GZS>7VH0ZC:I C6+3(JS"0L$(=4504
M#,ISUP<9I;S4=;T#Q)HUA-JAU&WUCS8=TENBFWE5=RLH0#*=<AB2,=35ZR\"
MZ?%8W=KJ5Y?:Q]IA^SM)J$V]EBX.U<8QR <CG(!SP*GL?"B6KV\D^J7M[+9Q
M-%9/<",FWR-I884;FQ@9;/3W.0#SRV\7>+G\+Z+KS:S"S76JG3WMFLDV%69E
M#$C#97'8C/&>Y.[>ZUX@TW3/&T7]L>?<:0L4UM<26T88!HPY4A0 ?0$@]>]7
MU^&=FF@V6CIK&HK;V=[]NB.(MWF9R,_)R 23^/TJ+Q3X8%EI'BW4TOM1N9M6
MM#&;58A(N\+MCVJB[N/NY]#D],T 9S^(O$GAVZ\/ZAJVJIJ-CJL+&6UCM5C\
MEA$'!5AR>^<_@.PGT/6?%NKV>B:N)"EG>L/M8D\A8D1_E4P]7W XP&SD]NU:
M_A?PQ&;#2+_4;V]OY+:T"00WB*HMRRX;Y0JG./ERV3CZT_2?A[I.CZE]I@N;
M][1)?.M].DN";:W?.=RIZY)(SG% ')Z=<ZKI/P]\6ZG:ZQ<F[MM0NS&\L<;C
M*R8W?=Y)'X>@%:>ZYB^)JW<NIWK(GA_[6T:K&1CS5W(!LZ':.GS>];@\!Z?]
MBUBQ:]U V>JS--+!YP"H6;<P7CC)Z]ZM/X2M'UNPU7[7>B>TMA:E5E"B>,,&
M ? &>1GC /0Y'% '(7/B;6;?P+8^.$U"24RRQM/IX1#"8FDV[$^7=N&1\Q;J
M#]*NZ1=>(]:\=Z[:_P!OM!I^DWL)6W%K&3*C*24+8! [9Y-;5MX$TRU"6R7%
MV=*CE$T>F-(# D@;<#TW$;N=I8C/:M'3/#EII6L:EJ=O+.9]18/<*[ J2. 0
M,<8'% $VO:F=&\/:CJ@C$AM+:28(3C<54G'Z5Q]QJ&L:38>'M?&L37L6HS6\
M=Y:.J>6PF P8B%!7:3TR<CJ:[Z:&*X@D@FC62*12CHPR&4C!!'I6'8^$-.L3
M9HDEU);6+F2TMI9MT<+8(! ZG ) R3C/% '->"M-DC\?>+I#J5])Y%U$"KNI
M$N8OX_E[=L8KT2L72_#-KI.KWVIP75V\]\P:X61P5<@8!P ,8''%;5 !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%<O\1=8NM"\!:K?V1=;E(PB.HR4+,%W>V,YS0!JS^(M#M;W[
M%<:SI\5UD#R)+E%?)Z#:3FM%'61%=&#*PR&!R"/6N<MK/3M!\"@+IWVRVBM!
M)-$%1FGXRS-N(#$\DY/-<W:>*[^VT?PM!X=T?_0-0+6UO_:,H#J%0E"=A("X
M'UPIXZ4 >DT5QEEKWB34=0NM)C@TR#4-.MDDO'8221--)N*1I@C V@$DD_>Z
M'%5M+\=W6JW7AK9;0PIJ4UQ:WEO(I,EO-$C%@&SCJ!P5S@T =Y17G5[XXUVR
MT#6[X6>GSRZ7J_V!N70.A,8#!<GYLR?W@![UJZ/XDUI?&+^'?$%I8Q2RVAO+
M66RD=E*AMI1MPSN[YX'% '84444 %%%% !1110 4444 %%%% !1110!3@TK3
M[6^GOK>QMXKNX_UTZ1 /)]3U-7*** "BBB@ HHHH **** "BBB@ HHHH ***
M* *-OHNE6EVUW;:99PW+?>FC@57/U8#-7J** "BBB@ HHHH **** "BBB@ I
M" P((!!X(/>EHH AM[2VM PMK>*$,<D1H%R?PJ:BB@ HHHH **** "BBB@ H
MHHH **** (H[6WA<O%!%&Q&"50 GG/\ ,D_C4M%% !1110 4444 %(0&&" 1
MZ&EHH 0*JC"@ >@%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !574M.M=6TVXT^]B\VVN$,<B9(R#[CI5JB@#C8_#7B*QT&30[
M/6;*>Q,1@ADO+1C+%&05VDJX#8&,' ]\TP^"KZSM_#%KIE]:I;Z(V\B: YF8
MJ5)^4C&0S'ZGO7:T4 <O<^&KZW\4W.OZ+?00S7L*PW<%S"71R@PC@A@00.,=
M"/2J4G@6XMK/1FTS4U34=-NI;HSW,&])WESYI9 1C.XXP>.GO7:T4 >3^+=!
MNO#G@3Q%]JU>&YEU/4X;J,M$(RKF6//?GA0<#H!776GAR_N-9EU^_P!0M7U$
MV7V2T:UA(BA4_,7PS$L2WOC''.<UTLUO!<*%GACE Y =0V/SJ155%"J % P
M!P!0!4TJ"]MM+MH=1NUO+Q$ EG6,(';UVCI5RBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "J&J:WI>B1)+JFH6UFCG:AGD"[C[9ZU?K)U.STF%Y
MM8U&&-_+M_*+2C< F<D 'NQ('OP* -*&>*Y@2>"5)89%#))&P96!Z$$=16?J
M'B30])D:+4=7L;655#&.:X56P>AVDYK/\"Z4^C^%XK=X6MQ)-+/';-U@1W+)
M&?0A2,CUS57Q=8:=I>@ZGJ$&F6L^IW3!(FFC$C/.Y6-/O9X&1P. !0!U%I=V
M]]:175K,DT$JAXY$.58'H0:BU#4[/2K5[F^G6"!/O2-T%)I.GQZ3I%GI\/\
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MHVFI1VUEJ+P V4LJPV<2RW#R @*S!U*K$!G))7GC- '9YHS7EVF>(_$FM?\
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M(?J:H:5X8U7265(M#U>2SB):ULY-5A,=N3GE1NY(R<9Z5ZT0#U HVK_='Y4
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MG.5B4AB79<@D84CJ.2.:L:5?7L5HJZ]/IT=T\K"%K:0A)DS\K ,<@G/3)^M
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M*FDR01WK%0DDZED09&XD#K@9P/7% #DTG3H[U+U+"U6ZCC\I)Q"H=4_NAL9
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M:\@TNV35;<6R^6/(20XPK)TVL5"D5UO@&Y8_VQ8W&F6=E>V]RIN#8$&WE+(
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M>MQO?QO"<^6A*N=A'S@9[9XSZ&K/A#3XD\>>(-1T=$309XH4'E*%BDG4?,4
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MYN;7:98987B<!N0V' )!]1Q5C4=6L]+$/VJ1@\[^7#'&C.\C8)PJJ"3P"3Z
M5S.G>8_Q3U&[%G>);3:;#$D[VLB(SJS,1N( S@CK]*E\4V]]!XJ\.:Y!:RW5
MG9&>*ZCA4NZ"10 X4<G!'. 3@T 3:KXSLHO"FKZIIS2S3V,<BM$;:3?%*$)
MD3;N4=,D@#'>HO",5U>0VFL'5-2>.>S07%K=QL%>8@,9$W ;1R1A0%_*LG4-
M-NI[7QOJ<%A<JFL6:VEI (F\V9Q$R>8R8R@)<+\V.%R<5UWAL.OAK38I8989
M8;:.*2.5"K*RJ 1_]<<4 <?J?C2;5-#\81V<=]8RZ6D@@F$3*V5CW98XPO/0
M<'%;'@_Q;8ZGI6D6,MS</J3Z=',QF@D7SB$7>RLP ?D\X)KG;G3-6BM_']B-
M)NY#JC2/:RHH*.&B"@#G.<^W%2V>E:DFO_#V9M/N1%INFO#>,8SB)S"$ /\
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M(&33[^XGDMQ=-;1*@DBB/0ON8 '@\ D\'CBLGQ)X3OK[QG87ED,:??6YM-8
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M#&TB?<<J"5^A[4\J&!# $'J#7"ZIXH6T\::)/'J<LFD7NGS3K!$@<3,-NS8
MN]B=QX'I76:/K-CKVG)?Z?*9(&9E^92K*P.""#R"#V- %Q(8HSE(T4G^ZH%
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MKVFM:3/8S6E[#IIN61V5@4=#CE3U!X(_G7$Q?\B7\,9,G>VJVZDYZC<QP?Q
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M8UF<RAA$[X8&,$#( #  X[9P,UWU% 'F\GP]UB]TWQ=;WVI6/F:X\<D;0Q.
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MA>+;P:5=B\_>0&1YY.<EFW#&=Q)X_P *KVW@"YL+S4(]/\0W-MHVH3&6?3Q
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MW(XXX],T 1Z;K7B2YU2UMI;5&M[JW<M<BQDB6UE RH.]_P!XIZ<;3D=LU!X
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MQ!RC2@$;AMV@,Q88X]L5O7WP[TO4=$GL;JXNFNI[L7KWZL%F\\<!A@8  X
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M?$7B[5M1UR'PY:R9TZY%M%B6W$990"QD$@WG.2/E(''KF@#TND+JI4%@"QP
M3UKSB75/$NH:YK,%OKJ6=O:Z9#>QK#;Q2[7=6.T.005XZ\YXQBJ=C?W?B#Q!
MX&OWU>Z2>\T^>66.%4"*RHH)4,I&22P.<^V* /5*QYKZPTS7[.P33Y1<ZB)&
M\^"W&P;>3YC#IG/%:]<MK6HZE:>//#EC!>[+&_CN5F@\I3EHX]RMN(SU(X!'
M2@#JJSX]7BDUZ;2!;W0EBMUG,QC_ '1!) 4-_>XZ5Y6WBGQ1#X9O=>DUQI3I
MNMFR%O\ 9HU6:,.%.\@9Z-VQT[GFNFUW5-7M?%>NV4>I2+;1>'WO[=%C0>3*
M&*YSC+?<SSGJ: .^HKS&U\2:W-)\/Y6U*3.L12+>KY<>UR$#!@-O!R>V*Q3X
MC\3VOAO5/$$GB">8Z9KC6@MC!$J31AT4AB%XX)Z8QUH ]HIGG1><(?,3S2NX
M)GYMO3./2N)CNM7\37OB#^SM8;3Y],O!:VT.%:/Y0K%Y!C+!LL,9  'KFLW2
MXIK[XPWTAU>ZDC72X9HS#(IC96;.T?+]SG([GN30!W>CZLNLV;W"V=[:!)6B
M\N\A\MSM_B ST/8UH5Y?9^*-7;0-,M9K^5KK4=<ET]KXHH:.-78<8 4,0 !Q
MZ^E6]5O]<T;5=?TI-5N)(/[&DU*RN&5&DMWC."A)7Y@?<=,XYYH ]%HKSG1[
M_6;?6O!;7.LW%W'K5C+)<PRH@0,L*NI7 R#SSR<\^M>C4 %%<67NO$WB7Q#I
MHU:ZL!I?DQVZ6K["&>/?YC_WAD@!3Q\A]:YVSUOQ#X@/@Y6U>:Q?5$O8+L01
MIM+1!AYBY&03C/7 XP!0!ZM1573K6:RTRUM9[I[J:&)4>X<8:4@8+'W/6N>\
M6W4Z7^D6L%W<_OGD+V-F=L]T O&U\C8JD@DDCL,YXH ZNBO%X_$GB&[\%:!.
M=7NK>ZF\2+I\DB["QC+-PQQ\Q&/H>^:W]/&M7>L^-O#EIK=Z'L5MI+"XF</(
MDDD18@DCE20..W:@#TFBO/O">LW'B:#0H#>7,=UIJ.VKQ^:=YF7]V$D_WFW/
MCIA<=*]!H *C>>*.6*)W >4D(IZM@9./PKCK:2X\4>(/$=LVHWEE_9LBVMM%
M;RF,H2@;SFQ][)Z Y&!TYKF-#N)_%.L^#=3U*2[2YN+.^2;R;F2)7,;(H90I
M&W/4XQG\* /0/#_B:#Q#/JD,5I<6TFG7)MI5GVY+ <XVDC'XUN5XM=75_9:;
MX]U2TU*[MY-.U<RPQPL%5F+(#OXRP(XP>/:MV?4M;\3^(=<TRRN8[62VM8#:
M(;^2W*&2/>9<(A\S!..3@8Z<T >F45Y?%'KFN>*[;2I/$]U#&^@I<S2Z>X"O
M,)2FY,J, XST&?H:]0H **\^\<7MP^K7%G:75Y(\&ER7!MK:1H%MV!)$\DJD
M$],!,')![5F_VQJL&A>"_%UUJ%PUH?+BU9/-*1%9!M65@" -K$9]<C- 'J=4
M-:O[C3-)GO+73YM0FCV[;:$X=\L!QGTSG\*XB^N;EM*TZ1]0OOM&KZ@T\.G1
M2L);B'DI$C%QY2A=K,<]R/05A:EJNK1_"7Q1/_:%W#=:=JTEO \=TS/'&)47
M9YG#, '89//2@#TK_A(%'BZ/P^;217>Q:\$Y8;<!PNW'7//M6PQ(4D L0. .
M]<->3+!\3K:>680JGAR9VE;D(!*A+'Z=:Y[PSJ.I-XD\)2&\O9;;44NS)-<7
M+9O J%@YAR5C /W<'..PZ4 >A^'-=/B#3IKLVC6HCN9;<(SAB=C;2>.G(/'M
M4-MXF%QXTNO#C6;QO;V@NO/+@AU+;< #I7G3VDUG\/M9U^RU;4+>_L]2N7MU
MCN"(@WVDC:8_NMNS_$#R?PJUJ6J7UAXYU_5((=M]%X7298R-VU]P.,=\'^5
M'K-%>:>%XKQM5T75XM=LI+>]1DFB@GFF:[/EDY8.Q"LI3D@#&"/:O2Z "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *S/$6BQ>(O#U]I$[F-+J(IO SL/4-CO@@&M.B@#BM+T+QA#:I
M#JFKV%TEK"R6Z0H\7G,5*!I6YX ). .3@]J+#PKJME\,3X7_ .)<]T;>2VW[
MG$15L_,>,[N3QZUVM% '%MX6U<6_AV[@N;2#5=&C,!&6>&XB*A64G *D[0>A
MQ[U2UWP+JNK6FJ3)<62ZCJ=S;2RABXBBC@^XBG&6.<Y) Z].*]!J@VL6BZZF
MC%G^V/;FY V';L#!3\W3.3TH Q=2\/:CJ'C'0-=WVJ)ID<JO%O8EVE7:V#MZ
M#@CU]JY^3X=ZI<>$M8T62]LT?4=3.H>:H9@F65BF,#/*@9]^E>D*RL,J01DC
M(/<=:S=:UZPT"VBN+]Y$CEE6%"D3/\S' !P..>YQ0!R>M>"M=U/5-=N8=3L4
MCU6P2UQ/"TKVV%(9(SD *Q))/7GIQ5S3?">JVOB>#6[F\LY)(]'&F&..-E!P
MVX-R3WP/U]JZR[NXK&SFNYRPBB4NY1"YP/0 $G\*BTG4[;6M*MM2LRQMKE!)
M&67!(/J* ."M?AOJFFZ!H4.G:Q!#J^B/,;>X,1,<R2L69'7J!SC@G_"_J7@K
M6M1L[2_;7E3Q):7+7$-TL6(4#*%:(+G[F .N2><]:[JB@#B-1@\5Z7H4MXNJ
MQ7&MSSQ_NX+)GAV*IQ$BY.T$Y)D)'7M@5V]%% '-^*/#5SK=]HU]9WD5M<Z9
M<F9?.B,B,"N"" 0?3O65;^"M;T_4M1_L_P 1B#3-3F:XN8?LV9$D;[YB;=\N
M??./J*[FB@#BG\&Z@;SQ7,EY;*FN6B6R*58F$(AC!)S\WRL3]<4EOX.U.&[\
M'S-?6A'A^!X& B;]\K((R1SP=JC\<]JZ237+./7X=%8RB\FA:9!Y9VE5QGYN
MAZCI6C0!YGHEEJ.N2^--/L]4LH["ZU26*8>7OE1615<J0<<C@9'!4]:WK3P=
M<:!JTM[X=NX8HY[6*WFM[N-G7,2!$<%2.<  CO[5LWTFG>&M+N]233PJ1)ND
M2S@&]QGL!C/6M.*030I* P#J& 88(SZCM0!QZ>")K*_T&>PO(532Y)IY/.B+
M-<2S B0DAAMX)(Z\X[5%K?@C4]2O-?>UU>"&'6+=8G\VV\R2(!=NQ6W<(>I&
M.I./6NXK'\0>)=.\-:1-J=\TCP0NL;B!-[*QQ@'TZCKCJ/6@#*TKPE?V'BR+
M7KG5(+EQIPT^2-+4Q_*&W!@=YYR,?2LQ9-$\;^-=.U#29I9DTL2"]F1&C1R&
M4QQ-N WX==XQD#9SU%>@4BJJC@ 9.>!0 M<[XL\-3>)8]+6&_2T.GW\=\I:
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MP-%]C.)1P=V?,^7D*<<]/>M[2-3BUC2X-0AAGA28$B.XCV2*02"&7L<@U<H
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M6TEQ]JC#2Y:";)/F1MU#9.>I_*K$?A2Q%M?1W$]W=RWT/D7%Q/+F1H^1L!
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M8;:^U*X^T311'<(QM"JI;N0!DGU)H YWQZDTOC+P7#!<R6SRSW4?G18WJ&B
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MS2_^O2+_ - %</<Z!#K_ (^\71WUU=6D,5I9E&MK@Q9^23#MCJ5(. >/8\4
M>DYHKQ32M4U7Q%<>&])U?4842XTIY1]K\Q1<.)G56^5E+-Y:*PR>Y/6O3/!T
M;6_AJ"U?5VU9K=WA-ZR%?,VL1W)SC[N<G.* -_-&:\\OIK37?'>N:#K-W):^
M19Q_V:%F\OAD)DF7G!=6.,GH%X[TEK+::SXIT_0+V]N+ZQBT9)[=V<J+QP^Q
MI6Q@DX4$=OF)H ]$S1FO$=1FU#^RH;)[R]^S6GBY+"VG%RX9X"22A.?FVD
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M2 H!R6)Z D \"C5;Z.U\&^,]#U>*0Z[/>RW"1F!G,J%E\N12 1M & >V,<4
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M G("@=!R3FM2&_N?#UG?S>)-1B:SBE!@O&0(60J.&5?X@P;D#G/2N:\(23>
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M[!<KW8S([[A[D_,/QH ]&\3^+-*\(V$5YJLDBQ2R>6HC3<2<$]/3C^585_\
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MYIUU<6LKB/S8&3Y7()"D$@]%)STJO;?$.R_MNSTC5-,O]*N[T VOVD(R39Z
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4
M]4T_^U--FLOM=S:B4;3+;,%D [X)!QGITK(O_!UKJ7A*/PW<W]\;-%5"X,8D
M=%^ZI.S&!QR #P.>N>CHH X2Z^%FF7N@6^AW.LZS+IMNX>*!I8OD(! Y\O.
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M HHHH **** "BBB@ HHHH **,T4 %%%% !1110 4444 %%%% !1110 4444
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M33>:Q0JP_AVD#K@ >@!J4/I<_ASQE!X@V+J\5W<L#.!YP!_U!BSSCA=N.XH
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M)=-)=%-\NS>T<>%.2 5Y; R<>XV-#UBVU_1+/5;,MY%U&)%#=5]5/N#D'Z4
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M2K&FV(IE>0-ISGV''7%>I44 <Q\0+2]N_"4HT^T>[N(KBWG6!#\SA)58@>^
M:P9WU.[UWQ#?_P!@:E%;W>BK!"71=Q<&3C:&)R=XX[=\5Z+52VU2PO;RZM+6
M[AFN+0@7$<;AC$3G ;'0\'CVH \WLM/U!(?ATCZ=>J=.#K=YMV_<DQ[!GCU_
M3GI61=Z/XBM_ANW@[^P;^XO;:^#+<Q[3%-&9C)O#$]><$'IU/?'M5% 'E5UI
MFJ6'BK67N?!\NM6FKLDL+^8@\H[ ICDY(VC&,]..,YK;T#2=0L/'TEQ-8&*T
M&CP6:RQ*!%YB<D*,Y"^F17=52?5K"/5X])>ZB6_DB,R6Y/S,@.-V/3@_E0!S
MOQ-TJ^UGP->6FG6[7%SYD4@B4C<P5P3C/4X!XJC'!JEQ\3[37Y='NX++^R&M
MF+%&*/YI8 @-W7'3."<5WM% 'D<V@ZW)\.+/2QH]U]MAUDW+1'9_J_-:3=G=
MCHP&,YS6AXDT?5+CQ)=W^A6&I:?K$DL*QW4; VMW%M3=YZDD#;EQTYP,9KT6
M\O;73[5[J\N(K>WC&7EE<*J_4FJ.F>)M$UB9H=/U.VN)5.#&K_-]0#R1P>?:
M@!^NW=[8Z-<S:=927E[L(AA3'+XX)R0,9ZUQ6O\ @.%_AZMKIR:F^H6Z)/:J
MUTY(N <EMA?8"26SZ;CBO1Z* /,_$%WK5X_A.[31[U-=MQ-++!#+'O10JJ^5
M)VLC$KSD8X]:J-!>S>%I]+AT'56U2+4X-0NHKDQ%I]TN]G!!"8/EL,#IC\:]
M UCPUI^M3PW,_GPW<(VQW5K,T,JJ3DKN4C(R.AJSIND6>E1NMLCEY"#+-+(T
MDDA'=G8DG^G:@#A?'/AZ^O/$NEZ_#X<BUZV6T:VGT^>15,9+;E<9XSDD'KT_
M$4-5\+:NO]C:U#X4TJX6W:5)M!58]L<3[<8)&TN"N2?4\<5ZO3)IH[>"2>9U
MCBC4N[L<!5 R2: /,=5T;59[;P_-:>%8[!(-<COGLK,1 QPHH!9R"%+GK@=L
M#M5R[L=5;4?'[KH]XR:G:1PV;#9B5EB,9Q\W'+9Y[ _2N[TW4K/5["*^T^X2
MXM9<[)4Z-@D']015J@#R*Y\+ZW%9>$]5;P]'K#V&G?8KS3+MDRI&,.N[*DY'
MOQC\-B;3-3A'AV2+PXMLB:I]NEM;!8@MK'Y13:Q&W<V6R2!ZCL,]D?$.DKJM
MUIAOHQ>6L'VB>(Y_=Q\?,3T'4=ZETC6=/UVQ%[IERMQ;%V02*" 2IP>H% 'G
M'B#P]K>N:1XUMK?2IXI+V[@N+7SF0"98Q&"!AC@G82,XZBO1HY[ZXT5YWL!#
M>M$Y6UDD5_FYVJQ''/&><#/7O5^B@#RNQ\.:S;IJD6EZ/?:=97.G313Z;/<Q
M/";AP OV?#G:,EB22!C@#TFM/#>NP_\ "O@VER?\2=76]/G1?N]RA 1\_P W
M3/';WXKTTD#J:J:IJMCHFG2ZAJ-P(+6(9>0@G'X $T >9:;HWBA=0T'4[[P[
M))J-C>2F[G>^0F0/&XS&,[4C&0<#'/8\FM6[T?69;?QW%%HDP_M<;;3$T(#_
M +H1$GY^.06Y[>_%>@Q2)-$DL9W(ZAE/J#TI] %#1!<KH5@MY;FWN5@198BX
M;8P !&0<$9[UP2>'=;N_"#^#+G2GA1KIW?4?-C:+RC.9<J,[M^.,$#U)KTRB
M@#R__A%M;TCQ#K!M/#6D:M%J%U)=V^I7/EJ]JTA^96!!9E'7 ]??CL?$]KK3
M>$+JVT&7&J>4J1.-J$\C=@]%)&<'M6_10!Y9:^'M>L=8U2^M/"ENL%]I@MVM
M[B^60NX+;A(<_,S COC'5L\5M^"_#]_HVM7SQ6UYIVB20H(M/NKI9MDN>2FU
MFVKCC&><].F.POKR#3K"XO;EBMO;Q--(P!.%4$DX'7@4W3=0MM5TVWU"S<R6
MUQ&)(V*D94C(X/- '&^.-!N]8U#?;Z#-//#:@V6IV=VD$T$V7RI+,"4^X>AZ
MM6:WA[Q7I.LM?)I.F>(3?VUNMVURZQM#-'&$9@6'*G&>!GZ=_3JBN)X[:WDG
ME+".-2S%5+$ >PY- '##P[KFF^-])UBWM[>\C&F?8+DJZPK$QEWLX7'W<$@
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M=;@P#,=G0 X R>@Z"O3T@2,X50J]<#@?E3;VZ2QL+B[D21T@B:5EC7<Q"C)
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MXCGU+28(VCM;1H%C*J5*?.XY;"L0!T[]A7:9J"\O+>PLY;NZE$4$*EW<]@*
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M6FL:0$-K>Q1Y4$+M.4).05'(S_A3;KPMKNH>&-1LKW7()=2U&,033_9L11Q
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MF8C<&\QVW<G=U  XH AT;QQ<^(]-T)=/AMX=1U."6>3S0SQP)&VQC@$%B6P
M,^O/'+;SQAKFGZ;IEM?:7';:W?W$T*JL;SQJL8+&0)'EV! &![Y) %4[/X:W
MNG:)H<5AK:6VKZ.THAO%M]RR1R,69&0GG[WK5_4O VH7UC83KXAFCU^TN6NA
MJ'D@JSLH1E\O. NU5&/;G.30!K>$];U+6+2Y&JZ;+:7%O,8PYMY(DN$[.BN-
MP^ASBN7O+S6M/\8>,KK0H=/=H+6UFF^U%N=J2': N.3SR2,>^:[+0M*N].BF
MEU'4&O[^X8-+-L$:  8540?=4#ZDDDU@GP=JB:AXKNX-4M$.NHB*&MF/DA1L
M'\?/R%O3G!Z<4 13^.KFYDL;;3K8I//ID>H2N;2:[6/S!\D>V+D'(.2<#'KF
MJ\OC#Q9.- BM-"M;:\U6&?=!?LZ-#)'U)& =G0CJ2#VZTG_"O]9MQI5[IOB-
M++5[*R%A).EH&CGA7[F48GYAQS_*M5_"FHIK>B7L&J0M'IQE:3[1 6DG:8YE
M.0P"Y[ # ]QQ0!C7'CK7S/J-G:6,$U]I<4:SQ0V5Q<+<3E0SHCIQ&O4 MG)]
MJU8]=U*Y\76=FNFV<#W6C->1&X1O.B?*#RW/8 L<@>G:FWW@G4!XFNM7T/Q%
M-I:ZAM^W0+ L@?:,!DW?=;'?!ZU9;PK>V_B2SU6PU&!(K33FL(H)K=G(7 (8
ML'&3N49X''OS0!S6D_$/Q!<Z/X=UJ]M-,%AJNHC3VBA$GFJS,ZAP2V !M&1S
M^&<#U"O/;;X;75OX:T;11K47EZ3J(OX9/L9)D8,6 8>9TRS9Q[=*["QL]1@U
M74+BZU/[3:3F/[-;>2%^SX&&^8<MD\\]* .1NYVU;XT6^E7H)LM.TPWMO$3\
MKS%@N\CO@$@>F#6GXCU*RM?%GAVTN=,GGO9II&L9XG4!2$PX;)!QM;..^!W%
M7==\+0ZQJ%GJMO<R6.K661;W<:AOE/5'4\,IR>.#Z$53_P"$6U._\1Z9J^LZ
MK;S-I;2FVBM+0Q [U"DN6=L\#H,4 8UGXR\1%-3U74(=,AT?1[NYM[ORB_FR
M^6OR[,G'WMHYZYZ#'-RX\3:YH\VA7VI_89M,U>:*W9((F62VDD&4Y+'>O8G
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MXJQ()Y.3D$')/-9TNFCPSHP\)Z7I6K:G;7D,L:32,K0P;LC:[<87))/!/U-
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M+.U^P_8T0&WP4VAB>,\C.<UY'#<-X?\  >J7]@#!(^NRVLTZL<QP&?#$<\'
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M** "BBC- !12;AZBEH **,YHH **,T9H **"<49% !1110 44F12T %%&:*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY"(P'# D8X6) , # 'IGK5#PW>P*OA675;'7(;+3"WV.5].VPJ)1M0R3!OF
M!&&"J#P3Q0!Z/>^-]!T^247-U(L44QMY)U@=HDF SY98 C=[?AUJ*Z\?^'+2
MX>VDO)?M,9CW0BVEW@28VMC;G'(Y[9 /)%>?>8WG:OITNF:]-HKZT]X5L[ 3
MABK@D+,'P%+KD@*2.F<YKJ/#[27?Q1U;58[.[%A>:= (+E[=UC<C!(#$8[T
M= _C'14NHX6N7"27/V1+CRF\IIO[@?&"<\>F>,YIFH>-M$TIIS=S3K#;S"WF
MN$MI'CCE(!V%E!YY'XD"N$\.Z/?V*IX;U/P=]LNK>Y+Q:G)\UL4+[O,))^\-
MQ^4<].G-4[CS&U#7M)DT;79]"N=6:ZD^Q60G#.K@L%E#C ++R,$C&,YH ](O
MO&NBZ?+/'-)<%K>!;BY"V[DP1MT+C&5]<$9]J@D\7)_PE]CHT%K/+#<6;71G
M6(D$;D"E?;YCDX]/>N-\2MJ7B*'798-$U*>UO-/C;37LE\I9PR9+3G(9BI;
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MZ8]":O:QK]IHSVD,J2S7=Y(8[:VA ,DI R<;B!@#DDD4 :M%<[!XTTFYT/\
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MD=S#-:I=1R PO&)%?L5(SG\J /,;CP1XG71O$NG6D&C)'K$R2J%E=5BX7<
MO0;2!ZYSQTKIM;TO7=3UOPS?16MDL>GS-/=(URV064H0GR<X!)R<9]JWM(UG
M3]=M&NM,N5N(%D:(N%(&Y>HY J_0!YQ=^%/$=UH7BZR%OIZR:U=>;"?M3$(I
M !W?)U 0?G[<Z7B+PWJ.OV$=O=:9IEPK6J1@23LCVDPW;G20)EARG''W?>MR
MT\5:/>ZO_9<-TQN6#&/=$RI-MX;RW(VOCOM)JUK.LV.@:5-J6I2F*TAV[W"%
ML98*. ,]2* ,RU\%Z,KV5W?V4%]JMND0:_EC'F.\8 #D^ORBNCID4B31)+&<
MHZAE/J#3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *;(N^-DW,NX$94X(^E.I&.U2QR0!G@9- '"
M>$-=73O"]U<ZI>7=S(=5N+>$.S32R$2%51!R3P.@X&">.36H_C_1(--N;R[%
MY;?9)T@N89;9O,A9\%=P&< YX;.#ZYKAYO#FLWG@T)_8#SS6>NR7YL+HJOVF
M%R_"D'KA\\^G?O8U/0[R3PCJ(TGPD^FBYGM?+L8PIF<QR;V=R#@# P!G/7UH
M [K2_%^F:KJ%Y8HMS;7%K&)V6[@,)>(_\M%W=5]^*I1_$+1GGM(6AU%&OD,E
MB?L;M]K4=2FT$].?FQP0>AK'N[:X?XAZEK5UIUQ%I3>'FMWEF(1=V[>RDY.W
MY<@GID&N=\,SW%E<^%Y]>T77$AT^/[/9320IY4'G;4&]@<G^%1D ^U $WB/Q
MQ?ZU\-_$.HV?V_39K.]$<$D0,9">8B8+ _>^8Y ->A:-XLT[6M2GTZ!+N&[A
MC$VRYMVC,D1X$BYZJ3^/M7FU[X>U_P#X5UXF\.KHMT]U/J;3P2*4*2J9E8%?
MFS]U2>0.W<UUUM9W[_%T:N=.N4L'T06OG.H $GF"3!Y]./K0!O:OXITW1=1M
M=/NA<M=7:,\$<5N[^9MZJI P6]NW4X%16GC#2[W0QJD?VA5,QMA;/$1/YP./
M*V?WN.GIST!K-\0V=[/\1/"5Y!93RVEE]J-Q.@!5/-CV+WSU'/H*XR7PSKEU
MIVHW*Z(97@\2RZJMA>*NV[@D&-HR2-V,\'IGUH ] C\;Z0;/4Y[@7%K)ID@C
MNK::+]ZC-]P *2&W=L$YI8/&=A)JTNEW%I?V=U#%YTWGP?)$F"0S.I*@$ \D
M]1CK7'ZK8R-X(U29?"5OHTMVT$5M96K)'</,LGRON0 $@D%5_P!D]C426][K
M$FI:=J]EK-GJ6NVALX;VYCC6(>6K.$Q&3C/SDD]>E ':6_C33YKBUBDM;^V6
M]4M9R7$(1;DCG:O.0Q'(# $]JYN'QY;Z[X<\12ZKI^K65A;S20&:VC)9%4*,
M;E)(?)8GC '?UF.G:MXBL?#6EWVE7%A)I5U#<W<[,IC)A4@+&0Q+;B0?89SS
MP<R/0M?M/"GB_P /C19YI+ZZN)K>>.6,))YI38!E@>FXDG&,=\T =<?%FG:;
MIUFD<=_>'^S1?$ *TBVX _>.689/L,DG/%5)?&[3^(M!L]-T^YN;+4[=[E9T
MV#S%"@@ ,PQC(SG!Z 9KG=1TCQ'>V=MIDVBW<UF=$6VBCCN4B1+D+AC,0WS
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M6$Z0E]_E!,8SGC?N[]* -2]\3ZE+_:,^AV%M>6NER-%=>;.4DD=5#.L8"D9
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MBB@ HHHH **** "BBB@ HHHH *CN#,MM*;=$><(3&KL55FQP"0#@9[X-244
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M?P[2XF%M;2SE'<1H7*1C+-@9P!W-0:5J"ZMI5M?I!/ MQ&)!%<)MD7/9AV-
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M=7_>@Y'WU;C//N>N:[&B@#F[CP78WM]JUS>W=W<IJL"V]Q;R>7Y81<[=N$#
MKDD'/4_2JUE\/M.L]1L+Y]1U6[FL(WB@^TW(8"-OX#A1D 9'T/.<#'6T4 <C
MHOPYT?0;\7%I<:BT*.9(+.:Y+V\#G/S*F.O/!.<5K^'?#EIX9L9+.QEN'@>1
MI=LS!L,QR<$ =36O10!BZ_X9M/$+V,D]S>6TUE(9(9K2;RW!(P1G!X(XJ@/
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M<:5_:\@6XU#^T6E$ W"7<&P,DC;E1P<_6M.;PG]IUC5;^:_?_B96/V&6)(@
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MCSSRJQ5=DBE,,A4 KPV/PKH_^$0TM]*N["Y-U<K>8%U-+</YLP' #."#@#C
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ME@) SMAE(/( QR.F!6AX<GTJ\T[0=?AUF8ZU-A;N**4N]W,4.Z-T[!22>F%
MXP*[33?"N@Z/J$U_IVDVMM=3??ECC /N!_=![@8S3[3PUH=CJDFIVNE6D-])
MNWSI$ QSUY]Z /,R3<_#2W\8VUU,/$XE4FX\Q@TDGG;3 5!QM.=H7&.E6-7T
MN&[U+XD/-/>'[%:Q3VZ_:I,1OY#2 @9[-R!T&>,5Z,OAW1EO#=KIEJ)S+YVX
M1C_6?W\=-WOUIDGAG1)6OFDTV!FOL?:B5_UV#D;O6@#A]+M!9>*?!ES%<71G
MUG39SJ#O.S&<B*-@3D\$%CC&,=JY)X6C\"76KI=W@U"V\1/##<?:I"T:%PI
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MD+2;F7!( /I@;?PQ7MU4_P"R-,Q&/[.M,1G*#R%^0]>..*N4 %%%% !1110
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M1P1D=.E 'L)NH5NTM3(//=&D5.Y52 3^;#\ZEKS?1;2*_P#B#I^HS/<BXN=
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M] U&*YDM]2BVVJ"2;S5:+:AZ-AP,K[CBFV/C+P[J5Y!:6FJP237$9EB7D;U
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M">9WE<R/(.C%\[LCMSQ5G1=;AO\ 0M'O+N6W@N=1M8IEAW@;F9 Q"@G)QFM
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MU<<DH#N&?Z8K6^,4<)\#^9*L9>.\@*,P&5.\9P>W&:[I;2V2X:X2WB6=AAI
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MZT!(8DA&P2N-QV@\ G85_#BFZ5=:'JPANX]/UZ2XT^QF2\6:1T%K&86#1KG
M<D@ */KQBO7:* /'K1UGM+C3S+-KV@#2747B0%+RT1B/W+'&&. "!C/R\C'7
MI/ 5_>SZKJ%M+>+K%I%!&(]7,!B=\,V(GSPQ7).1_>YZUWM% 'F'CG7AX8^(
M-EJ*Q^8TVEO;R+/$[1;?,R-I16.[/4$ $8YK"NH+*V\/^$;W3;W4M0T'1I)X
M+Z>Q5X)XY'7A]O#* 6_(]>>?3+[PU-/KDFKV&LW=A<RP+!*J)'(C*I)7AU.#
M\QZ&M+2],73()$^T37,LTGFS3S8WR/@#)V@ <*!@#H* /,+F+3DTFQN+33]0
M%G>>(+>]#72/*\RJ5,LK+@[%[<]<9[BD\4V5UJ=UXVM]*MI9)9EL9%C1&07"
MQ$^8JM@<CCH<\8%>O44 >06YTJ]L-:U73+379)6TB>SGN=2>61E=@-D*JQ)8
M[L\C@?C5D#^SOAGX5EBTD>?YMM'<7'V%I)+3;NS+L R2K9QG(R<X/?U:B@#Q
M".&Y70_'");:K<-+?6MW$T]JXDFC$B,6^Z!G )QP?;BM;7;E9O&%OKMW!XC3
M1M0TY88GL/-BDB='8E9$0[L$'(SZUZS10!Y7I\+^$]=T&]DT6^M]"6PGM8D"
M/<26KO-O#.JY8,RA<XS@DCM6_P##CS!I^M;[.ZM1)K%S-&D\#1G8S97&1[=N
ME=K10!YS=I'9>*?&@O\ 3;B==4M[=+1%MF<7.V':RA@"!\Q Y(]>U8,5A?>#
M;_27URPU>]LVT>&S+Z9*X:"52S%"(V&X<]2:]DHH \S%J="UWPC=1Z+>6MA$
ME[&EO$KS-$9"IC5N3M9L9/. <\\9IVJ^%=0NO&>J:3!OBT#7;=;J\D0[?+E0
M[6"^[_(3ZC=Z5Z510!Y9!X>\0:C\.-7%_&TFM-"ME"@;&^*W?C'/!<A^>^15
M6XM&\9:+?-IOA[5K354L)89)M2FE;:Q S#&9'YW'/., #L2*]=HH \RT"XBO
MKBWU%?"^KPZIIMM(L\U\\T@B;81Y<09R7W-Z#I[XJG8:=?P:+\/(GTV^5["Y
M9KI?LLF81@C+<<<D?SKUFB@#E?B+97=_X*NX+*VEN9Q+!((HAEF"RHQP.YP#
M5..Z>Y^(5MJC:;J45J-(EA+2V4G#^:K < \E5)_3J<5VU% 'BUOH^HQ:=X;O
MKC0=4NK6QDO(;NSB$D,\7FRET= "I88QG!QV/MZ)X,LDM--NVAT:32H;BZ::
M.&9RTK@A1ODRQ(8D'C/''>NEHH \TCN575/'MD-+N[N:ZF$<?DP%UD+6Z*$9
MA]WKG+8&#UK)U'0]9M].N=#ETR^D,.@I;07&GPC_ $J78P*RR9SM4]$Z'G@Y
M /I6E:!'I.IZE?1WUW,^H2"66.;R]H8 *"NU 1P .I_.M>@#S'PO%=)KGA7[
M7HNHQ);Z";&5YK0[8I<IU/0 A&Y]QG&:U=-%UHWCOQ5)-IFH26E[]GEAN8H=
MZ;4AP1QR3G@  G^==S10!XU;:9K%CH?A#4CH5_>Q:=;R65]IX1XYH]Q!WH.-
MW0=..!^&S=Z/%<:-"7\/:KI,4MZ]Y"^G'-U;2;%4/(JDY9CNSC.!C/<CTRB@
M#D?#=]KUEIFCV>KZ?<7-Q<S3++=*BIY2 DH\JC@,PQP#U/K77444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M DB;&1G!(((Y!!(-5-8\7V>C:Q#I4EEJ-Q=SQ-+"EM;[_,V]0#GKSU. .Y%
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MT34((;E;=;(2,F;IY>BK\W&,9)...:)/'$EC_:5MJ>C30ZG8V9OC;0SK(DL
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M:1W'GYF0.<+(Z8P$.1T8D9Z=AVE !1110 4444 %%%% !1110 4444 %%%%
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M/;^O%S6_#.JW?B,:AI=C<V6J0SPJNIPW$:PW4 "[_.CW9)'S  +SQVZ>BT4
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M&:M>.M"OM=TW3AIXC::QU&&],<C[?,5,Y4'&,G/?BBSTF67Q9=^)M5@BM/\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH/ H
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MH(+$E@ ,CN>U<GXB\0ZGJ7@OQ?ILR06NHZ5&8KIE1BDT3H2&3D%2P]=V/?-
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M;,RB9P S;G#J$'.!P3W]J76_&&N>'+K3[[4+>'^R=3@VQQ[0LEK=,H*I(Q8
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M?$9X]9GDNK6T@N8K@PQ!LB,E05V[3@8&<#..U 'KD,,5O$(H8DBC'144*!^
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M%#%#'&7>0HH7>YRS8'4^] #Z*** "BBB@ HHHH **** "BBB@ HHHH ****
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MYE\Q[83J [[F[#MV!QQUKT#7O#FG^(XK:+4!.5MIA/%Y4S1X<=&X/)':J_\
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ME^UG']K2/RDF&0RIC&T$=!["@#'^'D\]QX(L'N)Y)Y%>>/S)6+,0LSJN2>O
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"7*!;^/R6^]M!P3T)(QZYK5H **** "BJ>J:K9:+I\M_J$ZP6T>-SD$\DX
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M5"%_O<GI[U:1UD171@RL,A@<@B@!:*** "BBB@ HHHH **** "BBB@ HHHH
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M1--2+[)&T4#0NT;HC9W+N4@D')R"><GUH K> [^^O_#"-J$QN)H+B:W6Y/\
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MM,08RK.3RQY;DD]*[5-#TF-Y&32[)6D 5RMNH+ = >.<5,-.LED21;2W$D8
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ML-W/_JH))E5Y/]U2<G\*\>LQIL\^HZ3KU]?KXACU-I(;&VB16E;?F)HY#&6
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=@Z%BRHN,8.2I/7HI]JK1>(9M*TFP?Q-]D@U&[NEM4ALY"RLS/M7&[' ')]
M#]*K>#G;6-!N=<U*)1_;!\SRW486 +M13[8!;_@9KSFW32S\.? ]Q<^05AU\
M(\C@%5C,\I8,3T7&#S0![<]Q#$A>2:-%&,LS #GI1-/#;Q&6:5(XQU=V  _$
MUY FE^'=3\8^.&^S6,UC'IL,EOL"^4N8B2Z@?+G/.[J,\=:JKJ=N8?!$>JZF
MMK82:/MBN9X$FA$_ 8-O! . !GM^- 'M$US!;Q"6::..,X&]W '/3DT27,$(
M0RSQH'.U"S@;CZ#UKR.&QC32]*MM$U>&\:WENY+*'5XE-K>1 H&">@4GY#_O
M=JCGN(]0TS2]2TZVTY3:Z;(DVBZG@I)"LA#&%^F<J0#Z;: /9001D<BL'QCK
M=WX<\,W>L6EO%<FU4.T,C%=RE@#@]L9S^%6?#=U!=>&=+G@@DMH7M8S'#*?F
M1=HP#Z\5B_$^>*/X<:V'E1=T&U=S 9)88 ]Z -""^\1+>V N;"QDL[AB)7MI
MF+PC:2&(8#(S@'GC-;*W5N\[VZ7$33IRT8<%E'N.HKF],TB."-=9L-2NKIY-
M-\J,3RF3GAE*YZ'CD8Y[]*X'PHVAZCIWA]HM5N_^$@M;A=]I%'$D_FDXE,AV
M;FC."6)/('7.!0!Z\+VW%V;8W$?GXSY6_+?E0+^V:[-L+F+SP/\ 5EOF_*O$
MM"ETR_LH8M5UB>#7;?4&9K.**/[0THE.T*Q&XJ1C//2M:.Y@T[Q)9N&LM7TV
MYU,^3(#B\M)B3G=_>4'U[8H ]A'2HYS(+>0P[?,VG;NZ9]ZHZ5K6FZO#*VGW
ML-R(9&BE,9SM<'D&K\DB)&SLP"@9)/&!0!YI'X[\0CPSJ.OR6>GM:Z==203Q
M)(X9@C!203WYZ5WT.JVTFEPZB\JPP2QB3,I";01GG->(VNFW%]X:U+5+%SJ$
M=CK4\UUI7F?N[B/>#D#')[_A78:KXATO5M3\+ZBTZ/H4C2JQ;&V.X( 3S!VP
M-P&>XH ] _M2Q%NEP;Z#R)/N2&1<-]*E^UV_FQI]H3S'&47>,L/4#O7F,?AJ
MW\03>,-+LU TB8Q-9.J_NX[@)RR'H1D#..Y-%G=RZGX6U#6=:TZX']E6$FGM
M' =LC2*,2O&>W& #_LF@#T>/4;>]CF%C>P321\$(X8*?0XYKC_#_ ,0XI?#6
MG7NN3V\-Y?74EO&D9P#M=E!P>0/EY-<MX0O;.V^(NEL+^Q$$VAE%2U7:D>&4
MA"W_ "T8#/-4-+DL4\'>$;JY:$QP^(93+(0,(N^0_,>W:@#URVO-0D\0W*-<
MV3::($:)$;,P8GEB/[OI5ZUU*SNI)H[>ZBDDB^^BON*_4=J\MU5C)XM\8_V,
MR":70(VB6( EB-V0H]<=O<5'H=QX;U+[+>6>H7TES#8R1SP0HB&VC*$-Y@ &
M<'I[T >K6VJV-Y*T5M>V\LJ$ADCE!((Z\5>KR/POJMOHVJHM[/8WUC;Z:9(-
M4MEVM' "OR3*,_-T]^M>GZ;J=GJMC#>64RS03#<C ]10!8N)X[:(RRR+'&O+
M.S  #W)JK!J^GW-F;N&]MY+8''FI("N?K7._$NYM+?PS";RW\Z-KR$ EBJ1M
MNR';'51C..]>:W4UJ^G_ !$@FNX;EVAA<,L7EK(P4 LB]N>* /;;?5;*\GD@
MM[R"6:/!=(Y 2H/(X^E<WXF\526%_IEMIE]9.\M]';W43$-(J/G! S_LURA6
M*T\7Z =(6&*XGT";:8UQN? *9]]VZL@:MHLGA;PA$ B:G:ZE$+E&0^9&^&\P
MGZDB@#W,]*X[Q;XAU71M9T&VLGMS#J=U]E?SD.4XSN&",]*['<"N0>",BO-_
MB8UO+KGA&WFD95&I!I-C8*KL(SGM0!K>(_$&KZ7XAT"QM&MC!JEP8I#+&=T8
M5<DCYN_I6_-KFFV,T-K=ZA;PW$OW8Y) K-] :\\\3Z=I^C>+_!K03S'_ $UC
M(9IVE 79COTR:9%<6,&G>,--\0HGVZ>\EFC5QEKB-O\ 5;/7'3CI0!Z/>:YI
MFG,ZWFHV\+(@D99)0"$_O8J235K"&P%_)?0K9D9$S2#:?QKS'2K6./QUHT6L
M)#+=1>'56=I #B0$YS[XK+\,W)L=,\*7EPF[1[>[NHY@R']P[,?+<CL!Z^]
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MFXTI1<:]H)3"*.)5?Y9$]=O(_ &@#>UW7M,O-,*R:GJ>FI'?K;&>WA=2TH8
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MW\RT%W<N9&C2"*V?S'V@$L%(!VX9?FZ?,!G)% #&\)%ASK>K$XZM<Y_I3/\
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MX&9&?<Z#G@X4<@ ]:SK#2;EO@GIDEG82-?6-T)+R".+;/)&LY8IG&X'[C?\
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M:Q#$1KB8;1XWTRU;D^8H;+2?0J(@/]P^M<C81ZA_9%[>6UA=SPVOBYM2GMQ
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M-/MOAY>/HNI2?V6EW!=PI;D21M(@5>&QQ_M9Q[UZU%+',F^*1)$R1N0@BGT
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MC"M%)AL*>!SG;[UL^"=&N- \(V&G76!/&&9T#;A'N8ML![A<X_"M]F"J68@
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MC>[8X XP!GJ?:HM0\+ZG??#*PTI8T@UO2XH#:NL@($L( #!N,!@#UZ9KNZ*
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M2BXN5=S<(ZK]]P> K$8&3DYSV- %SQ%XJ_L'5=)T]=-GNY=2=XXC&ZJ RKD
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MY6&],DC^0Q+P%BS+R>&.?P]3UH [BBBB@ HHHH **** "BBB@ HHHH ****
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MUC;27<0Q'.\2F1!UP&(R.IJU110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !167IVOV.JZIJ>GVDADETYTCG88V[F&< YY(Q@
M^AXK4H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L/Q9JEUI6AM
M)96EY<7$SK AM8#*T6[.9"H[  _C@<9S6Y10!YOX(O[:#QIK&G6^G:O;QM!;
M*GVJV8!=B,29&[,V<Y)YYKTBJ5OI5I;:I>:E%&1=7BQK,^XD,$!"\=!U-7:
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "DI:* "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
L* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>exhibit1021-independentc005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit1021-independentc005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HKG-;\::?H>K)I<MIJ5W=M +C996K3;4+%03CIR#6AHFM1ZY:/<165
M_:JC[-M[;F%CP#D ]N>M &G1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *;)&DL3QR*&1P592."#U%.HH C@@AM;>*WMXTBAB0)'&@PJJ!
M@ #L *IZIH6DZVB+JFFVMX$^YY\0<K]">E:%% %+3=(T[1H#!IMC;6<1.2L$
M80$^IQUJ[110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %,DECA7=(ZH"<98XYI]<?X[TS27TJ\U/4=,N=3E%LT$,$<33>6
M2&.]5'"GIE_8#/J =AFFNZQH6=@JCJ2< 5SW@,VY\":+]ENWNXA:J!,XP21P
M1CM@Y'X5Q.I^(FU+Q/K>H:AI%WJ.@>'9/)6*$IY8D'^LD=&(WE>W4 <]>: /
M6%=74,K!E/((.0:AN+N&U ,TB1J> 7;;D_C4>EW=K?Z5:7ECC[)/"DD.!@!"
M,CCMQVKG_B1%&_P_UPNB.5M)&7>,@$#K]: .CAO;><L(Y48K]X*P)'Y&K%>0
M:?:2WNM^%+C0--GMFM8@^H7!C,43IL&$)Q\Y)]*VK?XB:E)I4NL2Z-%'IL#3
M12OY^7\U'V*JC'(8]Z /1"<8JE-K%A!>I9RW4*7+_=B+@,?PKG5\3:M;ZQ9Z
M9JMA;PR:@CFTDB=F3S%7)C?(R#SU'!P:XO2K\6^F>)=7\26-K=0VFLRD$Y>1
M9=ZJBID8VC- 'L:L&&12UY[:_$&_C?4([S34D%M9/=)+:K)L)7.8VW*"#T]:
ML6OC>_;1+W6);>RN;"*U%Q#-92,V23C8RGD$=2: .UN+B&TMWN+B18X8QN=V
M. H]:6"=+B)98B&C<!E8'(8'H17!2^++R^\&:OJ5U8Z7J%C':B5#;S%HY5ZL
MK9&5(],5;@\1W,C:;I&BVMHEW+IR7;"8-Y4$9^4* O).>* .VHKSJ?XB:DFG
MVDL6DP-=-J8TRYA>8CRY#W! .01@U<M?&6KC_A(;2[TZW?4=*V,B6KDI(KC*
MDEL8QD9_&@#M9IXK>%II75(U!)9N !4=O>0WENEQ;.LT+C*NAR"*X;3?%D_B
M"+Q!I%]%9-):6?F>9:LS(P9#D<^G2M?X?#/P]T+_ *\T/Z?_ %Z -67Q)HT.
M[S-2M5VDAMTH&*OVMU#>6ZSV\J2Q-]UT8,#^(KS!)5L?B;XL,.B'4"EK;N(X
MU3@[,]\=?:M6X\0CPW!I^E:59QP374+WC))%)(L0R-PVIS]YAQ]: /0**\Z?
MX@ZK]ET^W;2OL^IW)F#K)!(Z(L9 W!5^8AL\=*2;X@ZG;:-:3W]A%IDLMT]O
M)=744GD* ,J^!AL,>!GIWH ]&HK*T6^O;W28KB\%H)F)!:W?=&PSPRG/<=JX
M^_\ '^JZ?K=O;S6MDD,VH"T%L=YGV'@2$@[1D]C0!Z+3'D"*6;A1U)["O.K_
M ,<^(XKCQ.MI8:<T>@E7<NTA:6,KNP!QAL?A6H/$^H:O>V]CHZ6B2M91WERU
MTC,BB3[J  @Y/KVH ZFRU.SU*U%U9W"3P$D!T.02.#5.;Q3H5O.\,VJV<<J'
M#H\R@J?<5SGPM3_BBHRR)&QN)P40Y .\DXK&R8/BQXD6/1VU%6LK=S$FP8.#
MUW8!SB@#T:;5[&WTY]0EN$6TCC\QYLY4+ZY%1_V[I@N+*W-Y")[U"]N@;)D4
M#)(]L<UY?X7OVTWP#XJEBMXFFM;B65]*N5)2V4C.PCOGD\'%;6IR+=^,?A[/
MY:)Y]O<N0B@8S"G ]AF@#L#XFT9;2]NSJ$'V>Q8I=2;N(F]#6E#<1W$22Q,'
MCD 96!X((R#7E"W[Z3H_Q$O(+:UN/(U)F:&X3]VPVKU'>MV7Q+KA\1:?HNGP
M:;$EUI@O$DE5R$((&-H(X]!0!W^: :\YMO'FHW/A71+QHK2&^U*^^PN[!O)C
M(+ MUS_#@ GJ:W/"VN:KJ>I:O9WXM-FG3_9Q+"K#S6P&SR3T!P1ZT =52,P4
M%F( '))[4M<1\1)FD_L#2))VALM4U)(+IE;:73!/EY]&.![T ;T/BWP]<2K%
M%K=@[L2% G7DCL.:V:Y/Q_>Z?I/@RZ>_TZ2XTT!8Y!;E%>++ *RAN,AB,$=#
M@U2O?$'BV;Q9/H>E6FDQLM@EZKWAD.S+%2K;3R<@]./KT(!W-%<+<>)/$$^B
MZKKFG_8?L^F2RQ_9'A9FN1%Q(=^X;3D/M&T]!G.:M:;XJO-5O[Y+?[.ML-*M
M]0M6:)MP\T.</\W/W1TQUH ["BO/U\4^)+^'PD;(:8CZW:O))YD;XC=8]Q(Y
M/R\CCJ<=16OX1UO5;ZZUC2-;6!M0TN=$>:W4JDJ.NY#@DX..M '4U2M=7T^]
MU"[L+:Z22ZL]OGQ#.8]V<9_(UQ_BSQ;?:9K<NEQWD6F.]NK6$]U;EH+F4DY1
MI.BXP!^//I5>ZDUE?'?B)],FMH'32K:62:6,R8*^:0H7(ZG/.> />@#T6J&H
MZUIVDSV<%]<K#+>RB&W4J29')  &![CK7&_\)EJ=UH/A_4/,M[2*_M&DE=(3
M-*TX  2.(')!.23@X YQUK/N->N/$_@WP-K%U%'%/<:];;UCSMRKR+QGUVYH
M ]!M=;TZ^U6\TRVNEDO+(*;B(*?W>[.,G&.QZ&M"N$\._P#)7?&G_7&R_P#1
M=:6O:]?P^([31--C?>]L]U<2)")'5 P50H+ <G.2<\#WX .II"0/QKSFZ\9Z
M[I>GZ<_B&U.E(\DT5U>16_G*A7;Y9*@G:&!)YR?E]Z<+S5[[QAX70:W!)'/I
M\T[&VC5H7==H++SSG)^E 'HM9^EZWIVM"Y.GW G^RS&";",NUP 2.0,]1TKA
MD\;:ROB'3K:8V^+K4VLY[:.$R1PI@[<3@[3)\N2O/7H,52M[CQ%I[>.-2T:>
MQ$=EJ<D[07$3,9ML:%AN!&T;1QZGTH ]&?7-.CUV+17N<:C+$9DAV-R@ZG.,
M?K1I&MZ=KMM)<Z;<>?#%*T+ML9<.O4?,!7#1W_\ :GQ/\+:@J>6;K07G"GG;
MNPV/UIW_  EVLCP@^I.O,6K36MU/96N]H859E#K&2<_,%SG/!/6@#MK_ %S3
MM,O;*SNYS'<7LGE6Z"-FWMZ< @?CBM&O*M?U>?4K#P??66I6M\\VN!(+E8B%
MPP=5WIP00#R..E=;X3UG4+[4M>TO4IX)Y],N5C66*/RRZ,@8$KDX[C\* -K5
M-7L](BC>Z=]TS^7#%%&TDDK8)VJJ@DG )I-'UBQU[3DO].F\VW<E0Q4J00<$
M$$ @@\5Q7C.&[?XF>"1%>F,2/>>6/+!\LB)<GWS[]*8GB3Q1JL5WJ&@VIDBM
M;R2W6!Q L,B(^UF=C('5B,MP !QUZT >CU'<3QVMM+<2DB.)"[D*6( &3P.3
M]!7GTWB;Q-K!UBXT"VD)TZ^:TBB;R!!+LV[S(SL'!.3C;@#CKS7<SR-+H\LC
M)L9[<L5R#@E>F1P: &Z/J]EKVE0:GI\ADM)\F-RI7(#%>AYZ@U>KQ[PKX@U'
M3_!'@K1]+A=Y]16Z9C$8Q($C=B0GF';DY'7/ /%:FKZQXUTSPC>:E=2FUGTZ
M[#,@2"1Y[1F'+A<A7&3TP"!TH ]-J&ZN8[.UEN9MPBB4NY5"Y '7@ D_A7&:
MUXKO+33=<US3YEGL;6."WM8WV"-II"N9-V,X7S$&"<9#=.S+2Z\4)<WT&J03
M?V9/8R,DEY+;^:LP!R%$1Y4CGD9&.M '8Z7J5MK&EVVHV;,UM<QB2-F7!*GI
MQ5NO+;#6+S1OA]X3FW7T&DFS'VR[L(DDD@("E2RLK?N\;MQ ST_'T'0KHWN@
MV-R;R*\,D*L;F(864XY8# Q],#% &C17F&F^)]<;Q!I?FZA)=0WFHS6EP([=
M19J '*B)R Y8;>3\P///KGW_ (F\41:%XLU-=<VG0]3,,4:VL?[U=R+AB1TP
M3TP<GJ>P!ZU<7"6MM+<2;O+B0NVU2QP!DX Y)]A530]9M/$.CV^JV!<VL^XQ
MEUVD@,5SCZBN4NM5O/$>MZ[I5IJ$VGP:981.QA1"TDLJ,PW%@?E"@<#&23S5
MCX3_ /),-$_ZYR?^C7H [.LK0M?L_$-M<SV2S*MO<O;2":/8P=<9X//?O7'K
MXCU*V\91Z=K-U>:?+-J#+9J\:&TNX#PJJX7<'Z'!/7ZXKFH=0UGP[X;U[5[7
M4G22#Q-+&]OY:,DNZ10VXD%NA[$8H ]JK)D\06<?B6/062?[9) UPI\OY"BD
M \]SS7#>-/$VM:==^(7L;^9O[/@ADABLXT*09Y8W#..2V1A4.<<X'6M-YC<?
M%C0IV !DT25R!VRZF@#IM \0V7B.UNKBR695MKE[603)M(=<9XSTYJ2UUNUN
M]<O=(C29;FSC220NFU2KYQM/?[IKE?A;_P @[Q%_V'KO_P!EI+BPOM0^(VNQ
MV.K3::XTVU_>11(Y+;I<9W C'J!R?44 ==J.JQZ;-91R6]S+]KG$"M#'N"$]
MW/9>.M4E\56#/K2^7<[M'VFY!BYP5W J.IXYKA[7Q=KMWI/@JZDO52:]U1K*
M]6)%V3JCLN>1D9V]B.M:"_\ (8^)O_7&'_TDH [K3;^'5=*M-1MPP@NH4GCW
MC!VL 1D>N#5JL'P5_P B'X>_[!MO_P"BUKCI-:U>X\!R^.[359_M",\RV+!?
MLWE+*5,97&2<+][.<YP<<4 >GUE>(-?MO#FG"]NXKB2(R)%^Y3=@L0!GD8&2
M.:YBQ;6M8\9:Q;Q:_<VUI;)97"1^5&Q ?>S1_=QM(R,_>^[SQ@VOBD&/@2X"
M-M8W-MAL9P?/3M0!V5%>?F_U+1_$OB6PDUQWA72%OHI[X K;2Y=<X4 ;> <8
M_P#KYNB7^J7'BRUT6:^U5;74-'-P\EQ+B1I V/-C YB!Y^7CC' H ]2HKS#P
MOJE[J]O:>%[S4+U-8L+^;^T)4G82-%%T)8GHY=!CIC=CI4-MJ?B77M-OM=LM
M0@M)K2^D#">\9888HV(,<D(C(.5YSG=DCD=  >GW5P;6SFN!#),8D9Q%$,N^
M!G"CN3VJO:ZI%/:6,T\<EG+>8$=O<@+(&VEBI'J K'\*B\0R30^&]3EMYG@F
MCM9721,;E8*2",@CM7F;6[ZIXD^&,UU>7K2WNFRO,ZW+JQ86RG<"#P22<D=>
M] 'K^:*\TL[V\M/&]O!K,NIVTMQ?RBUN8[DRV=W%\^R(KG$;@$<8Y*\]:Z#Q
MW=R1:=86L-[<02W=]%%Y-J#YURO5HT8$;,@<OD8 H ZO-&:\J35=>LO /B,0
M2S_:+#53;+YEQYLT4!$195=N7<;V [\\9P*2>ZU+39?$6JZ5<ZU_9%AIWG6J
MWIDV&Y*D'B4;V4##8/ - 'JV:,UYMH-IJXOM&OO[?066HP-'*GVV2X>Y8QLP
M= RXC9>2<8'&,5G:,;^+1?!^N2:UJD]U=ZD+69)KDF)HV,@(*]"?E!R<G\,
M 'JD=U#+<36\<@:6';YBC^'(R,_A4U<)X(T:ULO$WBEXY+IFAU (OF74C@@P
MH3N!;#')/)R?RKNZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+78=&>5Q?31-,B>6V"B]3NQC]:T* ,#3]'U#1YM)L=/NH!H=G:>3+%(A,TC
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M\T\7ALGO8"I"2@X8E,YV*>"W3CO6IJFMV^FV=_,L<EU+8PB>:" KO"'.#\Q
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MM9<NH/*Y.T8<!AV]#7FVCW=]HW@W2$M-1N_-UC5I;1WGN]JQJLLGW6*ML9R
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M\L+74+-K2[@2:W;&Z-QE3@@CCZ@5'J&D6&K)$FH6D5RD3;T24;E#>N.F?Y4
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MTCUJWU2)O^$KTW32MB)8D#-;JA,;+MSEB3AN3S@5=\(7'A>\'AJ^L]4/]MO
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M+<:K92)-:((+>!GE4.L11R =H!.,8R.^<7O$6E:9:7'CC3K.U@6(Z+#<"W4
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M;LYP .#6YH/B&.X\(:3JVK75K;27=O'([.XC0L5R0,FN)^V6JW7Q3!N803"
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M3&W;CGKG(QB@#UBBL33M=BFUVYT!K6_2YLX5<W$\06.=>!N1L_-R>>!S6W0
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MM,T+".9U.&56QZYYZ''%))XRTF*\2%C<>2]S]D%WY)\CSLXV;_7/&>F>,YH
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M+2:*T:90JJ0\3 9/)8G!'?FLW6)DAU86L6F7>D Z 8;<VUJTT\R$G9!T95P
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M\5:QHR1,GA_6XEO+F5> DR\%1[LWEL?8&O0[2TM["SAM+6)8K>% D<:]%4<
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M]YI7B=]0AL/['L9+4K<V,=SYD,LY*G?&HX4#!&>#VQUKO*** "BBB@ HHHH
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M#$<XPP*@@^U21>,_#]Q%));ZBLXCF\C;#&\C,^,X55!+<<Y4$8YKSS59EO\
MP9XLLK>WU676M1D6Z:U?2Y8F(RBC8A!)7"<DGK6OXKL[F'4O"VNVNDZA=Z=!
M&\=U;62/%/'O10K;5P^0!@CC&,=Z .RA\4Z+<:7%J,%\LMM+)Y4?EHS.S_W
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MV5<OIOA2>W\31:[>W=K)=QVK6S&UM?),^2#ND.YLG@?YXKJ* "BBB@ HHHH
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MQ[0$A50"<L1D\'@>E)<>-KNX\5^'+/3+-I=.U.U>ZWEE#2KL!& ?NXSD^O\
M, [G-%>?V_BC0_#>E^(M9BTS4TCAU5HKX,X=A,=N6 +D!<L!Q^6*W++QC:S7
MVH6E[97>G26=J+UOM07YH#GYQM)QC'(//ZT =)17*6GCB.YN](M_[(OT_M>'
MS[)MT6'0#<2?G&"%(;')P?7BNKH **X?3/&MU)KGBE=2M/L^FZ.5!<.I\M0C
M,2>[%L# '3I6C!XQ4:OI^GZEIES8'4P392R.C+)@9VMM/RMCMS]: .GHHKB]
M3^)6E:9=7 = UK:W'V>XE%Q&'5L@$K%G<R@GDX['&: .THKD-2\?VVFW4^[3
M[E[&WNHK2:ZR%&^3H44\N!D9(]> :GU?QB=/?4#::5<ZA#IFT7LD) *$@-M4
M'[Y"D$XZ9'- '3Y&<9&>N*6O-YKR33/BCJ%UIVE7%Y+/HD<YA5PG/F-DL6.%
M. !CU_$UW&A:Q;Z_H=GJMJKK#=1B15<88>Q_&@#0HK!\5>)X?"MC!>7%E<W,
M4LZP'R-N59NG!(SGVK.@\=JE_?V.JZ/>:=<VUFU]'$[)(T\*YSMVG&[C[N:
M.OS2,ZH,LP4>I.*X^W\<27%^VF_V8(]0?3AJ$$;7 *E/[KD+E&''&#]:Q/\
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&
M92" 0>"#2U%<BX-M(+5HUGQ\AE!*@^X!!- 'AFD:=<:U\.4TK2=*N&U3^U'>
MVOT0(EMB7EO,[8&1@<\UT][J.L:!XC\:WVDVMC(EK#:W%RURS#<%B)(55'+'
MGDG'UKJO!'AJ]\*Z/+IUU>072F9ID>*(H06)+ Y)[]*I7WA#5;UO%).H6:KK
MD*PK_H[9A55*#/S<G:3Z<^W% "R>+KV'Q#H$,T5M%I&M1!X)BK%UD* B)N<
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M3&^U<V&G8A)VQC=EV&<L?D? XS@>M6CX%CF\ MX4NM1EGB"*D4_E*IBVX*X
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M#<7#R!I1(XW?,3SQ6Q\//[/L? ^A 2Q13W=K'\K2\R,!V!/7KTKH5T'24O\
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M5F1<B=F\UBK9P">-W0YKHOAMHMM:>&-.U=)+E[N^L(1.TL[.&VCC@G P#CZ
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M;)[QK-;RW:Z7K )5+C_@.<UY#X6DTG4T\/-8ZO?R:_9+L-DEO'$8G(Q+YK!
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M& .@_&ISX/T)EU-)+(RIJC;[Q)9G=9&['!8@$<8(QC QTJ/Q%X@ET^^T[2;
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MQ@@9R,KG&:Y/7_&MYKOPS\0Z@;:_TYK>Z,=O+#)LV@2(@5BK9+?,<@C'IG%
M'K]%8FE^*++5-7DTM(;NWND@%PJW,)C\R+=MWJ#SC/J >>E;= !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MRH #<@XSUP>?>K.FZ+JYUAK_ %O4XKM8'D^Q0P0^6L8;C<W]YMO'MD]<UT5
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M[K%% 'B?AV<V'AG0K^>&233K/7;B6[58RWEJRN(Y&7'W06!S]#5GQ4EO?_\
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MUL\=S8G*D0L[ !@>..O'8 9 /2:X5O&TZ?$V+1GC*Z1.KVD,YP ]V@#,!WP
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MOKB:SA6>006S,#&03N!Z%0!UZ=,9/%5-0\=B'6M M;#3[J\L]4B>X6>*/.]
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M"-W'7IS[5U= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@M&C4[G"@!RQ)P?GW+P!]T]:Y^\\1>*YO$^L:-I5AI.;*"*>.2XED.Y6W<$
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MP>-V#G%==X:U&?4](%S/=V=X"Y$=S9C$<J#&&QN;!Z@C/!% &Q1110 4444
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MI.ISM<S"XB9I;:5\;VCQPW08W''MZ[.E:%?6/C'5M6D>!K6]@AB10[&0>4"
M3D8YW'//YUTE% &#XRT:[\0>%KW2+-X(Y+I ADF) 49!S@ YZ5GWWAW5CKNE
M^(K%K)=2MK1K2XMY'81SQDY #A<K@\_=/6NNHH \]U?P+JFJ6D\S75I_:5WJ
M<-]-DL(T2)=J1KQD\ 98@=^*]!&<<]>^*6D90ZE6 *D8((X(H \M\(Z1J>O^
M!(M+D^QQZ1+?3--)O8S,BW#,4"XQR5QNW< ],\U?O_ ^N7,VJNEYIK&ZU*.^
MCFFC=I2B,I2%F[*-O&,]^.:[NRTZQTV(Q6-G;VL;'<4@B5 3ZX JS0!RUGHF
MN6?BR]U5;K3FMKZ&$7"&)]^^-"/D^; 4DYYR<5@V_@'6[+PYH45CJ=I:ZUH\
MDGE7 0O'+$Y)9&!&1U]^GOQZ/10!Q&I>&/$.I6MA)<W]G->PZG#?R#+I"BQ?
M=CC7GKSECS^F(]4\%ZEJESXMW7%I'!KEO#'$06+1-$,+N&,$')SCI[UW=% '
M$7GAC6=0TVWT_48M$U"S6T$#03*ZA)!PKJP!.<=>G;&._1:-HPT[PO::+<SM
M=B&V%O)(XQO&,'\*U:* .#M_!&J+X=M?"]U?VTFD6UPCB9483R1(X=8RO0<C
M&X$\#I6QX;T34=,UC7KV^>U9=2N5GC6 L2@"[<'('8#GUS7244 <UXJ\-W>M
MW>C7UC=0P7.F77GJ)XRR.",'."#6;-X,U&:U\4P/J%LW]N!1O\E@8B$"$D9Y
MR!G'&#7;T4 <I'X;U)=?T34VN[0_V=9-:O&(V'F;@,L#GC[HXY[UGV7P^D3P
M#>>&+R^B<RRM-%<QQ$&-RV\'!/8^_2N[HH XU/"VN77B#2-4U?5[&Z%A!+ \
M*6142B0 ,3ESR<#MCVIOCZPTW3/AYK\EO:6EJ7M"A:.)4W9( ' YY-=I4<]O
M#<Q^7/#'+'G.V10P_(T <=;^&]0UN'3K[4-4B3[+8R1V9LE9<-+&$\XDG[P&
M< =,GFJ^G>"=;T^;0IDUBP_XE,$END:6)571]NYC\_WSMY/3OC.<]W'%'#&L
M<2*B*,*JC  ]A3J .,T_P7=P> M1\,7>H0N+D3"*>*$C8)"6.03SAF/IQ67X
MB\H^%I/!>J:@FH>(+JW!LXX;9H^00$88R!M*Y))Z ]J]'I-HSG SZT 5-+L(
MM+TNVL822D$83<QR6/=B>Y)R2?4UP:27MY\6/$4.CZI902?V?!$XE3S"'^;D
M ,.5SR.GS#->D5#'9VL4[3QVT*3/G=(J ,V>N3UH XN/X?7%A-IITK6!##:6
M,EFZSV_FD[V+/*GS *[$\_UZ5ERZ?8^&/ X\"ZM?-J5Y?02I86\-HRESDL "
M 0"&(.6(Q]!7IU)@$@X&1T- '*S>"HKGP;I^BF[DBN[)H[B*]7YF6Y4[C+@G
MG+%B0?4TR[\(7>KQ7T^J:A;MJ-QI\FGQR06[+'#&^=Y"%R2QXYR,8''7/744
M <[#X?U.T\.Z1IMKK2Q3Z<44S_9<I/&J% C)O]"._49X[5-/\&7&D6<D>EZL
M+&6?4!>7'V>T41,F,&)(R2$!P.<DUUM% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<-LB)W.%)&>GMG!J5_'LLOB.XT?3?#]Y?-;B%Y)4D15\N09#C)Z8(XZ]>F*
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M-=90 R25(EW2.J#IECBDCFBESY<B/CKM8'%<U\1X8IOAYKGF1H^VU=UW#.&
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ME];107MO-,\3!TR%=6VD8P<$8[<5ELNG6=CI<]AK.G3:E!JTFIW$<CR)$S2
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M\[@JIW?*JC&!S4:_#N_CBN-FK6WF2:XVL*LELS1EF'^K==XW '!!R.E>A44
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MW7@YS<Z+=:?JLMO=:8LJ>;-&)C.)<;RV2/F)&<^O:LO_ (5M(NF6]DNNS/\
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M6E9M[LAS\I8\9[#IR : .NKQ+Q%9D>'?'>K0RW"7MAK0DMFCF9!&W[D,VT$
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M% !1110 4444 %%%% !1110 4444 %%%% !113)5=H76)PDA4A7*Y"GL<=Z
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M+RE!U;:I./TK@9=5UJQ\,:3XR&K2W0N3 UW8$)Y/ES,!MC 7(92X&223CG-
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M<M&0N=IZ;L>PR?PKET_X1W1[<:SINOW,4=SI<NY(9/.,F%+FX8,3\XZ9..2
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M_'XO8[!YTTN%OG"9#^6^\CT.XKD^I%=YX)E$W@30'$@?.G0 L#GD1@'\<YH
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M?ESGBM"O+/"T_E:]HEMI]Y;:KI$K37$*.FR[TUF5RP<*?NDMM^;N1Z UZG0
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M\-NR#O\ DYX)'&./?FNJHS0!QS_#C2Y-)U33I;[47BU&]^WR.7C#)-G)9<(
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MY\MF)\MP>=RYQD<$8Z'-:]]9QW]G):RO*L<@PQBD*-CZCD5EG6KG4M+T[4-
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M[9_I$N)L'(R-W;';MQTXK:DN8(HUDDFC1&("LS  D],'WJ)M3T]+<W#WULL
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M.HVNN6(O_P"P+<3V&H!7AU"/#94'.=X8.#CG)7-:^F:K:6/Q$2YOK=M/DO-
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MM/,VP\.FXCDY)Y&3G'TKI%UK2VU$Z>-1M/MN ?L_G+YA! ((7.2,$<UPE_\
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MK@Q; P8CD9S^!S63X<TRXO;&RTUO"=Y8:O8P-#)J5Z6,2,(RF^(Y^9F;' &
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MEF(.,#D>Y)P 37.7-IKNG^+M5NCI5QJ!U'288$DM]BQ)*H8,&)((&3G.">>
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M072"9'!VEA"?F* \$]>,@$<TV^UFVTO5O&>H:;H;+K%C9Q2W$TT^%N$",58
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M3/XUH4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOG26SCN-MG*L)C)&3E.?O;<+\V,$DXSBMY75\[6#8.#@YP?2EH Y;Q+X9O\
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M=M\I&V'<_P" XQZUC:9X)UZQ\*:?HE]!HNJV5NDJ26DQ= VY@RN'VDAER_(
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M,Y&<,.IXP.*L2>+]1L;?2=5U"QMETC4Y8HT\J0F:W\P90OGY6'3.,8]Z-/\
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MATGPPVDZ_J.I1:E,T-^XEEMFC7!D"A=V[&>V<# S0!B>)?\ DK?@C_KG??\
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MK96^RQAB-V!AR5"@DDX.\<"NBMO *:?-IEXFLZO=7&DHR6RR21X,94#R_N8
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M%W#<VHFT8'8A9B=K1;@H^?<R@$YXQ0!WMQ,8('E$4DNP9V1C+-[ 5R]C\1M
MO;6WNR;NVM+F7R8;FXMF6)WR1MW<@<@]<5T.E6]S::5:P7ER]S<I$HEF?&7?
M')X [^U>0^%/#VL>+?A58:-')96VE27<CSSEV:9D64MA5VX!W#KN- 'H<_CC
M3[?7)M'>QU,WD,?G.L=J7Q'G&_Y2<K].:N?\);HA\.IKRWR-ISX"2*K$LV<;
M0N-Q;/&,9KD;G^T8OC-=)I,5K)./#RJOVN9E5?WO!)"L3SCCC//-9/\ PCT_
MAKQ-X%L=1G2XBDOKRYN)44JC73KE,#''.,?C0!Z(OB>S6]MK6\ANK&2Z.VW-
MU%M65O[H8$@-['!-;1 (((R#7#_%N-9?A[>(,FY,T M0@RYE\Q=H7OGKTYQF
MNU@\W[/%YQ!EV#?CINQS0!DWWB6UT[7;'1I;:Z:ZO@WV;9&"C[1EN<\8'7-)
MJ/BBTTS7;+1Y;:[>[O@QMA&@*R;1EN<\8'7.*YKQL+X_$/P2--:V6[Q?[#<J
MQC_U2YR%(/3-4;X:V/BSX-_ME]/8[+WROL:.O_++G=N)]NE '8Z/XLTW6]7U
M#2K<3Q7U@1Y\,R;2,^G)S_\ 7%&M^+--T'4=/T^Y$\MY?L5MX8(][-C'7T'/
M7Z^E>;ZA')H7B>^\:P!O*L=;DMM1"\EK9XX1G'?:3G\:V;EFU/7?#VOR8*WF
MM".S..ELD,P0C_>)9_HP]* .TO/$=M:ZDFF107%YJ!C$K6ULJEHTSC<Q)"J/
MJ>>U2:3K]GJ\US;1"6&\M2!<6LZ[9(\C()'((/8@D>]<OX&D_P"*P\:QW/%]
M_:"MA^&,&W$9'^SBDND=OCA8/;.3MT9Q=JJ\!=YV9/J6QQQTH [VBBO+&U/4
M=0\ WWC6#5KV#48))I([;S?W")'(RB)HNARHY)^;)SGI0!Z1=:A#:F5.9;B.
M$S^1&1O9!QD D#KQUJ#0-9A\0Z%::M;Q210W2ET23&X#) SC([5Y_IMJE_\
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MJ^F7FISM:7,0VWEK,X?>L@_B0 L">P /85ZN* "BBB@ HHHH **** "BBB@
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M&T08]=JR(VW/HN!72YHS0!RH\!:8FF6UA!<WT$,%Y]N)212TL^0P=BRGH1G
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MY;R*"619-NTD;6R >,&MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "F31K-"\3%@KJ5)1RIP?0C!
M!]QS3Z* /']'E&A^"G-K=7%H+K7WL))_M#L((C.06 )(#8&-W7G.:ZRU-QH?
MQ%@T>UN+B;3+ZPDN&AGG:8P2(P&X,Q+!6R!@G&:UD\&>'DM]0MQIJ-#J#F2Y
MC=W978G=D GY>>?EQT'I5K2O#^GZ.SR6R2O,Z[#/<3/-)M'1=SDD*/0<4 <U
M\2G9'\(%&*G_ (2.T&0>QW@UER23:YI/BW5SJ-[9ZGI=S<1VPBNF5+<0J"OR
M [6W8).X'.3TKN=8\.Z9KS6K:E#+*;2430;+B2/9(.C?(PY'8]N<=:@NO".A
MWFH37LMD?.GV^?Y<SHD^WIYB*P5_^! T <AX?O9_'.I7\&J7-[:-;Z?9201V
MMR\.QY8M[2?*?F(8@#=D#'3K7.W/B+71:^"]6%K_ &AJL$.IQX P90@5/,Q_
M$=J[L#K[9KU34O"VC:K=K=75JPN%B,/FP3R0,8S_  $QLI*^QXHE\+:/+?:?
M>&U9)M.79:>5/)&D*]P$5@O(X/'( !XH C\(RV=SX:L[NQU"XOX9T#FXN)6=
MG;HV02=O((VC@8KD?%MW?:9K]_J-X+V71D6-$N]/NV#::X4$[X0P#!MRDG^Z
M17::'X:TGPW'-'I-N]O',V]X_/D==WJ S$ ^N,9X]!45YX2T6_O[B\N;:5Y;
MG;YZ_:91'+M  WQAMC# '!% ',6?F>+]3\5K-J5U;264HM[%K:Y9! AC#+*
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MJ6W@G:)IH8Y#$^^,NH.QL$9&>AP2,^YH \V\0:/:Z'KGP\L+1=J6]T81@XW
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M:7#!'=+HURL"* ,L%.P'UZ5Z4T4;.KLBETSM8CE<]<4&&,R"0QJ7'1B.1^-
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M?,4JA@I(+*#TR 3@XYQ[UX]I4FFS>(9[<W.D3K<>%VBCM[104WAE*1Y/^LD
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MN].1[5-2EFG63;;V]JQN$5&VLY3L >,GOQ[5Q6GV&J6WAW2=/N/#FI@VFO\
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MGA?1/%NFI::'>VNFI86++MU2(@R31*050)C@D8!)[9QD\UZ'0 4444 %%%%
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MAUO6%T]F8FQ^T#R\$DE0VW>!ST#5T]% #(HHX(4BB14C10J(HP% X  I]%%
M!1110 4444 %%%% !1110!@WOA.QN]4DU.&YO[&\FV">2SN6C\X*, ,O(.!W
MQGWK4L-/MM-MS#;(54L7=F8LSL>K,QR6/N:M44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 1W%O#=V\EO<1)+#*I1XW7*L#U!%8]IX/T
M&QECDAL!^Z(,:22O(D9'0JK,57'; XK<HH **** "JNH:;9:K9M::A;17-NQ
M!,<BY&0<@_6K5% &7IOAS2=)F\ZSM LVW8)7=I'"]=H9B2![#BM2BB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /';72->_X1_6K&#2+O[59^(3J026,+'=Q>
M8"%0L<-TW>G [D5UUK%+KWCS3]>AL+NTM;.PDAD>[@:%W=R"$"M@X7DYZ<\$
MUVE% '#>/+/S[VQN8X]9AN[>.1K:^TN)I3&^5^1T4'<K8SSQ\OO5&VEUJPUC
MPOJ>HZ'=22MI4MK/'80 K#*61E# '" A>IP 3V[>CT4 >,Z#9Z]X?TCPSK+^
M']0G73GO8KFSC3]_MF?*NJ9R?H<'\.:W]7GNKB+P[.WAZ[M8_P"VUO/L\%FT
MCQ0B-E+R^6"%<LV<=<'O@UZ/10!R?AI9QXM\4SRV=U!%<W$+P/+"5614B5"0
M?JOY<U1U:VOH_B-/-'I]W+;W^BBRCN(4RD<GFL3O.?E #9YZXXR>*[JB@#R/
MPOIT\;:7I=]X-O$U'29$,FH3L[6JHAY>+YOF<@8 4<$YZ#%3:5INI1_#?QC9
M/I5ZEW>7-U)!"T!#2++@(1Z^_I7JU% 'F%K9W\?B#X?7#:9?>5I^G/!=M]G;
M]R[1", \?W@?PYZ53LK#4T^'/C#3WTG4%N[Z]N)+>(V[9=9,;3^ASZ5ZW10!
MP=C>7+^.(M4?1M5BMAHGD,7M3D2A]Y3ZXX]">]8.G6^N0:#X6L7T34UMH7N$
MO1!$J7*$ME KL041@W+*0>,9%>M44 >*67A_7;?P;IMLVA7RR:9XFCO7C.UG
MDA!;)3YB6QD<GKZGFNBO=*U'5?B#JQ-A>VMOJ&@&Q6Y9/EBE;YL%@2.,XR,C
M/%>DT4 >9/IFK:OX&TSP?<Z/<V]];-;Q2WAVB&%(67]ZCY^8E5P .<L<X -0
MM9:FJ_$D?V1?G^TE*6>(?]<3&T?'MD@_3FO4Z* .=T&]O8;30].DT>[2-K!?
M-N'VJ(710-C#.<GM_P#KKHJ** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&DM%:EY(3-%+9W7GH,8RK_*NUN<]P?6M+Q#KUUI$]I!;6*2^>LC/=7$IAMX
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M-'U.98+6_B:=AE87S'(PQG(1@"1CN!BN161=0^,<%G?,&BL-(%Q9PL/E\QF
M:3W8#C/:M/Q+J<=MXJ\.V4^F+///<.UC.MQMV,J$2;QMX&UC@#.2.<4 =?2$
M@ DG '>EKEO'.J16NDPZ<]P8'U*3R"ZJS,D761L+S]WY<CNRT =%9WEOJ%G%
M=VDRS6\RAXY$.0P/<5/7G7PNO4LWU;PKYLCII\YFLC)&R,UM)\R\, >"3^=>
MBT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%0QWEM,^R*XB=C_"K@FIJ "BBH+N]M=/MVN+
MVYAMH%P#)-($49]SQ0!/13(I8YXDEBD62-QN5T.0P]0>]/H *S-6U"\L#;FU
MTBYU%9'(E^SO&IB&.N'89_ UIU!;7=M>P^=:7$5Q%DKOB<.N0<$9'I0!RNA:
M3?:%;^(=9@TH"ZU&;[3#I22JNW:N "W*AF.6.,@9QSBJGB+2-1U;5_#VKWFB
MF]LHK>1;S2M\;M')(G7YB%;!XSGW%=Y10!P'@^P\0^$?!L-L=+>]FDOV*6AN
ME4VMNQXRQR#C&< _Q5VNHW\6F:?->38*1+G&]4W'L,L0!^)%6JJ!]/U2*:#=
M;7D:-LECRL@5N#AAS@]#@T >)V\LJ?"R/0&B@%\FH+,1]OMMI3S3(2#YG8#'
MU(]\;][JD-QXRUV_2*PGMKK24MHEN;VW\N9P=Q1AYF0#G;G'45Z'+HOA^!0T
MVF:9&"< O!&/YBG+H.ANH9=)TYE(R"+9""/RH \I@L8I=*\1:=8:I;Z=I%W8
M[+;3[[4H9=MP3N)0J[;4[<GDG/:I],U2YE\5>'=4N(=.MH-.TY[617U: L3@
M#. <9/89^I%>F+HWA]Y6B73-,,B]4$$9(_#%2?\ "/Z+_P! ?3__  &3_"@#
MSK1-1N;/X<:KI,=]IUCJRO.ULQU"!Q)YCE^"&.#\Q7GOS],NVE\K4IKJ"QTZ
MW6\T26SE+ZS#)*9F;):1BWS$GW/'<=!Z?=6'ABRF@BNK+289+AQ'"DD,8,C'
MH%&.31;V'A>[O+FTM[+29;FU*B>)(8RT1(R-PQQF@#S:VS!9^!4,MB7T1W^U
M@:C;]"  5_><^OX5?T#5M3T S^'8K_19=/\ M#R6^K2:G&3'$[[BICY+/R?0
M9]J]$_X1[1?^@/I__@,G^%-DT+0HXVDDTK3D102S-;H  .Y.* /+H+6+3=5U
M.QC@\*ZC97MR\\&J7-U!YEL)#D[E()?:<X'Z^GJ&G7FH7&I7"/:0?V2L<;6=
MY%.',^1S\HZ ?K45CIOAK4K1;NQL-*N;=R0LL4$;*V"0<$#GD$5KJL<$(50L
M<4:X  PJ@?R% #F.%) )('0=Z\TM=%\0B+QQYNAR(VN(_P!E'VF$X)0H WS<
M'YL_@?:N\M=>T>^D,=GJUC<." 5AN$<@G@#@]ZT* /.K;0]<BO\ P!*^DR;-
M%LY(+PB>+Y6:(1<?-R/EW?0COD5O^-M(U75=,LYM$EB34=/O$O84E.%E*JRE
M">V0QKIJ* .$O]*\6>)="::\2STS4;>>&XL;59/-021ONW2,!WZ8&0,9[\37
MNDZKK6N6NMW.F?9FTRSN(X+8S(SSRRJ%/(.T* ."3GGH*[6B@#S>QT?Q%;Z5
MX+@ET0^9H\I^TA;J(_*(VC!!SSG=G'L14\/AG4QXN@U6VTY-,N1<LU]=6]SF
M&]@YPICZ[SE<D@8()R>*]!-)0!Y3%X0\22V6KW"6<=K?#Q -:LXYID990,_N
MR5)VG'X<CWQH2^%]>\0ZOK-UJ-G;Z;#JFDK9$"Z\YXG!8YP% ;G'<<'KG('=
MV6IV6HM<K9W*3-:S-!.%/^KD'53[U<H \_LK#QE/HT]MJ=A812V\#Q*]K(I>
M^8QL@)R,(N6#$YSD=!42>'?$MI\.M&TBWAC:YLIU2\M1<;%NH S9 D'0'(/8
MXR#Z'T6B@#R9_ 6NMX?\7Z9'8Z?;+J-S%=6:03_)\K*WE@;1C[N,G'/;'-=3
MJ&C:QK'B+P]J-U:6T,%I%<K=)'=,6'G+M 4A1D@ $G(Y/'2NN8A5+,0 !DD]
MJQXO%WAR>988M<T]G<[4 N%^<YQA3GDY]* .27PIKT_A(^"+F"V_LY65%U-9
M@28%D#A?+QGS,#;Z=\Y%6[_PSK=V/&:K#:!=8@CAM#YY^4*GEY?Y>.N>,^E=
MY10!F:193P>&[.PNU5)H[98)!&VX<+MR#@>F>E<=#X0UF7PBG@J^BMGTR.1
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M&1><X"_P],9YXS@9J4:%<GQ8NN2:DSHD#6Z6IA7:B-M)PW7.Y02>XP.U;E%
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M^=B!CKP"?6IM-\'ZU9^)K76I=2TXO%IGV!HHK-E0*"64*-_ S@GZ8 '8 ?\
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MFVY9KB60_.Q(8!<]@!Q0!G:YXR\3Z#;.VHPZ1;3VUH)S&-\WVQP3O$>U@R*
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M7M[-M5TF2XDD^R*YCD79\P!.#G=C'  ]:NW&L^(;35?$=BVI02-8:/'=0O\
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MD*%9WQE^.IP ,GV J3-)F@#C/^%9:.NF0Z=%?:K%:P78NX8UN0RQ."2H4,"
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MI:2K!I\AEM4%U+B)O4?-]?ID^IK=+!022 !R2:CBN(9XS)#-'(@X+(P(_,4
M8\W@W0IUU)9;)Y%U-E:\#7$A$I4@J?O<8(&,8QC'2FP>"O#UM>&[33E:=HC"
M[22/)O0YX8,2&X)&3DULQW=O+)Y<<\3OMW;5<$X]<>G(KF/B!XJN?"GAN;4+
M V4ES$R9AN&.2&8+D*"">3GZ T 6K;P'X:L[BUG@TT+):,7MR9I&$1/7:"V
M/;I3X?!'AN#6CK$6D6Z7Q?S#(,XW_P![;G;NZ\XSDDUT&<#)J**Y@GC,D,T<
MB*<%D<$#\10!+5'5]'L=>TZ33]2A,]I(07C\QD#8.1G:0<9[58CNK>63RXYX
MG?:&VJX)P>AQZ<C\Z?+-%!&9)I$C0=6=@ /Q- &4OA?25U2/4U@F%[';_95F
M^U2[A%C&W[WXYZYYZ\U63P-X<CTVWT]-.Q;6TQG@7SY-T3GJ5;=N /< XK<^
MTP^4LOG1^6V K[A@YZ8-"7,$D;R)-&R(2&8."%QUR>U &$_@7PT]A<V/]EHE
MK<R>9-%'(Z*S?@1QD X'&0*P5\*2W'Q(N[F[TVZ.E'3X[>&Z%V5;<O4$K)O(
M(.#N!R1SZUW*WELV_;<0G8NY\./E'J?04GVZT(C(NH,2'"'S!\Q]O6@"@_AG
M1WGT^8V**^G "TV,RB$<?= .!G SZC@\5%J'@_0-5O9[N^TR&>>XC$4S,3B1
M1TR,X)'9L9'8UIR:C917B6<EY;I=2#*0M*H=OHN<FL2SUK4)/']_HEP+?[)%
M8I=1&-2'^9ROS$G_ &>PH 6Z\!>%KV"TAN=$M9$M %AR#E1DG!.<D9).#D<U
MH7'AW1[J:SEFTZW9[-=EN=F/+7CY1CMP..E6KS4+/3XQ)>W<%M&3@--($!/U
M-+<7]G:6HNKFZ@AMSC][)(%3GIR>.: * \,:*+6^MCIT+07[F2ZC?+"5O[Q!
M[^_7IZ46?A?0K#3)]-M=*M([*?F: 1@K)_O9Z_C5V/4;&:!YXKRW>&-=[R+*
MI55ZY)SP/>F0ZSIEQ$TL&HVDL:@DNDZL !WR#0!%I'A_2= B>+2=/M[-)#E_
M*3!8^YZFEO=!TS4;^VOKRT26ZM3F"1B<QGVYXJ1-8TR6.:2/4;1TA :5EG4B
M,'D%CG@'WJ2'4;*XLVO(+RWEM5!)F2560 =?F!QQ0!E_\(;X?^Q369TR(VT\
MHFEC+,0[C.&//7FGCPGH0N&G_LV)I'9'?<2P=EQM+ G!(P,$^E7K?5M-N_\
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M;CGGGGO3I- T>:UM[672K)[>V;=#$T"E8SZJ,8'X4S3_ !%H^JK.;+4;>80
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M"TV]@2A&"O7IC_'K0!S_ ,*+RXOOAQIDMS*TLBF6,,YR=JR, ,^P %0>&/\
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MC9^'XW.+237+5;GK]S<3^60/TJ#XH:=H^KZ#=PW3%=4L;22\M65MK =#]5/
M(^E=;KFCVVO:3-I]R659,%9$X:-P<JZGU! -9USX8M_$&C);>)K2SN[Q8VB^
MTQ1X;!XW*2,H3UP"<'UH K^"=5U.^MM2L=7DCN+O2[MK1KN-=JW  !#8Z X.
M"!WJ'X?7,%I\.+&YN9XX8(_.9Y9'"JH\Y^23P*Z2+2K"#3/[-BLX$LMI0P*@
M"$'J,>^3GUJG)X=T^+0[G2]/L;&U@G4@Q&V#19/<ID T <Y=.J?&'2;]G$EG
M>:-)!;2@@IY@?>2&Z9*_I7&[9)C;:^RR-I3^,S/\P^58^$$I/0*&!YKU:#PW
MI@T"ST:[M(+RUM8T55GB5AE1C=C& >O3UJ\=.LCI_P#9YM(#9[/+^S^6/+V^
MFWIB@#R?Q?976L:YXYDT[,@M]'AMWVC<"^_S&4>^T'W&:V[Z>'5_%W@![)TV
MQ6T][($.1'$8E )QT&?EKO;'3K+2[;[/86D%K#DMY<,809/4X'>H;31].TYK
MB33["UM99^9'CA"[SS][&,\DT <EXNO+2]O?".K6EW;W%A#JZI)<0R!T4LK*
M,D9'WL#ZD5R/C'3;C5M1\<:E9*9[:T%DL@3D2F+#R(.QVC!(]:],T3PKI^DZ
M)/I;P6TT%S(TL\8@5(F+8&!'R , #'/3/)K5LM/L].M5M;*UAMK=<D1Q(%49
MZ\"@#@?%44GB/Q7:V^DSAQ%H5Z\C1D,K"= D8SVR1N'KMK(!%_X8^&EE;G=<
MPZC;F2+^)/)4^;D=MI&#FO4M/TG3M)C>/3K&VM$<[F6"((&/OBFV^CZ;:7\]
M];:?:PW<_P#K9XXE5W^I R: .4OF9/C1I/D\L^D3+/STC#Y4X_WJJ>*M+TO4
M/B;H,&I*K07%E<"2-Y2JR[2I52,\CDG'>NJTK1I+;4[S5K^6.?4;D",,BD+#
M".5B7/49))/&2>@P!6;KOA9M;\7Z;?W-I876FVUM+#+%<G<6+D<A=I'&T=^<
M]L<@'FU[G2=(_LR&]:'PROB1H5N)(S-$D6P$*02-T8DW9R<?+^!LWVF:9#I%
MU'%KB:A VL6+K+:!8;>%WDPZQ%'(SMPS <#((YS7L TO3QIO]G"QM_L.W9]F
M\H>7M]-N,5$= T8V4-F=)L6M8/\ 50M;H43Z#&!0!!I^B67AO1;BUT2U\E/G
MF2,,SYD(]R?0<5P7A.X\+7-CX;N0[?\ "2P2;)X8"!<O,PQ*9@?F*#)8YZ8X
M]*]4551 JJ%51@ #  JM%IMA!>27D-E;1W4@(>=(E#MGKE@,GH* /(+6^L+?
MP_XICOB[17/B^6$*LPC1B64CS&(.(_E.[@Y'%1VD=G-8?$VP>_T^53 MPJV@
MV0AQ&Q.Q=QZ-M!.>N/I7KJZ#HZ0S0II-BL4Q!E06R!9"#D;ACG!]:4Z'I)CD
MC.EV6R151U^SIAE7&T$8Y P,#MB@#S6RTS2K_P 4^"1<P03>=H.Z16.1(52/
M;N'\0'/!XX]JQK>RTNV\$6U_"(ENX/$2Q0S^9EHXQ<$!5.>%VD\#CG->Q_V'
MI&^)_P"RK'=$FR,_9TRB\\#C@<GCW-1?\(WH7E^7_8NF^6#NV_94QGUQB@#*
M^(5U9VO@;47O5E>WD5(F$,OED[G4#YL' YYX/&>*\WGGM9=5\>VL]WI<PET/
MS%2S 6(R)&Q&T9.XKQS^@KVV2"*:!H98D>)EVLC*"I'H1Z55_L72O+:/^S++
M8T8B*^0N"@.0N,= ><4 >7Z)9:98WOPQNK:."*YN+603R(0&D_T;HQ[_ #<<
M].E8&O7&BWOPAU":Y-L/$G]H%[I9<"X6?SL'CJ!LX Z8'J#7MZ:-I<80)IMF
MHC "!8%&T!MP XX^;GZ\U*^G6,LQFDL[=Y6 !=HE+$ Y'..QY^M &%XXU"Q@
M\ ZG=W'FSV3P!3]EE"EU<A00_( ^8<\\9ZUYJMQ9GQ)XFM;F\TB6*?PXQ$=G
M@0EUR549)WLH_BX/? KVZ2..:-HY45T8896&01Z$5"-/LE966TMPR)Y:D1C(
M3.=HXZ9[4 >3Z''9Z=XD^&ALA#"UWI4OVDQX!E)@4C>>I^8<9[CBNG\?7EM#
MJOARWE,$4\D\SPW%X^+6(JG)D7^(X8[1D<]_7M1!""I$48*]#M'%)/:V]TJ+
M<013!&#J)$#;6'0C/0CUH ^?5?3[OP);6UQ/:W$D7BH)@$ K"Q.<#.51L$X'
M''M6]K,&GVNH_$NQABM8K5-.@DC@55"+)Y?4#H#DC\37L*V5JA?;;0KO<N^(
MP-S'J3ZGWJ0V\!))AC);J2HYH \NTB+3K#QEX(6QCM8?M6CR^=Y04&4E$/S'
MN<@_D:Y*VU"PM_ /A739KF!+^T\2*T\+, \*B63)8?PCD=?Z5[\+>%2"(8P5
MZ$*.*/)B!+"-,D[B=HZ^M 'AWBC4-,N#X@FMIK:S>'681)%<'?=2R*Z!I5)/
M[N(#.,#G'4<"NXT_4[6X^,MRD$T4J3Z%$Z.K@@XE)P/J&S]*[GR8B6)C0EOO
M94<_6E$,2OO$:!_[P49H X#QA?VJ>-[*S:XM[&Z;3I=M]>CS(Q&[89(H\@-*
M=H[].QSBN1T;6K&Q\)> +R2^MF^Q3W"2P3/MCR4?EGY"LH(P#_>KVYD1F5F5
M25Z$CI7/:YH%_>:C8W^E7]O;/:(Z&VN+;S89 Q4DX!!5OEZCU]S0!YXZ:38?
M#;7+VQU#2Y)+G5H[J9;<[XHP9D*PNPY*@ \XQR<"HM3?P_K-AXTUW[3I$MW=
M6*>1;QR)*\6U=N_) (9F8#CGIZUW%QX)O+H2W3ZO#'J4EQ#,7BL@(-L6[8AC
MW98 L3DMG..F *T=-\.W,>HQW^KWMM>SP*RVX@LA J;L;B1N8D\#OCVH \_U
M2WT[2/!'A'6+2T"V8DMGU*>QB1W^6(@,V58':Y)Y!Y]\4FMOI#^&?$&M:7J5
M[<P7%Q:2RW<\8$$\J-C9L5%PN-NYL$'/<@U["$4+M"@+Z8XK'\1:'-K.G0V]
MG?MI\D$Z3HZQ"1"5Y"LA(#+G!QZ@4 >;?VMH.JGQ5XB,MG>2W.FB+^S+28F5
ME5=K.6*@CKC(!PHR?02>&-0LE\?::RZA%=I)X=,,:V\)6/Y74K$F>6(4'.XD
M]>G0=Y8>&[H:C;WVKZA!>2VNXP);V8MT5F4J6/S,2=I(ZXYZ5T(C1<;448&!
M@=!0!XA#JRVOA/P3<-=WL.G:?YD6HR648,EM*RXC)#*1Q\X/IN]2*]%\"0:;
M'9:A/I$][<VES=&;[3= +YSE1N9%"K\O3G')!KK" 1@C(-   P!@4 >'^*]0
MA=;UH6^RFW\1I-+:)$[295MIG=SG .!M"X&#WJ_?2:1=Q?$VX3[,PE@C,#8
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M[?G4^0,\,QPW0\8QWK8\'R:?JNL:?>0:;KC7UM"ZSS:G)(JVJD8,:YX<E@.
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MVHV%W<'.2/Q],HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR&+(VH!@Y*H(_P 5)K"UF+2]2\(>(M3T-=9O#<VD<$EU?.[-(XE0K&JL,L0
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M3GO[?41);I*L)81/DR-T15QEF]@":T-,UFQU=9S9RLS6\ABF1XVC>-L9PRL
M1P0>E>5BT5/#5@^C6&IWLFDZFUYJ%G-"]M<.)5<%D7.<<G !/3OS7;>#8;>6
M>_U2UT"YTF*Z$8S>@BYG9=V6<%FP!D 9YZ^U &CJ?B[0])N)X;R\*-;A#<%(
M7=8 YPOF,H(3/N16+>W]]'\6=,L(]0G^PW.G2RF $; P. 1Q^/.:Y'QM::G?
MS>+;<Z+J@=UB%K_9T&(KI<??F<<R%<8VY./0]:Z8Q7ES\2O#^J_V=>Q6BZ9)
M"[R0D>6[$D*V,XZ?J* #P3XC>+0M7N-;U&:?R=:FLX7D!=V VA$55&2?8#UK
MI$\6:(]C>7AO?+CLY/*N%EC=)(W[*48!LG(P,<]LUYA_PC>LG09ISHUS<?9O
M$DVH/8-F-KB!QM#*?4<\=>M6=<A1_#5UJ-GX=OM-%[=62VJR#-[+.CG#LA8_
M*HP%4D$X/*C!H ]%M?%FCW-Q=VYGD@N+./S+J*>%XS N,Y8D8''/7FI+/Q-I
M5]=_9(YY([@P^>L=Q!)"6C_O#>HR/ITKS9@_B6S\2PK::I!XAU:U4*E[8-:P
MNL.,(GS-R<]V[]A4]OH,GB/1[F.R\*S:+JBV<L$UQ>E@/,>/&R$[B2I)Y8C@
M>IZ &IJ_BW[;XU\)PZ3>WBV5U/*)08F2*X0+PRL0-XSW!QT/H:Z/Q7XH3PS;
M6CFUGF>YNHH%*0LZJ&< DD=\9P!DDXXKC2FKWVI>!A_PCFI0MI&Y;O<B!%_=
MA/E;=@C(/X5U/CZRO+O1[![*TENGMM3MKEXH0"Y1'RV 2,F@"]>^+=+L<*XO
M))1%Y[Q16DC/%'DC>Z[<J.#UY.#@&M.UO+;5-.CN[*X66WG3='-&<Y![BN1T
M\ZGI?C+6M5N=*O7L=6A@DA$:*\D+QKL,;!2<9^\#G'/)S6KX*TJYT/PI#;7<
M AE,DTYMXSN\D.[.$!'!P"!Q0!RW@/QI##ITEMK-]>W%Q)JLELEQ+&[HI+;8
MU9P-JYQP/Y9KJ]0\:Z'IMW-!<7$F()4AN)HXF>.!W^ZKL!QG],C.,UYPVAZR
M?AY+I_\ 9%[]J;7C="+R3GRMX;=^53^*M'US6(?$"/HE^TS7<<MDMGMC@>(,
MIWR#<#)(1D$,#@XP!B@#TRU\0Z?>:U>:/$TOV^T4/+$\3+\IZ,"1@@_6JT'B
M[3KK3;&]MH[N87J-+!#' 3*R+P7V]EY')_O#UK \4Z+JM]K&CZWH]M-;W-S&
M^G7JNP#Q02 G>=I(RAR1R>2*C\4Z-<Z=K^E:I9>'EU?3+>R:Q>SB($D0W*59
M0>#C:!0!VFF:G9ZYI<5]83&2VF!VM@J002""#R"""/PK@?!_C>PTW29(=9O[
M^60ZI/;M=3I)*D;;R$1I,8' ' Z>V:[3PU:-::.BG38--#NTBVD( \I2<@-C
MC=W..Y-<%_86L77@W4_"$FD3QW%Y?2N+J3:8$B:;?OW DYQT&,YQ]: .XU'Q
M;I>F272S&X>.SV_:YH8&=+?."-Q ]""<9P#DXIM_XOTJP>Y#&XG2TB66ZDMX
M3(D",,@L1_L_-@9..>E<3)H6H:5XAUNUG\(1:[9:E<M=6UR63:C,!E)-W101
MU_+.:BE\,WFE^)[\7G@RTU^UO1$UO<(D:B%Q&J,AW?=3Y>/0>N: .WN?&VCV
M]ZUFOVRXG%LMTHM[5Y \1Z,I P1[].V<\5K:5JEIK6EVVI6,ADMKA \;$8./
M<=C7*Z;I^I:?XNCN9-+;[/;:%':;K4(L3RJVXI&I;(7G SCI6AX!LKS3O!5A
M8:A:26MS K(\<A4G[Q.05)&,&@"3_A-=)^WV]N?M @N;DVD%X8L023@D>6&Z
MYRI&<8)!YHO?&>F6+S/)'=/96\IAN+Z*+?!"XX(8@YX) ) (!ZD8..>\-P>+
M=(T^U\-3:+$R6=P%CU5I4:/R V=VS.[?@D#@<G-1Q:)K=EX3U_PLVG2W!NY+
M@6EY$Z"(I,2<ME@P*ECD8/MF@#?U'QYI6G7FH6AM]1GGL(A-.L%HS80Y^8$X
M& !G/3TS4EAXYT?4=0L+2 78&HHSV<\ENR1S[1E@I/.0/;'H37/6NBZGINJ>
M(TCTV^N+:32(+*UG9XRT[1HR?WNIW Y..A]LQV.EZS"G@!7T6[']DHR7AWQ?
MN\Q&/^_SSSQV]^* -:3XFZ'%#>7#6^I_9;*Z-K=7!M"$A;(&6)[98#'WO:M;
M3_%=CJ&M3:2(+V"[CMQ=*MQ 4\V+.-R]^N!@@'VK@I?#VO-X+\;:>-&N3=:K
MJTMS:IOC^:-V4@D[\#&TY^HKJEM=1?XF6NJ'3+E;'^QVM6F9H\+(9%?! ;/1
M<<#K[<T 83>-;/0_#?VK1+?5+Y;G6&M6:[.3%(64LH!((')"KQSG.*V;/QQ/
M=^,9])DT:\M+>VLQ<3/<&-60%A\[?/@*!GID^U<G'X5\0R>#IX1I,J7<7B+^
MU%MY)8PTL6<X4AB-WL2*W+W0=;O?%^H7ITTI:ZQHWV%W$Z$VKG@[QGYL9_AS
M0!T,'C73);[3;:2*ZMUU/<;&>9 J7 4 \<[AD$$;@,Y&*YCQ5XECU<^&WT^'
M5%M)M<MXEO%)2"=/, 88#993V++@X.*B\-Z!K:Q6VD7WA'2K VB")]9C:-FD
M"K@%%"[MQXR21W[U&-*\6GPWX>T270A)/HVHV\C7*W4:Q310G*E>=W3 .0/Q
MZ4 =/\2PR_#[5IHYIX988A(CPRM&001W4C(YZ'BIX/&MG-J<FFMIVIPW@MVN
M88I[<1FX0==F3U]C@U/XSTJZUSP9JFFV:J;JX@*QJ[8!.0<9_"J7V*\UKQ9I
MFL7>GRZ=;Z5%.$$\D9>620!?X&8; H)SD$DCB@"SI_C&PU3PU#KEK;W;03S"
M"*$J@E=R^S&-V!SGJ1P":I?$R2:W^'^J7EM<W-M<P1J\<EO.T;*=RCJI&:I:
M'X>6'Q]JK6URCZ5#*MZ+=0<)=RH5;GH<*-WMY@K5^(&G7^L>#+_2]-M&N+FZ
M4(N'1%7# Y)8CT[9H Y6RU6*7QCX=L-%UNZOX;RSD_M2%;U[A(QY?#[BQ,;;
MN.".U2>!O&"V'AC0K2^M=1E6ZNY;3[>X+()6FDV+DG<W'&0"!TSUQWFDQO;:
M+!OLGAG6(!X<IN9E&.H;:<X&.?3.*\_M_#OB&W\$>'M/&CNUYINLB\DC^T1
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MEC-Q:2$[H]W8\#(Z8Z$UGS>!/$4FB^+M,@TJPM(M6EADMEBN1LC"LIVXVC@
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M -G+*LC*3,<G<6\M0 @Z'DG@$DT =AX?\,P: )7^W7^HW4N%:ZU"<S2!!DA
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M $'@'_/-W6])\5:I9Z3)+;VDMS'JT.H2P+/M2W2+&(U8C+$\DGU)XQBN\HH
MX&]\-:U?:CXV!MK>.#6K-(+:4SYPR1L@W#&1G=GVQ6WI:^);:UT:WFM-.2)!
MLO-LS,T:+& NTX )+#GL!QSUK5U#6=.TE[9+^\BMVN9!%"KGF1R0  ._45>H
M *R_$-IJ5YI#1Z1/%#>K-%*C2LRH0DBLRDJ"<$ CIWK4HH XN?0=2UCQ3INM
M7NFVEC+I7F,KPS^8]T2I4)G:NU.^3D\XP.:SU\+>(G\+1Z8UO8+/+JO]H2'[
M4VV-?.\[;]S).?EXX[^U>B44 <;!HFO:+J>M-IB6EU;ZO+]H!FF*&UF*[6R
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M]L@?AGUJSKVC:AJ.LZ)>VDELD>G3M,RR[LON0I@8Z<,3]:Z&B@#SN?X=ZF=
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M7B#3]<L=2GU>P<0:>+%H8[,JNP$$!?FZY')/X 4 <3I8'_"H[$X&1KZ8]O\
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MG'?W%I&T5KY=MY*INQN<C<<N0 .P'.!S3M,\*VNF>*=6UV.1C)J 3]UC"Q$
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M[CD8W*>%VC .1Z@GFO5:R-?\.V?B*&T2ZDGB>TN4NH)8&"LDBYP>01W]* .
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !12,RK]Y@/J:,@#.1CUH 6B@D 9)P*165AE6!'L: %HHS33(@."Z@^A- #
MJ*9YL?\ ?7\Z571CA64GV- #J*@>]M8[I+9[F%;AP2D32 .P]AU-3,ZK]Y@,
M^IH 6BD+J "6 !Z$F@$,,@@CU% "T444 %%%% !1110 4444 %%%% !1110
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M#>VLTW[N4*NW.1UR!@_@>M=*VF:KK6K:DFJZ3%!IVH:<EF["Y5V4@R$G&/\
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MU:.)]\HVA6^<8 &5<=,U%<>%-5FO_%\XDL0NNVJ6T?S.#'M1D#-P<G:Y/'<
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M4L?,;)Y<[L>V.^:T+W3+Z[\0Z?>?:8!86F]OL[1$LTC*5W[L\8!8 8_B/M@
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M9(Q$LJQ>7N4=,C)Y]3WH YSQCXKU;0;F[%L+"""WL3<Q&YC:5[IQDE%5'!4
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MC)LL8/)@C)&U<\%SQDL1D9SW/J:Q/!USY'B/Q7H:C$-E>I/$ N%59T\PJ/\
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MOC9D$Y'/3'% 'K5[<BSL;BZ,4DHAC:3RXEW.^!G"CN3C@4W3KP:AIMM>"&:
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ME"1"<W'G*5\LD@''7.01C\<ULURUW!]K\7:JBRR(JZ1$CO#)L="TDI&".0<
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MR1DC@<<5W6:* .4?P-!-K-YJ$^I74HO[5+6^A*1A;A54KD_+\N<Y^7%1^'/
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M9P,;LE<X('*YQ6@/"C?\)-8:Y)JUU+-:6[6X1TCQ(K<MG"CG..F,8KH\T9H
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M[32+"2]O91' A +>Y(  ]R2*@EO-13Q!!9IIN_3G@9Y+WS0/+D!X3;U.1WH
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M:TFKWNF))>+MRV]@K[>FY0<-^(.:DU+P/H.JZC/?W5I)Y]Q%Y,YBN)(UE4#
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M\?E2RF%=SIC&TGKC''TK321)8UDC=71P&5E.00>A!K@[CQZ\-IJ4KI+"]IJ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC*ZJ5N)#Y8;[VS+?(3ZK@T\>"]#'AZ30?L]P=,D?>T!O)CGG)&=V<9YQG&:
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MM7>WX-C\1-,6P,LBC2+ID@,[,C.I4# )(![9KH_^$2\.^5<Q?V)8".Y*F91
MH#XY&>.U31^'M(AN[:ZBTZW2>U3RX)%3!B7T7T% 'G_A:;P[>Z?H7B-M:FCU
MDRA+P^:3+<RMPT3IR=@)!  P% /'6LG1[A?[8\+:I#.Q2]O[C=?3S_Z3>1A7
MR95& $&T #G&.W2O5+;PWH=GJ;ZE;:390WKDEITA4.2>ISCJ:KQ^"O#$14QZ
M!IRE7$@_T=>&]>GN: ."_P"6'Q9_W&_]$-5S5[<:%I_ACQE&KM!:0P1ZC""2
MKQ,@59,=-R$CG&<'VKN#X9T1A>@Z9;$7QS=#9_KN<_-Z\UDZEH&JW<T>B6R:
M9;>%#$JS1JK_ &@@-DHO.T*1@>N"?:@"]X7M,6EQJLL82ZU67[5)QR$( C4_
M1 ,^Y-<?J>AVGB#XP7FFW\EVUF=%68Q1W+H"WF@=CTX' XR :]-    & .U4
MAHVFC5SJPLH?[0*;#<[?GVXQC/I0!Y(TUKJXUN:]\06FFZY9:A($=H&:\B".
M?+2$F4 @J-NT+@Y.<GFK&J:;97NH_$E+DW$K6EC%<PQR3/M1S;L^[;G&0V2!
MVSQ7I\GA[1IM535)-*LWOT.5N3"OF ]CNQG/O2MH.CO/<3-I=F9+E2L[&!?W
MPZX?CYNG>@#RM=3.I:AX9LM?OK*.RG\/QW"2:FK212W!P&)&]!OV]"QX[<FG
MW>G6VB:/X<\2I=C6(-+O&M;F\:W_ -;:LQ3(&6+!#PIR?:O3)_#&A75A%83Z
M1926D))BA>%2L9)R=HQQ^%7VLK5[,6;6T1M@H40[!L '08Z8H \F\/6%U#K-
MWX1N]'CM[?4;F+5O+"9$5M]]HR>Y5UCC_P"!''%>M7-M!>6[V]S#'-!(,/'(
MH96'H0>M.\F(SB?RT\X+L$FT;MN<XSZ9[4YT21&1U#(PPRL,@CT- 'B?A_[/
MI?PL@O$@$,-QJXAU&X@&R3[-YQ!RPP<=!UZ$UTNI:9!I?BZ>TTA!!IMWHLT]
MU;6WR1JZ$>7)A?ND],CKM/6N\M]&TNUM);2WTVSAMI>)(8X%5'^J@8-1VV@:
M/9V<MI;Z79Q6TW^MB6%=K_[PQS^- ',_#70K"T\+Z7J\(E:]N[")9I7F9]P
MX&"<#'3CTJIX]LY;G5#<1V^GZM'9V!>XTJ[^5UC+-^^A<@@/\I'M@>HKN[.Q
MM-/MUM[*UAMH%)(CAC"*,^PXJKJ&@Z1JTR3:AIEG=2H,*\T*NP'IDCIR>.E
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MTJ?3;"YNXKJ>RMI;F+_5S/$K.GT)&12OI]E),TSV=NTK#:SM$I8C&,$X].*
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MP#G@TGG1;=WF)M()SN&.*\:U.QT5=$M(;:_-]9R^)+9C=A4BB&\CS!"4Q@#
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M=>(+1WN[LQ(CD\3&,*JX &W<<8S]#7LFGZ=9:7:"VT^VBMK?<SB.)0J@DY.
M.G)H )=4T^$D2W]K&0VTAYE'S=<=>M.N=0LK)E%U>6\!?[HEE5=WTR:\;2'P
MU(?B+:ZHMG]J-W+]FC(7SL[3M\H'G);'3J<9IFKW!BMKBSU":WL]5B\,10W+
M78\R:Y8HQ$<2= =WWFY/3CJ: /:9KVTML^?<PQ87?\\@7Y>.>>W(_.L>T\::
M!>:I?6$6I6VZS$?F2-,H1F;=\JG/)&!G'J/>O.M%BT#Q!XD\(QWILKW?X;"2
M+(RMOE78-K>K#Y^#R"">HK6\.V>E#Q]XUT&ZBB1+L6\<-L5P6B$+!BH[ #'/
MN.Y% 'HXOK0P1SBZA,,A"I)Y@VL2<  ]":JZYK=AX=TB?4M1G6*")2>3@N<<
M*OJ3Z5Q/@RTOWO4\/WZ2?9_#$SK',PPMR&'[@_\  49L^^TUL_$] _PVUSY<
MD09''3YA0!O-K>E1627LVI6<5LYVB5YU"%O3<3C/M4\FHV4,:R2WENB,AD#-
M*H!0#);.>@'.:\HUW7=,?QCI>HRZO<V6@W&F&WM[ZV@C>,3>82ZGS(VP"NWD
M#L.V:CM]/\-1:SX)T^4,]HS7GDKJ6SS)58CR\KM&%9BVP$4 >J/KVCQV_P!H
M?5K%8/E_>-<(%^;[O.<<]O6IH]3T^:]:RBOK9[M5WM LJEPOJ5SG'O7E+VGA
MVSUGXAP1Q:?&EKI<,<"?+B/$+A@,]]VP'ODCUJ329M&MM3^&#6\ME&[V<PD9
M&4%G: +@GN3)N'^]D=: /0;/498;S5Y=2U73#90S*(1'(%-NNWD2DG .:OVV
MJZ=>W$UO:ZA:SS0?ZV.*96:/_> .1^->-:G/IPTOXH1F6UR;E#$NY?O8QD#U
MSD?6M6]N=(M/':"SACF@?PG+_HMF543C<6"IM_B*AC].: /24\0Z++'<R1:O
M8RK:H9)S'<*WE*.I;!X'!JKHWB_1-:T>35(-0M4MHB?-+SJ/*7<0I?GY-P&0
M#@\UYIX8O+-_%N@/'?030MHCP(D$#+&/F0+"I(+.5SEBQ)&"3CI6=IFJ-:_#
M?PK.PNFMM*OI/[5%O$"\ W2!"0RD';D'D'''0X- 'M8UK2FL&OUU.S-FC;6N
M!.OEJ<XP6SC.2!4MEJ%EJ5O]HL+RWNH=Q7S() ZY'49!QFO,/^)#>Z=>ZMIN
MLZG9I=WT,JZQ<Q 1?:%1_F*,JC9C )Q@DCT)KJOA[?W&I:'>3W4=KYPO9$-Q
M:*PANL!?WJ9['ID<$@XH M77C+2%UFZT.#4K5=2B@+ 2.,"3LF,C<W<J#G'I
M53P+XOBU[PWI<NI:A9+J]XDCFV615=@'8#:F<XPOZ5FW5W8:?\5K_P"WL(4N
M=(B6-MA)8B1]Q&!V!R3V[UQNDK;6_A'X?M J)/#K1^TLH =%#OG?W'RE<Y[$
M4 >S2:QI<-\MC+J5FEXQ"K;M.HD)/0!<YYJ[7ANRP>YUOP]KYUQM7GU&6XM[
M.V)$=[EMT<BL%.WMR3@ ?A7MEU=065I)<W,@CAC7<S'M0!R?B3QL-!\5Z1IG
MD[[2:14OI\<0&3(A&>Q)5B<]A[UUEU=V]C:R7-U-'#!&,O)(V H^M><7.@3^
M)_ 6J7]SJ<4?]IAKYD$(/DLH'EKNR""H10??=ZU3U/Q.FL?#C0-7NGEBU&SU
M"V>:/R691*I8'S5 +!& )! )R5P* /18_$FB26K7*ZM9"%%+.S3JNP X.X$_
M+@\<]Z;'XGT*:UN+J/5[)H+<J)G$PPA(R ?<^G7M7F,FH:9J/A[QW>07=L=2
MU&#S/LB6\@,:A!&,;T5F+$]0HY-7]7MXM-T'P?K=I92G3;8(=0_L]-LO,.Q'
M.!D[2S?3..] 'H<?B#1YM)_M1-3M389P9_- 4'I@GL<\8ZYJ,>)]#_LTZ@=6
MM%M YC,CRA<./X<'G=Q]WK7F>J_9([:V\0Z1IVLRZ4-52>\DWR"6;$;(951A
MD!25Y[D=L9JMXKCTR[\*:MJ.EV-_Y5[=VFZYNR^ZZ=&.[;&PSA5_B[\^F: /
M3Y/&7AN-+IVUNQVVI"S$2@[2>@]^AZ9Z'TJ[-K6F6^E)J<M] MC(JLD^_P"5
MP>F/4GT%<=]HT1/BBUQBT$*Z&%$GEC;G>6P#CKY?./2N2M9G@\(>#=6%O?S6
M&E37,=^EF&66%GR%;;P>,]?0^] 'J[>)]#338M0;5;06DKB..0R##.3C;Z[L
M]1U'>J-[X[\.VNC7VI)J<%Q%9ML<1-N)?!*J,>N#@].#Z5YWXABTR;PNEYIU
MA?0V]YK=O.SWN[?.1]^38W1<8!/?'L,W]65[CQ-\1(K9'D,^BHL2HI/F,L9!
M QU(SC\: /2=%UBTUW3(K^RE62)QSMSPW<<@=*SH]6AMM<UB:[\26+6%ND0-
MJ2B?8V.0=[YZL1P#_P#KN>'+Z'4- LY[<2>7Y2*#)&R$D*,\, ?;\*\^UNXM
MQJGQ*C)&Z?2X4B&T_O'$<BD+ZD,RCZF@#T&R\2:+J-\;&SU.VFN@@D\I)!N*
MD9R!W]_3O5^[N[>QM9+F[GC@@C&7DD8*JCZFO.;.>S7Q3X",.Q572YD8JF K
M,B  \<$LK#'J#71_$*<V_A*5Q8"\'GQ9!1G$.'!\TJO+!< X[_2@#;TW6=.U
MA938723&%MDJC(9#C."#R.*9J&O:3I,\,&H:C;6TTP9HTED +!023CTP#S7#
M>!GE3XB>)Y9AJ4T=[':M!=W5FT0F"1D,<[%4#) '3(QUK6\61K)XY\&N]N\L
M4-Q<-(PA+K'NBPA8@$#YL8)],]J -7_A-_#!@@G_ +<LQ'.YC0F3'S9QS_=Y
M[G%6=6\3:-H4L<6I7R022*7"[6;"C^)MH.U?<X%>8ZAI[OX*^(8ALK@W5YJI
M:)%MVS+'N0JRC'(SOY'I4_BA[JYN=2A6UU&$S: D44EI9O(]ZQ1SL=\$(JD\
MC@G/7M0!Z)J'BSP_I4JQ7NKVD4CQ^:J>8"Q7CG YYR,>O:D/B[P^NGV5^^KV
MJ6M\<6\COMWGOP>1C'.>G>N!\/;Y?%?@F<VETL-OH/D2O+;.@20*!@DCCH<>
MO;K6;I4,\?AGP[%<65WF'Q09Y(VMG)2+Y_G(QPOS#GWH ]4TWQ-HNKV-S>V6
MH0R6]JQ6=VRGEX&3NW $#'.>E01>,O#TMG=7?]J11PVN/.,RM$4ST^5@#S@X
MXY[5P&N6.H:C<>/8M/M+MIGN;.XB0))%]H6)4WA&P,G*GH<^E17<%G?>&M<O
M=.T375GDTQ[:2?4VGDF9V(V1(K,=P!R2<8''/)H ].TGQ#I.NM<KI=['=?9F
M"RF,'"DC(YQ@_A5;4_&7AW1YIX+_ %:WBFMU#2Q9+.H/3Y0"?PJSX?$)T&QD
MAB\O=;QA@8RC<*!@@@'C&.:XF[U&UTWXV7<EVDK(VA!1Y<#2G_69Z*#V!'Z4
M =5<^-_#-I;V=Q-K-LL5Y&TENP)8.J@DG@<=".>_'7BEF\9Z!!:P7+7S/%/;
MBZ4Q022$1'^-@JDHONV*\_TS3)]*U7P;'>6-PL7V^]NO)%JS+:QS B)6V@A3
MDCC^'\,UTEM)/X;\;^(9]1MKF6RU*.&6TFM[=I5 C3:8B%!PWIZ_6@#H9/%6
MBQZGI^GF[+7.H)OM!'#(ZS+C.5<*5X')YX')K/\ $VN:>^E74"Z_+I$L-W';
M/<K;L663A]@!&&RI'(R.:Y.7PMJVE?#32[NWAD;6M(N3?V\"C+*C.2T( _V&
MP5YY&!VK3\4:3>6_PV-IY,]WJ5U=Q7$RP1M(QD,RRO@#)PH! ]E'TH Z'Q/X
MDLM'L+N$WDL5\+5YD$%NTS1@#AV 5@JY[MQUK,\,>*XXO FAWVL7,T]]>PE@
ML4+2RS,"2=J("3@=>,"L6[N+W2?$OBF272]1O;?7;2,V%Q;6Q<#;$5\MA_"<
MGOBN:MM+O;/2?"VI:EH&K76GVUDUE=6L DCGB8MN$BJK*2#D#GT^E 'KA\3Z
M.='AU6.[\ZUG;9#Y,;.\C\_($ W;N#QC(P<]*P/!&N7&L^(/%"O>W%S:V]Q"
MMNL\?EM&"F64KM4@@\<C/'-<_%IE[H=[H&MZ?X<NHM)@NKEGL(U:6ZC65%59
M&5F)W9!) Z XZYK=\$?:IO%/BO4)M,O[.WO9X7@-W 8BP5-IX//6@"SXCUE]
M%\:: 9M0FCL+F&Z$EL%#!V14*[0!N9B6Z<^PK5@\6Z-<Z$-9CN7-H9/) $3F
M3S-VW9Y8&[=GMC-9>OM*/B#X9E6RO988([E99HK9WCC,@55RP&!RISZ=37&7
M.FZG>Z3/=PZ-?S"R\13:B]E+#)"]S;R%L&/(&6P>G4?S ._E\=>'[>PGO+B[
M>!+><6TZRP.KQ2'H&&.,YX)X/K3H_&NBSQ;[>6XG<RR0I#%;2-(Y0 L0H&=H
M# [NG([FN%UNQ-UX6U";3O"5_9B\N+0>4\#O<S>7(&=G4%L*%&!GD\^U:GC&
MRNX_%>G>(ET.\U?36L3:RVUMN6:-BV\/LX/L1V[T :NL^)=&U#3-%NH==N[.
M&YU"-87MHGS,ZM@POQ\H)/(;'2K=[\0/#UA=WEK-<7#361 N5CM)6\H=V.%X
M4?WNG(YKD==TFZ'A?1%L?#L]HHUN+4&L[>-I'BA4'<9,9^<]<>^.2#5NYAO)
MM2^(T<>F:@?[0M$BM&-JX69EA,1"L1@_,P_#GH* /1X9HKB".>%UDBD4.CJ<
MAE(R"*Q+KQCHMG-*DUQ((H9Q;S7(A8PQ2G^%GQ@'H#V!.#BK/AJ.6+POI4,T
M4D4L5I%&\<BX9650""/J*X!=-U>T\&ZYX/GTN[N+VZGG%K<I%F&596W"1G^Z
MF"3D'GCC- '6ZM\0/#NB:E)IU]>2)=1A&,:V[MD-T(P.1[C(K;U75+31=,GU
M&^9TMH%W2,D;.0/7"@G'O7(:'IUW8_$'#6EVUK;Z+!IXO'B(221"6.#Z8(Y]
M<BMWQM_R(7B'_L&W'_HMJ (+#QYH&I7ZV5O<3^?)"9H0UM(!,@&28SM^?'MG
MVS3+'X@^&]0DVP7Y"B*29I)(G1%5&*MN+  'C.#S@CU%<W8&?Q"/"-['I=_;
M0:)!Y]Q+<6[*TG[D*$B7^,L><CL!W."MOX>U;4OA%<:1':RV>I"XEE2*Y 7?
M_I!F4'J,%2!Z9H Z^W\5:=/>-9[;N*[^SFYC@FMW1Y8QU* CYC[=>>E,M?%^
MEWN@PZS;?:)+.:=8(R(3N9RVP87K]XX_^M66@N?$WB70=2_LJ[L%TLS/.UY%
ML8L\>SRT_O#)R2./E'J*IZ'X:O\ 3O'.H6K0@>'HYO[4M."?](D785],*0[8
M[94T :FGZMI$?B7Q+/\ VM>[[5(FO(+H,D-J%4C*!@/O $DC(/!'6L9O$3:I
M\3/#:6HU6WM9K:YD:.X4QQ3KL&QU7/)Z]0",CBL_4O#VLZMKGCU;6RFB&HV]
ML+.:8;4E:$ ,N<]R,#/45H%]<USQ5X7OI_#E[9QVD-U%=M(\8"-(B+E?FY4$
M=>I[#B@#H!XVTK[9:0LEVD%W.UO;WCP$022 XVAO?L<8/8FI[3Q59WUY;PP6
M]T8+F:2"&[VKY,CQABP!W9_A;&1S@XKAO#&@:Q8K;:#>^#]-$UG,I76VCC=6
MB5@0P&-QD(R!TP2"<8-7]+T'4K/Q7:7>EV5_I:O,S:I:S2*]G(I!)>/#$ARQ
M&,=.<@8P0#HO&WBAO"F@-?1VLMQ*[K%'M7*JS' +<CC^=83Z]]B^(C32Q:NR
MSZ,)8]. :1P_G%6(C!*J<*#G^IQ6K\1M'OM;\(R6^GP^=/'/%/Y8."X1@2![
MX[56CMM6?XEPZ[-H]S%:-H[VG^LC8B3S?, .&XRHQGIDXSWH V5\6:;-IVGW
MEJ9;G^T$+VT,:@.RJ,L2&( "]R2.<#J15K0M=L?$6FB^T^1FCWM&ZNNUXW7[
MRL.Q%>7Q>&]:M=%\-7LWAE=1;24GM+S3+G86D5V!$D><J0/\^M>C^%[*>STQ
MS-IEGI8FE,B65JJ@0K@ !BH +\9)'KCM0 M_XFM;*ZN;:.VO+R6TC$MR+6(-
MY*GD9R1DXYVC)QSBLF\\;AM6\.0Z79SWEGJWF2K/%L_>(L9.U0S @@E2<XQ@
MCD](X;?6/#7BC7+F/3+C5+#5I(YH6MW3?%*%VE'#L/E.!AN@Z5E6GA36?#T?
M@UK6P6^;2S=M=1PS)&$:<$X7<1E06(]<#I0!%H_BFW\.ZMXNDU"35+FWM]04
M-@/.+6+:,$DG@$D\#/W>E=AJ?BRRTYV2."YO6CA%Q*+4*?+C.<,=S#.<$@#)
MXZ5QEYX8U^?3?'D*Z6_F:O,C6@$\6''0G.[CIGG']*1_"^L66O)?R>$M/UVU
MNK"WBDAN7A$MK+&@7 +Y!![XS^G(!TMU\1M%@E@BMX=0OY+BT^V0+:6Q<R1^
MW3GK],$=:ZN&43P1S*K*)%# .N&&1GD=C7!V/A[5[/Q[HU^^G1"SMM+:UEDM
M/+CBCD9RV$3<&VC..F:[^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MNS<!B_E0JS;D ^48R1R>.P[6++XGV=[J6GPK;0&UU"5HH'BO%>96_@\R(#Y
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MR.^,DTK:)J][H&CP7&A:E8ZAI^EQ0V=_8W,8E691M:-QN V':AYXY/2O5J*
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MNW=<]>V*T&\.Z]8>(M4BMM!TJ_L-3N6N4O[DIYEH7 W;E()< \@#\QFO2:*
M,+Q#H#:QX,O-"2?:\MKY*2L /F &"0!C&0,X'TKGO#UKXLM8U-WH&E6;6<39
M%K(@;4)-N%Y _=KR2<\Y XQP>^HH \XL= \2:'XDM=:L;3SVU"$_VW ]PB*9
M=V0R8XR,D?3'.236/X>MM6U;3/&^B65C$;>^UV[A>\DF $(; <[.I(7!&.I/
M;%>OUGZ7HFG:*+@:?;" 7$AFFP['>YZL<D\GN>] ')76AZRGBC4[BWTX264N
MC#3H9#<(&++N()'8'=BJT?ASQ+;_  RTC1[=$COK25!=6RW)07$08DH)%^[D
M8S^(KT:B@#RQO!7B";2O%FF)IVF65OJJQR6PAG.V-E"#9M"#CY3SQSVK6DT;
MQ%=ZEX0O+C3K6,Z27^T*EUN^5D$?!*C) ^8CIV!-=[10!Y]:^&-=L/#^I>$H
MD@ETRZ:5(+]IL-##*27#)CEAN.,'!SVJS#X9U6QUS5Y;:WMGLKC2XK&W+W!#
MYC4@%AMQ@[OT]Z[BB@#$\(Z=>:1X4TW3;](EN+2!86\IRZMM&,@D#KZ8KE[;
MPQXBL?#]_P"$HDLY=,NFF6/4'EPT4,K$LICQ\SC<V#D#)'I7H=% '%P^'=3M
MOB-;ZS%;VXTR#2UTU 9SYF ^[?C;Z<8S5WQUX?O/$6A06]@\(N;>[BND69BJ
MOL.=I(!QUZX-=/10!R,6G:__ ,)C_;<UE8;?[+^R[$NFR9-V_NG3/RY_'':N
M>L?!GBC2K31+ZPDT]-6TQ9K:2"65F@N(9&+_ '@H(()Z8/0'VKT^B@#,T2'5
M8K)WUFXAEO)9#(5@!$<0P $7/) QU/4DUR-UX1UQ+CQHEH+*2WUZ+$322LKH
MQC*$$!2,#).<\XQCGCT&B@#SE?!NM27G@OSXK3[/HUA):7>VX.YM\7E$I\G8
M -SZX[9JYX:T'Q?I"VNCW5_IS:)9,/*FB5Q<RHIRJ-_"!T!X.0/?-=U10!YB
M?"/B<^#YM+^SZ:+IM7^WH?M3;=GF>803LZYP/H<^U=@WA#0;B^;4I]'M!J$F
M6DF49;<1@_-_6MZB@#@O#?AGQ9H:V^B/JMD^@VD@>*=8V%TZ!MPB/.T#L3SQ
MD50U?P-XCO-,\3:+:W.FKIVJWXO(Y9-_F@LRLZD#@8VC!YS^/'IE% '):;X;
MU&U\<R:]<2VK0OIR612,MNRI#;L$=,YXS5;1O!=U!X<\1:-J,T!35[BXG$D!
M8F/S1C&"!G& ??VKMJ* .,TO0?%D5@MKJNL6=TMK \=OY2O&9F*E5,QSR #T
M Y/)Y JK:^#M9MM-\)VHFL&;0Y2\C;G_ 'HVE1CY>.&/XUWM% '->%]!U+0;
MK4XY[NTEL+F[ENH52)A*&D;<0S%L8'3 '/K4&I>%]0NO%T^IV]Y:I8WM@+&[
MBDB8R; S$E"" "0V,G./0UUE% '%>'O#7B?2[:TTZ^UVWN--L2#!Y,;1S2JO
MW$=LX"#C( )(&#Q4.D^#M6TWP!JWAUI[)YKSSUCE#/M42Y!SQG(R<>OM7=T4
M <;#X9U9-5\*W32V7EZ+:/;R@,^9"Z*A*\<8V \^II]CX=UW2M&UFVT_4;2*
M]O;][V&X,198_,<,ZE3UX! /OT&*Z^B@!J;]B[R"^!N*C S[4ZBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *;)]VG4U_NT <
MAX$YA\0^VN7(_5:[$=!7'> A^Y\1?]AVY_FM=@OW1]* %HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH 3'-&*6B@5@HHHH&%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#'!]JYO^Q7M=1UBQN?#.E:JUW=R3V>I/+%Y:+(Q;]Z"=QVDGH"3C [&O1/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ K)UK0EUIK-SJ%[9O:2F6-K5D&6*E<D.K X!...]:U% '"
M>%_#FI:+XE\3:E/<ZE<J[J;=9I$VW7[M?F(51\P(V@\<=J/$NM>*9M%L8]/\
M-:@DMVNZ[\BXC$ENN>45NS$?Q8XSQST[NB@#D--U;7(/"EQ/!X0>UEM-D5II
MAN5#2*, G=T  )_[Y-)X[AOKA?#[V>F75V;758;R80;251 V>K#GYABNPHH
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M79_]^%_PH_X1_2/^@99?]^%_PH \Z,L=EKVI&!4EL5T!-,MYS>6X,KIG!P9
M0"&ZG'0UO> ]7T_2/!6F:?J-]9VUU;1&.1&NHFYR>058C%=/_P (_I'_ $"[
M+_OPO^%+_8&CCII=G_WX7_"@#A?&$6E:UXDT#4K/6K%5AE\F_P!MS&"UOD/C
MD]-R <<_-2>'[;1=*\>:YJKZM8"PE?S;)/M$>%DD4><V <@Y4#GL37>?V#I'
M_0,M/^_*_P"%)_8.D?\ 0,M/^_*_X4 </=:S9R_$F6^6XM?[/DTAK$71O(=H
MDWE\E=^[';IU[8YK!;4YH_"_A33S#9/+H]_!++Y6IVYWI$K*6&YA][(('USC
MOZO_ &%I'_0+L_\ OPO^%']A:1_T"[+_ +\+_A0!Q7AS7[*#QMXGOKN:VMK2
M_:!K>5[R!@WEQA#D*Y(SU''3K@\5'K%W9V7C"/Q5H.JZ1/*]O]GOK.6[5#.@
M(*E&Z!A@=<# KN?["TC_ *!=E_WX7_"C^PM(_P"@79?]^%_PH Y23Q?-J=E<
MO#J.FZ1(+:58(IKN*5WF*D(6*EE50<'C)/MC!X[1=MIXM\/ZS)_9,+012Q:A
M-)JJ22RNPP96.#D'^$ GK@A17KG]A:3_ - VT'_;!?\ "E_L73/^@?:?]^%_
MPH \?M+BYAT/0]&\[10FD:PMU]H;5$ G0.[A@ "5'S8YYSVQ6E>3:?/XQM]4
MLKG3]/NEO?,GU&WU!0EQ; _ZN2,')<C Z8XSGM7I_P#8VF=K"V_[]"E&D:<.
MEC:_]^5H \KT>633)9]'CU#PY)8M<M)!J@E4W$$;.6/R%3N?D@'. ?4#%>H:
M=<:E/=7AN[>VCLPR_8Y(I2S2H1R6&..U2C2K$'(L[<>WE+_A5M1M4 =!Z4 +
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !117)>*=1DFU[1/#$$TD!
MU)WEN)HV*L((AN**1R"QP,CH,^U '6T5R&L^+X?#4EQ96NC7$]KIEJDUR\96
M-(8CD*$W8W'"]!3?$^H'1&TSQ/9;_(FGA@OEYVO!)PKD= RDK@^Y'>@#L:**
M* "BBB@ J)KB%6*M*H(X()Z<9_D:EKS/XH:1;Z9X,UO6(9)QJ$DB2+.)2&CR
MRJ OH,4 >E+(C?=8'Z4;USC<"?05R%\FD>"X9=95'C\U4MQ"LVU'<DE<;C@'
MKSZ50;XG6D>GZI,]H)+O35626&WG616C8XWJPX..A]Z ._+ =3B@,",@Y^E<
M1/X]N+6>SBG\.WR&]N3;VQ+KB3Y-P/7OBJLOQ*FBL[ZXE\/7*_V9)LU &5<0
M=.0?XN"#Q0!WS3PI(L;2HKOG:I;!;'7 [T_<..>M<=J&HV$WC?P_&VFR274]
MO-+:W1?"QC9DC;W)K.B^)4S6L5[)X?N8[ WWV&:=IE/EOOV#Y1U&: /0B0.I
MI-ZXSN%<7KWCIM"N[GS-+D-E;2)').\H1G+=?+!^]C(SCUJO;>)-6NO'6L:;
M)8))I]I;HP"SCHP)W=.IP1U[T =VDL<BAHW#J>A4Y%.R *X/0?$FGVGA72ET
MG2S%)?SS1VMB),X8.Y<EO3()_&G7?Q ;3=-UE[S29$O]*5))K5)0=\3=)%;N
MN: .ZW#.,\TC.J#+, /4URFD^+IKWQ/%I%YI4EF]Q:&[MW:8.70$ @@=.36I
MXJMTN?#&II(H8"UE8 \<A#CGM0!J)<P2-M2:-FXX5@3S4FY<9R,5X/-=:=!\
M.=#GLK6[M=99(%COS&\:*Y(RSR'"D8]:]-_X2F:U\4Z?H-Q:J5O+8RPW@F^6
M0J 64#'7O]* .KR*:9HU!+, !U)X K+T;5'U6WGG-OY<2W#QQ-NSYJCC?]#S
M^5<OJ4Q\1_$K_A&[C(TRQL1=S1#(\^1FPH/L!0!W,=W;S8,4\<@/'R,&_E4G
MF)_>''7GI7"ZE:>'-#\2Z.L4+6-^9B(!;PL%G!4@K@<'&0<GI18^/;F[EOW?
M0I8;#3[F:"]NVG!$010V<8RW7H.E '=[AZTF]?45QZ^,KN!M,N-0TKR-.U)U
M2"=9]QC9@2OF#'&?;/6JUQX_EM]!U74CI0)TS4?L,L?G_>^8+N!Q_M=#0!W6
MY2< B@,&&0<UQ-[XUU1-<U+2=.\.O=W-E!'/DW"J'5O_ -5=!X:UN'Q'H5MJ
ML$;1+.N3&YR4()!4_0@B@#7HHKG_ !OIFI:QX0O['290EY(HV@L5$@!!9,CI
MN *_C0!MPW,%P&,$T<H4[6V,&P?0XJ6O-_"FI^']0UZW2WTI/#_B&SB>.73I
M(?+,T9'0,  P! (."< \8.:T8/'T]QX9TS6H])C>.[U(6,JI=Y$0,AC$@)0;
MAD#C ZB@#L8KJWFGEABN(I)8<>8BN"R9Z9';.#U]*);NVAN(;>6XBCGGW>3&
MS@-)@9.T=3@<G%>;P7^J:+XY\;R:+X?CU!%-K-*BW @Y\D$A1M.YB2Q[=#SD
MUM?\)!9:OJ?@_4$TJ*5-1$IMKF5L2VQ,3,X"X[A0"<T =I17!0?$.>Z:WO+;
M2GGTR:[-O^Z21Y@@8KYO"[=N1T!)Q^5:@\3ZC=+]OTS2UOM+^V?9,Q2_O2 Y
M1Y0,8VAAC&<D#/% '4T5Q?A+5->U'Q+X@6_^R&UMKL0;4E<F/$:D! 1C!R22
M<')]A4WCW4-5L[328=+DAA-YJ4%O)*\K(P!;=M& >#M()]#T.> #KJ*YE_$&
MJ7>H7VG:58V<MWI\<;77FW+!/,=2PC0A<GC^(@=>GIH^&]>M_$N@6VJVZ-&L
MP(:)SEHV4E64_0@T 7;J^L[%5:[NH+<,<*99 F?IFI8Y$E4/&ZNIZ%3D5Y]X
MK&IZ#XQ3Q*=&;6M(:S^SRQQ*&EM,$DLJGJ&SS].<8Y?8>+M"TCPO92Z')Y]M
MJ%[(EK"L#?Z.6)D=61 6^7)X _B';D 'H-%</9^.[NX@:.32)([N34$L;1I$
MDBCGW MYF'4, %5B1@],=^(/%FO>);+PUJA:SBLI8+F"%+I7+)/'(RJ2G=6&
M[!S^'L =N]]:1WL5G)=0)=2J6C@:0!W ZD+U(%6*Y2>_-OXRTN#4].TXS&RN
M)EOUR7B"%=P&1E00WKZU1G\<7L&@1>*C:6S>'Y)%!7<PN$B,FP2=U/8[>,#O
MF@#N:*X>^\7Z]'>>(8;+2+"6/2(DN-[W;9EC9&88&S[V%]<#U-.O_'#QW.D0
MPM8V/]HV*WD<FH.P1R<?N@PP W(Y)_"@#MJCGN(+:,23S1Q(65 TC!1N8@*,
MGN20!ZDTVTDEFLH)+B,13/&K21ALA6(Y&>^#7F_C#4K?5KB"Y>:(6EAJUK!;
M*90"\HG3S)< ]% 9!GU<^AH ].JC::UI5_<RVUGJ=G<W$7$D4,ZNR=N0#D5-
M<11:AI\L/FGRKB)D\R)N<,,94^O/6N,N_#FD1>,_#T.BZ;#:W&G%I[B:W0+L
M@V,BHY'4LQ&,Y.%8T =Q--%;PO-/*D42#<[NP55'J2>E5[#5=.U6)I=.O[6\
MC4X+V\RR 'TRI-,U72;/6K1;2_B\ZW$BR-$3\KE3D!AW&<''3BN:T'2;.+Q[
MJNH:39I:6$=LMI*80%BGG#$L0H[H,*3ZL1VH [.BLGQ+J=WI&@75[8VBW5S&
M!LC>0(HR0-S$D?*,Y/TKDE\>WS:5XJG@%A>/HL<<L<T:21QS*RDD%22<C:>0
M<&@#T.JEYJEAI\MM%>7D$$EU((H$D<!I7) PH[GD=/6N2M_&&J6OB#3+/6;:
MRCMM1L9+M#;EF>$HH8AB>&XST'7UK!UG4M9UJT\(:Q<?94TV^UNTDBME0^9
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MT6Z2[ATN>YBE*.&9-D#*Q;T^9E!]V%>AU6@T^RM9Y9[>T@AFF.99(XPK.?\
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M6\;7S<:] PUJWCAF"V6 FT%?E^?I@G /?&2:[2YG%M:S3LCN(D+E8UW,V!G
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M>]=Z9P&&1D<^M9MYX$CUL:I/K=TD][?VBV@D@BV+;QJV]=@)))WX8DGJ!TH
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ME@1Q5CQ7?7^F^%=3O=,B\V]AMV>%=N[G'7'?'7'M3_#6C1^'_#MCI<:HH@B
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M'4;FS-QJ]O;2&$J-R.W.<@^G3H<G(-<O)XDU+05\:V8O[J>.QNK2*VGG?>\
MGP'8L>,#.1D8!P.E>C:OH5CKAM/MRRM]DF6XA\N9H]LB]&^4C)';-51X1T;[
M3JL[VSR-JR[;U7F=EE &!\I.!@<#&,4 <KK<5YHFLQZ3!J6H7&GZO8W3R>==
M,\D,D2;@Z/U4'(& <>F*RK-KO3OA%X<N[/4;R%Y)[17"R\%6D"E?4#!Z BO0
M[#PQI6G',4,DC?9_LJM/,\I6+^XI8G Z<#K@>@JC_P (%H/]DQZ6(;H6<<BR
M)&+V;Y2O*X.[( /('0'F@#(877BO4/$4$6M7>FWNEW(AM%AE*)&NQ6$CH"-X
M9BWWLC ''KG_ -HZKXL\0ZUIUE?*JV,$#6<L>H/;??C#^=M16$@)(X;Y0,#'
M-=5JG@3PYK.K#4[[35EN]H5W$C*) ,8#@$!N@ZYZ4:[X$\-^)+R"[U33$FGA
M4*KJ[(2HZ!MI&1]: -+0I+F70K)[RY@N;GR@))X,[)&'!9<]CUKC[_1X9_C+
M8R/<WH+:6\^$NI$&5E0!< CY?5>A/6N]@@BMK>.""-8XHU"(B# 51P !Z5FZ
MCX;TK5=2MM0O;8R7-LI2-A(R@J2#M8 @,,@'!R* //UU*_O?AHWC6'5;J/5T
MD:?RS<OY&!*5\CRL[#D?*/EW$XYKU2-B\2.RE2R@E3V]JQ$\(:)'>-<):.H:
M7SS )W$!ER#O\K.S=D YQU%;M !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !4-W=)96LES*LC)&,L(XR[8]E )/X5-3)?]4_^Z: ,"V\<>';K[&4U HEZ
MVRVEF@DBCF;.,*[*%)SQC-;\L,<\9CFC22-NJNH(/X&O&/"VA:SXN^%&@Z.L
M5G!IAG>26\>8M,%6=S^[3;A6ZC)/3ZUU=K?>(+SQ3X@$FM"+3M&NHG$*6JLT
MT9CWM&3U'4<C)H [R*&.",1Q1I'&O147 'X4^O,9_$&O6W@>S\<)J9N-[)-<
M:?L3R?)=@I1.-VY<CDL>0>.U6)=9U;0_%FOZ7?:E/<K<62SZ.K;%)=FV;!A?
MO;V4#/;G% ';W.J16NJV6GM#<M+=ARDD<+-&FT9.]NBY[4S5M:M-%%H;L38N
MKA+:,QQEAO=@JY/0#)ZFN;O;_5-#\3^&+"XU26ZMYK2Z:[W1(#*\4:G=P.,E
MCQ["N=OI=1USP_X<\1SZQ*T5WK5K(+%$3RD0S *H.-VY<<G/)SQ0!ZQ17F%W
MK?B[7M2UL>'U9/[.O#:Q#[1$L>4P29$92QW9/(8<8[@U;>Y\3:YXNN=+M-?7
M3H!IMO>!HK=)=KL2"JD]5X/).>F* /1**!TYK!\;375OX'UN6R+"Y2SD*%/O
M#Y3DCW R: %?Q78&:1+6WO[U(9#'++:6KR(C#J,@?,1T^7-:6FZE::O81WUC
M+YMO)G:^TKG!*G@@$<@BL;P<(C\/M'_LDQ8^PQ^67Y7?M^;=CONSGWS7%6WB
M36+_ ,*^']2TU[?2#J&N_96@MX@\9#L^YFW#.2P)X(ZT >LT5P%JNIW'B+_A
M$;GQ!?G[%9?:WO8@L<UP7E(4$X(VJN <=3U]*S[/Q-K<EYI%K<7<@D@UZ;2K
MB0(H2[C16(;&.#P,XQWH ]/HKRW7M=UJUT#QT\&K7"2:9=1K;.%3<B,J$KG;
MTRQYZ\#FK UW5?#_ (N*7VH7-];S:%)J4T$BJH21.<1@#*C (P2>O)- '9:W
MXCM-!N-+@N8IW?4;M+2$QKD!V/5CV'Z\&MBO'=7BNKV'P!K]UJUU=2ZAJMI+
M) 67R(V8;L(H'&W[O4YYK:NM3O+?QO%#JFI:IIQFU +8D;7LKJ($#ROEY5SS
M][O0!WNI:E:Z1IUQJ%]*(K:!-\CD9P/H.I]JIZ1KIU2YN+:73+^PF@ ;;=1@
M!U/0JRD@].F<CN*YWXM6QF^'VH2BXGB\H(2D; +)F1!A@1SCJ.E.87(\66WA
M,:OJ MET][^2X:8&>5C($5-^. .3QUXH [>BO))/$'B"6"VT]=7FCGM/$RZ2
M]R(U_P!(B()!;C[PQSC /<5Z#'I4]IX8FT^XU6]NY C_ .ENX2;!)(^9<<CI
MF@#6AGAN(_,@E25-S+N1@1D$@C(]""/PJ2O&-#OM1TSP7X1M+2\N\ZW*5D,]
MR$\L)N(6-MIV;SCGD_0G(TM;G\5:/X:U;[1K!@GM[NVDM!'.)I%BED";9&**
M2,@XQ@]<F@#U6C->9WEKK5AX]T;0CXJU66UOXKF:5F\L.N!P%(7C'_ZL5FV]
M_KL?A>PU>3Q!?R2PZV+$1G:$DB\\H?,XRQ([Y';CU /3DU1GUZ32_L%XJI )
MOMAC_<,2<; W][OCTK0S7"ZC?:C'XUUVRCU*Y2W70Q=PH-N(9-[#*\?[(ZYZ
MFN<T36=:BC\":E/K-Y=-J\C07,$I7RRN" 0 ,Y'7)/)H ]=S566_B2.[,0:>
M6U7=)#%\SYV[@H'J1T'O7F,>LZPVKV%]#JEW=VTWB VCSHX2U,1)41+&W)(
MY8 #/0MUJWX8TQDM?&MW%J6HQW$6IW,2R?:"QPB(5)W9!/;/I0!Z#I=\^HZ7
M;7DEI/9O-&':WN%VO&?1AZU<S7F>DZM>Z['X2T:[O;Z%;S26O;BZAF,;SN
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MP,_C795Y+<?\DL\>?]A6^_\ 1HKIP4\0>-]=T?49)EALK:#[+%'*T>1(I+R
MKC)! 7/;'N: .TS1FO(WN=1M?#F@>*;J]GGCT?4)+:\E:1C]HM?-:(2LH^\P
MX/YGFFZ5-=-J.H>&9OM"1Z].E_ITGFNS1VA8EQN/*$*@('8OWH ]>S17E^M7
M,UCXC-Q?I.VCOJ4"6NIV-V2;5D*J8)8\_=+*P)_VNYKOM/T^*SU'4KF.]N)W
MNY%=XI9MZPD+C"#^$&@#2K";7[FYT^_O-(TMK]+?Y+?$PC^U.&(<*2.%&/O'
MJ0<>ID\6SW%KX.UJXM"1<1V4S1D'!!"'D?2N4U >1\"(Y+2:6!H]'BD22"5D
M8-L4GD'/7.10!U_]LF'5K:PO+5K<W29MY=X97<*2T9]& !/N 2.A%,\3ZZ?#
M?A^YU;[(UU'; -)&KA3MS@D9_E7,?$&66+P-I5W"S?:X+RSDAPV"S[@,9]P3
M6G\2_P#DF^N_]>W]10!):>,2=6T[3M4TN:PDU*,O9OYJRI(0NXJ2/NL 1UKJ
M,UQ>G^$+C4+O1]6UG5VNC8VY%K!;P_9U0NF"Q(8L6QW!'05R,5M=6/PQN/%L
M&IZG+JL*7,2,]RSK'&UP48A3U(4%@3GGDYP, 'L6:,UY_=:?:Z9XC\-/HLK?
M9=5\V*[M_,9EN8C$7\T@G[P('S=?F%97AN.Y6^N? UU/<RW%GJ?VN2=W+,]H
M '0EO]H[$(ST)H ]$M[S49-<O+6;31%I\4:-!>><#YS'[PV=1BJ&J>))=.\8
M:'H8L=\6J"8_:?,QL,:%B-N.<\=_6N1U34;O1M7^(=W9S2^;;Z?:R0^8[.(V
M*R$E02<<G..GM52XL-+LO&?@;4]%E^U27-O=MO>0L]T1;G:[$]R20?<T >LY
MIDKND+ND9D=5)5 0"Q],FO(_#4D&M0Z'KDGB*"#54O52YBC@?[1,[-AX7S+R
MO_ <*!D <UL>!/#UI<:QK.JS3WDD]CK5Y!;J]R[(J<*003SP>IST% '7^&];
MEUW2C=7%@UC<1RO#-;M*LFQU." R\-_CD=JV,UR_BZP7_A'K?3M/>RM7:YC6
MWMIEVPSLI+^20O0,%/Y57^']U;RV6J01Z9)IEU#?,+NS+ATBD*KQ&PXVD ''
M;)[8H M:GXEO1K-YI.BV,-[>V5LMS-'+-Y>[<?E13@C<0"<GCD>O'10N\D$;
MR1^5(R@LF<[3CD9[XKS6SL-+M?BIXLU">VB1+"R@N 8UPR$H69P!U/!_&L7P
M]/+!XS\%2*T5O;ZA:W)9A/NGN4,>Y7N", L6Y YP1U)Z '>:YXHU7P_X4U;6
MKW1X5:SN"L,/VK_6PEE57R <$EON^W6NH@E\VWBD(QO0-CTR*\4N&8_![QVC
M22.(]:EC3>Y8A5DA &3SP*ZU9K&T^)H%W)!#!-X:5I?,8*K_ +W!)SU^48^@
MH ]"S2%@,9(&>!7ANF)%J>B_#>VEGD>*>XNH[A4F(W@%CM;!]#^1K1OK.P'B
M[4?#.HZG96-A9VL(T]=0A,K>44)=HY&<;'W%N>O ["@#V%F"J68@*!DDGI57
M3=2M=5TZ&_M'WVTP+(Y&,C.,_I67:6]O?>!K>"Y)U"![%07NXP3. HP[*<\G
M ;GG\:\WT6\TB'PAX*LIFMAIUS.%U01%?FDV-Y2S8_A+=0W7;0![,&##(((]
M12,ZJ,L0![FN'\.6:Z7\2-<T[2U$>CK9PRO;QG$=O<,3\JKT7*C<<>U4M?U3
M1?\ A.]0TKQ?)!%8R:?&-/,X_=@-O$K9/"OG !XX% 'HQ8*,L0!ZDT;A@'(P
M>AS7F]K+I\GBGP]HUT\EWH;Z4XL#? .+F=7P68'ACY8!4XZ-QUKG;ZVM_LSV
M:,'TF#Q9;PV!\PC8K%3+&A[*&R!CI@^E 'M/F)C.Y<9QG/>@NJ]2!]37B]]H
MVE#4?B;;BRMQ;V%E%-9PA1L@D:W)9T7H&)4<CFM)[?3M5UOX=G4BMQ'=Z5)Y
MGGG'VAA%&0''1N23@]Z .T\9^)+CPUH]O>VL$,YENXH#YC$ !SC(QUKHA(A8
MJ&4D=@:\/U.$67@O4+>W8G28O%$:V!).T1@C<%)/*AMP&/0UU.OVTG@[QR-?
MTVP22/6H6LW6.,9%WR8CG&0'(P??DT >CAU*[@PV^N>*3S8\9WK@^]9^CZ)9
MZ1H-OI$4,9MXHO+92HQ(3]XD=\DDGZUY->^&KN:'6_ UG90[-/G;4[*X>/)2
M)E+*BGU+C9]-WH* /7M6FO8]+NFTS[,U^L9,*W#$)N_VL<XJFGB&VBO=,TJZ
MFA_M2\MS,4A;<B@+DMU^Z3P/7\ZX:\D37OAIXA\4:G:10RWVG[(4D4 HL:D#
M\3*6(]MM02C2HO'WA"XOUM%@?1#N>8+M9@ %Y/4],4 =MX4\22:S8S/J+6L%
MRM]/:1QQMC?Y;$<9.2>":Z2O$);;3%\$7VJ;+?[6OB8F.Z)&]1]I'W6[#;D\
M>YKVX$, 000>010 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %07=N;JT
ME@6>6W,BE?-AQO7W&01G\*GHH Q?#'AJW\*:.FE6=W=SVD9)B6X*$IDEC@JJ
MYR23SFFZ5X8@TG6]4U1+Z]GEU(JT\4Q0QY484J H(P..O(ZYK<HH YFU\#:9
M:0BT2>[;2UG^T)ISLI@5]VX8^7=@-SM+8SVK2U+P]I^JZIIFHW49:XTV1I+<
M@\ L,'([]C]0*U** ,F^\/6NH:Y8:M--<">Q#K"BL F'&'!&.<@ ?AQBL"3X
M8:(ZB)+S5H;5+@7,-K%>,L4+[BV47MR?P[8KM:* .1U#X=:+J&M/JGGZC;2S
M +=1VMTT:70 Q^\ Y/'7!&><UJ0>&;.W\2/KD4URMRT MS&' B\L=%VX['D=
MZVJ* ,W3=%@TR^U&[BN+J5[^42R+-+N5"!C"#^$?Y]*TB,C!Z444 <Y#X,L[
M%IQI5_J.F0SR&22WM)5\LL<YVAE;9G/\..@J/_A ]'32=.TRW>[MK73[C[5
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M#@=2<]<FJ\?@C1(H-(@2&<1Z3(9+,?:'_=L3GU^;\<\<5OQQK'D*#R<G-/H
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M)3($4.P +8Y('09_$T^B@"%K2VDM_(>WB:'_ )YE 5_+I338VA6)3:P;8O\
M5CRQA/IZ58HH IC2M.\OR_L%KLSNV^2N,^N,5;5510J@!0,  < 4M% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !5/5;X:9I-Y?&)Y?L\+2^6@)9R!G  ]:N56O[P6%C+=&"
MXN!&,^5;Q[Y&^B]Z .2\$:E=:W+)?/XNCU.-5Q)81V2P_9W/8D@/@8(&0,]:
M[:N2TBSCO?&EQX@MM.N+*%[(6\KW$)A:XDW@@E#@_*%QDCG=QTKK: "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HQ110 8HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F32I#$
MTDCJB*,EF. *?5#5M+BU?3I+*=I%CDX.P]J +<,BS1K(C!D89!4Y!J2J]G:Q
MV5M';0KMBC0*H]A5B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
&**** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>exhibit1021-independentc006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit1021-independentc006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HKFM2\7&#4;C3=)T>]U>]MMOVA8-J1Q;AD!G<@;L$' S6YI]V]]817
M,EI/:.XRT$X =#G&#@D?K0!9HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!6]X;T&+PYHL6GQ2O.P9I)9W^]+(QRS'TR3TH UZ*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ J*>WBN4\N>))4R&VNH89!R#@]P0#^%2T4 %4[O2M/OY8I+RPM;
MF2(YC::%7*'V)'%7** $50BA5 "@8 '04M%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"(\8W;&AD ^?H,Y/// Q72>+-<;P[X9O=42-))(0JHLC87<S!%+'T!8$^PH
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M%Q'HTD5K>/'JL?F1.L65B79O'F$'Y>#COS6O0!QL_A'59;[Q/<IJMHAURW2
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MFLI UU;@(0@4* 2N2>Q(Q@=15G2O#<NLV.H6,VH>)AHUW"(W_M61?.9L_P
M=2RKCKD#J,=Z] -+0!SNL>#-,US2+*POI+IGLBIM[Q'"3QD=PP  R ,\=AW
M-07?P_T2^T$Z5=&\F!F%P;N2X+7!E P'+GOCCTQVKJ:SHKO46UV>TDTT)IZ0
MJ\=[YX/F.3RFS&1CUS0!A?\ "N]+&CR::+[4\2RQRS7#SB2:4H=R!F93PIY
M&*TAX9B_MVYU?^T;[[1<6PM77,>T(,D8&S(.23G/4FMRB@#D[KX>:+>>'[+1
MYFN_*L6+6<ZRA9H!Z*X'3ZY[>@J4^ ](.EV5@SWCI:7:WJRO.6D>=1@.S'J0
M.,=/:NGK/US4)-)T.^U&*!9VM8'F\II-@8*,D9P>P]* ,Z?P7I-U<ZU/,)V;
M68UBO!YF ZJ,+CTP/3\<U3;PC)#XAT2\M+Z_$-@L@E>>]>0S*V?D*MG/)!SG
M@*!CH1T6F79O])L[UE"-<0)*5!X!90<?K5N@!" P((R#U!KG(_!6G6D4L&FW
M6H:=:S,S26UI<E8R6SG .=G7^'%=)D4E '.-X&T7[#I5E"MS;VVE2^=:1PSL
M-CY)W$GD]3U/<U=U+PY8:EJ$6H,9[>^BC:$7-M*8W,;=4)'49YYZ'D8K7R*3
M(QG/% &#>>#='O-*L-/,4T$5A()+:2"9DDC?G+!QSDY))[GFN6\8^#+33?!&
MK66A:??7$^I7$#2QQR/*3MD5BV">/E4\]2<9->C*Z21JZ.K(PR&4Y!%1O=6\
M44LLD\:1PY,K,P 3 R<GMQ0!EZ+H%AI\QU&(74EW- D9FO)&>58P.$Y^[ZD=
MSUS5C6-#LM<AA2\$X:"3S89()WB>-]I7<&4@]&/MS5JPO8=2T^VOK<DPW$2R
MIGKM8 C/YU+)+'#&9)9%1!U9C@#\: *>DZ/9Z+:-;V:. [F2221R\DKGJSL>
M6)]336T.Q;74UIEF-\D1A5_M$FT(<9&S=MY(!Z=0*O"6,QK()$*-C# \'/3F
ME1TD7<C*PR1D'/(.#0!CZEX5TC5M7MM5NXIS?6HVPRQW4L90=\!6 Y[^M.TG
MPQI.B1WL=C#*J7TAEN%DN))?,<]6^=C@GN1UXST%37<FJ+K=@EM]A_LUUD^U
M>:S"8G'R^6!QUZY[5<^U6^Y$^T1;G8JHWC+$=0/<4 8"^ ?#B:=;V"6DZV]M
M.MQ$JWDP*R+]T[M^>.PS@=JDO_ _AO4]835KO2XY+U=N9-[ 28Z;U!P_0?>!
MZ5MR7=M%,L,EQ$DK8VHS@,<],"L^P\1:9J-_?VEM<HSV+A)6WKM)VACCG/&1
MGT- "GPYIC:__;ABE-_Y7D;S<2;?+_N;-VW'.<8Z\]:I:1X$\-:#?R7VFZ6D
M%PX8;O,=@N[KM4DA<]. ..*VA?V9E$0NX/,.,)Y@R<].*<MY;.9 MQ"WE?ZS
M#@[/KZ4 96E^$M&T::"6S@GW6Z&.#SKJ681*>H0.Q"Y]JT[ZQM=2L9K*]@2>
MVF4I)&XR&%*;VU <FYA C4,_[P?*#W/H*5;NV>T%VMQ$;8KO$P<;-OKNZ8]Z
M ,^P\-Z9ID<J6T<X,D?E&22ZEDD5/[JNS%E'T(]:DT;0--T""2'3+=H(Y&WN
MIE=]S=V^8GD]SW[U874[![(WJ7ULUH.LXE4QC_@6<5&^LZ8D-S,VHV@CM>+A
MO.7$7^]SQ^- $>LZ!IGB"".#5;;[3"C;EC,C*N?4@$9/UZ5"/"^D"^BOOL\G
MVN*$P1S&XDWJA&" =WO3O#_B&P\2:8E]83QNK<E%<,R<G&X#H2!G!K1N;JWL
M[=I[J>*"%/O22N%4=N2>* ,4>"O#@T>72?[*A:PEE\YX69F&_P#O DY!X[5.
M/"F@KH?]BC2K8:;G=]G"<;O[WKN]^M.U'Q'I>G:!<:RUY;R6<4;,KQRJ1(5!
M^53G!)QC%9'A'5M6UL6^HOJ.F76G7%FDLD,"XEM9FPWEG!(( )!S@Y'2@#5/
MA;13IESIQL@;6Z;=.ID<F4\#YFSN/  Y/2L'QIX8;4-#T?2=.TPW-G:W\,TL
M'G!1Y*9W+EFSD@X']*V?$7B'^R)K&PM85N=4U"4Q6T#/M' RSL<'"J.3W]*@
MEF\66!LWE_LS48Y+B**X2VMI(6A1F 9P3(^X#.<8''- &E::!I5G:W%O%8Q>
M5=<SK+F0R\8^8MDMQQS4=IX8T:PAFBM;%(UFB\ER&;/E_P!P'.57D\# %67U
MC3(Y_(?4;19A(L)C,R[@[9PN,]3@X'M35US26U(Z<NIV9OAUMQ.OF?\ ?.<T
M 5(?"6@P:%)HB:9#_9DA+-;-EER>XR>#GGCOS1:^$?#UE<R7%OHUG'+)#Y#L
M(A\R=P?KW]>]73K.EK%/*VI68CMWV3.9UQ&V<88YX.>QJ.[U_1['/VO5;*#$
M?FGS)U7Y./FY/3D<^XH JV_A#P[:VEM:PZ/:)%;2&6#$?,;G&6#=0>!SG/ J
M:Y\,Z)=ZDNHW&F6TEV"#YC)]XCH2.C$=B<X[58;6-,2&TF;4+417CB.V?S5V
MS,>@4YY)]JNT 4)-#TJ6\EO9-.M6NI8S'),8E+NA&-I.,D>U9-WX-TR:XTT6
M]E86MK8S"=5AM560.&##8P^X"0,X&3C&:FAUF;4/$EU9VCQ)8:8 +V5U)9Y6
M7(13G "C!8G/4#CDUFOJEROA"6<^+])6X-T8X]2VIY0^;/EXS@MMR/UH ZV:
M"*Y@>">-)8I%*NCC(8'L163'X/\ #,0 C\/Z6H#;@!:)C/3/3K4<VK7.F>)X
M+&_>)K'4<K92A=K1RJN3&_8[ADJ?8@]C6]0!SFO:=K6JW"Z7!]ACT&XA\N\=
MMWGX)PR(!\H!7C)Z9/M6O?Z3IVJVJVVH6-M=6ZD,L4\0=01T.#Q7.^$]?N+B
MS\07&LW\#1Z?JLULL^T1HL:*F._J3U)ZUO6>NZ5J%E->6M_!+;P9\YP^!'@9
M.[/W>.>: (Y/#6A33&:71K!Y3%Y)=K9"?+QC;G'3'&/2K46G64%G%9Q6<$=M
M$5,<*Q@(A4[@0.@P0#]:J6_B71;JUN;F'4[=H;4!IVWX\L'."0>F<''KCBK&
MFZQI^KQ/)I]W'<+&=K[#RAQG!'4<<\T 61!$)S.(T\XJ$,FWYBH)(&?3)/YU
M4@T/2;6]:]M],LX;MNL\<"JY_P"! 9[FK-W=V]A:R75U,D,$8R[N< 5GP^)]
M$GM;JY74[=8K0@7!D;9Y)/3<&P5_&@!^B:-#HMK+%$4+32F:0QQ+&N[:%^55
MX PH_J2:TZS=,\0:3K,LT6G:A!=20JCR+&V2H894GZBM*@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KB-:_MR\\>Q:/9:_-8V<^FO<%4MXV9&61%^4D
M9R<]\\9QUR.WKA->TF?4_B5ITRRZM9P06$D?VNSC(7S&<$(6*LI&T,3G@$+R
M#B@#)T?Q1K=W=:=X;OK_ &7?]JWEE<7Z(JO*D"*XP.BEMZCH> >_-2:W>ZE;
MZ/XXT#4+MKR.WTTW5K<2*H?RY%<;&QP<%3SBNI?P/HS:/;:>JSQM:RF>&[24
MBX68G+2;^[$GG.0?2I3X1T]]+U*RGENIVU,8O+F20>;*.F,@  8R    "<=:
M .5M=1U&P_X5Q;V]](EG?6B1W%L$4J^VW# YQN[],XX%6]#O]6U_1-/\30ZX
M+:.2\9[FUF13$MN'*F(8&0XP/F)ZY[5K'P/9EM#/]I:C_P 27_CT&^/ITPWR
M<C;A?I[\U'9_#S0K'7'U.#[6H:7[1]C%PPMQ+D$2;/4$#KQ[=* .<U3Q/K&D
MCQ@@OVF:UOK2WM'E\M/)68*3SMV\;CR0>@)SS4HD\;VPU2U22.-[FS,EA#<7
MR33"4,H;8VP#!##&[@,1V.*Z>7P3I%RVL&Y^T7"ZN!]K223*DJ,*5&/E( &"
M/2H;#P!H^GZ3<6"2W\HG"J;B6Y+3(BL&14;^%01D 4 0>!=6&I'4(FGU-)[?
MRUEL=27][;-\W.[^)6QP?:K?C:^FL]+M%@U,V,D]Y%#\B;Y9P2<Q1CL[=CQC
MU%:&D:%;:1+<SI-<7-U<[?.N+F3?(X4849P!@9. !W-)K_AVP\1VL$%\)1Y$
MRW$,D,AC>.1<X96'(/- 'F-UKOB"V\'>,!/J-_93Z9?1+;[WCDF1)"N(V<9R
M/G'(.1Z]16]J6J:GX1UW5R=2NM2A30GOQ%<X($Z.%R, ;5.>0*UIOAIX>F@O
MX/\ 3DBOW5[A%NW(<J0<G).22 23SD=>N='_ (1#3WU8:E//>7,WV7[&Z3S;
MXY(B,%64C!SU/J>: .#O+2;_ (2+X<ZE/J=W>37CM)+YLF4W-&&)1>B]<8'8
M"O6F!*D D'U':N1MOAMH%K>6=P&U"063%K6&2]D,<)/]T9X'M77F@#QA+KQ+
M<>#->UY/%.H+<Z+?W$<496/9*B$9W@*,D@^P'IS6SI\NM>)/'>JVC:]J>GVT
M-K:7<=O&$!1G4,4.5Z=01U]3Q3O!'@\S1ZNVLP:E"LNJRW*VDLC+!,A.4)3H
M?<>PS79VOAFPL_$EWKT3W/VR[0)*#*=A Z?+TXQQ0!P[ZOJ6H> =4\86^J74
M&H6UQ-+';&3]U$D3E1"\?0Y49)/.6SD#%7-/O[WQM/KD2:I=:1>VJPK:P1R$
M>0&C5_,91C?EB1SQ@<>IZ27P5HTMW/,8IEAN)!-<6:3,+>9_[S1YP2>,]C@9
M!J/6/ /AW7M875+^R9KK9Y<ACE9!,O8.%(W8_P#UY% '*76H:SXC\4WNE:9J
M4#K;Z=;S6[_;I+7>SJ6,P$:,7'*_*?E&1P<U/H^I7_B+7;7P]J>J,XM=+^TS
M7&G3-"+N7S-F]67:2BX[8!)] *Z;6O OA[7KJVN;VQQ-;J$1X7:(F,?P':1E
M?;\JM7OA/0[][1YK!5>S3R[=X':%HTZ;04(.WVZ4 >7:/?WVG^&?"YM[ZY5Y
M_%36]P_F',R-*VX/C@YQ_/UK8\4ZG?VD/Q 6UU2[3['!:2P;9SF%GW%@I_A!
MXX%=G'X*\.Q:2^EQZ<J6;S"X,:RN") <A@V[(.?0BHV\!>&FBO(SIN%O55;G
M;/(#, <C<0V2<]^I[T <CJ']K:8FAVZZ[=7)UZ4/+]MNS H80C]VDB(3&&8Y
MPN.F!C-3WD'B.PT:YTR+45O[A+V)TLTOW2<PLK,T G8!BWRE@<[MH/MGL]0\
M,:-JVBQZ1J%DMS8Q!0D<CL2NWH0V=V>V<U"G@W08M/M[&*Q:*&WN/M,1BGD1
MQ+@C>7#!B<$CD]* *?@34[?4M'N?)?4 \-RT<MMJ#,TUJP S&68DL.X.>A]:
MB\3ZA,?%OAS0C<2VUGJ!G>9XG*-(8U!6,.,%02<G!R<8[UT6GZ79Z5%)'9P^
M6)7,DC%B[2.>K,S$EC[DTS5-&T_688XM0MEF$;B2-LE6C8=&5@05/N"* /-?
M$MYJ>DZ1XQTZTU:^5-/:RFM)S.S2Q><VUXRY.648R,G/S=:]'T?26TB&>-M0
MO;TS3&8O=R[RI( (7T7()QT&3CBJUSX1T2\TJXTRXLVDM+F02SJT\FZ5QC!=
M]VYN@ZGL/2M>"!+:WB@B#".) B[F+' &!DGD_4\T <7XLEFN?%%GI]K>W#R"
MQFFDL8;EK947( GDE4[@ >  &R>W4US=C?ZIJ]E\.1/J6H*-06X2\EAN6C,@
M6,[0V.I//S=>,YS@UZ)JWA;1-=NHKG4M/CN)HD:-7+,IVMU4X(R/8YJ*R\&^
M'M.-F;338XC9N7MR'8F-CU(R>_3Z<=* ."M+76==\)>*K*QU/4?MVD:S<16#
MB\EWLB%2(V;=E@1D#)[UUOA75E\5W,>N6\TRV45HD"P"1MOG, TFX=&*_*H/
M8[JGO=.N_#UI(_A/1[:>ZN[G?<K/<L@)(.9"3DDYQGN:U-!TB/0]&M["/:2@
M+2,HP'D8EG;';+$F@#-\>:I<Z/X0N[NT+H^Y(VF09,*,P5G_  !)K$O+&+2?
M&6@6NGW=V^GZU'<17<+7<D@?;'O656+$ANQ(/.17=W%O#=6\EO<1)+#(I5XW
M4,K ]00>HJAIGA_3-'8M8VWEMMV*6D9]B_W5W$[5X' P.!Z4 >20Z=;I\-_!
M)@>9#<:_;*[+.QVGS91E020I^@Z]:OZGJE[X:_X3RRL+F[%M9R6!1Y9Y)G@6
M8?O6#,2WJ>#D$YSTKO\ _A"/#6 %TB! )?/&S*X?.0PP>,$DCTR<=:N1^'-(
MCNKVY%C&TU\NRZ9R7$R^C D@_P!* //M2A:RT?6KFR\2I)!<:++=0VME)+PT
M?2<.9&*Y^Z1T8YZD&NJ\":9Y.@V6KR7U]<W.I6-M+.+B8N@?9G*C^'[V..RC
M\;UKX-\.V6GW5A:Z3;PVUWQ<)&"OF#T)SG'MTZ^M:MC8VVFV4-G9Q"*WA7;'
M&"<*/09H Y+XA7DME_83M<E+!M047D*/M>:/!X R"P'4@=JY6[35-#\,>(-9
M6ZU"&QNKZ)+-C<R-Y%DSKN=%+'9D$X/! ]*[#QQX?O==;2S#8V6HVEM*[W%C
M=2&(2Y7"D.%.-O)QWS[5%X8\'Q6,UU-/HUCIEM<0^2^G6\S3QR\@[Y"P )&"
M  O )R3G@ @N]/2P\::+9Z9(YT_4K6>.]M3,[*8U4%91R<')"[N^>M8OAR":
M:X'@B]>:2XTK46N9Y\L#); ;HR6_VBZKC/137H>EZ!I6B[_[.L8;<N "4'.!
MT&3V]NE6DL;6.^FO4@1;J9%CDE ^9E7. 3[9/YT >/S7ESK,OB![GQ-::1?V
M5^_$J2FX@1'^01_O0K*5&,!.<G.2<UT&C:/'K7C;Q*E[>ZF8[62RFAC6\EB"
M,T6]N W ))^7.!G Q79S^&=$NM7CU:?2K234(R"MPT0W@CH<]R,<9Z5/;Z+I
MEI>W%[;6%O%=7/\ KYDC >3_ 'CU- 'C-@MS'X&L]=CU"\&H1:^(O->[D.8S
M+M*!2<'.><CGFNFUN6;_ (3?Q99_:;D0?\([]I55G<;)%)P5P?E^@X-=Q_PB
M^@BR6R_L>Q^RK+YPA\A=@D_O8QC/O4DWA[1[BYEN9M,M9)Y8_*DD:(%G3&-I
M/<>U 'FNFK)IE[\-[FVO+MI=3@87CR7#/YP,*MM()Q@'IQQBH2AU6]N8%_Y#
MIUXI_:,5ZJ$VPDY3<&#!0H*; /O<CDDUZ=_PCFC*MF%TNS'V(DVO[E?W!SGY
M/[O/I7$IX%O'>YMK[P[X:NY+B221M6DW>8=[,=QCVYW<] X ]: /1XHUBB2-
M=VU0%&YBQP/4GD_C7E&L)I7B*V\>-KPB>_TLRI:1S/CR(A&#&Z G@LV23WR!
MZ5ZI9V_V2R@MO,:3RHUCWOU; QD^]4KWP[HNI7?VJ^TFQN;C9L\V:!7;;Z9(
MZ<F@#@]-N+;6?$>@Z-JB6]SH\GA]);6*7#1S3@J&]F95!X[<UD/J/]E?8M-U
M24GPHGB"XM=\A)1HE3]W&Q)YC60D$'C"<]*]6FT+2;BTAM)M-M'MX#F&(PKM
MC/\ LC''X4]]'TV73/[,DL+9K#;M^S&)3'CKC;C% 'D_BNVT"W\,7$NA7B7<
M$&LV\Z/$5:&S+D;DB=>%' ) /&X4[66L+CQ9\08[:6$J=",K""3&9D4G)VGE
M@>N?QKU,:'I2Z4=+&FV@T\C!M1"OEGG/W<8ZTR/PYH<2,D>CV"JR"-@+9,%1
MT7IT]J . C\,Z2/$?A&/[.Y34-+G%ZIGD(N0B1%1)\WS ;CP>.@["L>_D.D^
M !90W#6FE0>)YK29BAE2*U$DF RY^9,[<@]<X[UZX-&TM9(9%TVS#PKMB80+
MF,>BG' ^E$>BZ7#;S6\6FV:03_ZV-8%"R?[PQ@_C0!X[K&G:=;^!_%*6>M0Z
MK;YM9Q]CA6*VM7,@4A-K$!B.2!TX/>MK5='TK3_%OB'3K6WB^R7/AE[J:%CO
M$DRR-MD;=G+=]QYSS7HR:#I$=@M@NEV0LU.X6_V==@/KMQC-/31]+CN!<)IM
MFLX38)5@4,%QC&<9QCC'I0!C> QI:^#M,33!9C_186N!;;?]:8UR7V_Q'OGF
ML[Q*\<GC_P /V>KQ0R:/-#*(5F3<C7>1M#9&,[<[<]R:["TLK6P@\BSMH;>+
M.?+AC"+GUP*+NRM;^#R+RVAN(LY\N:,.N?7!H \9URVM+72-9CY&D6GB*V^P
M%'V"+)4S+"PQMP2PXZ$'N#7K^EZ18:-:M;:;;);P.YE*(3@L>IYI9='TR>UB
MM9M.M)+:+_5PO I1/H","KB(J(J(H55& H& !0!Q.OQ6_P#PM3PFQ5/-EMKU
M'SU90BX!_-OUKS2.QL;/X>S:G#!#'>VOB39'<8&^)1(,*"?NCGI7N]QI>GWE
MS'<W-A:SSQ8\N66%69,'(P2,CGFHDT'1XX3"FDV*Q%MVQ;= N<8SC'7!(^E
M'FOB62WTWQ/J&HE]-U:UDOK=;FUD*QWME(NP*T3'EAT./?C^(U4NXM"33/B-
M9S16"W:RSM;Q,BAU @4@J.H ([=Z]731=*CNUNX],LDN5QMF6!0XP,#!QGIQ
M4LFG64LDDDEG;O)*%$C-$I+A3D9..<'D>E 'EFK:9H_A_P )>%M=L+2W61KZ
MPEN;LMG<NT@LSD^K<FLK5[O1]1U7XE26\UE<0R:;#+"RE65F5,%U]2&(Y'<C
MUKVJ2RM9;0VDEM"]L1@PM&"A'^[TI/L-IM9?LL&U@ 1Y8P0.@_"@#RBSTG08
M_%_@RW2TL?+N])=KF/"D3MM1E+C^,[N1G/(]JQOM0A\"VRK=M!H]IXCE2Y:&
M-)E@AW$QDHP(*AL'&".G?%>W_P!GV>Y&^R093A3Y8^7Z>E.2SM8HWCCMX4C?
M[RJ@ ;ZCO0!X?XEL]$7X?^(I].U1M1CFN+60W#QQQ0&?=@B%550'\O[V/7ZU
MU0M=$@^*EW86:V8AG\/8:UCV;&<2!E^4=6VX/<XYKT8V5JT"P&VA,*G(C,8V
M@_3\30EE:I*LJ6T*R*,!Q& 0,8Z_3B@#COA3=:=-X#TZ*R>$SPPJ+H1C!5\G
MAO\ :X[\XQZBCQI,UGXK\)WM\5&APW,OVEW^Y',4Q"[YX #$X)Z&NUCACA4K
M%&B G)"KC)]:5XTD0I(JNC#!5AD&@#R;4/*BMOB3=V<\2Z)/9A8RC#RI+HQ$
M2%#TW9P#CJ2.XKN_ UQ#<>!-!,,L<@33X$8HP.UA&H(..X]*W!#$(UC$:;$Q
MM7:,#'3 J2@#@_&=K=:9XNT#Q='#)<65B)+>\2,%FBC<8\T*.H&><<X _#/\
M:ZYIFL3^'ET3Q \TTNI0I<0Z7>MO>W.=^5C;@=.2,UZ94:6\,<KRI$BR/]YP
MH!;ZGO0!YMI6G:+JGQ*\9*D.G37L'V62VWA6,<JH=SCOD/MW$=^M8_VBTU'X
M9VVB0A(_%UM=J$M<XN4NUEW-+CJ 1EB_3!ZU[+BFB-!(9-B[R-I;'./3- 'D
M7BJ]T^UE^(VF74CQ7-W##-;PI$2TH6W!+  <J&4[CV )-(+K05^)&BS:S]B2
MS_X1F-U:\1542^85R=PX;"D#/T%>P5@2^'[E_&\/B$7T0BBLVM/LQMR206#$
M[]_7('\/2@#C_#$NA:'X>M?[;CCCL[G7)GT-)[=CY2ESY14$93N03CKFO3^U
M4M0TV/4A"D\LHACD$C1(P"RXZ!^,D X. 1G'.1Q5V@#A/A^!;W7C.VNF42+K
MMQ,ZL>D;JI4GV('Z5P=O*+GX'ZK;V&V=SJQ7RX1O./.5N /]D9X[5[))H\9U
MR/5H)Y()]GE3HOW+A!G:&'JI)PPY&2.16E0!PWCW-YJ/@M+5A([:W#,NUNL:
MJS,?H%KNJSETF+^VFU6:5YIQ'Y4 ?&V!#C<% [L0,DY/ '2M"@#Q^$W<:WM[
M;0SO96WBYKVYAC@8L]N54+*!U*A@3P#TSVK3U:WL-7US6]9C2XGT*XTB.VNI
MK3=F6;S1AD ^\R+SGGT]J]-HH \CMWEN])UNVU>\DU6P5K5(==LH&2;(D^4'
M ^8Q,=QQGJ<^@ZGP//JS7VKV^I21WT41B$.JI 83=#!X8="RC R/6NSI: .1
M\=I>QP:/J-O!+<VVGZC'<7<$*EG:,9&X*/O;20V/:L36T6_US6-;L(I_L1\/
MR6LLBPN!/,Q/EJ%QEF R"<<;@/IZ31B@# \&06\?A/23%:_9Y$LXX9%>$QNK
M*,,K @'AMWYGUK?HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\_
M\0Z)9ZW\2;?3KZ:Z%K<Z1,TL,=RZ+*1(@ P#V!S@8SCG/- 'H%%>'RPP:K=^
M)?[3UZTTS4-*O&6U:>(O<PPQA?+,3>8H^;'0*<EN?O"M?7Q)8:U>:QJ%O%JN
MF-/;)+/ VR]TZ0*F!@\;"3DJ#_&: /3[;4;:[N[JV@E5Y;5E28*<[6(R!]<5
M!K,^J6]FCZ19PW5P95#)-+L 3^(@^OM7F%YH^DV5G\1?LT*6TUK\UN(9"C)_
MHRL<8([Y)_&I-6\/6&F^ ],U:"2Z-Y>2Z<\SO=.P=MR@D@G'1B/H!Z4 >N53
M&IVC:J=,64&[6'SVC'\*9P"?3)KSF\GT#5O$7BJP\5WZV-Q!+&+.22<1/%"$
M4AH2W1B02<#G(%1Z;I>@3_%2XEN+>("?2;>>)KG"2-*[$;NW[P@@<<YH ]%T
M6;59[ OK-K!:W7F,/+ADWKLSP<^M:"LKH'1@RL,@@Y!%>(^'YXH_#?A^QN4)
MT6YUZYBOB\A*LP+&)6_V2V"<GDKWS5KQ59QV2^-=.T]%718].CN_*C/R0W3'
M'R@?=RHR5^AQS0![+17F.AV%GHOQ$T&/3T\I;[1&:Y^<L9F!4AF))R??K6QX
M]N_)U#PU:WN!HEU?%+XN<(2%S&K_ .R6Y.>/E[T =A=W,=G9SW4I(CAC:1\#
M/ &3_*L#0-7U_57LKNXT^R72KVT^T))#,3)$3@JC CG*GJ.X/X\K/IUO;ZYX
MOT^SM[8Z%_9(N9(-H:.*Z(?&T=%)49(_W372_#BUMK?P!HKP011--:1O(T:!
M2[;>IQU/N: -O6+NXT_1[N\MH8YI8(FE$<CE P49(R <=/2N0MOB#?IHFD:[
MJ6C11:3J+K&9;:Y:5[<L<*74H.">X)[5VFI>5_9=WYY41&%P^\X&,'.:\U\
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M$9[>O:GV?BK0;^XE@M=6M)98HO.=5D'"=V]P.^.G?%>57\N8O&H#ZG>-?Z7
ML,\UDR"5E#YV@* J] ,^O>MJR"Q^,_ 3A"L4>CM&YV$!'9  #Z$D$?6@#NQX
MIT1M(N-6CU&&73[=]DEQ%ET!XZ%0<_>'(S^AJOXRU&[T[P7J>I:=/Y-Q!;--
M&YC#=!GH:Y2ST*YT[QO=^&H$']@WDR:S\K<Q[3AHL>C2!#CIM!'?CIOB""WP
M_P!<159G>T=%51DL3P  />@"3PUXFL=5MK6Q;4(I]6CM(Y+J->N[:-QXX/S'
M!QT/%7$\2Z.^IKIRW\1N6<QJO.&<=5#?=+#N <UYVC7)USP;!99BE;P_+;F4
MQG$,C1C;DXP#O3]*E\JXU7P!I7AE+.>WU^RG@C*O&RB%HG!:;?TVE0<-GDM@
M4 =X_BG18]3&GM?H+DS>0!M;;YF,[-V-N[VSFJK>//"RR1I_;EH3)+Y*E6R-
M_'!(X'7J>.OH:Y"6*YM_&"?V2+J:.;5"]WI%[;,R(1(<W44A&%' 8<XR<>U9
MK;+WPUXR\/"WGN]5O-7G2$K:-MD8LN#N V@+U.3Q^- 'H%WK-M8Z_>2S:[N@
MM;+?-ID< =HSN'[S*C=T(&WWS46G^.](N?#MIJ]S*]N+G 6+R9&=F(SM50N7
M./[H(K(DM;J/Q?-"\=S.X\-BT-P('V23!F)&[&,D<]>]8=E>W4?AGP=;-HVJ
MQ"SS#=W*Z:[3VK"+ \M2IX;.-V" ,]Z .H\3^)F?PK9ZQH&I8C>^@B+HBG<K
M2!&1@PRIY/H0:Z2+6M/FUN;1H[E6U""%9Y(<'*H3@'.,?A[BO)D6]C^'MU9-
MI.L?:(==6XV/9R%W0S[\C ^8[5R2..1SS7ID7B&TD\4_V0;"]CN'MO-2[DM]
ML4BC!VA^N1NY!''- #/$VMRZ:VG:?9;#J.J7'D0%^1&H&YY".^U>W<D5!->V
M\/B_2=/?Q')]JCMY=]B4!-S\H.]RH 4C&>@]JS_%4+P?$+P9J;[OLJ2W-JQ'
M17DBPF?J014>MPSM\6O#-PEM<O;PVMPLDR0NT:%AA06 P,X]: &W&JV7_"%Z
MQ._C6=8?MKH-22$;K=MP/EH /F Z9'8G%;&I:M/X?U?3#=71FTW49EL\N@#0
MS%?D(( R&*D$$<$CD#BN$NHKN?X;>-K6/3M0-Q<ZM/+!$;.0-(DDJE64;>1@
M'Z=ZZ7Q\&U71_#UI:>:)[S5+9H@4*NJKEV8@X(V@$GTH [JN&\3WFK0_$'PU
MI5GK5U:V>J"Y\Y(XX3M\J,,-I9"1D]<Y_"NYKSSQMI*:QX\\*_:]+GO-+MOM
M(NS]F=XU+H!'G Y^8#Z=Z ,'7/%FO_\ ",>*K9=5VW.C:A!;Q7T(6,RH[@$/
MQ@$=RN/\?0;?QKH-TE\T%U*YLHQ-,@MI=_EG^-5VY=?=017/_$30$C^&]UH^
M@:2=TDL12WLX.N'4DG ]!U-306]R?C'+J!LKH6,NC+;K.T#!/,\P/M)QQQ^O
M'6@#H(O%>D3:%;ZU%/*]A<2+'%(MO(6=F;:H"[=W)XZ4U/%FF/JRZ>!=!WF:
MWCF-K)Y+RKNW(),;21M;OV-<KX6T&ZT[QAJ&C JV@Z9-]NLP<Y6292!'Z84;
MSCJ-RFHK73]0MO&44^C6^JV\-QJ4K:C:7<.ZUV M^^C<CY2W4!3DEO04 ;VC
M:WI=K'K]^VLW]U!%?%95N8W_ -'<A0(HUV[B.0  #DGCWEN_$NE:KH.M)]MO
MM/:T3R[IEA=)[;</E8+@GIR"/Z5QUSIVM3)X@N['2KEKBWU^+4X(9XVC^TQQ
M@ [">I.T\=>GK70SZGJ&K^'];N_^$=O+%);)H%AEMP;JXF92H.%)^1<XY]2>
M .0#13Q3IFE:5I\3W%[?2-IXNP1$9)F@51F5P!QU&>^34EUXZ\/VCV*->22O
M?Q&6T$%O))YX SA2JD$^V<UQ,\&JW<&DV,NAZJ+7^PUMP]M"(I?M X,<KDAE
MC&T'&0#[U6T+3]6B?X<";1=1B_LQKJ.Z+P'$>\!58XZ G/7!P,XQB@#N+[4V
M\5^$+N7P_>WUI=)+Y8,<(69)4<91E?&/0Y(X_*K\NMG2H+2UOXY[O43:^=,M
MG"7SM #L .VX\#J>PK"^'5O=V\_BEKJQNK9;K69KN SPE-\;_=(S].1VXIOC
MG3!>ZE;SQV.KQ7UO;L;/5-,&]HY"3^[=,\J<#KQR>5H [.VNXKNQAO(=QAFC
M65..2I&1Q]*X_3?%?A_0]"N-0EU75KJTEU*2(S7L4CM%(2 4P5!11V!QW[UT
MVAC4$\/V U8)_: MT^T",#&_'.,<?EQ7F-_HFM7/@_4+*/1KPW$OB)KY$*J-
MT+2%PW7T'3W% '?6GC31KL:EN>XMCIL8EN%NK9XF5""0P5AD@XXXS[5):>(K
M+5[V72"M[97CV_G(DT9B=XCQO0]N>QP1Z5Q/B/PSJ^M^)/%?V>Q=8;[3(8K:
M:4 ))(C*Q7KD9QBKG@[3BEW'J(\#Q:'+:0NMPP0&2=ROW81_=Z\D^@YYH 9H
M5[%-X,\)KJ6K:O%<7%Z0DUN[GSW$CX25\$;3Z$\X]JZ?5?&FF:/<72317DL-
MD%-Y<6\.^.VW= ^#G.,$@ X!!.*XQ=/UVV\"^%[2'1+MK[3]56XFB*K\J*SD
MG[W.0XQ[@TS6(KVY\1>)K:RTC5;K3;UTANQ82PE)6$:[N9.5;!VG;Z#O0!TE
MYKFCZKK_ (8S/K5O/=K.UI&D;P1RJ4.3)D#. ,C'(R#T(-8_A;QU8:1I"6FJ
M/J<N-1N+>2_DB=XH29F""25N.F/7'?%2SF77/$?@75=*TF\73;'[0LV]5!M\
MCR@K#=U4H<XSQZU7M_#>K3^%]9\)3Z=-$U]?R3?;24,"PM*KY!W;BV 0!MZX
M[9- &Y<WMA<Z_P")8+>YU2/4(M-'F*6:.)0 VUX^AW9/WAQQ6-I6K6*^#/ O
M]KW.J?:;FX@\B6W+8DF)("ROT*G)R"<D ]<5<GLM2C\<>(KM=)O)+6XTE;:&
M50N'=<\#YL\[OT-8SZ/K0\&^!+/^Q+TW.EZE#/=1@)E$B)R?O8.<\?TH Z*Q
M\>733>(I;K0K_P"R:5/Y9$)A=D54!8L-XR>IPN>.];47BNSGTW1KV&VNG75Y
M%CMHU"%AE6;<V&P %4D\DCIC/%9/A[3]0TKQ5XECO+#-AJ%U]I2[,B^65*!=
MN.I.1SQBJW@?0YM-UK58%E631]-GDATP#)VB7;)(,]]IPH_X%0!UVK:M;Z-9
M"YN!(^Z1(HXHEW/+(QPJJ/4DUC)XWM$DU"VO=/OK._L;<W4EI(J,[P_WT*L5
M8>O-2>,='O=3M=.NM- >\TV]CO(X&<*LP7(9"3T)!.#ZUBZCHNH>(=0O=<;2
MY[1UTF:PM;6:2,2R/)G+-ABH4=!ENY.!QD W_#_BRV\22'[)8ZA%;F!)XKFX
M@*1RJW&%/J"#_,9&#6_6+X0L[K3O"&DV%[ 8;FVM4AD0LK<J,9!4D8.,C^E;
M5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !5"71=,FU2/4Y;"W>_C&$N
M&C!=1Z ]:OUQ?C3QG;Z%J&EZ4-0ALY;V;;/<L5)MH@,[L-D9)P!D$=: .BN/
M#^C7>IQZE<:79RWT9!2X>%2X(Z'=C/':FR>'-%EU,ZE)I5FUZ75S<-""Y9>
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M()XI6B.V0(X8H?0XZ&N._P"$WO4T^PUV;2D70;V5(UE$I,T*,<)*Z[<;2<<
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MVY<L&&..Q'L?6N@H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPIJ,&L:7(BO-<&0VT(3K(C%L$D#@*.I]*] \2ML\,:I\LCEK61%6.-G8EE(
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M;XVL]20LH8VKC<RD@X)!!'!/+9Y KLX;2VMGE>"".)IGWR%% +MZG'4^]34
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MR:21298P,L&"G*';R.OUS4&H:3KUUXW;6K.U%NAT62RCDDE0M',QWJ2!G@'
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M7<Y:9U0-&<D(0A)R>Y H JWGC/5X;W7K:V\.I*='1)I&>^""2-E9LK\IYPO
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M%\3_ !PE_/'/< 6>9(TV!E\L[>,G!VXS[YH [6QUO3M1U"^L;.Z66YL65;E
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M>R-).P('G$!CY1/ P&Z'!J&PM#:? 2WOK6\OH)S&CDQW<@!_?;<8S@*03D#
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M4RPI*T18HR?,IP1A@#UJ_0!YCJ'@'Q+J-GXAM9K_ $D1ZQ)!,QCCD7RWC*'
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MIO\ 8]E]B,GFFW\E=F_^]CU]Z%\+Z$LTDRZ39K)+%Y+LL0!:/CY?]W@<=.*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MAE$D%L3(HVJ1P"<$D5N:?%%HWQ>^P6)D^S7VC?:9]TK/YDHE($A))RV.,^]
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MV'F&1"9;ISY7E[ANY'?'2O)-#UFSL-(\'R:JR3>'HKB]A=F/F)!-YC"$R=>
MA.W/0$GL*T?%%MX?_P"%>W4FB$?8(M9BFAE=MR.[.N_R2?X1D]..&H ]8GOK
M2UECBN+J"*24XC220*7/L#UK"N-:U&#X@6&C$6W]GW-G+."%/F;D*CDYQCGT
MKSGQY=Z==W_B]!+:V]Q%:Q(_VMO,EG(3<@@3C8H/)89Y[#K736VI6=UX_P#"
M3QWD,N_1YP&$@.XY0?CRK?D: .A\9ZSJ.A6%E=6'V<B2^AMYA,A8[7<+\N",
M'GOFKZ2:E_PDTD;7-@=,^S K ,_:!)NY8]MF/UQ6!\39HH?#MBTLJ1C^U+3E
MV Z2 G] 3^%96IW.GVGQ'\0390[O#7F2K!($DD(9R<$<[M@7!Z@8H [F35;:
M>VN_[/O;2:Y@C9MJN)-C '&X YQGZ5B^!_%8\0>%]+N]0N;--2NU=C CA2<.
MP&%)ST6O/_#U]IL?B71'BU"P*3Z+-;000#/E$E-D1<\R/USG'.< 9YIZ+INF
MS?#WPQ'IT-L/%$>I(P\M1YZ,)CO,F.0H0#.[C 7VH ]4GN];C.OO'>:4R01J
M]D@5F>,A26$P!'4CC'_UJATW6=1U'1?#-^;K3H#>Q1RWB2Y#2!H]V(AGKGU[
M5@:?=:?:^*OB*@GMHE,<#XWJH/[C#'_OHX/N?6L=;FQ_LWX6R^=;[T:-'?<N
M1B'!!/LQQCUH ] LO&?A^_ENUBU:R"VTWDEVN$ <[58E>>1\V,^H-:PU&R98
M&6\MRMP<0D2C$A_V>>?PKAM$@TK5+SQGX=O6C\Z[U&8F#'SB,PQ#>!V&>A]:
M/ <>HNL.FZO;NI\,A[02,!LFDZ(Z=^(2!])* /0J*HZ1J]CKNGI?Z;/Y]LY9
M5?8RY*D@\, >H-7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAHV'1E8<J?<&KU% &5+X9T2;3UL)=,MI+4/YOE.F07_O'/5O<\UJ*H1 JC
MP*6B@" V=L;X7IA3[2(_*$N/F"9SMSZ9J"71M-FTZ73I+&!K.5F>2 I\C%FW
M$D=\L2?K5ZB@#*3PWHJ75I<KIMN)[-=EO)M^:)>>%/8<GCWHB\-:)#9W5I'I
M5H+:[;=<1>6"LI]6'<^]:M% &0OA70%TMM,71[-;%GWM;K$ C-ZD#J?K4T>@
MZ5#?PW\=A MW#$(8Y@OS(@&-H/ICM6C10!3U+2=.UFV^S:E8V]W"#N"3QAP#
MZC/0U ?#FBE+%/[*M-E@Q:U41 "$D@DJ.W(%:=% '&^+O!EK?:'JYT;2K1=8
MOXC&UQ@(S;B"Q+?A6GX8\/66C:9:,NE6UG?"W6*8Q $\=0&'8G)_&M^B@#.@
MT#2+;4&OX-,M8[MF+F9(@&W$8+?4CJ>M)'X>T:+43J,>E6:7A8OYRPJ&W'JV
M<=3Z]:TJ* ,]="TE-5;5$TRT6_88:Y$*^8?^!8S38/#^C6VI-J,&E645ZV<W
M"0*KG.<G(&<G)R:TJ* $(!!!&0>HK)B\*>'H+O[5#H6FQW'7S%M4!!]1QP:U
MZ* *:Z3IJ:BVHKI]H+YN#<B%?,/&/O8STXI'T;2Y-074'TVS:]4@BY:!3(,<
M#YL9J[10!3NM)TV]N!<7>GVEQ,$,8DEA5V"$$%<D9P03Q[FN6U;P2NH>,=%O
MEL-+;1K""2)[65>I?N$V%>.#U_*NUHH C@MX;6!(+>*.&&,;4CC4*JCT ' I
M@LK47C7@MH1=,GEM/Y8WE,YVENN/:IZ* *EGI>GZ>\CV5C;6S2G,AAA5"Y]\
M#FI+BSM;P*+FVAG"_=$J!L?3-3T4 5/[+T_=&WV&US'PA\E?DYSQQQR<TT:/
MI@0H-.M-I()7R%P2.G;W/YU=HH J_P!F6'FB7[#;>8(_*#^4N0G]W..GMTI#
MI>GE]YL;4MMV;C"N=N,8Z=,<?2K=% %9=.L4MWMUL[=87.6C$2A6/N,8/04Z
M6QM)X4AEM8)(DQL1XP57 P,#M4]% %=["S=R[VD#.R;"QC!)7T^GM2#3[(3)
M,+.W\U  K^4NY0.!@XXJS10!#<6MO=H$N;>*90<A9$# 'UYIJV%FEQ]H6T@6
M;&/,$8#8QCKUZ<58HH ACL[:$1B*WA019\L*@&S/7'IFE6W@CF>9(8UEDQO=
M5 9L=,GO4M% #=BEPY4%U! ;'(!Z_P A^5.HHH SM<M-3O=+>#2-3&FWA92M
MR8%FVC/(VMQR*71],_LJP$+SM<W#L9+BX=0K32'JQ X'H .  !VK0HH 145%
MVHH4=< 8I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<T96'*NQ= 2,#=UY^\ ,9XK9^'=C)8^&Y@(Y8;2:]GFLH9008X&;Y!@] >6
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M5MI)-+EF+6\HE=RK")@2,,%_#BN@FMAI\?@^*#1;JSMXM2>X^SQ0RS>1$4D
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M"JB#C/W5SC'5C7IM% 'F=C.ME\3M/U&=)A9W'AQ+>*98F93()5)7@'&!R<\
M5@6:0+\-K575DN4\0+/M$9#$"XSD\9P$.<_2O:Z04 97B*VN=3\+:E;:=*%N
M;BU=(7!QR5..:XG1_$%KJUC90Q^#[Z35-,LGBD%Q;>4L($15D5^<[B H7T.>
M,5Z910!XWX8F1-?\&W'V;45"6UQ#(BV$BP6S,!B)?ESP<Y9B?4GT6.0V'A.#
M0(M,U'S[/Q 'D2.T=EBB%UO4YQ\P*D8VY->QT4 >5:C+>Q^)I;G1?MOG3:FG
MVG1KNU9HKD*R 3QN5 CX4-G/!7VQ63%91K>ZUX?U[1O$%U=W-_--;+!<3_9;
ME6?<K-M8* #@DXX^HKVLT4 8VD^(;+4M3O\ 28H[F*ZTXJLBS1,@<'HR$_>7
M((S[>A!.+XOW6OB[PGJLMO.]C9R70N)8H6D$6^+:I8*"0,]ZZJWT^VM;FXN(
MHSYUP099&=F9L9P,DG"C)PHX&3@<FK- 'G.G^#VUS2/%R7$;6MKK5V9K-)(R
MC1E0-LI7JI+ '!P<#GK6UX#74+S2AK.LJG]H7$:094Y_=Q97.?\ :<N__ A6
MIKVA-KB6T8U74+!(G+2"RF\LS*1]UCUQ]*T[:WBM+6*V@01PPH(XT'15 P!^
M5 '*_$32;J^T*#4-.A,NI:3<QWUNBCYGVGYD'U&>/4"L&W\*:W:^-(2\OF6.
MKJM[JIV[E$T+[@@/0 [E'N$->FT4 <)X6AEA^(7C2[GM+B."X>W:"5[=PL@C
M0J^TD<X/IUZC-<Y;K='PK/=+IFI'R/%8U!H?L<@E,'GA]RJ0">/2O7J* /,;
MBVO[KQYK;#3M1@BUO1EM[:X\CY8FVD$N>B$>AY]JH>#-,A$^EVT_@W4;75M+
MV_:+VZ:0P*%&"T?SX9FQP N.?05Z[10!Y%;6FH1> ]"M&TG4A<6GB!;F6+[)
M)N$0G:0OC'3:P_'(KTGQ$'E\+ZHD4<DDDEG*B(B%F9BA   YZFM2B@#R6ST[
M4(8/AOOTV^']F^8+P?99"8<H%&[CUJ:RT[4;7P%JG@BZTZ\?4I'GCMY_)+PS
M+(Y82F0?*H&[)!(/' )XKU2B@#@=(BO= \?ZC'-INI7=M=V=G$E]%$&C'E(P
M8N2<YYZ#)/ITKEM!TO7]'\)^&-1AT>[FN=%O;EKFP:)DE=)MR[D!'S$!L\>O
MUKV>B@#RWQ#8:MK-K:Z[:^%S#;VM^+F33'4)<W:E2KR,%.-V"  <GY2>X%=/
MX+@5A?7\?AUM$CN/+41SC]_*4W99^3@<@*.O![$5U=(&#?=(/TH X?7[34;?
MXFZ-K%OIES>6J6,MNS0;?E=CD;LD8&.YK%MM(U2R\ :CX'FT^[GO&DDAM[L1
MEH9DD<L)6?HNW)R#SQQFO4Z* *5I9O9Z-!9>:99(;=8?,;JQ"XR?K7EUI8:X
M/AUHVA/H&H+=:?J,+3,0N&"RL[,OS<@#;SW+<9P:]>HH \O\0^&M2U[5?&4-
MK821)?V-LMO/*H5)I(FW%>N>> "1V]!5[P/IY.HQW:>"X_#TD,31W,KXW2L<
M?+'_ +.1DD^@ SR1Z%10!ROC/P]>:M_9>I:6R_VEI-T+F&-VPLR]'C)[9'0_
MXY&!XVDU'QGX6?1+/PWJ<-]++"VZZB1(H<,"3YF[!X!'RY//2O2:* ./TFVN
MHOB5KUY+I<Z6US;P1PW; ;3Y8.Y1SGG(/_ :P;?0]9@\!7?@B;2Y9IF:2&"]
M4K]G,;N7$A.=P*Y/RXSD=\UZ=10!YEJN@ZM9ZUXKAT_2+F\BUO2H[:"=98PB
MND3QD.6(QQC'')].V7#]NT+Q3\/X+S2[EKNUTN:WEMH&1W!"A21AL$<9Z]*]
M=2XADFDACFC:6+'F(K LF1D9';-9MUX=L;SQ#9ZY*9OMMFC1PE9"%"MUX[YH
M YO1K/5_#UIJNKQZ1)=7>L:IY_V(3*K01-@ L>FX#)(!/4#/%=U145Q<06D+
M37,T<,2_>>1@JCZDT <[XS\-W.NP6%WITZPZGI=P+JU\S[CD=4;T!]:Q?$YU
MSQ7I-MI2>&;ZSN!=03323S0&%%5@S897);ICA?RKT $, 000>A%+0!RMA::E
M#\1-9NY--E73KNU@CCN_-CQNCW9&T-NP=_7':N<M_"^NQ>![OP/+8EXGE=(=
M469#%Y3R>86=2V_>,D8"D$XYQS7IM54U*PDNFM8[VV:X3[T2RJ77ZC.: //M
M0\-Z[9^(?$)TW31>VFK:3':13O<I&(F6,IA@?F)Z'@8Y'(Y(-,T37[&X\!B;
M19672+>6.\>.XB(0R1A!U8$XQDX!XZ9KTNB@#R9/#7B=OM6H0Z2T-W::_)JU
MM;3W,>VZCD&"F58A7 '4\?-UZUMPZ?XDNM:U[4KC0[..._T^*"&WN+D2 E-_
MRN%&.=YS@X'J:[ZB@#B?!.@7NB:E?>3:76FZ&\:^3IUU<),R39)=E*LP5,8&
M-V2<G KMJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG=G>W.D:A-_$;=E_UA/8J5)!]2!0!JW6LZ7JM_X:N$U/5+0W4KM:PQ*R1W6
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MK^7@.%!/#8R5R,9%2Z)HVH:9XJU2_@\/:G':7FF!-UQ=)+*T@W$[B9"=QX
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MAN-)U(7%TJS1?*@+G(._G.\?D?;.F-"UC[1X^?\ LZ3&KQ!;/]['^\(A,?\
M>XY.><<>_% $EAXI-K+X5TS2M+OKC3;VT:2*XEDC,CHB# P6'(W*23CVSVTY
M_'FE6]SAXKG[$+G[(;X!/*$N[;C&[>1NXW!<9'6L.PT37M.M?!4R:299M*MI
MK:ZA-Q&I4LBJ&!R05RI/'..W:J?ASPIK?A^>?2O^$<TJXA$Y^S:TWE&18F;<
M=XQN=@.G09'IS0!?^(7B02^%M>M=.M-1G^QH8I[RU<1I;RX!VD[U9L!@3M!
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ME%NS;F4IMP7Y(!R!T- %V_\ '-Y;W^NVMGH$ES_9$,<\DAN457C968D=>RY
MYSWVU)IWC:>]UK1K6;19;:RUF!YK*X:=69MJ!_F0?=!4Y')/L*JGPQK46H^+
M9((K'[/JME%:V@:X<,GEQL@+_(>NXGC/3WI+7PSKT-SX*=HK#9H5NT-QBY8E
M\Q"+*_)Z#/./3WH CF^(M[':ZE?+X8N6L=+O7MKV7[3'NC5=N6"C.XC=R.@
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M"A(!"@#@8&<<XKT6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNKW.KV/C7Q=?:3/:PO::5!<2&XB,FX(LC;0 1C..N>/0]NZT+4I-<\,:?J0
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M<Q0'3YI5C4(50Y . 5/7').3Z8KJ++PW;6/B74->2YN7NKZ-(Y4<KY8"#"X
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*]<#T]*OI/J!UF6%[2)=.6$,ESYN7:3/*[,< #OF@"]12*RMG:P.#@X/0TM
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M=0VBWEL5B<-NX.3QGWKM)M2UN[M7M[GP?<RQR(4=7O("&!ZY^:@#2TJPL_\
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MTW6%#+J4&OB-)A*3M4W15E SC!!.<=:Z&X41_%3Q$OVM[9#X>+F8EF\HEN7
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MMKR:UH&F7%Q/;"_N;2.>6"-@""R@G"Y) YKB9+FSL?B+XY2ZDB@>XT^$P!\
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MG8]69CR3P/RK&U#X>>']2-^+B*Z$=]*)YHH[IU3S?[X4'&XXZUU)95QN8#/
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MU&WDU>:QBN)K?<JR#<@8G9U YXXZ8K=N;F"SMY+BYFCA@C&YY)&"JH]23TH
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MHOAXSKK,2J0-AR?W(4=!YF&';">IK7^*8,GP]U"V2&6:6=HE2**-G9L2*QX
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MHV#'[Q! )P3^M6-/BNM0\ 7^K>)+.>\ENHHK5H;-BTAAC8+O7 ^\6+R<?[-
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M5#07JPB=(VDC<2(>N"C,,CN#S4?B7Q!J6E^(=!L+/3WF@O9W66170%ML;ML
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$*A(U+EMH'09))J>@#SS0M$\;:+#_P (]#)8+I,=QF#40Y::*WW$[-A&"W0
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M+V@?;*4";BVX9'4[1MYQSC@P6?@.:RT_0_*U95U314:*WNQ:_))$1@I)'O\
MF&.X8'/(Q7:9J.6>*$QB614,C;$#'&YNN!ZG@_E0!Q6L_#Q]7T:_MCJJ1WVI
M7,=Q>WAM=V_R\;%1 XVJ, <ECUZDYK2M/"][!XYE\2RZG!)YMFMH]NEH5^4$
M'(;S#SN]NG'O73YHS0!A:UX;_M'5++5[*[^Q:K9@I'.8_,1XV^]&Z9&Y3[$$
M'D&J%[X*-]HFIV,FI$7&K2![^[6 ;I %"A4&<* % &=W&>YS769J..>*5I%C
MD5FB;8X!SM; .#[X(/XT 1V,=U#9Q1WD\4]PHPTD41C5O3Y2S8X]ZY&X^'SR
MVEVD6N3PSS:JNK1RB!2(YAP?E/WE(['H0#7;44 <YHOA:32=8U/4)M7NK[^T
M"AEBFCC"DA N3A?0< 8 'KUJ@OPTT-?#,>A;9&M8[X7N206+!L[3[;?D^E=E
MFLZ+4YI-<N=/;3KF."&)9%O6 \J0GJHYSD?TH T",C!&0:Y2+P-;PV,NE+?W
M']B2SF8V!5<#+;R@;&=A;MZ<9Q5ZZ\56D&H:);0Q27,.KLRP743*8AA2WKDY
M XP,>];U &)IOA]].\1:GJWV]Y?MX0/ 8E"H$!"8(YX!(]ZD\0^'K7Q%9P0W
M$DT,MM.MQ;SPD!XI%Z,,@COT(K7HS0!SK^$;>Z75'U&\N+JYU*T-E+-A4\N'
MYOE0 8'WB><Y/Y55M/ L$%_HE]-J^HW%SHZ,EN7,>TJR!""-G3: .#[]:ZS-
M&: .(D^&.ES:7=64U]>LTU\=12X5E26"X;[S(0O /'!STJS=_#^TU#1)=.OM
M5U.X>:6.6:[>1#*^SE5Y7 4$DX [GGDUU-S<P6=M+<W,R0P1*7DDD;"J!U)-
M<^GBJ[N-/.I6?AW4+BPVAXW#QK),AYW)&6SC&#R0?:@#2US0[7Q!H-SI%\7>
M&>/8SC&X$<AAQC((!Z5"?"^E_P!L:9J:0".;38'@ME3 548 =,=@#CZFK^G7
MT>IZ9:7\*NL5U"DR*X 8!E! .._-6LT <[>>$(+[4M3O9=1OU;4;3['(B&,*
MD?.-OR9!!8G))Y/X5%)X'TZ]GN)]6N+K4Y9[/[$S7)1<19W$#RU7G(!SUXKI
M\T9H YKPUX*LO#4GF17^IWS*GEP_;[DRB!./E08 4<#MGBNEHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *Q]:US^S+BPL;>!9]0U"5H[:)WV+\JEF
M9FP< *.P)/ K8KE?&7AW4M8.F:AHEW%;:KI<YF@\\'RY PVLC8Y (_P[YH 9
M_P )C=6]FD=_H[VVJ2ZA_9]O;O(1'<-_ST5RN?+QDYQVQS5:[\=7>DC5[75-
M)C34M/M/MJ1Q7.8[J$'#,K%01@C&",TV]\*:[JUE9ZA?:C:_V]:7:7D"(K?9
M8\#:8P#EL$9);KGVJ/5?".JZ^NJ:A>+8P:G=::=-@B29FBA1B2SE]@);)Z #
MIUYX +&D>.;N^UG1;&^T5;*/6+-KJUE%V)2=JABI4(,<'.<_KP&:-XTU'Q#9
M276FV>G/&T4C+_I;%[9UZ+.FS()Y/'ICOFH;?PCK46L^$;QFT_R]#LS:R@3.
M3)N0(67Y.P .#ZX]Z72/!E_%KMMJU\FFVUW':/!<RV#/_IC,  SJ54#&,]\G
M'3% &59ZU?WO@'0M1U_2;'5(KF\@*N\QS&SR;0Y4KU!;  .,=ZGB\5>)4UWQ
MG*8K![718E/DM*XPJQNXV_+RS=R<=!UQ3X?!WBF'P5IV@&XT=VLKJ&1''FJ#
M'&V\ G!RQ('8 #U[:O\ PB-^VO\ B.5KJV.F:] L=PNT^=&1$8\+C QSG)YX
MQCO0 6GC&]O+GPS&EC;A==L)+A,RMF*1(P^#QRIW 9Z]:Y^#7]6F^'.MZMK.
MG:;JL,5S/YEM([!2$EQC!4C:N.![#D&M'2/!WB.TO/"TMU?Z6(]#ADM]D44C
M%T957.21\Q"_0'L<XILG@K7U\(ZWX?AO=.>&]GE:!G5U95D?<2Q&>1R  /Q[
M4 :%YXIU:'QBWAC3='M)&73A>12R7)1=NX+@@+QSD8&>W3G$,/CZ:Y\.Z!=)
M8I%J.LW36B12,3'"ZLRL6(Y(&T\=\U-'X>UY?&B>)&?33-_90L&A#N%+9W[@
M=O3?@8_N\]>*Y/6=+U#1O"^A>'=0O](M[U]0FN(9Y2X@.&:3E^&C8-)Q@Y..
MO6@#N?"WB._UR\U2TO+"WMVTVX:UDDBG9O,< '<JE1A2#G[Q(JUXGUB]T>SM
MWLK6.0S3".2>=ML-JF"6DD.1\H ]16!X!GOH;N[TR5-%N(%3[1)>Z4[LIE8X
MQ(6)+.0,YSVYZBM?Q9X>O-;DTFXL;BV673[KS_)NXR\,@QC) YW#.1[_ )T
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MKY;"4"<M(6+%3(G& H*MP>>/QJYJ/B[Q!%?^*(+33].V:'&DY>69R9$*,^,
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MM.MTDDO+=K>V>5Y&9E+*X(*J JX7&3G/45OVOPXTNSL["UAO]4$5C=&\@4W
M(60YYP5QCD_]]'UJYX@\%:=XAU&VU)[F^L;^W7RQ<V$YAD9,YVDCMU_,T :'
MAV?4;C0+235A"-1"E+@0,&4.I*GD<9R.1V.16"\M_P")/$&NV5IK-QIPTORX
M84@5>9&0/YC[@=PYV[>G!]>.JL;&WTVQAL[5-D,2[5!))^I)Y)/4D]363?\
MA2SO=5EU.*ZO;&[GA$,\EG-L\U1TW @\C)P1R/6@#@['Q!XB\43^&($UE]-D
MU*TNQ<B&%&4/"Q3>I/()()QT';UKU&P@FM=.MK>YN3=3Q1*DD[+M,K 8+$#I
MD\XK&3P9I<.K:9J%N]Q;G38C%;0Q.!&%/WLC&3GOS714 >?Z'?7^N:)9^*5\
M1&W4W;/=6SA3"D <J8< 9#8V_,3G/L0*CBU#5-?\/^(=:M-8FM+NQNIX[:%
M#%&L/174CYMV,DGINXZ5LVWPZ\/VFO/JT,4ZL\OGFV\X_9_,SG?Y?3(/([ U
M/<^"-+N+N]F26]MH[\[KRVMYRD5P<8.Y?<<'!&>^: .9MKS6/$OBNV@&N7MA
M:7GA^#4O)MA'^[D=L85BI..,\\]><5EV<]YKVG?#N^O]0NVN+JXD65DE* E4
MDPV!QNXZUZ+_ ,(QIZZPVJ1&XBN3:BS'ERE52(=%5>@P>1[U1'@+14T:QTN/
M[7'!8S^?:NERPDB)SD*W4 Y/'O0!AZ7'JMSXO\017'B:^CL=&N8)(XVV;64Q
M!BLAQRO/L>Y)/(R_#VL:Q_PE7A@/?7]S:ZH+K[1<2MB"Z*QEU,49.Z-1Q@X7
M([5W=AX3TO3[C49HEG?^T4"7*33,ZNH&T#!/&%X^E9T/PYT""33GC^WC^SV8
MVX-Y(=BL,%.3POL,?E0!B:!=7VO^'].\5'Q)):-)<L;R%WW0B+>RB%5& K8*
MX;&[.*BT2QO[3P[XJ.CW%U+>IJ\T,2276"X#ID!FZ.5R QYR172V?P^\.V&N
MMJUO:.DAD\X0>8?(63^^(^@;W[=L5,?!&BF;4I56Z1]0D$LQ2Z=<.'#[E .%
M.Y0<CGB@"CX%U.*_.IPK<ZF)K=XUEL=2W-+:$KTWDG<&P2#4?CBZN=$U#1->
M%Y/%ID5TD&HQ"5A'Y;Y"R$ X^5CSZY&<X%=!H^@V>BFXD@:>:YN65I[FXD,D
MLNT87+'L!T'2K&J:7::UID^G7\0EM9UVR(3C(SG^8H \OTO5[Z>YU+PXM]?>
M=JMS%<Z5<O=R-(+)F)9E8G(VHC$#/.X YK2U@7$FL>--/EO[V2TBT1)X8C<,
M!&VV3I@@\[1G.<]\UWITFQ.IV^H_9T%S;PM!$X&-J,5)'_CHQZ<^M41X5TS^
MV+[4W%Q)/?0&WN%DG8HT?]W;G '7\SZT >?+I\<^C_#:.UO;N+[25+2B9G9?
M]&.X)N)V=P,8QU%=7X&NIS?^)=,FOKFZ6PU$QP_:9#(Z1E%(&X\D9W=:L6_P
M^T&U&GB!;R,Z?)YD#"[DR#C'//( &T#L.*V;#1-/TR\O;NS@,<]Z_F7#^8S>
M8W/."2!U[4 8?C&9WO=(L8KFX=IWE+:;;2&*2[ 3J9008U4D$G// K@6U/7)
M/"&A+)K%_!<GQ.--D>*XW-Y6YAM+8^?&!R1SZ5ZMJOA[2];FMIM0M?-EM2QA
MD61T9-W!P5(/.*S8/A_X9MXQ''IQ5%NOM:*)Y $E[,H#8&,G'IF@#F+&SO[_
M %?QOX9MM5OT6Q^S2V$S73F6*62(L?GSDJ3V/')J]X,UBY\2PZ5%-)<PSZ5"
MRZE'YS;FN 3&JOSD_==R">ZUNZAIC:(]_K.@:.+W6+QD$Z/>-&)0#C)+$J-H
MZ<<#@5:\/:;-8V<\]Y%#'?WTS7-RL/*JQ  4'OA0HSW()[T 8?Q8@N9_AMJJ
MVJNS*(W<)UV*ZEOPP#6CJ]_)/X&N-3\.WBQE+-KFU>-%96"H2%P> #C'M71D
M @@C(/45A'P;H'E/"EAY5NYR]O#-)'"W.3F-6"GKZ4 <3);:IJT?@:*XUV]M
MWU2VE:X:Q;R5V>27550?*" VW=C/Z5HZ/9C4?$^N>'[Z^U%H-*M[>&T5[MED
M960EI2R$;F)P,GICMDUUL_AO2;F[L;I[4K+8*%M?+E>-80.,*JD <<=.1P>*
M=?>']+U*Z6ZN;4&Y5#'YT;M&Y0]5+*02OL>* //-&U#4)]0\$275]<32F[O[
M228RL%NHXUD",P'#=!SBJ6J2W(\'^+&AU.^A:S\2!(7CNG!1"T*[<Y^[\Y..
MF:]0O?#NCZC:6UI=:?"\%JP:W0#;Y1'3:1@C\*YCQ=X)MIO"M]IWA_1K99K^
MXB>XV%8]RK('.2?H0 /6@"/3X+C1/BQ_9EI>7L^GW>E&YEBN;AY1'()-NY2Q
M)&?3W_+OJS-'T/3M(C9K*S$#R@>86<N_'12Q)) ],XK3H **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH ***YSQ+K-S9ZEHND64L<%SJL[Q_:)$W")$0NQ
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MZ&210=H'8(.A'U[T >M45QOA/5=4?Q;XGT'4;]K]--:V:&=XD1L2Q[B"$ &
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M7EM(4\E8O+&&&5 .[)/7.: /4:*Q/%\US;>#M8NK.ZEM;BWLY9HY8PI(*H6
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M-EO<*0) <X;YCM)X'0=ZV-2=E\=^(X(KF>-3X?$^V.=EVR;F&X8/!P%Z?UH
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M4,\(AVQAB?*W/&F3@<L,@GOS0![#?^*=&TZ^M+*>_@\^ZE:)5$B_(0I8EN>
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M'@,6Z,.AK(\=>*IM(\!W>NZ!=65PT+HOF9$J$%PIQM.,C<*X6'5+:#PC8W4
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MP@^SLTUU+)OC_NL&8A@.@!SCCTJ*V^'OARTDLWBMKG%E*9;5&O)BL!/78"V
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MB<\@D$]2#CI6I:ZMIU]<S6UI?VMQ/!_K8HIE9H_]X Y'XU9FFBMX7FFD2.)
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M>5HS&9E9?O%<Y7(.<9[U!=^$O#^H75O=7FDVMQ/;JJ1R2IN8!>@)/7'OFMK
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M-+Z&TM4>2\823,^T.HMUX*##9+Y/(Z#&:Z&^M/#VO_$^?^U/L=W9MH2&,R2
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MB<!?4#GIFK/B#P[JGB#Q%XD2"*[MX+_1XK:&1TQ&\JL7PQSQ_=Z?Q'\?3**
M.%\+6]S<7UG-<>#+;1KFVC87-T\<678KC;"5.<$Y))XP,<YR.Z%1^?#]H%OY
MJ><5+B/<-Q4$ G'7&2.?>I* "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7#>.9-,MOB=X-GU7[.MJ$N@[3J"H.P;<Y]&(QZ5S5S9RVFGZCK-I8W3>'_\
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MR7EY&T-G/4$9QC(/-<Y\2O%:IX5U>'2_[2$MJ51[^T)2."7<,H7# DX.#@$
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M"-=/-DT=KYA)RX?<-P&.1^7YUV- !1110 4444 %%%% !1110 4444 %%%%
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M &*,444 4M0TNWU,P"Y:4Q12"3RE<A)".1O ^\ 0#CI5VBB@ HQ110 4444
M&*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,4
M44 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 %
M%%% !1BBB@#)TCP[8Z)<7L]FUP7O9?.G\V=G#/W;!. >G3T'I6M110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1O3=12&%C(F9%<[OFQ_#C '?.>U;5SX6U27Q;-K\%];P2OH[::@523&Y;>)
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MW<"XN" F4.<X7Y>!P!SGI5P^$-NL0:G!K%_;SI9QVD@C$>V54)*E@5/.3GC
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M=,X!./:@#"\&^&432=%OK^749);6V00V5]TM)-H5R 5#$_> +$X!XXKM***
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MXR.E4==.M7_BS0H(X=-76[6PDGE07;Q8W,$^5PF64X;Y<=N>@R :,OQ-MHM
M35SH>I^2UX++:?*W>;D@@ /G@@CIS5J\\=?8?+M[O3TL=1D\QU@O[R.%!&A
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MI-.N-,F6VMHMB%=P56,D@()(8Y4<XP.F:OWW@+2=1TF[T^XFO"E[<"YNI1(
M\SC&,_+@ 8'  Z4:M\/]#UK5$U*[6Z%WY8CFDAG,1N%':3;C/X8H S9M<U%?
MB'I%FNIQMI]SI$ERZJJ^47'\8/7;WZUAZ3XIUMM=\+QM?7%Q!JLEREQ.T2+;
MS;1N5H 0' 7IE@,^]=Y-X4TNXUB'4W20306QM(D5]J+$005VCUS69:?#?0K.
M33Y$EU)FTZ1GM=][(1$",%5&<!?IUQR30!Q#>)?$5MX5U;7VUNYEET_76M(X
M&CC$;Q^8@P^%R>">A&*]8DTVVEU6+49 [SPQF.(%SL3/4A>FX],]<<>M8C^
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M*J$1,C'+=^@%+KVO^)-&\.:5=:A'8173:E%:W(2,R[D9\!T^8!3@9P<]>HH
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M)S7K% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;&9I)+;8IRXE8LV&..#[X[XU(O 7AF**_B&EH\5]_KTDD=@W3D9/!RH.1@Y
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M,MO^%WWLH-SO31ENU"W4HS()@ " W*\#Y/NGTKTN*)(8DBB14C10JJHP% Z
M5GW?A_2K[5(=3N;*-[R%=J2Y(.T$, <'# $ @'.#R* /.O#]WJ.M:7HFO+X@
MACG-RIO%%S*QFW-M:$PYVKR0!@<8!]Z2SLKR?PSXMUB37=8,^FW&I1VJ"]<*
MJHI"@\Y8@C.2>PKN8/!'AJVUI]8@TBWCU!R29DR"">I S@'D\@ U+9^$M%L=
M.O;"WLV6UO6+W,;3R-YI/4DEB>>_KWS0!YQ91W9O?A[&=8U;&MV4OVXF]D_>
M!84< <_+SW7!]Z>E]??\*V\<)_:%[NTK5+J&SE^TR>9&B%=H+YW-C)ZDUZ-#
MX6T6W:P:.R ;3\_9"9'8P ]0N3P.V.F..E'_  BNB"SN[3^ST^SWDGFW,>YM
MLK]V;GDGOZX'I0!Q^I6G]I_%6?1[F[O_ .S3X?\ M#6T=Y*B,_FA,G:P[8Z=
M>_4YP=)U.ZUWPEX)L[FYFN[BX6Y,EFTGEQW*1LRJTLF<A4 !P 23VXS7J2>'
M-)CO1>)9@7(M_LPEWMN\K&-F<]/Z\]:K'P7X;:TMK5M'M6@M69H(V7(CW?>Q
MZ ]QT- 'F.AQ?VSHO@R\U*:>XN4UF:T$S7#[A$%E.T-G/\(YZ\#FK1:3Q#>>
M(C>>(K?1[_3+YTMI)'?SK>V7;M9<2*I5N<Y!)SR3D5Z(O@OPVEC]B71K46WG
M&X\O9P)#GD?@2,=,&I+KPEX>O=1CO[G1K*6[C "RO""1CI]<=O2@#@]66S\3
M1>-4U>8SW6EVQ%I!O,7E)Y 82!<@99R<YST Z5VW@8@^ O#^/^@=!_Z *L7_
M (5T+5+YKV^TFUN+EH_+:1TR67T/K^-:%C86FF6<=G8VT5O;1C"11*%5?P%
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M.U@>#)Q^=)\1YD@T33VND9M+.IP#4< E1;Y.2V/X=VS-=1:V%G9;A:6D%ON
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MOWA21^$<L6Y'7 ]!0![+/<P6RAIYHXE)P#(P4$_C237EM;JK37$4:O\ =+N
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M6CSH[%BQ3Y5()&<?AFM3PQ:_\(WX#D%V'@MH!<3I%(#NA@+LZ*<\Y"D<=NE
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M .GM-3LU\4ZV6U\RI;01M-9.FV.S !RV[ISR34MMXVT"Z6Y9;UHQ;0+<R>=
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M^&6/:0QR3N)R23W/4]:Z&6SUV[U?PK=3:-Y4>G22&?9<HY56A,8[C)R<D#/
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M6W9QCWXK.\"R22^/?&;SZ?)83G[$9('D#X;;)DAAP0>HZ=>@H ]!I&*HI9B
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M)(8D:0*@WON;/900 .<U9\/6NJ0> O%D<6AR2WTU_<SP6M]:LJS(^,'# ;N
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M>:YRU\/ZCK'PQUS1/LT]A>W-Q<21BX39NW3&11GT(P#Z9KTFD#!LX(.#C@T
M<-+9:CXCU?PM/+IMS8-I3M/=O* N&V;?+0Y.X$]QQ@=<\4FF^%[^Q\?7NQ0/
M#[S?VHG/_+TRF,KCTY+_ %VUW)=0P4D GH,]:=0!Y;K>@ZSKFH^.8;.TN;9K
MV*S^QSS(%29H"2R@YZ-T&>#GTJ]<_P!M>(?$6D7+^';ZRA^P75I<R3-'B%Y
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M#O"X08#J0 Q/3@X^M7D\+:U%XXTG66N;:ZM[6UE@GDEE997:1BQ*KM("@D
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M6&'&]SZ#) _6K-(PRC =Q0!R6B>-TOO"MGJU[97$<UTP6&!%!:=F)(6/GYL
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MEVDZJSVZEO,7S@!AGR.^ %]S533O"^NZ7)XS6#0[6&SU6TC2SM[6Z7".(RF
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M+DQ?ZS#!@$Y! R#TR>M45\9ZUJOB'3=.TF"PA@U/25OX);D.S1Y(SN (SW&
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M*(LAE5CN;>K<$EB6^I-%[\/DGAL;BVUB\MM<M9&D.J\/)*S !]RGY2"  !T
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M$EA]IBA6Z9@0''EQL0V <CIG '>M?P7K?]M0W;KK']H1Q%5VS0"&X@?G<LB
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2Z6':#&Q7&,Y/S8 XP1P30!Z/16'X0NUOO"]G<)J?]IJ^\K=D89UWMC<,##
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M'&3(NS:0?EY)4!>,>O6JNB0KXG\5Q^*;C0[[339VIM8!?Q".5V9B6.W)P .
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M9'MCI6Y7&7/BQ;KQUH6F:5K-C-:7(G-S#$%=_D0D?-G@$^@_A/-=G0 4444
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M0XK0EU+Q+I.L:YX;M+V35;I=*%_ITLZ1B56+E"C$!5;GD9'MS6^? NC-H_\
M9[K.S_:/M?VTR?Z1Y^<^;OQ][\,8XQBGR>#+&>RO8;B\OYKF\\L27SRCSP$8
M,@4A0% (S@#J2>IH XH>-;JQ\,ZM+;:M?2W\3VUN;7588UGLI'<AF;"J&7!!
M!.1D<\&M7=XYLI-3BB?S5EL3)91W<T+3B=2H;;M4 @@YY& Q Z&M\^"=+N+;
M4(=2>YU-K^-(II;MU+[$R5 VA0,$DY SFJMA\.M&L=-GLO/U&X,RJ@GGNBTL
M2*P951N-H!4'CT% $'@G6O[3U34HVU+4#)%'$'TS4H@D]J_.XY &Y6&T@\_A
MD58O-1N=5\<OX>AOIK&&TLQ=RM!CS)BQ*@9(.%7KZDD=A6IH_ANUTBZGO/M%
MU>7TZJDEU=R!Y"B]%&   ,GM2:QX8L]8O8+\SW=G?P(8X[JTEV2!#R5.001[
M$&@#S7Q'>ZEK/@?6+:_U"Y\[1=62R:6)45+M?.CVLXV_>4$'"X&<=<UZM%IT
MD6CFQ.I7DDA1E^V.4\X$Y^;[NW(SQ\O:LF\\$:3>Z&='<W*6DDOGS^7+AYY,
MAM[MU)R ?_U"M^VA:WM8X6GEG9% ,LN-S^YP ,_04 >#K%*?@HMP]W/+))JX
MSYS;AN\\_-ZDGJ>>:]#L9-9M/&FK:%-KMU<Q/I27D4TD<>^&0NRG: NW'&<$
M'M5MOAMH)TR33@;Y;1YQ/Y0N6VJP);Y1T R<\>U:/_"*6O\ ;$NJ_;+_ .V2
MVHM7?SAS&!P,8P#G+9'<T <=;>(?$$W@;PWJQ%Y?))')+J(L2@N6 . RJ1R!
MGD#'\-=MX7U"#4_#MK<V^H'4$((^T,NUFP2/F&!AAW&*SHO 6G6UCI]K:7NI
MVPT\2"UDBN</&LF-RY(Y'RC@YK=TO2[71]/CLK-"L2$DECEF8G+,Q[DDDDT
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MD;1&'&2=J'JJY/R@]\8SB@#R[P^9;#2?AQ?0W5UYUW<FWE#3L4,6"H0)G:
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M??8(KN*YD^Q1G"R1-M!4QCL2^T?+R<<TZ]8G79+#QGK,FF)+I=JL#3VL4RS
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MK(./N^60H/3''>O=:;L7?OVC?C&['./2@#S/5M2T>Q^)$EW--'$K^&)GF:'
ME?#*PQZML4D9["L2WU-;:UU*V8VOBBQM] ECBO; &.5(&*CR)0F0IP,@XW
MGUKVFFJB)NV*J[CN.!C)]: /&-)OX)_B K6]\+V*Z\,F"W^SVS(F[S,"-!@D
MA0.22<<Y(Q@0Z+IVEWO@?PSIFGVD!\2P:A%+*(E"S6Q24EWFP,J O'S=3MQD
M@5[?10!XQKUP^I'XDV>DS">[,UJ[0PG<\D2*BR@ =<8(/Y=ZFN;BR\4:;J>H
M>$_[7NM833I+:26963RER"8?N@,YR< 9Q@G/3/L-% 'D<6L:3JGB/X?W&F02
MD6@FMY]EH^8"(=OEMA>,'MVSGH<UZY110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1139$$D;(2P
M# C*G!_ CI0!A7'B;^S?#5]K>L:=/81VA;,+,KNZ@X4C!Q\Q(QS5C1]2U.]F
MN(M1T@V6S#12I,)8Y5/3!X(8=P1]":\KUY&O/@IKT]U/<SRVNI2I$\D[L=OV
MI5 .3\W'KG%>OZ79PV.G0P0>9Y87(\R1G///5B30!+>3R6UI+/' T[(I;RU8
M*6QZ$\5R5G\2+"XTO3-5N-.O;73=1E,,-U)L94?<5 <*Q*@D'G&.*Z^Z_P"/
M.;_KFW\J\H\">%[KQ+\-?#T%YJBII,<S3M:0V^UY-LKD*TFX\;N>%']: .]\
M.^)?[>O]:M39M;G3+O[,<N&W\9SQT[UOYKPO5+0#3_B+JJ3W45U9:EOMVBG=
M C97YL*0"<<<YKJM>GG\.:YH7C&:XN6TJX18-1A$KE(G=?EE"9P!G@_AW- '
MI6:S[Z\OK?4-.@M=.-S;SR,MS.) OV=0N0V#][)XXK@[[2=2CT;3WAMX[R[O
M+JXU.\TF>Y:-Y5<9VH<]8]Z#'3//I6?:W,4TWP]GTR;45LI+RXB>*ZE8E2-W
MR.,X)4[@#UP* /7,UG6MYJ$NL7UM<:=Y-E"$-O=><&\\D'<-O5<'UKS[2[O2
M-3LGUS4-7GMM>M=2E$B13DR_+*RI L1)!#(5& .2<]:DUB[72[WX@.^HWUM$
M+>R*RQN9'C:3>,1AF &20.H S0!Z=FBO&E-Q#K'BK2V)LK8:#]J6VM;UV"2K
MRK;N"&P!N X/N*T/"D1MK_P)?"XN7N-3T^<7;RSN_FA8T*C!.!CM@4 >EZE/
M=V^FW$UA:"[NT0F*W,@C$C=AN/ ^M2V[RR6T3SQ>5*R O'NW;6QR,]\&L#Q]
M&'\!:XV^1&CLY)%:.0H0RJ2.01W'3O7%^)()6M;'4IK2+5M/M=%B:[M?/:.X
MMP0W[^(],D!@>_R4 >L5S_BOQ'+X;MK">.R%REU>Q6KGS-OE[S@-T.>_IVK1
ML[E)- M[JS622-K59(1)PS#;E<^_2O&)UTS5/ ^@>)9KF)];DUB'[=/)+AR?
M-.4(S@!1M(&. ,T >S6UQJ3ZU>P3V,<>G1I&;:Y$H+2L0=X*_P ..!_GC0S7
MF&I7EMI7B?QS<27=W% NEV[L]O)ODC+;Q\FXD*>1[#.:J^$818^,6AM);2R-
MUH"R+''-YF)-R*CR] TA')P!U/7J0#UFBO$?#^DV_B.?PRQ2..>%Y9-3NOM8
M4WV3E2I5M[$GD9 Q[5'J6CV,7@_QKJ:B7[;INMN+.9KAV:'!AP1ENO)YZ_E0
M![EFC->?G[%KWQ'U;3=<CBGLTT^%].CE.49'SYKKVW9*C(Y '!'-<]:6NK:C
MX7TN&&>TOFM+Z[^R6FJ,62^MD.P$MT+ -\I/'?M0![#FC->)C4[)Y?"EHQ@T
MG0Y(;L1PZDGVB!+A92"K_,@('(4MG&1WY%BV:TLKWP_HEUJR:CX9FOKK=.R[
M+=G"*8X02S QJQ;&3@GC^&@#T7P_K]SJ^JZY97-HEN=-N5@7:Y;>"H;=R!US
MZ5OUY_\ #R+3K+Q'XPL]/DMO)6_5XXX'!4 H,@#V)(/8'BHO'+6%[XILM/N#
M;F:/3YYL:D^VT1"0I?&,O(!G !&!DY'< ]%HS7CFEK/JO@GP<;.YTV]O;:&9
MVT[4&#)=*, C)SAU!&,^OH*] \"WEI?>#K"6QM);.W56C6"4Y,95B" W\0!S
M@^E ":%XDN-2\0:]IEY!;P?V;/%%&R2%O,WKN&<@<]./YUT,DL<*;Y75%Z98
MX%>1WFC:#JGB3XAOK:QDP+"T322E3&?(^\HSUSCG'MWK.LYVDU31++QK>BT1
MM#7RCJ$*LGF%R&R7X#[ O/7CJ.X!Z]J,VJ1W^G+8Q6K6CRE;QIF(94V\;/4Y
MJ^9HE.#(@.X)@L/O8SCZXKR.6WL;6^^':VEW<75O'?3PP7-U@-)&.%QCJO\
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M6S8E"A%)!],J3].:U_%>EZC=:1X8U6TTA]0_L\?Z3IKC9(R/&%; _O+CI[T
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)&13[W3K'4HEBOK.WNHU;<J3Q*X!]0".M9RZ_9:?HUA<:G=A))K=9/NEF;"
MLVU03@=2<8%:EK=6]]:Q75K,DT$JAXY$.58'N#0!#<Z3IMY)#)=:?:3O#Q$T
ML*L4_P!TD<?A4(\.Z((Y8QHVGB.4@R*+5,.1T)&.<9/YU!=>+-!LK][&YU**
M.>-TCD!!VH[\JK-C"D]@34VI>(M)TB0I?WBPE5#N2K$1J3@%R!A02" 3CH:
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M"A=RJ,Y"CKPH)/X"N;L/B)X=U&ZLH(+BX OCMMYI+9TBD?\ N!R,%O;\.O%
M%K5O#EUK&LQRW&KS?V/Y06;2Q$NV9@VX$OU R!D=\8S@D5T-<Q9>/M!U#438
MVTURTHG>W=FM9%6-T7<P8D#;P#UQT/I5J'Q;I<MS:0L;B);TD6DTT+)'<'J
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M$AFU&2X%K8^>0D:QR-O=GP<#OT/+ "KLOCE[/3HSJ.F-8:A)>/9I#<RE(F*
ML9!)MY3 X(')X]Z .N@@BM8(X((UBAC4*B(,!0.@ J2O.IOBD8='FNET?SY[
M>]2TF2*Y'EX<_(Z.5&X'![#!!SBM6+QI=0W6NVNJZ1]DGTRQ^WJD<_FB:+#'
M&=HP<KCOS0!V%%<./B 8- N=<N[6U?3X[5)8IK.[\U7E9MOE'*C:P)&?K[4R
MV^)5HM[>P7\4*Q6UF;LW-K*TL?!P8R2B_-R,=0<^M ':O<V\4\<$D\232_ZN
M-G 9^_ []#4U>9WUWJ5U\0O ]Y>V%K:_:/M#(T,N]]IASL<[1TSGCCG\_3*
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M'/)Z<GU:B@#R&_N/L.MZ5KE[!JT^B7&CQ6J3:<TB/#*K$E652#@^_<#TKO\
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M#E4)X8L2.F1C.?2O4** /(]!T*\T^(:%?^#WO+VWNV$&IR8:VD1I-WFOELY
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M<\#.%)_SZ5Z%<7,%I"TUS-'#$O+/(P51]2:7]W<V^4?=%*G#QOC((Z@C^8H
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M?\#JSXST[6M0O-'%C;_;-,CF=K^T6X$+3#;\F6/5 W)'?C@UUBJ$4*H 4#
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M+9!_']*S/%DM]#X^\(O86T=S+MO T;R;/DVQ[B#Z@5VLDB11M)(ZHB LS,<
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MND>2TGFAVQ7*H?FV'/;T(%9MS::HWCVPU*WTN1[;^Q9+9WDVA4E+!@K#/^R
M>W/6N:T.TU^'6/#.H7/AO53<6XN([QY)HPF]P!E$W;8T&.P&?0GD@'I6LZW:
MZ';Q27"RRRSR"&"W@7=),YYVJ,@9P">2!Q60?B!HBZ5'J#_:U0WGV*6/[.Q>
M";<%*28R%(R._/;-,\;1ZQ(=(.G6,]Y:+=%KU+5U2?9M.-C,1MYZD$'MD9KB
M+#0/$&GZ'J%NOAV[$G_"2QZG!%YT;;H0ZMC=N)R G4^HZ\T >AZ?XQTN^34V
ME%Q8?V9M:Y6]C\HJC#*OC/W2 <9YXZ5SJ>(7U7XDZ#%%:ZO90O;7,C)=C9%,
M-HV,JACR/FZ@$9%5_$&@:QKE]XQM[6QF@&H6=JMI<2E0DCPL69>N1G=@9&.O
MXVH+CQ#J_C'P[>W?AB[LHK*"=+F62>(J'D51\N&R0"OUYZ<4 =-XC\4Z=X7A
MM)=1%QMNIUMX_)A9_F/KC^74XX!JA'XYM)X(S!I6K273+([60MPLR(C%2S!F
M  )! YR>@&:J?$73]0U&VT'^S[&:[:TUB"\E6(J"(TW9^\1SR,5G>+='U+_A
M,(->@\+VGB"SDL%M9+2<QAXG#LP8;P1_%CB@#H&\<Z3)#I[6"W&H3W\;2P6U
ML@\PJH.\G<5 QC!!.<\ &GP^,K"[TK3+^PM[J\.I%A;V\:JLAVYWYWLH&W&#
MS],URMWH^OQ:AH\9T"%](:&9I]/TYXX!%*S95';C<@ 7./O$$D$8%4M-\/:@
M/ FDZ1K7A.[E%C)-AK2ZC6XB<MN22,[P,?,1C/8'&* .WB\8V<^GV5Q%8W[W
M%[)+%#8B-1-NC8J^06V@ CDEL<CUJM<_$'2+/2+W4+B&]C^P3K!>6YB!EMV)
MP"P!QM/&""0<\5S^G:3XNTU/#^LWL,FI7=D+BWN;=I4\\P2,"C;L[68!1D9Y
MSUJOXJ\,:MJ.@>+;RUTV4WFNO:)%9@IO182/G<[L9// )QQ[X .PM?&NESWU
M]:SQ7=DUI:F\+7<.P2P D&1!DDCCN ?:FZ=XNLM:OH=,:RU"SEO;0W5N9@J^
M;$<#<K(QVGD=<$5SNIZ/XCN/&$NKZ9I[0D>'6L8I9WCPMP3O&5W'(&<9P1GV
MYJIH>CZY;>,-$U5O#=S$@L6M[R>XO4>0R,5+.WS'@8. /R% !X(\=6FE^%M'
MM-5AU4B>>6(ZE+"S0!VFDVJTA.2>G(R/?@XT?[4;0O'/BR\D74+VVM[&VG,$
M;^84!+[BBLP '&<#WQ6;8^'=>N?!EKX,N=(>V$=WYDVH/+&T7EB<RY0!MQ8\
M+@@=3FNFT[3[\?$+7+^YTYTTZZM88(YG="'*;LY7=N .[CCL: -"U\5V5YI6
MD7\,%PRZK(J6\7R;^022?FQ@!23@DCTSQ5W6M9MM#L/M5RLLFZ18HHH5W22R
M,<*JC(R3]:Y#P/X<;3-:U6,3K-I6G74L>F)@_NO,VO(H)X.T_*"/5^>PUO'&
ME:GJ%EIMWH\,<]]IM_'=I;R.$$P *E=QX'#?I0!%#X\A%SJ=G>:-J5I>Z=:&
M]G@?RFS%ZJP?!./?L:L0^-]/GN/#\:VMV$UV(R6DA5<#"[B'&[(.,=,]:Y"V
MBU#6OB)XDM[RS6QNKOP\(A")A+LW' RP &>>V1[TNF^'?%._P.T^C0P)H1>&
M<->(6960*7&T$8XZ9)/MUH ZA?'EF=2M8&L;M+2[O7L(+P[-CS*2"-N[< 2"
M <=JYO3;FWLM7^);WRWEQ91&+S4CD+2",Q,6VDL", D]1CM6?<>%O%]U=Z5J
M%WHL5UJMCJPN)KQ[Y?W\08E1&,?NT QQC/0X)SC730=>\WX@L^DL/[9AV6>V
MXC.\^6T?]X8'S!N<<>_% %'6M:D&B^"]-TS1KN?1K[R3Y;S1[IT$9(A.6'/
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M<6]UHKNUM=B%&;:_W@5(VGC@''X&F)\,K#^R-3L)M3U"9KV]^WK<%D62"?\
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M_C^]TC5"MQ96L5J-06R6WEE*W4J$@>>BXP4R>/7!YH [^J>J:79:UILVGZC
ML]I. )(V) 8 Y'(YZ@5QEWXT\0?VKXILK'2K!O["2.4M+<-^\1D9^,+]X@#C
MH#GDU.?&E\-9\-%[6WBT;7H5>&=]QDCD9 PC;G&3G@T ==IVG6>DV$-C86Z6
M]K"NV.)!@*.O\R35JLK1=0NM2-]-+'"MHER\-JR$DR*AVLQ_X$& ^F>]<]K?
MC&\M/$EUHUA_9_VN&**2*WNV9'NMQY\LY"\#MU)S0!M6^GZ#'XMN;N%U.N-
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M0]UIAF?4_P"T#*/,"_ZSS"N,?WN.O2L#75;4O'>LR3ZIX?L3$D%L;?5G>/S
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M%)JDNJ:CIC6L5P1"87VF%,?=E). U:%OJ-E=3RP6]Y;S31?ZR..569/J >*
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M=H+2XC+H$V#&",*"",=<]S0!S6C:OK$NK7>GW-Y=W5A)H)NQ)>1HC/)G:70
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M=7$/D7#V=RT7G(.@8#@\<4EOX'TJUAT:*"6]1-(=GM?WY."W7.<Y&,C'3!-
M'+VOB"_T[Q3*FM7>IVUR9[F2WMFVR6M] JR;5B*K\K#Y#R<G'/)Q6GH#:C=V
M6C>(F\3EX=13_2H9-IB#2#")",?*RN=O.<XYS6Q;>#+"WU""Z:[U"=+>5IH+
M::?=%$[;LL%QG^(X!) ["H=)\ :'HM\UU9+=)\SO%"T[-% S=61#PIP2,^AH
M X?2=<\1Q^!-1\777B">X>V,UM';/$BQY,@178@<D$Y^@QZUH:G:>([;3-02
M[U5DT^YTZ9ESJ/FSM*D9?=&?+7"D#YE';IBNRTGP?I6D:)=:-&LT]A<EC)#<
MOO'S?>QQWJOHW@+1-$@N(84N9TF@-MBYG:39$>J)G[H/?'H/2@#E(WOM \&^
M!9;75KYDO;ZPBGBE=6!21%R@.W(4;> #W.<U=%]JNOZ1XEU>#5;BPNM,NIX;
M2&-L1H(1G]XI'S;SUSG QC'.=H_#[2?[+L=.%QJ(@L;A;F FZ9F5UX0Y.<!0
M. .!5J]\&:5>WEU<,;J%;P 7<%O.8X[C'=U'4D'!]1P: .0-]JVO>(%']M:A
M96USX;BU006[(OE2$XV@[<XXSSSVSCBNK^'^JW>M>!-(U"^D\VZEA/F/C&XA
MBN3[\5/+X3L9=8N-4\Z[2XGM#9$)+A$B_NJ,<<\_6LI/ D%C)X?M],EN8[;2
MYFE#R7+$A"0Q3:.&R1WZ GK0!%X_M1/JOA,?:+F,2:LD;"*9D!&QST!Z\#GJ
M.U8%_8W!\;>,C:ZK?6?V32;>16@D&]V6-BNYF!)Z<^N>:]#UO0+'Q!!;Q7JR
MYMYEGADAE:-XW'0AAR.I'XU03P3I$=S>SK]K#7MN+:<?:GPT8 "KUXP!@$<\
MGUH Y236-2UC3?#9%Y>3W-SI7VJ73["3R)9GPH\UI<J%4$GC/).,'MCZ1<77
MB2Q^'>HZG>W<EU<W-S%*Z3N@(02A6PI #8'+#D\UWW_" :"&L"L=VGV&(P1;
M;N09B/\ RS8[LE?8TD7P\\.Q:7:Z<EM<+;VD[3P;;J16C=LYPP8$#GH.* (?
MB4@C^&6M("Q"VP&6))/(ZD]:HV'A;4=9OO#.KZG>VPM=*@#V]O;Q,&=F1<,S
M$]L#@#M[\=3J^@:?K>E?V9>I*;/ !BBF:,,!T!VD9'M5BPTV#3M.2PMVG\A%
MV)YDS.RC&,!B<\?6@#QG05O=-\$0:Y9ZO?0R1:YY7V59 ('1IPK!EQ\V<]S7
M7:CK-WX-\<W'VZXN[O3-2M&DL$DF+!+A,DPJ.GS9&,\YP!WK<'P^\/KH_P#9
M0ANQ9?:/M/EB\E_UG7=G=GKS]>:A^QZIKVO6T>J:+'9Z;I%V9[>=[H3/=,JE
M48 #*CYMQR<Y 'K0!S^OIJ^CPP)?7&IW]E%8'[;<:;>ND]I,S,3,4# LG!"C
MH IJT=6N8_%.B7-GJ%W?VEQH<URL 8JDS(J;2%ZY.3UR1FNJU'PKI>IZD^H7
M"W*W$D MI##=21!XP2=K!6 (RQZ^M#>%-(.K:?J2P21W&GPB"V\N9U2-/[NP
M':1]1S@>E ',^'YQJ6E>'_%'_"23HTS8O83*TD4\D@QY(CSA"K8 P,X%9J:G
M>1^&O$<<VN7T;KXB>SAE ,LS)^[ BCY&TG) ((QDGCK786/@;PYIVO/K5IIJ
M1WS,S[@[;59A@E4SM!/J!WJ-_ /A^2SOK22VGDAOIQ<SJ]U*<RYSO&6^5O<8
MH X>ZOM9AT/Q_ U[J%D^GB"6V3[<TTD&^+<5$IYP<] >.@/>NHTV*ZTSX@6E
MF=4O[J.ZTB2>=;F<NK2K)& RK]U.&/"@"KLGP\\,R"]S8R+]N18[@I<R R 8
MZX;O@9/?O5^'PII4%[97B1W!N;*,102-<R,50 C:<MR#GG/7 ]!0!E^*+BYM
M_%WA)8+NXBBGNY8YHDD(20")B-P[X(K$M-1O].\70)KWVY8;C4919:A;WCR6
MLZMN5(7C#;4(R ..JCODUW5[HUAJ-[:7=U"SSVA+0,)&7RR>I !'../IFJEO
MX4T:UU 7L-JPD60RJAF=HUD))+A"=H8[CR!GF@#$^(MY<V%OX?GMKFXA+ZS;
MPR+%,R"1&)RK8/(X%<U<3ZQKUUX@O(=:M=.GTJ_DC$DEU,K6\4;#;F(?(RN!
MW!SD^@QT_B#2M7\3:E9V-QIZ6UC8ZI#>I=B=6$L:*<KM^\&+''3&._KL7'A#
MP]=ZT-8N-)MI-0#*WGLN3E> <=,C _*@#D[='\3S^+#J&IW=G?:9<&&V,-P\
M26JK&"LH4-@[CN8EL\<9Q63ILU]XJ\7:'!J=]?Q0WWAI+JXAM[EXE=R^-PP?
MESP?EQG SD9!]'O?#6CZA<RW%U81O+,H29@2OFJ.@< C>/8YKFM1\+3:A\3[
M34Y=-=M)@TPVBRQS+'LDW%L@*P;;M)7IWZ8YH YO2]0N[[3=*T=]1O=2N(=0
MO(4MQ*4^VPQDJKRS9R%7(/&2>.#44,VH7/@K04DU;4$E_P"$D%@98KM]QB\Y
MA@M_%C P2.U>E3^$?#]S!9P2Z3:F*R!%NH3 C!Z@8['N.]5SX#\+G;C1;9-L
MOG+Y>4VOU!&",8YQZ9..M '.:?8VLGC6Z\*W5Q>O8V%D);6*:\?=,9&)=\@@
MMMR%&>G/UK!\.AXOAAX,FBGN(F77(XR(YF575KQ@0P!PPX[YKU#4O#NCZQ<0
M7&HZ=!<S0 B-Y%R5!ZC/<>QXJ ^$M -I%:+I5M';12&5(HUV(KG^/ P-W P>
MH[4 <7XEL$UGQ2/"^D37*W4LOVS5;\3-NM(3@K&G. S< #L.<')JU(5_X3:]
MM[.]NC8OX76:+9=28!\PJ'0Y^4[57D8]>]=:_A?07N9[EM)M#/<-NFD\H;I#
MZL>_4T\^'-&+AQIMNKBW^RAE3!$.,; 1T7':@#RC0I+FUTKX>ZHE_?/>:A>M
M#<O+=.XDC);Y2I.,?A[U9U22[U6\\3VD#W4FO+J:Q:=>6\Y188ALS&'! 3"E
MMRYY)Z$UZ:/#.AK!:PC2K016;%[9!$ (6)R2OH<^E</=>![JYU*]-YX5T/49
M)[F69-1FNWC.&8D;T"$G:,# /;W)H W_ (@V%LWPVUB&1&D2"T=X_-=G(91P
M22221[UB7.G6%WJO@:SB=A;O'<F003LI)\A206!R,]QFNWT_2([;P[;Z1>,+
MV-+=8)3,-PE&,'(.>/8U#!X3\/6TMO+;Z+8Q26QS"T<"J8SZC'2@#S.?49M&
MTG^SQ="WTA/$EQ9O+<,\B0Q!<I&V'#;-W7GMZ<'M?!=I#8W.J6]OKD.H1'R9
M!;VR$06FY3\J$NWWL;L9XX/\5;2>&=#CMKJW72;/R+H[IXS"I64^K#N?>K>G
MZ98Z3:BUTZS@M8 21'#&$7/K@4 >4:KH=K<7_P 3IYFE,UK%'<P,DC*$?[.9
M < X)! &3[],U)>ZDE_XCTJQU[4[*"SET"*>(ZDC-#)*W#MQ(@WXZ$YQSC!K
MT=_#&AR&[+Z3:,;PYN<Q#]]SGYO7GUI9O#&A7-A!8SZ/92VMOGR87@5EC_W0
M1Q0!YI#':7%WHVC+K)UR2WL[F3?J!*6AA$A3S3R2[+A@N&Z+G([US=RWGP[^
M&\L\[33?V[:!F=MS<-(!G\ *]8NM!TB^:V:ZTNSF-J,0>9"K>4/1<C@<"HH_
M#&@Q01PIHNGB*)BZ)]F3:K'J0,=>.M 'FNHV>DV]Q\3C]GLXKA8%$'R*&4M:
M%FV]P3\Q..N#2Z#:1:9XE^&SVGF1MJ&DR&Z)D9O-Q;JP!R3P#T';H.*]-FT#
M1[BZDN9]*LI9Y$$;R/;JS,HZ DCD4[^Q-)W6[_V79;K8 0'[.F8AG.%X^7GT
MH DT[4['5K7[5IUW#=0;BOF0N&7(ZC(KS,LD7BRRU"2SL]1T^\UDI;:I:_)=
M0R[F'DR@C+(O(]@![5Z%H.B1Z':3Q)Y.Z>8SR"" 0QABJKA4'084=R<Y.>:G
M@T32;6Z-U;Z990W!))FCMU5R3U.0,\T >/V%YIL6L^&=7MKJVBAN=2N6:ZN)
M%^V31X?<TSC "9QA2#@8YJ[:6JV5Y\2KC1[*%;^TV_8VAA7?%F)L[,#COTKU
M'^P='$AD_LJQWM)YI;[.F2_][..O)YZ\T^WT;2[2[:[MM-LX;EL[IHX%5SGK
ME@,\T >8Z+:>&=3?39K+5+6Z:6RDCGT^WM4 D39NS<+D_=< ACSN(ZYJGH_A
MS2=;^%-C<Z'%IQ\0Z?%'=,UNB&5I%)(CEQR0P!&&[@>E>NVNF6%C)+):65M;
MO*<R-%$J%S[D#FLG4M(U.'[-#X:DTW3+9G<WBFUY;=@;DVX&X<]>IQ0!1\'3
M1>(9I_& MS$;^&.WMU<?,L29+<^\C/\ 4*IK+ABT_5/&GBRS\3Q6[I'%";5;
MHC:MKL.YD)Q@;@2Q'0]^!7<Z=86^EZ;;6%JFRWMHEBC7T51@?C1=:=8WS1M=
MV5O<-&<H9HE<J?;(XH \@TO35U?6?!4.O'SQ<65XN)'(-S"I'D[\G)^4YKTC
MQ%X6LM9\'3Z"L"+$(-EKGGRG480@GGCCGTS6TUG:O,LS6T+2IC:Y0%A]#4U
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.F2<D_G5RB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHS10 4444 %%%% !1110 4444 %%%% !1110 4449H **,T4 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!@^+O%-MX1T&74KB)YW7B*!#AI&^O8 <D]@*W$;?&KXQD UY/\1#
MK+Z3XDN;[0)6MUA^SVET+B$I##N4LVW=NRY SQT"CL:]$TO57?3[$:K!%IE]
M<Y5+22Y1V8C^Z1][CGCIF@#G+OX@7M@\%[=^&;F'0)IEB74#<*64,<!VB RJ
MGU)]..<5V=U<?9;2:X\J28Q(7\N)=SO@9PH[DUQFO^(-!U;4ETJYUS3K>PLI
MEFO?,ND4S,AW+$%)R1D M] .3G'6)JVGR7'V=;R$3B$7!A9PKK&?XBIY ^M
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MB5$<D#YL*,'( Y]A7BZIH%YX%\0Z/;Q6LGB!]6F2VMXT N-_G?(5QSM SR.
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M:>P>)\O,'8A#G"81@.3RIY- '?P^-M"N;836US+<%IY($BAMY'D=TP6P@7)
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M(E63V8 \BGGP9>&R%F=3L3:JV\0?V/%L#>H7IGWQ75O?6D?D[[J!?/;;%ND
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MD# /I5]?%OAYM/EO_P"V+-;6%@DDCRA=C$9 (/()'0=Z -D@'K28'H*SM/\
M$&D:K=SVEAJ-M<SP<R1Q2!BHSC/TSQ3M1UW2=(>)-1U&UM7ESL6:4*6QU(![
M>] %_ ]!1@>@K.L_$&D7^G3:A;:C;/9P,RRS;P%C(ZAB>F/>HX_$VCRP7<T5
M\CBT3S)D56+JI&0=F-QSVP.: -7 QTHP/2N*3QA::[X>TS4+;6DT0W%T@Q-&
M':5=Q'E+N &6 '(SBNBOO$6D:7.8;W4((9%"EPS?<#' +?W03T)Q0!IG.#C
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M6!!!&0#T[5/I6C0:4)&6>YNKB7 EN;J3?(X&<#/  &3@  <GCDUI44 %%%%
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MRD%Q#$;3=YEH7DW"1P 64. #CJ ?7BNX\"6-G9:+<?V=;7L-E-=/+"UXQWS
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M(V8\+C:.3TY->H8HQ0!X[J-F^F>*]2C\0Z/K-Q9:K;PB+^QI9O*&V((T#(C
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5C>*?$-OX6\.W>KW(#"%?DCW8,CGA5'U/Z9-;-<I\
M0]$NM<\*M%9IYL]M<172PXYE"-DJ/<C./?B@!O@[5%U>,SS^((=0U (&GM;9
MD$5ONY"@ 9..FXDYKK:X?3+&35?B.?$UO97=C:)IWV:4W,+0O<2%\@%#@X4
M<GV SBNXH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ Q11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
'%%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>exhibit1021-independentc007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit1021-independentc007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7%?%:2.'P'/+*I:-+JV9E SD"9,C'>N
MUK!\8:)<^(- -C:O$DOVB"7,I(7"2*QZ ]@: .8\9:[IOB+0M(M=#U"VNKR[
MU"V>WCB;<RA7#%F4<J% .<XQWK(U/Q)=:#\1O$WV:ZTRS:>&WW?VBLQW;8^)
M%\M2-OS$$$]17J,&E:=;7<EW;V%K%<R##S1PJKM]6 R:Y0Z#XGT?7=6O=#;1
M[F#4YUFD^W^8LB$*%V[ER&48X'&,T 2^&]1T3PS\/;6ZEUJ&YL8LF6]C4E6D
MDD)/R@$CYGZ8X]J[&N:\,>&&TJQO_P"U&MKJ[U&Z:[N1'%B$,< !5/8 #D\D
MUTM '$^-'77M8TOP=&<K=,+N_P  ';;1G.#Z;G"K^==L   !P*8(8A.9Q$@E
M*[3)M&XCTSZ4^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%4STR<'GI\WM6AH<>IW7PXA\(W.@ZE;7C6YLY99558D4D@OOSSP<@ $Y]N:
M(/%?BP^&O%6A:5JE]?VV@O9F66[B+&264DC#.!NP, D+S\P[5UW@YKF6UO9V
MULZQ8S3[[*Z)0GR]J_*=H R&W \"JVNPFYU:33]4T"35-!:TBVR+&LABEW2!
MOESN^[LY7)&!ZUG?#7PK-X;N->D2"XM=+NYT:RMKEP9%50<L0.F<C /.%&:
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MZOX@N-%NX=/OH6BBD8QY4DQX+ ,<#Y#^E &'HOC$ZQ9:EINJZ[J6C^+VFE2
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M0 444TL?0?G0 ZBF[_09'M2@Y&: %HHHH **0G%)OXSVH =13=V*=0 4444
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M;IVIZ@EI;F<-(C21/)"RI,B\$HW1NM87C.]U"T\3^%H+34;FWAU&\,-Q'&P
M*[2>,C@UD^$+:^L/$5O%IZ7T6B&-VFL[].+1^,"*3N,YXJ[XY%S+XJ\)RVUK
M=7$5G?&>=X8]PC4KMH V;WQ_HFGSWUO)+<O/8E/M"16S,8PV<,?]GCK5V_\
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ME>W5F8KRXN+:%9W2WMF?]VW1@>A'!-<7)93V'B#5/.\.6^L6VIS_ &F*=IT
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M50?!VF#I]N/_ &^R_P#Q=9R^(=/T_6_%]U%I%[]KTZ""6]/FJ?-4(Y4J"VT
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MH)RI1<=1USU%3_"S_DF>A_\ 7%O_ $-J .PHJO?3/;Z?<S1F(/'$SJ9FVID
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M+7]-T>2"=IM0$ACE51Y:[%+$$YZX'09INCZ_;:S=ZG;00W$3Z?/Y$OG*%RV
M<CGI@US O)M0U?X=7MP09[BWFED(& 6:V!/'U-7/!_\ R-'C+_L(I_Z)2@#8
MU?Q';:/J^D:=/!.\FIRM%$Z ;4(&?FR<_D#6S7GGQ%@DNO$W@R"*YDMG>^D
MFB +)\@Y&01GZBL75O$6O>&4US15U"XO?*OK.*VOIV57B2<$L&?! QMP&*G&
M[Z4 >NT5R'A9?$%IKM];:Q+;BVFB6:VMOMC7,L1!"M\S(IVGCKG!KKZ "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC(&>HH R/#_A;2O#-N\6G1."^ TLLAD=@.@W'L,G Z5LTU'5UW(P8>H.:=0
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MTP()898\;@0 $9<'/3/-5OA;:72>'I)IK]IH?M=RJP&) %83-EL@9R>>.G-
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M2!L,2SDY]L5#%>:_XOU378+?4([:XLHX!;N+Z:V6+,8;S1$J_.I;)^?M@<4
M>M9HS7G%M:7>M^+DM;K7M2\B;0;>[D%G<M"C2LS*708!4':#@8]_2NC\ WEQ
MJ'@+1;J[F>:XDMEWR.<LQ'&2>YXZT 3W?B-OMUS8:3IL^IW=KM\_RY$CCC8\
MA6=C]['. #VSC-6-)UM-4GN[5[.XL[NT*B:&?;D;@2I!4D$'!Y]JY'X33/'I
MNMZ?>'&J6^JS-=(W#9;&&]P<'!]JSM6UC5;FT\?6SWSH=&MXQ;W$ \F9B4+
MLR8SCG@ #D\4 >J9HS7DZ6\UJWA2*?5-3FM_$WEOJ+S71 W+#N5$(P4#LP!
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M;U!^AJ'1K-;/QKX5T_6(UENH?#Y@?>A<+*2/E)QC.T,.?ZT >I(ZR(KHP9&
M*L#P13JRM,U_3]2U*_TRU,BW&GL$E1XF0 '(!7(P1P>1Z5JT %%%% !1110
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M;[A<+;.0KL2!C*E<#!.X_+VR>:H>"/&-E>^']$@U#5/.U:]CR2RDAI#N8KN
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M7],T"*"34[H6\<T@B1V4E=Q(') P!SU.* -%E#*58 J1@@]Z2.-(D"1HJ(O
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M&<&IJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *1F5%+,0J@9))P *6N-^)[RQ^#C*(YY+6.Z@>]6
M!59C;AP7X;(/'8\>O&: .D&LZ8UJUT-2LS;JVTRB==@/IG.,U*+^S:6&);N
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MM/OUGN$C$NT(RAD)QN4D ,,\'!.#P:J^/@\G@/6H8XI999;5XXXXHV=F9A@
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M$"ZCF.XX:)68X (&#R,#Z]* .G/CUA9Z^S:)<K>Z)L>ZM#*A;RW7<&#+E2<
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M08(!;[YW8)' [9)QQD [>BN4A\1:E+\09='.GN+%+)9T=9$.X,Y7S#SD#Y2
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MNRZC;P<GI0!Y):Z-K$'AZ+3X_#E]"L'B07JH9$?;"LN[@E\M@ <]^V:T-?\
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M3^9*K_:K<2$EA'C"YR3@G/KBNUN[^UL!$;N=(5ED$2,YP"QZ#/09[9ZGBK-
M'(V>BZS;_$6^UMX;,Z?<6J6JD7#&4!#D,5V8YSTS6+-X)\03^&=2M3+I\=[<
MZS_:J(LCM&?F#&-FVY'W1R :](K#;QCX=666-]7M4:%PDH=]OEL> &S]W\:
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M>!-4T]-"O+35;9=7TJV^P^8\+-#-;]E90P.1QR#7=2R"*)Y"&(4%B%4L3CT
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ME6M@LXE+HRYYQT([U@ZOX9\3^(/"^H:=JFIZ>US<PI#&((W2) &#,[9)+,<
M= !CCJ:Z_3H9K?3+6"XV>='$J.8R2I(&.,T <WXONWGUGP]X;!*P:M/*;GT>
M&)-S1GV;(!]L^M69]<NVU6^T?0[&VEDTV"-YO.E,:Y<$I&H /)"YST&1U[5_
M&%G)!JF@^)(XGE72)Y/M"*,D02IL=P!R2N <#L#2)HUXOB6?Q-H%_:RV^J6T
M:SPS%C&Y48CD1E]NW<=Q0!G-\0KV[M] ?2]%667599K=HI[G8;>:,'*M\O(R
M"<^@Z9Q7::;+>3Z;;RZA;+;7;(#-"DF\(W<!N]<F/!=[:WOA^2UN;=TT^ZFN
M[EY=P::2;=O*@# 'S' SZ#WKMJ /.M>BTX?%NV?4; 7D#:(^(ELC<'<)AR0H
M)Z<9QQZ\UD:%JVN^!?#-JDVBR2)J>N&WL;*>81R012<HN.1SAN"1@UV4VB:R
MWC^'7T>P^R1VAL_*8OYA1G#%LXQG(''^0[QCX=O_ ! VBM92VT?]G:C'?-YV
M[YRG11@=\GF@"*S\2:S=WD&CR:?96NM"!KFYA>Y+I%'NVI@J.2W!]@#63J/Q
M$U"U\.3:G#I=N9M/O?L6J022G]PV0-ZD#YDY'/'7V-;^H^'KL>*(O$6DSP)>
M?9C:W$-PI\N9-P8'(Y5@>^#QQBF6G@ZV70]9L+YUFEUF66:\D1-HW.,#8#G
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MIT[1M:2SFCU..0V]Q9QN@22-=S(P9FR,=#D=.E<1X8\2:WX7^'NC:G):6+Z
MEPT,^&;SU5IG'F9^Z &.-N#TZ\\ 'J::UIDES>VZ7L+36*A[I%;)B!!/S>G
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M*=SDD]LX Z<T ='1FO.=$\<ZEK^B^'84:VM=4U::XC:8QDJJ0YWLJD_>/R@
MGC)/.,4[Q'+XHCT>QBO[RW@D&N6T'F01Y^TPF9=CD9^0Y'*]\>AH ]$HK@-7
M\5:AI_BC^R)M1BL9-D0M7NK7$%ZQP7_>9^5NH ]<=<UW] !17&^,=<U32[Z*
M*VNH[6W-I+*AC@^T333+]U=@'$8SEF_#(K%C\::_J?\ PA7V62SM1KT4PFS
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M1^'<T,CV\EVMU#/M;YK(G>VYQU.56/.<_/[5Z;9WUA<M-;V5S;RM:L(I8X9
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPDN-P&5VX.1TV_+CTSW)-='10!RA^'FA2:9J>GW"W%Q;ZC<F[F667D3'JZD
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M/ NJZ)X9TN&"6]0+@-C)SG+,QR0.?7K6MX9\,V.AV%JT=GY=X+=(I&>5I67
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MF=K/3+2 NI1O+B ^4G)7V!/;I1_PCNBBW2W&CZ?Y,;^8D?V9-JM_> Q@'WH
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MLY/OVZ0*(V^J@8- '$>3I=[\0;;1+NULI-&_LII+.VVJT$DWF?O#M^[O 'U
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCDH2.A/M4U8-MK-]+XTN]'>TM_L45L)DN(YMSALJ-KI_#G+$>H6MZ@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "HKFUM[VV>VNX(IX)!AXI4#*P]P>#4M-=UCC9W8*BC+,QP /4T
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MPMKJ.Z!6,-N>-@R]>V1S7.Z?X^F-YXGEU/3I[>PTB0)E"CLF%R0V&R68],9
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MKA9D+%LXW&/.X)D$9QGOC% ':45S<'BO[5J$D%MI\DL$5\;*65)D+1L#@LR
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MM9\$W8L56/25<7>9ERI9 G'KC&?I[U1U+P;K>I^&/&%B(;>&;5[T7-L'FS@
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MN;9R0LL3;E.#@\_45:H X&?P7='0+32+FQT_5;9_M$UV))3"8YY'WAHFVL0
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MPWSW17S8E<E04VD@@'!Y[<9H Z*^U.TL/%VN7%IHDDFM6NEK*9Y+C:DT620
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M)-Y\6ELJB-6W;@"PY*@X.W@<<YI3\/0=#U;2_P"U7"ZEJ/\ :,D@@&4DW*Q
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M\C;E?E'(' SG Z5#'X"TD:-/ID\MY<Q2W1O!)-*/,BF)R71E P<DG\: .?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN$&[ )(R!\QSCK5#1? /]CW" :[J-SI]NQ:SL)FS% <DKGNVW/ /H/05V5%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[K1E7\QB,@$-U]%-:G@;4?$?B!(]6OM1MOL227%N]K';[2[+(0K[LDC XQZ
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M\KG"X!92  26P!D_0'/7^%6UE]#:#7;B&34H9&B>6!E8XX*E@!@-@C(Q[]Z
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MF*;>J9-(TB[M9],O3;>'(#=:5?8 E@(.6B?^%OE()[86O4_[%TK]]_Q++/\
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M:WR_$'3;U]/NEM5T$6CS,@"I+O5]IY]%/XUW% !1110 4444 %%%% !1110
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MVI6-M=16L][;Q7$O^KB>55=_H"<FEEU"R@?9-=V\;;E7:\@!RQPHY/4G@>M
M"WME;:C936=Y"LUO,NV2-NC#T-9*^#= %G=6CV'G0W4:Q3">9Y244Y5068D
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MZL'4,I#*1D$'((IU9/A;_D4=%_Z\(/\ T6M:U !1110 4444 %%%% !1110
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M3"5VDNMX(,C,5R3@#CGKV' ]%TK5;+6M.BU#3YQ/:2[O+D (#8)4]>>H-7*
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M22QPSR%8X5C.'9V"DXW8 P.2157X8+,EIXD6XMH;:8:[.'A@.40[(^%.!Q^
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M0(TDMN<QNQ')7V-7JX[2_#MWH6O:19:7=WJZ+961CFAEVF*0DL0V>ID+$$\
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M7'AWPG?ZO:QQ22VJ!PDH.UOF (X(]: -RJFHZG9:3:&ZO[F.W@#*GF.<#).
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M*9-<M]2EBU&00Q#$4?)PNS 5@T:@XSELYXHU'Q;J>B7/CB66X%PNG&T2R1T
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MR\\'/Z>]/LO#GC#1KZ^T[2[[3AHMY=27 N95<W%OYARP4#Y20<X)^OM7H%%
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MO\/=5M=,#PWUDFJV^K2:G:RE&:/YQAXV'7!'<>@KTBJ.KZM9Z'I<^HWSNEM
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MKVUM]6TFQU.*+1=4>626*2 M+#Y@PZQMN P><9!QGO7:44 5EL88],&GQ@I
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MGJDMG?RVZV]VR1*T<X7HVQLX8<X.3QQS7144 <Q'X)M+?^QA:WES"FERO.@
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MO+.X*S2(3E@['.[)).?4FNCTO3(-(TZ*RMS(R)DEY7+O(Q.69F/4DDDFKE%
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MXC&9(ED!=![CJ*L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^H)-9:NB6\WVABR*5A&W_=^<\=*[2U\"^&[.XM9X-- DM'WVY::1A$?]D%B
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M;38/#OQ(M5^SPW1O)"D6T*^S$8) ZX)[]#FIXX;;2_%VA#0HK6WNKKPW*1Y
M53-*5RI/J2P'/M7KCV=M(7+V\3%\;RR [L=,^M(MC:*Z.MK"&3[I$8ROT]*
M/(?!:Z=?W?AZ:+6KV?5K-BDNGI:1120G&)?-8*&*9SDL222/XC7LU1);P12M
M)'#&LC_>95 +?4U+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M925!!(49XX.X# -=IXSU:Z\/>#YKJVD8SJT,)N&V_NP[JAD.>.,YZ'G'&,T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-A ?S9U7:3T!R>,X/Y5XYJVJV#WUS-%<P6(B\31/+;R%GG+K(JM,[$_N4P"
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MM[>S"*"(99CS[  #DDG@ <DUY$T>KO=Z9<SZ!K/VFVU]KB:WM[79;Q1_/@H
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M@@@U8O-0LM.C62]N[>VC8X#3RA 3Z9)I)M2L;<(9KVVC$BET+RJ-R@9)&3R
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MD. 6/0#U-<%H/BZ]UCPYXCN9_$5A:_9=0:WM-2:%1$$ 4@[2><C/<]: +Z^
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M;[.=YW3Q/C 7^+KCGUXK(TJQMC:MX;U31-;N-9MKQGC0W,XM)"9"RS;@VQ0
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M!M3$?[\C;R<G&=O&<8SCO6O10!PNI^$KJ?QW)/"B'1=5MU_M1&YWO$1L&/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 8HQ110 8HQ110 5C7WANVOO$EAKKW-REU8HR0JA79AOO9!4DY''7
MZ8K9HH **** "L30O"FD^')KJ:PAD\ZZ;=+++(TC'O@$]!DYQ6W10 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444A8#.: %HIHD
M1LX8''7%*&!Z'- "T4A(4<FESF@ HHI,B@!:**0L!WH 6BFEU'4X^M.S0 44
MPRHH)9L =2>,4JR(QPK G&>* '4449H **8LL;C*N&'M3\T %%&<4A( R: %
MHI%=7&5((]12>8F<;N?2@!U%)N'^137E2-2SMM4=2> /QH ?12;@1G/'K2"1
M"<!@3G% #J*3(-!8 9/3Z4 +14;3Q(Z(TBAG.%!/+?3UILMW;P.B2S(C.<(K
M'!8^P[T 344FX4M !1110 4444 %%17%S!:Q>;<3QPQY W2,%&3T&34M !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !15)]7TZ/58]+:]
M@%_(I=;;>-Y4#.<=A2W>K:?875M:W5Y##<73;((G<!I#_LCJ>M %RBBB@ HJ
MG<ZMI]G?6UC<7D,=U=$B"%F^>3 R<"FVFKZ??7UY96MU'+<V3*MQ&IYC+ D9
M^N#^5 %ZBJU]?VFF64EY?7$=O;1 %Y9&PJ\XY/U-26]Q#=VT5S XDAF021N.
MC*1D'\J ):*QG\6:!'93WC:K;BW@G-M(^[@2CJGN?I5J36M.AUFWTB2Y5=0N
M(FFBAP<L@ZG.,#\?0T 7Z*** "BJ=QJMC:ZG9:=/.$N[T2&WCVD^9L +<XP,
M CK5R@ HHHH **** "BBB@ HHHH **** "BBH;JYCL[2:ZFW>5#&TC[5+' &
M3@#DGCH* )J*J:;J-OJVFV]_:ES!.@=-Z%#@^H/(JW0 45GZ;K5EJT]]#:/(
MSV4WD3AXV3:^ <?,!G@]:2#7+&YUNYT>-Y?MEO$)9$>)E&TD@$$@ \@\C(H
MT:*** "BJE]J5KIUI<W-Q(=EM%YTJHI=E3GG:.>Q_(^E-TG5+?6M)M=2M-_V
M>YC$D>\8.#ZB@"[1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5A>+
MKN_M/#TQTVUN[BXD98C]C ,L:$_,ZY(Y"YQ[XK=K.UB^O[""&2PTF74BTH62
M.*9(V1,'+#>0#VXR.M &'X"DL;G3;BZLM8UC4"TGES1ZK(#+;.N<H5 &T\\^
MOK3/'EM:C2IM0U'Q%?Z5;01D0_8YC#F4@XSCER>,+['UJ;3;/4K!M?U[^S%:
M^OV1XM/6558K&FU0S\KO/)/4#@9XJQ=ZGJKV\<#^%9[DSVRM(OVB$Q)(0<QN
M68$@>H!S0!=\,R74OA?2I+V=+BZ:TC,LJ-N#MM&3D=?K3M?02:'>AG=,0NP:
M-L,"%)X_*L?2=.U7PEX4T72;"T349(Y5CN6\T1B)&8L[KGJ%S@#KC%:?B6Z2
MVT*\+E07B:-=SJ@)8$#EB!WH XCPEH$VL?#O3]4BU748=6G@,@N%N6.7&0,J
MV1CBKOA3Q\+K3M(CU6%SJ-[=2V+O$OR>;%G)/IG%9?A_7+W1? MEH,,=@E_;
MPF%KB;4(A$A.<-\K$MUZ<56?2;'0M.\-M8:G8ZA/IMZ]U= 7:1^<\@(9@2?4
MT =!K_Q!:'0-9N-,T^9[O3;M;259-H",<?-UY'./QK7L/&"R^(+;0[O3KJUO
M+B SH9-NUE7@X()[_P Z\\GM+B\T;Q;;M/I4<^I7T=U;H;^-MP4KE<]CA:V?
M%E];ZGX=TW4(+^PL-<L[A&MT^U*Q7<0C*V.V"3^ H ]!TS6(M5CN)8(G$44S
M1*Y(Q(5X)'MG(KE=+\;W,ESXAFU2R:VL=,G,8D!!P !P0#DL<\8K7TO5- TW
M3+>SCUBPVQK@YG3)/<GGUS7 W%J+C_A*+ 7^F1QWUY]MM;O[<F"X"[5*]>JX
MH [VT\713:O::9>V%U8SWB&2V\[:1*%&2,@G! P<&L;XLF2'PDMU!--#*MW
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ML[BSA2=K&RG$<SO<J[1.W)4*3DA21TZ5F75_')KOAB]_M+2IX].\UKIHKF-
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M'P[T'3=:?4K9;H*9?.%F9R;=9,YWB/ID'D9Z=L8%=70 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M13)6=(7:--[A253.-Q[#/:@!]%><+\3-171K?7;CPS)#HQF,-Q<&Z4F,[RFX
M+CYES@$\<Y&.YNZW\09M&NI_-TQ$MXKN.V07%QY<UR&(!DB3:0Z#(YSZ],4
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ML[JSU:XCMI$ACP+=Y 2A1L_.O&#GKU&.E '8V]E;6D$<%O!'%#&-J(BX51Z
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M_ 6&0#[XH M5R5E\/-&L-4:[@EOA;&?[2-.,_P#HJR]0PCQU!Y'. ?H*ZPL
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MF!YC$LT9E'5 PR/PH P%\!>&ELK.S33BD-F[R6^RXE5HR_WL,&W8/<9Q31X
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MYB:1[=757(#,,A,YQ@5UU !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %175Q'9VDUS,2(H4:1R!G
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MK:-DD#*S;@ !@#' !^I-;Q\(Z>;EI1).(OL)T^.W.QHHHB!PH93SP#DDY[Y
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M4/B3;KJMT%TRSAFLR-N828GD('&,9X]< <]ZZ_4-)EMO$D/B+3X!+.8/LEW
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M2KUS=6]G&)+F>*&,D*&E<*,GH,FJ[ZSI<=J;I]2LUMU<QF4SJ$#C^'.<9]J
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M6B:=')$I2-DMD!13G(!QP.3^=9VHZ)JMC'!:>#X]&TNTD9VNR]N0V2  R*F
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M^PUY+EK)I<VTIBD66)HV!['# '!'(-<QXUNXK?Q9H FC:U+1SK%J26[3R(Q
MS%&H!7>P!Y93P" .:Z_3].@T]9O*,CR32&2665MSNW3D^P  '8"KE 'A5CK%
MOI7A#PC-"TZ3Z;J=T6CGMI%3;NEW!MJ$@A3_  J<$\@58:6VU7P7JUSX<OOM
MUTVL1ZI?6MA&\;1H2,J@8!CC;G..2.@KT_7?#DFJZE8:E::I<6%[9;A&Z(LB
M,K8W!D8<YQU&#5K3-)DLIY;J[OYKZ\E4(TLBJ@51D[550 !DD\Y/OP* /*O$
M%M97WA7Q)?:1::S.]S9PQ/<W_F[Y7$JD1JC#+;0"2W;H.];]FR1?%#1)+>&0
M6H\/^2/+B(0-NW!.F <#H:]*HH XGX6S[?!-G82PW$-U:F031S0.FPM*Y R1
M@G&.F<9%/\3+=6?CCPYK,D,DVE0)/!*T:%C;O(  Y YP<;<]N_6NSHH \7\9
MV)FTCQ9>V5K<&SU&]LA!&('Q-(G,LBKC.#ZXP=IY->P6D%K%$7M(8HDEPY\M
M NXX !/O@ ?@*L44 >=:K>2>'_'NJSZMI-W?Z5K%I%!!);VYF*;00T)4<X8L
M3[YJ2REDT+Q5IUW=Z5-8Z5/HZVL*HID6T=9"WEO@':2I7GIE<9.,UZ#10!XT
MVD75E%I<LEI/]EG\6/J44'D,3!:<@,RX^0<@X(&-PJ?7X[R]L/B/;P6ES(LT
MUO+;XMW_ 'H0(LA4X^;!3MZ5Z]10!PUS+#JWQ"T.[&GWKVJ6-ROFS6$JHCLR
M@9++@9"MU['W%<CK\=Q*WBBWCTG4;1UOH&CMK.S9HKB-'0^<[A3GA3A01C'0
MG)KV>B@#S"*^FL-4\166J^%]4U6PU><7EM)'9%Q(I15$4@.-A7:,!L8Y)QQ5
MV6&_A\?3*=/N8S>Z%':1SV\+/!#,&<D%\8 &1U]J]"HH \L^R7>J?#W1?#+:
M1=VNKVMQ;Q$FU=8X#$XW3"3&TY4$Y!R2W%:_@2U<>(?%L]Q8W$2SZEY\#W%L
M\>]<$!E+ 9[_ )^]=W2T <S\0-)O];\$ZC8:9S=.JLB9QYFU@Q7/N!BLJY$_
MB;Q7X7U.VLKZU335FGNGN+5XBF] OE#< 6).<[<C ^E=W24 <+\-C.B^(DN;
M.\MGN-8N+J+S[22$/$VT*P+*!SCIUK0\=64%]IME'<6VHNJW0D6YTY6::T8(
MQ64!02><#&#]ZNKIH8,,J01ZB@#RWR?$(TO0-0U"UN+T6&MES)':,EQ+;LK*
M)7A"Y!R>1C.,$]Z@N+37YW\1WUCHMZDL>L6VI0P7$:J+J.-5R@Y//&>.>!WX
MKUE'6091@P]0<TZ@#S77;N_\3^#=>DM?"U[8R75JD(6XM\7-Q)G@87)V*,\M
M_>[8.;UA;W">.=!N187B6L>AFV>1X6Q'(60A6.!SA37>44 <U\0?^2>Z_P#]
M>4G\JYIH+_Q!<^$[O3]*N(#I-K),[74?E+N:(*L0S]X,0,D< #K7=:WI,.NZ
M/<Z9<2S107*&.0PD!BIZC)!J;3K5;&PALUGDG$""/?*07( XS@ 9Q[4 >5:/
M::J/$'A'4+C0]85[3[0+O,(2& O&55(HP<*@)'..1U)(P-;PII>HI\-O$6FR
MV%S#>3O>&**6,H9/,4[,9]<UZ.6 8 D GH,]:=0!YQJEE-J_PPMKI[6[TK4]
M$C2XMOM2JK>;"@YP"?E;D<X/M6NVIS^$O"/]L7VEW-U=W$AN;Z.U +0E@6;)
M)^ZB@)G/85KZCX9T[5-7M]3O/M#R6Z!5B\]EB.&W L@.&YP>?0>E:,]K:W\<
M8GC2:-7$BAN5W#H<=#CK]<'M0!,K!T5AT89KS2]L[XZM\1RFFWSKJEG#!9LM
MNV)G6%HS@XQ@,PY].>E>EI+'(7".K%&VL <[3C.#Z'!'YTC2QK*D;2()'SM4
ML,MCK@=Z .'\F]3Q'X,D.FWACM+&6&Y<19$+2+&J@GZQMG&<<'H:Z3Q5I<VM
M>%-5TRW95FN;9XXRW3<1QG\:UZ* //+%O$7B/2QH][X=;1V2RDM;B_E97.3'
MM BQS@G!)Z #')YJJ=(U?7/!FC>%KG2KBRNK"6W2:Z.TQ*D/&]&S\Q8*, =-
MW.*]-HH \DOM!UR?PKXWL1I5TTNIZIY]I%E?G0NI)ZX'"?RK;6PU _$*^U9-
M*NDL9-!^RH2%SY@;=LQG/3C/3-=XTT2S+$9$$C E4+#) [@5)0!XO9^$M<L?
M#_A6[E\.1:G)IL<]M>:7=>6<J[E@Z;LKD<>_ZUN7>C:[;#1_$.E>&[&UDL+N
M:3^QK<I&S12QI&267Y?,^4GZ$#G'/IE% 'GNN6OB#5M(LK_^PC#)#K%M>C3X
MY(S+Y<9RS,V0I9N.,\ #GKB+5=#U37/&]S/+I]S9PW?AUM.-RKHR0RNS.0<'
M)QD#([^W->CU$MS UPUNLT9G5=S1AAN ]2.N* .#32];U?2O#6D7^EM;2Z5=
MP37-T70Q,(!P8\')+X'88R<^^;J?AO7[KP5XPTJ/29?M.IZLUS:@S18>-G1L
MD[OEP$/7U%>IT4 0V8<65N)$,;B-=R,02IQR#C(_*N+UCP9-J7CUKS@:-?V8
M34X\_P"N>-OW:]<\@C/&,*1WKNJ* .(\*>&M1\.^&-0ANP;R_P!C6UN%906@
MCW"%020!]XGG'WN>E8]IH7B33M+\$30Z)Y]UHPFCN;9[J-/OQE P;)&.<\9/
M'2O2+:]M;U9&M;B*=8W,;F-PP5AU!QWY%3T >3WWA;Q#<>'/'%DFD2>=J^H"
M>T_?Q89"P.2=_&-O?U'OCT[31(-,M5FA:&41*'C<@E2!R"02/R-6J* /.]6T
M?Q S^-K6WT<SP:Q&#;3K<QKEO)6/&TD$8()R<< ]3@&I_P (SK5SJ'@Q)M*F
MCMM.TN2SO91-$2C/#Y7 W<XQGCL1WR*]/HH \V\)^'_$FEBTT>]T72D@L95V
MZPFPR31*V0 F,AB!@L<8'OS7H-XH>QN%*NP,; JGWCQT'O5BHYHDGA>&0$HZ
ME6 )&0?<4 >1>$-.U7Q-\./#VD'3?LUC%<B=[YY48-&DI;"*"6#DY'(  !Y.
M<5J67A7Q#I6HZAI<.DZ3=Z;=W$DT.J3E1+;ASD@J02Q!/ X'')YX]!TS3++1
M[%++3X!!;(24B4DA<\G&>E7* .2T'2M1L/&GB;49K)4M-0\DP,DJDL8E*\CL
M6SG\.:PX_!VKZQX9\4Z1J=M%8OJFH/?V\JS"54)*$*P&#P4'YUZ310!R TO5
M]:U'1KW6+&*W;22TQ6.X#_:)BA4;< ;5[\^P]:P]+\,^(+#X37WAMK"%M0F\
MZ)!]I&PK(2=V<=MQX[XKOAJ^GMJ[:2MW$VH+'YK6X.75..2.W4?G5V@#BUL-
M;_X2C0M0.E*+>SL)+:;_ $E-VY]G0=P"GKW]JR4\/>*!X8%D+& '^UI+JXM&
MN@%NK=W9S&7 XP6&1T..X.*]*HH \@OO 7B63P[XJTN"PTY%U:[BG@6&?:L8
M#*Q&"H&!MQ]>V*Z?4_"VHZ_XCNKJ[B@MK"XT5],8"8M(K.0Y8 +@A2,=1G&:
M[BB@#A](T?Q=<VBZ3XAN;-;"WB:$SVC$RW@*%!N!X4 ')[D@4GAG1O&.E06>
MBWMYIQTNQ*!+N'=Y\T:GY8]IX7H 3Z<#/4=S10!G:[I,6NZ#?:5,[1QW<+1%
MUZKD=?PKG8M!US4H=%L=:%DL&DW$5PUQ#,SO=/$/D(4J-@R<G)/(P.#FNSHH
M YGP_I6L6'B'7+R]CL!:ZC,DR>3.[NA5%3!!0 Y"@]>/>I_&F@3>)O"UWI=O
M-'%-(4=&DSMRCA@#CD [<9YQGO6AJ>M:=H_V;^T+E8/M,RP0Y4G>['  P*OT
M <:-!UZ7QS9>(YTTW$.G/:O$EP_WRQ88)3IT&?J<=JQ+7P+XCM/!-AH:G2FF
MMM3%ZTAN) K(LGF #]WG).1[ =\\>FT4 <-J?@[4=8UBVO;K^SXKBVOA/#J5
MNS+<K"&)$)4* W!VY)Z=B>O<BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD9@JECG &>!DT
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MF$;B5)8\ =NN,8.?_8>O)I'A[2H_#]T/[%UX7DCJ\022(S2,/+^;GAAUVXH
M[K4_&^DZ5+<>>MTUM:RK#=W<<68;=VQ@.<Y_B7[H.,\XKF1XDCT+XB^)O-.J
MWT$5G!-]GBW3"/@L[*"<*H!'<>@S3["#Q3H.JZYIL.@17]KJ=]+>VUVTRK%$
M9#DB4')XQG@']>)OL^JIXK\2W<NE7<D4VF1VT,J*N)Y$#9P-W&2W&?2@#N+"
M^M]3T^WOK5P]O<1K)&WJI&17+WWQ)T:PO]2LVM-5FETTK]I\FS9@BG)W$]E
M&<G&<C&:T/ MO=6?@K2K.]M9;6YMK=89(Y<9RHQG@GBN,M+VZM_B%\0;:TTJ
M[OI+E+5%,)0*C>20 Q9A@'=UYZ&@#K[GQSI,2VWV5+F_DN+(WZ16B!G$ _C(
M8COQCKGM5>\^(FB6D6F.L=_<C4X&GM1;6K.9 HR5'^UZCMWP.:Y5?"FMZ;!I
M&B/I\^HV$.E-&3#.D2"Z+,Q\PY#%!D8'(SV-)X9TS7K6[\#QW>@7D*:5!=0W
M$A>,@>8 %/WL_P )S[$4 ;EC\0Y;S6=3CCT'59;*VMH)4$<*>;\X=BS*S @$
M!<#D\'U%;5AXQL=3\.V>MVUM=-;7<ZP1(0@D+%]@.-V,9]\X!.*I6=GJ>G_$
M76;S[!OL-1AML77FJJQ^4K!@1US\PP,?B*R_"WA_['XXUB&"5'T6RG%W;0@9
M$5S,F& /3Y5SQV\P4 =QJ>HVVD:9<:A>.4M[=#)(P&2 /:N)\=:V]]X'\0Q)
M;:EIMW96\4X9I!&6#L0"&C<AA\K @FNPURW:[T.\MULH[WS8RAMI& $H/49)
M&.,]Z\Y_X1763X0\1:/IECJ,>G744:6%EJ,\1DB?<=^"&.(\!< DF@#LM-\9
M:?>7[:>]O?6TJ67VU7N(=JRP@X+KR3^! /M3=,\9Z?K5Y:V0MKVV&HP//92R
MA0+B, 9*E6)4\YYP:H7^FZW)XP35;*R:,#0Y;2.21X\).S!UW#<<@%<' /7T
MYKGM"\.ZY;>)_#^L2Z#.LD$,T-]+->))+(Q &[K@+UV@=NPZD S+Z:Y7X.>)
MK@7UZ)[35I5AE^U2;P/.1,%MV6&">#GUZU[+;DFVB)Y.P?RKRZY\+:_/\-O$
M&A+I4@O=0U%[B$--%MV-*K\G?Q@+@^Y'7DCU"TWFS@\R-HG\M=R,02IQT."1
M^1H \O\ B7XH:]\+3G2[;4A!!?) =1AE\N+>KX9<!@SKP1G!7/O77ZSXWL-&
MN[R VUS<_88UDO'A,8$*D%OXV!8X&<*"<$5Q<_A'Q+#X NO!T6E17*1W7F6M
M[]K559/-$G*GG=R1Z>Y[[%UHOB"U\6W]_%X?TK5K+4?*F N)$5[298U0_,RD
ME?ESP/ICN .UO55\0>)="L1I]W>:+>6DURJQR1JMSPFU^7!PH<\-@Y((!(XN
M6GB_2-"MK>QS>RZ=#/\ 8O[1GF1P'#%?FRV\J&^7=C'\Z!I.JP^,-!NS8O<1
M65E):W-VC11JS/L.Y8]P(4$-D8SSQFLS2?#_ (ETE[K1%TK3);)KEWMM68H7
MBC=R[;D()9AD@=L]<B@#5O/B1I]I%JLHTS4I8]*N!#>.L:@1@D#=RW(R>@R>
M"2 *TM9UZ(2W.E6UA>:A<"T,T\=JP0QQG('S%EPQP< '/&>*XR]\+Z_/I'CB
MWCTM_-UFZ62U#31 %<C);YN.GZBMR"Q\1Z=XGN]4M=-CGMM5M81/!)<JC6LR
M+MY.#N7'7&3Z"@"W\,I'E^'.BR2.SNT+%F8Y).]NIKH]2DCATRZDECDEC6)B
MZ1XW,N.0,D<X]ZXCP]<:WX.\.^&-%O=*MW:27[-,4O07C!<88+M^;[Q)P3@+
MG-=OJ44DVF7442[I'A=47.,D@@<T <CIGBK3-'\/>&X+#2=3:WU)"ME&"LC#
M + ,2_4C\!GDC%7K?QW83Z7=W3VEW'<6M]_9[V9"M(9\@!%(;:>O7/8UBZ9X
M9UVWLO!5O<6\.[19'-TZS#&W:R+M]>"">G2J][X2\1.=2O;*."*]76TU:S62
M4%9 J;"C8Z$C/^- $^G:PEE\0_$]_J5O/I\%KID,DHF8/P"Q++M)!!'''<8K
M4C^(NFO=FU-NYN&MGN8HXKB"4R!!EERKD!@.<$C@'&<5E7/AC7O$>IZY+J5G
M;:=;ZII:6@VW7FO$ZEB"0% /)YY^A-6+#2/%,VG-#J>G:1!-#;2)YMFPW73L
MA1<Y4;%^8L<')(&.,B@"S;_$2.==)8Z!JBKJT;-9L!&1*P7<5^]E?JP [].:
ME/Q MHO#^K:G/IEVDFDW!M[RU5HV=",8;.[!!R.G]*RX?#&O1VO@>(6\2/HC
M 79$XY7;L.WCG(Y[=<56O/!VNW&D^-;5;> /K5R);8F?@+D?>XXZ?K0!TNF>
M,Q?ZZNE3:3=V<LUG]MM3*\9\Z/(&,!C@\]#VZXKD=1U"*W^%6I-X=TF>SMFN
MY89UDN1OC;S0K]SG<25X/%;T/A_6$\::)J[6T7V>STHVDH\X;MYYXXY&1BLW
M_A&?$7_"!:EH?]GV_P!IN[Y[A6^U#:%:42<G;UXQ0!=TB]MM \71:8?#7]DS
MZT-RM'<JT#>4ISA1P&P1P!SG)Z5U>CZJVK"]<6K0Q6]U);([-GS=AVEA[9!'
MX&N5\=/:ZGI=I;)>V]IXF@NH)K&%9E>6.4N!]WJR[2<\8QSVKL=+L(]+TNVL
M822D$80,QR6QU)]R>?QH P/$/C0: ^H-_9DT]OIT<4ES+Y@3AR<! ?OD $D9
M':DN/&O_ !/X]&L-'NKRYFL5OH6$D<:/&2!G);([]1GCISFL3Q9X-UW7=1U[
MRX[">"]M8X[*:YG?-I@#>JIM(RS#.X8_'I5O2?#>NVWBRRUNZ@L@MKH@TXQ1
MW#,7<-N!!* 8Z#G]: +MAX\MM6T?1KO3K&>>ZU9G6&V+!=FS(D9VZ!5QUZG(
MP*I?#EG:_P#%IDL_L;_VLVZ $$*=B]".H/7\:R]%\">)/#^F>')+:;3Y;_1W
MN%DA\]Q'<PS-N(W;,JP.,<$=ZZ?PGH^K:9J.NW.IK9J-0O/M*+;RL^WY0N#E
M1Z=?T% &)XPEFL_BCX.GL[(7-S)%>H8U*HT@$8P"S= ,D_GCK@[%IXWCNM'C
MNAILXO9+]].2S#J29E)S\PXV@*26] :=K/A_4=0\>>'=:@-J+/2UG$H>5A(_
MFIM^4!2..O)Y]JPX_ ^MKI^]9[*+4;76Y-5M"DSM&ZN23&YV C@D9 - &E>Z
M^=0T_7M"U2Q6UU.#37N#$)!+'+&5(WHV 3AN.0#TK.\(:[+8^"/"^EZ?:"\U
M.ZLC)'$\GEQI&GWG=L' R0!P<DUIR^'M6U*]U75[J*T@O;G3#IUM;+.S(B$E
MBSOMZY/0+T'OQEZ9X,\0Z(GAV\LI--:_TZS>PNH9)G$4\).X%7V$J0P!^[^/
MJ 6OA@-MKXF7[(MH1KUP# O2/Y(^!P./PJIXI:>V^+?AR>QLEN;MK&Y4)O$>
M[CC<Q[#)/<^@KH/!^B:KHK:RVIR6;F_U![U/LQ8[=P4%3N Z;146K:!JEUX_
MT?7K46;6EC!)%(DLS*[;^"0 A' ]^?:@"&T\:W5WX=6\CT=SJ']H-ITML),Q
MPRJ2&9G XC&,EL53'Q*!\/W^HIIGVB73[U+.XCMK@.A+,%#HV!N!+#L#5"7P
M3XG?1Y[=7TCS)-;DU)K>2>5X)XW);RY,("<''8@X[5"_@7Q6+3785ET1SJ=]
M!>@^9*@1D97(QM/&5  ]\Y'2@#?E\8:U;:[8Z5<^&&CEOWG%L?ML;;EC4'<V
M/N]5SU[XSQG-E^).HVVA76KW/AY8[;3KPVFHG[6"4<2!#Y8"_/C(Z[>O&:W-
M4T;6+[Q=X<U>);%(-.287*M,^XF50I"?)@@;1R<9]!6!>>!-<O\ P?XAT26;
M3HWU;4VO5D61V$2M()"I^09(*@9XSD],<@&EJBP1?%?1+HK&A;3+HR28 )52
MA&3Z#)_,U!8_$J*]O-+*6D3V.IS^1$89]\\1)PK2Q[<*I/\ M'&16M>^'KR_
M\4:;J<OV;[-!92VLT7F-N;S,9(.WMC\<]JR_#GA3Q/H?D:0VM6;^'[64/"4A
M873*&W"-C]T+GJ>21D<4 7-'\77NL:TL-M:V4MC]IEMYO*N2;BUV!\-*FW@,
M4 '/\0ZT>&O%M]X@O(7BMK&73IE=C);7!:2U(QA)5*C#')Z>AZ]:SXO!>KW.
MO:;J]])ID&HV*N'O[,-YET2C* Z$!1U!)R<].!4^D>#=0B\5V6O:A_9T-U;P
M/%<2V.X&^+ #=(I "X.3QG)QSVH F^(^JZMI6B6CZ6]O'YUY##*\DC(_S.,!
M,#OSD]AG@]N;N+K6;'XIZK<V.GV,E_\ V)&\RO.RQ+A^3NVY8X '05VGC/P[
M/XDT6*UM9HHKF"ZBN8FE!*;D;.#CGIFLQ/"VLGQ1?ZU/<6$CW6E_8BJ;T ?K
MNQ@X&>.IXY]J (S\0DN],T>73[=!<:E;-<XF$CK"JD*<B-2Q^8X' '!Y[5O>
M%M<FU_1_M5S926=Q'*T,D;HRABO\2;@"5(((R/;M7)6OP^UO3=(T%M,U:UMM
M8TE)(#(49XKB)VW%6'!'-=QH]E=V=F?M]T+F]F?S)W4$(&P!A%).U0 !CZD\
MDT 9=SKFI7NIZA8Z!!:2R:<%%P;MF4/(PW!%Q[=2?4>]<HOC'5M?\4^%#I;P
MP65]#<2O;RA@1)&I5U<@\@'...HS73/X=U33_$M_J^B7ELJ:BB?:;:[1BHD4
M8$BE3GIP5[^HK.'P_ET^[T"YT?45BETQ9TD:YBW^9YV2[@ CYMQ) Z<^W(!C
MV.MZEX;L/$-Y9:=;2:?;Z_,+@O)M8JSHO[M1W&>^*U?$'C^XT[5KZRTVP:Y:
MPVB53;3N9G(#;$:-"JD*1RQZD=N:FN/!>HS^'M:TO^T+4-J>H&]\WR6Q&"ZM
MMQNYY0<Y[FEO/"&N1>);G5]#UY+$:BJ"_AD@\T!E4+OCST.!W_\ K4 ,F\7^
M(;O6?[.T?0X'>33XK^/[7*T9178J5<8X;((P,COGM72^(]2N='\.ZAJ5K#%-
M):0/.8Y7*@JJECR ><#_ /5698^&+S3_ !9%JD5_&UFFGI8M#)&6D<*68.7S
M][<QSQ5GQO(D?@3Q 7=5!TZX4%CCDQL /Q- &+:^+==BUK1$U;3;2'3=97;;
MM [/)#)LW 2=OF&<8Z8ZFJUKX[U'_A*-)TR\MK)/[1>9&M8V)FLR@)42,"5)
M(P2 !C/>I=#T"^URRT&]U35+2XL[*V#6HLHRC-(T>W>S;B,J,X '7GVJE8_#
M?5[(:"!KUI_Q)9G> I88WJ_W]_S\L?7^9H BA\7^,]7TK6;VQL](M;?3YKJ"
M21G=W4Q)D%1P#SZ^HXX.4M_%'B?0/"OAO4M2DTV?2[M+6.:Y$4GFP(ZCYWR^
M&)Z$\8)S@]*Z'P]X.N=*T/7-,O+^*==4GGG+PPE#&95PPY8YQVK%U!K7P[X0
MB\(>(;F35[BZM?(LX+6R8;E10J#C/.0#DF@#L=/O[R]UW4XA]G.G6I2*-E4[
MVEVAG!.<8 *C@=2>>*J^)M8OM*>S6U:S@BF\SS;J[!94*@;4"*P9F8G QD\'
M@U;\,Z*GA_P[9::I+/%&#*Y8DO(>78D^K$U2UWPY>:EX@TS5[#4H[2:SCEB8
M26XE!5\9*Y(VL-O7G\N" <K#\1=9O= \+W]II]AYNKWALY5E=P%<,1E<= <'
MKDCT-6X/'6J06^NVM]:6DVK6%]#96XM@R13O-@)G<21@YSSTJ+3?AG?V%AH=
MDVNQ20Z3?M>QYL\%N<A?O^[9/T].;E]\-QJ$GB SZJ0-6GCN4,<&UK>6/[C
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M;N53&L3;F4OYBX'&T855[]?6NXH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *SM7TBP\0Z<U
MG>!GAWA@T4I1D=3D$,IX((K'TOQ++XAE1(M)672+EY8?M:W(?;MSPZ 97./7
MC(SUKB?AYXK?0?"&C0W6F3&PN]0DM/MOFKQ*\C[1L^\1QR?KZ4 >C6/AN"TN
M(9Y[V_U"2#)A-[-O$9(QD  #.,C)YY//-;-<?J?CH:9J#H^F2FPBOH["2Z:3
M8WF. <JA'S*,C)![\4DOC>X'B+4=)M] N9AITL(N9Q<1A8XY 3YA&>P&<=<9
MZ8H [&FJR/G:P;!P<'.#Z5PUC\2M-U+4M/LS#;FUU-VB@=;M)) ?X?,B'*!O
MJ??%8?ACQ,?"VF3QOI+MICZ]/:FY650(RTI"@)U( '/3VS0!ZO36=$*AF52Q
MPH)QD^U<U?>*+Q;S4(]*TC[?#IO%W(;@1G?MW%(P0=S %2<D#G&<UB:A?:?K
MOC#P!J]F$DANC=.KE1NP(&(!]P<\=CF@#T!W2-=SLJC.,DXIU>7^+];GU[1;
M>[@T>)]+358(H+]YAY@*SJK.$V\*2I7.[)],5H^(OBA9:)J-Y;11VDXL"%N5
MDO!%*QP"1$A!WD ^HYX&30!W$]E;7,\$\\*226[%HF89V,1C(]\=ZGKAI_'U
M[/KYTK1/#LVI,;.*]63[4D6Z)\<_-TX/3KGMWJYI7C"YUG4%%EID<VG&Z>V>
M9+G,L!7=DRQ;?D!*\<]Q0!UM%%<]XL\32^&8]->/37O1>WD=IA)E0JSGCKUS
MSW XY(H Z&BN'3QW?P7&K6&H>'9H]4LK=;J"TMIA.;F)FV9! XP2,\'OZ4T?
M$-U7Q#$^G037>BVRW,BVMX)(W7&6&\J,,N#D8[4 =U17EVI>./%=UHNFWUMX
M=BL;6^N+-89YKX%I1(0=H"C*@],GL>G8;MSXN\00ZO<:3%X8BFO8+)+L[=0
M0@Y!&2N?O*0..>^!0!VE%</+\1[-=*T6Y$4<=QJEO]IV3RE4B08W98*2QR<
M!>>O%41\3[F;3=.N+70?.FO-0.G&,W.P"7J"I9/F4@@YXZT >C5DV'AVPTW6
M]1U>W\[[7J&W[06E)5MO"\=!@<#VKG)O&VJQ7D&ES:39VFLM;&Y-E<WO^M^9
MU5(G52&8A<^V0.><=NC%HU9AM)&2/2@!U%5=2U"WTG2[K4+MBMO;1-+(0,G
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M'?@-GJQS]!46A^,]7U/6K+39+BP:2^M9V)@@=DM)DQ\HD#;)AAAG:W!'49%
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MF:(SRM(!\J)$I#-R<D@' ]* .JHKS8^-M?N-)\(7-N+"*36IF@FWPNP1N0&
MW#CC./UJ5O&^J:;HNM?;/LMQJ%IJJZ;:NL31I(SA2"R[CC&XGKVH [0:UIYU
MPZ*+D?VB(?M'D;3GR\@;LXQU/K6A7F]C;WUM\;T2_OEO)#H+,LBPB+"F?[N
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MQYVKM(VC '?U->ST %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD]L<].!0!I->WOAOP=<7VN7:7UU9022RRQ1>6),9*@*.G&!^M<9?C5[J_P#
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MIX7T2PNEN+73HHG5VD15SL1SP65,[5)]0 : .&NBFLZ!XOU:6]N(]6TJZN1
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M[X>T2'P_I$=A#Y>T.\C>7&(T#,Q)"J.BC. ,GCJ2>:6/PYHL(O1'I=J!??\
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M,FO?$ M_$D%\7DMX[4"\>8N058D@LI& <\ #G&*]B31M+C:V9--LU-J"+<K
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MS?BYN[#[!&D9AC1CYJ'G<9,\ $]/QJMX4TS2;'0[:?2;6VB2Y@B=W@ Q*0H
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MUI=Y<SV]MJ-K-- "98TF4L@'!R,\=*B3Q'HDAD":M9,8XFG?;.IVQJ2I8\]
M01GVKSGPE>:!K5[H@\S57U/28&2>":-8X[)?+(<2-L7<I(P!DGG)[U!X?T;0
M3\(5ENK<VES+*8+B]MH1]HB)N!M).,E1\C$=,"@#U/3M7T[5TD?3KZWNUC;:
MYAD#;3UP<=*RH/&>C7/BJ;P_%=Q&YA0;B7QF0G&P>I &3CI65X!U.]U"[UA;
MN2SOQ$\035K(8CN_E/49QN7@';QSBLB\:ZMOB1XJAA\Z"\U+3(HM/E\IRK2!
M",[@,  ]R>* .[@\1:/<ZH^F0ZE;27R9S L@W9'4>Y'<=JT)IHK>%YII%CBC
M4L[N<!0.I)]*\H$Z:WX)\-Z+IVZ+Q#I]S:K) R%9+=XQ^\=AV4@,<G@Y[FNK
M^)"7)\,1RPP2W$,%[;SW4,0),D"N"XP.H]1[4 5M#\:?VY\1KW2[&^M[G28M
M.$ZF./!63>H(+'KP<_B*Z2Q\1Z-J5XUI9ZC;S7 !8(K<L 2"5_O#(/(S7F.I
M3R>(O&7B&?P^ERQN_#;0P3"W>,/)OY7+*,' QGUX[5MRSVWB6X\&MI-K);W=
MC=++<(L!3['$(V$D;\#;D@*!W^E &S\2]8U'0? ]WJ.EW"P7,3Q@.8PW#.%.
M,\9Y]ZM7UQ<GQ+/#:^(((S'ISO\ V;Y*NZON&)B<YQR!CO61\8 7^'%]$BEI
M))80B*,EB)%)P/H"?PJ"\U"T_P"%H3W E'E?\(XX+A3C/F>9C..NSG'I0!L>
M&/%4=UX5T&[U>Y1;[4H\JJH?WC9YP ..U:LWB718-3&G2ZC EV9!%L)_C(R%
M)Z!B.V<UY?\ #R\O?#B:1-?QS7NGZE:"%)DMV:6QD1N8B ,B/G.<=3SZU%9V
ML#S7?AC7].UNZU=;^2:#9)+]FF+.624D'"@;N3Z>_% 'IQ\8^'E@OISJ<7E6
M#B.Z?:V(F)( ;CU!JT^O:6C6:M>QJ;R%IX,Y&^-5#%O8 $'FN-UK0+O_ (3:
M[L;6*3^S/$UJ%OY%Z0F+ 8CL"R,%'N<]JG\ V>HVMM<2ZXN'TD-IEM(026B1
MLF0<?Q#8..NP4 ;.B:U:6GAFWN[[Q#%JBR2NBWR0[!,VYOE5%SG !'&?NYJ\
M?$VC+ID&I&_C^R7#F.%P#\[ D$ 8R3E3V[5Y?X=M!!\-=!CO9]5T>]L[JX>.
MZAM7)@?+'YTVG*,K?3MGK1J)UA[3P]KFMV=^UE;R7<=T=($MO)\[96?8-K -
M@D].ON* /7;#4+35+-+NRG2>!R0'3U!P1[$$8Q5FN&\-3V7A[3P]KHNL);:K
MJ(\HR*\LQ+* 990QRBD@]>V#WKN: "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%&11F@ HHI"0.I%
M"T49S10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBL(1<E9C%<VQ .94'0A@<]><5ZEI>H6=PD,$-TCR^0LOE,X\P(0,$KU'U]:
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MLB7!6"7G(+H/O8([\>N:VJX34_&VJ)X7O]4M='B"+8_:K>X%V)(V&<$$J/O
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M)D9AP1R,,.:K>)]!U)_&FGW^E;DCU&W?3M0D7/[N,?.)..^ R@GN5KNJ* .
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MPTBT%KIUG#:P Y$<*!1GUXH Q_#MOXH\P2^(I-.011[(X=.W[78D$N^['/&
M!ZGVQD^/VO%UCPBU@D+W(U,[%G8JA_=MD$@$CC/8\UW-9^H:'IFJSP3W]C#<
M2VYW0M(N3&?4>AH XW7O!VM:QI7B)\V:ZCJY@B2(S-Y4$,1R/FV99B=Q/'<>
ME:/B+0M?NM5TGQ!HDME#JMI$T,UO=.QAD1\%EW*,\$<' [5V-% 'EGC6'6[=
M/"<EY+:7.K2:]'((T+) AVX5 3E@O R<=23BM'5O!6M:HFM:DMS:V^J:@T"+
M;J[&'R(S_JW?;N._G.!Z#IFNSU#1--U:2WDU"RAN7MFWPM(N3&W'(]#P*OT
M>=6GA'Q,L_B5YQH4::O91VZQ6_F!(RJ,@XQP &S[X'2K$'A#7M-NM#U+3;JP
M^W6.EKI=S%.7,4L:\JP( (.>>E=[10!YW;V/BGPEH2QP7&ES7MSJCSM L4K"
M59&R44]1R>I& !DFO1*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,/@LV2<!AP3UKI?!.C:EHJZE!<-=)IK3J=/MKN=998$V_,"P)&,]!DX ]<T
M8.NRW6N_$V+0[W1I[C2X=/>0PF9 KEI OG#YNPX'\0YP*UK/QC8:=I5C)]CU
M$Z(9%M(M4G=7#8.P.WS;]I(QN([BG7&E:E/\2O[5^P3C3CIIT]I5GC!R7W[]
MN<E>WKGM63'X8UZY\$+X*OK5?)1UB&IB5&0VZN&!"9W!\#;C&.^: )+==_Q3
M\5PEY/+.E1' D88SUQSQ^%2^$-=CTGX>^&;>.WEO-0O8#]GMHR TA&6=BQX
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% #)4\R)T#LFX$;EZCW%4="T6U\/:1!I
M=D93:P9$8E;<5!.<9^I-:-% !1110 52U;3(-9TFYTVY:58+E#')Y3;6*GJ,
M^XX_&KM% %/2M-ATC2K73K9I&@MHQ%'YC;F"C@#/L./PJY110 4444 %%%%
M$,MI;37$,\L$;S09,3LH)3/!P>V14U%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M45GZSJT6AZ9-J%Q#/+;P*7E,*ABB@$EB"1P,=J -"BL-O%5BOANWUMHYU@NO
M+^S1L ))C(0(PHSU;(ZD>IQBK6D:NVJ"Y633[RQFMI?*>.Y0#)P""K*2K#!Z
M@T :5%,AFCGC$D+JZ$D!E.0<'!_44^@ HK/U;6;/1H8WNF<O,_EPPQ(7DE?K
MM51R3^@[UG)XK1+VWM+_ $G4K"2ZG\BW::-661L$_>1F"\ \'!XH Z&BBB@
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M@]J -RBDW#;NR,>M<O8^);_4/$WB;1H+6V\S2XH6MF,AQ*\B%AN..!T'&>]
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MCE,\5L9G,$<A_B6,G:#UQ@<=J .0U'4M0@\+>/)H]4NQ/I]ZPM6\X[H5"(P
M]LLW7^E6]1L-0UCXCW>D_P#"1:O9V1TN.Z$=I,(RKERN 0,@?*#ZGUQQ70:C
MX%\/:K>7EU>63.]XH$ZB9U1R!@,5!QN XSC-<_)X16[^(N][#48-*@TE;*&Y
MANC&"P9B02'WL"K8Y[C\: +7@_\ M'Q#X9T:\O\ 5;R.>QNY4=XWVB]",R#>
M.XXY]P:[FLF7PUI,@TM?L@1-+<26BQL5$9QCH.OXUK4 %%%% !1110 4444
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M/>6^GVD-U(,/-'"JNP]V R:+G2-,O+N.ZNM.M)[F/&R:6!6=<<C!(R* /,-
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MO-;\"ZOI]@";J6']VJG!<A@VW\0"/QK9.EZ>T?EM8VQ3=OVF%<;O7&.M6@
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MY!'L:?7)> K73K/3;Z/2;Z>]L&NV>.9U41%B 6$04 ; ?08SG'>NMH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%(2 "20 .I- '->+_ !C;>$AIIGC\S[7<K&_)'E19
M :0\'@%E'_ A6KK>M66@:3/J-_*L<,2YP2 7;LJYZDG@5QESI,OCJ'7;V&:R
M>PO(S86S3HQV)$QRZX.!F3)SZ*M8,FN6_B/X(7HO3#-J.F(L$^[#,C*X4/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBJVH7]MI=A/?7DHBMH$+R.03@#V')^@H LT5S6E>/?#VM:K%IMC=3O=RJ
MS(CVDL>0HR3EE KI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MIDL,4Z!)HTD4,K!74$9!!!Y[@@$>XI]% ',:>8]6\=:G>&+*:5$EC#(>1YC@
M22X^@,8_/UKIZIZ;IEOI4,T<&X^=/)<2,Y!+.[%CG [9P/8"KE !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>exhibit1021-independentc008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit1021-independentc008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HKE]0\5WRZS<Z9HF@3:K+9[/M<GVA($C+#<%!;[S8(./<<UH^'-?B\
M1::]RMM-:S0S-;W%M,,/%(O53V/4'(]: ->BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ#96NM_:(H'6+3M8^S*-Y*9;@85MK<9 YKM[6.6&TABGF,\J(JO*5V[V Y;
MZ9/.* /.ISK=QXPUB\\#E'#9AU%K_(MC<(H4>7_$7  !_AZ5N?#U[9-)O;,"
M\74X+MCJ2WC!I3.P!+97@J1C!'84U_"FMZ9?7TWAS7HK2WO;AKF6UNK03*LK
M?>96!! .!Q]:UO#WA[^Q/M=Q<7CWVI7SB2[NW0)YA4;5 4<*H'04 ;=%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4UT61"CJ&4]01D&G44  &!@5'+!%.H$L22
M<@.H-244 (JA%"J % P .@I:** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *RM4\1Z5HUS!;Z
MA=&&6<A85,3GS&/15(!R?;K6K7"?$C_C]\&_]C!;?UH ZC4_$&FZ1$LE[,Z;
MHVE"I"\C!%QN8JJDA1D9)&!D5;L[ZVO[&"]M9EDMIT$D<@X#*>0>:X.6.^E^
M.!A74"J#0C(H,0("F< KCWP.>M6_B6;JV\/Z:MC=M:1-J-O"\<:##*7&![ 8
MZ#K0!W-%<@FHZGK&O:GHUAJPMFTF*'SIOLRLTLL@9L'/ 4 #H,\]1BKW@K7Y
M_$?AJ*]NXDCNTDD@N%CSMWHQ4D9['&?QH 5O&_AU'N4?4=AM2!<;H9!Y.>F_
M*_+^.*W8I8YX4EB=9(W4,CJ<A@>A![BO+=/?4V\5_$&UT[2H[Y[B6*/][*JQ
MJ3$P^<'DK].:FMK?Q/X3B\)^$-/U"QWW5K<B2:2 OY3H ^0=WS %\ 8'3G/2
M@#T^BN(L;[Q%K<^HZ?#JL%I>:0L4,DB6ZNMS.8PS,0?NID@ #!ZGCH,VQ\<:
MI<MX8U>Y*6VDZI*]G=Q%!F&Y7<HPW]UF4]>10!W6L:S9:%8_;+]W2'S$CRJ%
MCEC@<#ZU8O+N&PLIKNX++#"A=RJ%R .O !)_"N#U77M<MO EQX@M[X 2WRM;
MI-;H2+9IA&@X '(._)!X('O5K5=2U#7;KQ1I]EJ'V&#2;81G9$CM-(\98EMP
M.% X&,$DGGB@#K]-U"WU;3+;4+1BUO<QK+&6&"5(R.*M5Y?X:UZ_ET/PSHNE
MK<X.C"YDEM4B,@*L(P!YK!<9SG@GICUJ:?Q)XQ@NO#-A>"SLKV^N9K6Y&Q90
M=J K)\K'!P<[<]1Z&@#TJBJNFQ7D.FV\6H7,=S>*@$LT<?EJ[>H7)Q_GITJU
M0 4444 %%%% !1110 4444 %%%% !4%[>0:=87%[<L5@MXVED8 DA5&3P.O2
MIZ:Z)(A21593U##(- '+_P#"?:6-173OL.L?;6B\\0?V?)O,><;L8SC/&:NZ
M7XNTW5]3BL+5;GS9+5KI6DA*+L5PA&3_ !!FP1VP<U@S?\EVM_\ L7C_ .CS
M2ZMI\UW\3+6VL[V33MVBSL\MNB[\&>,G;D$ ECDG![]SD '=45YKI'B35;_3
M?"6EW%^4N-3DO$N;U HD86[,,*", M@9/;GUR*/BGQ!X@\.Z+XKLH]5FEFTT
M6UQ:7C1IO\N:384?C!(YP< _A0!ZQ17GGD:X?'O]B-XHOQ:76F&]8I'$'C<2
M!<(2I"K\W<$\=>]4[37M7U#P%X=>;576[O+V2VG,"8N+E$>1<1\85B$!+' '
M)R* /3Z*\OM-;UR\\)WL,!U&YFT_69;2Z2.1!>?9ER<*PX:0?+R.H!Y[UU/@
M;48M3T.6>+4[F_074B W:;)H,8_=.,?>7U]Z +5YXKLK6\N+>*VO;PVO_'R]
MI 9%A.,[6QR6QV&2,C.,UJV%[#J6GVU];$M!<Q+-&2,$JP!''T-<#J6FZYHV
ML:IXB\'W4=]%+,3J&E7&0K2*N&,;=FZ<?SX%=9X3U:SUSPKINH:? 8+62$+'
M"?\ EGM.TK] 5(H L:YK=IX>TN34KX2_98L>8\:;M@Z9(ZU;LKI;VTBN4CD1
M)5#*)!@X/0X[5R_Q2_Y)IKG_ %Q7_P!#6MVSNH+'P[:7-S*L4*6\99VZ#Y10
M!I45Y%JOB#5K+4UU&UU.[ND/B 6196 M!"3CR=AP6<=V QGO5G5)-:6T\:W2
M>)-27^QYA):HI0#(B63#87E>2,<<=<T >J45Q&F/J5AXYL()]7N;V#4M,DN)
M8IL;8Y$9.8P/NC#XQ[=Z[>@#G['QAIE]XJO?#86>#4[1=[1S* '7@Y4@G/!!
M['!^M2^)/%6F^%K>VEOS*S74P@@BA4,[L?0$CCWSZ5YUXHL9K3Q-K_BZP7-[
MH=_;RN%',MN;:(2*?;&3^=1>,+J'Q+9VGB6+<UG_ &K:VFGEUVG8&S(__ GP
M/I&/6@#UY[B1++[0+69I-@;[.I7?G^[][;G\<>]<UI_CZRU/1AK%MI6K-IOS
M?Z0(%8#;G)VJQ8@$'D"NLSVK@O@^57X6:8SD!09R2>@'FO0!V6FZE9ZOI\-_
MI]PEQ:S#='(AX/\ GTJW7 ?"M1]@UZ:W!72YM7G>QS@*8\@97VR*[^@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ0S*YC_W@#QT/7TI(]9TN6YCMH]2LWGE+".)9U+/M)#8&<G&#GTP: +M%%%
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M1Q-"LO<(Q4D?FH_R30!YI::K/XF\&ZIKL$U[:)8Z*88S'.Z$W*H7D/7G:50
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M.F^+] U>XN;>RU*-Y;9#)*KJT>U!U?Y@,K_M#BL_XBV5SJ7@:\M[.UDN93)
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MLD*"1N  SBN,A6_33H]433-6-G8>(+NYN;>&)X9C%)N"NF,$[<G('KS7MM%
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MM?*"I 8 5 8 $%Y"!SN!('H!7L=% ''*][_PGYU=](OTM#HPA+%%)60.9"F
MQR<<<9&>*QO"VI7_ ()\!Z-:ZEH=[O\ MCP3[=O[D22LRMU^8'<HQZ_KZ55>
MXL;6[D@DN($E:W?S(MXSL?&-P'KSUH QO&ZZLWA.\&BVT=S>_+MB= ^1N&2H
M;@L!R,]Q7%6>EWB:YX@N&\)ZG/8W^GPH8[R97><ACO#$N<,0> #Q@?=KU:B@
M#C/ MCJ5C-J,<CZA_8W[M;&/4@/M$9&=XSU*=,9_^N<Z^U!]-^,LTJ6%W>!M
M#C0K:J&9<SG!P2.,\>V:]$K,70K-?$;:Z/-^W-;BV)W_ "^6#G;CIUYSUH \
M[L_"FHZ5<>%Y_P"S[J:6/5+B^N%BV%+=)AC:<D<CY>F1][VSTC0:MH7CG5-4
M33IM0TW4X8O^/8IYD,D:[<$,1E2.X/7MWKLZ* /.)_!>HQ_#[RHE0:W:WKZK
M:QQMD)+YC.(\\9^4[?3)].:N>)]'U(_"ZZTJ&TDO=4O$S*L&,><[;W;YB,+G
M./PKNZ* ."BM]9T?QA>:S!H]U?6FLVENAC61%DM)(U*[6#$ *<Y)!.#GK7*:
M3X/\0:/H'AN]G\.V^I2Z?'<07.F3.A9TED+JZDY4$$X(Z\>_'M%% 'F]SI&O
M6[:+KUEH-I!)97DLLFD6I12(I(UC)W !6D&"?^! =JU?"%AJ4/BGQ-JEWIDE
MC;:D\$D*RRHS_+'@Y"DXZ^O'(YKLZ* /-_&FA:YK>JZK;'3WOK*?3]FG%)UC
MC@FP0QE'!8Y.5Z@>V21!8Z1KVFW7A/6I=%FE73=)^PW%I!+&TP;:%# $A2..
MF[(KT^B@#SB?PEK<#C7[5(/[2&KG4FL5P 8C'Y9C#=/,*Y)/3)//>MO3M)GU
M/Q5>>(+^P:SAFT];".UF*F1U+%W9PI('4*!D]#G%=910!P7AKP5>V.D:OI6H
M3+]F,<UAIS*<E+9RS;CS]XE@/H@J'P=HGB+2H+32[W1=)MDM'&[4X-A:XC7@
M (!G<1U8D<>]>AT4 4=+N-0N89FU&Q6TD69TC59A)OC'W7R.F?3M5ZBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBG2%I!%(K'*$*#@,&S[[:U3X&TLGF?4/?_3).?\ QZE7P-I0!_>7Y^MY)_\
M%4 <)?:;=VWA!D2RO4CFU\7=O:1P2,\4'F9R5 RN>N#TS7KD4D4D2.A^4C(R
M,']:YX>!M*!),NH,?]J]D_QI_P#PA&D_]/O_ (&R_P"- 'G#0W?_  K;4-';
M2=2:ZCU3S#&MFY\Q#/N^7CYA@9R*U/$>EW^I^*=7CL;6ZC-SH'D0S_9V6,R
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M30Q*3@%F0@#/;DUQRZ7J/B2W\-:=-I=WIR:.R2W,]R%&YTCV!(\$[@2<D\#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHNJ>(=>LM.\1V>H6BZ=<W),ME*@"QVP8KD/C<9. >2!R1CBJC^(];U70=?\
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MJ%BD6W0,@'93C@<GI0!Y!X=N]%_MOPA<BXTZ*UG%XK)/*KW+*ZMS<2< EF.
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M=L:C;!*@VES["(D^Y6K/@BSN+I#8:[:HT/AR.73]\P!28L?O8/81!!D]=[4
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MNH Q*NRPXD#>8RIR0I ..]>:7,YE@^(P:6[NVOK:T:VGEM&C\_"D$@;0!RP
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M9%8]GXIT6_U 6%M?*]RP8QJ491(!U*$@!P/]DFD\16\^K^#]3M]..9[NRD6
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MG.<Y/'///-%SH6DWEM!;7.F6DL$!#11/"I6,CT&,"KLDL<,3RR.J1HI9F8X
M Y))K$MO&GAN\GMH+;6K262Y?9"J/G<V2,?4D''KCB@#3DTO3I;B.XDL+5YX
MP%21H5+*!T .,BHUT324MI+==+LE@D(9XA;H%8CH2,8-17_B+2=+E:.]OHX6
M0*9,@D1ACA2Q PN??%4;GQ?8V_BJWT/]XSR6S7#2+$[ 89 H&!SG<>>@Q[T
M:AT72C<K<'3+,SKC;+Y"[A@8&#C/  %0V>B0VNM7VJDJUS=!4RD80*B] <?>
M.2?F/L.,5?N+B&TMY+BXE2*&-2SR.<*H'4DUDCQ=H/DW$K:I!&ELBO-YI*%%
M;[IPP!P>QH T[RPL]0C6.]M(+E%.X+-&' /K@U%/I&F744,5SIUI-'"-L220
M*PC''"@CCH.GI6<?&GAL221_VS:;T3>0'ZC(''KR0,#)S65XJ\1[O"MMK.B:
MRL=L;R&)YHPA4HTJH^2P.W'/I0!U<MA9SRQ2RVD$DD0(C=XP2@/7![5"VB:4
MZPJVF63+#_J@;=2(_P#=XXZ#I573/%&BZS+<Q6&HQ3/:C=,.5VK_ 'N0,K[C
MBFV/BO1-1ODLK6_5KB1-\2.C)YJXSE"P <>ZYH V2H92K $$8(/>J<>CZ9#;
M2VT6G6D<$W^LB6!0K_48P:X[QQXOCLQ:VNEZI-%>#48;>58[<LC@N R&0J5!
M SP"#6]:WL3>+=3QX@$L<%LGFZ<8P%MCD_.7]\'@_P"% &S:65K8P^3:6T-O
M%G.R% BY]<"BZLK6]14N[:&=5;<JRQAP#ZC/>LZP\4:/J=^;&UO-USL\Q8WB
M>/S$_O(6 #K[KD5SFL^,+>?Q'X=L](U64B?4/*GC2 ^5-&%;)$A7#88*/E;O
M0!VLUI;7,:QSV\4L:$,JN@8 CH0#W%-:QM&+%K6 ESEB8QR?>J?B26X@\,:I
M/:7#V]Q#:R2QRHJDJ54D<,".WI7/^!_&%EJ6B:+97>HM+J]Q:!SO1AYK 9;#
MXVL1W .10!US6EL\:1M;Q,B?=4H"%^@I6MH'E$KPQM*O1R@)'XUE#Q9HAO8K
M3[</,EF-O&YB<1O*.J+)C86[8!SGBJ\7CKPU-?+9)JL9N#(\>TQN-K(,L&)&
M%P >N.A]* .A*@D$@9'0XZ4AC0A@5&&^]QU[<UD6GBK1[V\2TAN7$\D)GC22
MWDC\V,=63<HWC_=S6/I7BG1-)T*">\\1RWL-S>20QW=Q"X)?>?D/R\ =.<#
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M.FU,R(P8AD^;!&%)YP?;/%*_BNT^R:?+;6MW=S7]L+N&U@13*(L EFRP48W
M=>2<#- &]1BO.=3\46UUXD\&:SIT]_-8W@NU:"$.?-*I@ Q]-P8D9/3N<#-=
MEH.NVOB"QDN;:.>(Q3/;S0SH%DBD4X*L 2,]#U[T 7[B%I[:6%97B9T*B1/O
M(2,9'N*S- T$Z+;N9[^XU&]E"B:[N"-SA1@  = .>/<G)S46L>*;31[]-/\
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MEMVT@CH 23@\8YK4U+QE8V7V5+6&2_EN;?[4B0.B_N<<-EV YS@ <F@#H@
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MM"UM='N?$7BK3?$$-M&MO'&+-)U 2&S\L8,0/  8$DKWQZ"NHT#1]8@N&O\
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M;CCG//X].:]7HH \B\-Z?=PVMIX?U7PQJL^H65VK)>2S2M9E1)GSOO[0V,G
M!R<>M:&BZ!J%WX=\>67V2:VN=1U&[EM'GC,>])!A""1WY^F>>M>F9&<9Y]*
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M$A1P0"K# ('. <<D'&>W14Q88DDDD2-%>3!=@H!; P,GOQ3Z "BBB@ HHHH
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M;4#O;2#<^&+9.W"J %P6(W9..,$[>IZI9Z1:BXO92B%Q&H5"[.QZ*JJ"6/L
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MRWR[IH06*B,8^2,9'R]<C.T]M]?#NK^=XX=K:,?VU$%M<3 \B(Q_-Z<G/TH
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MEU;^(X=<U*YLY;V*T-L\EK;F)IR2/FD)8YP%_7\*ZN@ HHHH **** "BBB@
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M2<4E[?V>FVS7-]=06T"]99I BC\3Q7/?$&^CT[PA<75QI-OJENDD?FP7#[5
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M6WTXG3 [PK;,Y\^8H4#N2!M&">!GD]>*Q(O NMQ^&=!TPRZ:TVEZM_:/F%Y
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M:X;3O&EWJ.A7LS6=O#JEO?&P^R&0G]X6"KDXZ$'/TKM8@P1=P"M@$A>F<<T
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M^LXKO2;-+N.[@MB,HT;L4VLQP1L(#9/7..U=1X0BOH_"6G"\NXKB1K:-HW2
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MW+74S1Q")-Q &%0$X''J:W** .)N/ ,MQ9:_:'6"(];E66X/V8;D/<+\V,$
M#D''7FG7G@*XDO+74-.\07.FZBMNEM=SP1 BYC7 &48D*W'7FNDU+49=/EL4
MCT^YNQ<W"P.T"Y$ (/SOZ*,<GWK/7Q7$UYK]O]@NMVBK&TH&W,H92V5YQC S
MR1UH KS>#(7U;0+Z*^F1=%$GE1LH<RF08<NQY)/KZY-9$_PQW6=[IEKX@O;;
M1[FX6Y6Q$2,(W#ASAB,[<C@>O)S78Z+J::UHECJ<4;1QW<"3*C'E0PS@U>H
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M$'MQ0!G:=H=IIURUTK3SW31B+S[F4R.$'(4$]!GGW/)R:TJY]/$$[>/#X?\
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MVJFT_)TVJ!QCN>IS3)/AUH\]AK-G=3WMQ%JUQ]JFWN@,<N<[D*J,=NN>GUR
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MJ[T*VT:X@DDL[;8809GWH4^Z0^=V1ZYJO'X+T2*]NKI(+@275N+:4"[EVM$
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MIUG+*FFVL%M/!'&[*MO*_P!Y5YX!'.WISTKU!?#VCII?]F#3+7[#G=]G\H;
M?7%/&AZ2+$V7]F69M6;>T+0J4+>I!&"?>@#@-3L])\->*-"MKN20:/J9EDNG
MNI6DBFN0BA/,W'&#DGTSSVXIZU=Z?I5AIMAI^MEM$?5Y$N+BZ7[1;QDQEUB
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M0Q[Q<2,R*>H1BQ*#O\I'0>E)#X+T.WT*XT6*WN%TZX8M+#]LF^;/7G?D YY
M.#WKH** .>N_!'AZ_P!*M=-N[%I[:T.;?S+B0O%TX5]VX#@<9["G77@GP[>Z
M)%H]QID;V43^8B;V#*V<EMX.[)[G//>M^B@#!_X0OP^-$BT=-.6.RBE6=%CD
M='$B]'W@[MWOG-6[7P_IEEJIU.WMV6\-NMJ9#*YS&""!@G&>!SU]ZTZ* "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV[C@ENG$<"R''F.>B@],^U57\5:#$MZTNKVD8LG"7/F2!?*8YP#GUP<>N.*
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MT%NQQ@2-VZC/7&1G% &_@>@I<#&,<55U#4+?3--N-0NF86T$9ED9$+D*!DG
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNC&96Q&BLN[ ;YU^[U;MUS7K6*SM9T6UUVP%I=-,@6198Y()"CQNIR&4CH:
M.,\,:HDOC.>\U:WU:UU'4(4MK<7>G?9H6"!F*J0[Y8_,W)''3I6GXUM!>WFE
MQ[-6MI4$LD.IZ;&\AM7 4;710=RN"1^'U(U],\.1:?<)<3ZCJ&HSQKMBDOI0
M_E@]2 J@9(XSC.._6MD\4 >7M;:[)J7@&[U.QGDN+66Z:\D@M3A _P J,P48
M4G@D=CG-8TTCW-SXATY]+UVXT2?6Y+B06>GK-O*,-VV7>, NG3:2 ,9KV6*>
M*=2T,J2*#@E&! /IQ7.0^!K&VED6WU'5H+&5V=]/BNBL!+$DX &Y022<!@*
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MV[M^T'C=MQWZ<UCZ=X4UF\\,Z!X;U*Q%I!I=PD]Q<^<KB81DE5C"G/)/)8#
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M\CO;>94#A9$SC<IZCD\9';Z4 <)//K-A\0/&-UI]Q9BXMM+@FEDGA9@^R,G
M4,,9(ZYX]ZZ2'Q+J%QJO@K=%:>1K5H\TH\LEXW$'F':V>AR!TSQUYXE3P1*-
M2U>]DUB25]5LQ9SEX%!VA=H8$$#=C.>,$GH*GA\'&&7PXXU.0G0HVB@S"O[Q
M2@0AO^ @#C'K0!F>'?%UYJ_B(64][;V]RDTJW.E36YCEC1=VQHV)^?.%SQWS
MQ7>5R]KX2D76+"^O]3:]&G;OL8:!5D4LI4[G!^88/ P/4YKJ!0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?5XO,BCN92J1  %BS!23@D#@<Y[=@#MJ*\\3XH/)I>GW<.B-.]SJG]ELL=R
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M&^U,3J8+B8PE)(ER0-RC*G*G=Z9&,UV;:K)8>&VU35X!;206QGN8D?>$(7+
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC_&O1Z* . U/PGXCU6/2+B[OK*:]MM5BU*=2[I"GEC BB&&('<L><Y/TBOO
MVKWT_C+=-8QQ:_'$(B)'+1-&,+N&T9![XZ>]>B44 <;93^)M.U?0]*GETN6#
MR"MU#;QR;U500'#'C&0HYQDD@ XS73:MIL.KZ1>:=<#,5U"\3>P88S]:N44
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MRH+;C&LF<A">H Y&?7-;GBKP[_PDVCBQ%VUJRSQSK)Y8D7*-D!E/##V-;E%
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MTC(H"DJI)X ''-;'AS5+_4?%U_;P:\=2T>U@B=9/)B.^1PV5+HH'& < =^:
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M@XR"""."""#56?P?IMWI&I6%V]Q.=2P;JY=P)7*@!3D  ;=HP ,<=.3GH**
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M@SZ]/!XUL]!:S3R;FUDN%N/-YRA *[<<=>N: +'AWP]9^&=,_L^P>9K?S&D
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M2^#([6=8)VOY DK)O"'8.<=ZZ#P]X0MO#TGFC4M3U&58_*B?4+CS3"G4JF
M <#/T'I5G7?#=KKTMA/-/<6]S83>=;S6[ ,C=#PP(((]10!Y[J7B7Q5I.G>)
M=/;5HYK[2+JU\J\:U4>;'.R@*P'R@C/4#-:MUJ'B:Q\00^&7U*6^N+B*6^^T
MVT4,,@CW*J1J'.W@[B3@DC ]36UJ'@"PU'3;JSEU#44:\N5N;JX1X_,G9<;
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M,R!MP$AZMSSCIP!TXJ*#X?Z-#I>H:=(UU<07UP;N3SI 62<_\M$8 %6Z<^U
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MYX *_BF:ZMM>\,/!>W$44^H>1- C )(IC=OFXR>5'?'M7$7UUK4'ACQ7J_\
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M.VO(WN7E$Z21%C+AB0I7;N^4#OVIGPYM+S5?.UB]UO5)I+34+JW6"2X+1,G
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MYGN)]%M'>=MTH*?*S?WBO3=[XS5U= TI;];U;*-;A8?(#+D#R\8V$="OMC%
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M:0!3]#3Y[JWM8?.N)XHHO[\CA5_,UY#KMAI6B^/(-*NKNWT;1_L'^A>;;K+
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M>* /5K/7=*U"QEOK34;::UA)$LJR#:F!D[CVX]:6TUS3+Z.X>VOX)%MN9_G
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M\2+90WERAMYXEW&?#8,>,9Y/!]*8OQ"T1?$.I:7/-)"MDJ!I'MY "_S[QG&
M %7DXSDXS0!TMU8V=\%%W:P7 7E1+&'Q],TMQ96EW$L5S:PS1J<JDL88 ].
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MO-9UF6"VT^U>RBNY+29ENSY\)3=\[Q;,!6*@#YNXKK: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MR_$FEG6_#.IZ8K!7NK:2)&)X#%3@GVSBM2B@#@/"GB[3]'\.6&BZX)]/U.PA
M6UE@DMY#NV#:&4@$,"!D$57\2ZP7U[P]<W-A<:5N6X,>HR0M+) "-H147*AW
M7G#AL9Z9Z>CT4 >%:?J$:?"G[%,;A)[?6XR8YH74JIGW\9 '0,2!T[XS7=C4
M=.3XMSR>=$BKHF))3@*3Y@?ENA^3!^E=U10!Y%979F^'ME/:))=1V&NF[OK>
M-3O\C[1(X.SJ>JMCV]JT-6ELM2\57^N6$BMI\6A20WES@B.1V.8TZ?,X].HX
M'!XKTVB@#Q_5(M'B^$7AJ5;6VSOL4N-D +$J090P R>CD_CZUJRW>GP^-/&!
M\R)(GT>$#C"L0K<#U.&7CW%>ET4 >-Z?J4,5CX#WQ3VRII\D8U&*V>66.0 *
MT2I@C<<=2K>W7-=?\++F.3P1:VBK<++:O*DHFB9""9'..0,G!&<>M=K10 5X
MT8;:Y\'Z]X9;3Y7UV[U*=X(&M75@6E^27>5P% .=V<8X[U[+10!XUJ-C;0^)
M==TK7[#7ISJ$RR6@L9I?(O 44!6 .W((QD]._2MPK)!\3?# EMWC%OI+6\QC
M5GCBD(&$WXQ^=>DT4 >2@M;^"->\):CI]Q)K4T]QY,<<+-]I,C[HY0X&W +#
M))&-O.*T/#FG?\7-U9+^U:?;IMK$)YH"5=T"[L,1@G(!Z]O:O2J* /$O#^F*
MD<&A:QI7B*YUBTOLJK3S_8F;S"1-D':  =V>I]\U[;110!R/C-+RWU3P[K,4
M$MQ8Z==NUW%$I=@KH4$FP<MMW$\<C/UKF/$<7VR3Q;K=E;W(LKO1Q8*!;R!K
MJY^;#!,9("E5W8QUYX->JT4 >7WCB]\5>$FLDN8$.EW$/F_9G00LZ!4!X&#N
M!X/I67X4LH'M-*T/4?#FNOK>G7*$F>XG^R1%7R9E._8 %S@ <D@#(.:]DHH
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M*Z5=*=+A,=V6 Q$?*6/GGID$\=JS4TGQ$9M$OKOP[?2ZE::HTUUY,T:P!/G
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MMY?G7-N\*&1BJ@LI&20">_I7)Q>%?$-L_A6XMIM,%QH]D]E,)&D9&!5%#+@
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M;TL)(2,%,RN>3DX[>O:M3P[I.J6WCSQ+K%W8M!:ZHEMY),J,5,<>U@P!/<T
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MB+5=(U..WM3;6]L;1YUGDB,[S2@\1+&K!L8Y+8(%:OA[0[[2EEEU369M7OI
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MO2K>&^N.+B&,R/ GE@A%B)!E<MG[H/ )QZ8NK>(=9UGPGX9NS?QV9NM=2RN
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M*Z7 =1U3Q&NGRV4FJ.C+%,NUP@4?,RY^4LV21],\UU- !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M!.!DT5G:];QW7A[4H)3$$DM9%+2_=7Y3R?8=: +L4T5Q$LL,B21M]UT8$'Z$
M5)7E?@[Q5?Z'X6\+1WVD!-%ND2U6]$X+K(Q.TLG93]<_RK6F^)&&DN[;3_M&
MG171MG6,LURP#;3(J!<;0>V<D<\=* .^HK.UW6(- T.[U6Y5FBMDW%4ZL<X
M'U) KEX/'=Y')>17NF1.\=I)=PM:2N\9"#)C=F0;6P,YP0?Y@'0ZSX;L-=N[
M"YO6N-]A(98!%*4"OQAN.I&/U-;%<+I7CG4]1N=$631X88=;M9)+-C<Y(E2/
M>0X .$/8C)]1VK)\-^.=7@\-W6JZQ%;3_:-4:UM429P?,+XV8*G"*H)R,G"G
MB@#U"BO/[GX@ZA::3K4S:/'/<:9&LOF12LL$L;=U9E!W+W7'T-69O&>K6MS'
M8WNDVME>7+O);B:YWJL"XR[[ Q#9( '3)Z\4 =OFH(;RUN)IH8;B&26$@2HC
M@LF<XW =.AZ^E<A9>.9[ZPM(4TTIK-U=R6D<,A*Q$Q@,\H8C<8]I!!QDDX]Z
MS_A]]K_X3WQU]MA@AN/.M-Z0,2GW'P02!U&#^- 'H$EW;0W$5O+<1)--GRHV
M<!GQR=HZG'M4U<UK%XD'C+P_:R:5:3M<"?R;R1LR0,L99@HV\ C'(/KQZ\TW
MQ(U@:1>:N=$M196.I&RN,7+,Y 95R@VC.,GDX[4 >E456O[F2STZYN8K:2YD
MBC9U@B^](0,A1[GI7'Z%XTU+4=>.CW%OIKW;V)NU2WN#B!PP5H93AL,">2!^
M% '<T5P&E>-]:O8/#NHW.EV<.FZO-]F 6=FE60AR&QC&WY#QUJ[8^,+Q-1\0
MV.L6UO;SZ3")T$+,PGC()#+GZ 8QU.* .RHK/%_+9Z =0U6-(9(;8SW*1$L$
MPNY@.YQ@UA:9XAUR5["]OK"V&CWUHUT9X6.;10N]1(2?FRI'( P<]>M '6T5
MQ$WC'5+32+#Q)<6EM_85V\>44-Y\,4A 21CDJ>JY4#C/4TZY\5ZM;:5XIF,-
MDUQH<F1PX2:/RQ)C&<AMIQG)&: .UHKSZZ\:>(Y]<T_2M)TK3Y);[2EOXVGG
M8!2<9#8'0<\#.>.12^#[_P 3WOC#7HM3N-/:*VDACFCA#D(3%N CR<=3SGK0
M!VTNI64%_;V,MU$EW< F&$N-[@ DD#K@ &K5<-XP%ROCSP:]C' UT3>A/.)"
M_P"I'4@$\<G'\NM);>,=8D\.7UQ+:62W]GJK:=-)N*V\:JPW3-D@[0IZ9H [
MJFNZQHSNP5%!+,3@ >M>;MX^UN?PUKM_I]O87,^C76R5A'($F@QDNBEL@CKR
M<$#@UTB:[=:EJ)@TQK*YM5TU;J1W5L,\F?+ 8$X! )/!( 'KP ;MAJ%IJEE%
M>V%Q'<6TH)26-LJV#@X/U!%6:\TM_&NJ1:%X0?3-*TR,:U(T7DY:-(CD]-H.
M!WSSWXJU'X_O;+0?$UUJEK;/=Z)=+;_Z/N6.3<552=Q) !;GV% 'H-%<EI>N
MZTWC-_#]Z-/F2.R6\:Y@#*2&.W;M)/.X'OTQ5[7-7O8=3L-&THVZW]XLDOFW
M*LR11H!D[006.64 9'>@#?HKCI/$>O6UKIFG7EA;0:[J%U);Q,3N@V("QFP&
MS@J.%SG/I5#4O&&OZ+9Z]:7=O8RZGIEJM[#,JNL-Q <@G;DD,&!&,X]Z /0*
M*X%?$7BYO$-GI1AT8?VC9&Z@D_>$0!2N[</XS\W &WZU7?QYK4/@>TUDVE@]
MV-0^PW*%V5&(E,>Y3_#G'?I0!Z-17GMSXSU[PY>ZM;>(+2RG\G3S?VDEEN"L
M ZIY;;B3D,Z\XZ9^E,E\2^+A!?PO:&/_ $!YX[_^SY(TMY5!)0J[?,"!P>.<
M9!H ]%S17F.E>(M7TGPQX7L6FBN;W58!/$\=D\ABA6-6;<H?+OEAR-HY)QQB
MIYO%_BR'3]-\S3;6"[GU9=/8W44D:S*P)211G*@X((.<&@#T>C->8:WK_B*3
MPQXUT^ZN;2*^TE5_TFUB8"2*2/=@ L2K8/WLG^M>BZ>DZ6,2W,R32[1ETCV
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MUK3+?4K"4RVMPNZ-RI7(SCH>1TKA=%\2ZE=^*!INIZG/:7VZ<RZ7=6J1QR1
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MNJ:SK'B#S=9U2TBCTBWO$MX9=GE2,CM@$#( (Y'4]R0,4 >HT5YCI5[JQO\
MP+J<^L7DTFLQN+R%F A8>27&(P, @CJ.37;>*1J3>'+L:1S>G9L7S?*+C>NY
M0_\ "S+N /8D=* -C-&:\ED\3/::1-':7FI6DTVKP6=W!JMPWF6*LA) E;?A
M6VC#8.-Q/H:FUS4_$7A&PU8-J-J(IS ;6.6\EN)+57<([F5T!VG)QG..W0T
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M6@".^LXM1TZYL;@$PW,30R;3@[6!!P?H:X[1/!.K62PZ?JOB W^B6@*6UH(
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ML22P4Y)QP.,5'I/@F^@MY(-;\1W.K1K;O;6H,"Q>0K+L8\9+-MXR??UKLZ*
M//S\.;YM%TNW/B>9=2TD[=/OXK54\F/:%*%,_,"!@Y//YYLW?@?5+J#32_B/
MS;RUODOYKBXL@WGR(-J#:KJ$0#/ ]2<YKMZ* .,N? ]U>2^*3<:O$8]>C1"J
M6A4P;%V*02YW?+UX&3Z=*V#>'PQX=CFUJ^DO&B*I+<1VV"2S8!V)G &1Z]*V
MZ* //-,\--XA\/>*K.=Y;6#4M9DNK6X5>2H\LI( >HW)^(_.M!/!-^;^[U&Y
M\23SWMW8?8I6-K&J;<GD*.1U/?KR2>E=G10!R&H>"6U+P!%X3GU1O*1(XOM
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M^>UG5Y+AM2,Q=%/**H8A@PX)8+@$\5Z54"WMH]TUJMU"UPO+1"0%Q]1UJ>@
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MMY87\L/D3O;%,3*.FY75AD=CUH XA?%GB?5;OPI8Q7D.GW.H/?6MX5@60"2
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M!D6V4@ A >F0 ,\G'% &!\8HF;P)+*MQ/&%FB4HCX5P9%^\.^,<4S4;36?\
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M2NB3$=-Z*0K_ / @<UIPW=M<2/'#<12.GWE1P2OU Z5))(D4;22.J(HR68X
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MH6JZIJ&F6>I6R3VPPLCM\K-@[B <9"\9.>: .D%O"MT]R(D$[H(VDV_,5!)
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M/AS2F*3WDC/]G^THL4#MYD?!W(<8;@YX/ !ST- '3)&B%BB*NXY; QD^II2
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;-IR/K7&^%M-U!8].TR\\&6EGJ&G,OF:D\,;1,B=#&V<F1N![9)[8KT_%&*
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !37=8T9W8*JC)8G
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MM)KNZO)3%!!$R*6(4L>7( P >]8$^D:I)\0M"U<6$GV.VL&MYG\Q,H[>V[)
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MBD+3(BX4L,@!L  @''.<\8/3>+_#DGB;1DM8+U[*[@G2YMKA1G9*GW21Z<T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !11FB@ HHHS0 4444 %%%% !1110 449%&: "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **0,& *D$'H12T
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M)+KY'2,D&1GV?*#VP&/(]>*(^*MO)I,5W;:3+<RMJ2Z:\<4PV;V^ZR.0-RD
MD<#WQUK3\3>%=0E31+KPQ<06EYHI800S ^5)&RA2C8YZ*/\ /-4=8\*^)M<T
M_3Y+RZL&OX=3@OY(EDD2"-8@0(X_E8Y))))[_A0!:/C/6DU&QTR;PG)%J%Y'
M,Z1-?1E0(R!DL!T.?3/L:BE^(\$7AR#4)K-+:[FO)++R+BX"QI(A(<M( ?E
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ ILDB11M)(ZHB LS,<
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M#;-877E+&-LTA0B1=P4%<''(Z<F@#TVL_5-:L='DLDO'=&O;A;:#;&S!I&.
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M18+MX@/E!SO91@9 S[=*C@COM/\ B;XG8:E)/<QZ(LD4\T297!R 0H /3TH
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M.W(''(QBNE_YJW?_ /8 C_\ 1ST =#X>UVT\3:';:O8"46UQNV"50K?*Q4Y
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M(L%VG(  ''!]:]FH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M *YW;OKNY_2LV;X;V$GABRT5=1OD;3YS/97:LHEA<DGL ",DUVF:,T <=>^
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M%&\DL@(W'>IRJX!P,<GGM536=;\1VUCIT^M75W9V4=O)'>WNBF.58KE7*[I
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M/#7*KL<HY02J!@!P#\P&._TZ5;N?"VD7.MVNKO;LEW;1B)&BD9 R @J& (!
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MEU(:U!J,<6F26QE-O'$=N0Q7]WD*6+;^<D>U=RO@GPTFMG6$TBW6_,@E\P9
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ME+BXTFSDF10H=H5SM' !]0.P/ I]_H&D:I-'-?:;:W$L8VJ\D0) ],^GMTH
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M4LX*@X;"XZ']<U;T3P=86*W3W>FZ4#<^7NM;6U"P(4W8(!^\WSG+8'&!@8Y
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQKS*%[34_AGI&GVZ[?$MK=Q[;<8\^.Y60>8[ \X(RQ/3!H ZF^\73:AXEO\
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M^TY,3)@2MUP%8;JO>*+$V-QX.M[.SNI;:PO59C# \OEQ)&4RQ4'^\/<\^AH
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M4 =*!@8I" 00>0>U5M-U*TU?3H-0L)EFM9UWQR+D9'X\CZ5:H 15"J%4  =
M!2@8HHH *,444 (% Z #//%+BBB@ Q1110 8KG-0\.ZD^O2:MI6N&REFB2*:
M*:U6=&5=V,<@K]X]#C/:NCHH SM)TE=+BF+3-<75Q)YMS<.H4RO@+G X
M ]/7)K1Q110 8JFNFPC4VU!VDDGV&./>WRQ*<;@H[9*@D\GWQQ5RB@ Q1BBB
M@ Q1110 8HQ110 8I",C%+10!R=EX*GL(VLK?Q'J*:0<XL]L>5!)) EV[\')
M[Y]ZZB"".VMXX(4"11*$11T"@8 J2B@ Q1110 48HHH SM;THZSI<EDM]=V)
M<J1/:2;)%P0>#[XQ4VFZ;;Z58I:6P;RUR2SL69V)RS,3U))))]ZMT4 %%%%
M!BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIEDV 9"G#') SCZ5U'B[RCK7A">TM9C;K?BYEDAM7*HC)@,Q"X')'7FN^HH
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M[U51C+E>"3Z<X '/)KEO&.E:YJNL:M;/HLVH6$MB%L#%<+%&DN&W&7D,QSC
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M\\ #D[0!DGMBFZ/I_CM+(V>L3Z7+#:P,D36[,'NVVE5#DC"CD'@9R![UW5%
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M&CBPGTO4KAKI;BYE;S+1WQO^7^( \@?RJ6VTG7_#FOZQ<:=;1:G::F$E4RW
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M]?CDT"VE$D*I$5N2H8,L1?. N>N.2.. > #NJY*T\3:QJ!L-0LM)CGT:[NC
M&23,RQY8"<CILX!QUP:ZRN&T;P7K.C-_94.N)_PCBSF:.%8RMP@W;O*#YP$S
MU/4C(XS0!9NO%FIRZ5J6M:396UQIVGRR(R2.PEG6,XD92.!@@X!SG':H?^$R
MU74-;>PT;3K22%],CU&"YN)V4&-^FY0N0>#P/KGM1'X/U:PM=6TG3M2MQH^I
M/(_[^,M-;>9GS F#AASQG&"><][-OX3O+#7[C4+*ZM4MUTM--MK9XF.%3)4L
MP88Y.. >/2@#/E^(A;1_#=T!8V+ZS%(_F7TK"&(IMRN1W);@G'2H9O$'B:7Q
MMX=L'M[6W,]C+<2VQE8!G P=Q / [#GKS4^G^#M:M/"]EHMQ/I-[;6\+02VL
M\+F.9<Y5]V<JPY'0_A2VO@.^TN]\-W-AJD)?2K22TD:YB9MRL<Y4!AC'( )X
M&.N* ([?QIXDO=+U348M%L8;73GNHY7>Y9R6A4G@8&02",\=>G'-B'QS=/<>
M#S):VZV^OV[R2?,<P,D8<X/0CD=NU6M!\+7MIX?UK2=4GMG34IKB3?;!OE$V
M=PY],\5E67@#6([CPRUWK%F\6A+)%&B6A_>(RA1G+=2HY[# X/- &G;^(M>U
M*/3M3TO3K>YTF^G,87E98HLD"9B6 (XSM S@CG-8^F:OK*Z'XXOM1^Q:A%8W
M=TC6\B,J.L<,>5&2P"%0?EP<DG)YJ_H_@;5-'8:;#XB<^'$D\R.S-N/- W;O
M+\S/W,]>.02..M61X-O$M/$UE'JT(M-<>>3:UH2\+RJ$)W>9A@ .!@<]^U $
M6F^)KO4+?0--TBULK:[O-+6_DWH3#;184!512"?F. ,C %4;[XA:E9V"#^S+
M4ZC%K":5<PM,P3+#*NIQT8<\]/>KL7@F^TX:)>:;J<']IZ59?8=TMN1%<Q8&
M RALJ01G()Y[4W4/ ,^H6L6_58UO3JJ:I<SFU+"1T&U$5=XVJ% '4T :/A[Q
M%?7_ (EUO0]1@MDN--$+"2W+%761=W\7.16GXCUN+PYX?O-6FC:1+= 1&IP6
M8D*HSVR2.>U5+#P_<V?B_5-<>_CDCOHHHA;BW*F,1YQ\^XYZG/%7?$&B6OB/
M0;O2+PNL%R@5FC.&4@@@CZ$ T 8<NO:]I6N:?IVIP6,R:F)%MIX%>-8I57<(
MY,ELY .&&.G2H?!'B?7_ !7;VNJ3Z?86^DS1R*=DK-*)5?:.HQM(!]^,Y[5>
M3PWJ,UUIMSJ6K074FFHQM@EH8U,I7;YD@\P[B 3@#;U-2^"_#4GA+PW%H[WJ
MW@AD=DE$/E\,V[!&YNY//TH M>*KM]/\*:K>);V]S]GM9)6AN!E)%522".^0
M.E<VWB35TU'PUI&F6VE1+J6GF?YU?$&U%/"*1\O. ,]NHKJ=?TR36O#]_I<5
MPEN;R!X#*T>_:&!!.,CG!]:YZT\%7]OK.@ZB^LP2/I-B;,*;,CS@5QN)\S@]
M/U]> #GIO%/B#7]&T&YMY[.SE?6Q8W*"%V21T+,&'S@[/E&5ZY[XZZ=UXTUN
M:348]&M8KN72YOLTT0L9G^TRJ%+A'5BL74@!MW3FI[?P%J$.F" Z[ UU'JYU
M:*<6)"B0[MRLGF<J=QQ@C'O3Y/ NHV^K7-[H_BFZT]+[#7\0MDD\Z3&"ZYXC
M8]\ T 1OXJ\27OBFXT33+'3XI%L8;U?MID#(&(#(P7^+G'MCO5.X\7>+X],U
MO4H;/2);?1KN6&9 )0\R(%+%><*0"3DY^G'/0Z?X3_L_Q=+KD=Z#&UFEDML8
MC\L:XQ\^[DY!YQT/XUR^A:5=>(9?%EDNM0)I-SJTRSVT< :5D(7)63=\H8<<
MJ>AQ0!K#Q-XCU/Q ;'1K?3/L[V%O?QR77F A)&(*G:>6P"1CCBJ<?CCQ!>_9
M;O3M#FN+.>ZV&(63@B')'F";?M)X!QM[XSQFNDL?#;6'B:75HKQ?(:TCLUM1
M#@)&F2N&SUR3VK'T_P"'TNF74MO;^(;P:#+,9VTPQJ?F)R5$G4)ZJ ,]SS0!
ME:%K?B2.+QI?&XM+^:QOY(HXIAY"#:% .\OM1 ,D@Y)P?FR:C;QIK%YI?BBU
MAO;=Y;'3/MMOJ$=H\8=2K9 5CS@@@."1[&MF\^',5W#KMLNK3QVNK7(NVC\I
M28YMRMG)ZKE?N^]._P"$!FGU/5+R]UZ>?^TK'[%<(MNB9&UER.N!@@X'.1UP
M<4 9%GK6J:3X:\ 12?8;F/4'M8=SV[;XE,:\@ER-V,C=@=>@K6G\1Z[?:?K.
MK:.+06^E7,T(M)869[H18WG>&&TGY@!M/09SFG'P'.VG:!:OK;O_ &+.DL#/
M;+@A%"JI (XP.>223U'2K)\%F'^V(+#5);2QU=VEN85B#,KN,.T;9^4L,=0<
M=J *,/B?6]:\06UEI3V-O;7NB+J4+SPL[QEF4 '# 'J?3KWQ@[G@O6[CQ'X1
MT_5;N...XG5A(L>=NY7921GUVY_&H8?"AM/$<>K65ZL$<.G#3H;;R,JD8.0<
M[N2& _#CWJUX4T!O#&@0Z3]K-U'"S&.0Q[#AF+8/)SR3S0!'K.JWD>NZ;HFG
MM#%->)+-)/*A<1QQ[<[5R,L2P')P.3STKD]<UG5[_P +^,M&NIH(;[2+8F6X
MBA.VYADB9EPI;Y&(!!Y.".*Z[7/#<>KW^G:E#=/::CISLUO.JAAAAAE93U!'
MTJE=>#3<Z7K4!U$B\UG"WEUY /R!=@1%S\H Z9)ZD]Z +?A.TN(= L);V>&Y
MG-M&(Y4MQ&4C*+A.ISSWX^E5/%6MW^E7^F002P6]K=-(LDYC,TI<+E$CB!W-
MD]2 < =JW-)LIM.TNWLY[A;AH$6,2"/9E0 !D9//%96L^%1J>O6>M6VI7%C>
MVT+VY:-%<-&W4 ,#AL]#_.@#F+?QIXAOO#7A2_MQ8)<ZK?/9SK)"^T8:0!A\
MV1PF2.^>HJ=]<\5OIWBBWM+BTGU+19E\IQ;$"X0QARI7<<'DX(-7;#X>+8Z=
MI5E_;EY)'IEX;NWW1Q\,2QP?ER0=[9R>_&*GN8K;P5=ZIK\TFHWHU2>,26]O
M;>84<+A2H49 P,')]* 'Z'XEE\0/HC6$T;P26/VN^?:"03\BI['>)/\ OV17
M0ZE?1:7I=WJ$^?)M87F?'7:JDG^58G@K0H='TVYN([1K5]0N7NC _P!Z%&)*
M)[8')'8LU=%-#'<0203('BD4HZGH01@B@#A;CQ3K.E:%HOB*]DM9[+4)(A-:
MQQ%3"DW*%6R=Q7(SD<\XQ4'AU+Z7XK^+8YKU9$ABLU<&$8=2A8#KQC)YK9LO
M \-M;65A-J=U<Z783)/:VLBKE64DJ&?&6 )X''09S5ZP\-_8?%&HZX-0GDDO
MU19875=BJ@(4+QD8R>_- &S*LA@=8'1)=I",Z;E![9 (R/;(KQ\:]KGB#1_"
M%]+J"P&YUK[/)##"!&Q5F*L0>>-HXSCO7L,JL\3JCF-R"%<#.T^N#7'6_P .
M;2UT*QTR'4[Q&L+XWUM<80NCG.1@KM(RQZB@"K?^*+RP\6G3;_4VTTF>%+07
M%LIMKR([=Y\P#(DSO &0!QP<YKOJY>\\%Q:A%-:WNJ7MQ8331SO;2",Y9 O\
M6W."5!/X],UU% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%,E+B)S$JM( =JLVT$]@3@X'X&@!]
M%>:+\1]8/A@>)WT6S72H;DV]VBW3-*OS[-R_(!C)'7FM=/%6N7?B?4M,LM+L
M7M=.FA^T7,ET5Q$Z[B<%?O8YQTXZF@#M*J:GIEIK.G3:??1M):SKMD19&3</
M3*D''XUQTOCF_3PW%XK2QMWT)Y@&3>PG2#?L\S^Z3GG;Z=ZLCQA>6VNZ_IVH
M16T:V%D+VT=-Q^T1G//7L<+@=2: .DMWTW2?L6CI<1Q.R%;6"6<M(ZH,G&XE
MFP/K@5?KBY-9ND\4>$K/4]+T\WE_#.YE&3);,L>YE3(X!&%)SSSQ2Z!XNN]=
MU)8(?[/.R65+JT#LMQ:[<[2P;&02 "0,#=WH Z:*XT_7-/G6VNH[JV?=#(]O
M-T/1AN4Y!Y['(INCZ-8:!IL>GZ;"T-I&24C,C/MR<G!8D@9[5R.C^*9&T:S@
MT[2K&UO[_4[BUB@C^6%/++&20X SPI/8DFB\\9ZOI$6NV5[9VDNIZ7:"]21"
MR0W$)!R0.2I# C&?QH [VBN,TKQ+K;>)K.PU6ULEM]2L3=VHM69GBVA=RN3C
M=G=V QTYZU'X.\87OB6[4F33WA9':>WC#)<6;#&U'5C\W\7S  <4 =O1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
-HH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>exhibit1021-independentc009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit1021-independentc009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK-UO7=/\
M/6<=WJ<_D6[S)#YA'"LQP"?0>] &E17,Z;X[T;4]4@T^/[9!-=*6M&N;5XDN
M0!DE"1SQSVHU;QWHVD:E/82B\GGMD$MU]EM7E%NA&=SD#@8YH Z:BL_1=9M-
M?TU-0L?.-M)]QI86CWC .0& R.>O2K[,$1F.<*,G% "T5YOH6F:SXTT4>(9_
M%&IZ?-=N[VMO9.%A@0,0H92/G/&3DCK73^"-<G\0^$[._N]GVS+Q7 3IYB,5
M)QVSC/XT =#1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4V.FZ!I^NW*IK-Y;A=AR3)(B OSTR.]93S1)\:$1I$#MH!55+#)/GYP/P!-
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MA[X?+(8W U26)E8$9^^<'\=M37T5HFB_$2VCAA,5K?1O'"J@K'PN2!C [YH
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MB.W'^34.D^,](UK7;[2K.YC>2U*IG.#(V"6"@CD# Y]Z\G!6+X<SF*-TN_\
MA(_.0K$P?:'#!AQG&.<UWOA:>*R^('BJTD@GBDO+F.:'*,RNHBY?>!M SZGO
MB@#H]1\6:!I%T]K?ZM:6\\<?F/$\@W*O Y'OD8'4TR#QEX<N;JSMH-9M))KP
M P(KY+YZ?0G!X.#7*W\MG'\;8;BY53#'HAC,C1DJLGF%L9QUV'\C7$Z<(K7X
M:^#%:%H[BW\1)/<J(CO1%=R68 9QM*?I0![+?^*-$TR[^RWNI003#;N5CPF[
M[NX]%SVSC-/@\1:3<ZW-HT-XKZC"-TD 5LH..3QC'(_.O(O&]VU_#XPMHK6\
MMIGDA,<%M:.PO%7;^]DDP1@#. -O;.374>(X[NS.@^--"MWEO/+CL9K>4&/S
MHI>$W C((<J>G?T% '>6>HVNK6LTFGW(<([PEPI^21>",''0UP_@'Q]9WFE0
M6FNZ[;R:S-=2Q(C[59AO(4848&>WK7<:1IR:3I-K8HQ;R8PK.>KMU9C[DY)]
MS7C]AIGV_P"']SX2;3[A=??4&DC5[9E\C]Z#YI<C  7/()ZXH ]6O/$^BZ?>
MM9W6H113H4#@Y(C+G"[B!A<]LD5IS7$-O;/<32I'!&I=Y'8!54#))/I7C-_9
M06?B'Q#IOB#2=>OGU"Z:>R-E+*(;M2!A'"L%RN ,D=!STKN?%^C:EJ7PON=*
MLH56_-I$ODQMD$J5+("?8$"@#4A\9:!/'.Z:@,01>>X:)U;RLX\P*1ED_P!H
M CWJQ!XCTFZ%@;>[$HOP6MBB,1(!P3D#C&><UY]X<N-)?4(M=@T/Q"L]G;.E
MY+?//,8\C'DHK$ER6;TP "3BHO"7F>%/%$;2:9.=.UB S1B&UG<Z:Q8MY)RO
M"D]<#J,X Q0!Z"/%NA-JBZ<+]3</*85.QO+:0=4$F-A?_9SGVHF\6:';ZG_9
M\M\%N/-$!/EN8UD(R$,F-@8\<$YYKRKP[I"+%;>']6T/7IM;L[L.K/<S?8^)
M,^<#NV@ $G@<GZG'0:3>7NGPW_AB_P##=U?7Z:A+/:7#6VZVF+.9$E>3HN"<
MGN ..>* .TD\6Z+%:ZA</=2"/3G"7?\ H\F83_M#;G'?.,8YZ&J?_":V+>,H
M?#\:3.7L_M+3"%\<L@0#CD$,26Z#&,YS7':X;RS;Q]IS:7J$TVJ1K):O;VS/
M'(/)"GYAP,$="<^F:LVZ7D7Q TV\:PU"*&[\-I8QRBV8^7-YF</V7 YYQ0!V
MJ>+-$DU./3UO?W\KM'$3$XCD8=560C8Q&#P"3P:YSQWXPMK.PDM=-U6X@U&*
M[AA/DV[,C$NNZ-I"A4':2<!@>/PKF_"%J\=MI>@7_A35&U?3;E6%U.SFSCVO
MGS5.\#.TG  Y/U-,WZC;?#NX\+7>B:G)JUM>HS216S21S W(D\P2=#D?CSZ9
MP >H^(+J&ST"]FGU'^S4$1'VS:&\DG@-@]>36-:^-?#^G:?IEI=ZX;NZFLXY
M8Y/L\ADN00 &V*I.YL@[>O/3@U<\6R-<> M9*03F2?3I42%8BTFYXR NU<G.
M2![5Q/AR1H==\%F:QOU%OH36\KM92@12X48)*\'Y&'Y>M 'I&D:Q8:[IL>H:
M;<">UD)"N%*\@X(((!'([BL.7XD>$X9IHI-6"O#*(9<V\N(W)QACMPO/&3Q5
M;X9,X\,SPR6US;R)?7#;;B!HB5>0LI 8#(P17)7^D:G-X>\?P1Z7>M+J=^'M
M%^SMF5<@Y'' ^4]?;UH ]'L?%6C:E=3VUG=/+-##Y[((),O'G =,K^\&>ZYJ
M-_&&A)IUAJ#7CBTOY?)MI?L\N&?=M"GY?E.0?O8Z&N:LK6[E^(NA7ZV5VMG%
MHOV>29X&55D/S!3D>GZ\=:Y1+'7?^$/TK0FT34Y+G3M>665_+&P1AV8;23\P
MP<Y''J10!TZ>)KO0_%_C/[9/?7]EIUM!-#;JFXIN0L0-H&![GH!R:TYM=M-5
M7PQ-+JU_I=Q<3HZP);2HETVT$QDLN-O/7./0^F1+INHW7B;Q],FGW0CU#2UA
MM6>(J)76(H5!/&<D8]>U.NC?W>E>"L:)JD36%]$UPCP99$CC*%\*3QEN.YP>
M* -R\^)'ABRN;J":\FWVD@CN=MK*1"<XRQV\#) SWSQFHKJ_F;XC:"MMJ,LF
MGWEA/+Y2N/*;&S:PQUX;N3[5REE-)+>?$?3(=.NKN>\N&BB$46Y"S(5&6/"X
M)SSCBM&+0]0L=:\*:>;>YD2STB:RN+R.,F..1T4#GTRI_2@#J[?QGHUQ>VML
MDLP%X[):SO ZPSL.H1R,'OCL<<9K2U35[32((Y;MG'FR"*)(T+O(YZ*J@9)X
M/Y5YQX5TG48X],T?4?!L45[ILT>=4EVO#LC(.].<ER!@8Z$Y/3%=)XXM]9CN
M=$UK1K/[=)IEP[RV@.&DC="K%<]P"?SH TX_&.BR6%S=_:606UQ]EEB:-A*L
MV<",)C)8GH!G-1-XUTB.#47E^U1R:<@ENH'MV65(R,[]O=?<>E<UK%GKVMV]
MIKMMH?V-K+4H+U=/<J)[E54J[/@XW8("@GHI]0 :QHFH>*]3U;5+:RN;1?[$
MFTZ&.[41-/*^2.,GY1D<G')H ZYO%&FIJ.G6+&83:C UQ:XB8B157<>G0@=O
M>LV#XC>'+C[.Z3W2P3W'V9+A[218Q*20%+$8!.#U_'%<SIL6O7'B'P/<2:'J
M,4.F6,MO>RR!%RYB53QNZ;@".Y[#BJ3>&];_ .%>V^FKHMR+U=;-V\>]#F/S
M"V[[V!P0,>HH ["T\;;_ !-K]E=VDUMI^E1Q%KAXSA259W9CGA=NW'?\ZNQ>
M,]-,YAN8+ZSD-NUS$MQ;,IGC498H!DD@=5X/M7'ZOX<UG4-?\;VT5A<+#KMI
M;&VNMRB-3''@JYSD$L N #P<]*;HNEWD\(D/@.WTB[MK:99YU5"TKM&4"P\Y
M&2V22< #&3F@#>7XI^'6T^2^":E]F2 3^9]BDVL-VW ;&,YXY('.,YSB]9^/
M]#N]0N;)GN;9X+9KO?<P-&LD Y,BD]5QSVKC]1LKS3/V?)["_M)+:ZMH5C>.
M0@\^<IR""1CFM37++Q!K>KV^L:=HS6=Q8:7<+&MX8R9)I  (^&(( !.3@9/O
M0!T&G^-=.U"Z%LMM?Q2267V^$/!GSH,XW(%))/(^4X/(XKG]1^*UDV@37^CZ
M9J5R3 9(I7M]L(^<)DL3SAB.!GTXYQGZ%INM:;XLL-7;PYJCK_936MU)-=1/
M*TF]6)QOP%^7  Q]!5FST'6&^"1T)M-ECU.*/9]G=D!<B4/D$-CIZD=* .KN
M/%D5NF#I6IO<+;FZDMDB0R1QABN2-W.2#@*2?:MJTN4O+."ZBSY<T:R+N'."
M,C/YUY]XJTS4M<G2^30-4M-02V L;RRNHEEADW/E)?W@&S&P\9^\U;VFZ_J<
M&MZ=X?U736^T26"RO>QRJ4>557S!L'*C)P#^E &MJ.MP:?>6]DL,]U>W 9X[
M:W"E]B]7.X@!1P,D]2!6-_PL'2KBPL)M,BN+^YOY)(K>TC 20M&,N&+$*N!C
MJ><C&<UE^-=$U0^*=/\ $-AHEIKD,5LUI<6$Y0'!;<'4OP#G\?S.*ESH^O--
MI!_X1N*+3&DFDN=,TZXCA$3$*$#L-N\?*2V..>^ " =-#XWTN\T;3]0L$GNI
M-19H[2U10)9'4$LOS$ ;=IR2<<=>E<MXH\50ZCI^@ZG9G4+9[7Q'#97ENK-N
M!7)>,JA(DZ+C&<]NIK+T7POXMT/0M!N;;2D:_P!#N+D-:/<(!=12DY*$$@8X
MQG']#NZU9>*=<M]&N;G1A$\&LV]\;.&>)O)ACSG<Y*[I&+=!Q@#D'- '4^'_
M !-;Z]=:C:+:75G=Z?(J3P7*!6 891N"1@@9HU3Q(EC?MI]GI]UJ5\D(GE@M
MMH,<9. 26(&3@X49)QTK.T#3=1M/'OBK4;FRDBL]0^S?9Y2Z'=Y2%#D!B1DG
M(R.G7!XICZ?K&C^.[_6+.Q.H:=J=M&LZ1R(LL,L0(7&\J"I!]<Y^G(!F>*O&
M!U#PSI-SH<%S<6NHZA#;2LC+$^/,PT)W,"K-@KGIC/(R#6S:01>$O#=]J=MI
MVH;2OVE],:=9#!@?,$Y('<X!.>WI7-W7A;6[/PWIT5KIHN;]M<&L7,44R+'%
M^\WF,%B,\8' QP37I:'S(5+QE"RY*/@D9['&10!R]KX[LIWT%9;.XA76X]UI
M(7C9=W4JV&R"!CMU..M<_P"*];%W+HFHI:7L7V/Q(MEA'+?: H?=M13@Y90!
MD9XJFWPUU)-%U>*.7-U9W)?0 7'[E XDX/8L?E/3&VM[6]!U"&P\+66G6$EV
M--U"*\N9$DC3.T/O/S,,LS.3^= $E[XILM6\+^)(]0TS4K<Z<ACO;5643*C)
MN#*P;&,<\'M^=T>(;?3M.TVSTS3KN]E:Q6X2VC<%XX O!9F/))PHY))SZ&L&
M\TC79I/'>S19RNM0K':'SX>2(?*Y^?@9Y^GOQ1_97BO2+S3-9T?389YGTZ.Q
MO["YN I4QGY75@2O<_A[G@ IZ[KR:AXH\ ZW86U\ZW9NO]%'RN^$  *DA002
M>3VYSBNW\->)(O$EI=2I:S6LUI=/:3P3%2R2)C(RI([USMWH'B&Z\1^%=4NE
M2X>QFN)KO8ZA8A* H2,'!(0#DGD]>^!H>"=&U'1[KQ"U_;B-+_5);V$K(&^1
M\8!QT(Q]* )9O&0_MBZLK/3)KV*RN([>ZFAE3,3/MP=F=Q4;N6]CUP<<I:>(
MI/"FJ>+Y8M*O+VSM]01YG24;;>,QKDY8Y/))VC]!5S7O"VJZKXA^V6^EI8WZ
M7B-%J]M<A UN",K*F<NV 1C&.G('%.OO#FN7&G>-+>.Q3?K,H:V+3J !L5/F
M].A/>@#9USQNNE2W(MM,FO8;2S6]N90XB"QD\;=WWFP"<>W7/%9%_?QWOQ*\
M#7]HS"#4+*YDYXW(8@ZY'8\U0UCPKXHU47<<^GV-U'<:8EO;+/=G;82A"KE1
MM(8L?XN#TY'-7-.\->((]7\$W-W9VRIHMI);7!BN-WWHQ&I&0,G !/UXS0!:
M^%@VZ9X@3)(37;I5R2< ; !D^U=Y7(^!-(U/1HM8CU"RCMQ=ZC+>Q;)Q( ),
M?*>.HQ^M==0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[FNI8]1N8A+,06*K(0.F!T'85:U/QKHFDW\UI<S3%K;9]JDC@9X[4/\ <,C
M87/:@"$>$Y0% \0:F N<<Q\9_P" T'PG,QR?$6JD]B73(^AV\5+J7C?0=+N[
MBSFN99+V",2M;0P.\C(>Z@###N<'@58E\4Z4FCV>IQS//#>@?94@C+R3$@G"
MH.20 <^F#F@"O9^&7L[Q+@:UJ$F&W,CF/:WUPM;\4:Q1A% 4 G@# KAOASK,
M^L7WB9I+N]GAAOQ'"MX,/$-O*E>-O.>,5N:OXRTC1;J>"Y>9VMD66Z,$1D%L
MC'"L^.F>OK@9H WZ6N&U74+H?%+PO%;W]Q]AO+6X=X%?$;X3*MCOU[U)\/;V
M]NW\3QWE[/=?9=;GMXFF?<510H '8?A0!VM%8FJ^*M.TFXF@D2[GDMXQ+<"V
MMVE$"'H7(Z="<=<#.,5S?C+Q@BPZ'%IW]H2VFHW41>YL8V/FPD,2B.O.\[1P
M,'&: ._HKFK*5/#'A>ZU*[O-6O+09N@EVI>>",X^0@_,=O).22.?2BW\<:5<
M76CVZ1W@.KQ^99NT.%<=3DYX('..O(H Z0C((Z5QMEX-U:PMSI</B:0Z*0X\
ME[2-IL,26'F=#G)Y*YYJIXC\31-=Z/>VMS?V\-OKAT^Z10P67"2%AM7._P"9
M1BKEYXJT;7?!^M2S/JMC!;;[>\5(62Y@(&<X ...<GCUQS0!UEK;0V5I#:V\
M:QP0QK'&B]%4#  _ 5-7.77B6QT*PLX=NH:C+]E$VV)!)-Y2@9EDY _Q.<"N
M8UKQ7 ?&?A'4K.6_N;"[M+B86]MN?SCL^4"(?Q DC/\ +% 'I5%9?A_7[+Q)
MI8O[$2J@D:*2.9-KQNIP58=B*Y_2/'+WWB36[*\TVZL[/3@NZ>55"Q *S,TA
MW<9&,8!H [2BN=LO&-C=ZC:V<UI?6+7JEK-[R((MQCJ%Y)!QSA@#BJE[\0])
ML3O:UU":T:Y^R1W<$(>.6;IL7#;B<Y&<8)!P: .MHKF;[QQIMBTS-;7TMO;%
M!>7,4(,=J6QQ)D@Y ()"@X!YK-A\6RZUK^L:+'IVI1VB6T8CNX2J[=XD/F[@
MV0K +M(R>.U '<45YSX"\9VR:!X;TN]BU$W%Y&8TO)8CY4D@RQ7>3DG'?&/?
M@UOW?CK2K.5&EBN?L#7(M/[14(;?S22,9W;L @@MMP".M '3US__  BJ-XH.
MMSZKJ4ZJV^*QDGS;Q/MV[E3UQG\3FJUIX[L+W6I-*@T_57N(KG[-,WV7Y(6Q
MD,[9X4\X/L:TM:UU-'>T@2TGO+R\<I!;PLBLVT98Y=@  /?N* ->BO.]6UV.
M;Q'X1UB&TU0B5[R(V0!,A9%9,&,-M!#9^;TZG K7B^(&FRZ*M\;6Z2Y>^_LT
M6+!1+]I)P$/.T>N<XQ0!UM%<#XAUZV\1^ O%4:PW5K=:9'*DT3/M9)%7<I#(
M>1P#UY]*I2*4^(/@!P\G[W3IMZF1BIVP#'RYP.IZ"@#TNBLW6M8AT6T2:2.6
M:6:588((@"\TC=%&<#L22>  360/'6GI!?"YMKJ"]L[E+5[-E!DDD?\ U80@
M[6W=N>QSB@#J:*YC_A,X89=0M;S3;V"_LH!<FTPC/-%W>,AL, >#SQ5?2O'U
MMJ=]I,#Z5J%K%JT1>SN)D79(57<R\$D<9Y(P<<9'- '7T5RT/C(W=PB66C7E
MS#+-/!'/')'M+Q!CAOFRF[8<;L=LXKE)/%?]M_#N_O?$^A7[6'VIE8VTR#@3
M$*H*N&PN%!)')]: /5**XX^(]37Q]/H4&FN]M;6 F5!,F9,N 'Y.1C!&/?GM
M4D7CNUFT70]52PNC!J]V+2-05W1N691N&>GRL>* .MHK@=+\=S^;XHO-8M3;
MZ=I-P8LHRL4VJ!CCEF9C]!D#/>M/P_XZL]<UN32#"(;H0?:(]EQ',KIG!RR$
M@,.Z_J: .KHK&U;738ZA;:;9VAO=1N$>58!($"QK@%V8]!D@#@Y)]C7/W'Q+
MM+?3K6X;2+]KB2_&G36J[-\$Y_A//.1G! P<=10!W-%<=!\0+5;;7FU*PGL;
MC1C'Y\#.KEO,&8P".,D\=<#UQ5G1?&MGJ^O/HQ2);L6XN4,%PL\;)G!!9>C
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M*O0Q>3!'%O=]BA=\C99L=R>YJ2B@ HHHH *@2SM8[N2[2WB6YE 624( [ =
M3U(%3T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %<;\3+66Z\,VWEVTDZ1:A;RS+'&7Q&K98D '( ZUV5%
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M1V@[2.@W8!!S7=44 >4^&=$OM%UWPG8ZE;W<[6VF7$4TOV9WBB:1@RQEP"O
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M=:]NH4O8D>XMF&-@=7^4C R.,Y&#UKU2B@#R2P\+>(;#1?&=A%X;C@CU9/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% #!&!*TF6R1C&>*?110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG=M=3K$Q9(\\! 3C.!WP,DFN>TGPQXLTJ:XT6*\L/[ >=Y8KL;A=1(S%BB@
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MH*W=RB@[4*R%,[2 N,' SC/<@'2>*O%VO:"U]FXL1)8VD4R116S2_:GS^\+
M,3"@X +=<]34<-WKFJ?%'37BU6.&UFT7[;' UMN$<;R)NCSN&6.!\_;TJR_@
M/4-<M]1O+S5YM/GURTA74+6&!&"R(@488Y(7CD Y]ZT;?P-<VFJZ3J5OX@N$
MN+&R^PR%K>-A/$&W!>GRC.!QS@=0>: ,C3?&VJ-IL\$\E@VJSZ_)I-NT<3+$
MFW&79<Y.!DXSSE1GK4VJ^*==T*^U?29Y[2XN8M+DU2SNC;D JF=T;H&Z\'#
M_@>E6;?X<A=(U&RN=6D>6ZU/^U8;F&$1M;W/!W+\QR.!P?>K<W@N>]M]1DU'
M5S=:E>69L/M?V94$4!/S*J XR<GDGT],4 9>C>)?$1UKPG'J=Q936VOV4DWE
MP0%#"4B5P=Q8YSN]!BCP7XIU+6M72"^U*-+KRY'N]*FM/(EMSQMV$\NO7GGM
MTK5@\%217WARY;5G8:# T$"B!1YBL-IW')_@"CC'()[X#M,\&/:ZQ8ZEJ.JR
MZE-I\+16C20JCJ&&TEV'+G&0,\<D\GF@"CXY6\;Q5X/6P>&.Z:ZN CS*65?W
M)R2!C.!DXR,GN*RU\<:OINAZG!=RQ7NJ6NLC3(IH[<+N# $.8]P&<;@!N'(&
M:[#6O#C:QK&DZB+^6V;393+&D:*0Y(P<D]B./QK&E^&]C=VNMP7M]/.-5N!=
M%@JHT$HSAD(]/?\ K0!A:KXE\;Z'X>UB]N(PD=M'%-:W%[!$)7!<*R-''(0/
MO AO;!&3QH7NL>*]/N]-L)KJ.[FU>1I86LK:-9(8D12Z*)'"DY88))X!.#D
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "DQ2T4 %%%% !1110 4444 %%%% !1110 4444
M%%%% #9(TE0I(JNAX*L,@TJJ%     P .U+10 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%1RSQ0+NFE2-2<9=@!G\: )**:DB2H'C=74]&4Y!H,B
M*ZH74.V=JD\G'7% #J*1F55+,0% R23P*4$$9!R#0 44A( ))P!5>VU&QO"1
M:WMO.02"(I5;D=>AH LT444 %%%5H]0LYKZ>RBNX'NX K2P+("\8/(++U&:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M40\S4_[/>'[0?E^;;N!V\_3 JROBOQ-=Z[J.E6/AJ!S93QQ23O>@(@=0P8\
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MZC!;IJ:K]J@N(#(%=5P)$PPYZ @\'KGM4-[X L9/ ,/ABTE:+[* ]K<'[R3
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M*@) K*JX4$ $^O85T2?#O3/M-[<7&HZM=/?6IMKD3W6X2KM*AB !R QQV!Y
MS3C\/]/-CIEO_:6K>;ILOF6UU]I'FK\H3;G;@+M & !^9.0#BKSQ1XBM_"FO
MW$&L2_:+'Q*]A%))$C$P@JH4_+[YR,&M"^O/%%GXA@\(_P!J7&J7$EL]^]S$
MT=E(5W!5C4D,, AF.!DY'. <]$WPVT-[&\LS+J'DW=V+R4&Y)S(._/OR3U.!
MDFKGB+P3IGB86CW<MW!>6G^IO;641SJ.XW8[_2@"3P?+K<F@+'XA:%M2AD:.
M1XG5@P!R"=O .#@CVKB7UW6X?$.GW2:E<W,%SKOV&5HMOV+RB6 C0$;BX"\L
M,C((S7I&DZ5;:+IT=C:!_*3)W2.7=R3DLS'DDDUS!^%^A[%CCNM5BACN_M<$
M45V52!LDD1@#Y0<GW]"* ,JWN_$']J>)[UM=NIK30[EG6S$"%KE1$'\O( QZ
M# SR<YJ#PSJ?BJYGT76[B<_V;?LOVHSWD31-O&$6.,*"A#$#&2>QR:[;1_"]
MEHMY?W5O-=RO?$&=9YMZL0, X]<<51T;X?:%H.I"]L4N5V,SQ6[SLT,3-P65
M#P#C(S[T ,\>W=[8V.E3V5[-;9U.VBD6/&)$=P""2,X^A%<OJM[K<VK^.[1=
M?OHH='M4O+41!%(8PL^TD+DJ#QCKTR37>Z_X=M/$=O!!>374:03+,GD2[/G7
ME2?H>15"7P-IDUSK%PUS?^9J\0ANR)_OH,  <<<9'T)H XB&*77?&/@W4;K4
M+]);O1VNG6*XV;7")D( /XN<@8S^%.TO6?%&LZ1;^)[74((4%Z6N5FO3Y2Q;
MMODF$1G:V-N#DMDY[C'9MX!T5X=)C8WA_LN-H;=A<,K&-NJ,1C*X&,>G%)%\
M//#D&OOK$=HZS/)YS0^:?),G7?LZ9SS]>: //[_5-?@\/^,=37Q%J/FZ+JAB
MMER@5E#HN' 7D8/08%=3-J%QXF\1:]I;WUS90:9I\3*EK)Y9DDE0N7)[A0
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M$CYL-R>!QC/.<5B?VYKGB+1_"5[+J'ER/K'V.:..W4I(Z%R)2#Z;0<=.I],
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2/'6D:SK9T>WCO8KY59GBN+9H]FW&02>_/;TKIJ "BFR2)%&TDC*B*,LS'
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M@D6<<*"Q;.>WO7(:=\/=3N_ \FE7]NEAJ]G<O=Z?>Q3!RKLV[&1@@=C^![4
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MUW2(O#^I7LUI<V.K3Q02Q10%&MVE&493N.X#H<CFNM;1[)]"_L:2+S+'[/\
M9BCG.4V[<$^N.]8-CX+>%-+MK[5IKVPTJ59;.%H@K!E!"&1@?GVYXP!T&<T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 5-3TRUUC39]/O49[:==DB+(R;E[C*
MD'%%EIUOI^F1:?;"1+:*,11KYC$JH&  Q.>![U;HH S-$\/Z=X=M'M=,BDB@
M=S(4:9Y/F/4C<3C-:=%% !1110 5'/!%<P203QK)%(I5T<9# ]014E% &#IW
M@OP[I-W'=6.EQ1319,9W,P0GNH)('4]/6MZBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHJKJ=_#I6E7>H7 8PVL+SR;1D[54L<>^!0!:HKS^Q^)EA>'1(OMM@LNIR/E_
MG$<(4@>7SR9#N R=HZGT!IQ^-/%=UX\U3PK:0:,\UC 9A-(DJ+(,(0,;C@_.
M/RH ],HKRAOBO?WGP]F\46%C;126EP+>YM9PSAB2,,C@CC##@C^7-K5OB)K/
MAF#0=0U:SL+C3M51&+6Q>.2#*JQR&)#8W<=,X[9H ]-HKBO$OC6XL_$VF>&-
M#MH;C5KX>87N"1%#'@G<<<DX5CCVJMJ'C34?"?B?3=*\1_9;BSU$$0WUK"T6
MQ\@;60LW'(Y![]* .^HKSJ/QIKD/Q-3PGJ7]FV\+CS8;A8GS<+C(4 O\K'##
M//*]#FM&ZU3Q+)KFMPV-]IJV.F0K(6EL'9BY4MY61* <*%);_:'% ':45Y/H
MWC_Q/K7@?5/%:'2H(M/=T-I]ED<R[55B=_F#;]X=CTI8?B-XBB\$VWC"6WTZ
M]TYYBEU;0QO%);C?M&&+,'[=AU'7L >KT5YCXZ^(.I:+X<TGQ#H,ME-8ZB55
M8KBW8LN5)SN#CIC&,?C6_;WGBA?$,=F][IM[9$R03SP6,D;6TPC#KN!D8$8*
M]^^.#0!U]%>5Z/XQ\7:OKGB73([K2$;1"X#-928GVLPY_>_)G;[]:DT[XCZU
MX@^'%]KFEZ=:)JEE/Y<L<KXAV !BX+,O8],]J /4**X/1?%GB*]\8Z=87FF6
M\.FZAIJWD94_O8VV*6W#=P-S;1QZ>AKO* "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 A /44;1Z4M% #=@]_SI=H]!2T4 )M7THVKZ"EHH 3 ]*,#
MTI:* $P/2C:OH*6B@!-H]*4#%%% !28^OYTM% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'O0!+5#6=1;2-(N=0%L]PMO&TKQHP4[5!)(SQT%7ZR/%7_(GZW_UX3_^BVH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS08QY,>.N-HJ4    8 Z"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** $)P,UERZNO]NQ:7;IYDOEF6<YXB7MGW)[4GB+7(?#^DR7TP
MW8&V.,=9)#PB#W)P*K>&-(GL[%[O40O]JWC>;=E>0&[(#Z+T% &_VHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HI P.<$''7!IJS1/(\:R(SIC<H8$KGID=J 'T444 %%%(2 "20
M.YH 6BF12QSQK)%(LD;<AD.0?QI] !1110 445S'B;Q!JOARXCO1I)O]%"_Z
M0]L29X#GEBO1EQZ<B@#IZ*R=/\2Z-J>BG6+74(&L%4L\Q;:(\==V?ND>AK!M
M/B1I][XBL-+BTW4U@ORRVU]+!Y<4I"[B5SR1C'..] ':4444 %%%% !1110
M4444 %%(02I ZXKC/&NLW+-#X:T60_VMJ(R9%Y^S1 _-(?3C('O0!VE%<=\,
M[NYN_!EL;N<SS0R36_G,/F=8Y612?? %=CD9QWH **KV]_:73S);W,4K0OLE
M","4;T/H:DDGBCC:1Y55%7<6)P /6@"2BL[2=9T[6[,7NFW4=Q;ER@>-@5R.
MO(K0R#T(H 6BDW+G&1GTS1N [B@!:KWUU'96<MS-(L<42EG=S@* .2:S=?\
M$NE>&[1;C4;C9N^6.)>7<^BKWKE(M/UGQ]/'/K4$FG>'U8/%IY.);G!RID]%
M]OI0!;T)9O&.JQ>)+V-DTNVR-,MI!\SGH9V'J?X?09]:[E1@8ID48C0(JA5
M  '0#T%24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5F^(8=1N?#NH0Z3*(M0D@=;=R<;7(XY['WK2K.U
MVVOKS0[NWTR=8+V2/$,K$@*WJ<=J /,?",WAV\U#3-/^QOX?\26$R-<V\Y93
M>84AN<_O"3\PW9/IQDUT]IK&CZ=XF\77LFCS6EW9V\<]Y<^9O\] A*X )"G
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M]^*?A"SC!CU47CD\16D;2MCUX&.*S=-T7P%9S_:[_6;36;[&/M6JWZ7# =@
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M3,MNA),DA8E%QZYP*[1M(\8--/X?O!=W46O>3/=7./W5H2V9D'IP !76:"?
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MV\0:>?I,*3_A/O"O_0<LO^_HH Z2BN;/C[POVUJT;Z29I/\ A/O#'_07MO\
MOJ@#I:*YT>._#1'_ "%[?\S_ (4[_A-_#?\ T%8/R;_"@#H**Y__ (3?PW_T
M%8/_ ![_  I#XY\-#KJT'Z_X4 =#17._\)UX:_Z"T'Z_X4#QUX:) &K1$GH-
MK?X4 =%13$E61493E7 *GU&,T^@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"IXM-U+7O%6DZUJ.CKI0TM9<;YTEEF9UVX!0D!!R>><XX'- '8T444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!%;VL%I'Y=O#'"A);;&@49/4X'>I:** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JKJ%L]U8R
MQ174UJY'RS0XW*?49!'YBK507L_V:SEF\J67:/N0IN8]N!WH \\\ ^,+S6+2
M+0/$[21:K<VHN;:=&\O[3 ZY#*RGAQSG&.GL:QM:FU"+X<VNM+KFK1WTNH^0
M\RWKJ!&)GCQM!VCY5'..O-=##X2/B/X=Z-:317&F:SI<$2V]Q)'M>&9%4''J
MA(_'\*P]5TC7/^%4Z5H\VD7=SJ8O3/<1PQA@ )W8Y/3D'CUS0!KP7=Y9_$A/
M"D&KWE_I=QI[2S>9/NFM7R<$2KAAGCJ?XA[4> -:>R^'<WB#5KO4K]_.=9-S
MO.^%D**%4GCKSC\>E=G9I8V6G/>V>E&VW+N:&*V"2MCMM'>N-\"2ZKX=^'L\
M,N@7\FH6LDDBVA0(9@\A(VL>. <F@#T*"9;BWCG3=LD0.NX8.",\CM7)V,]_
M%\4+^PFU*XN+7^RTN$B?:%C9I6& % [ <G)]ZZR!WEMXI)(C$[(&:-CDJ2.A
M^E<C:K=/\5KN\.G7B6;:8MHMP\6(S(LC,>?3!X- %'QWK^H1W%M:Z5/)!%:W
MUJM[.AQN:20 0@_[IW-[%?6G_$!+NSL;G4_^$KFTV:,+_9UK'*D4<D@QQ)NY
MDR?< #KW-5/$_@.Z72HX],U+5[C?J4,[P-+&0NZ7<[_=!R"2V2>,>E:WB5[F
M_P!/O?#?_"/ZA?22VQAAOI4B,+,RXWLV1M(/)^4'(X'2@"_JFA7^O1Z?YFN7
MNGQ1Q;IAILOEM+(0/XL'Y1SQCO5#P58WKZ%J+RZSJ<T=S=RK:7$\RRRI"IV*
MP+ KDD$].A%:%Q9ZCHO@(6&G%[O4;>Q6VA<<%I-H0/\ 0'GZ"M.TM4T70[>T
MMXI)DM(%B1(P-S!0!QD@9X]: .<\$W^J7_PQM[WSFNM4>&X,;SG.^0.X7/MP
M!]*Y3P+JFIZGK^F"TO-1>ZBBD/B**_D8JCYP@1&^ZV<\+@8ZUTOA'2]:M?AD
MVCM!)INJQ13QQ/*5(#LS,K J3Q\P]^.E8/AWPI?P>)?#EY;Z'+I4NGV[PZK<
M22KMNLKP%P3OR26W$#KSTH M)JB7OCXV^L7_ (ETF9[O;86V[RK.Y1. ,X.X
MMM).<?> %3>-]%U:UT[4O$T?B74+>_M27M+>"0"W"9PJ%,?.S9ZGN<<X%:=X
MFK>*GL[*]\/2Z=%;7L=S)<37$;C$;[@(]I)); '(& 3UJIK&H>(Y_$9+>$+R
M\TZQD#6@2ZA02RC/[U@3G XVCMU/., #+J\FUOXAQ>'=3N;FS@CTD70BMYFA
M\V9CACN4Y.T9P,XR">U9%GXCUS4/AQ-##%J6HSP:DVG7%S9@&X-NK9:12>K[
M#MR.YS70:_IUQK^G6$-WX9AN=;:W#B>7 M[1V'S MG<P!_A .>/K5C3=,N/
M7AK3M,T?2)M757/VIHIDC?<>2X5B >>,9&!B@!WP]_LJ3P^]SI.J:I?Q2RGS
M#J4YDEB<#!0C^''7'O\ 2NNKGO#&CSV$VK:C=PI;W.J77GM CAA$H4* 2!RQ
MP23[^V3T- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW;0+FY6>(VS6S.LH8;"I4X(/3%>1:G>6O_#.NG(+F'?F%-N\9W"7)&/7'.*
M.ZUKQ/KGA2U34-:T^SN=-\Q4GFL'</ "<!BK#D9XZCK76R7=M%:_:I;B)+?
M/FLX"X/0Y/'.17#^/-?LM7\,76A:'-%JNIZB@AC@LY!)L4GEW*Y"J!W-;6JP
MG1?A[-%*L%Z;"P 87@W+,8U'WO4G;^>* *%AXR74-1T:VBNK1C=W=XLBK(I/
ME1LZQ]^I_=GU/YUUMO=VUVKFVN(IA&YC<QN&VL.JG'0CTKS#P;X9O++Q-:1R
M0Z.1I6FPI*5M"LA:0ELDYSY@$8Y]&KN?#4OA^5-1.@"$*MY(MWY2%?W_ !NS
MD<GIR.* ,OQ)J?C"WEO)M"T_3C96*AG-X[B2Y^7<PC X  (&2>H--E\8SWUA
MX<32H(TO]=7S$$^66WC5=SN0/O8X &1G/457\8^,]'@O3X:DUF&PEE3-Y.V2
M88CU5<?QL#QZ Y] :%UJ&FG6_!OB6Q!CT"(7-D)BFQ(@PV(QST4E" 3[>M '
M4^%=?DUF&^M;Q8TU+3;EK6Z6($(2/NNN><,.:3Q#<>*'G%KX;M[!66,227.H
M%_+.20$4*,EN,G.,9'K7,>&K76[J\\2ZOH5S9PPW^I[H);J%I%EC1=I90K#@
MGH<\@&M'7_&L?AN"STG4]4L4UNY7YYPA6*!,G]X5))Z=%SR1V% %C2_$>M^(
M/#$%SI^F16^I/-);3_:7S%;NF0S<<L,C  [GD\5-X=\0WTNC:M<>($MH9-*N
M)89I[?/E2*BABZYZ=2"/4&J>D>)/!MMX92T@U98],5VM!=2R-%YTFT,Y#\'<
M=V2W&23BJGA%K/0]*\1S2WDLWAF.Z,EK-/NE4QLH:3;P2R[V89YS@GGDT 6_
M!VM>(M?G.H7-[H,VDO&66&Q=GGB8X*HYSM! SGW%9FIZM\1K18+OR]!@@N[J
M.&"TD61YT\Q\*&P=I(!R<''!JSH-OHUQXZCU/PGY*Z>]E(NH-:J5@=]R&(<#
M;O'SDXY ZXSSKWJC5O'^GVP?,.D0->2J.1YLF8XP?0A1(?Q% &=XB\3:JWB=
M=!\.ZCH4%W%$KSKJ;L"[.?E5 O4@#)_WEK?UC6)=!\/I<7"+=:@56-8H5($L
MVW)P.2%&&8^B@^E<MXTNO!VMPZEI,R1S:_$-D,<4!%SYV/DV-C)&<<@XQUXJ
MQJNB^)BJWYO-.F,&F^08YXI"48I^]=<-@LQX]A^.0"'4/'%_IWPUT77&2%KW
M4#!&\KJ?*A+@DN0#T&.F1]:UO#/B&^U'Q!K6C7?V>Y_LTQ$7MLA1)-ZYVE23
MAA[$_A7$B[OH_@KHD5TEO+I]W)!:W,T418VUH>&<@Y^88QN'0G(K:^&:?V?J
MNNZ1IEPMYX;@=);&Y497<^2R!QP^/QH ]'HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH CGMX;J%H;B))8F^\DBAE/?D&H[:PL[)7%
MK:P0!_O"*,+N^N*L44 5%TO3T"A;&V4(_F*!"HPWJ..OO33H^F&%83IUH8E)
M94,"[03U(&*NT4 0O9VTEJ+5[:%K<  1,@*8'08Z<57&BZ4 H&F68"G<!Y"\
M'UZ>P_*KU% #$ABC)*1HI/7:H%.*A@0P!!Z@TM% "!5!) &3U/K38H8H0PBC
M1 S%F"J!DGJ3[T^B@"-K>%V+-#&S'J2H)I?*C\OR]B[/[N./RI]% "!0H 4
M = *8\$4C;GB1CZLH-244 1^1#LV>4FP'.W:,9I^T;=N!C&,4M% #418U"HH
M51V Q2A5!) &3U/K2T4 -\M-^_:-^,;L<XIV*** &A%"[0H"XQC'%*JJBA54
M*HZ #%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME[H>M:EH=KH][\.!/9VA!@$GB %HP!C ;&<8'3I5B[L/$%_I]C9W/PY606(
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHH R]&T;^R$N"]]=7T]Q()))[HJ7.%"@?*J@  =,=SZUJ444 %%%% !1110
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M=^UN^^%;F0;8V]<#J?<T\>%;4>)SKWVJ[^V&,0E3*-A3.<8QTXH YCP,MB/
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M6FMVNKZI9,3!<7^]=RE2#Y<8((/0C&*[)<;1CIBJ6GZ18Z5]I^Q0"(7,QGE
M)P7( )]N@J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 @ '0"@@,.0#]:6B@ HHHH **** "C HHH YW3M:%WKF
MLZ1-%M.GK&V]CP\<@)S_ ..FLOPI9QW?AG4[V95VZO<7%PP[;#\JC_OE169X
MAN6TKQ?X@G3B2?P\TJXZ91]H_'+UL7$G_"/_  PD9%P;/30/Q"#)_,F@#/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT'UK0OK&UU*TFM;RW2>"08>.09#"N?TKX?\ AW2M26^ALWDF0YB^T2M((?9
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M=!9VUK$(K>".*,<!44*!^ J8#'2B@!HC08PH&.GM2[5SG SZTN1ZT4 %%%%
M!1110 4449H **,CUHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ I&!*X S]:6HYXEG@DA<N%D4J2CE&
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MM9X5E$BATQT; R,$=JV8G9TRZ;&_NYS0 ^BBB@ HHHH **** "BBB@ HHHH
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MH&MV?B3QA/!IWVFUUFTBBAE2:-"K)"4P5)'\1'H,9]@8[7P_K<6J?#^X;3)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#2T4 4(-)LK;4[C48[5%N[@
M*LLHZL!G'\ZO#@=_QI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN81$T6#3I)Y;JU\)OKUVT4H1718F0"%MK*P*;MY!(/'/7!H ]M%_9M!'.+J
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
F4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>exhibit1021-independentc010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit1021-independentc010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 U/NTZFI]VG4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !112'.#CK0 M%1P^9Y0\W&_OBI* "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH :GW:=34^[3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH :GW:=34^[3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH :GW:=34^[3J "BBHKJX6TM)KEP2D4;2,%ZD 9XH EHKA/^%J:2UDNH1:7K
M,VF[4,M]':@PPD@9#'=U7.#@'!K;UGQ=8Z1%8F."ZU&:_!:UM[",2/*H )8<
M@;0".<]Z .@HKE_#/C>V\3ZG?6$.E:I9S60_?F\A5 K9X7ACSW^@-=10 45R
M'CFV\07&FWCZ?JL>G:=!9232/"I^TR2*&.T-T5>%Y'/7I2Z7K4NF_">TUJ=V
MFF@TA9R96),CB/(R>O)[^] '6A@:6O,E\(:D?")UY]>U<>(C;&\WK<GRA)MW
M!!']W;_#C%=QX:U5M<\,Z9JCJ%DNK9)74#@,0,@>V<T :M%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?3!?F_&G6?VT];CR%\S_ +ZQFKM !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #4^[3J:GW:=0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #4^[3J:GW:=0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #4^[3J:GW:=0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%'48- $'VZT_Y^H/\ OX*4W=L%#FXB
MVDX!WC!KYYN9]/TCXN>)GETF"[B6-UAMVM1)&CL8P&*XP ,DD\?K7JUU\--'
MG\+ZEH:HBPW-Q)<VS>6,VKMMP$]@5]N#B@#K_MEMM#?:(=I. =XQFC[=:?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% #4^[3J:GW:=0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 45RJ^-/M=]J,.DZ3<:C!ILGE74L4B*
M0X^\J(3ER/PSVS6[I.HIJ^CV6I1HR)=P).J-U4,H(!_.@"[11FC- !169X@U
M<Z%H5UJ:V4]X8%!\B 9=\L!Q],Y^@JSIUVU_I=I>/ \#7$*2F&3[T990=I]Q
MG% %JBC-&: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!J?=
MIU(..E+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1137W^6WE[=^#MW=
M,^] 'BFI^%KTWNJ^,O >JRVUU%=3K>V3L!ET<[^^"#C<%;L1["J$_C+5M>O?
M!MD\,-K97=JS-;"X:UAFD#21KEE!*K\BD#&,D?4:MQX-\;74LDDGAWPKND9F
MD*2SIYA9BQ+8<;N2>OK5C5O#?CW7+6WMM2\/^$IX;88A7,J^6,8P"K@@=.*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-U96TDKRQ0W3$RA2>"P).">N/>@#1UCQ%I6@B/\ M*[$)E!**$9V(&,G"@G
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M8QZAX>U&ZL]1U"&6-$B97:,$ NAX^93@@<9Q]:ZCP%9:O86E_;W\ES+8K/\
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M:0/=W4UY#Y]L+>V=O-7V..3USZ8.<5%;_$SP]=16\T1O3!-,MNTQM7"12,2
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M V[H1QGCFLJ^\'^(;GP9XMTE--Q<:MK#7MN3/'M$;2(WS'=P<)^H]Z .ZO\
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M?3XM.:T:3S4!W%BV0N<X[5RT'ACQ/;^&5TU=&#S+K@U+)NHPIC#[\=?O<8H
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MG:5&\D8 YR<=2!0!W5%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXENM>,UW/=3G*I/,7CA.,$QKVR.._<# -;U%% !1110 4444 %%%% !1110
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MB&FW-RI"M]E,91FY[CG'H6SVJ?PMX(E\/^+-2F&T:/$YETR%3PC2JHEX[8V
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 -3[M.I![4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 -3[M.IJ?=IU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1S
MF402& (9MIV!R0I/;)':I*1V5$9W8*JC)). !0!SO@O7KSQ%HTUW?101S1W<
MUN5@SMPC8'4YKHZX'X8W]H/"^IN+F)EBU"ZE?8P8JA<D-@<X(&1ZUU^C:O9:
M]I4&IZ=*9;2<$QN5*DX)4\'GJ#0!?K!\6>)8O#&E)<>2;B[N)5M[2V4X,LK?
M=&>P]36]7$?$FPU"6QTG5].MS<OH]^EY);H,M)&,[MOJ?:@"S=GQO9Z2U^D^
ME7-TJ!WL$M'P/[P1_,RQ SCCFMO4O$.C:-+%%J>J6EG)+_JUGE"%O?GM[UY_
M\1O$^D:QX&^T:)J@?56=/LD=O*5N5RP#C8#N'R@Y!%8'BFXL[6YU[3(,:;<+
MH\:.)$::6^_=Y"1@Y"*O\1QG.3QC- 'K^I^(M%T81'4M4M+3S1F/SI0N\>H]
M163/\0O#5OX@329=4M48P><TSRA8U)*[5R>,D,3]![UYS+JMG+I>DWVDZ]%:
MZG;Z!##+:ZA$1;7D2[@R G!WAE8<=<@ ]:U].U&SL/B3IMQJ5N;"&[\-001P
MR(Q"N9!^[Z=AG)/0#F@#T*U\4:#>W'V>UUBQFEV-)MCG5OE4D%N#T&#S[5)I
M?B#2-::1=,U*VNVB +B&0,5!Z$_6O&]$TV*X^#EU<:59VTNIQ7+M=^7&IG:'
MS<LF<9P4 X[C-=)KSGQ;KFC7G@ZY!GCT^Z$TT3;!$KQXB1_0[^@[8)[9H [Z
MV\2:)>W\MC;:M937<.?,A292RXZ\9[=_2H8O%WAR>Y@MHM<T^2:X;9"BW"DR
M'.,#GGD8KR_PI+H5^/#UC<+K#ZUI) E@F!2*U"C]XS';C80O0GG(%94MUI0^
M%;RPR6PO!KWF;XTV.2)20P'7&P\>@XH ]9TKQUH>M>(KO1K*]ADF@5"C"0$3
M$ABP0=]H R??VK0MO$^@W;3K;ZQ8R&W0R2XG7Y$!P6//0>O2O,KZ9QKGQ&TZ
MTW_VAJ4$#6:1QLQE3R3N((& ,'&>F2/6H]%OO#^N'39X8M3>\TZWD2Y2\.R&
MRC\I@P)VA2"P  _' Q0!ZE!XFT*Y8K!J]C(1"TYVSJ<1@D%^OW00>:+37-.U
MR&XCT;5;2:=$SN0B3R\CY6*@@D?EFO)-*TRWE^#.FW^FZ;;W5Y:SJVH)%&OG
M20K-O>-CC/("'![#I76)=66M_$?2M=T:X1K*TTZ4:C<+\JJC#,:,3W!R<=1C
MG% &IX2\2O+X'BUKQ#J,*LTTRM*RK&HVRLBJ /\ =Z<GZUO6.O:3J5A+?6>H
M02VL.?-D#X$>!D[L_=P/6O'?#M\+7P_X<U64-/I.GZU=->*B;_*+JWER%>N%
MW%L^]:'B"W@U:+QUK5A-/_8UQI\*F:WCR)YT.<KTR   Q_VCZ4 >B)XY\+/&
M[C7K!1&<,'F"M]0#R1WR.*N+XCT9]*_M1=2MC8;@GVC?\A8G &?J0*\V\':[
MI'B7QO\ ;M2O-/.H2:<-.BM(()0DHR6=LR(N#@$;1VXR:O\ AG1]3LO$\OA6
M90VB:1<_VC [-DLCAO)CQZ*^]OJ@H ['Q;XE@\*^'IM4EC,S@B."$'!ED;[J
M_P!?H#67J%MXVBT>?4+?5K5K]8-_]GK9@Q9QDJK9W%NP).#Z>B?$[0K[7O"!
MCTZ/S;NTN$NXXL_ZS9G*CWP3^526WQ$T:[L=ULEV^HD8&FFW<3[\<*1C &?X
MC\OO0!KZEXFTC18H&U6^BLVF7<J2$Y XR2!T SU/%.NO$NAV+PI=:M90M/$9
MX@\RC?& 3N'/3 //M7&)J4.A^.O$$GBBW%O;:K:VQMW=3+$P6/;)"#CD[B3C
M'/)QS7/Z5IK6'B#X?07MNP2)KZ3RY5W&&.3/D!^/E/3 [$>U 'J4?BC0Y=%.
MLQZG;MIP.WSPWRYSC'KG/;K38?%>@SI;/%JENRW,WV>$[N&EX^3_ 'OF''6O
M+K$:>WA[6HIKZYLU?Q1+<6M];1$B#*;DE(QRGRLN>G-32:A?S^$[?4]1ACFC
MLO$EM<37UG X2YA3;F?:1Z#!(&.* /0=6\16\NC:XNDZC$-2T^WDD=2F6B*@
MD94^N.#T[\USNE_$BRL]*\,0:M=[[Z_MA+<R&,_(OED[CM&,E@HP/4FL1M4A
MN_$GCR^C@O!;7.DI'#(UK( Y\O:!TXR6& <$@U7L;G^RV^&^J7%O=&UM+*X@
MG,5N\C1N8PH4JH)SGVH ].7Q9H+ZL-*75+<WID,0CR>7'5 >FX>F<UC1^/\
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M!EHHI/NNZY^4<<]QQQ7H5 !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 -3[M.I ,=*6@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "D(# @@$'@@]Z6B@!B11Q_<15X ^48X%.551=J@ #L!2T4 %%%%
M#/*C\TR^6OF$8WXYQ]:4QH7WE5+ 8SCG%.HH ;Y:;578NU<;1CICTIV*** #
M%&*** #%&*** #%&*** #%&*** #%97B'1$\0:/)I[W,UMN9)%EB(RK*P9<@
M\,,@<'BM6B@#EG\*ZC>Q*=4\17%Q/ 6>TDBMXXO)D(91)@#YF"L1SQR>.F-'
MP_H(T.WF$E[<7]W<2>9/=7!&^0XP!QP  , 5L44 %&*** #%&*** #%&***
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MX(;F&2: @31HX+1DC(# =,CGFN,TGXA/JVB7-Q%86O\ :46HC3TLUO"ZNQ(
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MH%&)>G7/\/3WH ] HKA+#QKJ-_X?OV-O:6^O6U^+ 6;[F02E@!D@@D$9.1T
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ML3@*H')8G@ 4 7**P_#_ (KL/$4UY;0175M>63!;BUNXO+D3(R#C)X/UK<H
M***Q?$_B:U\*:4=3OK:ZEM58*[VZJVS) &06!Y)[9H VJ*Y[3O&.G7VK1:5-
M!>6%_-'YL$-Y%M\Y,9)5@2I^F<UT- !1110 4444 %%<[K_B^TT70;K5H()+
M^*VF^SRB!@ C[@I#$GH"0. :Z*@ HHHH ***A:[@2\BM&E N)4:1$[E5*AC^
M!9?SH FHHHH ***PO$'B3^P+O286L99TU&]CLQ,KJ%C=SQD=3P">!CCJ* -V
MBL/1_$0U77M;THV4EO)I4D:,SN#YF\%@0!T& #Z\\XK<H ***AN;J&TA\Z>0
M)'N5,GU9@H'XD@4 345EOJ=VGB6+3!I<[6CVQF:_!'EJ^2/+(]<<_C6I0 44
M572^MGU"6P64&ZBC65X^ZJQ8*?Q*M^5 %BBLW4]1N[*ZT^&VTN:\2ZG\N62-
M@!;KC.]L]1_GTK1% "T5A:]XB?2K[3].M++[;J-]YAA@,HB&V-=S$L0?8 >_
M:KVC7\VIZ1;WEQ83V$T@.^VG^_&02,'\LCV(H OT444 %%%% !16/?ZU)_8E
MW?:)9MJD\#M$D"-L\QU;:P#'C@YY&>AK5B=GA1W0HS*"4)SM/I0 ^BBB@ HH
MHH **#TKG?"GB:3Q(-5\VQ^QR:??/9LGFB3)4#)R !U)H Z*BBB@ HHHH **
M** "BBJMEJ5IJ#W2VDZR_99S;S%>0L@ )7\-P_'B@"U1110 45F>(=3FT7P_
M?:I!:BZ:TA:8Q&39N51EN<'H 33]!U,ZSX?T[4S$(C=VT<YC#;MNY0<9[]:
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MF4 .2 $ )R2<D@=<#GJ* -^BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH :GW:=34^[3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'265G\H.<J@R3@*N!CUS7F4%_P"*-?@U'Q';ZI:V+V%Z[2)-J$RBWCC;_5O
ML9!! ^I/Y5[2*YFX^'_AJZ\0_P!N2Z</MA<2/AV".XZ,R9P3WZ=>30!P%^VI
M74_CYVU[5472(X;FT2*Y*A7:(O@\ E01P./?FI]/5K_XCV&HS27;W$_A2._=
M8KF1-TI<948/"G ^4<>U=X_@?093J;2P7,C:G_Q^DWLP\X Y (#@8'08[<=*
M8_@/PY)=:=</8,\FG1"&W+SR-A <JIRV6 /0'(% 'GGAVY\2ZK9Z3XI;6[:&
M*:]5+P_;II#(KR;/*%OL**W(VX]B3W&U\-M,O=2WZS>^(-7N&L[^Y@2WDN,Q
M.OW1O&,L>_7L*Z>U^'WAFRUR36+;35CNW8O\KML1CU95SA3R>1T[8K3T3P[I
MGAV&:+2X9(8YY/-D5YY) 7[M\['!/?'7O0!QOQ"EFGU>*SM;R_DGBTZ:Y-A:
MS&W51T$\DH8< \!<')]*S)KVYU'P/\.+N\F::XDUJSWR.<EB!(,GU/%=]JWA
M'0M<U"._U*P$]S''Y(?S'7*9SM8*0&&2>"#UJDGP\\,I9VEH+&80VDGFP@7D
MPVOV;A^H['MVH I>%O\ DI'CK_KI9?\ HBHO$EC<WGQ TBS36=1M;6]LKCSX
M8)MJD)LQM_ND[SEASQQBNDLO#FEZ=K-YJ]M#,M]>?\?$C7,K"3TRK,5XZ#C@
M<# KFO%>@7FO>.- F.FWC:;9),);J"Z6%E9U 4J0X?Y2.>/SH Y6*^U&.UNO
M#4^LZC<-:ZX+:V\AB9[V,+N,+2[@4QD%FSP,XSC%9;K=ZGH26^IW%X39>+EL
M4C^VR/Y<9*Y7?D%\$<,>1VQFO6)_ _AVYTNVTZ73]UO;2F:+$TBN)#G+;PP8
MDYY)/\J@3X=^%([.[M$TE4@O'5YD6:0;F4Y4CYOEP?3% '-ZW<7?A[QU!!8W
MEY);PZ%<SQV\T[R(70':3DY)X')R:S_#L6K75GH&O)XAC1;QDBO ;V:8W!DP
M&4(?EC<'.-N "/2N_@\':%;:E:ZA#9NES:0^1"PN9<+'_=V[L$'))R.3R>:K
MV/@#PMIFIR:E9:1%!=R*RF1)'&W=UVC.$/NH!':@#S)+K4H?!L>N?VSJ<EY9
M:^;:/?=,4:/S.5<?Q9SWR>,# XKIO#6BVD?Q?\5N)+K-L+62/-U(06>,EMPW
M?,.> <@=L5T8^'?AA=-&G"QG%F)O/$(OI]HD_O??ZUH)X4T1-<36A8@ZBB*@
MG:1V)"KM!.3@L!QN.3[T 9?B[SH-:\+W$-W<Q"35$MY(DE*QR(8Y&^91P3E1
MUKSW4EOQHOCF[_MS5_-T>_ M"+QP%Y4<^O'&#P.U>M:MX=TS7)[6:_CG>2T?
MS(#'=2Q;&_O (PY]^M9S> /#;VU[;O9W#0WT@END-].1,XYRWS\__J]!0!R^
MO:/:ZE\2/"4TTMT3?6MQ)*8KJ6,96-,; &^0>H&,]\U62ZN-=\%>)?$,NHWM
MKK-C/<.L<-RRBU\G)2/8#M(('.1SDUVS>"=">_M+YH+LW5H@2WE.H7&8U Q@
M?/TP.?7OFBZ\#^';W4Y]1GTX-<7#*TVV:14E(Z;T#!6_$'- '&6EC>^*?$5G
M'>ZUJUI'>Z!;W\\5K<&/;,S8.W/W!QT%8VHVEW;>#_&&JIKFL_:=*U=X;,F^
M<A%#1]>?FSN[YZ<8YSZJGA?2(_$ UU;>0:B$\L2_:)-H3&-NS=MQ[8QGGKS5
M _#WPRUE=V;6,[6]Y*)KA#>SGS7&<$_/SU_'C/08 .?T>,Z%X\G3^TKU[6?0
M/M]Q]HF:4>:) #)@]\=AQV KG/#\EU_PDOA%?-NGL]9AO%GGGN&\V^4)N#O&
M"1& 3A<,3CTKTR/P;H4>IQZB+25KI+?[*'DNI7'E;=NPJ6((QZCD\]>:JVGP
MZ\)6,MM+;Z) DEM*98G+NQ5C[D\CT4\#G YH X!K&"P^"6I7=E/<VUQ#-/M\
MFZD4*!<L@&T-C&.V.>M=%9+%XD\97.D:L\_D6>EVSVMNL[(LF\'?+A2,D':H
M]*Z(> _# COHQI$(6^E\VY 9OWC9SSSP,G.T<>U37/@[0KR*T2>Q+&T3RX)!
M-(LBI_=WAMQ7V)(H \RM9=0U:X\,6UYJNH%1JMWIYGAN7C,\,2G:QZ9)R06Q
MNQWS79_#L-;-XCTQ9II+:QU62*W$TA=D3:IVY)SC_&MZ;PGH=Q)8R/IZ!K !
M;78[)Y(!S\H4C'OZ]ZFTOP]I6BRSRZ=:B![AMTQ#L=[>IR3D^_6@#R_QY<37
M-[XHNM/NKJ672XH<RR7+0)8MC.(0OWW;J<@ 8QDUH7>F+K/CW4;:[O;]K8:'
M'<&%+N15+[B.QX' .!@9ZUV6I>!O#6L7]Q?7^DPSW-P@260LP+ #:#P>H'&>
MOO3H/!7AVVF\V#3$BD\DP;D=Q^[(P5Z].2?KSUYH \^T'5+C6QX'T75;F9K*
MZT^6>7+E?M,B9559AR< 9QGDXSVK=^%%O#91^*;2W<M%#KDZ(6;<2H"@$GOT
MZUT4_@;PU<Z5#IDVE1-9P2>9#'O;]VW?:<Y4<= <5>TGP[H^A&8Z5IMM:&8Y
MD,,84M]3Z>W04 >7:Q+=>(?$_B>SDU6RL+FRE1;9[J>6)X(PH(>+:P'49/'.
M1VQ38K=]:U_63>ZC?3QIX=AN@JW$D:-(T6=VW(P,\[>!GM7INI>$] UC4(K_
M %'2;6YNH@ LDB9. <@'U'UI)/">ARW]Q?/8@W-S&8II/,<%T(P5//3VH \\
MT77!??\ "%V'B&Z(T^XTMY@\LFU;BX4[0)#WPN2,]21U.*LQ7-O'JOAKPVVK
MW&HZ0;FZCEN)2<3RHH*1;P<,HWXQSDICM7;/X*\-R:2FE2:1;O91N9(XG!8(
MQZE23D?A5J;PYH]QI$6E2:;;&PBP8X @"H1R"N.A]QSR: /)O$C3Z=:>--*@
M-U-INGW%G-9GS6/V:23&\!O[HW?=Z#-=#XAC@?QKKXAO9 9?#;S.L,Y0K(K@
MJ?E.02 /J/:NYC\/:1%I,^EII\ LI]WG1%<B0MU+$\D^YYJE'X&\,11!$T6T
M4",Q!@N&"DDD!NHSD@\]#CIQ0!YMHML;23X=W:75VTNJ1RQ7?F7#,)$\O[N"
M< #MCZ]:S[4P:#X.\47=BQM9AK\MH\T3MOBM?,CW;5# G' XP>>HKUE? _AM
M%M573$"VA+6X$CXB)Y)7YN*LQ>%]"ANKRYCTFS$U[G[0YB!,F>3G/8GD^IH
M\RUZVBMM'UBYT[Q)%+#/I9N$L]-#QI&R%0LI/FL5)#8P>&YSR*[_ ,'^'[?2
M;!+Z.ZO+BXO;>%IWN)V<,0O4 \#KVJ6'P1X:M],GTV'1[:.TN&#31J"/,QR,
MG.2!Z9K7T_3[72["&QLH1#;0C;'&I)"CTYH \KU)K?Q!:_$:3592UQIZR16D
M9E*B%$C)4JN>-S#GUZ=*H7$<>I^'=(LT5+E[;PQ',T=U+Y<%N".)5Q\S2_)M
M&, =SVKU#4O!WAS6+XWNH:/:7%TRE&E9/F88QSCKQW/2D?P9X9DDMY'T+3R;
M>,Q1#R%PJG/&.G<_F: /,K:"TU;6_AQ<:IMF:XTZ<W,LCX+[8@1N;.>*@N9T
MGUBRUJSF5XW\2QQ?;[F7;=."^UH54=(0!_$>?05ZFW@KPRUI:VK:'8F"U?S(
M8S$,*QZGWS@9SG..:;-X&\+7$UQ+-H-@\EQ())6,(RS YS[<]<=>^: ->UU&
MQOGE2TO+>X:(@2+%*KE">QP>*XKQ+"/^%M>#L/*!/%>K(HD8 @0G&!G@\GD<
M_E6WH/A.#1=>U7542VC>](18K:+RU5%)()Y.6.>2,#C@5K7&D:9=WL=Y<Z=:
M3748VI/)"K.@] Q&1U- 'AL%C#;^#(M>1YO[3C\1^4EPTS$HOF<@9/&>_KWK
MIYKS0-9UOQ79>*[^*PU"WN=ME*\H1X(%4;'B)Z,3EB!SS7H7_"+>'OLQMO[!
MTOR"_F&+[)'M+XQNQC&<=Z==^&M#O[R"[N](LI[B !8Y)(%8J!T'(Z#MZ4 <
M1;>1J7Q6M_,BE>"Y\)#,=VOSLK3=''KCJ*Y'3+B"#P#\.7DGCCNXM>",6<*Z
MQ>>^\'N%X7/;I7M9T72VU(:DVFVC7XZ730J91QCAL9%5F\*^'GE:5M!TLR.X
MD9S9QY+C.&)QUY//O0!Y-K3V.N>&/'=YJ^Q]:LKQXH5E?YK>)2HC$?H#\V<?
M>YSFM^UCAF^(GA90Y>.XT!@X$A(/R@<<\<>E=[>^&M"U*X-Q?Z+IUU.0%\R>
MU1VP.@R1FG'P[HAN([@Z-IYGC78DGV9-RKZ XR!R>/>@#R#3=*LXO"OAC68V
M?[>/$B1&8REB$,[J4&3PI&"0.O4U9\111ZAKWB^QF:VN=1N)+>/3[I[F./[)
MA<[<LP9<=3L!SSGG->H_\(IX<^SK;_V!I?DJYD6/[''M#$ %@,8S@#GVKD;O
MP9JKZUJ$SZ/X7U.*\N&D2ZOXF,L28 5,;3PH  P1GKU- ';Z-8Q:;HUG9PL'
M2*)5#ABVXXY;)]3D_C7C=CH]M:>!O".LZ2)#KTE]%&KK*69T+MNCQG&P#DCM
MR?6O8=!TF/0M#M-,C?>MNFW/;.<G [#)X'88%+:Z%I%C=M=6FEV-O<-G=+#;
MHCG/7) SS0!XGK<=E;?#WQ]:RK!%/'XA=K6%@%909(\%%ZCY-W3MGM76^'K;
M1'^+FNRF"PWK!;26K@+EI'4EF4]V))R17?3^']%NKF6YN-(L)IY@!++);(S.
M 00&)&3@J#SZ#TJ4:5IPO(KP6%K]JB3RXYO)7>B_W0V,@>U '#_$>PMKSQ)X
M-2X0L)=1,3X<KE2,D<&N1O97T?2/&-E9%H-*AUV!)HXB0(8'(WA<<J"0!QV.
M*]EO-'TS4+F&YO=.M+F> YBEF@5VCYS\I(R.>>*9;Z%I%I)/);:58PO<9$[1
MVZ*9><_,0.>?6@#SW6-*TV'QI;6VD6UH=.O-'N'O[:- 8611F*3:.-V[&#UX
MK?\ A@=*;P1IO]GFR-R+:,7?V<KO#X_Y:8YSUZUTMAHVEZ4KKIVG6=FLARXM
MX%C#'WP!FIK*PL].A,-C:06L18L4@C"*6/4X'>@#SJYAM7\0_$V-@C;]/MI&
M4G.66&3G\,+61INGZ??CX8)=QQN);2XCD#'[ZB'(4^HR3QWR17JYT;2VDDD;
M3;,O)G>Q@7+9ZY..:1-$TJ-XW33+)6C.4*VZ@J<YR...: /%M0TC2;7P!XQO
M+>&,7&FZT\=BX<DVZB2,@1\_*.6Z=?PKL-0CMKKXM>'C+'"YNM)F\Y6 (D!&
M,$=QC(KN!H>DB-HQI=D(V(9E%NF"1G!(QVR?S-.&D::LL<JZ?:"2( 1N(5RF
M.F#CC% '@=E<Z?;?#30_*ELXG_M3&JO'&LDJP>8^WS4')3.W@\'"BMJ^.EZ=
M8:K)8ZTU_IEU<V+:FMA;+';0Q%L, %) 9E7Y@/QY(KV4:;8JDZ+96P6?F8")
M<2?[W'/XTEOI>GVED;*VL;:&T((,$<*JA!Z_*!B@#S>P;P]!\:K(Z*^GQPSZ
M,PQ:E0COOR  O&=HSZX%:/CZVTW_ (3#P?<:C#:>0;B:.:2X1=I7RR55BW&,
MDX![FNWMM*T^R<O:V-K YZM%"JG]!4ES9VUXBI=6\4ZJVX+*@8 ^O/>@#S"W
M_L+5!XWMM76W$ZDR022A<K:>4/):(GHHQD8/4CIFNG\%Z["-#T+2-4OA_;LM
M@LQ@F;]ZR]B<]\=CSP3ZUTLVFV-S,DT]E;2RI@(\D2LRXY&"1Q5.XT.&Z\06
MVJSL&:U4^0@C *L0RDENIX8@#@#)//& #EOB-?16>J^%1J+*NBO?,;SS%S&2
M%_=[_;))YXXSVKC-3OM!L[GXD):['LYDL@L=C,(]Q.0Y! /RAV^; /7'>O;9
M[>&ZA,-Q#'-$W5)%#*?P-1KI]FL4D2VD CD 5T$8PP P 1CGCB@#R30KC2$\
M6>(K2ZU#2+A+K28U=+50L#,JL2H!)W;57EOT'2IX+NV_X0'X;@W$61JEMD;Q
M_"L@;\B0#Z5ZD=*T\KM-C:X\ORL>2OW/[O3I[5'_ &)I6Q$_LRRVQDE!Y"X4
MGKCCCI0!YSJNFW/A[Q=?Z-I<&VS\6Q;8W10!;3#B4_3RR6^O%>D_V79?V1_9
M9MXVLO*\GR64%=F,8Q6/I&A:LFLR:EKVIQ7KPETL4AA\M8D8C)/JQ  ]N?6N
MDH \H\"V5Y_::^$]0MMUOX:NY;@2NH82;A^XY]</(WMM6LXKI?V_QY:'4(M-
M@?4+(1RQHK1HV>-R="F[[WZU[*L2*[NJ*'?&Y@.6QTS47V"SWL_V6#>R[6;R
MQDC.<'VS0!XMJ,HN/ _C>+5;/38[ZW-MNN[/#V\[XPIC'\+XX.,'YAP*ZFVN
M-&L?BDD\TUM_IVCVYMSM#;Y#*5&W'4]#D=N>@KT%+*UB@6".VA2%>1&L8"C\
M.E/$$0*D1)E!A3M'R_2@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH :GW:=34^[3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ H)P,GI17#_ !+O/L=AH_VH2?V/)J4::D4) \K!X8C^ G&?7&.]
M ';AE(R""/4&FQRQR@F.17 )!*G.".HKR77KO1=/TR]'AN\DET>?4K5M6^R2
M*;:W@<D.L948&[ W $_>'KBI]>A_X1OQ,TW@]5A%UHMS--;VB Q;HU_<R;1Q
MDDX'KCOF@#K]?\4RZ1KVBZ?!':3)?W0MY<S'S8L@G.P#IQU)_"NC,\*S"$RH
M)6&0A8;B/7%>**?"Z0_#[4K2XL?[1-U$;R<3#S"2F9#)SD_/W;I^-5+/['K$
ME_/J_B)+'7K74V<P?9%:[,BOA$B<MN88PH4<#]: /=OM$'GF#SH_. R8]PW8
M]<4YW2*-I)&5$499F. ![UY%?QBU\6+?S6UEJFGSZ^BB\3Y+VSG5PHB.1\R
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M6_@$]G<PW,)X$D,@=3^(XK$UWQ)+8ZQ8:'IMLMSJEZK2*)&*QPQKU=R 3CL
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MK6EOI\E^FI6;6<9P]PLZF-3Z%LX[BFQZ[I$NGR7\>J63V<9VO.LZE$/'!;.
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M#8:QXAM[S59M,O)XB]Y>1_ZZ4DJ2B*BGJ0"<<GZ5Z0"" 1T- "T444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** &I]VG4BC Q2T %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 E+110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !12'M2(X=<CI0 ZBBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **,YZ44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !39"X0E%
M#-V!-.HH 1<XY&/:EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>exhibit1021-independentc011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit1021-independentc011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE_B/\
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MQ.[/E\_>Z8[5Z#110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)F
MD2%VB022!240MM#'' SSCZT^@T >>:?\2[_5/$.H:'9^&3)>V&[S@;]%7Y6"
MG!*C/)%6M0\?WVG^$QK[^&YVCBFEANX1<KNMV23R^>/F&0>1T_6O.-(TZ[U/
MXI^+HK&XDCG2[\QHU Q+&MTA=23R.@/'7&*]>N_$.AG2=9>X DLK*4VURNP,
MLSLJDJH_B)WA<>N10!C6_P 19+_0]*U#3=(2\EU&9H4M(KP>8I49.<KT'\1Z
M#CKFFZI\0K[2/%&G^'KGP^IO;X*82E\"F"Q')V<=#VKSOPX\OPL^($,.LVJ0
MZ;JD9,3L?,:V5FX&[U&%#XZ\'L*VOB'')<_&GPI'!<M;R/#'LF0!BI\Q^0#P
M?QH ZO4_B#?:7XRM?#,N@*]Y=_-;NEZ-C(2P!/R9!^4Y'\Z9-\0M23QBOA1/
M#T?]J.F]"U_B(C87^\$)Z ]NM<CKMI=6?QZ\,I>:C)?2- C"22-$*C=*-N%
M';/XU<N"#^TQ9X(XM2#[?N'H Z.V^(.J77B2_P##T?AD/J=A#YTT:7Z[6'R_
M=8H,_?'7%)%\4;>\\&7'B.RTR25+-]E[;23;'A.0!@X(;K[?TKDX=,;4_C;X
MOM;?5;C3-UADW%NRY'$.02P.!D]B#QU%8?AR^\[X*>+;,64,2VK(/M,:G-P6
M<9+$DY(P.G8CCU /4=-\<ZEJ^FZ9=V'AMI6U%99(X_MBKLCC*@LQ*X&2V,5E
MZ3\5;K6;*^O+/PO,]O8.JW+?;$R@/?&.0,$\5L_"P#_A6FB'OY3_ /HQJY#X
M$ &#Q(#S_I2?R:@#TWQ!J=QH^B7.HV]HEU]F0RR1M+Y?R*"6(.#S@=/UKA?^
M%L74?A^U\1W'AMET2XE,7G1W@:5&!(Y0J..#T-=IXM_Y$S7?^P?<?^BVKP V
M&WX,Z=J\NJ22);WS!=+FD!@E.\_PJ V>IY)XSC&: /I.VN8KRUAN86W13(LB
M-C&5(R/TJ6LKPU=O?^&-+NY+3[&\MK&QM\8$?RC@#T].^,5JT %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M3)HDGA>&5=T<BE6'J#P:?10!S=I\/_"=C.\\&A6GF."&:0&3(/)^\34\_@OP
MS<6J6LFB67V=-Q2)(@JJ6QE@!@!OE'/7BMVB@#(N?"V@7J0+>:-8W/D1B*(W
M$"R%$'0 L"<5&?!WAEG5SX?TPNF-K&U3*XZ8XK;HH QI?"7AR>X^T2Z%ILD^
M<^8ULA;/UQ3?^$/\->=YW]@:9YO7?]E3=^>*VZ* ,-O!GAAW9V\/:67;[S&T
M3)^O%69/#>AS6,=C)H]@]I&<I ;=2BGV7&.U:=% &=;>']'L[.6TMM+LX;:7
M'F0QP*J/CU &#3+#PWH>E3^?I^CV-I-TWP6ZHWY@>YK4HH K7^G66J6QMK^T
M@NH"<F.:,.N?7!K.M_"'AJUF6:W\/Z7%(O1TM$!'XXK:HH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HI"<#-8NH^+M#TJ]6SO-1@CN",^7DEA]0!Q0!MT53L-3L]4B>6RN(YXU;:
M6C8$ U<H **3G'2EH **0-D9H+8H 6BDSR,#CUHS[4 +12$X'K3'E$<9=L #
MJ2< ?6@"2BLV77=.AU:WTJ2YC6^N$,D,.>74=36AOSTQ^= #J*3/L: <T +1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MLZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BJ-[<3VL\
M,F!]DY\X[<E?0]>E7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH 2EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&F"64GC)*]#UK,M/B#;W,MM<M8O'HEW=M96VHF4'?*"0,IU56*D YZCD#(H
MK+\/+F\UN[U'6M?:^%W8FPFACM%A#1X]<L0=WS9&.?;BET[X?7UI"L%[XGNM
M1M[:-TL8;B ;(&*E0S8.7(5B!DC%=%I>O+>ZG=Z5=6_V34K7YVAW[U>(GY9$
M; R#T/ (.1[G8S0!B>$]!E\,^'+;1Y+Q;M;;*QRB'RSM)S@C<<G)//';BL_6
M?!LVH^)O[;L]9GT^62S^Q3K'$KEX]V[Y2WW3GO@_A75YHS0!PND?#ZZT9/#T
M5OKQ>'1I)'19+0$OYF0ZY## P3C.2">IX%-?X<SW6G:A;7VNM)-/J U.WG@M
MO*:VN<8W#YCN&,<?KFN\S1F@#B8OA]+/>ZA=:SK]UJ+:A9BTN$\B.)649P0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:6'Q/9?$"YU">87&E>9#:0K<,HA1(\[@H./G(.<CD<53BFO=6E\.: NH6MG
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MSGXG26EMJWA"ZO$B2%-54RW$@ 54 R0Q/;O^!H [B?6M*M9;>*XU.RBDN0#
MDDZJ90>FT$_-^%6YA(T+B%T24J=C.NY0>Q(!&1^(KRBTNM%EN/&\6OM OVD"
M:U:=1\]J8_W7E9ZX[ <@GUKN/!(O+7P%I']K28N$M%:1I#C:N,C<3W"XS]*
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1129 ..] "T444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !3&C#2K)DY48QVI]% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !12-DKQUH'2@!:
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *B=)#/&ZN0@!!3'!J6B@!%^Z*
M6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHJ.>>&V@>>XE2*)!EY)&"JH]23TH DHJMI^HV>JV27MA<QW-M(6"2Q
MG*M@E3@]^014.GZUIFJSW,.GWT%T]J0LPA?<$)S@$CCL: +]%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !114<RR-"ZQ.J2$$*S+N /8D9&?SH Y/
MX7?\D]L/^NMS_P"E$E)X354\9>,U4 *+NW  ' _<+6KX5\//X8T9=,^W-=PQ
MLS1L\01E+,6;IU&YB1Z>]1:+X;N=)UW4M3?56N/[18//"8%50P "E2#D848Y
MSGK0!T-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
#!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464342256144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Apr. 29, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Astrana Health, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-4472349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1668 S. Garfield Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">2nd Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alhambra<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">282-0288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ASTH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,025,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001083446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464340399424">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 334,796<span></span>
</td>
<td class="nump">$ 293,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investment in marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,490<span></span>
</td>
<td class="nump">2,498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income taxes receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,783<span></span>
</td>
<td class="nump">1,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,281<span></span>
</td>
<td class="nump">17,450<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">538,810<span></span>
</td>
<td class="nump">461,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Land, property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,985<span></span>
</td>
<td class="nump">7,171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">119,707<span></span>
</td>
<td class="nump">71,648<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">410,267<span></span>
</td>
<td class="nump">278,831<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivableNoncurrent', window );">Income taxes receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,943<span></span>
</td>
<td class="nump">15,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">35,893<span></span>
</td>
<td class="nump">25,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue', window );">Investments in privately held entities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,396<span></span>
</td>
<td class="nump">6,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">645<span></span>
</td>
<td class="nump">345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">39,152<span></span>
</td>
<td class="nump">37,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,067<span></span>
</td>
<td class="nump">1,877<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">687,467<span></span>
</td>
<td class="nump">471,854<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,226,277<span></span>
</td>
<td class="nump">933,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">146,473<span></span>
</td>
<td class="nump">59,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_FiduciaryAccountsPayableCurrent', window );">Fiduciary accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,792<span></span>
</td>
<td class="nump">7,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">136,494<span></span>
</td>
<td class="nump">106,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,522<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividend payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">638<span></span>
</td>
<td class="nump">638<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">636<span></span>
</td>
<td class="nump">646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,007<span></span>
</td>
<td class="nump">4,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,750<span></span>
</td>
<td class="nump">19,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">31,960<span></span>
</td>
<td class="nump">18,940<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">355,272<span></span>
</td>
<td class="nump">218,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,756<span></span>
</td>
<td class="nump">4,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,015<span></span>
</td>
<td class="nump">1,033<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">37,716<span></span>
</td>
<td class="nump">36,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">368,448<span></span>
</td>
<td class="nump">258,939<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,652<span></span>
</td>
<td class="nump">3,586<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">418,587<span></span>
</td>
<td class="nump">303,919<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">773,859<span></span>
</td>
<td class="nump">522,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 12)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_MezzanineEquityAbstract', window );"><strong>Mezzanine equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsNetOfDividends', window );">Noncontrolling interest in Allied Physicians of California, a Professional Medical Corporation ("APC")</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(205,557)<span></span>
</td>
<td class="num">(205,883)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, value, issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">48<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">395,473<span></span>
</td>
<td class="nump">371,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">257,969<span></span>
</td>
<td class="nump">243,134<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">653,490<span></span>
</td>
<td class="nump">614,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,485<span></span>
</td>
<td class="nump">2,433<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">657,975<span></span>
</td>
<td class="nump">616,651<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, mezzanine equity and equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,226,277<span></span>
</td>
<td class="nump">933,361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">120,106<span></span>
</td>
<td class="nump">76,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetNoncurrent', window );">Loans receivable, non-current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">47,412<span></span>
</td>
<td class="nump">26,473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 62,354<span></span>
</td>
<td class="nump">$ 58,980<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The condensed consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#8217;s consolidated VIEs totaling $717.5&#160;million and $540.8&#160;million as of March&#160;31, 2024 and December&#160;31, 2023, respectively, and total liabilities of the Company&#8217;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $179.6&#160;million and $146.0&#160;million as of March&#160;31, 2024 and December&#160;31, 2023, respectively. These VIE balances do not include $299.5&#160;million of investment in affiliates and $110.1&#160;million of amounts due to affiliates as of March&#160;31, 2024, and $273.2&#160;million of investment in affiliates and $107.3&#160;million of amounts due to affiliates as of December&#160;31, 2023, as these are eliminated upon consolidation and not presented within the condensed consolidated balance sheets. See Note 16 &#8212; &#8220;Variable Interest Entities (VIEs)&#8221; for further details.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_FiduciaryAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_FiduciaryAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of Investment in privately held entity that does not report net asset value per share .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_MezzanineEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_MezzanineEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsNetOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests, Net of Dividends</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsNetOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due after one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464342624048">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">47,458,264<span></span>
</td>
<td class="nump">46,843,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">47,458,264<span></span>
</td>
<td class="nump">46,843,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, common, shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,584,340<span></span>
</td>
<td class="nump">10,584,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,226,277<span></span>
</td>
<td class="nump">$ 933,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">773,859<span></span>
</td>
<td class="nump">522,593<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember', window );">Variable Interest Entity, Not Primary Beneficiary</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">717,500<span></span>
</td>
<td class="nump">540,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">179,600<span></span>
</td>
<td class="nump">146,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investments in affiliates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">299,500<span></span>
</td>
<td class="nump">273,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Amount due to affiliates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 110,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Due from affiliates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,111,111<span></span>
</td>
<td class="nump">1,111,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">555,555<span></span>
</td>
<td class="nump">555,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The condensed consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#8217;s consolidated VIEs totaling $717.5&#160;million and $540.8&#160;million as of March&#160;31, 2024 and December&#160;31, 2023, respectively, and total liabilities of the Company&#8217;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $179.6&#160;million and $146.0&#160;million as of March&#160;31, 2024 and December&#160;31, 2023, respectively. These VIE balances do not include $299.5&#160;million of investment in affiliates and $110.1&#160;million of amounts due to affiliates as of March&#160;31, 2024, and $273.2&#160;million of investment in affiliates and $107.3&#160;million of amounts due to affiliates as of December&#160;31, 2023, as these are eliminated upon consolidation and not presented within the condensed consolidated balance sheets. See Note 16 &#8212; &#8220;Variable Interest Entities (VIEs)&#8221; for further details.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464340522304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 404,356<span></span>
</td>
<td class="nump">$ 337,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of services, excluding depreciation and amortization</a></td>
<td class="nump">330,399<span></span>
</td>
<td class="nump">289,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">38,722<span></span>
</td>
<td class="nump">21,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">5,096<span></span>
</td>
<td class="nump">4,292<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
<td class="nump">374,217<span></span>
</td>
<td class="nump">314,871<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">30,139<span></span>
</td>
<td class="nump">22,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income from equity method investments</a></td>
<td class="nump">632<span></span>
</td>
<td class="nump">2,484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(7,585)<span></span>
</td>
<td class="num">(3,269)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">3,996<span></span>
</td>
<td class="nump">3,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">1,099<span></span>
</td>
<td class="num">(6,392)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (loss) income</a></td>
<td class="num">(4,277)<span></span>
</td>
<td class="nump">1,204<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expenses, net</a></td>
<td class="num">(6,135)<span></span>
</td>
<td class="num">(2,964)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before provision for income taxes</a></td>
<td class="nump">24,004<span></span>
</td>
<td class="nump">19,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">7,142<span></span>
</td>
<td class="nump">6,921<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">16,862<span></span>
</td>
<td class="nump">12,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to non-controlling interest</a></td>
<td class="nump">2,027<span></span>
</td>
<td class="num">(644)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Astrana Health, Inc.</a></td>
<td class="nump">$ 14,835<span></span>
</td>
<td class="nump">$ 13,132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share &#8211; basic (in dollars per share)</a></td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share &#8211; diluted (in dollars per share)</a></td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=asth_HealthCareCapitationRevenueMember', window );">Capitation, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 365,910<span></span>
</td>
<td class="nump">$ 300,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_HealthCareOtherMember', window );">Risk pool settlements and incentives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">17,377<span></span>
</td>
<td class="nump">13,462<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember', window );">Management fee income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">4,078<span></span>
</td>
<td class="nump">9,896<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember', window );">Fee-for-service, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">15,937<span></span>
</td>
<td class="nump">12,062<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 1,054<span></span>
</td>
<td class="nump">$ 1,620<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=asth_HealthCareCapitationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=asth_HealthCareCapitationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_HealthCareOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_HealthCareOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464431056880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common&#160;Stock&#160;Outstanding</div></th>
<th class="th"><div>Additional Paid-in&#160; Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Non-controlling Interest</div></th>
<th class="th">
<div>Non-controlling Interest </div>
<div>Mezzanine</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, carrying amount, beginning balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Net (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,729)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_TemporaryEquityTransferOfCommonControlEntities', window );">Temporary Equity, Transfer Of Common Control Entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,769<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, carrying amount, ending balance at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,277<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,575,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 544,310<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">$ 360,097<span></span>
</td>
<td class="nump">$ 182,417<span></span>
</td>
<td class="nump">$ 1,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity', window );">Net (loss) income</a></td>
<td class="nump">14,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,132<span></span>
</td>
<td class="nump">1,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards</a></td>
<td class="num">(109)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(109)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(270,081)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredParValueMethod', window );">Purchase of treasury shares</a></td>
<td class="num">(9,539)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,539)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">3,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares', window );">Dividends</a></td>
<td class="num">(120)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(120)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_StockholdersEquityTransferOfCommonControlEntities', window );">Transfer of common control entities</a></td>
<td class="num">(2,447)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,447)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,488,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance at Mar. 31, 2023</a></td>
<td class="nump">551,007<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">352,697<span></span>
</td>
<td class="nump">195,549<span></span>
</td>
<td class="nump">2,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, carrying amount, beginning balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,237<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, carrying amount, ending balance at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(205,883)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,575,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 544,310<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">360,097<span></span>
</td>
<td class="nump">182,417<span></span>
</td>
<td class="nump">1,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares (in shares)</a></td>
<td class="num">(3,451,642)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">46,843,743<span></span>
</td>
<td class="nump">46,843,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 616,651<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">371,037<span></span>
</td>
<td class="nump">243,134<span></span>
</td>
<td class="nump">2,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Net (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, carrying amount, ending balance at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (205,557)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity', window );">Net (loss) income</a></td>
<td class="nump">16,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,835<span></span>
</td>
<td class="nump">1,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Purchase of non-controlling interest</a></td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest', window );">Sale of non-controlling interest</a></td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards</a></td>
<td class="num">$ (2,407)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,407)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares (in shares)</a></td>
<td class="num">(3,451,642)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 5,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of shares for business acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">631,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of shares for business acquisition</a></td>
<td class="nump">21,952<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">21,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_AcquisitionOfNonControllingInterestShares', window );">Acquisition of non-controlling interest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,340)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_NoncontrollingInterestIncreaseDecreaseFromBusinessCombination', window );">Acquisition of non-controlling interest</a></td>
<td class="num">(535)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(856)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares', window );">Dividends</a></td>
<td class="num">$ (95)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(95)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="nump">47,458,264<span></span>
</td>
<td class="nump">47,458,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance at Mar. 31, 2024</a></td>
<td class="nump">$ 657,975<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">$ 395,473<span></span>
</td>
<td class="nump">$ 257,969<span></span>
</td>
<td class="nump">$ 4,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_AcquisitionOfNonControllingInterestShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquisition of Non-Controlling Interest, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_AcquisitionOfNonControllingInterestShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders And Stock Repurchased During Period, Value, Release Of Hold Back Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_NoncontrollingInterestIncreaseDecreaseFromBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Increase (Decrease) from Business Combination</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_NoncontrollingInterestIncreaseDecreaseFromBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents number of share issued exercise of option and warrants during the period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents value of stock issued during the period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_StockholdersEquityTransferOfCommonControlEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stockholders' Equity, Transfer of Common Control Entities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_StockholdersEquityTransferOfCommonControlEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_TemporaryEquityTransferOfCommonControlEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Transfer Of Common Control Entities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_TemporaryEquityTransferOfCommonControlEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-23<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-23<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityNetIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of net income or loss attributable to temporary equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityNetIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredParValueMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the par value method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredParValueMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464340398112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 16,862<span></span>
</td>
<td class="nump">$ 12,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">5,096<span></span>
</td>
<td class="nump">4,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance cost</a></td>
<td class="nump">458<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">5,748<span></span>
</td>
<td class="nump">3,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_NoncashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">3,155<span></span>
</td>
<td class="nump">2,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_UnrealizedGainLossFromInvestmentInEquitySecurities', window );">Unrealized (gain) loss on investments</a></td>
<td class="num">(1,099)<span></span>
</td>
<td class="nump">5,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income from equity method investments</a></td>
<td class="num">(632)<span></span>
</td>
<td class="num">(2,484)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Unrealized loss on interest rate swaps</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred tax</a></td>
<td class="num">(7,248)<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherOperatingActivities', window );">Other</a></td>
<td class="nump">6,795<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of business combinations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Receivable, net</a></td>
<td class="num">(26,128)<span></span>
</td>
<td class="num">(26,373)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties', window );">Receivable, net &#8211; related parties</a></td>
<td class="num">(3,374)<span></span>
</td>
<td class="num">(9,730)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="num">(1,403)<span></span>
</td>
<td class="num">(94)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(4,255)<span></span>
</td>
<td class="num">(506)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">92<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">905<span></span>
</td>
<td class="num">(4,517)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">Fiduciary accounts payable</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_IncreaseDecreaseInMedicalLiabilities', window );">Medical liabilities</a></td>
<td class="num">(808)<span></span>
</td>
<td class="nump">17,141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable/receivable</a></td>
<td class="nump">14,542<span></span>
</td>
<td class="nump">6,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(3,083)<span></span>
</td>
<td class="num">(2,088)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="nump">298<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">5,977<span></span>
</td>
<td class="nump">7,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payments for business acquisition, net of cash acquired</a></td>
<td class="num">(50,649)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties', window );">Proceeds from repayment of loans receivable &#8211; related parties</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">2,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Purchase of investment &#8211; equity method</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(325)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToFundLongtermLoansToRelatedParties', window );">Issuance of loans receivable</a></td>
<td class="num">(20,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(369)<span></span>
</td>
<td class="num">(6,027)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_DepositForPurchaseOfProperty', window );">Deposit for purchase of property</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,824)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(71,039)<span></span>
</td>
<td class="num">(14,035)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Dividends paid</a></td>
<td class="num">(95)<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt', window );">Borrowings on long-term debt</a></td>
<td class="nump">110,000<span></span>
</td>
<td class="nump">1,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="num">(3,500)<span></span>
</td>
<td class="num">(153)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations', window );">Payment of finance lease obligations</a></td>
<td class="num">(179)<span></span>
</td>
<td class="num">(154)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of stock options and warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_PaymentForRepurchaseOfTreasuryStockFinancingActivities', window );">Repurchase of treasury shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,539)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsToMinorityShareholders', window );">Proceeds from sale of non-controlling interest</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsMinorityInterest', window );">Purchase of non-controlling interest</a></td>
<td class="num">(25)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">106,351<span></span>
</td>
<td class="num">(7,099)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">41,289<span></span>
</td>
<td class="num">(13,414)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, beginning of period</a></td>
<td class="nump">294,152<span></span>
</td>
<td class="nump">288,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, end of period</a></td>
<td class="nump">335,441<span></span>
</td>
<td class="nump">274,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">194<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">6,430<span></span>
</td>
<td class="nump">2,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_NonCashBusinessAcquisition', window );">Business acquisition in accounts payable and accrued liabilities</a></td>
<td class="nump">63,935<span></span>
</td>
<td class="nump">3,844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">4,910<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Common stock issued in business combination</a></td>
<td class="nump">21,952<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransferToInvestments', window );">Purchase of investments - equity method in accounts payable and accrued liabilities and other liabilities</a></td>
<td class="nump">9,487<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_DrawOnLetterOfCreditThroughRevolverLoan', window );">Draw on letter of credit through Revolver Loan</a></td>
<td class="nump">4,759<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract', window );"><strong>Reconciliation of cash, cash equivalents, and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">334,796<span></span>
</td>
<td class="nump">274,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">645<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</a></td>
<td class="nump">$ 335,441<span></span>
</td>
<td class="nump">$ 274,613<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_DepositForPurchaseOfProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deposit For Purchase Of Property</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_DepositForPurchaseOfProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_DrawOnLetterOfCreditThroughRevolverLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Draw On Letter Of Credit Through Revolver Loan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_DrawOnLetterOfCreditThroughRevolverLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_IncreaseDecreaseInMedicalLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of medical liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_IncreaseDecreaseInMedicalLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_NonCashBusinessAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Business Acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_NonCashBusinessAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_PaymentForRepurchaseOfTreasuryStockFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment For Repurchase Of Treasury Stock, Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_PaymentForRepurchaseOfTreasuryStockFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reconciliation Of Cash Cash Equivalents And Restricted Cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_UnrealizedGainLossFromInvestmentInEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrealized (Gain) Loss from Investment in Equity Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_UnrealizedGainLossFromInvestmentInEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsMinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends provided by the non-wholly owned subsidiary to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsMinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToFundLongtermLoansToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToFundLongtermLoansToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with collection, whether partial or full, of long-term loans to a related party. Alternate caption: Proceeds from Advances to Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from operating activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt and lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480602/954-210-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransferToInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of investments transferred to the entity's investments in noncash transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransferToInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464437046896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of Business</a></td>
<td class="text">Description of Business<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context dictates otherwise, references in these notes to the financial statements to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and similar words are references to Astrana Health, Inc. (&#8220;Astrana&#8221;), formerly known as Apollo Medical Holdings, Inc., and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (&#8220;VIEs&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Headquartered in Alhambra, California, Astrana is a leading provider-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, Astrana operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver accessible, high-quality care to patients in a cost-effective manner. Together with Astrana&#8217;s affiliated physician groups and consolidated subsidiaries and VIEs, the Company provides value-based care enablement services and care delivery with its consolidated care partners to serve patients in California, Nevada, and Texas, the majority of whom are covered by private or public insurance provided through Medicare, Medicaid, and health maintenance organizations (&#8220;HMOs&#8221;), with a small portion of our revenue coming from non-insured patients. The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company&#8217;s physician network consists of primary care physicians, specialist physicians, physician and specialist extenders, and hospitalists.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s three reportable segments are Care Partners, Care Delivery and Care Enablement, which are described as follows:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Care Partners</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Care Partners segment is focused on building and managing high-quality and high-performance provider networks by partnering with, empowering, and investing in strong provider partners aligned on a shared vision for coordinated care delivery. By leveraging the Company&#8217;s unique care enablement platform and ability to recruit, empower, and incentivize physicians to effectively manage total cost of care, the Company is able to organize partnered providers into successful multi-payer risk-bearing organizations that take on varying levels of risk based on total cost of care across membership in all lines of business, including Medicare fee for service (&#8220;FFS&#8221;), Medicare Advantage, Medicaid, Commercial, and Exchange. Through the Company&#8217;s network of &#8220;independent practice associations&#8221; (&#8220;IPAs&#8221;), &#8220;accountable care organizations&#8221; (&#8220;ACOs&#8221;), and Restricted Knox-Keene licensed health plan, the Company&#8217;s healthcare delivery entities are responsible for coordinating and delivering high-quality care to the Company&#8217;s patients and ensuring continuity of care in Astrana&#8217;s ecosystem across age, stage of life, or life circumstance. Beginning in 2024, in addition to participating in the ACO REACH Model, the Company began participating in the Medicare Shared Savings Program (&#8220;MSSP&#8221;). The MSSP was created to promote accountability and improve coordination of care for Medicare beneficiaries. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Care Delivery</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Care Delivery segment is a patient-centric, data-driven care delivery organization focused on delivering high-quality and accessible care to all patients. The Company&#8217;s care delivery organization includes primary care, multi-specialty care, and ancillary care services. This segment includes the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Primary care clinics, including post-acute care services;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Multi-specialty care clinics and medical groups, including hospitalist, intensivist, and physician advisory services, cardiac care and diagnostic testing, and specialized care for women&#8217;s health; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ancillary service providers, such as urgent care centers, outpatient imaging centers, ambulatory surgery centers, and full-service labs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Care Enablement</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Care Enablement segment is an integrated, end-to-end clinical, operational, financial, and administrative platform powered by the Company&#8217;s proprietary technology suite that enhances the delivery of high-quality, value-based care to patients and leads to superior clinical and financial outcomes. The Company provides solutions to providers, including independent physicians, provider and medical groups, accountable care organizations, and payers, including health plans and other risk-bearing organizations. The Company&#8217;s platform meets providers and payers where they are, with a wide spectrum of solutions across the total cost of care risk spectrum, ranging from solutions for fee-for-service entities to hospital-shared risk-bearing entities, and across patient types, including Medicare, Medicaid, Commercial, and Exchange patients. This segment includes the Company&#8217;s wholly owned subsidiaries which operate as management services organizations (&#8220;MSOs&#8221;), which enter into long-term management and/or administrative services agreements with IPAs, ACOs, clinics, or independent providers. By leveraging the Company&#8217;s care enablement platform, providers and payers can improve their ability to deliver high-quality care to their patients and achieve better patient outcomes.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464333861328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Summary of Significant Accounting Policies<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated balance sheet at December&#160;31, 2023, has been derived from the Company&#8217;s audited condensed consolidated financial statements, but does not include all annual disclosures required by generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). The accompanying unaudited condensed consolidated financial statements as of March&#160;31, 2024, and for the three months ended March&#160;31, 2024 and 2023, have been prepared in accordance with U.S. GAAP for interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited condensed consolidated financial statements and related notes to the financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2023, as filed with the SEC on February&#160;29, 2024. In the opinion of management, all material adjustments (consisting of normal recurring adjustments as well as intercompany accounts and transactions, which have been eliminated) considered necessary for a fair presentation have been made to make the condensed consolidated financial statements not misleading, as required by Regulation S-X, Rule 10-01. Operating results for the three months ended March&#160;31, 2024, are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2024, or any future periods.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheets as of March&#160;31, 2024 and December&#160;31, 2023, and the condensed consolidated statements of income for the three months ended March&#160;31, 2024 and 2023, include Astrana&#8217;s wholly owned subsidiaries and consolidated variable interest entities (&#8220;VIEs&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read or have access to our audited condensed consolidated financial statements for the fiscal year ended December&#160;31, 2023.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred but not reported (&#8220;IBNR&#8221;) claims), determination of hospital shared-risk and health plan shared-risk revenue and receivables (including constraints, completion factors and historical margins), income tax-valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition-related costs separately from the business combination.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reportable Segments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, the Company operates in three reportable segments:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Care Partners;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Care Delivery; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Care Enablement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 1 &#8212; &#8220;Description of Business&#8221; and Note 18 &#8212; &#8220;Segments&#8221; to the condensed consolidated financial statements for information on the Company&#8217;s segments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within ninety days from their date of purchase to be cash equivalents.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company believes it is not exposed to any significant credit risk with respect to its cash and cash equivalents and restricted cash. As of March&#160;31, 2024 and December&#160;31, 2023, the Company&#8217;s deposit accounts with banks exceeded the FDIC&#8217;s insured limit by approximately $353.6 million and $318.9 million, respectively. The Company has not experienced any losses to date and performs ongoing evaluations of these financial institutions to limit the Company&#8217;s concentration of risk exposure.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables, Receivables &#8211; Related Parties, Other Receivables and Loan Receivables</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements, incentive receivables, management fee income, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables &#8211; related parties are comprised of risk pool settlements, management fee income, and other receivables. Receivables &#8211; related parties are recorded and stated at the amount expected to be collected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s loan receivables consists of promissory notes that accrue interest per annum. As of March&#160;31, 2024, promissory notes are expected to be collected by their maturity dates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation and claims receivables relate to each health plan&#8217;s capitation and are received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#8217;s hospital shared-risk pool receivable, which is recorded quarterly based on reports received from the Company&#8217;s hospital partners and management&#8217;s estimate of the Company&#8217;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consist of receivables from fee-for-service (&#8220;FFS&#8221;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop-loss insurance premium reimbursements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains reserves for potential credit losses on the receivables. Management reviews the composition of the Company&#8217;s receivables and analyzes historical bad debts, customer concentrations, customer creditworthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regard to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (&#8220;CECL&#8221;) model. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risks</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disaggregates revenue from contracts by service type and payer type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The condensed consolidated statements of income present disaggregated revenue by service type. The following table presents disaggregated revenue generated by payer type for the three months ended March&#160;31, 2024 and 2023 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other third parties</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404,356&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,244&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payers that contributed the following percentages of net revenue:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payer A</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payer B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> *Less than 10% of total net revenues</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payers that contributed to the following percentages of receivables and receivables &#8211; related parties:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payer A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payer C</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives payments from the following sources for services rendered:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Commercial insurers;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Federal government under the Medicare program administered by CMS;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">State governments under Medicaid and other programs;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Other third-party payers (e.g., hospitals and IPAs); and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Individual patients and clients.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue primarily consists of the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Capitation revenue;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk pool settlements and incentives;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Management fee revenue; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FFS revenue.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk Pool Settlements and Incentives</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Shared Savings Program Revenue</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2024, Astrana participates in MSSP. The MSSP has multiple risk tracks, and Astrana is currently participating in the ENHANCED risk track. Under the MSSP Model, Astrana recruits a group of Participant and Preferred (in-network) Providers. Based on the Participant Providers that join our ACO, CMS grants us a pool of Traditional Medicare patients (beneficiaries) to manage (the &#8220;MSSP Aligned Beneficiaries&#8221;). The Company&#8217;s MSSP Aligned Beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. CMS continues to pay participant and preferred providers on a fee-for-service basis for Medicare-covered services provided to MSSP Aligned Beneficiaries. The Company continues to bear risk on all Medicare expenditures (both in-network and out-of-network), excluding drug expenditures covered by Medicare Part D, based on a budgetary benchmark established with CMS. Astrana&#8217;s shared savings or losses in managing the Company&#8217;s beneficiaries are generally determined on an annual basis after reconciliation with CMS. Pursuant to Astrana&#8217;s risk-share agreement with CMS, the Company is eligible to receive the surplus (&#8220;shared savings&#8221;) or is liable for the deficit (&#8220;shared losses&#8221;) according to the budgetary benchmark established by CMS based on Astrana&#8217;s efficiency, or lack thereof, in managing the expenditures associated with the Company&#8217;s MSSP Aligned Beneficiaries. The Company estimates the shared service revenue by analyzing the activities during the relevant time period in contemplation of the agreed upon benchmarks, metrics, performance criteria, and attribution criteria based on those and any other contractually defined factors. Revenue is not recorded and is constrained until the shared service revenue can be reasonably estimated by the Company and to the extent that it is probable that a significant reversal will not occur once any uncertainty associated with the variable consideration is subsequently resolved.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted for both items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the condensed consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the condensed consolidated financial statements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-07 "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures," which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for the Company&#8217;s annual periods beginning January 1, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on its financial statement disclosures.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for the Company&#8217;s annual periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on its financial statement disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464456422832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations, Asset Acquisitions, and Goodwill<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combinations, Asset Acquisitions, and Goodwill</a></td>
<td class="text">Business Combinations, Asset Acquisitions, and Goodwill<div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advanced Health Management Systems, L.P. (&#8220;AHMS&#8221;)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2024, the Company, through its wholly owned subsidiary, purchased all of the outstanding general and limited partnership interests of Advanced Health Management Systems, L.P. (&#8220;AHMS&#8221;). AHMS is engaged in the business of providing management, consulting, administrative and other support services to entities that provide or arrange for the provision of professional healthcare services. In addition, one of AHMS&#8217;s wholly owned subsidiaries is a Restricted Knox-Keene licensed health plan with members in the Los Angeles, California area. Total consideration for the acquisition was $63.9 million. As the cash was not paid on the closing date, the purchase price was accrued and presented within accounts payable and accrued expenses in the accompanying condensed consolidated balance sheet as of March&#160;31, 2024. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prime Community Care of Central Valley, Inc. (&#8220;PCCCV&#8221;)</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 29, 2024, the Company, through its consolidated subsidiary, acquired certain assets of Prime Community Care of Central Valley, Inc., a California professional medical corporation (&#8220;PCCCV&#8221;). Total consideration of the acquisition was approximately $10.3 million, consisting of cash funded upon the close date and contingent considerations of $2.3 million (&#8220;PCCCV contingent considerations&#8221;). Refer to Note 19 - &#8220;Fair Value Measurements of Financial Instruments&#8221; for additional information on contingent considerations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Community Family Care Medical Group IPA, Inc. (&#8220;CFC&#8221;)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2024, the Company, through its consolidated subsidiary, acquired certain assets of CFC. CFC is an IPA that manages the healthcare of members in the Los Angeles, California area. The group serves patients across Medicare, Medicaid, and Commercial payers. The total consideration for the purchase was $120.2 million, consisting of $91.0 million cash funded upon the close date, $22.0 million of the Company&#8217;s common stock, resulting in the issuance of 631,712 shares of common stock., and contingent considerations of $7.3 million (&#8220;CFC contingent considerations&#8221;). Refer to Note 19 - &#8220;Fair Value Measurements of Financial Instruments&#8221; for additional information on contingent considerations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advanced Diagnostic and Surgical Center, Inc. (&#8220;ADSC&#8221;)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2024, the Company acquired 95% of the equity interest of Advanced Diagnostic and Surgical Center, Inc. (&#8220;ADSC&#8221;). ADSC is a diagnostic and surgical center that also provides ambulatory surgery services. The total consideration consisted of cash funded upon close of the transaction and contingent considerations of $3.6 million (&#8220;ADSC contingent considerations&#8221;). Refer to Note 19 - &#8220;Fair Value Measurements of Financial Instruments&#8221; for additional information on contingent considerations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is still in the process of finalizing the purchase price allocation for these acquisitions, and therefore, the balances are subject to change as a result of any working capital or fair value adjustments, and seller indemnification obligations. The following table summarizes the preliminary purchase price allocation of the fair value of assets acquired and liabilities assumed  related to each acquisition at the acquisition date (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.257%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CFC</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;AHMS </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Others *</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net &#160;Total </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Total purchase consideration: </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Cash paid </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Cash payable </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Contingent consideration </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Common stock issued </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">120,214</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63,935</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,397</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">202,546</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Cash and cash equivalents </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Investment in marketable securities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Receivables </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Prepaid expenses and other current assets </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts due from affiliates</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Land, property and equipment </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Intangible assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Goodwill </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Restricted cash </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable assets acquired</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,132&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,809&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,400&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,341&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Accounts payable and accrued expenses </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Medical liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,645&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts due to affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Income taxes payable </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Deferred tax liability </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Noncontrolling interest </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identified liabilities assumed</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,918&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,874&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total net identifiable assets acquired </span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">120,214</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63,935</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,397</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">202,546</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Others consist of estimated fair values of the assets acquired, net of cash acquired, related to ADSC and PCCCV.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>Following the acquisition dates of CFC, AHMS, ADSC and PCCCV, the operating results have been included in our consolidated financial statements. For the period from the acquisition dates through March&#160;31, 2024, total revenues and net income were $33.2 million and $5.1 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Pro Forma Financial Information</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pro forma financial information in the table below presents the combined results of the Company and CFC, AHMS, ADSC and PCCCV as if the acquisitions had occurred on January 1, 2023. The pro forma information presented is shown for illustrative purposes only and is not necessarily indicative of future results of operations of the Company or results of operations of the Company that would have actually occurred had the transactions been in effect for the periods presented.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except per share amounts)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493,006&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,462&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - basic</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisitions were accounted for under the acquisition method of accounting. The fair value of the consideration for the acquired companies was allocated to acquired tangible and intangible assets and liabilities based upon their fair values. The excess of the purchase consideration over the fair value of the net tangible and identifiable intangible assets acquired was recorded as goodwill. Factors leading to goodwill being recognized are the Company&#8217;s expectation of synergies from combining operations of entities acquired and the Company, as well as the value of intangible assets that are not separately recognized, such as assembled workforce. The determination of the fair value of assets and liabilities acquired requires the Company to make estimates and use valuation techniques when market value is not readily available. The results of operations from the acquisitions have been included in the Company&#8217;s financial statements from the date of acquisition. Transaction costs associated with business acquisitions are expensed as they are incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time of acquisition, the Company estimates the amount of the identifiable intangible assets based on a valuation and the facts and circumstances available at the time. The Company determines the final value of the identifiable intangible assets as soon as information is available, but not more than one year from the date of acquisition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not deductible for tax purposes. The Company had no impairment of its goodwill or indefinite-lived intangible assets during the three months ended March&#160;31, 2024 and 2023. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying value of goodwill for the three months ended March&#160;31, 2024 was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:81.330%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,831&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(906)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410,267&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464451486848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets, Net</a></td>
<td class="text">Intangible Assets, Net<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2024, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.449%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net March 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized intangible assets:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Network relationships</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-21</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,137)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,002)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Member relationships</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7-14</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,154)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient management platform</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,060)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tradename/trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developed technology </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,419&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,712)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,707&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.449%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Network relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-21</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104,859)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,662)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-14</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,345)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient management platform</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,060)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tradename/trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(308)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,916&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131,268)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,648&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2024 and 2023, the Company recognized amortization expenses of $4.4 million and $3.0 million, respectively, in depreciation and amortization on the accompanying condensed consolidated statements of income. The Company determined that there was no impairment of its finite-lived intangible or long-lived assets during the three months ended March&#160;31, 2024 and 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense is estimated to be as follows for the following years ending December&#160;31 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.444%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (excluding the three months ended March 31, 2024)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,657&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464341661680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_EquityMethodAndOtherEquityInvestmentsTextBlock', window );">Investments in Other Entities</a></td>
<td class="text">Investments in Other Entities<div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Equity Method</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2024 and 2023, the Company&#8217;s equity method investment balance consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:23.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.734%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.349%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Ownership</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Initial Investment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allocation of Net Income </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Distribution </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LaSalle Medical Associates &#8211; IPA line of business</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pacific Medical Imaging &amp; Oncology Center, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAIPA MSO, LLC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other *</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,774&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,487&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,893&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:23.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.350%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Ownership</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Initial Investment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allocation of Net Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Distribution </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LaSalle Medical Associates &#8211; IPA line of business</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,849&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pacific Medical Imaging &amp; Oncology Center, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531 W. College, LLC **</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One MSO, LLC **</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAIPA MSO, LLC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other *</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,299&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,484&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Other consists of smaller equity method investments. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">** Investment were solely for the benefit of APC and its shareholders. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">I Health, Inc. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2024, a wholly owned subsidiary of the Company acquired a 25% equity interest in I Health, Inc. (&#8220;I Health&#8221;), a management service organization. The Company accounts for its investment in I Health under the equity method of accounting as the Company has the ability to exercise significant influence, but not control over I Health&#8217;s operations. The purchase agreement includes a call option that allows the Company to purchase an additional 25% equity interest on each of the first, second and third anniversary of the purchase (&#8220;I Health Call Option&#8221;). The cash consideration was not paid on the closing date, </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and was accrued and presented within accounts payable and accrued expenses and other liabilities in the accompanying condensed consolidated balance sheets. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no impairment loss recorded related to equity method investments for the three months ended March&#160;31, 2024 and 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_EquityMethodAndOtherEquityInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method And Other Equity Investments [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_EquityMethodAndOtherEquityInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464456917488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans Receivable<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_LoanReceivableTextBlock', window );">Loans Receivable</a></td>
<td class="text">Loans Receivable<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loans receivable</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IntraCare </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, the Company entered into a five-year convertible promissory note with IntraCare as the borrower. The principal on the note is $25.0 million, with interest on the outstanding principal amount and unpaid interest at a rate per annum equal to 8.81%, compounded annually. In the event that the convertible promissory note remains outstanding on or after the maturity date of July&#160;27, 2028, the outstanding principal balance and any unpaid accrued interest shall, upon the election of the Company, convert into IntraCare preferred shares.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BASS Medical Group</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 29, 2024, the Company provided BASS Medical Group (&#8220;BASS&#8221;) with a $20.0 million senior secured promissory note (&#8220;BASS secured promissory note&#8221;). The promissory note is secured by certain assets of BASS. BASS secured promissory note matures on January 11, 2031, and has an interest rate per annum equal to 8.21% compounded annually. The principal on the note, including unpaid interest, are due and payable on the maturity date.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the outstanding loans receivable under the CECL model by assessing the party&#8217;s ability to pay by reviewing their interest payment history quarterly, financial history annually, and reassessing any identified insolvency risk.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_LoanReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_LoanReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464438431888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="text">Accounts Payable and Accrued Expenses<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts payable and accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other accruals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,075&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitation payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subcontractor IPA payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due to related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other provider payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,473&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,949&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464337479136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock', window );">Medical Liabilities</a></td>
<td class="text">Medical Liabilities<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s medical liabilities consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,657&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired (see Note 3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,645&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,419)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,950)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,818&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,763&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136,286)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136,743)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97,837)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,736)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234,123)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198,479)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(503)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,494&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,396&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for liabilities related to future policy benefits and unpaid claims and claim adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//944-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464431116304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility, Bank Loans, and Lines of Credit<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Credit Facility, Bank Loans, and Lines of Credit</a></td>
<td class="text">Credit Facility, Bank Loans, and Lines of Credit<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s debt balance consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:63.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.471%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolver Loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Promissory Note Payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393,259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,750)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,061)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,561)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368,448&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,939&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our long-term debt was determined using Level 2 inputs primarily related to comparable market prices. As of March&#160;31, 2024, and December&#160;31, 2023, the carrying value was not materially different from fair value, as the interest rates on the Company&#8217;s debt approximated rates currently available to the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the future commitments of the Company&#8217;s debt for the years ending December 31 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:81.330%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (excluding the three months ended March 31, 2024)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393,259&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended Credit Facility</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amended Credit Agreement</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2021, the Company entered into an amended and restated credit agreement (as subsequently amended as described below, the &#8220;Amended Credit Agreement&#8221;) with Truist Bank, in its capacity as administrative agent for the lenders, issuing bank, swingline lender and lender, and the banks and other financial institutions from time to time party thereto, to, among other things, to amend and restate that certain credit agreement, dated September 11, 2019, by and among the Company, Truist Bank, and certain lenders thereto, in its entirety. The Amended Credit Agreement provides for a five-year revolving credit facility (the &#8220;Amended Credit Facility&#8221;) to the Company of $400.0 million (&#8220;Revolver Loan&#8221;), which includes a letter of credit sub-facility of up to $25.0 million (which was amended to $50.0&#160;million, as described below) and a swingline loan sub-facility of $25.0 million and which expires on June&#160;16, 2026. As of March&#160;31, 2024, the Company borrowed $94.8 million on the Revolver Loan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 20, 2022, an amendment was made to the Amended Credit Agreement, in which all amounts borrowed under the Amended Credit Agreement as of the effective date were automatically converted from London Interbank Offer Rate (&#8220;LIBOR&#8221;) Loans to Secured Overnight Financing Rate (&#8220;SOFR&#8221;) Loans with an initial interest period of one month on and as of the amendment effective date. Amounts borrowed under the Revolver Loan bear interest at an annual rate equal to either, at the Company&#8217;s option, (a) the Term SOFR Reference Rate (as defined in the Amended Credit Agreement), adjusted for any Term SOFR Adjustment (as defined in the Amended Credit Agreement) plus a spread ranging from 1.25% to 2.50%, as determined on a quarterly basis based on the Company&#8217;s Consolidated Total Net Leverage Ratio (as defined in the Amended Credit Agreement), or (b) a base rate, plus a spread ranging from 0.25% to 1.50%, as determined on a quarterly basis based on the Company&#8217;s Consolidated Total Net Leverage Ratio.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, the interest rate on the Revolver Loan was 7.42%. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 8, 2023, a Second Amendment to the Amended Credit Agreement was entered into, which, among other things, increased the letter of credit sub-facility from $25.0 million to $50.0&#160;million.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 3, 2023, the Company entered into a Third Amendment to the Amended Credit Agreement (&#8220;Third Amendment&#8221;) with Truist Bank and the other financial institutions party thereto. The Third Amendment provided a new term loan to the Company in an aggregate amount of up to $300.0&#160;million, with $180.0&#160;million funded at the closing of the Third Amendment, and $120.0&#160;million available to be drawn by the Company as delayed draw loans during the six months subsequent to the closing of the Third Amendment (collectively, the &#8220;Term Loan&#8221;). The Term Loan matures on November 3, 2028 (or such earlier date on which it is terminated in accordance with the provisions of the Amended Credit Agreement) and amortizes quarterly at 5% per annum for each of the first two years, 7.5% per annum for years three and four, and 10% per annum for year five. As of  March&#160;31, 2024, the Company borrowed $296.5 million on the Term Loan.  The Term Loan bears interest at an annual rate equal to either, at the Company&#8217;s option, (a) the Term SOFR Reference Rate, adjusted for any Term SOFR Adjustment, plus a spread from 1.50% to 2.75%, as determined on a quarterly basis based on the Company&#8217;s Consolidated Total Net Leverage Ratio, or (b) a base rate, plus a spread of 0.50% to 1.75%, as determined on a quarterly basis based on the Company&#8217;s Consolidated Total Net Leverage Ratio. As of March&#160;31, 2024, the interest rate on the Term Loan was 7.68%. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement requires the Company to comply with two key financial ratios, each calculated on a consolidated basis. The Company must maintain a maximum consolidated total net leverage ratio of not greater than 3.75 to 1.00 as of the last day of each fiscal quarter, provided that for any fiscal quarter during which the Company or certain subsidiaries consummate a permitted acquisition or investment, the aggregate purchase price is greater than $75.0&#160;million, the </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">maximum consolidated total net leverage ratio may temporarily increase by 0.25 to 1.00 to 4.00 to 1.00. The Company must maintain a minimum consolidated interest coverage ratio of not less than 3.25 to 1.00 as of the last day of each fiscal quarter.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Amended Credit Agreement, the terms and conditions of the Guaranty and Security Agreement (the &#8220;Guaranty and Security Agreement&#8221;) between the Company, Astrana Health Management, Inc. (&#8220;AHM&#8221;) and Truist Bank remain in effect. Pursuant to the Guaranty and Security Agreement, the Company and AHM have granted the lenders under the Amended Credit Agreement a security interest in substantially all of their assets to secure obligations under the Amended Credit Agreement, including, without limitation, all stock and other equity issued by their subsidiaries (including AHM) and all rights with respect to the $545.0&#160;million loan from the Company to Astrana Medical.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Promissory Note Payable</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FYB Promissory Note Agreement with CCHCA</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, For Your Benefit, Inc. entered into a promissory note agreement with Chinese Community Health Care Association. The principal on the promissory note is $2.0&#160;million, with a maturity date of May&#160;9, 2024. The interest rate is the prime rate plus 1.0%. The prime rate is updated annually on the effective date of the note and published by the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wall Street Journal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Financing Costs</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2024, and December&#160;31, 2023, the unamortized deferred financing cost was $5.7&#160;million and $6.1&#160;million, respectively. As of March&#160;31, 2024 and December&#160;31, 2023, $1.6&#160;million and $2.6&#160;million, respectively, of unamortized deferred financing costs was recognized in prepaid expenses and other current assets in the accompanying condensed consolidated balance sheets and consisted of unamortized deferred financing costs related to unborrowed amounts available on the Revolver Loan. As of March&#160;31, 2024, and December&#160;31, 2023, $4.1&#160;million and $3.6&#160;million, respectively, of unamortized deferred financing costs was recorded as a direct reduction against the amounts borrowed on the Term Loan and Revolver.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effective Interest Rate</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s average effective interest rate on its total debt during the three months ended March&#160;31, 2024 and 2023, was 6.51% and 5.69%, respectively. Interest expense in the condensed consolidated statements of income included amortization of deferred debt issuance costs for the three months ended March&#160;31, 2024 and 2023 of $0.5 million and $0.2 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lines of Credit</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">APC Business Loan</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;10, 2019, the APC Business Loan Agreement with Preferred Bank (the &#8220;APC Business Loan Agreement&#8221;) was amended to, among other things, decrease loan availability to $4.1 million, limit the purpose of the indebtedness under the APC Business Loan Agreement to the issuance of standby letters of credit, and include as a permitted lien, the security interest in all of its assets that APC granted to AHM under a Security Agreement dated on or about September 11, 2019, securing APC&#8217;s obligations to AHM under their management services agreement dated as of July 1, 1999, as amended.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standby Letters of Credit</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company established irrevocable standby letters of credit with Truist Bank under the Amended Credit Agreement for a total of $31.8 million for the benefit of CMS and certain health plans. Unless the institution provides notification that the standby letters of credit will be terminated prior to the expiration date, the letters will be automatically extended without amendment for additional one-year periods from the present or any future expiration date.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain IPAs consolidated by the Company established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $3.9 million for the benefit of certain health plans as of March&#160;31, 2024. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464337424208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mezzanine and Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Mezzanine and Stockholders' Equity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mezzanine and Stockholders&#8217; Equity</span><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Mezzanine Equity</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">APC</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the redemption feature of the APC shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as non-controlling interests in APC as mezzanine or temporary equity. APC&#8217;s shares were not redeemable, and it was not probable that the shares would become redeemable as of March&#160;31, 2024 and December&#160;31, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Stockholders&#8217; Equity</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, 41,048 holdback shares have not been issued to certain former AHM shareholders who were AHM shareholders at the time of closing of the 2017 merger of Astrana with AHM, as they have yet to submit properly completed letters of transmittal to Astrana in order to receive their pro rata portion of Astrana common stock as contemplated under the 2017 merger agreement. Pending such receipt, such former AHM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the 2017 Merger. The condensed consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares in connection with the 2017 merger.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury Stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of  March&#160;31, 2024, and December&#160;31, 2023, APC owned 7,132,698 shares of Astrana&#8217;s common stock. While such shares of Astrana&#8217;s common stock are legally issued and outstanding, they are treated as treasury shares for accounting purposes and excluded from shares of common stock outstanding in the condensed consolidated financial statements. APC&#8217;s ownership in Astrana was 13.04% and 13.22% as of March&#160;31, 2024, and December&#160;31, 2023, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, and December&#160;31, 2023, the Company had previously repurchased 3,451,642 shares of its common stock. These are included as treasury stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of both March&#160;31, 2024, and December&#160;31, 2023, the total treasury stock, including the Company&#8217;s stock held by APC, was 10,584,340.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 and 2023, certain consolidated subsidiaries of the Company paid distributions of $0.1 million and $0.1&#160;million, respectively, to the shareholders who own the non-controlling interests in the entities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464450003296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock-based compensation expense recognized under all of the Company&#8217;s stock plans for the three months ended March&#160;31, 2024 and 2023, and associated with the issuance of restricted shares of common stock and vesting of stock options that are included in general and administrative expenses in the accompanying condensed consolidated statements of income (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,748&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,445&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized compensation expense related to total share-based payments outstanding as of March&#160;31, 2024, was $42.4 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Options</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding stock options consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding at January&#160;1, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504,241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.03&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,271)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.61</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459,140&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.04&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.41</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024, no options were exercised. During the three months ended March&#160;31, 2023, options were exercised for 125,000 shares of the Company&#8217;s common stock, resulting in proceeds of $1.3 million. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants restricted stock to officers and employees, which is earned based on service conditions. The grant date fair value of the restricted stock is the grant date&#8217;s closing market price of the Company&#8217;s common stock. During the three months ended March&#160;31, 2024, the Company granted 296,428 shares of restricted stock with performance-based conditions and 255,781 shares of restricted stock without performance-based conditions. During the three months ended March&#160;31, 2024, the weighted average grant date fair value of restricted stock with and without performance-based conditions was $43.88 and $40.65, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan (&#8220;ESPP&#8221;)</span></div>The Company&#8217;s ESPP is a shareholder-approved plan that allows eligible employees to contribute a portion of their eligible earnings toward the semi-annual purchase of the Company&#8217;s common stock at a discounted price equal to 85% up to 90% of the fair market values of the stock on the exercise date, subject to a maximum number of shares that can be purchased during any single offering period as well as an annual maximum dollar amount of shares during any single calendar year. A maximum of 5,000,000 shares were authorized for issuance at the time the Plan was approved. For the three months ended March&#160;31, 2024, there are no shares purchased by employees.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464341530080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Matters</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laws and regulations governing the Medicare program and healthcare generally are complex and subject to interpretation. The Company believes it complies with all applicable laws and regulations and is unaware of any pending or threatened investigations involving allegations of potential wrongdoing. While no regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and exclusion from the Medicare and Medi-Cal programs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a risk-bearing organization, the Company is required to follow regulations of the Department of Managed Health Care (&#8220;DMHC&#8221;). The Company must comply with a minimum working capital requirement, tangible net equity (&#8220;TNE&#8221;) </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirement, cash-to-claims ratio, and claims payment requirements prescribed by the DMHC. TNE is defined as net assets less intangibles, less non-allowable assets (which include amounts due from affiliates), plus subordinated obligations. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the Company&#8217;s payer and provider contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services. Such differing interpretations may not come to light until a substantial period of time has passed following contract implementation. Liabilities for claims disputes are recorded when the loss is probable and can be estimated. Any adjustments to reserves are reflected in current operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standby Letters of Credit</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company established irrevocable standby letters of credit with Truist Bank for a total of $31.8 million for the benefit of CMS and certain health plans as of March&#160;31, 2024 (see Note 9 &#8212; &#8220;Credit Facility, Bank Loans, and Lines of Credit &#8212; Standby Letters of Credit&#8221;). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain IPAs consolidated by the Company established irrevocable standby letters of credit with Preferred Bank for a total of $3.9 million for the benefit of certain health plans as of March&#160;31, 2024 (see Note 9 &#8212; &#8220;Credit Facility, Bank Loans, and Lines of Credit &#8212; Standby Letters of Credit&#8221;). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of its business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company&#8217;s financial condition, cash flows, or results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability Insurance</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its insurance coverage is appropriate based upon the Company&#8217;s claims experience and the nature and risks of the Company&#8217;s business. In addition to the known incidents that have resulted in the assertion of claims, the Company cannot be certain that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against the Company, the Company&#8217;s affiliated professional organizations or the Company&#8217;s affiliated hospitalists in the future where the outcomes of such claims are unfavorable. The Company believes that the ultimate resolution of all pending claims, including liabilities in excess of the Company&#8217;s insurance coverage, will not have a material adverse effect on the Company&#8217;s financial position, results of operations, or cash flows; however, there can be no assurance that future claims will not have such a material adverse effect on the Company&#8217;s business. Contracted physicians are required to obtain their own insurance coverage.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company currently maintains liability insurance policies on a claims-made basis which are intended to cover malpractice liability and certain other claims, the coverage must be renewed annually, and may&#160;not continue to be available to the Company in future years at acceptable costs and on favorable terms.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464438100720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Transactions</a></td>
<td class="text">Related-Party Transactions<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Method Investments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, AHM recognized approximately $5.0 million in management fees from LMA. On August 31, 2023, the management service agreement between LMA&#8217;s IPA and AHM was terminated. LMA is accounted for under the equity method based on the 25% equity ownership interest held by APC in LMA&#8217;s IPA line of business (see Note 5 &#8212; &#8220;Investments in Other Entities - Equity Method&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 and 2023, APC paid approximately $0.8 million and $0.6 million, respectively, to PMIOC for provider services. APC and PMIOC have an Ancillary Service Contract together whereby PMIOC provides covered services on behalf of APC to enrollees of the plans of APC. PMIOC is accounted for under the equity method based on the 40% equity ownership interest held by APC (see Note 5 &#8212; &#8220;Investments in Other Entities &#8212; Equity Method&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 and 2023, the Company paid approximately $0.2 million and $0.2 million, respectively, to James Song, M.D., a Professional Corporation (&#8220;Song PC&#8221;) for provider services. Song PC is accounted for </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under the equity method based on the 25% equity ownership interest held by Astrana, as Astrana has the ability to exercise significant influence, but not control over, Song PC&#8217;s operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Astrana Board Members and Officers</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 and 2023, AHM recognized approximately $0.5 million and $0.5 million, respectively, in management fees from Arroyo Vista Family Health Center (&#8220;Arroyo Vista&#8221;). The Company has a managed service agreement with Arroyo Vista. Arroyo Vista&#8217;s chief executive officer is a member of the Company&#8217;s board of directors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 and 2023, the Company paid approximately $0.1 million and $64,000, respectively, to Arroyo Vista for services as a provider. The Company has provider contracts with Arroyo Vista. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 , the Company incurred rent expenses of approximately $0.9 million from certain properties that are managed by Allied Pacific Holdings Investment Management, LLC. During the three months ended March&#160;31, 2023, the Company incurred $0.9 million in rent expense from the same properties, but it was eliminated upon consolidation.  These properties were previously consolidated by Astrana until they were spun off on December 26, 2023. The chief executive officer of the real estate business managing these properties is also a member of the Company&#8217;s board of directors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024 and December&#160;31, 2023, the Company&#8217;s operating right-of-use asset balance included $12.7 million and $14.1 million, respectively, and the Company&#8217;s operating lease liabilities included $13.2 million and $14.5 million, respectively, for certain properties that are managed by Allied Pacific Holdings Investment Management, LLC.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 and 2023, the Company incurred approximately $0.6 million and $0.4 million in expenses payable to Third Way Health for call center services. One of Astrana&#8217;s officers is a board member of Third Way Health.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 and 2023, the Company paid approximately $45,000 and $0.2 million, respectively, to Sunny Village Care Center for services as a provider. The Company has provider contracts with Sunny Village Care Center. Sunny Village Care Center shares common ownership with certain Astrana board members.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, Astrana paid approximately $9.5 million to purchase Astrana&#8217;s stock from a board member. The Company did not make any similar purchases during the three months ended March&#160;31, 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024, the Company incurred rent expenses of approximately $38,000 to First Commonwealth Property, LLC for an office lease. First Commonwealth Property, LLC shares common ownership with certain board members of APC and AHM. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with Health Source MSO Inc., a California corporation (&#8220;HSMSO&#8221;), Aurion Corporation (&#8220;Aurion&#8221;), and AHMC for services provided to the Company. One of the Company&#8217;s board members is an officer of AHMC, HSMSO, and Aurion. Aurion is also partially owned by one of the Company&#8217;s board members. Revenue with AHMC and HSMSO consists of capitation, risk pool, and miscellaneous fees and expenses consisting of claims expenses, management fees, and consulting fees. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth revenue recognized and fees incurred related to AHMC, HSMSO, and Aurion for the three months ended March&#160;31, 2024 and 2023 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.138%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AHMC</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">HSMSO</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aurion</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AHMC</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">HSMSO</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aurion</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,363&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,084&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and AHMC have a risk-sharing agreement with certain AHMC hospitals to share the surplus and deficits of each of the hospital pools. Under this agreement, during the three months ended March&#160;31, 2024 and 2023, the Company has recognized risk pool revenues of $8.1 million and $13.0 million, respectively. The Company has a risk pool receivable balance of $58.8 million and $54.0 million as of March&#160;31, 2024 and December&#160;31, 2023, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">APC Board Members</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024 and 2023, the Company paid an aggregate of approximately $4.7 million and $9.4 million, respectively, to board members for provider services which included approximately $0.8 million and $0.9 million, respectively, to Astrana board members and officers who are also board members and officers of APC.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, affiliates wholly owned by the Company&#8217;s key personnel are reported in the accompanying condensed consolidated statements of income on a consolidated basis, together with the Company&#8217;s subsidiaries, and therefore, the Company does not separately disclose transactions between such affiliates and the Company&#8217;s subsidiaries as related-party transactions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intercompany Transactions</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of corporate practice of medicine laws, the Company uses designated shareholder professional corporations, of which the sole shareholder is a member of the Company&#8217;s key personnel, to engage in certain transactions and make intercompany loans from time to time.</span></div>For equity method investments, see Note 5 &#8212; &#8220;Investment in Other Entities &#8212; Equity Method&#8221;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464337441392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the liability method of accounting for income taxes as set forth in ASC 740 Income Taxes. Under the liability method, deferred taxes are determined based on differences between the financial statement and tax bases of assets and liabilities using enacted tax rates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an interim basis, the Company estimates what its anticipated annual effective tax rate will be and records a quarterly income tax provision in accordance with the estimated annual rate, plus the tax effect of certain discrete items that arise during the quarter. As the fiscal year progresses, the Company refines its estimates based on actual events and financial results during the quarter. This process can result in significant changes to the Company&#8217;s estimated effective tax rate. When this occurs, the income tax provision is adjusted during the quarter in which the estimates are refined so that the year-to-date provision reflects the estimated annual effective tax rate. These changes, along with adjustments to the Company&#8217;s deferred taxes and related valuation allowance, may create fluctuations in the overall effective tax rate from quarter to quarter.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective income tax rate for the three months ended March&#160;31, 2024 and 2023, was 29.8% and 35.7%, respectively. The tax rate for the three months ended March&#160;31, 2024, differed from the U.S. federal statutory rate primarily due to state income taxes and income from flow-through entities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, the Company does not have any unrecognized tax benefits related to various federal and state income tax matters. The Company will recognize accrued interest and penalties related to unrecognized tax benefits in income tax expense.</span></div>The Company is subject to U.S. federal income tax as well as income tax in California. The Company and its subsidiaries&#8217; state and federal income tax returns are open to audit under the statute of limitations for the years ended December 31, 2019 through December&#160;31, 2023, and for the years ended December 31, 2020 through December&#160;31, 2023, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464438517264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings Per Share<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is calculated using the weighted average number of shares of the Company&#8217;s common stock issued and outstanding during a certain period, and is calculated by dividing net income attributable to Astrana by the weighted average number of shares of the Company&#8217;s common stock issued and outstanding during such period. Diluted earnings per share is calculated using the weighted average number of shares of common stock and potentially dilutive shares of common stock outstanding during the period, using the as-if converted method for secured convertible notes and preferred stock, and the treasury stock method for options and common stock warrants.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024 and December&#160;31, 2023, APC held 7,132,698 shares of Astrana&#8217;s common stock, which are treated as treasury shares for accounting purposes and not included in the number of shares of common stock outstanding used to calculate earnings per share. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2024 and 2023, restricted stock of 118,142 and 136,932, respectively, were excluded from the computation of diluted weighted average common shares outstanding because the assumed proceeds, as calculated under the treasury stock method, resulted in these awards being antidilutive.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2024 and 2023, 973,461 and 395,472 of contingently issuable shares were excluded from the computation of diluted weighted average common shares outstanding because these conditions were not achieved as of March&#160;31, 2024 and 2023, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the earnings per share computations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; basic</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.28&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; diluted</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,260,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,555,406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; diluted</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,699,537&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,954,687&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the shares included in the diluted earnings per share computations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,260,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,555,406&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,083&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingently issuable shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,699,537&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,954,687&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464451437712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities (VIEs)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Variable Interest Entities (VIEs)</a></td>
<td class="text">Variable Interest Entities (VIEs)<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed consolidated financial statements include its subsidiaries and consolidated VIEs. A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity investment at risk lack any of the following three characteristics: decision-making rights, the obligation to absorb losses, or the right to receive the expected residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity&#8217;s economic performance and the obligation to absorb expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain state laws prohibit a professional corporation that has more than one shareholder from being a shareholder in another professional corporation. As a result, the Company cannot directly own shares in other professional corporations. However, an exception to this regulation permits a professional corporation that has only one shareholder to own shares in another professional corporation. In reliance on this exception, the Company designated certain key personnel as the nominee shareholders of professional corporations that hold controlling and non-controlling ownership interests in several medical corporations. Via a Physician Shareholder Agreement with the nominee shareholder, the Company has the ability to designate another person to be the equity holder of the professional corporation. In addition, these entities are managed by the Company&#8217;s wholly owned MSOs via MSA. In accordance with relevant accounting guidance, the professional corporations and their consolidated medical corporations are consolidated by the Company in the accompanying condensed financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to corporate practice of medicine laws, the Company operates by maintaining long-term MSAs with its affiliated IPAs and medical groups, each of which is owned and operated by physicians only, and employs or contracts with additional physicians to provide medical services. AHM is a wholly owned subsidiary of the Company and has entered into MSAs with several affiliated IPAs, including APC. APC arranges for the delivery of healthcare services by contracting with physicians or professional medical corporations for primary care and specialty care services. The physicians in the IPA are exclusively in control of, and responsible for, all aspects of the practice of medicine for enrolled patients. In accordance with relevant accounting guidance, APC has been determined to be a VIE of AHM, as AHM is its primary beneficiary with the ability, through majority representation on the APC Joint Planning Board and otherwise, to direct the activities (excluding clinical </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decisions) that most significantly affect APC&#8217;s economic performance. Therefore, APC and its wholly owned subsidiaries and VIEs are consolidated in the accompanying financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Astrana Medical and Astrana Care Partners Medical were formed in May 2019 and July 2021, respectively, as designated shareholder professional corporations. The Company&#8217;s Vice Chairman is the sole shareholder of Astrana Medical and Astrana Care Partners Medical. Via a Physician Shareholder Agreement, Astrana makes all the decisions on behalf of Astrana Medical and Astrana Care Partners Medical. Astrana has the obligation to absorb losses of, or the right to receive benefits from, Astrana Medical and Astrana Care Partners Medical. Therefore, Astrana Medical and Astrana Care Partners Medical are controlled by and consolidated by Astrana as the primary beneficiary of the VIEs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2024, a 25% equity interest of Eleanor Leung M.D. was re-acquired by the Company. As a result, Astrana Care Partners Medical now owns 100% of Eleanor Leung M.D.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes assets that can only be used to settle the liabilities of the Company&#8217;s VIEs, and to which the creditors of Astrana have no recourse, and liabilities to which the creditors of the Company&#8217;s VIEs have no recourse to the general credit of Astrana, as the primary beneficiary of the VIEs. These assets and liabilities, with the exception of investments in affiliates and amounts due to, or from, affiliates, which are eliminated upon consolidation, are included in the accompanying consolidated balance sheets (in thousands).</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,111&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,950&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes receivable, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in other entities &#8211; equity method</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliates*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in a privately held entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682,849</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537,998</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total assets</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016,960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiduciary accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount due to affiliates*</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,947</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,222</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,675&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,294&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Investment in affiliates includes the Company&#8217;s VIEs&#8217; investment in Astrana, which is reflected as treasury shares and eliminated upon consolidation. Amounts due to, or from, affiliates are receivables with Astrana&#8217;s subsidiaries. As a result, these balances are eliminated upon consolidation and are not reflected on Astrana&#8217;s condensed consolidated balance sheets  as of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2024, and December&#160;31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464333812912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating and finance leases for corporate offices, physicians&#8217; offices, and certain equipment. These leases have remaining lease terms of four months to seventeen years. Some of the leases may include options to extend the lease terms for up to ten years, and some of the leases may include options to terminate the leases within one year. As of March&#160;31, 2024, and December&#160;31, 2023, assets recorded under finance leases were $1.7&#160;million and $1.7 million, respectively, and accumulated depreciation associated with finance leases was $1.8&#160;million and $1.6 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the balance sheets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows (dollars in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,751&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(248)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,136&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,679&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.39 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.64 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.96 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.22 years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are future minimum lease payments under non-cancellable leases for the years ending December 31 (in thousands) below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (excluding the three months ended March 31, 2024)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,558&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,723&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,651&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,716&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating and finance leases for corporate offices, physicians&#8217; offices, and certain equipment. These leases have remaining lease terms of four months to seventeen years. Some of the leases may include options to extend the lease terms for up to ten years, and some of the leases may include options to terminate the leases within one year. As of March&#160;31, 2024, and December&#160;31, 2023, assets recorded under finance leases were $1.7&#160;million and $1.7 million, respectively, and accumulated depreciation associated with finance leases was $1.8&#160;million and $1.6 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the balance sheets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows (dollars in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,751&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(248)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,136&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,679&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.39 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.64 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.96 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.22 years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are future minimum lease payments under non-cancellable leases for the years ending December 31 (in thousands) below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (excluding the three months ended March 31, 2024)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,558&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,723&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,651&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,716&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464335622576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segments</a></td>
<td class="text">Segments<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the performance of its operating segments based on segment revenue growth as well as operating income.  Management uses revenue growth and total segment operating income as a measure of the performance of operating businesses separate from non-operating factors. The Company&#8217;s operations are based in the United States. All revenues of the Company are derived from the United States. The Company&#8217;s segments are not evaluated using asset information.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, our reportable segments enter into transactions with each other. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues recognized by a segment and expenses incurred by the counterparty are eliminated in consolidation and do not affect consolidated results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate costs are unallocated and primarily include corporate initiatives, corporate infrastructure costs and corporate shared costs, such as finance, human resources, legal, and executives.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts disclosed in prior period have been recast to conform to the current period presentation. Specifically, reclassifications were made between cost of services and general and administrative expenses in the accompanying segment table for the three months ended March 31, 2023. The following table presents information about our segments (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Care Partners</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Care Delivery</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Care Enablement</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intersegment Elimination</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Third-Party</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">382,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,878&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404,356&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intersegment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(56,732)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">397,095&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,719&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(56,732)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404,356&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,734)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,075)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353,899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,770&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(56,809)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,196&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(238)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,504&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,400)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Care Partners</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Care Delivery</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Care Enablement</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intersegment Elimination</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate Costs</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Third-Party</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314,637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">337,244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intersegment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33,598)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314,653&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,383&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,566&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33,598)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">337,244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,302)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">289,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,009&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,460)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">292,332&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,820&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">723&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34,762)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,321&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(966)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,746&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(483)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,164&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,409)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,373&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Balance includes general and administrative expenses and depreciation and amortization. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span> Income from operations for the intersegment elimination represents rental income from segments renting from other segments. Rental income is presented within other income which is not presented in the table.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//280/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464333695216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements of Financial Instruments</a></td>
<td class="text">Fair Value Measurements of Financial Instruments<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of March&#160;31, 2024, are presented below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market accounts*</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate collar</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,294&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,732&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AAMG contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VOMG contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DMG remaining equity interest purchase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sun Labs remaining equity interest purchase</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADSC contingent considerations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CFC contingent considerations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PCCCV contingent considerations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,908&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,908&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Included in cash and cash equivalents</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of December&#160;31, 2023, are presented below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market accounts*</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,340&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,340&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AAMG contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VOMG contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DMG remaining equity interest purchase</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sun Labs remaining equity interest purchase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate collar</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,836&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,088&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Included in cash and cash equivalents</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the fair value of Level 3 liabilities for the three months ended March&#160;31, 2024, was as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.444%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,836&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of existing Level 3 liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,908&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Marketable Securities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit are reported at par value, plus accrued interest, with maturity dates greater than ninety days. As of March&#160;31, 2024, and December&#160;31, 2023, certificates of deposit amounted to approximately $2.3 million and $2.2&#160;million, respectively. Investments in certificates of deposit are classified as Level 1 investments in the fair value hierarchy.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities are reported at fair value. These securities are classified as Level 1 in the valuation hierarchy, where quoted market prices from reputable third-party brokers are available in an active market and unadjusted. As of March&#160;31, 2024, and December&#160;31, 2023, the equity securities were approximately $0.2 million and $0.3&#160;million, respectively, in the accompanying condensed consolidated balance sheets. Gains and losses recognized on equity securities sold are recognized in the accompanying condensed consolidated statements of income as other income. The components comprising total gains and losses on equity securities are as follows (in thousands) for the periods listed below:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Total losses recognized on equity securities  </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,353)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Gains recognized on equity securities sold  </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Unrealized losses recognized on equity securities held at end of period  </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,353)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Derivative Financial Instruments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Collar Agreements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s collar agreement is designed to limit the interest rate risk associated with the Company&#8217;s Revolver Loan. The principal objective of the collar agreement is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#8217;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. Refer to Note 9 - &#8220;Credit Facility, Bank Loans, and Lines of Credit,&#8221; for further information on the Company&#8217;s debt. Under the terms of the agreement, the ceiling is 5.0% and the floor is 2.34%.  The collar agreement is not designated as a hedging instrument. Changes in the fair value of this contract are recognized as unrealized gain or loss on investments in the accompanying condensed consolidated statements of income and reflected in the accompanying condensed consolidated statements of cash flows as unrealized loss on investments. The estimated fair value of the collar was determined using Level 2.  As of March&#160;31, 2024 and December&#160;31, 2023, the fair value of the collar was $0.4&#160;million and $0.3 million, and presented within other assets and other long-term liabilities, respectively, in the accompanying condensed consolidated balance sheets. For the three months ended March&#160;31, 2024, the Company recognized unrealized gains of $0.7 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Remaining equity interest purchase</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the Company entered into a financing obligation to purchase the remaining equity interest in Diagnostic Medical Group of Southern California (&#8220;DMG&#8221;) and Sun Clinical Laboratories (&#8220;Sun Labs&#8221;) within three years from the date the Company consolidated DMG and Sun Labs. The purchase of the remaining DMG equity value is considered a financing obligation with a carrying value of $8.5&#160;million as of March&#160;31, 2024 and December&#160;31, 2023. Changes in the fair value of the remaining equity purchase are presented in unrealized gain and loss on investments in the accompanying condensed consolidated statements of income. The purchase of the remaining Sun Labs equity value is considered a financing obligation with a carrying value of $7.3 million and $7.8 million as of March&#160;31, 2024 and December&#160;31, 2023, respectively. For the three months ended March&#160;31, 2024, and 2023, the Company recognized an unrealized gain of $0.5 million and unrealized loss of $1.4 million, respectively, due to the change in the fair value of Sun Labs equity value obligation. As the financing obligations </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are embedded in the non-controlling interest, the non-controlling interests are recognized in other liabilities in the accompanying condensed consolidated balance sheets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent considerations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">All American Medical Group</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AAMG&#8221;)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon acquiring 100% of the equity interest in AAMG, the purchase price consisted of cash funded upon close of the transaction and additional consideration (&#8220;AAMG contingent consideration&#8221;) and stock consideration (&#8220;AAMG stock contingent consideration&#8221;) contingent on AAMG meeting revenue and capitated member metrics for fiscal years 2023  (&#8220;2023 metric&#8221;) and 2024 (&#8220;2024 metric&#8221;). If the contingent considerations are met, the settlement will be paid in the Company&#8217;s common stock. The total amount of stock that can be issued for the 2023 and 2024 metrics is 157,048 and 184,361, respectively. The Company determined the fair value of the contingent considerations using a probability-weighted model that includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of revenue and assigned probabilities to each such scenario in determining fair value. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024 and December&#160;31, 2023, the AAMG contingent consideration for the 2023 metric was valued at $3.5&#160;million and $2.6&#160;million, respectively, and was included within other liabilities in the accompanying condensed consolidated balance sheets. The 2023 metric was met, but remains in other liabilities until the shares are issued.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The AAMG contingent consideration for the 2024 metric was valued at $3.9&#160;million and $2.9&#160;million as of March&#160;31, 2024 and December&#160;31, 2023, respectively, and was included in other liabilities and other long-term liabilities in the accompanying condensed consolidated balance sheets, respectively. Changes in the AAMG contingent consideration are presented in general and administrative expenses in the accompanying condensed consolidated statements of income. The AAMG stock contingent consideration for 2023 and 2024 metric was valued at $5.6&#160;million as of March&#160;31, 2024 and December&#160;31, 2023 and is included in additional paid-in capital in the accompanying condensed consolidated balance sheets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADSC</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon acquiring 95% of the equity interest of Advanced Diagnostic and Surgical Center in 2024, the total consideration of the acquisition included contingent considerations. The contingent considerations will be settled in cash contingent on ADSC achieving revenue and EBITDA metrics for fiscal years 2023 (&#8220;ADSC 2023 Metric&#8221;) and 2024 (&#8220;ADSC 2024 Metric&#8221;) (collectively, &#8220;ADSC contingent considerations&#8221;). The Company determined the fair value of the contingent consideration using a probability-weighted model that includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of revenue and assigned probabilities to each such scenario in determining fair value. As of March&#160;31, 2024, the ADSC 2023 Metric and the 2024 Metric were valued at $2.0&#160;million and $1.6&#160;million, respectively and were included in other liabilities in the accompanying condensed consolidated balance sheets. Changes in the ADSC contingent considerations are presented in general and administrative expenses in the accompanying condensed consolidated statements of income.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CFC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon acquiring certain assets of CFC in 2024, the total consideration of the acquisition included contingent considerations. The contingent considerations will be settled in cash contingent upon CFC maintaining or exceeding the target member month amount for the first, second and third measurement period (&#8220;CFC contingent considerations&#8221;). The contingent liability will be paid after achieving the metric in each measurement period. The Company will pay $5.0&#160;million for each metric achieved for each measurement period or a total of $15.0&#160;million. In the event that the CFC first and/or second contingent considerations are not achieved during the first and/or the second measurement period, if the metric is met within the second and/or third measurement period, there is a catch-up payment that shall be paid concurrently with the payments of the CFC second contingent consideration and/or CFC third contingent consideration. The Company determined the fair value of the contingent consideration using a probability-weighted model that includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of revenue and assigned probabilities to each such scenario in determining fair value. As of March&#160;31, 2024, the first, second, and third metric were valued at $3.1&#160;million, $2.8&#160;million and $1.9&#160;million, respectively, and were all included in other long-term liabilities in the accompanying condensed consolidated balance sheets. Changes in the CFC contingent considerations are presented in general and administrative expenses in the accompanying condensed consolidated statements of income.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PCCCV</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon acquiring certain assets of PCCCV in 2024, the total consideration of the acquisition included contingent considerations. The contingent considerations will be settled in cash contingent upon PCCCV meeting certain metrics related to financial ratios and member months for the first and second measurement periods (&#8220;PCCCV contingent considerations&#8221;). The Company determined the fair value of the contingent considerations using a probability-weighted model that includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of revenue and assigned probabilities to each such scenario in determining fair value. As of March&#160;31, 2024, the value of the contingent consideration was valued at $2.3&#160;million. Changes in the PCCCV contingent considerations are presented in general and administrative expenses in the accompanying condensed consolidated statements of income.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464333503680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">I Health Promissory Note Payable</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2024, the Company received $8.3&#160;million as a promissory note with a maturity date of March 31, 2027. I Health may accelerate the maturity date if the Company does not exercise the call options (see Note 5 &#8212; &#8220;Investments in Other Entities - Equity Method&#8221;) The promissory note has an interest rate of 4.30% per annum on the principal amount. Accrued interest is payable on each anniversary of  the promissory note payable. I Health is accounted for under the equity method based on the 25% equity ownership interest held by the Company (see Note 5 &#8212; &#8220;Investments in Other Entities - Equity Method&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Elimination of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 24, 2024, the Company filed a Certificate of Elimination to its Restated Certificate of Incorporation with the Secretary of State of the State of Delaware, eliminating from the Certificate of Incorporation all matters set forth in the Amended and Restated Certificate of Designation with respect to the Company&#8217;s Series A Convertible Preferred Stock and Series B Convertible Preferred Stock and returning each of the Series A Preferred Stock and Series B Preferred Stock to the status of authorized and unissued shares of preferred stock of the Company, without designation as to series. There were no outstanding shares of the Series A Preferred Stock or Series B Preferred Stock as of April 24, 2024.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Drawdown on Revolver Loan</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to March&#160;31, 2024, the Company drew down $52.0&#160;million on its Revolver Loan.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464333712928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">$ 14,835<span></span>
</td>
<td class="nump">$ 13,132<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464339839392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464342190848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div>The accompanying condensed consolidated balance sheet at December&#160;31, 2023, has been derived from the Company&#8217;s audited condensed consolidated financial statements, but does not include all annual disclosures required by generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). The accompanying unaudited condensed consolidated financial statements as of March&#160;31, 2024, and for the three months ended March&#160;31, 2024 and 2023, have been prepared in accordance with U.S. GAAP for interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited condensed consolidated financial statements and related notes to the financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2023, as filed with the SEC on February&#160;29, 2024. In the opinion of management, all material adjustments (consisting of normal recurring adjustments as well as intercompany accounts and transactions, which have been eliminated) considered necessary for a fair presentation have been made to make the condensed consolidated financial statements not misleading, as required by Regulation S-X, Rule 10-01.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheets as of March&#160;31, 2024 and December&#160;31, 2023, and the condensed consolidated statements of income for the three months ended March&#160;31, 2024 and 2023, include Astrana&#8217;s wholly owned subsidiaries and consolidated variable interest entities (&#8220;VIEs&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read or have access to our audited condensed consolidated financial statements for the fiscal year ended December&#160;31, 2023.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred but not reported (&#8220;IBNR&#8221;) claims), determination of hospital shared-risk and health plan shared-risk revenue and receivables (including constraints, completion factors and historical margins), income tax-valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition-related costs separately from the business combination.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Reportable Segments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reportable Segments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, the Company operates in three reportable segments:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Care Partners;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Care Delivery; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Care Enablement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 1 &#8212; &#8220;Description of Business&#8221; and Note 18 &#8212; &#8220;Segments&#8221; to the condensed consolidated financial statements for information on the Company&#8217;s segments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within ninety days from their date of purchase to be cash equivalents.</span></div>The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company believes it is not exposed to any significant credit risk with respect to its cash and cash equivalents and restricted cash.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_ReceivablesReceivablesRelatedPartiesOtherReceivablesAndLoanReceivablesPolicyTextBlock', window );">Receivables, Receivables &#8211; Related Parties, Other Receivables and Loan Receivables</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables, Receivables &#8211; Related Parties, Other Receivables and Loan Receivables</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements, incentive receivables, management fee income, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables &#8211; related parties are comprised of risk pool settlements, management fee income, and other receivables. Receivables &#8211; related parties are recorded and stated at the amount expected to be collected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s loan receivables consists of promissory notes that accrue interest per annum. As of March&#160;31, 2024, promissory notes are expected to be collected by their maturity dates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation and claims receivables relate to each health plan&#8217;s capitation and are received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#8217;s hospital shared-risk pool receivable, which is recorded quarterly based on reports received from the Company&#8217;s hospital partners and management&#8217;s estimate of the Company&#8217;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consist of receivables from fee-for-service (&#8220;FFS&#8221;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop-loss insurance premium reimbursements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains reserves for potential credit losses on the receivables. Management reviews the composition of the Company&#8217;s receivables and analyzes historical bad debts, customer concentrations, customer creditworthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis. </span></div>Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regard to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (&#8220;CECL&#8221;) model.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risks</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risks</span></div>The Company disaggregates revenue from contracts by service type and payer type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The condensed consolidated statements of income present disaggregated revenue by service type.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives payments from the following sources for services rendered:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Commercial insurers;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Federal government under the Medicare program administered by CMS;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">State governments under Medicaid and other programs;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Other third-party payers (e.g., hospitals and IPAs); and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Individual patients and clients.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue primarily consists of the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Capitation revenue;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk pool settlements and incentives;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Management fee revenue; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FFS revenue.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk Pool Settlements and Incentives</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Shared Savings Program Revenue</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2024, Astrana participates in MSSP. The MSSP has multiple risk tracks, and Astrana is currently participating in the ENHANCED risk track. Under the MSSP Model, Astrana recruits a group of Participant and Preferred (in-network) Providers. Based on the Participant Providers that join our ACO, CMS grants us a pool of Traditional Medicare patients (beneficiaries) to manage (the &#8220;MSSP Aligned Beneficiaries&#8221;). The Company&#8217;s MSSP Aligned Beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. CMS continues to pay participant and preferred providers on a fee-for-service basis for Medicare-covered services provided to MSSP Aligned Beneficiaries. The Company continues to bear risk on all Medicare expenditures (both in-network and out-of-network), excluding drug expenditures covered by Medicare Part D, based on a budgetary benchmark established with CMS. Astrana&#8217;s shared savings or losses in managing the Company&#8217;s beneficiaries are generally determined on an annual basis after reconciliation with CMS. Pursuant to Astrana&#8217;s risk-share agreement with CMS, the Company is eligible to receive the surplus (&#8220;shared savings&#8221;) or is liable for the deficit (&#8220;shared losses&#8221;) according to the budgetary benchmark established by CMS based on Astrana&#8217;s efficiency, or lack thereof, in managing the expenditures associated with the Company&#8217;s MSSP Aligned Beneficiaries. The Company estimates the shared service revenue by analyzing the activities during the relevant time period in contemplation of the agreed upon benchmarks, metrics, performance criteria, and attribution criteria based on those and any other contractually defined factors. Revenue is not recorded and is constrained until the shared service revenue can be reasonably estimated by the Company and to the extent that it is probable that a significant reversal will not occur once any uncertainty associated with the variable consideration is subsequently resolved.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted for both items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the condensed consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-07 "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures," which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for the Company&#8217;s annual periods beginning January 1, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on its financial statement disclosures.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for the Company&#8217;s annual periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on its financial statement disclosures.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Derivative Financial Instruments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Collar Agreements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s collar agreement is designed to limit the interest rate risk associated with the Company&#8217;s Revolver Loan. The principal objective of the collar agreement is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#8217;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. Refer to Note 9 - &#8220;Credit Facility, Bank Loans, and Lines of Credit,&#8221; for further information on the Company&#8217;s debt. Under the terms of the agreement, the ceiling is 5.0% and the floor is 2.34%.  The collar agreement is not designated as a hedging instrument. Changes in the fair value of this contract are recognized as unrealized gain or loss on investments in the accompanying condensed consolidated statements of income and reflected in the accompanying condensed consolidated statements of cash flows as unrealized loss on investments. The estimated fair value of the collar was determined using Level 2.  As of March&#160;31, 2024 and December&#160;31, 2023, the fair value of the collar was $0.4&#160;million and $0.3 million, and presented within other assets and other long-term liabilities, respectively, in the accompanying condensed consolidated balance sheets. For the three months ended March&#160;31, 2024, the Company recognized unrealized gains of $0.7 million.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Investments in Marketable Securities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Marketable Securities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit are reported at par value, plus accrued interest, with maturity dates greater than ninety days. As of March&#160;31, 2024, and December&#160;31, 2023, certificates of deposit amounted to approximately $2.3 million and $2.2&#160;million, respectively. Investments in certificates of deposit are classified as Level 1 investments in the fair value hierarchy.</span></div>Equity securities are reported at fair value. These securities are classified as Level 1 in the valuation hierarchy, where quoted market prices from reputable third-party brokers are available in an active market and unadjusted.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_ReceivablesReceivablesRelatedPartiesOtherReceivablesAndLoanReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Receivables and receivables from related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_ReceivablesReceivablesRelatedPartiesOtherReceivablesAndLoanReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479515/805-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464422580912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregated Revenue by Each Payor Type</a></td>
<td class="text">The following table presents disaggregated revenue generated by payer type for the three months ended March&#160;31, 2024 and 2023 (in thousands):<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other third parties</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404,356&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,244&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Schedule of Contributions to Revenue and Receivables by Payor</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payers that contributed the following percentages of net revenue:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payer A</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payer B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> *Less than 10% of total net revenues</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payers that contributed to the following percentages of receivables and receivables &#8211; related parties:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payer A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payer C</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464333801920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations, Asset Acquisitions, and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions, by Acquisition</a></td>
<td class="text">The following table summarizes the preliminary purchase price allocation of the fair value of assets acquired and liabilities assumed  related to each acquisition at the acquisition date (in thousands):<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.257%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CFC</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;AHMS </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Others *</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net &#160;Total </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Total purchase consideration: </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Cash paid </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Cash payable </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Contingent consideration </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Common stock issued </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">120,214</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63,935</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,397</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">202,546</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Cash and cash equivalents </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Investment in marketable securities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Receivables </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Prepaid expenses and other current assets </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts due from affiliates</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Land, property and equipment </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Intangible assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Goodwill </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Restricted cash </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable assets acquired</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,132&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,809&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,400&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,341&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Accounts payable and accrued expenses </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Medical liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,645&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts due to affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Income taxes payable </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Deferred tax liability </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Noncontrolling interest </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identified liabilities assumed</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,918&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,874&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total net identifiable assets acquired </span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">120,214</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63,935</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,397</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">202,546</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Others consist of estimated fair values of the assets acquired, net of cash acquired, related to ADSC and PCCCV.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>Following the acquisition dates of CFC, AHMS, ADSC and PCCCV, the operating results have been included in our consolidated financial statements. For the period from the acquisition dates through March&#160;31, 2024, total revenues and net income were $33.2 million and $5.1 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Pro Forma Financial Information</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pro forma financial information in the table below presents the combined results of the Company and CFC, AHMS, ADSC and PCCCV as if the acquisitions had occurred on January 1, 2023. The pro forma information presented is shown for illustrative purposes only and is not necessarily indicative of future results of operations of the Company or results of operations of the Company that would have actually occurred had the transactions been in effect for the periods presented.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except per share amounts)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493,006&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,462&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - basic</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Change in Carrying Value of Goodwill</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying value of goodwill for the three months ended March&#160;31, 2024 was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:81.330%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,831&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(906)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410,267&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464333135760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets, Net</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2024, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.449%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net March 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized intangible assets:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Network relationships</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-21</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,137)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,002)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Member relationships</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7-14</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,154)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient management platform</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,060)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tradename/trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developed technology </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,419&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,712)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,707&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.449%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Network relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-21</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104,859)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,662)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-14</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,345)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient management platform</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,060)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tradename/trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(308)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,916&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131,268)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,648&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Future Amortization Expense</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense is estimated to be as follows for the following years ending December&#160;31 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.444%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (excluding the three months ended March 31, 2024)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,657&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464337488432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Schedule of Equity Method Investments</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2024 and 2023, the Company&#8217;s equity method investment balance consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:23.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.734%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.349%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Ownership</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Initial Investment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allocation of Net Income </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Distribution </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LaSalle Medical Associates &#8211; IPA line of business</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pacific Medical Imaging &amp; Oncology Center, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAIPA MSO, LLC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other *</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,774&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,487&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,893&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:23.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.350%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Ownership</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Initial Investment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allocation of Net Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Distribution </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LaSalle Medical Associates &#8211; IPA line of business</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,849&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pacific Medical Imaging &amp; Oncology Center, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531 W. College, LLC **</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One MSO, LLC **</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAIPA MSO, LLC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other *</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,299&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,484&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Other consists of smaller equity method investments. </span></div>** Investment were solely for the benefit of APC and its shareholders.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464337635152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts payable and accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other accruals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,075&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitation payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subcontractor IPA payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due to related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other provider payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,473&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,949&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464455992368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Schedule of Medical Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s medical liabilities consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,657&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired (see Note 3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,645&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,419)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,950)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,818&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,763&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136,286)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136,743)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97,837)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,736)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234,123)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198,479)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(503)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,494&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,396&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464337465072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility, Bank Loans, and Lines of Credit (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock', window );">Schedule of Credit Facility</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s debt balance consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:63.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.471%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolver Loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Promissory Note Payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393,259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,750)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,061)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,561)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368,448&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,939&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Commitments of Credit Facility</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the future commitments of the Company&#8217;s debt for the years ending December 31 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:81.330%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (excluding the three months ended March 31, 2024)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393,259&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464335830064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Share-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock-based compensation expense recognized under all of the Company&#8217;s stock plans for the three months ended March&#160;31, 2024 and 2023, and associated with the issuance of restricted shares of common stock and vesting of stock options that are included in general and administrative expenses in the accompanying condensed consolidated statements of income (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,748&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,445&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Transactions Under Stock Option Plans</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding stock options consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding at January&#160;1, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504,241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.03&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,271)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.61</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459,140&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.04&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.41</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464333859360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Fees Incurred and Revenue Earned from Related Party Transactions</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth revenue recognized and fees incurred related to AHMC, HSMSO, and Aurion for the three months ended March&#160;31, 2024 and 2023 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.138%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AHMC</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">HSMSO</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aurion</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AHMC</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">HSMSO</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aurion</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,363&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,084&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464333730144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share Computations</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the earnings per share computations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; basic</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.28&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; diluted</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,260,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,555,406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; diluted</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,699,537&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,954,687&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of Shares Included in the Diluted Earnings Per Share Computations</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the shares included in the diluted earnings per share computations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,260,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,555,406&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,083&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingently issuable shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,699,537&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,954,687&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464333751872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities (VIEs) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock', window );">Schedule of Assets and Liabilities, Variable Interest Entities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes assets that can only be used to settle the liabilities of the Company&#8217;s VIEs, and to which the creditors of Astrana have no recourse, and liabilities to which the creditors of the Company&#8217;s VIEs have no recourse to the general credit of Astrana, as the primary beneficiary of the VIEs. These assets and liabilities, with the exception of investments in affiliates and amounts due to, or from, affiliates, which are eliminated upon consolidation, are included in the accompanying consolidated balance sheets (in thousands).</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,111&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,950&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes receivable, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in other entities &#8211; equity method</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliates*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in a privately held entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682,849</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537,998</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total assets</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016,960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiduciary accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount due to affiliates*</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,947</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,222</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,675&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,294&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Investment in affiliates includes the Company&#8217;s VIEs&#8217; investment in Astrana, which is reflected as treasury shares and eliminated upon consolidation. Amounts due to, or from, affiliates are receivables with Astrana&#8217;s subsidiaries. As a result, these balances are eliminated upon consolidation and are not reflected on Astrana&#8217;s condensed consolidated balance sheets  as of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2024, and December&#160;31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-5A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-9<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfVariableInterestEntitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464333712400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Information Related to Lease Costs</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows (dollars in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,751&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(248)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,136&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,679&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.39 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.64 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.96 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.22 years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Operating Lease Payments Under Non-cancelable Leases</a></td>
<td class="text"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are future minimum lease payments under non-cancellable leases for the years ending December 31 (in thousands) below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (excluding the three months ended March 31, 2024)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,558&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,723&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,651&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,716&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Finance Lease Payments Under Non-cancelable Leases</a></td>
<td class="text"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are future minimum lease payments under non-cancellable leases for the years ending December 31 (in thousands) below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (excluding the three months ended March 31, 2024)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,558&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,723&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,651&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,716&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464334755712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Information about our Segments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts disclosed in prior period have been recast to conform to the current period presentation. Specifically, reclassifications were made between cost of services and general and administrative expenses in the accompanying segment table for the three months ended March 31, 2023. The following table presents information about our segments (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Care Partners</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Care Delivery</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Care Enablement</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intersegment Elimination</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Third-Party</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">382,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,878&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404,356&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intersegment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(56,732)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">397,095&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,719&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(56,732)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404,356&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,734)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,075)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353,899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,770&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(56,809)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,196&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(238)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,504&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,400)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Care Partners</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Care Delivery</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Care Enablement</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intersegment Elimination</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate Costs</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Third-Party</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314,637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">337,244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intersegment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33,598)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314,653&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,383&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,566&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33,598)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">337,244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,302)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">289,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,009&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,460)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">292,332&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,820&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">723&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34,762)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,321&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(966)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,746&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(483)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,164&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,409)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,373&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Balance includes general and administrative expenses and depreciation and amortization. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span> Income from operations for the intersegment elimination represents rental income from segments renting from other segments. Rental income is presented within other income which is not presented in the table.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464333789648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Carrying Amounts and Fair Values of Financial Instruments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of March&#160;31, 2024, are presented below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market accounts*</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate collar</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,294&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,732&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AAMG contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VOMG contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DMG remaining equity interest purchase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sun Labs remaining equity interest purchase</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADSC contingent considerations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CFC contingent considerations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PCCCV contingent considerations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,908&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,908&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Included in cash and cash equivalents</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of December&#160;31, 2023, are presented below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market accounts*</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,340&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,340&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AAMG contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VOMG contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DMG remaining equity interest purchase</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sun Labs remaining equity interest purchase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate collar</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,836&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,088&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Included in cash and cash equivalents</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Change in Fair Value of Level 3 Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the fair value of Level 3 liabilities for the three months ended March&#160;31, 2024, was as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.444%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,836&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of existing Level 3 liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,908&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsTextBlock', window );">Schedule of Gain (Loss) on Equity Securities</a></td>
<td class="text">The components comprising total gains and losses on equity securities are as follows (in thousands) for the periods listed below:<div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Total losses recognized on equity securities  </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,353)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Gains recognized on equity securities sold  </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Unrealized losses recognized on equity securities held at end of period  </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,353)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2C<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2C<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized and unrealized gain (loss) on investment in security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464435562128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464333581392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Amount deposit accounts exceeded FDIC insured limit | $</a></td>
<td class="nump">$ 353.6<span></span>
</td>
<td class="nump">$ 318.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear', window );">Risk pool surplus or deficits, settlement period after risk pool performance year</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risk Pool Surplus Or Deficits, Settlement Period After Performance Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464437250016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Disaggregated Revenue by Each Payer Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 404,356<span></span>
</td>
<td class="nump">$ 337,244<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=asth_CommercialMember', window );">Commercial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">49,512<span></span>
</td>
<td class="nump">40,019<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=asth_MedicareMember', window );">Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">246,564<span></span>
</td>
<td class="nump">216,310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=asth_MedicaidMember', window );">Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">81,263<span></span>
</td>
<td class="nump">67,339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=asth_OtherThirdPartiesMember', window );">Other third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 27,017<span></span>
</td>
<td class="nump">$ 13,576<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=asth_CommercialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=asth_CommercialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=asth_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=asth_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=asth_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=asth_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=asth_OtherThirdPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=asth_OtherThirdPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464335340192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Contributions to Revenue and Receivables by Payer (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Revenue | Payer A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">41.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Revenue | Payer B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">13.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Receivables and Receivables-Related Parties | Payer A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Receivables and Receivables-Related Parties | Payer C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_AccountsReceivableAndNetRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_AccountsReceivableAndNetRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=asth_PayorAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=asth_PayorAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=asth_PayorBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=asth_PayorBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=asth_PayerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=asth_PayerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464339911184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations, Asset Acquisitions, and Goodwill - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 29, 2024</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Revenue since acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual', window );">Net income since acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=asth_AdvancedHealthManagementSystemsLPMember', window );">AHMS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">$ 63,935,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=asth_PrimeCommunityCareOfCentralValleyIncMember', window );">Prime Community Care of Central Valley, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_ContingentConsideration', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=asth_CommunityFamilyCareMedicalGroupIPAInc.Member', window );">Community Family Care Medical Group IPA, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,214,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_ContingentConsideration', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_ConsiderationOfAcquisitionInCashFunded', window );">Consideration of acquisition in cash funded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessAcquisitionOfCommonStock', window );">Business acquisition of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Equity interest issued, number of shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">631,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=asth_AdvancedDiagnosticAndSurgicalCenterIncMember', window );">Advanced Diagnostic and Surgical Center, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Value of the contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_BusinessAcquisitionOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_BusinessAcquisitionOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_ConsiderationOfAcquisitionInCashFunded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consideration of Acquisition in Cash Funded</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_ConsiderationOfAcquisitionInCashFunded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_ContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_ContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=asth_AdvancedHealthManagementSystemsLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=asth_AdvancedHealthManagementSystemsLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=asth_PrimeCommunityCareOfCentralValleyIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=asth_PrimeCommunityCareOfCentralValleyIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=asth_CommunityFamilyCareMedicalGroupIPAInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=asth_CommunityFamilyCareMedicalGroupIPAInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=asth_AdvancedDiagnosticAndSurgicalCenterIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=asth_AdvancedDiagnosticAndSurgicalCenterIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464340375136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations, Asset Acquisitions, and Goodwill - Summary of Purchase Price Allocation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 410,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 410,267<span></span>
</td>
<td class="nump">$ 278,831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=asth_CommunityFamilyCareMedicalGroupIPAInc.Member', window );">CFC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_TotalPurchaseConsiderationAbstract', window );"><strong>Total purchase consideration:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_PaymentsToAcquireBusinessCashPayable', window );">Cash payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities', window );">Investment in marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates', window );">Amounts due from affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Land, property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total identifiable assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses', window );">Accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities', window );">Medical liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates', window );">Amounts due to affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest', window );">Noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total identified liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total net identifiable assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=asth_AdvancedHealthManagementSystemsLPMember', window );">AHMS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_TotalPurchaseConsiderationAbstract', window );"><strong>Total purchase consideration:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_PaymentsToAcquireBusinessCashPayable', window );">Cash payable</a></td>
<td class="nump">63,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Common stock issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">63,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">33,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities', window );">Investment in marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Receivables</a></td>
<td class="nump">11,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates', window );">Amounts due from affiliates</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Land, property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="nump">23,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">29,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash', window );">Restricted cash</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total identifiable assets acquired</a></td>
<td class="nump">99,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">7,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities', window );">Medical liabilities</a></td>
<td class="nump">13,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates', window );">Amounts due to affiliates</a></td>
<td class="nump">7,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="nump">1,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="nump">6,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest', window );">Noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total identified liabilities assumed</a></td>
<td class="nump">35,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total net identifiable assets acquired</a></td>
<td class="nump">63,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=asth_OtherAcquisitionsMember', window );">Other Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_TotalPurchaseConsiderationAbstract', window );"><strong>Total purchase consideration:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid</a></td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_PaymentsToAcquireBusinessCashPayable', window );">Cash payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Contingent consideration</a></td>
<td class="nump">5,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Common stock issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">18,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">3,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities', window );">Investment in marketable securities</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates', window );">Amounts due from affiliates</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Land, property and equipment</a></td>
<td class="nump">823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="nump">2,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">12,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total identifiable assets acquired</a></td>
<td class="nump">19,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities', window );">Medical liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates', window );">Amounts due to affiliates</a></td>
<td class="nump">54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="nump">271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest', window );">Noncontrolling interest</a></td>
<td class="nump">428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total identified liabilities assumed</a></td>
<td class="nump">1,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total net identifiable assets acquired</a></td>
<td class="nump">18,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=asth_TotalAcquisitionsMember', window );">Total Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_TotalPurchaseConsiderationAbstract', window );"><strong>Total purchase consideration:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_PaymentsToAcquireBusinessCashPayable', window );">Cash payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">54,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities', window );">Investment in marketable securities</a></td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Receivables</a></td>
<td class="nump">17,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates', window );">Amounts due from affiliates</a></td>
<td class="nump">3,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Land, property and equipment</a></td>
<td class="nump">823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="nump">52,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">132,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash', window );">Restricted cash</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total identifiable assets acquired</a></td>
<td class="nump">261,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">11,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities', window );">Medical liabilities</a></td>
<td class="nump">30,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates', window );">Amounts due to affiliates</a></td>
<td class="nump">7,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="nump">1,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="nump">6,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest', window );">Noncontrolling interest</a></td>
<td class="nump">428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total identified liabilities assumed</a></td>
<td class="nump">58,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total net identifiable assets acquired</a></td>
<td class="nump">$ 202,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 202,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Amounts Due From Affiliates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Restricted Cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities, Accounts Payable And Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities, Amounts Due To Affiliates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities, Income Taxes Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities, Medical Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities, Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_PaymentsToAcquireBusinessCashPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to Acquire Business, Cash Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_PaymentsToAcquireBusinessCashPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_TotalPurchaseConsiderationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Purchase Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_TotalPurchaseConsiderationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-5<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=asth_CommunityFamilyCareMedicalGroupIPAInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=asth_CommunityFamilyCareMedicalGroupIPAInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=asth_AdvancedHealthManagementSystemsLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=asth_AdvancedHealthManagementSystemsLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=asth_OtherAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=asth_OtherAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=asth_TotalAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=asth_TotalAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464340339824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations, Asset Acquisitions, and Goodwill - Schedule of Business Acquisition, Pro Forma Information, Nonrecurring Adjustments (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Business Acquisition, Pro Forma Revenue</a></td>
<td class="nump">$ 493,006<span></span>
</td>
<td class="nump">$ 382,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Business Acquisition, Pro Forma Net Income (Loss)</a></td>
<td class="nump">$ 16,661<span></span>
</td>
<td class="nump">$ 20,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic', window );">Net income per share - basic (in dollars per share)</a></td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="nump">$ 0.44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted', window );">Net income per share - diluted (in dollars per share)</a></td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="nump">$ 0.43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464338174336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations, Asset Acquisitions, and Goodwill - Schedule of Goodwill (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 278,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions</a></td>
<td class="nump">132,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Adjustments</a></td>
<td class="num">(906)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 410,267<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 16<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479405/805-10-25-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464431035456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets, Net - Schedule of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (135,712)<span></span>
</td>
<td class="num">$ (131,268)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">115,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible Assets, Gross</a></td>
<td class="nump">255,419<span></span>
</td>
<td class="nump">202,916<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net</a></td>
<td class="nump">119,707<span></span>
</td>
<td class="nump">71,648<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite lived assets:</a></td>
<td class="nump">2,150<span></span>
</td>
<td class="nump">2,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite lived assets:</a></td>
<td class="nump">2,150<span></span>
</td>
<td class="nump">2,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember', window );">Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite lived assets:</a></td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite lived assets:</a></td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=asth_NetworkRelationshipsMember', window );">Network relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">155,978<span></span>
</td>
<td class="nump">150,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(107,137)<span></span>
</td>
<td class="num">(104,859)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 48,841<span></span>
</td>
<td class="nump">$ 45,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=asth_NetworkRelationshipsMember', window );">Network relationships | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">11 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=asth_NetworkRelationshipsMember', window );">Network relationships | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">21 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=asth_ManagementContractsMember', window );">Management contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">$ 22,832<span></span>
</td>
<td class="nump">$ 22,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(17,002)<span></span>
</td>
<td class="num">(16,662)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">5,830<span></span>
</td>
<td class="nump">6,170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=asth_MemberRelationshipsMember', window );">Member relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">69,381<span></span>
</td>
<td class="nump">24,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(9,154)<span></span>
</td>
<td class="num">(7,345)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 60,227<span></span>
</td>
<td class="nump">$ 16,732<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=asth_MemberRelationshipsMember', window );">Member relationships | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=asth_MemberRelationshipsMember', window );">Member relationships | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">14 years<span></span>
</td>
<td class="text">14 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=asth_PatientManagementPlatformMember', window );">Patient management platform</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">$ 2,060<span></span>
</td>
<td class="nump">$ 2,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(2,060)<span></span>
</td>
<td class="num">(2,060)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Tradename/trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">$ 1,011<span></span>
</td>
<td class="nump">$ 1,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(320)<span></span>
</td>
<td class="num">(308)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 691<span></span>
</td>
<td class="nump">$ 703<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">$ 107<span></span>
</td>
<td class="nump">$ 107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 68<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=asth_NetworkRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=asth_NetworkRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=asth_ManagementContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=asth_ManagementContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=asth_MemberRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=asth_MemberRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=asth_PatientManagementPlatformMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=asth_PatientManagementPlatformMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464333655024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of finite-lived intangible assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464435562320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets, Net - Schedule of Future Amortization Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2023 (excluding the nine months ended September 30, 2023)</a></td>
<td class="nump">$ 20,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">22,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">18,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">14,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2028</a></td>
<td class="nump">12,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Thereafter</a></td>
<td class="nump">28,131<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 115,657<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464342346624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities - Schedule of Equity Method Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="nump">$ 25,774<span></span>
</td>
<td class="nump">$ 40,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_EquityMethodInvestmentAdditionalInvestment', window );">Initial Investment</a></td>
<td class="nump">9,487<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Net Income</a></td>
<td class="nump">632<span></span>
</td>
<td class="nump">2,484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">$ 35,893<span></span>
</td>
<td class="nump">$ 43,108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates &#8211; IPA line of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">% of Ownership</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="nump">$ 9,866<span></span>
</td>
<td class="nump">$ 5,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_EquityMethodInvestmentAdditionalInvestment', window );">Initial Investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Net Income</a></td>
<td class="nump">359<span></span>
</td>
<td class="nump">2,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">$ 10,225<span></span>
</td>
<td class="nump">$ 7,849<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging &amp; Oncology Center, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">% of Ownership</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="nump">$ 1,691<span></span>
</td>
<td class="nump">$ 1,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_EquityMethodInvestmentAdditionalInvestment', window );">Initial Investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Net Income</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">$ 1,718<span></span>
</td>
<td class="nump">$ 1,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_FiveThreeOneW.CollegeLLCMember', window );">531 W. College, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">% of Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_EquityMethodInvestmentAdditionalInvestment', window );">Initial Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Net Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_OneMSOLLCMember', window );">One MSO, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">% of Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_EquityMethodInvestmentAdditionalInvestment', window );">Initial Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Net Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,833<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_CAIPAMSOLLCMember', window );">CAIPA MSO, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">% of Ownership</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="nump">$ 13,660<span></span>
</td>
<td class="nump">$ 12,738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_EquityMethodInvestmentAdditionalInvestment', window );">Initial Investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Net Income</a></td>
<td class="nump">186<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">$ 13,846<span></span>
</td>
<td class="nump">$ 12,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_IHealthIncMember', window );">I Health, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">% of Ownership</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_EquityMethodInvestmentAdditionalInvestment', window );">Initial Investment</a></td>
<td class="nump">9,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Net Income</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">$ 9,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=us-gaap_OtherInvesteesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">% of Ownership</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="nump">$ 557<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_EquityMethodInvestmentAdditionalInvestment', window );">Initial Investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Net Income</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">$ 617<span></span>
</td>
<td class="nump">$ 362<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_EquityMethodInvestmentAdditionalInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Additional Investment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_EquityMethodInvestmentAdditionalInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_EquityMethodInvestmentsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_EquityMethodInvestmentsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the entity's equity method investment which has been sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSoldCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_LasalleMedicalAssociatesIpaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_LasalleMedicalAssociatesIpaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_PacificMedicalImagingAndOncologyCenterIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_PacificMedicalImagingAndOncologyCenterIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_FiveThreeOneW.CollegeLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_FiveThreeOneW.CollegeLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_OneMSOLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_OneMSOLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_CAIPAMSOLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_CAIPAMSOLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_IHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_IHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=us-gaap_OtherInvesteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=us-gaap_OtherInvesteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464523702464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Impairment of investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_IHealthIncMember', window );">I Health, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest (as a percent)</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_IHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_IHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464340206096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans Receivable (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2023</div></th>
<th class="th"><div>Jan. 29, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asth_IntraCareConvertiblePromissoryNoteReceivableMember', window );">IntraCare Convertible Promissory Note Receivable | Convertible Secured Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Revolving credit facility term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt, principal sum</a></td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">8.81%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asth_BassMedicalGroupMember', window );">BASS Medical Group | Senior Secured Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt, principal sum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.21%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=asth_IntraCareConvertiblePromissoryNoteReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=asth_IntraCareConvertiblePromissoryNoteReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=asth_BassMedicalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=asth_BassMedicalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=asth_SeniorSecuredPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=asth_SeniorSecuredPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464340688944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accounts payable and other accruals</a></td>
<td class="nump">$ 84,867<span></span>
</td>
<td class="nump">$ 9,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_SpecialtyCapitationPayableCurrent', window );">Capitation payable</a></td>
<td class="nump">10,225<span></span>
</td>
<td class="nump">4,503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_SubcontractorIPAPayable', window );">Subcontractor IPA payable</a></td>
<td class="nump">2,529<span></span>
</td>
<td class="nump">2,529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">5,293<span></span>
</td>
<td class="nump">4,407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyDepositLiabilities', window );">Due to related parties</a></td>
<td class="nump">11,679<span></span>
</td>
<td class="nump">9,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="nump">3,017<span></span>
</td>
<td class="nump">744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">12,410<span></span>
</td>
<td class="nump">20,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other provider payable</a></td>
<td class="nump">16,453<span></span>
</td>
<td class="nump">9,322<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total accounts payable and accrued expenses</a></td>
<td class="nump">$ 146,473<span></span>
</td>
<td class="nump">$ 59,949<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_SpecialtyCapitationPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of specialty capitation payable current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_SpecialtyCapitationPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_SubcontractorIPAPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subcontractor IPA Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_SubcontractorIPAPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyDepositLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deposits held by the entity for a related party (entity, shareholder, employee).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyDepositLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464342403952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Medical Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities, beginning of period</a></td>
<td class="nump">$ 106,657<span></span>
</td>
<td class="nump">$ 81,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions', window );">Acquired (see Note 3)</a></td>
<td class="nump">30,645<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract', window );"><strong>Components of medical care costs related to claims incurred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current period</a></td>
<td class="nump">235,237<span></span>
</td>
<td class="nump">223,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior periods</a></td>
<td class="num">(1,419)<span></span>
</td>
<td class="num">(8,950)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total medical care costs</a></td>
<td class="nump">233,818<span></span>
</td>
<td class="nump">214,763<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract', window );"><strong>Payments for medical care costs related to claims incurred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current period</a></td>
<td class="num">(136,286)<span></span>
</td>
<td class="num">(136,743)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior periods</a></td>
<td class="num">(97,837)<span></span>
</td>
<td class="num">(61,736)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total paid</a></td>
<td class="num">(234,123)<span></span>
</td>
<td class="num">(198,479)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease', window );">Adjustments</a></td>
<td class="num">(503)<span></span>
</td>
<td class="nump">857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities, end of period</a></td>
<td class="nump">$ 136,494<span></span>
</td>
<td class="nump">$ 98,396<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cost of settling unpaid claims after deduction of reinsurance recoveries related to the acquisition of a business. Includes, but is not limited to, claims which have been incurred but not reported.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -SubTopic 40<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -SubTopic 40<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of increase (decrease) in the liability for unpaid claims and claims adjustment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -SubTopic 40<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLossesAndLossAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464342419408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Credit Facility, Bank Loans, and Lines of Credit - Schedule of Credit Facility (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">$ 393,259<span></span>
</td>
<td class="nump">$ 282,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion of debt</a></td>
<td class="num">(20,750)<span></span>
</td>
<td class="num">(19,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: Unamortized financing costs</a></td>
<td class="num">(4,061)<span></span>
</td>
<td class="num">(3,561)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">368,448<span></span>
</td>
<td class="nump">258,939<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=asth_TermLoanMember', window );">Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">296,500<span></span>
</td>
<td class="nump">280,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Promissory Note Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=asth_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=asth_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464422580400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Credit Facility, Bank Loans, and Lines of Credit - Schedule of Maturities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2024</a></td>
<td class="nump">$ 17,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2025</a></td>
<td class="nump">16,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2026</a></td>
<td class="nump">117,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2027</a></td>
<td class="nump">24,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2028</a></td>
<td class="nump">217,750<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Total</a></td>
<td class="nump">$ 393,259<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464332398528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility, Bank Loans, and Lines of Credit - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 03, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 16, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>financial_ratio</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 08, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 10, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 393,259,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 282,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Average effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.69%<span></span>
</td>
<td class="nump">6.51%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Loan from company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 393,259,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_UnamortizedDeferredFinancingCosts', window );">Deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,061,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,561,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,585,000<span></span>
</td>
<td class="nump">$ 3,269,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Secured Overnight Financing Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Secured Overnight Financing Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Astrana Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Loan from company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 545,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolver Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,759,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asth_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Truist Bank | Standby Letters of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Term of facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asth_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Minimum | Secured Overnight Financing Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asth_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Minimum | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asth_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Maximum | Secured Overnight Financing Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asth_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Maximum | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asth_AmendedAndRestatedCreditAgreementMember', window );">Credit Agreement Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Drawdowns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 296,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asth_AmendedAndRestatedCreditAgreementMember', window );">Credit Agreement Amendment | Line of Credit | Truist Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_LineOfCreditFacilityAmountFundedAtClosing', window );">Amount funded at closing</a></td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asth_AmendedAndRestatedCreditAgreementMember', window );">Credit Agreement Amendment | Secured Debt | Truist Bank | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asth_AmendedAndRestatedCreditAgreementMember', window );">Credit Agreement Amendment | Secured Debt | Truist Bank | Debt Instrument, Redemption, Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asth_AmendedAndRestatedCreditAgreementMember', window );">Credit Agreement Amendment | Secured Debt | Truist Bank | Debt Instrument, Redemption, Period Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asth_CreditAgreementMember', window );">Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Average effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.68%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_DebtInstrumentNumberOfKeyFinancialRatios', window );">Number of key financial ratios | financial_ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_DebtInstrumentCovenantLeverageRatioMaximum', window );">Maximum consolidated leverage ratio (not greater than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_DebtCovenantAggregatePurchasePriceMaximum', window );">Debt covenant, aggregate purchase price, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_DebtInstrumentCovenantLeverageRatioIncrementalChange', window );">Consolidated leverage ratio, annual decrease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_DebtInstrumentCovenantLeverageRatioAdjustedMaximum', window );">Debt instrument, covenant, leverage ratio, adjusted maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_DebtInstrumentCovenantInterestCoverageRatioMinimum', window );">Minimum consolidated interest coverage ratio (not less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asth_SubordinatedLoanAgreementMember', window );">Subordinated Loan Agreement | Subordinated Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt, principal sum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolver Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfBankOverdrafts', window );">Proceeds from (repayments of) bank overdrafts</a></td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolver Loan | Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Revolving credit facility term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.42%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolver Loan | Amended Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_BridgeLoanMember', window );">Bridge Loan | Amended Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Amended Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=asth_NewTermLoanMember', window );">New Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | APC Business Loan Agreement | Preferred Bank | Allied Pacific Of California IPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | Allied Pacific Of California IPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Term of facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_DebtCovenantAggregatePurchasePriceMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Covenant, Aggregate Purchase Price, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_DebtCovenantAggregatePurchasePriceMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_DebtInstrumentCovenantInterestCoverageRatioMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_DebtInstrumentCovenantInterestCoverageRatioMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_DebtInstrumentCovenantLeverageRatioAdjustedMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Leverage Ratio, Adjusted Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_DebtInstrumentCovenantLeverageRatioAdjustedMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_DebtInstrumentCovenantLeverageRatioIncrementalChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Leverage Ratio, Incremental Change</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_DebtInstrumentCovenantLeverageRatioIncrementalChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_DebtInstrumentCovenantLeverageRatioMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Leverage Ratio, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_DebtInstrumentCovenantLeverageRatioMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_DebtInstrumentNumberOfKeyFinancialRatios">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Key Financial Ratios</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_DebtInstrumentNumberOfKeyFinancialRatios</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_LineOfCreditFacilityAmountFundedAtClosing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Amount Funded At Closing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_LineOfCreditFacilityAmountFundedAtClosing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_UnamortizedDeferredFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unamortized Deferred Financing Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_UnamortizedDeferredFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfBankOverdrafts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow from the excess drawing from an existing cash balance, which will be honored by the bank but reflected as a loan to the drawer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfBankOverdrafts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=asth_SecuredOvernightFinancingRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=asth_SecuredOvernightFinancingRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=asth_AstranaMedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=asth_AstranaMedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=asth_AmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=asth_AmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=asth_TruistBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=asth_TruistBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=asth_AmendedAndRestatedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=asth_AmendedAndRestatedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=asth_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=asth_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=asth_SubordinatedLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=asth_SubordinatedLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SubordinatedDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SubordinatedDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_BridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_BridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=asth_NewTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=asth_NewTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=asth_ApcBusinessLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=asth_ApcBusinessLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=asth_PreferredBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=asth_PreferredBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=asth_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=asth_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464342659600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mezzanine and Stockholders' Equity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_StockIssuedDuringPeriodSharesMerger', window );">Holdback shares not issued to former shareholders (in shares)</a></td>
<td class="nump">41,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury shares (in shares)</a></td>
<td class="nump">10,584,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,584,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury stock repurchased (in shares)</a></td>
<td class="nump">3,451,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,451,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Payments of ordinary dividends common stock</a></td>
<td class="nump">$ 95<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=asth_AlliedPacificOfCaliforniaIPAMember', window );">APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury shares (in shares)</a></td>
<td class="nump">7,132,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,132,698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=asth_AlliedPacificOfCaliforniaIPAMember', window );">APC | Apollo Medical Holdings, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest (as a percent)</a></td>
<td class="nump">13.04%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.22%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=asth_CDSCMember', window );">CDSC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Payments of ordinary dividends common stock</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=asth_CompanyAndAPCMember', window );">Company And APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury shares (in shares)</a></td>
<td class="nump">10,584,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,584,340<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_StockIssuedDuringPeriodSharesMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_StockIssuedDuringPeriodSharesMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=asth_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=asth_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_ApolloMedicalHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_ApolloMedicalHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=asth_CDSCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=asth_CDSCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=asth_CompanyAndAPCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=asth_CompanyAndAPCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464340557872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Share-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 5,748<span></span>
</td>
<td class="nump">$ 3,445<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">349<span></span>
</td>
<td class="nump">566<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=asth_StockAwardsAndUnitsMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 5,399<span></span>
</td>
<td class="nump">$ 2,879<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=asth_StockAwardsAndUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=asth_StockAwardsAndUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464422285184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense | $</a></td>
<td class="nump">$ 42.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock awards granted (in shares)</a></td>
<td class="nump">296,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance', window );">Contingent on performance (in shares)</a></td>
<td class="nump">255,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 40.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=asth_PerformanceBasedRestrictedStockMember', window );">Performance Based Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 43.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=asth_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_CommonStockDiscountedPricePercentage', window );">Common stock, discounted price, percentage</a></td>
<td class="nump">0.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_CommonStockDiscountedPricePercentageMaximum', window );">Common stock, discounted price, percentage (up to)</a></td>
<td class="nump">0.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=asth_ApcStockOptionMember', window );">APC Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Purchase price adjustment from merger | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_CommonStockDiscountedPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Discounted Price, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_CommonStockDiscountedPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_CommonStockDiscountedPricePercentageMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Discounted Price, Percentage, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_CommonStockDiscountedPricePercentageMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Contingent on Performance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=asth_PerformanceBasedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=asth_PerformanceBasedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=asth_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=asth_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=asth_ApcStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=asth_ApcStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464342525456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Stock Option Transactions Under Stock Option Plans (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">496,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">504,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(125,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited (in shares)</a></td>
<td class="num">(7,271)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance (in shares)</a></td>
<td class="nump">496,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">504,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares)</a></td>
<td class="nump">459,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 34.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited (in dollars per share)</a></td>
<td class="nump">50.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">33.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options exercisable (in dollars per share)</a></td>
<td class="nump">$ 28.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding</a></td>
<td class="text">1 year 7 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable</a></td>
<td class="text">1 year 4 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value (in millions)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding</a></td>
<td class="nump">$ 8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable</a></td>
<td class="nump">$ 8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Exercise Price [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464437945584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding</a></td>
<td class="nump">$ 393,259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asth_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Truist Bank | Standby Letters of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="nump">$ 31,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=asth_AmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=asth_AmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=asth_TruistBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=asth_TruistBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464422421184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 404,356<span></span>
</td>
<td class="nump">$ 337,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">39,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">5,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_RelatedPartyExpensesPayable', window );">Expenses payable</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_HealthCareOtherMember', window );">Risk pool settlements and incentives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">17,377<span></span>
</td>
<td class="nump">13,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=asth_SongPCMember', window );">Song PC | Provider Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction, amount of transaction</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=asth_AHMCMember', window );">AHMC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilities', window );">Amount outstanding under agreement</a></td>
<td class="nump">58,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=asth_AHMCMember', window );">AHMC | Related Party | Risk pool settlements and incentives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">8,100<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=asth_AlliedPacificHoldingsInvestmentManagementLLCMember', window );">Allied Pacific Holdings Investment Management, LLC | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">12,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">13,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=asth_AHMCMember', window );">AHMC | LMA | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=asth_AHMCMember', window );">AHMC | Arroyo Vista | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=asth_AlliedPacificOfCaliforniaIPAMember', window );">APC | Board Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=asth_AlliedPacificOfCaliforniaIPAMember', window );">APC | PMIOC | Provider Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction, amount of transaction</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=asth_AlliedPacificOfCaliforniaIPAMember', window );">APC | Sunny Village Care Center | Provider Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction, amount of transaction</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=asth_AlliedPacificOfCaliforniaIPAMember', window );">APC | Board Members | Provider Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction, amount of transaction</a></td>
<td class="nump">4,700<span></span>
</td>
<td class="nump">9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=asth_AlliedPacificOfCaliforniaIPAMember', window );">APC | Board Members Who Are Also Officers | Provider Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction, amount of transaction</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=asth_NetworkMedicalManagementMember', window );">NMM | Arroyo Vista | Provider Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction, amount of transaction</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=asth_ProfessionalMedicalCorporationMember', window );">AMG | First Commonwealth Property, LLC | Office Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction, amount of transaction</a></td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=asth_ProfessionalMedicalCorporationMember', window );">AMG | Allied Pacific Holdings Investment Management, LLC | Office Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction, amount of transaction</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_PmiocMember', window );">PMIOC | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest (as a percent)</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_SongPCMember', window );">Song PC | Astrana Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest (as a percent)</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_RelatedPartyExpensesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party, Expenses Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_RelatedPartyExpensesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income in future periods and obligations not separately disclosed in the balance sheet (other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_HealthCareOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_HealthCareOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=asth_SongPCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=asth_SongPCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=asth_ProviderServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=asth_ProviderServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=asth_AHMCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=asth_AHMCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=asth_AlliedPacificHoldingsInvestmentManagementLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=asth_AlliedPacificHoldingsInvestmentManagementLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=asth_AHMCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=asth_AHMCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=asth_LmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=asth_LmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=asth_ArroyoVistaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=asth_ArroyoVistaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=asth_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=asth_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=asth_PmiocMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=asth_PmiocMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=asth_SunnyVillageCareCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=asth_SunnyVillageCareCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=asth_BoardMembersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=asth_BoardMembersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=asth_BoardMembersWhoAreAlsoOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=asth_BoardMembersWhoAreAlsoOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=asth_NetworkMedicalManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=asth_NetworkMedicalManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=asth_ProfessionalMedicalCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=asth_ProfessionalMedicalCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=asth_FirstCommonwealthPropertyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=asth_FirstCommonwealthPropertyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=asth_OfficeLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=asth_OfficeLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_PmiocMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_PmiocMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_SongPCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_SongPCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=asth_AstranaMedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=asth_AstranaMedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464337890080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions - Schedule of Fees Incurred and Revenue Earned from Related Party Transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=asth_AHMCMember', window );">AHMC | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction, amount of transaction</a></td>
<td class="nump">$ 9,920<span></span>
</td>
<td class="nump">$ 14,484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=asth_AHMCMember', window );">AHMC | Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction, amount of transaction</a></td>
<td class="nump">7,557<span></span>
</td>
<td class="nump">6,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=asth_AHMCMember', window );">AHMC | Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction, amount of transaction</a></td>
<td class="nump">2,363<span></span>
</td>
<td class="nump">8,084<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=asth_HSMSOMember', window );">HSMSO | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction, amount of transaction</a></td>
<td class="nump">301<span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=asth_HSMSOMember', window );">HSMSO | Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction, amount of transaction</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=asth_HSMSOMember', window );">HSMSO | Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction, amount of transaction</a></td>
<td class="nump">301<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=asth_AurionMember', window );">Aurion | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction, amount of transaction</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=asth_AurionMember', window );">Aurion | Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction, amount of transaction</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=asth_AurionMember', window );">Aurion | Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction, amount of transaction</a></td>
<td class="num">$ (50)<span></span>
</td>
<td class="num">$ (50)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=asth_AHMCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=asth_AHMCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=asth_RelatedPartyTransactionRevenueRecognizedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=asth_RelatedPartyTransactionRevenueRecognizedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=asth_RelatedPartyTransactionExpensesIncurredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=asth_RelatedPartyTransactionExpensesIncurredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=asth_RelatedPartyTransactionRevenueExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=asth_RelatedPartyTransactionRevenueExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=asth_HSMSOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=asth_HSMSOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=asth_AurionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=asth_AurionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464337433984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">29.80%<span></span>
</td>
<td class="nump">35.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464339692032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Additional Information (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities not included in the calculation of earnings per share (in shares)</a></td>
<td class="nump">118,142<span></span>
</td>
<td class="nump">136,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities not included in the calculation of earnings per share (in shares)</a></td>
<td class="nump">973,461<span></span>
</td>
<td class="nump">395,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=asth_AlliedPacificOfCaliforniaIPAMember', window );">APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities not included in the calculation of earnings per share (in shares)</a></td>
<td class="nump">7,132,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,132,698<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_EarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Earnings Per Share [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_EarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=asth_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=asth_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464340480832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Schedule of Earnings Per Share Computations (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share &#8211; basic (in dollars per share)</a></td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share &#8211; diluted (in dollars per share)</a></td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding &#8211; basic (in shares)</a></td>
<td class="nump">47,260,351<span></span>
</td>
<td class="nump">46,555,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of common stock outstanding &#8211; diluted (in shares)</a></td>
<td class="nump">47,699,537<span></span>
</td>
<td class="nump">46,954,687<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464340800896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Schedule of Shares Included in the Diluted Earnings Per Share Computations (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding &#8211; basic (in shares)</a></td>
<td class="nump">47,260,351<span></span>
</td>
<td class="nump">46,555,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares', window );">Contingently issuable shares (in shares)</a></td>
<td class="nump">25,975<span></span>
</td>
<td class="nump">44,157<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of common stock outstanding &#8211; diluted (in shares)</a></td>
<td class="nump">47,699,537<span></span>
</td>
<td class="nump">46,954,687<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Adjustments to weighted average shares of common stock (in shares)</a></td>
<td class="nump">188,083<span></span>
</td>
<td class="nump">306,933<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Adjustments to weighted average shares of common stock (in shares)</a></td>
<td class="nump">225,128<span></span>
</td>
<td class="nump">48,191<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_EarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Earnings Per Share [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_EarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of contingently issuable shares. Contingently issuable shares are those shares that are issuable for little or no cash contingent on certain conditions being met.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-26<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 44<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-44<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 51<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-51<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-52<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-53<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 54<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-54<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 48<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-48<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 48<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464333717936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities (VIEs)- Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Variable interest entity, ownership percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481420/860-30-50-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481420/860-30-50-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481420/860-30-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464341745856">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Variable Interest Entities (VIEs) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 334,796<span></span>
</td>
<td class="nump">$ 293,807<span></span>
</td>
<td class="nump">$ 274,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investment in marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,490<span></span>
</td>
<td class="nump">2,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income taxes receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,783<span></span>
</td>
<td class="nump">1,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,281<span></span>
</td>
<td class="nump">17,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">538,810<span></span>
</td>
<td class="nump">461,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">119,707<span></span>
</td>
<td class="nump">71,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">410,267<span></span>
</td>
<td class="nump">278,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivableNoncurrent', window );">Income taxes receivable, non-current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,943<span></span>
</td>
<td class="nump">15,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">35,893<span></span>
</td>
<td class="nump">25,774<span></span>
</td>
<td class="nump">43,108<span></span>
</td>
<td class="nump">$ 40,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">39,152<span></span>
</td>
<td class="nump">37,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,067<span></span>
</td>
<td class="nump">1,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">687,467<span></span>
</td>
<td class="nump">471,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,226,277<span></span>
</td>
<td class="nump">933,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">146,473<span></span>
</td>
<td class="nump">59,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_FiduciaryAccountsPayableCurrent', window );">Fiduciary accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,792<span></span>
</td>
<td class="nump">7,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">136,494<span></span>
</td>
<td class="nump">106,657<span></span>
</td>
<td class="nump">$ 98,396<span></span>
</td>
<td class="nump">$ 81,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividend payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">638<span></span>
</td>
<td class="nump">638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">636<span></span>
</td>
<td class="nump">646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,007<span></span>
</td>
<td class="nump">4,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,750<span></span>
</td>
<td class="nump">19,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">31,960<span></span>
</td>
<td class="nump">18,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">355,272<span></span>
</td>
<td class="nump">218,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,015<span></span>
</td>
<td class="nump">1,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">37,716<span></span>
</td>
<td class="nump">36,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,756<span></span>
</td>
<td class="nump">4,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,652<span></span>
</td>
<td class="nump">3,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">418,587<span></span>
</td>
<td class="nump">303,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">773,859<span></span>
</td>
<td class="nump">522,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">120,106<span></span>
</td>
<td class="nump">76,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">62,354<span></span>
</td>
<td class="nump">58,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">212,134<span></span>
</td>
<td class="nump">184,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investment in marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income taxes receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">997<span></span>
</td>
<td class="nump">454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,891<span></span>
</td>
<td class="nump">9,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">334,111<span></span>
</td>
<td class="nump">275,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Land, property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,084<span></span>
</td>
<td class="nump">5,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">85,058<span></span>
</td>
<td class="nump">60,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">236,961<span></span>
</td>
<td class="nump">140,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivableNoncurrent', window );">Income taxes receivable, non-current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,943<span></span>
</td>
<td class="nump">15,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,560<span></span>
</td>
<td class="nump">12,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Investment in affiliates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">299,502<span></span>
</td>
<td class="nump">273,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue', window );">Investment in a privately held entity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">405<span></span>
</td>
<td class="nump">405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">26,082<span></span>
</td>
<td class="nump">28,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,214<span></span>
</td>
<td class="nump">1,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">682,849<span></span>
</td>
<td class="nump">537,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,016,960<span></span>
</td>
<td class="nump">813,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44,058<span></span>
</td>
<td class="nump">32,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_FiduciaryAccountsPayableCurrent', window );">Fiduciary accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,792<span></span>
</td>
<td class="nump">7,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">69,611<span></span>
</td>
<td class="nump">55,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividend payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">638<span></span>
</td>
<td class="nump">638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Income tax payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,431<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">602<span></span>
</td>
<td class="nump">646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,092<span></span>
</td>
<td class="nump">3,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Amount due to affiliates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">110,117<span></span>
</td>
<td class="nump">107,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,387<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">253,728<span></span>
</td>
<td class="nump">216,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">905<span></span>
</td>
<td class="nump">1,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">26,186<span></span>
</td>
<td class="nump">28,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,166<span></span>
</td>
<td class="nump">7,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,690<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">35,947<span></span>
</td>
<td class="nump">37,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">289,675<span></span>
</td>
<td class="nump">253,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary | Nonrelated Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">47,169<span></span>
</td>
<td class="nump">21,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary | Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 61,870<span></span>
</td>
<td class="nump">$ 58,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The condensed consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#8217;s consolidated VIEs totaling $717.5&#160;million and $540.8&#160;million as of March&#160;31, 2024 and December&#160;31, 2023, respectively, and total liabilities of the Company&#8217;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $179.6&#160;million and $146.0&#160;million as of March&#160;31, 2024 and December&#160;31, 2023, respectively. These VIE balances do not include $299.5&#160;million of investment in affiliates and $110.1&#160;million of amounts due to affiliates as of March&#160;31, 2024, and $273.2&#160;million of investment in affiliates and $107.3&#160;million of amounts due to affiliates as of December&#160;31, 2023, as these are eliminated upon consolidation and not presented within the condensed consolidated balance sheets. See Note 16 &#8212; &#8220;Variable Interest Entities (VIEs)&#8221; for further details.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_FiduciaryAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_FiduciaryAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due after one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464437250144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease option to extend (up to)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRenewalTerm1', window );">Finance lease option to extend (up to)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_LesseeOperatingLeaseTerminationPeriodIfApplicable', window );">Operating lease, termination period, if applicable</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_LesseeFinanceLeaseTerminationPeriodIfApplicable', window );">Finance lease, termination period, if applicable</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Assets recorded under finance leases</a></td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization', window );">Accumulated depreciation associated with finance leases</a></td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term, operating</a></td>
<td class="text">4 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm', window );">Remaining lease term, finance</a></td>
<td class="text">4 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term, operating</a></td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm', window );">Remaining lease term, finance</a></td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_LesseeFinanceLeaseTerminationPeriodIfApplicable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Finance Lease, Termination Period, If Applicable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_LesseeFinanceLeaseTerminationPeriodIfApplicable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_LesseeOperatingLeaseTerminationPeriodIfApplicable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Termination Period, If Applicable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_LesseeOperatingLeaseTerminationPeriodIfApplicable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRenewalTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRenewalTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464340739824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 3,159<span></span>
</td>
<td class="nump">$ 1,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_FinanceLeaseCostsAbstract', window );"><strong>Finance lease cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of lease expense</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">(226)<span></span>
</td>
<td class="num">(248)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost, net</a></td>
<td class="nump">$ 3,136<span></span>
</td>
<td class="nump">$ 1,679<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_FinanceLeaseCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_FinanceLeaseCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464339925184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Other Information Related to Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_CashPaidForLeaseLiabilitiesAbstractAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 2,837<span></span>
</td>
<td class="nump">$ 1,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flows from finance leases</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows from finance leases</a></td>
<td class="nump">$ 179<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_LeaseWeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted Average Remaining Lease Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">8 years 4 months 20 days<span></span>
</td>
<td class="text">6 years 7 months 20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases</a></td>
<td class="text">2 years 11 months 15 days<span></span>
</td>
<td class="text">3 years 2 months 19 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_LeaseWeightedAverageDiscountRateAbstract', window );"><strong>Weighted Average Discount Rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">6.15%<span></span>
</td>
<td class="nump">5.63%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases</a></td>
<td class="nump">5.53%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_CashPaidForLeaseLiabilitiesAbstractAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_CashPaidForLeaseLiabilitiesAbstractAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_LeaseWeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_LeaseWeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_LeaseWeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_LeaseWeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464342725024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Future Minimum Payments Under Non-cancelable Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2024 (excluding the three months ended March 31, 2024)</a></td>
<td class="nump">$ 5,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">7,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">7,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">6,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">6,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">22,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">55,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">13,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">42,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="nump">5,007<span></span>
</td>
<td class="nump">$ 4,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">37,716<span></span>
</td>
<td class="nump">36,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2024 (excluding the three months ended March 31, 2024)</a></td>
<td class="nump">560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_FinanceLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">1,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">1,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="nump">636<span></span>
</td>
<td class="nump">646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">$ 1,015<span></span>
</td>
<td class="nump">$ 1,033<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_FinanceLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_FinanceLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464341766976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 404,356<span></span>
</td>
<td class="nump">$ 337,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of services</a></td>
<td class="nump">330,399<span></span>
</td>
<td class="nump">289,397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_GeneralAndAdministrativeExpensesAndDepreciationAndAmortization', window );">General and administrative</a></td>
<td class="nump">43,818<span></span>
</td>
<td class="nump">25,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
<td class="nump">374,217<span></span>
</td>
<td class="nump">314,871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">30,139<span></span>
</td>
<td class="nump">22,373<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=us-gaap_HealthCarePatientServiceMember', window );">Third-Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">404,356<span></span>
</td>
<td class="nump">337,244<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=us-gaap_ProductAndServiceOtherMember', window );">Intersegment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Elimination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="num">(56,732)<span></span>
</td>
<td class="num">(33,598)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of services</a></td>
<td class="num">(26,734)<span></span>
</td>
<td class="num">(13,302)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_GeneralAndAdministrativeExpensesAndDepreciationAndAmortization', window );">General and administrative</a></td>
<td class="num">(30,075)<span></span>
</td>
<td class="num">(21,460)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
<td class="num">(56,809)<span></span>
</td>
<td class="num">(34,762)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">1,164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Elimination | Third-Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Elimination | Intersegment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="num">(56,732)<span></span>
</td>
<td class="num">(33,598)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of services</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_GeneralAndAdministrativeExpensesAndDepreciationAndAmortization', window );">General and administrative</a></td>
<td class="nump">16,400<span></span>
</td>
<td class="nump">5,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
<td class="nump">16,400<span></span>
</td>
<td class="nump">5,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(16,400)<span></span>
</td>
<td class="num">(5,409)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate Costs | Third-Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate Costs | Intersegment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=asth_CarePartnersMember', window );">Care Partners | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">397,095<span></span>
</td>
<td class="nump">314,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of services</a></td>
<td class="nump">314,966<span></span>
</td>
<td class="nump">266,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_GeneralAndAdministrativeExpensesAndDepreciationAndAmortization', window );">General and administrative</a></td>
<td class="nump">38,933<span></span>
</td>
<td class="nump">26,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
<td class="nump">353,899<span></span>
</td>
<td class="nump">292,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">43,196<span></span>
</td>
<td class="nump">22,321<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=asth_CarePartnersMember', window );">Care Partners | Operating Segments | Third-Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">382,318<span></span>
</td>
<td class="nump">314,637<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=asth_CarePartnersMember', window );">Care Partners | Operating Segments | Intersegment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">14,777<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=asth_CareDeliveryMember', window );">Care Delivery | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">30,719<span></span>
</td>
<td class="nump">25,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of services</a></td>
<td class="nump">24,794<span></span>
</td>
<td class="nump">20,692<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_GeneralAndAdministrativeExpensesAndDepreciationAndAmortization', window );">General and administrative</a></td>
<td class="nump">6,163<span></span>
</td>
<td class="nump">5,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
<td class="nump">30,957<span></span>
</td>
<td class="nump">26,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(238)<span></span>
</td>
<td class="num">(966)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=asth_CareDeliveryMember', window );">Care Delivery | Operating Segments | Third-Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">17,878<span></span>
</td>
<td class="nump">12,263<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=asth_CareDeliveryMember', window );">Care Delivery | Operating Segments | Intersegment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">12,841<span></span>
</td>
<td class="nump">13,120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=asth_CareEnablementMember', window );">Care Enablement | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">33,274<span></span>
</td>
<td class="nump">30,566<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of services</a></td>
<td class="nump">17,373<span></span>
</td>
<td class="nump">15,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_GeneralAndAdministrativeExpensesAndDepreciationAndAmortization', window );">General and administrative</a></td>
<td class="nump">12,397<span></span>
</td>
<td class="nump">9,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
<td class="nump">29,770<span></span>
</td>
<td class="nump">24,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">3,504<span></span>
</td>
<td class="nump">5,746<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=asth_CareEnablementMember', window );">Care Enablement | Operating Segments | Third-Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">4,160<span></span>
</td>
<td class="nump">10,139<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=asth_CareEnablementMember', window );">Care Enablement | Operating Segments | Intersegment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">29,114<span></span>
</td>
<td class="nump">20,427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of services</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_GeneralAndAdministrativeExpensesAndDepreciationAndAmortization', window );">General and administrative</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(483)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other | Operating Segments | Third-Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other | Operating Segments | Intersegment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_GeneralAndAdministrativeExpensesAndDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General and Administrative Expenses and Depreciation and Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_GeneralAndAdministrativeExpensesAndDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=us-gaap_HealthCarePatientServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=us-gaap_HealthCarePatientServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=asth_CarePartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=asth_CarePartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=asth_CareDeliveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=asth_CareDeliveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=asth_CareEnablementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=asth_CareEnablementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464341702912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements of Financial Instruments - Schedule of Carrying Amounts and Fair Values of Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market accounts</a></td>
<td class="nump">$ 31,804<span></span>
</td>
<td class="nump">$ 4,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="nump">2,258<span></span>
</td>
<td class="nump">2,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable securities &#8211; equity securities</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">348<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">34,732<span></span>
</td>
<td class="nump">7,340<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">36,908<span></span>
</td>
<td class="nump">22,088<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=asth_AAMGMember', window );">AAMG contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Value of the contingent consideration</a></td>
<td class="nump">7,407<span></span>
</td>
<td class="nump">5,475<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=asth_VOMGMember', window );">VOMG contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Value of the contingent consideration</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=asth_DmgMember', window );">DMG remaining equity interest purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent', window );">Remaining equity interest purchase</a></td>
<td class="nump">8,542<span></span>
</td>
<td class="nump">8,542<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=asth_ApolloSunLabsManagementLLCMember', window );">Sun Labs remaining equity interest purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent', window );">Remaining equity interest purchase</a></td>
<td class="nump">7,278<span></span>
</td>
<td class="nump">7,802<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=asth_ADSCMember', window );">ADSC contingent considerations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Value of the contingent consideration</a></td>
<td class="nump">3,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=asth_CFCMember', window );">CFC contingent considerations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Value of the contingent consideration</a></td>
<td class="nump">7,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=asth_PrimeCommunityCareMember', window );">PCCCV contingent considerations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Value of the contingent consideration</a></td>
<td class="nump">2,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=asth_InterestRateCollarMember', window );">Interest Rate Collar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Interest rate collar</a></td>
<td class="nump">438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market accounts</a></td>
<td class="nump">31,804<span></span>
</td>
<td class="nump">4,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="nump">2,258<span></span>
</td>
<td class="nump">2,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable securities &#8211; equity securities</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">348<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">34,294<span></span>
</td>
<td class="nump">7,340<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | AAMG contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Value of the contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | VOMG contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Value of the contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | DMG remaining equity interest purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent', window );">Remaining equity interest purchase</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Sun Labs remaining equity interest purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent', window );">Remaining equity interest purchase</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | ADSC contingent considerations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Value of the contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | CFC contingent considerations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Value of the contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | PCCCV contingent considerations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Value of the contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Interest Rate Collar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Interest rate collar</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable securities &#8211; equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">438<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | AAMG contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Value of the contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | VOMG contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Value of the contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | DMG remaining equity interest purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent', window );">Remaining equity interest purchase</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Sun Labs remaining equity interest purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent', window );">Remaining equity interest purchase</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | ADSC contingent considerations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Value of the contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | CFC contingent considerations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Value of the contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | PCCCV contingent considerations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Value of the contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Interest Rate Collar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Interest rate collar</a></td>
<td class="nump">438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable securities &#8211; equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">36,908<span></span>
</td>
<td class="nump">21,836<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | AAMG contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Value of the contingent consideration</a></td>
<td class="nump">7,407<span></span>
</td>
<td class="nump">5,475<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | VOMG contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Value of the contingent consideration</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | DMG remaining equity interest purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent', window );">Remaining equity interest purchase</a></td>
<td class="nump">8,542<span></span>
</td>
<td class="nump">8,542<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Sun Labs remaining equity interest purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent', window );">Remaining equity interest purchase</a></td>
<td class="nump">7,278<span></span>
</td>
<td class="nump">7,802<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | ADSC contingent considerations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Value of the contingent consideration</a></td>
<td class="nump">3,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | CFC contingent considerations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Value of the contingent consideration</a></td>
<td class="nump">7,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | PCCCV contingent considerations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Value of the contingent consideration</a></td>
<td class="nump">2,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Interest Rate Collar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Interest rate collar</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Equity Interest Purchase Obligation, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=asth_AAMGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=asth_AAMGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=asth_VOMGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=asth_VOMGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=asth_DmgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=asth_DmgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=asth_ApolloSunLabsManagementLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=asth_ApolloSunLabsManagementLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=asth_ADSCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=asth_ADSCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=asth_CFCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=asth_CFCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=asth_PrimeCommunityCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=asth_PrimeCommunityCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=asth_InterestRateCollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=asth_InterestRateCollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464333542640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements of Financial Instruments - Schedule of Change in Fair Value of Level 3 Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 21,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdditions', window );">Additions</a></td>
<td class="nump">13,161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value of existing Level 3 liabilities</a></td>
<td class="nump">1,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 36,908<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability, Additions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464341181680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements of Financial Instruments - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,099<span></span>
</td>
<td class="num">$ (6,392)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,893<span></span>
</td>
<td class="nump">43,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,774<span></span>
</td>
<td class="nump">$ 40,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=asth_ApolloSunLabsManagementLLCMember', window );">Apollo-Sun Labs Management, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent', window );">Equity interest purchase obligation, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationChangeInFairValueOfEquityInterestPurchaseObligation', window );">Change in fair value of equity interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=asth_AAMGMember', window );">AAMG contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=asth_AAMGMember', window );">AAMG contingent consideration | 2023 Metric</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Equity interest issued, number of shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=asth_AAMGMember', window );">AAMG contingent consideration | 2024 Metric</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Equity interest issued, number of shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=asth_AAMGMember', window );">AAMG contingent consideration | Other Liabilities | 2023 Metric</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Value of the contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=asth_AAMGMember', window );">AAMG contingent consideration | Other Noncurrent Liabilities | 2023 Metric</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Value of the contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=asth_AAMGMember', window );">AAMG contingent consideration | Other Noncurrent Liabilities | 2024 Metric</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Value of the contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=asth_AdvancedDiagnosticAndSurgicalCenterIncMember', window );">Advanced Diagnostic and Surgical Center, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Value of the contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=asth_AdvancedDiagnosticAndSurgicalCenterIncMember', window );">Advanced Diagnostic and Surgical Center, Inc | Other Noncurrent Liabilities | 2023 Metric</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Value of the contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=asth_AdvancedDiagnosticAndSurgicalCenterIncMember', window );">Advanced Diagnostic and Surgical Center, Inc | Other Noncurrent Liabilities | 2024 Metric</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Value of the contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=asth_CommunityFamilyCareMedicalGroupIPAInc.Member', window );">Community Family Care Medical Group IPA, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Equity interest issued, number of shares (shares)</a></td>
<td class="nump">631,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=asth_CommunityFamilyCareMedicalGroupIPAInc.Member', window );">Community Family Care Medical Group IPA, Inc. | Other Noncurrent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Value of the contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationContingentConsiderationLiabilityEachMeasurementPeriod', window );">Contingent consideration, liability, each measurement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=asth_CommunityFamilyCareMedicalGroupIPAInc.Member', window );">Community Family Care Medical Group IPA, Inc. | Other Noncurrent Liabilities | First Metric</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Value of the contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=asth_CommunityFamilyCareMedicalGroupIPAInc.Member', window );">Community Family Care Medical Group IPA, Inc. | Other Noncurrent Liabilities | Second Metric</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Value of the contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=asth_CommunityFamilyCareMedicalGroupIPAInc.Member', window );">Community Family Care Medical Group IPA, Inc. | Other Noncurrent Liabilities | Third Metric</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Value of the contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=asth_PCCCVMember', window );">PCCCV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Value of the contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_DMGAndSunLabsMember', window );">DMG And Sun Labs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase', window );">Equity interest purchase obligation, period to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_DmgMember', window );">DMG remaining equity interest purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=asth_InterestRateCollarMember', window );">Interest Rate Collar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_DerivativeCeilingInterestRate', window );">Derivative, ceiling interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFloorInterestRate', window );">Derivative, floor interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.34%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asth_MarketableSecuritiesCurrentMaturityPeriod', window );">Short-term marketable securities, maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_BusinessCombinationChangeInFairValueOfEquityInterestPurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Change in Fair Value Of Equity Interest Purchase Obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_BusinessCombinationChangeInFairValueOfEquityInterestPurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_BusinessCombinationContingentConsiderationLiabilityEachMeasurementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Liability, Each Measurement Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_BusinessCombinationContingentConsiderationLiabilityEachMeasurementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Equity Interest Purchase Obligation, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Equity Interest Purchase Obligation, Period to Purchase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_DerivativeCeilingInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Ceiling Interest Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_DerivativeCeilingInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asth_MarketableSecuritiesCurrentMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable Securities, Current, Maturity Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asth_MarketableSecuritiesCurrentMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asth_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481326/860-20-50-4D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFloorInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Floor rate on an interest rate derivative such as an interest rate floor or collar. If market rates falls below the floor rate, a payment or receipt is triggered on the contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFloorInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=asth_ApolloSunLabsManagementLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=asth_ApolloSunLabsManagementLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=asth_AAMGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=asth_AAMGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=asth_A2023MetricMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=asth_A2023MetricMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=asth_A2024MetricMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=asth_A2024MetricMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=asth_AdvancedDiagnosticAndSurgicalCenterIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=asth_AdvancedDiagnosticAndSurgicalCenterIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=asth_CommunityFamilyCareMedicalGroupIPAInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=asth_CommunityFamilyCareMedicalGroupIPAInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=asth_FirstMetricMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=asth_FirstMetricMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=asth_SecondMetricMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=asth_SecondMetricMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=asth_ThirdMetricMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=asth_ThirdMetricMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=asth_PCCCVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=asth_PCCCVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_DMGAndSunLabsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_DMGAndSunLabsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_DmgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_DmgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=asth_InterestRateCollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=asth_InterestRateCollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464333792960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements of Financial Instruments - Schedule of Gain (Loss) on Equity Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Total losses recognized on equity securities</a></td>
<td class="num">$ (116)<span></span>
</td>
<td class="num">$ (4,353)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Gains recognized on equity securities sold</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized losses recognized on equity securities held at end of period</a></td>
<td class="num">$ (116)<span></span>
</td>
<td class="num">$ (4,353)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140464422407808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2024</div></th>
<th class="th"><div>May 09, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Drew down on revolver loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 393,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_IHealthIncMember', window );">I Health, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Revolver Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from Lines of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | I Health Promissiory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from promissory note</a></td>
<td class="nump">$ 8,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_IHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asth_IHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=asth_RevolverLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=asth_RevolverLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=asth_IHealthPromissioryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=asth_IHealthPromissioryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>109
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M<(]GP*1<[$?OUC"Y@>OUL>]N@6\0]/NN$[A.,W:OP.X=CQUV6JE@9;!LMH^
M=RB!!L%6 GY!P&\E\ QY0R[$ZYI": @55/; ]QOFA >PW.W)<X!@!7Y0P ]:
MX=](2573#G3;KO>W_4\3GY62OPD38Q\'P1:=NMS <1Q_QU+N%V3Z[6/!%4E0
MPLB$)4PQVLBKW<0.7OU:^(/ Z7N#+5IU,0]C;[!CB@T*6H-63#^( $H)10^9
MHC"3%+K/%%.OY^B1*_0DF*X]T"W-Z)2%#*Z;&+2ZT'72A9R3D%YWH!"25+S0
MSO#C!]NW+IO2RSL9JT3#MLKD:_W>G+W+%2OC9 =>;2MND/-<J[]K([8WZ@+[
MS3/P+K=16<S!P*^C;)!S_9WIPB[3M=V>KQ^R%YA%4(<JJ0L1,IT"6J)VH,4U
M%'@P:(AI@US@X)UHR_QLMR?HFY0O,H4B*"@4WP?6J6] MF77P;:Z_-T97"9L
MNSUCCX#+5/!T'YM6*\<NVMQ:)396X.P<H#*%V^TY?$P%S'1T UL1G5(AH.P8
MZV382*G5U-&4WLE:E7B9^NWVW%_R?4/IF_O85_ON%:MR*/._W9[(:QR.KH!S
M!Y7-M+$ /D"P2J+,^W9[UMY%XK BV*ZG;7OUVR:P7[!*H,SP=GN*WT7@B$HX
M][ )KC8 ;2+5SJ],QK@]&>>+__:0Q=]NZMC%_U[6JL3+5(_;4_V[+/[<Q][&
M=Y]8E<-&W]Y>"+Q]\>-ZUF]>_ <(5DF4]0%NKP_>MOAQO2WWS&\;_UZY*ORR
M%L#MM< [+'U<[\YKX6\3J2+7>;_ZI$R(N#TA0O>$GF.*H*N?D^SUXX<^MH-+
M"4UQ%M%, D>XDCQA$90\$9J0A&0A1>8@3I>B8;*(H,H#"\34^ CX;U;3B$\1
M4[)JY<?#O>P:MT>Z,;5Z[DC%1*&09&A"T4);X%GRJNM->*N@]>*3A,V(/G0U
M(%0SR2JHE0<]?B?0A70]E+(D,<>VP.H$&HYNOWQDS'XA(HR+@STC-Z(A32>P
MB:S/Z\X13(,Y-2>_"?2 6DAMMQV'8YQR@98Q [<AS$&F..Q9$4<9=)8Q>:'@
M+.0+(4WMK2W.H,T4X&PEO?8SSYO02=F$ZE<GT-=T_2IO:&&ZUIMYFP$'5,!A
M/;X%[O4 GT"?LA%U/7>*QJ?:]^3(;*MK;XH3TWG(>NO1"'LU%"?0]'3Q$4ZM
MH.L<X[0A,$3/7QT-V"$035C*,C/ BSF8+(=\/00Z1B8E9EIHR50,N-2AZZ>+
MQI3JDP>*;!^9F84OS7]L7>XXJM S\E1/MS,C9U^::3=="/ J4$0588GL-J7E
MWL8A?4K%S'SLT/,88K0ZXRV>%A]4;LUWA^WGV+NXPU[C&Q_>F&\PO=+%Z@L.
MC/",P9)/Z!3<6=T -E"Q^BBRNE%\;CX33+A2/#67,241%5H WD\Y!"J_T0Z*
M3U/#_P%02P,$%     @ H(.I6"99DH2/!@  @B   !@   !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6RU6FM3VS@4_2N:M-.A,X18DN,'A<Q @"TSRV. [GXV
ML9)X:ENII03:7[_R(U9LR8(PWB^-;>Z]/D>ZNN=*[LD+S7ZR)2$<O"9QRDX'
M2\Y7QZ,1FRU)$K CNB*I^,N<9DG Q6VV&+%51H*P<$KB$;(L9Y0$43J8G!3/
M[K/)"5WS.$K)?0;8.DF"[/<YB>G+Z0 .M@\>HL62YP]&DY-5L""/A/]8W6?B
M;E1'":.$I"RB*<C(_'1P!H^GV,\="HM_(O+"=JY!3N69TI_YS75X.K!R1"0F
M,YZ'",3/ADQ)'.>1!(Y?5=!!_<[<<?=Z&_VJ("_(/ >,3&G\;Q3RY>G &X"0
MS(-US!_HRW=2$1KG\68T9L6_X*6T=?P!F*T9ITGE+! D45K^!J_50.PXB#AZ
M!U0YH+:#W>& *P=<$"V1%;0N AY,3C+Z K+<6D3++XJQ*;P%FRC-I_&19^*O
MD?#CD^G=[<7E[>/E!1!7CW=_7U^</8F;QR?Q<W-Y^_0([J[ ]>WT[N82#,&/
MQPMP\/DK^ RB%#PMZ9H%:<A.1EP@R>.-9M5;S\NWHHZW8G!#4[YDX#(-2=CT
M'PD&-0VTI7&.C %O@NP(8'@(D(5L#9[I^]VQ 0ZN1Q47\7!'O >R(>F:Z :F
M=+3UCOFB/6:K8$9.!V)5,I)MR&#RY1-TK&\Z5CT%:W"T:XZV*?KDB?(@%BNY
MDVGI[A3N>3793&S+QF/G9+39Y:":8>PBVZ[-&NC&-;JQ<0;N5B0+>)0N 'D5
M)8\1;9:.^YR,GH(UZ#HU7<<X&5/*.*!SD,>-9H0="MJS>!WF Q 2\<)9%)1E
M,PU!D-",1W^*![I1*5\U;LR(A7V_-7&J&?)\[+OZB7-K)JZ1R5\D%3,7ET!#
M4?$BQO.9W!#C3+HJ9L]%J 59M4(0>DB/V*L1>T;$%_N.KZ>@&%M^>UFH1C;R
M.Y#Z-5+_'4O6-(R^.HRNC:#; J<Q@[;G0CT\:$DQLHP K],930B89S0!M%S!
M--7KBZ5"L"!NYZC&#"'LX@Z@.ZH)S>6%+TDF1+" >U"-Z%<M4-AGC>DK6I,V
MDK31N^>'_%I'_#=("%_24 S%AC N^CNNGRZDS(.#VZM38X1LKT,(H-1B:)1!
M 9H3,1A\F_A:?%AY]= =>^,V0HT91H[? 5%**31K:0VQS"@M0EM->%^I&CHK
MR^K")\44&L5K\B,56X0X^D-"L!!; W 04\:^ E'OWIKWL8('6HJ2:*R&#NZJ
M=E"*(C2K8KE**["&H565;&@CMUWT-&8065WI*?4.F@6O+,JT@+HMS8<@)5P+
M556PH0.QDJ<:,^0[75BETD&SU%7K_YF(_2,!JXQNHF(_)VZWQ9 'KWII@:JB
M(=O:&;\*NFH&?;LSA:7T0;/VW>\'5E4X%]I*P5*M'!]UJ""2*HC,*GA+3(4
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M_$W]/,DCG3,@S;9*K6.2\=/=Y0C:XR*JN1FZD-$L\\3<^R0NK\?5@:3_@@1
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MB6]H2A96TL\H\JV.9I_3]))-V\I]81>L<2#Y=Q1G"8,?QX5[OUO* _+Y^,5
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MC$84H07X?N' ?/A !_0_EW_[?U!+ P04    " "@@ZE8],=<34L,   5(@
M&    'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;-5:67/;1A+^*U.*-A6G8(H
M>/I0E2Q'B3=VHK*3[,/6/@R!(3DQ@*%G -'*K]^O>W!2E.1D]R4/-G',]-U?
M=P_T8F_L1[=5JA2?\ZQP+T^V9;E[=G;FDJW*I1N9G2KP9FUL+DO<VLV9VUDE
M4]Z49V?1>#P[RZ4N3LY?\+-K>_["5&6F"W5MA:OR7-K;5RHS^Y<GX4GSX+W>
M;$MZ<';^8B<WZH,J?]U=6]R=M512G:O":5,(J]8O3R["9Z\FM)X7_*;5WO6N
M!6FR,N8CW;Q)7YZ,22"5J:0D"A(_-^I291D1@AB?:IHG+4O:V+]NJ%^Q[M!E
M)9VZ--F_=%IN7YXL3D2JUK+*RO=F_X.J]9D2O<1DCO\7>[]V.CL12>5*D]>;
M(4&N"_\K/]=VZ&U8C._9$-4;(I;;,V(I7\M2GK^P9B\LK08UNF!5>3>$TP4Y
MY4-I\59C7WG^JG)XXIRX-/E*%Y),Y0)QX1P"XB+Y5&FGZV>R2,7WQJ1[G64O
MSDHP)Q)G2<WHE6<4W<,H%N],46Z=^*Y(53K<?P:A6\FC1O)7T8,$WTD[$G$8
MB&@<31Z@%[>6B)E>_"<LP3K?L87X]\7*E18!]9]C=O!L)L?94)(]<SN9J)<G
MR"*G[(TZ.?_ZJW V?OZ $I-6B<E#U/^?[GR0T7$U_B)W<9'>R")1J?A!R:S<
MBG>R " @]4OQX=:5*L>&MZ/KD?CFZZ\6431^?O'#NP]\&3Y_(GXNL,$FVS88
M E%N%<FPD\4MW5A3;;9"ET[LMR;+;H79%^#FJI73J086!6)7@0*R.Q42 IDU
MDP"(N1*2ZF(C-JI05F8L>*9S76+I3MH23]U6[X0N2@5#@ <V_T\*C03=">V$
M*C;8EH(VB[-JS L..VMN- N6M[0#D<"V@",\AH53P(6F."7<8[D-J! @[W;&
MEH*<IA/E1&G J81GZ'HKRYHX]+="6BN+C1* ?Y:!7S$B>R'6D =W,,R654VD
M52WED7B#%$I3=GH@3*'8.+6NX?SY?0XA2:"_%.]A4:L3,O:/A?G\]$<%-\#^
M"<H"GGF>8I?) KB)JUSE*SBDL=A;X\0%Q,\4#'XI,PTU"BVAE9(C\8LI(3?9
M#,I:G_"-GK*7[GOIQ.DL'BT!P%F&)_"0XU6)=%M^71A836J8V#-.,N/(.:DL
ME0_')L!@-$C/FV22V(HB#J[A)"I(3])#4[E*3%4@G';R5JXR[\!FA_J\(P.T
M>M)BCG;B"852;QY2S62:A$A1NS**2>%KO>0H&N;-2%Q;%%S*G+PJ='D+DUEV
MV25$H^#_#<FAD"UOBJ2+W>O+R\O?[F9CM'PT&P?R];.1K6]) V5+2=8@"&&1
M_XR((-3W^B!<<Y7JA-UOD0W>^4<U.AXG-4(<AHG<@<EGC6Y!(:I/P_$H;H+&
M9R<2DGR$[1P[ZXJJH:AVO;A1'#7L;^R@Y80; _9LB=.H(SX4_?Y]G5+OU1I8
M@-3_R8!9N!1/14WB2FI+9JR4>*>DJRR#"[.\ J@7B88UWA1(S(I?U#0Y=9ID
MQPI=^):1K57<+]*HY\PK"7UJG[ZK'?0]XF4GWEQ?'(3=Y=5E/^C^*8L*L?,E
M1>"OA!VXC>@_AJ6"Q/%0Z='7HT$/ ;'CST$15FQ842ZEE/6 8[*Z3*P!Y'MK
M6(")O]*IKZ%D.V79)0 *\/.TR@>@K44BQK4P&H^B^V+T=!F.QFV,/1*Q 2(R
MZBVO4Z1V08OX0*H<;]'9)A\#]/5UP6KLI)VK&*>P?09GSL,(D 7-V0W]S:/@
M"W)D?B1'R(U_KPQI^XG76FX* _\DK/N'RFXX20C]E#W(D(O7'XZFR+$,Z6)_
M.?U'XSJ%1\C*IK49=#9_61)H@SM?WM,A$=<029B(SS"9.=-T)-B3KZI,E@9J
MT&I%OVVW<5_DUT$-J8_AKH_@6F74D,+)I&W^'XZN>#2[$UVLW=\KO'[IQ0'\
M G]D69./L'Q2]YQK,,_T'Y2L1SH:U%V3#)#&#>ICW?13"ZJPH&Z+ZJ[$">X;
MJ]7OF-;)**!,;2>5U!HC2 (2D*9\;G/D3I.KP6M-!KMA@\GT=PS-;!;/SV'@
MAYTU_)T7>JUK$<TJTYN^_FOTH6;/NG&[Y4\I]!\UMJ,_HZZ_H/RY7_$ZB'KR
MD-"^B+0)YB<(N=*9;[GQ'GY,H6;&%8G:<8D&JM];( \.VPUN$KYA+YG*@:A[
M\HPK%$\//Y.=G?A6_(1FSS<P_O]6^$$08">E!;>PIV(Y#I;+!2X8M*/GN JC
M8#H>T\4X#B9X6:_WO6FS;A8'RWAZ>'MY3^2)>1#-)NWJ:;!8SD48!^$LY+K6
M #W7!!@F"H/E-&K7-[_U8Y)Q'$3A!%<U8SQ:!#&(GA+@!=/)S,^BKE:7$YPN
M".C@+\XR;)H%LSF1B4%F2DK'P30D<M-)$,9+Y!Y*- <990G"Y*.J@T8EE?5>
MQ;Y&P'@L%F/D>Z+ !,OP,HBGH0C#8#&9M\O">1#"L-=6L1O:'K^;W$#<$M,Z
MHEKZ,Y 2H'21^Y$A1>"MK<F%7*\190@4!Q66X^4=V_FG;\$BH$S?H>^Y989D
MD1UK>+AE$<7\[TV!T7BC>33Q\D2S8(P8B>)@03_!?!R+*<5-W(WZ"*UPLJ#A
M8#&?453%X0(^Q^\DZD][[);.@./!M8]DQ!'B:JUE3X0VR>#%201G45PLP0Q:
MXM$RF' 01[,0#$/QMDO#9^+BBR:N4S$)8HA^2M'+Y",.$7+F=-%VK?T$AV.G
MXP5'=CSO*1+,)M.!SY#Y/8\U"\$'HDXG=+&<4F$UF(!*^5EUHL835/79N$LF
MW,4+\9IJ#)D#JUN1;KO\#&8S.&H>XFH9AZA$!54)"RCT'5E=]P]#8!(M^-_0
M#^HXK)UR@H8$)S%2G!,K1*#$E$^+8 Z5/)T"2/683[\@P[]ML*^N^@3!4()G
MLK0'S:Z=X89L A:D:12ZISUXYA)/T<'3UDC\6L@JY1.A:VL$GQ8/*G57AW_Q
M%57P$RZH?DV_5M>%UR/*BH[-F].!^M"!#]>X8%!== >-MA\+KBX#+@3!@;!4
M4?6=V=6)K03() PP?(@Q[!7CT8'D?7F[HPOJ';9F[QL 9'O5GCZAZNP,I8\I
M,B^A]H<FA:+N H4VHSXSY?)\PV5S797H?/I*$CQUS5=?9;#[HG7<4.Y-E:50
MF [%DK*2?/[4J$YV..@#'9R@V"UJO:;VI!VDE-4F=9T!R$I6J<%)][!$!P"2
M1.U*VNO'&G2T# !/N"=G8]?Y8-6-*H *0)QEC(0AS(D743"915S5M0<"7Z]0
M,BD%@A@T>B\[-D_IXP7Z[%,Q'G'BC$>3>Y>F.JM*SKAN<<PA, B:O;*J.:BB
MW()=J*^^>X*6*UB N^]Z->"E;KL&K9(/[WO/XW@T9U<2P/!YB^^]?%JV:[K"
M1(%VITX=-F K/O=M)EK=[R?KYI"<YMIH.MY""7-3:WY7)T*4H5!]G#LB8:,)
MZ6A58BQ%$JXW=1T=B2L$IP'*94KR,3#T;UXB7ND)[=L4Z&!3;JZ/S>)4U9*R
M[5W=;:$P@<$DW#UXH.&C@$%&M8?%@Y9V<-PB*3@@B?20U1KCKJI^QH-\A 8.
MK8_U9V>=] %Z<6J'N:2H''M3'@(0&HGR_DD5*E7>?+1YL L_;+X;%:SB"S?$
M"X/N[J-JZX??7SFOD>=6JF1;Z$]44/9;U;2#->,:Y>AS*2&<O)$Z(Y][L8]C
M%MO^"$#?J :(DJQ*N\\"AT[MJHJ#:^O9L27*8P,G8DL<PO2FWL301PR8RR1:
M-@?2W;>'@5#DM[HS2FM?W_)#R,AXBF'?3RXEG=H.V0[/'SH3L^H,BHTG'\D6
MG[\T)?7<TH3D&FIYMR7:)E5.'W1XWFQ<T<Q6).%P%&ZBJI:)Q]]A7C^6QJB'
MAF1QPP+?XQ[ LB7'2&XX267!WTENE;2/.*WMJ>L@0TA4<"'Q9]1$R]>4W:%>
M5.,*(S3NM.4>GS*S[-"%ZBD-S- 87<W3#!7Y&(ZFF'7JLX"2ZU[NZY[BNC?\
MML >Z#J)>KRO(SB1UO*GB]:XK20-_C_.@,N!J^=X=V<R]GVV>.7/&X+#PS"J
MGO-%L$ 7W/]0V8XF%]VY@OAF.9X]Z2@=R(%R':)+G<W%L>^Y9[U/]3G EO\@
M@7I5".>_VK=/V[]YN/"?^KOE_@\FP'>C"ZH :VP=C^;3$V']'R'XF]+L^,/_
MRI2ER?ER"R!2EA;@_=J8LKDA!NU?@IS_%U!+ P04    " "@@ZE8[/EV,NX$
M   ;#   &0   'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6S%5]MN&S<0_96!
M8@020&N7>Y=C"Y#C)@V0!$8N+8JB#]0NI27")562&]G]^@ZYLJSXU@9MT1<O
M2<T<SN7,<'RZU>:+;3EW<-5)9<]&K7.;DRBR=<L[9J=ZPQ7^LM*F8PZW9AW9
MC>&L"4J=C)(X+J*."36:GX:S2S,_U;V30O%+ [;O.F:NS[G4V[,1'=T<?!#K
MUOF#:'ZZ86O^D;O/FTN#NVB/THB.*RNT L-79Z,%/3G/O'P0^$GPK3U8@_=D
MJ?47OWG3G(UB;Q"7O'8>@>'G*W_)I?1 :,;O.\S1_DJO>+B^07\5?$=?ELSR
MEUK^+!K7GHVJ$31\Q7KI/NCMCWSG3^[Q:BUM^ O;039/1U#WUNENIXP6=$(-
M7W:UB\.!0A4_HI#L%))@]W!1L/*".38_-7H+QDLCFE\$5X,V&B>43\I'9_!7
M@7IN_D8YIM9B*3DLK.7.$GC/W6GD$-M+1/4.YWS 21[!2>&=5JZU\(-J>/.M
M?H0V[0U+;@P[3YX$?,?,%%)*((F3[ F\=.]H&O#21_!>:]ULA93 5 /WO(8+
M86NI;6\X_+I86F>0+K\]%(;AENSA6WP)G=@-J_G9"&O$<O.5C^;/G]$B?O&$
M#]G>A^PI].](UI,X#UOY,#@L'& JZG:?"P*NY?!2=QNFKI\_JQ):OK @;K79
M3EMQ1Z#66+_6\0;T*BBNM,1&(-0:QD+AB>XM9L1.3N"SY:M>PENQXC#^A3-C
M)_#::&L/#%C4==_UDGE ;]WM+V^0=RNAA.,@L<Z;G1DG\,FP!AL9-CEX'RW@
M"!)"\QB_P?;DQ?[DK:BQV?!!C))9'.]%AMVBT\:)/Q#[GK<GWAK??[!1H778
M;VPK-A8H/4XHT#PGL[*",8U+0M-R EE%JHRB^0H['_8XYP,52(<Z.20)J=($
MY4L2Q\D$<MS&\(YW2V[NW% >TPR*&4DK"N,9.I)-H(A)DI1PB6(>NKN]98.J
MOI,#WD'B(H9Q^$SVGH9H*=;QR-W&+8DQ C'%"]($98L9A0O^%1OZ!F/A>-TJ
M+?7Z&@I !U%HAC*5CROZG=$9KL8TS4E)T94CC,F,E"B'S+K@]>#3CESI_T"N
M;VRXRZ][!OX+//L'-(I)4<X\C3)2Y1CE#(F!R?E+&A6D*##V!:'E(S2BL><1
M5G=<8@9+DF;Y!%"O1/W_@D=Q-8$R3I_F$5*Y3'W<XH3,:#'PB)*DJ#R/2DJ*
MK )\G$/N76LXAVYXA;A_A>XTKM#Y[Y$,XU#KM0KY8$-F0EB 7VV&=H#<.LJF
M&;Z^4H9! F&.TFE\<T 0PFYX&"_D-<&LXEB ?;46 Y"7_P99JV  J^O!!,]7
MS%OCKVL"J;443>"@=?CQ$0]F"(4:? J?#LQON.,&!P,?P98YCXQOV)994!H$
MR@@3,N;5$66@[O% W0/^81"E5NOC0TY#TQMOV_=%=PJO>N??T8>B"0*UK1-=
M\,YI6'KJ[^K6?\V=.K[VI>HO])N#:KQ7X%A5/;H93!GSJUKVS=^V?1(X1FB6
M^6VHFQ2)AVMD8H5%4_EU"30C95;X=044"5_E/A4X"Z\P!Y"@)!KV23LF0YO+
M29&7\-"['QT,;!TWZS"66DP]NC#,;OO3_>2[& :^6_%A;$9/UD)9D'R%JO&T
MS$=@AE%TV#B]">/?4CL<)L.RQ>F=&R^ OZ^T=C<;?\'^_X'YGU!+ P04
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M:A:@YTNE[/:"#;0?:M-_ %!+ P04    " "@@ZE8PG&2AQH$  "Q"0  &0
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MSM^^>S-*T_X-+\7AX.:[IMH2&NCO-2 \&07Z/&4U!_22\$.@4T;;#;;:.T:
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MST'M FB_5LJ>%B[!]!=;_PM02P,$%     @ H(.I6'YB'M1  P  30<  !D
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MG0O89^Q?S 28)3<-?MZKG?QBXX_8"O[MYQ<K,$5Z$!\R\6N9*3J5* _[;:V
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M\^F1[ZRJ+RXO^#=_B]Q!T_P1AH-;T *\7^; ZN$+'5#_"/3E_P%02P,$%
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MM3GS(F_[X%KDA:4'H^5IS7.X ?NY7FF\&_4HF:A &J$DT[ ^\\ZCXXN$Y)W
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MOR P8KE YTM8HVH8S"8>T^VIO+VQJG8GX3ME\5SME@5^R( F 7R_5LIN;\A
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MKW,\;H7==7GC=.8_'TZU<SKQEPO!X1L:@/<SK5UY0PM4WY,O_@=02P,$%
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M7#:RS#:JA[YG8C3BX#X3PY0!?B)]?]9YXRN;?,QX"D-3^AU.N^;2UV0RCR9
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MR]2A6"+7@#1H!5E+KV#L&ZQ4%'"!1B&P;2L</XI;E=R"Y[Q3/'5^ YX"S&^
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M ELO5/6#-V588N;&TTH4;G/:0=&R )TO#$VBYH$-M%OM^%]02P,$%     @
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M#1I:7>5W7NI;HV;&U J"W6B/]1V@R/5U@.%OF#?M4K>J@^0SF>CE?; X3@M
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M2Z/A"&@!WL\=?%+\00?TWX>_^E]02P,$%     @ H(.I6$XHK;*E P  ? @
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MT'0$04L0H/82^%-_'4]ID\![+DA=[C5)](<I/#G3<VYU!D[Y3C8-JIRS&GZ
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M=4M#!#BOM';C!PF8WO'7?P%02P,$%     @ H(.I6 $3YS2#!   . L  !D
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M#-$QZ_,O]#:+ED"KU>,0N@H>0GS4YF'$"PN4_[P<"L# E@AO5+T1S>V+9UG
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M<SQ*.4NB#(XTTWAHIO'?;J;O6NLZ_ZY(78;@[<W&=89#'?6HX<,==>=!['O
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M3[&/GNF4SNL"02S@J*1#09^D/1PT'0.@_J _B0AE6U\T]06J3I9WY6E22(/
M;NPGHERQZO7\0^I[R0U!VCC+-D[>Q4G'JV!5AI ).O1*$R^I,@P+4=#MP:LE
M7%"3$JQ6Y$)=7L.9,7E<5RA5SE=PAQF6,VIA$\JTHBYFQ5XF8$P\&6ON \+]
M29?>M,I$B7!'_B2?U<W6.S7W[)D5E.('G/.,^,9*B8PS38W1:/)N8/HT!I-#
MPSJK%8V4 C\Z@X_0M],XIM_&U+^A41#UW\P]U_;]")Y8QA<\Z]Q,2[8TDL]9
MN;J!1XJS$,M7F) .E$9=UH/0/0//COM>1^<GW="S$R^%R=@$]_#\:,/]_00"
M@PCL.'9W=FF\&P=V&L8PA2_("IUOW!@E6XN^':8['V]7V^OCJK&/HIW5GK/8
M2TBR']E)$C;9,;B/$ ?^NQS9:3_XW\I[<2^4NCQ1Y> WJQS9<1J^4>#;7AR]
M64DHM?W?*'.:I!U;NE?EE.H7!1Y\[]%1(PE+;$M]=061 2:VG^X:Y*+O7N[
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M8D4/'FJG0.=;144T+)R#TQ.Z_ =02P,$%     @ H(.I6.BZ;SV) P  ]P<
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M))MGIIEHL;.M?2TT/11VF-/+C-(8T/Y&T)UH)R9 ]];/_P502P,$%     @
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M"(V]S4X+_)D :03P?"F$[A;&0/][,OL)4$L#!!0    ( *"#J5A_YC+P>@8
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M:K.T\2[@.X,.3\[$5I)*^62-SWGL!580<,BT9:#F=80M<&Z)C(S? Z<WI;3
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MM->$VJM0F@VE.5":"Z5Y*%I7.8T%:^HMV/7+O:FH7=Z8[NH99RL%^H(IE.9
M:2Z4YE6T_-E??;<=75Y/ZGMM5P*-\VKJG=?/-,J*1\!RQ_+)[LGS7CWW;%E
M'5<HS8'27"C-JVCM2MV:=@OU4AC#UC*(F*7;8H6+4&G.$EDN%:B/UJMHEL7:
MD5?''>/&+=?"-)AR:<X]545+(DC$-@HYNIRIRC M5[N4.Y+OB\463UQ*'A>;
M.T:5R/(3U/<;SN7+3MY O>9H\2]02P,$%     @ H(.I6,ZE/P+5#@  !IL
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M8<JJ'57MQLBR&0]K:7#8-,L<ISLHZX#G&RG-?F,)^O]%\@=02P,$%     @
MH(.I6)W5S6-D!P  9C<  !D   !X;"]W;W)K<VAE971S+W-H965T-3(N>&UL
MM9MM;]LV$(#_BN 50PLTM?@J.TL,M FZ!4B&H&FW#\,^,#8="]6+)]%).^S'
MCY(5TY0HJE*H+XE?[LYWI^/Q(46=/:79UWS#N?"^Q5&2GT\V0FQ/I]-\N>$Q
MR]^E6Y[(;]9I%C,AWV8/TWR;<;8JE>)H"GV?3F,6)I/%6?G9;;8X2W<B"A-^
MFWGY+HY9]OT#C]*G\PF8/'_P*7S8B.*#Z>)LRQ[X'1=?MK>9?#<]6%F%,4_R
M,$V\C*_/)^_!Z05%A4(I\4?(G_*CUUX1RGV:?BW>7*W.)W[A$8_X4A0FF/SW
MR"]X%!66I!__5$8GA]\L%(]?/UO_6 8O@[EG.;](HS_#E=B<3V83;\77;!>)
M3^G3;[P*B!3VEFF4EW^]ITK6GWC+72[2N%*6'L1ALO_/OE6).%( N$4!5@KP
M1Q50I5!F;KKWK SKD@FV.,O2)R\KI*6UXD69FU);1A,FQ66\$YG\-I1Z8G&5
M")8\A/<1]][G.1?Y6^]W63PGWITLF-5.?IRNO8:0]_J2"Q9&^1LI^>7NTGO]
MZHWWR@L3[_,FW>4L6>5G4R'=*WYDNJQ<^;!W!;:X<L.R=QX";SWH0VQ0O["K
M7_+E01WIZE.9E$-FX"$SL+2'6NQ]#)-0\)-K664K0P;^NI;RWI7@<?ZW*=:]
M<6PV7@S.TWS+EOQ\(D=?SK-'/EG\_!.@_B^FR!T9T_* #GE -NN+]\OE+MY%
M3,@TO(_33(3_LF($FH+>6Z*EI:*!/"Y. "(!@&?3Q^-XC'( TME!3G,5'US%
M5E<_IX)%)K_V:N3H]P @E 0UMZS6!Z:9''PGUG*[2F3SV9=<-+#DB,N2<V1,
MRP4]Y():KZ.A*?V:I;FQI]#&I86$8#"O75J#F _G@)H++C@X&O1U5'9/DYN!
MH0+G@5^OP*98 "AN&1:S@Y<S^[#(V$I._A(,3)Y9=?M6C2-C6ICS0YCS,1OV
MW&4>'!G3\@!\-:?['67YW$N\?2]A90I.C7.RWQP9@/BUNNR2TAT]@@\P=M.K
M?L'1=7-E3<^'0@Y@G<G[73CX0Q>N0TIW5#$!L$/!=;B4*,_-E&=5[7U%'%G3
M U5$ ?"8304X0HHJ%V, "E"$ JR3?K_J),T);^XWJG,,R@ *,P =O?U82:;W
M!79D3<^'HAG0A3,]+K"!: P7V/J#0P-2X /LY"-AK-A%\#(>E6N6?!-NS3W+
M*06YLJ9'K3@(C I"P"D)N;*FK^$5"D$["E4K5IF(4"6"=2TJ8!-W "'S8%8K
M;Z.<3X.Y>7Z%"HR@%31Z+;HK4\=.G  _ *B^N# +XAEI<_=HJ\3.+:T+[TKO
M>*6/9S,,ZIX9Q,@,MF *5)@"[9AB'/_>?]Z-'"'Q+C9Z[)1>7%G3XU?T D>E
M%^B47EQ9TW.AZ 7:Z>5+SM>[R+L.U]P8JUT; .\[9YFI6UP,4M6C4,@"[5LC
MK17-OK56M%-$<65-CU\A"@Q&K6A'/%+E8@RZ@8INH)UNNBK:K@UM%3U$58]"
MT0JT$L#BAB7L@<<\$=XR343&EL(\)SO%$E?6]"UUA27('[.,D15Z^N;"E34]
M%XIUD)UU.LJX0QN0]C(>I*I'H1 (V1%H&&BB)OA .$.-^R5=8KK31[=V'-[;
M009Z#'R_X:M)CE+:YJR"&33P[@YJWMXA,U1?BAJDJ/2_Q2N%%<@^N]_P^)YG
MW2M,NYG>0W:,C1.D* 39-TY>VKZ<$HDK:WHN%)$@^Z;)P('?W#ZA<S2K+XP,
M8A#[0=!2M0H=D'T&[S7P9\T!/0<$UUTUB 4(DQ97%1\@.Q^T#_MYHRE2'\+Z
MJM<@!FC0UCNQFL*Q?6?!-/#M2TN[P;YE[\J:'KZ:M;']ULT+6P!V>MO&E34]
M%VKNQ_:YOX-@.K2#=H#IT 1^)\!@Q0+8S@)M]=R^L+0;['T-Q]@JP4='1T;=
M*L%.MTI<6=-SH9@&OVBKI$,;8$M!#U'5HU"0@NU;);>RCHM59:P6F%M9V\71
M1V-43J'$E34]=@4E>-1M$NQTF\25-3T7BG7PB[9).K0MR\LAFGH,"H*P'8*&
M029NH@_T:7UAU"6E'V=3?$0Z[KST0$S2O(]R8O"T4TQW5;$,L6\$M")FI7><
MFH9/-A'='\43I.-V2G%@*V$QGPKKT2V[F=XG_L8X94H4?Q T9LLB3F'$E34]
M%PI&B'VKHZ-E=6A#(Q96@0U1U:,X.M%JG\V'-:W*J+9>\T%]8=PEI;NLF('8
MF:%7TVJ>*3U!L-$?3%)^RXE.HB9X8M]U:&]907-5/&]DKRD4^*C%)S71$ON$
M=\D?>91N9>H$7VZ2-$H?OAM=='K8PI4U/6@U,Y-1#UL0IW<U7%G33VVK*9_:
MI_R.MM6A3=N[UA!-/0;% K3CY,6@ID6;%  :A[L[A'2'%2S0CAL//5H6;9X&
M/4&-H_(F(=SBIIK>J7U[H;5AT>;#(+1^SL8@$]3;U?3H(:CB";0;ECV$2>Y%
M?"V5_'>!#"C;/]2U?R/2;?E<U'TJ1!J7+S=<XE96",COUVDJGM\4CUH='JU;
M_ ]02P,$%     @ H(.I6"X2Q-R6 @  ?P8  !D   !X;"]W;W)K<VAE971S
M+W-H965T-3,N>&ULK55=;YLP%/TK%INF5FH+ 9)-'4'*Q];EH5/5JMO#M <'
M+L&JL9GMA&Z_?M>&T*1-HSTL#\$V]YQ[[K5]2!JI'G0)8,ACQ84>>Z4Q]:7O
MZZR$BNH+68/ -X54%34X52M?UPIH[D 5]\,@&/D59<)+$[=VH])$K@UG FX4
MT>NJHNKW%+ALQM[ VR[<LE5I[(*?)C5=P1V8^_I&X<SO67)6@=!,"J*@&'N3
MP>5L:.-=P#<&C=X9$UO)4LH'.UGD8R^P@H!#9BP#Q<<&9L"Y)4(9OSI.KT]I
M@;OC+?MG5SO6LJ0:9I)_9[DIQ]X'C^10T#4WM[+Y ET]3F FN7;_I&EC1QB<
MK;6150=&!143[9,^=GW8 2#/84#8 <+G@/@50-0!(E=HJ\R5-:>&IHF2#5$V
M&MGLP/7&H;$:)NPNWAF%;QGB3+H0AHH56W(@$ZW!Z#/R%<_..9GD.;.-IIPL
M1'M:;-M/YF HX_H40^[OYN3D[6GB&Q1BZ?RL2SIMDX:O)(W(M12FU.23R"'?
MQ_M80%]%N*UB&AXEO*;J@D2#,Q(&87Q S^S?X=$1.5'?U,CQ1:_P74F9-XQS
M0D5.7G28S)G.N-1K!>3'9*F-PK/\\U 7VRSQX2SV?E_JFF8P]O ":U ;\-)W
M;P:CX..A%OPGLKV&Q'U#XF/LZ:22RK _[1&"1[0@#8<*;EE&CL7ZSR:-X\#^
M$G^S6\O+N"C8C]N3.>QE#H_*7%0U90H]RA!9D(()9N"<H\WDA#WM(G6[>$C^
M\(6LY\*/1;22_9V[7(%:.8O3))-K8=H+T:_V+CIQYO%L?8KNVIKA$TUKS7C<
M5TQHPJ% RN#B/:I2K=VU$R-KYQA+:=!_W+#$+P0H&X#O"RG-=F(3]-^<]"]0
M2P,$%     @ H(.I6,*Y/%^^ @  &@<  !D   !X;"]W;W)K<VAE971S+W-H
M965T-30N>&ULA95=;],P%(;_RE&8T":-Y?NCHXVT,0:[ $WK!A>("S<Y;:PY
M=K&=MO#KL9,N*C1K;Q+;.><\[^LX)^.UD,^J0M2PJ1E7$Z?2>GGINJJHL";J
M0BR1FR=S(6NBS50N7+642,HVJ69NX'F)6Q/*G7S<KMW+?"P:S2C'>PFJJ6LB
M?U\C$^N)XSLO"P]T46F[X.;C)5G@%/73\EZ:F=M7*6F-7%'!0>)\XESYE]<C
M&]\&?*.X5CMCL$YF0CS;R5TY<3PK"!D6VE8@YK;"#\B8+61D_-K6='JD3=P=
MOU2_;;T;+S.B\(-@WVFIJXF3.5#BG#1,/XCU9]SZB6V]0C#57F&]C?4<*!JE
M1;U--@IJRKL[V6SW82<A"%Y)"+8)0:N[ [4J;X@F^5B*-4@;;:K906NUS3;B
M*+<O9:JE>4I-GL[ON"9\06<,X4HIU.H<OIJC\ ZFYO67C5D6<[AM="--0"VD
MIG](NYT?-^9<*(33&]2$,G4&)T Y/%:B4827:NQJ(\]"W&(KY;J3$KPBY0N1
M%Q#ZYQ!X001/TQLX/3G[MXQKW/46@]YBT-8-7ZG[28AR31D#(POV_,(-5043
MRAK\<3536IJ#\G-(?4>)ABGVX[E42U+@Q#%?AT*Y0B=_^\9/O/<'/(2]A_!0
M]=QL20BGN"E84U*^ %TA<!,#M>"Z4H"\Q!*FN-18SU!"Z+7;&)X-&>E028NR
M'^W*E/>C:.RN!A1&O<+HF,)X"-9EQ;NP($S#85C<P^)CL&0(%N_!_,Q/LV%8
MTL.28[!T");LPZ(T2H9A:0]+C\&R(5BZ#PN\+!Z&93TL.PA[K- T\KE&.83,
M]M]<YH?^,'+4(T>'D4(3-D0;[1U*WX^3./T/Y^ZT.OO7,$UC0;D"AG.3Z%VD
M1J_L.G$WT6+9=K^9T*:7ML/*_+Q0V@#S?"Z$?IG8AMK_#O._4$L#!!0    (
M *"#J5BF]=<'$@@  +\Z   9    >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM
M;+V;47.CMA;'OXK&[=UI9[:Q)2&!=Q//)-YVFIG-369S>_O0N0_$5FRF&%R0
MD^ZWOP*S%D)P@$;)RZ[M'/TYYP#G=R30^7.:_9EOA9#H[UV<Y!>3K93[#]-I
MOMJ*79B?I7N1J+\\IMDNE.IKMIGF^TR$ZW+0+IZ2V8Q/=V&43!;GY6]WV>(\
M/<@X2L1=AO+#;A=F7Z]$G#Y?3/#DVP]?HLU6%C],%^?[<"/NA?QM?Y>I;].3
MRCK:B22/T@1EXO%B<HD_+/UR0&GQWT@\Y[7/J CE(4W_++Y<KR\FL\(C$8N5
M+"1"]=^36(HX+I24'W]5HI/3,8N!]<_?U'\I@U?!/(2Y6*;Q[]%:;B\FP02M
MQ6-XB.67]/E7407$"KU5&N?EO^BYLIU-T.J0RW17#58>[*+D^'_X=Y6(V@"E
MTSZ 5 -(<X#7,8!6 V@9Z-&S,JQ/H0P7YUGZC++"6JD5'\K<E*-5-%%2G,9[
MF:F_1FJ<7%PG3R*7ZKS('$4)NI5;D:&?$QG)2.3H)W2OKIOU(18H?40__W6(
MY%=T(^0V7:/ZR!\^"1E&<?ZC&O';_2?TP_<_HN\+O?]LTT,>)NO\?"J5M\4Q
MIZO*LZNC9Z3#,XINTD1N<^7-6JS-\5,5Y2E4\BW4*P(*WH39&:+X/2(SXK7X
MLQP^G +NT%/F::E'._2ZL_G'ES2.D;I*G\-L_;^VS!V5O7;EXL[_D._#E;B8
MJ%L[%]F3F"S>?8?Y[&-;V([$C"1XIR1XD/KB2FRB)(F2#;H*XS!9B;9HCQ*\
ME"C*TM.",-]7I_"I'H9MY<W(?'ZR,OQC)_\8Z-]UHFZ$,*Z=GC8'CQJL=NBY
M%_@-_VPC2EB[=_SD'0>]NXSC=!66Y5#=GO]61?\Z6:6[UB1RZ_"<DH:+M@WQ
M J_=1__DHP_Z^"G*918]' HOV_SRK6/.&EY!%H9+P<FE '1)%92>*RZPKB7*
M@CEM.&9;>13/@G;GYB?GYJ!SG\/[,%;U]D:LHY6Z\B[S/%U%H535^-UW <'X
M([J^NT3%L.*D/QQR]2EOK:_@@<96"4=B1D[P3%-J!A;+81CZXW.1E6LI=GEK
MV:P.XB@CKM3,E-3 C<$+Y5]%+FZ?$Y'EVVC?&FZ%_EG]UCFK%9TJCCXSTT&B
M'22O!KA*VM69<J1F)D*#'H,('0:Y2J->3>8!Y\US95LQWE6BL:8PAC$\#'.5
M"%2K01/3.8U@##-X#.5P"V79O.FD;40P[[K>-8PQ3.,^TF$;KU;Z(!/3+<U?
M# .XGW:50/VBPC-BUPG;S ^\C@8+:QACF,9WX2IZC%8GX%WOPDWA\+MPM_^(
M;M6ICM/-5[14%Z7(WA?G_JPU"/ HHRN&(S4S)[H'P/.WP)W3!L"5FCEWTQT
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MMZIQVWNPKS'EYYK<'";WJ'=F^_D-'^V?1J-1SV'4]S&40U/T*H+7>%^ ZRZ
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M[4M5#:Z:H"Q=CWB0:#J.&^;FFP"4#3#/YU+B9F(3-%\9R6]02P,$%     @
MH(.I6&ZT5 ]; P  D0P  !D   !X;"]W;W)K<VAE971S+W-H965T-3<N>&UL
MO5?;;N,V$/V5@;HH$B"U+K[$26T#B=/=9K$I@AC;/A1]H*6Q32Q%JB1M;X!^
M_ XI12L'BA8)C/K!$B6>,W...-1HLE?ZB]D@6OB:"VFFP<;:XC(,3;K!G)F>
M*E#2G972.;,TU.O0%!I9YD&Y"),H&H4YXS*83?RU>SV;J*T57.*]!K/-<Z8?
MKU&H_32(@Z<+#WR]L>Y".)L4;(T+M)^+>TVCL&;)>([2<"5!XVH:7,67\]@#
M_(P_.>Y-XQR<E*527]S@-IL&D<L(!:;643 Z['".0C@FRN/?BC2H8SI@\_R)
M_;T73V*6S.!<B;]X9C?38!Q ABNV%?9![7_'2M#0\:5*&/\/^VIN%$"Z-5;E
M%9@RR+DLC^QK940#0#SM@*0"),\!@Q< _0K0]T++S+RL&V;9;*+5'K2;36SN
MQ'OCT:2&2_<8%U;374XX._NDF#3P@"GR'5L*A),;M(P+<PJ_P.?%#9R\.X5W
MP"7<<2'(>#,)+<5UZ#"M8ER7,9(78L1PIZ3=&/A-9I@=XD/*MTXZ>4KZ.NDD
M_+@5/>C'9Y!$2;\EG_D/X$SV(+GP\$%'.OW:P[[G&[S =RNM9G.F$>9*[E!;
M[HR\URKGQBC]"'\HBTV/_SN8N,!TJS%[#FCSN3,/5_&7IF I3@,J:8-ZA\'L
MYY_B4?1KFTE'(CNP;%!;-O#L_1<LNTI3M976G'FI="C7(9,9O.>2R93+==.Q
MOS\1 =Q:S,T_;<8,CFG,D<@.C!G6Q@P[U](#[I38.?4IK0EN8<52+KA]!(LZ
M;Y/>S3>$1V2ZK6CGG< WRAS5,D>=:=W@TIY!H3D]Z8()]Q9ITU:2C#R)>R'M
M9LEP$NZ:*CKCO%'%>:WB_$>%C\1J03,J\!-&"Q@*U"E*>]HFIV2+XX:>J!>-
MQ_$S39U1WZAI7&L:=VJZOEHLX(Z67DJ/Y8-6VX*VJP5*KO1K=JK.(*\MR".1
M'?AQ4?MQ\;_N5!?'-.9(9 ?&Q-'WUB$Z1A%WL[Q6<L5VL"=$=?T<*FDT0?%1
M"[F;[M62XO9](8FCQB]^)C)L-'TYZK7OA0WXU5KV?_75NM^^\EUF^'UZV:S?
M,;WFM*@%K@@:]<[IU:#+_K<<6%7X%G*I+#6D_G1#WPRHW02ZOU)4&]7 !:B_
M0F;? %!+ P04    " "@@ZE8Y;R0E$\#  !6"@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970U."YX;6RMEM]OTS 0Q_\5*TR(2;#\3IK15MI:$'M 5-N !\2#
MFUY7"R<.MM-N_SVVDV5MXP8>>&GMY.[KSUU\9X]WC/\2&P")'@M:BHFSD;*Z
M=%V1;Z# XH)54*HW:\8++-64/[BBXH!7QJF@;N!YB5M@4CK3L7FVX-,QJR4E
M)2PX$G518/YT#93M)H[O/#^X)0\;J1^XTW&%'^ .Y-=JP=7,[516I(!2$%8B
M#NN)<^5?SGSC8"R^$=B)O3'2H2P9^Z4G-ZN)XVDBH)!++8'5WQ9F0*E64AR_
M6U&G6U,[[H^?U3^:X%4P2RQ@QNAWLI*;B3-RT K6N*;RENT^01M0K/5R1H7Y
M1;O&-@T=E-="LJ)U5@0%*9M__-@F8L_!CTXX!*U#\*\.8>L0FD ;,A/6'$L\
M'7.V0UQ;*S4],+DQWBH:4NK/>">Y>DN4GYQ>Y3FK2RG0 C_A)06$RQ52#WD-
M*_3A4>T6 0*]F8/$A(IS] Y]O9NC-V?GZ R1$MUO6"V4BQB[4M%H33=O5[YN
M5@Y.K/P9\PL4^F]1X 61Q7TV[#Z'O',/#]U=E8,N$4&7B,#HA2?TVOC%2P(P
M%>C'U5)(KO;:3UN C6)D5]0%>"DJG,/$414F@&_!F;Y^Y2?>>UNX_TGL(/BP
M"SX<4G_9!=7>+F!R US569,*6_R-:&)$=;_83D?1*$G'[G8_L+Y5YJ5Q9W0
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M$QMFLKD?- LMMO6(O13:#.SUX\;<J4!6 N;]2IC)HEU4!KI;VNQ?4$L#!!0
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M!A<P=?1FD" VX.1?O_BQ]_V3I.&0-/S,/3>-CV7J5+%5F>VVR?W$\[S,W8S
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MOWIWTC^)SO.JRC?;%R]MLK1%\P'U^U=Y7CV\T@QPFQ=_;!_VV?\#4$L#!!0
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M-:]WO[<R]6;\'19+RB1D9*$EO8M+W2U1[V_7)XH7U8[O(U>*Y]5A2G!"1-E
MWU]PKEY.R@3MOPRS_P!02P,$%     @ H(.I6'TC)'T/ P  KPL  !D   !X
M;"]W;W)K<VAE971S+W-H965T-C0N>&ULQ59=;]HP%/TK5E9-K;0V(5] !Y&
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M<TQRD5W)9@^*)^96<\:5XI$I+AGUF= -\/V<<_7RH <H+L;'_P-02P,$%
M  @ H(.I6']LTGT'!0  0AP  !D   !X;"]W;W)K<VAE971S+W-H965T-C8N
M>&ULM9E;;Z,X&(;_BL6.5JW4!FS(J9M$:I(9[5Q46_4PH[ETP4E0 6=MIVG_
M_1I#(1#BP,ISDW#P]]K?@[%?X\F>LE>^(42 ]SA*^-3:"+&]L6WN;TB,>8]N
M22+OK"B+L9"G;&WS+2,X4$%Q9"/'&=@Q#A-K-E'7[MEL0G<B"A-RSP#?Q3%F
M'W,2T?W4@M;GA8=PO1'I!7LVV>(U>23B>7O/Y)E=J 1A3!(>T@0PLII:M_!F
MB5 :H$K\",F>'QR#-)472E_3D^_!U'+2%I&(^"*5P/+OC2Q(%*5*LAW_YJ)6
M46<:>'C\J?Y-)2^3><&<+&CT,PS$9FJ-+!"0%=Y%XH'N_R9Y0OU4SZ<15[]@
MGY=U+.#ON*!Q'BQ;$(=)]H_?<Q ' <@[$8#R %0+@*<"W#S K=?@G@CP\@!/
MD<E241R66.#9A-$]8&EIJ98>*)@J6J8?)NES?Q1,W@UEG)@]"NJ_7L\EN0 L
M:"R[$\?J@5R#1]G'@EU$ %T!50S\LU6WGAB6I=1SX^ Y"0BKWK^/Y'UPL20"
MAQ&_E%+/CTMP\>42? $VX!O," =A(D-#P:_D17G\M*$[CI. 3VPATTH;9_MY
M"O,L!70B!1?<T41L./@JFQ(TQ"_U\1!I!&S)LX"*/J'.D5;Q#K,><.$50 [R
M&AJT:!_N-N6C#U\2_U1X)1NWZ"*NTG-/=1'UP)J>2Q;G-<>E(]8-WV*?3"TY
M)''"WH@U^_,/.'#^:F)B4FQI2*S"RRMX>3KUV9RLPR0)D[4<D.2;X!-P(3MX
MUNTOFS!F<GTEEX[3;S-O/!@/G8G]=@A(6VM70,=U]AT/>;"HLY)ZOTB]KTT]
M&P X6,L10L@1Y4SB_:-&U'/65M<U9T-B%3*#@LR@%1GR3I@?\O-L!F?9')>X
MAJCO.+5R2VW#_F?:PR+M8:NTI4%9D;!%EQ@>)S5$0UA+75MIUVYA2*S"9U3P
M&;7B(QT9%W+ZDZ/&%2#JO^WH,6HW>FC;T179<9VZT6-<P!AW>4?P2W0V^?%Q
M\OTQ].K):^OMFKPAL0HBZ)1^S='.QC^5DY4OTNT;8=*9@Z_YB +N6>B31OOD
MF)RGC:HM3:E5:1ZX7]C]_7MIG, #&D68<;"5=E?UR,8.F=<W.NB1KM=SW%J'
MU#>K,T1#:E6(J(2(.L_Z+6FAL[.<ON[.I RI54F53AIJC><)%]"2E7N>E5$/
M;4JMRJITT5!OHYNM0TM6F31$E1FJUQ_4@1GUU*;4JL!*[PW;F>]S7J(EPOXQ
M0M?M#<=UA$8M>JYV>OBLLBG=-^QDOPMKT9+%X*A5:-1SO#H*0TX[1_$[?#LL
MC3L<=O,9#R3]C)AVI@5-!,.^V.$(/!$6@XM?1$)L1F?2JB^,JBU-J54)E]8?
M=O;^C03U*A!\2/A@".+L&]88!/BCZ6O-0B_4&9Z^64@UBP.8M0L,&II5Y5:N
M$F#G94(C-[U*SLW[Y(9&I\$973Z84JM^F2S7#TB_?KA=KQE98T' =_D6APD/
M?? #1[ML/(S#*$KA-K[+R.@ZPJC:TI1:E6JYCD"=UQ&-!#.5P<%$,O+J'VP6
M^KHZDSFNTQL>U%G-N#3]J)WI/_,6YBKG,C9J\DVI963L@\V5F+"UVJ3BP*>[
M1&1; L758B/L5FW_U*[/X<TBV\XJ9;+=M3O,Y(J3@XBLI*33&TH7Q+(-J^Q$
MT*W:PGFA0M!8'6X(#@A+"\C[*TK%YTE:0;%M./L/4$L#!!0    ( *"#J5B&
M^VOT= (  #\&   9    >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;+65;6O;
M,!#'OXKPRFAAU(Z3N ]S#$G*6*&%TK3;B[$7BGV)1?602>>DA7WXG6S79&N:
MC4'?Q#KY[G^_.TN7=&/L@RL!D#TJJ=TH*!%7YV'H\A(4=\=F!9K>+(Q5',FT
MR]"M+/"B#E(RC*,H"147.LC2>N_&9JFI4 H--Y:Y2BENGR8@S684](+GC5NQ
M+-%OA%FZXDN8 =ZO;BQ98:=2" 7:":.9A<4H&/?.)XGWKQV^"-BXK37SE<R-
M>?#&93$*(@\$$G+T"IP>:YB"E%Z(,'ZTFD&7T@=NKY_5/]6U4RUS[F!JY%=1
M8#D*3@-6P()7$F_-YC.T]0R]7FZDJW_9IO%-3@*65PZ-:H.)0 G=//ECVX>M
M@#A^)2!N ^*:NTE44UYPY%EJS899[TUJ?E&76D<3G-#^H\S0TEM!<9A-C5("
MJ<OH&-<%FQJ-0B]!YP(<.[P Y$*Z(W; A&9WI:D<>;DT1,KM%<*\S3-I\L2O
MY+GF]ICU>Q]8',4#=C^[8(<'1[_+A(3>\<<=?USK]O^!?_R"_]L5N;-+!.6^
M[V)NM >[M?U].'<KGL,HH /OP*XAR-Z_ZR71QSWD_8Z\OT\]&RM3:61T41Q2
M3PEZ%V&CD=0:_H*ML_Y9/QZ>I>%Z1^Y!EWOPE]R@"Z!N62@$LO'2 O@>LI_L
MSE;"(9MP_4#6S*/-G]@5(()US"S:F%VL>W/^9S>'747#-SP'PS<@3SKR9.^W
MN.:/0E6*2<-I2*WINO&YD *?=H$F+X]#[S2*_C@-X=8\\*.5+M]2:,<D+"@N
M.CZA>FTSKAH#S:H>$7.#-'#J94D3'JQWH/<+8_#9\%.G^\_(?@%02P,$%
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MG&3EY1JC&%,9(+Y?$L+W-W*"YDAR\A]02P,$%     @ H(.I6$\/YTI" @
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MC;17HFXOZXGB&]MPW7*EVS<[+'1+#L(8Z/<KSM5N8C9HF_SY;U!+ P04
M" "@@ZE8H!\0;>$"  !R"   &0   'AL+W=O<FMS:&5E=',O<VAE970W,BYX
M;6RUEEUOFS 4AO^*Q::JE;9 ^$S;!*E-.VT7E:)&6R^F73AP$JP"9K9)NG^_
M8T,HC6C43=M-@LUY7Y_'X'.8[KAXE!F (D]%7LJ9E2E57=BV3#(HJ!SQ"DJ\
ML^:BH J'8F/+2@!-C:C(;==Q0KN@K+3BJ9E;B'C*:Y6S$A:"R+HHJ/AU#3G?
MS:RQM9^X9YM,Z0D[GE9T TM07ZN%P)'=N:2L@%(R7A(!ZYEU-;Z81SK>!'QC
ML).]:Z))5IP_ZL&7=&8Y.B'((5':@>+?%N:0Y]H(T_C9>EK=DEK8O]Z[?S+L
MR+*B$N8\?V"IRF;6Q"(IK&F=JWN^^PPM3Z#]$IY+\TMV;:QCD:26BA>M&#,H
M6-G\TZ=V'WH"]!D6N*W /13XKPB\5N 9T"8S@W5#%8VG@N^(T-'HIB_,WA@U
MTK!2/\6E$GB7H4[%MU24K-Q(L@!!EAD50#Z2);XK:9T#X6LR$##G154KJA^#
M)*<WH"C+Y1GJWA.;2!TBI[;"Y/02=M(F<MTDXKZ2B$?N>*DR26[+%-*7>ANA
M.C)W3W;M'C6\HV)$O/$'XCJN/Y#/_.UR[T@Z7K?1GO'SWK[1WZ]64@E\D7\,
M;5=CYP_;Z<-](2N:P,S"TRM!;,&*3]Z-0^=RB/4?F;T@]SMR_YC[,WF%Y.;U
M("?O)NYX?*D/($O(*2M)RO.<BE[,V=">- M-S$*Z/FUC9^2-I_:VSSH4Y$ZZ
MH!<,0<<0_"U#RO):0?H'%,%;*(:"7J,(.XKP*,6#*6J8*]V"P!K='E9]S!->
M%%A5L=XDCP2KO52T3)%XX%$UHD&R9OF@E[0?N:'C!8=T X%A$ 2^$PX31AUA
M]-\(^P_R"&,TP!B>GP=>=, X$!B>!WXXB0X8[5[Y+D!L3%>3F'!=JJ;>=;-=
MX[PR_>)@_AH;:M/_GFV:;HS5;,.P6N>P1DMG%&%:HNEPS4#QRC2)%5?8<LQE
MAA\%('0 WE]SKO8#O4#WF1'_!E!+ P04    " "@@ZE8!6MCIH #   ]#0
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M$1J./F!ZW7;,=F)5[9O.2EEL87Y8XD\&M O _;52=C]Q"?K?5O8'4$L#!!0
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M&F38=IQQ86(T')&W?E/ ']'P1^!]>Y_.=BI!D2^HMRRHMWDH;\.:T,A'X"V
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MEQN@Z*!, #Y?":%?&Z:#YB G_A]02P,$%     @ H(.I6&OL=V0% P  +@D
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M#JU7',+2(;1""V96UA75-!I(L2'26".:Z=C86&]4P[C9Q:F6^)>AGXX^ \9
MD7,RQ?Q(5BD0,2<3D>6" ]?*C*P)N7[!Q,'V] HT9:GZ@#Y/TRMR>O*!G!#&
MR>-2K!3EB1KX&HD9>#\N28P+$L$K)$)R)[A>*G+-$TCV_7T45*D*MJK&02W@
M'947)&R>D: 1M!Q\)O_O'M;0":L@AQ8OK _R]]%,:8F)^\,5H@*BY88PA_E2
MY32&H8>G58%<@Q>]?]?L-#ZZ]+T1V)[:5J6V58<>?<E!4LWX@J0V<V*AM$MP
M@=*Q*.:R64=AL]T?^.M=(<=&S6Z[61GM$6Q7!-NUVW'#..4Q_(->^RWWXXW
M]N1V*KF=VOT894)J]IO::Q//<R$;BO/L4E[ M?=B?K@O#IMVR[TMW8IGMY;G
M+=> ZC5!F@7'E-$92YEFX+Q4ND<<@M8!38=)X&;9JUCV:EE.5[."'..QR)SQ
MZQTM>AX$G0-F+J-6S\VM7W'KUW)[%)JF.VE]1C@X<[OO.'KA(<-CHV9G)P\*
MAOY.Z<E +FQ%5KCZBNOBOJYFJZ(_LK7N8'Z,CX&B=O^%*5X2>!LO&%>H:XZ0
MC8LN!DT6U;D8:)'; C<3&LNE[2[Q00/2&.#_N1!Z.S +5$^DZ ]02P,$%
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M'1Z1R:JL\L6FL1K!(LG6?^,_-_\1.PT<_XD&[J:!N]\@>**!MVG@O;0'?]/
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M=U#/%TRMDZJA ]3'W-/_ 5!+ P04    " "@@ZE8]+7(*S@#  #L$P  #0
M 'AL+W-T>6QE<RYX;6S=6%UOVC 4_2M1NDZM-#5 UI2L@+0A59JT397:A[U5
MACC!DF-GCNE@OWZ^=@@?]46L#QLLJ,2^Q^?<8_NF<3NH]9+3AQFE.EB47-3#
M<*9U]2&*ZNF,EJ2^DA45!LFE*HDV755$=:4HR6H@E3SJ=3I)5!(FPM% S,N[
M4M?!5,Z%'H9)&PK<[7,V#+O)^S!P<F.9T6'X=/'VQUSJVS>!NY^].SOK/%W>
M[L8O+' 91E[1ZP-$KSH=7!A 3#PY3'R?-B9]<Y#T'F5,N+\M;$>?&QW'.\=H
MJ8=F[*^9T+'DJ-GMT2"78KWI<>@"1IV4-'@F?!B."6<3Q8"5DY+QI0OW(#"5
M7*I FVHSZ;H0J7\YN.MZ4(B-3LF$5#:WR^"^)\WP'6#5 X.,\]9@+W2!T: B
M6E,E[DS'#K;!%U#0M!^7E7%8*++L]J[#-<'>3)*)5!E5;9INN J-!ISF8$>Q
M8@9W+:L(0*UE:1H9(X44Q'I8,9J&D9U2SA_@*?V>;VDO\HU]Z\"NB;9I##5-
M)^,ZH+^IYK0W9>-7Z085>Y;ZT]Q,1]@^U">]5S1G"]M?Y*T!3+V+JY.JXLN/
MG!6BI&[R!R<<#<B*%\RD8K],-BB5J0E0%0;/5&DVW8S\5*1ZI N]*J=%CGON
MG:#GO[O.!154$;YIVM3^,:_RJQW'-__*LOVMLFO8Z[%Y]1Z[R>M3,)F<@LF3
MJ,G^*9A,C]]D?)P>H^:0L7&2V3K'M-$ SHO#\!N</ODZ:3"9,ZZ9:'HSEF54
MO#C.&'E-)N9/F2U],SZC.9ES_=B"PW#=_DHS-B_3=M0]+$0S:MW^ M/K)NUA
MU>1B(J,+FHV;KBHFMAF8ALG:7$#81>[LY4<PCL/\"&!8'LP!QG$L+,__-)\^
M.A^'8=[Z7J2/<OHHQ[%\R-A^L#Q^3FHN_TS3-(Z3!%O1\=CK8(RM6Y+ CU\-
M\P8,+ ]D^K.UQG<;KY#]=8#MZ;X*P6:*5R(V4WRM ?&O&S#2U+_;6!Y@8+N
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MO:7SB<R2:R.:E^9.$\\/FBVKZSK+3NG<54%E=;K[Y=KN5W=?_@-02P,$%
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M*+)6%%DKBJP51=:*(FOU/V7],8Z'?QR_/-/>M,-S?K;\9^'F%U!+ 0(4 Q0
M   ( *"#J5@'04UB@0   +$    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ H(.I6$';54#O    *P(  !$
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M970R+GAM;%!+ 0(4 Q0    ( *"#J5BD\P>I: 8  *8:   8
M  " @;\9  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " "@
M@ZE8)EF2A(\&  ""(   &               @(%=(   >&PO=V]R:W-H965T
M<R]S:&5E=#0N>&UL4$L! A0#%     @ H(.I6-&NCMB3"@  2V$  !@
M         ("!(B<  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0
M   ( *"#J5BSPH$O:0H  )XQ   8              " @>LQ  !X;"]W;W)K
M<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " "@@ZE8_>![ZPH*  "_&@
M&               @(&*/   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L!
M A0#%     @ H(.I6,HJ!PA<%0  .C\  !@              ("!RD8  'AL
M+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( *"#J5CTQUQ-2PP
M !4B   8              " @5Q<  !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6Q02P$"% ,4    " "@@ZE8[/EV,NX$   ;#   &0              @('=
M:   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( *"#J5@^
M5=<6K@4  +0-   9              " @0)N  !X;"]W;W)K<VAE971S+W-H
M965T,3$N>&UL4$L! A0#%     @ H(.I6,)QDH<:!   L0D  !D
M     ("!YW,  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *"#J5@P\[0''04  "8-   9              "
M@;Z2  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ H(.I
M6&9>1*D+"   .Q0  !D              ("!$I@  'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6Q02P$"% ,4    " "@@ZE8<X2HDY8)  !;'@  &0
M        @(%4H   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0
M   ( *"#J5@5."Y:O00  %(+   9              " @2&J  !X;"]W;W)K
M<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ H(.I6(KHBD^S!   V@T
M !D              ("!%:\  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q0
M2P$"% ,4    " "@@ZE8WSSO*U0+  "O'@  &0              @('_LP
M>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( *"#J5B!>J,V
MP 4  '@6   9              " @8J_  !X;"]W;W)K<VAE971S+W-H965T
M,C,N>&UL4$L! A0#%     @ H(.I6'@7?Z%[!@  A \  !D
M ("!@<4  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " "@
M@ZE8MM>3-?L,  !1-   &0              @($SS   >&PO=V]R:W-H965T
M<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( *"#J5@OW:4F700  .$*   9
M          " @679  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#
M%     @ H(.I6#>0V"5' @  H04  !D              ("!^=T  'AL+W=O
M<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " "@@ZE8)MHO#D0"  "*
M!@  &0              @(%WX   >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM
M;%!+ 0(4 Q0    ( *"#J5C2=XLDMQ,  "L^   9              " @?+B
M  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ H(.I6$XH
MK;*E P  ? @  !D              ("!X/8  'AL+W=O<FMS:&5E=',O<VAE
M970S,"YX;6Q02P$"% ,4    " "@@ZE8D*PDH= &  #3#P  &0
M    @(&\^@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (
M *"#J5@!$^<T@P0  #@+   9              " @<,! 0!X;"]W;W)K<VAE
M971S+W-H965T,S(N>&UL4$L! A0#%     @ H(.I6%QE;RL1!   L D  !D
M             ("!?08! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"
M% ,4    " "@@ZE8.#BG(Q8#  # !@  &0              @('%"@$ >&PO
M=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( *"#J5A?&L^H3P,
M $X'   9              " @1(. 0!X;"]W;W)K<VAE971S+W-H965T,S4N
M>&UL4$L! A0#%     @ H(.I6.BZ;SV) P  ]P<  !D              ("!
MF!$! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " "@@ZE8
MG\$P+Q8$  #-"0  &0              @(%8%0$ >&PO=V]R:W-H965T<R]S
M:&5E=#,W+GAM;%!+ 0(4 Q0    ( *"#J5@Y6]$QY (  ($&   9
M      " @:49 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%
M  @ H(.I6 "_^70/ P  J@@  !D              ("!P!P! 'AL+W=O<FMS
M:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " "@@ZE8?^8R\'H&  !D#P
M&0              @($&( $ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+
M 0(4 Q0    ( *"#J5BU97B4I 0  ,@-   9              " @;<F 0!X
M;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ H(.I6):BR\'Y
M!   G L  !D              ("!DBL! 'AL+W=O<FMS:&5E=',O<VAE970T
M,BYX;6Q02P$"% ,4    " "@@ZE87=DX;"(%  !:$   &0
M@('", $ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( *"#
MJ5@XPO+Q00(  -,$   9              " @1LV 0!X;"]W;W)K<VAE971S
M+W-H965T-#0N>&UL4$L! A0#%     @ H(.I6- 00Z4% P  _ <  !D
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M=#0Y+GAM;%!+ 0(4 Q0    ( *"#J5C;B,3B' ,  * (   9
M  " @1%9 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @
MH(.I6*ONUIV1 @  .P8  !D              ("!9%P! 'AL+W=O<FMS:&5E
M=',O<VAE970U,2YX;6Q02P$"% ,4    " "@@ZE8G=7-8V0'  !F-P  &0
M            @($L7P$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4
M Q0    ( *"#J5@N$L3<E@(  '\&   9              " @<=F 0!X;"]W
M;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ H(.I6,*Y/%^^ @
M&@<  !D              ("!E&D! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX
M;6Q02P$"% ,4    " "@@ZE8IO77!Q((  "_.@  &0              @(&)
M; $ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( *"#J5C8
M@IPMOP(  '$(   9              " @=)T 0!X;"]W;W)K<VAE971S+W-H
M965T-38N>&UL4$L! A0#%     @ H(.I6&ZT5 ]; P  D0P  !D
M     ("!R'<! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *"#J5B= FFPCQ(   T3 0 9              "
M@0^) 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ H(.I
M6*0LKWUO!   <1@  !D              ("!U9L! 'AL+W=O<FMS:&5E=',O
M<VAE970V,RYX;6Q02P$"% ,4    " "@@ZE8?2,D?0\#  "O"P  &0
M        @(%[H $ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0
M   ( *"#J5AS3)5 W@0  "07   9              " @<&C 0!X;"]W;W)K
M<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ H(.I6']LTGT'!0  0AP
M !D              ("!UJ@! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q0
M2P$"% ,4    " "@@ZE8AOMK]'0"   _!@  &0              @($4K@$
M>&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( *"#J5B?O!XQ
MEP@  )1)   9              " @;^P 0!X;"]W;W)K<VAE971S+W-H965T
M-C@N>&UL4$L! A0#%     @ H(.I6%<8Q<%U!   GAP  !D
M ("!C;D! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    " "@
M@ZE83P_G2D("  ".!0  &0              @($YO@$ >&PO=V]R:W-H965T
M<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( *"#J5B ]6+,6 ,  / /   9
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M970W-2YX;6Q02P$"% ,4    " "@@ZE8><74=\@#  #4$0  &0
M    @($RW0$ >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    (
M *"#J5AK['=D!0,  "X)   9              " @3'A 0!X;"]W;W)K<VAE
M971S+W-H965T-S<N>&UL4$L! A0#%     @ H(.I6&W>-L&) P  A@P  !D
M             ("!;>0! 'AL+W=O<FMS:&5E=',O<VAE970W."YX;6Q02P$"
M% ,4    " "@@ZE8AXS=Z7<$   Y%@  &0              @($MZ $ >&PO
M=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    ( *"#J5C,X6!3@@D
M %)-   9              " @=OL 0!X;"]W;W)K<VAE971S+W-H965T.# N
M>&UL4$L! A0#%     @ H(.I6".$OT[4"P  E'T  !D              ("!
ME/8! 'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6Q02P$"% ,4    " "@@ZE8
M]TF/>^ "  #5!@  &0              @(&? @( >&PO=V]R:W-H965T<R]S
M:&5E=#@R+GAM;%!+ 0(4 Q0    ( *"#J5AT*IJ50 X   6]   9
M      " @;8% @!X;"]W;W)K<VAE971S+W-H965T.#,N>&UL4$L! A0#%
M  @ H(.I6(>E=D#: @  D0<  !D              ("!+10" 'AL+W=O<FMS
M:&5E=',O<VAE970X-"YX;6Q02P$"% ,4    " "@@ZE8G!1F@N<#  #R%@
M&0              @($^%P( >&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+
M 0(4 Q0    ( *"#J5CTM<@K. ,  .P3   -              "  5P; @!X
M;"]S='EL97,N>&UL4$L! A0#%     @ H(.I6)>*NQS     $P(   L
M         ( !OQX" %]R96QS+RYR96QS4$L! A0#%     @ H(.I6-9D],<I
M!@  ^3<   \              ( !J!\" 'AL+W=O<FMB;V]K+GAM;%!+ 0(4
M Q0    ( *"#J5@@%;X0A (  "8R   :              "  ?XE @!X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( *"#J5B);LQ^*P(
M +LP   3              "  ;HH @!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%
3!@    != %T @AD  !8K @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>390</ContextCount>
  <ElementCount>439</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>153</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Business Combinations, Asset Acquisitions, and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwill</Role>
      <ShortName>Business Combinations, Asset Acquisitions, and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNet</Role>
      <ShortName>Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Investments in Other Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntities</Role>
      <ShortName>Investments in Other Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Loans Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LoansReceivable</Role>
      <ShortName>Loans Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/AccountsPayableandAccruedExpenses</Role>
      <ShortName>Accounts Payable and Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Medical Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MedicalLiabilities</Role>
      <ShortName>Medical Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCredit</Role>
      <ShortName>Credit Facility, Bank Loans, and Lines of Credit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Mezzanine and Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MezzanineandStockholdersEquity</Role>
      <ShortName>Mezzanine and Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RelatedPartyTransactions</Role>
      <ShortName>Related-Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Variable Interest Entities (VIEs)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/VariableInterestEntitiesVIEs</Role>
      <ShortName>Variable Interest Entities (VIEs)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/Segments</Role>
      <ShortName>Segments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Fair Value Measurements of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstruments</Role>
      <ShortName>Fair Value Measurements of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Business Combinations, Asset Acquisitions, and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillTables</Role>
      <ShortName>Business Combinations, Asset Acquisitions, and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwill</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNetTables</Role>
      <ShortName>Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/IntangibleAssetsNet</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Investments in Other Entities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesTables</Role>
      <ShortName>Investments in Other Entities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/InvestmentsinOtherEntities</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/AccountsPayableandAccruedExpenses</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Medical Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MedicalLiabilitiesTables</Role>
      <ShortName>Medical Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/MedicalLiabilities</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditTables</Role>
      <ShortName>Credit Facility, Bank Loans, and Lines of Credit (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCredit</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/StockBasedCompensation</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Related-Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related-Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/RelatedPartyTransactions</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/EarningsPerShare</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Variable Interest Entities (VIEs) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables</Role>
      <ShortName>Variable Interest Entities (VIEs) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/VariableInterestEntitiesVIEs</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/Leases</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Segments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/SegmentsTables</Role>
      <ShortName>Segments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/Segments</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Fair Value Measurements of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsTables</Role>
      <ShortName>Fair Value Measurements of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstruments</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/DescriptionofBusinessDetails</Role>
      <ShortName>Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/DescriptionofBusiness</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Disaggregated Revenue by Each Payer Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofDisaggregatedRevenuebyEachPayerTypeDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Disaggregated Revenue by Each Payer Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Contributions to Revenue and Receivables by Payer (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofContributionstoRevenueandReceivablesbyPayerDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Contributions to Revenue and Receivables by Payer (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Business Combinations, Asset Acquisitions, and Goodwill - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillAdditionalInformationDetails</Role>
      <ShortName>Business Combinations, Asset Acquisitions, and Goodwill - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Business Combinations, Asset Acquisitions, and Goodwill - Summary of Purchase Price Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails</Role>
      <ShortName>Business Combinations, Asset Acquisitions, and Goodwill - Summary of Purchase Price Allocation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Business Combinations, Asset Acquisitions, and Goodwill - Schedule of Business Acquisition, Pro Forma Information, Nonrecurring Adjustments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillScheduleofBusinessAcquisitionProFormaInformationNonrecurringAdjustmentsDetails</Role>
      <ShortName>Business Combinations, Asset Acquisitions, and Goodwill - Schedule of Business Acquisition, Pro Forma Information, Nonrecurring Adjustments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Business Combinations, Asset Acquisitions, and Goodwill - Schedule of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillScheduleofGoodwillDetails</Role>
      <ShortName>Business Combinations, Asset Acquisitions, and Goodwill - Schedule of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets, Net - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Intangible Assets, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails</Role>
      <ShortName>Intangible Assets, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Intangible Assets, Net - Schedule of Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails</Role>
      <ShortName>Intangible Assets, Net - Schedule of Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Investments in Other Entities - Schedule of Equity Method Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesScheduleofEquityMethodInvestmentsDetails</Role>
      <ShortName>Investments in Other Entities - Schedule of Equity Method Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Investments in Other Entities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails</Role>
      <ShortName>Investments in Other Entities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Loans Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LoansReceivableDetails</Role>
      <ShortName>Loans Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/LoansReceivable</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Accounts Payable and Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/AccountsPayableandAccruedExpensesDetails</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Medical Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MedicalLiabilitiesDetails</Role>
      <ShortName>Medical Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/MedicalLiabilitiesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Schedule of Credit Facility (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityDetails</Role>
      <ShortName>Credit Facility, Bank Loans, and Lines of Credit - Schedule of Credit Facility (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Schedule of Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails</Role>
      <ShortName>Credit Facility, Bank Loans, and Lines of Credit - Schedule of Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails</Role>
      <ShortName>Credit Facility, Bank Loans, and Lines of Credit - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Mezzanine and Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MezzanineandStockholdersEquityDetails</Role>
      <ShortName>Mezzanine and Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/MezzanineandStockholdersEquity</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Stock-Based Compensation - Schedule of Share-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationScheduleofShareBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Share-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Transactions Under Stock Option Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationScheduleofStockOptionTransactionsUnderStockOptionPlansDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Stock Option Transactions Under Stock Option Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/CommitmentsandContingencies</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - Related-Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related-Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - Related-Party Transactions - Schedule of Fees Incurred and Revenue Earned from Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofFeesIncurredandRevenueEarnedfromRelatedPartyTransactionsDetails</Role>
      <ShortName>Related-Party Transactions - Schedule of Fees Incurred and Revenue Earned from Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/IncomeTaxes</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - Earnings Per Share - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails</Role>
      <ShortName>Earnings Per Share - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - Earnings Per Share - Schedule of Earnings Per Share Computations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShareScheduleofEarningsPerShareComputationsDetails</Role>
      <ShortName>Earnings Per Share - Schedule of Earnings Per Share Computations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - Earnings Per Share - Schedule of Shares Included in the Diluted Earnings Per Share Computations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShareScheduleofSharesIncludedintheDilutedEarningsPerShareComputationsDetails</Role>
      <ShortName>Earnings Per Share - Schedule of Shares Included in the Diluted Earnings Per Share Computations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9954516 - Disclosure - Variable Interest Entities (VIEs)- Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/VariableInterestEntitiesVIEsAdditionalInformationDetails</Role>
      <ShortName>Variable Interest Entities (VIEs)- Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9954517 - Disclosure - Variable Interest Entities (VIEs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails</Role>
      <ShortName>Variable Interest Entities (VIEs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9954518 - Disclosure - Leases - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesAdditionalinformationDetails</Role>
      <ShortName>Leases - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9954519 - Disclosure - Leases - Schedule of Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesScheduleofComponentsofLeaseExpenseDetails</Role>
      <ShortName>Leases - Schedule of Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9954520 - Disclosure - Leases - Schedule of Other Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesScheduleofOtherInformationRelatedtoLeasesDetails</Role>
      <ShortName>Leases - Schedule of Other Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9954521 - Disclosure - Leases - Schedule of Future Minimum Payments Under Non-cancelable Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails</Role>
      <ShortName>Leases - Schedule of Future Minimum Payments Under Non-cancelable Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9954522 - Disclosure - Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/SegmentsDetails</Role>
      <ShortName>Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/SegmentsTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9954523 - Disclosure - Fair Value Measurements of Financial Instruments - Schedule of Carrying Amounts and Fair Values of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails</Role>
      <ShortName>Fair Value Measurements of Financial Instruments - Schedule of Carrying Amounts and Fair Values of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9954524 - Disclosure - Fair Value Measurements of Financial Instruments - Schedule of Change in Fair Value of Level 3 Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofChangeinFairValueofLevel3LiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements of Financial Instruments - Schedule of Change in Fair Value of Level 3 Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9954525 - Disclosure - Fair Value Measurements of Financial Instruments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements of Financial Instruments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9954526 - Disclosure - Fair Value Measurements of Financial Instruments - Schedule of Gain (Loss) on Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofGainLossonEquitySecuritiesDetails</Role>
      <ShortName>Fair Value Measurements of Financial Instruments - Schedule of Gain (Loss) on Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="asth-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9954527 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/SubsequentEvents</ParentRole>
      <Position>85</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="asth-20240331.htm">asth-20240331.htm</File>
    <File>asth-20240331.xsd</File>
    <File>asth-20240331_cal.xml</File>
    <File>asth-20240331_def.xml</File>
    <File>asth-20240331_lab.xml</File>
    <File>asth-20240331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>asth-20240331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1159">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>115
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "asth-20240331.htm": {
   "nsprefix": "asth",
   "nsuri": "http://www.apollomed.net/20240331",
   "dts": {
    "inline": {
     "local": [
      "asth-20240331.htm"
     ]
    },
    "schema": {
     "local": [
      "asth-20240331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "asth-20240331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "asth-20240331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "asth-20240331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "asth-20240331_pre.xml"
     ]
    }
   },
   "keyStandard": 376,
   "keyCustom": 63,
   "axisStandard": 35,
   "axisCustom": 0,
   "memberStandard": 53,
   "memberCustom": 86,
   "hidden": {
    "total": 5,
    "http://xbrl.sec.gov/dei/2023": 5
   },
   "contextCount": 390,
   "entityCount": 1,
   "segmentCount": 153,
   "elementCount": 837,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 1159,
    "http://xbrl.sec.gov/dei/2023": 30,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "report": {
    "R1": {
     "role": "http://www.apollomed.net/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
     "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF INCOME",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
     "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-43",
      "name": "us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-49",
      "name": "us-gaap:TemporaryEquityNetIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.apollomed.net/role/DescriptionofBusiness",
     "longName": "0000007 - Disclosure - Description of Business",
     "shortName": "Description of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "longName": "0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwill",
     "longName": "0000009 - Disclosure - Business Combinations, Asset Acquisitions, and Goodwill",
     "shortName": "Business Combinations, Asset Acquisitions, and Goodwill",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.apollomed.net/role/IntangibleAssetsNet",
     "longName": "0000010 - Disclosure - Intangible Assets, Net",
     "shortName": "Intangible Assets, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntities",
     "longName": "0000011 - Disclosure - Investments in Other Entities",
     "shortName": "Investments in Other Entities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "asth:EquityMethodAndOtherEquityInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "asth:EquityMethodAndOtherEquityInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.apollomed.net/role/LoansReceivable",
     "longName": "0000012 - Disclosure - Loans Receivable",
     "shortName": "Loans Receivable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "asth:LoanReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "asth:LoanReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.apollomed.net/role/AccountsPayableandAccruedExpenses",
     "longName": "0000013 - Disclosure - Accounts Payable and Accrued Expenses",
     "shortName": "Accounts Payable and Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.apollomed.net/role/MedicalLiabilities",
     "longName": "0000014 - Disclosure - Medical Liabilities",
     "shortName": "Medical Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCredit",
     "longName": "0000015 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit",
     "shortName": "Credit Facility, Bank Loans, and Lines of Credit",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.apollomed.net/role/MezzanineandStockholdersEquity",
     "longName": "0000016 - Disclosure - Mezzanine and Stockholders' Equity",
     "shortName": "Mezzanine and Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.apollomed.net/role/StockBasedCompensation",
     "longName": "0000017 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.apollomed.net/role/CommitmentsandContingencies",
     "longName": "0000018 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.apollomed.net/role/RelatedPartyTransactions",
     "longName": "0000019 - Disclosure - Related-Party Transactions",
     "shortName": "Related-Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.apollomed.net/role/IncomeTaxes",
     "longName": "0000020 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.apollomed.net/role/EarningsPerShare",
     "longName": "0000021 - Disclosure - Earnings Per Share",
     "shortName": "Earnings Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.apollomed.net/role/VariableInterestEntitiesVIEs",
     "longName": "0000022 - Disclosure - Variable Interest Entities (VIEs)",
     "shortName": "Variable Interest Entities (VIEs)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.apollomed.net/role/Leases",
     "longName": "0000023 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.apollomed.net/role/Segments",
     "longName": "0000024 - Disclosure - Segments",
     "shortName": "Segments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstruments",
     "longName": "0000025 - Disclosure - Fair Value Measurements of Financial Instruments",
     "shortName": "Fair Value Measurements of Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.apollomed.net/role/SubsequentEvents",
     "longName": "0000026 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R28": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables",
     "longName": "9954472 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillTables",
     "longName": "9954473 - Disclosure - Business Combinations, Asset Acquisitions, and Goodwill (Tables)",
     "shortName": "Business Combinations, Asset Acquisitions, and Goodwill (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.apollomed.net/role/IntangibleAssetsNetTables",
     "longName": "9954474 - Disclosure - Intangible Assets, Net (Tables)",
     "shortName": "Intangible Assets, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesTables",
     "longName": "9954475 - Disclosure - Investments in Other Entities (Tables)",
     "shortName": "Investments in Other Entities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables",
     "longName": "9954476 - Disclosure - Accounts Payable and Accrued Expenses (Tables)",
     "shortName": "Accounts Payable and Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.apollomed.net/role/MedicalLiabilitiesTables",
     "longName": "9954477 - Disclosure - Medical Liabilities (Tables)",
     "shortName": "Medical Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditTables",
     "longName": "9954478 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit (Tables)",
     "shortName": "Credit Facility, Bank Loans, and Lines of Credit (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.apollomed.net/role/StockBasedCompensationTables",
     "longName": "9954479 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.apollomed.net/role/RelatedPartyTransactionsTables",
     "longName": "9954480 - Disclosure - Related-Party Transactions (Tables)",
     "shortName": "Related-Party Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.apollomed.net/role/EarningsPerShareTables",
     "longName": "9954481 - Disclosure - Earnings Per Share (Tables)",
     "shortName": "Earnings Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables",
     "longName": "9954482 - Disclosure - Variable Interest Entities (VIEs) (Tables)",
     "shortName": "Variable Interest Entities (VIEs) (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.apollomed.net/role/LeasesTables",
     "longName": "9954483 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.apollomed.net/role/SegmentsTables",
     "longName": "9954484 - Disclosure - Segments (Tables)",
     "shortName": "Segments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsTables",
     "longName": "9954485 - Disclosure - Fair Value Measurements of Financial Instruments (Tables)",
     "shortName": "Fair Value Measurements of Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.apollomed.net/role/DescriptionofBusinessDetails",
     "longName": "9954486 - Disclosure - Description of Business (Details)",
     "shortName": "Description of Business (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R45": {
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "9954487 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CashUninsuredAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofDisaggregatedRevenuebyEachPayerTypeDetails",
     "longName": "9954488 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Disaggregated Revenue by Each Payer Type (Details)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Disaggregated Revenue by Each Payer Type (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-60",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofContributionstoRevenueandReceivablesbyPayerDetails",
     "longName": "9954489 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Contributions to Revenue and Receivables by Payer (Details)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Contributions to Revenue and Receivables by Payer (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-68",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-68",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillAdditionalInformationDetails",
     "longName": "9954490 - Disclosure - Business Combinations, Asset Acquisitions, and Goodwill - Additional Information (Details)",
     "shortName": "Business Combinations, Asset Acquisitions, and Goodwill - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:GoodwillImpairmentLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:GoodwillImpairmentLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails",
     "longName": "9954491 - Disclosure - Business Combinations, Asset Acquisitions, and Goodwill - Summary of Purchase Price Allocation (Details)",
     "shortName": "Business Combinations, Asset Acquisitions, and Goodwill - Summary of Purchase Price Allocation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-77",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillScheduleofBusinessAcquisitionProFormaInformationNonrecurringAdjustmentsDetails",
     "longName": "9954492 - Disclosure - Business Combinations, Asset Acquisitions, and Goodwill - Schedule of Business Acquisition, Pro Forma Information, Nonrecurring Adjustments (Details)",
     "shortName": "Business Combinations, Asset Acquisitions, and Goodwill - Schedule of Business Acquisition, Pro Forma Information, Nonrecurring Adjustments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillScheduleofGoodwillDetails",
     "longName": "9954493 - Disclosure - Business Combinations, Asset Acquisitions, and Goodwill - Schedule of Goodwill (Details)",
     "shortName": "Business Combinations, Asset Acquisitions, and Goodwill - Schedule of Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
     "longName": "9954494 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets (Details)",
     "shortName": "Intangible Assets, Net - Schedule of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails",
     "longName": "9954495 - Disclosure - Intangible Assets, Net - Additional Information (Details)",
     "shortName": "Intangible Assets, Net - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails",
     "longName": "9954496 - Disclosure - Intangible Assets, Net - Schedule of Future Amortization Expense (Details)",
     "shortName": "Intangible Assets, Net - Schedule of Future Amortization Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesScheduleofEquityMethodInvestmentsDetails",
     "longName": "9954497 - Disclosure - Investments in Other Entities - Schedule of Equity Method Investments (Details)",
     "shortName": "Investments in Other Entities - Schedule of Equity Method Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:EquityMethodInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "asth:EquityMethodInvestmentAdditionalInvestment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
     "longName": "9954498 - Disclosure - Investments in Other Entities - Additional Information (Details)",
     "shortName": "Investments in Other Entities - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.apollomed.net/role/LoansReceivableDetails",
     "longName": "9954499 - Disclosure - Loans Receivable (Details)",
     "shortName": "Loans Receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-141",
      "name": "us-gaap:DebtInstrumentTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-141",
      "name": "us-gaap:DebtInstrumentTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesDetails",
     "longName": "9954500 - Disclosure - Accounts Payable and Accrued Expenses (Details)",
     "shortName": "Accounts Payable and Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.apollomed.net/role/MedicalLiabilitiesDetails",
     "longName": "9954501 - Disclosure - Medical Liabilities (Details)",
     "shortName": "Medical Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityDetails",
     "longName": "9954502 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Schedule of Credit Facility (Details)",
     "shortName": "Credit Facility, Bank Loans, and Lines of Credit - Schedule of Credit Facility (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-144",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails",
     "longName": "9954503 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Schedule of Maturities (Details)",
     "shortName": "Credit Facility, Bank Loans, and Lines of Credit - Schedule of Maturities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
     "longName": "9954504 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Additional Information (Details)",
     "shortName": "Credit Facility, Bank Loans, and Lines of Credit - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtInstrumentInterestRateDuringPeriod",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.apollomed.net/role/MezzanineandStockholdersEquityDetails",
     "longName": "9954505 - Disclosure - Mezzanine and Stockholders' Equity (Details)",
     "shortName": "Mezzanine and Stockholders' Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "asth:StockIssuedDuringPeriodSharesMerger",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "asth:StockIssuedDuringPeriodSharesMerger",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.apollomed.net/role/StockBasedCompensationScheduleofShareBasedCompensationExpenseDetails",
     "longName": "9954506 - Disclosure - Stock-Based Compensation - Schedule of Share-Based Compensation Expense (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Share-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
     "longName": "9954507 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.apollomed.net/role/StockBasedCompensationScheduleofStockOptionTransactionsUnderStockOptionPlansDetails",
     "longName": "9954508 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Transactions Under Stock Option Plans (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Stock Option Transactions Under Stock Option Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.apollomed.net/role/CommitmentsandContingenciesDetails",
     "longName": "9954509 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LineOfCredit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R68": {
     "role": "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
     "longName": "9954510 - Disclosure - Related-Party Transactions - Additional Information (Details)",
     "shortName": "Related-Party Transactions - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "asth:RelatedPartyExpensesPayable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofFeesIncurredandRevenueEarnedfromRelatedPartyTransactionsDetails",
     "longName": "9954511 - Disclosure - Related-Party Transactions - Schedule of Fees Incurred and Revenue Earned from Related Party Transactions (Details)",
     "shortName": "Related-Party Transactions - Schedule of Fees Incurred and Revenue Earned from Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-220",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-220",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.apollomed.net/role/IncomeTaxesDetails",
     "longName": "9954512 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
     "longName": "9954513 - Disclosure - Earnings Per Share - Additional Information (Details)",
     "shortName": "Earnings Per Share - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-248",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-248",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.apollomed.net/role/EarningsPerShareScheduleofEarningsPerShareComputationsDetails",
     "longName": "9954514 - Disclosure - Earnings Per Share - Schedule of Earnings Per Share Computations (Details)",
     "shortName": "Earnings Per Share - Schedule of Earnings Per Share Computations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareBasic",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R73": {
     "role": "http://www.apollomed.net/role/EarningsPerShareScheduleofSharesIncludedintheDilutedEarningsPerShareComputationsDetails",
     "longName": "9954515 - Disclosure - Earnings Per Share - Schedule of Shares Included in the Diluted Earnings Per Share Computations (Details)",
     "shortName": "Earnings Per Share - Schedule of Shares Included in the Diluted Earnings Per Share Computations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.apollomed.net/role/VariableInterestEntitiesVIEsAdditionalInformationDetails",
     "longName": "9954516 - Disclosure - Variable Interest Entities (VIEs)- Additional Information (Details)",
     "shortName": "Variable Interest Entities (VIEs)- Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-254",
      "name": "us-gaap:VariableInterestEntityOwnershipPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-254",
      "name": "us-gaap:VariableInterestEntityOwnershipPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails",
     "longName": "9954517 - Disclosure - Variable Interest Entities (VIEs) (Details)",
     "shortName": "Variable Interest Entities (VIEs) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-256",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
     "longName": "9954518 - Disclosure - Leases - Additional information (Details)",
     "shortName": "Leases - Additional information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.apollomed.net/role/LeasesScheduleofComponentsofLeaseExpenseDetails",
     "longName": "9954519 - Disclosure - Leases - Schedule of Components of Lease Expense (Details)",
     "shortName": "Leases - Schedule of Components of Lease Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "us-gaap:LeaseCostTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "us-gaap:LeaseCostTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.apollomed.net/role/LeasesScheduleofOtherInformationRelatedtoLeasesDetails",
     "longName": "9954520 - Disclosure - Leases - Schedule of Other Information Related to Leases (Details)",
     "shortName": "Leases - Schedule of Other Information Related to Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
     "longName": "9954521 - Disclosure - Leases - Schedule of Future Minimum Payments Under Non-cancelable Leases (Details)",
     "shortName": "Leases - Schedule of Future Minimum Payments Under Non-cancelable Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.apollomed.net/role/SegmentsDetails",
     "longName": "9954522 - Disclosure - Segments (Details)",
     "shortName": "Segments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails",
     "longName": "9954523 - Disclosure - Fair Value Measurements of Financial Instruments - Schedule of Carrying Amounts and Fair Values of Financial Instruments (Details)",
     "shortName": "Fair Value Measurements of Financial Instruments - Schedule of Carrying Amounts and Fair Values of Financial Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofChangeinFairValueofLevel3LiabilitiesDetails",
     "longName": "9954524 - Disclosure - Fair Value Measurements of Financial Instruments - Schedule of Change in Fair Value of Level 3 Liabilities (Details)",
     "shortName": "Fair Value Measurements of Financial Instruments - Schedule of Change in Fair Value of Level 3 Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails",
     "longName": "9954525 - Disclosure - Fair Value Measurements of Financial Instruments - Additional Information (Details)",
     "shortName": "Fair Value Measurements of Financial Instruments - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-368",
      "name": "asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofGainLossonEquitySecuritiesDetails",
     "longName": "9954526 - Disclosure - Fair Value Measurements of Financial Instruments - Schedule of Gain (Loss) on Equity Securities (Details)",
     "shortName": "Fair Value Measurements of Financial Instruments - Schedule of Gain (Loss) on Equity Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquitySecuritiesFvNiGainLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquitySecuritiesFvNiGainLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.apollomed.net/role/SubsequentEventsDetails",
     "longName": "9954527 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LineOfCredit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-390",
      "name": "us-gaap:ProceedsFromLinesOfCredit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asth-20240331.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "asth_A2023MetricMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "A2023MetricMember",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Metric",
        "label": "2023 Metric [Member]",
        "documentation": "2023 Metric"
       }
      }
     },
     "auth_ref": []
    },
    "asth_A2024MetricMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "A2024MetricMember",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Metric",
        "label": "2024 Metric [Member]",
        "documentation": "2024 Metric"
       }
      }
     },
     "auth_ref": []
    },
    "asth_AAMGMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "AAMGMember",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails",
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AAMG contingent consideration",
        "label": "AAMG [Member]",
        "documentation": "AAMG"
       }
      }
     },
     "auth_ref": []
    },
    "asth_ADSCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "ADSCMember",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ADSC contingent considerations",
        "label": "ADSC [Member]",
        "documentation": "ADSC"
       }
      }
     },
     "auth_ref": []
    },
    "asth_AHMCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "AHMCMember",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofFeesIncurredandRevenueEarnedfromRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AHMC",
        "verboseLabel": "AHMC",
        "label": "AHMC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "presentation": [
      "http://www.apollomed.net/role/LoansReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      },
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 9.0
      },
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesDetails",
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "totalLabel": "Total accounts payable and accrued expenses",
        "verboseLabel": "Accounts payable and accrued expenses",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Payable and Accrued Expenses",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable and other accruals",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "asth_AccountsReceivableAndNetRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "AccountsReceivableAndNetRevenueLineItems",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofContributionstoRevenueandReceivablesbyPayerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable And Net Revenue [Line Items]",
        "label": "Accounts Receivable And Net Revenue [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "asth_AccountsReceivableAndNetRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "AccountsReceivableAndNetRevenueTable",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofContributionstoRevenueandReceivablesbyPayerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable And Net Revenue [Table]",
        "label": "Accounts Receivable And Net Revenue [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofContributionstoRevenueandReceivablesbyPayerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Receivables and Receivables-Related Parties",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables, net",
        "verboseLabel": "Receivables, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r336"
     ]
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes payable",
        "label": "Accrued Income Taxes, Current",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r189"
     ]
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedIncomeTaxesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax payable",
        "label": "Accrued Income Taxes, Noncurrent",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r189"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "asth_AcquisitionOfNonControllingInterestShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "AcquisitionOfNonControllingInterestShares",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisition of non-controlling interest (in shares)",
        "label": "Acquisition of Non-Controlling Interest, Shares",
        "documentation": "Acquisition of Non-Controlling Interest, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r891",
      "r1103"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additional Paid-in\u00a0 Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r528",
      "r529",
      "r741",
      "r1028",
      "r1029",
      "r1030",
      "r1076",
      "r1105"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asth_AdvancedDiagnosticAndSurgicalCenterIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "AdvancedDiagnosticAndSurgicalCenterIncMember",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advanced Diagnostic and Surgical Center, Inc",
        "label": "Advanced Diagnostic and Surgical Center, Inc [Member]",
        "documentation": "Advanced Diagnostic and Surgical Center, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "asth_AdvancedHealthManagementSystemsLPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "AdvancedHealthManagementSystemsLPMember",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AHMS",
        "label": "Advanced Health Management Systems, L.P. [Member]",
        "documentation": "Advanced Health Management Systems, L.P."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r913",
      "r924",
      "r934",
      "r959"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r916",
      "r927",
      "r937",
      "r962"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r920",
      "r928",
      "r938",
      "r955",
      "r963",
      "r967",
      "r975"
     ]
    },
    "us-gaap_AllOtherSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllOtherSegmentsMember",
     "presentation": [
      "http://www.apollomed.net/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Segments [Member]",
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r973"
     ]
    },
    "asth_AlliedPacificHoldingsInvestmentManagementLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "AlliedPacificHoldingsInvestmentManagementLLCMember",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allied Pacific Holdings Investment Management, LLC",
        "label": "Allied Pacific Holdings Investment Management, LLC [Member]",
        "documentation": "Allied Pacific Holdings Investment Management, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "asth_AlliedPacificOfCaliforniaIPAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "AlliedPacificOfCaliforniaIPAMember",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allied Pacific Of California IPA",
        "verboseLabel": "APC",
        "label": "Allied Pacific Of California IPA [Member]",
        "documentation": "Allied Pacific Of California IPA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationScheduleofShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r530"
     ]
    },
    "asth_AmendedAndRestatedCreditAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "AmendedAndRestatedCreditAgreementMember",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Agreement Amendment",
        "label": "Amended and Restated Credit Agreement [Member]",
        "documentation": "Amended and Restated Credit Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "asth_AmendedCreditAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "AmendedCreditAgreementMember",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amended Credit Agreement",
        "label": "Amended Credit Agreement [Member]",
        "documentation": "Amended Credit Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt issuance cost",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r447",
      "r592",
      "r1019"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization expense",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r67",
      "r72"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities not included in the calculation of earnings per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r289"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareScheduleofSharesIncludedintheDilutedEarningsPerShareComputationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareScheduleofSharesIncludedintheDilutedEarningsPerShareComputationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "asth_ApcBusinessLoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "ApcBusinessLoanAgreementMember",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "APC Business Loan Agreement",
        "label": "APC Business Loan Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asth_ApcStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "ApcStockOptionMember",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "APC Stock Option",
        "label": "APC Stock Option [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asth_ApolloMedicalHoldingsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "ApolloMedicalHoldingsIncMember",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Apollo Medical Holdings, Inc",
        "label": "Apollo Medical Holdings, Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asth_ApolloSunLabsManagementLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "ApolloSunLabsManagementLLCMember",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails",
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Sun Labs remaining equity interest purchase",
        "terseLabel": "Apollo-Sun Labs Management, LLC",
        "label": "Apollo-Sun Labs Management, LLC [Member]",
        "documentation": "Apollo-Sun Labs Management, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "asth_ArroyoVistaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "ArroyoVistaMember",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arroyo Vista",
        "label": "Arroyo Vista [Member]",
        "documentation": "Arroyo Vista"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "verboseLabel": "Assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r222",
      "r250",
      "r300",
      "r321",
      "r327",
      "r372",
      "r412",
      "r413",
      "r415",
      "r416",
      "r417",
      "r419",
      "r421",
      "r423",
      "r424",
      "r559",
      "r563",
      "r583",
      "r680",
      "r784",
      "r891",
      "r904",
      "r1066",
      "r1067",
      "r1085"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "verboseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r230",
      "r250",
      "r372",
      "r412",
      "r413",
      "r415",
      "r416",
      "r417",
      "r419",
      "r421",
      "r423",
      "r424",
      "r559",
      "r563",
      "r583",
      "r891",
      "r1066",
      "r1067",
      "r1085"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current assets",
        "terseLabel": "Current assets",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r372",
      "r412",
      "r413",
      "r415",
      "r416",
      "r417",
      "r419",
      "r421",
      "r423",
      "r424",
      "r559",
      "r563",
      "r583",
      "r1066",
      "r1067",
      "r1085"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-current assets",
        "terseLabel": "Non-current assets",
        "label": "Assets, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asth_AstranaMedicalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "AstranaMedicalMember",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Astrana Medical",
        "label": "Astrana Medical [Member]",
        "documentation": "Astrana Medical"
       }
      }
     },
     "auth_ref": []
    },
    "asth_AurionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "AurionMember",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofFeesIncurredandRevenueEarnedfromRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aurion",
        "label": "Aurion [Member]",
        "documentation": "xxx_Aurion Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails",
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities \u2013 certificates of deposit",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r380",
      "r674",
      "r1036"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r970"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationScheduleofShareBasedCompensationExpenseDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r969"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r968"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Axis]",
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Domain]",
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r116"
     ]
    },
    "us-gaap_BaseRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BaseRateMember",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Base Rate",
        "label": "Base Rate [Member]",
        "documentation": "Minimum rate investor will accept."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "asth_BassMedicalGroupMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "BassMedicalGroupMember",
     "presentation": [
      "http://www.apollomed.net/role/LoansReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BASS Medical Group",
        "label": "Bass Medical Group [Member]",
        "documentation": "Bass Medical Group"
       }
      }
     },
     "auth_ref": []
    },
    "asth_BoardMembersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "BoardMembersMember",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Board Members",
        "label": "Board Members [Member]",
        "documentation": "Board Members"
       }
      }
     },
     "auth_ref": []
    },
    "asth_BoardMembersWhoAreAlsoOfficersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "BoardMembersWhoAreAlsoOfficersMember",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Board Members Who Are Also Officers",
        "label": "Board Members Who Are Also Officers [Member]",
        "documentation": "Board Members Who Are Also Officers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BridgeLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BridgeLoanMember",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bridge Loan",
        "label": "Bridge Loan [Member]",
        "documentation": "Financing which is expected to be replaced by a medium to long-term loan. The loan \"bridges\" the gap in time when otherwise no financing would be in place."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails",
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r883",
      "r884"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails",
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Axis]",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r91",
      "r553",
      "r883",
      "r884"
     ]
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity interest issued, number of shares (shares)",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Line Items]",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "asth_BusinessAcquisitionOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "BusinessAcquisitionOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business acquisition of common stock",
        "label": "Business Acquisition Of Common Stock",
        "documentation": "Business Acquisition Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest acquired",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillScheduleofBusinessAcquisitionProFormaInformationNonrecurringAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income per share - basic (in dollars per share)",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic",
        "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period."
       }
      }
     },
     "auth_ref": [
      "r985",
      "r986"
     ]
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillScheduleofBusinessAcquisitionProFormaInformationNonrecurringAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income per share - diluted (in dollars per share)",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Diluted",
        "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period."
       }
      }
     },
     "auth_ref": [
      "r985",
      "r986"
     ]
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillScheduleofBusinessAcquisitionProFormaInformationNonrecurringAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Pro Forma Net Income (Loss)",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r552"
     ]
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillScheduleofBusinessAcquisitionProFormaInformationNonrecurringAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Pro Forma Revenue",
        "label": "Business Acquisition, Pro Forma Revenue",
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r552"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asth_BusinessCombinationChangeInFairValueOfEquityInterestPurchaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "BusinessCombinationChangeInFairValueOfEquityInterestPurchaseObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of equity interest",
        "label": "Business Combination, Change in Fair Value Of Equity Interest Purchase Obligation",
        "documentation": "Business Combination, Change in Fair Value Of Equity Interest Purchase Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration transferred",
        "totalLabel": "Consideration transferred",
        "label": "Business Combination, Consideration Transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r5",
      "r14"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r5"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r5",
      "r95",
      "r556"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails": {
       "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails",
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value of the contingent consideration",
        "label": "Business Combination, Contingent Consideration, Liability",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r96",
      "r557"
     ]
    },
    "asth_BusinessCombinationContingentConsiderationLiabilityEachMeasurementPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "BusinessCombinationContingentConsiderationLiabilityEachMeasurementPeriod",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration, liability, each measurement period",
        "label": "Business Combination, Contingent Consideration, Liability, Each Measurement Period",
        "documentation": "Business Combination, Contingent Consideration, Liability, Each Measurement Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwill"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combinations, Asset Acquisitions, and Goodwill",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r554"
     ]
    },
    "asth_BusinessCombinationEquityInterestPurchaseObligationNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "BusinessCombinationEquityInterestPurchaseObligationNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails": {
       "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails",
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Remaining equity interest purchase",
        "terseLabel": "Equity interest purchase obligation, noncurrent",
        "label": "Business Combination, Equity Interest Purchase Obligation, Noncurrent",
        "documentation": "Business Combination, Equity Interest Purchase Obligation, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "asth_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity interest purchase obligation, period to purchase",
        "label": "Business Combination, Equity Interest Purchase Obligation, Period to Purchase",
        "documentation": "Business Combination, Equity Interest Purchase Obligation, Period to Purchase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income since acquisition",
        "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual",
        "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue since acquisition",
        "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual",
        "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total identifiable assets acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "documentation": "Amount of assets acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets:",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts due from affiliates",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Amounts Due From Affiliates",
        "documentation": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Amounts Due From Affiliates"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in marketable securities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities",
        "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Restricted Cash",
        "documentation": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Restricted Cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities:",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liability",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total identified liabilities assumed",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "documentation": "Amount of liabilities assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities, Accounts Payable And Accrued Expenses",
        "documentation": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities, Accounts Payable And Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts due to affiliates",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities, Amounts Due To Affiliates",
        "documentation": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities, Amounts Due To Affiliates"
       }
      }
     },
     "auth_ref": []
    },
    "asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes payable",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities, Income Taxes Payable",
        "documentation": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities, Income Taxes Payable"
       }
      }
     },
     "auth_ref": []
    },
    "asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medical liabilities",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities, Medical Liabilities",
        "documentation": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities, Medical Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "asth_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interest",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities, Noncontrolling Interest",
        "documentation": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities, Noncontrolling Interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total net identifiable assets acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land, property and equipment",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93"
     ]
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combinations",
        "label": "Business Combinations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basis of Presentation and Summary of Significant Accounting Policies",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r167",
      "r168"
     ]
    },
    "asth_CAIPAMSOLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "CAIPAMSOLLCMember",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesScheduleofEquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CAIPA MSO, LLC",
        "label": "CAIPA MSO, LLC [Member]",
        "documentation": "CAIPA MSO, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "asth_CDSCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "CDSCMember",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CDSC",
        "label": "CDSC [Member]",
        "documentation": "CDSC"
       }
      }
     },
     "auth_ref": []
    },
    "asth_CFCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "CFCMember",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CFC contingent considerations",
        "label": "CFC [Member]",
        "documentation": "CFC"
       }
      }
     },
     "auth_ref": []
    },
    "asth_CareDeliveryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "CareDeliveryMember",
     "presentation": [
      "http://www.apollomed.net/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Care Delivery",
        "label": "Care Delivery [Member]",
        "documentation": "Care Delivery"
       }
      }
     },
     "auth_ref": []
    },
    "asth_CareEnablementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "CareEnablementMember",
     "presentation": [
      "http://www.apollomed.net/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Care Enablement",
        "label": "Care Enablement [Member]",
        "documentation": "Care Enablement"
       }
      }
     },
     "auth_ref": []
    },
    "asth_CarePartnersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "CarePartnersMember",
     "presentation": [
      "http://www.apollomed.net/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Care Partners",
        "label": "Care Partners [Member]",
        "documentation": "Care Partners"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r218",
      "r854"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market accounts",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of period",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash, end of period",
        "totalLabel": "Total cash, cash equivalents, and restricted cash shown in the statement of cash flows",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r164",
      "r247"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r164"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Supplemental disclosures of non-cash investing and financing activities",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asth_CashPaidForLeaseLiabilitiesAbstractAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "CashPaidForLeaseLiabilitiesAbstractAbstract",
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash paid for amounts included in the measurement of lease liabilities:",
        "label": "Cash Paid For Lease Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashUninsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashUninsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount deposit accounts exceeded FDIC insured limit",
        "label": "Cash, Uninsured Amount",
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CertificatesOfDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CertificatesOfDepositMember",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certificates of Deposit",
        "label": "Certificates of Deposit [Member]",
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r898",
      "r899",
      "r900",
      "r901"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chief Executive Officer",
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r226",
      "r227",
      "r228",
      "r250",
      "r274",
      "r277",
      "r286",
      "r288",
      "r294",
      "r295",
      "r372",
      "r412",
      "r415",
      "r416",
      "r417",
      "r423",
      "r424",
      "r455",
      "r456",
      "r459",
      "r462",
      "r469",
      "r583",
      "r728",
      "r729",
      "r730",
      "r731",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r771",
      "r793",
      "r816",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r981",
      "r1022",
      "r1031"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r227",
      "r228",
      "r294",
      "r455",
      "r456",
      "r457",
      "r459",
      "r462",
      "r467",
      "r469",
      "r728",
      "r729",
      "r730",
      "r731",
      "r872",
      "r981",
      "r1022"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "asth_CommercialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "CommercialMember",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofDisaggregatedRevenuebyEachPayerTypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial",
        "label": "Commercial [Member]",
        "documentation": "ameh:CommercialMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Commitments and contingencies (Note 12)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r133",
      "r682",
      "r770"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r406",
      "r407",
      "r848",
      "r1061"
     ]
    },
    "asth_CommitmentsAndContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "CommitmentsAndContingenciesLineItems",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments And Contingencies [Line Items]",
        "label": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "asth_CommitmentsAndContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "CommitmentsAndContingenciesTable",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments And Contingencies [Table]",
        "label": "Commitments And Contingencies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "asth_CommonStockDiscountedPricePercentage": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "CommonStockDiscountedPricePercentage",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, discounted price, percentage",
        "label": "Common Stock, Discounted Price, Percentage",
        "documentation": "Common Stock, Discounted Price, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "asth_CommonStockDiscountedPricePercentageMaximum": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "CommonStockDiscountedPricePercentageMaximum",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, discounted price, percentage (up to)",
        "label": "Common Stock, Discounted Price, Percentage, Maximum",
        "documentation": "Common Stock, Discounted Price, Percentage, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common\u00a0Stock\u00a0Outstanding",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r894",
      "r895",
      "r896",
      "r898",
      "r899",
      "r900",
      "r901",
      "r1028",
      "r1029",
      "r1076",
      "r1100",
      "r1105"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r771"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, value, issued",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r684",
      "r891"
     ]
    },
    "asth_CommunityFamilyCareMedicalGroupIPAInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "CommunityFamilyCareMedicalGroupIPAInc.Member",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails",
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Community Family Care Medical Group IPA, Inc.",
        "verboseLabel": "CFC",
        "label": "Community Family Care Medical Group IPA, Inc. [Member]",
        "documentation": "Community Family Care Medical Group IPA, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "asth_CompanyAndAPCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "CompanyAndAPCMember",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company And APC",
        "label": "Company And APC [Member]",
        "documentation": "Company And APC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofContributionstoRevenueandReceivablesbyPayerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r58",
      "r123",
      "r124",
      "r334",
      "r847"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofContributionstoRevenueandReceivablesbyPayerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r58",
      "r123",
      "r124",
      "r334",
      "r725",
      "r847"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofContributionstoRevenueandReceivablesbyPayerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r58",
      "r123",
      "r124",
      "r334",
      "r847",
      "r984"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of Credit Risks",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r205"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofContributionstoRevenueandReceivablesbyPayerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r58",
      "r123",
      "r124",
      "r334"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofContributionstoRevenueandReceivablesbyPayerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r58",
      "r123",
      "r124",
      "r334",
      "r847"
     ]
    },
    "asth_ConsiderationOfAcquisitionInCashFunded": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "ConsiderationOfAcquisitionInCashFunded",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration of acquisition in cash funded",
        "label": "Consideration of Acquisition in Cash Funded",
        "documentation": "Consideration of Acquisition in Cash Funded"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsAdditionalInformationDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Axis]",
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r559",
      "r560",
      "r563",
      "r564",
      "r620",
      "r849",
      "r1065",
      "r1068",
      "r1069"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsAdditionalInformationDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Domain]",
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r559",
      "r560",
      "r563",
      "r564",
      "r620",
      "r849",
      "r1065",
      "r1068",
      "r1069"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://www.apollomed.net/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Axis]",
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r302",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r329",
      "r412",
      "r413",
      "r414",
      "r415",
      "r417",
      "r418",
      "r420",
      "r422",
      "r423",
      "r1066",
      "r1067"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://www.apollomed.net/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Domain]",
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r302",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r329",
      "r412",
      "r413",
      "r414",
      "r415",
      "r417",
      "r418",
      "r420",
      "r422",
      "r423",
      "r1066",
      "r1067"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r859"
     ]
    },
    "asth_ContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "ContingentConsideration",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration",
        "label": "Contingent Consideration",
        "documentation": "Contingent Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContingentConsiderationByTypeAxis",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration by Type [Axis]",
        "label": "Contingent Consideration by Type [Axis]",
        "documentation": "Information by type of contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContingentConsiderationTypeDomain",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration Type [Domain]",
        "label": "Contingent Consideration Type [Domain]",
        "documentation": "Description of contingent payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Contract liabilities",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r472",
      "r483"
     ]
    },
    "us-gaap_CorporateNonSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateNonSegmentMember",
     "presentation": [
      "http://www.apollomed.net/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Costs",
        "label": "Corporate, Non-Segment [Member]",
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r320",
      "r321",
      "r322",
      "r323",
      "r329",
      "r1034"
     ]
    },
    "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of services, excluding depreciation and amortization",
        "verboseLabel": "Cost of services",
        "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization",
        "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization."
       }
      }
     },
     "auth_ref": [
      "r990",
      "r991"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSoldDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Cost, Depreciation and Amortization",
        "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service."
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total expenses",
        "verboseLabel": "Total expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofFeesIncurredandRevenueEarnedfromRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r254",
      "r255",
      "r429",
      "r457",
      "r618",
      "r856",
      "r858"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "asth_CreditAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "CreditAgreementMember",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Agreement",
        "label": "Credit Agreement [Member]",
        "documentation": "Credit Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityDetails",
      "http://www.apollomed.net/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityDetails",
      "http://www.apollomed.net/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofContributionstoRevenueandReceivablesbyPayerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r334"
     ]
    },
    "asth_DMGAndSunLabsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "DMGAndSunLabsMember",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DMG And Sun Labs",
        "label": "DMG And Sun Labs [Member]",
        "documentation": "DMG And Sun Labs"
       }
      }
     },
     "auth_ref": []
    },
    "asth_DebtCovenantAggregatePurchasePriceMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "DebtCovenantAggregatePurchasePriceMaximum",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt covenant, aggregate purchase price, maximum",
        "label": "Debt Covenant, Aggregate Purchase Price, Maximum",
        "documentation": "Debt Covenant, Aggregate Purchase Price, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCredit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility, Bank Loans, and Lines of Credit",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r248",
      "r425",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r441",
      "r448",
      "r449",
      "r451"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoansReceivableDetails",
      "http://www.apollomed.net/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r142",
      "r143",
      "r188",
      "r190",
      "r257",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r432",
      "r437",
      "r438",
      "r439",
      "r440",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r593",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r1023"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis spread on variable rate",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total debt",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r190",
      "r452"
     ]
    },
    "asth_DebtInstrumentCovenantInterestCoverageRatioMinimum": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "DebtInstrumentCovenantInterestCoverageRatioMinimum",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum consolidated interest coverage ratio (not less than)",
        "label": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum",
        "documentation": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum"
       }
      }
     },
     "auth_ref": []
    },
    "asth_DebtInstrumentCovenantLeverageRatioAdjustedMaximum": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "DebtInstrumentCovenantLeverageRatioAdjustedMaximum",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, covenant, leverage ratio, adjusted maximum",
        "label": "Debt Instrument, Covenant, Leverage Ratio, Adjusted Maximum",
        "documentation": "Debt Instrument, Covenant, Leverage Ratio, Adjusted Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "asth_DebtInstrumentCovenantLeverageRatioIncrementalChange": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "DebtInstrumentCovenantLeverageRatioIncrementalChange",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated leverage ratio, annual decrease",
        "label": "Debt Instrument, Covenant, Leverage Ratio, Incremental Change",
        "documentation": "Debt Instrument, Covenant, Leverage Ratio, Incremental Change"
       }
      }
     },
     "auth_ref": []
    },
    "asth_DebtInstrumentCovenantLeverageRatioMaximum": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "DebtInstrumentCovenantLeverageRatioMaximum",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum consolidated leverage ratio (not greater than)",
        "label": "Debt Instrument, Covenant, Leverage Ratio, Maximum",
        "documentation": "Debt Instrument, Covenant, Leverage Ratio, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoansReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt, principal sum",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r128",
      "r426",
      "r593",
      "r868",
      "r869"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average effective interest rate",
        "label": "Debt Instrument, Interest Rate During Period",
        "documentation": "The average effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r126",
      "r444"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoansReceivableDetails",
      "http://www.apollomed.net/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate (as a percent)",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r427"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r432",
      "r437",
      "r438",
      "r439",
      "r440",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r450",
      "r593",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r1023"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoansReceivableDetails",
      "http://www.apollomed.net/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r257",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r432",
      "r437",
      "r438",
      "r439",
      "r440",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r593",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r1023"
     ]
    },
    "asth_DebtInstrumentNumberOfKeyFinancialRatios": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "DebtInstrumentNumberOfKeyFinancialRatios",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of key financial ratios",
        "label": "Debt Instrument, Number Of Key Financial Ratios",
        "documentation": "Debt Instrument, Number Of Key Financial Ratios"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Redemption, Period One",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodThreeMember",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Redemption, Period Three",
        "label": "Debt Instrument, Redemption, Period Three [Member]",
        "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Redemption, Period Two",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r77",
      "r80",
      "r125",
      "r126",
      "r128",
      "r135",
      "r176",
      "r177",
      "r257",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r432",
      "r437",
      "r438",
      "r439",
      "r440",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r450",
      "r593",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r1023"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoansReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving credit facility term",
        "label": "Debt Instrument, Term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: Unamortized financing costs",
        "terseLabel": "Unamortized deferred financing costs",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r437",
      "r453",
      "r868",
      "r869"
     ]
    },
    "us-gaap_DeferredCreditsAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCreditsAndOtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount outstanding under agreement",
        "label": "Deferred Credits and Other Liabilities",
        "documentation": "Total carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income in future periods and obligations not separately disclosed in the balance sheet (other liabilities)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred tax liability",
        "terseLabel": "Deferred tax liability",
        "label": "Deferred Income Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r535",
      "r681"
     ]
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred tax",
        "label": "Deferred Income Taxes and Tax Credits",
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "asth_DepositForPurchaseOfProperty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "DepositForPurchaseOfProperty",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deposit for purchase of property",
        "label": "Deposit For Purchase Of Property",
        "documentation": "Deposit For Purchase Of Property"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r305"
     ]
    },
    "us-gaap_DerivativeAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate collar",
        "label": "Derivative Asset",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r233",
      "r582",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r777",
      "r778",
      "r828",
      "r831",
      "r833",
      "r834",
      "r835",
      "r836",
      "r858",
      "r896",
      "r1101"
     ]
    },
    "asth_DerivativeCeilingInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "DerivativeCeilingInterestRate",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative, ceiling interest rate",
        "label": "Derivative Ceiling Interest Rate",
        "documentation": "Derivative Ceiling Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails",
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Contract [Domain]",
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r760",
      "r762",
      "r776",
      "r777",
      "r778",
      "r780",
      "r781",
      "r782",
      "r783",
      "r785",
      "r786",
      "r787",
      "r788",
      "r804",
      "r805",
      "r806",
      "r807",
      "r810",
      "r811",
      "r812",
      "r813",
      "r828",
      "r829",
      "r833",
      "r835",
      "r894",
      "r896"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative asset, fair value",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset",
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r114",
      "r153",
      "r231",
      "r858"
     ]
    },
    "us-gaap_DerivativeFloorInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeFloorInterestRate",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative, floor interest rate",
        "label": "Derivative, Floor Interest Rate",
        "documentation": "Floor rate on an interest rate derivative such as an interest rate floor or collar. If market rates falls below the floor rate, a payment or receipt is triggered on the contract."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails",
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instrument [Axis]",
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r115",
      "r117",
      "r118",
      "r760",
      "r762",
      "r776",
      "r777",
      "r778",
      "r780",
      "r781",
      "r782",
      "r783",
      "r785",
      "r786",
      "r787",
      "r788",
      "r804",
      "r805",
      "r806",
      "r807",
      "r810",
      "r811",
      "r812",
      "r813",
      "r828",
      "r829",
      "r833",
      "r835",
      "r858",
      "r894",
      "r896"
     ]
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative liability",
        "label": "Derivative Liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r233",
      "r582",
      "r753",
      "r754",
      "r755",
      "r756",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r785",
      "r787",
      "r788",
      "r829",
      "r830",
      "r831",
      "r833",
      "r834",
      "r835",
      "r836",
      "r858",
      "r1101"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Financial Instruments",
        "label": "Derivatives, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r109",
      "r110",
      "r111",
      "r119",
      "r256"
     ]
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DevelopedTechnologyRightsMember",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Developed technology",
        "label": "Developed Technology Rights [Member]",
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "DirectorMember",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Board Member",
        "label": "Director [Member]"
       }
      }
     },
     "auth_ref": [
      "r1035",
      "r1102"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofDisaggregatedRevenuebyEachPayerTypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofDisaggregatedRevenuebyEachPayerTypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Disaggregated Revenue by Each Payor Type",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1072"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r496",
      "r524",
      "r525",
      "r526",
      "r886"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend payable",
        "verboseLabel": "Dividend payable",
        "label": "Dividends Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "asth_DmgMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "DmgMember",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails",
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DMG remaining equity interest purchase",
        "label": "DMG [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "asth_DrawOnLetterOfCreditThroughRevolverLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "DrawOnLetterOfCreditThroughRevolverLoan",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Draw on letter of credit through Revolver Loan",
        "label": "Draw On Letter Of Credit Through Revolver Loan",
        "documentation": "Draw On Letter Of Credit Through Revolver Loan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/EarningsPerShareScheduleofEarningsPerShareComputationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Earnings per share \u2013 basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r272",
      "r274",
      "r286",
      "r287",
      "r288",
      "r292",
      "r574",
      "r575",
      "r675",
      "r695",
      "r860"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/EarningsPerShareScheduleofEarningsPerShareComputationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Earnings per share \u2013 diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r274",
      "r286",
      "r287",
      "r288",
      "r292",
      "r574",
      "r575",
      "r675",
      "r695",
      "r860"
     ]
    },
    "asth_EarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "EarningsPerShareLineItems",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareScheduleofSharesIncludedintheDilutedEarningsPerShareComputationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Line Items]",
        "label": "Earnings Per Share [Line Items]",
        "documentation": "[Line Items] for Earnings Per Share [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "asth_EarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "EarningsPerShareTable",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareScheduleofSharesIncludedintheDilutedEarningsPerShareComputationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Table]",
        "label": "Earnings Per Share [Table]",
        "documentation": "Earnings Per Share [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Earnings Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r289",
      "r290",
      "r291"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued compensation",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1075"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareScheduleofSharesIncludedintheDilutedEarningsPerShareComputationsDetails",
      "http://www.apollomed.net/role/StockBasedCompensationScheduleofShareBasedCompensationExpenseDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "verboseLabel": "Stock options",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "asth_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Purchase Plan",
        "label": "Employee Stock Purchase Plan [Member]",
        "documentation": "Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
      "http://www.apollomed.net/role/CommitmentsandContingenciesDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r980"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r212",
      "r237",
      "r238",
      "r239",
      "r258",
      "r259",
      "r260",
      "r262",
      "r268",
      "r270",
      "r293",
      "r373",
      "r374",
      "r470",
      "r527",
      "r528",
      "r529",
      "r544",
      "r545",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r573",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r611",
      "r720",
      "r721",
      "r722",
      "r741",
      "r816"
     ]
    },
    "asth_EquityMethodAndOtherEquityInvestmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "EquityMethodAndOtherEquityInvestmentsTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investments in Other Entities",
        "label": "Equity Method And Other Equity Investments [Text Block]",
        "documentation": "Equity Method And Other Equity Investments [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesScheduleofEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Domain]",
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r369",
      "r370",
      "r371"
     ]
    },
    "asth_EquityMethodInvestmentAdditionalInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "EquityMethodInvestmentAdditionalInvestment",
     "crdr": "debit",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesScheduleofEquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial Investment",
        "label": "Equity Method Investment, Additional Investment",
        "documentation": "Equity Method Investment, Additional Investment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment",
     "crdr": "debit",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of investments",
        "label": "Equity Method Investment, Other than Temporary Impairment",
        "documentation": "This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment."
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesScheduleofEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "% of Ownership",
        "terseLabel": "Equity interest (as a percent)",
        "label": "Equity Method Investment, Ownership Percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_EquityMethodInvestmentSoldCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentSoldCarryingAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesScheduleofEquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Distribution",
        "label": "Equity Method Investment, Amount Sold",
        "documentation": "Amount of the entity's equity method investment which has been sold."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesScheduleofEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investments in other entities \u2013 equity method",
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "terseLabel": "Investments in other entities \u2013 equity method",
        "label": "Equity Method Investments",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r367",
      "r1000",
      "r1045"
     ]
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]",
        "label": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asth_EquityMethodInvestmentsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "EquityMethodInvestmentsRollForward",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesScheduleofEquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investments [Roll Forward]",
        "label": "Equity Method Investments [Roll Forward]",
        "documentation": "Equity Method Investments [Roll Forward]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentsTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Equity Method Investments",
        "label": "Equity Method Investments [Table Text Block]",
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNi",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails",
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Marketable securities \u2013 equity securities",
        "terseLabel": "Equity securities",
        "label": "Equity Securities, FV-NI, Current",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r581",
      "r855"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investment in a privately held entity",
        "label": "Equity Securities, FV-NI and without Readily Determinable Fair Value",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) and investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofGainLossonEquitySecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofGainLossonEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total losses recognized on equity securities",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r698",
      "r1042"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofGainLossonEquitySecuritiesDetails": {
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofGainLossonEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gains recognized on equity securities sold",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r696",
      "r1042"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofGainLossonEquitySecuritiesDetails": {
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofGainLossonEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized losses recognized on equity securities held at end of period",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r697",
      "r1042"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r913",
      "r924",
      "r934",
      "r959"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r910",
      "r921",
      "r931",
      "r956"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails",
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r577",
      "r578",
      "r580"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails",
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r577",
      "r578",
      "r580"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Carrying Amounts and Fair Values of Financial Instruments",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r121",
      "r122",
      "r186"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r578",
      "r627",
      "r628",
      "r629",
      "r868",
      "r869",
      "r880",
      "r881",
      "r882"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements of Financial Instruments",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r485",
      "r490",
      "r578",
      "r627",
      "r880",
      "r881",
      "r882"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r485",
      "r490",
      "r578",
      "r628",
      "r868",
      "r869",
      "r880",
      "r881",
      "r882"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r578",
      "r629",
      "r868",
      "r869",
      "r880",
      "r881",
      "r882"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofChangeinFairValueofLevel3LiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Change in Fair Value of Level 3 Liabilities",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r122"
     ]
    },
    "asth_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdditions",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofChangeinFairValueofLevel3LiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability, Additions",
        "documentation": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability, Additions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofChangeinFairValueofLevel3LiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of existing Level 3 liabilities",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofChangeinFairValueofLevel3LiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r627",
      "r628",
      "r629",
      "r868",
      "r869",
      "r880",
      "r881",
      "r882"
     ]
    },
    "asth_FiduciaryAccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "FiduciaryAccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fiduciary accounts payable",
        "verboseLabel": "Fiduciary accounts payable",
        "label": "Fiduciary Accounts Payable Current",
        "documentation": "Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "asth_FinanceLeaseCostsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "FinanceLeaseCostsAbstract",
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofComponentsofLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease cost",
        "label": "Finance Lease Costs [Abstract]",
        "documentation": "Finance Lease Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/LeasesScheduleofComponentsofLeaseExpenseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofComponentsofLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest on lease liabilities",
        "label": "Finance Lease, Interest Expense",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r597",
      "r603",
      "r890"
     ]
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows from finance leases",
        "label": "Finance Lease, Interest Payment on Liability",
        "documentation": "Amount of interest paid on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r599",
      "r606"
     ]
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Leases",
        "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease liabilities",
        "label": "Finance Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r596",
      "r610"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease liabilities",
        "verboseLabel": "Finance lease liabilities",
        "netLabel": "Less: current portion",
        "label": "Finance Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Minimum Finance Lease Payments Under Non-cancelable Leases",
        "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Finance lease liabilities, net of current portion",
        "terseLabel": "Long-term lease liabilities",
        "label": "Finance Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future minimum lease payments",
        "label": "Finance Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 (excluding the three months ended March 31, 2024)",
        "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "asth_FinanceLeaseLiabilityToBePaidAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "FinanceLeaseLiabilityToBePaidAfterYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finance Lease, Liability, To Be Paid, After Year Four",
        "documentation": "Finance Lease, Liability, To Be Paid, After Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: imputed interest",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financing cash flows from finance leases",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r598",
      "r606"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets recorded under finance leases",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated depreciation associated with finance leases",
        "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization",
        "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r982",
      "r987"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/LeasesScheduleofComponentsofLeaseExpenseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofComponentsofLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of lease expense",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r597",
      "r603",
      "r890"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Finance leases",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r890"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Finance leases",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r608",
      "r890"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r382",
      "r383",
      "r450",
      "r467",
      "r571",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r694",
      "r865",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r1038",
      "r1039",
      "r1040",
      "r1041"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Financial Liabilities Fair Value Disclosure",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialSupportToNonconsolidatedLegalEntityAxis",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Support to Nonconsolidated Legal Entity [Axis]",
        "label": "Financial Support to Nonconsolidated Legal Entity [Axis]",
        "documentation": "Information by financial support arrangement provided to a nonconsolidated legal entity that is required to comply with or operate in accordance with requirements that are similar to those included in Rule 2a-7 of the Investment Company Act of 1940 for registered money market funds."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r734",
      "r735"
     ]
    },
    "us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialSupportToNonconsolidatedLegalEntityDomain",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Support to Nonconsolidated Legal Entity [Domain]",
        "label": "Financial Support to Nonconsolidated Legal Entity [Domain]",
        "documentation": "Financial support arrangement provided to a nonconsolidated legal entity that is required to comply with or operate in accordance with requirements that are similar to those included in Rule 2a-7 of the Investment Company Act of 1940 for registered money market funds."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r734",
      "r735"
     ]
    },
    "asth_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful Life",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r400"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 (excluding the nine months ended September 30, 2023)",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r399",
      "r400",
      "r402",
      "r659",
      "r660"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized intangible assets, Gross",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r660"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r71"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r659"
     ]
    },
    "asth_FirstCommonwealthPropertyLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "FirstCommonwealthPropertyLLCMember",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Commonwealth Property, LLC",
        "label": "First Commonwealth Property, LLC [Member]",
        "documentation": "First Commonwealth Property, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "asth_FirstMetricMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "FirstMetricMember",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Metric",
        "label": "First Metric [Member]",
        "documentation": "First Metric"
       }
      }
     },
     "auth_ref": []
    },
    "asth_FiveThreeOneW.CollegeLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "FiveThreeOneW.CollegeLLCMember",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesScheduleofEquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "531 W. College, LLC",
        "label": "Five Three One W. College LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r917",
      "r928",
      "r938",
      "r963"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r917",
      "r928",
      "r938",
      "r963"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r917",
      "r928",
      "r938",
      "r963"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r917",
      "r928",
      "r938",
      "r963"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r917",
      "r928",
      "r938",
      "r963"
     ]
    },
    "us-gaap_GainLossOnInvestmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnInvestmentsTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Gain (Loss) on Equity Securities",
        "label": "Gain (Loss) on Securities [Table Text Block]",
        "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security."
       }
      }
     },
     "auth_ref": [
      "r1010",
      "r1011"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "General and administrative expenses",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r795"
     ]
    },
    "asth_GeneralAndAdministrativeExpensesAndDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "GeneralAndAdministrativeExpensesAndDepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.apollomed.net/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expenses and Depreciation and Amortization",
        "documentation": "General and Administrative Expenses and Depreciation and Amortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillScheduleofGoodwillDetails",
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails",
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "verboseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r384",
      "r673",
      "r866",
      "r891",
      "r1048",
      "r1055"
     ]
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAcquiredDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillScheduleofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions",
        "label": "Goodwill, Acquired During Period",
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r866"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of goodwill",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r385",
      "r391",
      "r395",
      "r866"
     ]
    },
    "us-gaap_GoodwillPurchaseAccountingAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillPurchaseAccountingAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillScheduleofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments",
        "label": "Goodwill, Purchase Accounting Adjustments",
        "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r1054"
     ]
    },
    "us-gaap_GoodwillRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillRollForward",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillScheduleofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Roll Forward]",
        "label": "Goodwill [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "asth_HSMSOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "HSMSOMember",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofFeesIncurredandRevenueEarnedfromRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "HSMSO",
        "label": "HSMSO [Member]",
        "documentation": "xxx_HSMSO Member"
       }
      }
     },
     "auth_ref": []
    },
    "asth_HealthCareCapitationRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "HealthCareCapitationRevenueMember",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Capitation, net",
        "label": "Health Care Capitation Revenue [Member]",
        "documentation": "ameh_HealthCareCapitationRevenueMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_HealthCareOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HealthCareOtherMember",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk pool settlements and incentives",
        "label": "Health Care, Other [Member]",
        "documentation": "Service provided for maintenance, diagnosis and treatment of physical and mental health, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1073"
     ]
    },
    "us-gaap_HealthCarePatientServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HealthCarePatientServiceMember",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fee-for-service, net",
        "verboseLabel": "Third-Party",
        "label": "Health Care, Patient Service [Member]",
        "documentation": "Service provided to patient for maintenance, diagnosis and treatment of physical and mental health. Excludes service to resident in health care facility."
       }
      }
     },
     "auth_ref": [
      "r1073"
     ]
    },
    "asth_IHealthIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "IHealthIncMember",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesScheduleofEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "I Health, Inc.",
        "label": "I Health, Inc. [Member]",
        "documentation": "I Health, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "asth_IHealthPromissioryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "IHealthPromissioryNoteMember",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "I Health Promissiory Note",
        "label": "I Health Promissiory Note [Member]",
        "documentation": "I Health Promissiory Note"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of finite-lived intangible assets",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r1019",
      "r1058"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income before provision for income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r154",
      "r194",
      "r300",
      "r320",
      "r326",
      "r329",
      "r676",
      "r690",
      "r862"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesScheduleofEquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income from equity method investments",
        "negatedLabel": "Income from equity method investments",
        "verboseLabel": "Allocation of Net Income",
        "label": "Income (Loss) from Equity Method Investments",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r155",
      "r193",
      "r307",
      "r367",
      "r689"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Operations",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r531",
      "r538",
      "r539",
      "r542",
      "r546",
      "r548",
      "r549",
      "r550",
      "r733"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for income taxes",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r208",
      "r269",
      "r270",
      "r308",
      "r536",
      "r547",
      "r699"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r532",
      "r533",
      "r539",
      "r540",
      "r541",
      "r543",
      "r727"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for income taxes",
        "label": "Income Taxes Paid",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r50"
     ]
    },
    "us-gaap_IncomeTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes receivable",
        "label": "Income Taxes Receivable, Current",
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r1007"
     ]
    },
    "us-gaap_IncomeTaxesReceivableNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesReceivableNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes receivable",
        "verboseLabel": "Income taxes receivable, non-current",
        "label": "Income Taxes Receivable, Noncurrent",
        "documentation": "Carrying amount due after one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes."
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Receivable, net",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income taxes payable/receivable",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDueFromRelatedParties",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Receivable, net \u2013 related parties",
        "label": "Increase (Decrease) in Due from Related Parties",
        "documentation": "The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "asth_IncreaseDecreaseInMedicalLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "IncreaseDecreaseInMedicalLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Medical liabilities",
        "label": "Increase (Decrease) In Medical Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of medical liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities, net of business combinations:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r988",
      "r1018"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fiduciary accounts payable",
        "label": "Increase (Decrease) in Other Accounts Payable",
        "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other receivables",
        "label": "Increase (Decrease) in Other Receivables",
        "documentation": "Amount of increase (decrease) in receivables classified as other."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "asth_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) In Prepaid Expenses And Other Current Assets",
        "documentation": "The increase (decrease) during the reporting period in the value of prepaid expenses and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToContingentlyIssuableShares",
     "calculation": {
      "http://www.apollomed.net/role/EarningsPerShareScheduleofSharesIncludedintheDilutedEarningsPerShareComputationsDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareScheduleofSharesIncludedintheDilutedEarningsPerShareComputationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingently issuable shares (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of contingently issuable shares. Contingently issuable shares are those shares that are issuable for little or no cash contingent on certain conditions being met."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r276",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r288"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r401"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived Intangible Assets [Line Items]",
        "label": "Indefinite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite lived assets:",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r172"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r920",
      "r928",
      "r938",
      "r955",
      "r963",
      "r967",
      "r975"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r973"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r909",
      "r979"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r909",
      "r979"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r909",
      "r979"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets, Net",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Intangible Assets, Gross",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible assets, net",
        "totalLabel": "Intangible Assets, Net",
        "terseLabel": "Intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r70"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r196",
      "r240",
      "r304",
      "r591",
      "r801",
      "r902",
      "r1104"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r245",
      "r246"
     ]
    },
    "asth_InterestRateCollarMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "InterestRateCollarMember",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails",
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate Collar",
        "label": "Interest Rate Collar [Member]",
        "documentation": "Interest Rate Collar"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntersegmentEliminationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntersegmentEliminationMember",
     "presentation": [
      "http://www.apollomed.net/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intersegment Elimination",
        "label": "Intersegment Eliminations [Member]",
        "documentation": "Eliminating entries used in operating segment consolidation."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r329"
     ]
    },
    "asth_IntraCareConvertiblePromissoryNoteReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "IntraCareConvertiblePromissoryNoteReceivableMember",
     "presentation": [
      "http://www.apollomed.net/role/LoansReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IntraCare Convertible Promissory Note Receivable",
        "label": "IntraCare Convertible Promissory Note Receivable [Member]",
        "documentation": "IntraCare Convertible Promissory Note Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "asth_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investments in privately held entities",
        "label": "Investment In Privately Held Entity That Does Not Report Net Asset Value",
        "documentation": "Total of Investment in privately held entity that does not report net asset value per share ."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r303"
     ]
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "crdr": "debit",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in affiliates",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate."
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "asth_LasalleMedicalAssociatesIpaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "LasalleMedicalAssociatesIpaMember",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesScheduleofEquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LaSalle Medical Associates \u2013 IPA line of business",
        "label": "LaSalle Medical Associates IPA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/LeasesScheduleofComponentsofLeaseExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofComponentsofLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease cost, net",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r602",
      "r890"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Information Related to Lease Costs",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1080"
     ]
    },
    "asth_LeaseWeightedAverageDiscountRateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "LeaseWeightedAverageDiscountRateAbstract",
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Discount Rate",
        "label": "Lease Weighted Average Discount Rate [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asth_LeaseWeightedAverageRemainingLeaseTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "LeaseWeightedAverageRemainingLeaseTermAbstract",
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Remaining Lease Term",
        "label": "Lease Weighted Average Remaining Lease Term [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
      "http://www.apollomed.net/role/CommitmentsandContingenciesDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeFinanceLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining lease term, finance",
        "label": "Lessee, Finance Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1078"
     ]
    },
    "us-gaap_LesseeFinanceLeaseRenewalTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeFinanceLeaseRenewalTerm1",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease option to extend (up to)",
        "label": "Lessee, Finance Lease, Renewal Term",
        "documentation": "Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "asth_LesseeFinanceLeaseTerminationPeriodIfApplicable": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "LesseeFinanceLeaseTerminationPeriodIfApplicable",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease, termination period, if applicable",
        "label": "Lessee, Finance Lease, Termination Period, If Applicable",
        "documentation": "Lessee, Finance Lease, Termination Period, If Applicable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeFinanceLeasesTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Finance Leases [Text Block]",
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Minimum Operating Lease Payments Under Non-cancelable Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future minimum lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 (excluding the three months ended March 31, 2024)",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "asth_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining lease term, operating",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1078"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease option to extend (up to)",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "asth_LesseeOperatingLeaseTerminationPeriodIfApplicable": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "LesseeOperatingLeaseTerminationPeriodIfApplicable",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, termination period, if applicable",
        "label": "Lessee, Operating Lease, Termination Period, If Applicable",
        "documentation": "Lessee, Operating Lease, Termination Period, If Applicable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "us-gaap_LetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LetterOfCreditMember",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letter of Credit",
        "label": "Letter of Credit [Member]",
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "terseLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r250",
      "r372",
      "r412",
      "r413",
      "r415",
      "r416",
      "r417",
      "r419",
      "r421",
      "r423",
      "r424",
      "r560",
      "r563",
      "r564",
      "r583",
      "r769",
      "r861",
      "r904",
      "r1066",
      "r1085",
      "r1086"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities, mezzanine equity and equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r192",
      "r687",
      "r891",
      "r1024",
      "r1046",
      "r1077"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Liabilities, mezzanine equity and equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r217",
      "r250",
      "r372",
      "r412",
      "r413",
      "r415",
      "r416",
      "r417",
      "r419",
      "r421",
      "r423",
      "r424",
      "r560",
      "r563",
      "r564",
      "r583",
      "r891",
      "r1066",
      "r1085",
      "r1086"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current liabilities",
        "terseLabel": "Current liabilities",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r139",
      "r140",
      "r141",
      "r144",
      "r250",
      "r372",
      "r412",
      "r413",
      "r415",
      "r416",
      "r417",
      "r419",
      "r421",
      "r423",
      "r424",
      "r560",
      "r563",
      "r564",
      "r583",
      "r1066",
      "r1085",
      "r1086"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-current liabilities",
        "terseLabel": "Non-current liabilities",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/MedicalLiabilitiesDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medical liabilities",
        "periodStartLabel": "Medical liabilities, beginning of period",
        "periodEndLabel": "Medical liabilities, end of period",
        "verboseLabel": "Medical liabilities",
        "label": "Liability for Claims and Claims Adjustment Expense",
        "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r199"
     ]
    },
    "us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medical Liabilities",
        "label": "Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]",
        "documentation": "The entire disclosure for liabilities related to future policy benefits and unpaid claims and claim adjustments."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired (see Note 3)",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions",
        "documentation": "Amount of increase (decrease) in the cost of settling unpaid claims after deduction of reinsurance recoveries related to the acquisition of a business. Includes, but is not limited to, claims which have been incurred but not reported."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for medical care costs related to claims incurred:",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesDetails": {
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Current period",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year",
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesDetails": {
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prior periods",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years",
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total medical care costs",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims",
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process."
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of medical care costs related to claims incurred:",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medical Liabilities [Roll Forward]",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease)",
        "documentation": "Amount, after effects of reinsurance, of increase (decrease) in the liability for unpaid claims and claims adjustment expense."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicenseMember",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Licenses",
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r1073"
     ]
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails",
      "http://www.apollomed.net/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "netLabel": "Loan from company",
        "verboseLabel": "Amount outstanding",
        "terseLabel": "Drew down on revolver loan",
        "label": "Long-Term Line of Credit",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r190",
      "r1094"
     ]
    },
    "asth_LineOfCreditFacilityAmountFundedAtClosing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "LineOfCreditFacilityAmountFundedAtClosing",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount funded at closing",
        "label": "Line Of Credit Facility, Amount Funded At Closing",
        "documentation": "Line Of Credit Facility, Amount Funded At Closing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityAxis",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lender Name [Axis]",
        "label": "Lender Name [Axis]",
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r1023"
     ]
    },
    "us-gaap_LineOfCreditFacilityExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityExpirationPeriod",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of facility",
        "label": "Line of Credit Facility, Expiration Period",
        "documentation": "Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Line of Credit Facility, Interest Rate at Period End",
        "documentation": "The effective interest rate at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityLenderDomain",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility, Lender [Domain]",
        "label": "Line of Credit Facility, Lender [Domain]",
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r1023"
     ]
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityLineItems",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility [Line Items]",
        "label": "Line of Credit Facility [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum loan availability",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityTable",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility [Table]",
        "label": "Line of Credit Facility [Table]",
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r1023"
     ]
    },
    "us-gaap_LineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditMember",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit",
        "label": "Line of Credit [Member]",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
       }
      }
     },
     "auth_ref": []
    },
    "asth_LmaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "LmaMember",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LMA",
        "label": "LMA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asth_LoanReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "LoanReceivableTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/LoansReceivable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Loans Receivable",
        "label": "Loan Receivable [Text Block]",
        "documentation": "Loan Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of long-term debt",
        "negatedTerseLabel": "Less: Current portion of debt",
        "verboseLabel": "Current portion of long-term debt",
        "label": "Long-Term Debt, Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails": {
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r257",
      "r443"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails": {
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Long-Term Debt, Maturity, Year Four",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r257",
      "r443"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails": {
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r257",
      "r443"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails": {
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r257",
      "r443"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails": {
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt, net of current portion and deferred financing costs",
        "verboseLabel": "Long-term debt",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityDetails",
      "http://www.apollomed.net/role/LoansReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityDetails",
      "http://www.apollomed.net/role/LoansReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r73"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofContributionstoRevenueandReceivablesbyPayerDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofDisaggregatedRevenuebyEachPayerTypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r334",
      "r875",
      "r1072",
      "r1096",
      "r1097"
     ]
    },
    "asth_ManagementContractsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "ManagementContractsMember",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Management contracts",
        "label": "Management Contracts [Member]",
        "documentation": "Management Contracts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ManagementServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ManagementServiceMember",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Management fee income",
        "label": "Management Service [Member]",
        "documentation": "Contractually stipulated right to receive compensation for operating and managing business."
       }
      }
     },
     "auth_ref": [
      "r1073"
     ]
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investment in marketable securities",
        "terseLabel": "Investment in marketable securities",
        "label": "Marketable Securities, Current",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "asth_MarketableSecuritiesCurrentMaturityPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "MarketableSecuritiesCurrentMaturityPeriod",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term marketable securities, maturity period",
        "label": "Marketable Securities, Current, Maturity Period",
        "documentation": "Marketable Securities, Current, Maturity Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in Marketable Securities",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r408",
      "r409",
      "r410",
      "r411",
      "r492",
      "r657",
      "r719",
      "r761",
      "r762",
      "r824",
      "r825",
      "r826",
      "r827",
      "r837",
      "r850",
      "r851",
      "r864",
      "r872",
      "r885",
      "r893",
      "r1070",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "asth_MedicaidMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "MedicaidMember",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofDisaggregatedRevenuebyEachPayerTypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicaid",
        "label": "Medicaid [Member]",
        "documentation": "ameh:MedicaidMember"
       }
      }
     },
     "auth_ref": []
    },
    "asth_MedicareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "MedicareMember",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofDisaggregatedRevenuebyEachPayerTypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicare",
        "label": "Medicare [Member]",
        "documentation": "ameh:MedicareMember"
       }
      }
     },
     "auth_ref": []
    },
    "asth_MemberRelationshipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "MemberRelationshipsMember",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Member relationships",
        "label": "Member Relationships [Member]",
        "documentation": "Member Relationships"
       }
      }
     },
     "auth_ref": []
    },
    "asth_MezzanineEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "MezzanineEquityAbstract",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Mezzanine equity",
        "label": "MEZZANINE EQUITY [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asth_MezzanineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "MezzanineMember",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mezzanine",
        "label": "Mezzanine [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r408",
      "r409",
      "r410",
      "r411",
      "r492",
      "r657",
      "r719",
      "r761",
      "r762",
      "r824",
      "r825",
      "r826",
      "r827",
      "r837",
      "r850",
      "r851",
      "r864",
      "r872",
      "r885",
      "r893",
      "r1070",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling interest",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r191",
      "r250",
      "r372",
      "r412",
      "r415",
      "r416",
      "r417",
      "r423",
      "r424",
      "r583",
      "r686",
      "r773"
     ]
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "crdr": "debit",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of non-controlling interest",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests)."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r178",
      "r184"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofContributionstoRevenueandReceivablesbyPayerDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofDisaggregatedRevenuebyEachPayerTypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r334",
      "r875",
      "r1072",
      "r1096",
      "r1097"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Business",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r209"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r165",
      "r166"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash flows from operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income attributable to Astrana Health, Inc.",
        "terseLabel": "Net Income (Loss)",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r166",
      "r195",
      "r215",
      "r234",
      "r235",
      "r239",
      "r250",
      "r261",
      "r263",
      "r264",
      "r265",
      "r266",
      "r269",
      "r270",
      "r285",
      "r300",
      "r320",
      "r326",
      "r329",
      "r372",
      "r412",
      "r413",
      "r415",
      "r416",
      "r417",
      "r419",
      "r421",
      "r423",
      "r424",
      "r575",
      "r583",
      "r693",
      "r792",
      "r814",
      "r815",
      "r862",
      "r902",
      "r1066"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net income (loss) attributable to non-controlling interest",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r185",
      "r234",
      "r235",
      "r269",
      "r270",
      "r692",
      "r1009"
     ]
    },
    "asth_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (loss) income",
        "label": "Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity",
        "documentation": "Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity"
       }
      }
     },
     "auth_ref": []
    },
    "asth_NetworkMedicalManagementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "NetworkMedicalManagementMember",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NMM",
        "label": "Network Medical Management [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asth_NetworkRelationshipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "NetworkRelationshipsMember",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Network relationships",
        "label": "Network Relationships [Member]",
        "documentation": "Network Relationships"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements Not Yet Adopted",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "asth_NewTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "NewTermLoanMember",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Term Loan",
        "label": "New Term Loan [Member]",
        "documentation": "New Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "asth_NonCashBusinessAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "NonCashBusinessAcquisition",
     "crdr": "debit",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business acquisition in accounts payable and accrued liabilities",
        "label": "Non-Cash Business Acquisition",
        "documentation": "Non-Cash Business Acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r917",
      "r928",
      "r938",
      "r955",
      "r963"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "asth_NoncashLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "NoncashLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-cash lease expense",
        "label": "Noncash Lease Expense",
        "documentation": "Noncash Lease Expense"
       }
      }
     },
     "auth_ref": []
    },
    "asth_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends",
        "label": "Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders And Stock Repurchased During Period, Value, Release Of Hold Back Shares",
        "documentation": "Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders And Stock Repurchased During Period, Value, Release Of Hold Back Shares"
       }
      }
     },
     "auth_ref": []
    },
    "asth_NoncontrollingInterestIncreaseDecreaseFromBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "NoncontrollingInterestIncreaseDecreaseFromBusinessCombination",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition of non-controlling interest",
        "label": "Noncontrolling Interest, Increase (Decrease) from Business Combination",
        "documentation": "Noncontrolling Interest, Increase (Decrease) from Business Combination"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of non-controlling interest",
        "label": "Noncontrolling Interest, Increase from Sale of Parent Equity Interest",
        "documentation": "Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r81",
      "r184"
     ]
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-controlling Interest",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r470",
      "r1028",
      "r1029",
      "r1030",
      "r1105"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other expenses, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense)",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonrelated Party",
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r1025",
      "r1026"
     ]
    },
    "us-gaap_NotesAndLoansReceivableNetNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesAndLoansReceivableNetNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loans receivable, non-current",
        "label": "Financing Receivable, after Allowance for Credit Loss, Noncurrent",
        "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableToBanksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableToBanksMember",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Promissory Note Payable",
        "label": "Notes Payable to Banks [Member]",
        "documentation": "A written promise to pay a note to a bank."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesReceivableMember",
     "presentation": [
      "http://www.apollomed.net/role/LoansReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Secured Promissory Note",
        "label": "Notes Receivable [Member]",
        "documentation": "An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date(s) within one year of the balance sheet date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "asth_OfficeLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "OfficeLeaseMember",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office Lease",
        "label": "Office Lease [Member]",
        "documentation": "Office Lease"
       }
      }
     },
     "auth_ref": []
    },
    "asth_OneMSOLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "OneMSOLLCMember",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesScheduleofEquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One MSO, LLC",
        "label": "One MSO, LLC [Member]",
        "documentation": "One MSO, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income from operations",
        "verboseLabel": "Income (loss) from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r320",
      "r326",
      "r329",
      "r862"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/LeasesScheduleofComponentsofLeaseExpenseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofComponentsofLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r604",
      "r890"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease liabilities",
        "netLabel": "Operating lease liabilities",
        "terseLabel": "Less: current portion",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/LeasesScheduleofFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease liabilities, net of current portion",
        "terseLabel": "Long-term lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating cash flows from operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r600",
      "r606"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease right-of-use assets",
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating leases",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r890"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating leases",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r608",
      "r890"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://www.apollomed.net/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Segments",
        "label": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r329"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other provider payable",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "asth_OtherAcquisitionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "OtherAcquisitionsMember",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Acquisitions",
        "label": "Other Acquisitions [Member]",
        "documentation": "Other Acquisitions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other assets",
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "us-gaap_OtherInvesteesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherInvesteesMember",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesScheduleofEquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Nonconsolidated Investees, Other [Member]",
        "documentation": "Investment in group of nonconsolidated investees classified as other."
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "us-gaap_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount due to affiliates",
        "label": "Other Liabilities",
        "documentation": "Amount of liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r678",
      "r765",
      "r766",
      "r904",
      "r1102"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Other liabilities",
        "terseLabel": "Other liabilities",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r891"
     ]
    },
    "us-gaap_OtherLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesMember",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Liabilities",
        "label": "Other Liabilities [Member]",
        "documentation": "Primary financial statement caption encompassing other liabilities."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r120"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "verboseLabel": "Other long-term liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_OtherLongTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLongTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in affiliates",
        "label": "Other Long-Term Investments",
        "documentation": "Amount of long-term investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r679",
      "r1001"
     ]
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncurrentLiabilitiesMember",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Noncurrent Liabilities",
        "label": "Other Noncurrent Liabilities [Member]",
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other (loss) income",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due from affiliates",
        "label": "Other Receivables",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r779"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other receivables",
        "terseLabel": "Other receivables",
        "label": "Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "asth_OtherThirdPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "OtherThirdPartiesMember",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofDisaggregatedRevenuebyEachPayerTypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other third parties",
        "label": "Other Third Parties [Member]",
        "documentation": "ameh:OtherThirdPartiesMember"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r915",
      "r926",
      "r936",
      "r961"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r918",
      "r929",
      "r939",
      "r964"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r918",
      "r929",
      "r939",
      "r964"
     ]
    },
    "asth_PCCCVMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "PCCCVMember",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PCCCV",
        "label": "PCCCV [Member]",
        "documentation": "PCCCV"
       }
      }
     },
     "auth_ref": []
    },
    "asth_PacificMedicalImagingAndOncologyCenterIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "PacificMedicalImagingAndOncologyCenterIncMember",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesScheduleofEquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pacific Medical Imaging &amp; Oncology Center, Inc.",
        "label": "Pacific Medical Imaging and Oncology Center, Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asth_PatientManagementPlatformMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "PatientManagementPlatformMember",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patient management platform",
        "label": "Patient Management Platform [Member]",
        "documentation": "Patient Management Platform"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payables and Accruals [Abstract]",
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asth_PayerCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "PayerCMember",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofContributionstoRevenueandReceivablesbyPayerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payer C",
        "label": "Payer C [Member]",
        "documentation": "Payer C"
       }
      }
     },
     "auth_ref": []
    },
    "asth_PaymentForRepurchaseOfTreasuryStockFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "PaymentForRepurchaseOfTreasuryStockFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repurchase of treasury shares",
        "label": "Payment For Repurchase Of Treasury Stock, Financing Activities",
        "documentation": "Payment For Repurchase Of Treasury Stock, Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForLossesAndLossAdjustmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForLossesAndLossAdjustmentExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total paid",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid",
        "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r23"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for repurchase of shares",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDividendsCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Dividends paid",
        "terseLabel": "Payments of ordinary dividends common stock",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_PaymentsOfDividendsMinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDividendsMinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of non-controlling interest",
        "label": "Payments of Ordinary Dividends, Noncontrolling Interest",
        "documentation": "Amount of cash outflow in the form of ordinary dividends provided by the non-wholly owned subsidiary to noncontrolling interests."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "asth_PaymentsToAcquireBusinessCashPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "PaymentsToAcquireBusinessCashPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash payable",
        "label": "Payments to Acquire Business, Cash Payable",
        "documentation": "Payments to Acquire Business, Cash Payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid",
        "label": "Payments to Acquire Businesses, Gross",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r555"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments for business acquisition, net of cash acquired",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of investment \u2013 equity method",
        "label": "Payments to Acquire Equity Method Investments",
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "us-gaap_PaymentsToFundLongtermLoansToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToFundLongtermLoansToRelatedParties",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Issuance of loans receivable",
        "label": "Payments to Fund Long-Term Loans to Related Parties",
        "documentation": "The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates."
       }
      }
     },
     "auth_ref": [
      "r1014",
      "r1082"
     ]
    },
    "asth_PayorAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "PayorAMember",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofContributionstoRevenueandReceivablesbyPayerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payer A",
        "label": "Payor A [Member]",
        "documentation": "Payor A [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asth_PayorBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "PayorBMember",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofContributionstoRevenueandReceivablesbyPayerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payer B",
        "label": "Payor B [Member]",
        "documentation": "Payor B [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "asth_PerformanceBasedRestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "PerformanceBasedRestrictedStockMember",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Based Restricted Stock",
        "label": "Performance Based Restricted Stock [Member]",
        "documentation": "Performance Based Restricted Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Shares",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "asth_PmiocMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "PmiocMember",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PMIOC",
        "label": "PMIOC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asth_PreferredBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "PreferredBankMember",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Bank",
        "label": "Preferred Bank [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r455"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r771"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r455"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r771",
      "r790",
      "r1105",
      "r1106"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r683",
      "r891"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "verboseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "asth_PrimeCommunityCareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "PrimeCommunityCareMember",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PCCCV contingent considerations",
        "label": "Prime Community Care [Member]",
        "documentation": "Prime Community Care"
       }
      }
     },
     "auth_ref": []
    },
    "asth_PrimeCommunityCareOfCentralValleyIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "PrimeCommunityCareOfCentralValleyIncMember",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prime Community Care of Central Valley, Inc",
        "label": "Prime Community Care of Central Valley, Inc [Member]",
        "documentation": "Prime Community Care of Central Valley, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromCollectionOfLongtermLoansToRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from repayment of loans receivable \u2013 related parties",
        "label": "Proceeds from Collection of Long-Term Loans to Related Parties",
        "documentation": "The cash inflow associated with collection, whether partial or full, of long-term loans to a related party. Alternate caption: Proceeds from Advances to Affiliates."
       }
      }
     },
     "auth_ref": [
      "r1013",
      "r1082"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Drawdowns",
        "label": "Proceeds from Issuance of Debt",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfOtherLongTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings on long-term debt",
        "label": "Proceeds from Issuance of Other Long-Term Debt",
        "documentation": "Amount of cash inflow from issuance of long-term debt classified as other."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromLinesOfCredit",
     "crdr": "debit",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from Lines of Credit",
        "label": "Proceeds from Lines of Credit",
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r1023"
     ]
    },
    "us-gaap_ProceedsFromOtherOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromOtherOperatingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Proceeds from Other Operating Activities",
        "documentation": "Amount of cash inflow from operating activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ProceedsFromPaymentsToMinorityShareholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromPaymentsToMinorityShareholders",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of non-controlling interest",
        "label": "Proceeds from (Payments to) Noncontrolling Interests",
        "documentation": "Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromRelatedPartyDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from promissory note",
        "label": "Proceeds from Related Party Debt",
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ProceedsFromRepaymentsOfBankOverdrafts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromRepaymentsOfBankOverdrafts",
     "crdr": "debit",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from (repayments of) bank overdrafts",
        "label": "Proceeds from (Repayments of) Bank Overdrafts",
        "documentation": "The net cash inflow or outflow from the excess drawing from an existing cash balance, which will be honored by the bank but reflected as a loan to the drawer."
       }
      }
     },
     "auth_ref": [
      "r1016",
      "r1017",
      "r1020"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the exercise of stock options and warrants",
        "label": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductAndServiceOtherMember",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other revenue",
        "verboseLabel": "Intersegment",
        "label": "Product and Service, Other [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1073"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r331",
      "r658",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r853",
      "r873",
      "r892",
      "r989",
      "r1062",
      "r1063",
      "r1072",
      "r1096"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r331",
      "r658",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r853",
      "r873",
      "r892",
      "r989",
      "r1062",
      "r1063",
      "r1072",
      "r1096"
     ]
    },
    "asth_ProfessionalMedicalCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "ProfessionalMedicalCorporationMember",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AMG",
        "label": "Professional Medical Corporation [Member]",
        "documentation": "Professional Medical Corporation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income",
        "terseLabel": "Net income",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r234",
      "r235",
      "r243",
      "r250",
      "r261",
      "r269",
      "r270",
      "r300",
      "r320",
      "r326",
      "r329",
      "r372",
      "r412",
      "r413",
      "r415",
      "r416",
      "r417",
      "r419",
      "r421",
      "r423",
      "r424",
      "r558",
      "r561",
      "r562",
      "r575",
      "r583",
      "r676",
      "r691",
      "r740",
      "r792",
      "r814",
      "r815",
      "r862",
      "r888",
      "r889",
      "r903",
      "r1009",
      "r1066"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land, property and equipment, net",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r987",
      "r1059"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land, property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r677",
      "r688",
      "r891"
     ]
    },
    "asth_ProviderServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "ProviderServicesMember",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provider Services",
        "label": "Provider Services [Member]",
        "documentation": "Provider Services"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r408",
      "r409",
      "r410",
      "r411",
      "r484",
      "r492",
      "r519",
      "r520",
      "r521",
      "r630",
      "r657",
      "r719",
      "r761",
      "r762",
      "r824",
      "r825",
      "r826",
      "r827",
      "r837",
      "r850",
      "r851",
      "r864",
      "r872",
      "r885",
      "r893",
      "r896",
      "r1060",
      "r1070",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r408",
      "r409",
      "r410",
      "r411",
      "r484",
      "r492",
      "r519",
      "r520",
      "r521",
      "r630",
      "r657",
      "r719",
      "r761",
      "r762",
      "r824",
      "r825",
      "r826",
      "r827",
      "r837",
      "r850",
      "r851",
      "r864",
      "r872",
      "r885",
      "r893",
      "r896",
      "r1060",
      "r1070",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092"
     ]
    },
    "us-gaap_ReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables [Abstract]",
        "label": "Receivables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asth_ReceivablesReceivablesRelatedPartiesOtherReceivablesAndLoanReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "ReceivablesReceivablesRelatedPartiesOtherReceivablesAndLoanReceivablesPolicyTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Receivables, Receivables \u2013 Related Parties, Other Receivables and Loan Receivables",
        "label": "Receivables, Receivables \u2013 Related Parties, Other Receivables And Loan Receivables [Policy Text Block]",
        "documentation": "The Receivables and receivables from related parties."
       }
      }
     },
     "auth_ref": []
    },
    "asth_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of cash, cash equivalents, and restricted cash",
        "label": "Reconciliation Of Cash Cash Equivalents And Restricted Cash [Abstract]",
        "documentation": "Reconciliation Of Cash Cash Equivalents And Restricted Cash"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r910",
      "r921",
      "r931",
      "r956"
     ]
    },
    "us-gaap_RelatedPartyDepositLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDepositLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Due to related parties",
        "label": "Related Party Deposit Liabilities",
        "documentation": "Amount of deposits held by the entity for a related party (entity, shareholder, employee)."
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r615",
      "r616",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r789",
      "r791",
      "r823"
     ]
    },
    "asth_RelatedPartyExpensesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "RelatedPartyExpensesPayable",
     "crdr": "debit",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenses payable",
        "label": "Related Party, Expenses Payable",
        "documentation": "Related Party, Expenses Payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r615",
      "r616",
      "r617",
      "r618",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r789",
      "r791",
      "r823"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofFeesIncurredandRevenueEarnedfromRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party transaction, amount of transaction",
        "label": "Related Party Transaction, Amounts of Transaction",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r615"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofFeesIncurredandRevenueEarnedfromRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Axis]",
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r615",
      "r616",
      "r1084"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofFeesIncurredandRevenueEarnedfromRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Domain]",
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "asth_RelatedPartyTransactionExpensesIncurredMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "RelatedPartyTransactionExpensesIncurredMember",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofFeesIncurredandRevenueEarnedfromRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenses",
        "label": "Related Party Transaction, Expenses Incurred [Member]",
        "documentation": "Related Party Transaction, Expenses Incurred"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofFeesIncurredandRevenueEarnedfromRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r797",
      "r800"
     ]
    },
    "asth_RelatedPartyTransactionRevenueExpenseNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "RelatedPartyTransactionRevenueExpenseNetMember",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofFeesIncurredandRevenueEarnedfromRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net",
        "label": "Related Party Transaction, Revenue (Expense), Net [Member]",
        "documentation": "Related Party Transaction, Revenue (Expense), Net"
       }
      }
     },
     "auth_ref": []
    },
    "asth_RelatedPartyTransactionRevenueRecognizedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "RelatedPartyTransactionRevenueRecognizedMember",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofFeesIncurredandRevenueEarnedfromRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Related Party Transaction, Revenue Recognized [Member]",
        "documentation": "Related Party Transaction, Revenue Recognized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions [Abstract]",
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r615",
      "r616",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r789",
      "r791",
      "r823",
      "r1084"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Related-Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r612",
      "r613",
      "r614",
      "r616",
      "r619",
      "r736",
      "r737",
      "r738",
      "r798",
      "r799",
      "r800",
      "r820",
      "r822"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayments",
        "label": "Repayments of Debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfDebtAndCapitalLeaseObligations",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of finance lease obligations",
        "label": "Repayments of Debt and Lease Obligation",
        "documentation": "Amount of cash outflow for short-term and long-term debt and lease obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfOtherLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfOtherLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayment of long-term debt",
        "label": "Repayments of Other Long-Term Debt",
        "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofFeesIncurredandRevenueEarnedfromRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r254",
      "r255",
      "r429",
      "r457",
      "r618",
      "r857",
      "r858"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r911",
      "r922",
      "r932",
      "r957"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r912",
      "r923",
      "r933",
      "r958"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r919",
      "r930",
      "r940",
      "r965"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r999",
      "r1021",
      "r1093",
      "r1095"
     ]
    },
    "us-gaap_RestrictedCashEquivalentsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashEquivalentsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash Equivalents, Noncurrent",
        "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r845",
      "r846",
      "r1002",
      "r1021"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r1002",
      "r1021"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareScheduleofSharesIncludedintheDilutedEarningsPerShareComputationsDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted Stock",
        "terseLabel": "Restricted stock",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained earnings",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r178",
      "r685",
      "r723",
      "r724",
      "r732",
      "r772",
      "r891"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Retained Earnings",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r258",
      "r259",
      "r260",
      "r262",
      "r268",
      "r270",
      "r373",
      "r374",
      "r527",
      "r528",
      "r529",
      "r544",
      "r545",
      "r565",
      "r567",
      "r568",
      "r570",
      "r573",
      "r720",
      "r722",
      "r741",
      "r1105"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofDisaggregatedRevenuebyEachPayerTypeDetails",
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total revenue",
        "terseLabel": "Revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r302",
      "r319",
      "r324",
      "r325",
      "r331",
      "r333",
      "r334",
      "r481",
      "r482",
      "r658"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r852"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenue",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asth_RevolverLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "RevolverLoanMember",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolver Loan",
        "label": "Revolver Loan [Member]",
        "documentation": "Revolver Loan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolver Loan",
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r607",
      "r890"
     ]
    },
    "asth_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk pool surplus or deficits, settlement period after risk pool performance year",
        "label": "Risk Pool Surplus Or Deficits, Settlement Period After Performance Year",
        "documentation": "Risk Pool Surplus Or Deficits, Settlement Period After Performance Year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofContributionstoRevenueandReceivablesbyPayerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net Revenue",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r983"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "presentation": [
      "http://www.apollomed.net/role/LoansReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Payable and Accrued Expenses",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r91",
      "r553"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r91"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Earnings Per Share Computations",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesScheduleofEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Axis]",
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r369",
      "r370",
      "r371"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesScheduleofEquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Equity Method Investments [Line Items]",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r369",
      "r370",
      "r371",
      "r372",
      "r583"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesScheduleofEquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Equity Method Investments [Table]",
        "label": "Schedule of Equity Method Investments [Table]",
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r250",
      "r369",
      "r370",
      "r371",
      "r372",
      "r583"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r71",
      "r659"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets, Net",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r71"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Change in Carrying Value of Goodwill",
        "label": "Schedule of Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r866",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057"
     ]
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r172"
     ]
    },
    "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Medical Liabilities",
        "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Credit Facility",
        "label": "Schedule of Line of Credit Facilities [Table Text Block]",
        "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Commitments of Credit Facility",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofFeesIncurredandRevenueEarnedfromRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r130",
      "r796",
      "r797",
      "r800"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Fees Incurred and Revenue Earned from Related Party Transactions",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Contributions to Revenue and Receivables by Payor",
        "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]",
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.apollomed.net/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r64",
      "r65"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/SegmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Information about our Segments",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r64",
      "r65"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationScheduleofShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r494",
      "r495",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Transactions Under Stock Option Plans",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r84"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r77",
      "r78",
      "r79",
      "r80",
      "r176",
      "r177",
      "r178",
      "r226",
      "r227",
      "r228",
      "r294",
      "r455",
      "r456",
      "r457",
      "r459",
      "r462",
      "r467",
      "r469",
      "r728",
      "r729",
      "r730",
      "r731",
      "r872",
      "r981",
      "r1022"
     ]
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsAdditionalInformationDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Variable Interest Entities [Table]",
        "label": "Schedule of Variable Interest Entities [Table]",
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r105",
      "r106",
      "r559",
      "r560",
      "r563",
      "r564",
      "r638",
      "r639",
      "r640"
     ]
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfVariableInterestEntitiesTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Assets and Liabilities, Variable Interest Entities",
        "label": "Schedule of Variable Interest Entities [Table Text Block]",
        "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r105",
      "r106"
     ]
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Shares Included in the Diluted Earnings Per Share Computations",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Future Amortization Expense",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "asth_SecondMetricMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "SecondMetricMember",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second Metric",
        "label": "Second Metric [Member]",
        "documentation": "Second Metric"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecuredDebtMember",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Debt",
        "label": "Secured Debt [Member]",
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "asth_SecuredOvernightFinancingRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "SecuredOvernightFinancingRateMember",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Overnight Financing Rate",
        "label": "Secured Overnight Financing Rate [Member]",
        "documentation": "Secured Overnight Financing Rate"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.apollomed.net/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r329",
      "r334",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r404",
      "r405",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r866",
      "r989",
      "r1096"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/Segments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r312",
      "r323",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r334"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.apollomed.net/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Reportable Segments",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r333",
      "r863"
     ]
    },
    "asth_SeniorSecuredPromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "SeniorSecuredPromissoryNoteMember",
     "presentation": [
      "http://www.apollomed.net/role/LoansReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Secured Promissory Note",
        "label": "Senior Secured Promissory Note [Member]",
        "documentation": "Senior Secured Promissory Note"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Preferred Stock",
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1005",
      "r1006",
      "r1071"
     ]
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Preferred Stock",
        "label": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1005",
      "r1006",
      "r1071"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent on performance (in shares)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Contingent on Performance",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Contingent on Performance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock awards granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationScheduleofShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r494",
      "r495",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationScheduleofStockOptionTransactionsUnderStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value (in millions)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationScheduleofStockOptionTransactionsUnderStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationScheduleofStockOptionTransactionsUnderStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Options forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationScheduleofStockOptionTransactionsUnderStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r1074"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationScheduleofStockOptionTransactionsUnderStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationScheduleofStockOptionTransactionsUnderStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Options outstanding, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r501"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationScheduleofStockOptionTransactionsUnderStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationScheduleofStockOptionTransactionsUnderStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options outstanding, beginning balance (in dollars per share)",
        "periodEndLabel": "Options outstanding, ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r501"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationScheduleofStockOptionTransactionsUnderStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options exercisable (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationScheduleofStockOptionTransactionsUnderStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Exercise Price",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Exercise Price [Abstract]",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationScheduleofStockOptionTransactionsUnderStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (Years)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationScheduleofShareBasedCompensationExpenseDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Award [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationScheduleofStockOptionTransactionsUnderStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationScheduleofStockOptionTransactionsUnderStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationScheduleofStockOptionTransactionsUnderStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationScheduleofStockOptionTransactionsUnderStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationScheduleofStockOptionTransactionsUnderStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationScheduleofStockOptionTransactionsUnderStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Equity, beginning balance (in shares)",
        "periodEndLabel": "Equity, ending balance (in shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "asth_SongPCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "SongPCMember",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Song PC",
        "label": "Song PC [Member]",
        "documentation": "Song PC"
       }
      }
     },
     "auth_ref": []
    },
    "asth_SpecialtyCapitationPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "SpecialtyCapitationPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Capitation payable",
        "label": "Specialty Capitation Payable Current",
        "documentation": "Represents the amount of specialty capitation payable current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StandbyLettersOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StandbyLettersOfCreditMember",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Standby Letters of Credit",
        "label": "Standby Letters of Credit [Member]",
        "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r1064",
      "r1098",
      "r1099"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.apollomed.net/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r297",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r329",
      "r334",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r403",
      "r404",
      "r405",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r866",
      "r989",
      "r1096"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r226",
      "r227",
      "r228",
      "r250",
      "r274",
      "r277",
      "r286",
      "r288",
      "r294",
      "r295",
      "r372",
      "r412",
      "r415",
      "r416",
      "r417",
      "r423",
      "r424",
      "r455",
      "r456",
      "r459",
      "r462",
      "r469",
      "r583",
      "r728",
      "r729",
      "r730",
      "r731",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r771",
      "r793",
      "r816",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r981",
      "r1022",
      "r1031"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r39",
      "r212",
      "r237",
      "r238",
      "r239",
      "r258",
      "r259",
      "r260",
      "r262",
      "r268",
      "r270",
      "r293",
      "r373",
      "r374",
      "r470",
      "r527",
      "r528",
      "r529",
      "r544",
      "r545",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r573",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r611",
      "r720",
      "r721",
      "r722",
      "r741",
      "r816"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r259",
      "r260",
      "r293",
      "r658",
      "r726",
      "r752",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r771",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r780",
      "r781",
      "r782",
      "r783",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r791",
      "r794",
      "r795",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r816",
      "r897"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r259",
      "r260",
      "r293",
      "r658",
      "r726",
      "r752",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r771",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r780",
      "r781",
      "r782",
      "r783",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r791",
      "r794",
      "r795",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r816",
      "r897"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r914",
      "r925",
      "r935",
      "r960"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "asth_StockAwardsAndUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "StockAwardsAndUnitsMember",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationScheduleofShareBasedCompensationExpenseDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock",
        "label": "Stock Awards And Units [Member]",
        "documentation": "Stock Awards And Units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued in business combination",
        "label": "Stock Issued",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52",
      "r53"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares for business acquisition (in shares)",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r147",
      "r178"
     ]
    },
    "asth_StockIssuedDuringPeriodSharesMerger": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "StockIssuedDuringPeriodSharesMerger",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Holdback shares not issued to former shareholders (in shares)",
        "label": "Stock Issued During Period, Shares, Merger",
        "documentation": "Number of shares of stock issued during the period pursuant to merger."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued for vesting of restricted stock awards (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r178"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationScheduleofStockOptionTransactionsUnderStockOptionPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued for exercise of options and warrants (in shares)",
        "negatedTerseLabel": "Options exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r146",
      "r147",
      "r178",
      "r505"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares for business acquisition",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "documentation": "Value of stock issued pursuant to acquisitions during the period."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r39",
      "r178"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued for vesting of restricted stock awards",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r146",
      "r147",
      "r178"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r146",
      "r147",
      "r178"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price adjustment from merger",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r39",
      "r178"
     ]
    },
    "asth_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares issued for exercise of options and warrants (in shares)",
        "label": "Stock Issued During the Period Shares of Exercise of Option and Warrants",
        "documentation": "It represents number of share issued exercise of option and warrants during the period"
       }
      }
     },
     "auth_ref": []
    },
    "asth_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares issued for exercise of options and warrants",
        "label": "Stock Issued During the Period Value of Exercise of Option and Warrants",
        "documentation": "It represents value of stock issued during the period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r150",
      "r151",
      "r169",
      "r773",
      "r790",
      "r817",
      "r818",
      "r891",
      "r904",
      "r1024",
      "r1046",
      "r1077",
      "r1105"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Equity, beginning balance",
        "periodEndLabel": "Equity, ending balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98",
      "r107",
      "r212",
      "r213",
      "r238",
      "r258",
      "r259",
      "r260",
      "r262",
      "r268",
      "r373",
      "r374",
      "r470",
      "r527",
      "r528",
      "r529",
      "r544",
      "r545",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r573",
      "r584",
      "r585",
      "r589",
      "r611",
      "r721",
      "r722",
      "r739",
      "r773",
      "r790",
      "r817",
      "r818",
      "r843",
      "r903",
      "r1024",
      "r1046",
      "r1077",
      "r1105"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stockholders\u2019 equity",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity Note [Abstract]",
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mezzanine and Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r249",
      "r454",
      "r456",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r468",
      "r470",
      "r572",
      "r819",
      "r821",
      "r844"
     ]
    },
    "asth_StockholdersEquityTransferOfCommonControlEntities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "StockholdersEquityTransferOfCommonControlEntities",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfer of common control entities",
        "label": "Stockholders' Equity, Transfer of Common Control Entities",
        "documentation": "Stockholders' Equity, Transfer of Common Control Entities"
       }
      }
     },
     "auth_ref": []
    },
    "asth_SubcontractorIPAPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "SubcontractorIPAPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Subcontractor IPA payable",
        "label": "Subcontractor IPA Payable",
        "documentation": "Subcontractor IPA Payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/LeasesScheduleofComponentsofLeaseExpenseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/LeasesScheduleofComponentsofLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Sublease income",
        "label": "Sublease Income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r890"
     ]
    },
    "us-gaap_SubordinatedDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubordinatedDebtMember",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subordinated Debt",
        "label": "Subordinated Debt [Member]",
        "documentation": "This element represents domestic or foreign subordinated debt. Subordinated debt has a lower priority of repayment in liquidation of the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "asth_SubordinatedLoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "SubordinatedLoanAgreementMember",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subordinated Loan Agreement",
        "label": "Subordinated Loan Agreement [Member]",
        "documentation": "Subordinated Loan Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsegmentsAxis",
     "presentation": [
      "http://www.apollomed.net/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsegments [Axis]",
        "label": "Subsegments [Axis]",
        "documentation": "Information by business subsegments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsegmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsegmentsDomain",
     "presentation": [
      "http://www.apollomed.net/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsegments [Domain]",
        "label": "Subsegments [Domain]",
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r590",
      "r622"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r590",
      "r622"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r590",
      "r622"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r590",
      "r622"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r590",
      "r622"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events [Abstract]",
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r623"
     ]
    },
    "asth_SunnyVillageCareCenterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "SunnyVillageCareCenterMember",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sunny Village Care Center",
        "label": "Sunny Village Care Center [Member]",
        "documentation": "Sunny Village Care Center"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosures of cash flow information",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesDetails": {
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current period",
        "label": "Current Year Claims and Claims Adjustment Expense",
        "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs."
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesDetails": {
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior periods",
        "label": "Prior Year Claims and Claims Adjustment Expense",
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs."
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Temporary equity, carrying amount, beginning balance",
        "periodEndLabel": "Temporary equity, carrying amount, ending balance",
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r250",
      "r372",
      "r583"
     ]
    },
    "asth_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsNetOfDividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsNetOfDividends",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interest in Allied Physicians of California, a Professional Medical Corporation (\"APC\")",
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests, Net of Dividends",
        "documentation": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests, Net of Dividends"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityNetIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityNetIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (loss) income",
        "label": "Temporary Equity, Net Income",
        "documentation": "The portion of net income or loss attributable to temporary equity interest."
       }
      }
     },
     "auth_ref": []
    },
    "asth_TemporaryEquityTransferOfCommonControlEntities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "TemporaryEquityTransferOfCommonControlEntities",
     "crdr": "credit",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary Equity, Transfer Of Common Control Entities",
        "label": "Temporary Equity, Transfer Of Common Control Entities",
        "documentation": "Temporary Equity, Transfer Of Common Control Entities"
       }
      }
     },
     "auth_ref": []
    },
    "asth_TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "TermLoanMember",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan",
        "label": "Term Loan [Member]",
        "documentation": "Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "asth_ThirdMetricMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "ThirdMetricMember",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third Metric",
        "label": "Third Metric [Member]",
        "documentation": "Third Metric"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Axis]",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1035",
      "r1083"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Domain]",
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "asth_TotalAcquisitionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "TotalAcquisitionsMember",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Acquisitions",
        "label": "Total Acquisitions [Member]",
        "documentation": "Total Acquisitions"
       }
      }
     },
     "auth_ref": []
    },
    "asth_TotalPurchaseConsiderationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "TotalPurchaseConsiderationAbstract",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsAssetAcquisitionsandGoodwillSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total purchase consideration:",
        "label": "Total Purchase Consideration [Abstract]",
        "documentation": "Total Purchase Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TrademarksAndTradeNamesMember",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tradename/trademarks",
        "label": "Trademarks and Trade Names [Member]",
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_TrademarksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TrademarksMember",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trademarks",
        "label": "Trademarks [Member]",
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r973"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransferToInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransferToInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of investments - equity method in accounts payable and accrued liabilities and other liabilities",
        "label": "Transfer to Investments",
        "documentation": "Value of investments transferred to the entity's investments in noncash transactions."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52",
      "r53"
     ]
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r450",
      "r467",
      "r571",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r694",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r1038",
      "r1039",
      "r1040",
      "r1041"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Treasury stock, common, shares (in shares)",
        "terseLabel": "Treasury shares (in shares)",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockSharesAcquired",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of treasury shares (in shares)",
        "verboseLabel": "Treasury stock repurchased (in shares)",
        "label": "Treasury Stock, Shares, Acquired",
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r147",
      "r178"
     ]
    },
    "us-gaap_TreasuryStockValueAcquiredParValueMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockValueAcquiredParValueMethod",
     "crdr": "debit",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of treasury shares",
        "label": "Treasury Stock, Value, Acquired, Par Value Method",
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the par value method."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r82",
      "r178"
     ]
    },
    "asth_TruistBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "TruistBankMember",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Truist Bank",
        "label": "Truist Bank [Member]",
        "documentation": "Truist Bank"
       }
      }
     },
     "auth_ref": []
    },
    "asth_UnamortizedDeferredFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "UnamortizedDeferredFinancingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred financing costs",
        "label": "Unamortized Deferred Financing Costs",
        "documentation": "Unamortized Deferred Financing Costs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "asth_UnrealizedGainLossFromInvestmentInEquitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "UnrealizedGainLossFromInvestmentInEquitySecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized (gain) loss on investments",
        "label": "Unrealized (Gain) Loss from Investment in Equity Securities",
        "documentation": "Unrealized (Gain) Loss from Investment in Equity Securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrealizedGainLossOnDerivatives",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized loss on interest rate swaps",
        "label": "Unrealized Gain (Loss) on Derivatives",
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r810",
      "r811",
      "r812",
      "r813",
      "r832"
     ]
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on investments",
        "label": "Unrealized Gain (Loss) on Investments",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r61",
      "r203",
      "r204",
      "r206",
      "r207"
     ]
    },
    "asth_VOMGMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.apollomed.net/20240331",
     "localname": "VOMGMember",
     "presentation": [
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsAdditionalInformationDetails",
      "http://www.apollomed.net/role/FairValueMeasurementsofFinancialInstrumentsScheduleofCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "VOMG contingent consideration",
        "label": "VOMG [Member]",
        "documentation": "VOMG"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEs"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Variable Interest Entities (VIEs)",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss."
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableInterestEntityLineItems",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsAdditionalInformationDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entity [Line Items]",
        "label": "Variable Interest Entity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r559",
      "r560",
      "r563",
      "r564",
      "r638",
      "r639",
      "r640"
     ]
    },
    "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember",
     "presentation": [
      "http://www.apollomed.net/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entity, Not Primary Beneficiary",
        "label": "Variable Interest Entity, Not Primary Beneficiary [Member]",
        "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableInterestEntityOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableInterestEntityOwnershipPercentage",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable interest entity, ownership percentage",
        "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage",
        "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly)."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsAdditionalInformationDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entity, Primary Beneficiary",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r559",
      "r560",
      "r563",
      "r564"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Axis]",
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Domain]",
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "calculation": {
      "http://www.apollomed.net/role/EarningsPerShareScheduleofSharesIncludedintheDilutedEarningsPerShareComputationsDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareScheduleofSharesIncludedintheDilutedEarningsPerShareComputationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to weighted average shares of common stock (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.apollomed.net/role/EarningsPerShareScheduleofSharesIncludedintheDilutedEarningsPerShareComputationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareScheduleofEarningsPerShareComputationsDetails",
      "http://www.apollomed.net/role/EarningsPerShareScheduleofSharesIncludedintheDilutedEarningsPerShareComputationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average shares of common stock outstanding \u2013 diluted (in shares)",
        "totalLabel": "Weighted average shares of common stock outstanding \u2013 diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r288"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.apollomed.net/role/EarningsPerShareScheduleofSharesIncludedintheDilutedEarningsPerShareComputationsDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareScheduleofEarningsPerShareComputationsDetails",
      "http://www.apollomed.net/role/EarningsPerShareScheduleofSharesIncludedintheDilutedEarningsPerShareComputationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average shares of common stock outstanding \u2013 basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r288"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "12",
   "Subparagraph": "(f)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481410/810-10-15-12"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "12",
   "Subparagraph": "(f)(2)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481410/810-10-15-12"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "16",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-16"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481047/942-405-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(2)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2C",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2C"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b),(d)",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "e",
   "SubTopic": "470",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "280",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(c)(2)",
   "SubTopic": "20",
   "Topic": "860",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4D"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.27(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)-(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-5"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-24"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-4"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-5A"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-5A"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-6"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-9"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a),(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-7"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r180": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//805/tableOfContent"
  },
  "r181": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38"
  },
  "r182": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r183": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r184": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-23"
  },
  "r185": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r186": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r187": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r188": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r189": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r190": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r191": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r192": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r193": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r194": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r195": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r196": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r197": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3"
  },
  "r198": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3"
  },
  "r199": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(cc)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-26"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "44",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-44"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "48",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-48"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "48",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-48"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "51",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-51"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-52"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-53"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "54",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-54"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//280/tableOfContent"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-30/tableOfContent"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//944-40/tableOfContent"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-15"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-16"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-4"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480602/954-210-50-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-9"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-15"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-16"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>116
<FILENAME>0001628280-24-022272-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-24-022272-xbrl.zip
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M.U.9>96Y2#TFS9N&89(T%[*>D&ET["#Q966&_LQ%Y#'I_XQ]!#K&:",7=,W
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M#(QT=!/YV.N,4582?K+$7"HBX\Q)4G)DYI((660. ]LA9)FY+$1"G'Q".@Q
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M9S9'TWQ#KK&^TMD>C2UGBG'7=_2?CW1O0$[E@[FL!'.<24MFF$LB;.%,4)E
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MND_@0YFVOK^+)<.<6\!CN-PVUX9SZ&B>''B=];_F.'#WPE>IX)/(-5)UD;F
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M^)WHOD"!A!X<T7CT[VOZ;E"8_PE80R>$D6L'VXW C\#V!)RUZ".A1T S=\Q
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M:*+$1J#)(9A2^6*Z&*P5&G)=U)A:'.5>"QO;$1C9SL#T"L83=RERK\_W<BE
M38<QXS=LX[X97Q77236KK/'-#/E"SW[>P+'P422)Y*_JRM$]-+@A3]N0GZ!5
MUOE'EB_CO[E[Q@/F1<UY4]<[C#WX>Z"<#VAVH$BD8*TBUHX_CY8;>*80L\O
M'P$9A1YAK-5J+$"&&W4VC3H33\Z7N5]3"BOF/BI91+[OFKV)CWH61/V. -@J
M+F3EX.H@+<?=@[PH^QWN 4!DGMUM+J#CQ4DD8:M(*EE@EI2CFVQR)R*KM0KQ
M(;:.(JW0J&PXM9(7*9S/H3AID0&O8&#4L]A<IK#@6:RZ%$UR#HN-A.\86?Y0
M%$#V2]EW)XY6]2PYAY2%_WV,ZMRM,E.=VZD<I-C.3QGB84VL;2C2/*?W$_*"
M2P*7A&/R0L>)0@5$017EE'N?S47ALIVY!%TB%8AO.!-B_AETV/89W25X;&WD
MVC!63QACP/P0N5CXZU]JBBQ?"SWDF3IWT3;R++U@_,16B<WLU1-VNP2;'SII
MRJIABK =W?V- 'IF@Z2Y#:H6&E))9:+B@ .> _X#P"_[8H<COD80K_#EN,P[
M7,S=?^%.DV%:$Q\;W&WB5H1=*Q+/;;H)(+W)C-2YX\0AGPG(QW2<MF->EIAS
MG=BQ,%FYBA..$XX3+A-74<)]H<O(45N<A98^(^0.3)MF=,O+MEC'I&PDI0J[
MER$6D*X[(WCWE!30V8X/3R>! K)I-=W 198P1JXO.'W!'V(/@QE#$\,$JT-,
MET&VT-#?:%D!(A_W31O9N@DW>CY\0+M#EI8[!BV0)AR0IM!&1]=CQS.)G;IR
ML85\\Q5?OYF&/XQ,ZL*-06AU)<UO03T8!-C#K;>LT7VIG8):2:/1$F5$?:6A
MTL)/,GQBTTVU5^]+?=VH&4C2C(K>J\M8*1L(Z1J6*I+QNRH7HIN&LSS%& UP
ML>=B]+.(^C#C*V2]H:E'(+N(3P#G"B.VT3"$<DA]I3JC6>-KSR6"L#Z1S8)
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M6J%1UC11E=>[KK,FDKGO'_* ?>&3Y7C>9\$$YH[PA9TC$:MIAK:V*WJ_IAE
MY XE;FQ1*5/;I:S;+MZQG#DHY:9C.6</9P]G#V?/P9NOMO0R"+K61;;P#IR.
M0]S-IFVLF-?85K4"5E459?7H,\PX_%B$WY9]^\S KTJ<.BFQ;;D<?2RA3]F2
M!&,&?6'-SO$)ZH3@E_OZOZ#<13#I89R$6\(K<!*&3HYS)$QU3=W'A-"._E-
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M<?,7<>PL*1Z$55\; I8$)#\J)"_,4FG6&2*:J"NU6F#LLN%E<^(XH& ][9>
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M/EM ZEVR-#B]+(T [PS!)ATV!.X(1%TKAPU/SV$8>JS*_6$Z;_#J '6B1,.
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M:PJ+NJ@JDM5WT?Z!D*/:FO2Z'5D9I.O-[K=C-J("8W1Z&OG-=IRFB@)#M Y
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M$+B+%#CU.&9QKS49RJ->\QOL7G@%2]'-KW:/Y^!P'L]!7W3S*ZW1CE/J:##
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M3K30]Y:4:"[<DR5->H4E@L6T7RT"JL*?N:9A:LX;KB8N[JV]@I&^29H.[.[
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M["A57")''ZW:FEAV:@M(?2&9X=,E4+RNY(#R!VO(D*C:A/_B;IQG!H3XV%O
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M>7>6"WR/*O*).*N$VH;QZA\,WWD%+0M((9*D?FLR!Y1Z\T8T9U,\\*W4QX0
M8NW8*]-U;0#C@)T)!1I2M!3<F)K9CF._$H=;/@X8.N8:[!2.LNF=IBO]K5Q
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MC^1>1E'E9K'C-?C*HN44^+N&<_/RL.B!&C]WEHY-[LEGPOZ;)3?8Z"&C?Y1
MVHUCK=,"[>(<A2?6M>5VU:1M-RI=='LLZ;M&9%#@_D+;RKX//^[@+FL3*Y%I
M2RRC<HYM=AF<0O"P<3M]O46>4C2X'(V\HSS;(1/_^AWFC.Z-*U<WWV<1FYUX
M*X3Q&H5Q?$)IQ(XM(UD=IYV-#17&0U=1&Y])%;4C A!:#VE<4PFMSV3F;:N+
M]?^S]ZY-:B-9 NA?47!W;K@W5 R2>+HWB*@NVS.>:[L<MJ<[]M.$"B6%MH7$
M2%#EFE]_SSF9$@*]D2@$Y$2,NP ],D^>]W.@)_MB#?1D7ZP['S2BM?+!G!%M
MJ,IOIONG\LF#+:K4[/83EC:B>L2O+&R:E=:OBK\X93EZIT:C+1?^Y8L2JP=E
M+@401J*KUKGVS;+@S)4'T\%$Y>8;9B7;!+UZ"ZW)I#L>& =TT-)&@\::50TG
M#770,L;-+6J4__*K[J"E7'/WK'=LQI8/S \!D=H\:]]3,JCD*6DHZ? XGI*3
M+.X:6IG\8/Z2]( ZF4V79F*E;?%R+"BMW\\WH5#I_.@&H$:AK71G^OX+@.%V
MB3VK*YM,_<Y4GPS50:_V**KVI'%*VKA<VBAP]C5*&SA6:]Q3>ZVAC<N*#:2C
MPS?VY#FPH%2I)^.0,5(HZ#39*"D,.]-)7QT-Y%SMR\2E@J!V>5S*[;$U&#76
M8ZM=.:&MYJA??6]I!X'GO_!>B%_EJ,)">BAH)MHH;QV#FM$B)4/6436+2@4!
ML491:=(N5'IM?35S?(M&I54G3<7'L,'>R)D#E-JK;2+PBG;?L->9&A-#U1O3
M=D_?PZ(A/?AJT>\5;:TA=J<8-\+&7ZN;>+W(1D-IEJV[_QJ\-9]8$+Q5HD8.
MGD^4Y,UWQ=UU>&\J%2@4)2UZ[B/&?I"Q'#AJ<J@#'^FIHS8T.)/NFD:1IVC&
M3 /(@UT6)JEAH7.MVST#/OI/.$=DH?]AEC*W7=.=82)1[>YXETX.E6R#&(PQ
M<P\UM*\^6]J;Y:UKT:5!L,'<KCL$^Q=6G73ZG6E?[0VUT[<GD:Z<UV2[KXUG
M S!3U4$;\$PF.-5=G&P&ATK+S1K3G=),AY(U=M=9<G(0#-K-EX]D2GWQ>./(
M Q3B(7#;X5CM]QMN;'OZ2J\:F52Y>[AZFKM4@JM@?M8@.!S2,1BK$Z.V%[[R
M6358RK5?N'4.%2\,%K"DCKMST_:5)]/9,/3I>1M?<7;$M/)L8D$,?H8G60J.
M8'M4/K$GYBBZ8KNKS3I05CX\S8>E[C3RQ:H:G^I:X,<_V1HOF[&@J]Q2G1/5
M%?!S#HL+>"54F&J_\YNA4O'-3#C>Q9)Q<:ZW5G OOFTZL ++GL\9^2KGOK>,
M[0\>'M S;"PN  @H/MP%2W'IV]0B('.U\KV? E3\<H'L\";SR;0=VA_L-O:(
M;J)6ZY"ZJ\_F>N-3K=7]/$YO/_"-R?*KX3A9^#4<)^O0S@9%MV56V"::"J\V
M !$LR%HN;=X?)RS)2CT[;#6-/[Y@6SOL/8#/BI5QY)=O)<KO$D6;,4"*Q??U
M[@B5\)7'AQ.^)6JPGY@HNQ)\.':CX%2][2WF Y@,FW7V+<DRF7C)I3$\11"<
M#BU6&\0A&/MW$5F.*_.1W3SXS/SSQIS#ZM^:SK/Y$B!_C6,FH.4>4+/@L5O^
MIH]R2UF+JB?3BSF-3N8]1&*76.PWUKJ&D?[3075U^8^ZQKHZ'CM.*R.[Z'@B
MRGGE#?LY<S;$D9%%KQ<^ RT![ET0IP9ANUMU6#DB4:^18.N UMQP^ LV6BIX
M";;*U3>V$FT5[^=??=N=V2O3^<:6)@I4_W[^P4:[!5OC5C9O)IVI-GJ-)(\&
M\SPN.@0'G&1P95&VT]#/1_<+//;',W.>V&?BZE6)9X1MEX;J>-26V?!7(IJ'
M5Y;1<RKZ0('RX]FK3!9@;&@@5)I+7)5RHQ1=C*3<>#VZ0&N@,F5@+EQ?-:3
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MP32ZD(=@P*JK)YWR?\'CJ+S4X3&7BA&$;HJ;]"]"S$4YT(C""J 4$)X/1/B
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MFZ3KO%NBIZ 1=V=N_)471'X^3 AY .Y/H(Q%I').1P2$(I8/3\+XE_7P(HH
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M/1M<W#^!F>MM4-E]Y*8[)F%1Q C1P$,7,>A _+#ATD!D:^$3741X!XAJX_,
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M!SC'L6M;5!; $F-'P'5L3/\TJ1>""&+P1)YM@BEET2.!!_&;>4GU"NOCO$T
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M>4)>" \;5L9N+#%3<(<,53ZS_1';L ,1AIZ/'72F%JS8H-J.'YSCP25B+!2
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M(!J5S<3</5\JCV0#&M:Q@88V;,M(-JFEOVX1:]/H9" ZZ>/:8\W:J*6?2<9
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MX!@J2 (9E^9+J#@!+2"Q!PA8V ?V2X\N%/B)!+%9%4)^4&[G+GLVG0I;'A:
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M%?XK4>P24>S8@?4"*V_0F)4GT>MUT.M--?Q*!(X#V #\=1)>-L0AZ>K(2+:
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MH=R-F7B3&TWNF8\OG JH4\+YT]B;9!<6P@U#YL#M_C->/"97@84O!L@\VA:
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M9<DKF#D@=I:7-_IY!27YM9"%#VXN_L]_]72M^SY8N"!\UY>O@X;RN1PT4E<
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M1;8+7TQH(92IYS/% BC=,\7U*"W(IR6'8Q-3X,,(;A'9 LJ3[3AP58@7PQ,
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M'O-K>(N>(FYVY4"=K[5>HY\L/HM<18\K;)0@$#-MX_FTU98(VMB ,8>L)N9
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M.HZ<(&T59<W,2(&E1?\O5JN\497[L18R\]XSJ*5] 45 %BK7N:!/[W?4=O-
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M]J-QVU!^'PQNX 9JF1 0 <!2S8=$!D[,GTSY=S1\$'UHS""()E/1=H%:!<1
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MS_C&!5XQFD#$,][0F &9 .HEK'G('IGC346CK )W?0P4L64 C.N%*7"$7ZT
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M-CXUR/!+=3$^92NODH%"-D#X*(/8"/RW!VJ:\"$DSN*W\!D]8V$4".TM.UJ
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M[G\'! 8@7Z1?4VO5"^_\S@>:9%Q@H6Q(;A/KHM_%.?\]<H0 :!JPA<\7.:@
M>'FQ$>]8CK5)?+H*E031,K#N,[\"ZF]/^"5*-[_G2I3V*^-2_X$4<A45<L9_
M2_$FQ5LJWCIZ3^\U4;SAOV_%EK2F=HX!3D:<!5@(<[F<PR]C>7:%7Q.3H=8?
MBP;?;)T3LHPK#?@DDOFB\:5>347RI:KQI9;D2Y(OK<&7]'.<E>"-DJG4G"\1
MV8N$-3&LFKL*TAY%9XMY5WF&I)\R0Y)M6U<QM'9GYC!EVU;9MO4%QS]46;*W
MI627DGT-R6Z4E.P_7!#%+R3>C5,6[R?!E3J2*TFNM 97:@FN9,<<)<^54D;#
MF=(U#<AY*;:TL'V>9$M'PI:ZDBU)MK0&6VH+MN1Z[I\1!@'S;.E;_+6=J$LO
MRYG:DC,=.6?J2<XD.=,Z"E/OW.1Q?3:9.MZS4)@N^8=83TIR(43HJ"ANM+NJ
M8E2=>KOE4))!58U!]26#D@QJ'0;5CQF44)XX@\JI3)_B?%-D%LP->+[HWGA5
M7_*JX^956E,R*\FLUK'S6C&S^L75J:PV16;<E3N,+&[1#9Y,?[@W+M66WJBC
M9U.:9%.23:W#IKK"'Q6@=>=-P[P[:I$':A4;>X-.JHUX4U=J4$?.FG3)FB1K
M6H<U]6;R"M9/&'PY]B2=4<?.GF2=A61/:[&G?CGV-)OU]'(\2CJACIU'M?Y;
M5CQ+5K4VJ^HTSW]&$]/GCJC)G"=JKJPY:7E@S!0T)W-*EU4F?V./YM LJ@HN
M*$_F%[_A,TIA_\%8^0/7JBI?/Y5F?9VF9'WEJ+J*/6ID%W3)SY;S,^W<\3 ,
M.(0G13[G9U_@&]$/"[[#U*B%;&VN3\,L6R,^=6/ZH8NS1@L[T BV=G,^^/HW
M12^ZYLW:?1YP"9NW5"C/)7=<E"NYY"&XY.&:M?/B+\DH:\ H]7/BD&P(S&=B
MBX'-_!OLLC6Q@\ #4O[FA6P)DSPP=^2]4CYZON\],7];=ID\\ O&6?WRW'/'
M%<3'SSUK9UYWI74MF>SB?F(MO=WJ\Z:N3:/3B1N*Z0L;BLUDSB[H(H8MHL:+
M>HCMKG?758YGJ@!MX+A#Y2,\?LB[GF&'Q@!XE?AJ9QT62C2)/1G>6$7-4G;(
MEQQO+8Y7V$)1WZB%(F=^L5*TIP:*LG^B[)^XF_Z)IR:V:J?2RQH3*=J*19O1
M[>A"M/6-WHQH*PJ2+0B""2Z.S(H49^ *M_9$.2N<(,.%7IYK'()CM27'JBC'
MTF6AB>1893B6O@W'NAC#OW"0'\U@[+TDS]J!<T#RK,KR+.V__R*9UK$RK;23
MJW9NPX]3Y!%N:'&^<Y5^@X.H: N>/V_N?V(6F] H7B)C(Q->^OK[C&&_:@X,
M#P7=C6'O@7+;4+Z8$Q4,V$^-N2$RF9L:R_B&;)"ZBLS;W1G8R0:ILD%J48-4
M*8#W3)F&UM"D^"V&3K7%[_(%)N+7T#14?)L&_-$\_W-VB&0RB@U4<GL*0N_R
M%[,B\H5>C^ *D+DWD1]$)DAH#$IB03G<8C3UV(-[:_KWILN"\^M?#GM6!A8Y
MP/5F4Y>Z=M5(79>D?L2:MJ'II4C]L^V:\"?\)4F]=C%W0__+7RJ1S"G)=5-R
M+4>M\X(9[=AUJ5GK*3\:MXV+_[^]:VM*&XC"?V7')YAJ3 P@V&EGPL6:D5*'
MT)F^=3;9A>P8$IJ+E7_?/4M &(FB5;/H\B(#[.WD.Y?=_<Y16^FU8=9U<2=J
MD6@&F^QMRM_2&TKY]\S/&[JAV0/G+5U][KKEL8ZVV'RC7^UA']EAD@*; 74C
M+X-3I0VSJ5!:'DJ=SH5":8[2$;Z-PF@ZYW8^I2&<0"+'\^D4*]C*!MN.U5>P
M+89M!P=>%BPBF#X+KUU@\"D02P;B;N]\KP\#RD1XEXY9R!X!N J$98!YWVI_
M5%NM[X#D/G9IH*RTM/"]&O8^*GQW,<17*^ZVBC7D0[&^0''MHR)8K+\3W<!1
M')Y09,-CP(N*S%V<8G3. HHJ4! ,ISE9;AWP<+[G\0$P_X0@%JY1XHRJ K<$
M)EI%T$62.1?T2Z!V_F6IKZFH6![,*M 6@C:+0Y;X:\!]W[C=?J<Y980$M"1W
M^:FT.\U2E[V68.GE/%@4Q?Q]_O]HH-[*+,#AX<;7.(YQN&BFP@$)3*L<%4!V
MNIQ_W9B73X@'K<N;X_SJ/1$!;>)Q^YH%D*D+.1TL67Z-?,SC8A=(W=&4B7B8
M=X$]+XJ)N+X#>XR&=+(\6W:.+I&=TBEJZ$8%5ROUJH9&=TDB" .+7 PS7MAU
MA+ET9W.8%@Z"U2@/38\BI]=!V8P/![^(Z9^,)FEA.*.8X(\RP9O%3'!8 R-?
M#ICIML;ZV"--@O4::7ANRZ G=8*Q5Z-Z0R>_3\SZ@?3\<5E$[MC?!M;HY["W
M.=_M3'?C9/M^6GS$1*;&F=%<">*MU[+.40'M!(5DL?" JY(">2E'* ;0N_5\
M\)!+MHK1,FN'><,)$WEM8'<21*#4@(>SA-L#893B1489'\:E*.&26"23@1%P
MJ8^#,>2K04>"V)/_0-0>R$+>2/2'L]2/8KXZHNTB^C*2#%HMK5DWGYIC8/)6
M3TPR*.Q*JYG-%^FI;FIFXW27)(-GN>/&?T<KKZTQIULUQG)&0VM@H8N>U1]=
M'")[T-E]-V[4I(T97>Q=3^*(J]]1+LJQ>'U^UN,I(TKJ0FK;&?J.YRBO8+/#
MWF?_E]V>G[WY.DN+A(^3XU5AATL-:CL4Z]ZS1?&(9KU:^]P[B;!AEB(>EC*"
MEC+=K^>T^8P@']2Y[[-+VDSYC(X+V;\T8>0>ZZ"TN58>H"M77\;K2*L-RH$I
M!_8^'=A&G8^G^Z^7C1/?D=/9D"OXG+9FR>5U[G)*P-O\F%'(9@DG2Y,NR5PK
M#R3!%'H=*8[J9#DBJK>*3^6.W8C,^1\_G09?_P%02P,$%     @ H(.I6&T&
M4#]&&P  748! !$   !A<W1H+3(P,C0P,S,Q+GAS9.U=;7/;NK'^?GX%K[_T
M=":*[=C.VYRDHTAVHJEMZ5I*TO;+&8B$)-Q0A I2CI5?WP5(2I3XLH DV[BE
M.M,V%K&+!9X%L%@L%G_\[6'J._=4A(P''XY.7YX<.31PN<>"\8>CKX.KQMNC
MOWW\[;<__J?1^,>GNVNGS=WYE :1TQ*41-1S?K)HXD03ZGSGX@>[)T[/)]&(
MBVFC\5&1M?AL(=AX$CFO3EZ=I\72K^+]\(2.WM SMW%R^HXTSLGY16/XYNQU
M8WC^YI2XY.WHM3=\,7Y/3MV3$\\];=!S]W7C_.+U2>/M!1DVWKQ[^^;B@EZ\
MOCAU%=.'\'WH3NB4.-"T('S_$'XXFD31[/WQ\<^?/U_^/'O)Q?CXU<G)Z?$_
M;J[[JNA14M9GP8^UT@]#X:?ESX[EYR$):5J<A-%DK3B9<=_G4^J]#&AT+-M[
M<G9VFA:7S%@%>Q:$$0G<)7LO$HUH,:/A:3$1?#^6WV5%)]!]C5>G.5*<\E7C
MY*RQ+J07+<FR$EX<QQ^/'!)%@@WG$;T"H-MT1.8^D,R#?\^)ST:,>J!%/I5Z
MLE8@\SDB8DRC6S*EX8RX5*<7/_[F.!)=-IUQ$3E!CG9$PJ&2-12*[.S(B37A
MFKLD4@HN2X9ILW+ECZD?A?*OAOSKY4/H'1WKUSH/&V-"9D8U9VGBVI-?3"3(
MJ/7INW?OCA^DGA9+4*AWJGQ#_K-Q^@I4P:#:,@76KQO^:J1T^Y!A-4;-9$CI
M=I2A<$R6Z0)&J?X.=Q5C.<"-Q4@HC<0HGC TL4@)) @7)A6&U'TYYO?''F4Z
MXV^SN/R'R8A;8T)=SZ3.M+C\1T&=) AXI.CE+\EOLQD+1CS^ 7Z2NOH^5=@[
M.DJG[MSR53 KJ/][3X0KN(],(<<SP6=41(R&V:5/,9@(.OIP)!? 1CI!_SD3
M]"5(DA;)5; ^ZN1GJ(&&L$JH]EZO&I2RD(KWX2@$''P:=Y'-[??HR+3]0,("
M]E_1>I\,35L/)-3_?]]PE_BF#0<2=^YOH_62? #?'>9].&IQL-R/'/G;U[M.
MA0VE*HU+I^Q2ABL-_'BB_G/J-%96?L-15'\<;Y;=X#(/J=<-/JI_;X[IA#@I
M4D&XT2O:=.N#J) L^3'MO:H^[=ZV+V_[EVWX1[][W6DW!Y?M3\WKYFWKLO_E
M\G+0U^]PG!6*QBN H ]]25,X4IY.EJF3<'5BM@>X,GW<(P*:-Z$1 X'WB-TZ
M7Q3(LVV ='Y?J^6O=0>V/X#_O;F\'?2[5YW;5O?F<C= "_BA0)[K ;EB[72O
MG)CY ;Y5=]]<_NM?S=O.[67S%G[OMO[^I7O=OKSK7_[OU\[@G_N#%:D'A?MB
M&[B7E3I0JY.M]B].7/%!%580M9K]+U?7W>\[KJS%+%& 7V\#L.3OJ IJ!&2;
MAJY@,\F-CS[-0Q;0,-3&K)@:A>>--$=9Z/H\G LJ_UCQ<?C(23G5"(=/)&0A
M'_4RC2"!UY]/IT0L^*C/Q@$;@;T01$W7Y?,@8L&XQWWFPHY&&ZZ=*D%1?;N)
MJJI.XIFMT($:G:1*^2U3J;.JU4FKK9,*)%K?XM,A"Y0P83,,*8#Q[SD+534A
M]-YGSKV?S->W>XT9HU"_RT&=5.%DZWCAJ%J<;#4O%/YI335"MP.2!V,V]*GJ
ME/"61MH %M%B&)V>;&*TXA+C E@ HUI!<$_#2)H$H*Q=V(")2YAL(I,9M((%
M"LAI'I E,X<%CF+GI/QJA,LU)T%X1UW*[@EHIS88FW0H J\V$5 <G!6+&G5Z
MLM:&/;*0+8=9&7X1<^I=/LQH$!J,"9P3"LS9)C I3R=AJE:-A*V3\JT16C?4
MD\ZB:T:&S#>;L@I(43S.-_%(F#@9+C7J_9: YD=7Q)5-7WPBP0\U<8!.7DNK
MAX_B OI;74U^*$X7FSC%A$[*^H4CF<?37&QYJ0JDW1V7K!&(-_37+Q) \^66
M)^+NCPGW/2K"2S!.HX7!<*ID@T+V.C^T$H;QSBC#\B].S+1&(*GFP[Z1>K"1
MD+.\DD<;G!)R%)2<0T(Q:BA.3I95C:" 9D]9;)V"8K:XVI?3P,CA4,4#!27G
M3\AP4V-EC5^-D+FCO@S3[!$1+09"+ARNVEMKPU+* ,4DM_%/6#44+R?+K$:
M= (7.GA 'HQVDBL:K-M?%>SE);6CR&O4T9=$P$HY#GM4]"=$Z&\5<X1HE^=V
MZRD+!W@XBDF-.OX;$4SNPSI!1*$A4>JE^-:YU%?Y2B8H(+G->\K.2?DM?2?.
M[Y)EG4[6KRDQV;(GQ=$^S^W+8\(:=6R?CI7!H6^"I@1HY^8VV2EIC;KWBC#Q
MC?AS>@.*!;V@VL]'5RP@8-41OQ.$D9B;(6#"$P4IM\.6W!W%WLGREUOJ90U.
MIHH:@=F?#T/Z[SDTX/+>;,QL$J*PY';1*Q9.S*-&_;[+L>Z3GB'KG"6_>W=Q
M?OXF9WWMXRS9^3W]5YU,@UT &TC[ZFET(ZD*U8R<&;@?S8BKKY5>&$8%F.K"
M=NQ1_',FZ9:A!W6$O"".P!#5<@XH<#ESMS@>H9ZXE$45&,.#,$)1RMF[E4$*
M=00+/>XVQ$R7'PI=SB;6.D2O(X3Y(W%#S$H9H"#E3IH*3M;K"(GFD;@A3F9<
M4?#R)U*&Q^UU1+;X3-80R$HF*&ZY4ZNRX]TZXE-V&&B($,(&P^AM[HBK_&2Q
MCBAM'F 9HE-"CJ*B<0I61S2J3K(,D=%@A:)D?C161]#BLRM#>-:(4"!*SLOJ
MV-OI89;I0K].AO9XZ2%:'?O<X.3+$!9SSBAR.Y^LU1'AP@N7;1H1YN]X:S-E
M@N*6<S.47-YT?D]8U@F?74Y FIZGQ)"C229;5-2FV#Z: *A>Y#P;>SF8:3@K
MJ9R,6 ?M,@17)L7TYC[E(P")C,>"CN7VZH[>TV!.AXM+XDYZ9$&%K.TIM6XK
MP5!M?)3+R-*\2*25I=?D=1*!G>'"D2([2F9'87?0U6U50H9XJZRD<M\?\:2/
M@='JSEXX7*BN?AZ=W4) 5'?SMZOWK[MK<CL17ZJOY)J17:ISK,FU5&+#0^S]
M+.'[K!13MG<YO]NVY^F'E7H'Q5E..[VY<"<DI#W!7-H$U7"?1(=TZT?5*1^X
MM;4Z9>:V5"I'B>6LY#HHEPZXR]4JI<P4[ DN\WF3S(B]Y8&@[EP(6#^:WO_-
MD^/_1]?!_8J)JFH^DFQ[5<VLK$LN&8H7H+C<40W(3HTOG&P;G$PC#GIMI##I
M+T^GHILUHMJVM[BU=6U;A;/54&$*HM%6"&U^--6-K9BC:J ;!;>.<J[0 6Y-
M1/X\?53 _SP]0/[$D.]ECV7*%P6Y(&ZR!.3#+DEO0%_-(^C)YI2+B/U2@B8A
MBWN=R-%:4.1SYR%:PSNNU\E6G(9DUE05RB*75UC%V5!N:#3A7J:\N3[L7!6J
M%+G#D.HPZG7=B"MWXMK7* ^:D85K3RO!5NQ1#<@=0& :<%@7RA("FD):0HY"
MEO.[;Z8'K"48Z/T$4WBT&2* 79SD?->:-QYJB&+^QH(I;.4<4)QR3N'"2P\U
M1$7S?D+FN'&-P!3"/56'XIWSK!K?D]@XK%PG/ZB*#G8W!'886XWT/52%JDC.
M';JCBJQ$.&A'.61[L9CW41>J'SFGV1;Z<;"H-9.?FIL".MQ0C',^,SP5:BW!
M*[[\MII^U36<W/<MO65[J0R%/I^_I^Q&WOHTKVHO*E9GWUDQ9'N9Z[=@C6*O
MG6SW,(4;S0+R>U>%X6<O2WX-8/[,?.OY\&WOD\(6=:-ZDO.@Z<X1LI@3U[A^
M;U3)L_Y=B51+?:K(S6QL$>*L4+1SSK?*;,^U1*SLBO5>9OJMF&.HYA\AJKC5
M?9CM-;#.G%Q2&G8"&3M&/15OKN*WY?ULZHT$GY9QV)=B[$\25(MR_L-*+5H[
M9@71G%2V)+8]CG./Q7.D?"D[IRC50 UU+Y.:W/PT+4>*HIOS%F:3F]<2@,UL
M#7N9X(V8HJ#E_'<%B2$.$WH%IIE8@XTOTK2=Q\TT'G^[U8*BGO/*%:*^%LN0
M+Y"M^: *:R"I/^5:ZL\]ZC'Y2'R;^7-8FYY&27:K'U6?G,,/59]8(">52 9.
M@$Q.(M1!NPJTJRJAS%X6DJTK0/4CYQ5$\]@<EAA-Y/<)LC:>.4^?1EZB&N(6
M)PE:*3+;?FQJL$)1R_G=DB1&:V.-U7RLQ7V2O0<^G?$@SHJCOFUY_&+*%T4S
M']26HKE^'3RM1OZEBM3Z2&43!A6MF5E?$H]!Q.."NZ*LR1X#._].6"'8<>AI
M=K5,'2 17V8L.X">W VX@0JF\VF/+)0O6ITAW/+ )8$+O0:+V7Y48*O*4(7(
M><X*%2*YC)!4[J2U)^<E4']C)<!!07;#S.!"VIZJ.RC)TY[3)@D(C<]8-^A0
MV')^TU7JPQIVNT&&PHQU1818R/0!4Q4V3@)OR::$UA35)Q8+59J<W]8XZ^*&
MX9B(ZB2RJC.6%<^J[(T')=74A@D)QI0%2V*Y$[BG_MD.P?R/+@BJB#E7\JZ*
MJ(23#L(,([67 0F=L]I?-3! ?"]>PGW5ARK2[GED#T[$7:>HSX0%USP,>1"'
MZ?9E3INGFYCPZE$MRKF>=YR.I$C.[U*HOSHR/#6.7EX)5DO=VGSGT]A$+J%'
MT<V'G&X^%_K?CL<?QP_A>S*;2;^M_"7^.PAX++OZ"7ZAOE)SA18)H\F? S%G
M823O6MS0Z9"*(X<,0>>)&WTX M6G1TY IO3#4;Y<P'RU%TS+/0R%S][/J&#<
MDW)]./+F0E5^Y(0 1\0BE8WRL^#SV8>CN#B+Z/3(B>+BD6C(?X6G[ST^A?'5
M@8^2T]%QJ?CYVPDJNF=$15>Z5J<\4(DPN9^>0V3;-R)^N&S@%IQ,>B#^-B2^
MW$-_.'+5'1;-CHE_ 0E @\5"HU?:=,9#%EUQD2;6ZXYZ@H-DT:*T ZJ)K&WK
M-0F)[]/DQFD3%@F8N2,:=F:D6J,U"*U0\>LIUI"I70+#EI%>!E(,^7NU[,5E
MK6A&?T:E#1 M6F3&XEDTN77>DM&&050^E>"4> L9F!Y$%GW2T20=C?$T!VO,
M.#W%;5.H%2:$*\&GL,RN$@L/>#'!EW@>;2;7Q^[H+)E2O/9<ID+LJ88JZ^L.
M9%!SC:3Y1-P?<4A(:>=:)*&U<Z(<56WJLWLJ%OCXVRQIQ>CK005R1B !&:M/
M/3"FY,ZMNCTHF16-4RK7"<-YJFV#"8T5+E:M[NCR@0J72:6+[[& GGXG @R2
M"+%@MN>Z]YZ)?PGCD#.\4SI?*,R9$S YIBP,&1>+6Q[1:KBK:1X/:X/%\*J%
MC,!5 1OD;4_'U?)F"E@QEIHS-W,#K5KVXK)6-$-Y#F"7!Q-QP,:3*/%!!.,[
M@@T"+5(;=.N61C^Y^*&"$>3:/&&SL+II5116P-:$/SWJ)1D1QH)JV+S5-%8T
M:T"G,R[ V-AM3VW*QEJ#Z@H,I,$$D.H&]/O+%IB2=$ROKY&I':.R NI8&(,Q
M64%@18.NF#>'[9=8;.0APW9M*)VM>[;FJY-79S<4]CPN,O'D"UJQ+,C@EG"2
MC7ZLW/WERNXP;7AT^'C %"<9S9Z&I;^5MM>$A:W=<,5$&.GH9T%!&_1S,&'"
MTY&_H* -\B\OUD?PKY!Y-*VP1.=*RUN[/&=2"30W\A.H)T1+]UXHW1[P\Z+W
M$R@IW/F0=O+;XTCNU+5\^L-H=1S9XO<4K/Q(1C\(,J9W4H;X?1'JW9 '&<)7
MX>DW9V6P^!E@/(.-BT;;2RZ8IPD_T_O?U:/3D(D-([='7/GB6W)$T9F2L0P:
M"[QNX'*?CQ<M*KV9(#GF%#-D8X4=)Z\LD& !<C9[F ^EJ*@= "ZX^(2ADRUC
M1=?WJ<L#K26OJ*0-'1_KND \)YNEK.A\,'%;8.(6O)%59167DMAJ%?8$OY>V
M19^*>^929--95MH&7;N&+J<T]KK%P?D#*J;)BT^Q [XS:LYF/NC:AC&RAJ(Q
MGT?RV*=$QD;)[5R"TAW]G2Z6(53*FBCW$.DS>!P#A,'*-X:U#V]JP5-B\>8L
M/5%<1DT,?396W^5F%7$Z[,C56I>$;&Q $HL#\4H4EK5A8-\0\0-:#%*LXOH2
M;U"2CG@1#\M2> TXV#&8T\U ,WWW>NV]4)V-A28'6S6W_!!5Q0+L^V16AZFU
MVVZU1GVG\LR)>LUD]TCEX((F+A>P9M(GI>%+AEP>ZYQ:=R,>'SG+P(E5>$^2
M=*QZHM,@M,( U7 /P%XQCI<F?GPO8Q=?0P&S9_4V2(2DER"@ K%*BTI: 6&!
M65'BU4NOS2PNB3O)!,(C"]O^*K!U(8CM$88XE39+68&^=&O. ^CR*S)E_J*E
M=KC*NE+5='I-&'(O49>* 0\;K#50*'6S!W1#I1"^HW)*=V%14<LOLK_4([:A
MG9\X$8F^(=-344D;6I $0#0#U<W2*;M-_ 1.;D-;Y3B2MAVV"\J7LV(JZ4T9
MQ[S+V2)6"%WBZ4_SUL8._UN*J)DI%QNTK6!9OJ,N'P?L%_4Z'I1E(Y6@*WZX
M5#D*A1I*F>NS\ V,M>POF:RO25"$B6'P6!+8:CD,.%BRZ:YWS1;"MD(ZE,^]
M_=E,%'D-<$NRL*Q1%03/W99. /*J#1D/8$,2R3=]DUCB))1X]38D$HB\!2<;
M)HR<9R(;,'Y#Q7B]R=5>C2+:YXXJCR,-E:CR@J@,[((Y7;JB0%I7;CK'J%O+
MB,<S'Y2[/) /:*D>[8[DJ9#\K_0IWQ,_"718&;?R&S8I[<;SN8>X0JWY$PQA
M*>57V-$@1G,%@17&#>C=E"YW9RWTC+.\O WSSRW]*;U[\IDW+!(\5] &^56J
MO<QY*Z)<I<5M: ML?,/L'A_97):4MJ$EW=&()4>H"![Y@C;('Y\$=V?*^$N<
MX$L_VH!_HCW"O.8HHN*?E(@K/B]?I+=A9:MA_16:Q,&V@IU$FXZHC-9:WG5I
M\;#B $:#<OM&/VJ81%-ER4@&FKR *DUI-.(+H[)B)7NDK6+^'>NGWJP626#K
MF*KV<JQZ8Q=?29Z+#9-L>LUCM3$#7&]IE A=&3BL1VM/\##(Q7W8E^)V5E%)
M*]#R?2853$6RRDV(ST9<!(QT>DUD+M2@M&(^+'YYM2G# .*[[)\6JR))>E:U
M44DCAI:YJI29.9B0((XF"%='<]T@<])1OK-_>DF>VT\ C>,+_HW!'(RH4[Z@
M%=H#LT_L))4YR>+W5*1+1EH] %T49\204I9EQ( 9;+!^7[,\WO0QZK(VS"5)
M,H :7?ER-DR<1>$UJ1=+7A#?)CRGF/ZY73W-+S?(/8%L"2L&[9J/OSO*> 8Z
M*J+[:BY/.JMN:FF16SNTLL'.6VYP35C8:H2WVGWLADNFA!6:F\[D<@J0-]N)
M0 ](2LK;,$D6W)Q(DQ0H?S"Z@RPGM';L:43F[>$BH1WG(H^TT=_(%"#OG[DN
MM,Y++Q4^M>=!0R!;YT 5!4KDPT?Q_W<" T>.'K&M5Z$>2QGBC/WM.9CAS=%(
MG> ]@TJ62&&K'LHD&>>ZV33.[;OYV.>P$T.LB?4R-DC=$WQ$90:W0 ; J:';
MXD)N$&5-Z-U #5HK6IF\J0,C(1X]RS$'QCH66:5';*VYL<_I);E"E91<3C R
M^><33W2:DEAZN-2?!\'BFY1M3%7PDDH$@,P=E316[$V*+B>HBR6=U=,FW1%V
MS]+H[L,V[*T=JJVF=(WWNVB"LX*"5BB 3L#63M%>S[R=R?H\U/$UYL2K('AN
MKUU1@,(N]^>-.#W_I=LDPV5Z^WF9MU@K+V8IE16C4 ;Z=D?QW8PKXBK'7+Q$
MQG[)9M3R.4REXW)$]3G8NIWX&L"&U)>61?J(C;0-5FG;.KDG;2J"6,Q96;O&
M?*8!C%-?>B@\&*$R93N(<9_>JY"QEVTZ$S*1OCI4@G)Q!$_UVKPK6UM=!#?T
MUR\2P'# KB-N%+-B(D@.@9E0 2(,R_526MR*QNB%J]H8JUI\%+OI.I-S2H&%
M:_@>@S97:R>H.(0.=CO7T/#5"HO:Q#B=%6K\I0]V.Y*O(%O$"J&[,+%I;$MR
MQ:P0?NN@FB1T9N,,/DT9HG8FF/W_-'4_]U8B>]_Y^X0W!6WZ(8]CO$WN2I?3
MVC"-[QG+9:H5E8T=^F5.?)VT+4\NQG-K5Q.,:O2!B;4R5DP[=RS\T>/<[\_%
MS)^'7=&FH-,L"OLTBOQ,*@X5*Y&)R9-A$Z6K_HY<GW_?W9RYJ3TB[33=U ,(
ME16(&R53L/D5BLV;PY4AV26%[8G!1F+&T7O4^O3//E-F@V%NE^]\9/<'R"-O
M!AR>.W!8I>]%0M#7RU@QMMHWG^7;=\DVI?K%IZ*B-EA"2V]'[/?"+);2XL\]
M7MI0T[UR4[4HR^JX#):K"+ZJI-KW 45&R6;Q.8B6LV0MR+M%A%C(W./*A[M-
MX'@($UYWU&8R&7#@:;\\] @5V^IPSKX8(G.\2V=:>A:9>HK# 7V(/OE5@8VF
M;!YS4HO2:G2.Q@K>E__.HLG7@ ]#*M2ZV0EF<[6.9O(:W$FGN1ROL%]AX3*0
M.'UII5S3'J]">UUC:+AR\TG"E8T#;ZZX6#WTVAT-A()LH<YZE_>!FR[,J=4G
M,=NRLQ;1*_GF/)B0]]2#"0]V\"P-?Y$')S*K1_:81#LP?WN>M@;,[.CT6"9%
MEOF"H 7,55/'8_M:T&J?VP("F:E YI3U,E;,*JU6ZQLB=+:(#3(7/R@6WH&U
M ].9U)G2#;8&Y7/K4?&%A-2&DW^O+B; ]&1^MZ&:U2,U7S,J:'78E/I0L9<<
MRPFLV*-6/,^%>DOT:)];7]?NIJ_R=*2#R^38<0M.-LQ'*N6A?@*ETN(VM"4.
MQ&8>3(=KUQ%EN'#2&FRE-V+QW-J;3RW6'<EP8$%\L"]\NL!?)C/@8 /"V3PG
M:4@1%K=?26.IG=MLWGQ&YIM,"2L6B[8@/[O!-8TB]<"TVBX-)E##>)+-:5*^
MWNO26[N)Z\^';K*.<]'I-3'%+"UOJVNKZ=W+:KPV(^. 0P6N\DN+L;KR0[7>
M0C3C8<><DY[WA&O_7,XJL#8H]USFJ[RK LJ:^:7'?>8N<+_?(]5FBWMPB_>V
MXG/L 4^_[/,MKSSOYS\9?[3K4>LI8I_^>M9F_;:NO<D,%6>361GN_44H-RW7
M/;T)#B6W86[KTX!QH0+6Y1V;;+YL[-U1E-"*]LV'7'A2BZEG$&:"DMG0MD>Z
M+UY\_/;4M];+I+#5-%I??_%EOK2\+0MU]EI+3QUT4W_QA?K>)2 :+083$K6Y
MQ"FZHS,NHEL:S_+*L5V1)V(GKI:N&#V1Y+3]1 +LG:.BHE;LW[YUL2UGMH05
M(N>SCD#WS@CS,K>-E*V\9H88)#'18V?MAO1R.O/Y@E)U(+I\!M3'[LZ@9#:L
M?E=,R%, >57XI[*TP @!":(%ZJG5H7S2%OYQ# T,W0F=DH^__0=02P,$%
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M>#J7-R4X55^UXOG"W*[JN%:V+]D"7D=GE$O%N]ZG60,.IYLW>(Y@5>3 1!+
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M_1YY_U'LJI][(KI0QOM:\R=6+TLJE96/:0TBHX<H>?*+B$F+$&SRO0L@[76
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MLMFKE;3IFS69^\-XXO0XL!YZ"*J\)^C382+_J%X'7]G9LO2%<!6@+<R DFC
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MIE?/6EM#M+TK2V[U5KN78S8\#\V)P&O+4 \BD6^JM&$U?T&#]5H;QPS7S5M
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MP\XFU=($6;B"K&LG"19-G5-H0=8)>#Y*S47KR>T]+>6/U^+Q,::'$OYEF>-
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M&<J/@"KW4$,/HVENP7>2TMGIV2C,,9^<3J;SX;^[3(\!&>\F!<E &CJQ59T
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MK[X,L/SR)Z;KZ> [+G*K%@<B-]$G7A*+H9878\F,SE5#O]06#$4%"*8!-[9
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M$>!0K3W8[1N)O)?F"E,8?AZ0<;)8.D[G_;,&P\]_'XWR'X.KJTOP0L8H+7-
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M::O#6! 9U\7+5'OM!=M)29O>\!QUUD1:/0RO> 63+Q?#7/_QRW]?#[[#U;T
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M?M2,O/E(4D$L5<"9<J;F^\O(8K"."6E3,L9;Z5MO$X^">MD&:5N=]='^=3W
M.TF>70#V9* ^"NXT=FICI7:CS($:.=Y^= =H,LKX:"63-M;L;\M9\)+3X6HX
M-RB!?GP>E'G$BCTU8W911/-X1M71KS@=#Y9WLLX(E[UW3 I;^\R@9 &X9V E
MUL( A6*E:F+3%?CJHX]OBS26_:B9X%H'$BL:?0\-<"R1UL DS@>@*[*U2F)6
M&Y6PE.@]=%:C/FLU[B^XUE_CZ\%X,KV'!H-,'#*QJ&0BE?.Q7JH*)ET.*0;A
MHNBFQ@>//BLU'B:XUB''CYA&PWP/3LCH(J9:75XW!^DU\U@'J1#$*()*B7<+
M%C]\]EDI\D#1M0X2?OHR&-]'XU HGVUBH2:ZZJ@T 1&U@6..H.@_A]4Y"QL4
M^>#19Z7'PP37.J;W*XS_C=/J+][V-W\UOTCX%:;U+WZ\Q_%@E"\UV"1J5\X<
M0I@/TO%U\@=M_ (MMUFM5F!L4&_G5S[WOH3[]+SJ42FGG(P1,0=!<)AQD4R'
M4%NZ2C(B+&:9'!:NL'7VYDN9C'%(9[5>]'>LR1C"R**S\DR7PN=M@KW26./S
MWFC-M8'<F%/G.!GC$/X<K)?6]N6=LF\D@0P_WZW8IH-6@U&.LQ+JD+Z F842
M!7/!<XD2:3/M-H5MZVM>(B$:"[^'@1BWX%Y?C4;C>] 0C(RN&(*6!=G1*=3[
M"<Z,CA"U#CG'UB,QML!YB?QIK:4>:IKN0%N*J_:7NC?VY5)DE8()DM51KK1V
M="P"(HM68X[900JQ/R9MQ/47I1KJK8<\JW_2RN%J\!_,?R?AOAU-)N^&MU7>
MD\LDO"4XEAFD#70V7;:F'S(7P42>-+1/U'L$TDMF5$MM-0R-[CMY8^Y*?AHM
M?W+I-0=.OB0K-I$51X<S ^TM$^1J%H=T<LMN*=T-P+Q$GIU$D3U,QEC?LX)D
MHAV]FCR"F!)]'P!U8 ?]48D0O2K@V@]DW0#E);*KI78V3KHXR= G;H4ENA<F
M<ZCUBB27*(#<C.AB4-D5;;I%$E[TT*=C[EA[*N\A[4)KVKWZ L//^&9XQV9\
M;#&7H:0LZ^V]RP68SJ;6BEA1)T"Z['06>K6%:W?^[8'G+R(>3YUK[CP/OEQ?
M4YQ$)WRBCP4^$_[?1],[5RR31=U2OE0^B2BT93Y'.O0S1A8YD&<#0O!L/9CV
MN?=[(7V)_#RB;M=0LH\V'?<_H\F;R>2:9#BN_ZR!A=^NJTK>E8]?@'X^_^FE
M-SX+@$ KX&1B<+(N/,C"DN$)I5.95MD_1?= _A=ECZK[-10^N'WV/G-08XD:
M<LF$5!LRB0M]=F#(H2=7WA8>D(3:$U]?T'3;%N3L2ZMKF'A8^LP>@'^!].7.
MC+M%!H /PL0J->EY(A^?1P:&EWKM!-+:8NBDV-OHW ?12Z3AZ52ZAIBZCV&3
M'Z_C!/_[NO8<_3Z;U+'_\,A-CVHQ#+(3S$;#'5?>=<N@R)V,M;UX$;6GBT/-
MZ(0S#+@26H*.EK=.3-B$Y=#3<N6Y\\(B<HR  QBF,)&KKC30%NJ!%9M%3 5E
M2:V+^=;A.-8@Q"9Z7CVP#A;LNBR;4XPG7%W(LC#$&.5<XH96@);LO)S)59'
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M]*2.WOK_K-Y,O_MCB./)E\&W.T!CX-$@&A:UEP2TMAJU*I WJ[6U:'-TK?V
MSN#.A#;]**-A?' )M"[W79F?L<3@%*.A#<_P1">A%86%6GP@(B8KD@#9O%O4
MW?>?B>[W%FD/M[YW3[J*:W(#+'!OZ]@N!G5>UZQ1;0#I:N6>10@)T+9NE[$1
MS)DHOHVP-UX,[)FL/A/5!--_?1Y]_QNF_+>+/V"<:T+-N^'5C\>3T^^I_>YS
MYAI/^5;1]Y^\4Z[Z+BA;Y:;7DJN?8(+YU>CK-_(FYP.(QN-:!CNK\__IQ^V_
M\QY^S*Z#*ZP;;!?#_/X*AG<NK-M^,;U /*@W\724_CU[=BTA^2?I=#E )?M2
M9W%R%L$FIGU-RRK1,RZ"4%Z 4Z%;!'CC*TZP2_3(D/M]BYN(M8<KQ0]DN8P'
MB0S=&<1?[PFL$<G7O^,LE=U)K U[9\VG;.*XC,9?ZUBE&?2U+[_D9'7J4!T7
MIZKW,@MQH6,IH -IA8VZV_?;Z77GJ=Z>Q-VZ_]4O=,B/?B#.\"R;.M25+;#Y
M%%)-L6;* %DKULH:P]*LY*! 9BZ$ZU8N^<B+SI@$+46\L>O4!H-P\=?UETAO
M_5__U_\/4$L#!!0    ( *"#J5B<*AY*/7$  (J+   4    87-T:"TR,#(T
M,#,S,5]G,2YJ<&?LNP=45%VV+KH1!$0%E:Q H2 9R3F4B$0%! 0DED@L$)"<
M*041R0("DI&<2R1)+"4+(ADDYQRL(A9%A5O\K[MO]W_ZO-/GO#?N>&^,WHP)
MFQW67G.N-><WOQ4(OPCSP!5-50U5@(1X") (  !A 8A1\8': H"6%L '   E
M<([D&D!*/",A_@!A4(#LCW, X +.#K)WI, YXE\ZHIB](_O;^8OXN#_.286%
M 2 ^_G^?GQVBPJ+BLL*BLB*2["(BLB+"Q)-_>NVL/B3I]AX>+V2%A)S=[UA:
MNSRSN6/EXB3D8_E"2.2.L! @#_9Y86GE:./!_LS&#NJLP/V[$<'-#K56X#:2
MT!+6>J%L8P]5]W.ST??3?FSEYV@E8\T-5KQ,)>\CZ^/TPLG&PY+=Q^FYL[NL
MC\*M/TJ7)9Z?71:ZI2CO9FTKJW=?]2]/$/]3N/67NGA[>]_Q%KOCXF8G)"(C
M(R,D+"HD*BI(?$+0W=?9P])'T-F=XR\%W+=QMW*#OO" NCBSG_UO^<S%TT/A
MEJ<GU%K6UM)6XIFUM83@,TLQ:T$1$6M+04MK,1%!:S$Q:RD)$6E16Y%GM_Y:
M0:<7?_O\/S4%\7O$9V25W6PL/6SN$T7QS*2"PJ*"(I*/_VI2>:$_/2,O]*=*
M_N4*46_BV=^L=&:ROUG:QIEH7F^B'0E3@#) 3G:>_#P9.?EY<@H*<DJJ*U14
M%RY0T5'37+K"2,?$Q$C'P'"=]3;H^@T.%@8&=@%V#BYN7CY>9I"@L""/\&T>
M7IZS0D@H*"BH**EHJ:AH>:XS7.?Y;Q^$K\!52A(0^5-2DEO N:LDI%=)".T
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MU\@B'7$G5(U\E]A"&F]U5>B _ZD8_434=&"_!<@4%M^:B1JGEA.[7()X)T@
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MFU&W:M0&![X-%D)5'(@-:3SF$70155 SWYN6<G#Q[7S\PCEUB]L!+]UD([;
M"WX^O_'!A@0 ?0&$-OJ@J[>8N=[SF%=K7Y.W:I@ _./M.GQ_IOA8DUW>YO[6
M\=7^VTWK<>_#]8%B[FSX.\<-.#$5OZO(3D2K#P3@@-9X)$)WD$4:0_=1J4=$
M8]U_): *I;\(CSH0>BL[EI;OJ*B2V/3M6>SVI]K!:K:RUYDZ[A!]HW8("WBY
MU"<6WQB+(W&4Y94J;DO2C]J4D B\F(5LP+/#!F!$U-TAUF?&OVO[]^*.2\<D
M0ZGKXHVY6JWS/5TW?#781OG3 R+DQKL-#I*WNXHGUEM(49*YQ0\_&4^9E<6K
MS[Q4.LG\ZBU1KEYA?G4N]J.VN.EK@X-U_]E\&+3@29]OT;2*DR/5;KSQ$[ZB
M8ZXF4.=<M4I-4[RIS[VOYHE+.\F^3_H;LMNN[JICC.*Q!NCH(O2^X;/M(\Q]
M@: ^6QH %H@SPV=0("YHTB7MB;79Q$6LEI=N>T_6$5&;Q<&YXW"B?.#@P>,G
M+[&/[?8ERI%AG6RW1X*X["7'\>RCNT[Y7]K?]?IR<$07!N?-CR>.NR ?X#7A
M8>"M-2*I=*BC2QC8*55-ASY(XK<;. V*X'O36#IA;Z+UL[!$FZ@?UPDKXMTA
M)Y+"S3'JQ#K-2R7RM-=)\:=IX\9B76VHMX9 &?UCOWC'KUC_TWMM9/$F/J*#
MSI0G6H=#[[(>:U_ I =>]C7J@(2;),<<<NGU.^7>GZBKHH@]GAM%* UX<[^J
M>*MGVGTL7/_\67VIPRFKT-LFST7853E6B$ESRHTR?JYN(O$.;<4G]NF:R*J&
ME6R)T@V)3TVM4I"9WAVRVGK5X92C<#]7"YHC5N(HUQC)^WK,O==%], G/9>F
MW<@2U IG44]+;O/.AM74Z"QK.PH9(M4BQ-].:JG='9D/]^MV^I5- %Z11,C$
M\97+V.>U[)<BDSO[&=>IP]U])!R5QOCG4BIWN&?[1^)V("H!TNCB;/2"X45O
M29,*T3']3].!FE)J('@1/4I%<1;JM!;CZ,O&F_MT?;W#6'U=B?7R_>)BEE]1
MY_EZ-HRSK(,&V+A'L=SS:8ZX<[^WDUT"602YW\?;4*FKMYV3+<*6KF6AS6%7
MP.M@8@+@10"PSG ?Q.+S%A&TJ4ONEIKL:,:!GN_7IV;WKRE]P0ASDFZ]"W3L
MY;UW@5]<E?8"D_Y**=W,*5O'O$YDIM2HO%/V+\A6D%/^Z(%P'VB"W;S[)PDS
M)>7\$;R<?YX O 'MZ6*%B&FG' S'5',<:F?,.1H+%B^DU.:CFCP?4(SB7^R*
M]G!A<TSU2BOWE?0:%V31Q24Q3.;6:EZ#T4(,QMM@3 1@N<@G&8^X@='+2?![
M8ZPM5C0R>B!.]&U/[%UB"DH \!I3! #5<#PWL=;A-Q[9)%0T@WYSO.-]998I
M#IL7>[%26_@E==YX5\T&_@(Z"G\);54,Q3RP,D6T/(N-/;QZ8G\1IS$?>&$G
MI&P^];-:;F2KZN,3: =W4%=+P"-T8RZ:L_D]X" [!EZ:E&SM6+=VGE/J'Y:!
MI\F;HG0Z6KCC.F9+!<M+/6JKN)B^'DC+N*"O2G1H"21H[OW8X:SHR)A>KE30
M4.@S&SQPTC'YLN<1K;B+T1UU6H!28N9=M<67KJT_W7ADY->RG:W!&:_!':]%
M/ZN,#.MR5VN6EWM!<>K66;@G<-EF"T339)K;/K3)!AKA"%<U47G;77IHTTT?
MT%L_4*KOW//@M_!!GS8!T/Q"NY%<)^E.<P)UX5>=^R"QA2=%GY9OZ'6Y++[&
MCU7^O-1S3CMD7)X<PP+R0VGR2A<[\U7SCAFFUF/.+S3#M%!W$ACR<V9N]^5E
M,/OP^9=29\<JFR0BCUOA;!9HVG;=Z<Y^KC21"[[/::BS9DE/VXK 8<H0)^AQ
M$B8TNGDEO52BIMU10$](54^49L6L*HQ?T9OYM8^OKT+X>DY$2!0O<W"Q+3L/
M,^<!77SWN_8]S<VXG"1;JY?9GIP8H^]SU_%WS'PR5P-OM.W+7Z>Z%GLKH]PK
M4"?'CQJGDUVD]'W=P_+3</N#)#EO!?Y%4%<&AW*\J=#E^ZG->]ARR6W3CY@8
M"/+K,9P<)47,+!C1T7,[DWWMCZ2PC9-_ +6%#I8R=7&]HF@X2N=C;G"^BGW%
M::5QI(@M9Z4,9WJ"AJ$'3O%8[\L5Z%@RHSM;W#=:];EWS!4E4PO>T157Q(-N
MC #@_4$RN[UGE_6ASAZ:>3=1<BP>;O)Z_.W;,84WW\_'=C;"+V*-4;%AYF37
MJ^N2ML9FT2GO8A]F?:#Y2)]6A)5#O<E@]H=3.UA2W(XG90?IU5<8#^9Z:="5
M\G[3$U;*SPMWR+"QLPWT1BXM>84OAC^K''T/O9Z[8& =T,9[8+2M\Q%SSK$:
MG5)B8=]",G;(*NIR:V]R^CM=FK+3\Y@72A0H>F2@7VT(2F_5)4QV+51>F?\G
M9[5U9;VSL7K7[J]C)A:V&5DK9LVD.K444T'=U P%>(D8XL].!/[SA?T2?@OU
M(P50J2Y>Y9CC0$X[KF!X)^_=RNQM6^E.#5*)9R50\![59P)0<8'X6D2=F=KW
MYK\QU/_?L5+ZG^C]C@;O8*R"9&F)Y#WLN];"U53E02-,9AM7/O]ZE!4C5RYK
M+_[6>'4_-33>X?K,LF%2<>>Q?.6![FCLI]46'U37#@W,G3,)?Z7*5%KV8F,^
M#;__Z]-2]"Z6_WN3YY*@:6=#[]P6[3626S<\P8VO NE@8B/C,N;">4EKS6]Z
M+<_W&1FA;\@>1WCN!$[49%@<(6DSXG]HTN0<@%Z6.=04;(PWY ]-06N3&;TO
M#_%PB(I@SWO[>7^#L<ZILMBWW&-[L^@S0 #FY#Z#^88VN?TS9#7[\GQ'389K
M^'=$7273?-VAPAN<UZJ=3D(LPCV18ETO.HW%N[F[D%W>;# ]_K<HBC>>"!IU
M6M.AWP+ATH:IM^A;H@?PY*&<1W2.>L5YUBGK+=1HU&(T_9"@>>[8\RXRG3U-
MBNJ7[@3@''E+-)*F_3)%YU'H061&G7I]TM!S@<K3I2_'S/3(&I.APQM]W(^"
M3[6^)$WN,LRP5-8RZYSLZ/)I;+LMBF(\#99RP<H\<%&T($H6Q++1.40 K*\?
M?K:U'P]-\?-]"_ZP'1CMY^0N/ERE&%0NHY?P^IB*)R?N@ZY*0"^J?XFL;GC:
MQ[\UF4N.DTNN]%<:N=7,E2,=/5F<[,BSY>UH)-IW\78O[4 01X#3 %:0LU96
M+QKR^&&I@,O;9XI1N/Y/_1]OM<"(P1S.A Z?UBI]8.,\PU[Y@X^B0.T'[)IC
M<$Y#KK:(XILWY(GT-7->LL9LQM<US#-^+5>Q)*"''1SE'D1.C%V4OOTEI67;
M]:87^*Y,147_0FRT\X"XQ?61N^#],;  7BNB8&AZX_T23?BOI=&(3S:<5]PH
M=\QCWP1QH1O;8K*>CE58OX*MA [[#L9MO/D)OO38>^YRDYT5LR]6JCB1)8&.
MZR%L3J9"S\>F+B4G4RK"0-K:DT_IF#R:4V=WB]^> -!N9H7!V*K+G=7+FK2N
M0:7Z0HW;;&?ZZ^4+E^)^6\ 7Y>H% R1*+$S4&9XXW4[B!H0O77GG.S^^MN)7
MUP:)2)95#"E"NY@EK@U5"'*]F51=*4__2(78I>V4\]Q([7S<T+XO(N.@DYD\
M;0=KW4*_(@!$(H--J", 2QY_ON"Y]MBP*6[;#VR8BXW<59NS.(^H'Y6GSYZ;
MTUB=F7G2)C[D=+%^@H2;%'#S-UQQ!U^"+:?[0/#?DN8P@HX%%5+U>S7T!4.[
MOG,[Q(#""6L'J8,/ CQ13H'YI_=@WT$HBB$:'(@UP-2<+HAVI@<6C(/=I\>P
M%L*Z%<?Q]4)[]"=+D(^3WMB0'=A6/ &XJ8E09IFS#R  ]UB]]<-4!ET.Y?+C
MRK?G_<,9A"_2&W#.7R/W.813C8.A-PS"D^\-V/G2S/A_OT=R:/ 3)F+1B)+#
M:W1%@+>970E SF0+37'^>4'C)//00I,[^D:5@^CQSM2UJ$,2SXJ9E'MV/:_(
M?^50G);BM#5V'=-S(M8UI]BVG^74/RL+;M2A#'B( K_V2"BT]W[79F\#C6BB
M7',%V-2/Z#L&E35V>5O%#.,;%,!XQL(88N2[[4( SIAX* C9+.]--"\_#$L6
MB^7_P9/_G:T38G!F6\5UM%;YG$_LPFY<R>9G@>0Z_IMQH^="PIG52&->&IE;
MP) T> U0&&(ZF0"H*?B==^WU"NCP2#2^/9/%%$0,$WM/)'[G(_ )71:N%K%_
MGLGP4EY0&[%$A-"HG+"=G'+"NKW;P8<[C/C7CJ-!W %&@TV7RAT)  CSS:P\
M72LZ9=W:98%M.NNY.T04*X,:F:6H'%\>'I=-/!#YYKQL\VPYR7WS[KJ"3G:%
MY.:B8V.*\YU\W\+$R.\<M:NV\O$:FPZLBE#S=/>O):,S&CN%/W;ES5%V';-<
M<>V8]"3#Z*')[@_O:.XI3<^%2WRK$JNTN_TA/5Y;H_PRH_*H9V\(=72A^9RF
M;'G3P].@+QOH<2N*;UD@+29/Y.E+&,*="M3=XH#[M>[%K1J\TA [[[OSY%-+
MXW %&29PY*@*KL'^CIC NYNK5B+[._WDM6X?A\%?._:*\W$!?O&OYXW8E,B"
M*3F"+XL/_QH2BU;9;<S\-N\2RW9KT";F,NQZ7]@]Z]:?(1,$(!)_/AT3@7%I
M9>,="C#/X\K].!W^45Z6C8T+OP6WPJNJ!%PP![?U,SNP4:+H9),R.W(X!?OJ
MI8V7=@OG!H[ T7:R&ILQEPPA5)&IJ56*OW.*[&5K"AISC3=3GV?:Y(\\>S+5
M0F.UKC0?JVNT]?YD-=7+D@BP[/^]V:#]WU&SX+"OLS?<27,=I1ST?MYIU/&E
M/(",S/L-:]19F\NZ%=^FW.V_ABN4MVCHC[ <*%N>@>;;];$CA^MF"4"+*L5(
M#=$/R+&F!(#2.Z8,;N=62TL <LTQE+]BT_#G[KI\':<7_ZPCUBM6'=_=00R1
ME?+Q.N6BC71ZL;R'PFV=XH&Q#T Y)=_>B[Y['!5,K90/I\&E!]WBJLQ76X@V
M<4&G&!<(FO>+M8+#<"L@]*["9?]0MS^&&2)&;%2=KYU-/7;_WRVYX?^IJ(A.
MPU]%A!GE,$[Y%L$^*H=T3U/OHWF< ]7A:O!X&!1."WONL^%1!/*L2 "]?^$C
M)GDQJVT%4I+:X+H:-_$J=\>1\\@D$ZQO;*KE[WN^_#,S=Z9*A#BK\8=YFA\C
M$EO@*L@; E"+9\_'?F\8UXC=H> (N;DH<K*"F*<?Y[9Q7]]Z_#A[%0/2]U&[
M']:6R3PL'AE 5_7JF0#%[/. /G2MSI+)@:X9=W?M\NY9EJ36!F8X&S.C+(RM
M,9<5GW(8\CV:=ET!L],4\I^-@BFVI.-*Y26.RFFU47074@3FML?):$YLUU:X
M?TF!D+(G,8TW[]A/8\I879Q4'A1O$P!B(A9._-UD(QGY ET[:M5ZSH>62Q-O
M]>)8&EZZM=_[L#E+:\3)I6RNM[XVT3:\F5E;"=L1B%HP=Z"YZN.N/;HCLF)Q
M[_.K]!U.-\0C-S!59[5G_8IMM:]MR9V"<CK=)YF/#+FC:SXNS%%N8A#GRP4S
M[U-\#+!46VRGFH++X#Y&TKR6W?U! 'J!H,P C\6*(8E<>MFXR,U!5$;[D-GT
M _G=(2U^1F^K^!_:&N*F2H*C[8],/\9#S53?-AN'?P5EJ)G.DC2%Z*"ZPGX+
M49K:"\W'JRK0WW^9@/:L& M\GB5@JC8V1X5GVK"X,'PS2?U9_3@K2>9.LJN>
M7YGO:8FLZ_??ZPI4,<T\%5Q3WG;=CXOYXE?3&JDB-F=O-'H';S*M!2O5+,4I
M\]/<HR'/SXFC^ F[WG+1U/3)M.,L]>OVF^0/,A1\S9MGP0\]^3>&F;Z=C"%4
M&@[AX '\%1\I]9$UA+F@\UJ\8>+YP7V.,&XY7<5=BN?!/ENF]\H34[8LW87L
M**XW'"F:(&E"Y$TK-AGJ6I@_?=&_%,GI77[Z)>[],NM:2,@OZU.CJ3$0]/0R
M8JK]WN]>B/0]C;OHD]IXDD[WJ)'ND@AZP$#W)?#U7%*.^ZJ,R).Z<&B-([VI
M5J6MP)AA>T+\PP?]&QJX%$L"H"B).%Z!M98//G*;R;H>-*BK1M'AI'4SFD.)
MCNFQ&<EIS8X%U"+C5!WVW62$ &R]!V%X'7\XUH*H%(DDA<F/8P9A<]'^CN>.
MCYDR2[:IZEV/R[$?,.-#B(DDT/X2,;('&6'Y5PG V?0T_FQ,[ D!.!"#:(V?
MS4]7,> _X2%Q^J>B;?@ )]CO'B).:;DXG?]T:Y9ID2+^ZKFUO6+[LI\W/L'?
MMDC#OANB0#AO$.;<^%0-BK&+YH1OEH-(%Y8(P%V3R9BUPO<$@![#(N'053'3
ML1 NSI-FDSY^;_,IC:CPHQ*:3\LX]8.R$OZ\XU2=%Z3<I D6*0LTP9EW4'2\
MKK>K_<QSH\*%-%0MMU\R8+_"S= 7D25S:L/E32J+%SV3C3+NUR*[ZQF*?"E
M<PJ!#9Y]_IZ6LK5#W'$1/Z:M%Q[\5O2KQ*7NM)+"%C7,&]\ZG7N%3I+!EN8C
MP[XV"[4I<GX:$SSTGUBI2OCQ9(:._X6:-&;\DZZQ;'R@CN*3S3TMF?,!&:=J
M:-0A ;@J^:JP!_;Y8)R?:[A].(8)QYC(=MI<N@Z+L. D *_UOZ96E$2=[U%9
M(5*J<:,3HSUN\%W'!35;+X'E*I'OG,L))KJQDW*B#51:H\E:KXNWG>X(_;Y9
M_?F-QJ[MB[B.ZRL9L7?/*T$>X?O8SL5J#U%$U/ HM321&;\!;7[<^.)?AP^)
MU3?5-BM9*PUO%U!0] (O)'\-E'L8?(, ,)5 -LG(&7Q_")]*'??CY;;]QFLG
MIY2@SN],E.FNL+>J73MOP/;U!9\)?[R>V_1)ZNB:\>QS8BA-H'V-FFOMOX1N
M969;[1,X)&<VG3*@/#FT'"02I4!*^'O%6VA:0^0=^)&6%EG2GO743"?86S1V
MN:WAZ)A)XMC TF>J]8A-"+DSEE"<+=(CQO+2YN.[P'&(*R8JYC"/3WK7>T%D
M.&?$^C?MO ._6KN)PES88>\,OZY6LF'\AW3J,%;*(PXR_^L_*ZHV:+7,6:7:
M:$YX\(Q$6IB!P$>9G+:VT*")3G ;U$H CFB):>=@),3'2,)I<,%VCB7P7,L-
M=!?QKG([XA ]-]2R#'^#%R&F-X]00K@@J8.<F,4>6+B0<G1.Q"^D5YA4>(!N
M@?W1<EA3AI4 N9>0H<LW)7"H1^9V:D2C O\\K%5_$>LHBXQ7N QZ[EH\.?Y0
M=OY(:2#NNSSU<J!NWD:2K$*4EY]Y'D-2993 HVP#4#+,SRO9TBD?6EO+<)6R
MW"GW28X2EH_\O$F%3-_W+,'P#IVK_,T-1.CFH[;J:1$*X!P.,+9TA>5.==@M
MDNEMHEZ6NL$:E@IT;+>V.@)"Q/64Q.,>1K-45JJI,O&ID5W=@N1XHOIW6#\6
M1*,D-Y]<X32)TO !6,AEC+ 3&EA'/S'8186R*EJN&5ZP<N_6)GS"KCVVV$=S
M7^5+X-"&VYM([BR^A^_ Y)=/(DX,F\..3!&.+F_WINR6&S_'41[KE=$LTZR9
M/#8*GXHM*+QG89)E,JAB,.J2/730V'A:.^7B>+'_YH$!6=: T<W]"Y#[/CH[
M,DM=U74Z%Z!NB4D>U^8:,N^!&D%+(Z=6E1+[6E"?A"?U*/)F6*E%^K3YCZ%/
M/[V6D;F_+I%L\TLV6K(96&T)C]!3.5Q<9?4S&H!<P)/A:F=933M+.5VE:1C2
M\W*%MZT5U$YSL_1D#5VVA^=Y#LOU=*XY? K[_"G!IOJY='Q08TL$)5;] %Y<
MRI<HF"._'23[**@G[=!&D$-C^,!1HGKH>?GV3G+>"]4K@3Z;@9L[=$8RB[53
MC52K39;S+C0^#3,)IL.627K"=3R2#[/46/ 4'),-)KP%8VU1^10^C6)+H$@0
M50WHG-91D3&\6N.&@UEHFZJ.RCLOQ;"/1_)&:>/KSH66CB708P;9UQ<4\EN9
M5J([E7GA;Q5Y?61=R'Q:MAX\ZW>8:ZE)1,1PI-M-/PW9Y2_(T'9B/F"ZY%A6
MSXT2:E^VSXD8.= 9:.;&*QE"#K^!#ZX:;A8D$ #V4B',?!:&LM3S:X#C--$C
MR<[FM.A/)J0P:P3 9WP](\A+"U]/ &8EFJD+J]X'(I(W19OY%[(ZRI6_FK!V
MIM@43,ZH2?2:):=\N*)9LA0S)[1EX:CB/.0G-EZL+6'5*^'AC\"*Q]00P["@
M'!ZO $(.R8[C@.K?I^C#!;K'I])',OC<,+S^# %8R/.$8TB@<\>H=0+P)FX,
ML7Z^$#;7!:?,B;5C^W;( M[+_$T +G.4PP8N:A, 1*S:WQ?LHT+G+WU$4[1
M -X?P]!05D?\2Q-O'-8/7APT@.DXRO*TQW!EEKK2WG^B?D+RBAGGV,Z3.]'U
M:8P\>/P]4?&J(LS^$='9XRVR#D^D\+T6-18/_K1:K8(7^_#D(02UMLDAK"+0
MSO<J7N,K/4JM,Y9%8\F%44M %+2=)FI9I=WA_B/+D /\D'KTP&7GPJ(J\K@M
MLOW5D?FF@$ N^Q[I.3,",,<>6TR/RG=2!=L??"ZA^EEUH&01C?1>R!B/]61,
M7<B<NE_[E#M#[<?.>._#XR[]7Z 7-.?S?_47;QHF,4!;5C<-WMP^M&6G&1F?
MS:1&X@I#FZ0L<W_Q[)7G4IDRB8(-W7>UM0PT]LJIRX)X!T)S&T$+6=10-N;A
ML5[ERC=#@,PO13O%LIDGIZEC.1$KBJYUW%[TEW?RFP_+DL8_J;BZL$^B-%^-
MAGVD"-'7O1N;$B2!98K5J,F"(*.<CJ2_^9>R)(D(>6N?JKE.%2V]FO?$\'T5
M37Q*R4'&=HB2ZD1<X [!^OM"'=+$3]_=*;^[7M2^ B._I/C22(NW+E=ANY&1
M+ZLA<XUW8<;AN&UR)K.T0/-98\T[6;:N$= C526V-RU;2)>W3@$&"VF7;;O>
M5N1.Z\N(?%EX?QI,"7^YM0Z>4&XO2TXM?+,&F^E&/*\C.[ ,?:&8"R42V51/
M*T^W?5DJ#US.3)#:D(>N^G91U.Z]DJAX;8"^)P"U!*L.BP6U-5#9FUCG2RAH
MT'S8?#&H-)#UK(O=G_P(GE":CXY=U) W7M+2-[3EXK7A!\!MUY A>T"6FV-J
M1;=:(D@_)+M(3W=KA'\JZ J6-JW=$+G%QB,Z"=4F;7N.$*B[.!&.IP>G[,1<
MZ,)E!9 3\P>Q.0=7ER'Q(?@MX44HS8R.:Z?. /7A$25PB>0E']_CVK?+/T0J
MTHX>'V_:^L#:,#IA91T5X853QO?(*<,!P=VN4I";%G10Q9V-UEE[FY^F@XUV
M *OO\'3<8\J?B -17^+ ,Z[[-%_'5N@LOC%+-W9DW<2:H^5\YY<3'@_./MBA
M <M8IC@AYKH,"(!]$+OWG@F.-I-G[8VZG4H\+UUN;M0;BF#*7?Y% A ]>YZ8
M0G!TA J,(CX+*:4.9'JY[ZME'6F 7M$/:Q=*1AU_8AHW.O:4PO;+YT3P6XTH
M(M%6!(!SZ0P:+]42H='17.(_#+,PUJ,.@Z0V_]\?9?%6B6-F5>:X1,_!'E'Z
MCYFJV5JT5T36WR>8\Y!K+ULX1N^]!!K? W(!JP@EQ_W?[7-[H@YSA\="^#>.
M?G)5OWI,W9*[^^"E!,#V!K]I[)N]IJ,!30+@\M[9IXW%2<?DY%Y++2X)L9SZ
M@ !87H =T)66(S.,LY"*=B7$5Y[ ^J/AN!,(,O?OLU73G'J=C%6K9]$WHSC5
MBT)RBKZ"0F4C>*[^]Y:\O#,JQ]*@'P?8B8QZPD4%R1DGZ;7'&EQ'E;9SZ[$4
M,AP_L.#\_@K'I.OFA9C3[T-D"J^LHK(LQUK0 ^)IYA=5/@\='$PX0J^UAXQ0
MKTUGZM07E2H:6+O9,A6J\@G/Q YY]+*R=<H)WAFZ\>!))P//([[87D2SV5E<
M\*V=^664$F"*UB_PZ=?)W&UE*I>_&V$B,^!$F[7[?2OKMR=(FW_8OB!->[W!
MTT;3;, O*V/<<&_2K-?%_8:*_!VK.*:GI:3!-%\DZ/WZ=T0^<B6@F"OF[U8Z
MO!#\_G7I!UDI;)V8\W\M_5Y:>V=S;72PJ.2;EJ?B>]Q[>?7])YLM+%_<@GZJ
MS'SBSJELB\V6TQF-#CP/N1[TTWO'!F7UX.Z+9-T^TM-8@4\$H"O1<;MAI:2<
M8VV?SX%^RMR32.&KI/_U/4#=*,;P:LCE*5_,:J&C]8?N:X@?<[MP0RP)G +]
MZO2>>/CMK.#R5'EL 7Y#-:@8=.C24R+L]FL]-[34^/3M86PXXFIUUCEH?D6&
MLX0,H^21^IP8L3GG9B"P7@D4(@*K4H0N-/LRZAG^HTZ,+20TVI\OI@?<+Z'\
MJ*5A!&[3.'+G=GU#2IV&0)GQA],$@ZV"*[J*(1="8E@AWF>(/+#%7=GT9?CW
MS<;/*?/UH>UQ/6&7HF2O.&[!0A", DT0%X:4LB:O3';=.NB)WM:,PHU1V!W9
M@!#-J.[-;LW/Z<'4E!*TP?$CJ^T+EF^C\Q'N!X81)T8+<UWE1BKJ94VZM)NU
M_*&,5*XO0J8S0:AOQ_"/\MQ+B,OH"@G9.\5D55<3G->L>PD ((_GX)BMSZ=@
M[<^"AY0JG?9JKVF=K3CZ^)^L-")7BZSI#I!:R'CPI/Y;S$_R=[S2TS/T, ;V
M( FD FYZ_'B<,5G;^LN7N/RX?D-;&>Y]B0/8COFB"X?V<("4,]K_S:EY-P6:
M[MW+4X9IV/RY%FA%JLCG^@-F<S;-@-]>]$>,VPL+B&VAL!<6#].<:XQ.]:W=
M.#:8,%9$-OG*J =/-9"/DHHX:&9C"?&6S17>+!Z=0C[268 $F'RC+Z\V/%KG
M>,-Y-8<Z(OLI34\B%/I,S&0LHJ!A4T/%8,23GU44)*?75%L=>;K?4PE?U7)+
MSJ+#7K7OL$'=CKQ* .3#WP<Y7'Z:X,\F /T)HZJ?'#03 #%@+\HYZ5PU"<%/
MRM+\**I(5D>Q1981@&YNPT_-X)FZ+VH<2 IQ\;&E1-XN8Y5LE&$TS=LFJ:(-
MQB=[<';[NJL9>3$W-JEI%B"D#@SNT.-C26][JR]UB1_C:)"?TZ^>1."HX?%@
M*/PRS J]XZE.ZU11#DI](7VM@KX+'SQG*%'.[&@UU%/JUC<<J,,.+P#;@&EQ
MN0]& B1>G,2/MHP^)\;?I.<OYOW)OQ'MDWJ2V0![D\GI<@$]]6#T\_VKO9_G
MJ5%2Q)!E0:WVA;YZJ>\&6\6=V-H\8H;=$J$^8ZWB\TM4N.>3#)G?T#CSWBNS
MKO:=FX>_PS!'&53)J::&]N]AM/ ?N2@^_L*<5"]OOFNN\?'K01Z#%O6H_85V
M/-,X]YA']T5[H\^,MRD8AD16:'(2CG46IK(X*G[5W/8(=.*K+#TOG3F![%HJ
M7PLKRQ["/G#ARBUL/:?BRLP6H"E+FLE"/<%^FGJL0X/51SHWE!Z9>XTQF^*-
MS>O>?<4$H"F07"V@G*I$GF9MS0E//GB*??^@M&V,3_L[]7C5&6:F*["K.O!^
M!;!NRW#>OOAI;YHQN)FLG!G[K:)-'5VW%"UD'];.*,:^6:=DU[\XGS7V<3"0
MN4.^P'$A[FB%?I\[#&:_H\GP&$4=Z^0)4A;,_9#NOR-#AC?8GJ5"9RS &#^K
M%$#>PDWQYG?"DH7F9:6P9*D_'[WWEBZ9W](;>Z!<<T;!'ITMDE^"32KC-<<*
M"8!9-A$P'UA8_?.ADZH_AD[^I17,)5BUD+]?P1R@@FK#:]:])1;XA?@20\O,
M/PZ.C(UX*SPL1,,'%DKKT"(+[2APNSE?SP+IY/W5U07U;I[T^5/:&MCU1?Y9
MF'6:1$*[W^$&2%RRF%(Q;0Y\JEV75FVJ$&"NIAV5%UM(I!2+BH_.QD-/3H]J
M1Z/\+$+R.%S%/YNK@Z=)C B LDM/BP/<'E=ZYR'BB@![?R]U>KI_"B?W08=/
ML^>P881B+@F;R54)>:&\EL9%+3'-M^_&DT6^?8%1V@)97ZWQ],<[&=6&7N],
MIMAC*'6MHBE4'@E3+/,O94V,]3GC!: "2_S."5JQKC=(,'$0FS&#S%KYZ4FG
MD2@Y]K.-B-__NBM T097)J]8B^E,@'_]<&KFY"1#BAY.Y)XNYL"?X_^ZM34W
MZ?7=.8CQNPC+I'D;CV)*#VS[<(_><\@[_*#>8WJ=_V!@HX4)]ET-B<"]WB$
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M3"&3?V52D-$8_$0S>$=,B)%&T<VT:+U10UW"V?D7Q<2XY1 Z0 @DROB?8^F
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M%1/[ZC?H'[L5B//YLC.Z>_1G'QW 8_U?; ?]B)IUT6@$=P/"NR.9:_'<I[^
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MI$0A#],!/V1&Z #U/.>!^FT0"-U,U?U;4S$ZP.:4,98E"# 7Q$'3#*^YF(\
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M=LB99XHR$6_A(B:U31PLUZ?@ATP6'+FUTZDKN8WPG&AV,%,KJ+F,D?A1C73
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M4Z'!$L0%EHZ6PEM*'%N>2:1YW[>Y=IU@%Z$[%J&AF(+7>PV>/RL[-8'MP$=
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M4*6 'K+;DJ^H'!W6FM4HU.%3?1%^+52(5KSHK*=5LBV<;CC@]J&,D8-"_WX
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MJV;!W?#LE"B%J4AA49@6]3DN(%&<04Y5BIFD,4IRMP2>R\1&#["U]/RCZSU
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M:P9AS2'HB@&Z<@#V KH/MK* 6I@;T(IS QJ!3/I (](-V H%6JG 5JRF.6C
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ML'5^B(Q4$>>Y=OVD=OUB(B'-J?Y/QM,$%P5GD55._X7U1U;7FB!H*3KL8&>
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M[Q4@V CI[MH3CXT^(];IJ.AS#WGF\74<O'=M2'&; H+R+":Y=B!8FC"H_Y5
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M3G^)RJ0;^H"HQ_OVT./>69>K)_E O^]#B+>L6I>4KV=4%5E:I"DL$&40Y4Q
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MLADENNF<CW[Y_>9C!6RO;0^JG>:. A1,IT\@](JV7'BNYG$6WI,ML*<[J94
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MI@%=*Q&"? /0;KQO\AE G->?]W-P](<-MY@-?Q:L_2S:ZW8^BZONN[CR_6$
M'>^W>3/#OOS$/$T8'KP-VKL1QQOQX!;$=!55=W+5<57RF8R)V?PQNSVATJY&
M'N,BI1)G*DR20F0)"2/8[NY1.J/O^6PJ];03B*IZ"?G7?\FC,/P/Q P#Z)=R
M@<121X>KWC7 B.8XA'91S,6PP%;;#1Z:7F,[K^IYUMQ?J#(HD:?PY#B-24.2
M03'WPY#ABQW[K3=URO7@HGEI#FQM P7*\TQK,$YU1*"U-\XQI6&.LR@/*2LD
M$PIT;O,TJ;$W03:$44?9>9#" %YVJNH'!>"NAQL \ ;F9V7SU<S\-*%I&YN?
M%?B@R?GY.^#;E!]7*^,D7"_H_+4J*_ .Y:G[1]9+37:YD,OG:L\W;]FPWXP\
M*?_Y?4@?H@,7SV&I1]AR/">CTV[CR8=.MM%X3JS^'N/9:YW/\RT?Y3W]2U;?
M))?EBSGK8X;]M:7(:1(%BG$SG9<E9GQ)@EFN<LQ"$LHB-\U]";![[Q"]D?6U
MS5&O#7FTVM '']T;A"R44D>9"<.,R0(3&A!,BR+'@@12?W\LX!G\[*,OT!Q;
MDAZ%[0HME@O<,N$70SM/Q",N, O8 E)31M]Z@&R)>SWF:".EO_.-@]2F/MAH
M(_J1$XU6MUTP!OVFJIZE"&<LS!+&B,(J,L7R14)P(60]VYPG>:%-9 ZRC_V'
MCVP,3<L+O6Q7AB(J:Y+FU"[KF@IH#%FY&.[5>!X@.TUV%1N88Z]%;<AXGGB\
MQ[O/N<7=HZ>?/KPGU-$9POO77.R&W-%2S$A*BBQ/8TP#KB/WK*!:K5*. R(X
MX7IA531Q=#O,\\?6K+J9HYG>809YE+W5TWF5K%$!KXI062]8!0VI4=:\O@S^
MU[CZZ6^UIO5%&UC#=BYSV)_?KH'5SH]S<TS4'/31,7Q=T=+[U^N%^+RDB]YO
MZFC_=1N9<BGB,&0YED02K:(RP460F9/\44@IT7ZNA)R+&(7)T3WC'NFKGB-8
M;;+KK0"HE>"J;8K1O[1NCJS%Z/\2L!L[SML=-C4_QQN#62L?K^KZR*M"?S0B
M(+=1 ^.\/L"6^9N_1K>-\?L?\D"+5KV_&\.K?]&\TJ=&C'_SM)<]*F2#.];C
M4)YN7WI4Y'9VG\>EY-IV=%'I!XKZ2]]7694Q&:4)Q22(A&F95> B#PD.@X2&
M.4UE(D#=_8:(C>S_WJVTSUL^&34T,Z_[C$ ;B@X 9N<-^X(!MMCL4+U"[0H!
M62D<&H2>%]1;.] !4A,W_SPO]&&K3XM[+AL>JFU++YFI@J3(4J)P)F6*24&U
MIYQ%QETVC8,)B2+&7 :"[E !J;3KD,]>OM=]WMUQD.RT^6+186K<(S=.;G=0
M'L\C,W=IO,D8S*-BGAIM>?QB-\6\6RVYE*+ZI%DS&2LSO*>9;#++ Q('7&NG
MC,SBFP4Q9CQ),(^C6(0L$$D(2C6=)C7RJOMA1?\4RS^A,X@&H+'323\"PQ2S
MH]FX^1W5;MZ0/_T\+YLG)1T@-*FFGA=X7UTM[H#IK)#E[$,;$]ZOZ*)I;?M-
MFH9;LY 412H#AH,PC#'AJ<)49 J++*=,)#15F=6AUR$B8^MI2Q9MZ:*&L)WB
M#N(SK+*^I(8IJX/ UHIJ(]% =8B^O=%._<-6*0<?.HDZVHC5*:+5M0Z=(TPI
M]OWCP]U*BO7J<2$^S>F#=<>(8S>/K%?-*9C[\K&N$M2$I6G)9[IE II"'!5Z
M6*F\R O3J-.BHC\,95^='H:D<NOP</2)TW5V&!)HIZ/#X(5N/NBORZ7XLYS/
M[_1+_4$KN2VDW/;TJ&99'C,N"X+CT$RYBXL0YS0)<9!$O% %$P$'N:-65,?6
MS"TEF&]J!YF=F^H=")C*=N2O4,< ZA4UVR $=EY!$GOR8^UH3NK2@F#8]VYA
M-U_:C[-.2+<M.TB6!90J@5G" TQ(G..B4-KQ34F2$A5F A:7'J4RLN)_*ZM_
MHJ?E<HXJN5[/Y79Z4KDP@RK*%VCRZ#A6=A;@8@1@&K_34K+92QRSD>01F;SW
MC^S3>*.VD4?$/-TM\MC%#@44V@M0<J5=@7=T\<^N+20)19*I&*<T"DS:*,<L
MS@H<Q6&4Y&F6)EEJW83@"('1MVA:BLB0!.Q7'\-B6/U\2 C-#O6%\ZAUYT09
MW+L]=M]T.Z\#7._LFPY=YU@ORW](\3R7M^K(Q*+JW6OO;_?UT!N5I#*71. P
MHF;ERP6F@9)8YDS*E+,T9@)44PMD8&35Z]@QV<IC$[RJ*W.@O_<+]$?-%O"<
M'QAVNT5T3#!A6NX?1WCIKR,8OLJ#H>2G+2%V!.>@S-CU.0XKO7$:/B[,4XRK
MVBYOC#$2YJ3 @4@))CS,,2V4PBG)@UR0,&#$JGO920HC&YRZB]Z6)F"Q/PJ'
MQ6I_J9 P0[ GGTOSQ*." HKH+A78K0;.]L7"_)LA608=G*,W3N?A#/&]X^(,
M7NCFX[13ZNG\^_.3R;O7[6#YIM!$BL_R@<X_ZHAW_7K]5UG-" F$I)1B&D8%
M)C(M<)$F$JLX#/,TI))D"N+C0!D8V>1LV$$M/VVSXCY'J&8)-3RA/PQ70!<'
MC+J=BS,FEC#+YAU&L(?CBH4G#P=,?E(/QQ6<?0_'^3D.'DXWUG%;Y'J]$%_E
MNFTXWX0",<EDD9BM!_TG)F;Z3Q[G.<Y3'A4L9'E.[5M+VU <>P.BFT&ZY:&N
MY==<;*<_0((L>R@MO"7? ,%LC ]L8 X&1-Y!A\/J0=,Y(!"Y=AP2T(V75::^
M?EJN?EN8LXGOY[1\K(?=-S]LMC/:SK#-K\W9LVTC1AE(D<8%SG-B J%,NR]Q
M2'%BDC*$<14EH!)U'TR-G2=M^M)5]4G.1RE*KM=:;OQNOC33U+L3)GI=YC5O
M9F?#E"R*?W>KBKWH!=GY-U/##K-'&^YJR!O^4,- O7/4_MB;@]$R>=7]D^%S
ME.Y0/H'S7-Q[$4MO4@OL \13I<->GNT8"=)R]3N=/\OKJI+K^DC1MI[YBZ35
ML[8-M^:,D;829AM96_KE8M7]U73$JSZ7"WFSEH\Z3 PS094*L#&NF##"M",6
M)CI@+ +."YGG@H'"1)_<C1U#:EY1S>P5:MAMCLIN&48=QZBN*&R9K*_J<UUW
M=JS0'X9Q5',.C3.]OE/+(/2MWA0P0GV+EP2/8L< TU>(ZY6W:>/?,6 ]"(Y'
M(7+I5F;KFK][_4+_:[EZKQ>5Y:,V<>]>F[I;3?B[?*@]Q]I[[[5-R$12B"3'
M45YHBY[EVK;+L,"1#)D20:PX26#=P2YG"F(>G-HD]+?JZO;-)7MNFM5KO[D+
M,HU%Z)_H9J^FD_G2<@R4QU<$W0B= G;WK=$.7@UGS1_:,&A^M6$1=3RVP?XX
MAU3]@>9]"]69H3?:5+T4P-/;K!<_V<VX?I KK?JF)O!FH5WQ>C_,%!#6F?LL
M9#'AC.HWR%-,TD#AG"F.XU2((HJB0'O$$$=XB-C(?NV6--K2=MK_&$3,SHKY
MP@%FGYP@ !L;&]D\F9%!4I,:"!NA]U7?ZAY7I6;K[4/?T]7JU?AHCR;?.2LR
M0D6N),ZSF&*2B! 71"9F-ER2$9$5<9;!E/HTL9&5NCD?+X8.G\+QL55A/U(#
MTW3+Q0.N1\48^E?HU]6R\GAVP48H;[H[0&IBW3TO]*'N6MSC</IO/K]?46$>
MM1W84K6%,;:'  >>,?:&WWR.6MK]24F CNR#  PKID_9@7MY)\3V6 )M*YS;
M\<"A!T]W2M!"O)W#@C;7NXY67??[5[6?7T!3$A"J<!@$"29%07 >I %.XRC,
M:5[0E'+8.-4C5,8N2EPN7J0.)DRH^=TD:TSG/?T:RJI:KE[15^M9[L-0V2VA
M%P, 4].:7'^_W?^YH$&)O U'/49CXH&H V(>#D$=NMAIC:PGOYNY#."5<>_.
M"=;#WH%%DW;KS^X +8O[,ELMAA>("U\"!R3UOQ*>D,QU_=M_W)2KW@E1]M:Z
M4U?!%>CV>5VMZ<*LG%HMEWH]>*UGG#RN;17I]!-&7[[ZDV]J;]M>B0;D/J],
M?D2&*56/)NJ((@@$(*4Z+Z&3<@T\=C(E.R]:7]DLKG8YXW)]<W?]Y?OMY\_O
MNX,.C&N/,60X487 )&$"%WDN<)(34D^P4*G]0.V#QX^MB88>T@2OD"8).?-Q
M@,.P\ETN'4SI=@5S.M5R^*8!1UHND=3Q/(O=JP0>9SDEQ_!9EH.[)CS(<HKC
MW5,L)Z]RL G-$^KNR&9;]D?YU*4ZPEB),!!28Z3,014I<&YZ)/*(TB@)TTS%
MTMHVG"0SLHUHB#3%FAUA@!Z=1L?"8GB1&68Y6G%W:+K8C]-R ^R(%_G=[,DQ
M'#Q9E;-2#5J7TW=/9V7.2K!C;<Y?[9;@ZC5D?_T@GY95N>Z5]\PT<)&9U(L9
M30-,1)KB(I42AS)+!4FT 1+ :IEA@J-7PGQXEB8DW1M, ,MTG<',+N7E#P>8
M;>I/V7A%+>5^O:"_')B=B)Z286>(39H5LQ-\/SUF>9>#=_'ARZ_7"_']>:%U
MI5M!.-/!!16F%7K*F[,D+$M#S I"0IJSA.56!1VG"(Q=Q/'EU_J4E*:)#%'
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M5V@AZVJ8EA-4EQ_;CKNV!30(>)31,,5*9!(3)D-<B$+A0BF5"<%S1JVFIXX
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MZF]UDSK3EZ[<L&5I%%Q!MG!.1@+.R7#T$?NU1LSPT[3@W7)DCAX<]*T;%T>
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M;4Y3I):DW-;\^@/4A2R*9!% H4K>AW;+%@N9^14SD4CD!9=%RCD4=LP"DE)
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MZ<#^=O.E:D.B,R10@3CBT/CX!41<&?\>IQ(F.1%91E7"1>8U'*RSN)>*!@X
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MI>=_G/^L-FWN7+6>;6?O>(P_\>CH5XH[BN"-LK4K#8J5,CJ6+YZ3^O))?:#
MOA>)?;)&:^1_0:Z@L_BI]28[@_<(TSU[]WW,OQW<%_%-R<>%NM&G W''_ZK4
M)W9??_%*GB2<$PYQP96=HI-"IA,&25Y(F1,D-7(ZE ]E9.Q[PLZL;4O2>_S&
M()#[M7M*Z#PO#3U1\VI@%T/D 1WO!I&?K$5>#)"Z/?6BK!>8J+ 4:UL+]T;5
M_W^_O-E^4^M]XY].L>T,)[E,"B1A*B2"B"3F'(>P@IAF*<\9SG7N50;C0WQD
M4U01!HO5\BNT&VOX^ XO0-T.66/!Y&MV:NK@EY8/.]T=U,#M>>GV%8B8L1
M0:RT!1_2T^8N!(!RE, 0LD9H^\#EKJJ\;B7]]H>]5U*SA*19IG4&-<H$1'F!
M(5<IAC)C*"U%5B*&9MO5EBW<[,I92EY&9$?/647N["-@56F$JBENKL!2>3<)
M/ >4F[V((KZ?<>B2W'6$;ZC^)6:KOPN21>OO=X[.Q$W]+HA[W,GOT@-AJFO+
M,.:[_ %;CF$(J*6P>QC3FF><2ZCLG$_$!864Y!0B1G)<2)6*U'/B9P\UGV]P
MT'"(#NVZAUZ7.OC%MDH$:7;^*^T-GYM*1X+$3ZF?8W% -IY2.\@62:W[*$VJ
MV XB/U=MET?"E/NP149GO[]E3Q6]-X]J=Q?),:)*%0QJ*LP10&<<$JQ2B EE
M+,T8+A.G&M80XF,? 0[;O'CZ_5XHNBG]6-CX68&S77 Z,_"V*\ 5N&5S:5.6
M-[;'_C\46X./;%NW Q_C8C@$GDB&Q(OTI)8E!)3GIB9HC<#:I]5B\6ZU_I.M
MY?OE[@ME_N77Y8/Y-KU>L/E]9>_J'^0_'YN(2.W6[!2J%*G@A4ILEQUCEIA0
MD)?&+*$RHT5!"L*(\JJ2BL/7R!9KQUB5IE>S!FJ6Z@V[_G'/'FCXJRXIY]_M
MD^8(OU\F-%LZUFMTLXLO\'(\3>8+O!?_4K&X*,8J*HO$U;3E9W&A/"I4B[Q\
M0+.3:]N8X*/:KN>BR8R41&JJ&(9))J5Q!%$!:9HKR'+;"3%)4RJ$<S.3H^5'
M-IR6'*CI>334. :AWUX-%\W/['2DNIP.ZO2.W?N!#!(SK-^'RTOTZ^!Q5HC>
M#AW'3TW7@>,LQP<=-LY_*F8'C9L_ET83O\T?FC$_[*N:I5J6>2X8Q'F1080S
M 0E),624\!*5!)78Z[CH3'ED [+K_]".!JV;')FCT*KE!3SLF(G1..,4NF[N
MTBB8^5FF\^TR_N\C,YN94?SORB;9F;_:7]1_/TC%V_$+;B_C&JF?1@]&H[;2
M.$7W)^BBT0.'6P.-O@5".[!=6[?(>C^_+N?;MFP#$Y*P3 B8)^9,B+A((5-,
M0BD4STI=*$Z<+JK[R4R0VF8L]E9)L+$L^+;^.HF,@\<215X_^U"1!#5-8(B"
MBFJ($W-><M_F9D,1&-#$[ B)F!W*^N2ZW(GLY-,3=QSKD^"XLUCOIX.39E;W
MZH[].-6^V';E(=1.O,MP"1$5"M*$*:A+BCA74J>%5RBJC]CH^7G51:ZA'9 %
M<QXA-[<EEMQ^EF@O\OB]GETDC)?$<I[4U$DK%X4^D:1R^9G R0^=<,JE0,I,
M*LI0EC(H4JO:*D\AR7 .1<%1@HVJEZG7:<:'^,BJ_E'):C1R<-Z;%Y!)H919
MA<"$<@%1:E.;4\1@P4B9BTR4*,UFYOPT7\DO6[;>OBR<SQD9 NH5X.KK?%D-
MCUAI4"\](M*ESCG/9099K@JS&Q42,IGFY@^$I,RS0F#6(/UV*7\&G%LVAJ&L
MC.LT!;Z9P4_G)8%YR3!$J$ V BH@2W!>"&Y+&C._[)>QT U*AYG6++@Y!F,!
M-.2.Q^5R)^*$F  $8LV)\2$][;28 %".9L:$K!%XG9(?A-IQ23A/=0Y)DIL=
MD1BO@G-.H#'1E B4:DJEUW5*/NUU2AYVG9*'7*<$B^9]G9(/O$[)AURG!(L9
M?)UR\27Z7Z><%.+B=4K^@M<I)SD^NDXY_:D 4Q!S/E[G7YJ-NUMLHG1*J>VX
MD&*=0%28<PS-:0X3K72)I>:".A453LOVSWKNF?CE.9C&G_*5^)G<4\T9G">>
M7I^;>/JA>S!H7[A+F=)+OG"/S>*G?/%AF]!/]@7PV^\F?P^]^^ATW$RW/T^.
M\,&^/SWUEY^=?KNV!47;IUNCIMMFPON#U>L9*8J<D$1!(9$]L<C2N!.9@+K4
MQL'@*DV+%QN=?I;KD;V)#VQIS,U#0[T*!ZB6],M-4C__#MT"+C_=FQGN5$28
MH]Y*8GZRLM0#4=]>?-LO.D?](OH_X1CU\SR_=&.H\5[#F$/4+Q,/.,7:>O%Z
M2->B*CVMLWZ>%Y>_,ZB>$&66:R1SGE'(49::DZD09BM)"L@R3"@O2IPIIRD8
MPUD9>7_H-HM;:;!<+6&'UUTRH<>!9!CP#J?*R>#T,^J';.WR"J_ J3855IO!
MJ6U@,J ]3G.3 1YV0AL9>+\35Q2L>D]1PRA,=S**@L3!:2?.BH'-RLTK46NS
M@U497+=L?;.NYOG*JOO\K5I7;9=GA62YT&D!=<(+B)A*($L0@H3(-&&$YY0(
MO\M7-\*C7[ONV*@S/\V1@JW!]ZKS_B_S)9#FG;#UQMYN@XUER+,?@2.\;J>#
M^)#Y[01[K+[46!D6;"IYS40SK\"P43=*C]@>W4ON6-W2W8A.VSS="XBC7NI^
M3P^+B'3\KP_F']YOU?UF)AB3I"@)E((0B$K);%>S#*HRP2)+:9[I+"20<8K8
MR/[E;JOM.IJ_6^J@(N]9UML+FU_L8"@8@4=^;QR"C^=] D8^59\D]2*'X3ZA
MSYUA>Y\)R:5X,+OAJ@FB_GVUD+91LG%3FDMW))'01&*H-#/:+7)SK"RP;51$
MJ2I9(GGIU''>@=;8A\>*^.[^HB5?>=X^>0G]>+GD8$1#P4^K^P"(./_$0\;^
M1(;^)2;,:G"2Y3#%P>V1L-WX'9NOJ]V]B58M#V]#F,WOEC<VPO6X7MNA%DMI
M#B/K]J^OV&:^N;/1KIE*-28X3V&IM%'I1'#($YG#)$$"I5R72'B-DXC&V<BF
MP/)9>[95(+NF7@6@N^R WRM>/#?]>&_'S4-X$<S]#$\DN+U]B^C01')$XO$U
MJ=<2'<[G+DY\ @'^T)O[KZWK4VHA"ZRA,$;2'&P0@82*!!8(,R)$+C+IGO"U
M6W9DT_;FX]_ 6MVS>54BH>HYI;LJ^P?SU#?6DTO=AX>#:Q,DI9\QL0)&=E:.
MN.[U2_:?GLX%.>+PP-LX_JW_U));M:K:[]J)B=?W6]>))<\>&_G+??OV!M1-
M@@]F:E[?KQY=$P1.R=K_Q1XHIF<T+DA"K]DD9V0)FDOR?*W)9I*<$:([C^3<
M1\*<[K^M5O+/^6+1:28UDW;R9TDUY!FVW5DX@T00XSZS(F$H88+2Q,=]/D%C
M9(5J*8+?+4W0$/7T>$]!X^:[#A383[5\9?5V-WNDB>0XGJ(PJ0O8(^)S9Z[O
MHX$#/FTDVSAY2G9MX_5Z;=YR-7;HU=/^(TVOS:I[P<V#_>#F-SOXPR9UV HD
MVQ?D;F7_Z>9QN]F:PXCQE_Y+S;]^LY_YKM;LJWK[0ZW%?*-NUW.A9CR5A-E&
MW5EF.V,J; [+6<%@80L52Y27)2K];LM>5J#1;^$:+H&JJ5;I83&NWU[X>^!F
MVO[GO%L_*UHQ#2NNG[DH>]$ ?P+=SS7BU6U9;"?D2L(K4,M8)_XU4MI6R+]5
M^1 =2:] *RMHA 6MM* 2-^*TW)_BM<6:R?NRPDP[^?>G>'%'\X5_#J[\CX-W
M:V97-YR^>GJ_E'5 TO%,>.K9D?W8AF37"-E6$4_ T)]_G\N^@;)NLE\^(PX5
MV\\..T@<+Z!Z2;R@L^/)!2<[0/:)TSU%]GYNX/W-^^6#4>0/ZKM:Y$V,K50"
MX40PF";"'"EU8B=7EA02AI7Y18FRE ;=R!S3&EDE*U(@#[P\.0&-YW7(,('#
M+SAJNE>@D3]BK-)#Q-@7%2<HO<S5PWF1SUXF]#P2IK]WZ^HJXJG*N+)S95;+
M:A/?S%*J-*$RA4+99(DRL\D21$+.$ZH3G*<)I7Y'Q+.T1C^]M93;%$I1$;^J
M3VR;ZB!7_^AY>CN/'I*IS!4EYEAM+!Y2R)H]80OD5(X)*YBF3BW1HV(7Y(RT
MR(T&E9LMC * KUO2R-XDD[YNOC4UW7@V\*)HD2S@>3J3VK^+XCZW?I<?>)D8
M7.?D\NFQ[MS#D)*"<<@DTW8H;@8Y9:4QG++4.<U0D>MIPVI'/(YN:U_M>MIQ
M9GXA5+C-B/^";'<3.U\4FCT,0524"!(;]RQ37&BL19DDW+<%WHN^HL ^>6TX
M<]4-3*GJ_S_C:YLF3#GH1;Q<Y/$@N%@S_O/$$,]B^I.$!8_Y^Q\5Z3L+;^S@
MW7E"<?I<[898;LU/F[FLILZM]A..WC+QK<F:LJS=5F9O)GF!%1$E%)HEQLOF
M.:0Y01!3+K.,%UJ73GTGHG(ULD>^Y\D.I-TS=;7K6_5D3+EA#-SO.?-J?AKW
M'?7;[A=#WL]>G^X;T7D5KP]?16<>IN44=%@%MR_V*H;UD1K]E<1K$S72JQG<
M FH0A+X=GL*(O6@#IT'X7.K/-&SQP".F/;*^WVP>E7SS:/-ZZU6K6%[UNV9[
M;:^ZY(P61:D2JF"2F'T-)9F$/$D0S'4I<L&9V=JT3^#(FX.QTQZ;K%WP8&_U
M -NW1JX:!-RK]=<>_S42R([GB3&A\SPO5*-@:EY S4QCK*[:6'W]D?9@M^,I
MXE$@%(Y8KKXW_6E=^5!XCESUX(7\K\8_K9:W:O5)K:Z_?ZUR2\7VD2T63W9\
MMT?F](5E1C8IACJTN<:?S']M3LWAH;IAIYI*[IUA?0FCR[?I$>'Q,QMQD?&Z
M8G>4.>BV_=+:DUV\.PK9O8-W?21X&M5!2Y;WRS>/55^6SVIA&RG<LG7=_SD3
M68[,<9FE!8.(H@S23)604TRTRKDDB,Z6ZJM]QLW/<*3L]%VG]7>]2]_Y*_]9
M"37_;C,;KL!2;<&__QO)TO0_P;IFPW9/\9]<X0JKFU\1$ZK0P59'[9GF2^-7
MJ-H):_@ MQ>P"IERY2-YO(%73E2GGGWE \6),5A>CX>9DT]J6\_;^K#:;&;F
MR(G3JB:DT-08#<P@Q2F&6F*,RI+@,D>SK2U3<3,9!ZM[^0@[&NX[H3$%\WJ>
M&]MNUW/^N*URN+<K<&U'HB\9^+MBB^VWJH/ ?_B9AT.8/ YGX0@$>$D&@6:B
MW2^6G.>ESJ&,;H8N6#Q/+\=9,F^#=5*"2&;I<.U)C<])L9Z;F-,?&C9:SYBD
MUX_KM>TWK/*4L=RX=DF!E:U(YI!H1J$H\D33@F%2$A]K<DQB9)-2ES:*FM;P
MJ5@=:-RT:YC ?BIVT#6_H19_AM6Q))$G574(O,@\JF,!STV=.O'),,U[H];&
M';8SU&W\<\W$]LXL]&9EJ^IGI9)$RH1!G MB=G1%($\PA[DN)"NP3D3NE:76
M1VSD[6U/&K2TP>\U9<\2T%[$W%0S%@Y^2AH$@;>RNL@626U[24VJP"Y"/U=E
MIV<"L^[G2YNB\\%Z_KO[B^;6?F,. O]0;'WWYVJF.4I(@JJ&'^:8GR$%::$*
M2(B05+&"2NK5SM"1[LBJ;KXGV#,5WQ$O-^T> 04_16\8 !4'!S>:YCC#517,
MNP*6#6#XB)BL[R=XK,1]1ZK3)O'[07&4T._YN']D__4WF]DC;Y5:_VV]>GQX
MM]P/77>,ZO<L,7:.2TT96-*@HGT%WJU6V^5JZ]CNYQ($EX/VD:3WT^P^P2-/
MGG>4,2A W[?N9,%Y!^&Z@7F7CP>HX>J+6E35KDUJP2=V[UQ\>O+AT=/+[A_8
M\@FTE-O\&&!I>^C>2;D=M&ZHR)[Z%B2MGX[U212F72=7G$ZO^@0ZT*C>#P8&
MDM1FH]3-0Y6\L_Q:;:";O5G/RT(SI3.H;>T%8E5"J&8PS72:HCS'*<$^#F\_
MN9%5L:;F&4WJQ\<QLA1-:L\H4T77IK8WE&L/=Q-YY_,3,U8(JI_8M.$H)\&/
M0E-N3X5.^3@SB<K\W'66/]L.$3?ZUTW=5_-:&[VZ%N+Q_K&Z]GJC'M9*S.OD
M]J6\OE^MM_-_U?FN-,%:% F%BF0%1)Q(.QQ$0:Q005"!=88+']LP/LMCVY>>
M"875Y;GO))'17Z&;^?JY7HR?">R?)%C][>#T#RHAX$I#(T8]L- \8R4!'5%
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M_7IU?[]:5KUJ9Y1Q6I8YAPP1H^ T22 I$@9%B;$F6N1$NY<)7:(V\G:\:U7
M]O2KFZ2* ["Q+ 1TECB+G8.5B(F(G^G8@=$A7;6ZJ\'X$AN,@.X8,4 9V-0B
M!)RP#A27A'5J''%VD>G[/5R2YV2;AHL/!4XR9O/U;VSQJ#HM')IVQ?+&-H1X
M7-M.W:_89K[Y=;GB&[6N(FSOEP^/6]LO8FF/T-57Z#5;"#O"W3:26"T6[U9K
M6W$RRVC*4YM_J$MD#RRIA*Q0"$IC.S-<<EKD?F.0Q^9X9%-K^0>5  >]7$ K
M ZB;Q-12@$J,*] 5!%22@$-1KD!'&/"[%0<T\OB.8A[]&^%V+/NIWK/?!O(3
MO6+_6=)3P1YK$/7H_$X[Q7HJ^(]&8$]&.$9 [-<EN[?)3?]2\LU\4^72WJ[5
M_?SQ_GHIJX\VMT.O[67[)[6=%3+#B58E+&DN($I5"@G+JW37TNQ,1,H\#[@6
M&\C6-%=EMH?+7T&'.:#G2\-&%0JWG R)M_F_"I4+@G)&;:^F B+.."2R5# A
M0J:T3/.4E>$AS''>P9":[CWL4FE5Y1>\*/XA8=%141T8/>TBW#('?FG8^TN5
M\U$_T]X85SQ>@4\]520#8ZW!<(T2DO7GY@4CM\'0]0=XPY<-B!U=/Z[-YM<&
M$9,<4:ES8^[,'RBG!)),)C!-,2[2DF5E[A,([JX]>B2X)N81[#B0W"'*$RJ-
MG\FHJ81$@P_?I'N@)E2N\'AP(V/4@/ I*7JC+0</3!=9.<7G013EY >&]*,\
MDW_;UL14_?'NU(_MJX6-\#&!LK+(4X@3:CR>A%AC0!F4G'*>Z%1DRFM&0@ /
M(WLY7\0W)1\753;6N\>MG0WV<;Z<WS_>@V<IY6"7EU1U?K%9Y5!8P[NH3K[5
M9WQ+W@->B9L3-#+0?E:L;8[9EZ._70&NFI+UEK^F=2:P+(**Q^A=-(,0BMI=
MTX^#%^BZ&031Z6Z<84N%F;O_4O.OW\RQ\]KX#^RK^O1H3>B;^>+1_%L]N?'F
M<;O9LFJ*QCX;=E9*E1')$:1*4'O>KHY[QNYEPKS!DJ<*.<VN&\C'R&9O3ZA*
MI_RS81*PFLMF0.SSF[3PV;&A;\/-VDV L9_%:QD"#4>@9LGBV8Q'[C!T!1I6
MKSJY_?$,W4!P(AF[4"XF-7@#H7IN](8N%]C7C&V^V31_\S\[#?T[6U@MOUTM
MYN)I[T8D.LEP1C#4VB8!8'/"(^94!S7*4YZ1D@CNU]O,A>K(1LT2KRME[ \=
M-CP[FCD!Z&:9HL/B9X?.(G(%:A[ [\W_1_&QO*2/U>O,B>:T_<Y\8#CJ>>;U
M<'"9CG6];'70M1#K1[;85]>)'&4D*S D%&.(>,(@X1A!K%B2FF.@^977-7@/
MK9'-0TNY4HB6MDNIG#=F;K8A$A)^%B$8A)!*FDOBQ:N<.4MIZDJ92R*?J(RY
M^$B84G?[6=QLOZEUM^W%K""IYH56D.A205083X#E3,+$[/M)CKC.4Q5PK=A+
M=)I+PQT+=8%=VR)!&@;\-+P?0#<='XY'D);OR5H0*L+@L U./#UW$C&2IO?3
MFE37G<1^KNUN#_GI^V:]G=VN5_)1;*T5^:+6W^=";9I2$JI5B;%1<9R;G1LA
M4D#&,PD935*M:%ZFU*GG22^5L3?NFFZU936$/2MN^C'J5^5HDGMNU"%".RNO
MDU!]2FL6Z"BL^=M>6?O7GD1)G<1KE=/MP_[=_"L%OU5KW:0C>?3Q/_'HR#I6
M[Q&6Y&I]7R4;-*2O+K6T=Y*[7\4BB.RG7.'2>C7P[Y$IJ'7_J?4F:]K?(TRW
M77_?QT(O+MFFRFYX=A-6I R+K,S-R=1&ZEG&(26"0Z%HR4B*-")>[;S.T)GP
M O+]LOH^-O,V=WUVZNO'U_X)5^>0<[U#'(R'[SUA=2MH28Y\]=<K6+3KO=-4
M)K["ZQ7U^)JN_^,!*45U\P+KZ;(V':4H\@0EDD.CJ *B7"209CB#">5*ZIP1
M1+1S =KQ^B,K;$NP:D;BD9%S HA^/8P@GN^IL2-92-+1"1$]4H^&B1J6@.3V
M,OV2C\[+T9N"=.*QZ1*1SO-\D([4\[&PO?V+O?WB3Q_4UFKBC7Y=-3AIOCMI
MKLPVC@5DS&[P%#-(&:&0)SE.<)'*(O&ZBN\C-O8N7Y,&#6V[V=?4_3;T7KC<
M=O58(/B9EK/R1QQ3YR-AI#V^E]2D&[V+T,]W>Z=GPO3ZD]K:&RMSK/X^ETJ^
M>OIUH^3[Y?OE=[6Q"4#78CO_7@_R:B]-"%99D68%%$FN(5)20(H5@JGD*<>4
ME:E?FR9_%J:XGM:+U9\;8-\?F+>< +9CQ<\<!*#L9B3&Q<[/=!A>ZNOKEAL[
MENL7RY!!\"]@QQ/8,S7*?58X)I&,30 #DYJ@<(">&Z8!*P6<4+H5%DV=T[NV
MS*DZ=,^D9EIB<U81F90092J%K" 2IDR4";.S '.G9!DW<B.;H3>#:KD<$7,X
MV43%P<^D'!1>M7#LB/M$6ER_0.ZGH*BPA!V*!L'C=U9REK;WZ'1YE>E.4LX2
M'1RLW)\*],<,YW84^6IA/O3U_=+8#6-*V_D^[XP(7]A"W>A;9GNPVT2C[5/[
MJ1G*4YDQK&'!%(&(, 1IDC%HCF<E0D59I(77.6P(,V.?TU@=B5W:XHX]C\;3
MJ,E[^F=#4'?TU";"TM-G.^ *M 2K1N7U&+#* V[1KID#-7>[3T=TW2* %,N)
M&\+*M.Y<!-".'+L8:P:X>!_5O_[%EO.EJI?L)#=2A+#QZ7B:*5O?IB$I4@)S
M66I&18X4\2EQ/4/&1\^"JEUW=(&J"'OX+N>0<7#@(DCK9U4^OOU__^_ZT_M/
M;\';__OK^[M_1#WFN8C4ZX2<>W8ZU^,"]P<.QZ7/!BC9N[E\%'.V?FJ'!#:Y
MC:_;\4M91DI,",1YF4.C=H4-YV)8<LDSF62R(-CY%'6!V,ANPHXZ8.T RX>:
MOH?J7<*+ECJE*$L@L_5GJ-3$YF +@Y=B.,M30LK<PSA%1"S(2$V"F8/9BHB#
MG_G: [";>MJ0!J\OC*?R!\+CQ!D1D+#S9IUR8QU!??8[<@7DHP),;VT5G=GH
MGA0S/ZP!5T^KI03;;\KX[.M[M@"K796Q>!+VP7F=!JS6_Q%IEW $K'>WN+3&
M=+N&HS0'NX?K,\'3HE?WZH[]4-TIQRC)LJ+@.2PEMZ,0S0&4:*T@YP9<)5).
MI=?]P$DJ(^\;-4VPM42#Q[Z<AL?MN#A8:#^3U\A;T>N,>+ZZ:/!"9CV?%RS>
M<.<3-*:>YGQ>S!/CFWL^'*J;]6FLF1HULS?T4G)J_!,F("(*0T*HMFVEM=0)
MS3E&OD/;#R@X?3F'S&=OZ0%5$_15QD,\).>4F<,CS'-L3I0J+2#76D.I64)I
MH3 6GE;*'XTA]BDF%JXF*5A"7V/4"/?V@G !QN>D"-',SN'J$QN<DZ(=FYK3
M'PLS,F_O'Q:K)Z6:5/RJ5OX5VRAIIU.:]2OW\M.JN@Y4\MIVZ=S<K;9LT?V]
M#9M_6FW_H:HNGU^7-K:^7ZE^J$I6OOO&EC</]I'-+.<:8Y9KJ-)<6B=#0H*$
M@#*5I#!G5*Y+KU#WBTDRLJ'X=;G>L6);A.QX#;,<+_?"W6S4_XC7Z&<-*\JP
M(MUVM@+7Z[7YB&IF^[3B@(JU*V,VQ>+1MJH -7--IK81R9S&ZJ;/M5#QBBA^
M&OPCF?*7DV/23>/%7]?S[>GE&0J(I]YH;7BM4O*;#$^F%5&E\2N31#*(,EE
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MJE_KQ>I/S\X?P]Z6F\,]V3OPVZAKA;!_@K==X/>L@/HC]DT\^\?N$_'\\RA
M1?+8A_$RJ0\?!;;G7GV<14-RZ__^\74[ 5!F')LM">I$%Q#IE$/.=6G^*#2A
M"FELC:%K1OUNW9&=?DO()W=^+V^I2R4+FD)NZY20I@@2)$NH2I3;P65,BL0M
M+#) XJ"01[C,#I<687+X&4-+(WH]P!'?_54 ^X]/F/M_Q.-AQO_QKX-ZJ^R2
M&&[T)SM;=+DU')J/?VU;G-53IF8\93R5R&8K*G-X4%A"AHAQ424V?FF:%IAI
MC^1%/^K3I"YVV+&.RW*UA&+/T;ZE9-BMHSO4+HH7%;G ABL':!DF8(>+76?#
MJV84WBA(>=RDC8)8V U8+.1\.]5X G"A58WK:E/VJO&4\%FS&M^GPV(X-P_5
M=)'EUVH@JQWF/..*YSSE!<Q064*4TQP2;,Z72:Y05NB,H4SX7;H<$QG=T=B1
M!(OJ^D 8HGXGOA/(N!WCADGK9_;V8E;$ZN'S\0Y:YT6)='HZ06#2(]%Y 9^?
M<WH^&1@]7=W?KY95G62MR>\WFT<E9XJE+"]MHT=AAT7PDMJ86P$9044F<JXI
M+GU2K,_0&3U+RE(%&TOVJITC/*\HAX\-/@>98WAE.!">@9,:@R\U!C7-*U!3
MC1@,Z1<K5ICC#)5I QC]HAZ%)BY\/+ 2N2IV?,?FZ]_8XE&]F6_$8K5Y7*M9
M1@M4<%% H9$YEI<Y@81@#C56)==<)I)E/C'9LY0FB;>R_EI;3VS<5#2*Q)X'
MAXKD%;!$0445[,E&K#2^)%FL(N.S=*:M+[XD[E%I\<4')NH)],Y\469$(2J+
MTG9<5@E$),L@*12%0F+,LUS3DGCMP4%<C+Q#FZ\.&;DC4(6EF^:/CI"?5;C0
M#\@2?\%V0%W97ZH;4,7#S]T,J O3X%Y !XL%Q#9_N_GXMR:437B&,HDIS#*F
M(9)(04:)@@HCP@FS#8"<QLP_6W=D>V$)V:DV0R?Z=H!P""V&B>>G[)5D%V/Z
MO9)XA/[") J+[5E:D0)VQVSW1N0Z'Y\NY';,XT%,[<2OPYP*.T2N356\6[UB
MRS\VS?= XT)2I@I(I9V/DMJD)LD%+!#!F-&TR&3AXSB<I32RLM\:8,UI?;5N
M9AE>2K'UA,G-)X@BO)\IJ$BVTH+M"E14(U[X.<L6:5\_3V?2O?NBN,_WY\L/
M1&MQ8+[K[VQIPUNVMIEVFUNUKL(%;^:+QZV2,V/7E-F2$13V,(\4S2$510HI
ME1Q37 B,V,">!Q=8&%G9[5"">9U0_Z#6=6@.0"!KXE6X3JX6"[;>['_O&;D+
M@-W-1HP+II_Q.-TTP; #*GY RY M_JK#@5>@86K41@J.@(S76>$2 R_=:L$1
M((?>"ZXKA1FO*I19!S'?F!/+\NMME7=:14PZ3&QFFJ4:EX+ 5"AJ(Y$)Y#J1
M,%,LSTM<LCSQBE^X$A[94%D.JDKKE6ZO%/1J#7BK=VS/2L $:A=@W8S2&'#Y
MF:*Z?6G- JAY #435W60\ZIKI"*F9OJ*'G-4M0O9Z8=6>X!Q<GRUS_.AG1>O
MI5Q;0U;_[X/1IG2&A-09P2DTYJ*TB54I9!AI6*8"881YJ:E34F4OE9$-1M.H
ML*%XU?X +&UPLW0\S_3CU&\2HDGOI__!@@=T:^P1;$#3QE.K3MR[L4>PXQ:.
M?1^.IY;9C)4DRS-50E)29$XC.3(_V3^H%&61,X3=IA7T4GE)M;S[<S5<+;,!
M:NDE?42U[!,\BEIFHZAE]O)JF?FH91:HEKM-^9%OU'\_JN7V[7?SQUU54<_M
MK*E,4Y@;-30.M\20$\(A8=KLECPC)?>:(7**R,A*N2<)*IK@]XJJ9^_#D^@X
M>LT#9?;TD'W%]7>%>^2)Y?:>(C&MB]LCY)$[V_?9,&5\-U_: V&5D_=ASOA\
M872^:7*R>?.H/JD?V[L_U>*[^KA:;K]M9CA+68%SX]6R,C?;IY20"&[^2*@J
M"),\R[V">;X,C'^I7_@IK#>";LH\)BY^BMYPTB;([IBYLN%];J\VYK*YUH_B
M& ]%())I\"8_J=D(!>>Y20E>)\K>W]QFH9PK*7("L2 2HEP:;UP*"E5"1&K3
M>9/4J5UB+Y6)=_]!N[[7+=]@:8?N^]'O]GHE&F?G?XD[O5XQ+^S]4>[ROHAO
M2CXNU(TV9F"^-0;@NVTF=#B5I/(R[HP9>&5X_V,F4YHE1:$@XU1!Q!(&"3>Z
MB@LE2<FPS'.GWL8#>!A;DQN.3H[.N;(3R#UU.P!E1\T?%SM/N]"!K68'5OP<
M8]B<%(!E"E1<Q;0=X9C$LBP!'$QK=\(A.K)* Y8*K+>S/19;3V6N-J\?UVMC
M#V=%PDFN"@8%%00B4G!(2)9 I45"<YQC2M+94CEV03I#Q4E[=H7+GGV-ZIZG
MBSU1SW*[,\!P+J3$B8(I4;+.OF!:*5CPC!>,:9%F7@9["#3A1GDD<-SL; 21
M_6QI+6V'XA5H:$8L3>P7*E9]XADJTQ8I]HMZ5*EXX>/!;5M7]^I+VTOIFMO1
MSF([*Q$O19$5,+<3I)"2&K*""IBQ)).8((7\)L*<H3.VT]3M$=64>O;=BWM!
MY*:E$03WT]*FA^I>]-];FA']F0M2Q6N;>I+*U"U2^T0]T0ZU]^,!-0;OYNN-
M.5K97DO-$9RGI9:)R.PD!UO(E-H!BCB!HF R4VDJ2$F=2PV.EA]9*2MZH";H
MD99_C$*_ @Z7S3<@N1<KI.S@6#Z/ZH-!<H85(3B]1K]BA+-2]-8D'#\U76G"
M68X/*A3.?RK &MPLU<<O-Q\^M!VT!"(,Z;R ' L-$6;"'#%D;@P"IUE.J4JT
M4U+@J<7'=I^7"AAR5\ 0]-"4YP@XV($!<GGZR!V10JS <]D\;,  &<,L@-/K
M\[, 9V3HU?_GSTRG_6>X/=#]<Y_Q;X'^OB[,NUO+V]5B+LP1X':]$@'-T"\N
M-++:-_3!W9K)*H.UX:+J-&I94?+1)@%[MTF_C%"_J8@.CJ_G[H5+U%;JSF('
M-56_O/ID[=6=!>TV6G=_*+SE^O7R>1O54PTW<LXRG5,)2TH*B*0M6$*IAFF&
MB,2,IS3#7FV$7"F/;!,^KI;J"=RS]1]J"Y@0=NQM0"]G-Q#=3NZC0.-G$:I>
MRU;[C]LTC]S8Q%OXB'V7W>A.WF/9"XY3_93]%@BS)&_4VBR^G7]7G5#A#'--
M4BH)I"5.("HX@I0K&]=30F2%*(E?_?))*B-;B#W-7<#]R<] G,;&S1@,EMA/
M\3O"?K@HK+=R]PH329%/TYA4:7O%?*Z@_1^.5I6\:4L)/ZEM'2K\L-IL9@7'
MF.$L@YRD)40<84B%U5>4E%2I4A74*]'8F?+(2GNI=M;6*#<!ZU\L.\/KC\\
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MS%F%;0^JF7>A2L493S664!<LA^9$D$,FA88)X;+()=924+_, '\FQD\;L%T
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MHBSRE##I=(_K3WID+VS'")A7G( M^P$,:<_(J0>4;G9V'(#\;.<>FYH)8+@
ME@V;BV&TK,HVJ4;&W2JS0LQ&3O[B1S)M'H0G-5?^@#PW00$K!"98M:E;ATFG
M,T%EIE-B>\L7R/R12&C^)8$Y)6F15=WGJ4\Z^!DZ7@8C- N\3OM>-#2]DSG/
M0>1F&R(([F<(]GF7SS.](V9B]0L5*R'K#)5I\[+Z13U*S[KP<?^2L!-%(;]M
M;I5:_VV]>GSPK@5S7&[DG?QLK=)O&V"9 14W[C5?KB#UZ^Q(^/CI[__O[MU[
M(\>1/='_]U,06-QS>P!SKAZD1.T!%G"]9HU;53:J/3,XZ#\2?-HYDT[Y9*:K
MV_/I+ZE'OJ4D*4KV7&!W3G65Q(CX*2,8#,;##IH1BKH<)?>JYK*E,5D9EZ/0
M^_5;KJ]ZC&M^>-A\7JVJ0K&GC?64YH.W1E9D36PE'XR;J4F62UF^K(^.[OU=
M0R_)?%EA_<5UT\NADKK-7CXKE-_(Y<.EIINT?%:$@P'+YY_PT)/%XO,?DK\8
MA_FC_D(/Y4I[><UUL:W6]*PQM@XM%F!+&^R(.RA-'P 6*A1(=D>%ZA [X+0T
M6^'\%*MOX>G4S$*\ Z6S>=XC*>?Z22Z%%-=+8?J,FUD*'U=2S#?7VFI60;/M
MX/-<1B)/(8[2""(:%;! 7$&2*QE)E8N8V6?J6!(=^W*PH@FV1$'%UE-?C,4?
MOWYM'@L51\VN&:BZ,K4L@!.4/+*!;$%R2!$: 2R_O"$KT +E$SD*W9MD9+O6
M=)E'CM(=I".YONO9AIUSXRNN[^BK*>+2U/3?K%ZD^+H+4NTF2N^.KXJE2A6$
M0,R-\60Y@RQ%"<2)Q-@,A$9N$Q4\^1C;'VJX @U;E4HTC+4]W5S[F'L";A?C
MFP!&1P/<A^ >4P>#[8,&% )!$ZJGNB<7TW9='P;525_V@<OY#X/9K;KM;J#-
M5I3(2,&$I%Q[?44"BURF4)(D8U%,\Z1(74?!G)(9V2Y58U'V-<:S'7 '1G:V
M9KCD;J;$0VBO23#=,@6< W.&R.138+H%/3<#IN=ISR8P+\9_N54_Y'.YVAC+
M\*M\J!K,S'*61R1& F(4"XAB[6*0M(A@QC')B*)QGEI-4;A,:F1%K0G7 ^5:
MTF#=T';LY-(-EYV^A@'!36=W\N^H@E\OR>_>>.6B:*$:K'03FK:1RD6!3QJF
M7'[#,QVHF5UY)U?5%<1V%V$R8Y@GJ3XB)(E68C-$,E<<2II3DDM%*.9.R3\=
MA,9.]6G'J&JZ]668]W;;"96= H< P$U]_61W3]NY(%BH))TN,M.FY%P0]B0!
MY]+SGBG:_%&*EX6\57^CJ[FQ!S=+K1URO:D:RFJ7?'?V%(AF,27"=#G")@4G
M@RS)$NTSXT)R1'(4N^9=VU-W^77[)5,WO)A=JAXA51U2]PXG5Z#E$K1L@I9/
MQR1L!]3MC,)(2+K9B7T(NZ'2!_OJ'T8YWGO@$"JMV8'RM+G*[I"<)"![+.%Q
M9?/A93U?RO7Z8_G$YLLJ6FUR11^6\W])<2.TES)7%?5:/Z_Y?[_,5U5L=$]+
M];^]/!T$%>I[<-.O\KZ\WK8YFQ4XP4B;+2AX8L;>$P()27,8H804".<)%E9%
MF-.S/G:XLR8*Q(LT'0]<.\.]P:>TN(-ZMQ_(S<2V8H ].<!.$+ O2;N-M;*
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MXCG-1)%875WUDQG9A6OIFA+LNNNY1V^,"T#U6\YPXKL9O2DD=V@1% 0!O[Y
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MAU-;&_D"*6\OJ4E5V$;H8T6V>L<C9Z/M968&BWVL3B-MSY]<;\!IG$-)(W/
MXT(?\%(%BRA+,<E3@F*KEN^]5$97X)IL/<6N)NR06=")3;_N!I/836G/">N3
M3]$IM4/F1 CI_7(DG#ZY6QK$):%Z$QXZ7YXNM>$2_P=)#!<?#IX?MLN0;WYO
M15;@/"()3",B(2K2&-(D3R'!2!4QH@4A(E!^V#'MD>U20S58DM,)=!8&:CQ
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MI^:;K^5Z/4-<12C/8ZABTW1"\10R+"H5CE(E!4NR8K8I-W1AK;O-TD[F;$O
M_@@G-V!>#8UQUM)6]HA2S DO8(%2 E$BM-%"5$)&6*318$A*YFC<?63W.*</
ME]W:'GE(Y'@6U\(T\YA^,93^=&7^<_%2S12]*U?UG,K-9C5G+YLJ:V135B.;
MRN5&DUN8Q]JA'D'-U)'DX8Q2N_#4)NA(H#,&Y_@)/_/R2?L8B_)9BGO)'Y?E
MHGQX_6$J0K=7QBAG$2DD++)">PQ2<JUR2!^\4XH944E:8.RB=Q?HC:R,6^I@
MLR7OII:7\++3U8 HN"GP#H =95"3'L%_L!0SD+9>HC:I"EN*?JS7MJ\-K0']
M_/2\*%^E;-R5CCFMB^H3ZS_=JEUF57W4^UBN-^M=Z6&&D<*J4# 7L79-4LGT
M1IT3*'D>)9S&BK'"KS0T,*<C&YB#BM&N0<Z7YHY._.WL3-:[^"*.4;]+U:3-
MAQ#5:>HC?9YKS]:P>=5DK4Y473H2H,&+3D/S^4:UJ"/!W5VB.A9!OTU@/_E5
MGU=-,.^Q7.CWUW5/KYGV^$2!B@B*G"B3A9I"0E,*69$K43#)*<E=CIF7"(Y\
M^+PWKX#%?E_4)_FO?]'E?"F!K-O1&?VO_^AFE"]B:6=;0R+D9B+W$_@-")_[
M07 V<K:2!;)5%\E-:G)LA3^V'-;O^1F *C95YUOLC8(N<A[)."+Z>,<91+$J
M])^2%*8D3C!.*4FE90>O7CJCQX3K6"BMR+HI\WE<1)J*W/BS:8XH1((4D$21
MA"I+"WTTCB(NG7)%!J/B?9T0#A,[JS984C=35@M9TQMG3GBO0($LV'D:DYJM
M7C&/;57_P^Z]->ZD7/UE5;X\5]MVY2K5MN_'9GG]M+%MMG%AF9'US5 '%7E0
M>Q][#( ?<O.R6C8G#/O.')> Z=?)P)@XWED-A\.IHX>EH%XM/BZM/5G/#TLA
M]YN V+[BZ58\RY4^OS2M ZNHU:WZZ[K.[)PA13,:)1F,"QY!E!82TB13D$8L
M0:*(BB1U;)C>2V]\-Z.E#A951\N5H0]+!5_T?WCMM+WP)45$TSBGD!:9U-Z9
M0)!B7L TBO*8Q#26TBF^%@P\'V]D6N@LG950@#@Z+5LL*KI7=2S>@*%IU\Y,
M0/_%1L90?DPOK6G]&1NQ3_P:JY>&C)GX56IOJ3KD??GY?6YRI.:;Q_)E\T-2
M,5^\?I):M9[F2Q. _$+GJRJW:L9$HK 2"90T42:!1T"M_1A2;59Q3B5AN/"9
M.^'#S 3I/6U?>3!?FB$*J_E/NI&+5_ H%P*8 F_7@,T Z.WLR#1PNAF99N;"
MCJDK\.5O\/M-G4-<<P8:UL ^;\ P5V?'AI[$, 2AH*,9O!AY@UD-0P [/[QA
MT(H^!0#/DL_I8O-:W[284'<SR*?IOC"C49H5&4\A991!9,(LI, <:L^'<$$9
M1C%RR?*_1'!T"[8CW [U<TDAOXA7OTD*CX'C]5M+&NS!T$XB^W@A..,#ATO:
M?$A8?&>R;A/C3>X[K6\<37;\%C=^\O,!383ESZ&2Y&UQZ,^$O[C*A.GNMA(=
MYK1;O^6;9L4V-\OU9E7]4*I;Y5G,4YZGII-V)O21&"MB9LA3J(U@RI*$Z#,R
M=4NM.J$Q8;;#UW+Y ,V. 0P?8,?(NKE%=RQM/H>8G0LV$ ='(W<,P;T7!!ZI
M59U"!DNG.J4P<0I5IXBG:5/=C[K'H&OWR/@[]<V\:1%5%;)\FBLEM37@\LMR
MES]C&9)V6W5DS6V.!%MNP(X=L.-'GQ/*<K,L-PX=I!W!NQRV'@\WKU.4-61:
MYT.F#?E#X17G=B0U6=C;#X+]*+CG"AX'GNOK;W]ITH()2J(LSU/(6!*9-M@$
M%D5N;I%9) E'!8ZMXK='ZXYL)0PA8'+WY\L'$X71?US/1148*Y<.KOL>$!9'
M%C_QW)2YDLRCV]&>) ZG#3^)_(X5AE:@P\$IV[VG@+W'IW/W3WD\\.O/_+.?
M W^S%%+9-;G^.E_*FXU\6L\RF2'$HP*FL100(51 FD4QY"3A+!$*1;E3T9(/
M$R.;B!U+<-'1T/TWPPNHF'$\ WB!;G=(&!M*-W.TAV)76WPK%)V/$4-@"'3.
M\&)ATH/($)".3RJ#UO),^)5Z:7EXH=6F&+XV>?'K>O"?7O16[::(SF*EDDBR
M#!:92"'"",."Q00F N=9ABE*<J<0A3\K(YLQLYN!7^0?;2VCB<AM] ]<@B?M
M_CRN@=0,"?!-@_\(TO@*F!<<IWD/^ YV-FT:=-TL6\V3&=QU=-&]9>S*U(@R
M">[H7%R!+7LFH+(W+CA@2O)@E$(E*_LS,FT:\V# 3A*<AZ_H'M6Y7XGKU>K3
M2WUZL8W:'+XU]GEK5YP$6I+VD9<C 2]'5OQE<[,!]RM:&54G\9P"(^<E\0I\
M'"TU66#CO C[@8N.)]PTP8P+_UPE3EP+L3+=\_4?;U?WY>_+&24QY@6-($8\
MUL<51B')<@&)0GJG3S#-[';['AICAS4KJJ A>P4,80T+,*3M%*D/GWZ-"B2U
M8U#21V!KU;(0J4?']-NUCND_['2L;\U)E,U"J%;K;![U'!]Y__3P;?D\_[A<
MBY7XLJ /3F,D3]X>>V.JIB_>SY^,&?_V_>X&?&Q"@;*[79NMX)<WJN$R.T8'
M>\0%OQG:@0+Z_8+YSZ \77+:692=(IW,I.Q^<O"8Z[HOV _Y;/K2+!]NEJI<
M/55[YX?7YA]W]U!$\(1BG$#,,-,GW4A!PF,.%>$LXP5A/$H]9UN[\#'AA?T>
M'X RDP*HWP(-0_[#JYU0MSO73H"EFWTXZ/)04P5;GO:!O3+3+-LG)AI5[0-1
M^/G43ER\U5!J'ZAZ)E%[+>=GYGZ<-N\6"5<IR6*8<)E 1)"$Q#1N8A&-4)JE
MVN0ZQ>I.28QLG'[XMS,_ X>=:1DFI)O5^#%R%_-N60*I]QD"DVINMX#'2MGS
MI,<]_I?Y3WEO@L&W2_GW/W\L%POY(+]^_=A.$\A1(A1'L."F-DNA I(D*:#
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MA%*B=@;T$9):2&55MS3UE-  IMY/YC##O?CMQ(_OYG;7>&)>6!Z3)3%!F6.
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M)OL&<+0EHVE$4#%+BR0+0R33G@3<B$FV*8/-(AJ_5YS=_06KY[HZ?$C$74G
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MIRIJ(RY89W% G00-)N$2*N=8V92P)A1& (R1-,K];A<?BK#F>@!60\^31-N
M=3KUTS$">W;=D?F%GPWC((=R"<"C8\93:>N3++'"*Q)Y!&?1T&95N_)@*R'M
M]00\!BC'R[H)4[+)QJOAZ'(.:2!5Y+9LQ#(@Z&4TF@3J$DD<O \B2B]J5[_O
M(*6]UH$U87.(O"L"Y]E[*[T[_:__.GG_YOWIR7O\_MG+__WWL[>O3C]^.OT_
MO[[Y_)]W.:S4<^F15SY3+Z:G,%ZI1]/:[/5%2]NODQ$NEMGR,/FV@X\1-L7
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MC,F6*"^3X (0T$ E#=EG6OM>[?[4]7RUNSFL=J37)A%[$F-IXSU#N0.Z,&5
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M:>L3R&NMQ^WS;:P5U-4H%F]DN"A[NUYH5P-IC<C*E1F0$9>9D0)7F+*$<LI
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MN5/6EXS#-7GXZ_4L\&P-$V1S@Z<_DB?U'4V&7(IVO!BAL+5>>HJF"7L<M0;
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M]$-$MFS!OZD%'_YQ@_ 8I%4Y:A!;)6="9835P#3&(G-&G@=YK4\)_N:BTUB
M9H(_F'\=>)?O%AG+'HELLG>"%TSD+2,I14::L?I)P)S XD@_&B4;>YM[DCAM
M_N69KJG&%%O_J+S?CR]9>^T\,,X-L3,@1!MD[2^>$4V(3+:N93N S&FO'$:%
MS7X0/5J&'<#T.L]P&>_)8#SC@8ZT%Q3OD1GPM;4#8T6EPNL<UM8O_F[3T#7
MCA?Z@YF> R30 8+>SU-M-WWI@>B0A6<*HD_$"2X+N!@E,&6S"H(;QP;%67O
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M834+.66%="9+<-4+MA%<E)G<;*4"68M<?.OT30.R7Y)MWP>%^U0EC"'A#AR
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M-KR2Z,'(&)T.C*,N@]R9)Y>:UDXUA,<(G.U M_QDOLERW\K<7F?K8\H\..2
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MP'JA01FLH[C)+\Z)*9Y9#,R/,79Z7SJG#6NF1N8APGJ1@"2$(9D(H22J#'3
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MB>NAWD[[\&[JQ,^0;D26#H)U"$[EFA]7"9S,#+2R.D>;Z5?F*4?D9?5VVDN
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MLX_4%#VC^#MP-R\HI[^\S5RS;*TNBD*S6$>R>F? &:OI#\U3CBE(USJ"^8F
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M12??T]U\5TJL<"D86+025$[$J*!K>S3$8(I&'X<-';OOTSM"14LY+ELRM8=
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M\!_EM746SCM5 50[2.@(0#5%/J_/_PXLI"V*_?UMVU\;D@A&0$F-9"*-*@V
M(R,4='D5(W!/)^JL^GZO%N_5J\BZ"R@?)J,N,/<#9I?P%EE;>DV7AJOEH+ZZ
M7*[FWV#QYL\XO2P5*V?+)>#_IR_^S_,$S!CJ2FM!COL,EA,K5$0S%<U'JJRG
MP]3:7C#<F\PN8XT'XN0)",<56@>XW-S[\L,?,_P"7AX?81&+."_@7"HC(J 1
M8E)I8&%%*FWNT<\V4FB7&$A3._,QF+@N8YUU,#B.@#I WK;<T;=2%[C\D._]
MV;E!"X)JSXA0#OUI7R;7*L@DY1!CRAQ$.E'6;1-Y;3L1C*P!QQ%2!_C[\!U*
M]Y79Q3J;\&ER\77U(?]C"469K\X!T#16J+<5+9..K#?$ZK(C*FR.FBJI:X_1
MVTE0VYK)43%63Q#=H>K]Q(?U\)A7EXO"YW,M:"BO<(E(DI?N,5 \)4$DND]
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MR&$-M_?[;I<%=N,JJJ-8WZ\]=9?U1-J=#)"(UEX1R5'G!L$CT9%+EJ@U\?$
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MCT)HDA2@EK1>D:"S(!I2C#$;Z1\/0ZU6SCJ O+;YUEJ(V%+B6EL\39WR]72
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M>. 1#0UM@^3@K1B6X!W^S;:)W9%Q-2;_7X!>.]?<"ZJU)LRG1 I&B,O,$&,
M>08J*!CSQ5-_Z=M.]-A>@ND@=;%Q/]OS?$)+QV@H>;Y,),] 0N:") M":L\!
M?.VZT[T(;)ND;0G!*B+K5?&=9_3)J:)(?Y2Q,$D1SX,E"7)VD6=1OR'H1D+:
MIF5;XFLO$?2JUVX2?XY):Y4%HK)$'>VT)&$]5]" 2H[I0'WMT7N[Z&F<CFT)
MJT,D<D2SXM5XV+J7Z%- LS:H;3G+R!MN//$4(M%49Z!!1.]JOR-ZAJ3&2=B6
M"#M0+MT.$OH,%U=,._SY^.,EZKP$WTE8I4?=U]_X!-_+%(79Q2UL:(1$HV D
MLQ(ZE:Q,4DB9"!I*>EU'EVH?N6VT'-T?__HM_8?\^ OWVD#_\O/ZAU>CZ@W/
M3!HET,O(I5F1=L3[G$A"W:>]E3SDVLW/#B"S;3JT"G:>]-P?65@=6.2?4410
MJ/_E<CF9H6-Q<]#/_IPLS[73)B@K"02&MJ&2@MCD.7&:6AN=Y)+7?NJ]DZ#&
M&!L;#H_A5TTV/0#MBO;7\U(R< Z14JNM)UI25:JE#+&&.^220H8%I\#6MM$?
M$- 82/4$^Q@R!W.Y=;3]%7+NHU^L9KC<K_ MP.(\F&BHX90H5QXL:I^)HZB_
MO;<1M/;))_><-;1E[2XNJT.D-*_'LAXD_AJFDQ^P^'E-/M,\4RT<T=Y$(H4/
MQ"/@B0["(5\TWM;/VK];UFY;$E-1XD>PK >)OYF5>[$PXWH#(+RRGB;B<T!F
M,+#$LI10^WEF$UCTW<)@F3]>O6T%2D6I'\6V#J[_L^ET/>SFYJ:[WH55@JM"
M=@[.$PFX%>=])((EI;D&R*YV*ZO-E+0M%#D>*!7YW! MR\7J_-5\MIQ/)VG-
M_/5(ZK55I */@09-0**RD^OW9[IT?S%"Q\2,8&S02T+\Q#V4X._N$++]ZXTO
MCQ/Y'96XWQU^;HX55USZ@":U*3>ERHQXRQS)PAHO-37.#'JHM3>"6KH<M62Z
M$R(',+B#*^GV3<\C7>FEB#&!(\D$41)BLDSD0]69,M<<0%);.]JXA92>('.(
MC+<]HCJ"X1W@9CTO:'FUA3?3R;?);,VEZ\UDHSUN!DA*JCSK=WC3:D:) 1>B
MBQQ4K(V>G02UN;I&PU ]YG> I%?S!5[D?@6_S6?79^)Z(X*"Y5PZ0HUWI2FC
M(RZ(2'R*-E&N4PRU2W&V$M/&AQH-0768W@%Z/E^&Y?VX8;3,9^$IH3DB9YR,
MJ$:I)D99K1.CR+/:[T >D=#8VSYU>/X(_O<%G^M3I8)![](HPE4L<P0H$.<$
M)U'$Y'G2'N*( .HB,'^,2+?#XP#^=@"0OX.?KKY>!9E7$]S'9UC\F$2XUI:<
M4]"<&V*88$1J6Q*K01(3>&*1RJRJC^3:35$WT#E$W//1>-_%Q(^/BWFZC*NS
M6;K>R#I(=;V;*$(TWN#U;;TIC-(D.)=)XLBNA'\8<VV3>1<]C8,]57%4C>]=
MH&C'O?Y^,H.UA7@NO$@F(J<$T-*(0Q?;L)P-*RSZD\GZ4/LMV!"Z&@>83VT;
MU994!_?A)_@!LTMXB\Q%QV1=7?3/"2KIR^5J_@T6;_Z,T\M42H^6R])F+7WQ
M?YY3!8G:Z(B)98!PQ"U:2SU1U&7<M/7>U2Z@.8#,+K+A%;$R/ZW@NM"-K^;+
MU8?\M_D\+>^T_>W67@-2%B=KIN*OI[ 6[BR=?2L\_]_UGY]S5;J54U=L7%D"
MPHK8F#@1F87(;(BJ>M_YXZGN(J\_'G9/+-;VLR[_!C-8^&G91/HVF4U*&>=J
M\@/W_!UFI=G2+-W?]>/-!N.48XX1QP+:-"DKXD$ZXCPR/\J4TN/@_99J@N/H
MZ*+NH#XJ3RVA#F[]<@#+EFYV=P[@I&)&D^Q+&[E<!K:[9 CSBJH@(F< (VC)
M^S1T4:PPKLX[F.5=7,:WF:YWLX@FQOOY<GGNJ1/6ND"X*+AG+!(+S!.7D459
MX8_5:'U"[\AHVXYB=.@<R_B.QU&^]9/%[WYZ";^"7UXNUK5@RWF^>A8U\=-W
M,U3$E^L_O1O8^,HO%C^+:;M^+KSTLW2[S)9_]XB71R>FL,[#II9LK?1NZO;;
M91CK=%YV<=>3DE)N7%221",1_:7C5-#"$YNI9D8XE6SM"KM=]!S].O-F[>*L
MK6^)>T\.KT68/LP^07D66"0T2[_-9XN;W_[BEY/E57C#:PK&<4:"8)9(L(($
M3S,I(507DI61Z;$8<RSQC5M/UL+;DR>>383;@9%YN_%??M[^\N\3O,H6\>O/
M]_ #INMTE/?@5"ZF,S(1/3FI2' Y$T6%$T(":%/;]!Q&62=X/"ULMH&WG@Q[
M0N;]Z_'I_JY3%<E'K:-D)*-54$(-R+]21@&!>N:2Q/]6;[VP#X&=X+0B0K:!
ML+JX>L+BN]GWR]5RS3%V4[LC!+!4LA/,X<FED(CWP1-T%Q(HX2+-U9OR;B>G
M$YS5!\$VN!TID4[!Q6_>6#%*+6BT:7QVN!5K23 Y$ =<4>Z]5[EZ@Z+MY#1N
M[MP47(=(I%-PB>NM&">D+96JP%1$FR.6<\(YX8(+/#[)Q52]U]]V<AJW;&X*
MKD,DT@&X7L-B\F,=@;^+-WR:+/^U-B9H2$EXJDOG"TFD4H'84D'B:=2.@4LJ
MUO9R=]'3B>YJZBA4DU=7V+O)K'_!?_/Z? 9'I4C(E5@2Z9(F9))UG#"EJ >:
M @NU*P1WT=/6**LG]:UP.E($K5^'KY]VP'+UR:]P*].IOZE3DTDF"E$3ZV5Y
MGI8T\=8Z$C3E4GIGY.-I,%MRNMN^T LRCA7@O#8W&T(BP>3\/5SXZ9O9:K+Z
M>=49Q7IJN:%$*\.(S,(0)^6Z)I*!R%*!V&4J+2'^U\7\QW_CTE>Z!']QIT(V
M?+ 38ZC);74L_QM#YXKJZT-D%5C);,938Q)!C%MBL^3$!J$L37B2=G8;>AXW
M][_61ID<+:YY!=ZUOD'.SG[]VTWTP1BK$@<2LT;("\J(BXP3$;1*UB5C^;!.
M,G=KMA/LX0*9'\^=UD+]_<,MV58;O P-D&2T1S/)!=1CPI;(*(\E;!K-L.*N
MNS7;."3UA'H@=UH+]?6WBQMGFV:GF"M3.0L49<);"B\K MP#X+U$;1YV4&^7
M;'-KUQ/I8;QI+=&S=6G%Y\L9+K7\U<_\Q3IZ\_[]J^O-4!9U#!F(2PSYH:PE
M/CI&M W9Q"QLLL.L^.>^U*8ZKJ*>KLG)]@6]9Z\_WQ"N4W R 2,Y120\<HL6
MJ46%97W4-$K#8AP&@=LUV]2S513V8=QI?=I?O;VAVAIC-%62),=4,240EE)G
MXAP#_*QU^7$[]&WMV][N(]+JDXWJB?0PWK26Z,?%Y!N\FG_[=CDKG?N15S>V
M(K,B6<%*HSDT*W3Q&S, H3);'DO/.3=LMM6V+[29+%1/WE4XUT$LMT:\X?UM
M%2]0 !>2(DAIP;Y7Q&4T3GGPW%%N3,BCU1W6V$#CR9%=9"K:(:*#X_#*+[_B
MALK_O/F?R\D//WV0C+RK?3QGD7JAI2+,EP+S4O?H#&Y1"1F,R";)ZG.S!A/7
M227*Z0'T^$W)*-+L *9G/_QD6D[ZV_GB,^[J<V'>FK^O(:SN?G>>K?#,\5"R
MY:4%J*#(/:]+5ENCA<DU7GZ543J4MI>?%:X#TE%DV0%&RXE;_;RC_^V/WR;G
MR@JMP7GB=3&.K4<OEG&'YPP@2$8MQ-K9X4UTO/P<3QWL'2VC+A[>W>52KQAZ
MGJ1B&H(CF7H\*=&@4VT3&OG),$U=SEG7[FGUF(:7;TG60=A1LNE BUU1O<ED
M !!H%7A#HDT2N:)CL;$]29DY6C+TF=8N/MY*3.-YX]V@K8ZT.IAU>3,CYM7\
M6[CN=EKJ1)!;*(_2(7.2UF]>R\O'FW&>U%L C_8!5<*4UCVE>XFC)*NDM(^9
M6RXJ _( ,AN/,.\&JF-+N'5H<</^KJR-FQJECY>+^-4OX4.83B[6/[\WUS'@
M5@7C>$AS:5.NJ2V3D#113FD)T0>6'K50VA)_/(J,QN//FV/UQ(+LS)B\Q^US
M, F4MJ798CEYVDCBD\T$SYQ4.3 N]7@5U?<(:3P-O3DBZTFI ]ORMF7 O3UL
MLEV\#3$XZ@AXE7%;LKRNUHE09SRX4BM:/8@SD+3&P].[@>,8DJQFA?;1D^2K
M1\MF,KO]E^?YZOG-/8Z=O O)'C2U[#MR*.M.T6DD@V$"@5OZS$&92):)-\(3
MAWA$KXH!ZMVQ,GYC=AK9K4G6JN,?LWE8PN)'B=VN'Y3AC]'PP7_KRIKWTW@Y
M7?_R$P+A[7SQAU\D=$0S1U8)4D93$$D-VO!:"G1$A</_&*/C:&^6Q]I4)_FF
M8_&Y-1/:!1AZ,%@VJ*_25/7)YI</=[_\].C.O79HUVN=&P;6"867XKIYC*,H
M'8;"XM1';F40#$9[:%US(YV<@C[ .J!%Q6F1<_#Q^8ZNQCQ]7OG%ZOBHR*%\
MV,*&LY0F:S:=1X@BEL?0P(P@,JE O !-J,W*&AE]YNPY(VI4"CM)]W9U.OJ!
MQ N^7+;PX6]^,BN=(-_-2MMD2.]F;_QBAG]M>>ZE]9HJ1D#D2&1IB^Q!H;LG
M0A:"9FL>ORAI=N'LO;E.,MM=';.^$?:"C][NVUDGW#Q (EG),EE-4F*CP]]2
M$SAW-E!;>PQ".[MN_%3^7^I(U4/.D7;=FUGJ(U1V<V^7/[SMCWR:B-C.3Y\\
M\#6<$:>(;T'0VCJ;"'-EZ)97E'CM&5&@C7 Y4!Y'Z[[9=2?=%)VB,3HB5,(K
MSC--K%*:@-:"QY0E3SV6^O?>27<?O(W727<?X?9@OSQ5(^M>""ZZ()F2A"IN
MB53!$A<3(Q$Y"9(Z96/M&OTMI'2"N-,"8UN2[ @I=0"V+PL_6^*7[T;S((L^
M;+S*2DN?Y>8?W;X_DPP-G4PD2T"D#;ET^@F$LI I)!7!U49H3?H;P[H&H.:=
M2+<#9+^"Q6J2)_C7RKY>P_?Y<G(S)CLFO(]BLL3(4C^I;22!XS5%/3<J&2FU
MJCX 9SLY;7'7#B./WS=5$E@'V-O9*<\DI-\#,B6H@(QRN!=JULVQT>.!R!.K
MG2'Z=^AG><QE7DU>76%O0R\^%@)G,AJB\[KF-G$2 EKE$)AG4B833&T_YX7V
ML]Q+ZOOTL]Q'!*W+GK=V8,S4A=+7D^1(2Y1-H&.'OR?.:2[ .63/H^K\OTX_
MR[T$.*B?Y3[<; B)Y6)U;PKS5=GTK[#Z.D_O9C]P7^7\//U3@-_\-UB?*31;
MH^$\$2\!.6?+J[Q(!3%11>J\4=D,FJV!A-S3//B[.ZUS+(V=9)R:W(8GE6]C
M'&_;QTW/6JTX!(4[40*UOPR:!&4XT8+EX&V.>#PK('4W%6UTX&E1,!]%)*WO
MS=>__JUX4]?]SV[G/8!W>%EPPTLL5 ?B V.$&F,%;@S\8Y]S6Y? IXNW0TI-
MH<TK<K Y FX[(/((C&F>B7#"(]5<$:>$)3''K%DJK9G4,+GOU1VRNL<VJK0/
MXE8'SM;-<[*SB)Q9KC-]:QTH=%*H!STQPI1NQ2")S:"(!JJYLH):5_N1RQ92
M.LGW-W7O:TBI4["57R[@Y@!2(YE5,1*;2@,XRRWQA@DBM&4IZO*SV@_[GB6J
MK2=71?0#X'2X'%K?5,_V:F40+!>F%*R$\NB "^(":-3+ ";H#,D,ZYY8I>OM
M29%RA%3W:H>[#XM;X^5>NV[#A3"4(T/6@U]XCB1(EPBDY*54\NGKGTZ;F9\
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MH5: 'I&&,F>@$["T$-02X%!@>LH "HAB1+>4<Y@6"#$K0\-*8 (5EU BER
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M->;T <NV)X"N<#OJZLYBI\=37P7"8A?DSS4VY#_*H*/AL_3W)& +P@M= '7
M2TN>.Q@@#B9/ #,P2\Z9HNQL/,A[Z[Q@!_=</2C_D8;T4@(H<)<2 4SN.+U
M7<E73Y&.E!QQ+*$IO2]^%=!%%N5))M6$0^LX5CYSTB5, P;_%'Y1V>9']$UQ
MW]U?_U?N:L#^SIT]=_S9R8BOW=Z8=@R4M2KI5.==:&"4S.UZER]<^/"?L9YJ
MSB# Y0 2PD.91A"9#I5C.C%[?]T]DX5U[6IVU[H]]LQ3#1OS,@1,TLSPSO3+
M.93G3-))1Z1NVEVG\T)7,3UHUPB+/!#& A\.%[ZY,+G=KIRU&FBU!5,MFPY<
M.%1Q#AU;MMYV4FFWZD^V5BNU)]N>T]HXK9RTVW^ZVE:]4FUNI_;8382?#)AN
MD]'TW5YC;XX0ETPZ]>R1U#9GW95)]_/]^DO0@?$#Y+)E5E/X__V[]C.=D';)
M735[F7/%U:-=\NU@OPG5P7VN7 A9<O5M876E7'PYEE7B:.1SHD4"=;0I X_P
MI)U,77EF?I K/#DYS]U@>_U[46[N-MT:VO[:W3<*^&4L>$3ZCSS,L=Z3:[\/
M)0?[C;-S<J.!XC-W673'_3B\\6?,P-?6G#E:J?^S97OL:O8NTZ)C?ROWV-T&
M_C]02P,$%     @ H(.I6-OI$LX="   <2L  !4   !E>#,Q,C(P,C0P,S,Q
M,3 M<2YH=&WM6EU3(S<6?=]?H87:"539QI^ #4.5AX$:5R4PRY!*]FE+[E;3
M6M2M3DMMC_/K]URI_87MQ+,DQ%";!^)N25?WZAZ=>Z3I\]@FZN(\%CR\^-OY
MWZM5]E$'12)2RX)<<"M"5AB9/K"?0F$>6;5:]KK4V227#[%ES7JSS7[2^:,<
M<=]NI57B8FKG_,@_GQ^Y2<Z'.IQ<G(=RQ&3X?D^&)]V@U>ET@N-NL]UM\=/3
M9KW5YM%)1S3XL#/\=V,/0]'=CS%VHL3[O42FU5C0_+UVLW;2R>S96(8V[C7J
M]7_LN:X7YY%.+>;+,=[_]&96C%GQU5:YD@]ISX6TYX=.FP.M=-[;K[O_SJBE
M&O%$JDGONWN9",-NQ)C=Z82GWU4,3TW5B%Q&OJ.1OPKX!/?<X]B[? ([2J9B
M&D*C24ZSJY\_#3X,[EFK46LNN[P8.<\?$+S5F;>[X'R U1;YRWM_TH;WEU=W
M]X/KP67_?G![PVZOV>>[P<WEX'/_>W8]N.GC)W[=7J/'U=VK"^[SCW=??NS?
MW+/[VU?G^Y>K2Y>25KU):;G_=,6^].\^]&^NOE1O?_[^ZE^L?WE/+<UZ?3O8
M-;,_?XNTUVZ1085=QCP-><H^<!/K"ONA]J'6KU58('(KHPFS,;?O]CNG9]M&
M<I;Q, 3!596(;*]UO)RY_Q2&S/I7,@V1R%ZU>?*7+4"C-HWKY6=?7JE&M]:A
M91BPF(\$R\5(BC&JA8VE8;\4/ ?BU03O,YU;IE-VK?.$->K5?S(=L;ZQ.4\Y
M^R2XLG&%#=*@AK1UWVC:FCN7-FP?) MI22;L,=5C)<('4?'9*W,6:KB0:@@!
MS,!ERG@Z845J\T(@ D@#IQ*03,X2/.62*Q;Q *]RIA-IF=6^WTJ'5 3"&)Y/
MJ$O"'P7F7;!I\"Z$,YA2.8F!.:A#('-("G1+,1R>A")GXU@&,3,%_9F/'XM<
ME$8H@$0:!>U!,F8L;8P 328"YR#9S>":#A'F",-"-IPL+L,;1F7K]:!2L$BF
MR#M!:)[G"B")[FC.%]IE&H%JN)6P(]- %2%L DL+2:T AY+H*0,4",6$;J7F
M,"T18IY,C9T02C)<H1Z%0@=@4P- ;CKC_ E0F5BD]-A,@9N+!^D(SS).+[W?
M\+*R@#\S=6;%VS<,P?;.0?!^*5_O]D^;C9,S4X*L5!E$)#J*)!Y]R@>,Y\*!
M!B"00R4HN4P J4,E34S]J5L"%B4FI>=0FD!I4V <\6NNE3>5Y3H0(5X;=@"P
MA +H\XBX^AI ^SP(U@=UW14*/1HM7FUT#L2A&]KHA/[)/TH2G:E'+=EGQ&\+
M8/;@(E^VGBA:FBC"1!3G4XBC!VF"9\BP=F>W87O #W<&MYU:MT$+\5$8+!4R
MZ(KA[\.K0G4ZX(79?@@5S*$ 5,J9? G610X#(+&1-(X:T4NDS@ZI\3FI+A)S
M+A1WV"MK\!P_E9*TJ5&"8.&+T4J&[B["%$,C0\ES20%(KQ1<J4C)4F&H>KN]
M:ERI=T2JC8!#%L1-@S)(4QD4BA/_(RSGQ%P%8(37%(M2"+^&@CJ"HC%>A,^@
MY)W']G"7L-UJKV)[:V);@?CVE+@UTK$[1C(D '.C4T[<SPW 3R*54,WS<(HP
M8%[RH5323D@9K)N6]IL#H\.9WRI+71=$KBLQ7\N LB+/@'/CE$P0Z#QT#CBY
M^R!2"!0%N*-%9+2/J NDO(<T]IO,P/)O&=3!+H':$_;5B*O"L1IE7$01!*<<
M(5=FC7"<"9$M6-H_KM>2#L,8"(8U7K$.=6$W>[!-'>&SWH+D>/3[ARHVG I]
MMRV%7PGXXR!($[Q1&(:[!,.26WV&5Y%"Q_U2"+J6M7#\!D8E+:"#H,@)#PN%
M=XW51!N+]W1O"ELF@*'R2HD=;!@2 =C@NB>]2\=Q)!/NIH(N,=)BYM>A]RKF
M9J92B"7=1A"A*Q]N/4IJGS E'X4JKRV>]*\\>XF>"?Y=/^MUWLI9SUUXAM-M
M4YF3&7'K(G3GO$;@^P;9LB**9[YQ"&.K2U>HCWL!DTDBK17B-RK'4$.+4'LH
MX9\S<@" @Z@-%0+\G^3Y=%>*7PH)]]T.+-+ 76\<_O](]Z(*H:\@^+!8$O"C
MDS6=T0,I )>RRL^.5F/!'ZEL>P'H"K>3KNXN=GH]]4T@+$]!_EYC#?_Q$ .-
MF-'?1L"6@A=#@#KHTHK7#@;"P10),(-5<L&496?M1=Y;UP4[>.;JH_Q'.>BE
M B@(1XD D[M.+U%7\=53IB.M1H)*:,H?RG\5R$L6%4FF]$2@=1QKSYQ\"=/
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MKG"_3M5TY#]Y/7*?VOX74$L#!!0    ( *"#J5A=);=5P@0  "0>   4
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M_ETJVN%!J=J0YGMI/+T(]96=:NN(,_\T/2'U5X^1-ZOZTN^AS1'-#DYS8B<
MDX>,H#F^+<-]ZH7=HGDF(>O8RPYQT_55; 6,^L :@$$H=D]1S_<9$"XSL/LP
ML1DQ_V_L>!1'?<& <B3 .59".5[Z:^1IN^;-I'[GE+D%;(_@&)UC&7#=<^>6
MN^?,>\[\HSGS\T_2/6G>D^8]:=Z3YAEI?C&@]IQYSYF7Z.<:^K+S=#,ES9=/
M,WN1-*>R7CJLX[NY;.=C6J#0*X%M3Z&77EPF7!I.4Q<TQ)J<K[S*?&Y\,_OM
M9Q,\ANZ?J,TF6[R+>O&=OJ7-F[?#?P%02P,$%     @ H(.I6)@UDVTS*P
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M@7/D&*J#0XX1ZGO/0 [SQSGBSXHYC!ZY' _>#8HL!XXC&%);!8W80Y)U,"7
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M!H&?D"EJ>*A>I$%P H?O@X<81U.RC3#SS0H#=BT\N,\W$NMP6%A(%<GP@LE
M[E%L8U*(V5@TX,<ZJ2"C)$&0F@,5^(3D]S#E)+E'%H2<L;88&V4,C28" T4O
MC$?HVJDD.Z0BFP@X @Z9$TP?Q-4W94V@"@/B&6&G#)VN2Y(2" /<EV;O>!C9
M=*>>PQS>9J/KFABZJDE\10G;MWPWE8NZQT77QC-(RFF!L/W!@+PW\WLQG"K
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MHR5B4DRG)PM")]<CY2(FIWP'5A8"EG^8V_'U!X(E\8?))2&7QCQ%8/(6=L"
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M[  ##3,]\6FE?>"<49-;+24IYLY.[QRWK"W9-6G0X4O0I*R0$H [&Z>"%UB
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M,ZH$YMOAG'H<7+M54I"7Z)5+RV_JCN2*;)OT"P86A[I6@^/\P(LAAG+5NDT
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MA=Q_41#64M\VSK<TL(>H65VVS IIG2I]5OGIIERRA>,:\7/2)>M<!:B9<T]
M</@BU@LM]AXL)-?J<)Q0O-[(O8SJ'<79">K'H\J .J@.Q[3N-E]D^N:EP0:F
M08$EKOLIYG5CD"S->T&U_G5BNDQ5H(,91+FPG89!/NHVY*#LC,E5O5*A3H1N
M<FD^36XOQS<WYA.^U/[JMV3(QR9E[%BC'VD0$4)-QA<@;?%MIJA6.4-)X (M
ML^97QE]K2=P0>--#W&*H[8:L^9?FXMZL-IFA&C7X#4Z-HB]'_Y&8X\/C$V,N
M/TY>FJ.G)\^/7IP>_WP*<Z5?S.3"_.M+>.#@^.3T^>G3%VYE;Z^O?O_HEJ7
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M,#(T,#,S,5]D968N>&UL4$L! A0#%     @ H(.I6)PJ'DH]<0  BHL  !0
M             ( !):(" &%S=&@M,C R-# S,S%?9S$N:G!G4$L! A0#%
M  @ H(.I6#XFQ&WA=@$ :8@. !4              ( !E!,# &%S=&@M,C R
M-# S,S%?;&%B+GAM;%!+ 0(4 Q0    ( *"#J5B_,K@LQ^D  -FK"@ 5
M          "  :B*! !A<W1H+3(P,C0P,S,Q7W!R92YX;6Q02P$"% ,4
M" "@@ZE8\1P1_3((   4+   %0              @ &B= 4 97@S,3$R,#(T
M,#,S,3$P+7$N:'1M4$L! A0#%     @ H(.I6-OI$LX="   <2L  !4
M         ( !!WT% &5X,S$R,C R-# S,S$Q,"UQ+FAT;5!+ 0(4 Q0    (
M *"#J5A=);=5P@0  "0>   4              "  5>%!0!E>#,R,C R-# S
M,S$Q,"UQ+FAT;5!+ 0(4 Q0    ( *"#J5B8-9-M,RL  ,B,   <
M      "  4N*!0!E>&AI8FET,3 R,2UI;F1E<&5N9&5N=&,N:'1M4$L%!@
0   +  L W@(  +BU!0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>asth-20240331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:asth="http://www.apollomed.net/20240331"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="asth-20240331.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2024-04-29</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">asth:HealthCareCapitationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">asth:HealthCareCapitationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asth:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asth:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asth:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asth:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asth:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asth:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asth:OtherThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asth:OtherThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asth:PayorAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asth:PayorAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asth:PayorBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asth:PayorAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asth:PayorAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asth:PayerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">asth:PayerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:AdvancedHealthManagementSystemsLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-31</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:PrimeCommunityCareOfCentralValleyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-29</startDate>
            <endDate>2024-03-29</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:CommunityFamilyCareMedicalGroupIPAInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-31</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:AdvancedDiagnosticAndSurgicalCenterIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:OtherAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-31</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:TotalAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:CommunityFamilyCareMedicalGroupIPAInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:AdvancedHealthManagementSystemsLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:OtherAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:TotalAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">asth:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">asth:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">asth:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">asth:ManagementContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">asth:MemberRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">asth:MemberRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">asth:MemberRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">asth:PatientManagementPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">asth:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">asth:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">asth:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">asth:ManagementContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">asth:MemberRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">asth:MemberRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">asth:MemberRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">asth:PatientManagementPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:CAIPAMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:CAIPAMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:CAIPAMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:IHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:IHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:IHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">us-gaap:OtherInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">us-gaap:OtherInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">us-gaap:OtherInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:OneMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:OneMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:OneMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:CAIPAMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:CAIPAMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:CAIPAMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">us-gaap:OtherInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">us-gaap:OtherInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">us-gaap:OtherInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:IntraCareConvertiblePromissoryNoteReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:IntraCareConvertiblePromissoryNoteReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:BassMedicalGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">asth:SeniorSecuredPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-29</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">asth:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">asth:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-16</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-16</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-08</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-16</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">asth:SecuredOvernightFinancingRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">asth:SecuredOvernightFinancingRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:AmendedAndRestatedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">asth:TruistBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-03</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-03</startDate>
            <endDate>2023-11-03</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:AmendedAndRestatedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">asth:TruistBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-03</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:AmendedAndRestatedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">asth:TruistBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-03</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:AmendedAndRestatedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">asth:TruistBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-03</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:AmendedAndRestatedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">asth:SecuredOvernightFinancingRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">asth:SecuredOvernightFinancingRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AstranaMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:SubordinatedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:SubordinatedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">asth:NewTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">asth:NewTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:ApcBusinessLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">asth:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-10</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">asth:TruistBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">asth:TruistBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:CompanyAndAPCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:CompanyAndAPCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:CDSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:CDSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">asth:StockAwardsAndUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">asth:StockAwardsAndUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">asth:ApcStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">asth:PerformanceBasedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">asth:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:IHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:ProviderServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:ProviderServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:SongPCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:ProviderServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:SongPCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:ProviderServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:SongPCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AstranaMedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:ArroyoVistaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:ArroyoVistaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:ArroyoVistaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:ProviderServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:ArroyoVistaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:ProviderServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AlliedPacificHoldingsInvestmentManagementLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:OfficeLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:ProfessionalMedicalCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AlliedPacificHoldingsInvestmentManagementLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:OfficeLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:ProfessionalMedicalCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AlliedPacificHoldingsInvestmentManagementLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AlliedPacificHoldingsInvestmentManagementLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:SunnyVillageCareCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:ProviderServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:SunnyVillageCareCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:ProviderServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:FirstCommonwealthPropertyLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:OfficeLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:ProfessionalMedicalCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AHMCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionRevenueRecognizedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:HSMSOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionRevenueRecognizedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AurionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionRevenueRecognizedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AHMCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionRevenueRecognizedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:HSMSOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionRevenueRecognizedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AurionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionRevenueRecognizedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AHMCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionExpensesIncurredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:HSMSOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionExpensesIncurredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AurionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionExpensesIncurredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AHMCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionExpensesIncurredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:HSMSOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionExpensesIncurredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AurionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionExpensesIncurredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AHMCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionRevenueExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:HSMSOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionRevenueExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AurionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionRevenueExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AHMCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionRevenueExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:HSMSOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionRevenueExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AurionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:RelatedPartyTransactionRevenueExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AHMCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AHMCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:BoardMembersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:ProviderServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:BoardMembersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:ProviderServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:BoardMembersWhoAreAlsoOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:ProviderServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asth:BoardMembersWhoAreAlsoOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">asth:ProviderServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CarePartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CareDeliveryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CareEnablementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CarePartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CareDeliveryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CareEnablementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CarePartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CareDeliveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CareEnablementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CarePartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CareDeliveryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CareEnablementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CarePartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CareDeliveryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CareEnablementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CarePartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CareDeliveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">asth:CareEnablementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">asth:InterestRateCollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">asth:InterestRateCollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">asth:InterestRateCollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">asth:InterestRateCollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AAMGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AAMGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AAMGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AAMGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:VOMGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:VOMGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:VOMGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:VOMGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:DmgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:DmgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:DmgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:DmgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:ADSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:ADSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:ADSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:ADSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:CFCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:CFCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:CFCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:CFCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:PrimeCommunityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:PrimeCommunityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:PrimeCommunityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:PrimeCommunityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AAMGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AAMGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AAMGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:AAMGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:VOMGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:VOMGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:VOMGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:VOMGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:DmgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:DmgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:DmgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:DmgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">asth:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">asth:InterestRateCollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">asth:InterestRateCollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">asth:InterestRateCollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">asth:InterestRateCollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">asth:InterestRateCollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:DMGAndSunLabsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asth:DmgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:AAMGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="c-373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:AAMGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">asth:A2023MetricMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:AAMGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">asth:A2024MetricMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:AAMGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">asth:A2023MetricMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:AAMGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">asth:A2023MetricMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:AAMGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">asth:A2024MetricMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:AAMGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">asth:A2024MetricMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:AAMGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">asth:A2023MetricMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:AAMGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">asth:A2023MetricMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:AdvancedDiagnosticAndSurgicalCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">asth:A2023MetricMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:AdvancedDiagnosticAndSurgicalCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">asth:A2024MetricMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:CommunityFamilyCareMedicalGroupIPAInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:CommunityFamilyCareMedicalGroupIPAInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">asth:FirstMetricMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:CommunityFamilyCareMedicalGroupIPAInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">asth:SecondMetricMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:CommunityFamilyCareMedicalGroupIPAInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">asth:ThirdMetricMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">asth:PCCCVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:IHealthPromissioryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-01</endDate>
        </period>
    </context>
    <context id="c-389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asth:IHealthPromissioryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-01</instant>
        </period>
    </context>
    <context id="c-390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">asth:RevolverLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-05-09</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>asth:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="financial_ratio">
        <measure>asth:financial_ratio</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-28">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-29">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-30">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-31">0001083446</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-32">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2024-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-37392</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">Astrana Health, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">95-4472349</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">1668 S. Garfield Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-10">2nd Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Alhambra</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">91801</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">626</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">282-0288</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">ASTH</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-19">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-20">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-21">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-22">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-24">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-25" unitRef="shares">56025538</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:TreasuryStockCommonShares contextRef="c-3" decimals="INF" id="f-26" unitRef="shares">7132698</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares contextRef="c-4" decimals="INF" id="f-27" unitRef="shares">7132698</us-gaap:TreasuryStockCommonShares>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-33" unitRef="usd">334796000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-6" decimals="-3" id="f-34" unitRef="usd">293807000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-5" decimals="-3" id="f-35" unitRef="usd">2490000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-6" decimals="-3" id="f-36" unitRef="usd">2498000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-7" decimals="-3" id="f-37" unitRef="usd">120106000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-8" decimals="-3" id="f-38" unitRef="usd">76780000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-9" decimals="-3" id="f-39" unitRef="usd">62354000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-10" decimals="-3" id="f-40" unitRef="usd">58980000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:IncomeTaxesReceivable contextRef="c-5" decimals="-3" id="f-41" unitRef="usd">0</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable contextRef="c-6" decimals="-3" id="f-42" unitRef="usd">10657000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-5" decimals="-3" id="f-43" unitRef="usd">1783000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-6" decimals="-3" id="f-44" unitRef="usd">1335000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-45" unitRef="usd">17281000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-6" decimals="-3" id="f-46" unitRef="usd">17450000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-3" id="f-47" unitRef="usd">538810000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-6" decimals="-3" id="f-48" unitRef="usd">461507000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-5" decimals="-3" id="f-49" unitRef="usd">7985000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-6" decimals="-3" id="f-50" unitRef="usd">7171000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-5" decimals="-3" id="f-51" unitRef="usd">119707000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-6" decimals="-3" id="f-52" unitRef="usd">71648000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill contextRef="c-5" decimals="-3" id="f-53" unitRef="usd">410267000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-6" decimals="-3" id="f-54" unitRef="usd">278831000</us-gaap:Goodwill>
    <us-gaap:IncomeTaxesReceivableNoncurrent contextRef="c-5" decimals="-3" id="f-55" unitRef="usd">15943000</us-gaap:IncomeTaxesReceivableNoncurrent>
    <us-gaap:IncomeTaxesReceivableNoncurrent contextRef="c-6" decimals="-3" id="f-56" unitRef="usd">15943000</us-gaap:IncomeTaxesReceivableNoncurrent>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent contextRef="c-7" decimals="-3" id="f-57" unitRef="usd">47412000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent contextRef="c-8" decimals="-3" id="f-58" unitRef="usd">26473000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:EquityMethodInvestments contextRef="c-5" decimals="-3" id="f-59" unitRef="usd">35893000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-6" decimals="-3" id="f-60" unitRef="usd">25774000</us-gaap:EquityMethodInvestments>
    <asth:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue contextRef="c-5" decimals="-3" id="f-61" unitRef="usd">6396000</asth:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue>
    <asth:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue contextRef="c-6" decimals="-3" id="f-62" unitRef="usd">6396000</asth:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-5" decimals="-3" id="f-63" unitRef="usd">645000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-6" decimals="-3" id="f-64" unitRef="usd">345000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-65" unitRef="usd">39152000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-6" decimals="-3" id="f-66" unitRef="usd">37396000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-5" decimals="-3" id="f-67" unitRef="usd">4067000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-6" decimals="-3" id="f-68" unitRef="usd">1877000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c-5" decimals="-3" id="f-69" unitRef="usd">687467000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c-6" decimals="-3" id="f-70" unitRef="usd">471854000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="c-5" decimals="-3" id="f-71" unitRef="usd">1226277000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-6" decimals="-3" id="f-72" unitRef="usd">933361000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-73" unitRef="usd">146473000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-74" unitRef="usd">59949000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <asth:FiduciaryAccountsPayableCurrent contextRef="c-5" decimals="-3" id="f-75" unitRef="usd">7792000</asth:FiduciaryAccountsPayableCurrent>
    <asth:FiduciaryAccountsPayableCurrent contextRef="c-6" decimals="-3" id="f-76" unitRef="usd">7737000</asth:FiduciaryAccountsPayableCurrent>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-5" decimals="-3" id="f-77" unitRef="usd">136494000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-6" decimals="-3" id="f-78" unitRef="usd">106657000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-5" decimals="-3" id="f-79" unitRef="usd">5522000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-6" decimals="-3" id="f-80" unitRef="usd">0</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:DividendsPayableCurrent contextRef="c-5" decimals="-3" id="f-81" unitRef="usd">638000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent contextRef="c-6" decimals="-3" id="f-82" unitRef="usd">638000</us-gaap:DividendsPayableCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-83" unitRef="usd">636000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-6" decimals="-3" id="f-84" unitRef="usd">646000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-85" unitRef="usd">5007000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-6" decimals="-3" id="f-86" unitRef="usd">4607000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-5" decimals="-3" id="f-87" unitRef="usd">20750000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-6" decimals="-3" id="f-88" unitRef="usd">19500000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-89" unitRef="usd">31960000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-90" unitRef="usd">18940000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-91" unitRef="usd">355272000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-92" unitRef="usd">218674000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-5" decimals="-3" id="f-93" unitRef="usd">3756000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-6" decimals="-3" id="f-94" unitRef="usd">4072000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-95" unitRef="usd">1015000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-6" decimals="-3" id="f-96" unitRef="usd">1033000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-97" unitRef="usd">37716000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-6" decimals="-3" id="f-98" unitRef="usd">36289000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-5" decimals="-3" id="f-99" unitRef="usd">368448000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-6" decimals="-3" id="f-100" unitRef="usd">258939000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-5" decimals="-3" id="f-101" unitRef="usd">7652000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-6" decimals="-3" id="f-102" unitRef="usd">3586000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c-5" decimals="-3" id="f-103" unitRef="usd">418587000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c-6" decimals="-3" id="f-104" unitRef="usd">303919000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-5" decimals="-3" id="f-105" unitRef="usd">773859000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-6" decimals="-3" id="f-106" unitRef="usd">522593000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-5" id="f-107" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-6" id="f-108" unitRef="usd" xsi:nil="true"/>
    <asth:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsNetOfDividends contextRef="c-5" decimals="-3" id="f-109" unitRef="usd">-205557000</asth:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsNetOfDividends>
    <asth:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsNetOfDividends contextRef="c-6" decimals="-3" id="f-110" unitRef="usd">-205883000</asth:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsNetOfDividends>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-11"
      decimals="INF"
      id="f-111"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-12"
      decimals="INF"
      id="f-112"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-12"
      decimals="INF"
      id="f-113"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-11"
      decimals="INF"
      id="f-114"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-11"
      decimals="INF"
      id="f-115"
      unitRef="shares">1111111</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-12"
      decimals="INF"
      id="f-116"
      unitRef="shares">1111111</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-11"
      decimals="INF"
      id="f-117"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-12"
      decimals="INF"
      id="f-118"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-11" decimals="-3" id="f-119" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-12" decimals="-3" id="f-120" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-13"
      decimals="INF"
      id="f-121"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-14"
      decimals="INF"
      id="f-122"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-14"
      decimals="INF"
      id="f-123"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-13"
      decimals="INF"
      id="f-124"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-13"
      decimals="INF"
      id="f-125"
      unitRef="shares">555555</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-14"
      decimals="INF"
      id="f-126"
      unitRef="shares">555555</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-14"
      decimals="INF"
      id="f-127"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-13"
      decimals="INF"
      id="f-128"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-13" decimals="-3" id="f-129" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-14" decimals="-3" id="f-130" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-131"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-132"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-133" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-134" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-5" decimals="INF" id="f-135" unitRef="shares">47458264</us-gaap:CommonStockSharesIssued>
    <us-gaap:SharesOutstanding contextRef="c-5" decimals="INF" id="f-136" unitRef="shares">47458264</us-gaap:SharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-6" decimals="INF" id="f-137" unitRef="shares">46843743</us-gaap:CommonStockSharesIssued>
    <us-gaap:SharesOutstanding contextRef="c-6" decimals="INF" id="f-138" unitRef="shares">46843743</us-gaap:SharesOutstanding>
    <us-gaap:TreasuryStockCommonShares contextRef="c-5" decimals="INF" id="f-139" unitRef="shares">10584340</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares contextRef="c-6" decimals="INF" id="f-140" unitRef="shares">10584340</us-gaap:TreasuryStockCommonShares>
    <us-gaap:CommonStockValue contextRef="c-5" decimals="-3" id="f-141" unitRef="usd">48000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-6" decimals="-3" id="f-142" unitRef="usd">47000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-5" decimals="-3" id="f-143" unitRef="usd">395473000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-6" decimals="-3" id="f-144" unitRef="usd">371037000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-3" id="f-145" unitRef="usd">257969000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-6" decimals="-3" id="f-146" unitRef="usd">243134000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-147" unitRef="usd">653490000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-3" id="f-148" unitRef="usd">614218000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c-5" decimals="-3" id="f-149" unitRef="usd">4485000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c-6" decimals="-3" id="f-150" unitRef="usd">2433000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-151" unitRef="usd">657975000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-152" unitRef="usd">616651000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-3" id="f-153" unitRef="usd">1226277000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-6" decimals="-3" id="f-154" unitRef="usd">933361000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Assets contextRef="c-15" decimals="-5" id="f-155" unitRef="usd">717500000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-16" decimals="-5" id="f-156" unitRef="usd">540800000</us-gaap:Assets>
    <us-gaap:Liabilities contextRef="c-15" decimals="-5" id="f-157" unitRef="usd">179600000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-16" decimals="-5" id="f-158" unitRef="usd">146000000</us-gaap:Liabilities>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c-15" decimals="-5" id="f-159" unitRef="usd">299500000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:OtherLiabilities contextRef="c-15" decimals="-5" id="f-160" unitRef="usd">110100000</us-gaap:OtherLiabilities>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c-16" decimals="-5" id="f-161" unitRef="usd">273200000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:OtherReceivables contextRef="c-16" decimals="-5" id="f-162" unitRef="usd">107300000</us-gaap:OtherReceivables>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-17" decimals="-3" id="f-163" unitRef="usd">365910000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-18" decimals="-3" id="f-164" unitRef="usd">300204000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-19" decimals="-3" id="f-165" unitRef="usd">17377000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-20" decimals="-3" id="f-166" unitRef="usd">13462000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-21" decimals="-3" id="f-167" unitRef="usd">4078000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-22" decimals="-3" id="f-168" unitRef="usd">9896000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-23" decimals="-3" id="f-169" unitRef="usd">15937000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-24" decimals="-3" id="f-170" unitRef="usd">12062000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-25" decimals="-3" id="f-171" unitRef="usd">1054000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-26" decimals="-3" id="f-172" unitRef="usd">1620000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-173" unitRef="usd">404356000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-27" decimals="-3" id="f-174" unitRef="usd">337244000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-175" unitRef="usd">330399000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-27" decimals="-3" id="f-176" unitRef="usd">289397000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-177" unitRef="usd">38722000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-27" decimals="-3" id="f-178" unitRef="usd">21182000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization contextRef="c-1" decimals="-3" id="f-179" unitRef="usd">5096000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization contextRef="c-27" decimals="-3" id="f-180" unitRef="usd">4292000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostsAndExpenses contextRef="c-1" decimals="-3" id="f-181" unitRef="usd">374217000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-27" decimals="-3" id="f-182" unitRef="usd">314871000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-183" unitRef="usd">30139000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-27" decimals="-3" id="f-184" unitRef="usd">22373000</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-3" id="f-185" unitRef="usd">632000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-27" decimals="-3" id="f-186" unitRef="usd">2484000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-3" id="f-187" unitRef="usd">7585000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-27" decimals="-3" id="f-188" unitRef="usd">3269000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-3" id="f-189" unitRef="usd">3996000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-27" decimals="-3" id="f-190" unitRef="usd">3009000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-1" decimals="-3" id="f-191" unitRef="usd">1099000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-27" decimals="-3" id="f-192" unitRef="usd">-6392000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-193" unitRef="usd">-4277000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-27" decimals="-3" id="f-194" unitRef="usd">1204000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-195" unitRef="usd">-6135000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-27" decimals="-3" id="f-196" unitRef="usd">-2964000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-197" unitRef="usd">24004000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-27" decimals="-3" id="f-198" unitRef="usd">19409000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-199" unitRef="usd">7142000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-27" decimals="-3" id="f-200" unitRef="usd">6921000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-201" unitRef="usd">16862000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-27" decimals="-3" id="f-202" unitRef="usd">12488000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-203" unitRef="usd">2027000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-27" decimals="-3" id="f-204" unitRef="usd">-644000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-205" unitRef="usd">14835000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-27" decimals="-3" id="f-206" unitRef="usd">13132000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-207"
      unitRef="usdPerShare">0.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-27"
      decimals="2"
      id="f-208"
      unitRef="usdPerShare">0.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-209"
      unitRef="usdPerShare">0.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-27"
      decimals="2"
      id="f-210"
      unitRef="usdPerShare">0.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="c-28" decimals="-3" id="f-211" unitRef="usd">-205883000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="c-29"
      decimals="INF"
      id="f-212"
      unitRef="shares">46843743</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-29" decimals="-3" id="f-213" unitRef="usd">47000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-30" decimals="-3" id="f-214" unitRef="usd">371037000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-31" decimals="-3" id="f-215" unitRef="usd">243134000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-32" decimals="-3" id="f-216" unitRef="usd">2433000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-217" unitRef="usd">616651000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquityNetIncome contextRef="c-33" decimals="-3" id="f-218" unitRef="usd">326000</us-gaap:TemporaryEquityNetIncome>
    <asth:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity contextRef="c-34" decimals="-3" id="f-219" unitRef="usd">14835000</asth:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <asth:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity contextRef="c-35" decimals="-3" id="f-220" unitRef="usd">1701000</asth:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <asth:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity contextRef="c-1" decimals="-3" id="f-221" unitRef="usd">16536000</asth:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-35" decimals="-3" id="f-222" unitRef="usd">25000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-1" decimals="-3" id="f-223" unitRef="usd">25000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest contextRef="c-35" decimals="-3" id="f-224" unitRef="usd">150000</us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest contextRef="c-1" decimals="-3" id="f-225" unitRef="usd">150000</us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c-36"
      decimals="INF"
      id="f-226"
      unitRef="shares">5149</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-37" decimals="-3" id="f-227" unitRef="usd">-2407000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-1" decimals="-3" id="f-228" unitRef="usd">-2407000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-37" decimals="-3" id="f-229" unitRef="usd">5748000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-1" decimals="-3" id="f-230" unitRef="usd">5748000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c-36"
      decimals="INF"
      id="f-231"
      unitRef="shares">631712</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-36" decimals="-3" id="f-232" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-37" decimals="-3" id="f-233" unitRef="usd">21951000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-1" decimals="-3" id="f-234" unitRef="usd">21952000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <asth:AcquisitionOfNonControllingInterestShares
      contextRef="c-36"
      decimals="INF"
      id="f-235"
      unitRef="shares">22340</asth:AcquisitionOfNonControllingInterestShares>
    <asth:NoncontrollingInterestIncreaseDecreaseFromBusinessCombination contextRef="c-37" decimals="-3" id="f-236" unitRef="usd">-856000</asth:NoncontrollingInterestIncreaseDecreaseFromBusinessCombination>
    <asth:NoncontrollingInterestIncreaseDecreaseFromBusinessCombination contextRef="c-35" decimals="-3" id="f-237" unitRef="usd">321000</asth:NoncontrollingInterestIncreaseDecreaseFromBusinessCombination>
    <asth:NoncontrollingInterestIncreaseDecreaseFromBusinessCombination contextRef="c-1" decimals="-3" id="f-238" unitRef="usd">-535000</asth:NoncontrollingInterestIncreaseDecreaseFromBusinessCombination>
    <asth:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares contextRef="c-35" decimals="-3" id="f-239" unitRef="usd">-95000</asth:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares>
    <asth:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares contextRef="c-1" decimals="-3" id="f-240" unitRef="usd">-95000</asth:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="c-38" decimals="-3" id="f-241" unitRef="usd">-205557000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="c-39"
      decimals="INF"
      id="f-242"
      unitRef="shares">47458264</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-39" decimals="-3" id="f-243" unitRef="usd">48000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-40" decimals="-3" id="f-244" unitRef="usd">395473000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-41" decimals="-3" id="f-245" unitRef="usd">257969000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-42" decimals="-3" id="f-246" unitRef="usd">4485000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-247" unitRef="usd">657975000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="c-43" decimals="-3" id="f-248" unitRef="usd">14237000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="c-44"
      decimals="INF"
      id="f-249"
      unitRef="shares">46575699</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-44" decimals="-3" id="f-250" unitRef="usd">47000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-45" decimals="-3" id="f-251" unitRef="usd">360097000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-46" decimals="-3" id="f-252" unitRef="usd">182417000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-47" decimals="-3" id="f-253" unitRef="usd">1749000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-48" decimals="-3" id="f-254" unitRef="usd">544310000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquityNetIncome contextRef="c-49" decimals="-3" id="f-255" unitRef="usd">-1729000</us-gaap:TemporaryEquityNetIncome>
    <asth:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity contextRef="c-50" decimals="-3" id="f-256" unitRef="usd">13132000</asth:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <asth:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity contextRef="c-51" decimals="-3" id="f-257" unitRef="usd">1085000</asth:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <asth:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity contextRef="c-27" decimals="-3" id="f-258" unitRef="usd">14217000</asth:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c-52"
      decimals="INF"
      id="f-259"
      unitRef="shares">57825</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-53" decimals="-3" id="f-260" unitRef="usd">-109000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-27" decimals="-3" id="f-261" unitRef="usd">-109000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <asth:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants
      contextRef="c-52"
      decimals="INF"
      id="f-262"
      unitRef="shares">125000</asth:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants>
    <asth:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants contextRef="c-53" decimals="-3" id="f-263" unitRef="usd">1250000</asth:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <asth:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants contextRef="c-27" decimals="-3" id="f-264" unitRef="usd">1250000</asth:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-52"
      decimals="INF"
      id="f-265"
      unitRef="shares">270081</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod contextRef="c-53" decimals="-3" id="f-266" unitRef="usd">9539000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod contextRef="c-27" decimals="-3" id="f-267" unitRef="usd">9539000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-53" decimals="-3" id="f-268" unitRef="usd">3445000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-27" decimals="-3" id="f-269" unitRef="usd">3445000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <asth:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares contextRef="c-51" decimals="-3" id="f-270" unitRef="usd">-120000</asth:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares>
    <asth:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares contextRef="c-27" decimals="-3" id="f-271" unitRef="usd">-120000</asth:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares>
    <asth:TemporaryEquityTransferOfCommonControlEntities contextRef="c-49" decimals="-3" id="f-272" unitRef="usd">1769000</asth:TemporaryEquityTransferOfCommonControlEntities>
    <asth:StockholdersEquityTransferOfCommonControlEntities contextRef="c-53" decimals="-3" id="f-273" unitRef="usd">-2447000</asth:StockholdersEquityTransferOfCommonControlEntities>
    <asth:StockholdersEquityTransferOfCommonControlEntities contextRef="c-27" decimals="-3" id="f-274" unitRef="usd">-2447000</asth:StockholdersEquityTransferOfCommonControlEntities>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="c-54" decimals="-3" id="f-275" unitRef="usd">14277000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="c-55"
      decimals="INF"
      id="f-276"
      unitRef="shares">46488443</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-55" decimals="-3" id="f-277" unitRef="usd">47000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-56" decimals="-3" id="f-278" unitRef="usd">352697000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-57" decimals="-3" id="f-279" unitRef="usd">195549000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-58" decimals="-3" id="f-280" unitRef="usd">2714000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-59" decimals="-3" id="f-281" unitRef="usd">551007000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-282" unitRef="usd">16862000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-27" decimals="-3" id="f-283" unitRef="usd">12488000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-284" unitRef="usd">5096000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-27" decimals="-3" id="f-285" unitRef="usd">4292000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-1" decimals="-3" id="f-286" unitRef="usd">458000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-27" decimals="-3" id="f-287" unitRef="usd">237000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-288" unitRef="usd">5748000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-27" decimals="-3" id="f-289" unitRef="usd">3445000</us-gaap:ShareBasedCompensation>
    <asth:NoncashLeaseExpense contextRef="c-1" decimals="-3" id="f-290" unitRef="usd">3155000</asth:NoncashLeaseExpense>
    <asth:NoncashLeaseExpense contextRef="c-27" decimals="-3" id="f-291" unitRef="usd">2013000</asth:NoncashLeaseExpense>
    <asth:UnrealizedGainLossFromInvestmentInEquitySecurities contextRef="c-1" decimals="-3" id="f-292" unitRef="usd">1099000</asth:UnrealizedGainLossFromInvestmentInEquitySecurities>
    <asth:UnrealizedGainLossFromInvestmentInEquitySecurities contextRef="c-27" decimals="-3" id="f-293" unitRef="usd">-5755000</asth:UnrealizedGainLossFromInvestmentInEquitySecurities>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-3" id="f-294" unitRef="usd">632000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-27" decimals="-3" id="f-295" unitRef="usd">2484000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="c-1" decimals="-3" id="f-296" unitRef="usd">0</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="c-27" decimals="-3" id="f-297" unitRef="usd">-637000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-1" decimals="-3" id="f-298" unitRef="usd">-7248000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-27" decimals="-3" id="f-299" unitRef="usd">283000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:ProceedsFromOtherOperatingActivities contextRef="c-1" decimals="-3" id="f-300" unitRef="usd">6795000</us-gaap:ProceedsFromOtherOperatingActivities>
    <us-gaap:ProceedsFromOtherOperatingActivities contextRef="c-27" decimals="-3" id="f-301" unitRef="usd">0</us-gaap:ProceedsFromOtherOperatingActivities>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-302" unitRef="usd">26128000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-27" decimals="-3" id="f-303" unitRef="usd">26373000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties contextRef="c-1" decimals="-3" id="f-304" unitRef="usd">3374000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties contextRef="c-27" decimals="-3" id="f-305" unitRef="usd">9730000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c-1" decimals="-3" id="f-306" unitRef="usd">1403000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c-27" decimals="-3" id="f-307" unitRef="usd">94000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <asth:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets contextRef="c-1" decimals="-3" id="f-308" unitRef="usd">4255000</asth:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>
    <asth:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets contextRef="c-27" decimals="-3" id="f-309" unitRef="usd">506000</asth:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-1" decimals="-3" id="f-310" unitRef="usd">-92000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-27" decimals="-3" id="f-311" unitRef="usd">23000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="-3" id="f-312" unitRef="usd">905000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-27" decimals="-3" id="f-313" unitRef="usd">-4517000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="c-1" decimals="-3" id="f-314" unitRef="usd">56000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="c-27" decimals="-3" id="f-315" unitRef="usd">911000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <asth:IncreaseDecreaseInMedicalLiabilities contextRef="c-1" decimals="-3" id="f-316" unitRef="usd">-808000</asth:IncreaseDecreaseInMedicalLiabilities>
    <asth:IncreaseDecreaseInMedicalLiabilities contextRef="c-27" decimals="-3" id="f-317" unitRef="usd">17141000</asth:IncreaseDecreaseInMedicalLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="c-1" decimals="-3" id="f-318" unitRef="usd">14542000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="c-27" decimals="-3" id="f-319" unitRef="usd">6333000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-320" unitRef="usd">-3083000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-27" decimals="-3" id="f-321" unitRef="usd">-2088000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-1" decimals="-3" id="f-322" unitRef="usd">298000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-27" decimals="-3" id="f-323" unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-324" unitRef="usd">5977000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-27" decimals="-3" id="f-325" unitRef="usd">7720000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-1" decimals="-3" id="f-326" unitRef="usd">50649000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-27" decimals="-3" id="f-327" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties contextRef="c-1" decimals="-3" id="f-328" unitRef="usd">6000</us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties>
    <us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties contextRef="c-27" decimals="-3" id="f-329" unitRef="usd">2141000</us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-1" decimals="-3" id="f-330" unitRef="usd">27000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-27" decimals="-3" id="f-331" unitRef="usd">1000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="c-1" decimals="-3" id="f-332" unitRef="usd">0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="c-27" decimals="-3" id="f-333" unitRef="usd">325000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToFundLongtermLoansToRelatedParties contextRef="c-1" decimals="-3" id="f-334" unitRef="usd">20000000</us-gaap:PaymentsToFundLongtermLoansToRelatedParties>
    <us-gaap:PaymentsToFundLongtermLoansToRelatedParties contextRef="c-27" decimals="-3" id="f-335" unitRef="usd">0</us-gaap:PaymentsToFundLongtermLoansToRelatedParties>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-336" unitRef="usd">369000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-27" decimals="-3" id="f-337" unitRef="usd">6027000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <asth:DepositForPurchaseOfProperty contextRef="c-1" decimals="-3" id="f-338" unitRef="usd">0</asth:DepositForPurchaseOfProperty>
    <asth:DepositForPurchaseOfProperty contextRef="c-27" decimals="-3" id="f-339" unitRef="usd">8824000</asth:DepositForPurchaseOfProperty>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-340" unitRef="usd">-71039000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-27" decimals="-3" id="f-341" unitRef="usd">-14035000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-1" decimals="-3" id="f-342" unitRef="usd">95000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-27" decimals="-3" id="f-343" unitRef="usd">120000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt contextRef="c-1" decimals="-3" id="f-344" unitRef="usd">110000000</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt contextRef="c-27" decimals="-3" id="f-345" unitRef="usd">1617000</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:RepaymentsOfOtherLongTermDebt contextRef="c-1" decimals="-3" id="f-346" unitRef="usd">3500000</us-gaap:RepaymentsOfOtherLongTermDebt>
    <us-gaap:RepaymentsOfOtherLongTermDebt contextRef="c-27" decimals="-3" id="f-347" unitRef="usd">153000</us-gaap:RepaymentsOfOtherLongTermDebt>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations contextRef="c-1" decimals="-3" id="f-348" unitRef="usd">179000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations contextRef="c-27" decimals="-3" id="f-349" unitRef="usd">154000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-1" decimals="-3" id="f-350" unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-27" decimals="-3" id="f-351" unitRef="usd">1250000</us-gaap:ProceedsFromWarrantExercises>
    <asth:PaymentForRepurchaseOfTreasuryStockFinancingActivities contextRef="c-1" decimals="-3" id="f-352" unitRef="usd">0</asth:PaymentForRepurchaseOfTreasuryStockFinancingActivities>
    <asth:PaymentForRepurchaseOfTreasuryStockFinancingActivities contextRef="c-27" decimals="-3" id="f-353" unitRef="usd">9539000</asth:PaymentForRepurchaseOfTreasuryStockFinancingActivities>
    <us-gaap:ProceedsFromPaymentsToMinorityShareholders contextRef="c-1" decimals="-3" id="f-354" unitRef="usd">150000</us-gaap:ProceedsFromPaymentsToMinorityShareholders>
    <us-gaap:ProceedsFromPaymentsToMinorityShareholders contextRef="c-27" decimals="-3" id="f-355" unitRef="usd">0</us-gaap:ProceedsFromPaymentsToMinorityShareholders>
    <us-gaap:PaymentsOfDividendsMinorityInterest contextRef="c-1" decimals="-3" id="f-356" unitRef="usd">25000</us-gaap:PaymentsOfDividendsMinorityInterest>
    <us-gaap:PaymentsOfDividendsMinorityInterest contextRef="c-27" decimals="-3" id="f-357" unitRef="usd">0</us-gaap:PaymentsOfDividendsMinorityInterest>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-358" unitRef="usd">106351000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-27" decimals="-3" id="f-359" unitRef="usd">-7099000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-360" unitRef="usd">41289000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-27" decimals="-3" id="f-361" unitRef="usd">-13414000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="-3" id="f-362" unitRef="usd">294152000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-48" decimals="-3" id="f-363" unitRef="usd">288027000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-364" unitRef="usd">335441000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-59" decimals="-3" id="f-365" unitRef="usd">274613000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid contextRef="c-1" decimals="-3" id="f-366" unitRef="usd">194000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-27" decimals="-3" id="f-367" unitRef="usd">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-368" unitRef="usd">6430000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-27" decimals="-3" id="f-369" unitRef="usd">2991000</us-gaap:InterestPaidNet>
    <asth:NonCashBusinessAcquisition contextRef="c-1" decimals="-3" id="f-370" unitRef="usd">63935000</asth:NonCashBusinessAcquisition>
    <asth:NonCashBusinessAcquisition contextRef="c-27" decimals="-3" id="f-371" unitRef="usd">3844000</asth:NonCashBusinessAcquisition>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-372" unitRef="usd">4910000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-27" decimals="-3" id="f-373" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:StockIssued1 contextRef="c-1" decimals="-3" id="f-374" unitRef="usd">21952000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-27" decimals="-3" id="f-375" unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:TransferToInvestments contextRef="c-1" decimals="-3" id="f-376" unitRef="usd">9487000</us-gaap:TransferToInvestments>
    <us-gaap:TransferToInvestments contextRef="c-27" decimals="-3" id="f-377" unitRef="usd">0</us-gaap:TransferToInvestments>
    <asth:DrawOnLetterOfCreditThroughRevolverLoan contextRef="c-1" decimals="-3" id="f-378" unitRef="usd">4759000</asth:DrawOnLetterOfCreditThroughRevolverLoan>
    <asth:DrawOnLetterOfCreditThroughRevolverLoan contextRef="c-27" decimals="-3" id="f-379" unitRef="usd">0</asth:DrawOnLetterOfCreditThroughRevolverLoan>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-380" unitRef="usd">334796000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-59" decimals="-3" id="f-381" unitRef="usd">274613000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashEquivalentsNoncurrent contextRef="c-5" decimals="-3" id="f-382" unitRef="usd">645000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashEquivalentsNoncurrent contextRef="c-59" decimals="-3" id="f-383" unitRef="usd">0</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-384" unitRef="usd">335441000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-59" decimals="-3" id="f-385" unitRef="usd">274613000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NatureOfOperations contextRef="c-1" id="f-386">Description of Business&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless the context dictates otherwise, references in these notes to the financial statements to the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our,&#x201d; and similar words are references to Astrana Health, Inc. (&#x201c;Astrana&#x201d;), formerly known as Apollo Medical Holdings, Inc., and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (&#x201c;VIEs&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Headquartered in Alhambra, California, Astrana is a leading provider-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, Astrana operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver accessible, high-quality care to patients in a cost-effective manner. Together with Astrana&#x2019;s affiliated physician groups and consolidated subsidiaries and VIEs, the Company provides value-based care enablement services and care delivery with its consolidated care partners to serve patients in California, Nevada, and Texas, the majority of whom are covered by private or public insurance provided through Medicare, Medicaid, and health maintenance organizations (&#x201c;HMOs&#x201d;), with a small portion of our revenue coming from non-insured patients. The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company&#x2019;s physician network consists of primary care physicians, specialist physicians, physician and specialist extenders, and hospitalists.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s three reportable segments are Care Partners, Care Delivery and Care Enablement, which are described as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Care Partners&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Care Partners segment is focused on building and managing high-quality and high-performance provider networks by partnering with, empowering, and investing in strong provider partners aligned on a shared vision for coordinated care delivery. By leveraging the Company&#x2019;s unique care enablement platform and ability to recruit, empower, and incentivize physicians to effectively manage total cost of care, the Company is able to organize partnered providers into successful multi-payer risk-bearing organizations that take on varying levels of risk based on total cost of care across membership in all lines of business, including Medicare fee for service (&#x201c;FFS&#x201d;), Medicare Advantage, Medicaid, Commercial, and Exchange. Through the Company&#x2019;s network of &#x201c;independent practice associations&#x201d; (&#x201c;IPAs&#x201d;), &#x201c;accountable care organizations&#x201d; (&#x201c;ACOs&#x201d;), and Restricted Knox-Keene licensed health plan, the Company&#x2019;s healthcare delivery entities are responsible for coordinating and delivering high-quality care to the Company&#x2019;s patients and ensuring continuity of care in Astrana&#x2019;s ecosystem across age, stage of life, or life circumstance. Beginning in 2024, in addition to participating in the ACO REACH Model, the Company began participating in the Medicare Shared Savings Program (&#x201c;MSSP&#x201d;). The MSSP was created to promote accountability and improve coordination of care for Medicare beneficiaries. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Care Delivery&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Care Delivery segment is a patient-centric, data-driven care delivery organization focused on delivering high-quality and accessible care to all patients. The Company&#x2019;s care delivery organization includes primary care, multi-specialty care, and ancillary care services. This segment includes the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Primary care clinics, including post-acute care services;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Multi-specialty care clinics and medical groups, including hospitalist, intensivist, and physician advisory services, cardiac care and diagnostic testing, and specialized care for women&#x2019;s health; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Ancillary service providers, such as urgent care centers, outpatient imaging centers, ambulatory surgery centers, and full-service labs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Care Enablement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Care Enablement segment is an integrated, end-to-end clinical, operational, financial, and administrative platform powered by the Company&#x2019;s proprietary technology suite that enhances the delivery of high-quality, value-based care to patients and leads to superior clinical and financial outcomes. The Company provides solutions to providers, including independent physicians, provider and medical groups, accountable care organizations, and payers, including health plans and other risk-bearing organizations. The Company&#x2019;s platform meets providers and payers where they are, with a wide spectrum of solutions across the total cost of care risk spectrum, ranging from solutions for fee-for-service entities to hospital-shared risk-bearing entities, and across patient types, including Medicare, Medicaid, Commercial, and Exchange patients. This segment includes the Company&#x2019;s wholly owned subsidiaries which operate as management services organizations (&#x201c;MSOs&#x201d;), which enter into long-term management and/or administrative services agreements with IPAs, ACOs, clinics, or independent providers. By leveraging the Company&#x2019;s care enablement platform, providers and payers can improve their ability to deliver high-quality care to their patients and achieve better patient outcomes.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-387"
      unitRef="segment">3</us-gaap:NumberOfReportableSegments>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c-1" id="f-388">Basis of Presentation and Summary of Significant Accounting Policies&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated balance sheet at December&#160;31, 2023, has been derived from the Company&#x2019;s audited condensed consolidated financial statements, but does not include all annual disclosures required by generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;). The accompanying unaudited condensed consolidated financial statements as of March&#160;31, 2024, and for the three months ended March&#160;31, 2024 and 2023, have been prepared in accordance with U.S. GAAP for interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited condensed consolidated financial statements and related notes to the financial statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2023, as filed with the SEC on February&#160;29, 2024. In the opinion of management, all material adjustments (consisting of normal recurring adjustments as well as intercompany accounts and transactions, which have been eliminated) considered necessary for a fair presentation have been made to make the condensed consolidated financial statements not misleading, as required by Regulation S-X, Rule 10-01. Operating results for the three months ended March&#160;31, 2024, are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2024, or any future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated balance sheets as of March&#160;31, 2024 and December&#160;31, 2023, and the condensed consolidated statements of income for the three months ended March&#160;31, 2024 and 2023, include Astrana&#x2019;s wholly owned subsidiaries and consolidated variable interest entities (&#x201c;VIEs&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited condensed consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read or have access to our audited condensed consolidated financial statements for the fiscal year ended December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred but not reported (&#x201c;IBNR&#x201d;) claims), determination of hospital shared-risk and health plan shared-risk revenue and receivables (including constraints, completion factors and historical margins), income tax-valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition-related costs separately from the business combination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reportable Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024, the Company operates in three reportable segments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Care Partners;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Care Delivery; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Care Enablement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 1 &#x2014; &#x201c;Description of Business&#x201d; and Note 18 &#x2014; &#x201c;Segments&#x201d; to the condensed consolidated financial statements for information on the Company&#x2019;s segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within ninety days from their date of purchase to be cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;). The Company believes it is not exposed to any significant credit risk with respect to its cash and cash equivalents and restricted cash. As of March&#160;31, 2024 and December&#160;31, 2023, the Company&#x2019;s deposit accounts with banks exceeded the FDIC&#x2019;s insured limit by approximately $353.6 million and $318.9 million, respectively. The Company has not experienced any losses to date and performs ongoing evaluations of these financial institutions to limit the Company&#x2019;s concentration of risk exposure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Receivables, Receivables &#x2013; Related Parties, Other Receivables and Loan Receivables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements, incentive receivables, management fee income, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s receivables &#x2013; related parties are comprised of risk pool settlements, management fee income, and other receivables. Receivables &#x2013; related parties are recorded and stated at the amount expected to be collected.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s loan receivables consists of promissory notes that accrue interest per annum. As of March&#160;31, 2024, promissory notes are expected to be collected by their maturity dates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitation and claims receivables relate to each health plan&#x2019;s capitation and are received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#x2019;s hospital shared-risk pool receivable, which is recorded quarterly based on reports received from the Company&#x2019;s hospital partners and management&#x2019;s estimate of the Company&#x2019;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consist of receivables from fee-for-service (&#x201c;FFS&#x201d;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop-loss insurance premium reimbursements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains reserves for potential credit losses on the receivables. Management reviews the composition of the Company&#x2019;s receivables and analyzes historical bad debts, customer concentrations, customer creditworthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regard to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (&#x201c;CECL&#x201d;) model. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company disaggregates revenue from contracts by service type and payer type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The condensed consolidated statements of income present disaggregated revenue by service type. The following table presents disaggregated revenue generated by payer type for the three months ended March&#160;31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicaid&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other third parties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had major payers that contributed the following percentages of net revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.227%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payer A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payer B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; *Less than 10% of total net revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had major payers that contributed to the following percentages of receivables and receivables &#x2013; related parties:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payer A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payer C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company receives payments from the following sources for services rendered:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Commercial insurers;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Federal government under the Medicare program administered by CMS;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;State governments under Medicaid and other programs;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Other third-party payers (e.g., hospitals and IPAs); and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Individual patients and clients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue primarily consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Capitation revenue;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Risk pool settlements and incentives;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Management fee revenue; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;FFS revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Risk Pool Settlements and Incentives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medicare Shared Savings Program Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in 2024, Astrana participates in MSSP. The MSSP has multiple risk tracks, and Astrana is currently participating in the ENHANCED risk track. Under the MSSP Model, Astrana recruits a group of Participant and Preferred (in-network) Providers. Based on the Participant Providers that join our ACO, CMS grants us a pool of Traditional Medicare patients (beneficiaries) to manage (the &#x201c;MSSP Aligned Beneficiaries&#x201d;). The Company&#x2019;s MSSP Aligned Beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. CMS continues to pay participant and preferred providers on a fee-for-service basis for Medicare-covered services provided to MSSP Aligned Beneficiaries. The Company continues to bear risk on all Medicare expenditures (both in-network and out-of-network), excluding drug expenditures covered by Medicare Part D, based on a budgetary benchmark established with CMS. Astrana&#x2019;s shared savings or losses in managing the Company&#x2019;s beneficiaries are generally determined on an annual basis after reconciliation with CMS. Pursuant to Astrana&#x2019;s risk-share agreement with CMS, the Company is eligible to receive the surplus (&#x201c;shared savings&#x201d;) or is liable for the deficit (&#x201c;shared losses&#x201d;) according to the budgetary benchmark established by CMS based on Astrana&#x2019;s efficiency, or lack thereof, in managing the expenditures associated with the Company&#x2019;s MSSP Aligned Beneficiaries. The Company estimates the shared service revenue by analyzing the activities during the relevant time period in contemplation of the agreed upon benchmarks, metrics, performance criteria, and attribution criteria based on those and any other contractually defined factors. Revenue is not recorded and is constrained until the shared service revenue can be reasonably estimated by the Company and to the extent that it is probable that a significant reversal will not occur once any uncertainty associated with the variable consideration is subsequently resolved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted for both items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the condensed consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-07 "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures," which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for the Company&#x2019;s annual periods beginning January 1, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on its financial statement disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for the Company&#x2019;s annual periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on its financial statement disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-389">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;The accompanying condensed consolidated balance sheet at December&#160;31, 2023, has been derived from the Company&#x2019;s audited condensed consolidated financial statements, but does not include all annual disclosures required by generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;). The accompanying unaudited condensed consolidated financial statements as of March&#160;31, 2024, and for the three months ended March&#160;31, 2024 and 2023, have been prepared in accordance with U.S. GAAP for interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited condensed consolidated financial statements and related notes to the financial statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2023, as filed with the SEC on February&#160;29, 2024. In the opinion of management, all material adjustments (consisting of normal recurring adjustments as well as intercompany accounts and transactions, which have been eliminated) considered necessary for a fair presentation have been made to make the condensed consolidated financial statements not misleading, as required by Regulation S-X, Rule 10-01.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-390">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated balance sheets as of March&#160;31, 2024 and December&#160;31, 2023, and the condensed consolidated statements of income for the three months ended March&#160;31, 2024 and 2023, include Astrana&#x2019;s wholly owned subsidiaries and consolidated variable interest entities (&#x201c;VIEs&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited condensed consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read or have access to our audited condensed consolidated financial statements for the fiscal year ended December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-391">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred but not reported (&#x201c;IBNR&#x201d;) claims), determination of hospital shared-risk and health plan shared-risk revenue and receivables (including constraints, completion factors and historical margins), income tax-valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:BusinessCombinationsPolicy contextRef="c-1" id="f-392">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition-related costs separately from the business combination.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-393">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reportable Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024, the Company operates in three reportable segments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Care Partners;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Care Delivery; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Care Enablement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 1 &#x2014; &#x201c;Description of Business&#x201d; and Note 18 &#x2014; &#x201c;Segments&#x201d; to the condensed consolidated financial statements for information on the Company&#x2019;s segments.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-394"
      unitRef="segment">3</us-gaap:NumberOfReportableSegments>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-395">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within ninety days from their date of purchase to be cash equivalents.&lt;/span&gt;&lt;/div&gt;The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;). The Company believes it is not exposed to any significant credit risk with respect to its cash and cash equivalents and restricted cash.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashUninsuredAmount contextRef="c-5" decimals="-5" id="f-396" unitRef="usd">353600000</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount contextRef="c-6" decimals="-5" id="f-397" unitRef="usd">318900000</us-gaap:CashUninsuredAmount>
    <asth:ReceivablesReceivablesRelatedPartiesOtherReceivablesAndLoanReceivablesPolicyTextBlock contextRef="c-1" id="f-398">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Receivables, Receivables &#x2013; Related Parties, Other Receivables and Loan Receivables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements, incentive receivables, management fee income, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s receivables &#x2013; related parties are comprised of risk pool settlements, management fee income, and other receivables. Receivables &#x2013; related parties are recorded and stated at the amount expected to be collected.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s loan receivables consists of promissory notes that accrue interest per annum. As of March&#160;31, 2024, promissory notes are expected to be collected by their maturity dates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitation and claims receivables relate to each health plan&#x2019;s capitation and are received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#x2019;s hospital shared-risk pool receivable, which is recorded quarterly based on reports received from the Company&#x2019;s hospital partners and management&#x2019;s estimate of the Company&#x2019;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consist of receivables from fee-for-service (&#x201c;FFS&#x201d;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop-loss insurance premium reimbursements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains reserves for potential credit losses on the receivables. Management reviews the composition of the Company&#x2019;s receivables and analyzes historical bad debts, customer concentrations, customer creditworthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis. &lt;/span&gt;&lt;/div&gt;Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regard to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (&#x201c;CECL&#x201d;) model.</asth:ReceivablesReceivablesRelatedPartiesOtherReceivablesAndLoanReceivablesPolicyTextBlock>
    <asth:RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear contextRef="c-1" id="f-399">P18M</asth:RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-400">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risks&lt;/span&gt;&lt;/div&gt;The Company disaggregates revenue from contracts by service type and payer type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The condensed consolidated statements of income present disaggregated revenue by service type.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-401">The following table presents disaggregated revenue generated by payer type for the three months ended March&#160;31, 2024 and 2023 (in thousands):&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicaid&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other third parties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-60" decimals="-3" id="f-402" unitRef="usd">49512000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-61" decimals="-3" id="f-403" unitRef="usd">40019000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-62" decimals="-3" id="f-404" unitRef="usd">246564000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-63" decimals="-3" id="f-405" unitRef="usd">216310000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-64" decimals="-3" id="f-406" unitRef="usd">81263000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-65" decimals="-3" id="f-407" unitRef="usd">67339000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-66" decimals="-3" id="f-408" unitRef="usd">27017000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-67" decimals="-3" id="f-409" unitRef="usd">13576000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-410" unitRef="usd">404356000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-27" decimals="-3" id="f-411" unitRef="usd">337244000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock contextRef="c-1" id="f-412">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had major payers that contributed the following percentages of net revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.227%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payer A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payer B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; *Less than 10% of total net revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had major payers that contributed to the following percentages of receivables and receivables &#x2013; related parties:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payer A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payer C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-68" decimals="3" id="f-413" unitRef="number">0.340</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-69" decimals="3" id="f-414" unitRef="number">0.415</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-70" decimals="3" id="f-415" unitRef="number">0.135</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-71" decimals="3" id="f-416" unitRef="number">0.310</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-72" decimals="3" id="f-417" unitRef="number">0.360</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-73" decimals="3" id="f-418" unitRef="number">0.330</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-74" decimals="3" id="f-419" unitRef="number">0.410</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-420">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company receives payments from the following sources for services rendered:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Commercial insurers;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Federal government under the Medicare program administered by CMS;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;State governments under Medicaid and other programs;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Other third-party payers (e.g., hospitals and IPAs); and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Individual patients and clients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue primarily consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Capitation revenue;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Risk pool settlements and incentives;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Management fee revenue; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;FFS revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Risk Pool Settlements and Incentives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medicare Shared Savings Program Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in 2024, Astrana participates in MSSP. The MSSP has multiple risk tracks, and Astrana is currently participating in the ENHANCED risk track. Under the MSSP Model, Astrana recruits a group of Participant and Preferred (in-network) Providers. Based on the Participant Providers that join our ACO, CMS grants us a pool of Traditional Medicare patients (beneficiaries) to manage (the &#x201c;MSSP Aligned Beneficiaries&#x201d;). The Company&#x2019;s MSSP Aligned Beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. CMS continues to pay participant and preferred providers on a fee-for-service basis for Medicare-covered services provided to MSSP Aligned Beneficiaries. The Company continues to bear risk on all Medicare expenditures (both in-network and out-of-network), excluding drug expenditures covered by Medicare Part D, based on a budgetary benchmark established with CMS. Astrana&#x2019;s shared savings or losses in managing the Company&#x2019;s beneficiaries are generally determined on an annual basis after reconciliation with CMS. Pursuant to Astrana&#x2019;s risk-share agreement with CMS, the Company is eligible to receive the surplus (&#x201c;shared savings&#x201d;) or is liable for the deficit (&#x201c;shared losses&#x201d;) according to the budgetary benchmark established by CMS based on Astrana&#x2019;s efficiency, or lack thereof, in managing the expenditures associated with the Company&#x2019;s MSSP Aligned Beneficiaries. The Company estimates the shared service revenue by analyzing the activities during the relevant time period in contemplation of the agreed upon benchmarks, metrics, performance criteria, and attribution criteria based on those and any other contractually defined factors. Revenue is not recorded and is constrained until the shared service revenue can be reasonably estimated by the Company and to the extent that it is probable that a significant reversal will not occur once any uncertainty associated with the variable consideration is subsequently resolved.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-421">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted for both items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the condensed consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-422">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-07 "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures," which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for the Company&#x2019;s annual periods beginning January 1, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on its financial statement disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for the Company&#x2019;s annual periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on its financial statement disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c-1" id="f-423">Business Combinations, Asset Acquisitions, and Goodwill&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advanced Health Management Systems, L.P. (&#x201c;AHMS&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 31, 2024, the Company, through its wholly owned subsidiary, purchased all of the outstanding general and limited partnership interests of Advanced Health Management Systems, L.P. (&#x201c;AHMS&#x201d;). AHMS is engaged in the business of providing management, consulting, administrative and other support services to entities that provide or arrange for the provision of professional healthcare services. In addition, one of AHMS&#x2019;s wholly owned subsidiaries is a Restricted Knox-Keene licensed health plan with members in the Los Angeles, California area. Total consideration for the acquisition was $63.9 million. As the cash was not paid on the closing date, the purchase price was accrued and presented within accounts payable and accrued expenses in the accompanying condensed consolidated balance sheet as of March&#160;31, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prime Community Care of Central Valley, Inc. (&#x201c;PCCCV&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 29, 2024, the Company, through its consolidated subsidiary, acquired certain assets of Prime Community Care of Central Valley, Inc., a California professional medical corporation (&#x201c;PCCCV&#x201d;). Total consideration of the acquisition was approximately $10.3 million, consisting of cash funded upon the close date and contingent considerations of $2.3 million (&#x201c;PCCCV contingent considerations&#x201d;). Refer to Note 19 - &#x201c;Fair Value Measurements of Financial Instruments&#x201d; for additional information on contingent considerations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Community Family Care Medical Group IPA, Inc. (&#x201c;CFC&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 31, 2024, the Company, through its consolidated subsidiary, acquired certain assets of CFC. CFC is an IPA that manages the healthcare of members in the Los Angeles, California area. The group serves patients across Medicare, Medicaid, and Commercial payers. The total consideration for the purchase was $120.2 million, consisting of $91.0 million cash funded upon the close date, $22.0 million of the Company&#x2019;s common stock, resulting in the issuance of 631,712 shares of common stock., and contingent considerations of $7.3 million (&#x201c;CFC contingent considerations&#x201d;). Refer to Note 19 - &#x201c;Fair Value Measurements of Financial Instruments&#x201d; for additional information on contingent considerations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advanced Diagnostic and Surgical Center, Inc. (&#x201c;ADSC&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2024, the Company acquired 95% of the equity interest of Advanced Diagnostic and Surgical Center, Inc. (&#x201c;ADSC&#x201d;). ADSC is a diagnostic and surgical center that also provides ambulatory surgery services. The total consideration consisted of cash funded upon close of the transaction and contingent considerations of $3.6 million (&#x201c;ADSC contingent considerations&#x201d;). Refer to Note 19 - &#x201c;Fair Value Measurements of Financial Instruments&#x201d; for additional information on contingent considerations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is still in the process of finalizing the purchase price allocation for these acquisitions, and therefore, the balances are subject to change as a result of any working capital or fair value adjustments, and seller indemnification obligations. The following table summarizes the preliminary purchase price allocation of the fair value of assets acquired and liabilities assumed  related to each acquisition at the acquisition date (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.257%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;CFC&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;AHMS &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;Others *&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net &#160;Total &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;Total purchase consideration: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Cash paid &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Cash payable &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Contingent consideration &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Common stock issued &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;120,214&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;63,935&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,397&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;202,546&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Investment in marketable securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Receivables &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Prepaid expenses and other current assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts due from affiliates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Land, property and equipment &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Intangible assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Goodwill &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Restricted cash &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Accounts payable and accrued expenses &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Medical liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts due to affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Income taxes payable &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Deferred tax liability &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Noncontrolling interest &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identified liabilities assumed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total net identifiable assets acquired &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;120,214&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;63,935&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,397&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;202,546&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Others consist of estimated fair values of the assets acquired, net of cash acquired, related to ADSC and PCCCV.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;br/&gt;Following the acquisition dates of CFC, AHMS, ADSC and PCCCV, the operating results have been included in our consolidated financial statements. For the period from the acquisition dates through March&#160;31, 2024, total revenues and net income were $33.2 million and $5.1 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Pro Forma Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The pro forma financial information in the table below presents the combined results of the Company and CFC, AHMS, ADSC and PCCCV as if the acquisitions had occurred on January 1, 2023. The pro forma information presented is shown for illustrative purposes only and is not necessarily indicative of future results of operations of the Company or results of operations of the Company that would have actually occurred had the transactions been in effect for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.227%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share - basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share - diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisitions were accounted for under the acquisition method of accounting. The fair value of the consideration for the acquired companies was allocated to acquired tangible and intangible assets and liabilities based upon their fair values. The excess of the purchase consideration over the fair value of the net tangible and identifiable intangible assets acquired was recorded as goodwill. Factors leading to goodwill being recognized are the Company&#x2019;s expectation of synergies from combining operations of entities acquired and the Company, as well as the value of intangible assets that are not separately recognized, such as assembled workforce. The determination of the fair value of assets and liabilities acquired requires the Company to make estimates and use valuation techniques when market value is not readily available. The results of operations from the acquisitions have been included in the Company&#x2019;s financial statements from the date of acquisition. Transaction costs associated with business acquisitions are expensed as they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the time of acquisition, the Company estimates the amount of the identifiable intangible assets based on a valuation and the facts and circumstances available at the time. The Company determines the final value of the identifiable intangible assets as soon as information is available, but not more than one year from the date of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is not deductible for tax purposes. The Company had no impairment of its goodwill or indefinite-lived intangible assets during the three months ended March&#160;31, 2024 and 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the carrying value of goodwill for the three months ended March&#160;31, 2024 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.330%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(906)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-75" decimals="-5" id="f-424" unitRef="usd">63900000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-76" decimals="-5" id="f-425" unitRef="usd">10300000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <asth:ContingentConsideration contextRef="c-76" decimals="-5" id="f-426" unitRef="usd">2300000</asth:ContingentConsideration>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-77" decimals="-5" id="f-427" unitRef="usd">120200000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <asth:ConsiderationOfAcquisitionInCashFunded contextRef="c-77" decimals="-5" id="f-428" unitRef="usd">91000000</asth:ConsiderationOfAcquisitionInCashFunded>
    <asth:BusinessAcquisitionOfCommonStock contextRef="c-77" decimals="-5" id="f-429" unitRef="usd">22000000</asth:BusinessAcquisitionOfCommonStock>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c-77"
      decimals="INF"
      id="f-430"
      unitRef="shares">631712</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <asth:ContingentConsideration contextRef="c-77" decimals="-5" id="f-431" unitRef="usd">7300000</asth:ContingentConsideration>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired contextRef="c-78" decimals="2" id="f-432" unitRef="number">0.95</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-78" decimals="-5" id="f-433" unitRef="usd">3600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="c-1" id="f-434">The following table summarizes the preliminary purchase price allocation of the fair value of assets acquired and liabilities assumed  related to each acquisition at the acquisition date (in thousands):&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.257%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;CFC&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;AHMS &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;Others *&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net &#160;Total &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;Total purchase consideration: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Cash paid &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Cash payable &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Contingent consideration &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Common stock issued &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;120,214&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;63,935&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,397&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;202,546&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Investment in marketable securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Receivables &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Prepaid expenses and other current assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts due from affiliates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Land, property and equipment &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Intangible assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Goodwill &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Restricted cash &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Accounts payable and accrued expenses &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Medical liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts due to affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Income taxes payable &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Deferred tax liability &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Noncontrolling interest &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identified liabilities assumed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total net identifiable assets acquired &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;120,214&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;63,935&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,397&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;202,546&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Others consist of estimated fair values of the assets acquired, net of cash acquired, related to ADSC and PCCCV.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;br/&gt;Following the acquisition dates of CFC, AHMS, ADSC and PCCCV, the operating results have been included in our consolidated financial statements. For the period from the acquisition dates through March&#160;31, 2024, total revenues and net income were $33.2 million and $5.1 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Pro Forma Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The pro forma financial information in the table below presents the combined results of the Company and CFC, AHMS, ADSC and PCCCV as if the acquisitions had occurred on January 1, 2023. The pro forma information presented is shown for illustrative purposes only and is not necessarily indicative of future results of operations of the Company or results of operations of the Company that would have actually occurred had the transactions been in effect for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.227%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share - basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share - diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-77" decimals="-3" id="f-435" unitRef="usd">90998000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-75" decimals="-3" id="f-436" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-79" decimals="-3" id="f-437" unitRef="usd">12500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-80" decimals="-3" id="f-438" unitRef="usd">103498000</us-gaap:PaymentsToAcquireBusinessesGross>
    <asth:PaymentsToAcquireBusinessCashPayable contextRef="c-77" decimals="-3" id="f-439" unitRef="usd">0</asth:PaymentsToAcquireBusinessCashPayable>
    <asth:PaymentsToAcquireBusinessCashPayable contextRef="c-75" decimals="-3" id="f-440" unitRef="usd">63935000</asth:PaymentsToAcquireBusinessCashPayable>
    <asth:PaymentsToAcquireBusinessCashPayable contextRef="c-79" decimals="-3" id="f-441" unitRef="usd">0</asth:PaymentsToAcquireBusinessCashPayable>
    <asth:PaymentsToAcquireBusinessCashPayable contextRef="c-80" decimals="-3" id="f-442" unitRef="usd">63935000</asth:PaymentsToAcquireBusinessCashPayable>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-77" decimals="-3" id="f-443" unitRef="usd">7264000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-75" decimals="-3" id="f-444" unitRef="usd">0</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-79" decimals="-3" id="f-445" unitRef="usd">5897000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-80" decimals="-3" id="f-446" unitRef="usd">13161000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c-77" decimals="-3" id="f-447" unitRef="usd">21952000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c-75" decimals="-3" id="f-448" unitRef="usd">0</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c-79" decimals="-3" id="f-449" unitRef="usd">0</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c-80" decimals="-3" id="f-450" unitRef="usd">21952000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-77" decimals="-3" id="f-451" unitRef="usd">120214000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-75" decimals="-3" id="f-452" unitRef="usd">63935000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-79" decimals="-3" id="f-453" unitRef="usd">18397000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-80" decimals="-3" id="f-454" unitRef="usd">202546000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-81" decimals="-3" id="f-455" unitRef="usd">16674000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-82" decimals="-3" id="f-456" unitRef="usd">33950000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-83" decimals="-3" id="f-457" unitRef="usd">3515000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-84" decimals="-3" id="f-458" unitRef="usd">54139000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities contextRef="c-81" decimals="-3" id="f-459" unitRef="usd">50000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities contextRef="c-82" decimals="-3" id="f-460" unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities contextRef="c-83" decimals="-3" id="f-461" unitRef="usd">30000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities contextRef="c-84" decimals="-3" id="f-462" unitRef="usd">80000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables contextRef="c-81" decimals="-3" id="f-463" unitRef="usd">5351000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables contextRef="c-82" decimals="-3" id="f-464" unitRef="usd">11847000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables contextRef="c-83" decimals="-3" id="f-465" unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables contextRef="c-84" decimals="-3" id="f-466" unitRef="usd">17198000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets contextRef="c-81" decimals="-3" id="f-467" unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets contextRef="c-82" decimals="-3" id="f-468" unitRef="usd">36000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets contextRef="c-83" decimals="-3" id="f-469" unitRef="usd">11000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets contextRef="c-84" decimals="-3" id="f-470" unitRef="usd">47000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates contextRef="c-81" decimals="-3" id="f-471" unitRef="usd">3909000</asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates>
    <asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates contextRef="c-82" decimals="-3" id="f-472" unitRef="usd">0</asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates>
    <asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates contextRef="c-83" decimals="-3" id="f-473" unitRef="usd">0</asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates>
    <asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates contextRef="c-84" decimals="-3" id="f-474" unitRef="usd">3909000</asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAmountsDueFromAffiliates>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="c-81" decimals="-3" id="f-475" unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="c-82" decimals="-3" id="f-476" unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="c-83" decimals="-3" id="f-477" unitRef="usd">823000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="c-84" decimals="-3" id="f-478" unitRef="usd">823000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-81" decimals="-3" id="f-479" unitRef="usd">26000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-82" decimals="-3" id="f-480" unitRef="usd">23800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-83" decimals="-3" id="f-481" unitRef="usd">2703000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-84" decimals="-3" id="f-482" unitRef="usd">52503000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill contextRef="c-81" decimals="-3" id="f-483" unitRef="usd">90148000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-82" decimals="-3" id="f-484" unitRef="usd">29876000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-83" decimals="-3" id="f-485" unitRef="usd">12318000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-84" decimals="-3" id="f-486" unitRef="usd">132342000</us-gaap:Goodwill>
    <asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash contextRef="c-81" decimals="-3" id="f-487" unitRef="usd">0</asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash>
    <asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash contextRef="c-82" decimals="-3" id="f-488" unitRef="usd">300000</asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash>
    <asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash contextRef="c-83" decimals="-3" id="f-489" unitRef="usd">0</asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash>
    <asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash contextRef="c-84" decimals="-3" id="f-490" unitRef="usd">300000</asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="c-81" decimals="-3" id="f-491" unitRef="usd">142132000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="c-82" decimals="-3" id="f-492" unitRef="usd">99809000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="c-83" decimals="-3" id="f-493" unitRef="usd">19400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="c-84" decimals="-3" id="f-494" unitRef="usd">261341000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses contextRef="c-81" decimals="-3" id="f-495" unitRef="usd">4376000</asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses>
    <asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses contextRef="c-82" decimals="-3" id="f-496" unitRef="usd">7232000</asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses>
    <asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses contextRef="c-83" decimals="-3" id="f-497" unitRef="usd">250000</asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses>
    <asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses contextRef="c-84" decimals="-3" id="f-498" unitRef="usd">11858000</asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndAccruedExpenses>
    <asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities contextRef="c-81" decimals="-3" id="f-499" unitRef="usd">17508000</asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities>
    <asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities contextRef="c-82" decimals="-3" id="f-500" unitRef="usd">13137000</asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities>
    <asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities contextRef="c-83" decimals="-3" id="f-501" unitRef="usd">0</asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities>
    <asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities contextRef="c-84" decimals="-3" id="f-502" unitRef="usd">30645000</asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesMedicalLiabilities>
    <asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates contextRef="c-81" decimals="-3" id="f-503" unitRef="usd">0</asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates>
    <asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates contextRef="c-82" decimals="-3" id="f-504" unitRef="usd">7241000</asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates>
    <asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates contextRef="c-83" decimals="-3" id="f-505" unitRef="usd">54000</asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates>
    <asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates contextRef="c-84" decimals="-3" id="f-506" unitRef="usd">7295000</asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAmountsDueToAffiliates>
    <asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable contextRef="c-81" decimals="-3" id="f-507" unitRef="usd">34000</asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable>
    <asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable contextRef="c-82" decimals="-3" id="f-508" unitRef="usd">1604000</asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable>
    <asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable contextRef="c-83" decimals="-3" id="f-509" unitRef="usd">0</asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable>
    <asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable contextRef="c-84" decimals="-3" id="f-510" unitRef="usd">1638000</asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesIncomeTaxesPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="c-81" decimals="-3" id="f-511" unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="c-82" decimals="-3" id="f-512" unitRef="usd">6660000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="c-83" decimals="-3" id="f-513" unitRef="usd">271000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="c-84" decimals="-3" id="f-514" unitRef="usd">6931000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest contextRef="c-81" decimals="-3" id="f-515" unitRef="usd">0</asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest>
    <asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest contextRef="c-82" decimals="-3" id="f-516" unitRef="usd">0</asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest>
    <asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest contextRef="c-83" decimals="-3" id="f-517" unitRef="usd">428000</asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest>
    <asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest contextRef="c-84" decimals="-3" id="f-518" unitRef="usd">428000</asth:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNoncontrollingInterest>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-81" decimals="-3" id="f-519" unitRef="usd">21918000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-82" decimals="-3" id="f-520" unitRef="usd">35874000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-83" decimals="-3" id="f-521" unitRef="usd">1003000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-84" decimals="-3" id="f-522" unitRef="usd">58795000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-81" decimals="-3" id="f-523" unitRef="usd">120214000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-82" decimals="-3" id="f-524" unitRef="usd">63935000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-83" decimals="-3" id="f-525" unitRef="usd">18397000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-84" decimals="-3" id="f-526" unitRef="usd">202546000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual contextRef="c-1" decimals="-5" id="f-527" unitRef="usd">33200000</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual contextRef="c-1" decimals="-5" id="f-528" unitRef="usd">5100000</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="c-1" decimals="-3" id="f-529" unitRef="usd">493006000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="c-27" decimals="-3" id="f-530" unitRef="usd">382462000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="c-1" decimals="-3" id="f-531" unitRef="usd">16661000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="c-27" decimals="-3" id="f-532" unitRef="usd">20324000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-533"
      unitRef="usdPerShare">0.35</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="c-27"
      decimals="2"
      id="f-534"
      unitRef="usdPerShare">0.44</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-535"
      unitRef="usdPerShare">0.35</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="c-27"
      decimals="2"
      id="f-536"
      unitRef="usdPerShare">0.43</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-27" decimals="INF" id="f-537" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="INF" id="f-538" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="c-1" id="f-539">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the carrying value of goodwill for the three months ended March&#160;31, 2024 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.330%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(906)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill contextRef="c-6" decimals="-3" id="f-540" unitRef="usd">278831000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-1" decimals="-3" id="f-541" unitRef="usd">132342000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillPurchaseAccountingAdjustments contextRef="c-1" decimals="-3" id="f-542" unitRef="usd">-906000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:Goodwill contextRef="c-5" decimals="-3" id="f-543" unitRef="usd">410267000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-544">Intangible Assets, Net&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2024, the Company&#x2019;s intangible assets, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Useful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross March 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net March 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite lived assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Licenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Network relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11-21&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107,137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,002)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Member relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7-14&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient management platform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,060)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tradename/trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Developed technology &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135,712)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2023, the Company&#x2019;s intangible assets, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Useful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite lived assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Network relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11-21&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104,859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Management contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Member relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10-14&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient management platform&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,060)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tradename/trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(308)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(131,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2024 and 2023, the Company recognized amortization expenses of $4.4 million and $3.0 million, respectively, in depreciation and amortization on the accompanying condensed consolidated statements of income. The Company determined that there was no impairment of its finite-lived intangible or long-lived assets during the three months ended March&#160;31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future amortization expense is estimated to be as follows for the following years ending December&#160;31 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.444%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 (excluding the three months ended March 31, 2024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c-1" id="f-545">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2024, the Company&#x2019;s intangible assets, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Useful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross March 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net March 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite lived assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Licenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Network relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11-21&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107,137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,002)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Member relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7-14&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient management platform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,060)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tradename/trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Developed technology &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135,712)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2023, the Company&#x2019;s intangible assets, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Useful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite lived assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Network relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11-21&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104,859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Management contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Member relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10-14&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient management platform&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,060)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tradename/trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(308)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(131,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-85" decimals="-3" id="f-546" unitRef="usd">2150000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-85" decimals="-3" id="f-547" unitRef="usd">2150000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-86" decimals="-3" id="f-548" unitRef="usd">1900000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-86" decimals="-3" id="f-549" unitRef="usd">1900000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-87" id="f-550">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-88" id="f-551">P21Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-89" decimals="-3" id="f-552" unitRef="usd">155978000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-89" decimals="-3" id="f-553" unitRef="usd">107137000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-89" decimals="-3" id="f-554" unitRef="usd">48841000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-90" id="f-555">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-90" decimals="-3" id="f-556" unitRef="usd">22832000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-90" decimals="-3" id="f-557" unitRef="usd">17002000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-90" decimals="-3" id="f-558" unitRef="usd">5830000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-91" id="f-559">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-92" id="f-560">P14Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-93" decimals="-3" id="f-561" unitRef="usd">69381000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-93" decimals="-3" id="f-562" unitRef="usd">9154000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-93" decimals="-3" id="f-563" unitRef="usd">60227000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-94" id="f-564">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-94" decimals="-3" id="f-565" unitRef="usd">2060000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-94" decimals="-3" id="f-566" unitRef="usd">2060000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-94" decimals="-3" id="f-567" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-95" id="f-568">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-95" decimals="-3" id="f-569" unitRef="usd">1011000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-95" decimals="-3" id="f-570" unitRef="usd">320000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-95" decimals="-3" id="f-571" unitRef="usd">691000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-96" id="f-572">P6Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-96" decimals="-3" id="f-573" unitRef="usd">107000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-96" decimals="-3" id="f-574" unitRef="usd">39000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-96" decimals="-3" id="f-575" unitRef="usd">68000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c-5" decimals="-3" id="f-576" unitRef="usd">255419000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-5" decimals="-3" id="f-577" unitRef="usd">135712000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-5" decimals="-3" id="f-578" unitRef="usd">119707000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-97" decimals="-3" id="f-579" unitRef="usd">2150000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-97" decimals="-3" id="f-580" unitRef="usd">2150000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-98" id="f-581">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-99" id="f-582">P21Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-100" decimals="-3" id="f-583" unitRef="usd">150679000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-100" decimals="-3" id="f-584" unitRef="usd">104859000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-100" decimals="-3" id="f-585" unitRef="usd">45820000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-101" id="f-586">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-101" decimals="-3" id="f-587" unitRef="usd">22832000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-101" decimals="-3" id="f-588" unitRef="usd">16662000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-101" decimals="-3" id="f-589" unitRef="usd">6170000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-102" id="f-590">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-103" id="f-591">P14Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-104" decimals="-3" id="f-592" unitRef="usd">24077000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-104" decimals="-3" id="f-593" unitRef="usd">7345000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-104" decimals="-3" id="f-594" unitRef="usd">16732000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-105" id="f-595">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-105" decimals="-3" id="f-596" unitRef="usd">2060000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-105" decimals="-3" id="f-597" unitRef="usd">2060000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-105" decimals="-3" id="f-598" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-106" id="f-599">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-106" decimals="-3" id="f-600" unitRef="usd">1011000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-106" decimals="-3" id="f-601" unitRef="usd">308000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-106" decimals="-3" id="f-602" unitRef="usd">703000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-107" id="f-603">P6Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-107" decimals="-3" id="f-604" unitRef="usd">107000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-107" decimals="-3" id="f-605" unitRef="usd">34000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-107" decimals="-3" id="f-606" unitRef="usd">73000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c-6" decimals="-3" id="f-607" unitRef="usd">202916000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-6" decimals="-3" id="f-608" unitRef="usd">131268000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-6" decimals="-3" id="f-609" unitRef="usd">71648000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-5" id="f-610" unitRef="usd">4400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-27" decimals="-5" id="f-611" unitRef="usd">3000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-27" decimals="INF" id="f-612" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-1" decimals="INF" id="f-613" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c-1" id="f-614">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future amortization expense is estimated to be as follows for the following years ending December&#160;31 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.444%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 (excluding the three months ended March 31, 2024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="c-5" decimals="-3" id="f-615" unitRef="usd">20144000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-5" decimals="-3" id="f-616" unitRef="usd">22373000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-5" decimals="-3" id="f-617" unitRef="usd">18178000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-5" decimals="-3" id="f-618" unitRef="usd">14746000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-5" decimals="-3" id="f-619" unitRef="usd">12085000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <asth:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour contextRef="c-5" decimals="-3" id="f-620" unitRef="usd">28131000</asth:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-5" decimals="-3" id="f-621" unitRef="usd">115657000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <asth:EquityMethodAndOtherEquityInvestmentsTextBlock contextRef="c-1" id="f-622">Investments in Other Entities&lt;div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; Equity Method&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2024 and 2023, the Company&#x2019;s equity method investment balance consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.734%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.349%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;% of Ownership&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Initial Investment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Allocation of Net Income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Distribution &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LaSalle Medical Associates &#x2013; IPA line of business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pacific Medical Imaging &amp;amp; Oncology Center, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CAIPA MSO, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other *&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.880%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;% of Ownership&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Initial Investment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Allocation of Net Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Distribution &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LaSalle Medical Associates &#x2013; IPA line of business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pacific Medical Imaging &amp;amp; Oncology Center, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531 W. College, LLC **&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One MSO, LLC **&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CAIPA MSO, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other *&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Other consists of smaller equity method investments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;** Investment were solely for the benefit of APC and its shareholders. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;I Health, Inc. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 31, 2024, a wholly owned subsidiary of the Company acquired a 25% equity interest in I Health, Inc. (&#x201c;I Health&#x201d;), a management service organization. The Company accounts for its investment in I Health under the equity method of accounting as the Company has the ability to exercise significant influence, but not control over I Health&#x2019;s operations. The purchase agreement includes a call option that allows the Company to purchase an additional 25% equity interest on each of the first, second and third anniversary of the purchase (&#x201c;I Health Call Option&#x201d;). The cash consideration was not paid on the closing date, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and was accrued and presented within accounts payable and accrued expenses and other liabilities in the accompanying condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was no impairment loss recorded related to equity method investments for the three months ended March&#160;31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;</asth:EquityMethodAndOtherEquityInvestmentsTextBlock>
    <us-gaap:EquityMethodInvestmentsTextBlock contextRef="c-1" id="f-623">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2024 and 2023, the Company&#x2019;s equity method investment balance consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.734%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.349%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;% of Ownership&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Initial Investment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Allocation of Net Income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Distribution &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LaSalle Medical Associates &#x2013; IPA line of business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pacific Medical Imaging &amp;amp; Oncology Center, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CAIPA MSO, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other *&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.880%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;% of Ownership&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Initial Investment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Allocation of Net Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Distribution &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LaSalle Medical Associates &#x2013; IPA line of business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pacific Medical Imaging &amp;amp; Oncology Center, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531 W. College, LLC **&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One MSO, LLC **&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CAIPA MSO, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other *&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Other consists of smaller equity method investments. &lt;/span&gt;&lt;/div&gt;** Investment were solely for the benefit of APC and its shareholders.</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-108" decimals="2" id="f-624" unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments contextRef="c-109" decimals="-3" id="f-625" unitRef="usd">9866000</us-gaap:EquityMethodInvestments>
    <asth:EquityMethodInvestmentAdditionalInvestment contextRef="c-110" decimals="-3" id="f-626" unitRef="usd">0</asth:EquityMethodInvestmentAdditionalInvestment>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-110" decimals="-3" id="f-627" unitRef="usd">359000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount contextRef="c-110" decimals="-3" id="f-628" unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments contextRef="c-108" decimals="-3" id="f-629" unitRef="usd">10225000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-111" decimals="2" id="f-630" unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments contextRef="c-112" decimals="-3" id="f-631" unitRef="usd">1691000</us-gaap:EquityMethodInvestments>
    <asth:EquityMethodInvestmentAdditionalInvestment contextRef="c-113" decimals="-3" id="f-632" unitRef="usd">0</asth:EquityMethodInvestmentAdditionalInvestment>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-113" decimals="-3" id="f-633" unitRef="usd">27000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount contextRef="c-113" decimals="-3" id="f-634" unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments contextRef="c-111" decimals="-3" id="f-635" unitRef="usd">1718000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-114" decimals="2" id="f-636" unitRef="number">0.30</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments contextRef="c-115" decimals="-3" id="f-637" unitRef="usd">13660000</us-gaap:EquityMethodInvestments>
    <asth:EquityMethodInvestmentAdditionalInvestment contextRef="c-116" decimals="-3" id="f-638" unitRef="usd">0</asth:EquityMethodInvestmentAdditionalInvestment>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-116" decimals="-3" id="f-639" unitRef="usd">186000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount contextRef="c-116" decimals="-3" id="f-640" unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments contextRef="c-114" decimals="-3" id="f-641" unitRef="usd">13846000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-117" decimals="2" id="f-642" unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments contextRef="c-118" decimals="-3" id="f-643" unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <asth:EquityMethodInvestmentAdditionalInvestment contextRef="c-119" decimals="-3" id="f-644" unitRef="usd">9487000</asth:EquityMethodInvestmentAdditionalInvestment>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-119" decimals="-3" id="f-645" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount contextRef="c-119" decimals="-3" id="f-646" unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments contextRef="c-117" decimals="-3" id="f-647" unitRef="usd">9487000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-120" decimals="2" id="f-648" unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments contextRef="c-121" decimals="-3" id="f-649" unitRef="usd">557000</us-gaap:EquityMethodInvestments>
    <asth:EquityMethodInvestmentAdditionalInvestment contextRef="c-122" decimals="-3" id="f-650" unitRef="usd">0</asth:EquityMethodInvestmentAdditionalInvestment>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-122" decimals="-3" id="f-651" unitRef="usd">60000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount contextRef="c-122" decimals="-3" id="f-652" unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments contextRef="c-120" decimals="-3" id="f-653" unitRef="usd">617000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-6" decimals="-3" id="f-654" unitRef="usd">25774000</us-gaap:EquityMethodInvestments>
    <asth:EquityMethodInvestmentAdditionalInvestment contextRef="c-1" decimals="-3" id="f-655" unitRef="usd">9487000</asth:EquityMethodInvestmentAdditionalInvestment>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-3" id="f-656" unitRef="usd">632000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount contextRef="c-1" decimals="-3" id="f-657" unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments contextRef="c-5" decimals="-3" id="f-658" unitRef="usd">35893000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-123" decimals="2" id="f-659" unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments contextRef="c-124" decimals="-3" id="f-660" unitRef="usd">5684000</us-gaap:EquityMethodInvestments>
    <asth:EquityMethodInvestmentAdditionalInvestment contextRef="c-125" decimals="-3" id="f-661" unitRef="usd">0</asth:EquityMethodInvestmentAdditionalInvestment>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-125" decimals="-3" id="f-662" unitRef="usd">2165000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount contextRef="c-125" decimals="-3" id="f-663" unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments contextRef="c-123" decimals="-3" id="f-664" unitRef="usd">7849000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-126" decimals="2" id="f-665" unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments contextRef="c-127" decimals="-3" id="f-666" unitRef="usd">1878000</us-gaap:EquityMethodInvestments>
    <asth:EquityMethodInvestmentAdditionalInvestment contextRef="c-128" decimals="-3" id="f-667" unitRef="usd">0</asth:EquityMethodInvestmentAdditionalInvestment>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-128" decimals="-3" id="f-668" unitRef="usd">8000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount contextRef="c-128" decimals="-3" id="f-669" unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments contextRef="c-126" decimals="-3" id="f-670" unitRef="usd">1886000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-129" decimals="2" id="f-671" unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments contextRef="c-130" decimals="-3" id="f-672" unitRef="usd">17281000</us-gaap:EquityMethodInvestments>
    <asth:EquityMethodInvestmentAdditionalInvestment contextRef="c-131" decimals="-3" id="f-673" unitRef="usd">0</asth:EquityMethodInvestmentAdditionalInvestment>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-131" decimals="-3" id="f-674" unitRef="usd">-90000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount contextRef="c-131" decimals="-3" id="f-675" unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments contextRef="c-129" decimals="-3" id="f-676" unitRef="usd">17191000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-132" decimals="2" id="f-677" unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments contextRef="c-133" decimals="-3" id="f-678" unitRef="usd">2718000</us-gaap:EquityMethodInvestments>
    <asth:EquityMethodInvestmentAdditionalInvestment contextRef="c-134" decimals="-3" id="f-679" unitRef="usd">0</asth:EquityMethodInvestmentAdditionalInvestment>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-134" decimals="-3" id="f-680" unitRef="usd">115000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount contextRef="c-134" decimals="-3" id="f-681" unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments contextRef="c-132" decimals="-3" id="f-682" unitRef="usd">2833000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-135" decimals="2" id="f-683" unitRef="number">0.30</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments contextRef="c-136" decimals="-3" id="f-684" unitRef="usd">12738000</us-gaap:EquityMethodInvestments>
    <asth:EquityMethodInvestmentAdditionalInvestment contextRef="c-137" decimals="-3" id="f-685" unitRef="usd">0</asth:EquityMethodInvestmentAdditionalInvestment>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-137" decimals="-3" id="f-686" unitRef="usd">249000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount contextRef="c-137" decimals="-3" id="f-687" unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments contextRef="c-135" decimals="-3" id="f-688" unitRef="usd">12987000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-138" decimals="2" id="f-689" unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments contextRef="c-139" decimals="-3" id="f-690" unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <asth:EquityMethodInvestmentAdditionalInvestment contextRef="c-140" decimals="-3" id="f-691" unitRef="usd">325000</asth:EquityMethodInvestmentAdditionalInvestment>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-140" decimals="-3" id="f-692" unitRef="usd">37000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount contextRef="c-140" decimals="-3" id="f-693" unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments contextRef="c-138" decimals="-3" id="f-694" unitRef="usd">362000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-48" decimals="-3" id="f-695" unitRef="usd">40299000</us-gaap:EquityMethodInvestments>
    <asth:EquityMethodInvestmentAdditionalInvestment contextRef="c-27" decimals="-3" id="f-696" unitRef="usd">325000</asth:EquityMethodInvestmentAdditionalInvestment>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-27" decimals="-3" id="f-697" unitRef="usd">2484000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount contextRef="c-27" decimals="-3" id="f-698" unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments contextRef="c-59" decimals="-3" id="f-699" unitRef="usd">43108000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-117" decimals="2" id="f-700" unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-117" decimals="2" id="f-701" unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment contextRef="c-1" decimals="INF" id="f-702" unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment contextRef="c-27" decimals="INF" id="f-703" unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <asth:LoanReceivableTextBlock contextRef="c-1" id="f-704">Loans Receivable&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loans receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;IntraCare &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2023, the Company entered into a five-year convertible promissory note with IntraCare as the borrower. The principal on the note is $25.0 million, with interest on the outstanding principal amount and unpaid interest at a rate per annum equal to 8.81%, compounded annually. In the event that the convertible promissory note remains outstanding on or after the maturity date of July&#160;27, 2028, the outstanding principal balance and any unpaid accrued interest shall, upon the election of the Company, convert into IntraCare preferred shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;BASS Medical Group&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 29, 2024, the Company provided BASS Medical Group (&#x201c;BASS&#x201d;) with a $20.0 million senior secured promissory note (&#x201c;BASS secured promissory note&#x201d;). The promissory note is secured by certain assets of BASS. BASS secured promissory note matures on January 11, 2031, and has an interest rate per annum equal to 8.21% compounded annually. The principal on the note, including unpaid interest, are due and payable on the maturity date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the outstanding loans receivable under the CECL model by assessing the party&#x2019;s ability to pay by reviewing their interest payment history quarterly, financial history annually, and reassessing any identified insolvency risk.&lt;/span&gt;&lt;/div&gt;</asth:LoanReceivableTextBlock>
    <us-gaap:DebtInstrumentTerm contextRef="c-141" id="f-705">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-142" decimals="-5" id="f-706" unitRef="usd">25000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-142" decimals="4" id="f-707" unitRef="number">0.0881</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-143" decimals="-5" id="f-708" unitRef="usd">20000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-143" decimals="4" id="f-709" unitRef="number">0.0821</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c-1" id="f-710">Accounts Payable and Accrued Expenses&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounts payable and accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and other accruals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitation payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subcontractor IPA payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due to related parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other provider payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-711">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounts payable and accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and other accruals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitation payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subcontractor IPA payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due to related parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other provider payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-712" unitRef="usd">84867000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-713" unitRef="usd">9075000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <asth:SpecialtyCapitationPayableCurrent contextRef="c-5" decimals="-3" id="f-714" unitRef="usd">10225000</asth:SpecialtyCapitationPayableCurrent>
    <asth:SpecialtyCapitationPayableCurrent contextRef="c-6" decimals="-3" id="f-715" unitRef="usd">4503000</asth:SpecialtyCapitationPayableCurrent>
    <asth:SubcontractorIPAPayable contextRef="c-5" decimals="-3" id="f-716" unitRef="usd">2529000</asth:SubcontractorIPAPayable>
    <asth:SubcontractorIPAPayable contextRef="c-6" decimals="-3" id="f-717" unitRef="usd">2529000</asth:SubcontractorIPAPayable>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-5" decimals="-3" id="f-718" unitRef="usd">5293000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-6" decimals="-3" id="f-719" unitRef="usd">4407000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:RelatedPartyDepositLiabilities contextRef="c-5" decimals="-3" id="f-720" unitRef="usd">11679000</us-gaap:RelatedPartyDepositLiabilities>
    <us-gaap:RelatedPartyDepositLiabilities contextRef="c-6" decimals="-3" id="f-721" unitRef="usd">9271000</us-gaap:RelatedPartyDepositLiabilities>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-5" decimals="-3" id="f-722" unitRef="usd">3017000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-6" decimals="-3" id="f-723" unitRef="usd">744000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-724" unitRef="usd">12410000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-725" unitRef="usd">20098000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-726" unitRef="usd">16453000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-727" unitRef="usd">9322000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-728" unitRef="usd">146473000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-729" unitRef="usd">59949000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock contextRef="c-1" id="f-730">Medical Liabilities&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s medical liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical liabilities, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired (see Note 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of medical care costs related to claims incurred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,419)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,950)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments for medical care costs related to claims incurred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136,743)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61,736)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(198,479)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(503)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical liabilities, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock>
    <us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense contextRef="c-1" id="f-731">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s medical liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical liabilities, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired (see Note 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of medical care costs related to claims incurred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,419)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,950)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments for medical care costs related to claims incurred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136,743)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61,736)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(198,479)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(503)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical liabilities, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-6" decimals="-3" id="f-732" unitRef="usd">106657000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-48" decimals="-3" id="f-733" unitRef="usd">81255000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions contextRef="c-1" decimals="-3" id="f-734" unitRef="usd">30645000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions contextRef="c-27" decimals="-3" id="f-735" unitRef="usd">0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense contextRef="c-1" decimals="-3" id="f-736" unitRef="usd">235237000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense contextRef="c-27" decimals="-3" id="f-737" unitRef="usd">223713000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense contextRef="c-1" decimals="-3" id="f-738" unitRef="usd">-1419000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense contextRef="c-27" decimals="-3" id="f-739" unitRef="usd">-8950000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1 contextRef="c-1" decimals="-3" id="f-740" unitRef="usd">233818000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1 contextRef="c-27" decimals="-3" id="f-741" unitRef="usd">214763000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1 contextRef="c-1" decimals="-3" id="f-742" unitRef="usd">136286000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1 contextRef="c-27" decimals="-3" id="f-743" unitRef="usd">136743000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1 contextRef="c-1" decimals="-3" id="f-744" unitRef="usd">97837000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1 contextRef="c-27" decimals="-3" id="f-745" unitRef="usd">61736000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense contextRef="c-1" decimals="-3" id="f-746" unitRef="usd">234123000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense contextRef="c-27" decimals="-3" id="f-747" unitRef="usd">198479000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease contextRef="c-1" decimals="-3" id="f-748" unitRef="usd">-503000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease contextRef="c-27" decimals="-3" id="f-749" unitRef="usd">857000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-5" decimals="-3" id="f-750" unitRef="usd">136494000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-59" decimals="-3" id="f-751" unitRef="usd">98396000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-752">Credit Facility, Bank Loans, and Lines of Credit&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s debt balance consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.175%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.471%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revolver Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Promissory Note Payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unamortized financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,061)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,561)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of our long-term debt was determined using Level 2 inputs primarily related to comparable market prices. As of March&#160;31, 2024, and December&#160;31, 2023, the carrying value was not materially different from fair value, as the interest rates on the Company&#x2019;s debt approximated rates currently available to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following are the future commitments of the Company&#x2019;s debt for the years ending December 31 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.330%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 (excluding the three months ended March 31, 2024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amended Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amended Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 16, 2021, the Company entered into an amended and restated credit agreement (as subsequently amended as described below, the &#x201c;Amended Credit Agreement&#x201d;) with Truist Bank, in its capacity as administrative agent for the lenders, issuing bank, swingline lender and lender, and the banks and other financial institutions from time to time party thereto, to, among other things, to amend and restate that certain credit agreement, dated September 11, 2019, by and among the Company, Truist Bank, and certain lenders thereto, in its entirety. The Amended Credit Agreement provides for a five-year revolving credit facility (the &#x201c;Amended Credit Facility&#x201d;) to the Company of $400.0 million (&#x201c;Revolver Loan&#x201d;), which includes a letter of credit sub-facility of up to $25.0 million (which was amended to $50.0&#160;million, as described below) and a swingline loan sub-facility of $25.0 million and which expires on June&#160;16, 2026. As of March&#160;31, 2024, the Company borrowed $94.8 million on the Revolver Loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 20, 2022, an amendment was made to the Amended Credit Agreement, in which all amounts borrowed under the Amended Credit Agreement as of the effective date were automatically converted from London Interbank Offer Rate (&#x201c;LIBOR&#x201d;) Loans to Secured Overnight Financing Rate (&#x201c;SOFR&#x201d;) Loans with an initial interest period of one month on and as of the amendment effective date. Amounts borrowed under the Revolver Loan bear interest at an annual rate equal to either, at the Company&#x2019;s option, (a) the Term SOFR Reference Rate (as defined in the Amended Credit Agreement), adjusted for any Term SOFR Adjustment (as defined in the Amended Credit Agreement) plus a spread ranging from 1.25% to 2.50%, as determined on a quarterly basis based on the Company&#x2019;s Consolidated Total Net Leverage Ratio (as defined in the Amended Credit Agreement), or (b) a base rate, plus a spread ranging from 0.25% to 1.50%, as determined on a quarterly basis based on the Company&#x2019;s Consolidated Total Net Leverage Ratio.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024, the interest rate on the Revolver Loan was 7.42%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 8, 2023, a Second Amendment to the Amended Credit Agreement was entered into, which, among other things, increased the letter of credit sub-facility from $25.0 million to $50.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 3, 2023, the Company entered into a Third Amendment to the Amended Credit Agreement (&#x201c;Third Amendment&#x201d;) with Truist Bank and the other financial institutions party thereto. The Third Amendment provided a new term loan to the Company in an aggregate amount of up to $300.0&#160;million, with $180.0&#160;million funded at the closing of the Third Amendment, and $120.0&#160;million available to be drawn by the Company as delayed draw loans during the six months subsequent to the closing of the Third Amendment (collectively, the &#x201c;Term Loan&#x201d;). The Term Loan matures on November 3, 2028 (or such earlier date on which it is terminated in accordance with the provisions of the Amended Credit Agreement) and amortizes quarterly at 5% per annum for each of the first two years, 7.5% per annum for years three and four, and 10% per annum for year five. As of  March&#160;31, 2024, the Company borrowed $296.5 million on the Term Loan.  The Term Loan bears interest at an annual rate equal to either, at the Company&#x2019;s option, (a) the Term SOFR Reference Rate, adjusted for any Term SOFR Adjustment, plus a spread from 1.50% to 2.75%, as determined on a quarterly basis based on the Company&#x2019;s Consolidated Total Net Leverage Ratio, or (b) a base rate, plus a spread of 0.50% to 1.75%, as determined on a quarterly basis based on the Company&#x2019;s Consolidated Total Net Leverage Ratio. As of March&#160;31, 2024, the interest rate on the Term Loan was 7.68%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended Credit Agreement requires the Company to comply with two key financial ratios, each calculated on a consolidated basis. The Company must maintain a maximum consolidated total net leverage ratio of not greater than 3.75 to 1.00 as of the last day of each fiscal quarter, provided that for any fiscal quarter during which the Company or certain subsidiaries consummate a permitted acquisition or investment, the aggregate purchase price is greater than $75.0&#160;million, the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;maximum consolidated total net leverage ratio may temporarily increase by 0.25 to 1.00 to 4.00 to 1.00. The Company must maintain a minimum consolidated interest coverage ratio of not less than 3.25 to 1.00 as of the last day of each fiscal quarter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Amended Credit Agreement, the terms and conditions of the Guaranty and Security Agreement (the &#x201c;Guaranty and Security Agreement&#x201d;) between the Company, Astrana Health Management, Inc. (&#x201c;AHM&#x201d;) and Truist Bank remain in effect. Pursuant to the Guaranty and Security Agreement, the Company and AHM have granted the lenders under the Amended Credit Agreement a security interest in substantially all of their assets to secure obligations under the Amended Credit Agreement, including, without limitation, all stock and other equity issued by their subsidiaries (including AHM) and all rights with respect to the $545.0&#160;million loan from the Company to Astrana Medical.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Promissory Note Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;FYB Promissory Note Agreement with CCHCA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, For Your Benefit, Inc. entered into a promissory note agreement with Chinese Community Health Care Association. The principal on the promissory note is $2.0&#160;million, with a maturity date of May&#160;9, 2024. The interest rate is the prime rate plus 1.0%. The prime rate is updated annually on the effective date of the note and published by the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Wall Street Journal&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Financing Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2024, and December&#160;31, 2023, the unamortized deferred financing cost was $5.7&#160;million and $6.1&#160;million, respectively. As of March&#160;31, 2024 and December&#160;31, 2023, $1.6&#160;million and $2.6&#160;million, respectively, of unamortized deferred financing costs was recognized in prepaid expenses and other current assets in the accompanying condensed consolidated balance sheets and consisted of unamortized deferred financing costs related to unborrowed amounts available on the Revolver Loan. As of March&#160;31, 2024, and December&#160;31, 2023, $4.1&#160;million and $3.6&#160;million, respectively, of unamortized deferred financing costs was recorded as a direct reduction against the amounts borrowed on the Term Loan and Revolver.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Effective Interest Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s average effective interest rate on its total debt during the three months ended March&#160;31, 2024 and 2023, was 6.51% and 5.69%, respectively. Interest expense in the condensed consolidated statements of income included amortization of deferred debt issuance costs for the three months ended March&#160;31, 2024 and 2023 of $0.5 million and $0.2 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lines of Credit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;APC Business Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September&#160;10, 2019, the APC Business Loan Agreement with Preferred Bank (the &#x201c;APC Business Loan Agreement&#x201d;) was amended to, among other things, decrease loan availability to $4.1 million, limit the purpose of the indebtedness under the APC Business Loan Agreement to the issuance of standby letters of credit, and include as a permitted lien, the security interest in all of its assets that APC granted to AHM under a Security Agreement dated on or about September 11, 2019, securing APC&#x2019;s obligations to AHM under their management services agreement dated as of July 1, 1999, as amended.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Standby Letters of Credit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company established irrevocable standby letters of credit with Truist Bank under the Amended Credit Agreement for a total of $31.8 million for the benefit of CMS and certain health plans. Unless the institution provides notification that the standby letters of credit will be terminated prior to the expiration date, the letters will be automatically extended without amendment for additional one-year periods from the present or any future expiration date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain IPAs consolidated by the Company established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $3.9 million for the benefit of certain health plans as of March&#160;31, 2024. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock contextRef="c-1" id="f-753">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s debt balance consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.175%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.471%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revolver Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Promissory Note Payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unamortized financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,061)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,561)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-144" decimals="-3" id="f-754" unitRef="usd">296500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-145" decimals="-3" id="f-755" unitRef="usd">280000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-146" decimals="-3" id="f-756" unitRef="usd">94759000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-147" decimals="-3" id="f-757" unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-148" decimals="-3" id="f-758" unitRef="usd">2000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-149" decimals="-3" id="f-759" unitRef="usd">2000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-5" decimals="-3" id="f-760" unitRef="usd">393259000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-6" decimals="-3" id="f-761" unitRef="usd">282000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebtCurrent contextRef="c-5" decimals="-3" id="f-762" unitRef="usd">20750000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-6" decimals="-3" id="f-763" unitRef="usd">19500000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="c-5" decimals="-3" id="f-764" unitRef="usd">4061000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="c-6" decimals="-3" id="f-765" unitRef="usd">3561000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-5" decimals="-3" id="f-766" unitRef="usd">368448000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-6" decimals="-3" id="f-767" unitRef="usd">258939000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="c-1" id="f-768">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following are the future commitments of the Company&#x2019;s debt for the years ending December 31 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.330%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 (excluding the three months ended March 31, 2024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="c-5" decimals="-3" id="f-769" unitRef="usd">17000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-5" decimals="-3" id="f-770" unitRef="usd">16875000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-5" decimals="-3" id="f-771" unitRef="usd">117259000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c-5" decimals="-3" id="f-772" unitRef="usd">24375000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="c-5" decimals="-3" id="f-773" unitRef="usd">217750000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LineOfCredit contextRef="c-5" decimals="-3" id="f-774" unitRef="usd">393259000</us-gaap:LineOfCredit>
    <us-gaap:DebtInstrumentTerm contextRef="c-150" id="f-775">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-151" decimals="-5" id="f-776" unitRef="usd">400000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-152" decimals="INF" id="f-777" unitRef="usd">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-153" decimals="INF" id="f-778" unitRef="usd">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-154" decimals="INF" id="f-779" unitRef="usd">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-146" decimals="-5" id="f-780" unitRef="usd">94800000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-155"
      decimals="INF"
      id="f-781"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-156"
      decimals="INF"
      id="f-782"
      unitRef="number">0.0250</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-157"
      decimals="INF"
      id="f-783"
      unitRef="number">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-158"
      decimals="INF"
      id="f-784"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd contextRef="c-159" decimals="4" id="f-785" unitRef="number">0.0742</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-152" decimals="INF" id="f-786" unitRef="usd">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-153" decimals="INF" id="f-787" unitRef="usd">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <asth:LineOfCreditFacilityAmountFundedAtClosing contextRef="c-160" decimals="INF" id="f-788" unitRef="usd">300000000</asth:LineOfCreditFacilityAmountFundedAtClosing>
    <us-gaap:RepaymentsOfDebt contextRef="c-161" decimals="-5" id="f-789" unitRef="usd">180000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:ProceedsFromRepaymentsOfBankOverdrafts contextRef="c-162" decimals="-5" id="f-790" unitRef="usd">120000000</us-gaap:ProceedsFromRepaymentsOfBankOverdrafts>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-163"
      decimals="INF"
      id="f-791"
      unitRef="number">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-164"
      decimals="INF"
      id="f-792"
      unitRef="number">0.075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-165"
      decimals="INF"
      id="f-793"
      unitRef="number">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c-166" decimals="-5" id="f-794" unitRef="usd">296500000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-167" decimals="4" id="f-795" unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-168" decimals="4" id="f-796" unitRef="number">0.0275</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-169" decimals="4" id="f-797" unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-170" decimals="4" id="f-798" unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="c-171" decimals="4" id="f-799" unitRef="number">0.0768</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <asth:DebtInstrumentNumberOfKeyFinancialRatios
      contextRef="c-172"
      decimals="INF"
      id="f-800"
      unitRef="financial_ratio">2</asth:DebtInstrumentNumberOfKeyFinancialRatios>
    <asth:DebtInstrumentCovenantLeverageRatioMaximum
      contextRef="c-172"
      decimals="INF"
      id="f-801"
      unitRef="number">3.75</asth:DebtInstrumentCovenantLeverageRatioMaximum>
    <asth:DebtCovenantAggregatePurchasePriceMaximum contextRef="c-172" decimals="-5" id="f-802" unitRef="usd">75000000</asth:DebtCovenantAggregatePurchasePriceMaximum>
    <asth:DebtInstrumentCovenantLeverageRatioIncrementalChange
      contextRef="c-172"
      decimals="INF"
      id="f-803"
      unitRef="number">0.25</asth:DebtInstrumentCovenantLeverageRatioIncrementalChange>
    <asth:DebtInstrumentCovenantLeverageRatioAdjustedMaximum
      contextRef="c-172"
      decimals="INF"
      id="f-804"
      unitRef="number">4.00</asth:DebtInstrumentCovenantLeverageRatioAdjustedMaximum>
    <asth:DebtInstrumentCovenantInterestCoverageRatioMinimum
      contextRef="c-171"
      decimals="INF"
      id="f-805"
      unitRef="number">3.25</asth:DebtInstrumentCovenantInterestCoverageRatioMinimum>
    <us-gaap:LineOfCredit contextRef="c-173" decimals="-5" id="f-806" unitRef="usd">545000000</us-gaap:LineOfCredit>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-174" decimals="-5" id="f-807" unitRef="usd">2000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-175" decimals="3" id="f-808" unitRef="number">0.010</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <asth:UnamortizedDeferredFinancingCosts contextRef="c-5" decimals="-5" id="f-809" unitRef="usd">5700000</asth:UnamortizedDeferredFinancingCosts>
    <asth:UnamortizedDeferredFinancingCosts contextRef="c-6" decimals="-5" id="f-810" unitRef="usd">6100000</asth:UnamortizedDeferredFinancingCosts>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="c-176" decimals="-5" id="f-811" unitRef="usd">1600000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="c-177" decimals="-5" id="f-812" unitRef="usd">2600000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="c-5" decimals="-5" id="f-813" unitRef="usd">4100000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="c-6" decimals="-5" id="f-814" unitRef="usd">3600000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="c-27" decimals="4" id="f-815" unitRef="number">0.0651</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="c-1" decimals="4" id="f-816" unitRef="number">0.0569</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:InterestExpense contextRef="c-171" decimals="-5" id="f-817" unitRef="usd">500000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-178" decimals="-5" id="f-818" unitRef="usd">200000</us-gaap:InterestExpense>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-179" decimals="-5" id="f-819" unitRef="usd">4100000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-180" decimals="-5" id="f-820" unitRef="usd">31800000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityExpirationPeriod contextRef="c-181" id="f-821">P1Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-182" decimals="-5" id="f-822" unitRef="usd">3900000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityExpirationPeriod contextRef="c-183" id="f-823">P1Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-824">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Mezzanine and Stockholders&#x2019; Equity&lt;/span&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;Mezzanine Equity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;APC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the redemption feature of the APC shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as non-controlling interests in APC as mezzanine or temporary equity. APC&#x2019;s shares were not redeemable, and it was not probable that the shares would become redeemable as of March&#160;31, 2024 and December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024, 41,048 holdback shares have not been issued to certain former AHM shareholders who were AHM shareholders at the time of closing of the 2017 merger of Astrana with AHM, as they have yet to submit properly completed letters of transmittal to Astrana in order to receive their pro rata portion of Astrana common stock as contemplated under the 2017 merger agreement. Pending such receipt, such former AHM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the 2017 Merger. The condensed consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares in connection with the 2017 merger.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Treasury Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of  March&#160;31, 2024, and December&#160;31, 2023, APC owned 7,132,698 shares of Astrana&#x2019;s common stock. While such shares of Astrana&#x2019;s common stock are legally issued and outstanding, they are treated as treasury shares for accounting purposes and excluded from shares of common stock outstanding in the condensed consolidated financial statements. APC&#x2019;s ownership in Astrana was 13.04% and 13.22% as of March&#160;31, 2024, and December&#160;31, 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024, and December&#160;31, 2023, the Company had previously repurchased 3,451,642 shares of its common stock. These are included as treasury stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of both March&#160;31, 2024, and December&#160;31, 2023, the total treasury stock, including the Company&#x2019;s stock held by APC, was 10,584,340.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2024 and 2023, certain consolidated subsidiaries of the Company paid distributions of $0.1 million and $0.1&#160;million, respectively, to the shareholders who own the non-controlling interests in the entities.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <asth:StockIssuedDuringPeriodSharesMerger contextRef="c-1" decimals="INF" id="f-825" unitRef="shares">41048</asth:StockIssuedDuringPeriodSharesMerger>
    <us-gaap:TreasuryStockCommonShares contextRef="c-3" decimals="INF" id="f-826" unitRef="shares">7132698</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares contextRef="c-4" decimals="INF" id="f-827" unitRef="shares">7132698</us-gaap:TreasuryStockCommonShares>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-184" decimals="4" id="f-828" unitRef="number">0.1304</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-185" decimals="4" id="f-829" unitRef="number">0.1322</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-1" decimals="INF" id="f-830" unitRef="shares">3451642</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-186"
      decimals="INF"
      id="f-831"
      unitRef="shares">3451642</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c-187"
      decimals="INF"
      id="f-832"
      unitRef="shares">10584340</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c-188"
      decimals="INF"
      id="f-833"
      unitRef="shares">10584340</us-gaap:TreasuryStockCommonShares>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-189" decimals="-5" id="f-834" unitRef="usd">100000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-190" decimals="-5" id="f-835" unitRef="usd">100000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-836">Stock-Based Compensation&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the stock-based compensation expense recognized under all of the Company&#x2019;s stock plans for the three months ended March&#160;31, 2024 and 2023, and associated with the issuance of restricted shares of common stock and vesting of stock options that are included in general and administrative expenses in the accompanying condensed consolidated statements of income (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.227%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrecognized compensation expense related to total share-based payments outstanding as of March&#160;31, 2024, was $42.4 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s outstanding stock options consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.548%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options outstanding at January&#160;1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;504,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,271)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.41&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2024, no options were exercised. During the three months ended March&#160;31, 2023, options were exercised for 125,000 shares of the Company&#x2019;s common stock, resulting in proceeds of $1.3 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company grants restricted stock to officers and employees, which is earned based on service conditions. The grant date fair value of the restricted stock is the grant date&#x2019;s closing market price of the Company&#x2019;s common stock. During the three months ended March&#160;31, 2024, the Company granted 296,428 shares of restricted stock with performance-based conditions and 255,781 shares of restricted stock without performance-based conditions. During the three months ended March&#160;31, 2024, the weighted average grant date fair value of restricted stock with and without performance-based conditions was $43.88 and $40.65, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;)&lt;/span&gt;&lt;/div&gt;The Company&#x2019;s ESPP is a shareholder-approved plan that allows eligible employees to contribute a portion of their eligible earnings toward the semi-annual purchase of the Company&#x2019;s common stock at a discounted price equal to 85% up to 90% of the fair market values of the stock on the exercise date, subject to a maximum number of shares that can be purchased during any single offering period as well as an annual maximum dollar amount of shares during any single calendar year. A maximum of 5,000,000 shares were authorized for issuance at the time the Plan was approved. For the three months ended March&#160;31, 2024, there are no shares purchased by employees.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-837">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the stock-based compensation expense recognized under all of the Company&#x2019;s stock plans for the three months ended March&#160;31, 2024 and 2023, and associated with the issuance of restricted shares of common stock and vesting of stock options that are included in general and administrative expenses in the accompanying condensed consolidated statements of income (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.227%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-191" decimals="-3" id="f-838" unitRef="usd">349000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-192" decimals="-3" id="f-839" unitRef="usd">566000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-193" decimals="-3" id="f-840" unitRef="usd">5399000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-194" decimals="-3" id="f-841" unitRef="usd">2879000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-842" unitRef="usd">5748000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-27" decimals="-3" id="f-843" unitRef="usd">3445000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-5" decimals="-5" id="f-844" unitRef="usd">42400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-845">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s outstanding stock options consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.548%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options outstanding at January&#160;1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;504,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,271)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.41&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-6" decimals="INF" id="f-846" unitRef="shares">504241</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-6"
      decimals="2"
      id="f-847"
      unitRef="usdPerShare">34.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-186" id="f-848">P2Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-6" decimals="-3" id="f-849" unitRef="usd">4700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="c-1" decimals="INF" id="f-850" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-851"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-852" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-853"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="INF" id="f-854" unitRef="shares">7271</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-855"
      unitRef="usdPerShare">50.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-5" decimals="INF" id="f-856" unitRef="shares">496970</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-857"
      unitRef="usdPerShare">33.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-858">P1Y7M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-5" decimals="-3" id="f-859" unitRef="usd">8400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-5" decimals="INF" id="f-860" unitRef="shares">459140</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-861"
      unitRef="usdPerShare">28.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-862">P1Y4M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-5" decimals="-3" id="f-863" unitRef="usd">8400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-864" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-27"
      decimals="INF"
      id="f-865"
      unitRef="shares">125000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-195" decimals="-5" id="f-866" unitRef="usd">1300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-196"
      decimals="INF"
      id="f-867"
      unitRef="shares">296428</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <asth:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance
      contextRef="c-196"
      decimals="INF"
      id="f-868"
      unitRef="shares">255781</asth:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-197"
      decimals="2"
      id="f-869"
      unitRef="usdPerShare">43.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-196"
      decimals="2"
      id="f-870"
      unitRef="usdPerShare">40.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <asth:CommonStockDiscountedPricePercentage
      contextRef="c-198"
      decimals="INF"
      id="f-871"
      unitRef="number">0.85</asth:CommonStockDiscountedPricePercentage>
    <asth:CommonStockDiscountedPricePercentageMaximum
      contextRef="c-198"
      decimals="INF"
      id="f-872"
      unitRef="number">0.90</asth:CommonStockDiscountedPricePercentageMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-198"
      decimals="INF"
      id="f-873"
      unitRef="shares">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-874">Commitments and Contingencies&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Regulatory Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Laws and regulations governing the Medicare program and healthcare generally are complex and subject to interpretation. The Company believes it complies with all applicable laws and regulations and is unaware of any pending or threatened investigations involving allegations of potential wrongdoing. While no regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and exclusion from the Medicare and Medi-Cal programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a risk-bearing organization, the Company is required to follow regulations of the Department of Managed Health Care (&#x201c;DMHC&#x201d;). The Company must comply with a minimum working capital requirement, tangible net equity (&#x201c;TNE&#x201d;) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;requirement, cash-to-claims ratio, and claims payment requirements prescribed by the DMHC. TNE is defined as net assets less intangibles, less non-allowable assets (which include amounts due from affiliates), plus subordinated obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Many of the Company&#x2019;s payer and provider contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services. Such differing interpretations may not come to light until a substantial period of time has passed following contract implementation. Liabilities for claims disputes are recorded when the loss is probable and can be estimated. Any adjustments to reserves are reflected in current operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Standby Letters of Credit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company established irrevocable standby letters of credit with Truist Bank for a total of $31.8 million for the benefit of CMS and certain health plans as of March&#160;31, 2024 (see Note 9 &#x2014; &#x201c;Credit Facility, Bank Loans, and Lines of Credit &#x2014; Standby Letters of Credit&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain IPAs consolidated by the Company established irrevocable standby letters of credit with Preferred Bank for a total of $3.9 million for the benefit of certain health plans as of March&#160;31, 2024 (see Note 9 &#x2014; &#x201c;Credit Facility, Bank Loans, and Lines of Credit &#x2014; Standby Letters of Credit&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of its business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company&#x2019;s financial condition, cash flows, or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liability Insurance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that its insurance coverage is appropriate based upon the Company&#x2019;s claims experience and the nature and risks of the Company&#x2019;s business. In addition to the known incidents that have resulted in the assertion of claims, the Company cannot be certain that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against the Company, the Company&#x2019;s affiliated professional organizations or the Company&#x2019;s affiliated hospitalists in the future where the outcomes of such claims are unfavorable. The Company believes that the ultimate resolution of all pending claims, including liabilities in excess of the Company&#x2019;s insurance coverage, will not have a material adverse effect on the Company&#x2019;s financial position, results of operations, or cash flows; however, there can be no assurance that future claims will not have such a material adverse effect on the Company&#x2019;s business. Contracted physicians are required to obtain their own insurance coverage.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although the Company currently maintains liability insurance policies on a claims-made basis which are intended to cover malpractice liability and certain other claims, the coverage must be renewed annually, and may&#160;not continue to be available to the Company in future years at acceptable costs and on favorable terms.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-180" decimals="-5" id="f-875" unitRef="usd">31800000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-182" decimals="-5" id="f-876" unitRef="usd">3900000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-877">Related-Party Transactions&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity Method Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023, AHM recognized approximately $5.0 million in management fees from LMA. On August 31, 2023, the management service agreement between LMA&#x2019;s IPA and AHM was terminated. LMA is accounted for under the equity method based on the 25% equity ownership interest held by APC in LMA&#x2019;s IPA line of business (see Note 5 &#x2014; &#x201c;Investments in Other Entities - Equity Method&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2024 and 2023, APC paid approximately $0.8 million and $0.6 million, respectively, to PMIOC for provider services. APC and PMIOC have an Ancillary Service Contract together whereby PMIOC provides covered services on behalf of APC to enrollees of the plans of APC. PMIOC is accounted for under the equity method based on the 40% equity ownership interest held by APC (see Note 5 &#x2014; &#x201c;Investments in Other Entities &#x2014; Equity Method&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2024 and 2023, the Company paid approximately $0.2 million and $0.2 million, respectively, to James Song, M.D., a Professional Corporation (&#x201c;Song PC&#x201d;) for provider services. Song PC is accounted for &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;under the equity method based on the 25% equity ownership interest held by Astrana, as Astrana has the ability to exercise significant influence, but not control over, Song PC&#x2019;s operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Astrana Board Members and Officers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2024 and 2023, AHM recognized approximately $0.5 million and $0.5 million, respectively, in management fees from Arroyo Vista Family Health Center (&#x201c;Arroyo Vista&#x201d;). The Company has a managed service agreement with Arroyo Vista. Arroyo Vista&#x2019;s chief executive officer is a member of the Company&#x2019;s board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2024 and 2023, the Company paid approximately $0.1 million and $64,000, respectively, to Arroyo Vista for services as a provider. The Company has provider contracts with Arroyo Vista. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2024 , the Company incurred rent expenses of approximately $0.9 million from certain properties that are managed by Allied Pacific Holdings Investment Management, LLC. During the three months ended March&#160;31, 2023, the Company incurred $0.9 million in rent expense from the same properties, but it was eliminated upon consolidation.  These properties were previously consolidated by Astrana until they were spun off on December 26, 2023. The chief executive officer of the real estate business managing these properties is also a member of the Company&#x2019;s board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024 and December&#160;31, 2023, the Company&#x2019;s operating right-of-use asset balance included $12.7 million and $14.1 million, respectively, and the Company&#x2019;s operating lease liabilities included $13.2 million and $14.5 million, respectively, for certain properties that are managed by Allied Pacific Holdings Investment Management, LLC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2024 and 2023, the Company incurred approximately $0.6 million and $0.4 million in expenses payable to Third Way Health for call center services. One of Astrana&#x2019;s officers is a board member of Third Way Health.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2024 and 2023, the Company paid approximately $45,000 and $0.2 million, respectively, to Sunny Village Care Center for services as a provider. The Company has provider contracts with Sunny Village Care Center. Sunny Village Care Center shares common ownership with certain Astrana board members.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023, Astrana paid approximately $9.5 million to purchase Astrana&#x2019;s stock from a board member. The Company did not make any similar purchases during the three months ended March&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2024, the Company incurred rent expenses of approximately $38,000 to First Commonwealth Property, LLC for an office lease. First Commonwealth Property, LLC shares common ownership with certain board members of APC and AHM. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has agreements with Health Source MSO Inc., a California corporation (&#x201c;HSMSO&#x201d;), Aurion Corporation (&#x201c;Aurion&#x201d;), and AHMC for services provided to the Company. One of the Company&#x2019;s board members is an officer of AHMC, HSMSO, and Aurion. Aurion is also partially owned by one of the Company&#x2019;s board members. Revenue with AHMC and HSMSO consists of capitation, risk pool, and miscellaneous fees and expenses consisting of claims expenses, management fees, and consulting fees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth revenue recognized and fees incurred related to AHMC, HSMSO, and Aurion for the three months ended March&#160;31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.752%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.135%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.135%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.135%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.135%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.135%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.138%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AHMC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;HSMSO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aurion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AHMC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;HSMSO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aurion&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and AHMC have a risk-sharing agreement with certain AHMC hospitals to share the surplus and deficits of each of the hospital pools. Under this agreement, during the three months ended March&#160;31, 2024 and 2023, the Company has recognized risk pool revenues of $8.1 million and $13.0 million, respectively. The Company has a risk pool receivable balance of $58.8 million and $54.0 million as of March&#160;31, 2024 and December&#160;31, 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;APC Board Members&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2024 and 2023, the Company paid an aggregate of approximately $4.7 million and $9.4 million, respectively, to board members for provider services which included approximately $0.8 million and $0.9 million, respectively, to Astrana board members and officers who are also board members and officers of APC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, affiliates wholly owned by the Company&#x2019;s key personnel are reported in the accompanying condensed consolidated statements of income on a consolidated basis, together with the Company&#x2019;s subsidiaries, and therefore, the Company does not separately disclose transactions between such affiliates and the Company&#x2019;s subsidiaries as related-party transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intercompany Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because of corporate practice of medicine laws, the Company uses designated shareholder professional corporations, of which the sole shareholder is a member of the Company&#x2019;s key personnel, to engage in certain transactions and make intercompany loans from time to time.&lt;/span&gt;&lt;/div&gt;For equity method investments, see Note 5 &#x2014; &#x201c;Investment in Other Entities &#x2014; Equity Method&#x201d;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-199" decimals="-5" id="f-878" unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-200" decimals="2" id="f-879" unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-201" decimals="-5" id="f-880" unitRef="usd">800000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-202" decimals="-5" id="f-881" unitRef="usd">600000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-203" decimals="2" id="f-882" unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-204" decimals="-5" id="f-883" unitRef="usd">200000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-205" decimals="-5" id="f-884" unitRef="usd">200000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-206" decimals="2" id="f-885" unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-207" decimals="-5" id="f-886" unitRef="usd">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-208" decimals="-5" id="f-887" unitRef="usd">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-209" decimals="-5" id="f-888" unitRef="usd">100000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-210" decimals="-3" id="f-889" unitRef="usd">64000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-211" decimals="-5" id="f-890" unitRef="usd">900000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-212" decimals="-5" id="f-891" unitRef="usd">900000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-213" decimals="-5" id="f-892" unitRef="usd">12700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-214" decimals="-5" id="f-893" unitRef="usd">14100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-213" decimals="-5" id="f-894" unitRef="usd">13200000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-214" decimals="-5" id="f-895" unitRef="usd">14500000</us-gaap:OperatingLeaseLiabilityCurrent>
    <asth:RelatedPartyExpensesPayable contextRef="c-5" decimals="-5" id="f-896" unitRef="usd">600000</asth:RelatedPartyExpensesPayable>
    <asth:RelatedPartyExpensesPayable contextRef="c-59" decimals="-5" id="f-897" unitRef="usd">400000</asth:RelatedPartyExpensesPayable>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-215" decimals="-3" id="f-898" unitRef="usd">45000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-216" decimals="-5" id="f-899" unitRef="usd">200000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-217" decimals="-5" id="f-900" unitRef="usd">9500000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-218" decimals="-5" id="f-901" unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-219" decimals="-3" id="f-902" unitRef="usd">38000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="c-1" id="f-903">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth revenue recognized and fees incurred related to AHMC, HSMSO, and Aurion for the three months ended March&#160;31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.752%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.135%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.135%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.135%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.135%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.135%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.138%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AHMC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;HSMSO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aurion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AHMC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;HSMSO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aurion&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-220" decimals="-3" id="f-904" unitRef="usd">9920000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-221" decimals="-3" id="f-905" unitRef="usd">301000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-222" decimals="-3" id="f-906" unitRef="usd">0</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-223" decimals="-3" id="f-907" unitRef="usd">14484000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-224" decimals="-3" id="f-908" unitRef="usd">315000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-225" decimals="-3" id="f-909" unitRef="usd">0</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-226" decimals="-3" id="f-910" unitRef="usd">7557000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-227" decimals="-3" id="f-911" unitRef="usd">0</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-228" decimals="-3" id="f-912" unitRef="usd">50000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-229" decimals="-3" id="f-913" unitRef="usd">6400000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-230" decimals="-3" id="f-914" unitRef="usd">169000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-231" decimals="-3" id="f-915" unitRef="usd">50000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-232" decimals="-3" id="f-916" unitRef="usd">2363000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-233" decimals="-3" id="f-917" unitRef="usd">301000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-234" decimals="-3" id="f-918" unitRef="usd">-50000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-235" decimals="-3" id="f-919" unitRef="usd">8084000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-236" decimals="-3" id="f-920" unitRef="usd">146000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-237" decimals="-3" id="f-921" unitRef="usd">-50000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-238" decimals="-5" id="f-922" unitRef="usd">8100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-239" decimals="-5" id="f-923" unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DeferredCreditsAndOtherLiabilities contextRef="c-240" decimals="-5" id="f-924" unitRef="usd">58800000</us-gaap:DeferredCreditsAndOtherLiabilities>
    <us-gaap:DeferredCreditsAndOtherLiabilities contextRef="c-241" decimals="-5" id="f-925" unitRef="usd">54000000</us-gaap:DeferredCreditsAndOtherLiabilities>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-242" decimals="-5" id="f-926" unitRef="usd">4700000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-243" decimals="-5" id="f-927" unitRef="usd">9400000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-244" decimals="-5" id="f-928" unitRef="usd">800000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-245" decimals="-5" id="f-929" unitRef="usd">900000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-930">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the liability method of accounting for income taxes as set forth in ASC 740 Income Taxes. Under the liability method, deferred taxes are determined based on differences between the financial statement and tax bases of assets and liabilities using enacted tax rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an interim basis, the Company estimates what its anticipated annual effective tax rate will be and records a quarterly income tax provision in accordance with the estimated annual rate, plus the tax effect of certain discrete items that arise during the quarter. As the fiscal year progresses, the Company refines its estimates based on actual events and financial results during the quarter. This process can result in significant changes to the Company&#x2019;s estimated effective tax rate. When this occurs, the income tax provision is adjusted during the quarter in which the estimates are refined so that the year-to-date provision reflects the estimated annual effective tax rate. These changes, along with adjustments to the Company&#x2019;s deferred taxes and related valuation allowance, may create fluctuations in the overall effective tax rate from quarter to quarter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s effective income tax rate for the three months ended March&#160;31, 2024 and 2023, was 29.8% and 35.7%, respectively. The tax rate for the three months ended March&#160;31, 2024, differed from the U.S. federal statutory rate primarily due to state income taxes and income from flow-through entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024, the Company does not have any unrecognized tax benefits related to various federal and state income tax matters. The Company will recognize accrued interest and penalties related to unrecognized tax benefits in income tax expense.&lt;/span&gt;&lt;/div&gt;The Company is subject to U.S. federal income tax as well as income tax in California. The Company and its subsidiaries&#x2019; state and federal income tax returns are open to audit under the statute of limitations for the years ended December 31, 2019 through December&#160;31, 2023, and for the years ended December 31, 2020 through December&#160;31, 2023, respectively.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-931" unitRef="number">0.298</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-27" decimals="3" id="f-932" unitRef="number">0.357</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-933">Earnings Per Share&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is calculated using the weighted average number of shares of the Company&#x2019;s common stock issued and outstanding during a certain period, and is calculated by dividing net income attributable to Astrana by the weighted average number of shares of the Company&#x2019;s common stock issued and outstanding during such period. Diluted earnings per share is calculated using the weighted average number of shares of common stock and potentially dilutive shares of common stock outstanding during the period, using the as-if converted method for secured convertible notes and preferred stock, and the treasury stock method for options and common stock warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024 and December&#160;31, 2023, APC held 7,132,698 shares of Astrana&#x2019;s common stock, which are treated as treasury shares for accounting purposes and not included in the number of shares of common stock outstanding used to calculate earnings per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2024 and 2023, restricted stock of 118,142 and 136,932, respectively, were excluded from the computation of diluted weighted average common shares outstanding because the assumed proceeds, as calculated under the treasury stock method, resulted in these awards being antidilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2024 and 2023, 973,461 and 395,472 of contingently issuable shares were excluded from the computation of diluted weighted average common shares outstanding because these conditions were not achieved as of March&#160;31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a summary of the earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.447%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,260,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,555,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,699,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,954,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a summary of the shares included in the diluted earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.447%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,260,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,555,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingently issuable shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,699,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,954,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-246" decimals="0" id="f-934" unitRef="shares">7132698</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-247" decimals="0" id="f-935" unitRef="shares">7132698</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-248" decimals="0" id="f-936" unitRef="shares">118142</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-249" decimals="0" id="f-937" unitRef="shares">136932</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-250" decimals="0" id="f-938" unitRef="shares">973461</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-250" decimals="0" id="f-939" unitRef="shares">973461</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-251" decimals="0" id="f-940" unitRef="shares">395472</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-251" decimals="0" id="f-941" unitRef="shares">395472</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-942">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a summary of the earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.447%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,260,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,555,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,699,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,954,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-943"
      unitRef="usdPerShare">0.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-27"
      decimals="2"
      id="f-944"
      unitRef="usdPerShare">0.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-945"
      unitRef="usdPerShare">0.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-27"
      decimals="2"
      id="f-946"
      unitRef="usdPerShare">0.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-947" unitRef="shares">47260351</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-27" decimals="0" id="f-948" unitRef="shares">46555406</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-949" unitRef="shares">47699537</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-27" decimals="0" id="f-950" unitRef="shares">46954687</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock contextRef="c-1" id="f-951">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a summary of the shares included in the diluted earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.447%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,260,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,555,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingently issuable shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,699,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,954,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-952" unitRef="shares">47260351</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-27" decimals="0" id="f-953" unitRef="shares">46555406</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-252" decimals="0" id="f-954" unitRef="shares">188083</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-253" decimals="0" id="f-955" unitRef="shares">306933</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-248" decimals="0" id="f-956" unitRef="shares">225128</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-249" decimals="0" id="f-957" unitRef="shares">48191</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares contextRef="c-1" decimals="0" id="f-958" unitRef="shares">25975</us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares>
    <us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares contextRef="c-27" decimals="0" id="f-959" unitRef="shares">44157</us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-960" unitRef="shares">47699537</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-27" decimals="0" id="f-961" unitRef="shares">46954687</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:VariableInterestEntityDisclosureTextBlock contextRef="c-1" id="f-962">Variable Interest Entities (VIEs)&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s condensed consolidated financial statements include its subsidiaries and consolidated VIEs. A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity investment at risk lack any of the following three characteristics: decision-making rights, the obligation to absorb losses, or the right to receive the expected residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity&#x2019;s economic performance and the obligation to absorb expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain state laws prohibit a professional corporation that has more than one shareholder from being a shareholder in another professional corporation. As a result, the Company cannot directly own shares in other professional corporations. However, an exception to this regulation permits a professional corporation that has only one shareholder to own shares in another professional corporation. In reliance on this exception, the Company designated certain key personnel as the nominee shareholders of professional corporations that hold controlling and non-controlling ownership interests in several medical corporations. Via a Physician Shareholder Agreement with the nominee shareholder, the Company has the ability to designate another person to be the equity holder of the professional corporation. In addition, these entities are managed by the Company&#x2019;s wholly owned MSOs via MSA. In accordance with relevant accounting guidance, the professional corporations and their consolidated medical corporations are consolidated by the Company in the accompanying condensed financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to corporate practice of medicine laws, the Company operates by maintaining long-term MSAs with its affiliated IPAs and medical groups, each of which is owned and operated by physicians only, and employs or contracts with additional physicians to provide medical services. AHM is a wholly owned subsidiary of the Company and has entered into MSAs with several affiliated IPAs, including APC. APC arranges for the delivery of healthcare services by contracting with physicians or professional medical corporations for primary care and specialty care services. The physicians in the IPA are exclusively in control of, and responsible for, all aspects of the practice of medicine for enrolled patients. In accordance with relevant accounting guidance, APC has been determined to be a VIE of AHM, as AHM is its primary beneficiary with the ability, through majority representation on the APC Joint Planning Board and otherwise, to direct the activities (excluding clinical &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;decisions) that most significantly affect APC&#x2019;s economic performance. Therefore, APC and its wholly owned subsidiaries and VIEs are consolidated in the accompanying financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Astrana Medical and Astrana Care Partners Medical were formed in May 2019 and July 2021, respectively, as designated shareholder professional corporations. The Company&#x2019;s Vice Chairman is the sole shareholder of Astrana Medical and Astrana Care Partners Medical. Via a Physician Shareholder Agreement, Astrana makes all the decisions on behalf of Astrana Medical and Astrana Care Partners Medical. Astrana has the obligation to absorb losses of, or the right to receive benefits from, Astrana Medical and Astrana Care Partners Medical. Therefore, Astrana Medical and Astrana Care Partners Medical are controlled by and consolidated by Astrana as the primary beneficiary of the VIEs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2024, a 25% equity interest of Eleanor Leung M.D. was re-acquired by the Company. As a result, Astrana Care Partners Medical now owns 100% of Eleanor Leung M.D.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes assets that can only be used to settle the liabilities of the Company&#x2019;s VIEs, and to which the creditors of Astrana have no recourse, and liabilities to which the creditors of the Company&#x2019;s VIEs have no recourse to the general credit of Astrana, as the primary beneficiary of the VIEs. These assets and liabilities, with the exception of investments in affiliates and amounts due to, or from, affiliates, which are eliminated upon consolidation, are included in the accompanying consolidated balance sheets (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables, net &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land, property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes receivable, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in other entities &#x2013; equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliates*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in a privately held entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;682,849&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537,998&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;813,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fiduciary accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount due to affiliates*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,947&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,222&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*Investment in affiliates includes the Company&#x2019;s VIEs&#x2019; investment in Astrana, which is reflected as treasury shares and eliminated upon consolidation. Amounts due to, or from, affiliates are receivables with Astrana&#x2019;s subsidiaries. As a result, these balances are eliminated upon consolidation and are not reflected on Astrana&#x2019;s condensed consolidated balance sheets  as of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2024, and December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="c-254"
      decimals="INF"
      id="f-963"
      unitRef="number">0.25</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="c-255"
      decimals="INF"
      id="f-964"
      unitRef="number">1</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:ScheduleOfVariableInterestEntitiesTextBlock contextRef="c-1" id="f-965">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes assets that can only be used to settle the liabilities of the Company&#x2019;s VIEs, and to which the creditors of Astrana have no recourse, and liabilities to which the creditors of the Company&#x2019;s VIEs have no recourse to the general credit of Astrana, as the primary beneficiary of the VIEs. These assets and liabilities, with the exception of investments in affiliates and amounts due to, or from, affiliates, which are eliminated upon consolidation, are included in the accompanying consolidated balance sheets (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables, net &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land, property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes receivable, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in other entities &#x2013; equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliates*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in a privately held entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;682,849&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537,998&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;813,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fiduciary accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount due to affiliates*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,947&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,222&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*Investment in affiliates includes the Company&#x2019;s VIEs&#x2019; investment in Astrana, which is reflected as treasury shares and eliminated upon consolidation. Amounts due to, or from, affiliates are receivables with Astrana&#x2019;s subsidiaries. As a result, these balances are eliminated upon consolidation and are not reflected on Astrana&#x2019;s condensed consolidated balance sheets  as of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2024, and December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfVariableInterestEntitiesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-256" decimals="-3" id="f-966" unitRef="usd">212134000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-257" decimals="-3" id="f-967" unitRef="usd">184078000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-256" decimals="-3" id="f-968" unitRef="usd">50000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-257" decimals="-3" id="f-969" unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-258" decimals="-3" id="f-970" unitRef="usd">47169000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-259" decimals="-3" id="f-971" unitRef="usd">21120000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-260" decimals="-3" id="f-972" unitRef="usd">61870000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-261" decimals="-3" id="f-973" unitRef="usd">58707000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:IncomeTaxesReceivable contextRef="c-256" decimals="-3" id="f-974" unitRef="usd">0</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable contextRef="c-257" decimals="-3" id="f-975" unitRef="usd">1600000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-256" decimals="-3" id="f-976" unitRef="usd">997000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-257" decimals="-3" id="f-977" unitRef="usd">454000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-256" decimals="-3" id="f-978" unitRef="usd">11891000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-257" decimals="-3" id="f-979" unitRef="usd">9991000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-256" decimals="-3" id="f-980" unitRef="usd">334111000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-257" decimals="-3" id="f-981" unitRef="usd">275950000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-256" decimals="-3" id="f-982" unitRef="usd">5084000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-257" decimals="-3" id="f-983" unitRef="usd">5306000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-256" decimals="-3" id="f-984" unitRef="usd">85058000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-257" decimals="-3" id="f-985" unitRef="usd">60906000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill contextRef="c-256" decimals="-3" id="f-986" unitRef="usd">236961000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-257" decimals="-3" id="f-987" unitRef="usd">140157000</us-gaap:Goodwill>
    <us-gaap:IncomeTaxesReceivableNoncurrent contextRef="c-256" decimals="-3" id="f-988" unitRef="usd">15943000</us-gaap:IncomeTaxesReceivableNoncurrent>
    <us-gaap:IncomeTaxesReceivableNoncurrent contextRef="c-257" decimals="-3" id="f-989" unitRef="usd">15943000</us-gaap:IncomeTaxesReceivableNoncurrent>
    <us-gaap:EquityMethodInvestments contextRef="c-256" decimals="-3" id="f-990" unitRef="usd">12560000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-257" decimals="-3" id="f-991" unitRef="usd">12114000</us-gaap:EquityMethodInvestments>
    <us-gaap:OtherLongTermInvestments contextRef="c-256" decimals="-3" id="f-992" unitRef="usd">299502000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments contextRef="c-257" decimals="-3" id="f-993" unitRef="usd">273182000</us-gaap:OtherLongTermInvestments>
    <us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue contextRef="c-256" decimals="-3" id="f-994" unitRef="usd">405000</us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue>
    <us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue contextRef="c-257" decimals="-3" id="f-995" unitRef="usd">405000</us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue>
    <us-gaap:RestrictedCash contextRef="c-256" decimals="-3" id="f-996" unitRef="usd">40000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-257" decimals="-3" id="f-997" unitRef="usd">40000</us-gaap:RestrictedCash>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-256" decimals="-3" id="f-998" unitRef="usd">26082000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-257" decimals="-3" id="f-999" unitRef="usd">28796000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-256" decimals="-3" id="f-1000" unitRef="usd">1214000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-257" decimals="-3" id="f-1001" unitRef="usd">1149000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c-256" decimals="-3" id="f-1002" unitRef="usd">682849000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c-257" decimals="-3" id="f-1003" unitRef="usd">537998000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="c-256" decimals="-3" id="f-1004" unitRef="usd">1016960000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-257" decimals="-3" id="f-1005" unitRef="usd">813948000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-256" decimals="-3" id="f-1006" unitRef="usd">44058000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-257" decimals="-3" id="f-1007" unitRef="usd">32707000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <asth:FiduciaryAccountsPayableCurrent contextRef="c-256" decimals="-3" id="f-1008" unitRef="usd">7792000</asth:FiduciaryAccountsPayableCurrent>
    <asth:FiduciaryAccountsPayableCurrent contextRef="c-257" decimals="-3" id="f-1009" unitRef="usd">7737000</asth:FiduciaryAccountsPayableCurrent>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-256" decimals="-3" id="f-1010" unitRef="usd">69611000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-257" decimals="-3" id="f-1011" unitRef="usd">55157000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:DividendsPayableCurrent contextRef="c-256" decimals="-3" id="f-1012" unitRef="usd">638000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent contextRef="c-257" decimals="-3" id="f-1013" unitRef="usd">638000</us-gaap:DividendsPayableCurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent contextRef="c-256" decimals="-3" id="f-1014" unitRef="usd">8431000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent contextRef="c-257" decimals="-3" id="f-1015" unitRef="usd">0</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-256" decimals="-3" id="f-1016" unitRef="usd">602000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-257" decimals="-3" id="f-1017" unitRef="usd">646000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-256" decimals="-3" id="f-1018" unitRef="usd">3092000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-257" decimals="-3" id="f-1019" unitRef="usd">3305000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-256" decimals="-3" id="f-1020" unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-257" decimals="-3" id="f-1021" unitRef="usd">8542000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OtherLiabilities contextRef="c-256" decimals="-3" id="f-1022" unitRef="usd">110117000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities contextRef="c-257" decimals="-3" id="f-1023" unitRef="usd">107340000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-256" decimals="-3" id="f-1024" unitRef="usd">9387000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-257" decimals="-3" id="f-1025" unitRef="usd">0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-256" decimals="-3" id="f-1026" unitRef="usd">253728000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-257" decimals="-3" id="f-1027" unitRef="usd">216072000</us-gaap:LiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-256" decimals="-3" id="f-1028" unitRef="usd">905000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-257" decimals="-3" id="f-1029" unitRef="usd">1033000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-256" decimals="-3" id="f-1030" unitRef="usd">26186000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-257" decimals="-3" id="f-1031" unitRef="usd">28675000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-256" decimals="-3" id="f-1032" unitRef="usd">7166000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-257" decimals="-3" id="f-1033" unitRef="usd">7284000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-256" decimals="-3" id="f-1034" unitRef="usd">1690000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-257" decimals="-3" id="f-1035" unitRef="usd">230000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c-256" decimals="-3" id="f-1036" unitRef="usd">35947000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c-257" decimals="-3" id="f-1037" unitRef="usd">37222000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-256" decimals="-3" id="f-1038" unitRef="usd">289675000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-257" decimals="-3" id="f-1039" unitRef="usd">253294000</us-gaap:Liabilities>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-1041">Leases&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating and finance leases for corporate offices, physicians&#x2019; offices, and certain equipment. These leases have remaining lease terms of four months to seventeen years. Some of the leases may include options to extend the lease terms for up to ten years, and some of the leases may include options to terminate the leases within one year. As of March&#160;31, 2024, and December&#160;31, 2023, assets recorded under finance leases were $1.7&#160;million and $1.7 million, respectively, and accumulated depreciation associated with finance leases was $1.8&#160;million and $1.6 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial term of 12 months or less are not recorded on the balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of lease expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(248)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease cost, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Cash Flow Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Lease Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.39 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.64 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.96 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.22 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following are future minimum lease payments under non-cancellable leases for the years ending December 31 (in thousands) below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 (excluding the three months ended March 31, 2024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeFinanceLeasesTextBlock contextRef="c-1" id="f-1040">Leases&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating and finance leases for corporate offices, physicians&#x2019; offices, and certain equipment. These leases have remaining lease terms of four months to seventeen years. Some of the leases may include options to extend the lease terms for up to ten years, and some of the leases may include options to terminate the leases within one year. As of March&#160;31, 2024, and December&#160;31, 2023, assets recorded under finance leases were $1.7&#160;million and $1.7 million, respectively, and accumulated depreciation associated with finance leases was $1.8&#160;million and $1.6 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial term of 12 months or less are not recorded on the balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of lease expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(248)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease cost, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Cash Flow Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Lease Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.39 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.64 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.96 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.22 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following are future minimum lease payments under non-cancellable leases for the years ending December 31 (in thousands) below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 (excluding the three months ended March 31, 2024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-262" id="f-1042">P4M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeFinanceLeaseRemainingLeaseTerm contextRef="c-262" id="f-1043">P4M</us-gaap:LesseeFinanceLeaseRemainingLeaseTerm>
    <us-gaap:LesseeFinanceLeaseRemainingLeaseTerm contextRef="c-263" id="f-1044">P17Y</us-gaap:LesseeFinanceLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-263" id="f-1045">P17Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-5" id="f-1046">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeFinanceLeaseRenewalTerm1 contextRef="c-5" id="f-1047">P10Y</us-gaap:LesseeFinanceLeaseRenewalTerm1>
    <asth:LesseeOperatingLeaseTerminationPeriodIfApplicable contextRef="c-1" id="f-1048">P1Y</asth:LesseeOperatingLeaseTerminationPeriodIfApplicable>
    <asth:LesseeFinanceLeaseTerminationPeriodIfApplicable contextRef="c-1" id="f-1049">P1Y</asth:LesseeFinanceLeaseTerminationPeriodIfApplicable>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-5" decimals="-5" id="f-1050" unitRef="usd">1700000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-6" decimals="-5" id="f-1051" unitRef="usd">1700000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization contextRef="c-5" decimals="-5" id="f-1052" unitRef="usd">1800000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization contextRef="c-6" decimals="-5" id="f-1053" unitRef="usd">1600000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-1054">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of lease expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(248)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease cost, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Cash Flow Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Lease Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.39 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.64 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.96 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.22 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-1055" unitRef="usd">3159000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-27" decimals="-3" id="f-1056" unitRef="usd">1751000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-1" decimals="-3" id="f-1057" unitRef="usd">179000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-27" decimals="-3" id="f-1058" unitRef="usd">154000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-1" decimals="-3" id="f-1059" unitRef="usd">24000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-27" decimals="-3" id="f-1060" unitRef="usd">22000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:SubleaseIncome contextRef="c-1" decimals="-3" id="f-1061" unitRef="usd">226000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-27" decimals="-3" id="f-1062" unitRef="usd">248000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-1063" unitRef="usd">3136000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-27" decimals="-3" id="f-1064" unitRef="usd">1679000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-1065" unitRef="usd">2837000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-27" decimals="-3" id="f-1066" unitRef="usd">1742000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-1" decimals="-3" id="f-1067" unitRef="usd">24000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-27" decimals="-3" id="f-1068" unitRef="usd">22000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-1" decimals="-3" id="f-1069" unitRef="usd">179000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-27" decimals="-3" id="f-1070" unitRef="usd">154000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-1071">P8Y4M20D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-59" id="f-1072">P6Y7M20D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-1073">P2Y11M15D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-59" id="f-1074">P3Y2M19D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="4" id="f-1075" unitRef="number">0.0615</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-59" decimals="4" id="f-1076" unitRef="number">0.0563</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="4" id="f-1077" unitRef="number">0.0553</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c-59" decimals="4" id="f-1078" unitRef="number">0.0495</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-1080">&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following are future minimum lease payments under non-cancellable leases for the years ending December 31 (in thousands) below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 (excluding the three months ended March 31, 2024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-1079">&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following are future minimum lease payments under non-cancellable leases for the years ending December 31 (in thousands) below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 (excluding the three months ended March 31, 2024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c-5" decimals="-3" id="f-1081" unitRef="usd">5597000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c-5" decimals="-3" id="f-1082" unitRef="usd">560000</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-5" decimals="-3" id="f-1083" unitRef="usd">7362000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-5" decimals="-3" id="f-1084" unitRef="usd">599000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-5" decimals="-3" id="f-1085" unitRef="usd">7007000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo contextRef="c-5" decimals="-3" id="f-1086" unitRef="usd">345000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-5" decimals="-3" id="f-1087" unitRef="usd">6722000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree contextRef="c-5" decimals="-3" id="f-1088" unitRef="usd">265000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-5" decimals="-3" id="f-1089" unitRef="usd">6545000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour contextRef="c-5" decimals="-3" id="f-1090" unitRef="usd">27000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <asth:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour contextRef="c-5" decimals="-3" id="f-1091" unitRef="usd">22558000</asth:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <asth:FinanceLeaseLiabilityToBePaidAfterYearFour contextRef="c-5" decimals="-3" id="f-1092" unitRef="usd">7000</asth:FinanceLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-5" decimals="-3" id="f-1093" unitRef="usd">55791000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue contextRef="c-5" decimals="-3" id="f-1094" unitRef="usd">1803000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-5" decimals="-3" id="f-1095" unitRef="usd">13068000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount contextRef="c-5" decimals="-3" id="f-1096" unitRef="usd">152000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-5" decimals="-3" id="f-1097" unitRef="usd">42723000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability contextRef="c-5" decimals="-3" id="f-1098" unitRef="usd">1651000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-1099" unitRef="usd">5007000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-1100" unitRef="usd">636000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-1101" unitRef="usd">37716000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-1102" unitRef="usd">1015000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-1103">Segments&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the performance of its operating segments based on segment revenue growth as well as operating income.  Management uses revenue growth and total segment operating income as a measure of the performance of operating businesses separate from non-operating factors. The Company&#x2019;s operations are based in the United States. All revenues of the Company are derived from the United States. The Company&#x2019;s segments are not evaluated using asset information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, our reportable segments enter into transactions with each other. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues recognized by a segment and expenses incurred by the counterparty are eliminated in consolidation and do not affect consolidated results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate costs are unallocated and primarily include corporate initiatives, corporate infrastructure costs and corporate shared costs, such as finance, human resources, legal, and executives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain amounts disclosed in prior period have been recast to conform to the current period presentation. Specifically, reclassifications were made between cost of services and general and administrative expenses in the accompanying segment table for the three months ended March 31, 2023. The following table presents information about our segments (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.139%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.458%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Care Partners&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Care Delivery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Care Enablement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intersegment Elimination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Corporate Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Consolidated Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Third-Party&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;382,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;404,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intersegment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(56,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;397,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(56,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;404,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;314,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26,734)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;330,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(56,809)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;374,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Care Partners&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Care Delivery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Care Enablement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intersegment Elimination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Corporate Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Consolidated Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Third-Party&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;314,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;337,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intersegment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(33,598)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;314,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(33,598)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;337,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;266,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,302)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;289,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21,460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;292,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(34,762)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;314,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(966)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(483)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,409)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Balance includes general and administrative expenses and depreciation and amortization. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt; Income from operations for the intersegment elimination represents rental income from segments renting from other segments. Rental income is presented within other income which is not presented in the table.</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-1104">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain amounts disclosed in prior period have been recast to conform to the current period presentation. Specifically, reclassifications were made between cost of services and general and administrative expenses in the accompanying segment table for the three months ended March 31, 2023. The following table presents information about our segments (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.139%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.458%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Care Partners&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Care Delivery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Care Enablement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intersegment Elimination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Corporate Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Consolidated Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Third-Party&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;382,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;404,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intersegment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(56,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;397,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(56,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;404,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;314,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26,734)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;330,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(56,809)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;374,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Care Partners&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Care Delivery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Care Enablement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intersegment Elimination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Corporate Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Consolidated Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Third-Party&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;314,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;337,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intersegment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(33,598)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;314,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(33,598)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;337,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;266,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,302)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;289,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21,460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;292,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(34,762)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;314,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(966)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(483)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,409)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Balance includes general and administrative expenses and depreciation and amortization. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt; Income from operations for the intersegment elimination represents rental income from segments renting from other segments. Rental income is presented within other income which is not presented in the table.</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-264" decimals="-3" id="f-1105" unitRef="usd">382318000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-265" decimals="-3" id="f-1106" unitRef="usd">17878000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-266" decimals="-3" id="f-1107" unitRef="usd">4160000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-267" decimals="-3" id="f-1108" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-268" decimals="-3" id="f-1109" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-269" decimals="-3" id="f-1110" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-270" decimals="-3" id="f-1111" unitRef="usd">404356000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-271" decimals="-3" id="f-1112" unitRef="usd">14777000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-272" decimals="-3" id="f-1113" unitRef="usd">12841000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-273" decimals="-3" id="f-1114" unitRef="usd">29114000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-274" decimals="-3" id="f-1115" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-275" decimals="-3" id="f-1116" unitRef="usd">-56732000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-276" decimals="-3" id="f-1117" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-277" decimals="-3" id="f-1118" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-278" decimals="-3" id="f-1119" unitRef="usd">397095000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-279" decimals="-3" id="f-1120" unitRef="usd">30719000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-280" decimals="-3" id="f-1121" unitRef="usd">33274000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-281" decimals="-3" id="f-1122" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-282" decimals="-3" id="f-1123" unitRef="usd">-56732000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-283" decimals="-3" id="f-1124" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-1125" unitRef="usd">404356000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-278" decimals="-3" id="f-1126" unitRef="usd">314966000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-279" decimals="-3" id="f-1127" unitRef="usd">24794000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-280" decimals="-3" id="f-1128" unitRef="usd">17373000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-281" decimals="-3" id="f-1129" unitRef="usd">0</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-282" decimals="-3" id="f-1130" unitRef="usd">-26734000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-283" decimals="-3" id="f-1131" unitRef="usd">0</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-1132" unitRef="usd">330399000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization contextRef="c-278" decimals="-3" id="f-1133" unitRef="usd">38933000</asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization>
    <asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization contextRef="c-279" decimals="-3" id="f-1134" unitRef="usd">6163000</asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization>
    <asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization contextRef="c-280" decimals="-3" id="f-1135" unitRef="usd">12397000</asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization>
    <asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization contextRef="c-281" decimals="-3" id="f-1136" unitRef="usd">0</asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization>
    <asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization contextRef="c-282" decimals="-3" id="f-1137" unitRef="usd">-30075000</asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization>
    <asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization contextRef="c-283" decimals="-3" id="f-1138" unitRef="usd">16400000</asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization>
    <asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization contextRef="c-1" decimals="-3" id="f-1139" unitRef="usd">43818000</asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization>
    <us-gaap:CostsAndExpenses contextRef="c-278" decimals="-3" id="f-1140" unitRef="usd">353899000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-279" decimals="-3" id="f-1141" unitRef="usd">30957000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-280" decimals="-3" id="f-1142" unitRef="usd">29770000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-281" decimals="-3" id="f-1143" unitRef="usd">0</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-282" decimals="-3" id="f-1144" unitRef="usd">-56809000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-283" decimals="-3" id="f-1145" unitRef="usd">16400000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-1" decimals="-3" id="f-1146" unitRef="usd">374217000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-278" decimals="-3" id="f-1147" unitRef="usd">43196000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-279" decimals="-3" id="f-1148" unitRef="usd">-238000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-280" decimals="-3" id="f-1149" unitRef="usd">3504000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-281" decimals="-3" id="f-1150" unitRef="usd">0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-282" decimals="-3" id="f-1151" unitRef="usd">77000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-283" decimals="-3" id="f-1152" unitRef="usd">-16400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-1153" unitRef="usd">30139000</us-gaap:OperatingIncomeLoss>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-284" decimals="-3" id="f-1154" unitRef="usd">314637000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-285" decimals="-3" id="f-1155" unitRef="usd">12263000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-286" decimals="-3" id="f-1156" unitRef="usd">10139000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-287" decimals="-3" id="f-1157" unitRef="usd">205000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-288" decimals="-3" id="f-1158" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-289" decimals="-3" id="f-1159" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-290" decimals="-3" id="f-1160" unitRef="usd">337244000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-291" decimals="-3" id="f-1161" unitRef="usd">16000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-292" decimals="-3" id="f-1162" unitRef="usd">13120000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-293" decimals="-3" id="f-1163" unitRef="usd">20427000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-294" decimals="-3" id="f-1164" unitRef="usd">35000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-295" decimals="-3" id="f-1165" unitRef="usd">-33598000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-296" decimals="-3" id="f-1166" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-297" decimals="-3" id="f-1167" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-298" decimals="-3" id="f-1168" unitRef="usd">314653000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-299" decimals="-3" id="f-1169" unitRef="usd">25383000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-300" decimals="-3" id="f-1170" unitRef="usd">30566000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-301" decimals="-3" id="f-1171" unitRef="usd">240000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-302" decimals="-3" id="f-1172" unitRef="usd">-33598000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-303" decimals="-3" id="f-1173" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-27" decimals="-3" id="f-1174" unitRef="usd">337244000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-298" decimals="-3" id="f-1175" unitRef="usd">266323000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-299" decimals="-3" id="f-1176" unitRef="usd">20692000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-300" decimals="-3" id="f-1177" unitRef="usd">15621000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-301" decimals="-3" id="f-1178" unitRef="usd">63000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-302" decimals="-3" id="f-1179" unitRef="usd">-13302000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-303" decimals="-3" id="f-1180" unitRef="usd">0</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-27" decimals="-3" id="f-1181" unitRef="usd">289397000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization contextRef="c-298" decimals="-3" id="f-1182" unitRef="usd">26009000</asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization>
    <asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization contextRef="c-299" decimals="-3" id="f-1183" unitRef="usd">5657000</asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization>
    <asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization contextRef="c-300" decimals="-3" id="f-1184" unitRef="usd">9199000</asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization>
    <asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization contextRef="c-301" decimals="-3" id="f-1185" unitRef="usd">660000</asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization>
    <asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization contextRef="c-302" decimals="-3" id="f-1186" unitRef="usd">-21460000</asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization>
    <asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization contextRef="c-303" decimals="-3" id="f-1187" unitRef="usd">5409000</asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization>
    <asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization contextRef="c-27" decimals="-3" id="f-1188" unitRef="usd">25474000</asth:GeneralAndAdministrativeExpensesAndDepreciationAndAmortization>
    <us-gaap:CostsAndExpenses contextRef="c-298" decimals="-3" id="f-1189" unitRef="usd">292332000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-299" decimals="-3" id="f-1190" unitRef="usd">26349000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-300" decimals="-3" id="f-1191" unitRef="usd">24820000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-301" decimals="-3" id="f-1192" unitRef="usd">723000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-302" decimals="-3" id="f-1193" unitRef="usd">-34762000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-303" decimals="-3" id="f-1194" unitRef="usd">5409000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-27" decimals="-3" id="f-1195" unitRef="usd">314871000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-298" decimals="-3" id="f-1196" unitRef="usd">22321000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-299" decimals="-3" id="f-1197" unitRef="usd">-966000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-300" decimals="-3" id="f-1198" unitRef="usd">5746000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-301" decimals="-3" id="f-1199" unitRef="usd">-483000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-302" decimals="-3" id="f-1200" unitRef="usd">1164000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-303" decimals="-3" id="f-1201" unitRef="usd">-5409000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-27" decimals="-3" id="f-1202" unitRef="usd">22373000</us-gaap:OperatingIncomeLoss>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-1203">Fair Value Measurements of Financial Instruments&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and fair values of the Company&#x2019;s financial instruments as of March&#160;31, 2024, are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.227%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market accounts*&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate collar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AAMG contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;VOMG contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;DMG remaining equity interest purchase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sun Labs remaining equity interest purchase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ADSC contingent considerations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CFC contingent considerations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PCCCV contingent considerations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Included in cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and fair values of the Company&#x2019;s financial instruments as of December&#160;31, 2023, are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.227%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market accounts*&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AAMG contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;VOMG contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;DMG remaining equity interest purchase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sun Labs remaining equity interest purchase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate collar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Included in cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the fair value of Level 3 liabilities for the three months ended March&#160;31, 2024, was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.444%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of existing Level 3 liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificates of deposit are reported at par value, plus accrued interest, with maturity dates greater than ninety days. As of March&#160;31, 2024, and December&#160;31, 2023, certificates of deposit amounted to approximately $2.3 million and $2.2&#160;million, respectively. Investments in certificates of deposit are classified as Level 1 investments in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity securities are reported at fair value. These securities are classified as Level 1 in the valuation hierarchy, where quoted market prices from reputable third-party brokers are available in an active market and unadjusted. As of March&#160;31, 2024, and December&#160;31, 2023, the equity securities were approximately $0.2 million and $0.3&#160;million, respectively, in the accompanying condensed consolidated balance sheets. Gains and losses recognized on equity securities sold are recognized in the accompanying condensed consolidated statements of income as other income. The components comprising total gains and losses on equity securities are as follows (in thousands) for the periods listed below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.227%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Total losses recognized on equity securities  &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,353)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Gains recognized on equity securities sold  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Unrealized losses recognized on equity securities held at end of period  &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,353)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Rate Collar Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s collar agreement is designed to limit the interest rate risk associated with the Company&#x2019;s Revolver Loan. The principal objective of the collar agreement is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#x2019;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. Refer to Note 9 - &#x201c;Credit Facility, Bank Loans, and Lines of Credit,&#x201d; for further information on the Company&#x2019;s debt. Under the terms of the agreement, the ceiling is 5.0% and the floor is 2.34%.  The collar agreement is not designated as a hedging instrument. Changes in the fair value of this contract are recognized as unrealized gain or loss on investments in the accompanying condensed consolidated statements of income and reflected in the accompanying condensed consolidated statements of cash flows as unrealized loss on investments. The estimated fair value of the collar was determined using Level 2.  As of March&#160;31, 2024 and December&#160;31, 2023, the fair value of the collar was $0.4&#160;million and $0.3 million, and presented within other assets and other long-term liabilities, respectively, in the accompanying condensed consolidated balance sheets. For the three months ended March&#160;31, 2024, the Company recognized unrealized gains of $0.7 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Remaining equity interest purchase&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, the Company entered into a financing obligation to purchase the remaining equity interest in Diagnostic Medical Group of Southern California (&#x201c;DMG&#x201d;) and Sun Clinical Laboratories (&#x201c;Sun Labs&#x201d;) within three years from the date the Company consolidated DMG and Sun Labs. The purchase of the remaining DMG equity value is considered a financing obligation with a carrying value of $8.5&#160;million as of March&#160;31, 2024 and December&#160;31, 2023. Changes in the fair value of the remaining equity purchase are presented in unrealized gain and loss on investments in the accompanying condensed consolidated statements of income. The purchase of the remaining Sun Labs equity value is considered a financing obligation with a carrying value of $7.3 million and $7.8 million as of March&#160;31, 2024 and December&#160;31, 2023, respectively. For the three months ended March&#160;31, 2024, and 2023, the Company recognized an unrealized gain of $0.5 million and unrealized loss of $1.4 million, respectively, due to the change in the fair value of Sun Labs equity value obligation. As the financing obligations &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;are embedded in the non-controlling interest, the non-controlling interests are recognized in other liabilities in the accompanying condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent considerations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;All American Medical Group&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AAMG&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon acquiring 100% of the equity interest in AAMG, the purchase price consisted of cash funded upon close of the transaction and additional consideration (&#x201c;AAMG contingent consideration&#x201d;) and stock consideration (&#x201c;AAMG stock contingent consideration&#x201d;) contingent on AAMG meeting revenue and capitated member metrics for fiscal years 2023  (&#x201c;2023 metric&#x201d;) and 2024 (&#x201c;2024 metric&#x201d;). If the contingent considerations are met, the settlement will be paid in the Company&#x2019;s common stock. The total amount of stock that can be issued for the 2023 and 2024 metrics is 157,048 and 184,361, respectively. The Company determined the fair value of the contingent considerations using a probability-weighted model that includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of revenue and assigned probabilities to each such scenario in determining fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024 and December&#160;31, 2023, the AAMG contingent consideration for the 2023 metric was valued at $3.5&#160;million and $2.6&#160;million, respectively, and was included within other liabilities in the accompanying condensed consolidated balance sheets. The 2023 metric was met, but remains in other liabilities until the shares are issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The AAMG contingent consideration for the 2024 metric was valued at $3.9&#160;million and $2.9&#160;million as of March&#160;31, 2024 and December&#160;31, 2023, respectively, and was included in other liabilities and other long-term liabilities in the accompanying condensed consolidated balance sheets, respectively. Changes in the AAMG contingent consideration are presented in general and administrative expenses in the accompanying condensed consolidated statements of income. The AAMG stock contingent consideration for 2023 and 2024 metric was valued at $5.6&#160;million as of March&#160;31, 2024 and December&#160;31, 2023 and is included in additional paid-in capital in the accompanying condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ADSC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon acquiring 95% of the equity interest of Advanced Diagnostic and Surgical Center in 2024, the total consideration of the acquisition included contingent considerations. The contingent considerations will be settled in cash contingent on ADSC achieving revenue and EBITDA metrics for fiscal years 2023 (&#x201c;ADSC 2023 Metric&#x201d;) and 2024 (&#x201c;ADSC 2024 Metric&#x201d;) (collectively, &#x201c;ADSC contingent considerations&#x201d;). The Company determined the fair value of the contingent consideration using a probability-weighted model that includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of revenue and assigned probabilities to each such scenario in determining fair value. As of March&#160;31, 2024, the ADSC 2023 Metric and the 2024 Metric were valued at $2.0&#160;million and $1.6&#160;million, respectively and were included in other liabilities in the accompanying condensed consolidated balance sheets. Changes in the ADSC contingent considerations are presented in general and administrative expenses in the accompanying condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;CFC&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon acquiring certain assets of CFC in 2024, the total consideration of the acquisition included contingent considerations. The contingent considerations will be settled in cash contingent upon CFC maintaining or exceeding the target member month amount for the first, second and third measurement period (&#x201c;CFC contingent considerations&#x201d;). The contingent liability will be paid after achieving the metric in each measurement period. The Company will pay $5.0&#160;million for each metric achieved for each measurement period or a total of $15.0&#160;million. In the event that the CFC first and/or second contingent considerations are not achieved during the first and/or the second measurement period, if the metric is met within the second and/or third measurement period, there is a catch-up payment that shall be paid concurrently with the payments of the CFC second contingent consideration and/or CFC third contingent consideration. The Company determined the fair value of the contingent consideration using a probability-weighted model that includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of revenue and assigned probabilities to each such scenario in determining fair value. As of March&#160;31, 2024, the first, second, and third metric were valued at $3.1&#160;million, $2.8&#160;million and $1.9&#160;million, respectively, and were all included in other long-term liabilities in the accompanying condensed consolidated balance sheets. Changes in the CFC contingent considerations are presented in general and administrative expenses in the accompanying condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;PCCCV&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon acquiring certain assets of PCCCV in 2024, the total consideration of the acquisition included contingent considerations. The contingent considerations will be settled in cash contingent upon PCCCV meeting certain metrics related to financial ratios and member months for the first and second measurement periods (&#x201c;PCCCV contingent considerations&#x201d;). The Company determined the fair value of the contingent considerations using a probability-weighted model that includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of revenue and assigned probabilities to each such scenario in determining fair value. As of March&#160;31, 2024, the value of the contingent consideration was valued at $2.3&#160;million. Changes in the PCCCV contingent considerations are presented in general and administrative expenses in the accompanying condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="c-1" id="f-1204">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and fair values of the Company&#x2019;s financial instruments as of March&#160;31, 2024, are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.227%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market accounts*&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate collar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AAMG contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;VOMG contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;DMG remaining equity interest purchase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sun Labs remaining equity interest purchase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ADSC contingent considerations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CFC contingent considerations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PCCCV contingent considerations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Included in cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and fair values of the Company&#x2019;s financial instruments as of December&#160;31, 2023, are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.227%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market accounts*&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AAMG contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;VOMG contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;DMG remaining equity interest purchase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sun Labs remaining equity interest purchase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate collar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Included in cash and cash equivalents&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-304" decimals="-3" id="f-1205" unitRef="usd">31804000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-305" decimals="-3" id="f-1206" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-306" decimals="-3" id="f-1207" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-5" decimals="-3" id="f-1208" unitRef="usd">31804000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-304" decimals="-3" id="f-1209" unitRef="usd">2258000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-305" decimals="-3" id="f-1210" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-306" decimals="-3" id="f-1211" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-5" decimals="-3" id="f-1212" unitRef="usd">2258000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-304" decimals="-3" id="f-1213" unitRef="usd">232000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-305" decimals="-3" id="f-1214" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-306" decimals="-3" id="f-1215" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-5" decimals="-3" id="f-1216" unitRef="usd">232000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:DerivativeAssets contextRef="c-307" decimals="-3" id="f-1217" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-308" decimals="-3" id="f-1218" unitRef="usd">438000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-309" decimals="-3" id="f-1219" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-310" decimals="-3" id="f-1220" unitRef="usd">438000</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-304" decimals="-3" id="f-1221" unitRef="usd">34294000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-305" decimals="-3" id="f-1222" unitRef="usd">438000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-306" decimals="-3" id="f-1223" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-5" decimals="-3" id="f-1224" unitRef="usd">34732000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-311" decimals="-3" id="f-1225" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-312" decimals="-3" id="f-1226" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-313" decimals="-3" id="f-1227" unitRef="usd">7407000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-314" decimals="-3" id="f-1228" unitRef="usd">7407000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-315" decimals="-3" id="f-1229" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-316" decimals="-3" id="f-1230" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-317" decimals="-3" id="f-1231" unitRef="usd">17000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-318" decimals="-3" id="f-1232" unitRef="usd">17000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent contextRef="c-319" decimals="-3" id="f-1233" unitRef="usd">0</asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent>
    <asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent contextRef="c-320" decimals="-3" id="f-1234" unitRef="usd">0</asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent>
    <asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent contextRef="c-321" decimals="-3" id="f-1235" unitRef="usd">8542000</asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent>
    <asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent contextRef="c-322" decimals="-3" id="f-1236" unitRef="usd">8542000</asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent>
    <asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent contextRef="c-323" decimals="-3" id="f-1237" unitRef="usd">0</asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent>
    <asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent contextRef="c-324" decimals="-3" id="f-1238" unitRef="usd">0</asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent>
    <asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent contextRef="c-325" decimals="-3" id="f-1239" unitRef="usd">7278000</asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent>
    <asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent contextRef="c-326" decimals="-3" id="f-1240" unitRef="usd">7278000</asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-327" decimals="-3" id="f-1241" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-328" decimals="-3" id="f-1242" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-329" decimals="-3" id="f-1243" unitRef="usd">3632000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-330" decimals="-3" id="f-1244" unitRef="usd">3632000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-331" decimals="-3" id="f-1245" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-332" decimals="-3" id="f-1246" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-333" decimals="-3" id="f-1247" unitRef="usd">7767000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-334" decimals="-3" id="f-1248" unitRef="usd">7767000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-335" decimals="-3" id="f-1249" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-336" decimals="-3" id="f-1250" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-337" decimals="-3" id="f-1251" unitRef="usd">2265000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-338" decimals="-3" id="f-1252" unitRef="usd">2265000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-304" decimals="-3" id="f-1253" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-305" decimals="-3" id="f-1254" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-306" decimals="-3" id="f-1255" unitRef="usd">36908000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-5" decimals="-3" id="f-1256" unitRef="usd">36908000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-339" decimals="-3" id="f-1257" unitRef="usd">4842000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-340" decimals="-3" id="f-1258" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-341" decimals="-3" id="f-1259" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-6" decimals="-3" id="f-1260" unitRef="usd">4842000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-339" decimals="-3" id="f-1261" unitRef="usd">2150000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-340" decimals="-3" id="f-1262" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-341" decimals="-3" id="f-1263" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-6" decimals="-3" id="f-1264" unitRef="usd">2150000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-339" decimals="-3" id="f-1265" unitRef="usd">348000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-340" decimals="-3" id="f-1266" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-341" decimals="-3" id="f-1267" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-6" decimals="-3" id="f-1268" unitRef="usd">348000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-339" decimals="-3" id="f-1269" unitRef="usd">7340000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-340" decimals="-3" id="f-1270" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-341" decimals="-3" id="f-1271" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-6" decimals="-3" id="f-1272" unitRef="usd">7340000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-342" decimals="-3" id="f-1273" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-343" decimals="-3" id="f-1274" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-344" decimals="-3" id="f-1275" unitRef="usd">5475000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-345" decimals="-3" id="f-1276" unitRef="usd">5475000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-346" decimals="-3" id="f-1277" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-347" decimals="-3" id="f-1278" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-348" decimals="-3" id="f-1279" unitRef="usd">17000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-349" decimals="-3" id="f-1280" unitRef="usd">17000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent contextRef="c-350" decimals="-3" id="f-1281" unitRef="usd">0</asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent>
    <asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent contextRef="c-351" decimals="-3" id="f-1282" unitRef="usd">0</asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent>
    <asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent contextRef="c-352" decimals="-3" id="f-1283" unitRef="usd">8542000</asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent>
    <asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent contextRef="c-353" decimals="-3" id="f-1284" unitRef="usd">8542000</asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent>
    <asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent contextRef="c-354" decimals="-3" id="f-1285" unitRef="usd">0</asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent>
    <asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent contextRef="c-355" decimals="-3" id="f-1286" unitRef="usd">0</asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent>
    <asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent contextRef="c-356" decimals="-3" id="f-1287" unitRef="usd">7802000</asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent>
    <asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent contextRef="c-357" decimals="-3" id="f-1288" unitRef="usd">7802000</asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent>
    <us-gaap:DerivativeLiabilities contextRef="c-358" decimals="-3" id="f-1289" unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-359" decimals="-3" id="f-1290" unitRef="usd">252000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-360" decimals="-3" id="f-1291" unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-361" decimals="-3" id="f-1292" unitRef="usd">252000</us-gaap:DerivativeLiabilities>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-339" decimals="-3" id="f-1293" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-340" decimals="-3" id="f-1294" unitRef="usd">252000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-341" decimals="-3" id="f-1295" unitRef="usd">21836000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-6" decimals="-3" id="f-1296" unitRef="usd">22088000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-1297">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the fair value of Level 3 liabilities for the three months ended March&#160;31, 2024, was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.444%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of existing Level 3 liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-6" decimals="-3" id="f-1298" unitRef="usd">21836000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <asth:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdditions contextRef="c-1" decimals="-3" id="f-1299" unitRef="usd">13161000</asth:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdditions>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-1" decimals="-3" id="f-1300" unitRef="usd">1911000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-5" decimals="-3" id="f-1301" unitRef="usd">36908000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:MarketableSecuritiesPolicy contextRef="c-1" id="f-1302">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificates of deposit are reported at par value, plus accrued interest, with maturity dates greater than ninety days. As of March&#160;31, 2024, and December&#160;31, 2023, certificates of deposit amounted to approximately $2.3 million and $2.2&#160;million, respectively. Investments in certificates of deposit are classified as Level 1 investments in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;Equity securities are reported at fair value. These securities are classified as Level 1 in the valuation hierarchy, where quoted market prices from reputable third-party brokers are available in an active market and unadjusted.</us-gaap:MarketableSecuritiesPolicy>
    <asth:MarketableSecuritiesCurrentMaturityPeriod contextRef="c-362" id="f-1303">P90D</asth:MarketableSecuritiesCurrentMaturityPeriod>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-363" decimals="-5" id="f-1304" unitRef="usd">2300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-364" decimals="-5" id="f-1305" unitRef="usd">2200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-5" decimals="-5" id="f-1306" unitRef="usd">200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-6" decimals="-5" id="f-1307" unitRef="usd">300000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:GainLossOnInvestmentsTextBlock contextRef="c-1" id="f-1308">The components comprising total gains and losses on equity securities are as follows (in thousands) for the periods listed below:&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.227%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Total losses recognized on equity securities  &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,353)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Gains recognized on equity securities sold  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Unrealized losses recognized on equity securities held at end of period  &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,353)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GainLossOnInvestmentsTextBlock>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-1" decimals="-3" id="f-1309" unitRef="usd">116000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-27" decimals="-3" id="f-1310" unitRef="usd">4353000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c-1" decimals="-3" id="f-1311" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c-27" decimals="-3" id="f-1312" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-1" decimals="-3" id="f-1313" unitRef="usd">116000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-27" decimals="-3" id="f-1314" unitRef="usd">4353000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:DerivativesPolicyTextBlock contextRef="c-1" id="f-1315">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Rate Collar Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s collar agreement is designed to limit the interest rate risk associated with the Company&#x2019;s Revolver Loan. The principal objective of the collar agreement is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#x2019;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. Refer to Note 9 - &#x201c;Credit Facility, Bank Loans, and Lines of Credit,&#x201d; for further information on the Company&#x2019;s debt. Under the terms of the agreement, the ceiling is 5.0% and the floor is 2.34%.  The collar agreement is not designated as a hedging instrument. Changes in the fair value of this contract are recognized as unrealized gain or loss on investments in the accompanying condensed consolidated statements of income and reflected in the accompanying condensed consolidated statements of cash flows as unrealized loss on investments. The estimated fair value of the collar was determined using Level 2.  As of March&#160;31, 2024 and December&#160;31, 2023, the fair value of the collar was $0.4&#160;million and $0.3 million, and presented within other assets and other long-term liabilities, respectively, in the accompanying condensed consolidated balance sheets. For the three months ended March&#160;31, 2024, the Company recognized unrealized gains of $0.7 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <asth:DerivativeCeilingInterestRate
      contextRef="c-310"
      decimals="3"
      id="f-1316"
      unitRef="number">0.050</asth:DerivativeCeilingInterestRate>
    <us-gaap:DerivativeFloorInterestRate
      contextRef="c-310"
      decimals="4"
      id="f-1317"
      unitRef="number">0.0234</us-gaap:DerivativeFloorInterestRate>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-310" decimals="-5" id="f-1318" unitRef="usd">400000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-361" decimals="-5" id="f-1319" unitRef="usd">300000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-365" decimals="-5" id="f-1320" unitRef="usd">700000</us-gaap:UnrealizedGainLossOnInvestments>
    <asth:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase contextRef="c-366" id="f-1321">P3Y</asth:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase>
    <us-gaap:EquityMethodInvestments contextRef="c-367" decimals="-5" id="f-1322" unitRef="usd">8500000</us-gaap:EquityMethodInvestments>
    <asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent contextRef="c-368" decimals="-5" id="f-1323" unitRef="usd">7300000</asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent>
    <asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent contextRef="c-369" decimals="-5" id="f-1324" unitRef="usd">7800000</asth:BusinessCombinationEquityInterestPurchaseObligationNoncurrent>
    <asth:BusinessCombinationChangeInFairValueOfEquityInterestPurchaseObligation contextRef="c-370" decimals="-5" id="f-1325" unitRef="usd">500000</asth:BusinessCombinationChangeInFairValueOfEquityInterestPurchaseObligation>
    <asth:BusinessCombinationChangeInFairValueOfEquityInterestPurchaseObligation contextRef="c-371" decimals="-5" id="f-1326" unitRef="usd">1400000</asth:BusinessCombinationChangeInFairValueOfEquityInterestPurchaseObligation>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="c-372"
      decimals="2"
      id="f-1327"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c-373"
      decimals="INF"
      id="f-1328"
      unitRef="shares">157048</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c-374"
      decimals="INF"
      id="f-1329"
      unitRef="shares">184361</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-375" decimals="-5" id="f-1330" unitRef="usd">3500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-376" decimals="-5" id="f-1331" unitRef="usd">2600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-377" decimals="-5" id="f-1332" unitRef="usd">3900000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-378" decimals="-5" id="f-1333" unitRef="usd">2900000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-379" decimals="-5" id="f-1334" unitRef="usd">5600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-380" decimals="-5" id="f-1335" unitRef="usd">5600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired contextRef="c-78" decimals="2" id="f-1336" unitRef="number">0.95</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-381" decimals="-5" id="f-1337" unitRef="usd">2000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-382" decimals="-5" id="f-1338" unitRef="usd">1600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <asth:BusinessCombinationContingentConsiderationLiabilityEachMeasurementPeriod contextRef="c-383" decimals="-5" id="f-1339" unitRef="usd">5000000</asth:BusinessCombinationContingentConsiderationLiabilityEachMeasurementPeriod>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-383" decimals="-5" id="f-1340" unitRef="usd">15000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-384" decimals="-5" id="f-1341" unitRef="usd">3100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-385" decimals="-5" id="f-1342" unitRef="usd">2800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-386" decimals="-5" id="f-1343" unitRef="usd">1900000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-387" decimals="-5" id="f-1344" unitRef="usd">2300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-1345">Subsequent Events&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;I Health Promissory Note Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 1, 2024, the Company received $8.3&#160;million as a promissory note with a maturity date of March 31, 2027. I Health may accelerate the maturity date if the Company does not exercise the call options (see Note 5 &#x2014; &#x201c;Investments in Other Entities - Equity Method&#x201d;) The promissory note has an interest rate of 4.30% per annum on the principal amount. Accrued interest is payable on each anniversary of  the promissory note payable. I Health is accounted for under the equity method based on the 25% equity ownership interest held by the Company (see Note 5 &#x2014; &#x201c;Investments in Other Entities - Equity Method&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Elimination of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 24, 2024, the Company filed a Certificate of Elimination to its Restated Certificate of Incorporation with the Secretary of State of the State of Delaware, eliminating from the Certificate of Incorporation all matters set forth in the Amended and Restated Certificate of Designation with respect to the Company&#x2019;s Series A Convertible Preferred Stock and Series B Convertible Preferred Stock and returning each of the Series A Preferred Stock and Series B Preferred Stock to the status of authorized and unissued shares of preferred stock of the Company, without designation as to series. There were no outstanding shares of the Series A Preferred Stock or Series B Preferred Stock as of April 24, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Drawdown on Revolver Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to March&#160;31, 2024, the Company drew down $52.0&#160;million on its Revolver Loan.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c-388" decimals="-5" id="f-1346" unitRef="usd">8300000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-389"
      decimals="INF"
      id="f-1347"
      unitRef="number">0.0430</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c-200"
      decimals="2"
      id="f-1348"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c-390" decimals="-5" id="f-1349" unitRef="usd">52000000</us-gaap:ProceedsFromLinesOfCredit>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-1" id="f-1350">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-1" id="f-1351">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-1" id="f-1352">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-1" id="f-1353">false</ecd:Rule10b51ArrTrmntdFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc xlink:href="#f-72" xlink:label="f-72" xlink:type="locator"/>
        <link:loc
          xlink:href="#f-106"
          xlink:label="f-106"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-71" xlink:label="f-71" xlink:type="locator"/>
        <link:loc
          xlink:href="#f-105"
          xlink:label="f-105"
          xlink:type="locator"/>
        <link:footnote id="fn-1" xlink:label="fn-1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#x2019;s condensed consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The condensed consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#x2019;s consolidated VIEs totaling $717.5&#160;million and $540.8&#160;million as of March&#160;31, 2024 and December&#160;31, 2023, respectively, and total liabilities of the Company&#x2019;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $179.6&#160;million and $146.0&#160;million as of March&#160;31, 2024 and December&#160;31, 2023, respectively. These VIE balances do not include $299.5&#160;million of investment in affiliates and $110.1&#160;million of amounts due to affiliates as of March&#160;31, 2024, and $273.2&#160;million of investment in affiliates and $107.3&#160;million of amounts due to affiliates as of December&#160;31, 2023, as these are eliminated upon consolidation and not presented within the condensed consolidated balance sheets. See Note 16 &#x2014; &#x201c;Variable Interest Entities (VIEs)&#x201d; for further details.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-72"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-106"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-71"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-105"
          xlink:to="fn-1"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
